Patients	O
with	O
symptomatic	B
CNS	B
metastases	I
or	O
leptomeningeal	B
involvement	I

Patients	O
with	O
known	O
brain	B
metastases	I
,	O
unless	B
these	O
metastases	O
have	O
been	O
treated	B
and	O
/	O
or	O
have	O
been	B
stable	I
for	I
at	B
least	I
six	I
months	I
prior	I
to	I
study	I
start	I
.	O

Subjects	O
with	O
a	O
history	B
of	I
brain	B
metastases	I
must	O
have	O
a	O
head	B
CT	I
with	I
contrast	I
to	O
document	O
either	O
response	O
or	O
progression	O
.	O

Patients	O
with	O
bone	B
metastases	I
as	O
the	O
only	B
site	I
(	I
s	I
)	I
of	I
measurable	I
disease	I

Patients	O
with	O
hepatic	B
artery	I
chemoembolization	I
within	B
the	I
last	I
6	I
months	I
(	O
one	B
month	I
if	O
there	O
are	O
other	O
sites	O
of	O
measurable	O
disease	O
)	O

Patients	O
who	O
have	O
been	O
previously	B
treated	O
with	O
radioactive	B
directed	I
therapies	I

Patients	O
who	O
have	O
been	O
previously	B
treated	O
with	O
epothilone	B

Patients	O
with	O
any	O
peripheral	B
neuropathy	I
or	O
unresolved	B
diarrhea	I
greater	O
than	O
Grade	B
1	O

Patients	O
with	O
severe	B
cardiac	I
insufficiency	I
patients	O
taking	O
Coumadin	B
or	O
other	O
warfarin	B
-	I
containing	I
agents	I
with	B
the	I
exception	I
of	I
low	B
dose	I
warfarin	B
(	O
1	B
mg	I
or	I
less	I
)	O
for	O
the	O
maintenance	O
of	O
in	B
-	I
dwelling	I
lines	I
or	O
ports	O

Patients	O
taking	O
any	O
experimental	O
therapies	O
history	B
of	I
another	B
malignancy	I
within	B
5	I
years	I
prior	I
to	I
study	I
entry	I
except	B
curatively	B
treated	I
non	B
-	I
melanoma	I
skin	I
cancer	I
,	O
prostate	B
cancer	I
,	O
or	O
cervical	B
cancer	I
in	I
situ	I

Patients	O
with	O
active	B
or	O
suspected	B
acute	B
or	O
chronic	B
uncontrolled	B
infection	I
including	O
abcesses	B
or	O
fistulae	B

Patients	O
with	O
a	O
medical	O
or	O
psychiatric	B
illness	I
that	O
would	O
preclude	O
study	O
or	O
informed	O
consent	O
and	O
/	O
or	O
history	O
of	O
noncompliance	O
to	O
medical	O
regimens	O
or	O
inability	O
or	O
unwillingness	O
to	O
return	O
for	O
all	O
scheduled	O
visits	O

HIV	B
+	B
patients	O

Pregnant	B
or	O
lactating	B
females	O
.	O

Patients	O
with	O
biopsy	B
-	O
proven	B
metastatic	B
carcinoid	I
tumors	I
or	O
other	B
neuroendocrine	I
tumors	I
(	O
Islet	B
cell	I
,	O
Gastrinomas	B
and	O
VIPomas	B
)	O
with	O
at	O
least	O
one	O
measurable	B
lesion	I
(	O
other	B
than	I
bone	B
)	O
that	O
has	O
either	O
not	B
been	I
previously	O
irradiated	B
or	O
if	O
previously	O
irradiated	B
has	O
demonstrated	O
progression	O
since	O
the	O
radiation	B
therapy	I

The	O
patient	O
has	O
no	B
major	B
impairment	I
of	I
renal	I
or	I
hepatic	I
function	I
,	O
as	O
defined	O
by	O
the	O
following	O
laboratory	O
parameters	O
:	O
total	B
bilirubin	I
<	B
1	I
.	I
5	I
X	I
ULN	I
;	O
AST	B
,	O
ALT	B
<	B
2	I
.	I
5X	I
ULN	I
(	O
<	B
5	I
X	I
ULN	I
if	O
liver	B
metastases	I
are	O
present	O
)	O

Patients	O
on	O
Sandostatin	B
Lar	I
(	O
long	B
acting	I
somatostatin	I
analogue	I
)	O
must	O
be	O
on	O
a	O
stable	B
dose	I
for	B
30	I
days	I
prior	I
to	I
study	I
entry	I
and	O
short	B
acting	I
somatostatin	I
analogues	I
must	O
be	O
judged	O
to	O
be	O
on	O
a	O
clinically	B
stable	I
dose	I
by	O
the	O
investigator	O
prior	B
to	I
study	I
entry	I

Must	O
have	O
a	O
life	O
expectancy	O
of	O
greater	B
than	I
three	I
(	I
3	I
)	I
months	I

Karnofsky	B
Performance	I
Status	I
>	B
60	I

Female	B
patients	O
must	O
have	O
a	O
negative	B
serum	B
pregnancy	I
test	I
at	B
screening	I
.	O

(	O
Not	O
applicable	O
to	O
patients	O
with	O
bilateral	B
oophorectomy	I
and	O
/	O
or	O
hysterectomy	B
or	O
to	O
those	O
patients	O
who	O
are	O
postmenopausal	B
.	O
)	O

Women	B
of	O
child	B
-	I
bearing	I
potential	I
that	O
do	B
not	I
practice	O
adequate	B
contraception	I
.	O

Pregnant	B
or	O
lactating	B
.	O

Received	O
more	B
than	I
one	I
primary	B
chemotherapy	I
regimen	I
.	O

Concomitant	B
or	O
previous	B
malignancies	B
with	O
the	B
exception	I
of	I
adequately	B
treated	I
basal	O
cell	O
or	O
squamous	B
cell	I
skin	I
cancer	I
,	O
in	B
situ	I
cervical	I
cancer	I
,	O
incidental	B
carcinoid	I
,	O
or	O
other	B
cancer	I
from	O
which	O
the	O
patient	O
has	B
been	I
disease	I
free	I
for	B
5	I
years	I
.	O

Active	B
uncontrolled	I
infection	B
requiring	O
antibiotics	B
.	O

Concurrent	B
severe	B
medical	B
problems	I
unrelated	O
to	O
the	O
malignancy	B
which	O
would	O
limit	B
full	I
compliance	I
with	I
the	I
study	I
.	O

Received	O
radiation	B
to	O
more	B
than	I
10	I
%	I
of	O
bone	B
.	O

Prior	B
treatment	O
with	O
topotecan	B
or	O
gemcitabine	B
.	O

Hypersensitivity	B
to	O
camptothecin	B
or	O
nucleoside	B
analogues	I
.	O

Use	O
of	O
an	O
investigational	B
agent	I
within	B
30	I
days	I
.	O

Have	O
had	O
one	O
prior	B
platinum	B
-	I
based	I
chemotherapy	I
regimen	I
for	O
the	O
treatment	O
of	O
primary	B
disease	I
.	O

At	B
least	I
4	I
weeks	I
since	I
last	I
surgery	I
or	I
radiation	I
therapy	I
.	O

Must	O
have	O
had	O
a	B
treatment	I
-	I
free	I
interval	I
of	O
greater	O
than	O
6	O
months	O
following	O
response	O
to	O
platinum	B
.	O

ECOG	B
performance	I
status	I
of	O
0	B
,	O
1	O
,	O
or	O
2	O
.	B

Metastatic	O
disease	O
(	B
M1	I
)	I
/	I
stage	I
4	I
NSCLC	O

Pleural	O
or	O
pericardial	B
effusion	I
greater	B
than	I
100	I
ml	I
in	I
volume	I
as	O
documented	O
by	O
appropriate	O
imaging	O
(	O
positron	B
emission	I
tomography	I
[	O
PET	B
]	O
,	O
computed	O
tomography	O
[	O
CT	B
]	O
scan	O
or	O
ultrasound	B
)	O
.	O
If	O
an	O
effusion	O
greater	O
than	O
100	O
ml	O
is	O
documented	O
by	O
cytology	O
to	O
be	O
free	O
from	O
malignancy	O
and	O
the	O
investigator	O
feels	O
the	O
patient	O
is	O
capable	O
of	O
receiving	O
chemo	O
/	O
radiotherapy	O
for	O
their	O
primary	O
disease	O
/	O
NSCLC	O
,	O
the	O
investigator	O
should	O
discuss	O
the	O
patient	O
with	O
the	O
study	O
physician	O
at	O
Amgen	O
.	O
Effusions	O
smaller	O
than	O
100	O
ml	O
would	O
be	O
acceptable	O
,	O
unless	O
the	O
investigator	O
suspects	O
that	O
the	O
effusion	O
is	O
malignant	O
,	O
in	O
which	O
case	O
the	O
effusions	O
should	O
be	O
evaluated	O
by	O
cytology	O
.	O
Sponsor	O
approval	O
must	O
be	O
obtained	O
before	O
patient	O
is	O
randomized	O
.	O

Plan	O
to	O
remove	O
the	O
tumor	O
surgically	O
before	B
completing	I
the	I
protocol	I
chemo	I
/	I
radiotherapy	I
course	I

Shielding	B
of	O
any	B
part	I
of	I
the	O
esophagus	B
during	O
radiotherapy	B
(	O
including	O
posterior	B
spinal	I
cord	I
shielding	I
)	O

Prior	B
chemotherapy	B
,	O
radiotherapy	B
,	O
or	O
surgery	B
for	O
NSCLC	B

Prior	B
invasive	B
malignancy	B
during	B
the	I
past	I
3	I
years	I
other	B
than	I
non	B
-	I
melanomatous	I
skin	I
cancer	I
.	O

Note	O
:	O
Patients	O
with	O
prior	O
surgically	B
-	I
cured	I
malignancies	I
[	O
eg	O
,	O
stage	O
I	O
breast	O
cancer	O
or	O
prostate	O
cancer	O
,	O
in	O
-	O
situ	O
carcinoma	O
of	O
the	O
cervix	O
,	O
etc	O
]	O
are	B
not	I
excluded	O
;	O
however	O
,	O
sponsor	O
approval	O
must	O
be	O
obtained	O
before	O
patient	O
is	O
randomized	O
.	O

Presence	O
or	O
history	B
of	I
dysphagia	B
or	O
conditions	B
predisposing	I
to	I
dysphagia	I
(	O
eg	O
,	O
uncontrolled	B
gastroesophageal	B
reflux	I
disease	I
[	O
GERD	B
]	O
,	O
dyspepsia	B
,	O
etc	O
)	O

History	B
of	I
pancreatitis	B

Four	O
weeks	O
or	O
less	O
since	O
completion	O
of	O
treatment	B
using	O
an	O
investigational	B
product	I
/	O
device	O
in	O
another	O
clinical	O
study	O
or	O
presence	O
of	O
any	O
unresolved	B
toxicity	B
from	O
previous	B
treatment	B

Previous	B
treatment	B
on	O
this	O
study	O
or	O
with	O
a	O
fibroblast	B
growth	I
factor	I

Known	O
to	O
be	O
sero	B
-	I
positive	I
for	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
,	O
hepatitis	B
C	I
virus	I
(	I
HCV	I
)	I
,	O
or	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I

Pregnant	B
or	O
breastfeeding	B
women	B

Known	O
sensitivity	B
to	O
E	B
.	I
coli	I
derived	I
products	B

Compromised	B
ability	I
of	O
the	O
patient	O
to	O
give	O
written	O
informed	O
consent	O
and	O
/	O
or	O
to	O
comply	O
with	O
study	O
procedures	O

Refusal	O
to	O
sign	O
an	O
informed	O
consent	O
form	O
to	O
participate	O
in	O
this	O
study	O
,	O
and	O
sign	O
the	O
hospital	O
information	O
release	O
form	O
,	O
if	O
applicable	O

Unwilling	O
or	O
unable	O
to	O
complete	O
the	O
patient	O
reported	O
outcome	O
(	O
PRO	O
)	O
questionnaires	O

Psychological	O
,	O
social	O
,	O
familial	O
,	O
or	O
geographical	O
reasons	O
that	O
would	O
prevent	O
regular	O
follow	O
-	O
up	O

Patients	O
with	O
a	O
histologically	O
or	O
cytologically	B
proven	I
diagnosis	O
of	O
NSCLC	B

Unresectable	B
(	O
locally	B
advanced	I
)	O
stage	B
IIIa	I
or	I
IIIb	I
disease	I

Initial	B
radiotherapy	B
field	O
of	O
treatment	O
to	O
encompass	O
greater	O
than	O
or	O
equal	B
to	I
30	I
%	I
of	O
the	O
esophagus	B

Life	O
expectancy	O
greater	O
than	O
or	O
equal	B
to	I
6	I
months	I

Estimated	B
weight	I
loss	I
less	O
than	O
or	O
equal	B
to	I
10	I
%	I
in	O
the	O
3	B
months	I
before	I
study	I
randomization	I

Measurable	B
disease	I

18	O
years	O
of	O
age	B
or	O
older	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	B
)	O
performance	O
status	O
of	O
0	B
-	I
2	I

Hemoglobin	B
(	O
hgb	B
)	O
greater	O
than	O
or	O
equal	B
to	I
10	I
g	I
/	I
dL	I
without	B
transfusional	O
support	O
or	O
growth	O
factor	O
use	O
in	B
the	I
4	I
weeks	I
before	I
study	I
randomization	I

Absolute	B
neutrophil	I
count	I
(	O
ANC	B
)	O
greater	O
than	O
or	O
equal	B
to	I
1	I
.	I
5	I
x	I
10	I
^	I
9	I
/	I
L	I
without	B
growth	O
factor	O
use	O
in	B
the	I
2	I
weeks	I
before	I
study	I
randomization	I

Platelet	B
count	I
greater	O
than	O
or	O
equal	B
to	I
100	I
x	I
10	I
^	I
9	I
/	I
L	I

Serum	B
bilirubin	I
less	O
than	O
or	O
equal	B
to	I
1	I
.	I
5	I
x	I
institutional	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I

Serum	B
creatinine	I
less	B
than	I
or	O
equal	O
to	O
2	B
.	I
0	I
mg	I
/	I
dL	I
(	O
Note	O
:	O
Patients	O
with	O
a	O
serum	B
creatinine	I
greater	O
than	O
or	O
equal	O
to	O
1	O
.	O
4	O
and	O
less	O
than	O
or	O
equal	B
to	I
2	I
.	I
0	I
mg	I
/	I
dL	I
must	O
demonstrate	O
a	O
24	B
-	I
hour	I
urinary	I
creatinine	I
clearance	I
greater	O
than	O
or	O
equal	B
to	I
50	I
mL	I
/	I
min	I
)	O

Females	B
of	O
childbearing	B
potential	I
:	O
negative	B
serum	O
or	O
urine	B
pregnancy	I
test	I

Patient	O
must	O
give	O
written	O
informed	O
consent	O
before	O
participating	O
in	O
any	O
study	B
-	I
specific	I
procedure	B
,	O
randomization	B
,	O
or	O
receiving	O
investigational	B
product	I
.	O

Patients	O
with	O
reproductive	B
capability	I
must	O
agree	O
to	O
practice	O
adequate	B
contraception	B
methods	I
.	O

Are	O
pregnant	B
or	O
lactating	B
.	O

Have	O
participated	O
in	O
any	O
other	O
studies	O
involving	O
investigational	O
products	O
within	B
30	I
days	I
prior	I
to	I
entry	I
into	I
this	I
study	I
.	O

Are	O
undergoing	O
an	O
acute	B
withdrawal	I
syndrome	I
from	O
drugs	B
or	O
alcohol	B
.	O

Have	O
an	O
Axis	O
I	O
diagnosis	O
of	O
Schizophrenia	B
,	O
Schizoaffective	B
Disorder	I
,	O
Schizophreniform	B
Disorder	I
or	O
Bipolar	B
I	I
Disorder	I
as	O
diagnosed	O
by	O
the	O
Structured	B
Clinical	I
Interview	I
for	I
DSM	I
-	I
IV	I
Axis	I
I	I
Disorders	I
(	I
SCID	I
-	I
I	I
)	I
,	O
and	O
pertinent	O
subsequent	O
for	O
ruling	O
out	O
exclusionary	O
diagnoses	O
.	O

Have	O
an	O
unstable	O
medical	O
disorder	O
as	O
determined	O
by	O
physical	O
examination	O
or	O
laboratory	O
testing	O
.	O
The	O
primary	O
investigator	O
will	O
be	O
responsible	O
for	O
making	O
this	O
judgment	O
based	O
on	O
the	O
above	O
.	O

Had	O
an	O
unsatisfactory	O
response	O
to	O
a	O
previous	O
adequate	O
trial	O
of	O
quetiapine	O
as	O
judged	O
by	O
a	O
study	O
investigator	O
.	O

Patients	O
cannot	O
begin	O
psychotherapy	O
during	O
the	O
study	O
period	O
,	O
but	O
may	O
continue	O
if	O
started	O
prior	O
to	O
the	O
study	O
.	O

Patients	O
who	O
are	O
currently	O
receiving	O
quetiapine	O
therapy	O
may	O
not	O
undergo	O
a	O
washout	O
period	O
and	O
then	O
restart	O
quetiapine	O
in	O
the	O
study	O
.	O

Provide	O
written	O
informed	O
consent	O
before	B
beginning	I
any	I
study	I
related	I
activities	I

Be	O
between	O
age	B
18	O
and	O
55	O
years	O

Be	O
able	O
to	O
speak	O
,	O
read	O
and	O
write	O
English	O
and	O
follow	O
simple	O
instructions	O
for	O
completing	O
self	O
-	O
rated	O
scales	O

Meet	B
DSM	I
-	I
IV	I
criteria	I
for	O
BPD	B
as	O
assessed	O
by	O
the	O
Structured	B
Clinical	I
Interview	I
for	I
DSM	I
-	I
IV	I
Personality	I
Disorders	I
(	I
SCID	I
-	I
II	I
)	I
.	O

Any	O
other	O
primary	B
DSM	B
-	I
IV	I
diagnosis	B
;	O
DSM	B
-	I
IV	I
criteria	I
for	O
body	B
dysmorphic	I
disorder	I
,	O
bipolar	B
affective	I
disorder	I
,	O
schizophrenia	B
,	O
psychotic	B
disorder	I
,	I
current	O
alcohol	O
/	O
substance	B
abuse	I
.	O

A	O
previous	B
adequate	O
trial	O
of	O
topiramate	B

Comorbid	B
major	B
depressive	I
disorder	I
diagnosis	O
which	O
predates	B
OCD	I
diagnosis	I

Cognitive	B
behavioural	I
therapy	I
or	O
additional	B
psychotherapy	B
in	B
past	I
four	I
months	I

Allergy	B
or	O
hypersensitivity	B
to	O
topiramate	B

BMI	B
<	B
20	I

History	B
of	I
kidney	B
stones	I

Outpatient	O
with	O
primary	B
DSM	B
-	I
IV	I
OCD	B

Completion	O
of	O
a	O
14	B
-	I
week	I
open	O
label	O
trial	O
of	O
one	B
the	I
following	I
SRI	O
'	O
s	O
:	O
fluoxetine	B
80	B
mg	I
/	I
day	I
,	O
paroxetine	B
60	B
mg	I
/	I
day	I
,	O
fluvoxamine	B
300	B
mg	I
/	I
day	I
,	O
clomipramine	B
250	B
mg	I
/	I
day	I
,	O
sertraline	B
200	B
mg	I
/	I
day	I
,	O
citalopram	B
60	B
mg	I
/	I
day	I
,	O
escitalopram	B
30	B
mg	I
/	I
day	I
and	O
demonstrating	O
a	O
non	O
or	O
partial	O
responses	B
to	I
SRI	B
treatment	I
(	O
CGI	B
-	I
I	I
of	O
3	B
or	O
4	B
,	O
Y	B
-	I
BOCS	I
reduction	B
of	I
<	I
35	I
%	I
)	O

Stable	B
(	O
8	B
wks	I
or	I
longer	I
)	O
concurrent	B
medications	B
including	O
benzodiazepines	B
,	O
sedative	B
hypnotics	I
,	O
antipsychotics	B
,	O
and	O
antidepressants	B
.	O

Patients	O
who	O
have	O
received	O
prior	O
chemotherapy	B
for	O
unresectable	B
disease	I

Patients	O
with	O
any	O
active	B
or	O
uncontrolled	B
infection	B
,	O
including	O
known	O
HIV	B
infection	I
.	O

(	O
Patients	O
with	O
active	B
hepatitis	B
B	I
will	O
be	O
placed	O
on	O
lamivudine	B
.	O

Patients	O
with	O
active	B
hepatitis	B
C	I
will	O
be	O
eligible	O
if	O
liver	B
tests	I
qualify	B
(	O
5	O
.	O
1	O
.	O
9	O
)	O

Patients	O
with	O
psychiatric	B
disorders	I
that	O
would	O
interfere	B
with	I
consent	I
or	O
follow	O
-	O
up	O
.	O

Pregnant	B
or	O
lactating	B
women	B
.	O

Men	O
and	O
women	O
of	O
reproductive	B
potential	I
may	O
not	O
participate	O
unless	O
they	O
have	O
agreed	O
to	O
use	O
an	O
effective	B
contraceptive	I
method	I
.	O

Patients	O
with	O
any	O
other	O
severe	B
concurrent	B
disease	I
,	O
which	O
in	O
the	O
judgment	O
of	O
the	O
investigator	O
,	O
would	O
make	O
the	O
patient	O
inappropriate	O
for	O
entry	O
into	O
this	O
study	O
.	O

Unresectable	B
,	O
histologically	B
confirmed	B
hepatocellular	B
carcinoma	I
with	O
evident	O
disease	B
limited	I
to	I
liver	I
.	O

Tissue	O
from	O
tumor	O
must	O
be	O
available	O
.	O

This	O
may	O
be	O
paraffin	O
embedded	O
tissue	O
from	O
previous	O
biopsy	O
/	O
resection	O
or	O
if	O
it	O
is	O
not	O
available	O
,	O
a	O
repeat	O
biopsy	O
must	O
be	O
performed	O
.	O

The	O
requirement	O
for	O
biopsy	B
may	O
be	O
waived	O
if	O
alpha	B
-	I
fetoprotein	I
is	O
greater	B
than	I
500	I
ng	I
/	I
mL	I
and	O
in	O
the	O
investigators	O
opinion	O
not	O
explained	O
by	O
a	O
concurrent	O
hepatic	O
inflammatory	O
process	O
.	O

Patients	O
must	O
agree	O
to	O
have	O
a	O
20	B
cc	I
blood	B
sample	I
drawn	I
in	O
addition	O
to	O
routine	B
labs	I
with	B
each	I
cycle	I
of	I
chemotherapy	I
.	O

Patients	O
must	O
have	O
measurable	B
disease	I
.	O

If	O
prior	O
radiation	B
therapy	I
was	O
administered	O
,	O
measurable	B
disease	I
must	O
be	O
outside	B
the	I
radiation	I
field	I
.	O

Patients	O
must	O
have	O
a	O
Zubrod	B
performance	I
status	I
of	O
0	B
-	I
2	I
.	O

Patients	O
must	O
have	O
a	O
predicted	B
life	I
expectancy	I
of	O
at	B
least	I
12	I
weeks	I
.	O

Patients	O
must	O
have	O
a	O
pre	B
-	I
treatment	I
granulocyte	B
count	I
(	O
i	O
.	O
e	O
.	O
,	O
segmented	B
neutrophils	I
+	I
bands	I
)	O
of	O
greater	B
than	I
or	I
equal	I
to	I
1	I
,	I
500	I
/	I
mm3	I
,	O
a	O
hemoglobin	B
level	I
of	O
greater	B
than	I
or	I
equal	I
to	I
9	I
gm	I
/	I
dl	I
,	O
and	O
platelet	B
count	I
greater	B
than	I
or	I
equal	I
to	I
50	I
,	I
000	I
/	I
mm3	I
.	O

The	O
granulocyte	O
requirement	O
may	O
be	O
waived	O
if	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
the	O
lower	O
count	O
reflects	O
hypersplenism	O
with	O
adequate	O
bone	O
marrow	O
reserves	O
.	O

Patients	O
must	O
have	O
adequate	B
renal	B
function	I
as	O
documented	O
by	O
a	O
calculated	B
creatinine	I
clearance	I
≥	B
60	I
.	O

Patients	O
must	O
have	O
adequate	B
hepatic	B
function	I
as	O
documented	O
by	O
a	O
serum	B
bilirubin	I
less	B
than	I
or	I
equal	I
to	I
2x	I
the	I
institutional	I
upper	I
limit	I
of	I
normal	I
,	O
regardless	O
of	O
whether	O
patients	O
have	O
liver	O
involvement	O
secondary	O
to	O
tumor	O
.	O

Patients	O
may	B
not	I
have	I
ascites	B
or	O
the	O
ascites	B
must	O
be	O
responsive	B
to	I
diuretics	I
.	O

type	B
1	I
diabetic	I
or	O
non	B
-	I
diabetic	I

type	B
2	I
diabetic	I
,	O
age	B
18	B
and	I
over	I
,	O
informed	O
consent	O
,	O

1	O
.	O

Congestive	B
heart	I
failure	I
;	O

2	O
.	O

CABG	B
or	O
Percutaneous	B
Coronary	I
Intervention	I
(	I
PCI	I
)	I
procedure	O
;	O

3	O
.	O

Planned	O
need	O
for	O
major	B
surgery	I
(	O
e	O
.	O
g	O
.	O
valve	B
surgery	I
or	O
resection	B
of	I
aortic	I
or	I
left	I
ventricular	I
aneurysm	I
,	O
carotid	B
end	I
-	I
arterectomy	I
,	O
abdominal	B
aortic	I
aneurysm	I
surgery	I
etc	O
.	O
)	O
;	O

4	O
.	O

Congenital	B
heart	I
disease	I
;	O

5	O
.	O

Transmural	B
myocardial	I
infarction	I
within	B
the	I
previous	I
seven	I
days	I
and	O
CK	B
has	B
not	I
returned	I
to	O
normal	B
;	O

6	O
.	O

Chest	B
pain	I
lasting	B
longer	I
than	I
30	I
minutes	I
within	B
12	I
hours	I
pre	I
-	I
procedure	I
,	O
if	O
CK	B
enzymes	I
positive	B
(	O
≥	B
2x	I
the	I
normal	I
upper	I
limit	I
)	O
.	O

7	O
.	O

History	B
of	I
any	B
cerebrovascular	I
accident	I
;	O

8	O
.	O

Left	B
main	I
stenosis	I
of	O
50	B
%	I
or	I
more	I
;	O

9	O
.	O

Intention	O
to	O
treat	B
more	B
than	I
1	I
totally	B
occluded	I
major	I
epicardial	I
vessel	I
;	O

10	O
.	O

Single	O
vessel	O
(	O
single	B
territory	I
)	I
disease	I
.	O

1	O
.	O

Patients	O
with	O
stable	B
(	O
Canadian	B
Cardiovascular	I
Society	I
1	B
,	I
2	I
,	I
3	I
or	I
4	I
)	O
or	O
unstable	B
(	O
Braunwald	B
class	I
IB	B
,	O
IC	B
,	O
IIB	B
,	O
IIC	B
,	O
IIIB	B
,	O
IIIC	B
)	O
angina	B
pectoris	I
and	O
ischemia	B
,	O
or	O
patients	O
with	O
atypical	B
chest	I
pain	I
or	O
even	O
those	O
who	O
are	O
asymptomatic	B
provided	O
they	O
have	O
documented	O
myocardial	B
ischaemia	I
(	O
e	O
.	O
g	O
.	O
treadmill	B
exercise	I
test	I
,	O
radionuclide	B
scintigraphy	I
,	O
stress	B
echocardiography	I
,	O
Holter	B
tape	I
)	O
;	O

2	O
.	O

Patients	O
who	O
are	O
eligible	O
for	O
coronary	B
revascularization	I
(	O
angioplasty	B
or	O
CABG	B
)	O
;	O

3	O
.	O

At	B
least	I
2	I
lesions	B
(	O
located	B
in	I
different	I
vessels	I
and	O
in	O
different	O
territories	O
)	O
potentially	O
amenable	O
to	O
stent	B
implantation	I
;	O

4	O
.	O

de	B
novo	I
native	B
vessels	I
;	O

5	O
.	O

Multivessel	B
disease	I
with	O
at	B
least	I
one	I
significant	B
stenosis	I
in	I
LAD	I
and	O
with	O
treatment	B
of	I
the	I
lesion	I
in	B
another	I
major	I
epicardial	I
coronary	I
artery	I
.	O

A	O
two	O
-	O
vessel	O
disease	O
or	O
a	O
three	O
-	O
vessel	O
disease	O
may	O
be	O
viewed	O
as	O
a	O
combination	O
of	O
a	O
side	O
branch	O
and	O
a	O
main	O
epicardial	O
vessel	O
provided	O
they	O
supply	O
different	O
territories	O
;	O
left	O
anterior	O
descending	O
,	O
left	O
circumflex	O
and	O
right	O
coronary	O
artery	O
)	O
;	O

6	O
.	O

Total	B
occluded	I
vessels	I
.	O

One	B
total	B
occluded	I
major	I
epicardial	I
vessel	I
or	O
side	O
branch	O
can	O
be	O
included	O
and	O
targeted	O
as	O
long	O
as	O
one	O
other	O
major	O
vessel	O
has	O
a	O
significant	O
stenosis	O
amenable	O
for	O
SA	O
,	O
provided	O
the	O
age	O
of	O
occlusion	O
is	O
less	O
than	O
one	O
month	O
e	O
.	O
g	O
.	O
recent	O
instability	O
,	O
infarction	O
with	O
ECG	O
changes	O
in	O
the	O
area	O
subtended	O
by	O
the	O
occluded	O
vessel	O
.	O

Patients	O
with	O
total	B
occluded	I
vessels	I
of	O
unknown	B
duration	I
or	O
existing	O
longer	B
than	I
one	I
month	I
and	O
a	O
reference	B
over	B
1	I
.	I
50	I
mm	I
should	O
not	O
be	O
included	O
,	O
not	O
even	O
as	O
a	O
third	O
or	O
fourth	O
vessel	O
to	O
be	O
dilated	O
;	O

7	O
.	O

Significant	B
stenosis	I
has	O
been	O
defined	O
as	O
a	O
stenosis	B
of	O
more	B
than	I
50	I
%	I
in	I
luminal	I
diameter	I
(	O
in	O
at	O
least	O
one	O
view	O
,	O
on	O
visual	O
interpretation	O
or	O
preferably	O
by	O
QCA	O
)	O
;	O

8	O
.	O

Left	B
ventricular	I
ejection	I
fraction	I
should	O
be	O
at	B
least	I
30	I
%	I
.	O

Multiple	B
pregnancy	I
(	O
more	B
than	I
3	I
fetuses	B
)	O

Maternal	B
history	I
of	I
placental	B
abruptio	I

Fetus	B
with	O
IUGR	B

Pregnancy	B
complicated	O
with	O
pre	B
-	I
eclampsia	I

Unability	B
to	I
give	O
informed	O
consent	O

Pregnant	B
women	B
with	O
abdomen	B
discumfort	I
and	O
ultrasound	B
diagnosis	B
of	O
polyhydramnios	B
(	O
AFI	B
>	B
25cm	I
)	O

Single	B
or	O
twin	B
pregnancies	B

Any	O
condition	O
that	O
prevents	O
participation	O
in	O
the	O
study	O
,	O
including	O
pregnancy	B
and	O
other	O
contraindications	B
for	O
Ventavis	B
treatment	I
(	O
as	O
listed	O
in	O
the	O
current	O
Ventavis	B
Summary	I
of	I
Product	I
Characteristics	I
and	I
patient	I
package	I
insert	I
)	O

The	O
treating	O
physician	O
has	O
chosen	O
Ventavis	B
as	O
a	O
suitable	O
long	B
-	I
term	I
treatment	O
for	O
the	O
patient	O

Patient	O
with	O
primary	B
pulmonary	I
hypertension	I
(	O
i	O
.	O
e	O
.	O
Idiopathic	B
Pulmonary	I
Arterial	I
Hypertension	I
or	O
Familial	B
Pulmonary	I
Arterial	I
Hypertension	I
)	O
and	O
classified	O
as	O
NYHA	B
functional	I
class	I
III	B
(	O
NYHA	O
=	O
New	O
York	O
Heart	O
Association	O
)	O

No	B
prior	O
treatment	B
with	I
Ventavis	I
or	O
other	O
active	O
treatments	B
for	O
primary	B
pulmonary	I
hypertension	I
within	B
6	I
weeks	I
of	I
date	I
of	I
study	I
inclusion	I
(	O
unless	O
otherwise	O
advised	O
by	O
Bayer	O
Schering	O
Pharma	O
)	O

Patients	O
who	O
were	O
pregnant	B
,	O
nursing	B
or	O
not	B
able	O
to	O
give	O
written	O
informed	O
consent	O
were	O
excluded	O
.	O

Patients	O
suspected	O
to	O
have	O
vitamin	B
B12	I
deficiency	I
defined	O
as	O
a	O
plasma	B
vitamin	I
B12	I
below	B
the	I
reference	I
interval	I
(	O
<	B
200	I
pmol	I
/	I
L	I
)	O
.	O

Any	O
condition	O
/	O
illness	B
that	I
may	I
affect	I
the	I
study	I
outcomes	I
or	O
would	O
make	O
participation	O
potentially	O
harmful	O
such	O
as	O
pregnancy	B
or	O
breastfeeding	O
,	O
diabetes	B
mellitus	I
,	O
heart	B
disease	I
,	O
stroke	B
,	O
hypertension	B
,	O
malabsorption	B
syndromes	I
,	O
GERD	B
,	O
a	O
history	B
of	I
ulcer	B
,	O
according	O
to	O
a	O
detailed	O
medical	B
history	I
.	O

Abnormal	B
hepatic	B
function	I
(	O
liver	B
function	I
test	I
>	B
twice	I
the	I
normal	I
range	I
)	O
,	O
abnormal	B
renal	B
function	I
(	O
creatinine	B
>	B
1	I
.	I
1	I
mg	I
/	I
dl	I
)	O
,	O
fasting	B
plasma	I
glucose	I
in	B
the	I
diabetic	I
range	I
(	O
>	B
/	I
=	I
126	I
mg	I
/	I
dl	I
)	O
,	O
or	O
blood	B
pressure	I
>	B
140	I
/	I
90	I
mmHg	I
.	O

Present	O
alcoholism	B
or	O
drug	B
abuse	I
or	O
use	O
of	O
medications	B
that	I
could	I
interfere	I
with	I
the	I
treatment	I
including	O
bronchodilators	B
,	O
quinolone	B
antibiotics	I
,	O
monoamine	B
oxidase	I
inhibitors	I
,	O
anxiolytics	B
,	O
ranitidine	B
,	O
corticosteroids	B
,	O
growth	B
hormone	I
,	O
antihypertensives	B
.	O

Aged	B
at	B
least	I
18	I
years	I
with	O
an	O
ability	O
and	O
willingness	O
to	O
give	O
written	O
informed	O
consent	O
.	O

Body	B
mass	I
index	I
25	B
-	I
35	I
kg	I
/	I
m2	I

Users	O
of	O
at	O
least	O
2	O
cups	O
of	O
caffeinated	B
coffee	I
per	O
day	O
who	O
are	O
willing	O
to	O
be	O
randomized	O
to	O
any	O
of	O
the	O
interventions	O
.	O

Non	B
-	I
smoking	I

Undergoing	O
Interleukin	B
-	I
2	I
(	I
IL	I
-	I
2	I
)	I
therapy	I
within	B
8	I
weeks	I
of	I
study	I
entry	I

Diagnosed	O
with	O
a	O
medical	O
or	O
psychiatric	B
illness	I
that	I
may	I
interfere	I
with	I
study	I
participation	I

Pregnant	B

Diagnosis	O
reviewed	O
at	O
transplant	O
center	O
and	O
confirmed	O
to	O
fit	O
the	O
criterion	O
for	O
high	B
risk	I
blood	I
disease	I
or	O
cancer	B
,	O
as	O
defined	O
for	O
the	O
study	O

Estimated	B
life	I
expectancy	I
of	O
at	B
least	I
6	I
weeks	I
following	I
study	I
entry	I

Cancer	B
and	I
Leukemia	I
Group	I
B	I
(	I
CALGB	I
)	I
performance	I
status	I
less	B
than	I
or	I
equal	I
to	I
2	I

White	B
blood	I
cell	I
count	I
,	O
platelet	B
,	O
hematocrit	B
,	O
tuberculosis	B
,	O
aspartate	B
aminotransferase	I
(	I
AST	I
)	I
,	O
alanine	B
aminotransferase	I
(	I
ALT	I
)	I
,	O
alkaline	B
phosphatase	I
,	O
creatinine	B
,	O
and	O
HIV	B
test	I
results	I
reviewed	B
by	I
transplant	I
center	I

Multiple	B
gated	I
acquisition	I
(	I
MUGA	I
)	I
,	O
echocardiogram	B
,	O
cardiac	B
MRI	I
,	O
and	O
/	O
or	O
pulmonary	B
function	I
tests	I
(	I
PFT	I
)	I
performed	O
and	O
reviewed	B
by	I
transplant	I
center	I
(	O
for	O
individuals	O
with	O
an	O
ejection	O
fraction	O
and	O
diffusing	O
capacity	O
[	O
DLCO	O
]	O
of	O
40	O
-	O
50	O
%	O
,	O
the	O
appropriate	O
cardiology	O
or	O
pulmonary	O
consultations	O
should	O
be	O
considered	O
if	O
the	O
individual	O
has	O
severe	O
heart	O
or	O
lung	O
disease	O
at	O
the	O
initiation	O
of	O
therapy	O
)	O

Sufficient	B
number	I
of	O
umbilical	B
cord	I
blood	I
units	I
available	I
for	O
transplantation	B

If	O
female	B
,	O
willing	O
to	O
use	O
contraception	B
throughout	B
the	I
study	I

Body	B
mass	I
index	I
(	I
BMI	I
)	I
of	O
35	B
kg	I
/	I
m2	I
or	I
more	I
.	O

Significant	O
metabolic	O
and	O
endocrine	B
diseases	I
.	O

Diagnosis	O
of	O
cancer	B
.	O

Use	O
of	O
steroids	B
or	O
drugs	B
that	I
interfere	I
with	I
the	I
metabolism	I
of	I
estrogen	I
.	O

Use	O
of	O
any	O
systemic	B
estrogen	I
,	O
progestin	O
,	O
or	O
DHEA	B
in	B
the	I
eight	I
weeks	I
prior	I
to	I
randomization	I
.	O

Use	O
of	O
alternative	B
therapies	I
or	O
natural	B
products	I
to	O
treat	O
postmenopausal	B
symptoms	I
in	B
the	I
four	I
weeks	I
prior	I
to	I
randomization	I
.	O

Palpable	B
fibroids	I
or	O
uterine	B
prolapse	I
:	O
Grade	B
2	B
or	I
3	I
.	O

Cigarette	B
smoking	I

Healthy	B
postmenopausal	B
women	B
with	O
50	B
or	I
more	I
moderate	B
to	I
severe	I
hot	I
flushes	I
.	O

Women	B
between	B
40	I
to	I
70	I
years	I
of	O
age	B
.	O

Had	O
/	O
have	O
the	O
following	O
prior	O
/	O
concurrent	O
therapy	O
:	O

Systemic	B
corticosteroids	I
(	O
oral	B
or	O
injectable	B
)	O
within	B
7	I
days	I
of	I
first	I
dose	I
of	O
852A	B
(	O
topical	O
or	O
inhaled	B
steroids	I
are	B
allowed	I
)	O

Investigational	B
drugs	I
/	I
agents	I
within	B
14	I
days	I
of	I
first	I
dose	I
of	O
852A	B

Immunosuppressive	B
therapy	I
,	O
including	O
cytotoxic	B
agents	I
within	B
14	I
days	I
of	I
first	I
dose	I
of	O
852A	B
(	O
nitrosoureas	B
within	B
30	I
days	I
of	I
first	I
dose	I
)	O

Drugs	B
known	I
to	I
induce	I
QT	I
interval	I
prolongation	I
and	O
/	O
or	O
induce	O
Torsades	O
de	O
pointes	O
unless	O
best	O
available	O
drug	O
required	O
to	O
treat	O
life	O
-	O
threatening	O
conditions	O

Radiotherapy	B
within	B
3	I
weeks	I
of	I
the	I
first	I
dose	I
of	O
852A	B

Hematopoietic	B
cell	I
transplantation	I
within	B
4	I
weeks	I
of	I
first	I
dose	I
of	O
852A	B

Evidence	O
of	O
active	B
infection	I
within	B
3	I
days	I
of	I
first	I
dose	I
of	O
852A	B

Active	O
fungal	B
infection	I
or	O
pulmonary	B
infiltrates	I
(	O
prior	B
treated	I
disease	I
stable	B
for	B
2	I
weeks	I
is	B
allowable	I
)	O

Cardiac	B
ischemia	I
,	O
cardiac	B
arrhythmias	I
or	O
congestive	B
heart	I
failure	I
uncontrolled	B
by	I
medication	I

History	B
of	O
,	O
or	O
clinical	O
evidence	O
of	O
,	O
a	O
condition	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
could	O
confound	O
the	O
results	O
of	O
the	O
study	O
or	O
put	O
the	O
subject	O
at	O
undue	O
risk	O

Uncontrolled	B
intercurrent	O
or	O
chronic	B
illness	I

Active	B
autoimmune	B
disease	I
requiring	B
immunosuppressive	B
therapy	I
within	B
30	I
days	I

Active	B
coagulation	B
disorder	I
not	B
controlled	B
with	I
medication	I

Pregnant	B
or	O
lactating	B

Concurrent	B
malignancy	B
(	O
if	O
in	B
remission	I
,	O
at	B
least	I
5	I
years	I
disease	B
free	I
)	O
except	B
for	I
localized	B
(	I
in	I
-	I
situ	I
)	I
disease	I
,	O
basal	B
carcinomas	I
and	O
cutaneous	B
squamous	I
cell	I
carcinomas	I
that	O
have	O
been	O
adequately	B
treated	I

Any	O
history	B
of	I
brain	B
metastases	I
or	O
any	O
other	O
active	B
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disease	O

Adequate	B
performance	B
status	I
:	O

Breast	B
-	I
Karnofsky	I
score	I
>	B
50	I
;	O

Ovarian	B
,	O
endometrial	B
or	O
cervical	B
-	O
Gynecologic	B
Oncology	I
Group	I
(	I
GOG	I
)	I
performance	I
score	I
≤	B
2	I

If	O
female	B
and	O
of	O
childbearing	B
potential	I
,	O
are	O
willing	O
to	O
use	O
adequate	O
contraception	B
(	O
hormonal	B
,	O
barrier	B
method	I
,	O
abstinence	B
)	O
prior	B
to	I
study	I
entry	I
and	O
for	B
the	I
duration	I
of	I
study	I
participation	I
.	O

Normal	B
organ	I
function	I
within	B
14	I
days	I
of	I
study	I
entry	I

Diagnosis	O
of	O
one	O
of	O
the	O
following	O
malignancies	O
:	O

Metastatic	B
breast	I
cancer	I
(	O
BR	O
)	O

Metastatic	B
ovarian	I
cancer	I
(	O
OV	O
)	O

Metastatic	B
endometrial	I
cancer	I
(	O
EM	O
)	O

Metastatic	B
cervical	I
cancer	I
(	O
CX	O
)	O

Measurable	B
metastatic	B
disease	I
(	O
>	B
1cm	I
)	O
in	O
at	B
least	I
one	I
site	B
other	I
than	I
bone	I
-	I
only	I

Progression	O
on	O
or	O
failure	O
to	O
respond	O
to	O
at	O
least	O
one	O
previous	B
chemotherapy	B
regimen	I
for	O
metastatic	B
disease	I

Progression	O
on	O
prior	B
therapy	B
with	I
a	I
hormonal	I
agent	I
if	O
estrogen	O
receptor	O
or	O
progesterone	B
receptor	I
positive	I
,	O
and	O
/	O
or	O
with	O
trastuzumab	O
if	O
HER2	B
-	I
neu	I
positive	I
.	O

If	O
patient	O
has	O
progressed	O
through	O
hormone	O
or	O
trastuzumab	B
therapy	I
only	O
,	O
must	O
have	O
received	O
one	O
chemotherapy	B
regimen	I
.	O

Measurable	O
metastatic	B
disease	I
as	O
defined	O
by	O
Response	B
Evaluation	I
Criteria	I
in	I
Solid	I
Tumors	I
(	I
RECIST	I
)	I

Primary	B
tumor	I
must	O
have	O
been	O
diagnosed	O
histologically	B
as	O
either	O
epithelial	B
ovarian	I
cancer	I
,	O
fallopian	B
tube	I
cancer	I
,	O
or	O
primary	B
peritoneal	I
cancer	I
(	O
not	B
borderline	B
or	O
low	B
malignant	I
potential	I
epithelial	B
carcinoma	I
)	O
.	O

Subjects	O
must	O
have	O
failed	O
at	B
least	I
two	I
previous	B
chemotherapy	B
regimens	I
.	O

Paclitaxel	B
must	O
have	O
been	O
a	O
component	O
of	O
one	O
or	O
both	O
regimens	O
and	O
cisplatin	B
or	O
carboplatin	B
must	O
have	O
been	O
a	O
component	O
of	O
one	O
or	O
both	O
regimens	O
.	O

Measurable	B
metastatic	B
disease	I

Histologically	B
proven	B
recurrent	B
or	O
persistent	B
endometrial	B
cancer	I
that	O
is	O
not	B
amenable	B
to	I
curative	I
treatment	I
with	O
surgery	B
and	O
/	O
or	O
radiation	B
therapy	I
AND	O
has	O
failed	O
2	B
previous	B
treatment	B
regimens	I

Measurable	B
metastatic	B
disease	I

Histologically	B
proven	B
recurrent	B
or	O
persistent	B
squamous	B
cell	I
carcinoma	I
,	O
adenosquamous	B
carcinoma	I
,	O
or	O
adenocarcinoma	B
of	I
the	I
cervix	I
that	O
is	O
not	B
amenable	B
to	I
curative	I
treatment	I
with	O
surgery	B
and	O
/	O
or	O
radiation	B
therapy	I
AND	O
has	O
failed	O
2	B
previous	B
treatment	B
regimens	I
.	O

Have	O
participated	O
in	O
this	O
study	O
previously	O
,	O
or	O
any	O
other	O
study	O
using	O
exenatide	B
or	O
GLP	B
-	I
1	I
analogs	I
.	O

Have	O
participated	O
in	O
an	O
interventional	O
,	O
medical	O
,	O
surgical	O
,	O
or	O
pharmaceutical	O
study	O
within	B
30	I
days	I
of	I
screening	I
.	O

Have	O
characteristics	B
contraindicating	I
metformin	B
or	O
sulfonylurea	B
use	O
.	O

Have	O
been	O
treated	O
with	O
exogenous	B
insulin	I
for	B
more	I
than	I
1	I
week	I
within	B
the	I
3	I
months	I
prior	I
to	I
screening	I
.	O

Have	O
used	O
drugs	B
for	I
weight	I
loss	I
within	B
1	I
month	I
of	I
screening	I
.	O

Treated	O
with	O
a	O
stable	B
dose	I
of	O
one	B
of	I
the	I
following	I
for	O
at	B
least	I
3	I
months	I
prior	I
to	I
screening	I
:	O
*	O
>	B
=	I
1000	I
mg	I
/	I
day	I
immediate	B
-	I
release	I
metformin	I
;	O
or	O
metformin	B
>	B
=	I
1000	I
mg	I
/	I
day	I
and	O
sulfonylurea	B
;	O
or	O
sulfonylurea	B
/	O
metformin	B
combination	B
therapy	I
.	O

HbA1c	B
between	B
7	I
.	I
1	I
%	I
and	I
11	I
.	I
0	I
%	I
,	I
inclusive	I
.	O

Body	B
Mass	I
Index	I
(	I
BMI	I
)	I
>	B
21	I
kg	I
/	I
m	I
^	I
2	I
and	I
<	I
35	I
kg	I
/	I
m	I
^	I
2	I
.	O

Other	B
tumor	B
type	O
than	O
adenocarcinoma	B

Central	B
nervous	I
system	I
(	I
CNS	I
)	I
metastases	I
or	O
prior	O
radiation	B
for	O
CNS	B
metastases	I

Gastric	B
outlet	I
obstruction	I
or	O
intestinal	B
obstruction	I

Evidence	O
of	O
gastrointestinal	B
bleeding	I

The	O
patient	O
has	O
bony	B
lesions	I
as	O
the	B
sole	I
evaluable	B
disease	I
.	O

Past	O
or	O
concurrent	O
history	B
of	I
neoplasm	B
other	B
than	I
stomach	B
cancer	I
,	O
except	B
for	I
curatively	B
treated	B
non	B
-	I
melanoma	I
skin	I
cancer	I
or	O
in	B
situ	I
carcinoma	I
of	I
the	I
cervix	I
uteri	I

Pregnant	B
or	O
lactating	B
women	B
,	O
women	B
of	O
childbearing	B
potential	I
not	B
employing	I
adequate	O
contraception	B

Other	O
serious	B
illness	I
or	O
medical	B
conditions	I

Unstable	B
cardiac	I
disease	I
despite	O
treatment	B
,	O
myocardial	B
infarction	I
within	B
6	I
months	I
prior	I
to	I
study	I
entry	I

History	B
of	O
significant	O
neurologic	O
or	O
psychiatric	B
disorders	I
including	O
dementia	B
or	O
seizures	B

Active	B
uncontrolled	B
infection	B

Other	O
serious	B
underlying	I
medical	I
conditions	I
which	O
could	O
impair	O
the	O
ability	O
of	O
the	O
patient	O
to	O
participate	O
in	O
the	O
study	O

Concomitant	B
administration	O
of	O
any	O
other	O
experimental	B
drug	I
under	O
investigation	O
,	O
or	O
concomitant	B
chemotherapy	B
,	O
hormonal	B
therapy	I
,	O
or	O
immunotherapy	B

concomitant	B
drug	B
medication	B
;	O
The	O
following	O
drugs	O
cause	O
drug	O
interaction	O
with	O
S	O
-	O
1	O
.	O

i	O
.	O

Warfarin	B
,	O
phenprocoumon	B
:	O
increase	B
bleeding	B
tendency	I
ii	O
.	O

Increase	B
blood	B
concentration	I
of	I
phenytoin	I
iii	O
.	O
sorivudine	B
:	O
inhibit	O
DPD	O
-	O
>	O
increase	O
toxicity	O
according	O
to	O
fluoropyrimidine	B
iv	O
.	O
allopurinol	B
:	O
decrease	O
activity	O
of	O
S	O
-	O
1	O

Pathologically	B
proven	B
unresectable	B
adenocarcinoma	B
of	I
stomach	I

With	O
uni	B
-	I
dimensionally	I
measurable	I
disease	B
(	O
at	O
least	O
longest	B
diameter	I
2	O
cm	O
on	O
conventional	B
CT	I
scan	I
,	O
x	B
-	I
ray	I
or	O
physical	B
examination	I
,	O
or	O
1cm	O
on	O
spiral	B
CT	I
scan	I
)	O

Age	B
18	B
to	I
70	I
years	I
old	I

Estimated	B
life	I
expectancy	I
of	O
more	B
than	I
3	I
months	I

ECOG	B
performance	I
status	I
of	O
2	B
or	I
lower	I

Adequate	B
bone	B
marrow	I
function	I
(	O
absolute	B
neutrophil	I
count	I
[	I
ANC	I
]	I
≥	B
1	I
,	I
500	I
/	I
µL	I
,	O
hemoglobin	B
≥	B
9	I
.	I
0	I
g	I
/	I
dL	I
,	O
and	O
platelets	B
≥	B
100	I
,	I
000	I
/	I
µL	I
)	O

Adequate	B
kidney	B
function	I
(	O
serum	B
creatinine	I
<	B
1	I
.	I
5	I
mg	I
/	I
dL	I
)	O

Adequate	B
liver	B
function	I
(	O
serum	B
total	I
bilirubin	I
<	B
2	I
times	I
the	I
upper	I
normal	I
limit	I
(	I
UNL	I
)	I
;	O
serum	B
transaminases	I
levels	I
<	O
3	O
times	O
[	O
<	O
5	O
times	O
for	O
patients	O
with	O
liver	B
metastasis	I
]	O
UNL	O
)	O

No	B
prior	B
chemotherapy	B
but	O
prior	B
adjuvant	B
chemotherapy	I
finished	O
at	B
least	I
6	I
months	I
before	I
enrollment	I
was	B
allowed	I
.	O

(	O
but	O
,	O
prior	B
adjuvant	B
chemotherapy	I
with	O
capecitabine	B
or	O
S	B
-	I
1	I
or	O
camptothecin	B
analogues	I
was	O
excluded	B
)	O

No	B
prior	B
radiation	B
therapy	I
for	O
at	B
least	I
4	I
weeks	I
before	I
enrollment	I
in	O
the	O
study	O

Use	O
of	O
any	O
investigational	O
or	O
non	O
-	O
registered	O
product	O
(	O
drug	B
or	O
vaccine	B
)	O
other	O
than	O
the	O
study	O
vaccine	O
(	O
s	O
)	O
within	B
30	I
days	I
preceding	O
the	O
first	O
dose	O
of	O
study	O
vaccine	O
,	O
or	O
planned	O
use	O
during	B
the	I
study	I
period	I

Chronic	B
administration	O
(	O
defined	O
as	O
more	B
than	I
14	I
days	I
)	O
of	O
immunosuppressants	B
or	O
other	B
immune	I
-	I
modifying	I
drugs	I
within	B
six	I
months	I
prior	O
to	O
the	O
first	O
vaccine	O
dose	O
.	O

Planned	O
administration	O
/	O
administration	O
of	O
a	O
vaccine	B
not	B
foreseen	I
by	I
the	I
study	I
protocol	I
during	O
the	O
period	B
starting	I
one	I
month	I
before	I
each	I
dose	I
of	I
vaccine	I
(	I
s	I
)	I
and	O
ending	O
7	O
days	O
after	O
dose	B
1	I
and	O
dose	B
2	I
or	O
1	O
month	O
after	O
dose	B
3	I
.	O

Previous	O
vaccination	B
against	O
diphtheria	B
,	O
tetanus	B
,	O
pertussis	B
,	O
polio	B
,	O
hepatitis	B
B	I
,	O
Haemophilus	B
influenzae	I
type	I
b	I
,	O
and	O
/	O
or	O
S	B
.	I
pneumoniae	I
with	B
the	I
exception	I
of	I
vaccines	B
where	O
the	O
first	B
dose	I
can	I
be	I
given	I
within	B
the	I
first	I
two	I
weeks	I
of	I
life	I
according	O
to	O
the	O
national	O
recommendations	O

History	B
of	O
or	O
intercurrent	O
diphtheria	B
,	O
tetanus	B
,	O
pertussis	B
,	O
hepatitis	B
B	I
,	O
polio	B
,	O
and	O
Haemophilus	B
influenzae	I
type	I
b	I
diseases	O
.	O

History	B
of	O
allergic	B
disease	I
or	O
reactions	O
likely	O
to	O
be	O
exacerbated	B
by	O
any	O
component	O
of	O
the	O
vaccines	O
.	O

History	B
of	O
seizures	B
(	O
this	O
criterion	O
does	B
not	I
apply	I
to	O
subjects	O
who	O
have	O
had	O
a	O
single	B
,	O
uncomplicated	B
febrile	B
convulsion	I
in	O
the	O
past	O
)	O
or	O
neurological	B
disease	I
.	O

Acute	B
disease	I
at	B
the	I
time	I
of	I
enrolment	I

Any	O
confirmed	O
or	O
suspected	O
immunosuppressive	O
or	O
immunodeficient	B
condition	I
based	O
on	O
medical	O
history	O
and	O
physical	O

A	O
family	O
history	O
of	O
congenital	O
or	O
hereditary	B
immunodeficiency	I
.	O

Major	B
congenital	I
defects	I
or	O
serious	B
chronic	I
illness	I
.	O

Administration	O
of	O
immunoglobulins	B
and	O
/	O
or	O
any	B
blood	I
products	I
since	B
birth	I
or	O
planned	O
administration	O
during	B
the	I
active	I
phase	I
of	I
the	I
study	I
.	O

Male	O
or	O
female	O
between	B
,	I
and	I
including	I
,	I
6	I
-	I
12	I
weeks	I
(	O
42	O
to	O
90	O
days	O
)	O
of	B
age	I
at	B
the	I
time	I
of	I
the	I
first	I
vaccination	I
.	O

Subjects	O
for	O
whom	O
the	O
investigator	O
believes	O
that	O
their	O
parents	O
/	O
guardians	O
can	O
and	O
will	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O

Written	O
informed	O
consent	O
obtained	O
from	O
the	O
parent	B
or	O
guardian	B
of	O
the	O
subject	O
.	O

Free	B
of	O
obvious	B
health	B
problems	I
as	O
established	O
by	O
medical	O
history	O
and	O
clinical	O
examination	O
before	O
entering	O
into	O
the	O
study	O
.	O

Born	B
after	O
a	O
gestation	B
period	I
between	B
36	I
and	I
42	I
weeks	I
.	O

Pre	B
-	I
existing	I
eye	B
diseases	I
(	O
glaucoma	B
)	O
.	O

Insufficient	O
response	O
to	O
pregabalin	B
in	O
the	O
treatment	O
of	O
partial	B
seizure	I
,	O
or	O
patients	O
currently	O
receiving	O
pregabalin	B
treatment	O
.	O

Epilepsy	B
partial	B
seizure	I
subjects	O
.	O

Currently	O
taking	O
1	B
to	I
3	I
antiepileptic	B
drugs	I
.	O

Ductal	B
carcinoma	I
in	I
situ	I
(	O
DCIS	B
;	O
stage	B
0	B
cancer	B
)	O
,	O

Advanced	O
or	O
distant	B
metastatic	I
stage	B
,	O

Receiving	O
any	O
neoadjuvant	B
therapy	I
,	O

History	B
of	O
receiving	O
any	O
antibiotics	B
within	B
prior	I
3	I
months	I
,	O

History	B
of	O
immunodeficiency	B
,	O

Having	O
a	O
remote	B
infection	I
,	O

History	B
of	O
reaction	B
to	O
study	B
antibiotics	I
,	O

Denial	B
of	I
signing	O
the	O
consent	O
form	O
.	O

Women	B
at	O
any	B
age	I
with	O
early	B
stage	B
breast	B
cancer	I
(	O
stage	B
I	B
-	I
II	I
)	O
and	O
American	B
Society	I
of	I
Anesthesiologists	I
(	I
ASA	I
)	I
score	I
of	O
I	B
-	I
II	I
.	O

contra	B
-	I
indications	I
of	O
radiotherapy	B

angioplasty	B
with	I
stenting	I

over	B
18	I
years	I

successful	B
angioplasty	O
(	O
residual	B
stenosis	I
<	B
30	I
%	I
)	O
on	O
a	O
significant	B
stenosis	B
(	O
maximal	B
systolic	I
speed	I
3	B
times	I
>	I
from	I
basal	I
maximal	O
systolic	O
speed	O
,	O
stenosis	B
>	B
70	I
%	I
on	O
angiography	B
)	O
on	O
the	O
venous	O
-	O
prosthesis	O
anastomosis	O
or	O
on	O
the	O
venous	O
segment	O
5	O
cm	O
after	O
the	O
anastomosis	O
of	O
a	O
prosthetic	O
haemodialysis	O
vascular	O
access	O
(	O
at	O
least	O
1	O
month	O
old	O
)	O

social	O
security	O
affiliation	O

signed	O
informed	O
consent	O

Prior	B
treatment	O
with	O
a	O
bisphosphonate	B

Abnormal	B
renal	B
function	I
as	O
evidenced	O
by	O
a	O
calculated	B
creatinine	I
clearance	I
<	B
30	I
ml	I
/	I
minute	I
.	O

Corrected	B
(	I
adjusted	I
for	I
serum	I
albumin	I
)	I
serum	I
calcium	I
concentration	I
<	B
8	I
.	I
0	I
mg	I
/	I
dl	I
(	O
2	B
.	I
00	I
mmol	I
/	I
L	I
)	O
or	O
≥	B
12	I
.	I
0	I
mg	I
/	I
dl	I
(	O
3	B
.	I
00	I
mmol	I
/	I
L	I
)	O
.	O

Patients	O
with	O
clinically	O
symptomatic	O
brain	B
metastases	I

History	B
of	O
diseases	B
with	I
influence	I
on	I
bone	I
metabolism	I
such	O
as	O
Paget	B
'	I
s	I
disease	I
and	O
primary	B
hyperparathyroidism	I

Severe	O
physical	O
or	O
psychological	B
concomitant	I
diseases	I
that	O
might	O
impair	O
compliance	O
with	O
the	O
provisions	O
of	O
the	O
study	O
protocol	O
or	O
that	O
might	O
impair	O
the	O
assessment	O
of	O
drug	O
or	O
patient	O
safety	O
,	O
e	O
.	O
g	O
.	O
clinically	B
significant	I
ascites	B
,	O
cardiac	B
failure	I
,	O
NYHA	B
III	B
or	I
IV	I
,	O
clinically	B
relevant	I
pathologic	O
findings	O
in	O
ECG	B

Known	O
hypersensitivity	B
to	O
zoledronic	B
acid	I
or	O
other	B
bisphosphonates	I

Use	O
of	O
other	B
investigational	I
drugs	I
30	B
days	I
prior	I
to	I
the	I
date	I
of	I
randomization	I

Known	O
history	B
or	O
present	B
abuse	B
of	I
alcohol	I
or	O
drugs	O

Subjects	O
who	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
are	O
unlikely	O
to	O
cooperate	O
fully	O
during	O
the	O
study	O

Current	B
active	O
dental	B
problems	I
including	O
infection	B
of	I
the	I
teeth	I
or	O
jawbone	O
(	O
maxilla	O
or	O
mandibular	O
)	O
;	O
dental	O
or	O
fixture	B
trauma	I
,	O
or	O
a	O
current	B
or	O
prior	B
diagnosis	O
of	O
osteonecrosis	B
of	I
the	I
jaw	I
(	I
ONJ	I
)	I
,	O
of	O
exposed	B
bone	I
in	I
the	I
mouth	I
,	O
or	O
of	O
slow	B
healing	I
after	I
dental	I
procedures	I
.	O

Recent	B
(	O
within	B
6	I
weeks	I
)	O
or	O
planned	O
dental	O
or	O
jaw	B
surgery	I
(	O
e	O
.	O
g	O
.	O
extraction	B
,	O
implants	B
)	O

Other	O
protocol	O
defined	O
inclusion	O
/	O
exclusion	O
criteria	O
may	O
apply	O
.	O

Patients	O
with	O
histologically	B
confirmed	B
diagnosis	O
of	O
prostate	B
cancer	I
who	O
have	O
not	O
yet	O
developed	O
bone	B
metastases	I

Prostate	B
cancer	I
patients	O
with	O
a	O
rise	B
in	O
PSA	B
under	O
hormone	B
therapy	I
.	O

PSA	O
criteria	O
:	O

Patients	O
who	O
have	O
undergone	O
prostatectomy	B
:	O
any	O
rise	B
in	O
PSA	B
or	O

Patients	O
without	B
prostatectomy	B
:	O
2	B
consecutive	B
rises	B
in	O
PSA	B
levels	I
relative	O
to	O
a	O
previous	O
reference	O
value	O
,	O
separated	B
by	I
one	I
month	I
.	O

The	O
first	B
measurement	B
must	O
occur	O
one	B
month	I
after	I
the	I
reference	I
value	I
and	O
must	O
be	O
above	B
the	I
reference	I
value	I
.	O

The	O
second	B
confirmatory	O
measurement	B
taken	O
one	B
month	I
after	I
the	I
first	I
measurement	I
must	O
be	O
greater	B
than	I
the	I
first	I
measurement	I
.	O

Previous	B
chemotherapy	B
or	O
radiotherapy	B
must	O
have	O
been	O
performed	O
≥	B
8	I
weeks	I
prior	I
to	I
study	I
entry	I
.	O

Eastern	B
Cooperative	I
Oncology	I
Group	I
(	I
ECOG	I
)	I
score	I
of	O
0	B
,	I
1	I
or	I
2	I
(	O
patients	O
that	O
spend	O
less	B
than	I
50	I
%	I
of	O
time	O
in	O
bed	O
during	O
the	O
day	O
)	O

Adequate	B
liver	B
function	I
-	O
serum	B
total	I
bilirubin	I
concentration	I
less	B
than	I
1	I
.	I
5	I
x	I
upper	I
limit	I
of	I
normal	I
value	I

Age	B
:	O
≥	B
18	I
years	I

Patient	O
has	O
given	O
written	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
-	O
specific	O
procedures	O
.	O

Patients	O
with	O
psychiatric	O
or	O
addictive	B
disorders	I
which	O
prevent	B
them	O
from	O
giving	O
their	O
informed	O
consent	O
must	O
not	O
enter	O
the	O
study	O
.	O

use	O
more	B
than	I
2g	I
a	I
day	I
;	O
5	B
times	I
a	I
week	I
to	I
everyday	I

Subjects	O
who	O
are	O
diagnosed	O
as	O
suffering	O
from	O
psychotic	B
illness	I
according	O
to	O
DSM	B
-	I
IV	I
(	O
Axis	B
1	I
)	O
22	O
,	O
or	O
with	O
a	O
history	B
of	O
CNS	B
disease	I
,	O
a	O
history	B
of	O
infection	B
that	O
might	O
affect	B
CNS	I
(	O
HIV	B
,	O
syphilis	B
,	O
cytomegalovirus	B
,	O
herpes	B
)	O
,	O
or	O
a	O
history	B
of	O
head	B
injury	I
with	O
loss	B
of	I
consciousness	I
,	O
pregnant	B
women	O
.	O

Methadone	B
-	O
maintained	O
cocaine	B
-	I
dependent	I
patients	O
use	O
between	O
1g	B
to	I
2g	I
a	I
day	I
;	O
1	B
to	I
3	I
times	I
a	I
week	I

Administration	O
of	O
the	O
licensed	O
MF59	B
-	I
containing	I
vaccines	I
,	O
e	O
.	O
g	O
.	O
Fluad	B
™	O
or	O
Addigrip	B
™	O
or	O
virosome	B
-	I
based	I
influenza	I
vaccines	I
such	O
as	O
Inflexal	B
V	I
™	O
,	O
InfectoVac	B
Flu	I
™	O
or	O
Invivac	B
™	O
during	B
the	I
2006	I
-	I
2007	I
influenza	I
season	I
.	O

Administration	O
of	O
licensed	B
vaccines	I
within	O
2	O
weeks	O
(	O
for	O
inactivated	B
vaccines	I
)	O
or	O
4	O
weeks	O
(	O
for	O
live	B
vaccines	I
)	O
prior	O
to	O
enrolment	O
in	O
this	O
study	O
.	O

Planned	O
administration	O
of	O
a	O
vaccine	B
not	B
foreseen	B
by	I
the	I
study	I
protocol	I
up	B
to	I
30	I
days	I
after	O
the	O
second	B
vaccination	B
with	O
H5N1	B
vaccine	I
.	O

Chronic	B
administration	O
(	O
defined	O
as	O
more	B
than	I
14	I
days	I
)	O
of	O
immunosuppressants	B
or	O
other	B
immune	I
-	I
modifying	I
drugs	I
within	B
six	I
months	I
prior	I
to	O
the	O
first	O
administration	O
of	O
the	O
study	O
vaccine	O
.	O

Any	O
confirmed	B
or	O
suspected	B
immunosuppressive	O
or	O
immunodeficient	B
condition	I
,	O
based	O
on	O
medical	O
history	O
and	O
physical	O
examination	O
(	O
no	O
laboratory	O
testing	O
required	O
)	O
.	O

History	B
of	O
chronic	B
alcohol	I
consumption	I
and	O
/	O
or	O
drug	B
abuse	I
.	O

History	B
of	O
hypersensitivity	B
to	I
vaccines	I
.	O

History	B
of	O
allergic	B
disease	I
or	O
reactions	O
likely	O
to	O
be	O
exacerbated	O
by	O
any	O
component	O
of	O
the	O
vaccine	O
(	O
including	O
egg	O
and	O
thiomersal	B
allergy	I
)	O
.	O

Acute	O
clinically	O
significant	O
pulmonary	O
,	O
cardiovascular	O
,	O
hepatic	O
or	O
renal	B
functional	I
abnormality	I
,	O
as	O
determined	O
by	O
physical	O
examination	O
or	O
laboratory	O
screening	O
tests	O
.	O

Acute	B
disease	I
at	B
the	I
time	I
of	I
enrolment	I
.	O

Serious	B
chronic	B
disease	I
including	O
any	O
medically	O
significant	O
chronic	B
pulmonary	I
,	I
cardiovascular	I
,	I
renal	I
,	I
neurological	I
,	I
psychiatric	I
or	I
metabolic	I
disorder	I
,	O
as	O
determined	O
by	O
medical	O
history	O
and	O
physical	O
examination	O
.	O

Administration	O
of	O
immunoglobulins	B
and	O
/	O
or	O
any	B
blood	I
products	I
within	O
the	O
three	O
months	O
preceding	O
the	O
first	B
vaccination	B
or	O
during	B
the	I
study	I
.	O

Use	O
of	O
any	O
investigational	B
or	O
non	B
-	I
registered	I
product	B
(	O
drug	B
or	O
vaccine	B
)	O
other	B
than	I
the	O
study	B
vaccine	I
(	I
s	I
)	I
within	O
30	O
days	O
prior	O
to	O
the	O
first	B
vaccination	B
,	O
or	O
planned	O
use	B
during	B
the	I
study	I
period	I
.	O

Any	O
condition	B
which	B
,	I
in	I
the	I
opinion	I
of	I
the	I
investigator	I
,	I
prevents	I
the	I
subject	I
from	I
participation	I
in	I
the	I
study	I
.	O

Subjects	O
who	O
the	O
investigator	O
believes	O
that	O
they	O
can	O
and	O
will	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
should	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

A	O
male	B
or	O
female	B
aged	B
61	B
years	I
or	I
above	I
at	O
the	O
time	O
of	O
the	O
first	O
vaccination	O
.	O

Written	O
informed	O
consent	O
obtained	O
from	O
the	O
subject	O
.	O

Healthy	B
subjects	O
or	O
subjects	O
with	O
well	B
controlled	I
underlying	B
disease	I
.	O

History	B
of	O
a	O
seizure	B
disorder	I
other	B
than	I
a	O
single	B
childhood	B
febrile	I
seizure	I
.	O

History	B
or	O
presence	O
of	O
clinically	B
important	I
hepatic	I
or	I
renal	I
disease	I
or	O
other	O
medical	O
disease	O
.	O

Presence	O
or	O
recent	O
history	B
of	O
major	B
depressive	I
disorder	I
,	O
bipolar	B
disorder	I
,	O
psychotic	B
disorder	I
,	O
or	O
generalized	B
anxiety	I
disorder	I
requiring	B
therapy	I
.	O

Generally	O
healthy	B
,	O
postmenopausal	B
woman	B
who	O
seeks	O
treatment	O
for	O
hot	B
flushes	I
.	O

Meets	B
1	I
of	I
the	I
following	I
:	O
At	B
least	I
12	I
months	I
of	O
spontaneous	B
amenorrhea	I
;	O
At	B
least	I
6	I
months	I
of	O
spontaneous	B
amenorrhea	I
with	O
serum	B
follicle	I
-	I
stimulating	I
hormone	I
(	I
FSH	I
)	I
levels	I
>	B
40	I
mIU	I
/	I
mL	I
;	O
At	B
least	I
6	I
weeks	I
postsurgical	I
bilateral	B
oophorectomy	I
(	O
with	O
or	O
without	O
hysterectomy	O
)	O
.	O

Hysterectomized	B
without	B
bilateral	B
oophorectomy	I
and	O
with	O
serum	B
FSH	I
levels	I
>	B
40	I
mIU	I
/	I
mL	I
.	O

Diagnosis	O
of	O
brainstem	B
glioma	I

Concurrent	B
administration	O
of	O
any	B
other	I
anti	B
-	I
tumor	I
therapy	I

Pre	O
-	O
existing	O
uncontrolled	B
diarrhea	I

Cohort	O
1	O
:	O
Recurrent	O
or	O
refractory	B
medulloblastoma	I
in	O
which	O
current	O
standard	B
treatment	I
approaches	O
have	O
failed	B
;	O
biopsy	O
is	O
not	O
required	O
for	O
recurrent	O
disease	O
.	O

Cohort	O
2	O
:	O
Newly	O
-	O
diagnosed	O
high	B
-	I
grade	I
glioma	I
(	O
World	B
Health	I
Organization	I
[	I
WHO	I
]	I
grade	I
3	B
or	I
4	I
)	O

Life	B
expectancy	I
≥	B
3	I
months	I

Patients	O
will	O
be	O
excluded	O
if	O
they	O
have	O
known	O
middle	B
ear	I
disease	I
,	O
chronic	B
lung	I
disease	I
or	O
claustrophobia	B

The	O
study	O
will	O
include	O
40	O
post	O
-	O
deep	B
peel	I
women	B
(	O
exoderm	B
)	O
,	O
older	B
than	I
18	I
years	I
old	B
,	O
treated	O
by	O
the	O
same	O
dermatologist	O
(	O
dr	O
.	O
Landau	O
)	O
.	O

The	O
treatment	O
group	O
will	O
receive	O
5	O
consecutive	O
daily	O
hyperbaric	O
treatments	O
,	O
1	O
hours	O
long	O
each	O
,	O
at	O
2	O
ATF	O
,	O
starting	O
from	O
day	O
7	O
to	O
peel	O
.	O

Prior	O
to	O
treatment	O
,	O
each	O
patient	O
will	O
be	O
signed	O
on	O
informed	O
consent	O
and	O
will	O
have	O
complete	O
physical	O
examination	O
.	O

The	O
control	O
group	O
will	O
be	O
matched	O
by	O
the	O
following	O
parameters	O
:	O
age	B
,	O
skin	B
color	I
and	O
type	B
,	O
and	O
indication	O
for	O
peeling	O
,	O
and	O
will	O
be	O
picked	O
up	O
by	O
the	O
dermatologist	O
.	O

Subjects	O
not	B
able	O
to	O
give	O
informed	O
consent	O

Left	B
Bundle	I
Branch	I
Block	I

Thrombolytic	B
therapy	I
within	B
24	I
hours	I
before	I
randomization	I

Oral	B
anticoagulation	I
with	O
International	B
Normalized	I
Ratio	I
(	I
INR	I
)	I
>	B
2	I

Known	O
platelets	B
<	B
100	I
.	I
000	I
/	I
µl	I
or	O
known	O
hemorrhagic	B
diathesis	I

Stroke	B
or	O
Transient	B
Ischemic	I
Attack	I
(	I
TIA	I
)	I
within	B
the	I
past	I
6	I
months	I
or	O
any	O
permanent	O
residual	B
neurological	I
defect	I

Evidence	O
of	O
an	O
active	B
gastrointestinal	O
or	O
urogenital	B
bleeding	I

Major	B
surgery	I
within	B
6	I
weeks	I

History	B
of	O
allergic	B
reaction	I
to	O
abciximab	B
or	O
eptifibatide	B
or	O
any	O
component	B
used	I
in	I
the	I
study	I
(	O
including	O
contrast	B
media	I
)	O

Known	O
severe	B
renal	O
(	O
creatinine	B
clearance	I
<	B
30ml	I
/	I
min	I
)	O
or	O
hepatic	B
insufficiency	I
as	O
well	O
as	O
Alanine	B
transaminase	I
(	I
ALT	I
)	I
/	O
aspartate	B
transaminase	I
(	I
AST	I
)	I
elevations	B
=	O
3xUpper	B
limit	I
normal	I
(	I
ULN	I
)	I
;	O
isolated	O
AST	O
-	O
elevation	O
is	O
not	O
considered	O
an	O
exclusion	O
criteria	O
from	O
study	O
participation	O

Severe	O
concomitant	B
disease	O
with	O
life	B
expectation	I
<	B
1	I
year	I

Subject	O
has	O
participated	O
in	O
any	O
study	O
using	O
an	O
investigational	B
drug	I
or	O
device	B
within	O
30	O
days	O
or	O
within	B
5	I
half	I
-	I
lives	I
of	I
the	I
investigational	I
drug	I
(	O
whichever	O
is	O
longer	O
)	O
of	O
entry	O
into	O
this	O
study	O
.	O

Subjects	O
who	O
will	O
be	O
inaccessible	O
due	O
to	O
geographic	O
or	O
social	O
factors	O
during	B
treatment	I
or	I
follow	I
-	I
up	I

In	O
France	O
,	O
a	O
subject	O
is	O
neither	O
affiliated	O
with	O
nor	O
a	O
beneficiary	O
of	O
a	O
social	O
security	O
category	O
.	O

Women	B
must	O
be	O
postmenopausal	B
(	O
i	O
.	O
e	O
.	O
12	B
months	I
without	B
menstrual	B
period	I
)	O
,	O
or	O
surgically	B
sterile	I
,	O
i	O
.	O
e	O
.	O
women	B
of	O
child	B
bearing	I
potential	I
are	O
not	B
allowed	O
to	O
be	O
included	O
into	O
the	O
study	O
.	O

In	O
cases	O
of	O
doubt	B
a	O
pregnancy	B
test	I
should	O
be	O
performed	O
.	O

(	O
NB	O
-	O
post	O
menopausal	O
women	O
currently	O
receiving	O
hormone	O
replacement	O
are	O
permissible	O
)	O

Acute	B
myocardial	I
infarction	I
<	B
12	I
h	I
defined	O
as	O
:	O

1	O
.	O

Angina	B
or	O
equivalent	O
symptoms	O
>	B
20	I
min	I
and	O

2	O
.	O

ST	B
elevation	I
in	O
2	B
contiguous	B
ECG	I
leads	I
(	O
=	O
2	B
mm	I
precordial	B
lead	I
,	O
=	O
1	B
mm	I
limb	B
lead	I
)	O
.	O

This	O
ECG	O
recording	O
serves	O
as	O
baseline	O
ECG	O
,	O
i	O
.	O
e	O
.	O
ECG	O
I	O
.	O

Planned	O
primary	B
percutaneous	I
coronary	I
intervention	I

The	O
subject	O
has	O
given	O
written	O
informed	O
,	O
dated	O
consent	O
to	O
participate	O
in	O
the	O
study	O

asthma	B
and	O
COPD	B

asthma	B
or	O
COPD	B

Pregnant	B
or	O
lactating	B
women	B
.	O

Evolutive	B
skin	I
disease	I
on	O
the	O
testing	B
zone	I
(	O
lower	B
back	I
)	O
.	O

Patients	O
with	O
a	O
clinically	B
significant	I
disease	B
(	O
chronic	B
,	O
recurrent	B
or	O
active	B
)	O
.	O

Systemic	B
corticotherapy	I
or	O
immunosuppressive	B
treatment	I
during	B
the	I
previous	I
month	I
,	O
or	O
local	B
corticoid	I
treatment	I
the	B
week	I
before	I
the	O
patch	O
testing	O
.	O

Local	B
or	O
systemic	B
drug	B
use	O
which	O
interacts	B
with	I
the	I
outcome	I
measures	I
.	O

Exposure	B
to	I
sun	I
or	O
UV	O
radiations	O
,	O
15	B
days	I
before	I
the	I
patch	I
testing	I
.	O

Patients	O
deprived	B
of	I
their	I
civic	I
rights	I
,	O
in	B
custody	I
,	O
or	O
subject	B
to	I
a	I
tutorial	I
,	O
judiciary	O
or	O
administrative	O
decision	O
.	O

Patients	O
subject	B
to	I
a	I
protection	I
measure	I
.	O

Patients	O
in	O
a	O
critical	B
medical	I
situation	I
.	O

Patients	O
with	O
a	O
personal	O
situation	O
judged	O
by	O
the	O
investigator	O
as	O
unlikely	O
to	O
be	O
compatible	O
with	O
optimal	O
participation	O
in	O
the	O
study	O
,	O
or	O
which	O
could	O
constitute	O
a	O
risk	O
for	O
the	O
patient	O
.	O

Linguistic	O
barrier	O
or	O
psychological	B
profile	I
preventing	B
the	O
patient	O
from	O
signing	O
the	O
consent	O
form	O
.	O

Patient	O
still	B
in	I
an	I
exclusion	I
period	I
following	I
the	O
participation	O
in	O
another	O
clinical	O
trial	O
.	O

Patients	O
having	O
earned	O
more	O
than	O
4500	O
€	O
in	O
indemnities	O
for	O
participation	O
in	O
clinical	O
trials	O
during	B
the	I
previous	I
12	I
months	I
,	O
including	O
this	O
study	O
.	O

For	O
both	O
groups	O
:	O

Patients	O
aged	B
from	B
18	I
to	I
65	I
years	I
old	I
.	O

Both	B
genders	I
eligible	O
for	O
study	O
.	O

Female	B
participants	O
must	O
use	O
a	O
contraceptive	B
method	I
.	O

Feasibility	O
of	O
patch	O
testing	O
.	O

Participants	O
must	O
be	O
able	O
to	O
understand	O
and	O
sign	O
the	O
Informed	O
Consent	O
,	O
and	O
comply	O
with	O
all	O
aspects	O
of	O
the	O
protocol	O
.	O

Patients	O
must	O
be	O
registered	O
in	O
a	O
social	O
security	O
system	O
or	O
with	O
a	O
health	O
insurance	O
coverage	O

	O
First	O
group	O
:	O
allergic	B
patients	O

Patients	O
with	O
allergic	B
contact	I
dermatitis	I
to	O
para	B
-	I
phenylenediamine	I
(	I
PPD	I
)	I
based	O
on	O
a	O
history	O
of	O
PPD	B
contact	B
dermatitis	I
and	O
positive	B
PPD	B
patch	I
tests	I
.	O

	O
Second	O
group	O
:	O
healthy	O
volunteers	O

No	B
history	O
of	O
PPD	B
allergic	B
contact	I
dermatitis	I
,	O
with	O
a	O
negative	B
PPD	B
patch	I
test	I
.	O

History	B
of	O
significant	O
head	B
trauma	I
,	O
seizure	B
disorder	I
,	O
or	O
mental	B
retardation	I

History	B
of	O
alcohol	O
or	O
drug	B
abuse	I
or	O
dependence	O
within	B
1	I
month	I
prior	I
to	O
study	O
entry	O

History	B
of	O
violence	O
within	B
6	I
months	I
prior	I
to	O
study	O
entry	O

Diagnosis	O
of	O
schizophrenia	B
or	O
schizoaffective	B
disorder	I

If	O
entering	O
the	O
study	O
as	O
an	O
inpatient	O
,	O
hospitalization	O
was	O
recent	B

Currently	B
receiving	O
treatment	B
with	O
an	O
atypical	B
antipsychotic	I
and	O
continuation	B
on	I
the	I
medication	I
has	O
been	O
recommended	O

Assumes	O
primary	O
responsibility	O
for	O
taking	O
medication	O

Currently	O
living	O
in	O
a	O
stable	O
environment	O

Severe	B
Hypertension	I
Grade	O
3	B
WHO	O
classification	O
(	O
Mean	B
Sitting	I
Diastolic	I
Blood	I
Pressure	I
(	I
MSDBP	I
)	I
110	B
mmHg	I
and	O
/	O
or	O
Mean	B
Sitting	I
Systolic	I
Blood	I
Pressure	I
MSSBP	I
180	B
mmHg	I
)	O

Acetylsalicyclic	B
acid	I
(	I
ASA	I
)	I
treatment	I
>	B
1g	I
/	I
day	I
or	O
regular	O
use	O
of	O
Non	B
steroidal	I
anti	I
-	I
inflammatory	I
drug	I
(	I
NSAIDs	I
)	I

Kidney	B
disease	I
not	O
caused	O
by	O
diabetes	B
or	O
hypertension	B

Serum	B
potassium	I
<	B
3	I
.	I
5	I
or	O
>	B
5	I
.	I
1	I
mEq	I
/	I
L	I

GFR	B
<	B
40	I
ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I
as	O
measured	O
by	O
the	O
MDRD	B
formula	I

Serum	B
albumin	I
<	B
2	I
.	I
0mg	I
/	I
dL	I

History	B
of	O
hypertensive	B
encephalopathy	I
or	O
cerebrovascular	B
accident	I
at	O
any	B
time	I
prior	I
to	O
Visit1	O
.	O

Current	O
diagnosis	O
of	O
heart	B
failure	I
(	O
New	B
York	I
Heart	I
Association	I
(	I
NYHA	I
)	I
Class	I
II	B
-	I
IV	I
)	O

History	B
of	O
myocardial	B
infarction	I
,	O
unstable	B
angina	I
pectoris	I
,	O
coronary	B
bypass	I
surgery	I
,	O
or	O
any	O
percutaneous	B
coronary	I
intervention	I
(	I
PCI	I
)	I
during	B
the	I
6	I
months	I
prior	I
to	O
Visit	O
1	O

Second	O
or	O
third	B
degree	I
heart	I
block	I
without	B
a	O
pacemaker	B

Concurrent	O
potentially	B
life	I
threatening	I
arrhythmia	B
or	O
symptomatic	B
arrhythmia	B

Clinically	O
significant	O
valvular	B
heart	I
disease	I

Type	B
1	I
diabetes	I
mellitus	I

Uncontrolled	B
Type	B
II	I
diabetes	I
mellitus	I
(	O
Hemaglobin	B
subtype	I
A1C	I
(	I
HbA1C	I
)	I
>	B
11	I
%	I
)	O

History	O
of	O
malignancy	B
including	O
leukemia	B
and	O
lymphoma	B
(	O
but	O
not	O
basal	B
cell	I
skin	I
carcinoma	I
)	O
within	B
the	I
past	I
five	I
years	I

Participation	O
in	O
any	O
clinical	O
investigation	O
within	B
4	I
weeks	I
prior	I
to	I
dosing	I
or	O
longer	O
if	O
required	O
by	O
local	O
regulation	O
.	O

Donation	O
or	O
loss	O
of	O
400	B
mL	I
or	I
more	I
of	O
blood	O
within	B
8	I
weeks	I
prior	I
to	O
dosing	O
.	O

Significant	B
illness	I
within	B
the	I
two	I
weeks	I
prior	I
to	O
dosing	O
.	O

Any	O
surgical	O
or	O
medical	B
condition	I
which	O
might	O
significantly	O
alter	B
the	I
absorption	I
,	I
distribution	I
,	I
metabolism	I
,	I
or	I
excretion	I
of	I
study	I
drugs	I
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
any	O
of	O
the	O
following	O
:	O

History	B
of	O
major	B
gastrointestinal	I
tract	I
surgery	I
such	O
as	O
gastrectomy	B
,	O
gastroenterostomy	B
,	O
or	O
bowel	B
resection	I

-	O
Currently	B
active	I
or	O
previously	B
active	I
inflammatory	B
bowel	I
disease	I
during	B
the	I
12	I
months	I
prior	I
to	O
Visit	O
1	O
Currently	B
active	I
gastritis	B
,	O
duodenal	B
or	O
gastric	B
ulcers	I
,	O
or	O
gastrointestinal	O
/	O
rectal	B
bleeding	I
during	B
the	I
3	I
months	I
prior	I
to	O
Visit	O
1	O
.	O

Any	O
history	B
of	O
pancreatic	B
injury	I
,	O
pancreatitis	B
or	O
evidence	O
of	O
impaired	B
pancreatic	B
function	I
/	O
injury	O
as	O
indicated	O
by	O
abnormal	B
lipase	B
or	O
amylase	B
Evidence	O
of	O
hepatic	B
disease	I
,	O
a	O
history	B
of	O
hepatic	B
encephalopathy	I
,	O
a	O
history	B
of	O
esophageal	B
varices	I
,	O
or	O
a	O
history	B
of	O
portocaval	B
shunt	I

Current	B
treatment	O
with	O
cholestyramine	B
or	O
cholestipol	B
resins	I

History	B
of	O
immunocompromise	B
,	O
including	O
a	O
positive	B
HIV	B
test	I
result	O
.	O

History	B
of	O
a	O
positive	B
Hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
or	O
Hepatitis	B
C	I
test	I
result	O
.	O

History	B
of	O
drug	O
or	O
alcohol	B
abuse	I
within	B
the	I
12	I
months	I
prior	I
to	O
dosing	O
.	O

Persons	O
directly	O
involved	O
in	O
the	O
execution	O
of	O
this	O
protocol	O
.	O

Any	O
condition	B
that	B
in	I
the	I
opinion	I
of	I
the	I
investigator	I
or	I
the	I
Novartis	I
medical	I
monitor	I
would	I
jeopardize	I
the	I
evaluation	I
of	I
efficacy	I
or	O
safety	O

History	B
of	I
noncompliance	O
to	O
medical	O
regimens	O
or	O
unwillingness	O
to	O
comply	O
with	O
the	O
study	O
protocol	O

Known	O
or	O
suspected	O
contraindications	B
to	O
the	O
study	B
medications	I
,	O
including	O
history	B
of	I
allergy	B
to	O
Angiotensin	B
converting	I
enzyme	I
(	I
ACE	I
)	I
inhibitors	I
and	O
/	O
or	O
to	O
thiazide	B
diuretics	I
or	O
other	B
sulfonamide	B
derived	I
drug	I

Any	O
surgical	O
or	O
medical	B
condition	I
,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
may	O
place	B
the	I
patient	I
at	I
higher	I
risk	I
from	I
his	I
/	I
her	I
participation	I
in	I
the	I
study	I
,	O
or	O
is	O
likely	O
to	O
prevent	B
the	O
patient	O
from	O
complying	O
with	O
the	O
requirements	O
of	O
the	O
study	O
or	O
completing	O
the	O
study	O

Use	O
of	O
any	O
prescription	B
drug	I
or	O
over	B
-	I
the	I
-	I
counter	I
(	I
OTC	I
)	I
medication	I
which	O
is	O
prohibited	B
by	I
the	I
protocol	I
.	O

Patients	O
who	O
previously	B
participated	O
in	O
any	O
Aliskiren	B
study	O
.	O

Pregnant	B
or	O
nursing	B
woman	B
.	O

Other	B
protocol	B
-	I
defined	I
inclusion	O
/	O
exclusion	O
criteria	O
may	O
apply	O

Male	O
and	O
/	O
or	O
female	O
patients	O
from	O
30	B
-	I
80	I
years	I
of	B
age	I
with	O
a	O
diagnosis	O
of	O
Type	B
2	I
diabetes	I
(	O
WHO	O
criteria	O
)	O
.	O

Incipient	O
and	O
established	O
diabetic	B
nephropathy	I
(	O
urinary	B
albumin	I
excretion	I
≥	B
100	I
mg	I
/	I
day	I
but	O
≤	B
2000	I
mg	I
/	I
day	I
)	O
.	O

Glomerular	B
filtration	I
rate	I
(	I
GFR	I
)	I
≥	B
40	I
ml	I
/	I
min	I
(	O
estimated	O
using	O
Modification	B
of	I
Diet	I
in	I
Renal	I
Disease	I
(	I
MDRD	I
)	I
formula	I
)	O
in	B
the	I
last	I
4	I
months	I
.	O

Female	B
patients	O
must	O
be	O
postmenopausal	B
or	O
must	O
have	O
had	O
a	O
bilateral	B
oophorectomy	I
or	O
must	O
have	O
been	O
surgically	B
sterilized	I
or	O
hysterectomized	B
at	B
least	I
6	I
months	I
prior	I
to	I
screening	I
.	O

To	O
be	O
eligible	O
patients	O
must	O
fulfill	O
the	O
following	O
criteria	O
:	O
Patients	O
on	O
ongoing	O
hypertensive	B
therapy	I
must	O
have	O
a	O
blood	B
pressure	I
≥	B
135	I
/	I
85	I
mm	I
Hg	I
but	O
lower	B
than	I
170	I
/	I
105	I
mm	I
Hg	I
at	O
baseline	O
(	O
Day	O
-	O
1	O
)	O
AND	O
patients	O
must	O
be	O
on	O
stable	B
antihypertensive	B
medications	I
for	O
at	B
least	I
8	I
weeks	I
prior	I
to	I
baseline	I
(	O
Day	O
-	O
1	O
)	O
.	O
;	O
Newly	B
diagnosed	I
hypertensive	B
patients	I
must	O
have	O
a	O
blood	B
pressure	I
≥	B
135	I
/	I
85	I
mm	I
Hg	I
but	O
lower	B
than	I
170	I
/	I
105	I
mm	I
Hg	I
at	B
baseline	I
(	I
Day	I
-	I
1	I
)	I
.	O

Patients	O
must	O
be	O
on	O
stable	B
hypoglycemic	B
medications	I
for	O
at	B
least	I
8	I
weeks	I
prior	I
to	I
Visit	I
2	I
(	O
Day	O
-	O
1	O
)	O
.	O

Patients	O
must	O
be	O
willing	O
and	O
medically	O
able	O
to	O
discontinue	O
all	O
Angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
(	O
ACEI	O
)	O
,	O
Angiotensin	O
receptor	O
blocker	O
(	O
ARB	O
)	O
,	O
aldosterone	O
receptor	O
antagonist	O
and	O
potassium	O
sparing	O
diuretic	O
medications	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Oral	B
body	I
temperature	I
within	O
the	O
range	O
35	B
.	I
0	I
-	I
37	I
.	I
5	I
°	I
C	I

Able	O
to	O
provide	O
written	O
informed	O
consent	O
prior	B
to	I
study	I
participation	I
.	O

.	O

Able	O
to	O
communicate	O
well	O
with	O
the	O
investigator	O
and	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
study	O
.	O

Ongoing	O
allergen	B
immunotherapy	I

upper	B
respiratory	I
tract	I
infection	I

Pregnancy	B

Clinical	O
history	O
of	O
lactose	B
-	I
intolerance	I
or	O
allergies	B
to	I
cow	I
-	I
milk	I

Clinical	O
diagnosis	O
of	O
allergic	B
rhinitis	I
based	O
on	O
sneeze	B
attacks	I
,	O
runny	O
/	O
blocked	O
/	O
itchy	B
nose	I
in	O
the	O
absence	B
of	O
a	O
common	B
cold	I
during	B
the	I
previous	I
12	I
months	I
.	O

History	O
of	O
positive	B
skin	B
prick	I
test	I
or	O
blood	B
radio	I
-	I
allergosorbent	I
test	I
(	I
RAST	I
)	I
to	O
grass	B
and	O
/	O
or	O
ragweed	B
pollen	I

Psychosis	B

Tourette	B
syndrome	I

Intelligence	B
quotient	I
(	O
IQ	B
)	O
<	B
70	I

Pervasive	B
developmental	I
disorder	I
(	O
PDD	B
)	O

ADHD	B

patient	O
already	O
treated	O
by	O
medicines	O
which	O
could	O
interfere	O
with	O
the	O
study	O

low	B
level	B
of	I
vitamin	I
B12	I
and	O
folate	O
which	O
are	O
considered	O
as	O
clinically	O
relevant	O

clinically	O
relevant	O
pathologies	O
(	O
eg	O
:	O
pulmonary	B
illness	I
,	O
cardiovascular	B
illness	I
;	O
evolutive	B
cancer	I
,	O
neurological	B
illness	I
,	O
blood	B
illness	I
…	O
.	O
)	O

female	O
or	O
male	O
of	O
50	B
to	I
85	I
years	I
old	B
with	O
a	O
care	O
giver	O

Mini	B
Mental	I
Status	I
(	I
MMS	I
)	I
test	I
between	B
16	I
to	I
26	I
inclusive	I

Clinical	B
Dementia	I
Rating	I
(	I
CDR	I
)	I
test	I
inferior	B
or	I
equal	I
to	I
1	I

National	B
Institute	I
of	I
Neurological	I
and	I
Communicative	I
Disorders	I
and	I
Stroke	I
/	I
Alzheimer	I
'	I
s	I
Disease	I
and	I
Related	I
Disorders	I
Association	I
(	I
NINCDS	I
/	I
ADRDA	I
)	I
test	I
positive	B
for	O
an	O
Alzheimer	O
'	O
s	O
disease	O

Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
4th	I
Edition	I
(	I
DSM	I
IV	I
)	I
test	I
positive	B
for	O
dementia	O

Inadequate	B
bone	I
marrow	I
reserve	I

history	B
of	O
poorly	B
controlled	I
hypertension	I

histologically	B
confirmed	B
metastatic	B
cancer	I
that	O
is	O
not	B
amenable	I
to	O
surgery	B
or	O
radiation	B
therapy	I
with	O
curative	O
intent	O

measurable	B
lesion	I
by	O
CT	B
or	O
other	O
techniques	O
according	O
to	O
RECIST	O

Known	O
other	O
respiratory	B
disorders	I
or	O
signs	B
for	I
other	I
respiratory	I
disorders	I
(	O
e	O
.	O
g	O
.	O
asthma	B
,	O
lung	B
cancer	I
,	O
sarcoidosis	B
,	O
tuberculosis	B
,	O
lung	B
fibrosis	I
,	O
cystic	B
fibrosis	I
,	O
bronchoectasis	B
)	O
.	O

Known	O
history	O
of	O
significant	B
inflammatory	B
disease	I
,	O
other	B
than	I
COPD	B
(	O
e	O
.	O
g	O
.	O
rheumatoid	B
arthritis	I
and	O
systemic	B
lupus	I
erythematosus	I
)	O
.	O

Known	O
to	O
be	O
severely	B
alpha	B
-	I
1	I
-	I
antitrypsin	I
deficient	I
(	O
PI	O
SZ	O
or	O
ZZ	O
)	O

Having	O
undergone	O
lung	B
surgery	I
(	O
e	O
.	O
g	O
.	O
lung	B
resection	I
including	O
lung	B
volume	I
reduction	I
surgery	I
,	O
lung	B
transplant	I
)	O
or	O
subjects	O
scheduled	O
for	O
surgery	B
.	O

Concurrent	O
medication	B
from	I
Visit	I
1	I
and	O
for	O
the	O
duration	O
of	O
the	O
study	O
with	O
any	O
of	O
the	O
prohibited	O
medications	O
:	O
monoamine	B
oxidase	I
inhibitors	I
and	O
tricyclic	B
antidepressants	I
,	O
and	O
ritonavir	B
(	O
a	O
highly	O
potent	O
cytochrome	B
P450	I
3A4	I
inhibitor	I
)	O
.	O

Subjects	O
receiving	O
chronic	O
or	O
prophylactic	B
antibiotic	I
therapy	I
.	O

Serious	O
,	O
uncontrolled	B
disease	I
(	O
including	O
serious	O
psychological	B
disorders	I
)	O
likely	O
to	O
interfere	O
with	O
the	O
study	O
or	O
impact	O
on	O
subject	O
safety	O
.	O

Have	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
evidence	O
of	O
alcohol	O
,	O
drug	O
or	O
solvent	B
abuse	I
.	O

History	B
of	I
depression	B
.	O

History	O
or	O
presence	O
of	O
clinically	O
significant	O
drug	B
sensitivity	I
or	O
clinically	O
significant	O
allergic	B
reaction	I
to	O
corticosteroids	B
or	O
salmeterol	B
.	O

Moderate	B
or	O
severe	B
COPD	B
exacerbation	I
(	O
requiring	O
corticosteroids	B
or	O
increased	B
dosage	I
of	O
corticosteroids	B
and	O
/	O
or	O
antibiotics	B
or	O
hospitalization	O
)	O
within	B
the	I
4	I
weeks	I
prior	I
to	I
Visit	I
1	I

Lower	B
respiratory	I
tract	I
infection	I
within	B
the	I
4	I
weeks	I
prior	I
to	I
Visit	I
1	I
.	O

Pregnant	B
or	O
lactating	B
female	B
and	O
female	B
of	O
childbearing	B
potential	I
.	O

Subject	O
is	O
a	O
participating	O
investigator	O
,	O
sub	O
-	O
investigator	O
,	O
study	O
coordinator	O
,	O
or	O
other	O
employee	O
of	O
a	O
participating	O
investigator	O
,	O
or	O
is	O
an	O
immediate	O
family	O
member	O
of	O
the	O
before	O
mentioned	O
.	O
Subject	O
is	O
an	O
employee	O
of	O
GlaxoSmithKline	O
(	O
GSK	O
)	O
.	O

Subject	O
participated	O
in	O
an	O
investigational	O
drug	O
study	O
within	B
30	I
days	I
prior	I
to	I
Visit	I
1	I

Subject	O
must	O
have	O
a	O
diagnosis	O
of	O
COPD	B
based	O
on	O
the	O
American	B
Thoracic	I
Society	I
(	I
ATS	I
)	I
/	I
European	I
Respiratory	I
Society	I
(	I
ERS	I
)	I
criteria	I
.	O

Male	B
or	O
female	B
subjects	O
,	O
aged	B
>	B
=	I
40	I
years	I
.	O

Females	B
must	O
be	O
of	O
Non	B
Child	B
Bearing	I
Potential	I
.	O

The	O
definition	O
of	O
Non	B
Child	B
Bearing	I
Potential	I
is	O
as	O
following	O
:	O
Females	B
,	O
regardless	O
of	O
their	O
age	O
,	O
with	O
functioning	B
ovaries	I
and	O
who	O
have	O
a	O
current	O
documented	O
tubal	B
ligation	I
or	O
hysterectomy	B
,	O
or	O
females	B
who	O
are	O
post	B
-	I
menopausal	I
.	O

Have	O
diagnosed	O
COPD	B
stage	B
III	I
or	I
IV	I
according	O
to	O
GOLD	B
criteria	I
:	O
a	O
baseline	O
post	B
-	I
bronchodilator	I
Forced	B
Expiratory	I
Volume	I
,	I
measured	I
at	I
1	I
second	I
(	I
FEV1	I
)	I
<	B
50	I
%	I
of	I
predicted	I
normal	I
and	O
a	O
baseline	O
post	B
-	I
bronchodilator	I
FEV1	B
/	I
Inspiratory	I
Vital	I
Capacity	I
(	I
IVC	I
)	I
ratio	I
<	B
70	I
%	I
.	O

Have	O
experienced	O
at	B
least	I
2	I
moderate	B
or	O
severe	B
COPD	B
exacerbations	I
leading	O
to	O
medical	O
consultation	O
(	O
requiring	O
oral	B
corticosteroids	I
or	O
increasing	B
dosage	I
of	O
oral	B
corticosteroids	I
and	O
/	O
or	O
antibiotics	B
or	O
hospitalization	O
)	O
within	B
the	I
12	I
months	I
preceding	I
Visit	I
1	I
.	O

Have	O
stable	B
COPD	B
medication	I
within	B
4	I
weeks	I
prior	I
to	I
Visit	I
1	I
(	O
no	O
new	O
medication	O
added	O
and	O
no	O
dosage	O
changes	O
in	O
medication	O
)	O
.	O

Current	B
or	O
ex	B
-	O
smokers	B
with	O
a	O
smoking	B
history	I
of	O
at	O
least	O
10	B
pack	I
years	I
(	O
number	O
of	O
pack	O
years	O
=	O
[	O
number	O
of	O
cigarettes	O
per	O
day	O
/	O
20	O
]	O
x	O
number	O
of	O
years	O
smoked	O
,	O
e	O
.	O
g	O
.	O
,	O
20	O
cigarettes	O
per	O
day	O
for	O
10	O
years	O
,	O
or	O
10	O
cigarettes	O
per	O
day	O
for	O
20	O
years	O
)	O
.	O

Are	O
currently	O
managed	B
at	O
home	O
(	O
outpatients	O
)	O
,	O
are	O
ambulatory	B
and	O
able	O
to	O
travel	O
to	O
the	O
clinic	O
.	O

Subjects	O
can	O
be	O
treated	O
with	O
all	O
relevant	O
COPD	B
medication	I
.	O

This	O
includes	O
vaccines	B
,	O
inhaled	B
short	I
-	I
acting	I
beta	I
-	I
2	I
-	I
agonists	I
as	O
needed	O
,	O
short	B
-	I
acting	I
or	O
long	B
-	I
acting	I
anticholinergics	I
(	O
tiotropium	B
)	O
,	O
systemic	B
beta	I
-	I
2	I
-	I
agonists	I
,	O
theophylline	B
,	O
mucolytics	B
,	O
antioxidants	B
,	O
beta	B
-	I
1	I
-	I
agonists	I
(	O
for	O
cardiovascular	B
indication	I
)	O
,	O
non	B
-	I
invasive	I
ventilation	I
,	O
long	B
term	I
oxygen	B
therapy	O
and	O
can	O
have	O
Cor	B
Pulmonale	I
.	O

A	O
signed	O
and	O
dated	O
written	O
informed	O
consent	O
is	O
obtained	O
prior	B
to	I
participation	I
.	O

Able	O
to	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
and	O
be	O
available	O
for	O
study	O
visits	O
over	B
52	I
weeks	I
.	O

Systemic	B
therapy	I
or	O
radiotherapy	B
within	B
4	I
weeks	I
prior	I
to	I
Day	I
1	I

Prior	B
therapy	B
with	O
agents	B
targeting	I
the	I
DR5	I
apoptosis	I
pathway	I

Major	B
surgical	B
procedure	I
,	O
open	B
biopsy	I
,	O
or	O
significant	B
traumatic	B
injury	I
within	B
4	I
weeks	I
prior	I
to	I
Day	I
1	I
,	O
or	O
anticipation	O
of	O
need	O
for	O
major	B
surgical	B
procedure	I
during	B
the	I
course	I
of	I
the	I
study	I

Other	B
invasive	B
malignancies	I
within	B
5	I
years	I
prior	I
to	I
Day	I
1	I

Known	O
active	B
brain	B
metastases	I

Uncontrolled	B
intercurrent	B
illness	I
,	O
including	O
but	O
not	O
limited	O
to	O
ongoing	B
or	O
active	B
infection	B
requiring	O
parenteral	B
antibiotics	I
at	B
enrollment	I

Clinically	B
significant	I
,	O
symptomatic	B
cardiovascular	B
disease	I
,	O
New	B
York	I
Heart	I
Association	I
(	I
NYHA	I
)	I
Grade	B
II	I
or	I
greater	I
congestive	B
heart	I
failure	I
,	O
serious	B
cardiac	B
arrhythmia	I
,	O
Grade	B
II	I
or	I
greater	I
peripheral	B
vascular	I
disease	I
,	O
or	O
history	B
of	I
major	B
heart	B
surgery	I
within	B
6	I
months	I
of	I
Day	I
1	I
,	O
or	O
any	O
situation	O
that	O
would	O
likely	O
limit	O
compliance	O
with	O
study	O
requirements	O

Known	O
to	O
be	O
positive	B
for	O
hepatitis	B
C	I
or	O
hepatitis	B
B	I
surface	I
antigen	I

History	B
of	O
other	B
disease	B
,	O
metabolic	B
dysfunction	I
,	O
physical	B
examination	I
finding	O
,	O
or	O
clinical	B
laboratory	I
finding	O
giving	O
reasonable	O
suspicion	O
of	O
a	O
disease	B
or	O
condition	B
that	O
contraindicates	B
use	O
of	O
an	O
investigational	B
drug	I
or	O
that	O
might	O
affect	O
interpretation	O
of	O
the	O
results	O
of	O
the	O
study	O
or	O
render	O
the	O
patient	O
at	O
high	O
risk	O
for	O
treatment	B
complications	I

Use	O
of	O
anticoagulation	B
therapy	O

Participation	O
in	O
clinical	O
trials	O
or	O
undergoing	O
other	O
investigational	O
procedures	O
within	B
30	I
days	I
prior	I
to	I
Day	I
1	I

Pregnancy	B
or	O
breast	O
feeding	O

Known	O
sensitivity	B
to	O
any	B
of	I
the	I
products	I
administered	I
during	I
the	I
study	I

Any	O
disorder	B
that	O
compromises	B
the	I
ability	I
of	I
the	O
patient	O
to	O
give	B
written	I
informed	I
consent	I
and	O
/	O
or	O
comply	B
with	I
study	I
procedures	I

Ability	O
to	O
understand	O
and	O
willingness	O
to	O
sign	O
a	O
written	O
informed	O
consent	O
document	O

Age	B
≥	B
18	I
years	I

Histologic	B
diagnosis	O
of	O
chondrosarcoma	B
,	O
verifiable	O
after	O
enrollment	O

Measurable	O
disease	O

Previously	O
treated	O
or	O
incurable	O
disease	O
without	O
options	O
for	O
standard	O
of	O
care	O
therapy	O

ECOG	B
performance	I
status	I
of	O
0	B
-	I
2	I

Life	O
expectancy	O
of	O
>	B
3	I
months	I

For	O
patients	O
of	O
reproductive	B
potential	I
(	O
males	O
and	O
females	O
)	O
,	O
use	O
of	O
reliable	O
means	O
for	O
contraception	B
(	O
e	O
.	O
g	O
.	O
,	O
contraceptive	B
pill	I
,	O
intrauterine	B
device	I
[	I
IUD	I
]	I
,	O
physical	B
barrier	I
)	O
throughout	B
the	I
trial	I
and	O
for	B
1	I
year	I
following	I
their	I
final	I
exposure	I
to	O
study	O
treatment	O

Patients	O
who	O
have	O
taken	O
either	O
morphine	B
with	O
daily	B
dose	I
more	I
than	I
120mg	I
or	O
Fentanyl	B
with	O
daily	B
dose	I
more	I
than	I
50ug	I
/	I
hr	I

Patients	O
with	O
significant	O
abnormalities	B
in	I
hepatic	I
or	I
renal	I
function	I
which	O
would	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
prevent	O
the	O
patients	O
involvement	O
in	O
the	O
study	O

Patients	O
with	O
significant	O
clinical	O
abnormalities	B
in	I
CNS	I
,	O
respiratory	O
or	O
cardiovascular	O
function	O
,	O
which	O
in	O
the	O
investigators	O
judgement	O
prevents	O
participation	O
in	O
the	O
study	O

Patients	O
who	O
have	O
taken	O
antidepressants	B
or	O
anti	B
-	I
epileptic	I
drugs	I
,	O
sedative	B
hypnotics	I
,	O
selective	B
serotonin	I
reuptake	I
inhibitor	I
,	O
short	B
-	I
acting	I
analgesics	I
,	O
topical	B
medications	I
and	O
anesthetics	B
and	O
/	O
or	O
muscle	B
relaxants	I
when	O
taking	O
Tramadol	B
/	O
Acetaminophen	B

Patients	O
with	O
a	O
histologically	B
,	O
radiologically	B
or	O
haematologically	B
confirmed	B
malignancy	B
whose	O
pain	B
is	O
judged	O
by	O
the	O
investigator	O
to	O
be	O
caused	O
by	O
the	O
malignancy	O

Patients	O
must	O
have	O
been	O
on	O
a	O
stable	O
daily	O
dose	O
of	O
weak	B
opioids	I
or	O
strong	B
opioids	I
for	O
at	B
least	I
72	I
hours	I
prior	I
to	I
the	I
start	I
the	I
study	I
and	O
must	O
remain	O
at	O
the	O
same	O
dosage	O
for	O
the	O
duration	O
of	O
the	O
study	O

Patients	O
must	O
have	O
a	O
VAS	B
(	I
Visual	I
analog	I
scale	I
)	I
>	B
=	I
40mm	I

Clinically	O
significant	B
cardiac	B
disease	I
(	O
New	B
York	I
Heart	I
Association	I
Class	B
III	I
/	I
IV	I
)	O
,	O
or	O
severe	B
debilitating	B
puhnonary	I
disease	I
.	O

Uncontrolled	B
serious	I
active	O
infection	B
.	O

Anticipated	O
survival	O
of	O
less	B
than	I
3	I
months	I
.	O

Active	O
CNS	O
or	O
epiduraltumor	B

Inability	B
or	O
unwillingness	O
to	O
comply	O
with	O
the	O
treatment	O
protocol	O
,	O
follow	B
-	I
up	I
,	O
or	O
research	O
tests	O
.	O

-	O
Patients	O
residing	O
in	O
the	O
following	O
clinical	O
states	O
wit	O
!	O

be	O
considered	O
:	O
A	O
.	O

Rising	B
PSA	B
:	O
Patients	O
with	O
a	O
history	B
of	I
localized	B
disease	I
who	O
have	O
undergone	O
definitive	B
radiation	B
or	O
surgery	B
.	O

These	O
patients	O
must	O
demonstrate	O
progression	O
of	O
disease	O
biochemically	B
as	O
outlined	O
below	O
.	O

Patients	O
in	O
this	O
group	O
may	O
not	O
have	O
radiographically	B
evident	I
disease	B
.	O

B	O
.	O

Non	B
-	I
castrate	I
metastatic	B
:	O
Patients	O
must	O
present	O
with	O
radiographic	B
evidence	O
of	O
metastatic	B
disease	I
at	B
the	I
time	I
of	I
diagnosis	I
or	O
after	O
treatment	B
for	O
localized	B
disease	I
.	O

These	O
patients	O
must	O
show	O
newly	B
detected	I
disease	O
or	O
progressing	B
disease	I
in	I
bone	I
or	O
in	O
soft	O
tissue	O
.	O

Biochemical	O
progression	O
is	O
defined	O
as	O
:	O
minimum	B
no	I
.	I
of	I
determinations	I
:	O
3	B
Interval	B
:	O
>	B
2	I
weeks	I
Minimal	B
Baseline	I
PSA	I
value	I
(	B
ng	I
/	I
ml	I
)	I
:	I
2	I
Minimal	B
%	I
increase	I
in	I
range	I
of	I
values	I
:	O
50	B
%	I

Diagnosis	O
of	O
prostate	B
adenocarcinoma	I
histologically	B
confirmed	B
at	O
MSKCC	O
.	O

Patient	O
must	O
have	O
level	B
of	I
serum	I
testosterone	I
above	B
the	I
lower	I
limit	I
of	I
normal	I
.	O

Karnofskcy	B
performance	I
status	I
(	I
KPS	I
)	I
>	B
_	I
70	I
%	I
.	O

Patients	O
must	O
have	O
adequate	B
organ	B
function	I
as	O
defined	O
by	O
the	O
following	O
laboratory	O
criteria	O
:	O

WBC	B
>	B
_	I
3500	I
/	I
mm3	I
,	O
platelet	B
count	I
>	B
_	I
100	I
,	I
000	I
/	I
mm3	I
.	O

Bilirubin	B
<	B
2	I
.	I
0	I
mg	I
/	I
dl	I
or	O
SGOT	B
<	B
3	I
.	I
0	I
X	I
the	I
upper	I
limit	I
of	I
normal	I
.	O

Creatinine	B
<	B
_	I
1	I
.	I
6	I
mg	I
/	I
dl	I
or	O
creatinine	B
clearance	I
>	B
_	I
60	I
cc	I
/	I
min	I
.	O

Prior	B
hormonal	B
therapy	I
is	O
allowed	O
as	O
:	O

1	O
.	O

Neoadjuvant	B
treatment	I
prior	O
to	O
radiation	B
therapy	I
or	O
radical	B
prostatectomy	I
,	O
provided	O
that	O
the	O
total	B
duration	I
of	I
exposure	I
does	B
not	I
exceed	I
10	I
months	I
.	O

2	O
.	O

One	B
cycle	I
of	O
intermittent	B
therapy	I
up	O
to	O
a	O
maximum	B
exposure	I
of	O
10	B
months	I
.	O

Patients	O
must	O
be	O
at	B
least	I
18	I
years	I
of	O
age	B
.	O

Patients	O
must	O
have	O
signed	O
an	O
informed	O
consent	O
document	O
stating	O
that	O
they	O
understand	O
the	O
investigational	O
nature	O
of	O
the	O
proposed	O
treatment	O

Prior	B
treatment	B
with	O
more	B
than	I
6	I
cycles	I
of	O
traditional	O
alkylating	B
agent	I
-	I
based	I
chemotherapy	B
regimens	I

Prior	B
treatment	B
with	O
more	B
than	I
2	I
cycles	I
of	O
carboplating	B
-	I
based	I
chemotherapy	B
regimens	I

For	O
colorectal	B
cancer	I
patients	O
in	O
the	O
expanded	O
cohorts	O
,	O
prior	B
treatment	B
with	O
more	B
than	I
2	I
systemic	B
chemotherapy	I
regimens	I
in	O
the	O
metastatic	B
setting	O

Advanced	B
solid	I
tumor	I
malignancy	I
(	O
during	O
expansion	O
at	O
the	O
maximum	O
tolerated	O
dose	O
,	O
entry	O
will	O
be	O
limited	O
to	O
patients	O
wtih	O
adenocarcinoma	O
of	O
the	O
colon	O
or	O
rectum	O
)	O

Eastern	B
Cooperative	I
Oncology	I
Group	I
(	I
ECOG	I
)	I
0	B
or	I
1	I

Age	B
less	B
than	I
10	I
years	I
or	O
greater	B
than	I
55	I
years	I
,	O
at	B
time	I
of	I
consent	I

Estimated	B
IQ	I
<	B
70	I

Uncontrolled	B
epilepsy	I
(	O
seizure	B
within	B
6	I
months	I
prior	I
to	I
consent	I
)	O

4	O
.	O

Presence	O
of	O
medical	O
conditions	O
that	O
might	O
interfere	O
with	O
participation	O
,	O
or	O
where	O
participation	O
would	O
be	O
contraindicated	O

History	B
of	O
neurological	B
injury	I
:	O
head	B
trauma	I
,	O
poorly	B
-	I
controlled	I
seizure	B
disorder	I
(	O
seizure	B
within	B
the	I
preceding	I
six	I
months	I
)	O
,	O
stroke	B
,	O
prior	B
neurosurgery	B
,	O
or	O
under	O
the	O
care	O
of	O
a	O
neurologist	O
or	O
neurosurgeon	O
as	O
determined	O
by	O
interview	O

History	B
of	O
claustrophobia	B

Implanted	O
or	O
irremovable	B
metal	I
in	I
the	I
body	I
(	O
including	O
certain	O
tattoos	O
and	O
permanent	O
make	O
-	O
up	O
)	O

Current	B
pregnancy	B
(	O
as	O
verified	O
by	O
testing	O
prior	O
to	O
both	O
initial	O
dose	O
administration	O
of	O
citalopram	O
or	O
placebo	O
and	O
prior	O
to	O
magnetic	O
resonance	O
imaging	O
)	O
due	O
to	O
the	O
risk	O
that	O
may	O
be	O
associated	O
with	O
SSRI	O
treatment	O
and	O
magnetic	O
resonance	O
imaging	O
on	O
fetal	O
health	O

Medical	O
contraindications	O
to	O
SSRI	B
therapy	I
as	O
determined	O
by	O
history	B
(	O
including	O
induction	O
of	O
mania	B
or	O
hypomania	B
during	B
SSRI	I
therapy	I
,	O
or	O
known	O
drug	B
allergy	I
)	O

Concomitant	O
medication	O
that	O
would	O
interfere	O
with	O
study	O
participation	O

Prior	B
history	B
of	O
citalopram	B
treatment	B
failure	B
at	O
appropriate	O
doses	O
and	O
duration	O

Prior	O
history	O
of	O
treatment	O
failure	O
to	O
two	O
previous	O
SSRI	O
trials	O
at	O
appropriate	O
doses	O
and	O
duration	O

Ongoing	O
need	O
for	O
psychoactive	B
medication	I
other	B
than	I
study	B
medication	I
[	O
excepting	B
stable	O
doses	O
(	O
greater	B
than	I
three	I
months	I
duration	O
)	O
of	O
anticonvulsant	B
medication	I
for	O
seizure	B
disorder	I
,	O
or	O
diphenhydramine	B
(	O
Benadryl	O
®	O
)	O
for	O
sleep	O
]	O

Ambulatory	O
status	O
(	O
outpatient	O
)	O
at	B
time	I
of	I
consent	I

Age	B
10	B
-	I
55	I
years	I

Clinical	B
diagnosis	I
of	O
Autism	B
Spectrum	I
Disorder	I

IQ	B
greater	B
than	I
or	I
equal	I
to	I
70	I

Score	O
greater	B
than	I
8	I
on	O
Children	B
'	I
s	I
Yale	I
-	I
Brown	I
Obsessive	I
Compulsive	I
Scale	I

Free	B
of	I
psychoactive	B
medication	I
for	O
at	B
least	I
:	I
one	I
month	I
for	O
fluoxetine	B
;	O
two	O
weeks	O
for	O
other	O
SSRIs	B
and	O
neuroleptics	B
;	O
and	O
five	O
days	O
for	O
stimulants	B
prior	B
to	I
MRI	I
scanning	I
[	O
excepting	B
stable	B
doses	I
(	O
greater	B
than	I
three	I
months	I
duration	O
)	O
of	O
anticonvulsant	B
medication	I
for	O
seizure	B
disorder	I
]	O

1	O
.	O

Have	O
dementia	B
or	O
delirium	B
(	O
as	O
determined	O
by	O
the	O
palliative	O
care	O
specialist	O
)	O
at	B
study	I
entry	I
.	O

2	O
.	O

Are	O
pregnant	B

3	O
.	O

Have	O
been	O
taking	O
corticosteroids	B
for	O
longer	B
than	I
48	I
hours	I
.	O

4	O
.	O

Have	O
pulmonary	B
edema	I
,	O
ascites	B
or	O
pitting	B
edema	I
on	O
clinical	O
examination	O
.	O

5	O
.	O

Are	O
unable	B
to	I
walk	I
.	O

6	O
.	O

Have	O
a	O
history	B
of	O
serious	B
adverse	B
gastrointestinal	I
events	I
(	O
i	O
.	O
e	O
.	O
,	O
bleeding	B
or	O
perforation	B
)	O
,	O
history	B
of	O
a	O
coagulopathy	B
or	O
current	B
anti	B
-	I
coagulant	I
use	O
.	O

7	O
.	O

Have	O
an	O
ALT	B
/	I
AST	I
>	B
3x	I
upper	I
limit	I
of	I
normal	I
.	O

8	O
.	O

Patients	O
on	O
methotrexate	B
.	O

9	O
.	O

Patients	O
taking	O
melatonin	B
receptor	I
agonists	I
(	O
such	O
as	O
Rozerem	B
®	O
[	O
ramelteon	B
]	O
)	O
.	O

1	O
.	O

Are	O
referred	O
to	O
the	O
Cachexia	O
Clinic	O
with	O
involuntary	B
weight	I
loss	I
of	O
>	B
5	I
%	I
of	I
their	I
premorbid	I
weight	I
within	B
the	I
previous	I
6	I
months	I
.	O

2	O
.	O

Are	O
18	O
years	O
of	B
age	I
or	O
older	O

3	O
.	O

Have	O
a	O
Karnofsky	B
performance	I
score	I
of	O
60	B
or	I
higher	I
.	O

4	O
.	O

Can	O
maintain	O
oral	O
food	O
intake	O
during	O
the	O
study	O

5	O
.	O

Can	O
understand	O
the	O
study	O
procedures	O
and	O
can	O
sign	O
an	O
informed	O
consent	O
form	O
.	O

6	O
.	O

Are	O
not	B
currently	B
taking	O
melatonin	B
.	O

7	O
.	O

Are	B
taking	I
megestrol	B
acetate	I
and	O
continue	B
to	O
lose	O
weight	O
despite	O
at	B
least	I
2	I
weeks	I
of	O
therapy	B
.	O

8	O
.	O

Have	O
a	O
calculated	B
creatinine	I
clearance	I
of	O
>	B
/	I
=	I
60	I
cc	I
/	I
min	I
.	O

Age	B
less	B
than	I
18	I

Clinical	O
or	O
laboratory	O
evidence	O
of	O
systemic	O
infection	O

Current	O
pregnancy	B
as	O
assessed	O
by	O
preoperative	B
urine	B
HCG	I
test	I

Serious	B
,	O
uncontrolled	B
,	O
non	B
-	I
malignant	I
illness	I

Malignant	B
illness	I
requiring	O
systemic	B
chemotherapy	I
in	B
the	I
last	I
6	I
months	I

Documented	O
allergy	B
to	O
oxycodone	B
,	O
morphine	B
sulfate	I
or	O
acetaminophen	B

Contraindication	B
to	I
peripheral	I
nerve	I
blockade	I
or	O
general	O
anesthesia	O
including	O
:	O

1	O
.	O
patient	O
refusal	O

2	O
.	O
active	O
infection	O
at	O
site	O
of	O
planned	O
block	O

3	O
.	O
documented	O
allergy	O
to	O
any	O
local	O
or	O
general	O
anesthetic	O
medications	O

4	O
.	O
significant	B
coagulopathy	B
(	O
prothrombin	B
time	I
>	B
15	I
seconds	I
,	O
INR	B
>	B
1	I
.	I
5	I

5	O
.	O
pre	B
-	I
existing	I
neuropathy	B
and	O
medical	O
conditions	O
or	O
deformities	O
which	O
would	O
compromise	O
block	O
or	O
anesthetic	O
safety	O

Planned	O
pleurodesis	B

Current	B
use	O
of	O
high	B
dose	I
inhaled	B
or	O
systemic	B
steroids	B

Current	B
use	O
of	O
Amiodarone	B
(	O
Cordarone	B
)	O

Morbid	B
obesity	I
(	O
BMI	B
=	O
40kg	B
/	I
m2	I
)	O

Patients	O
with	O
clinically	B
significant	I
mental	B
health	I
issues	I
such	O
as	O
psychosis	B
requiring	O
treatment	B
with	O
antipsychotic	B
medications	I
.	O

Patients	O
unable	O
to	O
consent	O

Patients	O
with	O
active	B
infections	B
requiring	O
antibiotics	B
within	B
one	I
month	I
of	I
registration	I

Participation	O
in	O
other	O
clinical	O
trials	O
that	O
may	O
interfere	O
with	O
this	O
study	O

Age	B
greater	B
than	I
18	I

Planned	O
thoracoscopy	B
with	O
low	B
probability	I
(	I
by	I
surgeon	I
estimate	I
)	I
of	I
conversion	I
to	I
open	I
procedure	I

1	O
.	O

Institutionalized	O
subjects	O
will	O
not	O
be	O
used	O
.	O

2	O
Social	O
Habits	O
:	O

1	O
.	O

Use	O
of	O
any	O
tobacco	B
products	I
.	O

2	O
.	O

Ingestion	O
of	O
any	O
alcoholic	O
,	O
caffeine	O
-	O
or	O
xanthine	O
-	O
containing	O
food	O
or	O
beverage	O
within	O
the	O
48	O
hours	O
prior	O
to	O
the	O
initial	O
dose	O
of	O
study	O
medication	O
.	O

3	O
.	O

Ingestion	O
of	O
any	O
vitamins	O
or	O
herbal	O
products	O
within	O
the	O
48	O
hours	O
prior	O
to	O
the	O
initial	O
dose	O
of	O
the	O
study	O
medication	O
.	O

4	O
.	O

Any	O
recent	O
,	O
significant	O
change	O
in	O
dietary	O
or	O
exercise	O
habits	O
.	O

5	O
.	O

Positive	O
test	O
for	O
any	O
drug	O
included	O
in	O
the	O
urine	O
drug	O
screen	O
.	O

3	O
.	O

Medications	O
:	O

1	O
.	O

Use	O
of	O
any	O
medication	B
within	B
the	I
14	I
days	I
prior	I
to	O
the	O
initial	O
dose	O
of	O
study	O
medication	O
.	O

2	O
.	O

Use	O
of	O
any	O
medication	B
known	I
to	I
alter	I
hepatic	I
enzyme	I
activity	I
within	B
28	I
days	I
prior	I
to	O
the	O
initial	O
dose	O
of	O
study	O
medication	O
.	O

3	O
.	O

Use	O
of	O
hormonal	B
contraceptives	I
and	O
hormonal	B
replacement	I
therapy	I
within	B
three	I
months	I
prior	I
to	O
the	O
initial	O
dose	O
of	O
study	O
medication	O
.	O

4	O
.	O

Diseases	O
:	O

a	O
.	O

History	B
of	O
any	O
significant	B
chronic	B
disease	I
and	O
/	O
or	O
hepatitis	B
.	O

b	O
.	O

History	B
of	O
drug	O
and	O
/	O
or	O
alcohol	B
abuse	I
.	O

c	O
.	O

Acute	O
illness	O
at	O
the	O
time	O
of	O
either	O
the	O
prestudy	O
medical	O
evaluation	O
or	O
dosing	O
.	O

d	O
.	O

Positive	B
HIV	O
,	O
Hepatitis	O
B	O
,	O
or	O
Hepatitis	B
C	I
test	I
.	O

e	O
.	O

Renal	B
disease	I
or	O
renal	B
dysfunction	I
(	O
as	O
suggested	O
by	O
serum	B
creatinine	I
levels	I
greater	B
than	I
or	I
equal	I
to	I
1	I
.	I
5	I
mg	I
/	I
dL	I
(	O
for	O
males	B
)	O
and	O
greater	B
than	I
or	I
equal	I
to	I
1	I
.	I
4	I
mg	I
/	I
dL	I
(	O
for	O
females	B
)	O
or	O
abnormal	B
creatinine	I
clearance	I
)	O
.	O

5	O
.	O

Abnormal	O
and	O
clinically	O
significant	O
laboratory	O
test	O
results	O
:	O

1	O
.	O

Clinically	O
significant	O
deviation	O
from	O
the	O
Guide	O
for	O
Clinically	O
Relevant	O
Abnormalities	O
(	O
see	O
Part	O
II	O
ADMINISTRATIVE	O
ASPECTS	O
OF	O
BIOEQUIVALENCE	O
PROTOCOLS	O
)	O
.	O

2	O
.	O

Abnormal	B
and	I
clinically	I
relevant	I
ECG	I
tracing	I
.	O

6	O
.	O

Donation	O
or	O
loss	O
of	O
a	O
significant	O
volume	O
of	O
blood	O
or	O
plasma	O
(	O
>	O
450	O
mL	O
)	O
within	O
28	O
days	O
prior	O
to	O
the	O
initial	O
dose	O
of	O
study	O
medication	O
.	O

7	O
.	O

Subjects	O
who	O
have	O
received	O
an	O
investigational	O
drug	O
within	O
30	O
days	O
prior	O
to	O
the	O
initial	O
dose	O
of	O
study	O
medication	O
.	O

8	O
.	O

Allergy	B
or	O
hypersensitivity	B
to	O
metformin	B
hydrochloride	I
.	O

9	O
.	O

History	B
of	O
difficulty	B
in	I
swallowing	I
medication	I
,	O
or	O
any	O
gastrointestinal	B
disorder	I
which	O
could	O
affect	B
the	I
drug	I
absorption	I
.	O

1	O
.	O

Age	B
:	O
18	B
years	I
and	I
older	I
.	O

2	O
.	O

Sex	O
:	O
Male	B
and	O
non	B
-	O
pregnant	B
,	O
non	B
-	O
lactating	B
female	B

1	O
.	O

Women	B
of	O
childbearing	B
potential	I
must	O
have	O
negative	B
serum	O
(	O
Beta	B
HCG	I
)	O
pregnancy	O
tests	O
performed	O
within	B
14	I
days	I
prior	I
to	I
the	I
start	I
of	I
the	I
study	I
and	O
on	B
the	I
evening	I
prior	I
to	I
each	I
dose	I
administration	I
.	O

If	O
dosing	O
is	O
scheduled	O
on	O
Sunday	O
or	O
Monday	O
,	O
the	O
HCG	O
pregnancy	O
test	O
should	O
be	O
given	O
within	O
48	O
hours	O
prior	O
to	O
dosing	O
of	O
each	O
study	O
period	O
.	O

An	O
additional	O
serum	O
(	O
Beta	O
HCG	O
)	O
pregnancy	O
test	O
will	O
be	O
performed	O
upon	O
completion	O
of	O
the	O
study	O
.	O

2	O
.	O

Women	B
of	O
childbearing	B
potential	I
must	O
practice	O
abstinence	B
or	O
be	O
using	O
an	O
acceptable	B
form	I
of	O
contraception	B
throughout	B
the	I
duration	I
of	I
the	I
study	I
.	O

Acceptable	O
forms	O
of	O
contraception	O
include	O
the	O
following	O
:	O

(	O
1	O
)	O
intrauterine	B
device	I
in	O
place	O
for	B
at	I
least	I
3	I
months	I
prior	I
to	I
the	I
start	I
of	I
the	I
study	I
and	O
remaining	O
in	B
place	I
during	I
the	I
study	I
period	I
,	O
or	O
(	O
2	O
)	O
barrier	B
methods	I
containing	O
or	O
used	O
in	O
conjunction	O
with	O
a	O
spermicidal	B
agent	I
,	O
or	O
(	O
3	O
)	O
postmenopausal	B
accompanied	O
with	O
a	O
documented	O
postmenopausal	O
course	O
of	O
at	B
least	I
one	I
year	I
or	O
surgical	B
sterility	I
(	O
tubal	B
ligation	I
,	O
oophorectomy	B
or	O
hysterectomy	B
)	O
.	O

3	O
.	O

During	B
the	I
course	I
of	I
the	I
study	I
,	O
from	O
study	O
screen	O
until	O
study	O
exit	O
-	O
including	O
the	O
washout	O
period	O
,	O
women	B
of	O
childbearing	B
potential	I
must	O
use	O
a	O
spermicide	B
containing	I
barrier	I
method	I
of	I
contraception	I
in	B
addition	I
to	I
their	O
current	B
contraceptive	B
device	I
.	O

This	O
advice	O
should	O
be	O
documented	O
in	O
the	O
informed	O
consent	O
form	O
.	O

3	O
.	O

Weight	B
:	O
At	B
least	I
60	I
kg	I
(	O
132	O
lbs	O
)	O
for	O
man	B
and	O
48	O
kg	O
(	O
106	O
lbs	O
)	O
for	O
women	B
and	O
within	B
15	I
%	I
of	I
Ideal	I
Body	I
Weight	I
(	I
IBW	I
)	I
,	O
as	O
referenced	O
by	O
the	O
Table	O
of	O
"	O
"	O
Desirable	O
Weights	O
of	O
Adults	O
"	O
"	O
Metropolitan	O
Life	O
Insurance	O
Company	O
,	O
1999	O
(	O
See	O
Part	O
II	O
ADMINISTRATIVE	O
ASPECTS	O
OF	O
BIOEQUIVALENCE	O
PROTOCOLS	O
)	O
.	O

4	O
.	O

All	O
subjects	O
should	O
be	O
judged	O
normal	B
and	O
healthy	B
during	O
a	O
pre	B
-	I
study	I
medical	I
evaluation	I
(	O
physical	B
examination	I
,	O
laboratory	B
evaluation	I
,	O
12	B
-	I
lead	I
ECG	I
,	O
hepatitis	O
B	O
and	O
hepatitis	B
C	I
tests	I
,	O
HIV	B
test	I
,	O
and	O
urine	B
drug	I
screen	I
including	O
amphetamine	B
,	O
barbiturates	B
,	O
benzodiazepine	B
,	O
cannabinoid	B
,	O
cocaine	B
,	O
opiates	B
,	O
phencyclidine	B
,	O
and	O
methadone	B
)	O
performed	O
within	B
14	I
days	I
of	I
the	I
initial	I
dose	I
of	I
study	I
medication	I
.	O

Patients	O
:	O

Who	O
are	O
pregnant	B
or	O
planning	O
to	O
become	O
pregnant	B
during	B
the	I
study	I
or	O
in	B
the	I
future	I

With	O
a	O
elevated	B
post	B
-	I
void	I
residual	I
(	O
defined	O
as	O
PVR	B
>	B
100cc	I
)	O

With	O
a	O
bleeding	B
condition	I
or	O
on	O
anti	B
-	I
coagulant	I
therapy	I

With	O
immunosuppression	O
(	O
i	O
.	O
e	O
.	O
HIV	B
,	O
lymphoma	B
)	O

With	O
multiple	B
sclerosis	I
or	O
other	O
progressive	B
neurological	I
disease	I

With	O
evidence	O
of	O
a	O
local	O
or	O
systemic	B
infection	I
,	O
including	O
urinary	B
tract	I
infection	I

With	O
evidence	O
of	O
intrinsic	B
sphincter	I
deficiency	I
as	O
defined	O
by	O
a	O
maximal	B
urethral	I
closure	I
pressure	I
of	O
<	B
20	I
cm	I
H2O	I

Previous	B
sub	B
-	I
urethral	I
sling	I

Predominant	B
overactive	B
bladder	I
symptoms	O

Are	O
at	B
least	I
18	I
years	I
of	O
age	B

Demonstrate	O
a	O
positive	B
cough	B
stress	I
test	I
during	O
complex	B
multi	I
-	I
channel	I
urodynamic	I
testing	I

Demonstrate	O
impact	O
of	O
stress	B
urinary	I
incontinence	I
on	O
quality	B
of	I
life	I
questionnaire	I

Are	O
able	O
to	O
comprehend	O
and	O
sign	O
a	O
written	O
informed	O
consent	O

Understand	O
and	O
are	O
willing	O
to	O
comply	O
with	O
the	O
study	O
requirements	O
,	O
including	O
agreeing	O
to	O
be	O
available	O
for	O
the	O
follow	O
-	O
up	O
evaluations	O

Are	O
psychologically	B
stable	I
and	O
suitable	B
for	I
interventions	I
determined	B
by	I
the	I
investigator	I

Are	O
ambulatory	B
and	O
able	B
to	I
use	I
a	I
toilet	I
independently	I

History	B
of	O
any	O
chemotherapy	B
for	O
MBC	B
.	O

An	O
interval	O
of	O
<	B
6	I
months	I
from	O
the	O
completion	O
of	O
cytotoxic	B
chemotherapy	I
in	O
the	O
neo	O
-	O
adjuvant	O
or	O
adjuvant	B
setting	I
until	O
the	O
time	O
of	O
metastatic	B
diagnosis	I
.	O

Trastuzumab	B
≤	B
21	I
days	I
prior	I
to	I
randomization	I
.	O

Hormone	B
therapy	I
<	B
7	I
days	I
prior	I
to	I
randomization	I
.	O

Current	B
peripheral	B
neuropathy	I
of	O
Grade	B
≥	B
3	I
.	O

History	O
of	O
other	B
malignancy	B
within	B
the	I
last	I
5	I
years	I
,	O
except	B
for	I
appropriately	O
treated	B
carcinoma	B
in	I
situ	I
of	I
the	I
cervix	I
,	O
non	B
-	I
melanoma	I
skin	I
carcinoma	I
,	O
Stage	B
I	B
uterine	B
cancer	I
,	O
or	O
other	O
cancers	O
with	O
a	O
similar	O
outcome	O
as	O
those	O
previously	O
mentioned	O
.	O

Previous	B
radiotherapy	B
for	O
the	O
treatment	O
of	O
unresectable	B
,	O
locally	B
advanced	I
or	O
metastatic	B
breast	B
cancer	I
is	O
not	O
allowed	O
if	O
more	B
than	I
25	I
%	I
of	O
marrow	B
-	I
bearing	I
bone	I
has	I
been	I
irradiated	I
or	O
the	O
last	O
fraction	O
of	O
radiotherapy	O
has	O
been	O
administered	O
within	O
approximately	O
3	O
weeks	O
prior	O
to	O
randomization	O
.	O

Brain	B
metastases	I
that	O
are	O
untreated	B
,	O
symptomatic	B
,	O
or	O
require	B
therapy	I
to	O
control	O
symptoms	O
or	O
any	O
radiation	B
,	O
surgery	B
,	O
or	O
other	B
therapy	I
to	I
control	I
symptoms	I
from	O
brain	B
metastases	I
within	B
2	I
months	I
prior	I
to	I
randomization	I
.	O

History	O
of	O
exposure	O
to	O
the	O
following	O
cumulative	O
doses	O
of	O
anthracyclines	B
:	O
Doxorubicin	B
or	O
liposomal	B
doxorubicin	I
>	B
500	I
mg	I
/	I
m	I
^	I
2	I
;	O
epirubicin	B
>	B
900	I
mg	I
/	I
m	I
^	I
2	I
;	O
mitoxantrone	B
>	B
120mg	I
/	I
m	I
^	I
2	I
and	O
idarubicin	B
>	B
90	I
mg	I
/	I
m	I
^	I
2	I
.	O

Current	B
unstable	B
angina	I
.	O

History	O
of	O
symptomatic	B
congestive	B
heart	I
failure	I
,	O
or	O
ventricular	B
arrhythmia	I
requiring	O
treatment	B
.	O

History	O
of	O
myocardial	B
infarction	I
within	B
6	I
months	I
prior	I
to	I
randomization	I
.	O

Left	B
ventricular	I
ejection	I
fraction	I
(	I
LVEF	I
)	I
below	B
50	I
%	I
within	B
approximately	I
28	I
days	I
prior	I
to	I
randomization	I
.	O

History	B
of	O
decreased	B
LVEF	B
or	O
symptomatic	B
congestive	B
heart	I
failure	I
(	I
CHF	I
)	I
with	O
previous	B
adjuvant	B
trastuzumab	B
treatment	O
.	O

Cardiac	B
troponin	I
I	I
≥	B
0	I
.	I
2	I
ng	I
/	I
mL	I
within	B
28	I
days	I
of	I
randomization	I
.	O

Severe	B
dyspnea	B
at	O
rest	O
because	O
of	O
complications	B
of	O
advanced	B
malignancy	I
or	O
requiring	O
current	B
continuous	B
oxygen	I
therapy	I
.	O

Current	O
severe	B
,	O
uncontrolled	B
systemic	B
disease	I
(	O
eg	O
,	O
clinically	B
significant	I
cardiovascular	O
,	O
pulmonary	O
,	O
or	O
metabolic	B
disease	I
;	O
wound	B
healing	I
disorders	I
;	O
ulcers	B
;	O
or	O
bone	B
fractures	I
)	O
.	O

Major	B
surgical	B
procedure	I
or	O
significant	B
traumatic	B
injury	I
within	B
approximately	I
28	I
days	I
prior	I
to	I
randomization	I
or	O
anticipation	O
of	O
the	O
need	O
for	O
major	B
surgery	I
during	O
the	O
course	O
of	O
study	O
treatment	B
.	O

Current	B
pregnancy	B
or	O
lactation	B
.	O

History	B
of	I
receiving	O
any	O
investigational	B
treatment	I
within	B
approximately	I
28	I
days	I
prior	I
to	I
randomization	I
.	O

Current	B
known	O
infection	O
with	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
,	O
active	O
hepatitis	O
B	O
and	O
/	O
or	O
hepatitis	B
C	I
virus	I
.	O

History	B
of	I
intolerance	B
(	O
including	O
Grade	B
3	B
-	I
4	I
infusion	B
reaction	I
)	O
or	O
hypersensitivity	B
to	O
trastuzumab	B
,	O
murine	B
proteins	I
,	O
or	O
docetaxel	B
.	O

Known	O
hypersensitivity	B
to	O
any	O
of	O
the	O
study	B
drugs	I
,	O
including	O
the	O
excipients	O
,	O
or	O
any	O
drugs	B
formulated	I
in	I
polysorbate	I
80	I
.	O

Assessed	O
by	O
the	O
investigator	O
to	O
be	O
unable	O
or	O
unwilling	O
to	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
.	O

Histologically	O
or	O
cytologically	B
confirmed	I
adenocarcinoma	B
of	I
the	I
breast	I
with	O
locally	O
advanced	O
or	O
metastatic	B
disease	I
,	O
and	O
a	O
candidate	O
for	O
chemotherapy	B
.	O

Human	B
epidermal	I
growth	I
factor	I
receptor	I
2	I
(	I
HER2	I
)	I
-	O
positive	B
.	O

No	B
prior	B
chemotherapy	B
for	O
their	O
metastatic	B
breast	I
cancer	I
(	I
MBC	I
)	I
.	O

Measurable	B
disease	I
.	O

Age	B
≥	B
18	I
years	I
.	O

For	O
women	B
of	O
childbearing	B
potential	I
and	O
men	B
with	O
partners	O
of	O
childbearing	O
potential	O
,	O
agreement	O
to	O
use	O
a	O
highly	B
effective	I
,	O
non	B
-	I
hormonal	I
form	O
of	O
contraception	B
or	O
2	B
effective	O
forms	O
of	O
non	B
-	I
hormonal	I
contraception	I
by	O
the	O
patient	O
and	O
/	O
or	O
partner	O
.	O

Contraception	B
use	O
must	O
continue	B
for	I
the	I
duration	I
of	I
study	I
treatment	I
and	O
for	B
at	I
least	I
6	I
months	I
after	I
the	I
last	I
dose	I
of	I
study	I
treatment	I
.	O

Male	B
patients	O
whose	O
partners	O
are	O
pregnant	O
should	O
use	O
condoms	B
for	B
the	I
duration	I
of	I
the	I
study	I
.	O

The	O
other	B
types	I
of	O
pulmonary	B
hypertension	I
.	O

Subjects	O
who	O
refuse	O
to	O
subscribe	O
written	O
informed	O
consents	O
or	O
can	O
'	O
t	O
cooperate	O
with	O
the	O
trial	O
well	O
.	O

Subjects	O
with	O
serious	B
acute	B
or	O
chronic	B
disease	I
involved	I
liver	I
,	O
kidney	O
,	O
and	O
brain	O
or	O
have	O
to	O
use	O
potent	B
CYP3A4	B
-	I
inhibitor	I
or	O
nitrate	B
to	O
treat	O
the	O
underlying	B
diseases	I
.	O

Subjects	O
who	O
are	O
currently	B
treated	O
with	O
sildenafil	B
for	O
PAH	B
or	O
taking	O
sildenafil	B
or	O
tadalafil	B
.	O

Other	O
contraindications	O
in	O
package	O
insert	O
.	O

Subjects	O
aged	B
12	B
-	I
65	I
.	O

Confirmed	O
idiopathic	B
pulmonary	I
hypertension	I
,	O
connective	B
tissue	I
disease	I
associated	I
pulmonary	B
hypertension	I
,	O
congenital	B
heart	I
disease	I
(	O
with	O
Eisenmenger	B
syndrome	I
)	O
associated	O
pulmonary	B
hypertension	I
.	O

Baseline	B
6	B
-	I
minutes	I
walking	I
distance	I
150m	B
-	I
550m	I
.	O

WHO	B
pulmonary	I
hypertension	I
function	I
II	B
-	I
III	I
with	O
non	O
-	O
responder	O
to	O
calcium	B
channel	I
blockers	I
.	O

Documented	O
written	O
informed	O
consent	O
.	O

Cardio	B
-	I
vascular	I
pathologies	I
,	O
evoluting	B
and	O
uncontrolled	B
,	O
(	O
severe	B
HTA	B
)	O
,	O
cardiac	B
deficiency	I
,	O
severe	B
angor	B
,	O
severe	B
arrhythmia	B
.	O

Infectious	B
pathologies	I
evoluting	B
and	O
requiring	O
antibiotherapy	B
.	O

Patients	O
HIV	B
+	B
.	O

Transplanted	B
patients	O
or	O
patients	O
suffering	O
from	O
severe	B
auto	I
-	I
immune	I
disease	I
.	O

Psychiatric	B
troubles	I
that	O
do	B
not	I
allow	I
the	I
protocol	I
follow	I
-	I
up	I
.	O

Pregnant	B
or	O
breast	B
-	I
feeding	I
women	B
.	O

No	B
contraception	B
.	O

HLA	B
-	I
A2	I
melanoma	B
patients	O
with	O
:	O

either	O
loco	O
-	O
regional	O
or	O
lymph	B
node	I
metastasis	I

transit	B
nodules	I
not	B
surgically	B
resectable	O

measurable	B
cutaneous	O
or	O
visceral	B
metastasis	I

Patients	O
'	O
tumor	O
express	O
Melan	O
-	O
A	O
/	O
MART	O
-	O
1	O
antigen	O
.	O

No	B
chemotherapy	B
treatment	O
(	O
except	B
for	I
Deticene	B
used	O
before	B
the	I
first	I
T	I
cell	I
clones	I
infusion	I
)	O
or	O
radiotherapy	B
or	O
immunotherapy	B
in	B
the	I
last	I
4	I
weeks	I
before	I
infusion	I
.	O

No	O
other	O
melanoma	B
treatment	B
during	B
the	I
protocol	I
.	O

Life	O
expectancy	O
should	O
be	O
greater	B
than	I
6	I
months	I
.	O

General	O
state	O
with	O
Karnowsky	B
greater	B
than	I
80	I
,	O
ECOG	B
=	O
0	B
,	I
1	I
or	I
2	I
.	O

Patient	O
should	O
be	O
negative	B
for	O
HIV	B
and	O
B	O
and	O
C	B
hepatitis	I
.	O

Biological	O
parameters	O
at	B
the	I
beginning	I
of	I
the	I
study	I
:	O
leucocytes	B
³	B
2000	I
elements	I
per	I
mm3	I
,	O
hemoglobin	B
³	B
10	I
.	I
5g	I
/	I
dl	I
,	O
platelets	B
³	B
100	I
000	I
per	I
mm3	I
,	O
phosphatases	B
alcalines	I
transaminases	I
£	B
1	I
time	I
1	I
/	I
2	I
compared	I
to	I
the	I
normal	I
.	O

Signed	O
informed	O
consent	O

Contraindication	B
to	O
Clopidogrel	B

Smoking	B
(	O
current	B
smokers	B
and	O
patients	O
who	O
quit	B
smoking	I
less	B
than	I
six	I
months	I
)	O

Malignancy	B
(	O
diagnosed	O
or	O
under	O
investigation	O
)	O

Haematological	B
disorders	I
(	O
Anaemia	B
,	O
malignancy	B
,	O
bleeding	B
disorders	I
)	O

Women	B
of	O
child	B
-	I
bearing	I
potential	I

Use	O
of	O
corticosteroids	B
/	O
other	O
antithrombotic	B
agents	I
(	O
warfarin	B
)	O

Chronic	B
liver	I
disease	I
(	O
Cirrhosis	B
,	O
malignancy	B
and	O
patients	O
with	O
more	B
than	I
twice	I
the	I
upper	I
limit	I
of	O
liver	B
function	I
tests	I
)	O

Unable	O
to	O
consent	O
.	O

Use	O
of	O
other	O
investigational	B
study	I
drugs	I
within	B
1	I
year	I
prior	I
to	I
study	I
entry	I

Previous	B
participation	O
in	O
this	O
study	O

Patients	O
with	O
T2DM	B
and	O
CAS	B
as	O
defined	O
below	O
:	O

Clinical	O
definitions	O

T2DM	B
:	O
Diagnosed	O
according	O
to	O
the	O
WHO	B
criteria	I
[	O
53	O
]	O
.	O

CAD	B
:	O
Presence	O
of	O
any	O
one	O
of	O
the	O
following	O
:	O
Angina	B
plus	O
positive	B
exercise	B
tolerance	I
test	I
,	O
enzyme	O
and	O
/	O
or	O
Q	B
wave	I
positive	I
myocardial	B
infarction	I
,	O
angiographic	B
evidence	I
(	O
>	B
50	I
%	I
stenosis	B
of	I
one	I
vessel	I
)	O
,	O
percutaneous	B
or	O
surgical	B
coronary	B
revascularisation	I
.	O

Aged	B
between	B
18	I
and	I
75	I

Provided	O
written	O
consent	O
for	O
participation	O
in	O
the	O
trial	O
prior	B
to	I
any	I
study	I
-	I
specific	I
procedures	I
or	I
requirements	I
.	O

Prior	B
endobronchial	B
treatment	I
for	O
emphysema	B

Pleural	O
or	O
interstitial	B
disease	I
that	O
precludes	B
surgery	B
.	O

Prior	B
lung	B
transplant	I
,	O
LVRS	B
,	O
median	B
sternotomy	I
,	O
bullectomy	B
or	O
lobectomy	B
.	O

Clinically	B
significant	I
bronchiectasis	B

Pulmonary	B
nodule	I
requiring	O
surgery	B

History	B
of	O
recurrent	B
respiratory	B
infections	I
(	O
>	O
3	O
hospitalization	B
in	O
the	O
last	O
year	O
)	O

Clinically	B
significant	I
(	O
>	B
4	I
Tablespoons	I
per	I
day	I
)	O
sputum	O
production	O

Fever	B
,	O
elevated	B
white	B
cell	I
count	I
,	O
or	O
other	O
evidence	O
of	O
active	B
infection	I

Dysrhythmia	B
that	O
might	O
pose	B
a	I
risk	I
during	B
exercise	I
or	O
training	O

Congestive	B
heart	I
failure	I
within	B
6	I
mo	I
and	O
LVEF	B
<	B
45	I
%	I

Evidence	O
or	O
history	B
of	O
Cor	B
Pulmonale	I

Resting	B
bradycardia	I
(	O
<	B
50	I
beats	I
/	I
min	I
)	O
,	O
frequent	B
multifocal	B
PVCs	I
,	O
complex	B
ventricular	I
arrhythmia	I
,	O
sustained	B
SVT	I

History	B
of	O
exercise	B
-	I
related	I
syncope	B

MI	B
within	B
6	I
mo	I
and	O
LVEF	B
<	B
45	I
%	I

Evidence	O
of	O
systemic	B
disease	I
or	O
neoplasia	B
expected	B
to	I
compromise	I
survival	I
during	B
5	I
-	I
yr	I
period	I

Any	O
disease	B
or	O
condition	B
that	O
interferes	B
with	I
completion	I
of	I
initial	I
or	I
follow	I
-	I
up	I
assessments	I

Patient	O
is	O
currently	B
enrolled	O
in	O
another	O
clinical	O
trial	O

Patient	O
is	O
unable	O
to	O
complete	O
3	B
minutes	I
of	I
unloaded	I
peddling	I
on	I
cycle	I
ergometer	I

Alpha	B
-	I
1	I
-	I
Antitrypsin	I
Deficiency	I

Patient	O
diagnosed	O
by	O
HRCT	B
Core	I
Lab	I
with	O
eligible	O
heterogeneous	B
disease	I
distribution	I
and	O
at	B
least	I
one	I
complete	B
oblique	I
fissure	I
.	O

Age	B
from	B
40	I
to	I
75	I
years	I

BMI	B
<	B
32	I
kg	I
/	I
m2	I

FEV1	B
<	B
40	I
%	I
of	I
predicted	I
value	I
,	O
FEV1	B
/	I
FVC	I
<	B
70	I
%	I

TLC	B
>	B
120	I
%	I
predicted	I
,	O
RV	B
>	B
150	I
%	I
predicted	I
.	O

Stable	B
with	O
<	O
20	O
mg	O
prednisone	B
(	O
or	O
equivalent	O
)	O
qd	O

PaCO2	B
<	B
50mm	I
Hg	I

PaO2	B
>	B
45	I
mm	I
Hg	I
on	B
room	I
air	I

6	B
-	I
min	I
walk	I
of	O
>	B
50m	I
(	O
without	B
rehabilitation	B
)	O
or	O
>	B
100m	I
(	O
with	O
rehabilitation	B
)	O

Nonsmoking	B
for	B
4	I
months	I
prior	I
to	I
initial	I
interview	I
and	O
throughout	B
screening	I

The	O
patient	O
agrees	O
to	O
all	O
protocol	O
required	O
follow	O
-	O
up	O
intervals	O
.	O

The	O
patient	O
has	O
no	B
child	B
bearing	I
potential	I

The	O
patient	O
is	O
willing	O
and	O
able	O
to	O
complete	O
protocol	O
required	O
baseline	B
assessments	I
and	O
procedures	O

Current	B
viral	O
or	O
bacterial	B
infection	I
.	O

Positive	B
serology	B
for	I
HIV	I
,	O
HCV	O
,	O
HBV	O
.	O

Age	B
:	O
>	B
or	I
=	I
16	I
years	I

Weight	B
:	O
more	B
than	I
40	I
Kg	I

Autoimmune	B
Hemolytic	I
anemia	I
with	O
clinical	O
and	O
biochemical	O
evidence	O
of	O
hemolysis	B
refractory	O
to	O
treatment	B
,	O
in	B
relapse	I
or	O
steroids	B
dependant	O

Idiopathic	B
thrombocytopenic	I
purpura	I
with	O
platelet	B
counts	I
<	B
50	I
,	I
000	I
,	O
refractory	O
to	O
treatment	B
,	O
in	B
relapse	I
or	O
steroids	B
dependant	O

No	O
positive	B
HIV	O
1	O
or	O
HIV	B
2	I
test	I
at	B
screening	I

no	O
history	B
of	O
significant	B
skin	B
disease	I
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
rash	B
or	O
eruptions	B
,	O
drug	B
allergies	I
,	O
food	B
allergy	I
,	O
dermatitis	B
,	O
eczema	B
,	O
psoriasis	B
,	O
or	O
urticaria	B

no	O
history	B
of	O
allergy	B
to	O
drugs	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
sulphonamides	B
and	O
penicillins	B

no	O
previously	B
demonstrated	O
clinically	B
significant	I
allergy	B
or	O
hypersensitivity	B
to	O
any	O
of	O
the	O
excipients	B
of	I
the	I
investigational	I
medication	I
administered	O
in	O
this	O
trial	O

no	O
female	B
subject	O
of	O
childbearing	B
potential	I
without	B
use	O
of	O
effective	B
nonhormonal	B
birth	I
control	I
methods	O
,	O
or	O
not	B
willing	O
to	O
continue	O
practicing	O
these	O
birth	B
control	I
methods	I
for	B
at	I
least	I
30	I
days	I
after	I
the	I
end	I
of	I
the	I
treatment	I
period	I

no	O
positive	B
pregnancy	B
test	I
or	O
breast	O
feeding	O
at	B
screening	I

Non	B
-	O
smoking	B
,	O
or	O
smoking	B
no	B
more	I
than	I
10	I
cigarettes	I
,	I
or	I
2	I
cigars	I
,	I
or	I
2	I
pipes	I
per	I
day	I
for	B
at	I
least	I
3	I
months	I
prior	I
to	I
selection	I

Normal	B
weight	I
as	O
defined	O
by	O
a	O
Body	B
Mass	I
Index	I
(	O
BMI	B
,	O
weight	B
in	I
kg	I
divided	I
by	I
the	I
square	I
of	I
height	I
in	I
meters	I
)	O
of	O
18	B
.	I
0	I
to	I
30	I
.	I
0	I
kg	I
/	I
m2	I
,	I
extremes	I
included	I

Able	O
to	O
comply	O
with	O
protocol	O
requirements	O
.	O

Healthy	B
on	O
the	O
basis	O
of	O
a	O
medical	B
evaluation	I
that	O
reveals	O
the	O
absence	B
of	O
any	O
clinically	B
relevant	I
abnormality	B
and	O
includes	O
a	O
physical	B
examination	I
,	O
medical	B
history	I
,	O
electrocardiogram	B
(	O
ECG	B
)	O
,	O
vital	B
signs	I
,	O
and	O
the	O
results	O
of	O
blood	O
biochemistry	O
,	O
blood	O
coagulation	O
,	O
and	O
hematology	B
tests	I
and	O
a	O
urinalysis	B
carried	O
out	O
at	B
screening	I
.	O

Recent	O
participation	O
(	O
within	B
28	I
days	I
)	O
in	O
other	O
research	O
studies	O

Recent	B
significant	B
blood	B
donation	I
or	O
plasma	B
donation	I

Pregnant	B
or	O
lactating	B

Test	O
positive	B
at	B
screening	I
for	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
,	O
hepatitis	B
B	I
surface	I
antigen	I
(	I
HbsAg	I
)	I
,	O
or	O
hepatitis	B
C	I
virus	I
(	I
HCV	I
)	I

Recent	B
(	O
2	B
-	I
year	I
)	O
history	B
or	O
evidence	O
of	O
alcoholism	B
or	O
drug	B
abuse	I

History	O
or	O
presence	O
of	O
significant	O
cardiovascular	O
,	O
pulmonary	O
,	O
hepatic	O
,	O
gallbladder	O
or	O
biliary	O
tract	O
,	O
renal	O
,	O
hematologic	O
,	O
gastrointestinal	O
,	O
endocrine	O
,	O
immunologic	O
,	O
dermatologic	O
,	O
neurologic	O
,	O
or	O
psychiatric	O
disease	O

Subjects	O
who	O
have	O
used	O
any	O
drugs	B
or	I
substances	I
known	I
to	I
inhibit	I
or	I
induce	I
cytochrome	I
(	I
CYP	I
)	I
P450	I
enzymes	I
and	O
/	O
or	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
within	B
28	I
days	I
prior	I
to	I
the	I
first	I
dose	I
and	O
throughout	B
the	I
study	I

Drug	O
allergies	B
to	O
quinine	B
sulfate	I
or	O
rosiglitazone	B

Healthy	B
adults	B
18	O
-	O
45	O
years	O
of	B
age	I

Non	B
-	O
smoking	B

Non	B
-	O
pregnant	B
(	O
post	B
-	I
menopausal	I
,	O
surgically	B
sterile	O
or	O
using	O
effective	B
contraceptive	B
measures	I
)	O

Body	B
mass	I
index	I
(	I
BMI	I
)	I
less	B
than	I
or	I
equal	I
to	I
32	I

Medically	B
healthy	I
on	O
the	O
basis	O
of	O
medical	B
history	I
and	O
physical	B
examination	I

Hemoglobin	B
>	B
or	I
=	I
to	I
11	I
.	I
5g	I
/	I
dL	I

Completion	O
of	O
the	O
screening	B
process	I
within	B
28	I
days	I
prior	I
to	I
dosing	I

Provision	O
of	O
voluntary	O
written	O
informed	O
consent	O

Endoscopically	B
confirmed	O
gastric	B
and	O
/	O
or	O
duodenal	B
ulcers	I
on	B
Day	I
1	I
.	O

Endoscopically	B
confirmed	O
active	B
upper	B
gastrointestinal	I
hemorrhage	I
on	B
Day	I
1	I
.	O

Current	B
or	O
past	B
history	I
of	O
aspirin	B
-	O
induced	O
asthma	B
or	O
hypersensitivity	O
to	O
NSAIDs	B
.	O

Past	B
or	O
planned	O
surgery	B
affecting	B
gastric	I
acid	I
secretion	I
.	O

Clinically	B
significant	I
hepatic	O
or	O
renal	B
disorder	I
.	O

Serious	B
cardiac	B
dysfunction	I
,	O
hypertension	B
,	O
or	O
hematological	B
disorder	I
.	O

The	O
patient	O
was	O
on	O
nonsteroid	B
anti	I
-	I
inflammatory	I
drug	I
(	I
NSAID	I
)	I
treatment	O
on	B
the	I
day	I
when	I
consent	I
was	I
obtained	I
,	O
and	O
requires	O
the	O
long	O
-	O
term	O
continuous	O
treatment	O
even	O
after	O
treatment	O
with	O
the	O
investigational	O
drug	O
is	O
started	O
.	O

The	O
patient	O
was	O
confirmed	O
to	O
have	O
a	O
history	B
of	O
gastric	B
ulcer	I
or	O
duodenal	B
ulcer	I
.	O

ASA	B
3	I
+	I

No	B
current	B
treatment	O
plan	O
at	O
OHSU	O

Severely	B
carious	B
teeth	I
resulting	O
in	O
inability	B
to	I
isolate	I
for	I
procedure	I

Unable	O
to	O
understand	O
or	O
sign	O
consent	O
form	O

ASA	B
1	I

ASA	B
2	I

Pts	O
have	O
current	O
treatment	O
plan	O
at	O
OHSU	O
for	O
extraction	O
of	O
some	O
or	O
all	O
of	O
remaining	O
teeth	O
and	O
scheduled	O
for	O
delivery	O
of	O
a	O
removable	O
appliance	O
post	O
extraction	O

Teeth	O
used	O
are	O
able	O
to	O
be	O
isolated	O
with	O
rubber	O
dam	O

Understand	O
and	O
sign	O
consent	O
form	O

Known	O
or	O
suspected	O
allergy	O
to	O
trial	B
product	I
(	I
s	I
)	I
or	O
related	B
products	I

Subjects	O
who	O
are	O
unlikely	O
to	O
comply	O
with	O
protocol	O
requirements	O
,	O
e	O
.	O
g	O
.	O
uncooperative	O
attitude	O
,	O
inability	O
to	O
return	O
for	O
the	O
final	O
visit	O

Subjects	O
who	O
previously	O
enrolled	O
in	O
this	O
study	O

Females	B
of	O
childbearing	B
potential	I
who	O
are	O
pregnant	B
,	O
breast	B
-	I
feeding	I
or	O
intend	O
to	O
become	O
pregnant	B
or	O
are	O
not	B
using	O
adequate	B
contraceptive	B
methods	I

The	O
receipt	O
of	O
any	O
investigational	B
product	I
within	B
3	I
months	I
prior	I
to	I
this	I
trial	I

After	O
the	O
investigator	O
has	O
taken	O
the	O
decision	O
to	O
use	O
human	O
insulin	O
or	O
insulin	O
analogues	O
to	O
treat	O
the	O
subject	O
,	O
any	O
type	B
2	I
diabetic	I
previously	B
inadequately	B
controlled	I
with	O
two	B
or	I
more	I
OADs	B
is	O
eligible	O
for	O
the	O
study	O

The	O
selection	O
of	O
the	O
subjects	O
will	O
be	O
at	O
the	O
discretion	O
of	O
the	O
individual	O
investigator	O

Significant	B
illness	B
,	O
trauma	B
or	O
surgical	B
procedures	I
.	O

Clinically	B
significant	I
laboratory	B
abnormalities	O
.	O

Clinically	B
significant	I
medical	B
history	I

body	B
mass	I
index	I
(	I
BMI	I
)	I
between	B
19	I
to	I
30	I
kg	I
/	I
m2	I
and	O
body	B
weight	I
between	O
50	B
to	I
100	I
kg	I
inclusive	I

No	B
Down	B
syndrome	I

No	B
other	B
major	B
disease	I
that	O
prohibits	O
study	O
treatment	O
(	O
e	O
.	O
g	O
.	O
,	O
severe	B
congenital	B
heart	I
disease	I
)	O

Not	B
requiring	O
significant	O
therapy	O
modification	O
owing	O
to	O
study	B
therapy	I
associated	O
complications	B

No	B
complications	B
due	O
to	O
other	B
interventions	B

No	B
one	O
with	O
missing	O
data	O
that	O
are	O
needed	O
for	O
the	O
differential	O
diagnosis	O
,	O
or	O
for	O
selection	O
of	O
the	O
proper	O
therapy	O
arm	O

Cytologically	B
proven	I
acute	B
lymphoblastic	I
leukemia	I
(	O
ALL	B
)	O

No	B
relapse	B
of	O
a	O
previously	B
unrecognized	I
ALL	B

Patients	O
must	O
meet	O
one	O
of	O
the	O
following	O
risk	O
criteria	O
:	O

Standard	B
-	I
risk	I
(	O
SR	B
)	O
group	O
meeting	O
all	B
of	O
the	O
following	O
criteria	B
:	O

Blasts	B
<	B
1	I
,	I
000	I
/	I
µL	I
in	O
peripheral	B
blood	I
(	O
PB	B
)	O
on	B
day	I
8	I

Aged	B
1	B
to	I
<	I
6	I
years	I

Initial	B
WBC	B
<	B
20	I
,	I
000	I
/	I
µL	I

M1	O
(	B
5	I
%	I
)	O
or	O
M2	O
(	O
=	B
5	I
%	I
to	I
<	I
25	I
%	I
)	O
blasts	O
in	O
bone	B
marrow	I
on	B
day	I
15	I
;	O

M1	B
marrow	I
on	B
day	I
33	I
.	O

Aged	B
<	B
1	I
or	I
=	I
6	I
years	I
and	O
/	O
or	O
WBC	B
=	B
20	I
,	I
000	I
/	I
µL	I

Blasts	B
<	B
1	I
,	I
000	I
/	I
µL	I
in	O
PB	B
on	B
day	I
8	I

M1	O
or	O
M2	B
marrow	I
on	B
day	I
15	I

M3	O
(	O
=	B
25	I
%	I
)	O
marrow	O
on	B
day	I
15	I
OR	O
meets	B
SR	B
criteria	I
but	O
M3	B
marrow	I
on	B
day	I
15	I
and	O
*	O
M1	B
marrow	I
on	B
day	I
33	I
.	O

Meets	B
IR	B
criteria	I
and	O
M3	B
marrow	I
on	B
day	I
15	I
(	O
not	B
SR	B
and	O
M3	B
on	B
day	I
15	I
)	O

Blasts	B
=	B
1	I
,	I
000	I
/	I
µL	I
in	O
PB	B
on	B
day	I
8	I

M2	O
or	O
M3	B
marrow	I
on	B
day	I
33	I

Translocation	B
t	I
(	I
9	I
;	I
22	I
)	I
[	O
BCR	B
/	I
ABL	I
+	B
]	O
(	O
Philadelphia	B
chromosome	I
-	O
positive	B
)	O
or	O
t	B
(	I
4	I
;	I
11	I
)	I
[	O
MLL	B
/	I
AF4	I
+	B
]	O
.	O

Enrollment	O
in	O
another	O
trial	O

Lack	O
of	O
consent	O

Infants	B
in	O
the	O
newborn	O
intensive	O
care	O
unit	O

TPN	B
cholestasis	I
of	O
at	B
least	I
2	I
.	I
5	I
mg	I
/	I
dl	I

Anticipated	O
TPN	B
treatment	I
for	B
at	I
least	I
one	I
month	I

signed	O
informed	O
consent	O

1	O
.	O

Patient	O
has	O
an	O
allergy	O
to	O
nickel	B
.	O

2	O
.	O

Patient	O
has	O
a	O
diagnosis	O
of	O
bowel	B
obstruction	I
,	O
bowel	B
strangulation	I
,	O
peritonitis	B
,	O
bowel	B
perforation	I
,	O
local	O
or	O
systemic	B
infection	I
,	O
ischemic	B
bowel	I
,	O
carcinomatosis	B
or	O
extensively	B
spread	I
inflammatory	B
bowel	I
disease	I
.	O

3	O
.	O

Patient	O
is	O
participating	O
in	O
another	O
clinical	O
trial	O
which	O
may	O
affect	O
this	O
study	O
'	O
s	O
outcomes	O
.	O

4	O
.	O

Patient	O
has	O
been	O
taking	O
regular	B
steroid	B
medication	I
.	O

5	O
.	O

Patient	O
has	O
contraindications	O
to	O
general	B
anesthesia	I
.	O

6	O
.	O

Patient	O
has	O
preexisting	O
sphincter	B
problems	I
or	O
evidence	O
of	O
extensive	B
local	B
disease	I
in	I
the	I
pelvis	I
.	O

1	O
.	O

Patient	O
is	O
over	O
18	O
years	B
old	I
.	O

2	O
.	O

Patient	O
is	O
scheduled	O
for	O
a	O
non	B
-	I
emergency	I
procedure	O
.	O

3	O
.	O
Subject	O
signs	O
and	O
dates	O
a	O
written	O
informed	O
consent	O
form	O
(	O
ICF	O
)	O
and	O
indicates	O
an	O
understanding	O
of	O
the	O
study	O
procedures	O
.	O

Lack	O
of	O
consent	O

Age	B
from	B
birth	I
to	I
21	I
years	I

All	O
solid	B
organ	I
transplant	I
recipients	O
receiving	O
their	O
care	O
at	O
Seattle	O
Children	O
'	O
s	O
Hospital	O

Signed	O
consent	O
,	O
and	O
when	O
age	O
appropriate	O
,	O
signed	O
assent	O

Visible	O
skin	B
pathology	I
,	O
excessive	B
freckles	B
,	O
or	O
skin	B
blemishes	I
in	O
the	O
test	O
area	O
.	O

History	O
of	O
skin	B
disease	I
or	O
hypersensitivity	B
and	O
repeated	O
contact	B
allergies	I
.	O

Sarcoma	B
or	O
squamous	B
cell	I
histology	B
.	O

Metastatic	B
disease	I
to	B
the	I
breast	I
.	O

Current	B
tobacco	O
use	O
.	O

Must	O
have	O
pathologically	B
confirmed	B
invasive	B
adenocarcinoma	I
or	O
ductal	B
carcinoma	I
in	I
situ	I
of	B
the	I
breast	I
.	O

Patients	O
must	O
have	O
undergone	O
segmental	B
mastectomy	I
(	O
i	O
.	O
e	O
.	O
,	O
lumpectomy	B
)	O
.	O

Patients	O
must	O
not	B
have	O
received	O
prior	O
radiation	B
therapy	I
to	O
the	O
breast	O
.	O

Patients	O
must	O
not	B
have	O
active	B
local	B
-	I
regional	I
disease	I
prior	O
to	O
registration	O
.	O

Patients	O
must	O
not	O
be	O
pregnant	O
because	O
of	O
the	O
potential	O
for	O
fetal	O
harm	O
as	O
a	O
result	O
of	O
radiation	O
treatment	O
.	O
Women	O
of	O
child	O
-	O
bearing	O
age	O
will	O
be	O
given	O
a	O
serum	O
pregnancy	O
test	O
prior	O
to	O
study	O
entry	O
to	O
ensure	O
they	O
are	O
not	O
pregnant	O
.	O
They	O
will	O
also	O
be	O
counseled	O
on	O
the	O
importance	O
of	O
avoiding	O
pregnancy	O
and	O
hormonal	O
contraception	O
while	O
undergoing	O
radiation	O
therapy	O
.	O

Patients	O
must	O
not	O
have	O
a	O
serious	O
medical	O
or	O
psychiatric	O
illness	O
which	O
prevents	O
informed	O
consent	O
or	O
compliance	O
with	O
treatment	O
.	O

All	O
patients	O
must	O
be	O
informed	O
of	O
the	O
investigational	O
nature	O
of	O
this	O
study	O
and	O
give	O
written	O
informed	O
consent	O
in	O
accordance	O
with	O
institutional	O
and	O
federal	O
guidelines	O
.	O

1	O
.	O

Had	O
a	O
neurological	B
condition	I
other	B
than	I
that	O
associated	O
with	O
their	O
pain	B
diagnosis	I
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
interfere	O
with	O
their	O
ability	O
to	O
participate	O
in	O
the	O
study	O

2	O
.	O

Were	O
taking	O
a	O
lidocaine	B
-	I
containing	I
product	I
that	O
could	B
not	I
be	I
discontinued	I
while	O
receiving	O
lidocaine	B

3	O
.	O

Were	O
taking	O
class	B
1	I
anti	I
-	I
arrhythmic	I
drugs	I
(	O
e	O
.	O
g	O
.	O
,	O
mexiletine	B
,	O
tocainide	B
)	O

1	O
.	O

Had	O
a	O
diagnosis	O
of	O
PHN	B
,	O
DN	B
,	O
CRPS	B
,	O
carpal	B
tunnel	I
syndrome	I
,	O
HIV	B
neuropathy	B
,	O
idiopathic	B
sensory	B
neuropathy	I
,	O
or	O
other	O
peripheral	B
neuropathy	I
(	O
upon	O
mutual	O
agreement	O
of	O
the	O
sponsor	O
and	O
investigator	O
)	O

2	O
.	O

Patients	O
with	O
PHN	B
must	O
have	O
had	O
pain	B
>	B
3	I
months	I
after	O
rash	B
healing	I

3	O
.	O

Patients	O
with	O
DN	B
must	O
have	O
had	O
Type	B
I	I
or	I
II	I
diabetes	I
and	O
painful	B
distal	B
symmetric	B
sensorimotor	B
polyneuropathy	I
with	O
or	O
without	O
dynamic	B
allodynia	I
of	O
the	O
lower	O
extremities	O

4	O
.	O

Patients	O
with	O
CRPS	B
must	O
have	O
met	B
current	O
IASP	B
(	I
International	I
Association	I
for	I
the	I
Study	I
of	I
Pain	I
)	I
diagnostic	I
criteria	I

5	O
.	O

Patients	O
with	O
carpal	B
tunnel	I
syndrome	I
must	O
have	O
had	O
a	O
diagnosis	O
by	O
combination	O
clinical	B
neurological	I
examination	I
(	O
e	O
.	O
g	O
.	O
,	O
Phalen	O
'	O
s	O
and	O
Tinel	B
'	I
s	I
signs	I
)	O
,	O
electrodiagnostic	B
testing	O
,	O
and	O
daily	B
painful	B
symptoms	I
of	O
at	B
least	I
3	I
months	I
'	I
duration	I

6	O
.	O

Patients	O
with	O
HIV	B
neuropathy	I
must	O
have	O
had	O
HIV	B
,	O
subjective	B
symptoms	I
of	O
painful	B
peripheral	B
neuropathy	I
,	O
and	O
daily	B
painful	B
symptoms	I
of	O
at	B
least	I
3	I
months	I
'	I
duration	I

7	O
.	O

Patients	O
with	O
idiopathic	B
sensory	I
neuropathy	I
must	O
have	O
had	O
pain	B
of	O
at	B
least	I
3	I
months	I
'	I
duration	I

8	O
.	O

Reached	O
an	O
average	B
daily	B
pain	I
rating	I
during	B
the	I
baseline	I
week	I
of	O
pain	O
ratings	O
greater	B
than	I
4	I
on	O
the	O
0	B
-	I
to	I
-	I
10	I
numerical	I
pain	I
rating	I
scale	I
(	O
Question	O
5	O
of	O
the	O
BPI	O
)	O

9	O
.	O

Had	O
never	O
received	O
an	O
analgesic	B
regimen	I
that	O
contained	O
lidocaine	B
or	O
gabapentin	B

1	O
.	O

Currently	B
pregnant	B
or	O
last	B
pregnancy	B
outcome	I
within	B
3	I
months	I
prior	I
to	I
enrolment	I

2	O
.	O

Currently	B
breast	B
-	I
feeding	I

3	O
.	O

Participated	O
in	O
any	O
other	O
research	O
study	O
within	O
60	O
days	O
prior	O
to	O
screening	O

4	O
.	O

Previously	O
participated	O
in	O
any	O
HIV	O
vaccine	O
study	O

5	O
.	O

Untreated	B
urogenital	B
infections	I
(	O
either	O
symptomatic	B
or	O
asymptomatic	B
)	O
within	B
2	I
weeks	I
prior	I
to	I
enrollment	I

6	O
.	O

Presence	O
of	O
abnormal	B
physical	I
finding	I
on	I
the	I
vulva	I
,	O
vaginal	O
walls	O
or	O
cervix	O
during	O
pelvic	O
/	O
speculum	B
examination	I
and	O
/	O
or	O
colposcopy	B

7	O
.	O

History	B
of	O
significant	B
urogenital	O
or	O
uterine	B
prolapse	I
,	O
undiagnosed	B
vaginal	B
bleeding	I
,	O
urethral	B
obstruction	I

8	O
.	O

Pap	B
smear	I
result	O
at	B
screening	I
that	O
requires	O
cryotherapy	B
,	O
biopsy	B
,	O
treatment	B
(	O
other	O
than	O
for	O
infection	O
)	O
,	O
or	O
further	B
evaluation	I

9	O
.	O

Any	O
Grade	B
2	I
,	I
3	I
or	I
4	I
baseline	B
haematology	B
,	O
chemistry	B
or	O
urinalysis	B
laboratory	B
abnormality	O
according	O
to	O
the	O
DAIDS	B
Table	I
for	I
Grading	I
Adverse	I
Experiences	I

10	O
.	O

Unexplained	B
,	O
undiagnosed	B
abnormal	B
bleeding	B
per	I
vagina	I
,	O
bleeding	B
per	I
vagina	I
during	O
or	O
following	B
vaginal	I
intercourse	I
,	O
or	O
gynaecologic	B
surgery	I
within	B
90	I
days	I
prior	I
to	I
enrollment	I

11	O
.	O

Any	O
history	B
of	O
anaphylaxis	B
or	O
severe	B
allergy	B
resulting	O
in	O
angioedema	B
;	O
or	O
a	O
history	B
of	O
sensitivity	O
/	O
allergy	B
to	I
latex	I

12	O
.	O

Any	O
serious	B
acute	B
,	O
chronic	B
or	O
progressive	B
disease	B

13	O
.	O

Any	O
condition	O
(	O
s	O
)	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
might	O
interfere	O
with	O
adherence	O
to	O
study	O
requirements	O
or	O
evaluation	O
of	O
the	O
study	O
objectives	O

1	O
.	O

Women	B
18	B
to	I
40	I
years	I
of	O
age	B
inclusive	O
who	O
can	O
give	O
written	O
informed	O
consent	O

2	O
.	O

Available	O
for	O
all	O
visits	O
and	O
consent	O
to	O
follow	O
all	O
procedures	O
scheduled	O
for	O
the	O
study	O

3	O
.	O

Agree	O
to	O
daily	B
application	O
of	O
gel	B
and	O
monitoring	B
as	O
per	O
Daily	O
Monitored	O
Adherence	O
(	O
DMA	O
)	O
method	O

4	O
.	O

Healthy	B
and	O
self	B
-	I
reported	I
sexually	B
active	I

5	O
.	O

HIV	B
-	O
negative	B
as	O
determined	O
by	O
a	O
HIV	B
rapid	I
test	I
at	B
time	I
of	I
enrollment	I

6	O
.	O

On	O
a	O
stable	O
form	O
of	O
contraception	O
and	O
willing	O
to	O
continue	O
on	O
this	O
stable	O
method	O
of	O
contraception	O
,	O
OR	O
,	O
Have	O
undergone	O
surgical	O
sterilisation	O
at	O
least	O
3	O
months	O
prior	O
to	O
enrollment	O

7	O
.	O

In	O
the	O
absence	B
of	O
the	O
use	O
of	O
exogenous	B
hormone	I
(	O
s	O
)	O
,	O
have	O
a	O
self	O
-	O
reported	O
regular	B
menstrual	B
cycle	I
defined	O
as	O
having	O
a	O
minimum	B
of	I
21	I
days	I
and	O
a	O
maximum	B
of	I
36	I
days	I
between	O
menses	O

8	O
.	O

Upon	O
pelvic	O
/	O
speculum	B
examination	I
and	O
colposcopy	B
at	B
the	I
time	I
of	I
enrollment	I
,	O
the	O
cervix	O
and	O
vagina	O
appear	O
normal	B
as	O
determined	O
by	O
the	O
investigator	O

9	O
.	O

Asymptomatic	O
for	O
genital	B
infections	I
at	B
the	I
time	I
of	I
enrollment	I

10	O
.	O

Willing	O
to	O
refrain	B
from	O
use	O
of	O
vaginal	B
products	I
or	O
objects	O
within	B
14	I
days	I
prior	I
to	I
enrollment	I
and	O
for	B
the	I
duration	I
of	I
the	I
study	I

11	O
.	O

Willing	O
to	O
answer	O
acceptability	O
and	O
adherence	O
questionnaires	O
throughout	B
the	I
study	I

12	O
.	O

Willing	O
to	O
refrain	O
from	O
participation	O
in	O
any	O
other	O
research	O
study	O
for	O
the	O
duration	O
of	O
this	O
study	O

13	O
.	O

Willing	O
to	O
provide	O
adequate	O
locator	O
information	O
for	O
study	O
retention	O
purposes	O
and	O
be	O
reachable	O
per	O
local	O
standard	O
procedures	O

Subject	O
are	O
pregnant	B

Subject	O
is	O
unable	O
to	O
perform	O
tasks	O
associated	O
with	O
study	O

Subject	O
are	O
at	B
least	I
18	I
years	I
of	O
age	B

Subject	O
has	O
confirmed	O
Pulmonary	B
Hypertension	I
and	O
Interstitial	B
Lung	I
Disease	I

Subject	O
are	O
able	O
to	O
complete	O
study	B
procedures	I
,	O
such	O
as	O
spirometry	B
,	O
and	O
Pulmonary	B
Exercise	I
test	I
.	O

Other	O
neuromuscular	B
disease	I

Contraindication	B
to	O
weight	O
bearing	O
on	O
lower	O
extremities	O

Pressure	B
sores	I
where	O
harness	B
would	O
be	O
applied	O

Uncontrollable	B
hypotension	B
when	B
upright	I

Lower	B
limb	I
contractures	I
impeding	O
range	O
of	O
motion	O
necessary	O
for	O
ambulation	O

Prior	O
enrolment	O
in	O
a	O
BWATT	O
program	O

Unable	O
to	O
commit	O
to	O
intervention	O
for	O
duration	O
of	O
protocol	O

Children	B
between	O
the	O
ages	B
of	O
4	B
-	I
18	I
with	O
incomplete	B
ASIA	B
C	B
or	I
D	I
spinal	B
cord	I
injuries	I
at	B
least	I
12	I
months	I
before	I
study	I
enrolment	I

Non	O
-	O
ambulatory	O
or	O
'	O
exercise	O
only	O
'	O
ambulators	O
with	O
or	O
without	O
assistive	B
devices	I

Normal	B
motor	O
and	O
cognitive	B
development	I
up	B
to	I
time	I
of	I
injury	I

Medical	B
Stability	I

diabetes	B

ischemic	B
heart	I
disease	I
or	O
any	O
abnormality	B
on	O
treadmill	B
stress	I
test	I

inflammatory	O
or	O
chronic	B
disorder	I

pregnancy	B

lactation	B

creatinine	B
level	I
of	O
1	B
,	I
5	I
mg	I
/	I
dL	I
or	I
more	I

gastrointestinal	B
problems	I
or	O
musculoskeletal	B
disorders	I
that	O
would	O
prevent	B
them	O
to	O
follow	O
the	O
test	B
diets	I
or	O
exercise	B
interventions	I

liver	B
dysfunction	I
with	O
a	O
factor	B
of	I
at	I
least	I
3	I
above	I
the	I
upper	I
limit	I
of	I
normal	I
in	O
AST	O
and	O
ALT	B
levels	I

thyroid	B
dysfunction	I
,	O
with	O
serum	B
TSH	I
out	B
of	I
normal	I
limits	I

use	O
of	O
immunosuppressive	B
drugs	I
,	O
corticosteroids	B
or	O
anorexigen	B

men	B
and	O
women	B
30	B
-	I
55	I
years	I
with	O
BMI	B
30	B
-	I
40	I
and	O
waist	B
95	B
cm	I
or	I
more	I

normal	B
OGTT	B

normal	B
treadmill	B
stress	I
test	I

plus	O
2	B
of	I
4	I
:	O

1	O
.	O
low	B
serum	B
levels	I
of	I
HDL	I
cholesterol	I
(	O
<	B
40	I
mg	I
⁄	I
dL	I
for	O
men	B
or	O
<	B
50	I
mg	I
⁄	I
dL	I
for	O
women	B
)	O
;	O

2	O
.	O
hypertriglyceridemia	B
(	O
triglyceride	B
levels	I
of	O
150	B
mg	I
⁄	I
dL	I
or	I
greater	I
)	O
;	O

3	O
.	O
impaired	B
glucose	I
homeostasis	I
(	O
fasting	B
plasma	I
glucose	I
concentration	I
of	O
110	B
mg	I
⁄	I
dL	I
or	I
greater	I
or	O
glucose	B
of	O
140	B
mg	I
⁄	I
dL	I
or	I
greater	I
after	O
OGTT	B
or	O

4	O
.	O
hypertension	B
(	O
systolic	B
blood	I
pressure	I
≥	B
140	I
or	O
diastolic	B
blood	I
pressure	I
≥	B
90	I
mmHg	I
or	O
treatment	B
with	O
antihypertensive	B
drugs	I
)	O
.	O

Malignancy	B
and	O
other	O
significant	B
medical	B
conditions	I
that	O
will	O
impact	O
follow	O
up	O
within	O
this	O
program	O
.	O

Those	O
less	B
than	I
18	I
years	I
of	O
age	B
.	O

Concomitant	B
interstitial	B
lung	I
disease	I
,	O
sarcoidosis	B
,	O
other	O
significant	O
lung	B
disease	I
.	O

Those	O
who	O
have	O
had	O
a	O
transplant	B
.	O

Significant	O
travel	O
with	O
work	O
.	O

Unable	O
to	O
make	O
appointments	O
(	O
every	O
three	O
to	O
six	O
months	O
over	O
2	O
years	O
)	O
.	O

Those	O
residing	O
in	O
another	O
country	O
or	O
planned	O
absence	O
for	O
more	O
than	O
one	O
month	O
.	O

Adults	B
(	O
18	B
and	I
older	I
)	O
with	O
physiologically	O
confirmed	O
SA	B
or	O
mild	B
-	O
moderate	B
asthma	B
and	O
followed	O
by	O
an	O
asthma	O
specialist	O
for	B
at	I
least	I
6	I
months	I
.	O

Must	O
agree	O
to	O
have	O
regular	O
clinic	O
visits	O
(	O
minimum	O
3	O
-	O
4	O
per	O
year	O
for	O
SA	O
,	O
1	O
-	O
2	O
for	O
mild	O
-	O
moderate	O
asthma	O
)	O
.	O

Must	O
have	O
good	B
compliance	I
with	O
medications	B
Patients	O
with	O
asthma	B
and	O
COPD	B
.	O

previous	O
unusual	B
response	I
to	O
esmolol	B

inclusion	O
in	O
other	O
randomized	O
studies	O

esmolol	B
administration	O
in	B
the	I
previous	I
30	I
days	I

emergency	B
operation	B

end	B
diastolic	I
diameter	I
>	B
60	I
mm	I
and	O
/	O
or	O
an	O
ejection	B
fraction	I
<	B
50	I
%	I

written	O
informed	O
consent	O

age	B
>	B
18	I
years	I

none	O
,	O
all	O
patients	O
meeting	O
the	O
inclusion	O
criteria	O
will	O
be	O
eligible	O
.	O

acute	B
myocardial	I
infarction	I
or	O

ischemic	B
cardiomyopathy	I
with	O
or	O
without	O
previous	B
myocardial	B
infarction	I
or	O

dilated	B
cardiomyopathy	I
due	O
to	O
valvular	B
heart	I
disease	I
,	O
hypertensive	B
heart	I
disease	I
,	O
history	B
of	O
myocarditis	B
(	O
no	B
active	B
myocardial	B
infection	I
present	O
)	O

Patients	O
with	O
systolic	B
blood	I
pressure	I
<	B
100	I
mmHg	I
or	O
basal	B
heart	B
rate	I
<	B
60	I
/	I
min	I

Portal	B
vein	I
thrombosis	I

Uncontrolled	B
ascites	B
or	O
hepatic	B
encephalopathy	I

Severe	B
coagulation	B
disorder	I
:	O
prothrombin	B
time	I
<	B
40	I
%	I
(	O
or	O
INR	B
>	B
1	I
.	I
7	I
)	O
or	O
platelet	B
count	I
<	B
30	I
,	I
000	I
/	I
mm3	I

Medium	B
or	O
large	B
sized	O
gastric	O
or	O
duodenal	B
varices	I

Coexisting	B
malignancy	B

Severe	B
cardiovascular	B
disorder	I
,	O
renal	B
failure	I
,	O
peritonitis	B
,	O
sepsis	B

Severe	B
erosive	B
esophagitis	I
,	O
severe	B
esophageal	B
stricture	I
,	O
active	B
gastric	O
or	O
duodenal	B
ulcer	I

Contraindication	B
to	O
beta	B
-	I
blocker	I

Pregnancy	B

Refusal	O
to	O
give	O
consent	O
to	O
participate	O
in	O
the	O
trial	O

Liver	B
cirrhosis	I

Age	B
between	B
18	I
and	I
70	I
years	I

Esophageal	B
varices	I
with	O
high	O
bleeding	O
risk	O
:	O
more	B
than	I
F2	B
and	O
red	B
color	I
sign	I

No	B
previous	O
history	O
of	O
upper	B
gastrointestinal	I
bleeding	I

No	B
previous	O
history	O
of	O
endoscopic	O
,	O
radiologic	O
,	O
or	O
surgical	B
therapy	I
for	O
varices	B
or	O
ascites	B

Do	B
not	I
take	O
beta	B
-	I
blocker	I
,	O
ACE	B
inhibitor	I
,	O
or	O
nitrate	B

Child	B
-	I
Pugh	I
score	I
<	B
12	I

Known	O
asthmatic	B
or	O
history	B
of	O
allergy	B
towards	O
peanut	B
or	O
milk	B
products	I

Concurrent	O
participation	O
in	O
another	O
clinical	O
trial	O

Severe	B
illness	B
warranting	O
hospital	B
referral	I

At	B
least	I
18	I
years	I
of	O
age	B

No	B
more	I
than	I
20	I
wk	I
of	O
gestation	B

Given	O
Ante	O
-	O
natal	O
Cards	O
of	O
the	O
Ghana	O
Health	O
Service	O

Completed	O
the	O
initial	O
routine	B
ante	I
-	I
natal	I
examination	I
at	O
the	O
clinics	O

HIV	B
negative	B
or	O
status	B
unknown	I
(	O
as	O
from	O
the	O
Ante	O
-	O
natal	O
card	O
)	O

Free	O
from	O
chronic	B
disease	I
e	O
.	O
g	O
.	O
malignancy	B
requiring	O
frequent	O
medical	O
attention	O
(	O
as	O
from	O
the	O
Ante	O
-	O
natal	O
card	O
)	O

Residing	O
in	O
the	O
Manya	O
Krobo	O
or	O
Yilo	O
Krobo	O
district	O

Prepared	O
to	O
sign	O
an	O
informed	O
consent	O

Living	O
in	O
the	O
area	O
throughout	B
the	I
duration	I
of	I
the	I
study	I

Acceptance	O
of	O
home	O
visitors	O

1	O
.	O

Patients	O
over	O
the	O
age	B
of	O
85	O
years	O
except	O
at	O
the	O
discretion	O
of	O
the	O
Investigator	O
and	O
with	O
agreement	O
of	O
the	O
Sponsor	O
.	O

2	O
.	O

Diagnosis	O
of	O
acute	B
promyelocytic	I
leukemia	I

3	O
.	O

Diagnosis	O
of	O
chronic	B
myelogenous	I
leukemia	I
(	I
CML	I
)	I
in	O
blast	B
crisis	I

4	O
.	O

AML	B
in	B
relapse	I
or	O
refractory	B
after	O
3	B
or	I
more	I
previous	B
lines	B
of	I
chemotherapy	I
(	O
and	O
/	O
or	O
HSCT	O
)	O
treatment	O

5	O
.	O

AML	B
or	O
antecedent	B
MDS	B
secondary	O
to	O
prior	B
chemotherapy	B

6	O
.	O

Persistent	O
clinically	B
significant	I
non	B
-	I
hematological	I
toxicity	B
that	O
is	O
Grade	B
>	I
1	I
by	O
NCI	B
CTCAE	I
v4	I
from	O
prior	B
chemotherapy	B

7	O
.	O

Patients	O
who	O
have	B
had	I
HSCT	B
and	O
are	O
within	O
100	O
days	O
of	O
transplant	B
and	O
/	O
or	O
are	O
still	B
taking	O
immunosuppressive	B
drugs	I
and	O
/	O
or	O
have	O
clinically	B
significant	I
graft	B
-	I
versus	I
-	I
host	I
disease	I
requiring	O
treatment	B
and	O
/	O
or	O
have	O
>	B
Grade	I
1	I
persistent	B
non	B
hematological	I
toxicity	B
related	O
to	O
the	O
transplant	B

8	O
.	O

Clinically	O
active	O
central	B
nervous	I
system	I
(	I
CNS	I
)	I
leukemia	I
.	O

Patients	O
with	O
CNS	O
leukemia	O
,	O
which	O
is	O
controlled	O
,	O
but	O
who	O
are	O
still	O
receiving	O
IT	O
therapy	O
at	O
study	O
entry	O
may	O
be	O
considered	O
eligible	O
and	O
continue	O
receive	O
IT	O
therapy	O
at	O
the	O
discretion	O
of	O
the	O
Investigator	O
and	O
with	O
agreement	O
of	O
the	O
Sponsor	O
.	O

9	O
.	O

Patients	O
who	O
have	O
previously	O
received	O
AC220	B

10	O
.	O

Disseminated	B
intravascular	I
coagulation	I
(	I
DIC	I
)	I
(	O
diagnosis	O
by	O
laboratory	O
or	O
clinical	O
assessment	O
)	O

11	O
.	O

Major	B
surgery	I
within	B
4	I
weeks	I
prior	I
to	I
enrollment	I
in	O
the	O
study	O

12	O
.	O

Radiation	B
therapy	I
within	O
4	O
weeks	O
prior	O
to	O
,	O
or	O
concurrent	B
with	I
study	I

13	O
.	O

Use	O
of	O
concomitant	O
drugs	O
that	O
prolong	B
QT	I
/	I
QTc	I
interval	I
and	O
/	O
or	O
are	O
CYP3A4	B
inhibitors	I
are	O
prohibited	O
with	B
the	I
exception	I
of	I
antibiotics	B
,	O
antifungals	B
,	O
and	O
other	O
antimicrobials	B
that	O
are	O
used	O
as	O
standard	O
of	O
care	O
to	O
prevent	O
or	O
treat	O
infections	O
and	O
other	O
such	O
drugs	O
that	O
are	O
considered	O
absolutely	O
essential	O
for	O
the	O
care	O
of	O
the	O
patient	O
.	O

14	O
.	O

Uncontrolled	B
or	O
significant	B
cardiovascular	B
disease	I

15	O
.	O

Women	O
who	O
are	O
pregnant	B
,	O
lactating	B
,	O
or	O
unwilling	O
to	O
use	O
contraception	B
if	O
of	O
childbearing	B
potential	I

16	O
.	O

Men	B
who	O
are	O
unwilling	O
to	O
use	O
contraception	B
if	O
their	O
partners	O
are	O
of	O
childbearing	O
potential	O

17	O
.	O

Active	B
,	O
uncontrolled	B
infection	B

18	O
.	O

Human	B
immunodeficiency	I
virus	I
positivity	B

19	O
.	O

Active	B
hepatitis	B
B	I
or	O
C	O
or	O
other	O
active	B
liver	B
disease	I

20	O
.	O

History	B
of	O
cancer	B
,	O
except	B
Stage	B
1	I
cervix	I
or	O
nonmelanotic	B
skin	B
cancer	I
,	O
with	O
the	O
possible	O
exception	O
of	O
patients	O
in	O
complete	O
remission	O

1	O
.	O

Males	B
and	O
females	B
age	B
≥	B
18	I
years	I
in	O
second	B
relapse	B
or	O
refractory	B
.	O

2	O
.	O

Males	B
and	O
females	B
age	B
≥	B
60	I
years	I
in	O
first	B
relapse	B
or	O
refractory	B
.	O

3	O
.	O

Must	O
have	O
baseline	B
bone	B
marrow	I
sample	I
taken	O
.	O

4	O
.	O

Morphologically	B
documented	I
primary	B
AML	B
or	O
AML	B
secondary	O
to	O
myelodysplastic	B
syndrome	I
(	O
MDS	B
with	O
≥	B
20	I
%	I
bone	B
marrow	I
or	O
peripheral	B
blasts	I
)	O
,	O
as	O
defined	O
by	O
the	O
World	B
Health	I
Organization	I
(	I
WHO	I
)	I
criteria	I
,	O
confirmed	O
by	O
pathology	B
review	I
at	O
treating	O
institution	O
.	O

5	O
.	O

Able	O
to	O
swallow	O
the	O
liquid	O
study	O
drug	O
.	O

6	O
.	O

ECOG	B
performance	I
status	I
of	O
0	B
to	I
2	I

7	O
.	O
In	O
the	O
absence	O
of	O
rapidly	O
progressing	O
disease	O
,	O
the	O
interval	O
from	O
prior	O
treatment	O
to	O
time	O
of	O
AC220	O
administration	O
will	O
be	O
at	O
least	O
2	O
weeks	O
for	O
cytotoxic	O
agents	O
or	O
at	O
least	O
5	O
half	O
-	O
lives	O
for	O
noncytotoxic	O
agents	O
.	O
The	O
use	O
of	O
chemotherapeutic	O
or	O
antileukemic	O
agents	O
other	O
than	O
hydroxyurea	O
is	O
not	O
permitted	O
during	O
the	O
study	O
with	O
the	O
possible	O
exception	O
of	O
intrathecal	O
(	O
IT	O
)	O
therapy	O
at	O
the	O
discretion	O
of	O
the	O
Investigator	O
and	O
with	O
the	O
agreement	O
of	O
the	O
Sponsor	O
.	O

8	O
.	O

Persistent	O
chronic	O
clinically	B
significant	I
non	B
-	I
hematological	I
toxicities	B
from	O
prior	B
treatment	B
must	O
be	O
≤	B
Grade	I
1	I
.	O

9	O
.	O

Prior	O
therapy	B
with	O
FLT3	B
inhibitors	I
is	O
permitted	O
,	O
except	B
previous	O
treatment	B
with	O
AC220	B
.	O

10	O
.	O

Serum	B
creatinine	I
≤	B
1	I
.	I
5	I
×	I
ULN	I
and	O
glomerular	B
filtration	I
rate	I
(	I
GFR	I
)	I
>	B
30	I
mL	I
/	I
min	I

11	O
.	O

Serum	B
potassium	I
,	O
magnesium	O
,	O
and	O
calcium	O
levels	O
should	O
be	O
at	B
least	I
within	I
institutional	I
normal	I
limits	I
.	O

12	O
.	O

Total	B
serum	I
bilirubin	I
≤	B
1	I
.	I
5	I
×	I
ULN	I

13	O
.	O

Serum	B
aspartate	I
transaminase	I
(	I
AST	I
)	I
and	O
/	O
or	O
alanine	B
transaminase	I
(	I
ALT	I
)	I
≤	B
2	I
.	I
5	I
×	I
ULN	I

14	O
.	O

Females	B
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
pregnancy	B
test	I
(	O
urine	B
β	I
-	I
hCG	I
)	O
.	O

15	O
.	O

Females	O
of	O
childbearing	O
potential	O
and	O
sexually	O
mature	O
males	O
must	O
agree	O
to	O
use	O
a	O
medically	O
accepted	O
method	O
of	O
contraception	O
throughout	O
the	O
study	O
.	O

16	O
.	O

Written	O
informed	O
consent	O
must	O
be	O
provided	O
.	O

Patients	O
with	O
any	B
other	I
primary	B
DSM	B
-	I
IV	I
psychiatric	B
diagnosis	I
in	B
addition	I
to	I
Obsessive	B
Compulsive	I
Disorder	I
.	O

Patients	O
who	O
currently	O
fulfil	O
criteria	O
for	O
DSM	B
-	I
IV	I
eating	B
disorder	I
,	O
body	B
dysmorphic	I
disorder	I
,	O
current	O
alcohol	O
or	O
substance	B
abuse	I
,	O
or	O
who	O
have	O
a	O
lifetime	O
history	O
of	O
bipolar	B
disorder	I
.	O

Patients	O
with	O
a	O
history	O
of	O
Schizophrenia	B
and	O
other	B
psychotic	B
disorders	I
,	O
Delirium	B
,	O
Dementia	B
,	O
and	O
Amnestic	B
and	O
other	B
cognitive	B
disorders	I
.	O

Subjects	O
with	O
a	O
concurrent	O
Axis	B
II	I
Cluster	I
A	I
Personality	B
Disorder	I

Borderline	O
or	O
Antisocial	B
Personality	I
Disorder	I
.	O

Subjects	O
who	O
based	O
on	O
history	O
or	O
mental	B
status	I
examination	I
have	O
a	O
significant	B
risk	O
of	O
committing	O
suicide	O
,	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
.	O

Subjects	O
with	O
a	O
history	O
of	O
more	O
than	O
three	O
adequate	O
trials	O
with	O
an	O
SSRI	O
.	O

Subjects	O
who	O
have	O
had	O
an	O
adequate	O
trial	O
of	O
pregabalin	O
.	O

Subjects	O
who	O
have	O
initiated	O
psychotherapy	B
in	B
the	I
last	I
4	I
months	I
prior	I
to	I
the	I
first	I
visit	I
.	O

Subjects	O
who	O
,	O
during	O
the	O
course	O
of	O
the	O
study	O
,	O
would	O
be	O
likely	O
to	O
require	O
treatment	O
with	O
prohibited	O
concomitant	O
therapy	O
.	O

Prior	O
use	O
of	O
or	O
a	O
known	O
allergy	B
or	O
hypersensitivity	B
to	O
pregabalin	B
.	O

Subjects	O
who	O
have	O
participated	O
in	O
any	O
clinical	O
trial	O
within	O
30	O
days	O
prior	O
to	O
entering	O
the	O
study	O
,	O
or	O
in	O
a	O
clinical	O
trial	O
involving	O
a	O
psychotropic	O
medication	O
within	O
the	O
6	O
months	O
prior	O
to	O
entering	O
the	O
study	O
.	O

Any	O
subject	O
who	O
has	O
been	O
taking	O
benzodiazepines	O
before	O
entering	O
the	O
study	O
who	O
:	O
1	O
)	O
cannot	O
tolerate	O
being	O
free	O
of	O
benzodiazepines	O
for	O
4	O
weeks	O
,	O
or	O
2	O
)	O
has	O
signs	O
or	O
symptoms	O
of	O
benzodiazepine	O
withdrawal	O
or	O
rebound	O
at	O
the	O
end	O
of	O
those	O
4	O
weeks	O
.	O
Should	O
a	O
patient	O
entering	O
the	O
study	O
,	O
who	O
is	O
currently	O
on	O
benzodiazepines	O
develop	O
discontinuation	O
symptoms	O
with	O
discontinuation	O
of	O
their	O
benzodiazepine	O
,	O
we	O
will	O
treat	O
these	O
symptoms	O
with	O
a	O
more	O
gradual	O
benzodiazepine	O
taper	O
.	O
Study	O
will	O
be	O
delayed	O
until	O
the	O
patient	O
is	O
able	O
to	O
tolerate	O
the	O
discontinuation	O
for	O
4	O
weeks	O
.	O

Patients	O
with	O
a	O
current	O
seizure	B
disorder	I
,	O
organic	B
brain	I
disorder	I
or	O
a	O
history	B
of	I
seizure	I
disorders	I
(	O
except	B
for	O
febrile	B
seizures	I
in	O
childhood	B
)	O
.	O

Patients	O
with	O
thyroid	B
pathology	I
,	O
the	O
treatment	B
of	O
which	O
has	O
not	B
been	O
stabilized	B
for	O
at	B
least	I
three	I
months	I
.	O

Patients	O
on	O
neuroleptic	B
drugs	I
in	B
the	I
two	I
months	I
prior	I
to	I
study	I
entry	I
or	O
cognitive	B
behavioural	I
therapy	I
specific	O
to	O
OCD	B
within	B
four	I
weeks	I
of	I
study	I
entry	I

Pregnant	O
or	O
lactating	O
females	O
,	O
or	O
if	O
sexually	O
active	O
and	O
of	O
childbearing	O
potential	O
,	O
not	O
using	O
adequate	O
methods	O
of	O
birth	O
control	O
.	O

Patients	O
with	O
a	O
history	O
or	O
evidence	O
of	O
a	O
medical	O
condition	O
that	O
would	O
expose	O
them	O
to	O
an	O
increased	O
risk	O
of	O
a	O
significant	O
adverse	O
event	O
or	O
interfere	O
with	O
assessments	O
of	O
safety	O
and	O
efficacy	O
during	O
the	O
trial	O
.	O

Patients	O
receiving	O
psychotropics	B
of	O
any	O
kind	O
,	O
including	O
betablockers	B
and	O
other	O
anticonvulsants	B
.	O

Sleep	B
medication	I
such	O
as	O
oral	B
chloral	B
-	I
hydrate	I
or	O
zopiclone	B
are	O
acceptable	B
.	O

Patients	O
using	O
any	O
herbal	B
psychoactive	I
treatments	I
,	O
e	O
.	O
g	O
.	O
St	B
John	I
'	I
s	I
Wort	I
,	O
Valerian	B
,	O
Kava	B
Kava	I
,	O
L	B
-	I
tryptophan	I
.	O

Patients	O
with	O
any	O
condition	O
or	O
on	O
any	O
therapy	O
that	O
,	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
,	O
or	O
as	O
indicated	O
in	O
the	O
pregabalin	O
product	O
label	O
,	O
may	O
pose	O
a	O
risk	O
to	O
the	O
subject	O
.	O

Patients	O
who	O
have	O
had	O
a	O
major	O
life	O
event	O
in	O
the	O
past	O
three	O
months	O
,	O
which	O
in	O
the	O
judgement	O
of	O
the	O
investigator	O
is	O
influencing	O
their	O
current	O
condition	O
.	O

Patients	O
having	O
clinically	O
significant	B
abnormal	I
laboratory	O
,	O
or	O
ECG	B
findings	I
not	O
resolved	O
by	O
further	O
examinations	O
.	O

Must	O
be	O
an	O
outpatient	O
with	O
a	O
primary	B
DSM	B
-	I
IV	I
Obsessive	B
-	I
Compulsive	I
Disorder	I
.	O

Patients	O
must	O
have	O
a	O
score	B
of	I
greater	I
than	I
20	I
on	O
the	O
Yale	B
-	I
Brown	I
Obsessive	I
Compulsive	I
Scale	I
(	O
Y	B
-	I
BOCS	I
;	O
Goodman	O
et	O
al	O
.	O
,	O
1989b	O
)	O
.	O

Diagnosis	O
of	O
comorbid	B
DSM	B
-	I
IV	I
major	B
depressive	I
episode	I
will	O
be	O
allowed	O
in	O
the	O
study	O
provided	O
that	O
the	O
diagnosis	O
is	O
secondary	O
to	O
OCD	B
,	O
they	O
have	O
a	O
baseline	B
Montgomery	B
Depression	I
Rating	I
Scale	I
(	O
MADRS	B
)	O
score	B
of	I
less	I
than	I
or	I
equal	I
to	I
19	I
,	O
and	O
the	O
onset	B
of	I
OCD	I
predates	B
the	I
onset	I
of	I
the	I
current	I
episode	I
of	I
depression	I
by	I
five	I
or	I
more	I
years	I
.	O

The	O
ability	O
to	O
comprehend	O
and	O
comply	O
with	O
protocol	O
requirements	O
.	O

Written	O
consent	O
must	O
be	O
provided	O
prior	O
to	O
study	O
entry	O
.	O

All	O
women	B
of	O
childbearing	B
potential	I
(	O
WOCBP	B
)	O
must	O
be	O
practicing	O
a	O
medically	B
acceptable	I
method	O
of	O
birth	B
control	I

All	O
female	O
subjects	O
of	O
childbearing	O
potential	O
(	O
WOCBP	O
)	O
,	O
including	O
those	O
who	O
are	O
practicing	O
a	O
medically	O
acceptable	O
method	O
of	O
birth	O
control	O
,	O
must	O
have	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
72	O
hours	O
prior	O
to	O
the	O
start	O
of	O
study	O
medication	O
.	O

Subjects	O
with	O
hemoglobin	B
SC	I
or	O
SB	B
+	I
thalassemia	I

Subjects	O
on	O
chronic	B
transfusion	B
program	I

Subjects	O
who	O
have	O
received	O
RBC	B
transfusions	I
cannot	B
have	I
>	B
15	I
%	I
adult	I
hemoglobin	I

Known	O
positive	O
status	O
for	O
HIV	B
,	O
active	B
hepatitis	B
B	I
or	O
hepatitis	B
C	I

Pregnant	B
or	O
breast	O
feeding	O
women	B

Individuals	O
with	O
a	O
history	B
of	O
malignancy	B
are	O
ineligible	O
except	O
for	O
the	O
following	O
circumstances	O
.	O

Individuals	O
with	O
a	O
history	O
of	O
malignancy	O
are	O
eligible	O
if	O
they	O
have	O
been	O
disease	B
-	I
free	I
for	B
at	I
least	I
5	I
years	I
and	O
are	O
deemed	O
by	O
the	O
investigator	O
to	O
be	O
at	O
low	O
risk	O
for	O
recurrence	O
of	O
that	B
malignancy	I
.	O

Individuals	O
with	O
the	O
following	O
cancer	O
are	B
eligible	I
if	O
diagnosed	O
and	O
adequately	B
treated	B
within	B
the	I
past	I
5	I
years	I
:	O
cervical	O
or	O
breast	B
cancer	I
in	I
situ	I
,	O
and	O
basal	O
cell	O
or	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
skin	I

Subjects	O
with	O
a	O
history	B
of	O
thrombosis	B
or	O
other	O
reason	O
(	O
other	B
than	I
sickle	B
cell	I
disease	I
)	O
for	O
enhanced	O
thrombotic	B
risk	O

Subjects	O
with	O
unresolved	B
infections	B

Severe	O
or	O
uncontrolled	O
medical	B
conditions	I
that	O
could	O
compromise	B
study	I
participation	I

Subjects	O
on	O
fetal	B
hemoglobin	O
inducing	O
agents	O

Subjects	O
on	O
any	O
other	O
experimental	O
treatment	O
within	O
90	O
days	O
of	O
the	O
first	O
dose	O
of	O
study	O
drug	O
or	O
who	O
have	O
not	O
recovered	O
from	O
the	O
side	O
effects	O
of	O
such	O
therapy	O

Known	O
allergic	B
reaction	I
to	O
a	O
histone	B
deacetylase	I
inhibitor	I

Subjects	O
who	O
have	O
received	O
valproic	B
acid	I
for	O
treatment	B
of	O
epilepsy	B
within	B
30	I
days	I
of	I
enrollment	I

Subjects	O
who	O
have	O
received	O
any	O
HDAC	B
inhibitors	I
other	B
than	I
valproic	B
acid	I

Diagnosis	O
of	O
sickle	B
cell	I
disease	I

Clinically	B
significant	I
disease	O
defined	O
as	O
at	O
least	O
1	O
painful	B
episode	I
per	O
year	O
averaged	O
over	O
the	B
previous	I
3	I
years	I
or	O
a	O
history	B
of	O
priapism	B
,	O
stroke	B
,	O
acute	B
chest	I
syndrome	I
,	O
avascular	B
necrosis	I
,	O
multi	B
-	I
organ	I
failure	I
or	O
the	O
need	O
for	O
chronic	B
narcotic	B
medications	I
for	O
pain	B
from	O
sickle	B
cell	I
disease	I

Must	O
have	O
failed	O
a	O
previous	O
attempt	O
at	O
treatment	O
with	O
hydroxyurea	O
defined	O
as	O
the	O
inability	O
to	O
achieve	O
a	O
significant	O
absolute	O
increase	O
in	O
%	O
fetal	O
hemoglobin	O
or	O
the	O
inability	O
to	O
tolerate	O
hydroxyurea	O
treatment	O
due	O
to	O
severe	O
side	O
effects	O
such	O
as	O
but	O
not	O
limited	O
to	O
myelosuppression	O
,	O
gastrointestinal	O
symptoms	O
,	O
edema	O
or	O
hepatic	O
enzyme	O
elevations	O
or	O
have	O
contraindications	O
to	O
hydroxyurea	O

18	O
years	O
of	O
age	B
or	O
older	O

Hematologic	O
laboratory	O
values	O
as	O
outlined	O
in	O
the	O
protocol	O

Non	O
-	O
hematologic	O
laboratory	O
values	O
as	O
outlined	O
in	O
the	O
protocol	O

Must	O
agree	O
not	B
to	O
donate	B
blood	I
or	O
other	O
bodily	O
fluid	O
while	O
taking	O
the	O
study	B
drug	I
and	O
for	B
28	I
days	I
thereafter	I

Women	B
of	O
child	B
-	I
bearing	I
potential	I
(	O
WCBP	B
)	O
must	O
have	O
a	O
negative	B
serum	B
pregnancy	I
test	I
72	O
hours	O
or	O
less	O
prior	O
to	O
starting	O
treatment	B

Women	B
of	O
child	B
-	I
bearing	I
potential	I
and	O
men	B
must	O
agree	O
to	O
use	O
2	B
forms	I
of	O
adequate	B
contraception	B
prior	B
to	I
study	I
entry	I
and	O
for	B
the	I
duration	I
of	I
study	I
participation	I

Current	B
unstable	B
medical	O
condition	O
(	O
e	O
.	O
g	O
.	O
unstable	B
angina	I
,	O
myocardial	B
infarction	I
or	O
coronary	B
revascularization	I
in	B
the	I
preceding	I
12	I
months	I
,	O
cardiac	B
failure	I
,	O
chronic	B
renal	O
failure	O
,	O
chronic	B
hepatic	O
disease	O
,	O
severe	B
pulmonary	B
disease	I
,	O
blood	B
disorders	I
,	O
poorly	B
controlled	B
diabetes	B
,	O
chronic	B
infection	O
)	O

Able	O
to	O
give	O
fully	O
informed	O
consent	O
in	O
writing	O

Males	B
or	O
females	B
aged	B
>	B
/	I
=	I
50	I
years	I

No	B
significant	B
disease	B
or	O
drug	B
use	I

Absence	B
of	I
any	O
sign	O
of	O
dementia	B
/	O
cognitive	B
impairment	I
in	O
neuropsychological	B
examinationsPatients	I
for	O
brain	O
imaging	O
:	O

Patient	O
and	O
designee	O
capable	O
of	O
giving	O
fully	O
informed	O
consent	O
in	O
writing	O

Patient	O
fulfils	B
DSM	O
-	O
IV	O
and	O
NINCDS	B
-	I
ADRA	I
criteria	I
for	O
probable	O
Alzheimers	B
disease	I

choroidal	B
neovascularization	I
caused	O
by	O
other	B
eye	O
diseases	O

ocular	B
surgery	I
within	B
the	I
past	I
3	I
mouths	I

history	B
of	O
uveitis	B

intraocular	B
pressure	I
higher	B
than	I
25	I
mmHg	I
,	O
or	O
glaucoma	B

history	O
of	O
systemic	B
or	O
ocular	B
thromboembolic	B
events	I
.	O

choroidal	B
neovascularization	I
caused	O
by	O
age	B
-	I
related	I
macula	B
degeneration	I

no	B
previous	B
treatment	B

a	O
follow	O
-	O
up	O
at	B
least	I
12	I
months	I

a	O
baseline	B
visual	B
acuity	I
ranging	O
from	O
a	O
letter	B
score	I
of	I
0	I
to	I
70	I
on	O
the	O
Early	B
Treatment	I
Diabetic	I
Retinopathy	I
Study	I
chart	I

Subjects	O
with	O
evidence	O
of	O
liver	B
cirrhosis	I

Evidence	O
of	O
HCC	B

Co	O
-	O
infection	O
with	O
hepatitis	B
B	I
virus	I
,	O
HIV	B

Subjects	O
chronically	B
infected	O
with	O
HCV	B
Genotype	B
1	I

HCV	B
RNA	I
viral	I
load	I
of	O
≥	B
10	I
*	I
5	I
*	I
IU	I
/	I
mL	I
(	O
100	B
,	I
000	I
IU	I
/	I
mL	I
)	O
at	B
screening	I

1	O
.	O

Taking	O
a	O
tetracycline	B
within	B
6	I
months	I
or	O
history	B
of	O
adverse	B
reaction	I
to	O
minocycline	B
or	O
another	O
tetracycline	B
.	O

2	O
.	O

Enhanced	O
risk	O
from	O
lumbar	B
puncture	I
,	O
including	O
documented	O
or	O
suspected	O
cerebral	B
mass	I
lesion	I
predisposing	O
to	O
brain	B
herniation	I
or	O
bleeding	B
diathesis	I
.	O

3	O
.	O

Pregnancy	B
or	O
expectation	O
of	O
pregnancy	B
during	B
the	I
study	I
.	O

4	O
.	O

Active	B
opportunistic	B
infection	O
or	O
active	B
neurological	B
disease	I
that	O
might	O
confound	O
evaluation	O
.	O

5	O
.	O

ADC	B
Stage	I
>	B
1	I
.	O

6	O
.	O

Hemoglobin	B
<	B
10	I
Gms	I
/	I
dL	I
.	O

7	O
.	O

BUN	B
or	O
creatine	B
above	B
the	I
normal	I
limits	I
.	O

8	O
.	O

Taking	O
other	O
drugs	O
known	O
to	O
reduce	O
the	O
metabolism	O
of	O
minocycline	B
and	O
thus	O
increase	O
the	O
probability	O
of	O
toxicity	O
.	O

1	O
.	O

HIV	B
infection	I
with	O
plasma	O
and	O
CSF	B
HIV	I
RNA	I
concentrations	I
(	O
using	O
Roche	B
Amplicor	I
assay	I
)	O
>	B
1	I
,	I
000	I
copies	I
/	I
mL	I
(	O
available	O
after	O
baseline	O
LP	O
)	O
.	O

2	O
.	O

Off	O
antiretroviral	B
therapy	I
(	I
ART	I
)	I
for	O
>	B
6	I
weeks	I
before	I
the	I
study	I
and	O
no	B
plans	O
to	O
begin	O
treatment	B
for	B
the	I
study	I
duration	I
.	O

(	O
The	O
decision	O
of	O
whether	O
or	O
not	O
a	O
subject	O
takes	O
antiretroviral	O
therapy	O
will	O
be	O
made	O
by	O
the	O
subject	O
in	O
consultation	O
with	O
his	O
/	O
her	O
primary	O
care	O
provider	O
prior	O
to	O
screening	O
for	O
this	O
study	O
.	O
)	O

3	O
.	O

Predicted	O
adherence	O
to	O
the	O
medication	O
.	O

4	O
.	O

Capable	O
of	O
providing	O
informed	O
consent	O
.	O

5	O
.	O

>	O
18	B
years	I
old	B

6	O
.	O

CD4	B
cell	I
counts	I
>	B
150	I
cells	I
/	I
μL	I
(	O
though	O
likely	O
most	O
,	O
if	O
not	O
all	O
,	O
will	O
be	O
>	B
250	I
cells	I
/	I
μL	I
)	O
.	O

7	O
.	O

When	O
available	O
,	O
subjects	O
will	O
be	O
screened	O
for	O
stability	O
of	O
blood	O
CD4	O
and	O
HIV	O
RNA	O
levels	O
.	O

NA	O

Patients	O
with	O
angina	B
or	O
silent	B
ischemia	B
and	O
documented	B
ischemia	B

Patients	O
who	O
are	O
eligible	O
for	O
intracoronary	B
stenting	I

Age	B
>	B
18	I
years	I

De	B
novo	I
lesion	I
CTO	B

Reference	O
vessel	O
size	O
2	B
.	I
5	I
mm	I
by	O
visual	O
estimation	O

At	B
least	I
one	I
CTO	B
lesions	I
located	O
in	O
proximal	O
or	O
mid	O
epicardial	O
coronary	B
artery	I
.	O

(	O
If	O
the	O
patient	O
has	O
two	O
CTO	O
lesions	O
,	O
one	O
CTO	O
lesion	O
should	O
be	O
located	O
in	O
proximal	O
or	O
mid	O
epicardial	O
coronary	O
artery	O
)	O

Angiographically	B
defined	I
total	B
occlusion	I
over	O
3	B
months	I

If	O
no	O
definite	O
symptom	O
with	O
total	O
occlusion	O
,	O
two	O
experienced	O
operators	O
decide	O
CTO	O
in	O
consideration	O
of	O
angiographical	O
morphology	O
(	O
degree	O
of	O
calcification	O
,	O
bridging	O
collaterals	O
,	O
non	O
-	O
tapered	O
stump	O
,	O
angiographic	O
filling	O
from	O
collaterals	O
)	O

1	O
.	O

Prior	B
treatment	O
with	O
gemcitabine	B
,	O
carboplatin	B
(	O
except	O
in	O
the	O
adjuvant	O
setting	O
)	O
,	O
or	O
Iniparib	B
.	O

2	O
.	O

Past	B
or	O
current	B
history	B
of	O
neoplasm	B
other	O
than	O
the	O
entry	B
diagnosis	I
,	O
with	B
the	I
exception	I
of	I
treated	B
non	B
-	I
melanoma	I
skin	I
cancer	I
or	O
carcinoma	B
in	I
-	I
situ	I
of	O
any	O
primary	O
site	O
,	O
or	O
invasive	B
cancers	B
treated	B
definitively	O
,	O
with	O
treatment	O
ending	O
>	B
5	I
years	I
previously	I
and	O
no	B
evidence	O
of	O
recurrences	O
.	O

3	O
.	O

A	O
history	B
of	O
cardiac	B
disease	I
,	O
as	O
defined	O
by	O
:	O

Malignant	B
hypertension	I

Unstable	B
angina	I

Congestive	B
heart	I
failure	I

Myocardial	B
infarction	I
within	B
the	I
previous	I
6	I
months	I

Symptomatic	B
,	O
unstable	B
or	O
uncontrolled	B
,	O
cardiac	B
arrhythmias	I
.	O

Patients	O
who	O
have	O
stable	B
,	O
rate	B
-	I
controlled	I
atrial	B
fibrillation	I
are	B
eligible	I
for	O
study	O
enrollment	O
.	O

4	O
.	O

Active	B
brain	B
metastases	I
.	O

Patients	O
with	O
treated	B
brain	B
metastases	I
are	B
eligible	I
,	O
if	O
(	O
1	O
)	O
radiation	B
therapy	I
was	O
completed	O
at	B
least	I
2	I
weeks	I
prior	I
to	I
study	I
entry	I
;	O
(	O
2	O
)	O
follow	B
-	I
up	I
scan	I
shows	O
no	B
disease	B
progression	I
;	O
and	O
(	O
3	O
)	O
patient	O
does	O
not	B
require	O
steroids	B
.	O

5	O
.	O

Women	B
who	O
are	O
pregnant	B
or	O
lactating	B
.	O

6	O
.	O

Any	O
serious	B
,	O
active	B
infection	B
(	O
>	B
Grade	I
2	I
)	O
at	O
the	O
time	O
of	O
treatment	O
.	O

7	O
.	O

A	O
serious	B
underlying	O
medical	B
condition	I
that	O
would	O
impair	B
the	I
ability	I
of	I
the	I
patient	I
to	I
receive	I
protocol	I
treatment	I
.	O

8	O
.	O

A	O
major	B
surgical	B
procedure	I
,	O
or	O
significant	B
traumatic	B
injury	I
≤	B
28	I
days	I
of	I
beginning	I
treatment	I
,	O
or	O
anticipation	O
of	O
the	O
need	O
for	O
major	B
surgery	I
during	B
the	I
course	I
of	I
the	I
study	I
.	O

9	O
.	O
Uncontrolled	B
or	O
intercurrent	B
illness	B
including	O
,	O
that	O
in	B
the	I
opinion	I
of	I
the	I
investigator	I
may	I
increase	I
the	I
risks	I
associated	O
with	O
study	O
participation	O
or	O
administration	O
of	O
the	O
investigational	O
products	O
,	O
or	O
that	O
may	O
interfere	O
with	O
the	O
interpretation	O
of	O
the	O
results	O
.	O

10	O
.	O

History	O
of	O
any	O
medical	O
or	O
psychiatric	B
condition	I
or	O
laboratory	B
abnormality	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
may	O
increase	O
the	O
risks	O
associated	O
with	O
the	O
study	O
participation	O
or	O
administration	O
of	O
the	O
investigational	O
products	O
,	O
or	O
that	O
may	O
interfere	O
with	O
the	O
interpretation	O
of	O
the	O
results	O
.	O

11	O
.	O

Known	O
or	O
suspected	O
allergy	B
/	O
hypersensitivity	B
to	O
any	O
agent	B
given	I
in	I
the	I
course	I
of	I
this	I
trial	I
.	O

The	O
above	O
information	O
is	O
not	O
intended	O
to	O
contain	O
all	O
considerations	O
relevant	O
to	O
a	O
patient	O
'	O
s	O
potential	O
participation	O
in	O
a	O
clinical	O
trial	O
.	O

Eligible	O
patients	O
must	O
meet	O
the	O
following	O
criteria	O
to	O
be	O
enrolled	O
in	O
the	O
study	O
:	O

1	O
.	O

Newly	B
diagnosed	O
,	O
stage	B
IV	B
squamous	B
cell	I
lung	I
cancer	I
.	O

This	O
includes	O
patients	O
who	O
present	O
with	O
disseminated	B
metastases	B
,	O
and	O
those	O
with	O
a	O
malignant	B
pleural	O
or	O
pericardial	B
effusion	I
(	O
i	O
.	O
e	O
.	O
,	O
formerly	O
stage	B
IIIB	I
in	O
the	O
6th	B
TNM	I
staging	I
system	I
)	O
.	O

2	O
.	O

Patients	O
who	O
have	O
received	O
prior	O
adjuvant	B
therapy	I
for	O
early	B
-	I
stage	I
lung	I
cancer	I
are	O
eligible	O
if	O
at	O
least	O
12	O
months	O
have	O
elapsed	O
from	O
that	O
treatment	B
.	O

3	O
.	O

Histologically	B
confirmed	B
squamous	B
cell	I
bronchogenic	I
carcinoma	I
.	O

Patients	O
whose	O
tumors	O
contain	O
mixed	B
non	I
-	I
small	I
cell	I
histologies	I
are	O
eligible	O
,	O
as	O
long	O
as	O
squamous	B
carcinoma	I
is	O
the	O
predominant	B
histology	I
.	O

Mixed	B
tumors	I
with	O
small	B
cell	I
anaplastic	I
elements	I
are	O
not	B
eligible	O
.	O

Cytologic	O
specimens	O
obtained	O
by	O
brushings	O
,	O
washings	O
,	O
or	O
needle	O
aspiration	O
of	O
the	O
defined	O
lesion	O
are	O
acceptable	O
.	O

4	O
.	O

Patients	O
with	O
previous	B
radiotherapy	B
as	O
definitive	O
therapy	O
for	O
locally	B
advanced	I
non	B
-	I
small	I
cell	I
lung	I
cancer	I
are	O
eligible	O
,	O
as	O
long	O
as	O
the	O
recurrence	O
is	O
outside	O
the	O
original	O
radiation	O
therapy	O
port	O
.	O

Radiation	B
therapy	I
must	O
have	O
been	O
completed	O
>	B
4	I
weeks	I
prior	I
to	I
the	I
initiation	I
of	I
study	I
treatment	I
.	O

Patients	O
who	O
have	O
received	O
chemo	B
/	O
radiation	B
for	O
locally	B
advanced	I
NSCLC	B
are	O
not	B
eligible	O
.	O

Patients	O
who	O
have	O
received	O
palliative	B
radiation	I
therapy	I
for	O
symptomatic	B
metastases	O
must	O
have	O
completed	O
treatment	O
>	B
14	I
days	I
prior	I
the	I
initiation	I
of	I
the	I
study	I
treatment	I
.	O

5	O
.	O

Presence	O
of	O
evaluable	O
(	O
measureable	O
or	O
non	O
-	O
measurable	O
)	O
disease	O
.	O

6	O
.	O

ECOG	B
Performance	I
Status	I
of	O
0	B
or	I
1	I
.	O

7	O
.	O

Laboratory	O
values	O
as	O
follows	O
:	O

Absolute	B
neutrophil	I
count	I
(	I
ANC	I
)	I
>	B
1	I
,	I
500	I
/	I
microL	I
and	O
platelets	B
>	B
100	I
,	I
000	I
/	I
microL	I
(	O
≤	B
72	I
hours	I
prior	I
to	I
initial	I
treatment	I
)	O
.	O

Hemoglobin	B
>	B
9	I
g	I
/	I
dL	I
(	O
Note	O
:	O
Patients	O
may	O
be	O
transfused	O
or	O
receive	O
erythropoietin	O
to	O
maintain	O
or	O
exceed	O
this	O
level	O
)	O
.	O

Bilirubin	B
<	B
ULN	I
.	O

Alanine	B
aminotransferase	I
(	I
ALT	I
)	I
and	O
aspartate	B
aminotransferase	I
(	I
AST	I
)	I
≤	B
2	I
.	I
5	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
if	O
no	B
liver	B
involvement	I
or	O
≤	B
5	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
with	O
liver	B
involvement	I
.	I

Creatinine	B
<	B
2	I
.	I
0	I
mg	I
/	I
dL	I
,	O
or	O
creatinine	B
clearance	I
>	B
40	I
mL	I
/	I
min	I
(	O
as	O
calculated	O
by	O
the	O
Cockcroft	B
-	I
Gault	I
method	I
.	O

8	O
.	O
Women	O
of	O
childbearing	O
potential	O
must	O
have	O
a	O
negative	O
serum	O
pregnancy	O
test	O
performed	O
within	O
7	O
days	O
prior	O
to	O
start	O
of	O
treatment	O
.	O
Women	O
of	O
childbearing	O
potential	O
or	O
men	O
with	O
partners	O
of	O
childbearing	O
potential	O
must	O
use	O
effective	O
birth	O
control	O
measures	O
during	O
treatment	O
and	O
at	O
least	O
6	O
months	O
after	O
the	O
last	O
dose	O
of	O
the	O
study	O
treatment	O
.	O
If	O
a	O
woman	O
becomes	O
pregnant	O
or	O
suspects	O
she	O
is	O
pregnant	O
while	O
participating	O
in	O
this	O
study	O
,	O
she	O
must	O
agree	O
to	O
inform	O
her	O
treating	O
physician	O
immediately	O
.	O
Sexually	O
active	O
men	O
must	O
agree	O
to	O
use	O
a	O
medically	O
acceptable	O
form	O
of	O
birth	O
control	O
during	O
treatment	O
and	O
at	O
least	O
6	O
months	O
after	O
the	O
last	O
dose	O
.	O
If	O
a	O
female	O
partner	O
becomes	O
pregnant	O
during	O
the	O
course	O
of	O
the	O
study	O
the	O
treating	O
physician	O
should	O
be	O
informed	O
immediately	O
.	O

9	O
.	O

>	B
18	I
years	I
of	O
age	B
.	O

10	O
.	O

Ability	O
to	O
understand	O
the	O
nature	O
of	O
this	O
study	O
,	O
give	O
written	O
informed	O
consent	O
,	O
and	O
comply	O
with	O
study	O
requirements	O
.	O

11	O
.	O

Patients	O
entering	O
this	O
study	O
must	O
be	O
willing	O
to	O
provide	O
tissue	O
from	O
a	O
previous	O
tumor	O
biopsy	O
(	O
if	O
available	O
)	O
for	O
correlative	O
testing	O
.	O
An	O
exception	O
to	O
this	O
is	O
when	O
the	O
national	O
/	O
local	O
regulations	O
prohibits	O
some	O
of	O
the	O
key	O
activities	O
of	O
this	O
research	O
like	O
the	O
export	O
of	O
samples	O
to	O
third	O
countries	O
,	O
storage	O
of	O
coded	O
samples	O
or	O
global	O
gene	O
expression	O
profiling	O
without	O
a	O
pre	O
-	O
specified	O
list	O
of	O
target	O
genes	O
.	O
If	O
tissue	O
is	O
not	O
available	O
,	O
a	O
patient	O
will	O
still	O
be	O
eligible	O
for	O
enrollment	O
into	O
the	O
study	O
.	O

Intolerance	B
or	O
allergy	B
to	O
ASA	B
,	O
clopidogrel	B
or	O
ticlopidine	B
precluding	B
treatment	B
for	B
12	I
months	I

Concurrent	O
participation	O
in	O
other	O
investigational	O
study	O

Femoral	B
sheath	I
(	I
artery	I
)	I

At	B
least	I
two	I
of	O
the	O
following	O
additional	O
criteria	O

At	B
least	I
70	I
yrs	I
old	B

Female	B
gender	O

Diabetes	B

Creatinine	B
clearance	I
<	B
60mL	I
/	I
min	I

History	B
of	O
gastro	O
-	O
intestinal	O
or	O
other	B
organ	B
bleeding	I

Baseline	B
anemia	B

Current	B
treatment	B
with	O
glycoproteins	B
IIb	I
-	I
IIIa	I
inhibitors	I

NA	O

Stage	O
IA	O
or	O
IIA	O
disease	O

Not	O
specified	O

No	O
prior	O
therapy	O

an	O
underlying	B
infectious	B
disease	I

chromosomal	B
abnormality	I

metabolic	B
disorder	I

specific	O
brain	B
related	O
disorder	B
(	O
such	O
as	O
tuberous	B
sclerosis	I
)	O

history	O
of	O
fetal	B
cytomegalovirus	B
infection	I

birth	B
asphyxia	I

a	O
history	O
of	O
major	B
head	I
injury	I

a	O
chronic	B
use	I
of	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drugs	I
,	O
(	O
NSAID	B
)	O

known	O
brain	B
damage	I

Epilepsy	B

Abnormal	B
Electro	B
-	I
cardiogram	I
(	O
ECG	B
)	O

Epileptiform	B
EEG	B

Use	O
of	O
psychostimulants	B
,	O
anti	B
-	I
depressants	I
,	O
neuroleptics	B
or	O
anti	B
-	I
convulsive	I
agents	I
within	B
the	I
past	I
month	I
.	O

Lack	O
of	O
cooperation	O
in	O
the	O
screening	O
phase	O

A	O
formal	O
diagnosis	O
of	O
Autism	B
or	O
Pervasive	B
Developmental	I
Disorder	I
not	I
otherwise	I
specified	I
(	O
PDD	B
-	I
NOS	I
)	O
,	O
given	O
by	O
a	O
child	O
neurologist	O
.	O

Age	B
:	O
10	B
-	I
18	I
years	I
.	O

A	O
signed	O
parental	O
consent	O
form	O
.	O

1	O
.	O

The	O
patient	O
is	O
pregnant	B
or	O
breastfeeding	O
.	O

2	O
.	O

Evidence	O
of	O
STEMI	B
within	B
72	I
hours	I
of	O
the	O
intended	O
treatment	B
on	O
infarct	O
related	O
or	O
non	B
-	I
infarct	I
related	I
artery	I
.	O

3	O
.	O

Cardiogenic	B
shock	I
on	O
presentation	O
or	O
during	O
current	B
hospitalization	B
.	O

4	O
.	O

Left	B
ventricular	I
ejection	I
fraction	I
less	B
than	I
20	I
%	I
.	O

5	O
.	O

Known	O
allergies	B
to	O
:	O
aspirin	B
,	O
clopidogrel	B
(	O
Plavix	B
)	O
and	O
ticlopidine	B
(	O
Ticlid	B
)	O
,	O
heparin	B
,	O
bivalirudin	B
,	O
stainless	O
steel	O
,	O
or	O
contrast	B
agent	I
(	O
which	O
cannot	O
be	O
adequately	O
premedicated	O
)	O
.	O

6	O
.	O

A	O
platelet	B
count	I
less	B
than	I
75	I
,	I
000	I
cells	I
/	I
mm3	I
or	O
greater	B
than	I
700	I
,	I
000	I
cells	I
/	I
mm3	I
or	O
a	O
WBC	B
less	B
than	I
3	I
,	I
000	I
cells	I
/	I
mm3	I
.	O

7	O
.	O

Acute	O
or	O
chronic	B
renal	I
dysfunction	I
(	O
creatinine	B
greater	B
than	I
2	I
.	I
5	I
mg	I
/	I
dl	I
or	O
less	B
than	I
150µmol	I
/	I
L	I
)	O
.	O

8	O
.	O

Subject	O
is	O
currently	O
participating	O
in	O
an	O
investigational	O
drug	O
or	O
device	O
study	O
that	O
has	O
not	O
completed	O
the	O
primary	O
endpoint	O
or	O
that	O
clinically	O
interferes	O
with	O
the	O
current	O
study	O
endpoints	O
.	O
(	O
Note	O
:	O
Trials	O
requiring	O
extended	O
follow	O
-	O
up	O
for	O
products	O
that	O
were	O
investigational	O
,	O
but	O
have	O
since	O
become	O
commercially	O
available	O
,	O
are	O
not	O
considered	O
investigational	O
trials	O
)	O
.	O

9	O
.	O

Prior	O
participation	O
in	O
this	O
study	O
.	O

10	O
.	O

Within	B
30	I
days	I
prior	I
to	I
the	I
index	I
study	I
procedure	I
,	O
the	O
subject	O
has	O
undergone	O
a	O
previous	B
coronary	B
interventional	I
procedure	I
of	O
any	O
kind	O
.	O

Note	O
:	O
This	O
exclusion	O
criterion	O
does	O
not	B
apply	O
to	O
post	O
-	O
STEMI	B
patients	O
.	O

11	O
.	O

Stroke	B
or	O
transient	B
ischemic	I
attack	I
within	B
the	I
prior	I
3	I
months	I
.	O

12	O
.	O

Active	B
peptic	B
ulcer	I
or	O
upper	B
gastrointestinal	I
bleeding	I
within	B
the	I
prior	I
3	I
months	I
.	O

13	O
.	O

Subject	O
has	O
active	B
sepsis	B
.	O

14	O
.	O

Unprotected	B
left	B
main	I
coronary	I
artery	I
disease	I
(	O
stenosis	B
greater	B
than	I
50	I
%	I
)	O
.	O

15	O
.	O

In	O
the	O
investigator	O
'	O
s	O
opinion	O
,	O
subject	O
has	O
a	O
co	O
-	O
morbid	O
condition	O
(	O
s	O
)	O
that	O
could	O
limit	O
the	O
life	B
expectancy	I
to	O
less	B
than	I
one	I
year	I
,	O
or	O
limit	O
the	O
subject	O
'	O
s	O
ability	O
to	O
participate	O
in	O
the	O
study	O
or	O
comply	O
with	O
follow	O
-	O
up	O
requirements	O
or	O
impact	O
the	O
scientific	O
integrity	O
of	O
the	O
study	O
.	O

16	O
.	O

Subject	O
has	O
normal	O
or	O
insignificant	O
coronaries	O
(	O
i	O
.	O
e	O
.	O
coronary	B
lesion	I
(	O
s	O
)	O
less	O
than	O
50	O
%	O
stenosis	B
)	O
.	O

17	O
.	O

Any	O
target	O
vessel	O
has	O
evidence	O
of	O
:	O

excessive	O
thrombus	B
(	O
e	O
.	O
g	O
.	O
requires	O
target	B
vessel	I
thrombectomy	I
)	O

tortuousity	B
(	O
greater	B
than	I
60	I
degree	I
angle	B
)	O
that	O
makes	O
it	O
unsuitable	B
for	I
proper	I
stent	B
delivery	I
and	I
deployment	I
,	O

heavy	B
calcification	B
.	O

18	O
.	O

Any	O
target	B
lesion	I
requires	O
treatment	B
with	O
a	O
device	O
other	B
than	I
percutaneous	B
transluminal	I
coronary	I
angioplasty	I
(	I
PTCA	I
)	I
prior	O
to	O
stent	B
placement	I
(	O
e	O
.	O
g	O
.	O
but	O
not	O
limited	O
to	O
,	O
directional	B
coronary	I
atherectomy	I
,	O
excimer	B
laser	I
,	O
rotational	B
atherectomy	I
,	O
etc	O
.	O
)	O
.	O

19	O
.	O

Any	O
lesion	B
that	O
is	O
located	O
in	O
a	O
saphenous	B
vein	I
graft	I
,	O
however	O
,	O
lesions	O
located	O
within	B
the	I
native	I
vessel	I
but	O
accessed	B
through	I
the	I
graft	I
are	O
eligible	O
.	O

20	O
.	O

The	O
target	O
vessel	O
is	O
in	O
a	O
"	O
last	O
remaining	O
"	O
epicardial	O
vessel	O
(	O
e	O
.	O
g	O
.	O
greater	O
than	O
2	O
non	O
-	O
target	O
epicardial	O
vessels	O
and	O
the	O
bypass	O
grafts	O
to	O
these	O
territories	O
[	O
if	O
present	O
]	O
are	O
totally	O
occluded	O
)	O
.	O

1	O
.	O

Subject	O
is	O
at	B
least	I
18	I
years	I
old	B
.	O

2	O
.	O

Subject	O
requires	O
single	O
-	O
or	O
multi	B
-	I
vessel	I
percutaneous	B
coronary	I
intervention	I
(	I
PCI	I
)	I
of	O
de	B
novo	I
or	O
restenotic	B
target	B
lesion	I
(	O
including	O
in	B
-	I
stent	I
restenotic	B
lesions	O
)	O
.	O

3	O
.	O

Subject	O
'	O
s	O
lesion	O
(	O
s	O
)	O
is	O
(	O
are	O
)	O
amenable	B
to	I
stent	I
treatment	I
with	O
currently	O
available	O
FDA	O
-	O
approved	O
bare	O
metal	O
or	O
drug	B
eluting	I
stents	I
.	O

4	O
.	O

Subject	O
is	O
an	O
acceptable	O
candidate	O
for	O
elective	B
,	O
urgent	B
or	O
emergency	B
coronary	B
artery	I
bypass	I
graft	I
(	I
CABG	I
)	I
.	O

5	O
.	O

Subject	O
has	O
clinical	O
evidence	O
of	O
ischemic	B
heart	I
disease	I
in	O
terms	O
of	O
a	O
positive	B
functional	B
study	I
,	O
or	O
documented	O
symptoms	O
.	O

6	O
.	O

Documented	O
stable	B
angina	O
pectoris	O
[	O
Canadian	B
Cardiovascular	I
Society	I
Classification	I
(	I
CCS	I
)	I
1	B
,	I
2	I
,	I
3	I
,	I
or	I
4	I
]	O
,	O
unstable	B
angina	O
pectoris	O
with	O
documented	O
ischemia	B
(	O
Braunwald	B
Class	I
IB	B
-	I
C	I
,	I
IIB	I
-	I
C	I
,	I
or	I
IIIB	I
-	I
C	I
)	O
,	O
non	B
-	I
ST	I
segment	I
elevation	I
myocardial	I
infarction	I
,	O
or	O
documented	O
silent	B
ischemia	O
.	O

7	O
.	O

Subject	O
is	O
willing	O
and	O
able	O
to	O
undergo	O
percutaneous	B
intervention	I
at	O
SOS	O
hospital	O
,	O
if	O
randomized	O
to	O
SOS	O
study	O
arm	O
.	O

8	O
.	O

Subject	O
and	O
the	O
treating	O
physician	O
agree	O
that	O
the	O
subject	O
will	O
comply	O
with	O
all	O
follow	O
-	O
up	O
evaluations	O
.	O

9	O
.	O

Subject	O
has	O
been	O
informed	O
of	O
the	O
nature	O
of	O
the	O
study	O
and	O
agrees	O
to	O
its	O
provisions	O
and	O
has	O
provided	O
written	O
informed	O
consent	O
as	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
/	O
Ethics	O
Committee	O
of	O
the	O
respective	O
clinical	O
site	O
.	O

10	O
.	O

The	O
target	B
lesion	I
(	O
s	O
)	O
is	O
(	O
are	O
)	O
de	B
novo	I
or	O
restenotic	B
(	O
including	O
in	B
-	I
stent	I
restenotic	I
)	O
native	O
coronary	B
artery	I
lesion	I
(	O
s	O
)	O
with	O
greater	B
than	I
50	I
and	I
less	I
than	I
100	I
%	I
stenosis	B
(	O
visual	O
estimate	O
)	O
,	O
or	O
the	O
target	B
lesion	I
is	O
an	O
acute	B
(	O
less	B
than	I
1	I
month	I
)	O
total	B
occlusion	I
as	O
evidenced	O
by	O
clinical	O
symptoms	O
.	O

11	O
.	O

Target	B
lesions	I
(	O
s	O
)	O
is	O
(	O
are	O
)	O
located	O
in	O
an	O
infarct	B
(	O
if	O
not	B
treated	O
with	O
primary	B
PCI	I
)	O
or	O
non	B
-	I
infarct	I
-	I
related	I
artery	I
with	O
a	O
70	B
%	I
or	I
greater	I
stenosis	B
(	O
by	O
visual	O
estimate	O
)	O
more	O
than	O
72	O
hours	O
following	O
the	O
ST	B
segment	I
elevation	I
myocardial	I
infarction	I
(	I
STEMI	I
)	I
.	O

Lesions	O
treated	O
with	O
PCI	O
more	O
than	O
72	O
hours	O
following	O
STEMI	O
would	O
be	O
subject	O
to	O
the	O
same	O
protocol	O
inclusion	O
/	O
exclusion	O
criteria	O
listed	O
above	O
and	O
below	O
with	O
the	O
exception	O
that	O
a	O
target	O
lesion	O
of	O
70	O
%	O
or	O
greater	O
stenosis	O
may	O
be	O
treated	O
with	O
or	O
without	O
symptoms	O
or	O
abnormal	O
stress	O
test	O
)	O
.	O

Inability	O
to	O
obtain	O
consent	O

Subjects	O
under	B
18	I
years	I
of	O
age	B

Non	O
-	O
English	O
speaking	O
subjects	O

Subjects	O
that	O
are	O
unable	B
to	I
lay	I
flat	I
due	O
to	O
pulmonary	B
complications	I
,	O
increased	B
intracranial	I
pressure	I
(	I
ICP	I
)	I
,	O
or	O
unstable	B
spinal	B
cord	I
injuries	I

Subjects	O
with	O
known	O
cardiac	B
abnormalities	I
(	O
atrial	B
septal	I
defects	I
or	O
ventricular	B
septal	I
defects	I
,	O
severe	B
tricuspid	B
valve	I
disease	I
,	O
severe	B
pulmonary	B
hypertension	I
,	O
Ejection	B
fraction	I
<	B
15	I
%	I
)	O

Prisoners	B

Subjects	O
with	O
known	O
upper	B
extremity	I
deep	I
vein	I
thromboses	I
(	O
subclavian	B
or	O
distal	B
)	O

Subjects	O
with	O
non	B
-	I
functional	I
CICC	O
or	O
PICC	B
distal	I
ports	I

Subjects	O
with	O
femoral	B
CICCs	I

Pregnant	B
women	B

Subject	O
'	O
s	O
ability	O
to	O
lay	O
in	O
a	O
supine	O
position	O
with	O
their	O
hands	O
at	O
their	O
sides	O
during	O
CVP	B
measurements	I

A	O
consent	O
form	O
signed	O
by	O
the	O
patient	O
or	O
patient	O
'	O
s	O
representative	O

Subjects	O
that	O
are	O
age	B
18	B
-	I
90	I

Subjects	O
that	O
have	O
an	O
indwelling	B
CICC	I
and	O
are	O
transitioning	O
to	O
a	O
PICC	B
for	O
long	O
-	O
term	O
IV	O
access	O

CICC	B
placed	I
in	B
the	I
internal	I
jugular	I
vein	I
or	I
subclavian	I
vein	I
position	I

Meets	B
criteria	O
for	O
Major	B
Depressive	I
Episode	I
,	O
by	O
Diagnostic	B
Statistical	I
Manual	I
of	I
Mental	I
Disorder	I
-	I
IV	I
(	I
TR	I
)	I
criteria	I

Clinically	B
significant	I
agitation	B
/	I
aggression	I
for	O
which	O
either	O
1	O
)	O
the	O
frequency	O
of	O
agitation	B
/	I
aggression	I
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Very	B
frequently	I
'	O
,	O
or	O
2	O
)	O
the	O
frequency	O
of	O
agitation	B
/	I
aggression	I
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Frequently	B
'	O
AND	O
the	O
severity	O
of	O
the	O
agitation	B
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Moderate	B
'	O
,	O
or	O
'	O
Marked	B
'	O

Clinically	B
significant	I
delusions	B
for	O
which	O
either	O
1	O
)	O
the	O
frequency	O
of	O
delusions	B
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Very	B
frequently	I
'	O
,	O
or	O
2	O
)	O
the	O
frequency	O
of	O
delusions	B
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Frequently	B
'	O
AND	O
the	O
severity	O
of	O
the	O
delusions	B
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Moderate	B
'	O
,	O
or	O
'	O
Marked	B
'	O

Clinically	B
significant	I
hallucinations	B
for	O
which	O
either	O
1	O
)	O
the	O
frequency	O
of	O
hallucinations	B
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Very	B
frequently	I
'	O
,	O
or	O
2	O
)	O
the	O
frequency	O
of	O
hallucinations	B
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Frequently	B
'	O
AND	O
the	O
severity	O
of	O
the	O
hallucinations	B
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Moderate	B
'	O
,	O
or	O
'	O
Marked	B
'	O

Treatment	O
with	O
psychotropic	B
medications	I
in	B
the	I
2	I
weeks	I
prior	I
to	I
randomization	I
with	B
the	I
exception	I
of	I
approved	O
treatments	O
for	O
dementia	B
(	O
ChEIs	B
and	O
memantine	B
)	O
,	O
selective	B
serotonin	I
reuptake	I
inhibitor	I
antidepressants	I
,	O
and	O
trazodone	B
(	O
if	O
used	O
as	O
an	O
aid	O
to	O
facilitate	O
sleep	O
and	O
not	O
as	O
an	O
antidepressant	O
)	O
;	O
other	B
psychotropics	I
(	O
with	B
the	I
exclusion	I
of	I
antipsychotics	B
)	O
,	O
if	O
stable	B
for	B
3	I
months	I
,	O
may	O
be	O
allowed	O
only	O
with	O
Steering	O
Committee	O
approval	O
on	O
a	O
case	O
by	O
case	O
basis	O
.	O

Note	O
that	O
antipsychotics	O
are	O
expressly	O
prohibited	O
.	O

Treatment	O
with	O
methylphenidate	B
is	O
contraindicated	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O

Failure	O
of	O
treatment	O
with	O
methylphenidate	B
in	O
the	O
past	O
for	O
apathy	O
after	O
convincing	O
evidence	O
of	O
an	O
adequate	O
trial	O
as	O
judged	O
by	O
study	O
physician	O

Treatment	O
with	O
a	O
medication	O
that	O
would	O
prohibit	O
the	O
safe	O
concurrent	B
use	O
of	O
methylphenidate	B
such	O
as	O
monoamine	B
oxidase	I
inhibitors	I
and	O
tricyclic	B
antidepressants	I

Need	O
for	O
acute	B
psychiatric	B
hospitalization	I
or	O
is	O
suicidal	B

Uncontrolled	B
hypertension	O
(	O
medication	B
non	I
-	I
compliance	I
or	O
past	B
3	I
months	I
with	O
a	O
diastolic	B
reading	I
of	O
105	B
as	O
verified	O
by	O
compartment	B
pressure	I
of	I
the	I
rectus	I
sheath	I
(	I
CPRS	I
)	I
)	O

Symptomatic	B
coronary	B
artery	I
disease	I
deemed	O
to	O
be	O
significant	O
by	O
study	O
physician	O
at	B
the	I
time	I
of	I
screening	I

Lack	B
of	I
appetite	I
that	O
results	O
in	O
significant	B
unintentional	B
weight	I
loss	I
as	B
determined	I
by	I
the	I
study	I
physician	I
in	B
the	I
last	I
three	I
months	I

Significant	B
communicative	B
impairments	I

Current	O
participation	O
in	O
a	O
clinical	O
trial	O
or	O
in	O
any	O
study	O
that	O
may	O
add	O
significant	O
burden	O
or	O
affect	O
study	O
outcomes	O

Hyperthyroidism	B
,	O
advanced	B
arteriosclerosis	B
,	O
symptomatic	B
cardiovascular	B
disease	I
,	O
serious	B
structural	B
cardiac	I
abnormalities	I
,	O
cardiomyopathy	B
,	O
serious	B
heart	B
rhythm	I
abnormalities	I
,	O
or	O
a	O
family	O
history	O
of	O
sudden	B
death	I
or	O
death	O
related	B
to	I
heart	I
problems	I

Glaucoma	B
,	O
pheochromocytoma	B
,	O
or	O
known	O
or	O
suspected	O
hypersensitivity	B
to	O
methylphenidate	O
or	O
its	B
excipients	I

Central	B
Nervous	I
System	I
(	I
CNS	I
)	I
abnormalities	I
(	O
e	O
.	O
g	O
.	O
,	O
cerebral	B
aneurysm	I
)	O
and	O
/	O
or	O
other	O
vascular	B
abnormalities	I
such	O
as	O
vasculitis	B
or	O
pre	B
-	I
existing	I
stroke	B
,	O
motor	B
tics	I
or	O
a	O
family	O
history	O
or	O
diagnosis	O
of	O
Tourette	B
'	I
s	I
syndrome	I
,	O
seizures	B
(	O
convulsions	B
,	O
epilepsy	B
)	O
,	O
or	O
abnormal	B
EEGs	B

Any	O
condition	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O
,	O
makes	O
it	O
medically	O
inappropriate	O
or	O
risky	O
for	O
the	O
patient	O
to	O
enroll	O
in	O
the	O
trial	O

Possible	B
or	O
probable	B
Alzheimer	B
'	I
s	I
disease	I
(	O
National	B
Institute	I
of	I
Neurological	I
and	I
Communicative	I
Disorders	I
and	I
Stroke	I
-	I
Alzheimer	I
'	I
s	I
Disease	I
and	I
Related	I
Disorders	I
Association	I
(	I
NINCDS	I
-	I
ADRDA	I
)	I
criteria	I
)	O
,	O
with	O
Mini	B
-	I
Mental	I
State	I
Exam	I
(	I
MMSE	I
)	I
score	B
of	I
10	I
-	I
26	I
inclusive	I
;	O
MMSE	B
scores	B
above	I
26	I
in	O
those	O
who	O
nevertheless	O
meet	O
criteria	O
for	O
AD	B
may	O
be	O
allowed	O
with	O
Steering	O
Committee	O
approval	O
on	O
a	O
case	O
by	O
case	O
basis	O

Clinically	O
significant	O
apathy	B
for	O
at	B
least	I
four	I
weeks	I
for	O
which	O
either	O
1	O
)	O
the	O
frequency	O
of	O
apathy	O
as	O
assessed	O
by	O
the	O
Neuropsychiatric	B
Inventory	I
(	I
NPI	I
)	I
is	O
'	O
Very	B
frequently	I
'	O
,	O
or	O
2	O
)	O
the	O
frequency	O
of	O
apathy	O
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Frequently	B
'	O
or	O
'	O
Often	B
'	O
AND	O
the	O
severity	O
of	O
apathy	O
as	O
assessed	O
by	O
the	O
NPI	B
is	O
'	O
Moderate	B
'	O
or	O
'	O
Marked	B
'	O

A	O
medication	O
for	O
apathy	B
is	O
appropriate	O
,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O

Provision	O
of	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
study	O
by	O
patient	O
or	O
surrogate	O
(	O
if	O
the	O
patient	O
is	O
unable	O
to	O
provide	O
informed	O
consent	O
)	O
and	O
caregiver	O

Availability	O
of	O
primary	O
caregiver	O
,	O
who	O
spends	O
greater	O
than	O
ten	O
hours	O
a	O
week	O
with	O
the	O
patient	O
and	O
supervises	O
his	O
/	O
her	O
care	O
,	O
to	O
accompany	O
the	O
patient	O
to	O
study	O
visits	O
and	O
to	O
participate	O
in	O
the	O
study	O

Sufficient	O
fluency	O
,	O
of	O
both	O
the	O
patient	O
and	O
caregiver	O
,	O
in	O
written	O
and	O
spoken	O
English	O
to	O
participate	O
in	O
study	O
visits	O
,	O
physical	O
exams	O
,	O
and	O
outcome	O
assessments	O

No	B
change	O
to	O
AD	B
medications	I
within	B
the	I
month	I
preceding	I
randomization	I
,	O
including	O
starting	O
,	O
stopping	O
,	O
or	O
dosage	O
modifications	O

Treatment	B
with	O
stable	B
doses	I
of	O
selective	B
serotonin	I
reuptake	I
inhibitor	I
antidepressants	I
(	I
SSRIs	I
)	I
is	O
appropriate	O
if	O
stable	O
for	O
3	O
months	O
prior	O
to	O
randomization	O
.	O
Other	O
psychotropics	O
(	O
with	O
the	O
exclusion	O
of	O
antipsychotics	O
)	O
,	O
if	O
stable	O
for	O
3	O
months	O
,	O
may	O
be	O
allowed	O
only	O
with	O
Steering	O
Committee	O
approval	O
on	O
a	O
case	O
by	O
case	O
basis	O
.	O

current	B
alcohol	B
abuse	I
or	O
drug	B
dependence	I

pregnancy	B

active	O
opportunistic	B
infection	I
or	O
significant	B
co	B
-	I
morbidities	I

current	B
prohibited	B
concomitant	B
medication	B

a	O
likelihood	O
of	O
diminished	O
response	O
to	O
any	O
of	O
the	O
study	O
treatment	O
arms	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
based	O
on	O
HIV	O
genotypic	O
resistance	O
testing	O

HIV	B
-	I
1	I
infected	I
males	B
or	O
females	B

over	B
18	I
years	I
of	O
age	B

signed	O
informed	O
consent	O

currently	O
receiving	O
a	O
stable	O
antiretroviral	B
regimen	I
comprising	O
of	O
:	O

two	B
or	I
more	I
licensed	B
NRTIs	B

one	B
licensed	B
NNRTI	B
or	O
boosted	B
protease	I
inhibitor	I

no	O
previous	O
protease	B
inhibitor	I
resistance	O
documented	O
on	O
HIV	B
-	I
1	I
genotypic	O
resistance	O
testing	O

failure	O
of	O
current	B
antiretroviral	B
regimen	I
due	O
to	O
:	O

toxicity	B
,	O
intolerance	B
or	O
virological	B
failure	I
if	O
receiving	O
an	O
NNRTI	B
containing	O
regimen	O
at	B
screening	I

toxicity	B
or	O
intolerance	B
if	O
receiving	O
a	O
boosted	O
-	O
protease	B
inhibitor	I
regimen	O
at	B
screening	I
(	O
with	O
plasma	B
HIV	I
RNA	I
<	B
400	I
copies	I
/	I
mL	I
at	B
screening	I
)	O

willing	O
to	O
modify	O
antiretroviral	B
therapy	I
,	O
in	O
accordance	O
with	O
the	O
randomisation	O
assignment	O

no	B
previous	B
exposure	O
to	O
etravirine	B

subjects	O
in	O
good	B
health	I
upon	O
medical	B
history	I
,	O
physical	B
exam	I
,	O
and	O
laboratory	B
testing	I
in	O
the	O
opinion	O
of	O
the	O
investigator	O

have	O
no	O
serologic	O
evidence	O
of	O
active	O
HBV	B
infection	I
evidenced	O
by	O
negative	B
hepatitis	B
B	I
surface	I
antigen	I

female	B
subjects	O
who	O
are	O
heterosexually	B
active	I
and	O
of	O
childbearing	B
potential	I
(	O
i	O
.	O
e	O
.	O
,	O
not	B
surgically	B
sterile	O
or	O
at	B
least	I
two	I
years	I
post	B
menopausal	I
)	O
must	O
practice	O
contraception	B
as	O
follows	O
from	O
screening	O
through	O
completion	O
of	O
the	O
study	O
:	O

barrier	B
contraceptives	I
(	O
condom	B
,	O
diaphragm	B
with	B
spermicide	I
)	O

IUD	B
or	O
Depo	B
PLUS	O
a	O
barrier	B
contraceptive	I

female	B
subjects	O
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
pregnancy	B
test	I
.	O

Inability	O
to	O
provide	O
informed	O
consent	O
or	O
to	O
comply	O
with	O
study	O
assessments	O
(	O
e	O
.	O
g	O
.	O
due	O
to	O
cognitive	O
impairment	O
or	O
geographic	O
distance	O
)	O
.	O

Age	B
=	B
17	I
.	O

Allergy	B
to	O
povidone	B
iodine	I
.	O

Any	O
condition	O
requiring	O
antibiotics	B
14	O
days	O
prior	O
to	O
arriving	O
for	O
surgery	B
.	O

Patients	O
with	O
chronic	B
immunosuppression	B
(	O
such	O
as	O
HIV	B
/	I
AIDS	I
)	O
.	O

Unable	O
to	O
adhere	O
to	O
follow	O
up	O
schedule	O
and	O
treatment	O
.	O

Patients	O
scheduled	O
to	O
undergo	O
revision	B
total	I
knee	I
arthroplasty	I
for	O
infectious	B
reasons	I
.	O

Scheduled	O
to	O
undergo	O
revision	B
total	I
knee	I
arthroplasty	I

Blood	B
donation	I
of	O
more	B
than	I
450ml	I
in	B
the	I
previous	I
three	I
months	I
.	O

Subject	O
with	O
an	O
abnormal	B
karyotype	I
in	O
favor	O
of	O
Turner	B
syndrome	I
or	O
having	O
a	O
premutation	B
of	I
the	I
FMR1	I
gene	I
or	O
a	O
syndromic	B
form	I

Subject	O
exclusion	O
period	O
in	O
another	O
study	O
without	O
direct	O
individual	O
benefit	O

Subject	O
refusing	O
to	O
sign	O
the	O
consent	O
form	O

Patients	O
of	O
familial	O
cases	O
of	O
POF	O
:	O

Female	B
subjects	O
between	O
16	O
and	O
40	O
years	B
or	O
women	B
older	B
than	I
40	I
years	I
with	O
a	O
cessation	B
of	I
ovarian	I
function	I
before	O
the	O
age	B
of	O
40	O
years	O
with	O
increased	B
levels	B
of	I
FSH	I

Primary	B
or	O
secondary	B
amenorrhea	B
for	B
more	I
than	I
three	I
months	I
with	O
LH	B
and	O
FSH	B
>	B
30mUI	I
/	I
ml	I

No	B
cases	O
of	O
fragile	B
X	I
syndrome	I
in	O
the	O
family	O
or	O
blepharophimosis	B
syndrome	I

At	B
least	I
two	I
cases	O
in	O
the	O
family	O

Origin	O
Caucasian	B

Patient	O
signing	O
the	O
consent	O
form	O
for	O
at	O
least	O
the	O
blood	O
sample	O

Patient	O
with	O
Social	O
Security	O

Population	O
Index	O
related	O
topics	O
:	O

The	O
presence	B
of	I
cycles	I
until	O
the	O
age	B
of	O
40	O
years	O
with	O
proven	O
fertility	O
,	O
at	O
least	O
one	O
child	O

Amenorrhea	B
and	O
FSH	B
>	B
30mUI	I
/	I
ml	I
according	O
to	O
the	O
criteria	O
of	O
the	O
index	O
subject	O

Men	O
of	O
the	O
family	O
of	O
index	O
case	O

Population	O
control	O
:	O

Women	B
of	O
Caucasian	B
origin	I

Women	B
who	O
had	O
regular	B
cycles	I
until	O
at	O
least	O
age	B
40	O
and	O
at	O
least	O
one	O
child	O

Lack	O
of	O
land	O
autoimmune	B
(	O
no	B
history	B
of	O
thyroid	B
disease	I
or	O
diabetes	B
type	I
1	I
)	O

Woman	O
signing	O
the	O
consent	O
form	O
for	O
at	O
least	O
the	O
blood	O
sample	O

With	O
the	O
history	O
of	O
cognitive	B
disorders	I

With	O
chronic	B
neurological	I
disorders	I

Cannot	O
communicate	O
with	O
investigators	O

Cannot	O
stand	O
general	B
anesthesia	I

Patients	O
with	O
informed	O
consents	O

Without	B
basal	B
disorders	I
of	I
neurology	I
and	O
psychiatrics	O

Severe	B
intercurrent	B
infection	B

Known	O
HIV	B
positivity	I

Pregnant	B
or	O
lactating	B

History	O
of	O
hypersensitivity	B
reactions	I
to	O
murine	B
protein	O
-	O
containing	O
products	O
.	O

Histopathological	B
verification	O
of	O
glioblastoma	B
multiforme	I
(	O
GBM	B
:	O
WHO	B
grade	B
IV	I
)	O
in	B
remission	I
(	O
Group	B
A	I
)	O
or	O
with	O
active	B
disease	O
(	O
Group	B
B	I
)	O
.	O

CMV	B
-	O
positive	O
GBM	B

CMV	B
seropositive	I

Life	O
expectancy	O
6	B
weeks	I
or	I
greater	I

Karnofsky	B
/	I
Lansky	I
score	B
50	I
or	I
greater	I

Patient	O
or	O
parent	O
/	O
guardian	O
capable	O
of	O
providing	O
informed	O
consent	O

Bilirubin	B
less	B
than	I
1	I
.	I
5x	I
upper	I
limit	I
of	I
normal	I
,	O
AST	B
less	B
than	I
3x	I
upper	I
limit	I
of	I
normal	I
,	O
serum	O
creatinine	O
less	O
than	O
1	O
.	O
5x	O
normal	O
and	O
Hgb	O
8	O
.	O
0	O
g	O
/	O
dL	O
or	O
greater	O

Pulse	B
oximetry	I
of	O
90	B
%	I
or	I
greater	I
on	B
room	I
air	I

Sexually	O
active	O
patients	O
must	O
be	O
willing	O
to	O
utilize	O
one	O
of	O
the	O
more	O
effective	O
birth	O
control	O
methods	O
for	O
6	O
months	O
after	O
the	O
CTL	O
infusion	O
.	O
The	O
male	O
partner	O
should	O
use	O
a	O
condom	O
.	O

Patients	O
should	O
have	O
been	B
off	I
other	O
investigational	O
antineoplastic	B
therapy	I
for	B
one	I
month	I
prior	I
to	I
entry	I
in	I
this	I
study	I
.	O

Informed	O
consent	O
explained	O
to	O
,	O
understood	O
by	O
and	O
signed	O
by	O
patient	O
/	O
guardian	O
.	O
Patient	O
/	O
guardian	O
given	O
copy	O
of	O
informed	O
consent	O
.	O

1	O
.	O

Atrial	B
fibrillation	I
;	O

2	O
.	O

Subject	O
underwent	O
cardiac	B
pacemaker	I
treatment	O
;	O

3	O
.	O

Subject	O
underwent	O
metal	B
graft	I
treatment	O
;	O

4	O
.	O

Claustrophobia	B
;	O

5	O
.	O

Acute	B
myocardial	I
infarction	I
,	O
cardiac	B
ischemia	I
indicated	O
by	O
6	B
-	I
minute	I
walk	I
test	I
,	O
hypertrophic	B
cardiomyopathy	I
,	O
constrictive	B
pericarditis	I
,	O
significant	B
valve	B
disease	I
or	O
congenital	B
heart	O
disease	O
,	O
severe	B
pulmonary	O
hypertension	O
;	O

6	O
.	O

Ischemic	B
heart	I
failure	I
without	B
the	O
revascularization	B
or	O
undergone	O
the	O
revascularization	B
within	B
last	I
6	I
months	I
;	O

7	O
.	O

Subject	O
underwent	O
cardiac	B
surgery	I
or	O
cerebrovascular	B
events	I
within	B
the	I
previous	I
six	I
months	I
;	O

8	O
.	O

Subjects	O
who	O
plan	O
to	O
have	O
cardiac	B
transplantation	I
;	O

9	O
.	O

Severe	O
hepatic	O
and	O
renal	B
insufficiency	I
(	O
serum	B
creatinine	I
>	B
2	I
.	I
0	I
mg	I
/	I
dl	I
,	O
AST	B
or	O
ALT	B
is	O
five	B
times	I
higher	I
than	I
the	I
upper	I
limit	I
of	I
normal	I
range	I
)	O
;	O

10	O
.	O

Subject	O
needs	O
mechanical	B
ventilation	I
;	O

11	O
.	O

Systolic	O
blood	B
pressure	I
<	B
90mmHg	I
,	O
or	O
>	B
160mmHg	I
;	O

12	O
.	O

Chronic	B
heart	I
failure	I
complicated	O
with	O
acute	B
hemodynamic	I
disturbance	I
or	O
acute	B
decompensation	I
within	B
last	I
1	I
month	I
;	O

13	O
.	O

Mobitz	B
Type	B
II	I
or	I
III	I
°	O
atrial	B
ventricular	I
block	I
，	O
severe	B
ventricular	B
arrhythmia	I
(	O
polymorphic	B
and	O
frequent	B
premature	O
ventricular	O
beats	O
,	O
frequent	B
non	B
-	I
sustained	I
ventricular	B
tachycardia	I
)	O
;	O

14	O
.	O

Serum	B
potassium	I
<	B
3	I
.	I
2mmol	I
/	I
L	I
,	O
or	O
>	B
5	I
.	I
5mmol	I
/	I
L	I
;	O

15	O
.	O

Female	B
subject	O
is	O
pregnant	B
or	O
plan	O
to	O
become	O
pregnant	B

16	O
.	O

Childbearing	O
-	O
aged	O
female	B
subject	O
who	O
is	O
unmarried	O
or	O
dose	O
not	B
bear	O
child	O
;	O

17	O
.	O

Subject	O
with	O
life	O
expectancy	O
less	B
than	I
6	I
months	I
as	O
assessed	O
by	O
investigators	O
;	O

18	O
.	O

Subject	O
participated	O
in	O
any	O
other	O
clinical	O
trial	O
within	O
the	O
previous	O
three	O
months	O
;	O

19	O
.	O

Subject	O
with	O
previous	B
history	I
of	O
tumor	B
,	O
or	O
current	B
tumor	B
patient	O
,	O
or	O
subject	O
with	O
pre	B
-	I
cancerous	I
disease	I
manifested	O
by	O
pathological	B
examination	I
(	O
such	O
as	O
ductal	B
carcinoma	I
in	I
situ	I
or	O
cervical	B
epithelial	I
dysplasia	I
)	O

20	O
.	O

Examinations	B
(	O
physical	B
examination	I
,	O
X	B
-	I
ray	I
examination	I
,	O
type	B
-	I
B	I
ultrasonic	I
detection	I
or	O
other	B
methods	I
)	O
reveal	O
that	O
the	O
subject	O
has	O
malignant	B
mass	I
,	O
gland	B
hyperplasia	I
or	O
adenoma	B
with	O
endocrine	B
activity	I
,	O
or	O
impact	B
on	I
heart	I
,	O
or	O
endocrine	O
function	O
(	O
such	O
as	O
pheochromocytoma	B
,	O
thyroid	B
enlargement	I
)	O
;	O

21	O
.	O

The	O
Investigator	O
deemed	O
for	O
whatever	O
reason	O
that	O
the	O
subject	O
is	O
not	O
likely	O
to	O
complete	O
the	O
study	O
or	O
comply	O
with	O
the	O
study	O
procedures	O
(	O
due	O
to	O
administration	O
or	O
any	O
other	O
reason	O
)	O
.	O

1	O
.	O

Age	B
:	O
18	B
-	I
75	I
years	I
old	O
,	O
no	O
limitation	O
in	O
gender	O
;	O

2	O
.	O

Left	B
ventricular	I
ejection	I
fraction	I
(	I
LVEF	I
)	I
≤	B
40	I
%	I
(	O
ECHO	B
)	O
;	O

3	O
.	O

Patients	O
with	O
chronic	B
heart	I
failure	I
(	O
NYHA	B
class	B
II	I
or	I
III	I
)	O
;	O

4	O
.	O

In	B
the	I
past	I
one	I
month	I
,	O
the	O
clinical	O
condition	O
(	O
including	O
history	B
,	O
clinical	B
symptoms	I
and	O
signs	O
)	O
was	O
relatively	B
stable	I
;	O

5	O
.	O

Patients	O
on	O
standard	O
treatment	O
of	O
chronic	B
heart	I
failure	I
at	O
the	O
target	O
dose	O
or	O
maximum	O
tolerance	O
dose	O
for	B
over	I
1	I
month	I
,	O
or	O
unchanged	O
dose	O
in	B
last	I
1	I
month	I
;	O

6	O
.	O

Understand	O
and	O
sign	O
the	O
informed	O
consent	O
form	O
;	O

FEV1	B
>	B
=	I
80	I
%	I
or	O
FEV1	B
<	B
20	I
%	I
of	I
predicted	I
value	I
post	O
-	O
bronchodilator	B
.	O

FEV1	B
/	I
SVC	I
>	B
=	I
70	I
%	I

History	B
of	O
lung	B
transplant	I
.	O

Any	O
lung	B
surgery	I
within	B
the	I
past	I
two	I
years	I
.	O

On	O
any	O
thoracic	B
surgery	I
waiting	O
list	O
.	O

End	O
of	O
last	O
exacerbation	B
less	B
than	I
6	I
weeks	I
prior	I
to	I
screening	I
/	I
re	I
-	I
screening	I
visit	I
.	O

Clinically	B
significant	I
intercurrent	B
illnesses	I
(	O
except	B
for	I
respiratory	O
or	O
liver	B
disease	I
secondary	O
to	O
AAT	B
deficiency	I
)	O
,	O
including	O
:	O
cardiac	B
,	O
hepatic	B
,	O
renal	B
,	O
endocrine	B
,	O
neurological	B
,	O
hematological	B
,	O
neoplastic	B
,	O
immunological	B
,	O
skeletal	B
or	O
other	B
)	O
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
could	O
interfere	O
with	O
the	O
safety	O
,	O
compliance	O
or	O
other	O
aspects	O
of	O
this	O
study	O
.	O
Patients	O
with	O
well	O
-	O
controlled	O
,	O
chronic	O
diseases	O
could	O
possibly	O
be	O
included	O
after	O
consultation	O
with	O
the	O
treating	O
physician	O
and	O
the	O
sponsor	O
.	O

Active	B
smoking	O
during	B
the	I
last	I
12	I
months	I
from	I
screening	I
date	I
.	O

Pregnancy	B
or	O
lactation	B
.	O

Woman	B
of	O
child	B
-	I
bearing	I
potential	I
not	B
taking	O
adequate	B
contraception	B
deemed	B
reliable	I
by	I
the	I
investigator	I
.	O

Presence	O
of	O
psychiatric	O
/	O
mental	B
disorder	I
or	O
any	O
other	B
medical	I
disorder	I
which	O
might	O
impair	O
the	O
patient	O
'	O
s	O
ability	O
to	O
give	O
informed	O
consent	O
or	O
to	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
study	O
protocol	O
.	O

Evidence	O
of	O
ongoing	B
viral	B
infection	I
with	O
HCV	B
,	O
HBV	B
and	O
/	O
or	O
HIV	B
.	O

Evidence	O
of	O
alcohol	B
abuse	I
or	O
history	B
of	O
alcohol	B
abuse	I
or	O
illegal	O
and	O
/	O
or	O
legally	O
prescribed	O
drugs	O
.	O

IgA	B
Deficiency	I

History	B
of	O
life	B
threatening	I
allergy	O
,	O
anaphylactic	B
reaction	I
,	O
or	O
systemic	O
response	O
to	O
human	B
plasma	I
derived	I
products	B
.	O

Participation	O
in	O
another	O
clinical	O
trial	O
within	O
30	O
days	O
prior	O
to	O
baseline	O
visit	O
.	O

Inability	O
to	O
attend	O
scheduled	O
clinic	O
visits	O
and	O
/	O
or	O
comply	O
with	O
the	O
study	O
protocol	O
.	O

Any	O
other	O
factor	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
prevent	O
the	O
patient	O
from	O
complying	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
.	O

Diagnosis	O
of	O
emphysema	B
confirmed	O
by	O
CT	B
scan	I
.	O

If	O
a	O
report	O
of	O
past	B
CT	B
scan	I
is	O
not	B
available	I
at	O
site	O
documenting	O
then	O
a	O
CT	B
scan	I
is	O
to	O
be	O
performed	O
at	B
screening	I

Male	B
or	O
female	B
patients	O
at	B
least	I
18	I
years	I
of	O
age	B
.	O

Able	O
and	O
willing	O
to	O
sign	O
an	O
informed	O
consent	O
.	O

Patient	O
with	O
record	O
of	O
congenital	B
AAT	I
deficiency	I
of	I
phenotype	I
PiZZ	I
(	I
homozygote	I
)	I
or	O
other	O
rare	B
phenotypes	I
related	I
to	I
AAT	I
deficiency	I
and	O
with	O
AAT	B
serum	I
level	I
≤	B
11	I
micromole	I
.	O

For	O
patients	O
receiving	O
IV	B
AAT	I
augmentation	I
therapy	I
the	O
serum	O
AAT	O
level	O
threshold	O
does	O
not	O
apply	O
.	O

FEV1	B
/	I
SVC	I
<	B
70	I
%	I
of	I
predicted	I
value	I
post	O
bronchodilator	B
(	O
SVC	O
is	O
slow	O
VC	O
)	O
and	O
FEV1	B
<	B
80	I
%	I
of	I
predicted	I
value	I
post	O
-	O
bronchodilator	B

History	O
of	O
at	B
least	I
two	I
moderate	B
or	O
severe	B
exacerbations	B
that	O
required	O
change	O
in	O
treatment	B
(	O
antibiotics	B
,	O
systemic	B
steroids	O
,	O
hospitalization	B
)	O
in	B
the	I
last	I
18	I
months	I
prior	I
to	I
date	I
of	I
screening	I
,	O
with	O
at	B
least	I
one	I
of	O
these	O
occurring	O
within	B
the	I
last	I
12	I
months	I
prior	I
to	I
screening	I
.	O

Ability	O
to	O
comply	O
with	O
completion	O
of	O
electronic	O
diary	O
.	O

Ability	O
to	O
self	O
-	O
administer	O
inhaled	O
AAT	O
.	O

No	O
significant	O
abnormalities	O
in	O
serum	O
hematology	O
,	O
serum	O
chemistry	O
and	O
serum	O
inflammatory	O
/	O
immunogenic	O
markers	O
according	O
to	O
the	O
Principal	O
Investigator	O
'	O
s	O
judgment	O
,	O
taking	O
into	O
considerations	O
the	O
potential	O
effects	O
of	O
the	O
AAT	O
deficiency	O
.	O

No	O
significant	O
abnormalities	O
in	O
urinalysis	O
according	O
to	O
the	O
Principal	O
Investigator	O
'	O
s	O
judgment	O
,	O
taking	O
into	O
considerations	O
the	O
potential	O
effects	O
of	O
the	O
AAT	O
deficiency	O
.	O

No	B
significant	B
abnormalities	O
in	O
ECG	B
per	O
investigator	O
judgment	O
.	O

Negative	B
for	O
HBsAg	B
and	O
for	O
antibodies	B
to	I
HCV	I
,	O
HIV	B
-	I
1	I
.	O

AAT	B
deficient	I
patients	O
who	O
are	O
either	O
naïve	B
(	O
not	B
receiving	I
IV	B
augmentation	I
therapy	I
)	O
or	O
AAT	O
deficient	O
patients	O
(	O
receiving	O
IV	B
augmentation	I
therapy	I
)	O
,	O
if	O
they	O
have	O
been	O
stable	B
on	O
regular	O
therapy	B
for	B
at	I
least	I
3	I
months	I
prior	I
to	I
the	I
screening	I
visit	O
and	O
are	O
willing	O
to	O
continue	O
the	O
same	O
regime	O
throughout	B
this	I
trial	I
.	O

Note	O
that	O
only	O
sites	O
in	O
Germany	O
can	O
recruit	O
patients	O
who	O
are	O
currently	O
being	O
treated	O
with	O
IV	O
AAT	O
.	O
Patients	O
who	O
stopped	O
IV	O
augmentation	O
treatment	O
6	O
months	O
prior	O
to	O
screening	O
date	O
and	O
will	O
not	O
re	O
-	O
start	O
this	O
treatment	O
for	O
the	O
course	O
of	O
the	O
study	O
will	O
be	O
considered	O
Naïve	O
.	O

Non	B
-	O
pregnant	B
,	O
non	B
-	O
lactating	B
female	B
patients	O
,	O
whose	O
screening	O
pregnancy	B
test	I
is	O
negative	B
and	O
who	O
are	O
using	O
contraceptive	B
methods	I
deemed	B
reliable	I
by	I
the	I
investigator	I
,	O
or	O
who	O
are	O
at	B
least	I
2	I
years	I
post	B
-	I
menopausal	I
or	O
surgically	B
sterilized	O
.	O

Surgery	B
and	O
/	O
or	O
previous	B
ocular	B
pathology	I
(	O
presence	O
of	O
scar	B
/	O
change	O
in	O
the	O
cornea	O
,	O
glaucoma	B
,	O
retinopathies	B
,	O
etc	O
.	O
)	O
.	O

Patient	O
has	O
diabetes	B
or	O
is	O
immunodepressed	B
.	O

Any	O
systemic	B
infection	B
during	B
the	I
study	I
.	O

Signs	O
and	O
/	O
or	O
symptoms	O
of	O
ocular	B
inflammation	I
/	O
infection	O
(	O
bacterial	O
,	O
viral	O
,	O
fungal	O
,	O
caused	B
by	I
Chlamydia	I
,	O
by	O
Mycobacterium	O
,	O
Acanthamoeba	O
or	O
of	O
allergic	B
etiology	I
)	O
.	O

Have	O
used	O
any	O
systemic	B
or	O
topical	B
antibiotics	O
for	O
ocular	B
infection	I
in	B
the	I
previous	I
14	I
days	I
.	O

Patient	O
has	O
known	O
hypersensitivity	B
to	O
any	O
of	O
the	O
components	B
of	I
the	I
formulations	I
used	O
in	O
the	O
study	O
.	O

Patient	O
is	O
indicated	O
to	O
have	O
an	O
ocular	B
refractive	I
surgery	I
performed	O
(	O
myopia	B
,	O
astigmatism	B
,	O
hypermetropy	B
)	O
by	O
the	O
Lasik	B
method	I
.	O

Patient	O
presents	O
a	O
normal	B
eye	B
fundus	I
.	O

Patient	O
has	O
intraocular	B
pressure	I
(	I
IOP	I
)	I
≤	B
20	I
mmHg	I
.	O

Diabetes	B
Mellitus	I

Acute	B
coronary	I
syndrome	I
in	B
the	I
past	I
6	I
months	I

Cardiac	B
arrhythmias	I
(	O
2nd	O
and	O
3rd	B
degree	I
heart	I
block	I
or	O
premature	B
ventricular	I
complexes	I
in	O
Lown	B
classes	I
4	I
or	O
5	O
)	O

Symptoms	O
suggestive	O
of	O
obstructive	O
or	O
central	B
sleep	I
apnea	I
(	O
with	O
a	O
score	B
of	I
>	I
10	I
on	O
Epworth	B
sleepiness	I
scale	I
)	O

Patients	O
taking	O
Clonidine	B

Body	B
mass	I
index	I
(	O
BMI	B
)	O
>	B
34	I

Patients	O
unable	O
to	O
give	O
consent	O

Pregnant	O
women	O

Patients	O
with	O
leg	B
injury	I
involving	O
nerve	B
damage	I

Patients	O
taking	O
anticoagulant	B
medication	O

Patients	O
with	O
significant	B
bleeding	B
disorder	I
or	O
liver	B
disorder	I

Hemoglobin	B
<	B
1	I
.	I
05	I
g	I
/	I
dl	I
at	B
the	I
time	I
of	I
initiation	I
of	I
therapy	I

patients	O
with	O
unilateral	B
or	O
bilateral	B
nephrectomy	B

Planned	B
kidney	B
transplant	I
in	B
the	I
next	I
4	I
months	I

Life	O
expectancy	O
under	B
6	I
months	I

Oliguria	B
(	O
urine	B
output	I
less	B
than	I
400	I
ml	I
per	I
day	I
)	O

Adult	B
(	O
age	B
18	B
years	I
and	I
older	I
)	O

Patients	O
with	O
end	B
-	I
stage	I
renal	I
disease	I
(	O
ESRD	B
)	O
/	O
chronic	B
kidney	I
disease	I
(	O
CKD	B
)	O
stage	B
5	I

Inability	O
to	O
comply	O
with	O
study	O
requirements	O
.	O

Metastatic	B
breast	B
cancer	I
.	O

Patients	O
with	O
orthopedic	O
or	O
neuromuscular	B
disorders	I
that	O
preclude	O
participation	O
in	O
exercise	O
.	O

Rheumatoid	B
arthritis	I
.	O

History	B
of	O
MI	B
,	O
angina	B
or	O
congestive	B
heart	I
failure	I
.	O

Pregnant	B
or	O
lactating	B
females	B
.	O

Patients	O
that	O
are	O
high	B
risk	B
for	I
moderate	I
exercise	I
based	O
on	O
ACSM	B
risk	I
classification	I
.	O

Patients	O
who	O
exceed	O
minimal	O
physical	O
activity	O
recommendations	O
from	O
the	O
US	O
Surgeon	O
General	O
'	O
s	O
Report	O
:	O
Accumulation	O
of	O
30	O
minutes	O
or	O
more	O
of	O
moderate	O
physical	O
activity	O
on	O
most	O
days	O
of	O
the	O
week	O
.	O

Morbidly	B
obese	I
with	O
BMI	B
≥	B
40	I

Post	B
menopausal	I
women	B
with	O
a	O
history	B
of	O
estrogen	B
positive	I
breast	B
cancer	I
who	O
are	O
receiving	O
aromatase	B
inhibitors	I
for	B
at	I
least	I
one	I
month	I
.	O

Patients	O
must	O
complain	O
of	O
mild	B
to	O
moderate	B
arthralgia	B
.	O

Ability	O
to	O
understand	O
and	O
sign	O
informed	O
consent	O
.	O

Patients	O
meet	O
criteria	O
for	O
low	B
to	O
moderate	B
risk	B
for	I
moderate	I
exercise	I
based	O
oon	O
the	O
ACSM	B
guidelines	I
.	O

The	O
patient	O
has	O
a	O
known	O
hypersensitivity	B
or	O
contraindication	B
to	O
any	O
of	O
the	O
following	O
medications	O
:	O
Heparin	B
,	O
Aspirin	B
,	O
Clopidogrel	B
,	O
Cilostazol	B

Uncontrolled	B
hypertension	B

History	B
of	O
bleeding	B
diathesis	I
or	O
known	O
coagulopathy	B
(	O
including	O
heparin	B
-	I
induced	I
thrombocytopenia	I
)	O
,	O
or	O
refuses	O
blood	B
transfusions	I
.	O

Baseline	B
hemogram	B
with	O
Hb	B
<	B
10g	I
/	I
dL	I
or	O
PLT	B
count	I
<	B
100	I
,	I
000	I
/	I
μL	I

Patients	O
already	O
taking	O
warfarin	B
,	O
cilostazol	B
or	O
any	O
other	O
type	O
of	O
anti	B
-	I
platelet	I
agents	I
except	B
aspirin	B
and	O
clopidogrel	B

Gastrointestinal	O
or	O
genitourinary	B
bleeding	I
within	B
the	I
prior	I
3	I
months	I
,	O
or	O
major	B
surgery	I
within	B
2	I
months	I
.	O

Pregnancy	B

Acute	B
Myocardial	I
Infarction	I
Undergoing	O
Primary	B
percutaneous	I
coronary	I
intervention	I
.	O

major	B
systemic	I
disease	I

Pregnant	B
woman	B
with	O
infection	O
of	O
human	B
immunodeficiency	I
virus	I
or	O
hepatitis	B
C	I
virus	I

Pregnant	B
woman	B
is	O
receiving	O
any	O
drug	B
with	I
antiviral	I
activity	I
or	O
any	O
form	O
of	O
drug	B
therapy	I
for	O
hepatitis	B
B	I
virus	I

Pregnant	B
woman	B
whose	O
ultrasonographic	B
examination	I
reveals	O
congenital	B
anomaly	I
of	I
the	I
fetus	I

Pregnant	B
woman	B
whose	O
amniocentesis	B
reveals	O
any	O
genetic	B
abnormality	I

pregnant	B
women	B
in	O
30	B
to	I
32	I
weeks	I
of	O
gestation	B
,	O
with	O
positive	B
HBsAg	B
and	O
HBeAg	B
,	O
serum	B
viral	I
load	I
above	B
8log10	I
copies	I
per	I
mL	I

Pregnancy	O
:	O
Women	O
who	O
are	O
pregnant	O
or	O
lactating	O
.	O

Asthma	B
:	O
Subjects	O
with	O
a	O
current	B
diagnosis	O
of	O
asthma	B
.	O

(	O
Subjects	O
with	O
a	O
prior	B
history	B
of	O
asthma	B
are	O
eligible	O
if	O
they	O
also	O
have	O
a	O
current	O
diagnosis	O
of	O
COPD	B
)	O
.	O

alpha	B
1	I
-	I
antitrypsin	I
deficiency	I
:	O
Subjects	O
with	O
known	O
alpha	B
-	I
1	I
antitrypsin	I
deficiency	I
as	O
the	O
underlying	O
cause	O
of	O
COPD	B
.	O

Other	B
respiratory	I
disorders	I
:	O
Subjects	O
with	O
active	O
tuberculosis	B
,	O
lung	B
cancer	I
,	O
bronchiectasis	B
,	O
sarcoidosis	B
,	O
pulmonary	B
fibrosis	I
,	O
pulmonary	B
hypertension	I
,	O
interstitial	B
lung	I
diseases	I
or	O
other	O
active	B
pulmonary	I
diseases	I
.	O

Lung	B
resection	I
or	O
transplantation	B
:	O
Subjects	O
with	O
lung	B
volume	I
reduction	I
surgery	I
within	B
the	I
12	I
months	I
prior	I
to	I
Screening	I
or	O
having	O
had	O
a	O
lung	B
transplant	I
.	O

A	O
moderate	B
/	O
severe	B
COPD	B
exacerbation	I
that	O
has	O
not	B
resolved	O
at	B
least	I
14	I
days	I
prior	I
to	I
Visit	I
1	I
and	O
at	B
least	I
30	I
days	I
following	I
the	I
last	I
dose	I
of	I
oral	I
corticosteroids	I
(	O
if	O
applicable	O
)	O
.	O

Current	O
severe	B
heart	B
failure	I
(	O
New	B
York	I
Heart	I
Association	I
class	B
IV	I
)	O
.	O

Subjects	O
will	O
also	O
be	O
excluded	O
if	O
they	O
have	O
a	O
known	O
ejection	B
fraction	I
of	O
<	B
30	I
%	I
or	O
if	O
they	O
have	O
an	O
implantable	B
cardioverter	I
defibrillator	I
(	I
ICD	I
)	I
.	O

Other	O
diseases	O
/	O
abnormalities	O
:	O
Any	O
life	B
-	I
threatening	I
condition	I
with	O
life	O
expectancy	O
<	B
3	I
years	I
,	O
other	B
than	I
vascular	B
disease	I
or	O
COPD	B
,	O
that	O
might	O
prevent	O
the	O
subject	O
from	O
completing	O
the	O
study	O
.	O

End	B
stage	I
chronic	I
renal	I
disease	I
:	O
Subjects	O
will	O
be	O
excluded	O
if	O
on	O
renal	B
replacement	I
therapy	I
(	O
hemodialysis	B
or	O
peritoneal	B
)	O
.	O

Drug	O
/	O
food	B
allergy	I
:	O
Subjects	O
with	O
a	O
history	O
of	O
hypersensitivity	B
to	O
any	O
of	O
the	O
study	B
medications	I
(	O
e	O
.	O
g	O
.	O
beta	B
-	I
agonists	I
,	O
corticosteroid	B
)	O
or	O
components	B
of	I
the	I
inhalation	I
powder	I
(	O
e	O
.	O
g	O
.	O
lactose	B
,	O
magnesium	B
stearate	I
)	O
.	O

In	O
addition	O
,	O
patients	O
with	O
a	O
history	B
of	O
severe	B
milk	B
protein	I
allergy	I
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O
,	O
contraindicates	O
the	O
subject	O
'	O
s	O
participation	O
will	O
also	O
be	O
excluded	O
.	O

Drug	O
/	O
alcohol	B
abuse	I
:	O
Subjects	O
with	O
a	O
known	O
or	O
suspected	O
history	B
of	O
alcohol	O
or	O
drug	B
abuse	I
within	B
the	I
last	I
2	I
years	I
.	O

Oxygen	O
therapy	O
:	O
Subjects	O
receiving	O
treatment	O
with	O
long	B
-	I
term	I
oxygen	I
therapy	I
(	I
LTOT	I
)	I
or	O
nocturnal	B
oxygen	I
therapy	I
required	O
for	O
greater	B
than	I
12	I
hours	I
a	I
day	I
.	O

Oxygen	O
prn	O
use	O
(	O
i	O
.	O
e	O
.	O
<	O
=	O
12	O
hours	O
per	O
day	O
)	O
is	O
not	O
exclusionary	O
.	O

Questionable	O
validity	O
of	O
consent	O
:	O
Subjects	O
with	O
a	O
history	O
of	O
psychiatric	O
disease	O
,	O
intellectual	O
deficiency	O
,	O
poor	O
motivation	O
or	O
other	O
conditions	O
that	O
will	O
limit	O
the	O
validity	O
of	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O
or	O
the	O
potential	O
compliance	O
to	O
study	O
procedures	O
.	O

Affiliation	O
with	O
investigator	O
site	O
:	O
Study	O
investigators	O
,	O
sub	O
-	O
investigators	O
,	O
study	O
coordinators	O
,	O
employees	O
of	O
a	O
participating	O
investigator	O
or	O
immediate	O
family	O
members	O
of	O
the	O
aforementioned	O
are	O
excluded	O
from	O
participating	O
in	O
this	O
study	O
.	O

Additional	O
medication	O
:	O
Use	O
of	O
the	O
following	O
medications	O
within	O
the	O
following	O
time	O
intervals	O
prior	O
to	O
Visit	O
1	O
or	O
during	O
the	O
study	O
(	O
unless	O
otherwise	O
specified	O
)	O
:	O

Medication	O
No	B
use	O
within	O
the	O
following	O
time	O
intervals	O
prior	O
to	O
Screening	O
or	O
thereafter	O
at	O
any	O
time	O
during	O
the	O
study	O
(	O
unless	O
otherwise	O
specified	O
)	O
Inhaled	B
Long	I
acting	I
beta	I
-	I
agonists	I
(	I
LABA	I
)	I
48	B
hours	I
ICS	B
/	I
LABA	I
combination	I
products	I
48	B
hours	I
Inhaled	B
corticosteroids	I
48	B
hours	I
Tiotropium	B
1	B
week	I
Systemic	B
,	O
Oral	B
,	O
parenteral	B
,	O
intra	B
-	I
articular	I
corticosteroids	B
30	B
days	I
(	O
oral	B
and	O
systemic	B
corticosteroids	B
may	O
be	O
used	O
to	O
treat	O
COPD	B
exacerbations	I
during	B
the	I
study	I
)	O
Cytochrome	B
P450	I
3A4	I
strong	I
inhibitors	I
including	O
but	O
not	O
limited	O
to	O
antiretrovirals	B
(	O
protease	B
inhibitors	I
)	O
(	O
e	O
.	O
g	O
.	O
Indinavir	B
,	O
Nelfinavir	B
,	O
Ritonavir	B
,	O
Saquinavir	B
)	O
;	O
Imidazole	O
and	O
Triazole	B
anti	I
-	I
fungals	I
(	O
e	O
.	O
g	O
.	O
Ketaconazole	B
,	O
Itraconazole	B
)	O
;	O
Clarithromycin	B
,	O
Telithromycin	B
,	O
Amiodarone	B
,	O
and	O
Nefazodone	B
6	B
weeks	I
Grapefruit	B
is	O
allowed	O
up	O
to	O
Visit	O
1	O
,	O
then	O
limited	O
to	O
no	O
more	O
than	O
one	O
glass	O
of	O
grapefruit	O
juice	O
(	O
250	O
mL	O
/	O
8	O
ounces	O
)	O
or	O
one	O
grapefruit	O
per	O
day	O
Any	O
other	O
investigational	B
drug	I
30	B
days	I
or	O
5	B
half	I
lives	I
whichever	O
is	O
longer	O
.	O

Type	O
of	O
subject	O
:	O
outpatient	O
.	O

Informed	O
consent	O
:	O
Subjects	O
must	O
give	O
their	O
signed	O
and	O
dated	O
written	O
informed	O
consent	O
to	O
participate	O
.	O

Gender	O
:	O
Male	B
or	O
female	B
.	O

Female	O
subjects	O
must	O
be	O
post	O
-	O
menopausal	O
or	O
using	O
a	O
highly	O
effective	O
method	O
for	O
avoidance	O
of	O
pregnancy	O
.	O
The	O
decision	O
to	O
include	O
or	O
exclude	O
women	O
of	O
childbearing	O
potential	O
may	O
be	O
made	O
at	O
the	O
discretion	O
of	O
the	O
investigator	O
in	O
accordance	O
with	O
local	O
practice	O
in	O
relation	O
to	O
adequate	O
contraception	O
.	O

Age	B
:	O
>	B
=	I
40	I
and	I
<	I
=	I
80	I
years	I
of	O
age	B
at	B
Screening	I
(	O
Visit	O
1	O
)	O
.	O

Tobacco	O
use	O
:	O
Subjects	O
with	O
a	O
current	B
or	O
prior	B
history	B
of	O
>	B
=	I
10	I
pack	I
-	I
years	I
of	O
cigarette	O
smoking	O
at	B
screening	I
(	O
Visit	O
1	O
)	O
.	O

Previous	B
smokers	I
are	O
defined	O
as	O
those	O
who	O
have	O
stopped	O
smoking	O
for	B
at	I
least	I
6	I
months	I
prior	I
to	I
Visit	I
1	I
.	O

Airflow	O
Obstruction	O
:	O

Subjects	O
with	O
a	O
measured	O
post	O
-	O
albuterol	B
/	O
salbutamol	B
forced	B
expiratory	I
volume	I
in	I
1	I
second	I
(	I
FEV1	I
)	I
/	I
(	I
forced	I
vital	I
capacity	I
)	I
FVC	I
ratio	I
of	O
<	B
=	I
0	I
.	I
70	I
at	B
Screening	I
(	O
Visit	O
1	O
)	O
.	O

Subjects	O
with	O
a	O
measured	O
post	O
-	O
albuterol	B
/	O
salbutamol	B
FEV1	B
>	B
=	I
50	I
and	I
<	I
=	I
70	I
%	I
of	I
predicted	I
normal	I
values	I
calculated	O
using	B
NHANES	I
III	I
reference	I
equations	I
[	O
Hankinson	O
,	O
1999	O
;	O
Hankinson	O
,	O
2010	O
]	O
at	B
Screening	I
(	O
Visit	O
1	O
)	O
.	O

Post	O
-	O
bronchodilator	B
spirometry	B
will	O
be	O
performed	O
approximately	B
15	I
minutes	I
after	I
the	O
subject	O
has	O
self	B
-	I
administered	I
4	B
inhalations	B
(	O
i	O
.	O
e	O
.	O
,	O
total	O
400mcg	B
)	O
of	O
albuterol	B
/	O
salbutamol	B
via	O
a	O
metered	B
dose	I
inhaler	I
(	I
MDI	I
)	I
with	B
a	I
valved	I
-	I
holding	I
chamber	I
.	O

The	O
FEV1	O
/	O
FVC	O
ratio	O
and	O
FEV1	O
percent	O
predicted	O
values	O
will	O
be	O
calculated	O
.	O

Symptoms	B
of	I
COPD	I
:	O
Subjects	O
must	O
score	B
2	I
or	I
higher	I
on	O
the	O
modified	B
Medical	I
Research	I
Council	I
Dyspnea	I
scale	I
(	O
Visit	O
1	O
)	O

Cardiovascular	O
disease	O
:	O

For	O
patients	O
>	B
=	I
40	I
years	I
of	O
age	B
:	O
any	O
one	O
of	O
the	O
following	O
:	O

Established	O
(	O
i	O
.	O
e	O
.	O
by	O
clinical	O
signs	O
or	O
imaging	B
studies	I
)	O
coronary	B
artery	I
disease	I
(	I
CAD	I
)	I
Established	O
(	O
i	O
.	O
e	O
.	O
by	O
clinical	O
signs	O
or	O
imaging	B
studies	I
)	O
peripheral	B
vascular	I
disease	I
(	I
PVD	I
)	I
Previous	B
stroke	B
Previous	B
MI	B
Diabetes	B
mellitus	I
with	O
target	B
organ	I
disease	I
OR	O

For	O
patients	O
>	B
=	I
60	I
years	I
of	O
age	B
:	O
any	O
2	O
of	O
the	O
following	O
:	O

Being	O
treated	O
for	O
hypercholesterolemia	B
Being	O
treated	O
for	O
hypertension	B
Being	O
treated	O
for	O
diabetes	B
mellitus	I
Being	O
treated	O
for	O
peripheral	B
vascular	I
disease	I

Subjects	O
with	O
a	O
supine	B
BP	I
>	B
140	I
mm	I
Hg	I
systolic	I
or	O
>	B
90	I
mm	I
Hg	I
diastolic	I
or	O
<	B
100	I
mm	I
Hg	I
systolic	I
or	O
<	B
60	I
mm	I
Hg	I
diastolic	I
based	O
on	O
the	O
average	O
of	O
the	O
triplicate	O

Serum	B
potassium	I
>	B
=	I
5	I
.	I
1	I
mmol	I
/	I
L	I
or	O
<	B
3	I
.	I
5	I
mmol	I
/	I
L	I
at	B
screening	I
,	O
confirmed	O
by	O
a	O
single	O
repeat	O
if	O
deemed	O
necessary	O
.	O

Estimated	B
GFR	I
<	B
60	I
mL	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
using	O
the	O
Cockcroft	O
-	O
Gault	O
formula	O
measurement	O
of	O
the	O
individual	O
parameters	O
following	O
at	O
least	O
5	O
minutes	O
of	O
rest	O
at	O
Screening	O
.	O

Male	B
and	O
/	O
or	O
female	B
healthy	B
volunteers	O
,	O
age	B
18	B
to	I
55	I
years	I
.	O

Females	B
must	O
be	O
of	O
non	B
-	O
childbearing	B
potential	I
.	O

Body	B
Mass	I
Index	I
(	I
BMI	I
)	I
of	O
17	B
.	I
5	I
to	I
30	I
.	I
5	I
kg	I
/	I
m2	I
;	O
and	O
a	O
total	B
body	I
weight	I
>	B
50	I
kg	I
(	I
110	I
lbs	I
)	I
.	O

Subjects	O
who	O
are	O
willing	O
and	O
able	O
to	O
comply	O
with	O
scheduled	O
visits	O
,	O
treatment	O
plan	O
,	O
laboratory	O
tests	O
,	O
diet	O
restrictions	O
and	O
other	O
trial	O
procedures	O
.	O

History	B
of	O
other	O
significant	B
skin	B
disease	I
,	O
or	O
skin	B
manifestations	I
of	O
allergic	B
illness	I
or	O
other	O
dermatologic	B
condition	I
,	O
except	B
chronic	B
moderate	I
or	O
severe	B
atopic	B
dermatitis	I
,	O
that	O
would	O
interfere	O
with	O
the	O
trial	O
assessments	O
or	O
compromise	O
the	O
patient	O
'	O
s	O
safety	O
according	O
to	O
the	O
opinion	O
of	O
the	O
Investigator	O

Present	O
symptoms	O
of	O
other	O
skin	B
diseases	I
,	O
except	B
chronic	B
atopic	I
dermatitis	I
,	O
that	O
could	B
disturb	I
the	I
study	I
assessment	I
and	I
evaluation	I
of	I
the	I
skin	I

Current	O
use	O
of	O
any	O
active	B
systemic	B
medication	I
for	O
chronic	B
atopic	I
dermatitis	I
within	B
one	I
month	I

Current	O
use	O
of	O
active	B
topical	B
medication	I
in	O
the	O
planned	O
investigational	O
area	O
for	O
chronic	B
atopic	I
dermatitis	I
within	B
two	I
weeks	I

History	O
of	O
a	O
sunny	O
holiday	O
,	O
UV	B
-	I
light	I
therapy	I
or	O
solarium	O
use	O
within	B
one	I
month	I
before	I
beginning	I
of	I
study	I
treatments	I
,	O
or	O
planning	O
such	O
during	B
the	I
study	I
or	O
within	B
7	I
days	I
after	I
the	I
study	I

Allergy	B
to	O
cis	B
-	I
UCA	I
,	O
or	O
any	O
constituents	O
of	O
the	O
placebo	B
emulsion	I
cream	I
or	O
any	O
constituents	O
of	O
Protopic	B
®	I
ointment	I

History	B
of	O
any	O
skin	B
-	I
related	I
cancer	I

Congenital	O
or	O
acquired	B
immunodeficiency	I
or	O
ongoing	B
therapy	O
that	O
cause	O
immunosuppression	B

Earlier	O
participation	O
in	O
a	O
clinical	O
study	O
performed	O
with	O
cis	O
-	O
UCA	O

Any	O
clinically	B
significant	I
laboratory	B
test	I
result	O

Suspected	O
current	B
drug	O
or	O
alcohol	B
abuse	I

Clinically	B
significant	I
illness	B
during	B
the	I
4	I
weeks	I
prior	I
to	I
the	I
first	I
dose	I
administration	I

Any	O
other	O
condition	O
that	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
would	O
interfere	O
with	O
the	O
evaluation	O
of	O
the	O
study	O
results	O
or	O
constitute	O
a	O
health	O
hazard	O
for	O
the	O
patient	O

Unwillingness	O
or	O
doubtful	O
capacity	O
to	O
comply	O
with	O
the	O
protocol	O

Doubtful	O
availability	O
to	O
complete	O
the	O
study	O

Informed	O
consent	O
obtained	O
prior	O
to	O
any	O
screening	O
procedure	O

Caucasian	B
male	B
or	O
female	B
patient	O

At	B
least	I
18	I
years	I
of	O
age	B

Weight	B
at	B
least	I
45	I
kg	I

Patient	O
with	O
moderate	B
or	O
severe	B
chronic	B
atopic	I
dermatitis	I

Good	B
general	I
health	I
ascertained	O
by	O
medical	B
history	I
,	O
physical	B
examination	I
and	O
laboratory	B
determinations	I
,	O
showing	O
no	B
signs	O
of	O
clinically	B
significant	I
findings	O
,	O
except	B
chronic	B
atopic	I
dermatitis	I

Negative	B
pregnancy	B
test	I
(	O
premenopausal	B
female	B
patient	O
)	O
at	O
screening	O
and	O
use	O
of	O
adequate	O
contraceptive	O
measures	O
(	O
both	O
male	O
and	O
female	O
patients	O
)	O
throughout	O
the	O
study	O
and	O
30	O
days	O
after	O
the	O
last	O
cis	O
-	O
UCA	O
dose	O

Subjects	O
were	O
not	O
to	O
have	O
a	O
history	O
or	O
presence	O
of	O
significant	O
cardiovascular	O
,	O
pulmonary	O
,	O
hepatic	O
,	O
renal	O
,	O
haematologic	O
,	O
gastrointestinal	O
,	O
endocrine	O
,	O
immunologic	O
,	O
dermatologic	O
,	O
neurologic	O
,	O
or	O
psychiatric	O
disease	O
.	O

Subjects	O
were	O
not	O
to	O
have	O
any	O
history	B
or	O
presence	O
or	O
family	O
history	O
of	O
schizophrenia	B
,	O
other	O
psychotic	B
illness	I
,	O
severe	B
personality	I
disorder	I
,	O
depression	B
,	O
or	O
other	O
significant	B
psychiatric	B
disorder	I
.	O

Subjects	O
were	O
not	B
to	O
have	O
a	O
postural	B
drop	I
of	I
20	I
mmHg	I
or	O
more	O
in	O
systolic	B
blood	I
pressure	I
at	B
screening	I
.	O

Subjects	O
were	O
not	O
to	O
have	O
participated	O
in	O
a	O
previous	O
clinical	O
trial	O
within	O
90	B
days	I
prior	I
to	I
study	I
initiation	I
.	O

Subjects	O
were	O
not	B
to	O
have	O
donated	B
plasma	I
within	B
90	I
days	I
prior	I
to	I
study	I
initiation	I
.	O

Subjects	O
were	O
not	B
to	O
have	O
donated	B
blood	I
within	B
90	I
days	I
prior	I
to	I
study	I
initiation	I
.	O

Subjects	O
were	O
not	B
to	O
have	O
had	O
an	O
abnormal	O
diet	O
or	O
substantial	B
changes	O
in	O
eating	O
habits	O
within	B
30	I
days	I
prior	I
to	I
study	I
initiation	I
.	O

Subjects	O
were	O
not	O
to	O
have	O
had	O
treatment	O
with	O
any	O
known	O
enzyme	B
-	I
altering	I
agents	I
(	O
barbiturates	B
,	O
phenothiazines	B
,	O
cimetidine	B
etc	O
.	O
)	O
within	B
30	I
days	I
prior	I
to	I
or	I
during	I
the	I
study	I
.	O

Subjects	O
were	O
to	O
have	O
no	B
history	O
of	O
known	O
hypersensitivity	B
or	O
idiosyncratic	B
reaction	I
to	O
the	O
study	B
drug	I
or	O
related	O
compounds	O
.	O

Subjects	O
were	O
not	B
to	O
use	O
any	O
prescription	B
medication	I
within	O
14	O
days	O
prior	O
to	O
or	O
during	B
the	I
study	I
.	O

Subjects	O
were	O
not	B
to	O
use	O
any	O
over	B
-	I
the	I
-	I
counter	I
medication	I
within	O
7	O
days	O
prior	O
to	O
or	O
during	B
the	I
study	I
.	O

Subjects	O
were	O
not	B
to	O
have	O
a	O
history	B
of	O
alcohol	O
or	O
drug	B
abuse	I
within	B
2	I
years	I
prior	I
to	I
the	I
study	I
(	O
subjects	O
with	O
a	O
history	O
of	O
previous	O
use	B
of	I
cannabis	I
were	O
not	B
excluded	I
unless	O
they	O
had	O
used	O
cannabis	O
or	O
cannabinoid	O
based	O
medicine	O
within	O
30	O
days	O
prior	O
to	O
study	O
drug	O
administration	O
or	O
were	O
unwilling	O
to	O
abstain	O
for	O
the	O
duration	O
of	O
the	O
study	O
)	O
.	O

Healthy	B
males	O
between	B
18	I
and	I
45	I
years	I
of	O
age	B
(	O
inclusive	O
)	O
.	O

Body	B
mass	I
index	I
to	O
be	O
between	B
18	I
to	I
30	I
kg	I
/	I
m2	I
(	O
inclusive	O
)	O
as	O
calculated	O
by	O
weight	O
(	O
Kg	O
)	O
/	O
height	O
(	O
m2	O
)	O
.	O

Subjects	O
were	O
to	O
have	O
no	B
clinically	B
significant	I
abnormal	B
findings	I
on	O
physical	B
examination	I
,	O
ECG	B
,	O
medical	B
history	I
,	O
or	O
clinical	B
laboratory	I
results	O
during	B
screening	I
.	O

Subjects	O
were	O
to	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
have	O
no	B
clinically	B
significant	I
abnormal	B
findings	I
of	O
renal	O
and	O
hepatic	B
function	I
as	O
determined	O
by	O
serum	B
creatinine	I
,	O
total	B
bilirubin	I
,	O
and	O
transaminase	B
levels	I
.	O

Subjects	O
were	O
to	O
be	O
non	B
-	O
users	B
of	I
tobacco	I
products	I
(	O
minimum	B
of	I
6	I
months	I
prior	I
to	I
the	I
start	I
of	I
the	I
study	I
)	O
.	O

Subjects	O
were	O
to	O
have	O
a	O
negative	B
screen	B
for	I
HIV	I
I	I
and	O
II	O
,	O
HBsAg	B
,	O
and	O
antibody	B
to	I
Hepatitis	I
C	I
virus	I
.	O

Subjects	O
were	O
to	O
have	O
a	O
negative	B
urine	B
screen	I
for	I
alcohol	I
,	O
drugs	O
of	O
abuse	O
(	O
screening	O
only	O
)	O
,	O
and	O
cotinine	O
.	O

Subjects	O
were	O
to	O
use	O
an	O
appropriate	O
barrier	O
method	O
of	O
contraception	O
(	O
condom	O
and	O
spermicide	O
)	O
in	O
addition	O
to	O
having	O
their	O
female	O
partner	O
use	O
another	O
form	O
of	O
barrier	O
contraception	O
(	O
e	O
.	O
g	O
.	O
female	O
condom	O
or	O
occlusive	O
cap	O
with	O
spermicide	O
)	O
during	O
the	O
study	O
and	O
for	O
3	O
months	O
following	O
administration	O
of	O
the	O
study	O
drug	O
.	O

Subjects	O
were	O
able	O
to	O
comply	O
with	O
the	O
protocol	O
and	O
the	O
restrictions	O
and	O
assessments	O
therein	O
.	O

Subjects	O
were	O
to	O
give	O
voluntary	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
trial	O
.	O

Age	B
<	B
18	I
years	I
old	I

Patient	O
unable	O
to	O
communicate	O
or	O
to	O
understand	O
the	O
study	O

Patient	O
refusing	O
to	O
participate	O
to	O
the	O
study	O

contraindication	B
to	O
laparoscopy	B

women	B

proven	O
pelvic	B
floor	I
dysfunction	I

informed	O
consent	O

Presence	O
of	O
organic	B
pathology	I
identified	O
by	O
upper	B
endoscopy	I
or	O
other	O
investigations	B

Presence	O
of	O
sliding	B
hiatus	B
hernia	I
as	O
defined	O
by	O
flap	O
valve	O
grade	B
IV	I
disruption	O
of	O
morphology	O
at	B
gastro	I
-	I
esophageal	I
junction	I

Concurrent	O
medications	B
that	O
affect	O
gastrointestinal	B
motility	I

Presence	O
of	O
acid	B
reflux	I
or	O
heartburn	B
symptoms	I
of	O
more	B
than	I
twice	I
a	I
month	I

History	O
of	O
gastric	B
surgery	I

H	B
.	I
pylori	I
infection	I

Use	O
of	O
PPI	B
or	O
NSAID	B
in	B
the	I
past	I
4	I
weeks	I

Pregnancy	B

Known	O
hypersensitivity	B
to	O
PPI	B

Patients	O
with	O
functional	B
dyspepsia	I
that	O
fulfill	O
Rome	B
III	I
criteria	I
with	O
inadequate	B
relief	I
of	O
dyspeptic	B
symptoms	I

Age	B
>	B
18	I

Provision	O
of	O
written	O
consent	O

NA	O

Patient	B
age	I
>	B
=	I
18	I
years	I

Zubrod	B
performance	I
status	I
of	O
0	B
-	I
3	I

T1	B
-	B
3	I
N0	B
M0	B
adenocarcinoma	B
of	O
the	O
prostate	B

Prostate	B
volume	I
=	B
100	I
cc	I

Signed	O
study	O
-	O
specific	O
consent	O
form	O

Extension	B
of	I
local	I
tumor	I
to	O
involve	O
adjacent	B
organs	I
other	B
than	I
seminal	B
vesicles	I
(	O
T4	O
)	O

Prostate	B
volume	I
>	B
100	I
cc	I

Nodal	B
involvement	I

Metastatic	B
disease	I

Prior	B
pelvic	B
radiotherapy	B
except	B
as	O
part	O
of	O
combination	B
therapy	I
for	O
prostate	B
cancer	I

History	B
of	O
scleroderma	B

Patients	O
with	O
psychiatric	O
or	O
addictive	B
disorder	I
that	O
would	O
preclude	O
obtaining	O
informed	O
consent	O

Treatment	O
with	O
any	O
investigational	O
drug	O
within	O
30	O
days	O
of	O
entry	O
to	O
this	O
protocol	O

Current	O
treatment	O
with	O
Telbivudine	B

Severe	B
hepatitis	B
activity	O
as	O
documented	O
by	O
ALT	B
>	B
10	I
x	I
ULN	I

History	O
of	O
decompensated	B
cirrhosis	B
(	O
defined	O
as	O
jaundice	B
in	O
the	O
presence	O
of	O
cirrhosis	B
,	O
ascites	B
,	O
bleeding	B
gastric	I
or	O
esophageal	B
varices	I
or	O
encephalopathy	B
)	O

Pre	B
-	I
existent	I
neutropenia	B
(	O
neutrophils	B
<	B
1	I
,	I
500	I
/	I
mm3	I
)	O
or	O
thrombocytopenia	B
(	O
platelets	B
<	B
90	I
,	I
000	I
/	I
mm3	I
)	O

Co	B
-	I
infection	I
with	O
hepatitis	B
C	I
virus	I
,	O
hepatitis	B
D	I
virus	I
or	O
human	B
immunodeficiency	I
virus	I
(	O
HIV	B
)	O

Other	O
acquired	B
or	O
inherited	B
causes	O
of	O
liver	B
disease	I
:	O
alcoholic	B
liver	I
disease	I
,	O
obesity	B
induced	I
liver	I
disease	I
,	O
drug	B
related	I
liver	I
disease	I
,	O
auto	B
-	I
immune	I
hepatitis	I
,	O
hemochromatosis	B
,	O
Wilson	B
'	I
s	I
disease	I
or	O
alpha	B
-	I
1	I
antitrypsin	I
deficiency	I

Alpha	B
fetoprotein	I
>	B
50	I
ng	I
/	I
ml	I

Hyper	O
-	O
or	O
hypothyroidism	B
(	O
subjects	O
requiring	O
medication	B
to	O
maintain	O
TSH	O
levels	O
in	O
the	O
normal	O
range	O
are	O
eligible	O
if	O
all	O
other	O
inclusion	O
/	O
exclusion	O
criteria	O
are	O
met	O
)	O

Immune	B
suppressive	I
treatment	I
within	B
the	I
previous	I
6	I
months	I

Contra	B
-	I
indications	I
for	O
alfa	B
-	I
interferon	I
therapy	I
like	O
suspected	O
hypersensitivity	B
to	O
interferon	B
or	O
Peginterferon	B
or	O
any	O
known	O
pre	O
-	O
existing	O
medical	O
condition	O
that	O
could	O
interfere	O
with	O
the	O
patient	O
'	O
s	O
participation	O
in	O
and	O
completion	O
of	O
the	O
study	O
.	O

Pregnancy	O
,	O
breast	O
-	O
feeding	O

Other	O
significant	B
medical	B
illness	I
that	O
might	O
interfere	O
with	O
this	O
study	O
:	O
significant	B
pulmonary	B
dysfunction	I
in	B
the	I
previous	I
6	I
months	I
,	O
malignancy	B
other	B
than	I
skin	B
basocellular	I
carcinoma	I
in	B
previous	I
5	I
years	I
,	O
immunodeficiency	B
syndromes	I
(	O
e	O
.	O
g	O
.	O
HIV	B
positivity	I
,	O
auto	B
-	I
immune	I
diseases	I
,	O
organ	B
transplants	I
other	B
than	I
cornea	O
and	O
hair	B
transplant	I
)	O

Any	O
medical	O
condition	O
requiring	O
,	O
or	O
likely	O
to	O
require	O
chronic	B
systemic	B
administration	I
of	I
steroids	I
,	O
during	B
the	I
course	I
of	I
the	I
study	I

Substance	B
abuse	I
,	O
such	O
as	O
alcohol	B
(	O
>	B
80	I
g	I
/	I
day	I
)	O
,	O
I	B
.	I
V	I
.	I
drugs	I
and	O
inhaled	B
drugs	I
in	B
the	I
past	I
2	I
years	I
.	I

Any	O
other	O
condition	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
would	O
make	O
the	O
patient	O
unsuitable	O
for	O
enrollment	O
,	O
or	O
could	O
interfere	O
with	O
the	O
patient	O
participating	O
in	O
and	O
completing	O
the	O
study	O

Chronic	B
hepatitis	I
B	I
(	O
HBsAg	B
positive	B
>	B
6	I
months	I
)	O

HBeAg	B
negative	B
within	O
six	O
months	O
prior	O
to	O
initiation	O
of	O
peginterferon	B
alfa	I
-	I
2a	I

HBV	B
DNA	I
<	B
200	I
IU	I
/	I
ml	I
during	O
nucleos	B
(	I
t	I
)	I
ide	I
analogue	I
(	O
except	B
Telbivudine	B
)	O
treatment	O
within	O
one	O
month	O
prior	O
to	O
initiation	O
of	O
peginterferon	B
alfa	I
-	I
2a	I

Compensated	B
liver	B
disease	I

Age	B
>	B
18	I
years	I

Written	O
informed	O
consent	O

neurological	B
diseases	I

previous	B
pelvic	B
surgeries	I

diabetes	B

cognitive	B
difficulties	I

vaginal	O
and	O
urinary	B
infection	I

presence	O
of	O
stress	O
urinary	O
or	O
urgency	B
incontinence	I

Age	B
less	B
than	I
15	I
or	O
greater	B
than	I
25	I
and	O
not	B
participating	O
in	O
the	O
day	O
care	O
center	O

100	O
orphans	O
/	O
vulnerable	O
youth	O
aged	O
15	O
to	O
25	O
will	O
be	O
recruited	O
through	O
their	O
participation	O
at	O
the	O
day	O
care	O
center	O
,	O
on	O
a	O
voluntary	O
basis	O
.	O

The	O
patient	O
is	O
participating	O
in	O
another	O
clinical	O
study	O
using	O
an	O
investigational	O
product	O
.	O

The	O
patient	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
is	O
unable	O
to	O
adhere	O
to	O
the	O
requirements	O
of	O
the	O
study	O
.	O

The	O
patient	O
and	O
/	O
or	O
the	O
patient	O
'	O
s	O
parent	O
/	O
legal	O
guardian	O
is	O
willing	O
and	O
able	O
to	O
provide	O
signed	O
informed	O
consent	O
.	O

The	O
patient	O
has	O
a	O
confirmed	O
GAA	B
enzyme	I
deficiency	I
from	O
skin	B
,	O
blood	B
,	O
or	O
muscle	B
tissue	I
and	O
/	O
or	O
2	B
confirmed	O
GAA	O
gene	O
mutations	O
.	O

Infant	B
and	O
toddler	B
Pompe	B
disease	I
patients	O
can	O
be	O
included	O
in	O
the	O
study	O
only	O
under	O
condition	O
(	O
minimal	O
body	O
weight	O
)	O
that	O
the	O
trial	O
-	O
related	O
blood	O
loss	O
(	O
including	O
any	O
losses	O
in	O
the	O
maneuver	O
)	O
will	O
not	O
exceed	O
3	O
percent	O
of	O
the	O
total	O
blood	O
volume	O
during	O
a	O
period	O
of	O
4	O
weeks	O
and	O
will	O
not	O
exceed	O
1	O
percent	O
at	O
any	O
single	O
time	O
.	O

The	O
patient	O
,	O
if	O
female	O
and	O
of	O
childbearing	O
potential	O
,	O
must	O
have	O
a	O
negative	O
pregnancy	O
test	O
(	O
urine	O
beta	O
-	O
human	O
chorionic	O
gonadotropin	O
)	O
at	O
screening	O
.	O
Note	O
:	O
All	O
female	O
patients	O
of	O
childbearing	O
potential	O
and	O
sexually	O
mature	O
males	O
must	O
agree	O
to	O
use	O
a	O
medically	O
accepted	O
method	O
of	O
contraception	O
throughout	O
the	O
study	O
.	O

For	O
patients	O
previously	O
treated	O
with	O
alglucosidase	O
alfa	O
the	O
patient	O
has	O
received	O
alglucosidase	B
alfa	I
for	B
at	I
least	I
6	I
months	I
.	O

Unable	O
to	O
participate	O
for	O
administrative	B
reasons	I

Psychiatric	B
troubles	I

Pain	B
at	I
rest	I
or	O
critical	B
limb	I
ischemia	I

Unable	B
to	I
walk	I
(	O
ex	O
:	O
wheelchair	O
subjects	O
)	O

French	O
Native	O
language	O

18	O
years	O
old	B
or	O
older	O

Signed	O
consent	O

Covered	O
by	O
the	O
French	O
social	O
care	O
system	O

any	O
condition	O
that	O
would	O
contra	O
-	O
indicate	O
Magnetic	O
Resonance	O
Imaging	O
or	O
administration	O
of	O
contrast	O
agent	O

male	B
and	O
female	B
patients	O
over	O
the	O
age	B
of	O
18	O
years	O
.	O

written	O
informed	O
consent	O
(	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
[	O
IRB	O
]	O
/	O
Independent	O
Ethics	O
Committee	O
[	O
IEC	O
]	O
)	O
obtained	O
prior	O
to	O
any	O
study	O
specific	O
procedures	O
.	O

patient	O
with	O
mild	B
to	O
severe	B
carotid	B
artery	I
disease	I

Inability	O
to	O
give	O
informed	O
consent	O

Possible	O
pregnancy	B
(	O
confirmed	B
by	O
urine	B
test	I
)	O

Women	B
who	O
are	O
breastfeeding	O

Severe	B
claustrophobia	B

Inability	B
to	I
lie	I
flat	I
for	O
20	B
-	I
30	I
minutes	I
(	O
the	O
anticipated	O
amount	B
of	I
time	I
to	I
complete	I
the	I
MRI	I
procedure	I
)	O

Individuals	O
with	O
cochlear	B
implants	I

Individuals	O
with	O
non	B
-	O
MRI	B
compatible	I
aneurysm	B
clips	I

Potential	O
contraindications	O
to	O
regadenoson	O
use	O
due	O
to	O
:	O

Contraindication	B
to	O
administration	O
of	O
Gadolinium	B
(	I
Gd	I
)	I
based	I
contrast	I
agents	I
(	I
GBCA	I
)	I
:	O

Aged	B
18	B
years	I
or	I
older	I

Scheduled	O
for	O
invasive	B
coronary	I
angiography	I

Current	O
pregnancy	B
or	O
lactation	B

Liver	B
disease	I
or	O
elevated	B
liver	B
enzymes	I

Established	O
diagnosis	O
of	O
diabetes	B
mellitus	I

Abnormal	B
serum	B
glucose	I
levels	I
either	O
at	B
fasting	I
or	O
after	O
the	O
2	B
-	I
hr	I
oral	I
glucose	I
tolerance	I
test	I
meeting	B
criteria	O
for	O
the	O
diagnosis	O
of	O
diabetes	B
mellitus	I
according	O
to	O
the	O
American	O
Diabetes	O
Association	O
.	O

Insulin	B
sensitizing	I
treatment	I
within	O
3	O
months	O
prior	O
to	O
or	O
during	B
the	I
eight	I
week	I
study	I
period	I
.	O

Hormonal	O
treatment	O
involving	O
estrogen	B
or	O
progesterone	B
3	O
months	O
prior	O
to	O
or	O
during	B
the	I
study	I
period	I
,	O
with	O
the	O
exception	B
of	O
medroxyprogesterone	B
acetate	I
for	O
withdrawal	B
bleeding	I
.	O

Systemic	B
or	O
inhaled	B
corticosteroids	O
.	O

Known	O
hypersensitive	B
reaction	I
to	I
cinnamon	I
.	O

Patients	O
with	O
seizure	B
disorders	I
,	O
known	O
cardiovascular	B
disease	I
,	O
or	O
cerebrovascular	B
disease	I
.	O

Body	B
mass	I
index	I
(	I
BMI	I
)	I
range	B
20	I
-	I
50	I
(	O
excluding	O
all	O
women	O
with	O
BMI	O
under	O
20	O
or	O
over	O
50	O
)	O
.	O

Patients	O
aged	B
greater	B
than	I
18	I
years	I
of	O
age	B

Ability	O
to	O
understand	O
and	O
willingness	O
to	O
comply	O
with	O
the	O
study	O
protocol	O

Written	O
informed	O
consent	O

Patients	O
meeting	B
the	O
Rotterdam	B
PCOS	I
workshop	I
criteria	I
for	I
polycystic	I
ovary	I
syndrome	I
,	O
defined	O
by	O
oligomenorrhea	B
or	O
amenorrhea	B
and	O
at	B
least	I
one	I
of	O
the	O
following	O
two	O
signs	O
:	O
clinical	O
or	O
biochemical	O
evidence	O
of	O
hyperandrogenism	B
or	O
ultrasound	B
finding	O
of	O
polycystic	B
appearing	I
ovaries	I
.	O

Weight	B
stable	B
(	O
<	B
3	I
kg	I
weight	I
change	I
within	B
last	I
3	I
months	I
)	O

Constant	B
habitual	I
activity	I
patterns	I
(	O
no	O
deviation	O
>	O
1x	O
/	O
wk	O
at	O
30	O
min	O
/	O
session	O
within	O
last	O
3	O
months	O
)	O

Constant	B
habitual	I
diet	I
patterns	I
within	B
last	I
3	I
months	I

Willingness	O
to	O
eat	O
a	O
chocolate	O
-	O
flavored	O
snack	O
at	B
test	I
sessions	I
and	O
two	O
week	O
training	O
period	O

No	B
allergies	B
to	O
any	O
test	O
foods	O

Not	B
planning	O
to	O
change	O
use	O
of	O
medications	B
known	I
to	I
influence	I
appetite	I
or	O
metabolism	O

Not	B
diabetic	B

No	B
history	B
of	O
GI	B
pathology	I

Non	B
-	O
smoker	B
for	B
one	I
year	I
or	I
more	I

HCV	O
,	O
HIV	O
,	O
HDV	B
coinfection	I
.	O

Uncontrolled	B
HCC	B
,	O
malignancy	B
or	O
decompensated	B
liver	B
cirrhosis	I
(	O
CTP	B
score	I
=	B
7	I
)	O
.	O

Uremia	B
patients	O
or	O
Creatinine	B
=	B
2	I
mg	I
/	I
dl	I
.	O

HBsAg	B
-	O
positive	B
for	O
more	B
than	I
6	I
months	I
(	O
HBeAg	B
-	O
positive	B
or	O
HBeAg	B
-	O
negative	B
)	O
.	O

Age	B
>	B
20	I
y	I
/	I
o	I
.	O

Under	O
lamivudine	B
/	O
adefovir	B
treatment	O
for	O
more	B
than	I
1	I
year	I
due	O
to	O
previous	O
lamivudine	O
resistance	O
(	O
LAM	O
-	O
R	O
)	O
,	O
current	O
HBV	B
DNA	I
is	O
undetectable	B
(	O
<	B
20	I
IU	I
/	I
ml	I
)	O
during	B
enrollment	I
.	O

Any	O
other	B
variety	I
of	O
LAL	B

Patients	O
with	O
a	O
history	B
of	O
coronary	B
artery	I
disease	I
,	O
valvular	O
or	O
hypertensive	B
heart	I
disease	I

Patients	O
with	O
chronic	B
liver	I
disease	I

Patients	O
with	O
chronic	B
respiratory	I
failure	I

Renal	B
failure	I
not	B
due	O
to	O
LAL	B

Patients	O
with	O
positive	B
HIV	B
status	I

No	B
serious	B
neurological	B
abnormalities	I
due	O
to	O
LAL	B

Impact	O
on	O
overall	O
severe	O
(	O
grade	O
3	O
or	O
4	O
of	O
the	O
WHO	O
scale	O
)	O
not	O
attributable	O
to	O
the	O
LAL	O

Pregnant	O
or	O
breastfeeding	O

initial	O
blast	B
crisis	I
CML	B

Patients	O
with	O
Ph	B
(	I
BCR	I
/	I
ABL	I
)	I
positive	B
de	B
novo	I
<	B
55	I
years	I
old	B
(	O
it	O
is	O
advisable	O
to	O
include	O
patients	O
over	O
55	O
years	O
LAL07OPH	O
protocol	O
)	O
.	O

Performance	B
status	I
0	B
-	I
2	I
(	O
Appendix	O
B	O
)	O
may	O
include	O
patients	O
with	O
performance	O
status	O
>	O
2	O
attributable	O
to	O
LAL	O
.	O

Patients	O
without	B
functional	B
impairment	I
of	I
organs	I
:	O
liver	O
function	O
:	O
total	B
bilirubin	I
,	O
AST	B
,	O
ALT	B
,	O
alfa	B
-	I
GT	I
and	O
alkaline	B
phosphatase	I
less	B
than	I
3	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
laboratory	O
renal	O
function	O
:	O
serum	B
creatinine	I
<	B
2	I
mg	I
/	I
dL	I
or	O
clearance	B
creatinine	I
>	B
30	I
ml	I
/	I
min	I
(	O
except	O
renal	O
function	O
attributable	O
to	O
LAL	O
)	O
cardiac	B
function	I
(	O
Appendix	O
B	O
)	O
normal	B
:	O
ventricular	B
EF	I
>	B
50	I
%	I
,	O
absence	B
of	I
severe	B
chronic	I
respiratory	I
disease	I
.	O

In	O
the	O
event	O
that	O
alterations	O
are	O
secondary	O
to	O
the	O
disease	O
is	O
at	O
the	O
discretion	O
of	O
the	O
investigator	O
to	O
determine	O
if	O
the	O
patient	O
can	O
be	O
included	O
in	O
the	O
trial	O
.	O

previous	B
brain	B
surgery	I
;	O

cognitive	B
impairment	I
(	O
<	B
120	I
points	I
on	O
the	O
Mattis	B
Dementia	I
Rating	I
Scale	I
)	O

moderate	B
-	I
to	I
-	I
severe	I
depression	B
(	O
>	B
25	I
points	I
on	O
the	O
Beck	B
Depression	I
Inventory	I
)	O

marked	O
brain	B
atrophy	I
as	O
detected	O
by	O
magnetic	B
resonance	I
imaging	I

other	O
medical	O
or	O
psychiatric	O
coexisting	O
disorders	O
that	O
could	O
increase	O
the	O
surgical	O
risk	O
or	O
interfere	O
with	O
completion	O
of	O
the	O
trial	O

ages	B
of	O
7	B
and	I
75	I
years	I

marked	O
disability	B
owing	O
to	O
primary	B
generalized	B
or	O
segmental	B
dystonia	B
,	O
despite	O
optimal	B
pharmacologic	B
treatment	I

disease	B
duration	I
of	O
at	B
least	I
5	I
years	I
.	O

Contraindication	B
to	O
bariatric	B
surgery	I

Pregnancy	B

Affiliation	O
of	O
health	O
care	O
assurance	O

Psychiatric	B
disorders	I

Type	B
2	I
diabetes	I
mellitus	I
with	O
HbA1c	B
>	B
7	I
.	I
5	I
%	I

Body	B
mass	I
index	I
>	B
35	I
and	I
<	I
50	I
kg	I
/	I
m2	I

Candidate	O
for	O
Gastric	B
By	I
-	I
Pass	I

Treatment	B
with	O
GLP1	B
(	I
glucagon	I
-	I
like	I
peptide	I
)	I
analogue	I
or	O
insulin	B

1	O
.	O

The	O
subject	O
is	O
a	O
pregnant	B
or	O
lactating	B
female	B
.	O

2	O
.	O

The	O
subject	O
has	O
pre	B
-	I
existing	I
sustained	B
supine	B
hypertension	I
greater	B
than	I
180mmHg	I
systolic	I
and	O
110mmHg	B
diastolic	I
BP	B
or	O
had	O
these	O
measurements	O
at	B
the	I
Screening	I
Visit	I
.	O

Sustained	O
is	O
defined	O
as	O
persistently	B
greater	B
at	O
2	O
separate	O
measurements	B
at	O
least	O
5	O
minutes	O
apart	O
with	O
the	O
subject	O
supine	O
and	O
at	O
rest	O
for	O
the	O
5	O
minutes	O
.	O

3	O
.	O

Subjects	O
taking	O
concomitant	B
medications	B
of	I
interest	I
are	O
excluded	O
unless	O
those	O
medications	O
are	O
reviewed	O
and	O
discussed	O
with	O
the	O
Medical	O
Monitor	O
or	O
Study	O
Physician	O
and	O
documented	O
prior	O
to	O
enrolling	O
the	O
subject	O
.	O

If	O
agreement	O
is	O
reached	O
between	O
the	O
Investigator	O
and	O
Sponsor	O
for	O
the	O
subject	O
to	O
continue	O
in	O
the	O
study	O
,	O
all	O
allowed	O
medications	O
should	O
be	O
maintained	O
at	O
a	O
constant	O
dose	O
throughout	O
the	O
study	O
.	O

4	O
.	O

The	O
Principal	O
Investigator	O
deems	O
any	O
clinical	O
laboratory	O
test	O
(	O
at	O
the	O
Screening	O
Visit	O
)	O
abnormality	O
to	O
be	O
clinically	O
significant	O

5	O
.	O

The	O
subject	O
has	O
participated	O
in	O
other	O
studies	O
of	O
investigational	O
drugs	O
or	O
devices	O
within	O
30	O
days	O
prior	O
to	O
enrollment	O
in	O
this	O
study	O
(	O
other	O
than	O
Study	O
SPD426	O
-	O
406	O
)	O
.	O

6	O
.	O

Current	O
or	O
relevant	O
history	O
of	O
physical	O
or	O
psychiatric	O
illness	O
,	O
any	O
medical	O
disorder	O
that	O
may	O
require	O
treatment	O
or	O
make	O
the	O
subject	O
unlikely	O
to	O
fully	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
study	O
or	O
complete	O
the	O
study	O
,	O
or	O
any	O
condition	O
that	O
presents	O
undue	O
risk	O
from	O
the	O
investigational	O
product	O
or	O
study	O
procedures	O
.	O

7	O
.	O

The	O
subject	O
has	O
a	O
concurrent	O
chronic	O
or	O
acute	B
illness	I
,	O
disability	B
,	O
or	O
other	B
condition	I
(	O
including	O
significant	O
unexpected	O
laboratory	O
or	O
electrocardiogram	B
[	I
ECG	I
]	I
findings	O
)	O
that	O
might	O
confound	O
the	O
results	O
of	O
the	O
tests	O
and	O
/	O
or	O
measurements	O
administered	O
in	O
this	O
study	O
,	O
or	O
that	O
might	O
have	O
increased	O
the	O
risk	O
to	O
the	O
subject	O
.	O

8	O
.	O

Known	O
or	O
suspected	O
intolerance	O
or	O
hypersensitivity	O
to	O
the	O
investigational	O
product	O
(	O
s	O
)	O
,	O
closely	O
-	O
related	O
compounds	O
,	O
or	O
any	O
of	O
the	O
stated	O
ingredients	O
.	O

9	O
.	O

Prior	O
enrollment	B
failure	I
or	O
randomization	O
in	O
this	O
study	O
.	O

10	O
.	O

History	O
of	O
alcohol	B
abuse	I
or	O
other	O
substance	B
abuse	I
within	B
the	I
last	I
year	I
.	O

1	O
.	O

Male	B
and	O
female	B
subjects	O
must	O
be	O
18	O
years	O
of	O
age	B
or	O
older	O
and	O
ambulatory	O
.	O

2	O
.	O

Females	B
of	O
child	B
-	I
bearing	I
potential	I
(	O
FOCP	O
)	O
must	O
have	O
a	O
negative	B
serum	B
beta	I
human	I
chorionic	I
gonadotropin	I
(	I
HCG	I
)	I
pregnancy	I
test	I
.	O

3	O
.	O

A	O
documented	O
history	O
of	O
severe	B
Symptomatic	B
Orthostatic	I
Hypotension	I
(	I
SOH	I
)	I
that	O
,	O
in	O
the	O
judgment	O
of	O
the	O
treating	O
physician	O
,	O
has	O
required	O
treatment	O
with	O
midodrine	B
HCl	I
,	O
and	O
has	O
been	O
at	O
a	O
stable	B
dose	I
for	B
at	I
least	I
3	I
months	I
.	O

4	O
.	O

The	O
subject	O
has	O
manifested	O
at	B
least	I
1	I
of	O
the	O
following	O
symptoms	O
while	O
standing	O
or	O
had	O
a	O
medical	O
history	O
of	O
1	B
of	O
the	O
following	O
when	O
not	B
treated	B
for	O
orthostatic	B
hypotension	I
(	I
OH	I
)	I
:	O
dizziness	B
,	O
lightheadedness	B
,	O
feeling	B
faint	I
,	O
or	O
feeling	B
like	I
they	I
might	I
black	I
out	I
.	O

1	O
.	O

Need	O
for	O
combined	B
organ	I
transplantation	I
with	O
an	O
extra	B
-	I
renal	I
organ	I
and	O
/	O
or	O
islet	B
cell	I
transplant	I
.	O

2	O
.	O

Recipients	O
of	O
previous	B
non	O
-	O
renal	O
solid	O
organ	O
and	O
/	O
or	O
islet	B
cell	I
transplantation	I
.	O

3	O
.	O

Infection	B
with	I
HIV	I
.	O

4	O
.	O

Inability	O
or	O
unwillingness	O
of	O
a	O
participant	O
and	O
/	O
or	O
guardian	O
to	O
provide	O
informed	O
consent	O

1	O
.	O

Male	B
and	O
female	B
recipients	O
of	O
all	O
races	O
,	O
≥	B
18	I
years	I
of	O
age	B
.	O

2	O
.	O

Patients	O
undergoing	O
primary	B
or	O
subsequent	B
deceased	O
-	O
donor	O
or	O
living	B
donor	I
kidney	I
transplantation	I
.	O

3	O
.	O

Subject	O
and	O
/	O
or	O
guardian	O
must	O
be	O
able	O
to	O
provide	O
informed	O
consent	O
.	O

4	O
.	O

Subject	O
and	O
/	O
or	O
guardian	O
must	O
be	O
able	O
to	O
comply	O
with	O
the	O
study	O
protocol	O
.	O

cauda	B
equina	I
or	O
conus	B
lesion	B

currently	B
use	O
ventilator	B

colostomy	B
,	O
or	O
do	B
not	I
perform	I
regular	B
bowel	I
care	I
for	O
any	O
reason	O

any	O
skin	B
breakdown	I
(	O
pressure	B
sores	I
)	O

do	O
not	B
speak	O
English	O

are	O
under	B
19	I
years	I
old	B

are	O
pregnant	B
or	O
think	O
you	O
might	O
be	O
pregnant	B

medical	O
/	O
psychiatric	B
condition	I
or	O
substance	B
abuse	I
that	O
is	O
likely	O
to	O
affect	O
your	O
ability	O
to	O
complete	O
this	O
study	O

currently	B
using	O
medications	B
containing	I
lidocaine	I

allergy	B
to	O
lidocaine	B

traumatic	B
spinal	I
cord	I
injury	I
at	B
least	I
one	I
year	I
ago	I

regular	O
bowel	O
care	O
routine	O
(	O
at	B
least	I
four	I
weeks	I
)	O

Unstable	B
patient	B

Joint	B
contracture	I

Spasticity	B

Loss	O
of	O
function	O
is	O
expected	O
to	O
be	O
improved	O
by	O
reliable	O
tendon	B
transfer	I
,	O
tenodesis	B
or	O
arthrodesis	B
that	O
is	O
available	O

Evidence	O
of	O
recovering	O
finger	B
/	O
thumb	B
extension	O
at	B
4	I
-	I
6	I
months	I

Greater	B
than	I
12	I
months	I
from	O
spinal	B
cord	I
injury	I

Subject	O
not	O
fluent	O
in	O
English	O
or	O
an	O
appropriate	O
translator	O
not	O
available	O

Cervical	B
spine	I
injury	I
with	O
functional	O
loss	O
in	O
the	O
upper	B
extremity	I

Greater	B
than	I
4	I
months	I
out	O
from	O
C	B
-	I
spine	I
injury	I

Stable	B
motor	O
recovery	O

Medically	B
stable	B

International	B
Classification	I
for	I
Surgery	I
of	I
the	I
Hand	I
in	I
Tetraplegia	I
of	O
0	B
-	I
5	I
at	B
6	I
months	I

Grade	B
0	I
finger	B
/	O
thumb	B
extension	B
at	B
6	I
months	I

Subjects	O
fluent	O
in	O
English	O
or	O
when	O
not	O
fluent	O
,	O
an	O
appropriate	O
translator	O
is	O
present	O

implanted	O
hardware	O
or	O
other	O
material	O
that	O
would	O
prohibit	O
treatment	O
planning	O
or	O
delivery	O

chemotherapy	B
for	O
a	O
malignancy	B
within	B
the	I
previous	I
5	I
years	I

history	O
of	O
an	O
invasive	B
malignancy	I
(	O
other	B
than	I
this	O
prostate	B
cancer	I
,	O
or	O
basal	O
or	O
squamous	B
skin	I
cancers	I
)	O
within	B
prior	I
5	I
years	I

hormone	B
ablation	I
for	B
2	I
months	I
prior	I
to	I
treatment	I
or	O
during	B
treatment	I

histologically	B
proven	I
prostate	B
adenocarcinoma	I
within	B
1	I
year	I
of	I
enrollment	I

Low	O
risk	O
:	O
Gleason	B
<	B
or	I
=	I
6	I
&	O
PSA	B
<	B
or	I
=	I
10	I
&	O
Clinical	B
Stage	I
T1b	B
-	I
T2a	I
,	O
Nx	B
or	O
N0	B
,	O
Mx	B
or	O
M0	B

Intermediate	O
risk	O
:	O
Gleason	B
<	B
or	I
=	I
6	I
&	O
PSA	B
<	B
or	I
=	I
10	I
&	O
Clinical	B
Stage	I
T2b	B
OR	O
Gleason	B
=	B
7	I
&	O
PSA	B
<	B
or	I
=	I
10	I
&	O
Clinical	B
Stage	I
T1b	B
-	I
T2b	I
OR	O
Gleason	B
<	B
or	I
=	I
6	I
&	O
PSA	B
>	B
10	I
&	I
<	I
or	I
=	I
20	I
&	O
Clinical	B
Stage	I
T1b	B
-	I
T2b	I
,	O
Nx	B
or	O
NO	B
,	O
Mx	B
or	O
M0	B

ECOG	B
Performance	I
Status	I
0	B
-	I
1	I

No	B
prior	O
prostate	B
radiation	I
or	O
other	O
definitive	B
therapy	I

Patients	O
with	O
prior	O
fistulotomy	B
,	O
fistulectomy	B
,	O
LIFT	B
,	O
cutting	B
seton	I
or	O
advancement	B
flap	I
procedure	I

Fistula	B
with	O
multiple	B
tracts	I

Recto	B
-	I
vaginal	I
fistula	I

Active	O
infection	O
in	O
the	O
anal	B
fistula	I

Physical	O
allergies	O
or	O
cultural	O
objections	O
to	O
porcine	O
products	O

Patient	O
is	O
not	O
medically	O
fit	O
to	O
undergo	O
the	O
LIFT	O
procedure	O
as	O
judged	O
by	O
the	O
treating	O
physician	O

Previous	O
diagnosis	O
of	O
collagen	B
disorder	I

History	B
of	O
Crohn	B
'	I
s	I
Disease	I
,	O
Irritable	B
Bowel	I
Syndrome	I
,	O
radiation	B
therapy	I
in	O
the	O
rectoanal	B
region	I

Persistent	O
primary	B
or	O
recurrent	B
trans	B
-	I
sphincteric	I
anal	I
fistula	I

A	O
previous	B
history	I
of	O
intolerance	B
to	O
the	O
study	B
drug	I
or	O
related	B
compounds	I
and	O
additives	O

History	O
of	O
alcoholism	B
,	O
drug	B
abuse	I
,	O
psychiatric	O
,	O
psychological	O
or	O
other	O
emotional	B
problems	I
that	O
are	O
likely	O
to	O
invalidate	O
informed	O
consent	O

Sleep	B
apnoea	I

Chronic	B
obstructive	I
pulmonary	I
disease	I

BMI	B
=	B
35	I
or	O
weight	B
<	B
50	I
kg	I

SpO2	B
<	B
90	I
%	I

Concomitant	B
drug	B
therapy	I
known	O
to	O
cause	O
significant	O
enzyme	O
induction	O
or	O
inhibition	O
of	O
CYP	O
3A4	O
.	O

Pregnancy	B
or	O
nursing	B
.	O

ASA	B
I	B
-	I
III	I

Colonoscopy	B

Written	O
informed	O
consent	O
from	O
participating	O
subject	O

Serious	O
suicidal	B
tendency	I

The	O
score	B
of	I
the	I
sixth	I
item	I
of	I
HAMA	I
=	B
3	I

The	O
score	B
of	I
HAMD	I
=	B
21	I

Pregnant	B
or	O
lactating	B
women	B

History	O
of	O
allergic	B
or	O
hypersensitivity	B
to	O
tandospirone	B

Serious	B
or	O
unstable	B
cardiac	O
,	O
renal	O
,	O
neurologic	O
,	O
cerebrovascular	O
,	O
metabolic	O
,	O
or	O
pulmonary	B
disease	I

Secondary	B
anxiety	I
disorders	I

Drug	O
or	O
alcohol	B
dependence	I
within	B
1	I
year	I

Patients	O
currently	B
taking	O
benzodiazepine	B
drugs	I

Drivers	B
and	O
dangerous	B
machine	I
operators	I

Participated	O
in	O
other	O
clinical	O
studies	O
in	O
the	B
last	I
30	I
days	I

Patients	O
with	O
clinically	B
significant	I
ECG	B
or	O
laboratory	B
abnormalities	O

Patients	O
with	O
a	O
history	O
of	O
epilepsy	B

Patients	O
with	O
abnormal	B
TSH	B
concentration	O

18	B
-	I
65	I
years	B
old	I

Male	B
or	O
female	B

Diagnosed	O
with	O
GAD	B
according	O
to	O
DSM	B
-	I
IV	I

HAMA	B
score	I
=	B
17	I

Provide	O
with	O
written	O
informed	O
consent	O

Agree	O
to	O
be	O
washed	B
-	I
out	I
for	B
two	I
weeks	I
if	O
receiving	O
SSRI	B
,	O
SNRI	B
or	O
NASA	B
.	O

Partial	B
mole	I

History	O
of	O
treatment	B
for	O
molar	B
pregnancy	I
like	O
prior	O
evacuation	B
or	O
chemotherapy	B

Women	B
requiring	O
hysterectomy	B
for	O
treatment	O
of	O
H	B
Mole	I

Ultrasound	B
confirmed	O
complete	B
mole	I

Allergy	B
to	O
any	O
of	O
proposed	B
medications	I

Patients	O
with	O
any	O
active	B
infection	I
including	O
HBV	B
,	O
HCV	B
and	O
HIV	B
.	O

All	O
renal	O
(	O
only	O
)	O
male	B
and	O
female	B
recipients	O
aged	B
=	B
60	I
,	O
years	O
undergoing	O
kidney	B
transplantation	I
from	O
a	O
living	O
or	O
deceased	B
donor	I
,	O
including	O
Expanded	B
Criteria	I
Donors	I
(	I
ECD	I
)	I
.	O

Panel	B
Reactive	I
Antibody	I
(	I
PRA	I
)	I
<	B
30	I
%	I
.	O

Patients	O
who	O
consented	O
to	O
participate	O
in	O
the	O
study	O
by	O
signing	O
the	O
informed	O
consent	O
form	O
before	O
the	O
transplant	O
surgery	O
to	O
the	O
1st	O
post	O
-	O
operative	O
day	O
)	O
.	O

Age	B
less	B
than	I
14	I
years	I

Pregnancy	B

Estimated	B
life	I
expectancy	I
(	O
due	O
to	O
comorbidities	O
)	O
less	B
than	I
90	I
days	I

Presence	O
of	O
relative	O
or	O
absolute	B
contraindications	I
to	O
CPFA	B

Admission	B
from	O
an	O
other	O
ICU	O
where	O
the	O
patient	O
remained	O
for	B
more	I
than	I
24	I
hours	I

Absence	O
of	O
informed	O
consent	O

All	O
patients	O
admitted	B
to	O
the	O
ICU	O
in	O
septic	B
shock	I

All	O
patients	O
that	O
develop	O
septic	B
shock	I
while	B
in	I
the	I
ICU	I

Metastatic	B
tumor	B

Locally	B
unresectable	I
tumor	B

Previous	B
gastric	B
resection	I

ASA	B
IV	B
-	I
V	I

Age	B
under	B
18	I
years	I

Preoperative	B
complete	B
parenteral	I
or	I
enteral	I
feeding	I

Immunosuppressive	B
therapy	I
before	O
operation	B

Severe	B
malnutrition	B

Lack	O
of	O
the	O
patient	O
'	O
s	O
consent	O
for	O
the	O
trial	O
participation	O
,	O
feeding	O
tube	O
insertion	O
or	O
epidural	O
analgesia	O

Primary	B
periampullary	B
tumor	I

R0	O
,	O
R1	B
resection	I

Chronic	B
pancreatitis	I
requiring	O
pancreatoduodenectomy	B

Patients	O
with	O
a	O
history	O
of	O
an	O
untreated	B
malignancy	B
(	O
except	B
local	B
skin	I
cancers	I
)	O

Ischemic	B
stroke	I
(	O
determined	O
using	O
the	O
Questionnaire	B
for	I
Verifying	I
Stroke	I
-	I
Free	I
Status	I
(	I
QVSFS	I
)	I

Patients	O
on	O
renal	B
dialysis	I
or	O
with	O
end	B
-	I
stage	I
hepatic	I
dysfunction	I

Acute	B
infection	B
/	O
inflammation	B
(	O
Temperature	B
>	B
101	I
.	I
5	I
F	I
,	O
and	O
/	O
or	O
WBC	B
>	B
15	I
,	I
000	I
)	O

Inability	O
to	O
obtain	O
informed	O
consent	O
from	O
patient	O
or	O
next	O
of	O
kin	O

Anticoagulant	B
use	O
(	O
warfarin	B
or	O
heparin	B
)	O

Diagnosis	O
of	O
heart	B
failure	I
according	O
to	O
Framingham	B
criteria	I

Informed	O
consent	O

Age	B
18	B
years	I
or	I
above	I

underlying	O
lung	O
or	O
heart	B
disase	I

contra	B
indication	I
to	O
dexamethasone	B

immune	B
deficient	I
state	I

preterm	B
birth	I

previous	B
intubation	B
or	O
apnea	B
history	B

croup	O
children	B
between	B
6	I
month	I
and	I
5	I
years	I
old	B

Westley	B
croup	I
score	I
between	B
3	I
and	I
11	I

Prior	B
chemotherapy	B
Prior	B
treatment	B
with	O
gefitinib	B
,	O
erlotinib	B
,	O
or	O
other	O
drugs	B
that	I
target	I
EGFR	I
Patients	O
must	O
not	O
be	O
receiving	O
any	O
other	O
investigational	O
agents	O
Any	O
evidence	O
of	O
interstitial	B
lung	I
disease	I

Pathologic	B
confirmation	B
of	O
lung	B
adenocarcinoma	I
with	B
measurable	I
disease	I
,	O
defined	O
as	O
at	B
least	I
one	I
lesion	B
that	O
can	B
be	I
accurately	I
measured	I
in	I
at	I
least	I
one	I
dimension	I
(	O
longest	O
diameter	O
to	O
be	O
recorded	O
on	O
CT	O
)	O
;	O
Patients	O
must	O
have	O
previously	O
untreated	B
locally	B
advanced	I
or	O
metastatic	B
NSCLC	B
;	O
Patients	O
must	O
have	O
lung	B
cancer	I
with	B
a	I
documented	I
EGFR	I
activating	I
mutation	I
(	O
exon	B
19	I
deletion	I
,	O
L858R	B
)	O
.	O

a	O
history	B
of	O
non	B
-	I
standard	I
treatment	I
(	O
chemotherapy	B
or	O
surgery	B
)	O

secondary	B
osteosarcoma	I
or	O
well	B
-	I
differentiated	I
parosteal	B
osteosarcoma	I

evident	O
dysfunction	B
of	I
cardia	I
,	O
liver	O
and	O
kidney	O
,	O
or	O
pregnant	B
women	O
or	O
women	O
during	O
lactation	B

histologically	B
diagnosed	O
primary	B
classical	B
osteosarcoma	I
in	B
extremities	I

staging	B
IIB	I

MRI	B
showing	O
no	B
skip	O
lesion	O

receive	O
standard	B
neo	I
-	I
adjuvant	I
chemotherapy	I
,	O
adjuvant	B
chemotherapy	I
,	O
and	O
standard	B
surgical	I
treatment	I

Contraindication	B
of	I
CT	I
Known	B
allergy	I
to	O
iodinated	B
contrast	I
media	I
or	O
history	O
of	O
contrast	B
-	I
induced	I
nephropathy	I
Decreased	B
renal	B
function	I
:	O
elevated	B
serum	B
creatinine	I
(	O
>	B
1	I
.	I
5mg	I
/	I
dl	I
)	O
Contraindication	B
to	O
beta	B
-	I
blockers	I
Severe	B
arrhythmia	B
:	O
arterial	B
fibrillation	I
or	O
uncontrolled	B
tachyarrhythmia	I
,	O
or	O
advanced	B
atrioventricular	I
block	I
(	O
second	O
or	O
third	B
degree	I
heart	I
block	I
)	O

Contraindication	B
of	O
MRI	B
Claustrophobia	B
Metallic	B
hazards	I
Pacemaker	B
implant	I
eGFR	B
<	B
30	I
ml	I
/	I
min	I

Unstable	O
or	O
uncooperative	B
patients	I

Limited	B
life	B
expectancy	I
due	O
to	O
cancer	B
or	O
end	O
-	O
stage	O
renal	O
or	O
liver	B
disease	I

Evidence	O
of	O
severe	B
symptomatic	B
heart	B
failure	I
(	O
NYHA	B
Class	B
III	I
or	I
IV	I
)	O

Previous	B
myocardial	B
infarction	I
,	O
coronary	B
artery	I
intervention	I
,	O
coronary	B
artery	I
bypass	I
surgery	I
,	O
or	O
other	B
cardiac	I
surgery	I

Men	B
and	O
women	B
patients	O
,	O
with	O
age	B
ranging	B
40	I
-	I
80	I
.	O

Suspected	O
coronary	B
artery	I
disease	I
who	O
are	O
supposed	O
to	O
undergo	O
invasive	B
coronary	I
angiography	I
with	O
appropriate	O
clinical	O
indications	O

Patients	O
who	O
are	O
willing	O
to	O
sign	O
the	O
informed	O
consent	O
form	O

score	O
level	B
D	I
on	O
the	O
SIGAM	B
mobility	I
grade	I

have	O
experienced	O
1	B
or	I
more	I
falls	O
in	B
the	I
last	I
month	I
before	I
the	I
study	I

have	O
a	O
residual	B
limb	I
length	I
which	O
does	B
not	I
allow	O
for	O
seven	O
inches	O
clearance	O
of	O
bracket	O
attachment	O
for	O
the	O
PowerFoot	O

the	O
residual	O
limb	O
must	O
be	O
stable	O
in	O
volume	O
(	O
no	O
change	O
in	O
socket	O
or	O
socket	O
padding	O
in	O
last	O
6	O
months	O
)	O
and	O
without	O
pain	O
that	O
limits	O
function	O

the	O
sound	O
-	O
side	O
(	O
contralateral	O
)	O
lower	O
extremity	O
must	O
be	O
free	B
of	O
impediments	B
that	I
affect	I
gait	I
,	O
range	O
of	O
motion	O
,	O
or	O
limb	O
muscle	O
activity	O

Any	O
diagnosed	O
cardiovascular	O
,	O
pulmonary	O
,	O
neurological	O
,	O
and	O
/	O
or	O
orthopedic	B
conditions	I
that	O
would	O
interfere	B
with	I
subject	I
participation	I

weigh	B
more	B
than	I
200	I
lbs	I

are	O
high	B
level	I
ambulators	I
corresponding	O
to	O
levels	B
E	I
to	I
F	I
of	O
the	O
Special	B
Interest	I
Group	I
of	I
Amputee	I
Medicine	I
(	I
SIGAM	I
)	I
mobility	I
grade	I

have	O
the	O
ability	B
to	I
follow	I
multi	I
-	I
step	I
commands	I
.	O

Past	O
history	O
of	O
hypersensitivity	B
to	O
aripiprazole	B

Primary	O
diagnosis	O
of	O
MDD	B
with	O
psychotic	B
feature	I
,	O
bipolar	B
disorder	I
,	O
schizophrenia	B
,	O
schizoaffective	B
disorder	I
,	O
other	B
psychotic	B
disorder	I
or	O
anxiety	B
disorder	I
,	I
a	O
history	O
of	O
alcohol	O
/	O
drug	B
abuse	I
within	B
the	I
past	I
12	I
months	I
,	O
or	O
a	O
diagnosis	O
of	O
dementia	B

Clinically	O
significant	O
current	O
Axis	B
II	I
(	O
DSM	B
-	I
IV	I
-	I
TR	I
)	O
diagnosis	B

A	O
significant	B
risk	O
of	O
suicide	O
corroborated	O
by	O
a	O
score	B
of	I
=	I
5	I
on	I
item	I
10	I
(	O
suicidal	O
thoughts	O
)	O
on	O
the	O
MADRS	B
scale	I
or	O
by	O
clinical	O
judgment	O
of	O
the	O
investigator	O

Pregnancy	O
or	O
in	O
breast	O
-	O
feeding	O

Presence	O
of	O
a	O
serious	B
medical	B
illness	I
including	O
cardiac	B
,	O
hepatic	B
,	O
renal	B
,	O
respiratory	B
,	O
endocrinologic	B
,	O
neurologic	B
,	O
or	O
hematologic	B
disease	I
or	O
physical	B
disorder	I
judged	O
to	O
significantly	O
affect	O
central	O
nervous	O
system	O
function	O

Patients	O
taking	O
antipsychotics	B
,	O
mood	B
stabilizer	I
or	O
any	O
psychotropic	B
medications	I
besides	B
antidepressants	B
,	O
except	B
benzodiazepines	B
or	O
beta	B
blockers	I
or	O
hypnotics	B

Patients	O
with	O
past	O
treatment	O
failures	O
of	O
aripiprazole	B

Age	B
:	O
18	B
-	I
65	I

Patients	O
with	O
major	B
depressive	I
disorder	I
according	O
to	O
DSM	B
-	I
IV	I
criteria	I
that	O
have	O
lasted	B
>	I
8	I
weeks	I

MADRS	B
total	O
score	B
of	I
18	I
or	I
higher	I

Patients	O
who	O
responded	O
inadequately	O
(	O
a	O
score	B
of	I
>	I
18	I
on	O
the	O
MADRS	B
)	O
to	O
first	B
-	I
line	I
antidepressant	B
treatment	O
of	B
4	I
week	I
duration	O

Current	O
use	O
of	O
standard	B
antidepressant	B
treatment	O
in	O
monotherapy	B
or	O
combination	O
of	O
2	B
antidepressants	B
:	O
escitalopram	B
(	O
10	B
-	I
20mg	I
/	I
d	I
)	O
,	O
fluoxetine	B
(	O
20	B
-	I
40mg	I
/	I
d	I
)	O
,	O
paroxetine	B
CR	I
(	O
25	B
-	I
50mg	I
/	I
d	I
)	O
,	O
sertraline	B
(	O
100	B
-	I
150mg	I
/	I
d	I
)	O
,	O
mirtazapine	B
(	O
15	B
-	I
45mg	I
/	I
d	I
)	O
,	O
duloxetine	B
(	O
30	B
-	I
60mg	I
/	I
d	I
)	O
or	O
venlafaxine	B
ER	I
(	O
150	B
-	I
225mg	I
/	I
d	I
)	O

Non	B
-	I
compliance	I
with	O
DOTPlus	B
.	O

Alternatively	O
DOT	O
can	O
be	O
done	O
by	O
telephoning	O
patient	O
on	O
a	O
daily	O
basis	O
5	O
times	O
a	O
week	O
and	O
having	O
patient	O
annotate	O
taking	O
drug	O
in	O
a	O
log	O
which	O
would	O
be	O
reviewed	O
by	O
clinic	O
staff	O

History	O
of	O
being	O
treated	B
for	O
tuberculosis	B
in	B
the	I
prior	I
2	I
years	I
unless	O
there	O
is	O
DST	B
,	O
including	O
PCR	B
testing	I
,	O
showing	O
sensitivity	B
to	O
rifamycin	B
.	O

Known	O
hypersensitivity	B
to	O
rifampin	B
or	O
rifabutin	B
.	O

Liver	B
enzymes	I
greater	B
than	I
2	I
times	I
ULN	I
.	O

Bilirubin	B
greater	B
than	I
2	I
times	I
ULN	I
.	O

Serum	B
creatinine	I
greater	B
than	I
3	I
times	I
ULN	I
.	O

Hemoglobin	B
less	B
than	I
7	I
.	I
0	I
gms	I
even	B
if	I
receiving	I
erythropoietin	I
.	O

Absolute	B
neutrophil	I
count	I
less	B
than	I
750	I
cells	I
/	I
mm3	I
even	B
if	I
receiving	I
G	I
-	I
CSF	I
.	O

Fasting	B
triglycerides	I
greater	B
than	I
400	I
mg	I
/	I
dL	I
.	O

Fasting	B
cholesterol	I
>	B
1	I
.	I
6	I
upper	I
limits	I
of	I
normal	I
.	O

GI	B
intolerance	I
of	O
tuberculosis	B
medications	I
requiring	O
discontinuation	B
of	O
tuberculosis	B
medications	I
.	O

Fasting	B
glucose	I
greater	B
150	I
mg	I
/	I
dL	I
.	O

Pregnant	B
women	B
.	O

Use	O
of	O
one	O
of	O
the	O
prohibited	O
medications	O

Any	O
condition	O
that	O
the	O
investigators	O
feel	O
could	O
compromise	O
the	O
use	O
of	O
the	O
current	O
medication	O
.	O

Have	O
a	O
CD4	B
cell	I
count	I
of	O
50	B
cells	I
/	I
mm3or	I
less	I

Hepatitis	B
B	I
or	O
C	O
infection	O

Alcohol	O
or	O
illicit	O
drug	O
use	O
,	O
which	O
in	O
the	O
investigators	O
opinion	O
may	O
affect	O
participation	O
in	O
study	O
.	O

Antiretroviral	B
naive	B

Taking	O
Kaletra	B
containing	O
regimen	B
with	O
suppressed	B
viral	B
load	I
.	O

Taking	O
an	O
NNRTI	B
or	O
integrase	B
containing	O
regimen	B
without	B
prior	B
history	O
of	O
use	O
of	O
PI	B
for	B
more	I
than	I
2	I
weeks	I

Taking	O
an	O
NNRTI	B
or	O
integrase	B
containing	O
regimen	B
with	O
prior	B
exposure	O
to	O
PI	B
greater	B
than	I
2	I
weeks	I
.	O

It	O
must	O
be	O
clearly	O
stated	O
in	O
the	O
source	O
document	O
that	O
PI	O
was	O
switched	O
to	O
another	O
agent	O
for	O
convenience	O
.	O

Taking	O
another	O
PI	B
containing	O
regimens	B
with	O
suppressed	B
viral	B
load	I
.	O

It	O
must	O
be	O
clearly	O
stated	O
in	O
source	O
document	O
that	O
if	O
another	O
PI	O
was	O
used	O
for	O
greater	O
than	O
2	O
weeks	O
the	O
regimen	O
was	O
switched	O
to	O
another	O
agent	O
for	O
convenience	O
.	O

Subjects	O
with	O
prior	O
history	O
of	O
PI	O
use	O
may	O
be	O
enrolled	O
,	O
if	O
there	O
is	O
a	O
genotype	O
showing	O
no	O
resistance	O
to	O
Kaletra	O
Other	O
Inclusion	O
criteria	O

Be	O
at	B
least	I
18	I
years	I
of	O
age	B
and	O
able	O
to	O
give	O
informed	O
consent	O
.	O

Diagnosed	O
with	O
TB	B
by	O
criteria	B
per	I
Brazilian	I
Ministry	I
of	I
Health	I

Have	O
a	O
good	B
clinical	I
response	I
to	O
TB	B
.	O

Tolerating	O
tuberculosis	B
therapy	O
containing	O
rifampin	B
for	B
the	I
2	I
weeks	I
prior	I
to	I
screening	I
,	O
except	B
for	O
persons	O
taking	O
protease	B
inhibitors	I
at	B
time	I
of	I
diagnosis	I
of	I
TB	I
.	O
,	O
.	O

Subjects	O
taking	O
protease	O
inhibitors	O
will	O
be	O
screened	O
and	O
initiate	O
visit	O
1	O
within	O
3	O
days	O
of	O
starting	O
TB	O
medication	O

HIV	B
positive	B
with	O
documentation	O
present	O
in	O
source	O
document	O
.	O

Have	O
a	O
CD4	B
cell	I
count	I
greater	B
than	I
50	I
cells	I
/	I
mm3if	I
not	B
taking	O
ART	B
.	O

Persons	O
with	O
cd4	O
<	O
50	O
may	O
be	O
enrolled	O
,	O
if	O
it	O
is	O
felt	O
that	O
in	O
the	O
best	O
interest	O
of	O
the	O
patient	O
,	O
that	O
enrollment	O
in	O
the	O
study	O
will	O
allow	O
for	O
quicker	O
initiation	O
of	O
antiretroviral	O
therapy	O
than	O
referral	O
to	O
another	O
treatment	O
center	O
.	O

1	O
.	O

For	O
subjects	O
in	O
Cohort	O
A	O
:	O
previous	B
therapy	B
for	B
more	I
than	I
48	I
hours	I
with	O
any	O
parenteral	B
antibiotic	O
with	B
activity	I
against	I
S	I
.	I
aureus	I
within	O
72	O
hours	O
of	O
positive	O
blood	B
culture	I
results	O
.	O

2	O
.	O

For	O
subjects	O
in	O
Cohort	O
B	O
:	O
previous	B
therapy	B
for	B
more	I
than	I
48	I
hours	I
with	O
any	O
parenteral	B
antibiotic	O
with	B
activity	I
against	I
MRSA	I
,	O
except	B
vancomycin	B
and	O
/	O
or	O
daptomycin	B
,	O
within	O
72	O
hours	O
of	O
positive	O
blood	B
culture	I
results	O
confirming	O
persistence	O
.	O

3	O
.	O

Previous	O
episode	O
of	O
S	B
.	I
aureus	I
bacteremia	O
within	B
3	I
months	I
.	O

4	O
.	O

Known	O
left	B
-	I
sided	I
endocarditis	O
or	O
prosthetic	B
heart	I
valve	I
.	O

5	O
.	O

Osteomyelitis	B
or	O
prosthetic	B
joint	I
infection	I
except	B
new	B
onset	I
nonhardware	B
-	I
associated	I
vertebral	B
osteomyelitis	I
.	O

6	O
.	O

History	B
of	O
any	O
hypersensitivity	B
or	O
allergic	B
reaction	I
to	O
any	O
β	B
-	I
lactam	I
antibacterial	I
agent	I
.	O

7	O
.	O

Evidence	O
of	O
significant	O
hepatic	O
,	O
hematologic	O
,	O
or	O
immunologic	B
impairment	I
.	O

8	O
.	O

Pregnant	B
or	O
nursing	B
females	B
.	O

1	O
.	O

Presence	O
of	O
bacteremia	B
due	O
solely	O
to	O
:	O

S	O
.	O
aureus	O
on	O
at	B
least	I
1	I
blood	B
culture	I
within	B
72	I
hours	I
of	I
beginning	I
study	I
drug	I
(	O
Cohort	O
A	O
)	O
OR	O

MRSA	O
on	O
a	O
baseline	B
blood	B
culture	I
and	O
on	O
at	B
least	I
1	I
additional	I
blood	B
culture	I
after	O
at	O
least	O
72	O
hours	O
of	O
vancomycin	B
and	O
/	O
or	O
daptomycin	B
treatment	O
(	O
Cohort	O
B	O
)	O
.	O

2	O
.	O

Male	B
or	O
female	B
≥	B
18	I
years	I
of	O
age	B
.	O

3	O
.	O

If	O
female	B
of	O
childbearing	B
potential	I
must	O
be	O
willing	O
to	O
practice	B
sexual	I
abstinence	I
or	O
dual	B
methods	B
of	I
contraception	I
during	B
treatment	I
and	O
for	B
at	I
least	I
30	I
days	I
after	I
the	I
last	I
dose	I
of	I
study	I
drug	I
.	O

4	O
.	O

Expectation	O
of	O
survival	B
for	B
at	I
least	I
2	I
months	I
.	O

Plan	O
for	O
diagnostic	B
-	I
only	I
coronary	B
angiography	I

On	O
colchicine	B
chronically	B

History	O
of	O
intolerance	B
to	O
colchicine	B

Glomerular	B
filtration	I
rate	I
<	B
30mL	I
/	I
minute	I
or	O
on	O
dialysis	B

Active	B
malignancy	B
or	O
infection	B

History	O
of	O
myelodysplasia	B

High	B
-	I
dose	I
statin	I
load	O
<	B
24	I
hours	I
prior	I
to	I
procedure	I

Use	O
of	O
oral	B
steroids	I
or	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
agents	I
other	B
than	I
aspirin	B
within	B
72	I
hours	I
or	O
3	O
times	O
the	O
agent	O
'	O
s	O
half	O
-	O
life	O
(	O
whichever	O
is	O
longer	O
)	O

Use	O
of	O
strong	B
CYP3A4	I
/	I
P	I
-	I
glycoprotein	I
inhibitors	I
(	O
specifically	O
ritonavir	B
,	O
ketoconazole	B
,	O
clarithromycin	B
,	O
cyclosporine	B
,	O
diltiazem	B
and	O
verapamil	B
)	O

Unable	O
to	O
consent	O

Participating	O
in	O
a	O
competing	O
study	O

Patients	O
must	O
be	O
more	B
than	I
18	I
years	I
of	O
age	B
and	O
referred	O
for	O
coronary	B
angiography	I

History	B
or	O
presence	O
of	O
any	O
clinically	B
significant	I
disease	O
or	O
disorder	O

Any	O
condition	O
or	O
disease	O
that	O
would	O
render	O
the	O
subject	O
unsuitable	O
for	O
the	O
study	O
,	O
place	O
the	O
subject	O
at	O
undue	O
risk	O
or	O
interfere	O
with	O
the	O
ability	O
of	O
the	O
subject	O
to	O
complete	O
the	O
study	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O

History	O
of	O
clinically	B
significant	I
hypersensitivity	B
or	O
allergic	B
drug	I
reactions	I

Any	O
suspicion	O
or	O
history	B
of	O
alcohol	B
abuse	I
and	O
/	O
or	O
consumption	B
of	I
other	I
drugs	I
of	I
abuse	I

Regular	B
smoker	I
(	O
>	B
5	I
cigarettes	O
,	O
>	B
1	I
pipeful	O
or	O
>	B
1	I
cigar	I
per	I
day	I
)	O

Positive	B
for	O
hepatitis	B
B	I
,	O
hepatitis	B
C	I
or	O
HIV	B
infection	I

Dietary	B
restrictions	I
that	O
would	B
prohibit	I
the	I
consumption	I
of	I
standardized	I
meals	I

Participation	O
in	O
an	O
investigational	O
drug	O
or	O
device	O
study	O
within	O
90	O
days	O
prior	O
to	O
screening	O
,	O
as	O
calculated	O
from	O
the	O
follow	O
-	O
up	O
from	O
the	O
previous	O
study	O

Healthy	B
male	B
volunteers	O
,	O
18	O
to	O
45	O
years	O
of	O
age	B
,	O
inclusive	O
.	O

Healthy	O
status	O
is	O
defined	O
by	O
absence	B
of	O
evidence	O
of	O
any	O
active	O
or	O
chronic	O
disease	O
following	O
a	O
detailed	O
medical	O
and	O
surgical	B
history	I
,	O
a	O
complete	O
physical	B
examination	I
including	O
vital	B
signs	I
,	O
12	B
-	I
lead	I
ECG	I
,	O
hematology	B
,	O
blood	B
chemistry	I
,	O
serology	B
and	O
urinalysis	B

Body	B
mass	I
index	I
(	I
BMI	I
)	I
18	B
to	I
30	I
kg	I
/	I
m2	I
inclusive	I

Male	B
subjects	O
(	O
whether	O
surgically	B
sterilized	I
or	O
not	B
)	O
with	O
female	B
partners	O
of	O
child	B
-	I
bearing	I
potential	I
must	O
use	O
two	B
forms	B
of	I
contraception	I
,	O
one	O
of	O
which	O
must	O
be	O
a	O
barrier	B
method	I
,	O
for	B
the	I
duration	I
of	I
the	I
study	I
and	O
for	B
77	I
days	I
after	I
the	I
last	I
dose	I

patient	O
refusal	O

age	B
less	B
than	I
40	I
or	O
over	B
80	I
years	I

combined	B
surgical	I
procedures	I

emergency	B
surgery	I

Left	B
ventricular	I
ejection	I
fraction	I
less	B
than	I
50	I
per	I
cent	I

calculated	B
creatinine	I
clearance	I
less	B
than	I
60	I
mL	I
per	I
minute	I

age	B
over	B
40	I

composite	B
head	I
and	I
neck	I
tumor	I
resection	I

treated	B
hypertension	B

hypertension	B
medications	I
taken	O
on	B
morning	I
of	I
surgery	I
(	O
except	B
diuretics	B
)	O

Any	O
concomitant	B
cardiovascular	B
procedure	I
to	O
CABG	B
(	O
i	O
.	O
e	O
.	O
valve	O
,	O
aortic	O
or	O
carotid	B
surgery	I
)	O

Acute	B
ST	I
-	I
segment	I
-	I
elevation	I
myocardial	I
infarction	I
(	O
STEMI	B
)	O

NSTE	B
-	I
ACS	I
with	O
cardiogenic	B
shock	I
warranting	O
emergent	O
salvage	B
surgery	I
within	B
12	I
hrs	I
from	I
hospital	I
admission	I

History	O
of	O
atrial	B
fibrillation	I
or	O
muscle	B
disease	I
(	O
myopathy	B
)	O

Current	O
renal	O
(	O
creatinine	B
>	B
2x	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
,	O
dialysis	B
,	O
kidney	B
transplant	I
)	O
or	O
hepatic	B
dysfunction	I
(	O
AST	B
/	O
ALT	B
>	B
2x	I
ULN	I
,	O
liver	B
transplant	I
or	O
neoplasm	B
)	O

Inability	B
of	O
oral	B
drug	I
intake	O

Patients	O
on	O
chronic	B
statin	B
treatment	B
(	O
>	B
30	I
days	I
)	O
scheduled	O
for	O
isolated	B
CABG	B
,	O
including	O
on	B
-	I
or	I
off	I
-	I
pump	I
or	I
repeat	I
(	O
redo	B
'	I
s	I
)	O
revascularisation	B
procedures	I

Stable	O
or	O
unstable	B
angina	I
,	O
including	O
non	B
ST	I
-	I
segment	I
-	I
elevation	I
acute	I
coronary	I
syndrome	I
(	O
NSTE	B
-	I
ACS	I
)	O

Age	B
=	B
18	I
years	I

Written	O
informed	O
consent	O

Previous	B
treated	B
with	O
anti	B
-	I
diabetic	I
medication	I

Pregnant	B
or	O
nursing	B
women	B
.	O

Impaired	B
liver	I
function	I
(	O
ALT	B
>	B
120	I
U	I
/	I
L	I
)	O

Impaired	B
renal	I
function	I
(	O
Serum	B
creatinine	I
>	B
1	I
.	I
5	I
mg	I
/	I
dL	I
in	O
male	B
,	O
>	B
1	I
.	I
4	I
mg	I
/	I
dL	I
in	O
female	B
)	O

Recently	B
suffered	O
from	O
MI	B
or	O
CVA	B
.	O

Patients	O
are	O
acute	B
intercurrent	I
illness	I
.	O

2	B
-	I
hour	I
C	I
-	I
peptide	I
level	I
<	B
1	I
.	I
8	I
ng	I
/	I
mL	I
.	O

Recently	B
diagnosed	I
type	B
2	I
diabetic	I
patients	O
.	O

Fasting	B
plasma	I
glucose	I
between	B
200	I
-	I
300	I
mg	I
/	I
dl	I
(	O
A1C	B
level	I
between	B
7	I
%	I
and	I
10	I
%	I
)	O
.	O

Those	O
who	O
age	B
between	B
30	I
and	I
80	I
years	I
old	I
and	O
can	O
inject	B
insulin	I
by	O
themselves	O
.	O

fetal	B
anomalies	I

contra	B
-	I
indications	I
for	O
medical	B
induction	I
of	I
labor	I

placental	B
pathologies	I

St	B
.	I
p	I
.	I
surgery	B
with	I
opening	I
the	I
uterine	I
cavity	I
(	O
incl	O
.	O
caesarean	B
section	I
)	O

PROM	B

multiple	B
gestations	I

<	B
37	I
-	I
0	I
weeks	I
of	O
gestation	B

St	B
.	I
p	I
.	I
cervical	B
tear	I

medical	B
indication	I
for	O
induction	B
of	I
labor	I

18	B
years	I
of	O
age	B

signed	O
informed	O
consent	O

cephalic	B
presentation	I

no	B
PROM	B

37	B
+	I
0	I
-	O
42	B
+	I
0	I
weeks	B
of	I
gestation	I

Bishop	B
-	I
Score	I
=	B
6	I

no	B
contra	B
-	I
indication	I
for	O
medical	B
induction	I
of	I
labor	I

no	B
clinical	O
signs	O
of	O
infection	B

Psychotic	B
depression	I
by	O
DSM	B
-	I
IV	I
,	O
i	O
.	O
e	O
.	O
,	O
presence	O
of	O
delusions	B
with	O
a	O
SCID	B
-	I
R	I
score	I
higher	B
than	I
2	I
;	O

High	B
suicide	O
risk	O
,	O
i	O
.	O
e	O
.	O
intent	O
or	O
plan	O
to	O
attempt	O
suicide	O
in	B
near	I
future	I
;	O

Presence	O
of	O
any	O
Axis	B
I	I
psychiatric	B
disorder	I
(	O
other	B
than	I
unipolar	B
major	I
depression	I
)	O
or	O
substance	B
abuse	I
;	O

History	O
of	O
psychiatric	B
disorders	I
other	B
than	I
unipolar	B
major	I
depression	I
or	O
generalized	B
anxiety	I
disorder	I
(	O
bipolar	B
disorder	I
,	O
hypomania	B
,	O
and	O
dysthymia	B
are	O
exclusion	O
criteria	O
)	O
;	O

Dementia	B
:	O
Diagnosis	O
of	O
dementia	O
by	O
DSM	B
-	I
IV	I
;	O

Mild	B
Cognitive	I
Impairment	I
(	O
MCI	B
)	O
;	O

Acute	B
or	O
severe	B
medical	B
illness	I
,	O
i	O
.	O
e	O
.	O
,	O
delirium	B
,	O
metastatic	B
cancer	I
,	O
decompensated	B
cardiac	O
,	O
liver	O
or	O
kidney	B
failure	I
,	O
major	B
surgery	I
,	O
stroke	B
or	O
myocardial	B
infarction	I
during	O
the	O
three	B
months	I
prior	I
to	I
entry	I
;	O
or	O
use	O
of	O
drugs	B
known	O
to	O
cause	O
depression	B
,	O
e	O
.	O
g	O
.	O
,	O
reserpine	B
,	O
alpha	B
-	I
methyl	I
-	I
dopa	I
,	O
steroids	B
,	O
sympathomimetics	B
withdrawal	I
;	O

Neurological	B
brain	B
disease	I
and	O
/	O
or	O
history	O
of	O
electroconvulsive	B
therapy	I
;	O

History	O
of	O
any	O
use	O
of	O
citalopram	B
or	O
escitalopram	B
during	O
the	O
current	B
episode	B
or	O
need	O
for	O
drugs	B
that	O
may	O
interact	O
with	O
these	O
agents	B
,	O
i	O
.	O
e	O
.	O
drug	O
metabolized	O
by	O
the	O
2D6	O
P450	O
isoenzyme	O
system	O
;	O

Current	O
involvement	O
in	O
psychotherapy	B
;	O

Contraindications	B
to	O
MRI	B
scanning	O
including	O
cardiac	B
pacemaker	I
,	O
metallic	B
objects	I
and	O
metallic	B
implants	I
contraindicating	O
MRI	O
,	O
cardiac	B
stent	I
,	O
claustrophobia	B
;	O

Inability	O
to	O
speak	O
English	O
;	O

Corrected	B
visual	B
acuity	I
<	B
20	I
/	I
70	I
;	I
Color	B
blindness	I
.	O

Age	B
:	O
60	B
-	I
85	I
years	I
,	O
right	O
-	O
handed	O
;	O

Diagnosis	O
:	O
Major	B
depression	I
,	O
unipolar	B
(	O
by	O
Structured	O
Clinical	O
Interview	O
for	O
Diagnostic	O
and	O
Statistical	O
Manual	O
(	O
DSM	B
)	O
IV	O
(	O
SCID	B
-	O
R	O
)	O
and	O
DSM	B
-	I
IV	I
criteria	I
)	I
;	O

Age	B
of	O
onset	B
of	I
first	I
episode	I
=	B
50	I
years	I
with	O
up	O
to	O
three	B
depressive	B
episodes	I
;	O

Severity	O
of	O
depression	B
:	O
A	O
24	B
-	I
Item	I
Hamilton	I
Depression	I
Rating	I
Scale	I
(	O
HDRS	B
)	O
=	B
20	I
.	O

Patient	O
has	O
been	O
permanently	B
discontinued	B
from	O
nilotinib	B
treatment	B
in	O
the	O
parent	O
study	O
due	O
to	O
unacceptable	B
toxicity	I
,	O
non	O
-	O
compliance	O
to	O
study	B
procedures	I
,	O
withdrawal	B
of	O
consent	O
or	O
any	O
other	O
reason	O

Patient	O
has	O
participated	O
in	O
a	O
Novartis	B
sponsored	I
combination	O
trial	O
where	O
nilotinib	O
was	O
dispensed	O
in	O
combination	O
with	O
another	O
study	O
medication	O
and	O
patient	O
is	O
still	O
receiving	O
combination	O
therapy	O

Patients	O
who	O
are	O
currently	B
receiving	O
treatment	B
with	O
any	B
medications	I
that	O
have	B
the	I
potential	I
to	I
prolong	I
the	I
QT	I
interval	I
or	O
inducing	B
Torsade	I
de	I
Pointes	I
and	O
the	O
treatment	O
cannot	O
be	O
either	O
safely	O
discontinued	O
at	O
least	O
one	O
week	O
prior	O
to	O
nilotinib	O
treatment	O
or	O
switched	O
to	O
a	O
different	O
medication	O
prior	O
to	O
start	O
of	O
nilotinib	O
treatment	O
and	O
for	O
the	O
duration	O
of	O
the	O
study	O

Pregnant	O
or	O
nursing	O
(	O
lactating	O
)	O
women	B
,	O
where	O
pregnancy	O
is	O
defined	O
as	O
the	O
state	O
of	O
a	O
female	O
after	O
conception	O
and	O
until	O
the	O
termination	O
of	O
gestation	O
,	O
confirmed	O
by	O
a	O
positive	B
hcG	O
laboratory	O
test	O
.	O

Women	B
of	O
child	O
-	O
bearing	O
potential	O
,	O
defined	O
as	O
all	O
women	B
physiologically	O
capable	O
of	O
becoming	O
pregnant	O
,	O
unless	B
they	O
are	O
using	O
highly	B
effective	I
methods	I
of	O
contraception	O
during	B
the	I
study	I
and	O
for	B
30	I
days	I
after	I
the	I
final	I
dose	I
of	I
nilotinib	I
.	O

Patient	O
is	O
currently	B
enrolled	O
in	O
a	O
Novartis	B
-	I
sponsored	I
,	O
Oncology	O
Clinical	O
Development	O
&	O
Medical	O
Affairs	O
study	O
receiving	O
nilotinib	B
and	O
has	O
fulfilled	O
all	O
their	O
requirements	O
in	O
the	O
parent	O
study	O

Patient	O
is	O
currently	B
benefiting	O
from	O
the	O
treatment	B
with	O
nilotinib	B
,	O
as	O
determined	O
by	O
the	O
investigator	O

Patient	O
has	O
demonstrated	O
compliance	O
,	O
as	O
assessed	O
by	O
the	O
investigator	O
,	O
with	O
the	O
parent	O
study	O
protocol	O
requirements	O

Willingness	O
and	O
ability	O
to	O
comply	O
with	O
scheduled	O
visits	O
,	O
treatment	O
plans	O
and	O
any	O
other	O
study	O
procedures	O

Written	O
informed	O
consent	O
obtained	O
prior	B
to	I
enrolling	I
in	I
roll	I
-	I
over	I
study	I

NA	O

Patient	O
>	B
18	I
years	I
of	O
age	B

Patient	O
presents	O
with	O
acute	B
coronary	I
syndrome	I
(	O
ACS	B
)	O
or	O
stable	B
coronary	B
artery	I
disease	I
(	O
CAD	B
)	O

Patient	O
is	O
eligible	O
for	O
PCI	B

Patient	O
is	O
willing	O
and	O
able	O
to	O
provide	O
informed	O
written	O
consent	O

Patient	O
not	O
able	B
to	I
receive	I
12	B
months	I
of	O
dual	B
anti	I
-	I
platelet	I
therapy	I

Failure	O
of	O
index	B
PCI	B

Patient	O
or	O
physician	O
refusal	O
to	O
enroll	O
in	O
the	O
study	O

Patient	O
with	O
known	O
CYP2C19	B
genotype	I
prior	B
to	I
randomization	I

Planned	O
revascularization	B
of	O
any	B
vessel	I
within	B
30	I
days	I
post	I
-	I
index	I
procedure	I
and	O
/	O
or	O
of	B
the	I
target	I
vessel	I
(	I
s	I
)	I
within	B
12	I
months	I
post	I
-	I
procedure	I

Anticipated	O
discontinuation	O
of	O
clopidogrel	B
or	O
ticagrelor	B
within	B
the	I
12	I
month	I
follow	I
up	I
period	I
,	O
example	O
for	O
elective	B
surgery	I

Serum	B
creatinine	I
>	B
2	I
.	I
5	I
mg	I
/	I
dL	I
within	B
7	I
days	I
of	I
index	I
procedure	I

Platelet	B
count	I
<	B
80	I
,	I
000	I
or	I
>	I
700	I
,	I
000	I
cells	I
/	I
mm3	I
,	O
or	O
white	B
blood	I
cell	I
count	I
<	B
3	I
,	I
000	I
cells	I
/	I
mm3	I
if	O
persistent	O
(	O
at	O
least	O
2	O
abnormal	O
values	O
)	O
within	B
7	I
days	I
prior	I
to	I
index	I
procedure	I
.	O

History	O
of	O
intracranial	B
hemorrhage	I

Known	O
hypersensitivity	B
to	O
clopidogrel	B
or	O
ticagrelor	B
or	O
any	B
of	I
its	I
components	I

Patient	O
is	O
participating	O
in	O
an	O
investigational	O
drug	O
or	O
device	O
clinical	O
trial	O
that	O
has	O
not	O
reached	O
its	O
primary	O
endpoint	O

Patient	O
previously	O
enrolled	O
in	O
this	O
study	O

Patient	O
is	O
pregnant	B
,	O
lactating	B
,	O
or	O
planning	O
to	O
become	O
pregnant	B
within	B
12	I
months	I

Patient	O
has	O
received	O
an	O
organ	B
transplant	I
or	O
is	O
on	O
a	O
waiting	O
list	O
for	O
an	O
organ	B
transplant	I

Patient	O
is	O
receiving	O
or	O
scheduled	O
to	O
receive	O
chemotherapy	B
within	B
30	I
days	I
before	I
or	I
after	I
the	I
procedure	I

Patient	O
is	O
receiving	O
immunosuppressive	B
therapy	I
or	O
has	O
known	O
immunosuppressive	O
or	O
autoimmune	B
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
human	B
immunodeficiency	I
virus	I
,	O
systemic	B
lupus	I
erythematous	I
,	O
etc	O
.	O
)	O

Patient	O
is	O
receiving	O
chronic	B
oral	B
anticoagulation	I
therapy	I
(	O
i	O
.	O
e	O
.	O
,	O
vitamin	B
K	I
antagonist	I
,	O
direct	B
thrombin	I
inhibitor	I
,	O
Factor	B
Xa	I
inhibitor	I
)	O

Concomitant	B
use	O
of	O
simvastatin	B
/	O
lovastatin	B
>	B
40	I
mg	I
qd	I

Concomitant	B
use	O
of	O
potent	B
CYP3A4	I
inhibitors	I
(	O
atazanavir	B
,	O
clarithromycin	B
,	O
indinavir	B
,	O
itraconazole	B
,	O
ketoconazole	B
,	O
nefazodone	B
,	O
nelfinavir	B
,	O
ritonavir	B
,	O
saquinavir	B
,	O
telithromycin	B
and	O
voriconazole	B
)	O
or	O
inducers	O
(	O
carbamazepine	B
,	O
dexamethasone	B
,	O
phenobarbital	B
,	O
phenytoin	B
,	O
rifampin	B
,	O
and	O
rifapentine	B
)	O

Non	B
-	I
cardiac	I
condition	I
limiting	O
life	O
expectancy	O
to	O
less	B
than	I
one	I
year	I
,	O
per	O
physician	O
judgment	O
(	O
e	O
.	O
g	O
.	O
cancer	O
)	O

Known	O
history	O
of	O
severe	B
hepatic	B
impairment	I

Patient	O
has	O
a	O
history	O
of	O
bleeding	B
diathesis	I
or	O
coagulopathy	B
or	O
will	O
refuse	O
blood	B
transfusions	I

Patient	O
has	O
an	O
active	B
pathological	B
bleeding	I
,	O
such	O
as	O
active	B
gastrointestinal	B
(	I
GI	I
)	I
bleeding	I

Inability	B
to	I
take	I
aspirin	B
at	O
a	O
dosage	O
of	O
100	B
mg	I
or	I
less	I

Current	O
substance	B
abuse	I
(	O
e	O
.	O
g	O
.	O
,	O
alcohol	O
,	O
cocaine	O
,	O
heroin	O
,	O
etc	O
.	O
)	O

Immunocompromised	B
patients	O
:	O

Patients	O
with	O
a	O
known	O
congenital	B
or	O
acquired	B
immunodeficiency	B
.	O

Patients	O
who	O
received	O
chemotherapy	B
less	B
than	I
6	I
weeks	I
ago	I
.	O

Patients	O
who	O
received	O
corticosteroids	B
in	B
the	I
last	I
6	I
weeks	I
.	O

Patients	O
who	O
received	O
immunosuppressive	B
medication	I
in	B
the	I
last	I
6	I
weeks	I
(	O
e	O
.	O
g	O
.	O
cyclosporin	B
,	O
cyclophosphamide	B
,	O
azathioprine	B
)	O
.	O

Patients	O
with	O
chronic	B
obstructive	I
pulmonary	I
disease	I
who	O
are	O
on	O
systemic	B
corticosteroids	I
.	O

Patients	O
who	O
require	O
intensive	O
care	O
unit	O
treatment	O
.	O

Patients	O
with	O
tropical	B
worm	I
infection	I
.	O

Patients	O
with	O
dexamethasone	B
intolerance	B
.	O

Pregnant	O
and	O
breastfeeding	O
women	O
.	O

18	O
years	B
or	O
older	O

Chest	B
radiograph	I
showing	O
new	B
opacities	B
.	O

Cough	B

Production	O
of	O
sputum	B

Temp	B
>	B
38	I
,	I
0	I
°	I
C	I
or	O
<	B
36	I
,	I
0	I
°	I
C	I

Audible	O
abnormalities	O
by	O
chest	B
examination	I
compatible	O
with	O
pneumonia	B

Leukocytosis	B
(	O
>	B
10	I
.	I
000	I
cells	I
/	I
mm3	I
)	O
,	O
leftward	B
shift	I
(	I
>	I
10	I
%	I
)	O
or	O
leucopenia	B
(	O
<	B
4000	I
cells	I
/	I
mm3	I
)	O

C	B
-	I
reactive	I
protein	I
>	B
15	I
mg	I
/	I
l	I
(	O
three	B
fold	I
higher	I
than	I
the	I
upper	I
limit	I
of	I
normal	I
)	O

Patients	O
who	O
may	O
receive	O
therapeutically	B
effective	I
doses	B
via	O
an	O
external	B
beam	I
approach	O
to	O
the	O
lesion	O
of	O
interest	O
as	O
specified	O
by	O
MSKCC	B
Radiation	I
Oncology	I
Department	I
dose	I
constraint	I
criteria	I
.	O

Patients	O
with	O
kyphoplasty	B
cement	I
or	O
hardware	O
that	O
would	O
preclude	B
effective	I
catheter	I
placement	I
.	O

Patients	O
with	O
paraspinal	B
extension	I
of	I
disease	I
with	O
visceral	B
involvement	I
.	O

Abnormal	B
complete	B
blood	I
count	I
.	O

Any	O
of	O
the	O
following	O
:	O

Platelet	B
count	I
<	B
75	I
,	I
000	I
/	I
ml	I

Hb	B
level	I
<	B
9gm	I
/	I
dl	I

WBC	B
<	B
3	I
.	I
5	I
/	I
ml	I

Abnormal	B
coagulation	B
profile	I
:	O
INR	B
>	B
2	I
.	I
5	I
and	O
/	O
or	O
PTT	B
>	B
80	I

Patients	O
who	O
are	O
on	O
anticoagulation	B
medication	I
that	O
may	B
not	I
be	I
safely	I
held	I
for	I
the	I
procedure	I
(	O
≥	B
5	I
days	I
for	O
antiplatelet	B
agents	I
and	O
warfarin	B
;	O
≥	B
24	I
hours	I
for	O
low	B
-	I
molecular	I
weight	I
heparin	I
formulations	O
)	O
will	O
be	O
excluded	O
.	O

Contraindications	O
to	O
general	B
anesthesia	I

Patients	O
must	O
have	O
histologic	B
proof	B
of	O
a	O
malignancy	B
suitable	O
for	O
radiation	B
therapy	I
.	O

Patients	O
must	O
have	O
received	O
prior	B
external	B
beam	I
radiation	I
therapy	I
to	O
the	O
region	O
proposed	O
for	O
HDR	B
brachytherapy	I
treatment	O
;	O
evaluation	O
of	O
doses	O
previously	O
delivered	O
to	O
spinal	O
cord	O
/	O
cauda	O
equine	O
,	O
pelvis	O
,	O
and	O
other	O
critical	O
structures	O
(	O
bowel	O
,	O
kidneys	O
,	O
rectum	O
)	O
will	O
be	O
taken	O
into	O
consideration	O
.	O

If	O
repeat	B
irradiation	I
would	O
exceed	B
any	I
normal	I
tissue	I
constraint	I
set	O
by	O
MSKCC	B
Radiation	I
Oncology	I
Department	I
dose	I
constraint	I
criteria	I
,	O
the	O
patient	O
will	O
potentially	O
be	O
eligible	O
.	O

If	O
the	O
total	O
prior	O
radiation	O
dose	O
to	O
the	O
cord	O
or	O
pelvis	O
exceeds	O
100	O
Gy	O
BED	O
equivalent	O
,	O
the	O
patient	O
will	O
be	O
potentially	O
eligible	O
,	O
where	O
a	O
total	O
of	O
100	O
BED	O
Gy	O
equivalent	O
is	O
determined	O
by	O
the	O
biological	O
equivalent	O
dose	O
(	O
BED	O
)	O
calculation	O
;	O
BED	O
=	O
nd	O
(	O
1	O
+	O
d	O
/	O
α	O
/	O
β	O
)	O
,	O
where	O
n	O
=	O
number	O
of	O
fractions	O
and	O
d	O
=	O
dose	O
per	O
fraction	O
;	O
α	O
/	O
β	O
is	O
the	O
constant	O
for	O
spinal	O
cord	O
late	O
effect	O
and	O
equals	O
2	O
.	O
[	O
Rades	O
2005	O
,	O
Nieder	O
2005	O
,	O
Sahgal	O
2012	O
]	O

KPS	B
≥	B
60	I

Age	B
≥	B
18	I
years	I
old	I

younger	B
than	I
18	I
years	I
old	B

HBsAg	B
positive	I
or	O
HBcAb	B
negative	I
or	O
hepatitis	B
B	I
virus	I
DNA	I
positive	I
at	B
baseline	I

pregnant	B
or	O
lactating	B
women	B

treatment	O
-	O
naive	O
patients	O
with	O
lymphoma	B

HBsAg	B
negative	B
/	O
HBcAb	B
positive	B
/	O
hepatitis	B
B	I
virus	I
DNA	I
negative	B
at	B
baseline	I

treated	O
with	O
chemotherapy	B
and	O
/	O
or	O
immunosuppressive	B
therapy	I

life	O
expectancy	O
of	O
more	B
than	I
3	I
months	I

younger	B
than	I
18	I
years	I
old	B

HBsAg	B
negative	I
at	B
baseline	I

pregnant	B
or	O
lactating	B
women	B

treatment	B
-	O
naive	B
patients	O
with	O
B	B
-	I
cell	I
lymphoma	I

HBsAg	B
positive	I
at	B
baseline	I

treated	O
with	O
rituximab	B
-	O
based	O
immunochemotherapy	B

life	O
expectancy	O
of	O
more	B
than	I
3	I
months	I

IIEF	B
<	B
21	I

Operations	B
in	B
the	I
past	I
6	I
months	I
which	O
could	O
limit	B
the	I
erectile	I
function	I

Erectile	B
dysfunction	I
in	O
the	O
history	B
or	O
current	B
medication	B
for	O
erectile	B
dysfunction	I

Current	O
involvement	O
in	O
another	O
comparable	O
study	O
.	O

Localized	O
intermediate	B
-	I
risk	I
or	O
high	B
-	I
risk	I
prostate	B
cancer	I
cT3	B

Gleason	B
score	I
=	B
7	I
(	O
3	B
+	I
4	I
and	O
/	O
or	O
4	B
+	I
3	I
)	O
and	O
/	O
or	O

PSA	B
=	B
20	I
ng	I
/	I
ml	I

intact	O
preoperative	B
erectile	O
function	O
with	O
an	O
IIEF	B
=	B
21	I
(	O
IIEF	O
-	O
6	O
)	O
.	O

Biliary	B
strictures	I
caused	O
by	O
confirmed	B
benign	B
tumors	I

Biliary	B
strictures	I
caused	O
by	O
malignancies	B
other	B
than	I
pancreatic	B
cancer	I
,	O
distal	B
CBD	I
cholangiocarcinoma	I
and	O
other	B
periampullary	I
cancers	I

Surgically	B
altered	I
biliary	I
tract	I
anatomy	I
,	O
not	B
including	O
prior	B
cholecystectomy	B

Neoadjuvant	B
chemotherapy	I
for	O
current	O
malignancy	B

Palliative	O
indication	O
due	O
to	O
reasons	O
other	O
than	O
surgical	O
candidate	O
status	O

Previous	B
biliary	B
drainage	I
by	I
ERCP	I
/	I
PTC	I

Patients	O
for	O
whom	O
endoscopic	B
techniques	I
are	O
contraindicated	B

Participation	O
in	O
another	O
investigational	O
trial	O
within	O
90	O
days	O

Pregnancy	B

Age	B
18	B
or	I
older	I

Willing	O
and	O
able	O
to	O
comply	O
with	O
the	O
study	O
procedures	O
and	O
provide	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O

Diagnosis	O
of	O
probable	O
pancreatic	B
cancer	I
,	O
distal	B
common	I
bile	I
duct	I
(	I
CBD	I
)	I
cholangiocarcinoma	I
and	O
other	B
periampullary	B
cancers	I
(	O
histology	O
not	O
required	O
)	O

Biliary	B
obstructive	I
symptoms	I
or	O
signs	O

Bilirubin	B
level	I
at	B
/	I
above	I
100	I
umol	I
per	I
liter	I
(	O
5	O
.	O
8	O
mg	O
/	O
dL	O
)	O

Distal	B
biliary	I
obstruction	I
consistent	O
with	O
pancreatic	B
cancer	I
,	O
distal	B
CBD	I
cholangiocarcinoma	I
or	O
other	B
periampullary	B
malignancy	I

Location	O
of	O
distal	B
biliary	I
obstruction	I
is	O
such	O
that	O
it	O
would	O
allow	O
the	O
proximal	O
end	O
of	O
a	O
stent	B
to	O
be	O
positioned	O
at	B
least	I
2cm	I
from	I
the	I
hilum	I

Patients	O
deemed	B
as	I
resectable	I
by	O
pancreatic	B
protocol	I
CT	I
or	O
MRI	O

Surgical	B
candidate	I
per	B
pancreatobiliary	I
surgeon	I
after	O
multi	O
-	O
disciplinary	O
discussion	O

Surgery	B
intent	O
within	B
4	I
weeks	I

Endoscopic	O
and	O
surgical	B
treatment	I
to	O
be	O
provided	O
by	O
same	O
team	O

Had	O
dose	B
increase	I
of	O
anti	B
-	I
TNF	I
agent	I
or	O
DMARD	B
in	B
the	I
last	I
6	I
months	I

Had	O
change	B
of	O
anti	B
-	I
TNF	I
agent	I
or	O
DMARD	B
in	B
the	I
last	I
6	I
months	I

Treated	O
currently	O
with	O
golimumab	B
or	O
certolizumab	B

Treated	O
with	O
greater	B
than	I
10	I
mg	I
of	O
prednisone	B
(	O
or	O
equivalent	O
)	O
daily	B
in	B
the	I
last	I
6	I
months	I

Treated	O
with	O
greater	B
than	I
5	I
mg	I
of	O
prednisone	B
(	O
or	O
equivalent	O
)	O
daily	B
in	B
the	I
last	I
3	I
months	I

Treated	O
with	O
intramuscular	B
or	O
intravenous	B
corticosteroids	B
in	B
the	I
last	I
6	I
months	I
for	O
RA	B
activity	O

Treated	O
with	O
anakinra	B
,	O
abatacept	B
,	O
or	O
tocilizumab	B
in	B
the	I
last	I
6	I
months	I

Treated	O
with	O
rituximab	B
in	B
the	I
last	I
12	I
months	I

Treated	O
with	O
an	O
investigational	B
RA	B
drug	I
in	B
the	I
last	I
6	I
months	I

Pregnant	B
(	O
or	O
anticipate	O
pregnancy	B
during	O
the	O
study	O
period	O
)	O
or	O
lactating	B
women	B

Absence	B
of	I
documentation	O
in	O
the	O
medical	O
record	O
of	O
clinical	B
remission	I
for	B
the	I
last	I
6	I
months	I

Unwilling	O
to	O
discontinue	B
anti	B
-	I
TNF	I
agent	I

Absence	B
of	I
documentation	O
of	O
negative	B
tuberculin	B
skin	I
test	I
,	O
negative	B
QuantiFERON	B
-	I
TB	I
Gold	I
test	I
,	O
or	O
treatment	B
for	O
latent	B
tuberculosis	B
prior	O
to	O
starting	O
treatment	O
with	O
the	O
anti	B
-	I
TNF	I
agent	I

Treatment	O
of	O
solid	B
malignancy	I
or	O
non	B
-	I
melanoma	I
skin	I
cancer	I
within	B
the	I
past	I
5	I
years	I
,	O
or	O
any	O
history	O
of	O
melanoma	B
or	O
hematologic	B
or	O
lymphoproliferative	B
malignancy	I

Absence	O
of	O
documentation	O
of	O
age	B
-	I
appropriate	I
cancer	B
screening	I
at	B
the	I
time	I
of	I
randomization	I

Absence	B
of	I
documentation	O
of	O
negative	B
hepatitis	B
B	I
serologies	I
,	O
absence	B
of	I
completion	O
of	O
treatment	B
for	O
chronic	B
hepatitis	I
B	I
,	O
or	O
absence	B
of	O
suppressive	B
antiviral	I
treatment	I

Unable	O
to	O
provide	O
informed	O
consent	O

Anticipate	O
not	O
being	O
available	O
or	O
able	O
to	O
comply	O
with	O
the	O
schedule	O
of	O
study	O
visits	O

Age	B
greater	B
than	I
or	I
equal	I
to	I
18	I
years	I

Have	O
RA	B
,	O
as	O
defined	O
by	O
the	O
1987	B
revised	I
American	I
College	I
of	I
Rheumatology	I
criteria	I

In	O
sustained	B
clinical	I
remission	I
for	B
the	I
last	I
6	I
months	I
while	O
receiving	O
treatment	O
with	O
either	O
etanercept	B
,	O
infliximab	B
,	O
or	O
adalimumab	B
,	O
and	O
greater	B
than	I
or	I
equal	I
to	I
1	I
DMARD	B
(	O
methotrexate	B
,	O
hydroxychloroquine	B
,	O
sulfasalazine	B
,	O
leflunomide	B
,	O
minocycline	B
,	O
cyclosporine	B
,	O
azathioprine	B
,	O
gold	B
,	O
penicillamine	B
)	O
.	O

DAS28	B
should	O
be	O
less	B
than	I
2	I
.	I
6	I
on	O
each	O
visit	B
over	B
the	I
preceding	I
6	I
months	I
,	O
with	O
at	B
least	I
one	I
visit	B
2	B
-	I
4	I
months	I
before	I
enrollment	I
.	O

If	O
there	O
is	O
no	O
visit	O
6	O
months	O
before	O
enrollment	O
,	O
the	O
nearest	O
visit	O
in	O
the	O
6	O
-	O
12	O
month	O
period	O
before	O
enrollment	O
should	O
be	O
considered	O
and	O
have	O
a	O
DAS28	O
less	O
than	O
2	O
.	O
6	O
.	O

Diagnosis	O
as	O
CD	B
first	B
time	I
or	O
first	B
year	I
.	O

No	B
history	B
of	O
using	O
5	B
-	I
ASA	I
,	O
biological	O
or	O
immunomodulatory	B
therapy	I

Moderate	B
to	O
severe	B
CD	B
define	O
as	O
HBI	B
score	I
>	B
4	I
.	O

Montreal	O
classification	O
:	O
no	O
limitation	O
,	O
except	O
age	O
>	O
6	O
.	O

Patient	O
has	O
been	O
permanently	O
discontinued	O
from	O
pasireotide	O
study	O
treatment	O
in	O
the	O
parent	O
study	O
due	O
to	O
unacceptable	O
toxicity	O
,	O
non	O
-	O
compliance	O
to	O
study	O
procedures	O
,	O
withdrawal	O
of	O
consent	O
or	O
any	O
other	O
reason	O

Patient	O
has	O
participated	O
in	O
a	O
Novartis	O
sponsored	O
combination	O
trial	O
where	O
pasireotide	O
was	O
dispensed	O
in	O
combination	O
with	O
another	O
study	O
medication	O
and	O
is	O
still	O
receiving	O
combination	O
therapy	O
.	O
(	O
only	O
patients	O
receiving	O
pasireotide	O
monotherapy	O
can	O
be	O
included	O
)	O

Pregnant	O
or	O
nursing	O
(	O
lactating	O
)	O
women	O
,	O
where	O
pregnancy	O
is	O
defined	O
as	O
the	O
state	O
of	O
a	O
female	O
after	O
conception	O
and	O
until	O
the	O
termination	O
of	O
gestation	O
,	O
confirmed	O
by	O
a	O
positive	O
hCG	O
laboratory	O
test	O

Total	O
abstinence	O
(	O
when	O
this	O
is	O
in	O
line	O
with	O
the	O
preferred	O
and	O
usual	O
lifestyle	O
of	O
the	O
subject	O
.	O
Periodic	O
abstinence	O
(	O
e	O
.	O
g	O
.	O
,	O
calendar	O
,	O
ovulation	O
,	O
symptothermal	O
,	O
post	O
-	O
ovulation	O
methods	O
)	O
and	O
withdrawal	O
are	O
not	O
acceptable	O
methods	O
of	O
contraception	O

Female	B
sterilization	I
(	O
have	O
had	O
surgical	O
bilateral	B
oophorectomy	I
with	O
or	O
without	O
hysterectomy	B
)	O
or	O
tubal	B
ligation	I
at	B
least	I
six	I
weeks	I
before	I
taking	I
study	I
treatment	I
.	O

In	O
case	O
of	O
oophorectomy	O
alone	O
,	O
only	O
when	O
the	O
reproductive	O
status	O
of	O
the	O
woman	O
has	O
been	O
confirmed	O
by	O
follow	O
up	O
hormone	O
level	O
assessment	O

Male	B
sterilization	I
(	O
at	B
least	I
6	I
months	I
prior	I
to	I
screening	I
)	O
.	O

For	O
female	O
subjects	O
on	O
the	O
study	O
the	O
vasectomized	O
male	O
partner	O
should	O
be	O
the	O
sole	O
partner	O
for	O
that	O
subject	O
.	O

Use	O
of	O
oral	O
,	O
injected	O
or	O
implanted	O
hormonal	O
methods	O
of	O
contraception	O
or	O
other	O
forms	O
of	O
hormonal	O
contraception	O
that	O
have	O
comparable	O
efficacy	O
(	O
failure	O
rate	O
<	O
1	O
%	O
)	O
,	O
for	O
example	O
hormone	B
vaginal	I
ring	I
or	O
transdermal	B
hormone	I
contraception	I

Placement	O
of	O
an	O
intrauterine	B
device	I
(	O
IUD	B
)	O
or	O
intrauterine	B
system	I
(	O
IUS	B
)	O

Barrier	O
methods	O
of	O
contraception	B
:	O
Condom	B
or	O
Occlusive	B
cap	I
diaphragm	I
or	O
cervical	O
/	O
vault	B
caps	I
)	O
with	O
spermicidal	B
foam	I
/	O
gel	O
/	O
film	O
/	O
cream	O
/	O
vaginal	O
suppository	O
In	O
case	O
of	O
use	O
of	O
oral	O
contraception	O
women	O
should	O
have	O
been	O
stable	O
on	O
the	O
same	O
pill	O
for	O
a	O
minimum	O
of	O
3	O
months	O
before	O
taking	O
study	O
treatment	O

Sexually	O
active	O
males	O
unless	O
they	O
use	O
a	O
condom	O
during	O
intercourse	O
while	O
taking	O
drug	O
and	O
for	O
1	O
months	O
after	O
pasireotide	O
s	O
.	O
c	O
.	O
last	O
dose	O
and	O
3	O
months	O
after	O
pasireotide	O
LAR	O
last	O
dose	O
and	O
should	O
not	O
father	O
a	O
child	O
in	O
this	O
period	O
.	O
A	O
condom	O
is	O
required	O
to	O
be	O
used	O
also	O
by	O
vasectomized	O
men	O
in	O
order	O
to	O
prevent	O
delivery	O
of	O
the	O
drug	O
via	O
seminal	O
fluid	O
If	O
a	O
study	O
patient	O
or	O
partner	O
becomes	O
pregnant	O
or	O
suspects	O
being	O
pregnant	O
during	O
the	O
study	O
or	O
within	O
1	O
month	O
after	O
the	O
final	O
dose	O
of	O
pasireotide	O
s	O
.	O
c	O
.	O
or	O
3	O
months	O
after	O
the	O
final	O
dose	O
of	O
pasireotide	O
LAR	O
,	O
the	O
Study	O
Doctor	O
needs	O
to	O
be	O
informed	O
immediately	O
and	O
ongoing	O
study	O
treatment	O
with	O
pasireotide	O
has	O
to	O
be	O
stopped	O
immediately	O
For	O
patients	O
taking	O
pasireotide	O
LAR	O
,	O
the	O
future	O
dose	O
injections	O
will	O
be	O
cancelled	O
.	O

Patient	O
is	O
currently	O
participating	O
in	O
a	O
Novartis	O
Oncology	O
sponsored	O
study	O
receiving	O
pasireotide	O
(	O
LAR	O
and	O
/	O
or	O
s	O
.	O
c	O
.	O
)	O
and	O
has	O
fulfilled	O
all	O
required	O
assessments	O
in	O
the	O
parent	O
study	O
(	O
unless	O
the	O
study	O
is	O
being	O
terminated	O
)	O
and	O
patients	O
that	O
are	O
benefiting	O
from	O
the	O
study	O
drug	O
have	O
no	O
other	O
alternatives	O

Patient	O
is	O
currently	O
benefiting	O
from	O
the	O
treatment	O
with	O
pasireotide	O
,	O
as	O
determined	O
by	O
the	O
investigator	O

Patient	O
has	O
demonstrated	O
compliance	O
,	O
as	O
assessed	O
by	O
the	O
investigator	O
,	O
with	O
the	O
parent	O
study	O
requirements	O

Willingness	O
and	O
ability	O
to	O
comply	O
with	O
scheduled	O
visits	O
,	O
treatment	O
plans	O
and	O
any	O
other	O
study	O
procedures	O

Written	O
informed	O
consent	O
obtained	O
prior	O
to	O
enrolling	O
in	O
roll	O
-	O
over	O
study	O
and	O
receiving	O
study	O
medication	O
•	O
If	O
consent	O
cannot	O
be	O
expressed	O
in	O
writing	O
,	O
it	O
must	O
be	O
formally	O
documented	O
and	O
witnessed	O
,	O
ideally	O
via	O
an	O
independent	O
trusted	O
witness	O

any	O
neurological	B
conditions	I
other	B
than	I
PD	B
;	O

significant	B
musculoskeletal	O
or	O
cardiopulmonary	B
diseases	I
;	O

other	O
disorders	B
that	I
may	I
affect	I
balance	I
or	I
locomotion	I
;	O

taken	O
any	O
structured	B
behavioral	I
or	I
exercise	I
programs	I
in	B
the	I
past	I
3	I
months	I

or	O
they	O
are	O
receiving	O
regular	B
physical	I
rehabilitation	I
at	B
present	I
;	O

unstable	B
condition	I
on	O
anti	B
-	I
parkinsonian	I
medications	I
;	O

surgical	O
interventions	O
for	O
PD	B
;	O

communication	O
or	O
cognitive	B
deficits	I
with	O
mini	B
-	I
mental	I
state	I
examination	I
,	I
(	I
MMSE	I
)	I
<	B
24	I
/	I
30	I
(	O
Folstein	O
et	O
al	O
.	O
,	O
1975	O
)	O
;	O

a	O
history	B
of	O
more	B
than	I
two	I
falls	B
in	B
the	I
previous	I
12	I
months	I
.	O

diagnosed	O
with	O
PD	B
by	B
a	I
neurologist	I
(	O
Fahn	O
and	O
Elton	O
,	O
1987	O
)	O
;	O

aged	B
30	B
to	I
85	I
years	I
;	O

at	O
modified	B
Hoehn	I
and	I
Yahr	I
(	I
H	I
&	I
Y	I
)	I
stage	B
1	I
.	I
5	I
to	I
3	I
(	O
Hoehn	O
and	O
Yahr	O
,	O
1967	O
;	O
Goetz	O
et	O
al	O
.	O
,	O
2004	O
)	O
;	O

able	O
and	O
willing	O
to	O
give	O
written	O
consent	O
for	O
participation	O
in	O
the	O
study	O
;	O

living	O
at	O
home	O
in	O
the	O
community	O
;	O

able	O
to	O
walk	O
independently	O
for	B
30	I
metres	I
with	O
or	O
without	O
an	O
assistive	O
device	O
.	O

History	O
of	O
seizures	B
within	B
last	I
10	I
years	I

History	O
of	O
epilepsy	B

History	O
of	O
prior	B
stroke	B

Currently	O
prescribed	O
medication	B
with	O
anti	B
-	I
epileptic	I
activity	I
(	O
keppra	B
,	O
dilantin	B
,	O
tegretol	B
,	O
lamictal	B
,	O
topamax	B
,	O
etc	O
.	O
)	O

Brain	B
tumor	I

Pregnant	B
or	O
nursing	B
woman	B

Known	O
levetiracetam	B
allergy	B

Adult	B
(	O
=	O
18	O
years	B
)	O

Presence	O
of	O
intracranial	B
aneurysm	I
(	O
with	O
or	O
without	B
rupture	I
)	O

Treating	B
surgeon	I
has	O
recommended	O
surgical	B
repair	I
of	O
the	O
aneurysm	B

Subject	O
has	O
documented	O
typical	O
atrial	B
flutter	I
.	O

Subject	O
has	O
any	O
history	O
of	O
successful	O
or	O
unsuccessful	O
treatment	O
of	O
AF	B
with	O
class	B
I	I
or	O
III	O
antiarrhythmic	B
or	O
sotalol	B
with	O
the	O
intention	O
to	O
prevent	O
an	O
AF	O
recurrence	O
.	O
Patients	O
pretreated	O
with	O
above	O
AAD	O
at	O
maximum	O
48	O
hours	O
with	O
the	O
intention	O
to	O
convert	O
an	O
AF	O
episode	O
are	O
allowed	O
.	O

Subject	O
had	O
any	O
previous	O
left	B
atrial	B
ablation	I
.	O

Subject	O
had	O
any	O
previous	O
cardiac	B
surgery	I
,	O
e	O
.	O
g	O
.	O
prosthetic	B
valves	I
.	O

Subject	O
has	O
permanent	B
pacemaker	I
or	O
defibrillator	B
implant	I
.	O

Subject	O
has	O
2	O
°	O
type	O
II	O
,	O
3	B
°	I
degree	I
AV	I
-	I
block	I
or	O
left	O
/	O
right	B
bundle	I
branch	I
block	I
pattern	O
.	O

Subject	O
has	O
unstable	B
angina	I
pectoris	I
.	O

Subject	O
has	O
history	O
of	O
previous	O
myocardial	B
infarction	I
or	O
percutaneous	B
intervention	I
during	O
the	O
last	B
three	I
months	I
.	O

Subject	O
has	O
symptomatic	B
carotid	B
stenosis	I
.	O

Subject	O
has	O
chronic	B
obstructive	I
pulmonary	I
disease	I
with	O
detected	O
pulmonary	B
hypertension	I
or	O
any	O
other	O
evidence	O
of	O
significant	B
lung	B
disease	I
.	O

Subject	O
has	O
any	O
contraindication	B
for	O
oral	B
anticoagulation	I
.	O

Subject	O
has	O
any	O
history	O
of	O
previous	O
transient	B
ischemic	I
attack	I
or	O
stroke	B
.	O

Subject	O
has	O
known	O
intra	B
-	I
cardiac	I
thrombus	I
formation	O
.	O

Subject	O
has	O
any	O
significant	B
congenital	B
heart	I
defect	I
corrected	O
or	O
not	O
(	O
except	B
for	O
patent	B
foramen	I
ovale	I
that	O
is	O
allowed	O
)	O
.	O

Subject	O
has	O
evidence	O
of	O
congestive	B
heart	I
failure	I
(	O
NYHA	B
class	I
II	B
,	O
III	B
or	O
IV	B
)	O
in	O
sinus	B
rhythm	I
.	O

Subject	O
has	O
hypertrophic	B
cardiomyopathy	I
.	O

Subject	O
has	O
abnormal	B
long	B
or	O
short	B
QT	B
interval	I
,	O
signs	O
of	O
Brugada	B
syndrome	I
,	O
known	O
inheriting	B
ion	I
channel	I
disease	I
on	O
the	O
family	O
,	O
arrhythmogenic	B
right	B
ventricular	I
dysplasia	I
.	O

Subject	O
has	O
sarcoidosis	B
.	O

Subject	O
has	O
pulmonary	B
vein	I
stent	I
.	O

Subject	O
has	O
myxoma	B
.	O

Exclusion	O
criteria	O
based	O
on	O
laboratory	O
abnormalities	O

Subject	O
has	O
thrombocytosis	B
(	O
platelet	B
count	I
>	B
600	I
,	I
000	I
/	I
µl	I
)	O
or	O
thrombocytopenia	B
(	O
platelet	B
count	I
<	B
100	I
,	I
000	I
/	I
µl	I
)	O
.	O

Subject	O
has	O
any	O
untreated	B
or	O
uncontrolled	B
hyperthyroidism	B
or	O
hypothyroidism	B
.	O

Subject	O
has	O
renal	B
dysfunction	I
with	O
glomerular	B
filtration	I
rate	I
<	B
60	I
ml	I
/	I
min	I
.	O

Subject	O
has	O
known	O
cryoglobulinaemia	B
.	O

General	O
exclusion	O
criteria	O

Subject	O
has	O
a	O
reversible	O
causes	O
for	O
AF	O
like	O
hyperthyroidism	B
and	O
alcoholism	B
.	O

Subject	O
is	O
a	O
pregnant	O
woman	O
or	O
woman	O
of	O
childbearing	O
potential	O
not	O
on	O
adequate	O
birth	O
control	O
:	O
only	O
woman	O
with	O
a	O
highly	O
effective	O
method	O
of	O
contraception	O
[	O
oral	O
contraception	O
or	O
intra	O
-	O
uterine	O
device	O
]	O
(	O
who	O
must	O
have	O
a	O
negative	O
pregnancy	O
test	O
within	O
1	O
week	O
of	O
the	O
start	O
of	O
the	O
therapy	O
)	O
or	O
sterile	O
woman	O
can	O
be	O
enrolled	O
.	O

Subject	O
is	O
a	O
breastfeeding	O
woman	O
.	O

Subject	O
has	O
an	O
active	B
systemic	B
infection	I
.	O

Subject	O
is	O
employed	O
by	O
Medtronic	O
or	O
by	O
the	O
department	O
of	O
any	O
of	O
the	O
investigators	O
or	O
is	O
a	O
close	O
relative	O
of	O
any	O
of	O
the	O
investigators	O
.	O

Subject	O
is	O
unwilling	O
or	O
unable	O
to	O
comply	O
fully	O
with	O
study	O
procedures	O
and	O
follow	O
-	O
up	O
due	O
to	O
any	O
disease	O
condition	O
,	O
which	O
can	O
raise	O
doubt	O
about	O
compliance	O
and	O
influencing	O
the	O
study	O
outcome	O
especially	O
any	O
kind	O
of	O
cancer	O
,	O
severe	O
bleeding	O
in	O
history	O
or	O
a	O
suspected	O
pro	O
-	O
coagulant	O
state	O
.	O

Legal	O
incapacity	O
or	O
evidence	O
that	O
a	O
subject	O
cannot	O
understand	O
the	O
purpose	O
and	O
risks	O
of	O
the	O
study	O
or	O
inability	O
to	O
comply	O
fully	O
with	O
study	O
procedures	O
and	O
follow	O
up	O
.	O

Subject	O
has	O
a	O
life	O
expectancy	O
of	O
=	B
1	I
year	I
.	O

Subject	O
is	O
currently	O
enrolled	O
or	O
planning	O
to	O
participate	O
in	O
a	O
potentially	O
confounding	O
drug	O
or	O
device	O
trial	O
during	O
the	O
course	O
of	O
this	O
study	O
.	O
Co	O
-	O
enrollment	O
in	O
concurrent	O
trials	O
is	O
only	O
allowed	O
when	O
documented	O
pre	O
-	O
approval	O
is	O
obtained	O
from	O
the	O
Medtronic	O
study	O
manager	O
.	O

Subject	O
has	O
been	O
diagnosed	O
with	O
symptomatic	B
paroxysmal	B
atrial	I
fibrillation	I
as	O
defined	O
above	O
and	O
at	B
least	I
two	I
symptomatic	B
episodes	B
in	O
the	O
last	B
six	I
months	I
prior	I
to	I
inclusion	I
.	O

At	B
least	I
one	I
episode	B
of	O
AF	B
must	O
be	O
documented	O
during	O
the	O
prior	B
year	I
by	O
any	O
kind	O
of	O
ECG	B
recording	O
.	O

Subject	O
has	O
structural	B
normal	B
heart	B
with	O
an	O
LVEF	B
=	B
50	I
%	I
,	I
thickness	B
of	I
the	I
inter	I
-	I
ventricular	I
septum	I
=	B
12	I
mm	I
and	O
left	B
atrium	I
diameters	I
(	O
short	B
axis	I
)	O
<	B
46	I
mm	I
obtained	O
by	O
transthoracic	B
echocardiography	I
.	O

Subject	O
has	O
normal	B
ECG	B
parameters	O
(	O
QRS	B
width	I
in	O
the	O
12	B
channel	I
surface	I
ECG	I
=	B
120	I
ms	I
,	O
QTc	B
-	I
interval	I
<	B
440	I
ms	I
,	O
PQ	B
-	I
interval	I
=	B
210	I
ms	I
;	O
all	O
parameters	O
should	O
be	O
measured	O
at	O
sinus	B
rhythm	I
)	O
.	O

Subject	O
is	O
at	B
least	I
18	I
and	I
not	I
older	I
than	I
75years	I
old	B
.	O

Subject	O
is	O
able	O
and	O
willing	O
to	O
give	O
informed	O
consent	O
.	O

congenital	B
or	O
valvular	B
cardiomyopathy	B
;	O

ischemic	B
heart	I
disease	I
;	O

endocrine	B
diseases	I
:	O
male	B
hypogonadism	I
,	O
hyperthyroidism	B
,	O
adrenal	B
diseases	I
,	O
pituitary	B
diseases	I

proliferative	B
retinopathy	I
or	O
autonomic	B
neuropathy	I
;	O

contraindications	B
to	O
sildenafil	B
use	O
or	O
CMR	B
imaging	I
;	O

age	B
35	B
-	I
75	I
years	I
;	O

Diagnosis	O
of	O
Type	B
2	I
Diabetes	I
from	O
at	B
least	I
3	I
years	I
;	O

HbA1c	B
<	B
10	I
%	I
;	O

normal	B
blood	I
pressure	I
or	O
controlled	B
hypertension	I
;	O

BMI	B
<	B
40	I
;	O

1	O
.	O

Are	O
unable	O
to	O
understand	O
and	O
sign	O
the	O
consent	O
form	O

2	O
.	O

Are	O
pregnant	B
or	O
lactating	B

3	O
.	O

Are	O
physically	B
unable	I
to	I
sit	I
upright	I
and	I
still	I
for	B
40	I
minutes	I

4	O
.	O

Have	O
undergone	O
bilateral	B
mastectomy	I

5	O
.	O

Are	O
not	B
scheduled	O
to	O
undergo	O
conventional	B
ultrasound	I

1	O
.	O

Have	O
a	O
finding	O
of	O
a	O
mass	B
lesion	I
on	O
mammography	B
or	O
breast	B
MRI	I
(	O
BIRADS	B
0	B
,	I
4	I
or	I
5	I
)	O
that	O
is	O
>	B
0	I
.	I
5	I
cm	I
and	I
<	I
2	I
cm	I
in	O
size	B
and	O
has	O
had	O
or	O
will	O
have	O
additional	O
workup	O
with	O
focused	O
ultrasound	O
.	O

2	O
.	O

Have	O
a	O
finding	O
of	O
a	O
mass	B
lesion	I
on	O
ultrasound	B
(	O
BIRADS	B
0	B
,	I
4	I
or	I
5	I
)	O
that	O
is	O
>	B
0	I
.	I
5	I
cm	I
and	I
<	I
2	I
cm	I
in	O
size	B
.	O

3	O
.	O

Have	O
a	O
positive	B
finding	I
on	O
MBI	B
that	O
is	O
<	B
2	I
cm	I
in	O
size	B
and	O
requires	O
additional	O
diagnostic	O
workup	O
with	O
focused	O
ultrasound	O
.	O

Hospitalization	O
for	O
acute	B
decompensated	I
HF	I
within	B
previous	I
30	I
days	I

Hospitalization	O
for	O
myocardial	B
infarction	I
or	O
cardiac	B
surgery	I
within	B
previous	I
90	I
days	I

Presence	O
of	O
a	O
left	B
ventricular	I
assist	I
device	I

History	O
of	O
heart	B
transplantation	I

Poorly	B
controlled	I
hypertension	B
(	O
>	O
170	O
/	O
>	O
110	O
)	O

Poorly	B
controlled	I
diabetes	B
(	O
HbA1c	B
>	B
9	I
.	I
0	I
)	O

Severe	B
renal	B
failure	I
with	O
estimated	B
glomerular	I
filtration	I
rate	I
<	B
30	I
ml	I
/	I
min	I

Prior	O
stroke	B
with	O
functional	B
impairment	I
or	O
other	O
severe	O
,	O
uncontrolled	O
medical	O
problems	O
that	O
may	O
impair	O
ability	O
to	O
participate	O
in	O
the	O
study	O
exams	O
,	O
based	O
on	O
medical	O
history	O
and	O
review	O
of	O
medical	O
records	O

Severe	O
chronic	B
insomnia	I
,	O
with	O
reported	O
usual	O
sleep	O
duration	O
<	B
4	I
hours	I

Severe	O
daytime	B
sleepiness	I
,	O
defined	O
as	O
Epworth	B
Sleepiness	I
Scale	I
score	B
18	I
or	I
higher	I
or	O
a	O
report	O
of	O
falling	O
asleep	O
driving	O
during	O
the	O
previous	O
year	O
,	O
and	O
deemed	O
a	O
safety	O
risk	O
by	O
study	O
physician	O

Awake	B
resting	B
oxyhemoglobin	B
saturation	I
<	B
89	I
%	I

Pregnancy	B

Smoking	O
by	O
subject	O
or	O
other	O
person	O
in	O
the	O
subject	O
'	O
s	O
bedroom	O
,	O
or	O
other	O
open	O
flame	O
in	O
bedroom	O

Current	O
use	O
of	O
a	O
positive	B
airway	I
pressure	I
device	I
(	O
including	O
continuous	O
or	O
bi	B
-	I
level	I
positive	I
airway	I
pressure	I
or	O
adaptive	B
servo	I
-	I
ventilation	I
)	O
or	O
supplemental	B
oxygen	I
therapy	I

Veteran	B
receiving	O
care	O
within	O
the	O
Veterans	O
Health	O
Administration	O
healthcare	O
system	O

Age	B
18	B
years	I

Physician	O
diagnosis	O
of	O
chronic	B
heart	I
failure	I
,	O
American	B
Heart	I
Association	I
Stage	I
C	B
-	I
D	I

LVEF	B
<	B
45	I
%	I

No	B
change	B
in	O
active	O
cardiac	B
medications	I
for	B
4	I
weeks	I
prior	I
to	I
randomization	I

Ability	O
to	O
provide	O
informed	O
consent	O

Moderate	B
to	O
severe	B
central	O
or	O
mixed	O
central	O
and	O
obstructive	B
sleep	I
apnea	I
,	O
defined	O
as	O
an	O
apnea	B
-	I
hypopnea	I
index	I
(	O
AHI	B
)	O
15	B
events	I
per	I
hour	I
,	I
with	O
a	O
central	B
AHI	I
>	B
5	I
events	I
/	I
hour	I

Patients	O
are	O
not	B
expected	O
to	O
be	O
alive	O
for	O
longer	B
than	I
3	I
months	I
.	O

Mini	B
-	I
mental	I
State	I
Examination	I
(	I
MMSE	I
)	I
[	O
18	O
]	O
score	O
=	B
23	I
.	O

history	O
of	O
dementia	B
,	O
psychiatric	B
illness	I
or	O
any	O
diseases	B
of	I
central	I
nervous	I
system	I
.	O

current	B
use	O
of	O
sedatives	B
or	O
antidepressant	B
.	O

alcoholism	B
and	O
drug	B
dependence	I
.	O

patients	O
previously	O
included	O
in	O
this	O
study	O
(	O
for	O
patients	O
who	O
have	O
second	O
intra	O
-	O
abdominal	O
surgery	O
during	O
the	O
study	O
period	O
)	O
.	O

difficult	O
to	O
follow	O
up	O
or	O
patients	O
with	O
poor	O
compliance	O
.	O

uncontrolled	B
hypertension	I
(	O
>	B
180	I
/	I
100	I
mmHg	I
)	O

major	O
elective	B
gastrointestinal	O
,	O
gynecological	O
,	O
prostate	O
or	O
bladder	B
surgery	I
patients	O
who	O
are	O
=	O
60	O
years	O
old	B
.	O

the	O
surgery	O
is	O
laparoscopic	B
surgery	I
and	O
is	O
expected	O
to	O
last	B
for	O
=	B
2	I
hours	I
under	B
general	I
anesthesia	I
and	O
the	O
patient	O
will	O
stay	B
in	I
hospital	I
for	O
at	B
least	I
7	I
days	I
after	I
surgery	I
.	O

lack	B
of	I
serious	O
hearing	O
and	O
vision	B
impairment	I
and	O
be	O
able	B
to	I
read	I
so	O
that	O
neurobehavioral	B
tests	I
can	O
be	O
performed	O
.	O

Prior	B
receipt	O
of	O
investigational	B
anti	B
-	I
HIV	I
vaccine	I

Ongoing	B
therapy	B
with	O
any	O
of	O
the	O
following	O
:	O
Systemic	B
corticosteroids	I
.	O

Short	B
course	I
less	B
than	I
or	I
equal	I
to	I
21	I
days	I
of	O
corticosteroids	B
is	B
allowed	I
;	O
Systemic	B
chemotherapeutic	I
agents	I
;	O
Nephrotoxic	B
systemic	I
agents	I
,	O
including	O
aminoglycosides	B
,	O
amphotericin	B
B	I
,	O
cidofovir	B
,	O
cisplatin	B
,	O
foscarnet	B
,	O
pentamidine	B
;	O
Immunomodulatory	B
treatments	I
including	O
Interleukin	B
-	I
2	I
;	O
Investigational	B
agents	I

Known	O
allergy	B
/	O
sensitivity	B
or	O
any	O
hypersensitivity	B
to	O
components	B
of	I
study	I
drugs	I
(	O
ART	B
)	O
or	B
their	I
formulations	I

Active	B
drug	O
or	O
alcohol	O
use	B
or	O
dependence	O
that	O
would	B
interfere	I
with	I
adherence	I
to	I
study	I
requirements	I

Serious	B
medical	O
or	O
psychiatric	B
illness	I
that	O
would	B
interfere	I
with	I
the	I
ability	I
to	I
adhere	I
to	I
study	I
requirements	I

Chronic	O
or	O
acute	B
hepatitis	I
B	I
infection	I

Use	O
of	O
female	B
hormonal	I
products	I
based	O
on	O
estrogen	B
or	O
derivatives	O

Adult	B
men	B
who	I
have	I
sex	I
with	I
men	I
,	O
and	O
transgender	B
women	I

Unaware	B
of	O
HIV	B
status	I
at	B
enrollment	I
in	I
follow	I
-	I
up	I
cohort	I

High	O
risk	O
for	O
HIV	B
infection	I

Willing	O
to	O
test	B
for	I
HIV	I

No	B
prior	B
ART	B
,	O
including	O
prior	B
administration	B
of	O
pre	O
-	O
and	O
post	B
-	I
exposure	I
prophylaxis	I
in	B
the	I
last	I
30	I
days	I

Willing	O
to	O
provide	O
informed	O
consent	O

A1C	B
>	B
7	I
.	I
0	I
%	I

2hr	B
glucose	I
during	I
OGTT	I
>	B
200	I
mg	I
/	I
dL	I

Total	B
cholesterol	I
>	B
280	I
mg	I
/	I
dL	I

Previous	B
diabetic	B
history	B
,	O
coronary	B
artery	I
disease	I

Allergy	B
to	O
rosuvastatin	B
or	O
parvastatin	B

Baseline	B
ALT	B
more	B
than	I
3	I
times	I
UNL	I

Serum	B
Cr	I
>	B
2	I
.	I
0	I
mg	I
/	I
dL	I

Pregnancy	B
,	O
breast	O
feeding	O
or	O
plan	O
to	O
be	O
pregnant	B
woman	B
.	O

Age	B
35	B
-	I
70	I
years	I
old	I

Fasting	B
blood	I
glucose	I
100	B
-	I
125	I
mg	I
/	I
dL	I

Gallbladder	B
'	I
s	I
wall	I
>	B
3mm	I
,	O
atrophied	B
gallbladder	I
,	O
gallstone	B
obstruct	I
the	O
Hartmann	B
'	I
s	I
pouch	I
.	O

Abdominal	B
ultrasound	I
display	O
the	O
contractibility	B
of	I
gallbladder	I
is	O
poor	B
.	O

The	O
aged	B
patients	O
with	O
bad	B
heart	I
and	I
lung	I
function	I
.	O

Patients	O
who	O
has	O
acute	B
cholecystitis	I
,	O
pancreatitis	B
,	O
pancreaticobiliary	B
diseases	I
,	O
especially	O
choledocholithiasis	B
.	O

Pregnant	B
or	O
lactational	B
women	B
.	O

Clinical	B
diagnosis	I
of	O
calculous	B
cholecystitis	I
.	O

Volunteers	O
must	O
not	B
have	B
been	I
vaccinated	B
against	O
HPV	B
-	I
Gardasil	I
-	I
9	I
(	O
both	O
partners	O
)	O

Any	B
history	I
of	O
cervical	O
,	O
penile	O
,	O
oral	O
or	O
anal	B
cancers	I

Being	O
pregnant	B
or	O
plan	O
on	O
immediately	O
becoming	O
pregnant	B

Couple	O
must	O
have	O
been	O
in	O
a	O
new	O
relationship	O
that	O
started	O
no	B
more	I
than	I
six	I
months	I
prior	I
to	I
study	I
entry	I

Both	O
partners	O
plan	O
on	O
remaining	O
in	O
Montreal	O
for	B
at	I
least	I
1	I
year	I

Plan	O
on	O
having	O
continued	O
sexual	O
contact	O
with	O
partner	O

Be	O
willing	O
to	O
comply	O
with	O
study	O
procedures	O

1	O
.	O

Active	B
thromboembolic	B
disease	I
,	O
history	B
of	O
thromboembolic	B
disease	I
(	O
including	O
retinal	B
vein	I
or	O
artery	B
occlusion	I
)	O
,	O
known	O
inherited	B
thrombophilia	I
,	O
or	O
family	O
history	O
of	O
thrombosis	B
in	O
a	O
first	O
degree	O
relative	O

2	O
.	O

Subject	O
has	O
a	O
severe	B
medical	O
or	O
psychiatric	B
illness	I
that	O
,	O
in	B
the	I
opinion	I
of	I
the	I
Investigator	I
,	I
would	I
affect	I
subject	I
safety	I
or	I
compliance	I

3	O
.	O

Clinical	O
evidence	O
of	O
severe	B
bleeding	B
disorder	I
.	O

Patients	O
with	O
mild	B
bleeding	B
disorders	I
such	O
as	O
type	B
1	I
von	I
Willebrand	I
disease	I
,	O
mild	B
platelet	I
function	I
defects	I
such	O
as	O
platelet	B
storage	I
pool	I
or	I
release	I
defects	I
,	O
and	O
patients	O
with	O
bleeding	B
due	O
to	O
Ehlers	B
Danlos	I
syndrome	I
WILL	O
be	O
eligible	O
to	O
participate	O
in	O
the	O
study	O
.	O

4	O
.	O

Pregnancy	B
within	B
the	I
past	I
6	I
months	I
and	O
/	O
or	O
breast	B
-	I
feeding	I

5	O
.	O

Use	O
of	O
hormonal	B
contraception	I
(	O
estrogen	B
and	O
progestin	B
)	O
within	B
3	I
months	I
of	I
study	I
entry	I
,	O
or	O
anticipated	O
need	O
to	O
initiate	O
estrogen	B
-	O
containing	O
hormonal	O
contraception	O
during	B
the	I
study	I
period	I

6	O
.	O

Use	O
of	O
systemic	B
steroids	I
within	B
1	I
month	I
of	I
study	I
entry	I

7	O
.	O

History	B
of	O
subarachnoid	B
hemorrhage	I

8	O
.	O

History	B
of	O
Hepatitis	B
B	I
,	O
C	O
,	O
or	O
HIV	B

9	O
.	O

Baseline	B
creatinine	B
>	O
20	O
%	O
above	O
the	O
upper	O
limit	O
of	O
normal	O
for	O
age	B

10	O
.	O

Severe	B
anemia	B
(	O
hemoglobin	B
<	B
8	I
g	I
/	I
dL	I
)	O

11	O
.	O

Systolic	B
blood	I
pressure	I
<	B
85	I
or	O
diastolic	B
blood	I
pressure	I
<	B
55	I

12	O
.	O

Heart	B
rate	I
<	B
50	I
at	B
time	I
of	I
screening	I

13	O
.	O

Use	O
of	O
intranasal	B
DDAVP	I
during	B
menses	I
will	O
be	O
permitted	O
,	O
but	O
only	O
if	O
the	O
patient	O
has	O
a	O
history	O
of	O
using	O
DDAVP	O
consistently	O
for	O
≥	O
3	O
menstrual	O
cycles	O
prior	O
to	O
study	O
enrollment	O
,	O
so	O
that	O
change	O
in	O
menstrual	O
blood	O
loss	O
due	O
to	O
addition	O
of	O
Lysteda	O
can	O
be	O
assessed	O
.	O
Use	O
of	O
one	O
-	O
time	O
DDAVP	O
during	O
a	O
DDAVP	O
/	O
Stimate	O
challenge	O
is	O
also	O
permitted	O
during	O
the	O
study	O
period	O
,	O
as	O
is	O
use	O
of	O
DDAVP	O
in	O
the	O
event	O
of	O
severe	O
epistaxis	O
,	O
trauma	O
,	O
or	O
surgical	O
procedures	O
during	O
the	O
study	O
period	O
.	O

1	O
.	O

Menstruating	B
females	B
10	B
-	I
19	I
years	I
of	O
age	B

2	O
.	O

Non	B
-	I
smoker	I

3	O
.	O

Physician	O
and	O
patient	O
have	O
agreed	O
to	O
initiate	O
Lysteda	B

4	O
.	O

Diagnosis	O
of	O
HMB	B
based	O
on	O
the	O
medical	O
judgment	O
of	O
the	O
principal	O
or	O
site	O
investigator	O

5	O
.	O

Subjects	O
must	O
report	O
menstrual	B
periods	I
occurring	O
within	B
21	I
-	I
60	I
days	I
from	I
the	I
start	I
of	I
one	I
period	I
to	O
the	O
start	O
of	O
the	O
next	O
menstrual	O
period	O

6	O
.	O

Negative	B
pregnancy	B
test	I

7	O
.	O

Informed	O
consent	O
obtained	O
and	O
signed	O

8	O
.	O

Informed	O
assent	O
obtained	O
and	O
signed	O

9	O
.	O

Understanding	O
of	O
study	O
procedures	O

10	O
.	O

Ability	O
to	O
comply	O
with	O
study	O
procedures	O
for	O
the	O
entire	O
length	O
of	O
the	O
study	O

11	O
.	O

Subjects	O
should	O
be	O
either	O
sexually	B
inactive	I
(	O
abstinent	O
)	O
or	O
agree	O
to	O
use	O
a	O
barrier	B
method	I
with	I
spermicide	I
in	O
the	O
event	O
of	O
sexual	O
activity	O
throughout	O
the	O
study	O
period	O

Pre	O
-	O
existing	O
hemoptysis	B
of	O
a	O
severity	B
>	B
grade	I
3	I
by	O
NCI	B
CTCAE	I
criteria	I
within	B
4	I
weeks	I
prior	I
to	I
study	I
entry	I

Uncontrolled	B
hypertension	B

CHF	B
,	O
angina	B
or	O
arrhythmias	B

LVEF	B
<	B
1	I
UNL	I

Existing	O
a	O
second	B
malignancy	I
within	B
5	I
years	I

Infected	O
with	O
HIV	B

Histologic	B
or	O
cytologic	B
diagnosis	O
of	O
stage	B
IIIB	I
/	I
IV	I
NSCLC	B

ECOG	B
PS	I
:	O
0	B
,	I
1	I

Unidimensional	O
or	O
bi	O
-	O
dimensional	O
measurable	B
disease	O

Receive	O
prior	O
treatment	B
including	O
first	O
-	O
line	O
platinum	B
-	I
based	I
chemotherapy	I
,	O
standard	B
second	B
-	I
line	I
chemotherapy	I
and	O
1	B
EGF	I
/	I
EGFR	I
inhibitor	I

Evidence	O
of	O
disease	B
progression	I

Life	O
expectancy	O
>	B
12	I
weeks	I

Neutrophils	B
>	B
1	I
.	I
5	I
109	I
/	I
l	I
,	O
Platelets	B
>	B
100	I
109	I
/	I
l	I
,	O
Hemoglobin	B
>	B
9g	I
/	I
dl	I
,	O
Total	B
bilirubin	I
<	B
1	I
.	I
5	I
UNL	I
,	O
AST	B
(	I
SGOT	I
)	I
and	O
ALT	B
(	I
SGPT	I
)	I
<	B
2	I
.	I
5	I
UNL	I
,	O
Alkaline	B
phosphatases	I
<	B
5	I
UNL	I
,	O
Creatinine	B
<	B
1	I
UNL	I

Known	O
or	O
suspected	O
sensitivity	O
to	O
Dexamethasone	B
Acetate	I
(	I
DXA	I
)	I

Mechanical	B
tricuspid	I
heart	I
valve	I

Subject	O
is	O
enrolled	O
in	O
any	O
other	O
concurrent	O
study	O
without	O
prior	O
written	O
approval	O
from	O
Boston	O
Scientific	O
(	O
BSC	O
)	O
,	O
with	O
the	O
exception	O
of	O
local	O
mandatory	O
governmental	O
registries	O
and	O
observational	O
studies	O
/	O
registries	O
that	O
are	O
not	O
in	O
conflict	O
and	O
do	O
not	O
affect	O
the	O
following	O
:	O

Schedule	O
of	O
procedures	O
for	O
the	O
RELIANCE	O
4	O
-	O
Front	O
Study	O
(	O
i	O
.	O
e	O
.	O
should	O
not	O
cause	O
additional	O
or	O
missed	O
visits	O
)	O
;	O

RELIANCE	O
4	O
-	O
Front	O
Study	O
outcome	O
(	O
i	O
.	O
e	O
.	O
involve	O
medications	O
that	O
could	O
affect	O
the	O
heart	O
rate	O
of	O
the	O
subject	O
)	O
;	O

Conduct	O
of	O
the	O
RELIANCE	O
4	O
-	O
Front	O
Study	O
per	O
Good	O
Clinical	O
Practice	O
(	O
GCP	O
)	O
/	O
International	O
Organization	O
for	O
Standardization	O
(	O
ISO	O
)	O
14155	O
:	O
2011	O
/	O
21	O
CFR	O
812	O
/	O
local	O
regulations	O

Currently	O
on	O
the	O
active	O
heart	O
transplant	O
list	O

Documented	O
life	O
expectancy	O
of	O
less	B
than	I
12	I
months	I

Women	B
of	O
childbearing	B
potential	I
who	O
are	O
or	O
might	O
be	O
pregnant	B
at	B
the	I
time	I
of	I
study	I
enrollment	I
(	O
method	O
of	O
assessment	O
upon	O
physician	O
discretion	O
)	O

Currently	B
requiring	O
chronic	B
dialysis	I

Willing	O
and	O
capable	O
of	O
providing	O
informed	O
consent	O

Has	O
an	O
indication	O
for	O
implantation	O
of	O
a	O
single	O
or	O
dual	O
chamber	O
ICD	O
or	O
CRT	O
-	O
D	O
system	O
in	O
their	O
respective	O
geography	O

Subjects	O
planned	O
to	O
be	O
implanted	O
with	O
the	O
RELIANCE	B
4	I
-	I
FRONT	I
Passive	I
Fixation	I
Lead	I

Willing	O
and	O
capable	O
of	O
participating	O
in	O
all	O
testing	O
/	O
visits	O
associated	O
with	O
this	O
clinical	O
study	O
at	O
an	O
approved	O
clinical	O
study	O
center	O
and	O
at	O
the	O
intervals	O
defined	O
by	O
this	O
protocol	O

Age	B
18	B
or	I
above	I
,	O
or	O
of	B
legal	I
age	I
to	O
give	O
informed	O
consent	O
specific	O
to	O
state	O
and	O
national	O
law	O

1	O
.	O

Deny	O
to	O
sign	O
the	O
informed	O
consent	O
;	O

2	O
.	O
type	B
1	I
diabetes	I
;	O

3	O
.	O

Family	O
history	O
of	O
hypertriglyceridemia	B
or	O
fasting	B
triglyceride	I
>	B
4	I
.	I
56	I
mmol	I
/	I
L	I
;	O

4	O
.	O

Have	O
severe	B
liver	B
disease	I
,	O
kidney	B
disease	I
or	O
cancer	B
;	O

5	O
.	O

Participating	O
in	O
the	O
other	O
clinical	O
trial	O
within	O
30	O
days	O
;	O

6	O
.	O

Other	B
diseases	I
or	O
conditions	O
,	O
for	B
which	I
the	I
doctor	I
of	I
the	I
patients	I
do	I
not	I
agree	I
his	I
or	I
her	I
participating	I
.	O

1	O
.	O

Fasting	B
glucose	I
>	B
7	I
.	I
0	I
or	O
have	O
diabetes	B
medication	O
;	O

2	O
.	O

Male	B
,	O
35	B
-	I
80	I
years	I
;	O
female	B
,	O
postmenopausal	B
to	B
80	I
years	I
;	O

3	O
.	O

Agree	O
to	O
participant	O
in	O
the	O
trial	O
.	O

History	O
of	O
acute	B
coronary	I
syndrome	I
in	B
the	I
past	I
30	I
days	I
.	O

History	O
of	O
congesting	B
heart	I
failure	I
with	O
left	B
ventricular	I
ejection	I
fraction	I
<	B
30	I
%	I
or	O
exacerbation	B
in	B
the	I
past	I
30	I
days	I
.	O

Current	B
dialysis	B
treatment	I
.	O

Known	O
furosemide	B
hypersensitivity	B
.	O

Contraindications	B
to	O
placement	B
of	I
a	I
Foley	I
catheter	I
in	O
the	O
bladder	B
.	O

Subject	O
is	O
65	B
years	I
old	B
who	O
is	O
able	O
and	O
willing	O
to	O
give	O
an	O
informed	O
consent	O
.	O

Patients	O
undergoing	B
planned	B
trans	B
-	I
femoral	I
TAVI	I
.	O

Calculated	B
eGFR	I
below	B
60ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I
(	O
MDRD	O
)	O

Women	B
who	O
are	O
pregnant	O
or	O
breastfeeding	O

Known	O
or	O
suspected	O
,	O
acquired	O
or	O
bleeding	O
or	O
coagulation	B
disorder	I
in	B
the	I
subject	I
or	O
a	O
first	B
degree	I
relative	I

Active	B
bleeding	B
or	O
at	O
high	O
risk	O
for	O
bleeding	B
.	O

Brain	B
,	O
spinal	B
,	O
ophthalmologic	B
,	O
or	O
major	B
surgery	B
or	O
trauma	B
within	B
the	I
past	I
90	I
days	I
other	B
than	I
the	O
elective	B
knee	I
/	I
hip	I
surgery	I

Active	B
hepatobiliary	B
disease	I

Hemoglobin	B
<	B
9	I
g	I
/	I
dL	I

Platelet	B
count	I
<	B
100	I
,	I
000	I
/	I
mm3	I

Creatinine	B
clearance	I
<	B
30	I
mL	I
/	I
min	I

Age	B
=	B
18	I
years	I

Subjects	O
undergoing	B
elective	B
total	B
knee	I
or	I
hip	I
replacement	I
or	O
a	O
revision	O
of	O
at	B
least	I
one	I
component	I
of	O
a	O
total	O
knee	O
or	O
hip	O
replacement	O

Women	B
of	O
child	B
-	I
bearing	I
potential	I
,	O
who	O
are	O
biologically	B
able	I
to	I
conceive	I
,	O
not	B
employing	O
two	B
forms	O
of	O
highly	B
effective	I
contraception	I
or	O
who	O
are	O
pregnant	B
.	O

Women	B
who	O
are	O
breast	B
-	I
feeding	I

Fertile	B
males	B
unwilling	O
to	O
use	O
contraception	O

Patients	O
with	O
brain	B
metastases	I
or	O
any	O
history	B
of	O
brain	B
metastases	I

Patients	O
who	O
have	O
undergone	O
major	B
surgery	I
(	O
e	O
.	O
g	O
.	O
,	O
intra	B
-	I
thoracic	I
,	O
-	O
abdominal	O
,	O
or	O
-	O
pelvic	O
)	O
<	B
/	I
=	I
4	I
weeks	I
prior	I
to	I
starting	I
study	I
treatment	I
or	O
who	O
have	O
not	B
recovered	B
from	I
such	I
therapy	I

Patients	O
with	O
a	O
history	B
of	O
pulmonary	B
embolism	I
,	O
or	O
untreated	B
deep	B
vein	I
thrombosis	I
within	B
the	I
past	I
6	I
months	I

Impairment	B
of	I
gastrointestinal	I
(	I
GI	I
)	I
function	I
or	O
GI	B
disease	I
that	O
may	B
significantly	I
alter	I
the	I
absorption	I
of	I
dovitinib	I

The	O
subject	O
has	O
had	O
another	O
active	B
malignancy	I
within	B
the	I
past	I
5	I
years	I
except	B
for	O
cervical	B
cancer	I
in	I
situ	I
,	O
in	B
situ	I
carcinoma	I
of	I
the	I
bladder	I
or	O
non	B
-	I
melanoma	I
carcinoma	I
of	I
the	I
skin	I
.	O

Patients	O
who	O
have	O
received	O
the	O
last	O
administration	O
of	O
an	O
anticancer	B
therapy	I
including	O
chemotherapy	B
,	O
immunotherapy	B
,	O
hormonal	B
therapy	I
and	O
monoclonal	B
antibodies	I
<	B
/	I
=	I
2	I
weeks	I
prior	I
to	I
starting	I
the	I
study	I
drug	I
,	O
or	O
who	O
have	O
not	O
recovered	B
from	I
the	I
side	I
effects	I
of	I
such	I
therapy	I

Cirrhosis	B
,	O
chronic	B
active	I
hepatitis	I
or	O
chronic	B
persistent	I
hepatitis	I

Patients	O
who	O
are	O
currently	O
receiving	O
prasugrel	B

No	B
concurrent	O
use	O
of	O
isoniazid	B
,	O
labetolol	B
,	O
trovafloxacin	B
,	O
tolcapone	B
,	O
and	O
felbamate	B

No	B
concurrent	O
use	O
of	O
other	B
investigational	I
drugs	I
or	O
antineoplastic	B
therapies	I
.	O

Patients	O
with	O
impaired	B
cardiac	I
function	I
or	O
clinically	B
significant	I
cardiac	B
diseases	I
.	O

Patients	O
with	O
a	O
confirmed	O
diagnosis	O
of	O
:	O

1	O
.	O

Stage	B
4	I
colon	B
cancer	I
either	O
s	O
/	O
p	O
metastasectomy	B
or	O
post	O
-	O
initial	O
chemotherapy	B
or	O
maintenance	B
"	I
standard	I
of	I
care	I
"	I
,	O
either	O
involving	O
5	B
-	I
fluorouracil	I
/	I
leucovorin	I
(	I
5	I
-	I
FU	I
/	I
LV	I
)	I
alone	O
or	O
continual	O
bevacizumab	B
alone	O
.	O

Patients	O
in	O
maintenance	O
cohort	O
must	O
have	O
had	O
2	B
consecutive	O
CT	B
scans	I
showing	O
stable	B
disease	B
and	O
not	B
be	O
experiencing	O
significant	O
prior	B
treatment	B
-	I
related	I
toxicity	I
above	O
Grade	O
1	O
.	O

2	O
.	O

Pancreas	B
cancer	I
,	O
either	O
s	O
/	O
p	O
resection	B
and	O
adjuvant	B
chemotherapy	I
or	O
locally	B
advanced	I
pancreas	B
cancer	I
s	O
/	O
p	O
chemotherapy	B
and	O
radiation	B
.	O

Initial	O
chemotherapy	B
or	O
radiation	B
therapy	I
may	O
have	O
been	O
stopped	O
between	B
2	I
weeks	I
and	I
2	I
months	I
prior	I
to	I
study	I
start	I
,	O
and	O
patients	O
must	O
have	O
recovered	O
from	O
prior	B
treatment	B
related	O
toxicity	O
to	O
grade	O
1	O
or	O
less	O
.	O

Prior	B
surgery	B
,	O
including	O
tumor	B
resection	I
or	O
metastasectomy	B
must	O
have	O
been	O
performed	O
at	B
least	I
4	I
weeks	I
prior	I
to	I
study	I
enrollment	I
.	O

No	O
concomitant	O
anti	O
-	O
cancer	O
treatment	O
is	O
allowed	O

Age	B
>	B
/	I
=	I
18	I
years	I

Performance	B
status	I
of	O
0	B
-	I
1	I

Adequate	B
hepatic	O
,	O
bone	O
marrow	O
,	O
and	O
renal	B
function	I

Partial	B
thromboplastin	I
time	I
(	I
PTT	I
)	I
must	O
be	O
<	B
/	I
=	I
1	I
.	I
5	I
x	I
upper	I
normal	I
limit	I
of	O
institution	O
'	O
s	O
normal	O
range	O
and	O
INR	B
(	I
International	I
Normalized	I
Ratio	I
)	I
<	B
1	I
.	I
5	I
.	O

Life	O
expectancy	O
>	B
/	I
=	I
4	I
months	I
for	O
maintenance	O
cohorts	O
and	O
>	B
/	I
=	I
6	I
months	I
for	O
adjuvant	O
cohorts	O

Women	B
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
serum	B
pregnancy	I
test	I
within	B
14	I
days	I
prior	I
to	I
initiation	I
of	I
treatment	I
and	O
must	O
not	B
be	O
lactating	B
.	O

Subject	O
is	O
capable	O
of	O
understanding	O
and	O
complying	O
with	O
protocol	O
demands	O
and	O
able	O
to	O
sign	O
and	O
date	O
the	O
informed	O
consent	O

Participation	O
in	O
the	O
4	B
weeks	I
preceding	I
inclusion	I
or	O
planned	O
participation	O
during	O
the	O
present	O
trial	O
period	O
in	O
another	O
clinical	O
trial	O
investigating	O
a	O
vaccine	O
,	O
drug	O
,	O
medical	O
device	O
,	O
or	O
medical	O
procedure	O
.	O

Receipt	O
of	O
any	O
vaccine	B
in	B
the	I
4	I
weeks	I
preceding	I
each	I
trial	I
vaccination	I
or	O
planned	O
receipt	O
of	O
any	O
vaccine	B
in	B
the	I
4	I
weeks	I
following	I
each	I
trial	I
vaccination	I
,	O
except	B
for	I
:	O

(	O
i	O
)	O
influenza	B
vaccination	I
,	O
which	O
may	O
be	O
received	O
at	B
least	I
2	I
weeks	I
before	I
study	I
vaccines	I
.	O

(	O
ii	O
)	O
measles	O
(	O
M	O
)	O
or	O
measles	B
,	I
mumps	I
,	I
rubella	I
(	I
MMR	I
)	I
routine	I
vaccination	I
,	O
which	O
can	O
be	O
administered	O
concomitantly	B
with	I
the	I
first	I
dose	I
of	I
study	I
vaccine	I
as	O
per	O
routine	O
immunization	O
schedule	O

(	O
iii	O
)	O
for	O
subjects	O
enrolled	O
at	O
Indian	O
sites	O
:	O
oral	B
poliomyelitis	I
vaccine	I
(	I
OPV	I
)	I
received	O
during	B
National	I
Immunization	I
Days	I
(	I
NIDs	I
)	I
and	O
supplementary	O
immunization	O
activity	O
days	O
(	O
SIADs	O
)	O

Previous	O
vaccination	B
against	I
meningococcal	I
disease	I
with	O
either	O
the	O
study	B
vaccine	I
or	O
another	B
meningococcal	I
vaccine	I

Receipt	O
of	O
immune	B
globulins	I
,	O
blood	B
or	O
blood	B
-	I
derived	I
products	I
in	B
the	I
past	I
3	I
months	I

Known	O
or	O
suspected	O
congenital	O
or	O
acquired	B
immunodeficiency	I
;	O
or	O
receipt	O
of	O
immunosuppressive	B
therapy	I
,	O
such	O
as	O
anti	B
-	I
cancer	I
chemotherapy	I
or	O
radiation	B
therapy	I
,	O
within	B
the	I
preceding	I
6	I
months	I
;	O
or	O
long	B
-	I
term	I
systemic	B
corticosteroid	I
therapy	I
(	O
prednisone	B
or	O
equivalent	O
for	B
more	I
than	I
2	I
consecutive	I
weeks	I
within	B
the	I
past	I
3	I
months	I
)	O

History	O
of	O
meningococcal	B
diseases	I
,	O
confirmed	B
either	O
clinically	O
,	O
serologically	B
,	O
or	O
microbiologically	B

At	O
high	O
risk	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
for	O
meningococcal	O
disease	O
during	O
the	O
trial	O

Known	O
or	O
suspected	O
systemic	B
hypersensitivity	I
to	O
any	O
of	O
the	O
vaccine	B
components	I
,	O
or	O
history	B
of	O
a	O
life	B
-	I
threatening	I
reaction	I
to	O
the	O
vaccine	B
used	B
in	I
the	I
trial	I
or	O
to	O
a	O
vaccine	B
containing	O
any	O
of	O
the	O
same	O
substances	O

Known	O
thrombocytopenia	B
,	O
contraindicating	B
intramuscular	B
vaccination	I

Bleeding	B
disorder	I
,	O
or	O
receipt	O
of	O
anticoagulants	B
in	B
the	I
3	I
weeks	I
preceding	I
inclusion	I
,	O
contraindicating	B
intramuscular	B
vaccination	I

In	O
an	O
emergency	O
setting	O
,	O
or	O
hospitalized	B
involuntarily	B

Chronic	O
illness	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
is	O
at	O
a	O
stage	O
where	O
it	O
might	O
interfere	O
with	O
trial	O
conduct	O
or	O
completion	O

For	O
subjects	O
enrolled	O
at	O
Indian	O
sites	O
:	O
Moderate	B
or	O
severe	B
acute	B
illness	I
/	O
infection	O
(	O
according	O
to	O
investigator	O
judgment	O
)	O
on	B
the	I
day	I
of	I
vaccination	I
or	O
febrile	B
illness	I
(	O
temperature	B
≥	B
38	I
.	I
0	I
°	I
C	I
)	O
.	O

For	O
subjects	O
enrolled	O
at	O
Russian	O
sites	O
:	O
Acute	B
disease	I
of	O
any	O
severity	O
on	B
the	I
day	I
of	I
vaccination	I
or	O
febrile	B
illness	I
(	O
axillary	B
temperature	I
≥	B
37	I
.	I
0	I
°	I
C	I
)	O
.	O

A	O
prospective	O
subject	O
should	O
not	O
be	O
included	O
in	O
the	O
study	O
until	O
the	O
condition	O
has	O
resolved	O
or	O
the	O
febrile	O
event	O
has	O
subsided	O
.	O

Receipt	O
of	O
oral	B
or	O
injectable	B
antibiotic	B
therapy	I
within	B
72	I
hours	I
prior	I
to	I
the	I
first	I
blood	I
draw	I

Identified	O
as	O
a	O
natural	O
or	O
adopted	O
child	O
of	O
the	O
Investigator	O
or	O
employee	O
with	O
direct	O
involvement	O
in	O
the	O
proposed	O
study	O

Personal	O
history	B
of	O
Guillain	B
-	I
Barré	I
Syndrome	I
.	O

Male	B
and	O
female	B
subjects	O
aged	B
9	B
to	I
17	I
months	I
on	B
the	I
day	I
of	I
inclusion	I

Informed	O
consent	O
form	O
has	O
been	O
signed	O
and	O
dated	O
by	O
the	O
parent	O
(	O
s	O
)	O
or	O
other	O
legally	O
acceptable	O
representative	O
(	O
s	O
)	O
(	O
if	O
applicable	O
)	O

Subject	O
and	O
parent	O
/	O
legally	O
acceptable	O
representative	O
(	O
if	O
applicable	O
)	O
able	O
to	O
attend	O
all	O
scheduled	O
visits	O
and	O
to	O
comply	O
with	O
all	O
trial	O
procedures	O
.	O

Cases	O
(	O
with	O
a	O
history	O
of	O
TBI	O
)	O
:	O

1	O
.	O

History	B
of	O
penetrating	B
brain	I
injury	I

2	O
.	O

History	B
of	O
disabling	O
neurological	O
or	O
psychiatric	O
condition	O
such	O
as	O
epilepsy	B
(	O
besides	B
posttraumatic	B
epilepsy	I
)	O
,	O
multiple	B
sclerosis	I
,	O
cortical	B
stroke	I
,	O
hypoxic	B
-	I
ischemic	I
encephalopathy	I
,	O
encephalitis	B
,	O
or	O
schizophrenia	B

Controls	O
(	O
without	O
a	O
history	O
of	O
TBI	O
)	O
:	O

History	B
of	O
disabling	B
neurological	I
or	I
psychiatric	I
condition	I
such	O
as	O
epilepsy	B
,	O
multiple	B
sclerosis	I
,	O
cortical	B
stroke	I
,	O
hypoxic	B
-	I
ischemic	I
encephalopathy	I
,	O
encephalitis	B
,	O
or	O
schizophrenia	B

Cases	O
(	O
with	O
a	O
history	O
of	O
TBI	O
)	O
:	O

1	O
.	O

Ages	B
50	B
-	I
95	I
years	I

2	O
.	O

History	B
of	O
traumatic	B
brain	I
injury	I
of	O
sufficient	B
severity	I
to	O
have	O
resulted	O
in	O
medical	O
attention	O
(	O
ascertained	O
via	O
the	O
Ohio	B
State	I
University	I
TBI	I
Identification	I
Questionnaire	I
—	I
OSU	I
TBI	I
-	I
ID	I
,	O
and	O
based	O
on	O
DoD	O
/	O
VA	O
criteria	O
)	O

3	O
.	O

Residence	O
in	O
AFRH	O
-	O
Washington	O
D	O
.	O
C	O
.	O
or	O
the	O
Veterans	O
Home	O
of	O
California	O
-	O
Yountville	O

4	O
.	O

MMSE	B
score	B
≥	I
20	I

5	O
.	O

Capacity	O
to	O
provide	O
consent	O
to	O
participate	O
in	O
research	O
(	O
assessment	O
made	O
by	O
study	O
physician	O
)	O

6	O
.	O

Ability	O
to	O
read	O
and	O
write	O
English	O

Controls	O
(	O
without	O
a	O
history	O
of	O
TBI	O
)	O
:	O

1	O
.	O

Ages	B
50	B
-	I
95	I
years	I

2	O
.	O

No	B
history	B
of	O
traumatic	B
brain	I
injury	I
of	O
sufficient	B
severity	I
to	O
have	O
resulted	O
in	O
medical	O
attention	O
(	O
ascertained	O
via	O
the	O
Ohio	B
State	I
University	I
TBI	I
Identification	I
Questionnaire	I
—	I
OSU	I
TBI	I
-	I
ID	I
)	O

3	O
.	O

Residence	O
in	O
AFRH	O
-	O
Washington	O
or	O
the	O
Veterans	O
Home	O
of	O
California	O
-	O
Yountville	O

4	O
.	O

MMSE	B
score	B
≥	I
20	I

5	O
.	O

Capacity	O
to	O
provide	O
consent	O
or	O
assent	O
to	O
participate	O
in	O
research	O

6	O
.	O

Ability	O
to	O
read	O
and	O
write	O
English	O
-	O

Failure	O
to	O
provide	O
informed	O
consent	O

Inability	B
to	I
complete	I
400	I
m	I
walk	I
within	I
15	I
minutes	I
without	I
sitting	I
or	O
interpersonal	O
assistance	O
,	O
as	O
an	O
indicator	O
of	O
disablement	O
and	O
likely	O
inability	O
to	O
fully	O
engage	O
in	O
the	O
exercise	O
intervention	O

Primary	O
indication	O
for	O
ACE	B
inhibitor	I
use	O
,	O
i	O
.	O
e	O
.	O
Congestive	B
Heart	I
Failure	I
,	O
CAD	B
,	O
diabetes	B

Known	O
hypersensitivity	O
to	O
ACE	B
inhibitors	I

Resistant	B
hypertension	B
,	O
defined	O
as	O
BP	B
>	B
140	I
/	I
90	I
,	O
despite	O
the	O
use	O
of	O
three	B
or	I
more	I
anti	B
-	I
hypertensive	I
drugs	I

Office	O
or	O
average	O
home	O
SBP	B
>	B
180	I
mm	I
Hg	I
or	O
DBP	B
>	B
110	I
mm	I
Hg	I
(	O
Average	O
home	O
BP	O
in	O
any	O
seven	O
day	O
period	O
during	O
trial	O
)	O

Primary	B
renal	I
disease	I

Serum	B
creatinine	I
>	B
2	I
.	I
5	I
mg	I
/	I
dL	I
in	O
men	B
,	O
or	O
>	B
2	I
.	I
0	I
mg	I
/	I
dL	I
in	O
women	B

Serum	B
potassium	I
>	B
5	I
.	I
0	I
molar	I
equivalent	I
/	I
L	I

Urinary	O
protein	O
>	B
1	I
on	O
dipstick	O

Abnormal	B
liver	B
enzymes	I
(	O
Aspartate	B
transaminase	I
(	I
AST	I
)	I
,	O
Alanine	B
transaminase	I
(	I
ALT	I
)	I
,	O
or	O
alkaline	B
phosphatase	I
>	B
2	I
.	I
5	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
)	O

Severe	B
cardiac	B
disease	I
,	O
including	O
New	B
York	I
Heart	I
Association	I
Class	B
III	I
or	I
IV	I
congestive	B
heart	I
failure	I
,	O
clinically	B
significant	I
aortic	B
stenosis	I
,	O
history	B
of	O
cardiac	B
arrest	I
,	O
use	O
of	O
a	O
cardiac	B
defibrillator	I
,	O
or	O
uncontrolled	B
angina	I

Acute	B
myocardial	I
infarction	I
identified	O
by	O
ECG	B

Lives	O
in	O
a	O
nursing	O
home	O
(	O
persons	O
living	O
in	O
assisted	O
or	O
independent	O
housing	O
will	O
not	O
be	O
excluded	O
)	O

Significant	B
cognitive	B
impairment	I
,	O
defined	O
as	O
a	O
known	O
diagnosis	O
of	O
dementia	B
or	O
a	O
Mini	B
-	I
Mental	I
State	I
Examination	I
exam	O
score	B
<	I
24	I

Unable	B
to	I
communicate	I
because	O
of	O
severe	B
hearing	I
loss	I
or	O
speech	B
disorder	I

Severe	B
visual	B
impairment	I
,	O
which	O
would	O
preclude	O
completion	O
of	O
the	O
assessments	O
and	O
/	O
or	O
intervention	O

Other	O
significant	B
co	B
-	I
morbid	I
disease	I
that	B
would	I
prevent	I
participation	I
in	I
exercise	I

Planning	O
to	O
move	O
out	O
of	O
the	O
area	O
during	O
the	O
study	O
time	O
frame	O

Simultaneous	O
participation	O
in	O
another	O
intervention	O
trial	O

Age	B
65	B
years	I
and	I
older	I

Hypertension	B
-	O
untreated	B
(	O
Systolic	B
Blood	I
Pressure	I
(	I
SBP	I
)	I
≥	B
140	I
mm	I
Hg	I
or	O
Diastolic	B
Blood	I
Pressure	I
(	I
DBP	I
)	I
≥	B
90	I
mm	I
Hg	I
)	O
or	O
treated	B

Physical	O
limitations	O
evidenced	O
by	O
either	O
:	O

Score	B
≤	I
10	I
on	O
the	O
Short	B
Physical	I
Performance	I
Battery	I
OR	O
Walking	B
speed	I
<	B
1	I
.	I
2	I
m	I
/	I
sec	I
during	O
400	B
m	I
usual	I
-	I
paced	I
test	I

Sedentary	B
lifestyle	I
,	O
defined	O
as	O
<	B
150	I
min	I
/	I
wk	I
of	O
moderate	B
physical	I
activity	I
as	O
assessed	O
by	O
CHAMPS	B
questionnaire	I

Willingness	O
to	O
participate	O
in	O
all	O
study	O
procedures	O

Clinically	B
significant	I
abnormalities	B
of	I
glucose	I
metabolism	I

Spinal	B
cord	I
compression	I
or	O
brain	B
metastases	I
unless	B
asymptomatic	B
,	O
treated	B
and	O
stable	B
(	O
not	B
requiring	O
steroids	B
)	O

Evidence	O
of	O
severe	B
or	O
uncontrolled	B
systemic	B
diseases	I
,	O
including	O
active	B
bleeding	I
diatheses	I
or	O
active	B
infections	I
including	O
hepatitis	B
B	I
,	O
C	O
and	O
Human	B
Immunodeficiency	I
Virus	I
(	I
HIV	I
)	I

Evidence	O
of	O
clinically	B
significant	I
cardiac	B
abnormalities	I
,	O
uncontrolled	B
hypotension	I
,	O
left	B
ventricular	I
ejection	I
fraction	I
below	B
the	I
lower	I
limit	I
of	I
normal	I
for	O
the	O
site	O
or	O
experience	O
of	O
significant	B
cardiac	B
interventional	I
procedures	I

A	O
bad	O
reaction	O
to	O
AZD5363	B
or	O
any	O
drugs	O
similar	O
to	O
it	O
in	O
structure	O
or	O
class	O

Aged	B
at	B
least	I
18	I
years	I

The	O
presence	O
of	O
a	O
solid	B
,	I
malignant	I
tumour	I
,	O
excluding	B
lymphoma	B
,	O
that	O
is	O
resistance	B
to	I
standard	I
therapies	I
or	O
for	B
which	I
no	I
standard	I
therapies	I
exist	I

The	O
presence	O
of	O
at	B
least	I
one	I
lesion	B
that	O
can	O
be	O
accurately	B
assessed	I
at	I
baseline	I
by	O
Computerised	B
Tomography	I
(	I
CT	I
)	I
,	O
Magnetic	B
Resonance	I
Imaging	I
(	I
MRI	I
)	I
or	O
plain	B
X	I
-	I
ray	I
and	O
is	O
suitable	B
for	I
repeated	I
assessment	I

Estimated	O
life	O
expectancy	O
of	O
more	B
than	I
12	I
weeks	I

HCV	O
,	O
HIV	O
,	O
or	O
HDV	B
coinfection	I
.	O

HCC	B
or	O
other	O
malignancy	B
within	B
3	I
years	I
.	O

Decompensated	B
liver	I
cirrhosis	I
(	O
CTP	B
score	I
=	B
7	I
)	O
.	O

Uremia	B
patients	O
under	O
hemodialysis	B
or	O
continuous	B
ambulatory	I
peritoneal	I
dialysis	I
or	O
patients	O
with	O
Ccr	B
<	B
50	I
mL	I
/	I
min	I

Pregnant	O
or	O
breastfeeding	O
women	O
.	O

Women	O
of	O
child	O
-	O
bearing	O
potential	O
(	O
WOCBP	O
)	O
who	O
are	O
unwilling	O
or	O
unable	O
to	O
use	O
an	O
acceptable	O
method	O
of	O
contraception	O
to	O
avoid	O
pregnancy	O
throughout	O
the	O
study	O
and	O
for	O
up	O
to	O
4	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
study	O
drug	O
.	O

Age	B
:	O
from	O
20	B
to	I
90	I
y	I
/	I
o	I
.	O

HBsAg	B
-	O
positive	B
for	O
more	B
than	I
6	I
months	I
and	O
HBV	B
DNA	I
<	B
2000	I
IU	I
/	I
ml	I
(	O
Subgroup	O
1	O
)	O
or	O
HBsAg	B
-	O
negative	B
but	O
anti	B
-	I
HBc	I
positive	B
with	O
HBV	B
DNA	I
<	B
2000	I
IU	I
/	I
ml	I
(	O
Subgroup	O
2	O
)	O
.	O

Inflammatory	B
arthritis	I
patients	O
who	O
plan	O
to	O
treat	O
with	O
biological	B
agents	I
,	O
including	O
Humira	B
or	O
Enbrel	B
or	O
Simponi	B
or	O
Orencia	B
or	O
Mabthera	B
or	O
Actemra	B
;	O
as	O
first	O
line	O
biologic	O
treatment	O
is	O
indicated	O
.	O

IBS	B
subtype	I
with	O
constipation	B

medication	O
:	O
antidepressants	B
or	O
H1	B
-	I
receptor	I
antagonists	I

pregnancy	B
,	O
breast	O
feeding	O

co	O
-	O
morbidity	O
:	O
severe	B
kidney	O
-	O
and	O
/	O
or	O
liver	B
disease	I
or	O
other	O
gastrointestinal	B
diseases	I

Irritable	B
Bowel	I
Syndrome	I
(	I
IBS	I
)	I
(	O
ROME	B
III	I
criteria	I
)	O
:	O
subtype	O
with	O
diarrhea	B
or	O
mixed	B
form	I

age	B
18	B
-	I
65	I
years	I

Previous	O
treatment	O
with	O
brentuximab	B
vedotin	O
.	O

Previously	O
received	O
an	O
allogeneic	B
transplant	I
.	O

Patients	O
with	O
current	O
diagnosis	O
of	O
primary	B
cutaneous	I
ALCL	I
(	O
patients	O
whose	O
ALCL	O
has	O
transformed	O
to	O
sALCL	B
are	O
eligible	O
)	O
.	O

Known	O
cerebral	O
/	O
meningeal	B
disease	I
including	O
signs	O
or	O
symptoms	O
of	O
progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O

Female	O
patients	O
who	O
are	O
lactating	O
and	O
breastfeeding	O
or	O
pregnant	O

Known	O
human	B
immunodeficiency	I
virus	I
(	O
HIV	B
)	O
positive	B

Known	O
hepatitis	B
B	I
surface	I
antigen	I
-	O
positive	B
,	O
or	O
known	O
or	O
suspected	O
active	B
hepatitis	B
C	I
infection	I

Male	B
or	O
female	B
patients	O
age	B
18	B
years	I
or	I
older	I
,	O
with	O
relapsed	B
or	O
refractory	B
sALCL	B
who	O
have	O
previously	O
received	O
at	B
least	I
1	I
multiagent	O
chemotherapy	B

Bidimensional	O
measurable	O
disease	O

An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	B
)	O
performance	O
status	O
of	O
0	B
or	I
1	I

Female	O
patients	O
who	O
are	O
postmenopausal	O
for	O
at	O
least	O
1	O
year	O
before	O
the	O
screening	O
visit	O
,	O
surgically	O
sterile	O
,	O
or	O
agree	O
to	O
practice	O
2	O
effective	O
methods	O
of	O
contraception	O
,	O
at	O
the	O
same	O
time	O
,	O
from	O
the	O
time	O
of	O
signing	O
the	O
informed	O
consent	O
form	O
through	O
30	O
days	O
after	O
the	O
last	O
dose	O
of	O
study	O
drug	O
,	O
or	O
agree	O
to	O
practice	O
true	O
abstinence	O

Male	O
patients	O
who	O
agree	O
to	O
practice	O
effective	O
barrier	O
contraception	O
during	O
the	O
entire	O
study	O
treatment	O
period	O
through	O
6	O
months	O
after	O
the	O
last	O
dose	O
of	O
study	O
drug	O
or	O
agree	O
to	O
practice	O
true	O
abstinence	O

Clinical	O
laboratory	O
values	O
as	O
specified	O
in	O
the	O
study	O
protocol	O

1	O
.	O
bilateral	B
AT	I

2	O
.	O
insertional	B
AT	I

3	O
.	O
local	B
steroid	I
injection	I
within	B
6	I
weeks	I
or	O
physical	B
therapy	I
within	B
4	I
weeks	I

4	O
.	O
inability	O
to	O
comply	O
with	O
follow	O
-	O
up	O
criteria	O

5	O
.	O
history	B
of	O
surgery	B
on	I
the	I
Achilles	I
tendon	I
or	O
systemic	B
diseases	I
(	O
general	B
inflammatory	I
diseases	I
such	O
as	O
rheumatologic	B
disorders	I
and	O
diabetes	B
)	O

6	O
.	O
daily	B
use	O
of	O
opioids	B
for	O
pain	B

7	O
.	O
anticoagulation	O
or	O
immunosuppressive	B
therapy	I

8	O
.	O
intent	O
to	O
use	O
NSAIDs	B
or	O
steroids	B

9	O
.	O
self	O
-	O
reported	O
pregnancy	B

1	O
.	O
age	B
18	B
-	I
65	I
years	I
,	I
inclusive	I

2	O
.	O
diagnosis	O
of	O
moderate	B
to	I
severe	I
AT	B
,	O
confirmed	O
by	O
Dr	O
.	O
Wilson	O
using	O
clinical	O
symptoms	O
and	O
exam	O
findings	O
consistent	O
with	O
chronic	B
AT	I
(	O
>	B
6	I
month	I
duration	I
)	O
-	O
which	O
includes	O
pain	B
while	I
palpating	I
the	I
intratendinous	I
swelling	I
part	I
of	I
the	I
Achilles	I
tendon	I
and	O
relief	B
of	I
pain	I
when	I
tendon	I
placed	I
under	I
tension	I
-	O
and	O
pre	O
-	O
procedure	O
US	O

3	O
.	O
self	O
-	O
reported	O
AT	B
-	I
related	I
pain	I
for	B
at	I
least	I
6	I
months	I
and	O
VAS	B
(	I
Visual	I
Analog	I
Scale	I
)	I
pain	I
>	B
5	I
(	O
0	B
-	I
10	I
scale	I
)	O

4	O
.	O
self	O
-	O
reported	O
failure	B
of	I
eccentric	I
exercise	I
protocol	I
(	O
at	B
least	I
75	I
%	I
completion	O
)	O

5	O
.	O
self	O
-	O
reported	O
failure	B
of	I
at	I
least	I
2	I
of	I
the	I
3	I
most	I
common	I
treatments	I
for	I
AT	I
(	O
NSAIDS	B
,	O
rest	B
/	O
ice	B
or	O
taping	B
)	O

6	O
.	O
patient	O
considered	O
surgery	B
but	O
decided	O
to	O
wait	O
and	O
/	O
or	O
refused	O
surgery	O
-	O

current	B
or	O
recent	B
(	O
within	B
one	I
week	I
of	I
surgery	I
)	O
systemic	O
antibiotic	B
use	O
,	O
intolerance	B
to	O
both	O
clindamycin	B
and	O
cephalexin	B
,	O
discovery	O
of	O
a	O
persistent	B
cutaneous	I
malignancy	I
at	O
the	O
site	B
of	I
the	I
defect	I
following	O
the	O
reconstructive	B
procedure	I
and	O
previous	O
reconstruction	O
at	O
the	O
site	O
of	O
the	O
skin	O
/	O
soft	O
-	O
tissue	O
defect	O
.	O

all	O
adult	O
patients	O
with	O
a	O
nasal	O
or	O
facial	B
skin	I
/	I
soft	I
tissue	I
defect	I
requiring	O
reconstruction	B
limited	O
to	O
or	O
including	O
a	O
full	B
-	I
thickness	I
skin	I
graft	I

Indication	B
for	O
emergent	B
cesarean	I
or	O
known	O
fetal	B
anomaly	I

Anti	B
-	I
hypertensive	I
therapy	I
received	O
in	O
the	O
past	B
12	I
hours	I

History	O
of	O
eclampsia	B
or	O
other	O
adverse	O
CNS	B
complication	I
(	O
e	O
.	O
g	O
.	O
,	O
stroke	B
or	O
PRES	B
)	O
in	B
this	I
pregnancy	I

Actively	O
wheezing	B
at	B
time	I
of	I
enrollment	I
or	O
history	O
of	O
asthma	B
complications	I

Known	O
coronary	B
artery	I
disease	I
or	O
type	B
I	I
DM	I
with	O
microvascular	B
complications	I
or	O
signs	O
of	O
heart	B
failure	I
or	O
clinical	O
dissection	B
of	I
the	I
aorta	I

Pregnant	O
gestational	B
age	I
>	B
=	I
28	I
weeks	I

Systolic	B
blood	I
pressure	I
>	B
=	I
160	I
mm	I
Hg	I
OR	O
a	O
diastolic	B
blood	I
pressure	I
of	O
>	B
=	I
110	I
mm	I
Hg	I
measured	O
twice	O
more	O
than	O
15	O
minutes	O
apart	O

Able	O
to	O
swallow	O
pills	O

>	B
=	I
18	I
years	B

Intracranial	B
infection	I
.	O

Severe	B
respiratory	O
and	O
circulatory	B
system	I
diseases	I
.	O

Hematologic	B
malignancies	I
.	O

Positive	O
serological	O
tests	O
such	O
as	O
AIDS	B
,	O
hepatitis	B
B	I
virus	I
,	O
hepatitis	B
C	I
virus	I
and	O
syphilis	B
（	O
antigen	O
or	O
antibody	O
）	O
.	O

Tumors	B
.	O

Genetic	O
and	O
metabolic	B
diseases	I
.	O

Patients	O
with	O
diagnosis	O
of	O
cerebral	B
palsy	I
.	O

Patients	O
'	O
curator	O
must	O
be	O
able	O
to	O
give	O
voluntary	O
consent	O
.	O

Use	O
of	O
smoking	B
cessation	I
medications	B
or	O
interventions	B
in	B
last	I
30	I
days	I

Unstable	O
medical	O
illness	O
that	O
requires	O
immediate	O
medical	O
care	O

AUDIT	B
score	B
of	I
<	I
5	I
or	I
>	I
26	I

Pregnancy	B
or	O
other	O
Nicotine	B
Replacement	I
Therapy	I
(	O
NRT	B
)	O
contraindications	B

Current	O
history	O
or	O
in	O
past	B
6	I
months	I
of	O
psychotic	B
disorder	I
or	O
major	B
depressive	I
disorders	I
that	O
is	O
not	B
stable	I
on	O
treatment	O
for	B
past	I
3	I
months	I

Cognitive	B
impairment	I

Currently	O
Homeless	B

Smoked	O
at	B
least	I
100	I
cigarettes	I
in	O
lifetime	O

AUDIT	B
score	B
of	I
>	I
or	I
equal	I
to	I
5	I
,	I
<	I
or	I
equal	I
to	I
26	I

Aged	B
18	B
years	I
or	I
older	I

Willing	O
to	O
attend	O
study	O
sessions	O
and	O
follow	O
other	O
study	O
protocol	O

uncontrolled	B
hypertension	B

uncontrolled	B
diabetes	B

creatinine	B
>	B
2	I
,	I
5	I
mg	I
/	I
dl	I

potassium	B
>	B
6	I
mg	I
/	I
dl	I

acute	B
coronary	I
syndrome	I

hypertrophic	B
cardiomyopathy	I

heart	B
failure	I
NYHA	B
II	B
-	I
IV	I

previous	B
treatment	B
with	O
diuretics	B

age	B
>	B
18	I
years	I

1	O
.	O

Patients	O
with	O
C	B
class	I
by	O
child	B
-	I
pugh	I
score	I

2	O
.	O

Patients	O
in	O
the	O
acute	B
phase	I
of	O
severe	B
hepatitis	I

3	O
.	O

Patients	O
have	O
been	O
diagnosed	O
with	O
cancer	B
of	I
the	I
liver	I

4	O
.	O

Patients	O
with	O
severe	B
cardiopulmonary	B
cerebral	I
disease	I
,	O
and	O
in	O
the	O
failure	O
state	O

5	O
.	O

Patients	O
in	O
Highly	B
allergic	I
constitution	I

6	O
.	O

Patients	O
with	O
moderately	B
severe	I
mental	B
disease	I

Patients	O
with	O
hepatocirrhosis	B
:	O
according	O
to	O
the	O
standard	O
of	O
child	O
-	O
pugh	O
,	O
liver	O
functions	O
to	O
achieve	O
class	O
A	O
or	O
B	O
patients	O
,	O
Including	O
C	O
class	O
patients	O
but	O
can	O
achieve	O
B	O
class	O
after	O
treatment	O

•	O
Patients	O
without	B
PN	B
during	O
their	O
hospitalization	B

Patients	O
with	O
PN	B
during	O
their	O
hospitalization	B

Patients	O
hospitalized	B
in	O
medical	O
,	O
surgical	O
or	O
ICU	O
wards	O

Signed	O
informed	O
consent	O
either	O
from	O
the	O
patient	O
,	O
their	O
legally	O
authorized	O
representative	O
or	O
a	O
direct	O
family	O
member	O

endometrial	B
thickness	I
<	B
7	I
mm	I
or	O
no	B
triple	O
layer	O
endometrium	O
and	O
/	O
or	O
functional	O
follicles	O

Uterine	B
abnormality	I

Chronic	B
medical	I
disease	I

oocyte	B
donation	I
cycles	I

Endometrial	B
thickness	I
=	B
7	I
mm	I
after	O
stimulation	B

18	B
-	I
45	I
years	B

IVF	O
/	O
ICSI	B
fertilisation	I

BMI	B
>	B
18	I
,	I
5	I
<	I
30	I
kg	I
/	I
m2	I

cycle	B
length	I
25	B
-	I
34	I
days	I

NA	O

intolerance	B
of	O
or	O
allergy	B
to	O
ticagrelor	B
or	O
prasugrel	B

history	O
of	O
any	O
stroke	B
,	O
transient	B
ischemic	I
attack	I
or	O
intracranial	B
bleeding	I

known	O
intracranial	B
neoplasm	I
,	O
intracranial	B
arteriovenous	I
malformation	I
or	O
intracranial	B
aneurysm	I

active	B
bleeding	B
,	O
clinical	B
findings	I
,	I
that	I
in	I
the	I
judgement	I
of	I
the	I
investigator	I
are	I
associated	I
with	I
an	I
increased	I
risk	I
of	I
bleeding	I

fibrin	B
-	I
specific	I
fibrinolytic	B
therapy	I
less	B
than	I
24	I
h	I
before	I
randomization	I
,	O
non	B
-	I
fibrin	I
-	I
specific	I
fibrinolytic	B
therapy	I
less	B
than	I
48	I
h	I
before	I
randomization	I

known	O
platelet	B
count	I
<	B
100	I
.	I
000	I
/	I
µL	I
at	B
the	I
time	I
of	I
screening	I

known	O
anemia	B
(	O
hemoglobin	B
<	B
10	I
g	I
/	I
dL	I
)	O
at	B
the	I
time	I
of	I
screening	I

oral	B
anticoagulation	I
that	O
cannot	B
be	I
safely	I
discontinued	I
for	B
the	I
duration	I
of	I
the	I
study	I

INR	B
known	O
to	O
be	O
greater	B
than	I
1	I
.	I
5	I
at	B
the	I
time	I
of	I
screening	I

chronic	B
renal	I
insufficiency	I
requiring	O
dialysis	B

moderate	B
or	O
severe	B
hepatic	B
dysfunction	I
(	O
Child	B
Pugh	I
B	B
or	I
C	I
)	O

increased	O
risk	O
of	O
bradycardia	B
events	I
(	O
Sick	B
Sinus	I
,	O
AV	B
block	I
grade	B
II	B
or	I
III	I
,	O
bradycardia	B
-	I
induced	I
syncope	I
)	O

index	O
event	O
is	O
an	O
acute	B
complication	O
(	O
<	B
30	I
days	I
)	O
of	O
PCI	O

concomitant	B
medical	I
illness	I
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
is	B
associated	I
with	I
a	I
life	I
expectancy	I
<	I
1	I
year	I

concomitant	O
oral	O
or	O
i	B
.	I
v	I
.	I
therapy	I
with	O
strong	B
CYP3A	I
Inhibitors	I
(	O
e	O
.	O
g	O
.	O
ketoconazole	B
,	O
itraconazole	B
,	O
voriconazole	B
,	O
telithromycin	B
,	O
clarithromycin	B
,	O
nefazodone	B
,	O
ritonavir	B
,	O
saquinavir	B
,	O
nelfinavir	B
,	O
indinavir	B
,	O
atazanavir	B
,	O
grapefruit	B
juice	I
>	B
1	I
L	I
/	I
d	I
)	O
,	O
CYP3A	B
substrates	I
with	I
narrow	I
therapeutic	I
indices	I
(	O
e	O
.	O
g	O
.	O
cyclosporine	B
,	O
quinidine	B
)	O
,	O
or	O
strong	B
CYP3A	I
inducers	I
(	O
e	O
.	O
g	O
.	O
rifampin	B
/	O
rifampicin	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
dexamethason	B
,	O
phenobarbital	B
)	O
that	O
cannot	O
be	O
safely	O
discontinued	O

=	B
1	I
doses	I
of	O
ticagrelor	B
or	O
prasugrel	B
within	B
5	I
days	I
before	I
randomisation	I

no	O
written	O
informed	O
consent	O

participation	O
in	O
another	O
investigational	O
drug	O
study	O

previous	O
enrolment	O
in	O
this	O
study	O

for	O
women	O
of	O
childbearing	O
potential	O
no	O
negative	O
pregnancy	O
test	O
and	O
no	O
agree	O
to	O
use	O
reliable	O
method	O
of	O
birth	O
control	O
during	O
the	O
study	O

Pregnancy	O
,	O
giving	O
birth	O
within	O
the	O
last	O
90	O
days	O
,	O
or	O
lactation	O

inability	O
to	O
cooperate	O
with	O
protocol	O
requirements	O

Pregnant	B
or	O
lactating	B
women	B

Patients	O
with	O
severe	B
organ	B
dysfunction	I
or	O
failure	O

With	O
severe	B
cardiovascular	O
disease	B
,	I
or	I
mental	I

Extraliver	B
metastases	B

Histologically	B
confirmed	O
colorectal	B
adenocarcinoma	I

Disease	O
limited	O
to	O
the	O
liver	O
Unresectable	B
disease	I
by	O
surgery	B
or	O
other	B
local	B
therapies	I

Age	B
>	B
18	I
years	I

ECOG	B
performance	I
status	I
0	B
-	I
2	I
,	O
Child	B
pugh	I
A	B
or	O
B	B

Expected	O
survival	O
=	B
3	I
months	I

Adequate	B
hematological	O
,	O
hepatic	O
,	O
and	O
renal	B
function	I

OAT	B
required	O
for	O
reasons	O
not	B
related	O
to	O
AF	B
(	O
i	O
.	O
e	O
.	O
,	O
prosthetic	B
valve	I
,	O
PV	B
stenosis	I
,	O
previous	O
pulmonary	B
embolism	I
,	O
presence	O
of	O
spontaneous	B
echo	I
contrast	I
[	O
SEC	B
]	O
at	O
standard	B
echo	I
performed	O
at	O
3	B
-	I
months	I
follow	I
-	I
up	I
)	O
.	O

Any	O
cardiac	B
surgery	I
within	B
the	I
past	I
60	I
days	I
(	O
2	B
months	I
)	O
or	O
valvular	B
cardiac	I
surgical	I
procedure	O
at	O
any	O
time	O
(	O
i	O
.	O
e	O
.	O
,	O
ventriculotomy	B
,	O
atriotomy	B
,	O
and	O
valve	B
repair	I
or	O
replacement	O
and	O
presence	O
of	O
a	O
prosthetic	B
valve	I
)	I

Previous	O
myocardial	B
infarction	I
(	O
MI	B
)	O
or	O
a	O
percutaneous	B
coronary	I
intervention	I
PCI	B
within	B
the	I
past	I
3	I
months	I

Awaiting	O
cardiac	B
transplantation	I
or	O
other	O
cardiac	B
surgery	I
within	B
the	I
next	I
365	I
days	I
(	O
12	O
months	O
)	O

Documented	O
left	B
atrial	I
thrombus	I

Significant	B
pulmonary	B
disease	I
,	O
(	O
e	O
.	O
g	O
.	O
,	O
restrictive	B
pulmonary	I
disease	I
,	O
constrictive	O
or	O
COPD	B
)	O
or	O
any	O
other	O
disease	O
or	O
malfunction	O
of	O
the	O
lungs	O
or	O
respiratory	O
system	O
that	O
produces	O
chronic	O
symptoms	O

Significant	O
medical	O
problem	O
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
would	O
preclude	O
enrollment	O
in	O
this	O
study	O

Women	O
who	O
are	O
pregnant	O
(	O
as	O
evidenced	O
by	O
pregnancy	O
test	O
if	O
pre	O
-	O
menopausal	O
)	O

Acute	O
illness	O
or	O
active	O
systemic	B
infection	I
or	O
sepsis	B

Unstable	B
angina	I

Contraindication	B
to	O
anticoagulation	B
(	O
i	O
.	O
e	O
.	O
,	O
heparin	B
,	O
warfarin	B
or	O
another	O
commercially	O
available	O
anticoagulation	O
medication	O
)	O

History	O
of	O
blood	O
clotting	O
or	O
bleeding	B
abnormalities	I

Life	O
expectancy	O
less	B
than	I
360	I
days	I
(	O
12	O
months	O
)	O

Uncontrolled	B
Heart	B
Failure	I
or	O
NYHA	B
Class	I
III	I
or	O
IV	O
heart	B
failure	I

Enrollment	O
in	O
a	O
clinical	O
study	O
evaluating	O
another	O
device	O
or	O
drug	O
,	O
within	O
the	O
past	O
6	O
months	O

Unable	O
or	O
unwilling	O
to	O
comply	O
with	O
protocol	O
requirements	O

Successful	B
cardiac	B
ablation	I
for	O
AF	B

Documented	O
freedom	B
from	O
AF	B
recurrence	I
(	O
symptomatic	O
or	O
asymptomatic	O
arrhythmic	B
recurrences	I
lasting	O
longer	B
than	I
30	I
seconds	I
)	O
3	B
months	I
after	I
successful	I
cardiac	I
ablation	I
(	O
AF	O
recurrence	O
during	O
3	O
-	O
month	O
blanking	O
period	O
is	O
excluded	O
)	O
.	O

Patient	O
must	O
have	O
been	O
on	O
a	O
commercially	O
approved	O
anticoagulation	B
therapy	I
for	O
at	B
least	I
two	I
(	I
2	I
)	I
months	I
prior	I
to	I
randomization	I
in	O
the	O
OAT	O
Study	O
.	O

CHADS2	B
score	I
=	B
2	I
or	O
CHA2DS2	B
-	I
VASc	I
score	I
(	O
=	B
3	I
)	O

Left	B
ventricular	I
ejection	I
fraction	I
>	B
25	I
%	I

LA	B
size	I
<	B
65	I

High	B
risk	O
for	O
thromboembolic	O
events	O
(	O
i	O
.	O
e	O
.	O
,	O
CHADS2	B
score	I
=	B
2	I
or	O
CHA2DS2	B
-	I
VASc	I
score	I
=	B
3	I
)	O
and	O
require	O
OAT	B
before	B
undergoing	I
cardiac	I
ablation	I

Able	O
and	O
willing	O
to	O
comply	O
with	O
all	O
pre	O
-	O
and	O
follow	O
-	O
up	O
testing	O
and	O
requirements	O

Signed	O
informed	O
consent	O
form	O

Age	B
18	B
years	I
or	I
older	I

If	O
smoking	O
and	O
/	O
or	O
other	O
drug	B
addiction	I
is	O
present	O

If	O
local	B
anesthetic	I
allergy	B
is	O
present	O

Patient	O
subjected	O
to	O
chemical	B
or	O
radiotherapy	B

if	O
Hepatic	B
disease	I
is	O
present	O

If	O
immunodepression	B
is	O
present	O

If	O
Pregnancy	B
is	O
present	O

If	O
Diabetes	B
is	O
present	O

If	O
Heart	B
disease	I
is	O
present	O

Single	B
unit	I
implant	I
rehabilitation	I

Maxilla	B
and	O
mandible	B

Must	O
accept	O
treatment	O
plan	O

Must	O
sign	O
informed	O
consent	O

dental	B
extraction	I
performed	O
at	B
least	I
3	I
month	I
prior	I

Must	O
have	O
at	B
least	I
6	I
mm	I
of	O
residual	B
bone	I

Absence	B
of	O
oral	B
lesions	I

keratinized	B
tissue	I
must	I
be	I
present	I

Active	O
substance	B
dependency	I

History	B
of	O
severe	B
head	I
injury	I

Non	B
-	I
affective	I
psychosis	I

Premorbid	B
IQ	I
of	O
over	B
70	I

A	O
service	O
user	O
of	O
the	O
early	O
intervention	O
service	O

Aged	B
18	B
or	I
over	I
(	O
up	B
to	I
the	I
age	I
of	I
35	I
which	O
is	O
the	O
limit	O
for	O
the	O
early	O
intervention	O
service	O
)	O

Psychiatrically	B
stable	I
enough	O
to	O
attend	O
to	O
completion	O
(	O
no	B
hospitalisations	B
or	O
medication	O
changes	O
in	B
last	I
4	I
weeks	I
)	O

Hemochromatosis	B
,	O
iron	B
overload	I
,	O
defined	O
as	O
TSAT	B
>	B
45	I
%	I

Known	O
hypersensitivity	B
to	O
Ferinject	B
®	I
.	O

Known	O
active	B
infection	I
,	O
CRP	B
>	B
20	I
mg	I
/	I
L	I
,	O
clinically	B
significant	I
bleeding	B
,	O
active	B
malignancy	B
.	O

Chronic	B
liver	I
disease	I
and	O
/	O
or	O
screening	O
alanine	B
transaminase	I
(	I
ALT	I
)	I
or	O
aspartate	B
transaminase	I
(	I
AST	I
)	I
above	B
three	I
times	I
the	I
upper	I
limit	I
of	I
the	I
normal	I
range	I
.	O

Immunosuppressive	B
therapy	I
or	O
renal	B
dialysis	I
(	O
current	O
or	O
planned	O
within	B
the	I
next	I
6	I
months	I
)	O
.	O

History	O
of	O
erythropoietin	B
,	O
i	O
.	O
v	O
.	O
or	O
oral	B
iron	I
therapy	I
,	O
and	O
blood	B
transfusion	I
in	B
previous	I
12	I
weeks	I
and	O
/	O
or	O
such	O
therapy	O
planned	O
within	B
the	I
next	I
6	I
months	I
.	O

Unstable	B
angina	I
pectoris	I
as	O
judged	O
by	O
the	O
investigator	O
,	O
clinically	B
significant	I
uncorrected	O
valvular	B
disease	I
or	O
left	B
ventricular	I
outflow	I
obstruction	I
,	O
obstructive	B
cardiomyopathy	I
,	O
poorly	B
controlled	I
fast	B
atrial	I
fibrillation	I
or	O
flutter	O
,	O
poorly	B
controlled	I
symptomatic	B
brady	B
-	I
or	O
tachyarrhythmias	B
.	O

Acute	B
myocardial	I
infarction	I
or	O
acute	B
coronary	I
syndrome	I
,	O
transient	B
ischemic	I
attack	I
or	O
stroke	B
within	B
the	I
last	I
3	I
months	I
.	O

Coronary	B
-	I
artery	I
bypass	I
graft	I
,	O
percutaneous	B
intervention	I
(	O
e	O
.	O
g	O
.	O
cardiac	O
,	O
cerebrovascular	O
,	O
aortic	O
;	O
diagnostic	O
catheters	O
are	O
allowed	O
)	O
or	O
major	B
surgery	I
,	O
including	O
thoracic	O
and	O
cardiac	B
surgery	I
,	O
within	B
the	I
last	I
3	I
months	I
.	O

Participation	O
in	O
a	O
CHF	O
training	O
program	O
.	O

Known	B
HIV	I
/	O
AIDS	B
.	O

Inability	O
to	O
fully	O
comprehend	O
and	O
/	O
or	O
perform	O
study	O
procedures	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
.	O

Vitamin	O
B12	O
and	O
/	O
or	O
serum	B
folate	I
deficiency	I
according	O
to	O
the	O
laboratory	O
(	O
re	O
-	O
screening	O
is	O
possible	O
after	O
substitution	O
therapy	O
)	O
.	O

Pregnancy	B
or	O
lactation	B
.	O

Participation	O
in	O
another	O
clinical	O
trial	O
within	O
previous	O
30	O
days	O
and	O
/	O
or	O
anticipated	O
participation	O
in	O
another	O
trial	O
during	O
this	O
study	O
.	O

Anticoagulation	B

Patients	O
with	O
chronic	B
heart	I
failure	I
of	O
New	B
York	I
Heart	I
Association	I
Class	B
II	I
or	I
III	I
,	O
a	O
left	B
ventricular	I
ejection	I
fraction	I
of	O
=	B
40	I
%	I
for	O
patients	O
in	O
NYHA	B
class	B
II	I
or	O
=	B
45	I
%	I
for	O
patients	O
in	O
NYHA	B
class	B
III	I
,	O
a	O
hemoglobin	B
level	I
at	B
the	I
screening	I
visit	I
between	B
9	I
.	I
5	I
-	I
13	I
.	I
5	I
g	I
/	I
dl	I
,	O
and	O
iron	B
deficiency	I
,	O
which	O
is	O
defined	O
as	O
serum	B
ferritin	I
level	I
<	B
100µg	I
/	I
l	I
or	O
between	B
100	I
and	I
299	I
µg	I
/	I
l	I
,	O
when	O
transferring	B
saturation	I
is	O
<	B
20	I
%	I
.	O

Age	B
=	B
18	I
years	I

Obtained	O
informed	O
consent	O

Stable	B
pharmacological	B
therapy	I
during	B
the	I
last	I
4	I
weeks	I
(	O
with	B
the	I
exception	I
of	I
diuretics	B
)	O

Patients	O
with	O
>	B
14	I
follicles	B
on	B
day	I
of	I
trigger	I

Previous	B
hyperresponse	B
with	O
OHSS	O
development	O

Previous	B
low	B
response	I
(	O
less	B
than	I
3	I
oocytes	B
on	O
a	O
high	B
dose	I
of	I
FSH	I
stimulation	I
)	O

Endocrine	B
disorders	I

Age	B
between	B
20	I
and	I
40	I

Normal	B
menstrual	I
cycles	I
:	O
25	B
-	I
34	I
days	I

Oligomenorrhea	B
/	O
amenorrhea	B
or	O
polycystic	B
syndrome	I
(	O
defined	O
according	O
to	O
the	O
Rotterdam	B
criteria	I
2004	I
)	O

BMI	B
>	B
18	I
and	I
<	I
35	I
kg	I
/	I
m2	I

Refusal	O

Contraindication	B
to	O
neuraxial	B
(	O
coagulopathy	B
,	O
anticoagulant	B
use	O
,	O
local	B
infection	I
,	O
sepsis	B
etc	O
)	O
.	O
Rupture	B
of	I
membranes	I
.	O

Drop	O
-	O
out	O
:	O
Patients	O
may	O
choose	O
to	O
drop	O
-	O
out	O
of	O
the	O
study	O
at	O
any	O
time	O
.	O
The	O
physicians	O
involved	O
in	O
this	O
study	O
may	O
choose	O
to	O
end	O
a	O
patient	O
'	O
s	O
involvement	O
in	O
the	O
study	O
at	O
their	O
discretion	O
.	O

Healthy	B
patients	O
age	B
18	B
and	I
older	I

Breech	O
presentation	O

Singleton	B
gestation	I
.	O
scheduled	O
for	O
ECV	B
desiring	O
CSE	B
.	O

Inmate	B
of	I
a	I
correctional	I
facility	I
(	O
i	O
.	O
e	O
.	O
prisoners	B
)	O
.	O

Pregnancy	B

Documented	O
or	O
suspected	O
family	O
or	O
personal	B
history	I
of	O
malignant	B
hyperthermia	I
.	O

Patient	O
unable	B
to	I
receive	I
either	O
propofol	B
or	O
isoflurane	B
due	O
to	O
allergy	B
or	O
other	O
specific	O
contraindication	O
.	O

Surgical	O
patients	O
60	O
years	O
of	O
age	B
or	O
older	O

Surgery	B
scheduled	B
to	I
last	I
at	I
least	I
2	I
hours	I
(	O
including	O
time	O
for	O
anesthesia	O
induction	O
,	O
etc	O
)	O

English	O
speaking	O
ability	O
.	O

Ability	O
to	O
give	O
informed	O
consent	O

Richter	B
'	I
s	I
syndrome	I
,	O
Burkitt	B
'	I
s	I
lymphoma	I
,	O
or	O
Burkitt	B
-	I
like	I
Lymphoma	I
(	O
transformed	O
DLBCL	B
from	O
Follicular	B
NHL	I
are	O
eligible	O
)	O
.	O

Prior	B
transplant	B
with	O
stem	B
cell	I
infusion	I
90	O
days	O
or	O
active	B
graft	B
-	I
versus	I
-	I
host	I
treatment	I
within	B
8	I
weeks	I
of	I
Day	I
1	I
.	O

Prior	B
therapy	B
with	O
SYK	B
inhibitors	I
.	O

Chronic	O
treatment	O
with	O
strong	B
CYP3A4	I
inhibitor	I
/	O
inducer	O
,	O
acid	B
reducing	I
agent	I
,	O
Proton	B
pump	I
inhibitors	I

Known	O
lymphomatous	B
involvement	I
of	I
the	I
CNS	I
.	O

Persistent	O
,	O
unresolved	O
NCI	B
CTCAE	I
v4	I
.	I
0	I
≥	B
Grade	I
2	I
,	O
previous	B
drug	B
-	I
related	I
toxicity	I
(	O
except	B
alopecia	B
,	O
erectile	B
impotence	I
,	O
hot	B
flashes	I
,	O
libido	B
,	O
neuropathy	B
)	O
.	O

Prior	O
monoclonal	B
antibody	I
,	O
radioimmunoconjugate	B
,	O
antibody	B
drug	I
conjugate	I
,	O
phototherapy	B
,	O
radiotherapy	B
,	O
chemotherapy	B
,	O
immunotherapy	B
,	O
immunosuppressive	B
therapy	I
,	O
or	O
any	O
test	O
agent	O
within	O
3	O
weeks	O
or	O
for	O
alemtuzumab	B
8	B
weeks	I
of	I
Day	I
1	I
.	O

For	O
CTCL	B
:	O
(	O
TSEBT	B
)	O
within	B
12	I
weeks	I
,	O
or	O
initiation	O
of	O
topical	B
steroid	I
,	O
nitrogen	B
mustard	I
,	O
or	O
topical	B
retinoid	I
within	B
2	I
weeks	I
.	O

(	O
Stable	O
topical	O
≥	B
4	I
weeks	I
prior	I
to	I
Day	I
1	I
allowed	O
)	O
.	O

Known	O
carrier	O
or	O
infection	B
for	I
HIV	I
/	O
Hep	O
B	O
or	O
C	O
.	O

HCV	B
ab	I
+	I
must	O
be	O
PCR	B
-	I
.	O

HBV	B
ab	I
+	I
must	O
be	O
HBsAg	B
-	I
or	O
undetectable	B
DNA	I

Active	O
infection	B
requiring	O
systemic	B
treatment	I
,	O

Significant	B
GI	B
disease	I
,	O
previous	O
major	B
gastric	O
/	O
bowel	B
surgery	I
,	O
difficulty	B
swallowing	I
or	O
malabsorption	B
syndrome	I
.	O

Major	B
surgery	B
within	B
4	I
weeks	I

Previous	O
malignancies	B
within	B
2	I
yrs	I
.	I
unless	O
relapse	O
risk	O
is	O
small	O
(	O
<	O
5	O
%	O
)	O
.	O

Current	O
use	O
of	O
systemic	B
steroids	I
>	B
20	I
mg	I
QD	I
prednisone	B
(	O
or	O
equivalent	O
)	O

Breastfeeding	O
or	O
pregnant	B
(	O
intention	O
to	O
become	O
)	O
females	B
or	O
participation	O
in	O
other	O
clinical	O
trials	O

Phase	O
1	O
Specific	O
Patient	O
at	B
least	I
18yrs	I
of	O
age	B
with	O
histologically	B
confirmed	B
CLL	B
/	O
SLL	B
or	O
B	B
-	I
cell	I
Non	I
-	I
Hodgkin	I
lymphoma	I
(	O
DLBCL	B
,	O
FL	B
,	O
MCL	B
,	O
MZL	B
,	O
lymphoplasmacytic	B
lymphoma	I
)	O
.	O

Phase	O
2a	O
Inclusion	O

Histological	B
evidence	O
:	O
FL	B
Grade	B
1	B
-	I
3A	I
/	O
iNHL	B
,	O
with	O
relapsed	O
or	O
refractory	B
disease	I
(	O
iNHL	B
includes	O
LPL	B
/	O
WM	B
,	O
MZL	B
)	O
;	O
aNHL	B
,	O
defined	O
as	O
DLBCL	B
,	O
FL	B
Grade	B
3B	B
,	O
MCL	B
,	O
and	O
transformed	B
NHL	I
with	O
relapsed	B
disease	I
;	O
CLL	B
/	O
SLL	B
,	O
PTCL	B
,	O
or	O
CTCL	B
(	O
with	O
MF	B
/	O
SS	B
)	O
with	O
relapsed	O
or	O
refractory	O
.	O

Received	O
BCR	O
and	O
/	O
or	O
BCL2	B
inhibitors	I
were	O
intolerant	B
or	O
had	O
relapsed	B
/	O
refractory	B
disease	I
afterwards	B
.	O

Prior	B
treatment	B
for	O
lymphoid	B
malignancy	I
for	O
progressive	O
/	O
refractory	B
disease	I

≥	B
1	I
prior	I
regimen	I
(	O
min	B
2	I
cycles	I
)	O
with	O
antibody	B
conjugate	I
,	O
cytotoxic	B
chemotherapy	I
,	O
or	O
TKI	B
alone	O
or	O
in	O
combination	O
.	O

Measureable	B
disease	I
defined	O
as	O
:	O
≥	B
1	I
lesion	I
≥	B
1	I
.	I
5	I
cm	I
single	O
dimension	O
via	O
CT	B
,	O
CT	B
/	I
PET	I
with	O
nodal	O
or	O
mass	B
lesions	I
;	O
Quantifiable	O
circulating	B
tumor	I
cells	I
;	O
or	O
for	O
Waldenström	B
'	I
s	I
macroglobulinemia	I
presence	O
of	O
IgM	B
l	I
>	B
2X	I
ULN	I
;	O
For	O
CTCL	B
:	O
mSWAT	B
>	B
0	I

Ability	O
to	O
provide	O
diagnostic	O
reports	O

General	O
Inclusion	O

ECOG	B
Score	I
of	O
0	B
or	I
1	I
.	O

Hematologic	B
ANC	I
>	B
1000	I
/	I
uL	I
and	O
platelet	B
>	B
75	I
,	I
000	I
/	I
uL	I
,	O

Serum	B
creatinine	I
of	O
<	B
1	I
.	I
5	I
ULN	I
or	O
calculated	B
CrCl	I
of	O
>	B
50	I
mL	I
/	I
min	I

Bilirubin	B
<	B
20	I
.	I
0mg	I
/	I
dL	I
(	O
if	O
Gilberts	B
then	O
<	B
2	I
.	I
5	I
mg	I
/	I
dL	I
)	O
and	O
AST	B
/	I
AST	I
<	B
2	I
.	I
5	I
ULN	I

Inability	O
to	O
obtain	O
consent	O
from	O
patient	O
or	O
patients	O
kin	O

Pregnant	O
women	O

less	B
than	I
18	I
years	I
of	O
age	B
of	O
more	B
than	I
80	I
years	I
of	O
age	B

Hunt	B
Hess	I
Grade	I
5	B
SAH	B

Adult	B
patient	O
,	O
age	B
18	B
-	I
80	I
years	I
old	I
,	O
with	O
ruptured	B
aneurysm	I
(	O
s	O
)	O
who	O
experience	O
cerebral	B
vasospasm	I
post	B
operatively	I
within	I
3	I
-	I
21	I
days	I
.	O

History	O
of	O
ischaemic	B
heart	I
disease	I
,	O
cardiac	B
failure	I
,	O
cerebrovascular	B
disease	I
,	O
liver	B
impairment	I
(	O
ALT	B
/	O
AST	B
>	B
50IU	I
/	I
L	I
)	O
or	O
stage	B
3	B
-	I
5	I
chronic	B
kidney	I
disease	I
.	O

History	O
of	O
overdose	B
or	O
suicidal	B
ideation	I

Patients	O
weighing	B
<	B
55kgs	I
.	O

Patients	O
with	O
chronic	B
pain	I
requiring	B
treatment	I
,	O
with	O
a	O
known	B
allergy	I
to	O
paracetamol	B
,	O
or	O
concomitant	B
use	O
of	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatories	I
,	O
oral	B
anticoagulants	I
or	O
corticosteroids	B
.	O

=	B
18	I
years	B
old	I
,	O
men	B
or	O
post	B
-	I
menopausal	I
women	B
(	O
women	O
with	O
no	B
periods	I
for	B
12	I
months	I
or	I
more	I
,	O
or	O
those	O
who	O
have	O
had	O
a	O
surgical	B
menopause	B
)	O

Treated	B
hypertensive	B
patients	O
with	O
an	O
average	B
daytime	I
ambulatory	I
blood	I
pressure	I
measurement	I
(	I
ABPM	I
)	I
<	B
150	I
/	I
95mmHg	I
on	O
stable	B
doses	I
of	O
one	B
or	I
more	I
antihypertensive	B
medication	I
(	O
at	B
least	I
one	I
of	O
which	O
should	O
be	O
;	O
an	O
ACE	B
inhibitor	I
,	O
angiotensin	B
receptor	I
blocker	I
or	O
diuretic	B
)	O
for	B
3	I
months	I
,	O
or	O
untreated	B
hypertensive	B
patients	I
with	O
an	O
average	B
daytime	I
ABPM	I
=	B
135	I
/	I
85	I
but	I
<	I
150	I
/	I
95	I
.	O

DSM	B
-	I
IV	I
-	I
TR	I
substance	B
-	I
related	I
disorders	I
(	O
except	B
nicotine	B
)	O

significant	O
medical	O
or	O
neurological	O
conditions	O

mental	B
retardation	I
or	O
organic	B
brain	I
damage	I

DSM	B
-	I
IV	I
-	I
TR	I
major	B
depressive	I
disorder	I

aged	B
between	B
20	I
and	I
80	I

durg	B
-	O
naive	B
or	O
drug	B
-	O
free	B

Invasive	B
hepatocellular	B
carcinoma	I
without	B
any	O
isolated	B
tumor	I

Disease	O
needing	O
2	O
injections	O
of	O
Therasphere	O

Thrombosis	B
extending	B
into	I
the	I
porta	I
(	O
thrombosis	B
of	O
one	O
of	O
left	O
or	O
right	B
branch	I
authorized	B
)	O
,	O
extra	B
hepatic	I
metastasis	I

Previous	O
treatment	O
by	O
chemoembolization	B
,	O
radiofrequency	B
less	B
than	I
3	I
months	I
before	I
radioembolization	I

No	B
antiangiogenic	B
concomitant	I
treatment	I
,	O
15	O
days	O
before	O
and	O
15	B
days	I
after	I
radioembolization	I
,	O
including	O
Sorafenib	B

Associated	B
disease	I
which	O
could	B
prevent	I
patient	I
from	I
receiving	I
treatment	I

RMI	B
contre	O
-	O
indication	O
(	O
particle	O
or	O
metal	O
prosthesis	O
,	O
pacemaker	O
,	O
claustrophobia	O
)	O
or	O
contrast	O
product	O
contre	O
-	O
indication	O
(	O
allergy	O
)	O

Patient	O
already	O
participating	O
in	O
an	O
other	O
therapeutic	O
trial	O
with	O
an	O
experimental	O
drug	O

Pregnant	B
or	O
childbearing	B
potential	I
women	B
or	O
breastfeeding	O
women	B

minors	B
,	O
persons	O
deprived	O
of	O
liberty	O
or	O
protected	O
adults	O
(	O
maintenance	O
of	O
justice	O
,	O
guardianship	O
or	O
supervision	O
)	O
Unable	O
to	O
comply	O
with	O
trial	O
medical	O
follow	O
-	O
up	O
for	O
geographical	O
,	O
social	O
or	O
psychological	O
reasons	O

Unable	O
to	O
sign	O
an	O
informed	O
consent	O

Early	B
,	O
intermediate	B
,	O
advanced	B
,	O
non	B
metastatic	B
Hepatocellular	B
Carcinoma	I
.	O

Indication	O
for	O
radioembolization	B
validated	O
after	O
pluridisciplinary	O
committee	O
meeting	O
.	O

Isolated	O
target	O
on	O
initial	O
imagery	O
(	O
invasive	O
hepatocellular	O
carcinoma	O
excluded	O
)	O

WHO	B
(	I
World	I
Health	I
organization	I
)	I
Performance	I
status	I
:	O
0	B
,	I
1	I
or	I
2	I

If	O
cirrhosis	B
,	O
Child	O
A	B
score	O
with	O
total	B
bilirubin	I
less	B
than	I
30	I
micromoles	I
per	I
liter	I

Creatinine	B
clearance	I
more	B
or	I
equal	I
to	I
30	I
mL	I
/	I
min	I

Patient	O
informed	O
and	O
consent	O
signature	O
obtained	O

Use	O
of	O
any	O
investigational	B
or	O
non	B
-	I
registered	I
drug	B
or	O
vaccine	B
product	I
within	B
30	I
days	I
preceding	I
the	I
administration	I
of	I
the	I
study	I
vaccine	I
or	O
planned	O
use	O
within	B
the	I
first	I
six	I
weeks	I
of	I
the	I
study	I
period	I

Has	O
received	O
any	O
licensed	B
or	O
other	B
investigational	I
influenza	B
vaccine	I
within	B
3	I
months	I
prior	I
to	I
enrollment	I
in	I
this	I
study	I
or	O
expected	O
receipt	O
of	O
any	B
influenza	I
vaccination	I
before	B
the	I
Day	I
21	I
blood	O
collection	O

History	B
of	O
excessive	B
alcohol	I
use	I
,	O
drug	B
abuse	I
or	O
significant	B
psychiatric	B
illness	I

Tobacco	B
use	I
within	B
3	I
months	I
of	I
enrollment	I
and	O
throughout	B
first	I
6	I
months	I
of	I
the	I
study	I

Has	O
a	O
chronic	B
illness	I
(	O
e	O
.	O
g	O
.	O
,	O
liver	O
or	O
kidney	B
disease	I
)	O
,	O
receiving	O
a	O
concomitant	B
therapy	B
or	O
have	O
any	B
other	I
condition	I
that	O
could	B
interfere	I
with	I
the	I
subject	I
'	I
s	I
participation	I
in	I
the	I
study	I
or	O
in	O
the	O
interpretation	O
of	O
the	O
study	O
results	O

Clinically	B
significant	I
abnormal	B
liver	B
function	I
tests	I
at	B
screening	I

Positive	B
serology	O
for	O
HBsAg	O
,	O
HCV	O
or	O
HIV	B
antibodies	I

Pregnant	B
or	O
lactating	B
female	B

Having	O
cancer	B
or	O
have	O
received	O
treatment	O
for	O
cancer	B
within	B
three	I
years	I
(	O
persons	O
with	O
a	O
history	B
of	O
cancer	B
who	O
are	O
disease	B
-	I
free	I
without	B
treatment	B
for	B
three	I
years	I
or	I
more	I
are	O
eligible	O
)	O
,	O
excluding	O
minor	O
skin	O
cancers	O
,	O
which	O
are	O
allowed	O
unless	O
located	O
at	O
the	O
vaccination	O
site	O

Persons	O
with	O
impaired	B
immune	I
responsiveness	I
(	O
of	O
any	O
cause	O
)	O
,	O
including	O
diabetes	B
mellitus	I
and	O
autoimmune	B
disorders	I

Persons	O
presently	O
receiving	O
or	O
having	O
a	O
recent	O
history	O
of	O
receiving	O
(	O
within	B
the	I
past	I
six	I
months	I
)	O
any	B
medication	I
or	O
therapeutic	B
modality	I
that	O
affects	B
the	I
immune	I
system	I
such	O
as	O
allergy	B
shots	I
,	O
immune	B
globulin	I
,	O
interferon	B
,	O
immunomodulators	B
,	O
radiation	B
therapy	I
,	O
cytotoxic	B
drugs	I
or	O
drugs	O
known	B
to	I
be	I
frequently	I
associated	I
with	I
significant	I
major	I
organ	I
toxicity	I
,	O
or	O
systemic	B
corticosteroids	I
(	O
oral	B
or	O
injectable	B
)	O
.	O

Inhaled	O
and	O
topical	O
corticosteroids	O
are	O
allowed	O
.	O

Persons	O
with	O
a	O
history	B
of	O
severe	B
allergic	B
reaction	I
after	B
previous	I
vaccinations	I
or	O
hypersensitivity	O
to	O
any	O
seasonal	B
influenza	I
vaccine	I
component	I

Persons	O
with	O
a	O
history	O
of	O
Guillain	B
-	I
Barré	I
Syndrome	I

Receipt	B
of	I
blood	I
or	O
blood	O
products	O
8	B
weeks	I
prior	I
to	I
vaccination	I
or	O
planned	O
administration	O
during	B
the	I
three	I
week	I
study	I
period	I
following	I
vaccination	I

Donation	B
of	I
blood	I
or	O
blood	O
products	O
within	B
8	I
weeks	I
prior	I
to	I
vaccination	I
or	O
during	B
the	I
three	I
week	I
study	I
period	I
following	O

An	O
oral	B
temperature	I
>	B
100	I
.	I
4	I
°	I
or	O
acute	B
disease	I
within	B
72	I
hours	I
prior	I
to	I
vaccination	I
,	O
defined	O
as	O
the	O
presence	O
of	O
a	O
moderate	O
or	O
severe	B
illness	I
(	O
as	O
determined	O
by	O
the	O
investigator	O
through	O
medical	O
history	O
and	O
physical	O
examination	O
;	O
for	O
example	O
,	O
those	O
requiring	O
an	O
absence	O
from	O
work	O
)	O
with	O
or	O
without	O
fever	O
.	O

Body	B
Mass	I
Index	I
>	B
29	I
.	I
9	I

Any	O
disorder	B
of	I
coagulation	I

A	O
clinical	O
diagnosis	O
of	O
influenza	B
within	B
the	I
previous	I
12	I
months	I

Any	O
other	O
condition	O
or	O
circumstance	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Principal	O
Investigator	O
,	O
poses	O
an	O
unacceptable	O
risk	O
for	O
participation	O
in	O
the	O
study	O

Males	B
and	O
females	B
aged	B
18	B
-	I
40	I
years	I
of	O
age	B
at	B
the	I
time	I
of	I
vaccination	I
in	O
good	B
health	I
as	O
determined	O
by	O
medical	B
history	I
,	O
physical	B
exam	I
,	O
laboratory	B
assessments	I
and	O
the	O
clinical	O
judgment	O
of	O
the	O
Principal	O
Investigator	O

Able	O
to	O
provide	O
informed	O
consent	O
indicating	O
that	O
they	O
understand	O
the	O
purpose	O
of	O
this	O
study	O
and	O
are	O
willing	O
to	O
adhere	O
to	O
the	O
procedures	O
described	O
in	O
this	O
protocol	O

If	O
the	O
subject	O
is	O
a	O
female	O
of	O
childbearing	O
potential	O
,	O
she	O
must	O
use	O
adequate	O
contraceptive	O
precautions	O
(	O
e	O
.	O
g	O
.	O
,	O
intrauterine	O
contraceptive	O
device	O
,	O
oral	O
contraceptives	O
or	O
other	O
equivalent	O
hormonal	O
contraception	O
)	O
for	O
2	O
months	O
prior	O
to	O
vaccination	O
and	O
continue	O
to	O
use	O
such	O
precautions	O
for	O
a	O
minimum	O
of	O
three	O
months	O
after	O
vaccination	O
.	O
She	O
must	O
also	O
have	O
a	O
negative	O
urine	O
pregnancy	O
test	O
within	O
24	O
hours	O
prior	O
to	O
receiving	O
study	O
vaccine	O
.	O
Women	O
at	O
least	O
one	O
year	O
post	O
-	O
menopausal	O
or	O
surgically	O
sterile	O
will	O
not	O
be	O
considered	O
of	O
childbearing	O
potential	O
.	O

Willing	O
to	O
receive	O
the	O
unlicensed	O
vaccine	B
given	O
as	O
an	O
IM	B
injection	I

Willing	O
to	O
provide	O
multiple	O
blood	O
specimens	O
collected	O
by	O
venipuncture	O

Cases	O
of	O
rectal	B
tumours	I
below	B
12cm	I
from	I
anal	I
verge	I
,	O
or	O
locally	B
advanced	I
tumours	I
invading	B
blood	I
vessels	I
,	O
nerves	O
or	O
bone	O
.	O

Multiple	B
bone	I
metastasis	I
or	O
central	B
nervous	I
system	I
metastasis	I

Other	B
neoplastic	B
disease	I
in	B
the	I
5	I
previous	I
years	I
,	O
except	B
squamous	O
or	O
basal	B
cell	I
skin	I
carcinoma	I
or	O
cervical	B
"	I
in	I
situ	I
"	I
carcinoma	I

Significant	B
heart	B
disease	I
(	O
chronic	B
congestive	I
heart	I
failure	I
,	O
symptomatic	B
coronary	I
disease	I
)	O
or	O
myocardial	B
infarction	I
in	B
the	I
previous	I
6	I
months	I

Peripheral	B
neuropathy	I

Patients	O
who	O
do	O
not	O
give	O
informed	O
consent	O

colorectal	B
cancer	I
above	B
to	I
12	I
cm	I
from	I
the	I
anal	I
verge	I

unresectable	B
synchronous	B
metastases	B

no	B
contraindications	B
for	O
chemotherapy	B

absence	B
of	O
peritoneal	B
carcinomatosis	I
,	O
central	O
nervous	O
system	O
o	O
bone	B
metastasis	I
.	O

performance	B
status	I
ECOG	B
=	B
2	I
(	O
Eastern	B
Cooperative	I
Oncology	I
Group	I
)	O

uncontrolled	B
concomitant	B
medical	B
conditions	I
that	I
may	I
compromise	I
to	I
chemotherapy	I

significant	B
symptomatic	B
cardiac	B
disease	I

not	B
pregnancy	B
or	O
breastfeeding	O

Children	O
who	O
are	O
uncooperative	B
and	O
difficult	O
to	O
manage	O
,	O
have	O
major	B
systemic	B
diseases	I
,	O
or	O
are	O
on	O
long	B
-	I
term	I
medication	B
will	O
be	O
excluded	O
.	O

Kindergarteners	B
who	O
have	O
joined	O
our	O
outreach	O
dental	O
service	O
will	O
be	O
invited	O
to	O
join	O
this	O
study	O
.	O

Preschool	B
children	I
aged	B
3	B
-	I
4	I
years	I
who	O
have	O
tooth	B
decay	I
and	O
are	O
attending	O
the	O
first	O
year	O
of	O
kindergarten	O
will	O
be	O
invited	O
to	O
join	O
this	O
study	O
.	O

1	O
.	O

Currently	O
enrolled	O
in	O
another	O
research	O
trial	O
for	O
investigative	O
nutritional	O
or	O
other	O
therapies	O
thought	O
to	O
have	O
an	O
impact	O
on	O
immune	O
system	O
functioning	O
.	O

2	O
.	O

Unable	O
to	O
consent	O
to	O
the	O
study	O
.	O

3	O
.	O

Women	B
who	O
are	O
pregnant	B
or	O
are	O
attempting	O
conception	O
,	O
especially	O
in	O
the	O
presence	O
of	O
a	O
history	O
of	O
recurrent	B
spontaneous	B
abortion	I
.	O

4	O
.	O

Other	B
medical	B
complications	I
that	O
might	O
preclude	B
one	O
from	O
participating	O
in	O
the	O
study	O
,	O
i	O
.	O
e	O
.	O
,	O
recent	B
heart	B
attack	I
or	O
stroke	B
or	O
chronic	B
kidney	I
disease	I
.	O

5	O
.	O

Currently	O
taking	O
immunomodulatory	B
medication	I
,	O
i	O
.	O
e	O
.	O
interferon	B
.	O

6	O
.	O

Currently	B
taking	O
other	B
medications	B
thought	O
to	O
have	O
an	O
impact	B
on	I
immune	I
system	I
functioning	I
,	O
i	O
.	O
e	O
.	O
,	O
chemotherapeutic	B
agents	I
.	O

7	O
.	O

Known	O
allergy	O
to	O
rice	B
,	O
rice	B
bran	I
,	O
or	O
related	O
food	O
products	O
.	O

8	O
.	O

Known	O
allergy	B
to	I
mushrooms	I
or	O
related	O
food	O
products	O
.	O

9	O
.	O

History	B
of	O
malignancies	B
related	B
to	I
the	I
NK	I
cell	I
line	I
,	O
including	O
:	O
NK	B
cell	I
leukemias	I
and	O
T	B
-	I
cell	I
large	I
granular	I
lymphocyte	I
leukemias	I
,	O
NK	B
-	I
cell	I
lymphoproliferative	I
disease	I
of	I
granular	I
lymphocytes	I
,	O
and	O
NK	B
cell	I
lymphomas	I
,	O
e	O
.	O
g	O
.	O
,	O
nasal	O
and	O
nasal	B
-	I
like	I
NK	I
/	I
T	I
-	I
cell	I
lymphomas	I
.	O

10	O
.	O

Current	B
smoker	O
.	O

1	O
.	O

Women	B
and	O
men	B
ages	B
18	B
years	I
and	I
over	I
.	O

2	O
.	O

Interest	O
in	O
participating	O
in	O
a	O
novel	O
nutritional	O
supplement	O
program	O
.	O

3	O
.	O

Willingness	O
to	O
follow	O
recommendations	O
.	O

Having	O
significant	O
medical	O
illnesses	O
that	O
would	O
interfere	O
with	O
the	O
conduct	O
of	O
the	O
study	O

Clinically	O
significant	O
abnormal	O
laboratory	O
finding	O

Having	O
comorbid	B
psychiatric	B
conditions	I
according	O
to	O
the	O
criteria	O
set	O
forth	O
in	O
the	O
DSM	B
-	I
IV	I
(	O
administered	O
by	O
the	O
Mini	O
-	O
International	O
Neuropsychiatric	O
Interview	O
(	O
MINI	O
)	O
)	O

The	O
current	O
OCD	B
symptoms	I
are	O
too	O
severe	B
that	O
the	O
patient	O
cannot	O
finish	O
the	O
evaluation	O
or	O
receive	O
the	O
ERP	O

Being	O
currently	O
at	O
risk	O
for	O
suicide	O

Being	O
pregnant	O
or	O
having	O
the	O
intention	O
to	O
be	O
pregnant	O
before	O
the	O
end	O
of	O
the	O
study	O

A	O
history	O
of	O
having	O
inadequate	B
response	B
to	O
adequate	O
SSRIs	B
or	O
CBT	B
treatment	O

Subjects	O
who	O
are	O
unable	O
to	O
undergo	O
the	O
MRI	B

Having	O
been	O
diagnosed	O
with	O
primary	B
OCD	I
as	O
defined	O
by	O
the	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
(	O
DSM	B
-	I
IV	I
-	O
)	O
criteria	O
;	O
Cleaning	O
or	O
checking	O
as	O
primary	O
OCD	O
symptoms	O

Yale	B
-	I
Brown	I
Obsessive	I
-	I
Compulsive	I
Scale	I
(	O
Y	B
-	I
BOCS	I
)	O
score	B
of	I
=	I
16	I

Never	B
receiving	O
adequate	B
treatment	B
or	O
stop	B
receiving	O
treatment	B
for	B
at	I
least	I
8	I
weeks	I

Having	O
an	O
education	O
degree	B
of	I
high	I
school	I
or	O
above	O

Accepting	O
to	O
participate	O
in	O
the	O
study	O

Any	O
intraocular	B
inflammation	I
in	O
the	O
study	O
eye	O
present	O
during	O
the	O
screening	O
slit	B
lamp	I
examination	I

Score	O
greater	B
than	I
"	I
0	I
"	I
on	O
the	O
Ocular	B
Pain	I
Assessment	I
in	O
the	O
study	O
eye	O
at	B
Screening	I

Any	O
intraocular	B
inflammation	I
in	O
the	O
study	O
eye	O
present	O
during	O
the	O
screening	O
slit	B
lamp	I
examination	I

Has	O
a	O
cataract	B
and	O
is	O
expected	O
to	O
undergo	O
clear	B
corneal	I
cataract	I
surgery	I
with	B
phacoemulsification	I
and	O
implantation	B
of	I
a	I
posterior	I
chamber	I
intraocular	I
lens	I

Has	O
a	O
potential	O
post	O
-	O
operative	O
pinhole	B
corrected	I
Snellen	I
VA	I
of	O
at	B
least	I
20	I
/	I
200	I
or	I
better	I
in	O
both	B
eyes	I

Patients	O
not	O
capable	O
or	O
willing	O
to	O
provide	O
informed	O
consent	O

Patients	O
starting	O
Adalimumab	B
less	O
than	O
five	O
half	O
-	O
lives	O
after	O
the	O
interruption	O
of	O
a	O
previous	B
anti	B
-	I
TNF	I
therapy	I
.	O

Patients	O
aged	B
of	O
18	B
and	I
over	I
,	O

Satisfying	O
the	O
1987	B
American	I
College	I
of	I
Rheumatology	I
(	I
ACR	I
)	I
criteria	I
for	O
RA	B

Receiving	O
a	O
prescription	O
of	O
Adalimumab	B
40	O
mg	O
subcutaneous	B
every	O
two	O
weeks	O
.	O

preexisting	O
pectoral	O
,	O
axillar	O
,	O
thoracic	O
homolateral	B
pain	O

habitual	B
opioid	O
consumption	O
;	O

drug	O
-	O
alcoholics	B
addiction	I
;	O

ICU	O
postoperative	O
recovery	O
;	O

kidney	B
failure	I
(	O
creatinin	B
>	B
2	I
g	I
/	I
dl	I
,	O
creatinin	B
<	I
clearance	I
30	B
ml	I
/	I
h	I
)	O
and	O
/	O
or	O
hepatic	B
failure	I
(	O
cholinesterase	B
<	B
2000	I
UI	I
)	O
;	O

cardiac	B
arrhythmias	I
o	O
;	O

Epilepsy	B
;	O

Psychiatric	B
,	I
cognitive	I
disorders	I
,	O
mental	B
retardation	I
;	O

Coagulopathies	B
(	O
INR	B
>	B
2	I
,	O
activated	B
partial	I
thromboplastin	I
time	I
-	I
aPTT	I
>	B
44	I
sec	I
)	O
;	O

platelet	B
count	I
less	B
than	I
100	I
.	I
000	I
/	I
mm3	I
;	O

BMI	B
>	B
30	I
;	O

Allergies	B
to	O
study	B
drugs	I
.	O

F	B
;	O
age	B
18	B
to	I
70	I

American	B
Society	I
of	I
Anesthesiologists	I
(	I
ASA	I
)	I
I	B
e	I
II	I
;	O

breast	B
cancer	I
(	O
DIN	B
2	B
e	I
3	I
,	O
o	O
LIN	B
2	B
e	I
3	I
sec	I
.	O
Tavassoli	O
)	O
scheduled	O
for	O
nipple	B
-	I
sparing	I
mastectomy	I
,	O
simple	B
mastectomy	I
,	O
skin	B
-	I
sparing	I
mastectomy	I
,	O
skin	B
-	I
reducing	I
mastectomy	I
c	O
,	O
lymphnode	B
biopsy	I
and	O
axillary	B
dissection	I
;	O

immediate	B
sub	B
-	I
pectoral	I
prosthetic	I
reconstruction	I
;	O

signed	O
informed	O
consent	O
.	O

Thalassemia	B
syndromes	I
;	O

Myelodysplastic	B
syndrome	I
(	I
MDS	I
)	I
or	O
myelofibrosis	B
;	O

Diamond	B
Blackfan	I
anemia	I
;	O

Primary	B
bone	I
marrow	I
failure	I
;	O

Baseline	B
LIC	B
>	B
30	I
mg	I
/	I
g	I
dw	O
(	O
measured	O
by	O
MRI	B
)	O
;	O

Unable	O
or	O
unwilling	O
to	O
undergo	O
a	O
7	O
day	O
washout	O
period	O
if	O
currently	O
being	O
treated	O
with	O
deferiprone	O
or	O
deferoxamine	O
or	O
deferasirox	O
;	O

Previous	O
discontinuation	B
of	I
treatment	I
with	O
deferiprone	B
or	O
deferoxamine	B
due	O
to	O
adverse	O
events	O
;	O

History	O
or	O
presence	O
of	O
hypersensitivity	B
or	O
idiosyncratic	B
reaction	I
to	O
deferiprone	B
or	O
deferoxamine	B
;	O

Treated	O
with	O
hydroxyurea	B
within	B
30	I
days	I
;	O

History	O
of	O
malignancy	B
;	O

Evidence	O
of	O
abnormal	B
liver	B
function	I
(	O
serum	B
ALT	I
level	I
(	I
s	I
)	I
>	B
5	I
times	I
upper	I
limit	I
of	I
normal	I
at	B
screening	I
or	O
creatinine	B
levels	I
>	B
2	I
times	I
upper	I
limit	I
of	I
normal	I
at	B
screening	I
)	O
;	O

A	O
serious	B
,	O
unstable	B
illness	I
,	O
as	B
judged	I
by	I
the	I
Investigator	I
,	O
during	B
the	I
past	I
3	I
months	I
before	I
screening	I
/	I
baseline	I
visit	I
including	O
but	O
not	O
limited	O
to	O
:	O
hepatic	O
,	O
renal	O
,	O
gastro	O
-	O
enterologic	O
,	O
respiratory	O
,	O
cardiovascular	O
,	O
endocrinologic	O
,	O
neurologic	O
or	O
immunologic	B
disease	I
;	O

Clinically	B
significant	I
abnormal	B
12	B
-	I
lead	I
ECG	I
findings	B
;	O

Cardiac	B
MRI	I
T2	I
*	I
<	B
10ms	I
;	O

Myocardial	B
infarction	I
,	O
cardiac	B
arrest	I
or	O
cardiac	B
failure	I
within	B
1	I
year	I
before	I
screening	I
/	I
baseline	I
visit	I
;	O

Unable	B
to	I
undergo	I
MRI	B

Presence	O
of	O
metallic	O
objects	O
such	O
as	O
artificial	O
joints	O
,	O
inner	O
ear	O
(	O
cochlear	O
)	O
implants	O
,	O
brain	O
aneurysm	O
clips	O
,	O
pacemakers	O
,	O
and	O
metallic	O
foreign	O
bodies	O
in	O
the	O
eye	O
or	O
other	O
body	O
areas	O
that	O
would	O
prevent	O
use	O
of	O
MRI	O
imaging	O

Male	B
or	O
female	B
=	B
2	I
years	I
of	O
age	B
;	O

Have	O
sickle	B
cell	I
disease	I
(	O
confirmed	O
by	O
Hb	B
electrophoresis	I
or	O
more	B
specific	I
tests	I
)	O
or	O
other	B
conditions	I
with	I
iron	I
overload	I
from	O
repeated	B
blood	B
transfusions	I
(	O
see	O
exclusion	O
criteria	O
for	O
exceptions	O
)	O
;	O

Baseline	B
LIC	I
>	B
7	I
mg	I
/	I
g	I
dw	O
(	O
measured	O
by	O
MRI	B
)	O
;	O

Patients	O
who	O
have	O
received	O
no	B
less	I
than	I
20	I
transfusions	B
of	I
RBCs	I
;	O

Patients	O
who	O
have	O
received	O
at	O
least	O
1	O
transfusion	B
per	O
year	O
in	B
the	I
last	I
2	I
years	I
and	O
who	O
are	O
expected	B
to	I
have	I
a	I
continuing	I
requirement	I
(	O
based	O
on	O
Investigator	O
'	O
s	O
judgement	O
)	O
during	B
the	I
duration	I
of	I
the	I
trial	I

NA	O

>	O
18	B
years	I
old	B

Acute	B
symptomatic	B
BV	B

Signed	O
informed	O
consent	O

Insufficient	O
knowledge	O
of	O
German	O

Illiteracy	O

Pregnancy	B

Acute	B
illness	I

Known	O
allergies	B
against	O
ingredients	B
of	I
the	I
investigational	I
products	I

Pregnancy	B

Patients	O
with	O
chronic	B
kidney	I
disease	I
stage	O
with	O
eGFR	B
<	B
30	I
ml	I
/	I
min	I
(	O
CKD	B
stage	B
IV	I
and	O
V	O
)	O

Nephrotic	B
range	I
proteinuria	B
(	O
urinary	B
protein	I
>	B
3	I
.	I
5	I
gm	I
/	I
day	I
)	O

History	B
or	O
renal	B
transplantation	I

History	B
of	O
multiple	B
myeloma	I

Known	O
history	B
of	O
hypersensitivity	B
reaction	I
or	O
intolerability	B
to	O
Ace	B
Inh	I
or	O
ARB	B
.	O

Type	B
2	I
Diabetes	I

Hypertension	B

Estimated	B
glomerular	I
filtration	I
rate	I
(	I
eGFR	I
)	I
>	B
30	I
ml	I
/	I
min	I

Use	O
of	O
Ace	B
Inh	I
and	O
ARB	B
for	O
control	B
of	I
blood	I
pressure	I
who	O
are	O
willing	O
to	O
be	O
placed	O
on	O
alternate	O
drug	O
(	O
s	O
)	O
in	O
the	O
washout	O
period	O
for	O
blood	O
pressure	O
control	O

Other	O
causes	O
of	O
heart	B
failure	I
other	B
than	I
diastolic	B
dysfunction	I
,	O
such	O
as	O
restrictive	B
cardiomyopathy	I
or	O
infiltrative	B
cardiomyopathy	I

Women	B
who	O
are	O
pregnant	B
or	O
nursing	B

Liver	B
cirrhosis	I
,	O

Primary	B
valvular	I
disease	I

Acute	B
coronary	I
syndrome	I

Causes	B
of	I
PH	I
other	B
than	I
that	O
of	O
heart	B
failure	I
,	O
such	O
as	O
:	O
chronic	B
thromboembolic	I
PH	I
,	O
sickle	B
-	I
cell	I
disease	I
,	O
or	O
sarcoidosis	B

Severe	B
bradycardia	B
or	O
greater	B
than	I
1st	I
degree	I
heart	B
block	I

Decompensated	B
heart	B
failure	I

Current	O
use	O
of	O
a	O
third	B
generation	I
beta	I
-	I
blocker	I
(	O
nebivolol	B
,	O
carvedilol	B
,	O
or	O
labetalol	B
)	O
or	O
high	B
dose	I
of	O
any	B
beta	I
-	I
blockers	I
(	O
greater	B
than	I
100	I
mg	I
daily	I
of	O
metoprolol	B
,	O
or	O
equivalent	O
)	O

Adults	B
(	O
=	B
18	I
years	I
of	O
age	B
)	O
with	O
World	B
Health	I
Organization	I
Group	I
2	I
Pulmonary	B
Hypertension	I
(	B
Mean	I
pulmonary	I
artery	I
pressure	I
=	B
25	I
mmHg	I
and	O
pulmonary	B
capillary	I
wedge	I
pressure	I
=	B
15	I
mmHg	I
)	O

New	B
York	I
Heart	I
Association	I
class	B
II	I
-	I
IV	I
symptoms	B

Left	B
ventricular	I
ejection	I
fraction	I
(	I
LVEF	I
)	I
=	B
45	I
%	I

Conversion	O
from	O
laparoscopic	O
to	O
open	O
surgery	O

History	B
of	O
Chronic	B
pain	I
or	O
ongoing	B
treatment	B
for	O
chronic	B
pain	I

Age	B
less	B
than	I
18	I
yrs	I

Allergy	B
to	O
local	B
anesthetics	I

Age	B
18	B
or	I
older	I
with	O
unilateral	B
or	O
bilateral	B
inguinal	B
herna	I
for	O
laparoscopic	B
repair	I

American	B
Society	I
of	I
Anesthesiology	I
(	I
ASA	I
)	I
Class	I
I	B
and	I
II	I

Pulseless	B
extremity	I

Compromised	B
neurologic	I
status	I
on	O
exam	O
(	O
specifically	O
assessment	O
of	O
radial	O
,	O
ulnar	O
,	O
and	O
median	B
nerve	I
)	O

Known	O
allergy	B
to	O
local	B
anesthetics	I
(	O
7	O
)	O
Not	B
scheduled	O
for	O
closed	B
reduction	I
with	I
percutaneous	I
pinning	I
under	O
general	B
anesthesia	I

Bleeding	B
diathesis	I

American	B
Society	I
of	I
Anesthesiologist	I
(	I
ASA	I
)	I
status	I
4	B
or	I
higher	I
.	O

Sleep	B
apnea	I
by	O
polysomnography	B

Supracondylar	B
fracture	I

Age	B
2	B
-	I
17	I
years	I

American	B
Society	I
of	I
Anesthesiologists	I
Status	I
1	B
-	I
3	I

Scheduled	O
for	O
closed	B
reduction	I
with	I
percutaneous	I
pinning	I
under	O
general	B
anesthesia	I

1	O
)	O
Refusal	O
of	O
epidural	B
catheter	I
2	O
)	O
Pregnancy	B
3	O
)	O
Bleeding	B
History	B
4	O
)	O
Inability	O
to	O
understand	O
how	O
to	O
use	O
the	O
PCA	O
device	O
5	O
)	O
Medication	B
interfering	B
with	I
blood	I
coagulation	I
6	O
)	O
Patients	O
allergic	B
to	O
local	B
anesthetics	I
7	O
)	O
Patient	O
refusal	O
to	O
participate	O
in	O
study	O
8	O
)	O
Developmental	B
delay	I

Patients	O
age	B
8	B
-	I
18	I
years	I
2	O
)	O
Patients	O
undergoing	O
minimally	B
invasive	I
pectus	I
excavatum	I
repair	I
via	O
Nuss	B
procedure	I
3	O
)	O
American	B
Society	I
of	I
Anesthesiology	I
Status	I
I	B
-	I
III	I

abnormal	B
renal	I
function	I

currently	B
pregnant	B
,	O
or	O
trying	O
to	O
become	O
pregnant	B

being	O
treated	B
with	O
a	O
beta	B
-	I
blocker	I

use	O
of	O
illicit	B
drugs	I

systolic	B
blood	I
pressure	I
between	B
140	I
-	I
160	I
mmHG	I

between	B
18	I
-	I
80	I
years	I
old	B

The	O
patients	O
have	O
other	B
cancers	I
at	B
the	I
same	I
time	I
or	O
have	O
the	O
history	O
of	O
other	B
cancers	I
except	B
controlled	B
skin	I
basal	I
cell	I
carcinoma	I
or	O
skin	B
squamous	I
cell	I
carcinoma	I
or	O
carcinoma	B
in	I
situ	I
of	I
cervix	I
uterus	I
;	O

The	O
patients	O
have	O
active	B
infections	B
that	O
were	O
not	B
suitable	B
for	I
chemotherapy	I
;	O

The	O
patients	O
have	O
severe	B
non	B
-	I
cancerous	I
diseases	I
.	O

The	O
patients	O
have	O
history	O
of	O
neoadjuvant	B
hormone	I
therapy	I
.	O

The	O
patients	O
have	O
bilateral	B
breast	I
cancers	I
or	O
DCIS	B
or	O
metastatic	B
breast	I
cancers	I
.	O

The	O
patients	O
are	O
undergoing	O
current	O
administration	O
of	O
anti	B
-	I
cancer	I
therapies	I
,	O
or	O
are	O
attending	O
other	O
clinical	O
trials	O
.	O

The	O
patients	O
are	O
pregnant	B
or	O
lactational	B
,	O
or	O
they	O
refuse	B
to	I
practice	I
contraception	B
during	B
the	I
whole	I
trial	I
.	O

The	O
patients	O
are	O
in	O
some	O
special	O
conditions	O
that	O
they	O
can	O
'	O
t	O
understand	O
the	O
written	O
informed	O
consent	O
,	O
such	O
as	O
they	O
are	O
demented	O
or	O
hawkish	O
.	O

The	O
patients	O
have	O
allergic	B
history	O
or	O
contraindication	B
of	O
tamoxifen	B
.	O

The	O
patients	O
signed	O
the	O
written	O
informed	O
consent	O

The	O
patients	O
present	O
with	O
operable	B
unilateral	B
invasive	B
breast	B
cancers	I
without	B
distant	B
metastasis	I
(	O
stage	B
I	B
,	I
II	I
,	I
and	I
III	I
)	O

The	O
breast	B
tumor	I
'	O
s	O
positive	B
ER	I
/	I
PR	I
rate	I
is	O
<	B
1	I
%	I
,	O
and	O
positive	B
ER	I
-	I
beta1	I
rate	I
is	O
=	B
10	I
%	I
by	O
IHC	B
.	O

The	O
patients	O
have	O
no	B
history	I
of	O
neoadjuvant	B
hormone	I
therapy	I
.	O

The	O
patients	O
have	O
normal	B
cardiac	I
functions	I
by	O
echocardiography	B
.	O

The	O
patients	O
'	O
ECOG	B
scores	I
are	O
=	B
0	I
-	I
2	I
.	O

Female	B
patient	O
who	O
is	O
=	B
18yrs	I
,	O
and	O
=	B
65yrs	I
.	O

The	O
patients	O
are	O
non	O
-	O
pregnant	O
,	O
and	O
disposed	O
to	O
practice	O
contraception	O
during	O
the	O
whole	O
trial	O
.	O

The	O
patients	O
underwent	O
neoadjuvant	B
chemotherapy	I
plus	O
surgery	B
or	O
directly	B
modified	I
radical	B
mastectomy	I
or	O
breast	B
-	I
conserving	I
surgery	I
(	O
plus	O
sentinel	B
lymph	I
node	I
biopsy	I
or	O
axillary	B
lymph	I
node	I
dissection	I
)	O
after	B
diagnosis	I
of	I
breast	I
cancer	I
.	O

The	O
patients	O
underwent	O
chemotherapy	B
,	O
radiation	B
therapy	I
or	O
targeted	B
therapy	I
(	O
herceptin	B
)	O
after	O
surgery	B
according	O
to	O
the	O
2013	B
NCCN	I
guideline	I
.	O

The	O
results	O
of	O
patients	O
'	O
blood	O
tests	O
are	O
as	O
follows	O
:	O

Evidence	O
of	O
decompensated	B
liver	B
disease	I
(	O
Childs	B
B	B
-	I
C	I
)	O
,	O
hepato	B
-	I
cellular	I
carcinoma	I
,	O
pre	B
-	I
existing	I
severe	B
depression	B
or	O
other	B
psychiatric	B
disease	I
,	O
significant	B
cardiac	B
disease	I
,	O
significant	B
renal	B
disease	I
,	O
seizure	B
disorders	I
or	O
severe	B
retinopathy	B
.	O

received	O
telbivudine	B
as	O
the	O
antiviral	B
therapy	I
or	O
have	O
received	O
more	B
than	I
one	I
NA	B
in	B
the	I
past	I
.	O

received	O
interferon	B
or	O
peginterferon	B
treatment	B
in	B
the	I
past	I
.	O

received	O
antiviral	B
therapy	I
for	O
any	O
systemic	B
anti	I
-	I
viral	I
,	O
anti	O
-	O
neoplastic	O
or	O
immuno	B
-	I
modulatory	I
treatment	I
(	O
including	O
supraphysiologic	B
doses	I
of	O
steroids	B
and	O
radiation	B
)	O
within	B
the	I
past	I
6	I
months	I
.	O

Positive	B
test	O
at	B
screening	I
for	O
anti	O
-	O
HIV	O
,	O
anti	O
-	O
HCV	O
.	O

Patients	O
who	O
are	O
expected	O
to	O
need	O
systemic	B
antiviral	I
therapy	I
other	O
than	O
that	O
provided	O
by	O
the	O
study	O
at	B
any	I
time	I
during	I
their	I
participation	I
in	I
the	I
study	I
are	O
also	O
excluded	O
.	O

Exception	B
:	O
patients	O
who	O
have	O
had	O
a	O
limited	O
(	O
<	B
=	I
7	I
days	I
)	O
course	O
of	O
acyclovir	B
for	O
herpetic	B
lesions	I
more	B
than	I
1	I
month	I
prior	I
to	I
the	I
first	I
administration	I
of	I
test	I
drug	I
are	O
not	O
excluded	O
.	O

Serum	B
total	I
bilirubin	I
>	B
3	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
at	B
screening	I
.	O

History	O
or	O
other	O
evidence	O
of	O
bleeding	B
from	O
esophageal	B
varices	I
or	O
other	B
conditions	B
consistent	I
with	I
decompensated	I
liver	I
disease	I
.	O

History	O
or	O
other	O
evidence	O
of	O
a	O
medical	B
condition	I
associated	O
with	O
chronic	B
liver	I
disease	I
other	B
than	I
HBV	B
(	O
e	O
.	O
g	O
.	O
,	O
hemochromatosis	B
,	O
autoimmune	B
hepatitis	I
,	O
metabolic	B
liver	I
diseases	I
including	O
Wilson	B
'	I
s	I
and	O
alpha1	B
-	I
antitrypsin	I
deficiency	I
,	O
alcoholic	B
liver	I
disease	I
,	O
toxin	B
exposures	I
,	O
thalassemia	B
)	O
.	O

Women	B
with	O
ongoing	B
pregnancy	B
or	O
who	O
are	O
breast	O
feeding	O
.	O

Neutrophil	B
count	I
<	B
1500	I
cells	I
/	I
mm3	I
or	O
platelet	B
count	I
<	B
90	I
,	I
000	I
cells	I
/	I
mm3	I
at	B
screening	I
.	O

Hemoglobin	B
<	B
11	I
.	I
5	I
g	I
/	I
dL	I
for	O
females	B
and	O
<	B
12	I
.	I
5	I
g	I
/	I
dL	I
for	O
men	B
at	B
screening	I
.	O

Serum	B
creatinine	I
level	I
>	B
120	I
umol	I
/	I
ml	I
for	O
men	B
and	O
>	B
105	I
umol	I
/	I
ml	I
for	O
women	B
at	B
screening	I
.	O

History	O
of	O
severe	B
psychiatric	B
disease	I
,	O
especially	O
depression	B
.	O

Severe	B
psychiatric	B
disease	I
is	O
defined	O
as	O
major	B
depression	I
or	O
psychosis	B
,	O
a	O
period	O
of	O
treatment	B
with	O
an	O
antidepressant	B
medication	I
or	O
major	B
tranquilizer	I
at	O
therapeutic	B
doses	I
for	O
depression	B
or	O
psychosis	B
for	B
at	I
least	I
3	I
months	I
,	O
a	O
suicidal	B
attempt	I
,	O
hospitalization	B
for	O
psychiatric	B
disease	I
,	O
or	O
a	O
period	O
of	O
disability	B
due	O
to	O
a	O
psychiatric	B
disease	I
.	O

History	O
of	O
immunologically	B
mediated	I
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
inflammatory	B
bowel	I
disease	I
,	O
idiopathic	B
thrombocytopenic	I
purpura	I
,	O
lupus	B
erythematosus	I
,	O
autoimmune	B
hemolytic	I
anemia	I
,	O
scleroderma	B
,	O
severe	B
psoriasis	B
,	O
rheumatoid	B
arthritis	I
)	O
.	O

History	O
or	O
other	O
evidence	O
of	O
chronic	B
pulmonary	I
disease	I
associated	O
with	O
functional	B
limitation	I
.	O

Severe	B
cardiac	B
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
NYHA	B
Functional	B
Class	I
III	I
or	I
IV	I
,	O
myocardial	B
infarction	I
within	B
6	I
months	I
,	O
ventricular	B
tachyarrhythmias	I
requiring	O
ongoing	B
treatment	B
,	O
unstable	B
angina	I
or	O
other	B
significant	B
cardiovascular	B
diseases	I
)	O
.	O

History	O
of	O
a	O
severe	B
seizure	B
disorder	I
or	O
current	B
anticonvulsant	B
use	O
.	O

Evidence	O
of	O
an	O
active	B
or	O
suspected	O
cancer	B
or	O
a	O
history	O
of	O
malignancy	B
where	O
the	O
risk	B
of	I
recurrence	I
is	O
>	B
=	I
20	I
%	I
within	I
2	I
years	I
.	O

Patients	O
with	O
a	O
lesion	B
suspicious	O
of	O
hepatic	B
malignancy	I
on	O
a	O
screening	B
imaging	I
study	I
will	O
only	O
be	O
eligible	O
if	O
the	O
likelihood	B
of	I
carcinoma	I
is	O
<	B
=	I
10	I
%	I
following	O
an	O
appropriate	O
evaluation	O
.	O

History	O
of	O
having	O
received	O
any	O
systemic	B
anti	O
-	O
neoplastic	O
(	O
including	O
radiation	B
)	O
or	O
immunomodulatory	B
treatment	I
(	O
including	O
systemic	B
corticosteroids	B
)	O
<	B
=	I
6	I
months	I
prior	I
to	I
the	I
first	I
dose	I
of	I
study	I
drug	I
or	O
the	O
expectation	O
that	O
such	O
treatment	B
will	O
be	O
needed	O
at	B
any	I
time	I
during	I
the	I
study	I
.	O

Major	B
organ	I
transplantation	I
.	O

Thyroid	B
disease	I
with	O
thyroid	B
function	I
poorly	B
controlled	I
on	B
prescribed	I
medications	I
.	O

Patients	O
with	O
abnormal	B
thyroid	B
stimulating	I
hormone	I
or	O
T4	B
concentrations	I
,	O
with	O
elevation	B
of	O
antibodies	B
to	I
thyroid	I
peroxidase	I
and	O
any	O
clinical	B
manifestations	I
of	I
thyroid	I
disease	I
are	O
excluded	O
.	O

History	O
or	O
other	O
evidence	O
of	O
severe	B
retinopathy	B
(	O
e	O
.	O
g	O
.	O
CMV	B
retinitis	I
,	O
macula	B
degeneration	I
)	O
or	O
clinically	B
relevant	I
ophthalmological	B
disorder	I
due	O
to	O
diabetes	B
mellitus	I
or	O
hypertension	B

Inability	O
or	O
unwillingness	O
to	O
provide	O
informed	O
consent	O
or	O
abide	O
by	O
the	O
requirements	O
of	O
the	O
study	O
.	O

History	O
or	O
other	O
evidence	O
of	O
severe	O
illness	O
or	O
any	O
other	O
conditions	O
which	O
would	O
make	O
the	O
patient	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
unsuitable	O
for	O
the	O
study	O
.	O

Patients	O
with	O
a	O
value	O
of	O
alpha	B
-	I
fetoprotein	I
>	B
100	I
ng	I
/	I
mL	I
are	O
excluded	O
,	O
unless	B
stability	B
(	O
less	B
than	I
10	I
%	I
increase	B
)	O
has	O
been	O
documented	O
over	O
at	B
least	I
the	I
previous	I
3	I
months	I
.	O

Evidence	O
of	O
drug	O
and	O
/	O
or	O
alcohol	B
abuse	I
(	O
20g	B
/	I
day	I
for	O
women	B
&	O
30g	B
/	I
day	I
for	O
men	B
)	O
.	O

Patients	O
included	O
in	O
another	O
trial	O
or	O
having	O
been	O
given	O
investigational	O
drugs	O
within	O
12	O
weeks	O
prior	O
to	O
screening	O

Any	O
known	O
history	O
of	O
hypersensitivity	B
to	O
interferon	B
.	O

Male	B
&	O
female	B
patients	O
>	B
=	I
18	I
and	I
<	I
70	I
years	I
of	O
age	B

Positive	B
HBeAg	B
before	B
starting	I
NA	I
treatment	I

Treated	B
by	O
a	O
single	B
NA	B
(	O
lamivudine	B
,	O
adefovir	B
,	O
entecavir	B
or	O
tenofovir	B
)	O
for	B
6	I
months	I
to	I
5	I
years	I

Developed	O
HBeAg	B
seroconversion	B
(	O
HBeAg	B
negative	B
and	O
ant	B
-	I
HBe	I
negative	B
)	O
with	O
undetectable	B
HBV	B
DNA	I
by	O
PCR	B
based	I
assay	I
on	O
NA	B
treatment	B
.	O

Negative	B
urine	O
or	O
serum	B
pregnancy	I
test	I
(	O
for	O
women	B
of	O
childbearing	B
potential	I
)	O
documented	O
within	B
the	I
24	I
-	I
hour	I
period	I
prior	I
to	I
the	I
first	I
dose	I
of	I
test	I
drug	I
.	O

Additionally	O
,	O
all	O
females	O
must	O
be	O
using	O
reliable	O
contraception	O
during	O
the	O
study	O
and	O
for	O
3	O
months	O
after	O
treatment	O
completion	O

No	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
study	O
,	O
mental	O
illness	O
,	O
which	O
don	O
'	O
t	O
allow	O
to	O
obtain	O
informed	O
consent	O
and	O
conduct	O
the	O
treatment	O
according	O
to	O
the	O
protocol	O

Pregnancy	B

HIV	B
infection	I

Active	B
cancer	B

Active	B
hepatitis	B
virus	I
infection	I

Adult	B
acute	I
myeloid	I
leukemia	I

Age	B
:	O
≥	B
18	I
and	I
≤	I
60	I

Clinical	O
condition	O
of	O
the	O
patient	O
allows	O
to	O
carry	O
out	O
induction	O
therapy	O
:	O
ECOG	B
performance	I
status	I
:	O
≤	B
2	I
and	O
the	O
Hematopoietic	B
Cell	I
Transplant	I
-	I
Co	I
-	I
morbidity	I
Index	I
(	I
HCT	I
-	I
I	I
)	I
:	O
≤	B
3	I

Informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O
(	O
ICF	O
signed	O
)	O

The	O
second	O
early	O
induction	O
start	O
criteria	O
is	O
in	O
addition	O
to	O
the	O
listed	O
above	O
,	O
the	O
percentage	B
of	I
the	I
blasts	I
on	O
the	O
level	O
>	B
10	I
%	I
on	B
7th	I
day	I
.	O

Pregnancy	B

Tuberculosis	B

Hepatitis	B
B	I
or	I
C	I
carrier	I
status	O

Human	B
immunodeficiency	I
virus	I
-	O
positive	B
status	O

Retransplantation	B
or	O
multiorgan	B
transplantation	B

History	O
of	O
rheumatoid	B
arthritis	I

Use	O
of	O
drugs	O
that	O
might	O
have	O
enhanced	O
or	O
inhibited	O
CYP3A4	O
or	O
P	O
-	O
gp	O
activity	O

De	B
novo	I
kidney	B
transplants	I

20	B
-	I
65	I
years	I
old	B

aspartate	B
aminotransferase	I
/	O
alanine	B
aminotransferase	I
within	B
2	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
range	I

Diabetes	B
mellitus	I
or	O
plasma	B
glucose	I
>	B
11	I
,	I
1	I
at	B
admission	I
.	O

Receiving	B
steroids	B
at	B
the	I
time	I
of	I
transplantation	I
or	O
likely	O
to	O
need	O
steroids	B
after	B
transplantation	I
.	O

Multiorgan	B
transplants	I
and	O
/	O
or	O
previously	B
transplanted	B
with	I
any	I
other	I
organ	I
than	I
kidney	I
.	O

Panel	B
reacting	I
antibodies	I
(	I
PRA	I
)	I
>	B
25	I
%	I
in	O
most	B
recent	I
test	I
or	O
considered	O
to	O
be	O
of	O
high	O
risk	O
for	O
rejection	B
which	O
requires	O
an	O
enhanced	B
immunosuppression	I
.	O

Renal	B
transplants	I
from	O
HLA	B
-	I
identical	I
sibling	I
.	O

Hypersensitivity	B
to	O
,	O
or	O
disability	B
to	O
take	O
immunosuppressive	B
drugs	I
.	O

Blood	B
group	I
(	I
ABO	I
)	I
-	I
incompatible	I
transplants	B
.	O

Unlikely	O
to	O
comply	O
with	O
the	O
study	O
requirements	O
.	O

Transplant	B
from	O
donor	B
positive	B
for	I
HIV	I
,	O
HBsAg	O
,	O
Hepatitis	O
C	O
.	O

Female	O
of	O
childbearing	O
potential	O
planing	O
/	O
being	O
pregnant	O
or	O
unwilling	O
to	O
use	O
contraception	O
.	O

First	O
or	O
second	O
single	O
kidney	O
(	O
cadaveric	O
or	O
living	B
donors	I
)	O
transplant	O
recipients	O
.	O

Considered	O
for	O
a	O
standard	B
immunosuppressive	I
protocol	I
.	O

Must	O
be	O
capable	O
of	O
giving	O
written	O
informed	O
connect	O
for	O
participation	O
in	O
the	O
study	O
for	O
24	O
months	O
.	O

Current	B
or	O
recent	B
infection	B

Clinically	B
significant	I
laboratory	B
abnormalities	O

Pregnancy	B

Moderate	B
to	I
severe	I
rheumatoid	B
arthritis	I

Taking	O
methotrexate	B
without	B
adequate	O
control	O
of	O
symptoms	O

Have	O
at	B
least	I
one	I
cardiovascular	B
risk	I
factor	I
(	O
eg	O
,	O
current	B
smoker	O
,	O
high	B
blood	I
pressure	I
,	O
high	B
cholesterol	I
levels	I
,	O
diabetes	B
mellitus	I
,	O
history	B
of	O
heart	B
attack	I
,	O
family	O
history	O
of	O
coronary	B
heart	I
disease	I
,	O
extra	B
-	I
articular	I
RA	B
disease	I
)	O

Columbia	B
-	I
Suicide	I
Severity	I
Rating	I
Scale	I
(	O
C	B
-	I
SSRS	I
)	O
for	O
suicidal	B
ideation	I
and	O
behavior	O
in	B
past	I
year	I
.	O

Hypersensitivity	B
to	O
morphine	B
,	O
naltrexone	B
.	O

A	O
life	O
expectancy	O
(	O
assessed	O
by	O
investigator	O
)	O
of	O
less	B
than	I
6	I
months	I
or	O
is	O
no	O
longer	O
capable	O
of	O
taking	O
medication	O
orally	O
.	O

Undergone	O
surgery	B
within	B
3	I
days	I
prior	I
to	I
the	I
first	I
day	I
of	I
dosing	I
.	O

Children	B
7	O
-	O
17	O
with	O
moderate	B
to	O
severe	B
pain	B
requiring	O
around	B
the	I
clock	I
treatment	I
with	O
an	O
opioid	B
analgesic	I
.	O

Be	O
an	O
experienced	O
opioid	O
user	O
,	O
defined	O
as	O
any	O
subject	O
treated	O
with	O
opioid	B
therapy	I
,	O
equivalent	B
or	O
equal	O
to	O
>	B
20	I
mg	I
per	I
day	I
of	O
morphine	B
,	O
for	O
a	O
period	O
of	O
3	B
consecutive	I
days	I
immediately	I
prior	I
to	I
first	I
day	I
of	I
dosing	I
.	O

Congestive	B
heart	I
failure	I
or	O
coronary	B
artery	I
disease	I

Blood	B
pressure	I
averaging	O
>	B
159	I
/	I
99	I
mmHg	I

Serum	B
creatinine	I
>	B
1	I
.	I
5	I
mg	I
/	I
dL	I

Diabetes	B
mellitus	I
or	O
other	O
systemic	B
illness	I

Left	B
ventricular	I
hypertrophy	I
by	O
echocardiography	B
or	O
ECG	B

Pregnancy	B

Hypersensitivity	B
to	O
spironolactone	B
,	O
chlorthalidone	B
,	O
amlodipine	B
,	O
human	B
recombinant	I
insulin	I
or	O
Definity	O

Any	O
history	O
of	O
substance	B
abuse	I
(	O
other	B
than	O
tobacco	O
)	O

History	O
of	O
gouty	B
arthritis	I

Patients	O
with	O
right	B
-	I
to	I
-	I
left	I
,	I
bi	B
-	I
directional	I
,	O
or	O
transient	B
right	B
-	I
to	I
-	I
left	I
cardiac	B
shunts	I

Hypersensitivity	B
to	O
perflutren	B
,	O
blood	B
,	O
blood	B
products	I
or	O
albumin	B

Normotensive	B
controls	B

Stage	B
I	I
(	O
140	O
-	O
159	O
/	O
90	O
-	O
99	O
mmHg	O
)	O
untreated	B
subjects	O
with	O
essential	B
hypertension	I

Patients	O
with	O
PA	B
and	O
stage	B
I	I
(	O
140	O
-	O
159	O
/	O
90	O
-	O
99	O
mmHg	O
)	O
hypertension	B

amide	O
and	O
/	O
or	O
esther	B
local	I
anaesthetic	I
allergy	B

paraben	B
allergy	B

Child	B
-	I
Pugh	I
grade	I
B	B
/	O
C	B
liver	B
failure	I

renal	B
insufficiency	I
(	O
calculated	B
glomerular	I
filtration	I
rate	I
under	B
60	I
ml	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
according	O
to	O
Cockcroft	B
-	I
Gault	I
scale	I
)	O

dementia	B

those	O
presenting	O
with	O
swallowing	B
problem	I

chronic	B
pain	I
condition	I

chronic	B
use	I
of	O
pain	B
medication	I

pregnancy	B

lactation	B

elective	B
procedure	I

weight	B
over	B
40	I
kg	I

American	B
Society	I
of	I
Anesthesiology	I
class	I
I	B
-	I
III	I

first	B
upper	B
GI	I
endoscopy	B
procedure	I

finnish	O
or	O
/	O
and	O
swedish	O
speaking	O

Known	O
pregnancy	B
or	O
breast	B
-	I
feeding	I
.	O

Medical	B
illness	I
unrelated	I
to	I
the	I
tumor	I
which	O
in	O
the	O
opinion	O
of	O
the	O
attending	O
physician	O
and	O
principal	O
investigator	O
will	O
preclude	O
administration	O
of	O
the	O
agent	O
.	O

This	O
includes	O
patients	O
with	O
uncontrolled	B
infection	I
,	O
chronic	B
renal	I
insufficiency	I
,	O
myocardial	B
infarction	I
within	B
the	I
past	I
6	I
months	I
,	O
unstable	B
angina	I
,	O
cardiac	B
arrhythmias	I
other	B
than	I
chronic	B
atrial	I
fibrillation	I
and	O
chronic	O
active	O
or	O
persistent	B
hepatitis	I
,	O
or	O
New	B
York	I
Heart	I
Association	I
Classification	B
III	I
or	I
IV	I
heart	B
disease	I
.	O

18	O
years	O
of	O
age	B
or	O
older	O

Histologically	B
confirmed	B
diagnosis	O
of	O
melanoma	B
,	O
breast	B
cancer	I
or	O
gynecologic	B
cancer	I
at	O
MSKCC	O

Have	O
one	O
of	O
the	O
following	O
disease	O
histories	O
:	O

Newly	B
-	I
diagnosed	I
or	O
recurrent	B
(	O
local	B
,	O
regional	B
,	O
metastatic	B
)	O
malignant	B
melanoma	I
or	O
breast	B
cancer	I
patients	O
in	O
whom	O
SLN	O
mapping	O
is	O
indicated	O

Residual	B
clinically	B
or	O
radiographically	B
evident	B
tumor	B
,	O
including	O
primary	B
cutaneous	I
and	O
mucosal	B
melanomas	I

Prior	B
radiation	B
therapy	I
,	O
chemotherapy	B
,	O
or	O
surgery	B
in	O
patients	O
requiring	O
flap	B
reconstruction	I
in	O
the	O
head	B
and	I
neck	I
region	I
.	O

Newly	O
diagnosed	O
patients	O
with	O
previous	B
excisional	B
biopsy	I
.	O

OR	O

Newly	O
-	O
diagnosed	O
gynecologic	B
cancer	I
patients	O
in	O
whom	O
SLN	B
mapping	I
and	O
surgical	B
excision	I
is	O
indicated	O
OR	O

Normal	B
baseline	B
cardiac	B
function	I
based	O
upon	O
pre	B
-	I
operative	I
evaluation	O

At	O
the	O
discretion	O
of	O
the	O
operating	O
surgeon	O
,	O
ANC	B
>	B
1000	I
/	I
mcl	I
and	O
platelets	B
>	B
100	I
,	I
000	I
/	I
mcl	I
.	O

At	O
the	O
discretion	O
of	O
the	O
operating	O
surgeon	O
,	O
Bilirubin	B
level	I
of	O
<	B
2	I
.	I
0	I
mg	I
/	I
dl	I
in	B
the	I
absence	I
of	I
a	O
history	B
of	O
Gilbert	B
'	I
s	I
disease	I
(	O
or	O
pattern	O
consistent	O
with	O
Gilbert	O
'	O
s	O
)	O
.	O

For	O
melanoma	B
patients	O
,	O
If	O
patients	O
have	O
a	O
history	B
of	O
malignancy	B
other	B
than	I
melanoma	B
,	O
and	O
other	O
skin	B
cancers	I
in	B
the	I
past	I
five	I
years	I
,	O
their	O
inclusion	O
is	O
up	O
to	O
the	O
discretion	O
of	O
the	O
physician	O
.	O

All	O
patients	O
of	O
childbearing	O
and	O
child	O
-	O
creating	O
age	O
must	O
be	O
using	O
an	O
acceptable	O
form	O
of	O
birth	O
control	O

Women	B
who	O
are	O
pre	B
-	I
menopausal	I
must	O
have	O
a	O
negative	B
serum	B
pregnancy	I
test	I

irreversible	B
status	I
of	O
primary	B
disease	I

any	O
history	O
of	O
malnutrition	B
before	B
enrollment	I

history	O
of	O
steroid	B
cortisol	I
administration	O

severe	B
liver	B
dysfunction	I
(	O
Child	B
-	I
Pugh	I
Score	I
C	B
)	O

pregnancy	B

refuse	O
to	O
enrollment	O

re	B
-	I
admission	I
to	O
ICU	O
and	O
has	O
been	O
enrolled	O
during	O
former	O
admission	O
to	O
ICU	O

need	O
mechanical	B
ventilation	I
for	B
more	I
than	I
2	I
days	I

mean	B
blood	I
pressure	I
more	B
than	I
60mmHg	I

predicted	O
ICU	O
stay	O
more	B
than	I
7	I
days	I

tolerance	B
of	O
parenteral	O
or	O
enteral	B
nutrition	I

1	O
)	O
preoperative	B
diagnosis	O
of	O
delirium	B
or	O
dementia	B
;	O
2	O
)	O
MMSE	B
score	I
of	O
=	B
20	I
out	I
of	I
30	I
on	O
preoperative	B
testing	O
(	O
more	B
than	I
mild	I
cognitive	B
impairment	I
)	O
or	O
delirium	B
on	O
preoperative	B
CAM	B
testing	I
;	O
3	O
)	O
language	O
barriers	O
that	O
would	O
preclude	O
testing	O
;	O
4	O
)	O
preoperative	B
steroid	B
use	O
within	O
3	O
days	O
of	O
surgery	B
;	O
or	O
5	O
)	O
anticipation	O
of	O
postoperative	B
intubation	B
.	O

patients	O
=	B
70	I
years	I
of	O
age	B
,	O
undergoing	O
a	O
noncardiac	B
surgical	I
procedure	I
under	O
general	B
anesthesia	I
,	O
with	O
an	O
anticipated	O
duration	O
of	O
postoperative	B
admission	B
of	O
at	B
least	I
2	I
days	I
.	O

Infants	B
who	O
have	O
already	O
received	O
postnatal	O
vitamin	B
D	I
supplementation	O

prematurity	B
(	O
<	O
37	O
weeks	O
)	O
/	O
low	O
birthweight	B
<	B
2500	I
g	I

poor	B
health	I
due	O
to	O
a	O
current	B
or	O
past	B
significant	B
disease	I
state	I
or	O
congenital	B
abnormality	I
.	O

Healthy	B
,	O
term	B
,	O
breastfeeding	O
infants	B
who	O
will	O
be	O
predominately	O
breastfed	O
for	B
at	I
least	I
6	I
-	I
months	I
.	O

This	O
will	O
be	O
determined	O
by	O
answering	O
yes	O
/	O
no	O
to	O
question	O
'	O
do	O
you	O
intend	O
to	O
breastfeed	O
until	O
your	O
infant	O
is	O
at	O
least	O
6	O
months	O
of	O
age	O
.	O
'	O

pregnant	B
or	O
breastfeeding	O
patients	O

patient	O
with	O
a	O
history	B
of	I
hypersensitivity	B
to	O
colistin	B

patient	O
hospitalized	B
in	O
critical	O
care	O
units	O

patient	O
infected	O
by	O
multi	B
drug	I
resistant	I
Gram	B
negative	I
bacteria	I
susceptibly	O
only	B
to	O
colistin	B

source	O
of	O
infection	O
:	O
blood	O
,	O
respiratory	O
,	O
intra	O
abdominal	O
or	O
urinary	O

Cardiopulmonary	B
arrest	I

Pregnancy	B

Severe	B
right	B
heart	I
failure	I

Age	B
greater	B
than	I
or	I
equal	I
to	I
18	I
years	I
old	I

Requirement	O
for	O
vasoactive	B
drugs	I
via	O
a	O
central	B
venous	I
catheter	I
for	O
the	O
treatment	O
of	O
shock	B
.	O

Shock	O
will	O
be	O
defined	O
as	O
mean	B
arterial	I
pressure	I
less	B
than	I
70	I
mmHg	I
or	O
systolic	B
blood	I
pressure	I
less	B
than	I
100	I
mmHg	I
despite	O
administration	O
of	O
at	O
least	O
1000	O
mL	O
of	O
crystalloid	O
or	O
500	O
mL	O
of	O
colloid	O
,	O
unless	O
there	O
is	O
an	O
elevation	O
in	O
the	O
central	O
venous	O
pressure	O
to	O
>	O
12	O
mmHg	O
or	O
in	O
the	O
pulmonary	O
artery	O
occlusion	O
pressure	O
to	O
>	O
14	O
mmHg	O
coupled	O
with	O
signs	O
of	O
tissue	O
hypoperfusion	O
(	O
e	O
.	O
g	O
.	O
altered	O
mental	O
state	O
,	O
mottled	O
skin	O
,	O
urine	O
output	O
<	O
0	O
.	O
5	O
mL	O
/	O
kg	O
body	O
weight	O
for	O
one	O
hour	O
,	O
or	O
a	O
serum	O
lactate	O
level	O
of	O
>	O
2	O
mmol	O
per	O
liter	O
)	O
.	O

Primary	O
groups	O
:	O
Vaccination	O
against	O
typhoid	B
fever	I
within	B
5	I
years	I
before	I
dosing	I
.	O

History	B
of	O
clinical	B
typhoid	I
fever	I
,	O
clinical	B
paratyphoid	I
A	I
or	I
B	I
fever	I
.	O

Immunization	O
with	O
any	B
other	I
vaccine	O
(	O
oral	B
or	O
parenteral	B
)	O
within	B
4	I
weeks	I
prior	I
to	I
study	I
start	I
or	O
planned	O
vaccination	B
during	B
the	I
study	I

Current	B
intake	O
of	O
antibiotics	B
or	O
end	B
of	I
antibiotic	B
therapy	I
<	B
8	I
days	I
before	I
first	I
IMP	I
administration	I

Chronic	O
(	O
longer	B
than	I
14	I
days	I
)	O
administration	O
of	O
immunosuppressants	B
or	O
other	B
immune	B
-	I
modifying	I
drugs	I
within	O
6	O
months	O
before	O
the	O
first	O
dose	O
of	O
investigational	B
vaccine	I
;	O
oral	B
corticosteroids	I
in	O
dosages	B
of	O
=	B
0	I
.	I
5	I
mg	I
/	I
kg	I
/	I
d	I
prednisolone	B
or	I
equivalent	I
are	O
excluded	B
;	O
inhaled	O
or	O
topical	O
steroids	O
are	O
allowed	O

Acute	B
or	O
chronic	B
clinically	B
significant	I
gastrointestinal	B
disease	I

Male	B
or	O
female	B
subjects	O
aged	B
=	B
18	I
to	I
=	I
65	I
years	I

General	B
good	I
health	I
as	O
established	B
by	I
medical	I
history	I
and	O
physical	B
examination	I

Written	O
informed	O
consent	O

Females	B
of	O
childbearing	O
potential	O
must	O
agree	O
to	O
use	O
an	O
efficacious	B
hormonal	O
or	O
barrier	B
method	I
of	O
birth	B
control	I
during	B
the	I
study	I
.	O

Abstinence	O
is	O
acceptable	O
.	O

Available	O
for	O
all	O
visits	O
scheduled	B
in	I
this	I
study	I
.	O

Lifetime	O
history	O
of	O
Bipolar	B
Disorder	I
,	O
Dementia	B
,	O
Autism	B
Spectrum	I
Disorder	I
,	O
Schizophrenia	B
,	O
or	O
any	O
other	O
Psychotic	B
Disorder	I
.	O

Psychotic	B
symptoms	I
occurring	O
at	O
any	O
time	O
during	O
the	O
current	B
major	B
depressive	I
episode	I
.	O

Current	O
(	O
past	B
12	I
months	I
)	O
diagnosis	O
of	O
Panic	B
disorder	I
,	O
Obsessive	B
Compulsive	I
Disorder	I
,	O
Posttraumatic	B
Stress	I
Disorder	I
,	O
Anorexia	B
Nervosa	I
,	O
or	O
Bulimia	B
Nervosa	I
.	O

Alcohol	O
or	O
Drug	B
Dependence	I
within	B
12	I
months	I
or	O
Abuse	O
within	B
3	I
months	I
(	O
excluding	O
nicotine	B
and	O
caffeine	B
)	O
of	O
baseline	O
visit	O
,	O
as	O
assessed	O
by	O
history	O
and	O
urine	B
drug	I
screen	I
.	O

Clinical	O
evidence	O
of	O
a	O
severe	B
Personality	B
Disorder	I
,	O
as	O
assessed	O
by	O
the	O
study	O
psychiatrist	O
,	O
which	O
would	O
impede	O
participation	O
or	O
completion	O
of	O
the	O
trial	O
.	O

Known	O
neurological	B
disorders	I
or	O
documented	O
serious	B
head	B
injury	I
.	O

Serious	B
and	O
unstable	B
medical	B
illnesses	I
including	O
cardiovascular	B
disease	I
and	O
cancer	B
.	O

Active	O
medical	O
conditions	O
with	O
known	O
mood	O
changes	O
(	O
endocrine	O
,	O
autoimmune	B
disorders	I
)	O
.	O

Current	O
diabetes	B
mellitus	I
.	O

For	O
women	O
,	O
pregnancy	O
,	O
lactation	O
,	O
or	O
unwillingness	O
to	O
comply	O
with	O
birth	O
control	O
requirements	O
.	O

Use	O
of	O
any	O
of	O
the	O
following	O
treatments	B
or	O
any	O
other	O
alternative	B
therapy	I
within	B
2	I
weeks	I
of	I
the	I
pre	I
-	I
treatment	I
PET	I
scan	I
that	O
may	O
have	O
beneficial	O
effects	O
on	O
mood	B
,	O
including	O
St	B
John	I
'	I
s	I
Wort	I
,	O
S	B
-	I
adenosyl	I
methionine	I
(	O
SAMe	B
)	O
,	O
n	B
-	I
3	I
fatty	I
acids	I
,	O
or	O
light	B
therapy	I
.	O

Use	O
of	O
antidepressant	B
medication	I
within	O
1	O
month	O
of	O
the	O
pre	B
-	I
treatment	I
PET	B
scan	I
(	O
within	O
5	O
weeks	O
for	O
fluoxetine	B
and	O
protryptyline	B
)	O
.	O

Failure	O
to	O
achieve	O
a	O
much	O
improved	O
status	O
(	O
i	O
.	O
e	O
.	O
equivalent	O
to	O
>	O
50	O
%	O
symptom	O
reduction	O
)	O
with	O
any	O
lifetime	O
treatment	O
course	O
of	O
CBT	O
(	O
defined	O
as	O
a	O
minimum	O
of	O
4	O
sessions	O
of	O
a	O
specified	O
manual	O
-	O
driven	O
therapy	O
by	O
a	O
CBT	O
-	O
trained	O
therapist	O
)	O
or	O
escitalopram	O
(	O
defined	O
as	O
a	O
minimum	O
of	O
6	O
weeks	O
of	O
at	O
least	O
10	O
mg	O
/	O
day	O
)	O
.	O

Clinically	O
significant	O
active	B
suicidal	B
ideation	I
or	O
self	B
-	I
injurious	I
behavior	I
necessitating	O
immediate	B
treatment	B
,	O
as	O
determined	O
by	O
the	O
investigator	O
.	O

Received	O
electroconvulsive	B
therapy	I
in	B
the	I
past	I
6	I
months	I
or	O
during	O
the	O
current	B
depressive	B
episode	I
.	O

Currently	O
responding	O
to	O
medication	O
treatment	O
,	O
without	O
clinical	O
reasons	O
to	O
change	O
.	O

Current	O
treatment	O
with	O
weekly	B
individual	B
or	O
group	B
psychotherapy	B
of	O
any	O
type	O
targeted	O
at	O
depressive	B
symptoms	I
.	O

QTc	B
>	B
500	I
milliseconds	I
on	O
EKG	B
at	B
screening	I
.	O

Contraindications	B
for	O
MRI	B
,	O
including	O
,	O
but	O
not	B
limited	O
to	O
pacemaker	B
,	O
aneurysm	B
clips	I
,	O
neurostimulators	B
,	O
cochlear	B
implants	I
,	O
metal	B
in	O
eyes	B
,	O
steel	B
worker	I
,	O
intra	B
-	I
uterine	I
devices	I
for	O
birth	O
control	O
.	O

Maintenance	O
or	O
prophylactic	O
therapy	O
for	O
stable	O
medical	O
conditions	O
.	O

Hypnotic	B
medication	I
prescribed	O
or	O
approved	O
by	O
the	O
study	O
physician	O
,	O
(	O
up	O
to	O
a	O
three	O
doses	O
per	O
week	O
)	O
for	O
insomnia	B
,	O
as	O
long	O
if	O
not	B
the	B
night	I
before	I
a	I
PET	I
/	I
MRI	I
or	I
clinic	I
ratings	I
visit	I
.	I

Antipsychotic	B
medications	I
,	O
whether	O
prescribed	O
for	O
sleep	O
or	O
other	O
indications	O
,	O
are	O
prohibited	O
.	O

Men	B
or	O
women	B
aged	B
18	B
-	I
60	I
years	I
.	O
Primary	B
psychiatric	O
diagnosis	O
of	O
Major	B
Depressive	I
Disorder	I
,	O
without	B
psychotic	B
features	I
,	O
confirmed	O
via	O
SCID	O
-	O
IV	O
structured	O
diagnostic	O
interview	O
.	O

Screening	B
Hamilton	I
Depression	I
Rating	I
Scale	I
(	O
HAMD	B
)	O
=	B
18	I
;	O
and	O
Baseline	B
HAMD	B
=	B
15	I
.	O

If	O
the	O
patient	O
is	O
a	O
woman	O
of	O
child	O
-	O
bearing	O
potential	O
,	O
she	O
must	O
agree	O
to	O
use	O
an	O
acceptable	O
form	O
of	O
birth	O
control	O
for	O
duration	O
of	O
study	O
participation	O
.	O

Able	O
to	O
understand	O
and	O
provide	O
informed	O
consent	O
for	O
participation	O
.	O

Bone	B
age	I
reading	O
more	B
than	I
14	I
.	I
0	I
years	I

Follicle	B
stimulating	I
hormone	I
>	B
20	I
IU	I
/	I
L	I

Current	B
height	B
less	B
than	I
5th	I
percentile	I
AND	O
/	O
OR	O

Predicted	B
adult	I
height	I
(	O
based	O
on	O
bone	B
age	I
)	O
more	B
than	I
10	I
cm	I
below	I
target	I
height	I
(	O
mid	B
parental	I
height	I
)	O

Evidence	O
of	O
puberty	O
:	O
physical	B
signs	I
and	O
serum	B
luteinizing	I
hormone	I
>	B
0	I
.	I
3	I
IU	I
/	I
L	I
and	O
testosterone	B
>	B
15	I
ng	I
/	I
dl	I

1	O
.	O

Subject	O
is	O
a	O
post	B
-	I
menopausal	I
woman	B
,	O
defined	O
as	O
either	O
;	O
six	B
(	I
6	I
)	I
months	I
or	I
more	I
(	O
immediately	B
prior	I
to	I
screening	I
visit	I
)	O
without	B
a	O
menstrual	B
period	I
,	O
or	O
prior	B
hysterectomy	B
and	O
/	O
or	O
oophorectomy	B

2	O
.	O

Subject	O
is	O
pregnant	B
or	O
lactating	B
or	O
is	O
attempting	O
or	O
expecting	O
to	O
become	O
pregnant	O
during	O
the	O
study	O

3	O
.	O

Women	B
with	O
abnormally	O
high	B
liver	B
enzymes	I
or	O
liver	B
disease	I
.	O

(	O
ALT	B
or	O
AST	B
exceeding	B
2	I
.	I
0	I
x	I
ULN	I
AND	O
total	B
bilirubin	I
exceeding	B
1	I
.	I
5	I
x	I
ULN	I
at	B
screening	I
and	O
confirmed	O
on	O
repeat	O
)	O
.	O

4	O
.	O

Received	O
an	O
investigational	B
drug	I
in	B
the	I
30	I
days	I
prior	I
to	I
the	I
screening	I
for	O
this	O
study	O

5	O
.	O

Women	B
with	O
a	O
history	B
of	O
PCOS	B

6	O
.	O

Concurrent	O
use	O
of	O
any	O
testosterone	B
,	O
progestin	B
,	O
androgen	B
,	O
estrogen	B
,	O
anabolic	B
steroids	I
,	O
DHEA	B
or	O
hormonal	B
products	I
for	B
at	I
least	I
2	I
weeks	I
prior	I
to	I
screening	I
and	O
during	B
the	I
study	I
.	O

7	O
.	O

Use	O
of	O
oral	B
contraceptives	I
in	B
the	I
preceding	I
2	I
weeks	I
.	O

Use	O
of	O
Depo	B
-	I
Provera	I
®	I
in	B
the	I
preceding	I
10	I
months	I
.	O

8	O
.	O

Has	O
an	O
IUD	B
in	O
place	O

9	O
.	O

Women	B
currently	O
using	O
narcotics	B

10	O
.	O

Women	B
currently	O
taking	O
spironolactone	B

11	O
.	O

Infectious	O
disease	O
screen	O
is	O
positive	O
for	O
HIV	B
or	O
Hepatitis	B
A	I
,	O
B	O
or	O
C	O
.	O

12	O
.	O

Clinically	O
significant	O
abnormal	O
findings	O
on	O
screening	O
examination	O
or	O
any	O
condition	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
would	O
interfere	O
with	O
the	O
participant	O
'	O
s	O
ability	O
to	O
comply	O
with	O
the	O
study	O
instructions	O
or	O
endanger	O
the	O
participant	O
if	O
she	O
took	O
part	O
in	O
the	O
study	O

1	O
.	O

Speak	O
,	O
read	O
,	O
and	O
understand	O
English	O
or	O
Spanish	O
and	O
is	O
willing	O
and	O
able	O
to	O
provide	O
written	O
informed	O
consent	O
on	O
an	O
IRB	O
-	O
approved	O
form	O
prior	O
to	O
the	O
initiation	O
of	O
any	O
study	O
procedures	O
;	O

2	O
.	O

Healthy	B
,	O
premenopausal	B
female	B
age	B
18	B
-	I
47	I
;	O

3	O
.	O

History	B
of	O
menstrual	B
events	I
that	I
occur	I
in	I
regular	I
cycles	I

4	O
.	O

Agreement	O
not	O
to	O
attempt	O
to	O
become	O
pregnant	O

5	O
.	O

Agrees	O
to	O
use	O
double	O
-	O
barrier	O
contraception	O
during	O
the	O
study	O
and	O
for	O
30	O
days	O
after	O
discontinuation	O
of	O
study	O
medication	O
.	O

Acceptable	O
double	O
-	O
barrier	O
methods	O
are	O
:	O
male	O
condom	O
with	O
spermicide	O
;	O
male	O
condom	O
with	O
diaphragm	O
;	O
diaphragm	O
containing	O
spermicide	O
plus	O
additional	O
intra	O
-	O
vaginal	O
spermicide	O
;	O

6	O
.	O

Has	O
a	O
negative	B
pregnancy	B
test	I
at	B
the	I
Screening	I
visit	I
.	O

An	O
exception	O
for	O
the	O
pregnancy	O
test	O
requirement	O
will	O
be	O
granted	O
for	O
subjects	O
reporting	O
surgical	O
sterilization	O
in	O
medical	O
history	O

7	O
.	O

Normal	B
laboratory	B
values	O
or	O
clinically	B
insignificant	I
findings	B
at	B
screening	I
as	O
determined	O
by	O
the	O
Investigator	O
;	O

8	O
.	O

Subject	O
is	O
willing	O
to	O
remain	O
in	O
the	O
clinic	O
overnight	O
for	O
PK	O
assessment	O
on	O
Days	O
0	O
and	O
8	O

9	O
.	O

Ability	O
to	O
complete	O
the	O
study	O
procedures	O
in	O
compliance	O
with	O
the	O
protocol	O
.	O

Contraindications	B
and	O
/	O
or	O
known	O
hypersensitivity	B
to	O
the	O
active	O
substance	O
and	O
/	O
or	O
any	O
of	O
the	O
excipients	O
of	O
epoetin	B
beta	I
treatment	I

Poorly	B
controlled	I
hypertension	B
as	O
assessed	O
by	O
the	O
investigator	O

History	O
of	O
Acute	B
Myeloid	I
Leukemia	I
(	O
AML	B
)	O
or	O
high	B
risk	O
for	O
AML	O

Administration	O
of	O
another	O
investigational	O
drug	O
within	O
1	O
month	O
before	O
screening	O
or	O
planned	O
during	O
the	O
study	O
period	O

Previously	O
documented	O
evidence	O
of	O
Pure	B
Red	I
Cell	I
Aplasia	I
(	O
PRCA	B
)	O

Adult	B
participants	O
with	O
low	O
or	O
intermediate	B
-	I
1	I
risk	I
MDS	B

No	O
previous	O
treatment	O
with	O
hematopoietic	B
growth	I
factors	I
within	B
3	I
months	I
prior	I
to	I
screening	I

Symptomatic	B
anemia	B
(	O
hemoglobin	B
<	B
10	I
g	I
/	I
dL	I
)	O
as	O
determined	O
by	O
investigator	O

Serum	B
erythropoietin	I
<	B
500	I
milliunits	I
/	I
milliliter	I
(	O
mU	O
/	O
mL	O
)	O
within	B
14	I
days	I
prior	I
to	I
the	I
first	I
dose	I
of	I
study	I
treatment	I

Require	O
no	B
red	B
blood	I
cell	I
transfusion	I
or	O
dependent	O
on	O
<	B
4	I
units	I
within	B
8	I
weeks	I
prior	I
to	I
screening	I

Clinically	O
stable	B
for	B
at	I
least	I
1	I
month	I
prior	I
to	I
entry	I
into	I
the	I
study	I

For	O
female	O
participants	O
of	O
childbearing	O
potential	O
and	O
male	O
participants	O
with	O
partners	O
of	O
childbearing	O
potential	O
,	O
agreement	O
(	O
by	O
participants	O
and	O
/	O
or	O
partner	O
)	O
to	O
use	O
highly	O
effective	O
form	O
(	O
s	O
)	O
of	O
contraception	O

unstable	B
condition	B
,	O
COPD	B
exacerbation	I

mild	B
(	O
GOLD	B
1	B
)	I
or	O
very	B
severe	I
COPD	B
(	O
GOLD	B
4	B
)	O

requirement	O
for	O
oxygen	B
therapy	I
at	O
low	O
altitude	O
residence	O

hypoventilation	B

pulmonary	B
hypertension	I

more	B
than	I
mild	I
or	O
unstable	B
cardiovascular	B
disease	I

use	O
of	O
drugs	O
that	O
affect	O
respiratory	O
center	O
drive	O

internal	O
,	O
neurologic	O
or	O
psychiatric	B
disease	I
that	O
interfere	O
with	O
protocol	O
compliance	O
including	O
current	O
heavy	B
smoking	O
(	O
>	B
20	I
cigarettes	I
per	I
day	I
)	O
,	O
inability	B
to	O
perform	O
6	B
min	I
walk	I
test	I
.	O

previous	O
intolerance	B
to	O
moderate	B
altitude	O
(	O
<	B
2600m	I
)	O
.	O

exposure	O
to	O
altitudes	O
>	O
1500m	O
for	O
>	O
2	O
days	O
within	O
the	O
last	O
4	O
weeks	O
before	O
the	O
study	O
.	O

pregnant	O
or	O
nursing	O
patients	O

chronic	B
obstructive	I
pulmonary	I
disease	I
(	O
COPD	B
)	O
,	O
GOLD	B
grade	I
2	B
-	I
3	I

residents	O
at	O
low	O
altitude	O
(	O
<	O
800	O
m	O
)	O

Hemodynamically	B
unstable	I
in	O
need	O
of	O
acute	O
treatment	O

Most	B
recent	I
hCG	B
>	B
5000	I
mIU	I
/	I
mL	I

Patient	O
obtaining	O
care	O
in	O
relation	O
to	O
a	O
recently	O
completed	O
pregnancy	O
(	O
delivery	O
,	O
spontaneous	O
or	O
elective	O
abortion	O
)	O

Diagnosis	O
of	O
gestational	B
trophoblastic	I
disease	I

Subject	O
unwilling	O
or	O
unable	O
to	O
comply	O
with	O
study	O
procedures	O

Known	O
hypersensitivity	O
to	O
MTX	B

Presence	O
of	O
clinical	O
contraindications	O
for	O
treatment	O
with	O
MTX	O

Prior	O
medical	O
or	O
surgical	B
management	I
of	O
this	O
gestation	B

Subject	O
unwilling	O
to	O
accept	O
a	O
blood	O
transfusion	O

Female	B
with	O
a	O
persisting	O
pregnancy	B
of	O
unknown	B
location	I
:	O

A	O
pregnancy	B
of	O
unknown	B
location	I
is	O
defined	O
as	O
a	O
pregnancy	B
in	O
a	O
woman	B
with	O
a	O
positive	B
pregnancy	B
test	I
but	O
no	O
definitive	O
signs	O
of	O
pregnancy	O
in	O
the	O
uterus	O
or	O
adnexa	O
on	O
ultrasound	O
imaging	O
.	O

A	O
definitive	O
sign	O
of	O
gestation	O
includes	O
ultrasound	O
visualization	O
of	O
a	O
gestational	O
sac	O
with	O
a	O
yolk	O
sac	O
(	O
with	O
or	O
without	O
an	O
embryo	O
)	O
in	O
the	O
uterus	O
or	O
in	O
the	O
adnexa	O
.	O

Ultrasound	B
must	O
be	O
performed	O
within	B
7	I
days	I
prior	I
to	I
randomization	I
.	O

Persistence	B
of	I
hCG	I
is	O
defined	O
as	O
at	B
least	I
2	I
serial	O
hCG	B
values	O
(	O
over	B
2	I
-	I
14	I
days	I
)	O
,	O
showing	O
<	B
15	I
%	I
rise	I
per	I
day	I
,	O
or	O
<	B
50	I
%	I
fall	I
between	I
the	I
first	I
and	I
last	I
value	I
.	I

Patient	O
is	O
hemodynamically	B
stable	I
,	O
hemoglobin	B
>	B
10	I
mg	I
/	I
dL	I

Greater	B
than	I
or	I
18	I
years	I
of	O
age	B

Kidney	B
,	O
parathyroid	B
,	O
congenital	B
bone	B
metabolic	B
disease	B

Osteoporosis	B

Known	O
allergy	B
or	O
hypersensitivity	B
reaction	O
to	O
dexmedetomidine	B

Organ	B
dysfunction	I
(	O
renal	O
/	O
hepatic	B
failure	I
or	O
leukemia	B
)	O

Cardiac	B
disease	I
(	O
congenital	B
or	O
acquired	B
)	O

Airway	O
or	O
thoracic	B
malformation	I

Cerebral	B
palsy	I

Hypotonia	B

Need	O
for	O
premedication	B

Current	B
/	O
recent	B
upper	B
respiratory	I
infection	I
(	O
within	O
four	O
weeks	O
prior	O
to	O
the	O
surgery	B
)	O

Asthma	B

Allergy	B
or	O
intolerance	B
to	O
clonidine	B

Non	O
-	O
English	O
speaking	O
parents	O
/	O
patients	O
.	O

Patients	O
between	B
3	I
to	I
16	I
years	I
of	O
age	B
undergoing	B
adenotonsillectomy	B
,	O
with	O
or	O
without	O
myringotomy	B
or	O
myringoplasty	B

ASA	B
1	B
&	I
2	I

Weight	B
<	B
800	I
g	I
;	O

Airway	B
anomalies	I
;	O

Pulmonary	B
air	I
leaks	I
;	O

Craniofacial	O
or	O
cardiothoracic	B
malformations	I

Mild	B
-	I
to	I
-	I
moderate	I
RDS	B
;	O

Postnatal	B
age	I
2	B
to	I
48	I
hours	I
;	O

Gestational	B
age	I
27	B
0	I
/	I
7	I
to	I
36	I
6	I
/	I
7	I
weeks	I
;	O

Treated	O
with	O
nasal	B
CPAP	I
modalities	O
=	B
5	I
cm	I
H2O	I
and	O
FiO2	B
between	B
0	I
.	I
30	I
and	I
0	I
.	I
60	I
for	B
at	I
least	I
2	I
hours	I
to	O
maintain	O
SpO2	B
90	B
-	I
95	I
%	I
;	O

Informed	O
consent	O

1	O
.	O

Diagnosis	O
:	O
Diagnosis	O
of	O
CP	B
secondary	I
to	I
neuronal	I
migration	I
.	O

2	O
.	O

Co	O
-	O
morbidities	O
:	O
Medical	O
conditions	O
that	O
may	O
prevent	O
the	O
administration	O
of	O
rehabilitation	O
therapies	O
at	O
the	O
intensity	O
required	O
by	O
the	O
study	O
,	O
or	O
that	O
may	O
compromise	O
the	O
study	O
ability	O
to	O
maintain	O
blindness	O
,	O
or	O
that	O
have	O
a	O
co	O
-	O
morbidity	O
not	O
typically	O
associated	O
with	O
CP	O
(	O
i	O
.	O
e	O
.	O
cancer	O
,	O
cystic	O
fibrosis	O
)	O
.	O

3	O
.	O

Co	O
-	O
interventions	O
:	O
Anticipated	O
pharmacological	O
intervention	O
or	O
procedure	O
or	O
participation	O
in	O
other	O
studies	O
that	O
may	O
interfere	O
with	O
this	O
study	O
.	O

1	O
.	O

Age	B
:	O
12	B
to	I
36	I
months	I
of	I
age	I
(	O
The	O
diagnosis	O
of	O
CP	O
is	O
often	O
uncertain	O
under	O
the	O
age	O
of	O
12	O
months	O
.	O
The	O
cutoff	O
at	O
36	O
months	O
is	O
to	O
have	O
a	O
population	O
of	O
young	O
children	O
when	O
the	O
brain	O
is	O
most	O
"	O
plastic	O
"	O
and	O
most	O
susceptible	O
to	O
reorganization	O
)	O
.	O

2	O
.	O

Diagnosis	O
:	O
Diagnosis	O
of	O
spastic	B
CP	I
confirmed	O
by	O
a	O
pediatric	O
neurologist	O
or	O
pediatric	O
rehabilitation	O
specialist	O
.	O

3	O
.	O

Etiology	O
:	O
The	O
insult	O
to	O
the	O
central	O
nervous	O
system	O
that	O
caused	O
the	O
motor	O
dysfunction	O
must	O
have	O
occurred	O
during	O
gestation	O
or	O
within	O
one	B
year	I
after	I
birth	I
independent	O
of	O
gestational	O
age	O
.	O

4	O
.	O

Disease	O
severity	O
level	O
:	O
Gross	B
Motor	I
Function	I
Classification	I
System	I
(	I
GMFCS	I
)	I
levels	B
I	I
,	I
II	I
and	I
III	I
.	O

Pregnant	O
or	O
breast	O
feeding	O

History	O
of	O
Stomach	O
or	O
esophagus	B
surgery	I

Peptic	B
ulcer	I
or	O
reflux	B
esophagitis	I

Zollinger	B
-	I
Ellison	I
syndrome	I
or	O
primary	B
esophageal	I
motility	I
disorders	I

Malignant	B
tumor	I

Bleeding	B
tendency	I
or	O
coagulopathy	B

Contraindication	B
of	O
ALBIS	B

Long	B
term	I
use	O
of	O
aspirin	B
or	O
P2Y12	B
receptor	I
antagonist	I
within	B
1month	I

Patients	O
who	O
tool	O
medicine	O
such	O
as	O
PPI	B
,	O
APA	B
,	O
H2blocker	B
,	O
Muscarine	B
receptor	I
antagonist	I
,	O
anti	B
-	I
gastic	I
agent	I
,	O
antacid	B
,	O
anticaogulant	B
,	O
Bisphosphonate	B
agents	I
,	O
Cytotoxic	B
drug	I
,	O
NSAID	B
,	O
adrenal	B
cortex	I
hormone	I
agents	I
(	O
topical	B
treatment	I
is	O
allowed	B
)	O

Terminal	B
patient	B

Age	B
between	B
20	I
and	I
80	I
years	I

Patients	O
undergoing	O
percutaneous	B
coronary	I
intervention	I
and	O
need	O
to	O
take	O
dual	B
antiplatelet	I
therapy	I
continuously	B
at	B
least	I
12weeks	I

Modified	B
Lanza	I
Score	I
grade	I
0	B
-	I
1	I
measured	O
by	O
upper	B
gastrointestinal	I
endoscopy	I

mild	B
gastrointestinal	B
symptom	I

Creatinen	B
in	O
blood	O
=	B
3mg	I
/	I
dl	I

BUN	B
=	B
50mg	I
/	I
dl	I

Birilubin	B
=	B
3mg	I
/	I
dl	I

AST	B
and	O
ALT	B
=	B
80U	I
/	I
L	I

Have	O
osteoporosis	B

Have	O
a	O
10	O
yr	O
probability	O
of	O
hip	B
fracture	I
>	B
3	I
%	I
or	O
major	B
fracture	I
>	B
20	I
%	I
based	O
on	O
results	O
of	O
the	O
FRAX	O
tool	O

Currently	O
take	O
bisphosphonates	B
,	O
estrogen	B
replacement	I
therapy	I
,	O
glucocorticosteroids	B
,	O
or	O
other	O
drugs	B
affecting	I
bone	I

Currently	O
participate	B
in	I
a	I
resistance	I
training	I
or	O
high	O
impact	O
weight	O
bearing	O
exercise	O
program	O
two	B
or	I
more	I
times	I
weekly	I

Weigh	B
>	B
300	I
lbs	I

Have	O
abnormal	B
results	I
for	O
the	O
following	O
laboratory	O
tests	O
:	O
serum	B
25	I
(	I
OH	I
)	I
D	I
;	O
serum	B
creatinine	I
;	O
serum	B
calcium	I
;	O
PTH	B
;	O
TSH	B

Have	O
Paget	B
'	I
s	I
disease	I
,	O
heart	B
disease	I
,	O
uncontrolled	B
hypertension	I
,	O
renal	B
disease	I
,	O
or	O
other	B
concomitant	I
conditions	I
that	I
prohibit	I
participation	I
in	I
exercises	I
,	O
risedronate	B
therapy	I
,	O
or	O
use	O
of	O
CaD	B
supplements	I
.	O

Women	B
who	O
are	O
in	O
their	O
first	O
5	O
years	O
of	O
menopause	B

Have	O
a	O
T	B
score	I
between	B
-	I
1	I
and	I
-	I
2	I
.	I
49	I
at	O
the	O
femoral	B
neck	I
,	O
total	B
hip	I
,	O
or	O
L1	B
-	I
L4	I
spine	I

Be	O
19	O
years	O
of	O
age	B
or	O
older	O

Have	O
their	O
health	O
care	O
provider	O
'	O
s	O
permission	O
to	O
enroll	O
in	O
the	O
study	O
.	O

Age	B
<	B
20	I
or	O
>	B
35	I
years	I
.	O

Body	B
mass	I
index	I
(	O
BMI	B
)	O
<	B
18	I
.	I
5	I
kg	I
/	I
m2	I
or	O
>	B
25	I
kg	I
/	I
m2	I
.	O

Presence	O
of	O
any	O
infertility	B
factor	I
other	B
than	I
anovulation	B
/	O
oligoovulation	B
.	O

Previous	O
history	O
of	O
ovarian	B
surgery	I
or	O
surgical	B
removal	I
of	O
one	B
ovary	B
.	O

Previous	O
exposure	O
to	O
cytotoxic	B
drugs	I
or	O
pelvic	B
irradiation	I
.	O

Metabolic	O
or	O
hormonal	B
abnormalities	I
.	O

Infertile	B
women	B
with	O
eugonadotrophic	B
anovulation	B
/	O
oligoovulation	B
.	O

Unexplained	B
infertility	B
.	O

Pacing	B
threshold	I
(	O
s	O
)	O
(	O
at	B
0	I
.	I
4	I
or	I
0	I
.	I
5	I
ms	I
)	O
and	O
/	O
or	O
sensing	B
amplitude	I
(	O
s	O
)	O
and	O
/	O
or	O
impedance	B
(	O
s	O
)	O
are	O
not	B
measurable	I

Meet	O
one	B
or	I
more	I
of	O
the	O
contraindications	B
for	O
MRI	B
including	O
Psychiatric	B
disorders	I
,	O
anxiety	B
,	O
claustrophobia	B
Cardiac	B
disorders	I
that	O
represent	O
a	O
contraindication	B
to	O
MRI	B

Cardiac	B
surgery	I
already	O
scheduled	O
in	B
the	I
next	I
three	I
months	I

Have	O
other	O
medical	B
implants	I
that	O
may	O
interact	B
with	I
MRI	I
,	O
e	O
.	O
g	O
.	O
abandoned	B
implantable	I
cardioverter	I
defibrillator	I
(	I
ICD	I
)	I
leads	I
or	O
pacemaker	B
leads	I
other	B
than	I
MRI	B
conditional	I
,	O
lead	B
extensions	I
,	O
other	B
active	B
medical	I
devices	I
,	O
non	B
-	I
MRI	I
compatible	I
devices	I
,	O
mechanical	B
valve	I

Have	O
other	O
metallic	B
artifacts	I
/	O
components	O
in	O
body	O
that	O
may	O
interact	B
with	O
MRI	B

Subjects	O
for	O
whom	O
a	O
single	B
dose	B
of	I
1	I
.	I
0	I
milligram	I
(	I
mg	I
)	I
dexamethasone	B
acetate	I
may	O
be	O
contraindicated	B

Subjects	O
who	O
require	O
a	O
legally	O
authorized	O
representative	O
to	O
obtain	O
consent	O

Subjects	O
who	O
are	O
immediate	B
candidates	O
for	O
an	O
ICD	B

Subjects	O
with	O
medical	B
conditions	I
that	O
preclude	B
the	O
testing	B
required	I
by	I
the	I
protocol	I
or	O
limit	B
study	I
participation	I

Subjects	O
who	O
are	O
enrolled	O
or	O
intend	O
to	O
participate	O
in	O
another	O
clinical	O
trial	O
(	O
of	O
an	O
investigational	O
drug	O
or	O
device	O
,	O
new	O
indication	O
for	O
an	O
approved	O
drug	O
or	O
device	O
,	O
or	O
requirement	O
of	O
additional	O
testing	O
beyond	O
standard	O
clinical	O
practice	O
)	O
during	O
this	O
clinical	O
study	O

Being	O
pregnant	B

Have	O
a	O
life	O
expectancy	O
of	O
less	B
than	I
three	I
months	I

Subjects	O
with	O
exclusion	O
criteria	O
required	O
by	O
local	O
law	O
(	O
e	O
.	O
g	O
.	O
age	O
,	O
breastfeeding	O
)	O

Approved	O
clinical	B
indication	I
for	O
pectoral	B
pacemaker	I
exchange	I
(	O
e	O
.	O
g	O
.	O
elective	B
replacement	I
indication	I
(	I
ERI	I
)	I
,	O
end	B
of	I
service	I
(	I
EOS	I
)	I
)	O

a	O
single	O
or	O
dual	B
chamber	I
MRI	B
conditional	I
pacemaker	B
(	O
BSCI	B
)	O
or	O

Any	O
comparable	B
successor	B
IPG	I
(	O
MRI	B
conditional	I
system	I
,	O
BSCI	B
)	O
compatible	O
with	O

Implanted	B
Fineline	I
-	I
II	I
-	I
leads	I
(	O
BSCI	B
)	O
,	O
MRI	B
conditional	I

The	O
ascertained	B
lead	I
impedance	I
is	O
between	B
200	I
and	I
1500	I
Ohm	I
.	O

All	O
pacing	B
capture	I
thresholds	I
(	O
PCT	B
)	O
do	B
not	I
exceed	I
2	I
.	I
0	I
V	I
@	I
0	I
.	I
4	I
or	I
0	I
.	I
5	I
ms	I
in	O
pacemaker	B
dependent	I
patients	O

Male	B
or	O
female	B
18	O
years	B
or	I
older	I

Understand	O
the	O
nature	O
of	O
the	O
procedure	O

Give	O
written	O
informed	O
consent	O

Able	O
to	O
complete	O
all	O
testing	O
required	O
by	O
the	O
clinical	O
protocol	O

Ability	O
to	O
measure	O
atrial	O
and	O
/	O
or	O
ventricular	O
pacing	O
threshold	O
(	O
s	O
)	O
at	O
0	O
.	O
4	O
or	O
0	O
.	O
5	O
ms	O

Patient	O
body	B
height	I
greater	B
or	I
equal	I
to	I
140	I
cm	I

Pectoral	B
implanted	I
device	I

Subjects	O
who	O
are	O
able	O
and	O
willing	O
to	O
undergo	O
elective	B
cardiac	O
magnetic	O
resonance	O
(	O
MR	B
)	O
scanning	O
without	B
sedation	I
(	O
MRI	O
-	O
group	O
)	O

Subjects	O
who	O
are	O
geographically	B
stable	I
and	O
available	O
for	O
follow	O
-	O
up	O
at	O
the	O
study	O
center	O
for	B
the	I
length	I
of	I
the	I
study	I

Serious	O
adverse	B
reaction	I
to	O
any	O
vaccination	B
,	O
as	O
respiratory	B
difficulty	I
,	O
angioedema	B
and	O
anaphylaxis	B
;	O

Acute	O
or	O
chronic	B
disease	I
,	O
as	O
diabetes	B
,	O
heart	B
disease	I
,	O
systemic	B
arterial	I
hypertension	I
;	O

Use	O
of	O
anti	B
-	I
allergic	I
with	O
antigen	B
injections	I
in	O
a	O
maximum	B
timeline	I
of	I
14	I
days	I
before	I
the	I
vaccination	I
;	O

Use	O
of	O
immunoglobulin	B
in	B
the	I
past	I
12	I
months	I
before	I
the	I
study	I
vaccination	I
;	O

Use	O
of	O
blood	B
products	I
within	B
12	I
months	I
before	I
the	I
vaccination	I
;	O

Use	O
of	O
any	B
vaccine	I
type	I
within	B
30	I
days	I
before	I
the	I
vaccination	I
of	I
the	I
study	I
;	O

Chronic	B
use	I
of	O
any	B
medication	I
,	O
except	B
homeopathy	B
,	O
and	O
trivial	B
ones	I
,	O
as	O
nasal	B
physiologic	I
solution	I
and	O
vitamins	B
;	O

Previous	O
immunosuppressive	O
or	O
cytotoxic	B
medication	I
,	O
in	B
the	I
last	I
6	I
months	I
.	O

Individuals	O
who	O
have	O
made	O
use	O
of	O
this	O
kind	O
of	O
medication	O
in	O
non	O
-	O
immunosuppressant	O
doses	O
,	O
as	O
nasal	O
corticosteroid	O
for	O
allergic	O
rhinitis	O
of	O
topic	O
corticosteroid	O
for	O
non	O
-	O
complicated	O
dermatitis	O
,	O
for	O
more	O
than	O
14	O
days	O
,	O
are	O
allowed	O
to	O
be	O
included	O
in	O
the	O
study	O
.	O

Use	O
of	O
any	O
kind	O
of	O
medication	B
under	I
investigation	I
within	B
one	I
year	I
before	I
the	I
vaccination	I
.	O

Unstable	B
asthma	I
or	O
which	O
may	O
have	O
required	O
urgent	B
care	I
,	O
hospitalization	B
or	O
intubation	B
within	B
the	I
last	I
2	I
years	I
,	O
or	O
which	O
requires	O
use	O
of	O
oral	O
or	O
intravenous	B
corticosteroid	I
.	O

Coagulopathies	B
diagnosed	O
by	O
a	O
physician	O
or	O
report	O
of	O
capillary	B
fragility	I
(	O
ex	O
:	O
bruises	B
or	O
bleedings	B
without	B
justifiable	I
cause	I
;	O

Convulsions	B
,	O
except	B
the	O
ones	O
caused	O
by	O
fever	B
,	O
before	B
2	I
years	I
old	I
;	O

Psychiatric	B
disease	I
which	O
difficults	B
the	I
adherence	I
to	I
the	I
protocol	I
,	O
such	O
as	O
psychosis	B
,	O
obsessive	B
-	I
compulsive	I
disorders	I
,	O
bipolar	B
disease	I
under	O
treatment	B
,	O
diseases	O
which	O
require	O
treatment	O
with	O
lithium	B
and	O
suicidal	B
ideas	I
in	B
the	I
last	I
5	I
years	I
from	I
the	I
inclusion	I
;	O

Active	B
malignant	B
(	O
p	O
.	O
e	O
.	O
any	B
kind	I
of	O
cancer	B
)	O
or	O
treated	B
disease	O
,	O
to	B
which	I
the	I
individual	I
may	I
relapse	I
during	B
the	I
study	I
;	O

Asplenia	B
(	O
absence	B
of	I
spleen	B
or	O
its	O
removal	O
)	O
;	O

Positive	B
HIV	B
in	B
the	I
screening	I
examination	I
of	O
history	O
of	O
any	O
immunosuppressant	B
disease	I
;	O

Positive	B
serology	B
for	I
C	I
hepatitis	I
in	B
the	I
screening	I
evaluation	I
;	O

Positive	B
Antigen	B
HBs	I
in	B
the	I
screening	I
evaluation	I
;	O

Alcoholism	B
(	O
CAGE	B
criteria	I
)	O
,	O
used	O
for	O
detection	O
of	O
abusive	O
drinkers	O
or	O
alcoholic	O
,	O
validated	O
in	O
the	O
Brazilian	O
population	O
with	O
sensibility	O
of	O
88	O
%	O
and	O
specificity	O
of	O
83	O
%	O
,	O
if	O
two	O
or	O
more	O
answers	O
,	O
among	O
four	O
possible	O
,	O
are	O
afirmative	O
(	O
Mansur	O
and	O
Monteiro	O
,	O
1983	O
)	O
,	O
or	O
according	O
to	O
medical	O
decision	O
;	O

Abuse	B
of	I
illicit	I
drugs	I
,	O
according	O
to	O
medical	O
decision	O
;	O

Acquired	O
or	O
congenital	B
immunodeficiency	I
;	O

Allergy	O
to	O
the	O
vaccine	B
compounds	I
,	O
as	O
egg	B
,	O
neomycin	B
and	O
gelatin	B
.	O

Male	B

Age	B
between	B
18	I
and	I
49	I
years	I
old	I
;	O

Willing	O
to	O
provide	O
name	O
,	O
address	O
,	O
telephone	O
and	O
other	O
contact	O
information	O
in	O
order	O
to	O
be	O
contacted	O
,	O
whenever	O
needed	O
(	O
example	O
:	O
in	O
case	O
of	O
missing	O
any	O
scheduled	O
visit	O
,	O
contact	O
for	O
confirmation	O
of	O
scheduling	O
a	O
visit	O
,	O
urgent	O
safety	O
notifications	O
)	O
;	O

Willing	O
to	O
strictly	O
follow	O
the	O
study	O
protocol	O
;	O

Capacity	O
for	O
understanding	O
and	O
signing	O
in	O
the	O
Informed	O
Consent	O
Form	O
;	O

To	O
understand	O
the	O
impossibility	O
of	O
participating	O
in	O
another	O
clinical	O
trial	O
during	O
the	O
time	O
of	O
participation	O
in	O
the	O
study	O
,	O
until	O
6	O
months	O
after	O
its	O
conclusion	O
;	O

Intellectual	O
level	O
which	O
allows	O
to	O
filling	O
in	O
the	O
diaries	O
for	O
registering	O
of	O
symptoms	O
at	O
home	O
;	O

Willing	O
to	O
undergo	O
to	O
serological	B
testing	I
to	I
HIV	I
,	O
HBV	O
and	O
HCV	O
;	O

Being	O
in	O
good	B
health	I
,	O
with	O
no	O
significant	O
medical	O
history	O
;	O

Physical	B
examination	I
at	B
screening	I
period	I
without	O
clinically	O
significant	O
changes	O
;	O

Lab	O
examination	O
at	O
screening	O
period	O
within	O
the	O
normal	O
ranges	O
,	O
determined	O
by	O
the	O
laboratory	O
or	O
abnormal	O
values	O
,	O
grading	O
below	O
1	O
or	O
2	O
,	O
according	O
to	O
medical	O
decision	O
.	O

Patients	O
who	O
have	O
coma	B
,	O
convulsion	B
or	O
paralysis	B
due	O
to	O
intracranial	B
hemorrhage	I
or	O
central	B
nervous	I
system	I
leukemia	B
at	B
diagnosis	I
.	O

Patients	O
less	B
than	I
16	I
years	I
old	B
with	O
newly	O
diagnosed	O
PML	B
-	I
RARa	I
positive	B
acute	B
promyelocytic	I
leukemia	I
.	O

Current	B
or	O
chronic	B
history	B
of	O
liver	B
disease	I
,	O
or	O
known	O
hepatic	O
or	O
biliary	B
abnormalities	I
(	O
with	O
the	O
exception	B
of	O
Gilbert	B
'	I
s	I
syndrome	I
or	O
asymptomatic	B
gallstones	B
)	O
.	O

History	B
of	O
regular	B
alcohol	I
consumption	I
within	B
6	I
months	I
of	I
the	I
study	I
defined	O
as	O
:	O
An	O
average	B
weekly	I
intake	I
of	O
>	B
21	I
units	I
for	O
males	B
or	O
>	B
14	I
units	I
for	O
females	B
.	O

One	O
unit	O
is	O
equivalent	O
to	O
8	O
gram	O
of	O
alcohol	O
:	O
a	O
half	O
-	O
pint	O
(	O
approximately	O
240	O
milliliter	O
[	O
mL	O
]	O
)	O
of	O
beer	O
,	O
1	O
glass	O
(	O
100	O
mL	O
)	O
of	O
wine	O
or	O
1	O
(	O
25	O
mL	O
)	O
measure	O
of	O
spirits	O
.	O

History	O
of	O
sensitivity	O
to	O
heparin	B
or	O
heparin	B
-	O
induced	O
thrombocytopenia	O
.	O

History	B
of	O
sensitivity	O
to	O
any	O
of	O
the	O
study	B
medications	I
,	O
or	O
components	O
thereof	O
or	O
a	O
history	O
of	O
drug	O
or	O
other	O
allergy	B
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
or	O
GSK	O
Medical	O
Monitor	O
,	O
contraindicates	O
their	O
participation	O
.	O

Gastrointestinal	B
disease	I
or	O
with	O
gastrointestinal	B
surgical	I
history	O
which	O
can	O
affect	B
the	I
absorption	I
of	I
the	I
investigational	I
product	I
.	O

A	O
positive	B
pre	B
-	I
study	I
Hepatitis	B
B	I
surface	I
antigen	I
or	O
positive	B
Hepatitis	B
C	I
antibody	I
result	O
within	B
3	I
months	I
of	I
screening	I

Urinary	B
cotinine	I
levels	I
indicative	O
of	O
smoking	B
or	O
history	B
or	O
regular	B
use	I
of	I
tobacco	I
-	O
or	O
nicotine	O
-	O
containing	O
products	O
within	B
6	I
months	I
prior	I
to	I
screening	I
.	O

A	O
positive	B
pre	B
-	I
study	I
drug	O
/	O
alcohol	B
screen	I
.	O

A	O
positive	B
test	O
for	O
Human	B
Immunodeficiency	I
Virus	I
(	I
HIV	I
)	I
antibody	I
.	O

Pregnant	B
females	B
as	O
determined	O
by	O
positive	B
serum	B
hCG	I
test	I
at	B
screening	I
or	O
prior	B
to	I
dosing	I
.	O

Where	O
participation	O
in	O
the	O
study	O
would	O
result	O
in	O
donation	O
of	O
blood	O
or	O
blood	O
products	O
in	O
excess	O
of	O
500	O
mL	O
within	O
a	O
90	O
day	O
period	O
.	O

Lactating	B
females	B
.	O

The	O
subject	O
has	O
participated	O
in	O
a	O
clinical	O
trial	O
and	O
has	O
received	O
an	O
investigational	O
product	O
within	O
the	O
following	O
time	O
period	O
prior	O
to	O
the	O
first	O
dosing	O
day	O
in	O
the	O
current	O
study	O
:	O
90	O
days	O
,	O
5	O
half	O
-	O
lives	O
or	O
twice	O
the	O
duration	O
of	O
the	O
biological	O
effect	O
of	O
the	O
investigational	O
product	O
(	O
whichever	O
is	O
longer	O
)	O
.	O

Exposure	O
to	O
more	B
than	I
four	I
new	B
chemical	I
entities	I
within	B
12	I
months	I
prior	I
to	I
the	I
first	I
dosing	I
day	I
.	O

Male	B
and	O
females	B
aged	B
between	B
18	I
and	I
65	I
years	I
of	O
age	B
inclusive	O
,	O
at	B
the	I
time	I
of	I
signing	I
the	I
informed	I
consent	I
.	O

Healthy	B
as	B
determined	I
by	I
a	I
responsible	I
and	I
experienced	I
physician	I
,	O
based	O
on	O
a	O
medical	B
evaluation	I
including	O
medical	B
history	I
,	O
physical	B
examination	I
,	O
laboratory	B
tests	I
and	O
cardiac	B
monitoring	I
.	O

A	O
subject	O
with	O
a	O
clinical	B
abnormality	I
or	O
laboratory	B
parameter	I
(	O
s	O
)	O
which	O
is	O
/	O
are	O
not	O
specifically	O
listed	O
in	O
the	O
inclusion	O
or	O
exclusion	O
criteria	O
,	O
outside	B
the	I
reference	I
range	I
for	O
the	O
population	O
being	O
studied	O
may	O
be	O
included	O
only	O
if	O
the	O
Investigator	O
in	O
consultation	O
with	O
the	O
GSK	O
Medical	O
Monitor	O
if	O
required	O
agree	O
and	O
document	O
that	O
the	O
finding	O
is	O
unlikely	O
to	O
introduce	O
additional	O
risk	O
factors	O
and	O
will	O
not	O
interfere	O
with	O
the	O
study	O
procedures	O
.	O

Body	B
weight	I
>	B
=	I
50	I
kilogram	I
(	I
kg	I
)	I
and	O
body	B
mass	I
index	I
within	B
the	I
range	I
19	I
-	I
24	I
.	I
9	I
kg	I
/	I
m	I
^	I
2	I
(	O
inclusive	O
)	O
.	O

A	O
female	B
subject	O
is	O
eligible	O
to	O
participate	O
if	O
she	O
is	O
of	O
:	O
Non	B
-	O
childbearing	B
potential	I
defined	O
as	O
pre	B
-	I
menopausal	I
females	B
with	O
a	O
documented	O
tubal	B
ligation	I
or	O
hysterectomy	B
for	O
this	O
definition	O
,	O
"	O
documented	O
"	O
refers	O
to	O
the	O
outcome	O
of	O
the	O
investigator	O
'	O
s	O
/	O
designee	O
'	O
s	O
review	O
of	O
the	O
subject	O
'	O
s	O
medical	O
history	O
for	O
study	O
eligibility	O
,	O
as	O
obtained	O
via	O
a	O
verbal	O
interview	O
with	O
the	O
subject	O
or	O
from	O
the	O
subject	O
'	O
s	O
medical	O
records	O
;	O
or	O
postmenopausal	B
defined	O
as	O
12	B
months	I
of	O
spontaneous	B
amenorrhea	I
[	O
in	O
questionable	O
cases	O
a	O
blood	O
sample	O
with	O
simultaneous	O
follicle	B
stimulating	I
hormone	I
(	I
FSH	I
)	I
>	B
40	I
milli	I
-	I
international	I
units	I
per	I
milliliter	I
(	I
MlU	I
/	I
mL	I
)	I
and	O
estradiol	B
<	B
40	I
picograms	I
per	I
mililiter	I
(	I
pg	I
/	I
mL	I
)	I
[	O
<	B
147	I
picomole	I
per	I
liter	I
]	O
is	O
confirmatory	O
]	O
.	O

Females	B
on	O
hormone	B
replacement	I
therapy	I
(	I
HRT	I
)	I
and	O
whose	O
menopausal	B
status	I
is	O
in	B
doubt	I
will	O
be	O
required	O
to	O
use	O
one	O
of	O
the	O
contraception	O
methods	O
if	O
they	O
wish	O
to	O
continue	O
their	O
HRT	O
during	O
the	O
study	O
.	O

Otherwise	O
,	O
they	O
must	O
discontinue	O
HRT	O
to	O
allow	O
confirmation	O
of	O
post	O
-	O
menopausal	O
status	O
prior	O
to	O
study	O
enrollment	O
.	O

For	O
most	O
forms	O
of	O
HRT	O
,	O
at	O
least	O
2	O
-	O
4	O
weeks	O
will	O
elapse	O
between	O
the	O
cessation	O
of	O
therapy	O
and	O
the	O
blood	O
draw	O
;	O
this	O
interval	O
depends	O
on	O
the	O
type	O
and	O
dosage	O
of	O
HRT	O
.	O

Following	O
confirmation	O
of	O
their	O
post	O
-	O
menopausal	O
status	O
,	O
they	O
can	O
resume	O
use	O
of	O
HRT	O
during	O
the	O
study	O
without	O
use	O
of	O
a	O
contraceptive	O
method	O
;	O
Child	O
-	O
bearing	O
potential	O
with	O
negative	O
pregnancy	O
test	O
as	O
determined	O
by	O
serum	O
human	O
chorionic	O
gonadotrophin	O
(	O
hCG	O
)	O
test	O
at	O
screening	O
or	O
prior	O
to	O
dosing	O
AND	O
;	O
Agrees	O
to	O
use	O
one	O
of	O
the	O
contraception	O
methods	O
listed	O
in	O
protocol	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
(	O
as	O
determined	O
by	O
the	O
product	O
label	O
or	O
investigator	O
)	O
prior	O
to	O
the	O
start	O
of	O
dosing	O
to	O
sufficiently	O
minimize	O
the	O
risk	O
of	O
pregnancy	O
at	O
that	O
point	O
.	O

Female	O
subjects	O
must	O
agree	O
to	O
use	O
contraception	O
until	O
the	O
follow	O
-	O
up	O
contact	O
visit	O
;	O
OR	O
has	O
only	O
same	O
-	O
sex	O
partners	O
,	O
when	O
this	O
is	O
her	O
preferred	O
and	O
usual	O
lifestyle	O
.	O

Male	O
subjects	O
with	O
female	O
partners	O
of	O
child	O
-	O
bearing	O
potential	O
must	O
agree	O
to	O
use	O
one	O
of	O
the	O
contraception	O
methods	O
listed	O
in	O
Protocol	O
.	O

This	O
criterion	O
must	O
be	O
followed	O
from	O
the	O
time	O
of	O
the	O
first	O
dose	O
of	O
study	O
medication	O
until	O
the	O
follow	O
-	O
up	O
contact	O
visit	O
.	O

Capable	O
of	O
giving	O
written	O
informed	O
consent	O
,	O
which	O
includes	O
compliance	O
with	O
the	O
requirements	O
and	O
restrictions	O
listed	O
in	O
the	O
consent	O
form	O

Alanine	B
aminotransferase	I
,	O
alkaline	B
phosphatase	I
and	O
bilirubin	B
<	B
=	I
1	I
.	I
5x	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
(	O
isolated	O
bilirubin	B
>	B
1	I
.	I
5xULN	I
is	O
acceptable	O
if	O
bilirubin	O
is	O
fractionated	O
and	O
direct	B
bilirubin	I
<	O
35	O
%	O
)	O
.	O

Based	O
on	O
single	B
or	O
averaged	B
corrected	B
QT	I
interval	I
(	I
QTc	I
)	I
values	O
of	O
triplicate	O
electrocardiograms	B
obtained	O
over	B
a	I
brief	I
recording	I
period	I
:	O
QTcF	B
<	B
450	I
msec	I

Patients	O
with	O
liver	B
disease	I
(	O
documented	O
liver	B
function	I
test	I
abnormality	B
)	O

Patients	O
with	O
renal	B
disease	I
(	O
documented	O
glomerular	B
filtration	I
rate	I
<	B
60mL	I
/	I
min	I
/	I
1	I
.	I
73m2	I
)	O

Patients	O
with	O
a	O
baseline	B
(	O
pre	B
-	I
operative	I
)	O
opioid	B
use	O
greater	B
than	I
30	I
mg	I
of	I
morphine	I
equivalents	I
/	I
day	I
.	O

Patients	O
with	O
active	O
alcohol	B
dependence	I

Patients	O
with	O
active	O
illicit	B
drug	I
dependence	I

Patients	O
<	B
18	I
years	I
of	O
age	B
and	O
>	B
70	I
years	I
of	O
age	B

Patients	O
allergic	B
to	O
any	O
medication	B
given	O
in	O
either	O
arm	O
(	O
list	O
medications	O
)	O

Patients	O
who	O
have	O
a	O
seizure	B
disorder	I

Subjects	O
undergoing	O
a	O
single	B
level	I
lumbar	B
decompression	I
and	O
fusion	O

>	B
18	I
years	I
of	I
age	I
and	I
<	I
70	I
years	I
of	O
age	B

The	O
subject	O
is	O
willing	O
and	O
able	O
to	O
understand	O
,	O
sign	O
and	O
date	O
the	O
study	O
specific	O
patient	O
informed	O
consent	O
and	O
HIPAA	O
authorization	O
to	O
volunteer	O
participation	O
in	O
the	O
study	O

Patients	O
with	O
documented	O
allergies	B
to	O
propofol	B
,	O
dexmedetomidine	B
,	O
fentanyl	B
,	O
eggs	O
or	O
egg	O
products	O
,	O
or	O
soy	O
or	O
soy	O
products	O
.	O

A	O
heart	B
rate	I
less	B
than	I
50	I
beats	I
/	I
minute	I
or	O
grade	B
2	I
or	O
3	O
AV	B
heart	I
block	I

Mean	B
arterial	I
pressure	I
less	B
than	I
55	I
mmHg	I
despite	O
appropriate	O
fluid	B
resuscitation	I
and	O
vasopressor	B
support	O
.	O

Current	O
triglyceride	B
level	I
>	B
400	I
mg	I
/	I
dl	I

Men	B
and	O
women	B
18	B
-	I
89	I
years	I
old	B

with	O
the	O
diagnosis	O
of	O
sepsis	B
(	O
as	O
specified	O
below	O
)	O
within	B
the	I
previous	I
24	I
hours	I

who	O
require	O
mechanical	B
ventilation	I
,	O
and	O

provide	O
informed	O
consent	O
either	O
personally	O
or	O
by	O
an	O
authorized	O
representative	O
.	O

contraindication	B
to	O
ketamine	B
and	O
lidocaine	B

patients	O
involved	O
to	O
other	O
studies	O

more	O
or	O
equal	O
to	O
American	B
Society	I
of	I
Anesthesiologist	I
(	I
ASA	I
)	I
class	I
III	O

not	O
alert	O

patients	O
who	O
need	O
suturing	B
for	O
laceration	B
under	O
procedural	B
anesthesia	I
using	O
ketamine	B

Age	B
<	B
1m	I
or	I
>	I
24	I
months	I
of	I
age	I

No	B
secure	O
diagnosis	O
of	O
epilepsy	B

<	O
4	O
seizures	B
/	O
week	O
on	O
average	O
in	O
baseline	O
period	O

Trial	O
of	O
<	B
2	I
AEDs	B

Continues	O
on	O
corticosteroids	B
in	O
previous	B
3	I
months	I
prior	I
to	I
randomisation	I

Metabolic	B
disease	I
contraindicating	B
use	O
of	O
the	O
ketogenic	B
diet	I
e	O
.	O
g	O
.	O
pyruvate	B
carboxylase	I
deficiency	I
,	I
MCAD	B
from	O
previous	O
medical	O
investigation	O
and	O
screening	O
at	O
baseline	O
.	O

Progressive	B
neurological	B
disease	I

Severe	B
gastroesophageal	B
reflux	I

Previous	B
treatment	O
with	O
the	O
ketogenic	B
diet	I

Concurrent	O
participation	O
in	O
another	O
clinical	O
trial	O
of	O
an	O
investigational	O
medicinal	O
product	O
.	O

Patients	O
who	O
are	O
prescribed	O
AEDs	O
not	O
listed	O
in	O
the	O
trial	O
IMPs	O

Age	B
between	B
1	I
month	I
and	I
24	I
months	I
of	I
age	I
(	O
not	O
beyond	O
second	O
birthday	O
at	O
baseline	O
)	O
.	O

Diagnosis	O
of	O
epilepsy	B
confirmed	O
.	O

At	O
least	O
an	O
average	O
of	O
4	O
seizures	B
/	O
week	O
in	O
baseline	O
period	O
.	O

Failed	B
response	B
to	O
previous	O
trial	O
of	O
two	B
anti	B
-	I
epileptic	I
drugs	I
.	O

In	O
the	O
case	O
of	O
infantile	O
spasms	O
this	O
could	O
include	O
a	O
trial	O
of	O
corticosteroids	B
.	O

Children	O
with	O
written	O
informed	O
consent	O
from	O
parent	O
/	O
guardian	O
.	O

Patients	O
who	O
had	O
history	B
of	O
systemic	B
antibiotic	I
usage	O
over	B
the	I
previous	I
4	I
months	I

Patients	O
who	O
were	O
pregnant	B

Patients	O
who	O
had	O
received	O
non	B
-	I
surgical	I
periodontal	I
treatment	I
within	B
the	I
past	I
6	I
months	I

Patients	O
who	O
had	O
received	O
surgical	B
periodontal	I
treatment	I
within	B
the	I
past	I
12	I
months	I

Patients	O
who	O
were	O
smokers	B

Patients	O
with	O
a	O
history	O
of	O
stroke	B
or	O
an	O
acute	B
cardiovascular	I
event	I
over	B
the	I
previous	I
12	I
months	I
.	O

Patients	O
should	O
have	O
at	B
least	I
12	I
teeth	B
present	I

Patients	O
with	O
Moderate	B
to	O
Advanced	B
Chronic	B
periodontitis	I

Patients	O
with	O
2	B
or	I
more	I
interproximal	O
sites	O
(	O
not	O
on	O
same	O
tooth	O
)	O
with	O
probing	O
pocket	O
depths	O
of	O
5mm	B
or	I
more	I
and	O
2	B
or	I
more	I
interproximal	O
sites	O
(	O
not	O
on	O
same	O
tooth	O
)	O
of	O
probing	O
attachment	O
loss	O
of	O
4mm	B
or	I
more	I
which	O
bled	O
on	O
probing	B
.	O

Patients	O
who	O
have	O
had	O
a	O
prior	B
abdominal	B
myomectomy	I

Post	O
-	O
menopausal	O
women	B

Patients	O
with	O
known	O
bleeding	O
/	O
clotting	B
disorders	I

Patients	O
with	O
a	O
history	B
of	O
gynecologic	B
malignancy	I

History	B
of	O
allergic	B
reactions	I
attributed	O
to	O
compounds	O
of	O
similar	O
chemical	O
or	O
biologic	O
composition	O
to	O
misoprostol	B

Any	O
cases	O
converted	O
to	O
abdominal	B
hysterectomy	I
or	O
other	B
additional	B
elective	B
surgical	B
procedures	I
performed	O
at	O
time	O
of	O
abdominal	B
myomectomy	I
will	O
be	O
excluded	O
from	O
data	O
analysis	O

Uncontrolled	B
intercurrent	B
illness	I
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
ongoing	B
or	O
active	B
infection	B
,	O
symptomatic	B
congestive	B
heart	I
failure	I
,	O
unstable	B
angina	I
pectoris	I
,	O
cardiac	B
arrhythmia	I
,	O
or	O
psychiatric	B
illness	I
/	O
social	O
situations	O
that	O
would	O
limit	O
compliance	O
with	O
study	O
requirements	O
.	O

Patients	O
presenting	O
for	O
abdominal	B
myomectomy	I
with	O
documented	O
uterine	B
fibroids	I
on	O
pelvic	B
imaging	I
(	O
pelvic	B
ultrasound	I
or	O
MRI	O
)	O
within	B
in	I
last	I
12	I
months	I

Age	B
=	B
18	I
years	I
and	I
=	I
50	I
years	I

Pre	O
-	O
operative	B
hemoglobin	B
>	B
8	I
g	I
/	I
dl	I

Willing	O
to	O
have	O
buccal	B
administration	I
of	O
misoprostol	B
or	O
a	O
placebo	B
at	B
least	I
one	I
hour	I
pre	I
-	I
procedure	I
.	O

Ability	O
to	O
understand	O
and	O
the	O
willingness	O
to	O
sign	O
a	O
written	O
informed	O
consent	O
.	O

Admissible	B
medical	O
/	O
surgical	B
history	I

Can	O
be	O
previously	B
treated	B
with	O
Depo	B
-	I
Lupron	I
,	O
Depo	B
-	I
Provera	I
,	O
or	O
Oral	B
Contraceptive	I
pills	I

Intraoperative	O
use	O
of	O
vasopressin	O
and	O
uterine	O
tourniquet	O
is	O
permissible	O

Can	O
have	O
had	O
prior	O
Cesarean	O
delivery	O

NA	O

Aged	B
between	B
18	I
-	I
70	I
years	I

Meets	O
the	O
Diagnostic	B
and	I
Statistical	I
Manual	I
(	I
DSM	I
)	I
IV	I
and	I
DSM	I
-	I
V	I
diagnostic	I
criteria	I
for	O
generalised	B
anxiety	I
disorder	I
(	O
GAD	B
)	O
based	O
on	O
structured	B
interview	I
(	O
Mini	B
International	I
Neuropsychiatric	I
Interview	I
-	I
Plus	I
6	I
[	I
MINI	I
-	I
Plus	I
6	I
]	I
.	O
Note	O
that	O
while	O
the	O
MINI	O
-	O
Plus	O
6	O
uses	O
the	O
DSM	O
-	O
IV	O
criteria	O
,	O
the	O
same	O
criteria	O
are	O
used	O
in	O
the	O
DSM	O
-	O
V	O
)	O
.	O

Presents	O
with	O
anxiety	B
(	O
Hamilton	B
Anxiety	I
Rating	I
Scale	I
=	B
18	I
)	O
at	B
the	I
time	I
of	I
study	I
entry	I

Fluent	O
in	O
written	O
and	O
spoken	O
English	O

Provides	O
a	O
signed	O
copy	O
of	O
the	O
consent	O
form	O

Primary	B
diagnosis	I
other	B
than	I
GAD	B

Presentation	O
of	O
moderate	B
to	I
severe	I
depressive	B
symptoms	I
(	O
Montgomery	B
-	I
Asberg	I
Rating	I
Scale	I
:	O
MADRS	B
=	B
18	I
at	B
time	I
of	I
study	I
entry	I
or	O
=	B
24	I
at	B
any	I
time	I
during	I
study	I
)	O

Presentation	O
of	O
suicidal	B
ideation	I
(	O
=	B
3	I
on	O
MADRS	B
suicidal	I
thoughts	I
domain	I
at	B
time	I
of	I
study	I
entry	I
or	O
at	B
any	I
time	I
during	I
study	I
)	O

Current	O
diagnosis	O
of	O
bipolar	B
disorder	I
or	O
schizophrenia	B
on	O
structured	B
interview	I
(	O
MINI	B
Plus	I
)	O

Current	O
substance	O
/	O
alcohol	B
use	I
disorder	I
on	O
structured	B
interview	I
(	O
MINI	B
Plus	I
)	O
Page	O
21	O
of	O
39	O
Commercial	O
-	O
in	O
-	O
Confidence	O

Currently	B
taking	B
an	O
antidepressant	B
,	O
mood	B
stabiliser	I
,	O
antipsychotic	B
,	O
anticonvulsant	B
,	O
warfarin	B
or	O
thyroxin	B
,	O
or	O
current	B
regular	B
use	B
(	O
more	B
than	I
2	I
days	I
per	I
week	I
)	O
of	O
a	O
benzodiazepine	B
or	O
opioid	B
-	I
based	I
analgesic	I

Current	B
use	B
of	O
a	O
psychotropic	B
nutraceutical	I
(	O
e	O
.	O
g	O
.	O
St	B
John	I
'	I
s	I
wort	I
)	O

Previous	B
intolerance	B
to	O
kava	B

Three	B
or	I
more	I
failed	B
trials	B
of	I
pharmacotherapy	I
for	O
the	O
current	B
GAD	B
episode	I

Recently	B
commenced	O
psychotherapy	B
(	O
within	B
four	I
weeks	I
of	I
study	I
entry	I
)	O

Known	O
or	O
suspected	O
clinically	B
unstable	I
systemic	B
medical	B
disorder	I

Diagnosed	O
hepato	B
-	I
biliary	I
disease	I
/	O
inflammation	O

Elevated	B
liver	B
enzymes	I
at	O
baseline	B
blood	B
test	I

Pregnancy	B
or	O
breastfeeding	O
,	O
or	O
trying	B
to	I
conceive	I

Not	B
using	O
medically	B
approved	I
contraception	B
(	O
including	O
abstinence	B
)	O
if	O
female	B
and	O
of	O
childbearing	B
age	O

Unable	O
to	O
participate	O
in	O
all	O
scheduled	O
visits	O
,	O
treatment	O
plan	O
,	O
or	O
other	O
trial	B
procedures	I
according	O
to	O
the	O
protocol	O
(	O
except	B
for	I
the	O
optional	O
genetic	O
component	O
)	O

All	O
adult	B
patients	O
with	O
chronic	B
myeloid	I
leukaemia	I
in	O
any	B
phase	I
(	O
chronic	B
,	O
accelerated	B
or	O
blastic	B
)	O
who	O
undergo	O
allogeneic	B
stem	I
cell	I
transplantation	I
between	B
01	I
/	I
01	I
/	I
2010	I
and	I
30	I
/	I
09	I
/	I
2013	I
and	O
have	O
been	O
previously	B
treated	O
with	O
Nilotinib	B
or	O
Dasatinib	B
,	O
regardless	O
of	O
their	O
response	O
to	O
these	O
drugs	O
.	O

Allergy	B
to	O
ceftriaxone	B
or	O
macrolides	B

Major	B
typhoid	B
fever	I
-	O
associated	O
complications	B

Inability	O
to	O
swallow	O
oral	B
medication	I

Underlying	B
illness	I

Pregnancy	B

Lactation	B

Treatment	O
within	B
the	I
past	I
4	I
days	I
with	O
an	O
antibiotic	B
that	O
may	O
be	O
effective	O
against	O
typhoid	B
fever	I

Blood	B
culture	I
-	O
proven	B
typhoid	B
fever	I
(	O
S	B
.	I
typhi	I
or	O
S	B
.	I
paratyphi	I
)	O

Signed	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O
.	O

Subject	O
unwilling	B
to	O
cease	O
use	O
of	O
any	O
treatment	B
for	O
erectile	B
dysfunction	I
during	B
the	I
study	I
,	O
including	O
oral	B
medication	I
,	O
vacuum	B
devices	I
,	O
constrictive	B
devices	I
,	O
injections	B
,	O
urethral	B
suppositories	I
,	O
gels	B
,	O
any	O
over	B
-	I
the	I
-	I
counter	I
or	O
nonprescription	B
medications	B
,	O
and	O
products	O
purchased	O
via	O
the	O
internet	O

Subject	O
receiving	O
dopamine	B
agonists	I
,	O
nitrates	B
,	O
alpha	B
-	I
receptor	I
blocking	I
agents	I
,	O
or	O
antihypertensive	B
medication	I
(	O
see	O
other	O
exclusionary	O
medications	O
listed	O
below	O
)	O

Subject	O
with	O
a	O
history	O
of	O
syncope	B
within	B
the	I
last	I
6	I
months	I
prior	I
to	I
screening	I

Subject	O
with	O
symptomatic	B
postural	B
hypotension	I
(	O
severe	B
dizziness	B
or	O
fainting	B

Subject	O
with	O
hypotension	B
and	O
a	O
resting	O
systolic	B
blood	I
pressure	I
of	O
<	B
90	I
mmHG	I
or	O
hypertension	B
with	O
a	O
resting	O
systolic	B
blood	I
pressure	I
>	B
170	I
mmHG	I
or	O
a	O
resting	O
diastolic	B
blood	I
pressure	I
>	B
110	I
mmHG	I

Subject	O
with	O
any	O
underlying	O
cardiovascular	B
condition	I
,	O
including	O
unstable	B
angina	I
pectoris	I
,	O
which	O
preclude	B
sexual	O
activity	O

Subject	O
with	O
a	O
history	O
of	O
myocardial	B
infarction	I
,	O
stroke	B
or	O
life	B
-	I
threatening	I
arrhythmia	B
within	B
6	I
months	I
prior	I
to	I
screening	I

Subject	O
with	O
uncontrolled	B
atrial	B
fibrillation	I
/	O
flutter	O
at	B
screening	I
(	O
defined	O
as	O
ventricular	B
response	I
rate	I
=	B
100	I
bpm	I
)	O

Subject	O
with	O
a	O
bleeding	B
disorder	I

Subject	O
with	O
a	O
history	O
of	O
prostatectomy	B
because	O
of	O
prostate	B
cancer	I
,	O
including	O
nerve	B
sparing	I
techniques	I
.	O

Subjects	O
with	O
a	O
history	B
of	I
surgical	B
procedures	I
for	O
the	O
treatment	O
of	O
benign	B
prostate	I
hypertrophy	I
are	O
permitted	B
,	O
with	B
the	I
exception	I
of	I
cryosurgery	B
,	O
cryotherapy	B
or	O
cryoablation	B

Subject	O
with	O
hereditary	B
degenerative	I
retinal	I
disorders	I
such	O
as	O
retinitis	B
pigmentosa	I

Subject	O
with	O
a	O
history	B
of	I
loss	B
of	I
vision	I
because	O
of	O
non	B
-	I
arteritic	I
anterior	I
ischemic	I
optic	I
neuropathy	I
(	O
NAION	B
)	O
,	O
history	O
of	O
temporary	B
or	O
permanent	B
loss	B
of	I
vision	I
,	O
including	O
unilateral	B
loss	B
of	I
vision	I

Subject	O
with	O
a	O
history	B
of	I
congenital	B
QT	I
prolongation	I

Subject	O
with	O
a	O
penile	B
anatomical	I
abnormality	I
(	O
e	O
.	O
g	O
.	O
,	O
penile	B
fibrosis	I
,	O
fractures	O
,	O
or	O
Peyronie	B
'	I
s	I
disease	I
)	I
which	O
,	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
,	O
could	O
significantly	O
impair	B
sexual	I
performance	I
.	O

This	O
will	O
be	O
based	O
on	O
subject	O
'	O
s	O
reported	O
medical	O
history	O
(	O
penile	B
exam	I
not	O
required	O
)	O

Subject	O
with	O
primary	O
hypoactive	O
sexual	O
desire	O
.	O

Subject	O
with	O
a	O
spinal	B
cord	I
injury	I

Subject	O
with	O
a	O
severe	B
chronic	O
or	O
acute	B
liver	I
disease	I
,	O
history	O
of	O
moderate	B
(	O
Child	B
-	I
Pugh	I
B	B
)	O
,	O
or	O
severe	B
(	O
Child	B
-	I
Pugh	I
C	B
)	O
hepatic	B
impairment	I

Subject	O
with	O
clinically	B
significant	I
chronic	B
hematological	B
disease	I
which	O
could	O
lead	O
to	O
priapism	B
such	O
as	O
sickle	B
cell	I
anemia	I
,	O
multiple	B
myeloma	I
,	O
and	O
leukemia	B

Subject	O
with	O
active	B
peptic	B
ulceration	I

Subject	O
with	O
a	O
history	B
of	I
malignancy	B
within	B
the	I
past	I
5	I
years	I
(	O
other	B
than	I
squamous	O
or	O
basal	B
cell	I
skin	I
cancer	I
)	O

Subject	O
with	O
a	O
history	B
of	I
a	O
positive	B
test	B
for	I
Hepatitis	I
B	I
surface	I
antigen	I
(	I
HbsAg	I
)	I
or	O
Hepatitis	O
C	O

Subject	O
with	O
a	O
known	O
hypersensitivity	B
to	O
any	O
component	O
of	O
the	O
investigational	B
medications	B
,	O
monoamine	B
oxidase	I
inhibitors	I
,	O
phosphodiesterase	B
type	I
5	I
inhibitors	I
or	O
phenylethylamines	B

Subjects	O
with	O
a	O
history	B
of	I
drug	O
or	O
alcohol	B
abuse	I
within	B
the	I
past	I
6	I
months	I

Subjects	O
currently	B
consuming	O
=	B
5	I
units	I
of	O
alcohol	O
per	O
day	O

Subject	O
who	O
is	O
illiterate	O
or	O
unable	B
to	I
understand	O
the	O
Informed	O
Consent	O
Form	O
,	O
questionnaires	O
or	O
subject	O
diary	O

Subject	O
who	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
will	O
be	O
noncompliant	O
with	O
the	O
visit	O
schedule	O
or	O
study	O
procedures	O

Subject	O
with	O
any	O
unstable	B
medical	O
,	O
psychiatric	O
,	O
or	O
substance	B
abuse	I
disorder	I
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
is	O
likely	B
to	I
affect	I
the	I
subject	I
'	I
s	I
ability	I
to	I
complete	I
the	I
study	I
or	O
preclude	B
the	I
subject	I
'	I
s	I
participation	I
in	I
the	I
study	I

Diagnosis	O
of	O
any	B
other	I
neurologic	B
disease	I

Uncontrolled	B
Diabetes	B
(	O
Hemoglobin	B
A1C	I
>	B
7	I
.	I
5	I
)	O

Diagnosis	O
of	O
idiopathic	B
Parkinson	I
'	I
s	I
disease	I
that	O
is	O
optimally	O
treated	B
(	O
motor	B
fluctuations	I
<	B
20	I
%	I
of	I
subject	I
'	I
s	I
awake	I
time	I
)	O
.	O

Subjects	O
may	O
be	O
on	O
levodopa	O
therapy	O
but	O
must	O
be	O
stable	O
at	O
the	O
time	O
of	O
entry	O
into	O
the	O
study	O

Sexually	O
active	O
(	O
i	O
.	O
e	O
.	O
=	B
1	I
attempt	I
/	I
week	I
)	O
males	B
,	O
40	B
-	I
64	I
years	I
of	O
age	B
(	O
inclusive	O
)	O
at	O
time	O
of	O
screening	O

Diagnosis	O
of	O
moderate	B
erectile	B
dysfunction	I
(	O
defined	O
according	O
to	O
the	O
NIH	O
Consensus	O
Development	O
Panel	O
on	O
Impotence	O
)	O
for	B
more	I
than	I
6	I
months	I
and	O
demonstrating	O
and	O
incomplete	B
response	B
to	O
tadalafil	B
alone	O

Subject	O
demonstrating	O
an	O
IIEF	B
-	I
5	I
drug	I
-	I
free	I
baseline	I
score	I
that	O
is	O
=	B
10	I
but	I
=	I
16	I
,	O
and	O
an	O
IIEF	B
-	I
5	I
tadalafil	I
-	I
alone	I
baseline	I
score	I
that	O
is	O
=	B
18	I

Subject	O
in	O
a	O
stable	B
heterosexual	O
relationship	O
for	O
at	B
least	I
6	I
months	I
.	O

(	O
2	O
)	O

Subject	O
motivated	O
to	O
seek	O
treatment	B
for	O
erectile	B
dysfunction	I
.	O

Subject	O
with	O
a	O
total	B
serum	I
testosterone	I
level	I
=	B
300	I
ng	I
/	I
dL	I
,	O
with	O
or	O
without	O
supplementation	O

Hoehn	B
and	I
Yahr	I
Scale	I
score	I
of	O
1	B
-	I
3	I

Patient	O
able	O
to	O
consent	O
and	O
comply	O
with	O
protocol	O
requirements	O

Patients	O
under	B
18	I

Pregnancy	B
and	O
Lactation	B

Patients	O
allergic	B
to	O
polyglycolic	O
/	O
trimethylene	B
carbonate	I

Carrier	O
of	O
prosthetic	B
mesh	I
in	O
the	O
ostomy	B

Patients	O
presenting	O
midline	B
hernia	I
.	O

Patients	O
affected	O
by	O
inflammatory	B
bowel	I
disease	I

Patients	O
undergoing	O
a	O
loop	B
ileostomy	I
closure	I

Subjects	O
with	O
known	O
intolerance	B
to	O
blood	B
products	I
or	O
to	O
one	O
of	O
the	O
components	O
of	O
the	O
study	O
product	O
or	O
is	O
unwilling	O
to	O
receive	O
blood	O
products	O
;	O

Female	O
subjects	O
,	O
who	O
are	O
of	O
childbearing	O
age	O
(	O
i	O
.	O
e	O
.	O
adolescent	O
)	O
,	O
who	O
are	O
pregnant	O
or	O
nursing	O
;	O

Subject	O
is	O
currently	O
participating	O
or	O
plans	O
to	O
participate	O
in	O
any	O
other	O
investigational	O
device	O
or	O
drug	O
without	O
prior	O
approval	O
from	O
the	O
Sponsor	O
;	O

Subjects	O
who	O
are	O
known	O
,	O
current	O
alcohol	O
and	O
/	O
or	O
drug	B
abusers	I

Subjects	O
admitted	O
for	O
trauma	B
surgery	I

Subjects	O
with	O
any	O
pre	O
or	O
intra	O
-	O
operative	O
findings	O
identified	O
by	O
the	O
surgeon	O
that	O
may	O
preclude	O
conduct	O
of	O
the	O
study	O
procedure	O
.	O

Subject	O
with	O
TBS	B
in	O
an	O
actively	O
infected	O
field	O
(	O
Class	B
III	I
Contaminated	I
or	O
Class	B
IV	I
Dirty	I
or	I
Infected	I
)	O

TBS	O
is	O
from	O
large	O
defects	O
in	O
arteries	O
or	O
veins	O
where	O
the	O
injured	O
vascular	O
wall	O
requires	O
repair	O
with	O
maintenance	O
of	O
vessel	O
patency	O
and	O
which	O
would	O
result	O
in	O
persistent	O
exposure	O
of	O
the	O
EVARREST	O
™	O
or	O
SURGICEL	O
®	O
to	O
blood	O
flow	O
and	O
pressure	O
during	O
healing	O
and	O
absorption	O
of	O
the	O
product	O
;	O

TBS	B
with	O
major	B
arterial	I
bleeding	I
requiring	O
suture	B
or	O
mechanical	B
ligation	I
;	O

Bleeding	O
site	O
is	O
in	O
,	O
around	O
,	O
or	O
in	O
proximity	O
to	O
foramina	O
in	O
bone	O
,	O
or	O
areas	O
of	O
bony	O
confine	O
.	O

Paediatric	O
subjects	O
aged	B
=	B
28	I
days	I
(	I
=	I
1	I
month	I
)	I
to	I
<	I
18	I
years	I
,	O
requiring	O
non	B
-	I
emergent	I
open	B
hepatic	B
,	O
abdominal	B
,	O
retroperitoneal	B
,	O
pelvic	B
or	O
thoracic	B
(	O
non	B
-	I
cardiac	I
)	O
surgical	B
procedures	I
.	O

i	O
)	O
The	O
first	O
36	O
subjects	O
to	O
be	O
enrolled	O
will	O
be	O
subjects	O
aged	O
=	O
1	O
years	O
to	O
<	O
18	O
years	O
.	O
ii	O
)	O
The	O
next	O
4	O
subjects	O
to	O
be	O
enrolled	O
will	O
be	O
subjects	O
aged	O
=	O
28	O
days	O
to	O
<	O
1	O
year	O
.	O

The	O
subject	O
'	O
s	O
parent	O
/	O
legal	O
guardian	O
must	O
be	O
willing	O
to	O
give	O
permission	O
for	O
the	O
subject	O
to	O
participate	O
in	O
the	O
trial	O
,	O
and	O
provide	O
written	O
informed	O
consent	O
for	O
the	O
subject	O
.	O
In	O
addition	O
,	O
assent	O
must	O
be	O
obtained	O
from	O
paediatric	O
subjects	O
who	O
possess	O
the	O
intellectual	O
and	O
emotional	O
ability	O
to	O
comprehend	O
the	O
concepts	O
involved	O
in	O
the	O
trial	O
.	O
If	O
the	O
paediatric	O
subject	O
is	O
not	O
able	O
to	O
provide	O
assent	O
(	O
due	O
to	O
age	O
,	O
maturity	O
and	O
/	O
or	O
inability	O
to	O
intellectually	O
and	O
/	O
or	O
emotionally	O
comprehend	O
the	O
trial	O
)	O
,	O
the	O
parent	O
/	O
legal	O
guardian	O
'	O
s	O
written	O
Informed	O
Consent	O
for	O
the	O
subject	O
will	O
be	O
acceptable	O
for	O
the	O
subject	O
to	O
be	O
included	O
in	O
the	O
study	O
.	O

Presence	O
of	O
an	O
appropriate	O
mild	O
or	O
moderate	O
bleeding	O
soft	O
tissue	O
or	O
hepatic	O
parenchyma	O
Target	O
Bleeding	O
Site	O
(	O
TBS	O
)	O
identified	O
intra	O
-	O
operatively	O
by	O
the	O
surgeon	O
;	O

Ability	O
to	O
firmly	O
press	O
trial	O
treatment	O
at	O
TBS	O
until	O
4	O
minutes	O
after	O
randomisation	O

1	O
.	O

Personal	O
history	B
of	I
stroke	B
,	O
brain	B
lesions	I
,	O
previous	B
neurosurgery	B
,	O
any	O
personal	B
history	I
of	I
seizure	B
or	O
fainting	B
episode	I
of	O
unknown	B
cause	I
,	O
or	O
head	B
trauma	I
resulting	I
in	I
loss	I
of	I
consciousness	I
,	O
lasting	B
over	I
30	I
minutes	I
or	O
with	O
sequela	B
lasting	B
longer	B
than	I
two	I
days	I
.	O

Justification	O
:	O
Stroke	O
or	O
head	O
trauma	O
can	O
lower	O
the	O
seizure	O
threshold	O
,	O
and	O
are	O
therefore	O
contra	O
-	O
indications	O
for	O
TMS	O
.	O
Fainting	O
episodes	O
or	O
syncope	O
of	O
unknown	O
cause	O
could	O
indicate	O
an	O
undiagnosed	O
condition	O
associated	O
with	O
seizures	O
.	O

Screening	B
tool	O
:	O
TMS	B
adult	I
safety	I
questionnaire	I
,	O
Medical	B
History	I
.	O

2	O
.	O

First	B
-	I
degree	I
family	O
history	O
of	O
any	O
neurological	B
disorder	I
with	O
a	O
potentially	B
hereditary	I
basis	I
,	O
including	O
migraines	B
,	O
epilepsy	B
,	O
or	O
multiple	B
sclerosis	I
.	O

1	O
.	O

Justification	O
:	O
Neurological	O
disorders	O
can	O
lower	O
the	O
seizure	O
threshold	O
,	O
and	O
are	O
therefore	O
contra	O
-	O
indications	O
for	O
TMS	O
.	O
First	O
-	O
degree	O
family	O
history	O
of	O
certain	O
neurological	O
disorders	O
with	O
a	O
hereditary	O
component	O
increases	O
the	O
risk	O
of	O
the	O
subject	O
having	O
an	O
undiagnosed	O
condition	O
that	O
is	O
associated	O
with	O
lowered	O
seizure	O
threshold	O
.	O

2	O
.	O

Screening	B
tool	O
:	O
TMS	B
adult	I
safety	I
screening	I
,	O
Medical	B
History	I
.	O

3	O
.	O

Cardiac	B
pacemakers	I
,	O
neural	B
stimulators	I
,	O
implantable	B
defibrillator	I
,	O
implanted	B
medication	I
pumps	I
,	O
intracardiac	B
lines	I
,	O
or	O
acute	B
,	O
unstable	B
cardiac	B
disease	I
,	O
with	O
intracranial	B
implants	I
(	O
e	O
.	O
g	O
.	O
aneurysm	B
clips	I
,	O
shunts	B
,	O
stimulators	B
,	O
cochlear	B
implants	I
,	O
or	O
electrodes	B
)	O
or	O
any	O
other	O
metal	B
object	I
within	I
or	I
near	I
the	I
head	I
that	O
precludes	B
MRI	B
scanning	I
.	O

1	O
.	O

Justification	O
:	O
Any	O
metal	O
around	O
the	O
head	O
is	O
a	O
contraindication	O
for	O
both	O
MRI	O
and	O
TMS	O
,	O
as	O
both	O
methods	O
involve	O
exposure	O
to	O
a	O
relatively	O
strong	O
magnetic	O
field	O
.	O

2	O
.	O

Screening	B
tool	O
:	O
TMS	B
adult	I
safety	I
screening	I
,	O
MRI	B
safety	I
screening	I
,	O
Medical	B
History	I
.	O

4	O
.	O

Noise	B
-	I
induced	I
hearing	I
loss	I
or	O
tinnitus	B
.	O

1	O
.	O

Justification	O
:	O
individuals	O
with	O
noise	O
-	O
induced	O
hearing	O
problems	O
may	O
be	O
particularly	O
vulnerable	O
to	O
the	O
acoustic	O
noise	O
generated	O
by	O
TMS	O
and	O
MRI	O
equipment	O
.	O

2	O
.	O

Screening	B
tools	O
:	O
TMS	B
adult	I
safety	I
screening	I
.	O

5	O
.	O

Current	B
use	I
(	O
any	B
use	I
in	B
the	I
past	I
4	I
weeks	I
,	O
chronic	B
use	I
within	B
6	I
past	I
six	I
months	I
)	O
of	O
any	O
investigational	B
drug	I
or	O
of	O
any	O
medications	B
with	O
psychotropic	O
,	O
anti	O
or	O
pro	B
-	I
convulsive	I
action	I
.	O

1	O
.	O

Justification	O
:	O
The	O
use	O
of	O
certain	O
medications	O
or	O
drugs	O
can	O
lower	O
seizure	O
threshold	O
and	O
is	O
therefore	O
contra	O
-	O
indicated	O
for	O
TMS	O
.	O

2	O
.	O

Screening	B
tools	O
:	O
MRI	B
safety	B
screening	I
questionnaire	I
,	O
Medical	B
history	I
,	O
Medical	O
Assessments	O
:	O
Urine	B
toxicology	I
analyzes	I
for	O
presence	O
of	O
a	O
broad	O
range	O
of	O
prescription	B
and	O
nonprescription	B
drugs	B
.	O

6	O
.	O

Lifetime	B
history	I
of	I
major	B
depressive	I
disorder	I
,	O
schizophrenia	B
,	O
bipolar	B
disorder	I
,	O
mania	B
,	O
or	O
hypomania	B
.	O

1	O
.	O

Justification	O
:	O
The	O
population	O
of	O
interest	O
here	O
is	O
a	O
healthy	O
control	O
population	O
with	O
no	O
psychiatric	O
disorders	O
.	O
In	O
subjects	O
with	O
depression	O
,	O
bipolar	O
disorder	O
,	O
mania	O
or	O
hypomania	O
,	O
there	O
is	O
a	O
small	O
chance	O
that	O
TMS	O
can	O
trigger	O
(	O
hypo	O
)	O
manic	O
symptoms	O
.	O

2	O
.	O

Screening	O
tools	O
:	O
SCID	O
Screen	O
Patient	O
Questionnaire	O
.	O

Potential	O
diagnoses	O
will	O
be	O
further	O
evaluated	O
by	O
a	O
counsellor	O
.	O

7	O
.	O

Meet	B
current	O
DSM	B
V	I
criteria	I
for	O
moderate	B
to	I
severe	I
substance	B
use	I
disorder	I
(	O
excluding	B
nicotine	B
)	O
,	O
smoke	O
daily	O
,	O
or	O
urine	B
toxicology	I
positive	B
for	O
any	O
illicit	B
substance	I
inconsistent	B
with	I
history	I
given	O
.	O

1	O
.	O

Justification	O
:	O
The	O
population	O
of	O
interest	O
here	O
is	O
a	O
healthy	O
control	O
population	O
with	O
no	O
substance	O
use	O
disorder	O
.	O

Current	O
use	O
of	O
illicit	O
substances	O
could	O
impact	O
on	O
seizure	O
threshold	O
and	O
is	O
therefore	O
contra	O
-	O
indicated	O
for	O
TMS	O
.	O

2	O
.	O

Screening	O
tools	O
:	O
SCID	B
Screen	I
Patient	I
Questionnaire	I
.	O

Potential	O
diagnoses	O
will	O
be	O
further	O
evaluated	O
by	O
a	O
counsellor	O
,	O
Drug	O
Use	O
Survey	O
(	O
DUS	O
)	O
,	O
Substance	O
Use	O
Disorder	O
Evaluation	O
,	O
Medical	O
Assessments	O
:	O
urine	O
qualitative	O
drug	O
screen	O
is	O
performed	O
for	O
methadone	O
,	O
benzodiazepines	O
,	O
cocaine	O
,	O
amphetamine	O
/	O
methamphetamine	O
,	O
opiates	O
,	O
barbiturates	O
,	O
and	O
tetrahydrocannabinol	O
.	O

8	O
.	O

Have	O
met	B
DSM	B
V	I
criteria	I
for	O
moderate	B
to	I
severe	I
substance	B
use	I
disorder	I
(	O
excluding	B
nicotine	B
,	O
alcohol	B
and	O
cannabis	B
)	O
in	B
the	I
past	I
,	O
or	O
have	O
met	B
DSM	B
V	I
criteria	I
for	O
moderate	B
to	I
severe	I
substance	B
use	I
disorder	I
for	O
cannabis	B
or	O
alcohol	B
in	B
the	I
past	I
5	I
years	I
.	O

1	O
.	O

Justification	O
:	O
the	O
population	O
of	O
interest	O
here	O
is	O
a	O
healthy	O
control	O
population	O
with	O
no	O
present	O
or	O
past	O
substance	O
use	O
disorder	O
.	O

2	O
.	O

Screening	O
tools	O
:	O
SCID	B
Screen	I
Patient	I
Questionnaire	I
.	O

Potential	O
diagnoses	O
will	O
be	O
further	O
evaluated	O
by	O
a	O
counselor	O
.	O

Drug	B
Use	I
Survey	I
(	I
DUS	I
)	I
,	O
Substance	B
Use	I
Disorder	I
Evaluation	I
.	O

9	O
.	O

History	B
of	O
myocardial	B
infarction	I
,	O
angina	B
,	O
congestive	B
heart	I
failure	I
,	O
cardiomyopathy	B
,	O
stroke	B
or	O
transient	B
ischemic	I
attack	I
,	O
or	O
any	O
heart	B
condition	I
currently	B
under	B
medical	I
care	I
.	O

1	O
.	O

Justifications	O
:	O
the	O
risk	O
of	O
TMS	O
for	O
individuals	O
with	O
a	O
heart	O
condition	O
is	O
unknown	O
.	O

2	O
.	O

Screening	O
tool	O
:	O
physical	O
assessment	O
(	O
EKG	O
)	O
,	O
medical	O
history	O
.	O

10	O
.	O

Pregnant	B
women	B
or	O
women	B
with	O
reproductive	B
potential	I
who	O
are	O
sexually	B
active	I
and	O
not	B
using	O
an	O
acceptable	B
form	I
of	I
contraception	B
.	O

1	O
.	O

Justification	O
:	O
it	O
is	O
unknown	O
whether	O
TMS	O
poses	O
a	O
risk	O
to	O
fetuses	O
.	O

2	O
.	O

Screening	O
tool	O
:	O
Medical	B
assessments	I
(	O
urine	B
pregnancy	I
test	I
)	O
at	B
the	I
beginning	I
of	I
each	I
visit	I
that	O
involves	O
TMS	B
or	O
MRI	B
.	O

11	O
.	O

History	B
of	O
learning	B
disability	I
or	O
current	B
ADHD	B

1	O
.	O

Justification	O
:	O
Subjects	O
should	O
be	O
able	O
to	O
perform	O
cognitive	O
tasks	O
to	O
a	O
high	O
degree	O
of	O
accuracy	O
,	O
both	O
in	O
the	O
MRI	O
scanner	O
and	O
outside	O
the	O
scanner	O
.	O

Subjects	O
with	O
ADHD	B
/	O
LD	B
may	O
engage	O
different	O
neural	O
circuitry	O
even	O
if	O
they	O
can	O
perform	O
the	O
tasks	O
.	O

2	O
.	O

Screening	O
tool	O
:	O
Wechsler	B
Abbreviated	I
Scale	I
of	I
Intelligence	I
,	O
Medical	B
history	I
,	O
Adult	B
ADHD	I
Self	I
-	I
Report	I
Scale	I
.	O

12	O
.	O

Participation	O
in	O
an	O
rTMS	B
session	I
less	B
than	I
two	I
weeks	I
ago	I
.	O

1	O
.	O

Justification	O
:	O
in	O
order	O
to	O
limit	O
exposure	O
to	O
TMS	O
,	O
we	O
will	O
not	O
enroll	O
subjects	O
who	O
have	O
received	O
TMS	O
less	O
than	O
two	O
weeks	O
ago	O
.	O

2	O
.	O

Screening	O
tool	O
:	O
TMS	B
safety	I
screening	I
questionnaire	I
.	O

Subjects	O
must	O
:	O

1	O
.	O

Be	O
able	O
to	O
give	O
valid	O
informed	O
consent	O

2	O
.	O

Be	O
18	B
55	I
years	I
of	O
age	B
.	O

1	O
.	O

Justification	O
:	O
Many	O
neural	O
processes	O
change	O
with	O
age	O
,	O
and	O
these	O
changes	O
could	O
introduce	O
unwanted	O
variability	O
in	O
both	O
behavioral	O
and	O
MRI	O
signals	O
.	O

In	O
addition	O
,	O
the	O
risk	O
of	O
difficult	O
-	O
to	O
-	O
detect	O
medical	O
abnormalities	O
such	O
as	O
silent	O
cerebral	O
infarcts	O
increases	O
with	O
age	O
.	O

2	O
.	O

Screening	O
tool	O
:	O
History	B
.	O

Government	O
-	O
issued	O
forms	O
of	O
identification	O
(	O
e	O
.	O
g	O
.	O
driver	O
s	O
license	O
,	O
birth	O
certificate	O
)	O
will	O
be	O
required	O
when	O
participant	O
appears	O
to	O
be	O
out	O
of	O
age	O
range	O
.	O

3	O
.	O

Be	O
in	O
good	B
health	I
.	O

1	O
.	O

Justification	O
:	O
Many	O
illnesses	O
may	O
alter	O
neural	O
functioning	O
as	O
well	O
as	O
fMRI	O
signals	O
.	O

2	O
.	O

Screening	O
tools	O
:	O
Medical	B
Assessment	I
,	O
Medical	B
History	I
and	O
Physical	B
Examination	I
.	O

Medical	O
assessments	O
include	O
:	O
Vital	B
Signs	I
,	O
EKG	B
,	O
oral	B
HIV	I
test	I
,	O
height	O
/	O
weight	B
measurements	I
,	O
urinalysis	B
and	O
blood	B
sample	I
.	O

Tests	O
on	O
the	O
blood	O
sample	O
include	O
CBC	B
,	O
complete	B
metabolic	I
profile	I
,	O
TSH	B
,	O
ESR	B
,	O
STS	B
and	O
HIV	B
(	O
if	O
needed	O
to	O
confirm	O
a	O
positive	B
salivary	B
test	I
for	I
HIV	I
)	O
.	O

The	O
following	O
individual	O
laboratory	O
results	O
will	O
independently	O
disqualify	B
individuals	O
:	O
Cholesterol	B
>	B
250	I
mg	I
/	I
dl	I
,	O
Hemoglobin	B
<	B
10	I
.	I
5	I
g	I
/	I
dl	I
,	O
WBC	B
<	B
2400	I
/	I
microl	I
,	O
LFTs	B
>	B
3Xnormal	I
,	O
HCG	B
positive	B
,	O
Casual	O
serum	B
glucose	I
>	B
200	I
mg	I
/	I
dl	I
,	O
Urine	B
protein	I
>	B
1	I
+	I
.	O

The	O
MAI	O
will	O
retain	O
discretion	O
to	O
exclude	O
at	O
less	O
extreme	O
values	O
,	O
depending	O
on	O
the	O
clinical	O
presentation	O
.	O

(	O
Serum	B
glucose	I
over	B
140	I
mg	I
/	I
dl	I
will	O
be	O
followed	O
up	O
with	O
a	O
fasting	B
serum	I
glucose	I
assessment	I
.	O
Those	O
with	O
fasting	O
glucose	O
below	O
100	O
mg	O
/	O
dl	O
may	O
be	O
considered	O
for	O
the	O
protocol	O
.	O
Others	O
will	O
be	O
rejected	O
and	O
referred	O
for	O
work	O
-	O
up	O
.	O
)	O
MAI	O
will	O
make	O
the	O
final	O
judgment	O
on	O
any	O
questionable	O
lab	O
results	O
.	O

4	O
.	O

Right	B
-	I
handed	I
.	O

1	O
.	O

Justification	O
:	O
Using	O
right	O
-	O
handed	O
individuals	O
will	O
reduce	O
variability	O
in	O
BOLD	O
MRI	O
data	O
.	O

2	O
.	O

Screening	O
tool	O
:	O
Edinburgh	B
Handedness	I
Inventory	I
.	O

5	O
.	O

Estimated	B
IQ	I
greater	B
than	I
or	I
equal	I
to	I
85	I

1	O
.	O

Justification	O
:	O
Subjects	O
must	O
be	O
able	O
to	O
perform	O
a	O
cognitively	O
challenging	O
task	O
to	O
a	O
high	O
standard	O
.	O

2	O
.	O

Screening	O
tool	O
:	O
Wechsler	B
Abbreviated	I
Scale	I
of	I
Intelligence	I
.	O

preterm	B
delivery	I
(	O
<	B
37	I
weeks	I
of	O
gestation	B
)	O

birth	B
weight	I
<	B
2500	I
g	I

multiple	B
pregnancy	I

major	B
illness	I
or	O
congenital	B
anomaly	I

being	O
<	B
50	I
%	I
breastfed	O
at	B
the	I
time	I
of	I
inclusion	I

food	B
allergy	I

anaemia	B
(	O
Hb	B
<	B
105	I
g	I
/	I
L	I
[	O
10	B
.	I
5	I
g	I
/	I
dL	I
]	O
)	O
at	B
inclusion	I
,	O
lack	O
of	O
informed	O
consent	O

Term	O
singleton	B
infants	I
(	O
>	B
37	I
weeks	I
gestational	B
age	I
)	O

Birth	B
weight	I
>	B
2500g	I

Healthy	B
at	B
inclusion	I

Breastfed	B
exclusively	B
or	O
predominantly	B
(	O
>	B
50	I
%	I
meals	I
)	O
at	B
inclusion	I

No	B
previous	B
iron	B
supplementation	I

No	B
previous	B
blood	B
transfusion	I

Informed	O
consent	O
given	O

1	O
.	O

History	O
or	O
presence	O
of	O
allergy	B
to	O
the	O
study	B
drugs	I
or	O
their	O
components	O
or	O
drugs	O
of	O
their	O
class	O
,	O
or	O
a	O
history	O
of	O
drug	O
or	O
other	O
allergy	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
physician	O
responsible	O
,	O
contraindicates	O
their	O
participation	O

2	O
.	O

Any	O
finding	O
of	O
the	O
medical	O
examination	O
(	O
including	O
blood	O
pressure	O
,	O
pulse	O
rate	O
and	O
electrocardiogram	O
)	O
deviating	O
from	O
normal	O
and	O
of	O
clinical	O
relevance	O

3	O
.	O

History	O
or	O
diagnosis	O
of	O
any	O
significant	B
medical	B
conditions	I
:	O
Including	O
but	O
not	O
limited	O
to	O
gastrointestinal	O
,	O
hepatic	O
,	O
renal	O
,	O
respiratory	O
,	O
cardiovascular	O
,	O
metabolic	O
,	O
immunologic	O
,	O
hematological	O
,	O
psychiatric	O
,	O
neurological	O
,	O
oncological	O
or	O
hormonal	B
disorders	I

4	O
.	O

Known	O
elevated	B
liver	B
enzymes	I
in	O
past	O
clinical	O
trials	O
with	O
any	O
compound	O
(	O
experimental	O
or	O
marketed	O
)	O

5	O
.	O

Clinically	B
relevant	I
laboratory	B
abnormalities	I
(	O
e	O
.	O
g	O
.	O
Hgb	B
<	B
11g	I
/	I
dL	I
,	O
Hct	B
<	B
30g	I
/	I
dL	I
,	O
total	B
cholesterol	I
>	B
240mg	I
/	I
dL	I
,	O
triglycerides	B
>	B
500mg	I
/	I
dL	I
,	O
fasting	B
glucose	I
>	B
130mg	I
/	I
dL	I
,	O
liver	B
function	I
tests	I
>	B
2	I
.	I
5x	I
upper	I
limit	I
of	I
normal	I
,	O
baseline	B
international	B
normalized	I
ratio	I
>	B
1	I
.	I
2	I
)	O

6	O
.	O

History	B
of	O
evidence	O
of	O
clinically	B
significant	I
hepatic	O
,	O
cardiac	O
,	O
pulmonary	O
,	O
endocrine	O
,	O
immunological	O
,	O
gastrointestinal	O
,	O
hematological	O
,	O
vascular	O
or	O
collagen	B
disease	I

7	O
.	O

History	O
of	O
alcohol	B
abuse	I
or	O
use	B
of	I
any	I
illicit	I
drugs	I

8	O
.	O

Unable	O
to	O
abstain	O
from	O
more	O
than	O
one	O
beer	O
or	O
alcohol	O
equivalent	O
per	O
day	O
for	O
the	O
duration	O
of	O
the	O
study	O

9	O
.	O

Use	O
of	O
tobacco	B
products	I
and	O
/	O
or	O
history	B
of	O
smoking	O
within	B
the	I
past	I
2	I
months	I

10	O
.	O

Pregnant	B
or	O
breast	O
feeding	O

11	O
.	O

Sexually	B
active	I
women	B
of	O
childbearing	B
age	B
who	O
do	O
not	B
use	O
an	O
acceptable	B
barrier	B
method	I
of	I
birth	I
control	I

12	O
.	O

Hypersensitivity	B
to	O
caffeine	B
,	O
warfarin	B
,	O
vitamin	B
K	I
,	O
omeprazole	B
,	O
dextromethorphan	B
,	O
midazolam	B
,	O
tipranavir	B
,	O
ritonavir	B
or	O
their	O
excipients	O

13	O
.	O

Concomitant	B
treatment	O
with	O
other	O
experimental	B
compounds	I

14	O
.	O

Concomitant	B
administration	O
of	O
any	O
prescription	O
or	O
over	O
the	O
counter	O
medications	B
known	I
to	I
alter	I
P450	I
enzyme	I
or	I
P	I
-	I
gp	I
activity	I

15	O
.	O

Concomitant	B
administration	O
of	O
any	O
prescription	O
or	O
over	O
the	O
counter	O
medications	B
known	I
to	I
be	I
highly	I
dependent	I
on	I
P450	I
or	I
P	I
-	I
gp	I
for	I
clearance	I
for	O
which	O
elevated	B
plasma	B
concentrations	I
are	O
known	O
to	O
be	O
associated	O
with	O
serious	B
toxicity	B

16	O
.	O

Concomitant	B
administration	O
of	O
any	O
food	B
product	I
known	I
to	I
alter	I
P450	I
enzyme	I
or	I
P	I
-	I
gp	I
activity	I
such	O
as	O
grapefruit	B
juice	I
,	O
Seville	B
oranges	I

17	O
.	O

Concomitant	O
administration	O
of	O
any	O
drug	B
that	I
could	I
affect	I
bleeding	I
(	O
e	O
.	O
g	O
.	O
,	O
aspirin	B
,	O
clopidogrel	B
,	O
ticlopidine	B
,	O
warfarin	B
,	O
heparin	B
,	O
low	B
-	I
molecular	I
weight	I
heparin	I
)	O

18	O
.	O

Concomitant	B
administration	O
of	O
oral	B
contraceptives	I
(	O
may	O
be	O
included	O
with	O
7	O
-	O
day	O
washout	O
period	O
)	O

19	O
.	O

Concomitant	B
administration	O
of	O
any	O
herbal	B
medications	I

20	O
.	O

Inadequate	B
venous	B
access	I

21	O
.	O

Renal	O
or	O
hepatic	B
insufficiency	I

22	O
.	O

Clinically	B
unacceptable	I
result	O
at	O
the	O
screening	O
physical	B
examination	I

23	O
.	O

Use	O
of	O
investigational	B
medications	I
within	B
30	I
days	I
before	I
study	I
entry	I

24	O
.	O

HIV	B
-	O
positive	B

25	O
.	O

Body	B
Mass	I
Index	I
(	I
BMI	I
)	I
>	B
30	I
kg	I
/	I
m²	I

1	O
.	O

Signed	O
informed	O
consent	O

2	O
.	O

Healthy	B
subjects	O
aged	B
between	B
18	I
years	I
and	I
45	I
years	I
inclusive	I

3	O
.	O

Weighing	B
at	B
least	I
50	I
kg	I

4	O
.	O

Volunteers	O
must	O
be	O
hospitalized	O
on	O
Days	O
1	O
-	O
4	O
,	O
7	O
-	O
9	O
,	O
and	O
17	O
-	O
20	O
for	O
pharmacokinetic	O
assessments	O
for	O
each	O
biomarker	O
and	O
TPV	O
/	O
r	O
(	O
Days	O
7	O
-	O
9	O
and	O
17	O
-	O
20	O
)	O

5	O
.	O

Volunteers	O
must	O
be	O
willing	O
to	O
complete	O
all	O
study	O
-	O
related	O
activities	O

6	O
.	O

Each	O
volunteer	O
must	O
have	O
a	O
valid	O
social	O
security	O
number	O

7	O
.	O

Each	O
volunteer	O
must	O
have	O
acceptable	O
medical	B
history	I
,	O
physical	B
examination	I
and	O
laboratory	B
test	I

Pediatric	B
patients	O
(	O
under	O
18	O
years	B
)	O
Pregnancy	B
Patients	O
who	O
are	O
unresponsive	O
at	B
baseline	I
,	O
who	O
have	O
neurologic	B
deficits	I
at	B
baseline	I
,	O
or	O
who	O
are	O
allergic	B
to	O
dexmedetomidine	B

Adult	B
patients	O
(	O
18years	B
old	O
or	O
older	O
)	O
undergoing	O
living	O
-	O
donor	O
or	O
deceased	B
-	I
donor	I
liver	I
transplantation	I

Need	O
for	O
long	B
-	I
term	I
oral	I
anticoagulation	I
;	O

Drug	B
-	I
eluting	I
stent	I
implantation	B
within	O
3	O
months	O
prior	O
to	O
TAVI	B
procedure	I
;	O

Bare	B
-	I
metal	I
stent	I
implantation	B
within	O
1	O
month	O
prior	O
to	O
TAVI	B
procedure	I
;	O

Allergy	B
or	O
intolerance	B
to	O
aspirin	B
or	O
clopidogrel	B
.	O

Drug	B
-	I
eluting	I
stent	I
implantation	B
within	O
3	O
months	O
prior	O
to	O
TAVI	B
procedure	I
;	O

Bare	B
-	I
metal	I
stent	I
implantation	B
within	O
1	O
month	O
prior	O
to	O
TAVI	B
procedure	I
;	O

Allergy	B
or	O
intolerance	B
to	O
(	B
N	I
)	I
OAC	I
or	O
clopidogrel	B
.	O

Need	O
for	O
long	B
-	I
term	I
oral	I
anticoagulation	I
;	O

Patient	O
has	O
provided	O
written	O
informed	O
consent	O
.	O

Allergy	B
or	O
contraindication	B
to	O
paracetamol	B
,	O
Prasugrel	B
or	O
Ticagrelor	B

Paracetamol	B
ingestion	O
in	B
the	I
previous	I
48	I
hours	I

Patient	O
treated	O
with	O
drugs	B
supposed	I
to	I
alter	I
gastric	I
emptying	I
times	I
(	O
calcium	B
antagonists	I
,	O
Alimentary	B
tract	I
treatments	I
,	O
opioid	B
analgesics	I
,	O
tricyclic	B
antidepressants	I
,	O
antibiotics	B
)	O
.	O

Conditions	O
or	O
pathologies	B
supposed	I
to	I
alter	I
gastric	I
emptying	I
times	I
(	O
Thyroid	B
dysfunction	I
,	O
chronic	B
renal	I
failure	I
,	O
Parkinson	B
'	I
s	I
disease	I
,	O
scleroderma	B
,	O
amyloidosis	B
,	O
any	O
gastrointestinal	B
disease	I
,	O
any	O
not	O
cured	O
malignancy	B
,	O
and	O
any	O
advanced	B
psychiatric	O
or	O
neurological	B
disease	I
)	O
.	O

Presence	O
of	O
vomiting	B

Cardiogenic	B
shock	I
,	O
ventricular	B
arrhythmia	I
or	O
resuscitated	B
cardiac	B
arrest	I

Hepatic	B
insufficiency	I

Severe	B
respiratory	B
disease	I

Pregnant	B
or	O
breastfeeding	O
women	B

Patient	O
over	B
18	I
years	B
weighing	B
between	B
65	I
and	I
85	I
Kg	I

Referred	O
for	O
STEMI	B
within	O
6	O
hours	O
from	O
beginning	O
of	O
chest	B
pain	I
or	O
stable	B
coronary	B
artery	I
disease	I
requiring	O
a	O
loading	B
dose	I
of	O
Prasugrel	B
or	O
Ticagrelor	B
according	O
to	O
the	O
international	O
recommendations	O
.	O

No	B
previous	B
treatment	B
with	O
Clopidogrel	B
,	O
Prasugrel	B
or	O
Ticagrelor	B
.	O

Patient	O
fasting	O
for	B
at	I
least	I
6	I
hours	I
.	I

Affiliate	O
or	O
receiving	O
a	O
social	O
security	O
system	O
.	O

Written	O
informed	O
consent	O
.	O

Renal	B
insufficiency	I
(	O
>	O
265	O
µmol	O
/	O
l	O
)	O

Incapability	O
to	O
give	O
informed	O
consent	O

Cardiogenic	B
shock	I
of	O
patient	O
with	O
KILLIP	B
III	B
or	I
IV	I

pregnant	B
or	O
breast	O
feeding	O
females	B

insufficient	B
contraception	B
(	O
only	O
for	O
substudy	O
3	O
)	O

Patients	O
with	O
heart	B
transplantation	I

Patient	O
with	O
coronary	B
artery	I
disease	I

Age	B
between	B
18	I
and	I
80	I
years	I

NA	O

Healthy	B

Male	B

>	B
7	I
Metabolic	B
Equivalents	I

Written	O
informed	O
consent	O

Chronic	B
pain	I
syndrome	I

Drug	B
abuse	I

Alcohol	B
abuse	I

Suspicion	O
of	O
neurologic	B
dysfunction	I
at	O
tested	B
sites	I

Ongoing	B
treatment	B
with	O
antidepressants	B

Ongoing	B
treatment	B
with	O
analgesics	B

Pretreatment	B
with	O
any	O
CYP3A	B
inducers	I
or	O
inhibitors	O

Known	O
allergy	B
to	O
tested	B
drugs	I

Elevated	B
eye	I
pressure	I

Obstructive	B
uropathy	I

Heart	B
disease	I

Pulmonary	B
disease	I

Neurological	B
disease	I

Psychiatric	B
illness	I

NA	O

Healthy	B

Male	B

>	B
7	I
Metabolic	B
Equivalents	I

Written	O
informed	O
consent	O

Chronic	B
pain	I
syndrome	I

Drug	B
abuse	I

Alcohol	B
abuse	I

Suspicion	O
of	O
neurologic	B
dysfunction	I
at	O
tested	B
sites	I

Ongoing	B
treatment	B
with	O
antidepressants	B

Ongoing	B
treatment	B
with	O
analgesics	B

Pretreatment	B
with	O
any	O
CYP3A	B
inducers	I
or	O
inhibitors	O

Known	O
allergy	B
to	O
tested	B
drugs	I

Elevated	B
eye	I
pressure	I

Obstructive	B
uropathy	I

Heart	B
disease	I

Pulmonary	B
disease	I

Neurological	B
disease	I

Psychiatric	B
illness	I

Preoperative	B
use	O
of	O
an	O
anticoagulant	B
(	O
Plavix	B
,	O
warfarin	B
,	O
lovenox	B
,	O
etc	O
.	O
)	O

History	O
of	O
hypersensitivity	B
to	O
EACA	B

History	O
of	O
thromboembolic	B
event	I
(	O
e	O
.	O
g	O
.	O
,	O
PE	B
or	O
DVT	B
)	O

History	O
of	O
renal	B
insufficiency	I
or	O
failure	O

Congenital	B
or	O
acquired	B
coagulopathy	B
as	O
evidence	O
by	O
INR	B
>	O
1	O
.	O
4	O
or	O
PTT	B
>	B
1	I
.	I
4	I
times	I
normal	I
,	O
or	O
Platelets	B
<	B
150	I
,	I
000	I
/	I
mm3	I
on	O
preoperative	B
laboratory	I
testing	I

Use	O
of	O
hormone	B
replacement	I
therapy	I
or	O
hormonal	B
contraceptive	I
agents	I
within	B
days	I
prior	I
to	I
surgery	I

Use	O
of	O
acetylsalicylic	B
acid	I
(	O
ASA	B
)	O
,	O
antiplatelet	B
agents	I
within	B
7	I
days	I
prior	I
to	I
surgery	I

Pregnant	B

Breastfeeding	O

Not	B
received	I
neuraxial	B
anesthesia	I

Scheduled	O
for	O
bilateral	B
varus	B
rotational	I
osteotomy	I
(	O
VRO	B
)	O
with	O
or	O
without	O
associated	O
soft	O
tissue	O
and	O
osseous	B
procedures	I

Hypersensitivity	B
on	O
Colchicine	B

The	O
existence	O
of	O
intra	B
-	I
cardiac	I
thrombus	I
on	O
trans	B
-	I
esophageal	I
echocardiography	I

Pregnancy	B

Patients	O
needed	O
to	O
pericardiocentesis	B
during	O
RFCA	B
for	O
paroxysmal	B
or	O
persistent	B
atrial	B
fibrillation	I
.	O

Participant	O
has	O
a	O
clinically	B
significant	I
abnormal	B
physical	I
examination	I
,	O
vital	O
signs	O
or	O
12	O
lead	O
ECG	O
(	O
including	O
QTc	B
greater	B
than	I
(	I
>	I
)	I
450msec	I
,	O
Left	B
Bundle	I
Branch	I
Block	I
,	O
permanent	B
pacemaker	I
or	O
implantable	B
cardioverter	I
defibrillator	I
)	O
at	B
Screening	I
or	I
admission	I

Participant	O
has	O
a	O
history	B
of	O
or	O
current	O
liver	O
or	O
renal	B
insufficiency	I
;	O
significant	B
cardiac	O
,	O
vascular	O
,	O
pulmonary	O
,	O
gastrointestinal	O
,	O
endocrine	O
,	O
neurologic	O
,	O
hematologic	O
,	O
rheumatologic	O
,	O
psychiatric	O
,	O
or	O
metabolic	B
disturbances	I

Use	O
of	O
any	B
prescription	I
or	O
over	B
-	I
the	I
-	I
counter	I
medication	I
,	O
herbal	B
medication	I
,	O
vitamins	B
,	O
or	O
mineral	B
supplements	I
within	B
14	I
days	I
prior	I
to	I
study	I
drug	I
administration	I
(	O
not	B
including	O
paracetamol	B
)	O
.	O

Medication	B
for	O
chronic	B
use	I
in	O
age	B
related	I
disease	I
will	O
be	O
allowed	O
after	O
approval	O
by	O
both	O
the	O
investigator	O
and	O
to	O
the	O
sponsor	O
.	O

No	O
change	O
in	O
dose	O
or	O
regimen	O
will	O
be	O
permitted	O
during	O
the	O
study	O
that	O
is	O
,	O
from	O
the	O
Screening	O
visit	O
until	O
the	O
follow	O
-	O
up	O
visit	O

Participant	O
has	O
a	O
history	B
of	O
spontaneous	B
,	O
prolonged	B
or	O
severe	B
bleeding	B
of	O
unclear	B
origin	I

Participant	O
has	O
a	O
history	B
of	O
epilepsy	B
or	O
fits	B
or	O
unexplained	B
black	B
-	I
outs	I
other	B
than	I
vasovagal	B
collapse	I

Body	B
mass	I
index	I
(	O
BMI	B
;	O
weight	B
[	I
kilogram	I
(	I
kg	I
)	I
]	I
/	I
height	I
^	I
2	I
[	I
meter	I
square	I
(	I
m	I
^	I
2	I
)	I
]	I
)	O
between	B
18	I
and	I
30	I
kg	I
/	I
m	I
^	I
2	I
,	O
(	O
inclusive	O
)	O

Be	O
healthy	O
for	O
their	O
age	O
group	O
with	O
or	O
without	O
medication	O
on	O
the	O
basis	O
of	O
physical	B
examination	I
,	O
medical	B
history	I
,	O
vital	B
signs	I
,	O
and	O
12	O
-	O
lead	O
electrocardiogram	O
(	O
ECG	O
)	O
performed	B
at	I
Screening	I
or	I
admission	I
.	O

Minor	O
deviations	O
in	O
ECG	B
,	O
which	B
are	I
not	I
considered	I
to	I
be	I
of	I
clinical	I
significance	I
to	I
the	I
investigator	I
,	O
are	O
acceptable	O

Be	O
healthy	B
on	O
the	O
basis	O
of	O
clinical	B
laboratory	I
tests	I
performed	B
at	I
Screening	I
.	O

If	O
the	O
results	O
of	O
the	O
serum	B
chemistry	I
panel	I
[	O
including	O
liver	B
enzymes	I
]	O
,	O
hematology	B
,	O
or	O
urinalysis	B
are	O
outside	B
the	I
normal	I
reference	I
ranges	I
,	O
the	O
participant	O
may	O
be	O
included	O
only	O
if	O
the	O
investigator	O
judges	O
the	O
abnormalities	O
or	O
deviations	O
from	O
normal	O
to	O
be	O
not	O
clinically	O
significant	O
.	O

This	O
determination	O
must	O
be	O
recorded	O
in	O
the	O
participants	O
'	O
source	O
documents	O
and	O
initialed	O
by	O
the	O
investigator	O

Men	O
who	O
are	O
sexually	O
active	O
with	O
a	O
woman	O
of	O
childbearing	O
potential	O
and	O
have	O
not	O
had	O
a	O
vasectomy	O
must	O
agree	O
to	O
use	O
a	O
barrier	O
method	O
of	O
birth	O
control	O
for	O
example	O
,	O
either	O
condom	O
with	O
spermicidal	O
foam	O
/	O
gel	O
/	O
film	O
/	O
cream	O
/	O
suppository	O
or	O
partner	O
with	O
occlusive	O
cap	O
(	O
diaphragm	O
or	O
cervical	O
/	O
vault	O
caps	O
)	O
with	O
spermicidal	O
foam	O
/	O
gel	O
/	O
film	O
/	O
cream	O
/	O
suppository	O
,	O
and	O
all	O
men	O
must	O
also	O
not	O
donate	O
sperm	O
during	O
the	O
study	O
and	O
for	O
3	O
months	O
after	O
receiving	O
the	O
last	O
dose	O
of	O
study	O
drug	O
.	O

In	O
addition	O
,	O
their	O
female	O
partners	O
should	O
also	O
use	O
an	O
appropriate	O
method	O
of	O
birth	O
control	O
for	O
at	O
least	O
the	O
same	O
duration	O

Participants	O
'	O
must	O
have	O
signed	O
an	O
informed	O
consent	O
document	O
indicating	O
that	O
they	O
understand	O
the	O
purpose	O
of	O
and	O
procedures	O
required	O
for	O
the	O
study	O
and	O
are	O
willing	O
to	O
participate	O
in	O
the	O
study	O

Have	O
history	O
of	O
female	B
sterilization	I
procedure	I

Desire	O
for	O
conception	O
in	B
the	I
next	I
12	I
months	I

Not	B
sexually	O
active	O
with	O
a	O
male	B
partner	I

Women	B
age	B
18	B
-	I
45	I

Within	O
6	O
months	O
of	O
expiration	O
or	O
beyond	O
the	O
end	O
of	O
the	O
FDA	O
-	O
approved	O
duration	O
of	O
use	O
of	O
the	O
levonorgestrel	O
intrauterine	O
device	O
(	O
LNG	O
-	O
IUD	O
=	O
5	O
years	O
)	O
OR	O
the	O
etonogestrel	O
-	O
releasing	O
subdermal	O
implant	O
(	O
ENG	O
implant	O
=	O
3	O
years	O
)	O

Able	O
to	O
consent	O
in	O
English	O
or	O
Spanish	O
.	O

Not	B
pregnant	B
at	B
the	I
time	I
of	I
enrollment	I

hypoglycemia	B
SE	I
;	O
psychogenic	B
SE	I
;	O
any	O
other	O
pseudo	B
-	I
SE	I

30	B
min	I
or	I
more	I
of	O
(	O
1	O
)	O
continuous	B
clinical	O
seizure	B
activities	O
or	O
(	O
2	O
)	O
recurrent	B
seizure	B
activities	O
without	B
recovery	I
(	O
returning	O
to	O
baseline	O
)	O
between	O
seizures	O
;	O

clinical	O
data	O
is	O
complete	O
.	O

NA	O

Patients	O
who	O
meet	O
1987	O
ACR	O
criteria	O
for	O
SLE	B
with	O
1996	O
modifications	O

SLEDAI	B
>	B
/	I
=	I
6	I
at	B
screening	I
visit	I

Positive	B
ANA	B
OR	O
anti	B
-	I
dsDNA	I
within	B
one	I
year	I
of	I
screening	I

In	O
the	O
opinion	O
of	O
the	O
investigator	O
there	O
is	O
intent	O
to	O
treat	O
with	O
a	O
biologic	O
(	O
e	O
.	O
g	O
.	O
patient	O
failed	O
standard	O
of	O
care	O
treatment	O
)	O
however	O
there	O
is	O
no	O
organ	O
threatening	O
disease	O

Moderate	B
or	O
severe	B
endometriosis	B
.	O

Hydrosalpinx	B
.	O

Uterine	B
abnormalities	I
or	O
myoma	B
.	O

Previous	O
uterine	B
surgery	I
.	O

Women	B
with	O
PCOS	B
as	O
defined	O
by	O
the	O
Rotterdam	B
criteria	I
.	O

Presence	O
of	O
at	B
least	I
2	I
cryopreserved	B
good	B
quality	O
cleavage	O
-	O
stage	O
embryo	O
(	O
good	O
quality	O
cleavage	O
-	O
stage	O
embryos	O
display	O
stage	O
-	O
specific	O
cell	O
division	O
,	O
have	O
blastomeres	O
of	O
fairly	O
equal	O
size	O
with	O
few	O
to	O
no	O
cytoplasmic	O
fragments	O
)	O
.	O

women	B
undergoing	B
caesarean	B
section	I
at	O
less	B
than	I
37	I
weeks	I
of	O
gestation	B
.	O

Hypertension	B
with	O
pregnancy	B
.	O

Cardiac	O
and	O
coronary	B
diseases	I
with	O
pregnancy	B

Women	O
with	O
a	O
singleton	B
pregnancy	I
undergoing	O
cesarean	B
section	I
after	B
37	I
weeks	I
of	O
gestation	B
.	O

Women	B
undergoing	O
cesarean	B
section	I
with	O
general	B
anesthesia	I
will	O
be	O
excluded	O
,	O
because	O
carbetocin	O
is	O
licensed	O
for	O
use	O
with	O
regional	O
anaesthesia	O
only	O
.	O

women	B
undergoing	O
cesarean	B
section	I
at	O
less	B
than	I
37	I
weeks	I
of	O
gestation	B
.	O

Women	B
with	O
a	O
singleton	B
pregnancy	I
undergoing	O
cesarean	B
section	I
after	B
37	I
weeks	I
of	O
gestation	B
.	O

Known	O
intolerance	O
to	O
the	O
doxycycline	B
Body	B
weight	I
<	B
40	I
kg	I
Pregnancy	B
or	O
breastfeeding	O
History	B
of	I
severe	B
allergic	B
reaction	I
or	O
anaphylaxis	B
Alcohol	O
or	O
drug	B
abuse	I

M	B
.	I
perstans	I
mg	I
-	O
positive	B
status	O
Good	B
general	I
health	I
without	B
any	O
clinical	O
condition	O
requiring	O
long	B
-	I
term	I
medication	I
.	O

Normal	B
renal	O
and	O
hepatic	B
laboratory	I
profiles	I

micturition	B
problems	O
,	O

neurological	B
history	I
or	O

previous	O
lower	B
abdominal	I
surgery	I
with	O
an	O
abnormal	B
micturition	B

ASA	B
(	O
American	O
Society	O
of	O
Anesthesiologists	O
)	O
class	B
1	I
&	I
2	I
,	O

undergoing	O
day	O
-	O
case	O
knee	B
arthroscopy	I

The	O
patient	O
'	O
s	O
data	O
will	O
be	O
excluded	O
if	O
they	O
die	O
within	B
3	I
days	I
of	I
hospital	I
admission	I
.	O

All	O
adult	B
patients	O
18	O
years	O
of	O
age	B
or	O
older	O
admitted	B
to	O
the	O
intensive	O
care	O
units	O
of	O
St	O
.	O
Boniface	O
General	O
Hospital	O
with	O
a	O
diagnosis	O
of	O
acute	B
pulmonary	I
blastomycosis	I
requiring	O
mechanical	B
ventilation	I
.	O

Non	O
-	O
English	O
speaking	O
patients	O

Pregnant	O
women	O
(	O
women	O
of	O
childbearing	O
potential	O
will	O
be	O
advised	O
to	O
undergo	O
regular	O
pregnancy	O
testing	O
)	O

Patients	O
who	O
had	O
previously	O
undergone	O
operative	O
therapy	O
for	O
the	O
condition	O

Patient	O
must	O
be	O
18	O
years	B
or	O
older	O

Must	O
meet	O
the	O
following	O
definition	O
for	O
adhesive	B
capsulitis	I
as	O
defined	O
by	O
the	O
American	B
Academy	I
of	I
Orthopedic	I
Surgeons	I
:	O
Self	O
-	O
limiting	O
condition	O
resulting	O
from	O
any	O
inflammatory	O
process	O
about	O
the	O
shoulder	O
in	O
which	O
capsular	O
scar	O
tissue	O
is	O
produced	O
,	O
resulting	O
in	O
pain	O
and	O
limited	O
range	O
of	O
motion	O
;	O
also	O
called	O
frozen	O
shoulder	O

Must	O
be	O
amenable	O
to	O
randomization	O
into	O
either	O
cohort	O

Pregnancy	B
and	O
breast	O
feeding	O
mother	O
;	O

Estimated	O
life	O
expectancy	O
<	B
12	I
months	I
;	O

Scheduled	O
major	B
surgery	I
in	B
the	I
next	I
6	I
months	I
;	O

Inability	O
to	O
follow	O
the	O
protocol	O
and	O
comply	O
with	O
follow	O
-	O
up	O
requirements	O
or	O
any	O
other	O
reason	O
that	O
the	O
investigator	O
feels	O
would	O
place	O
the	O
patient	O
at	O
increased	O
risk	O
;	O

Previous	B
enrolment	O
in	O
this	O
study	O
or	O
treatment	O
with	O
an	O
investigational	B
drug	I
or	O
device	B
under	O
another	O
study	O
protocol	O
in	O
the	O
past	O
30	O
days	O
.	O

WHO	B
group	B
II	I
,	I
III	I
,	I
IV	I
,	I
V	I
PH	B

Severe	B
Renal	B
dysfunction	I
(	O
Ccr	B
<	B
30	I
ml	I
/	I
min	I
)	O

Blood	B
platelet	I
count	I
<	B
100	I
,	I
000	I
/	I
L	I

Expected	O
life	O
span	O
<	B
6	I
-	I
month	I

Systematical	B
inflammation	I

Malignant	B
cancer	I
(	O
s	O
)	O

Tricuspid	B
valve	I
stenosis	I
,	O
Supra	B
-	I
pulmonary	I
valve	I
stenosis	I

Allergic	B
to	O
studied	B
drugs	I
or	O
metal	O
materials	O
.	O

Provision	O
of	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
specific	O
procedures	O
;	O

Men	B
and	O
women	B
18	O
years	B
and	O
older	O
;	O

Group	B
I	I
PAH	B
,	O
defined	O
as	O
a	O
mPAP	B
=	B
25mmHg	I
,	O
PCWP	B
<	B
15mmHg	I
and	O
PVR	B
[	O
The	O
PVR	O
=	O
(	B
mPAP	I
-	I
PCWP	I
)	I
/	I
CO	I
]	O
>	B
3	I
.	I
0	I
Woods	I
unit	I
.	O

don	B
'	I
t	I
have	I
Diabetes	B
and	O
abnormal	B
metabolism	I
of	I
sugar	I

not	B
noticed	O
as	O
bipolar	B
disorder	I

have	O
an	O
organic	B
brain	I
disease	I

pregnant	B
or	O
breastfeeding	O
women	B

don	B
'	I
t	I
have	I
heart	B
disease	I

have	O
actively	B
suicidal	I
thought	I
(	O
Suicidal	B
ideation	I
score	I
of	I
MADRS	I
is	O
6	B
)	O

who	O
are	O
judged	O
by	O
the	O
investigator	O
to	O
should	O
be	O
excluded	O
from	O
the	O
study	O

major	B
depressive	I
episode	I
in	O
type2	B
bipolar	I
disorder	I
or	O
bipolar	B
disorder	I
NOS	B
.	O
(	O
MADRS	B
more	B
than	I
20	I
point	I
)	O

18years	O
to	O
65years	B

subjects	O
who	O
sign	O
the	O
informed	O
consent	O
document	O

Smokers	B

Patients	O
under	O
chronic	B
use	I
of	O
medications	B

Neurological	B
diseases	I

Coronary	B
artery	I
disease	I

Acute	B
heart	I
failure	I

Chronic	B
renal	B
failure	I
(	O
GFR	B
<	B
30	I
ml	I
/	I
min	I
)	O

Chronic	B
obstructive	B
pulmonary	I
disease	I

Mild	B
OSA	I
and	O
patients	O
with	O
BMI	B
over	B
40	I
kg	I
/	I
m2	I
.	O

Metabolic	B
Syndrome	I
(	O
ATP	B
III	B
)	O

Moderate	B
to	I
severe	I
OSA	B

Teeth	B
with	O
clinical	O
symptoms	O
of	O
irriversible	B
pulpitis	I
or	O
pulp	B
necrosis	I
or	O
acute	B
dental	I
infection	I

Children	O
with	O
systemic	B
illness	I
that	O
contraindicated	B
vital	B
pulp	I
treatment	I
such	O
a	O
sickle	B
cell	I
disease	I

Teeth	O
that	O
are	O
not	O
restorable	O

Pediatric	B
patients	O
with	O
deep	B
dental	I
decay	I
in	O
primary	B
molars	I

Teeth	B
with	O
signs	O
and	O
symptoms	O
of	O
reversible	B
pulpitis	I

recent	B
surgery	B
(	O
<	B
3	I
months	I
)	O

previous	B
chemotherapy	B

previous	B
transfusion	B
of	I
blood	I
products	I

neurodevelopmental	B
disorders	I
(	O
including	O
Trisomy	B
21	I
)	O

supplemental	B
oxygen	I
requirement	O
(	O
<	B
3	I
months	I
)	O

asthma	B
requiring	O
regular	B
therapy	I

obstructive	B
sleep	I
apnea	I

the	O
presence	O
of	O
concurrent	B
infection	B
or	O
inflammation	B

a	O
known	O
allergy	B
to	O
dexmedetomidine	B
hydrochloride	I

aged	B
between	B
3	I
-	I
36	I
months	I

having	O
primary	B
corrective	B
heart	I
surgery	I

Prior	B
trombosis	B
or	O
myocardial	B
infarction	I
,	O
congenital	B
coagulation	I
disorder	I
,	O
use	O
of	O
anti	B
-	I
coagulants	I
prior	B
to	I
surgery	I
,	O
prior	B
thoracic	B
surgery	I
,	O
pregnancy	B
,	O
pre	B
-	I
operative	I
fibrinogen	B
concentration	I
<	B
1g	I
/	I
L	I

Elective	B
surgery	I
for	O
thoracic	B
aneurysm	I

Prior	O
systemic	B
therapy	I
targeting	I
PD	I
-	I
1	I
:	I
PD	I
-	I
L1	I
axis	I
.	O

Patients	O
who	O
are	O
curable	B
by	O
conventional	B
multidisciplinary	I
management	I
.	O

Patients	O
with	O
severe	B
and	O
/	O
or	O
uncontrolled	B
concurrent	B
medical	B
disease	I
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
could	O
cause	O
unacceptable	O
safety	O
risks	O
or	O
compromise	O
compliance	O
with	O
the	O
protocol	O
.	O

Patients	O
who	O
have	O
received	O
wide	B
field	I
radiotherapy	I
≤	B
4	I
weeks	I
or	O
limited	B
field	I
radiation	I
for	I
palliation	I
<	B
2	I
weeks	I
prior	I
to	I
screening	I
or	O
who	O
have	O
not	B
recovered	B
adequately	B
from	O
side	O
effects	O
of	O
such	B
therapy	I
.	O

Patients	O
who	O
have	O
active	O
infections	B
requiring	O
therapy	B
.	O

Patients	O
that	O
are	O
known	O
to	O
be	O
positive	B
for	O
Human	B
Immunodeficiency	I
Virus	I
(	I
HIV	I
)	I
(	O
HIV	B
1	I
/	I
2	I
antibodies	I
)	O
,	O
active	B
Hepatitis	I
B	I
(	O
HBsAg	B
reactive	B
)	O
,	O
or	O
Hepatitis	B
C	I
(	O
HCV	B
RNA	I
[	I
qualitative	I
]	I
is	O
detected	B
)	O
;	O
patients	O
with	O
negative	B
Hepatitis	B
C	I
antibody	I
testing	O
may	O
not	O
need	O
RNA	O
testing	O
.	O

Patients	O
that	O
have	O
a	O
known	O
psychiatric	O
or	O
substance	B
abuse	I
disorder	I
that	O
would	O
interfere	O
with	O
cooperation	O
with	O
the	O
requirements	O
of	O
the	O
trial	O
.	O

Patients	O
who	O
received	O
systemic	B
anti	I
-	I
cancer	I
treatment	I
prior	B
to	I
the	I
first	I
dose	I
of	I
study	I
drug	I
within	O
the	O
following	O
time	O
frames	O
:	O

Patients	O
with	O
active	B
autoimmune	B
disease	I
or	O
a	O
documented	O
history	B
of	O
autoimmune	B
disease	I
or	O
syndrome	O
that	O
requires	O
systemic	B
steroids	I
or	O
immunosuppressive	B
agents	I
.	O

Patients	O
with	O
vitiligo	B
or	O
resolved	B
childhood	B
asthma	I
/	O
atopy	B
would	O
be	O
exception	O
to	O
this	O
rule	O
.	O

Patients	O
that	O
require	O
inhaled	O
steroids	O
or	O
local	O
steroid	O
injections	O
would	O
not	O
be	O
excluded	O
from	O
the	O
study	O
.	O

Patients	O
with	O
hypothyroidism	B
not	B
from	O
autoimmune	B
disease	I
that	O
is	O
stable	O
on	O
hormone	B
replacement	I
will	O
not	O
be	O
excluded	O
from	O
the	O
study	O
.	O

Women	B
who	O
are	O
pregnant	B
or	O
nursing	B
/	O
breastfeeding	O
.	O

Known	O
hypersensitivity	O
to	O
pembrolizumab	B
or	O
another	O
mAb	B
.	O

Has	O
a	O
history	B
of	O
(	O
non	O
-	O
infectious	O
)	O
pneumonitis	B
that	O
required	O
steroids	B
or	O
current	B
pneumonitis	B
.	O

Patients	O
with	O
untreated	B
central	B
nervous	I
system	I
disease	I
.	O

Patients	O
with	O
controlled	B
treated	B
CNS	B
lesions	I
who	O
have	O
undergone	O
surgery	B
or	O
stereotactic	B
radiosurgery	I
and	O
stable	B
for	B
4	I
weeks	I
are	O
eligible	O
.	O

Inability	B
to	I
comply	I
with	I
protocol	I
required	I
procedures	I
.	I

Patients	O
with	O
medical	B
conditions	I
that	O
require	O
chronic	B
systemic	B
corticosteroid	I
therapy	I
or	O
require	O
any	O
other	O
form	O
of	O
immunosuppressive	B
medication	I
.	O

However	O
,	O
patients	O
using	O
physiologic	B
replacement	I
doses	I
of	O
hydrocortisone	B
,	O
or	O
its	O
equivalent	O
,	O
will	O
be	O
considered	O
eligible	O
for	O
this	O
study	O
:	O
up	B
to	I
20	I
mg	I
hydrocortisone	B
(	O
or	O
5	B
mg	I
of	O
prednisone	B
)	O
in	B
the	I
morning	I
and	O
10	B
mg	I
hydrocortisone	B
(	O
or	O
2	B
.	I
5	I
mg	I
prednisone	B
)	O
in	B
the	I
evening	I
.	O

Patients	O
with	O
the	O
risk	O
factors	O
for	O
bowel	B
obstruction	I
or	O
bowel	B
perforation	I
(	O
examples	O
include	O
but	O
not	O
limited	O
to	O
a	O
history	B
of	O
acute	B
diverticulitis	I
,	O
intra	B
-	I
abdominal	I
abscess	I
,	O
abdominal	B
carcinomatosis	I
)	O
.	O

Patients	O
who	O
have	O
received	O
a	O
live	B
vaccine	I
within	B
30	I
days	I
prior	I
to	I
the	I
first	I
dose	I
of	I
trial	I
treatment	I
.	O

Age	B
≥	B
18	I
years	I
(	O
Age	B
≥	B
12	I
years	I
for	O
patients	O
with	O
bone	B
sarcomas	I
)	O
.	O

Histologically	B
confirmed	B
diagnosis	O
of	O
unresectable	B
,	O
recurrent	B
,	O
and	O
/	O
or	O
metastatic	B
high	B
grade	I
soft	O
-	O
tissue	O
or	O
bone	B
sarcoma	I
of	O
one	O
of	O
the	O
following	O
subtypes	O
:	O
soft	B
tissue	I
sarcomas	I
(	O
leiomyosarcoma	B
,	O
poorly	B
differentiated	I
/	O
de	B
-	I
differentiated	I
liposarcoma	B
,	O
high	B
grade	I
pleomorphic	B
undifferentiated	B
sarcoma	B
/	O
MFH	B
and	O
synovial	B
sarcoma	I
)	O
,	O
and	O
bone	B
sarcomas	I
(	O
Ewing	B
sarcoma	I
,	O
osteosarcoma	B
,	O
and	O
chondrosarcoma	B
[	O
de	B
-	I
differentiated	I
or	O
mesenchymal	B
]	O
)	O
.	O

ECOG	B
Performance	I
Status	I
of	O
0	B
or	I
1	I
.	O

At	O
least	O
one	O
site	O
of	O
measurable	B
disease	I
on	O
CT	O
/	O
MRI	B
scans	I
as	O
defined	O
by	O
RECIST	O
1	O
.	O
1	O
.	O

Baseline	B
imaging	B
must	O
be	O
performed	O
within	B
30	I
days	I
of	I
dosing	I
.	O

At	O
least	O
one	O
site	O
of	O
accessible	O
disease	O
for	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
core	O
biopsies	O
for	O
at	O
least	O
20	O
patients	O
per	O
arm	O
on	O
the	O
expansion	O
cohorts	O
.	O

Patients	O
may	O
have	O
received	O
1	B
-	I
3	I
prior	B
systemic	B
therapies	I
in	O
the	O
metastatic	B
setting	I
.	O

Adequate	B
organ	I
function	I
within	B
14	I
days	I
of	I
dosing	I

Must	O
be	O
willing	O
to	O
provide	O
and	O
have	O
available	O
archival	O
tissue	O
for	O
PD	O
-	O
L1	O
testing	O
.	O

Written	O
,	O
voluntary	O
informed	O
consent	O
.	O

Fertile	O
men	B
and	O
women	B
of	O
childbearing	B
potential	I
must	O
agree	O
to	O
use	O
an	O
effective	O
method	O
of	O
birth	B
control	I
from	B
providing	I
signed	I
consent	I
and	O
for	B
120	I
days	I
after	I
last	I
study	I
drug	I
administration	I
.	O

Women	B
of	O
childbearing	B
potential	I
include	O
pre	B
-	I
menopausal	I
women	B
and	O
women	B
within	B
the	I
first	I
2	I
years	I
of	I
the	I
onset	I
of	I
menopause	I
.	O

Women	B
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
pregnancy	B
test	I
≤	B
72	I
hours	I
prior	I
to	I
Day	I
1	I
of	O
study	O
.	O

Effective	O
methods	O
of	O
birth	B
control	I
include	O
:	O
surgically	B
sterile	I
,	O
barrier	B
device	I
(	O
condom	B
,	O
diaphragm	B
)	O
,	O
contraceptive	B
coil	I
,	O
intrauterine	B
device	I
(	I
IUD	I
)	I
,	O
and	O
abstinence	B
.	O

Life	O
expectancy	O
of	O
>	B
12	I
weeks	I
.	O

Patients	O
with	O
central	B
nervous	I
system	I
disease	I
are	O
eligible	O
for	O
enrollment	O
if	O
they	O
have	O
received	O
prior	O
radiotherapy	B
or	O
surgery	B
to	O
sites	O
of	O
CNS	B
metastatic	I
disease	I
and	O
are	O
without	B
evidence	O
of	O
clinical	B
progression	I
for	B
at	I
least	I
4	I
weeks	I
prior	I
to	I
screening	I
,	O
have	O
no	B
evidence	O
of	O
new	B
or	O
enlarging	B
brain	B
metastases	I
,	O
and	O
are	O
off	B
steroids	B
for	O
at	O
least	O
7	O
days	O
before	O
first	O
dose	O
of	O
pembrolizumab	B
.	O

History	O
or	O
known	O
presence	O
of	O
central	B
nervous	I
system	I
metastases	I
.	O

History	O
of	O
another	B
malignancy	B
except	B
:	O
Malignancy	B
treated	B
with	I
curative	I
intent	I
and	O
with	O
no	B
known	O
active	B
disease	I
present	O
for	B
>	I
=	I
5	I
years	I
prior	I
to	I
enrolment	I
and	O
felt	O
to	O
be	O
at	O
low	O
risk	O
for	O
recurrence	B
by	O
the	O
treating	O
physician	O
;	O
Adequately	B
treated	B
non	B
-	I
melanomatous	I
skin	I
cancer	I
or	O
lentigo	B
maligna	I
without	B
evidence	B
of	I
disease	I
;	O
Adequately	B
treated	B
cervical	B
carcinoma	I
in	I
situ	I
without	B
evidence	O
of	O
disease	B
;	O
Prostatic	B
intraepithelial	I
neoplasia	I
without	B
evidence	O
of	O
prostate	B
cancer	I
.	O

Known	O
immediate	O
or	O
delayed	B
hypersensitivity	I
reaction	I
or	O
idiosyncrasy	B
to	O
drugs	B
chemically	I
related	I
to	I
panitumumab	I
or	O
excipients	O
that	O
contraindicates	O
their	O
participation	O
.	O

Prior	O
anti	O
-	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFr	B
)	O
antibody	O
therapy	O
(	O
e	O
.	O
g	O
.	O
,	O
panitumumab	B
or	O
cetuximab	B
)	O
or	O
treatment	B
with	I
small	I
molecule	I
EGFr	I
inhibitors	I
(	O
e	O
.	O
g	O
.	O
,	O
gefitinib	B
,	O
erlotinib	B
,	O
lapatinib	B
)	O
.	O

Antitumor	B
therapy	I
(	O
e	O
.	O
g	O
.	O
,	O
chemotherapy	B
,	O
hormonal	B
therapy	I
,	O
immunotherapy	B
,	O
antibody	B
therapy	I
,	O
radiotherapy	B
)	O
,	O
or	O
investigational	B
agent	I
or	O
therapy	B
<	B
=	I
30	I
days	I
before	I
first	I
dose	I
of	I
study	I
treatment	I
or	O
not	B
recovered	I
from	I
any	I
acute	I
toxicity	I
.	O

Other	B
investigational	B
procedure	I
<	B
=	I
30	I
days	I
before	I
study	I
entry	I
.	O

History	O
of	O
interstitial	B
lung	I
disease	I
(	O
ILD	B
)	O
e	O
.	O
g	O
.	O
,	O
interstitial	B
pneumonitis	I
,	O
pulmonary	B
fibrosis	I
or	O
evidence	O
of	O
ILD	B
on	O
baseline	B
chest	B
computer	I
tomography	I
.	O

Subject	O
previously	O
enrolled	O
to	O
this	O
study	O
.	O

History	O
of	O
keratitis	B
,	O
ulcerative	B
keratitis	I
or	O
severe	B
dry	B
eye	I
.	O

Major	B
surgery	I
(	O
e	O
.	O
g	O
.	O
,	O
requiring	O
general	B
anesthesia	I
)	O
<	B
=	I
30	I
days	I
before	I
first	I
dose	I
of	I
study	I
treatment	I
.	O

Subjects	O
must	O
have	O
recovered	O
from	O
any	O
surgery	O
related	O
toxicities	O
.	O

Minor	B
surgical	I
procedure	I
(	O
e	O
.	O
g	O
.	O
,	O
open	B
biopsy	I
)	O
<	B
=	I
7	I
days	I
before	I
first	I
dose	I
of	I
study	I
treatment	I
,	O
or	O
not	B
yet	I
recovered	B
from	O
prior	B
minor	B
surgery	I
Note	O
:	O
uncomplicated	O
placement	O
of	O
vascular	O
access	O
device	O
,	O
fine	O
needle	O
aspiration	O
,	O
thoracocentesis	O
or	O
paracentesis	O
>	O
=	O
3	O
days	O
prior	O
to	O
first	O
dose	O
of	O
study	O
treatment	O
is	O
acceptable	O
.	O

Clinically	B
significant	I
cardiovascular	B
disease	I
(	O
including	O
myocardial	B
infarction	I
,	O
unstable	B
angina	I
,	O
symptomatic	B
congestive	B
heart	I
failure	I
,	O
serious	B
uncontrolled	B
cardiac	B
arrhythmia	I
)	O
<	B
=	I
6	I
months	I
prior	I
to	I
enrolment	I
.	O

History	O
of	O
any	O
medical	O
or	O
psychiatric	O
condition	O
or	O
laboratory	O
abnormality	O
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
may	O
increase	O
the	O
risk	O
associated	O
with	O
the	O
study	O
participation	O
or	O
investigational	O
product	O
administration	O
,	O
compliance	O
with	O
the	O
study	O
procedures	O
or	O
may	O
interfere	O
with	O
the	O
interpretation	O
of	O
the	O
results	O
.	O

Unstable	B
pulmonary	B
embolism	I
,	O
deep	B
vein	I
thrombosis	I
,	O
or	O
other	B
significant	B
arterial	O
/	O
venous	B
thromboembolic	I
event	I
<	B
=	I
30	I
days	I
before	I
first	I
dose	I
of	I
study	I
treatment	I
.	O

If	O
on	O
anticoagulation	B
,	O
subject	O
must	O
be	O
on	O
stable	B
therapeutic	B
dose	I
prior	B
to	I
first	I
dose	I
of	I
study	I
treatment	I
.	O

Subject	O
who	O
is	O
pregnant	B
or	O
breast	O
feeding	O
,	O
or	O
planning	O
to	O
become	O
pregnant	O
during	B
treatment	I
and	O
within	B
2	I
months	I
after	I
the	I
discontinuation	I
of	I
study	I
treatment	I
.	O

Known	O
positive	B
test	B
(	I
s	I
)	I
for	I
human	I
immunodeficiency	I
virus	I
infection	I
(	O
testing	O
is	O
not	O
required	O
in	O
the	O
absence	O
of	O
clinical	O
suspicion	O
)	O
.	O

Active	B
infection	B
requiring	O
systemic	B
treatment	I
or	O
any	B
uncontrolled	B
infection	I
<	B
=	I
14	I
days	I
prior	I
to	I
first	I
dose	I
of	I
study	I
treatment	I
(	O
with	B
the	I
exception	I
of	I
uncomplicated	B
urinary	B
tract	I
infection	I
or	O
upper	B
respiratory	I
tract	I
infection	I
)	O
.	O

Subject	O
has	O
any	O
kind	O
of	O
disorder	O
that	O
compromises	O
the	O
ability	O
of	O
the	O
subject	O
to	O
give	O
written	O
informed	O
consent	O
and	O
/	O
or	O
to	O
comply	O
with	O
study	O
procedures	O
or	O
is	O
unwilling	O
or	O
unable	O
to	O
comply	O
with	O
study	O
requirements	O
.	O

Subject	O
or	O
subject	O
'	O
s	O
legally	O
acceptable	O
representative	O
has	O
provided	O
informed	O
consent	O
.	O

Male	B
or	O
female	B
>	B
=	I
18	I
years	I
of	O
age	B
.	O

Histologically	B
or	O
cytologically	B
confirmed	B
diagnosis	O
of	O
adenocarcinoma	B
of	O
the	O
colon	B
or	O
rectum	B
.	O

Wild	O
-	O
type	O
KRAS	O
(	O
without	O
mutation	O
in	O
exon	O
2	O
[	O
codons	O
12	O
and	O
13	O
]	O
,	O
exon	O
3	O
[	O
codons	O
59	O
and	O
61	O
]	O
,	O
and	O
exon	O
4	O
[	O
codons	O
117	O
and	O
146	O
]	O
)	O
and	O
wild	O
-	O
type	O
NRAS	O
(	O
without	O
mutation	O
in	O
exon	O
2	O
[	O
codons	O
12	O
and	O
13	O
]	O
,	O
exon	O
3	O
[	O
codons	O
59	O
and	O
61	O
]	O
,	O
and	O
exon	O
4	O
[	O
codons	O
117	O
and	O
146	O
]	O
)	O
tumor	O
status	O
.	O

Eastern	B
Cooperative	I
Oncology	I
Group	I
(	I
ECOG	I
)	I
performance	I
status	I
of	O
0	B
,	I
1	I
or	I
2	I
.	O

Measurable	O
or	O
non	B
-	I
measurable	I
disease	I
per	O
RECIST	B
Version	I
1	I
.	I
1	I
.	O

Must	O
have	O
failed	B
after	O
fluoropyrimidine	O
-	O
,	O
oxaliplatin	O
-	O
,	O
and	O
irinotecan	B
-	I
containing	I
chemotherapy	I
regimens	O
for	O
metastatic	B
disease	I
.	O

Failure	O
is	O
defined	O
as	O
either	O
disease	B
progression	I
(	O
clinical	O
or	O
radiological	O
)	O
or	O
intolerance	B
to	O
the	B
regimen	I
.	O

Metastatic	B
relapse	I
within	B
6	I
months	I
after	I
completing	I
adjuvant	I
chemotherapy	I
(	O
with	O
either	O
an	O
irinotecan	O
or	O
oxaliplatin	B
containing	I
regimen	I
)	O
will	O
also	O
be	O
considered	O
as	O
treatment	O
failure	O
of	O
a	O
prior	O
regimen	O
for	O
metastatic	O
disease	O
.	O

Laboratory	O
:	O
Adequate	B
baseline	I
organ	I
function	I
defined	O
by	O
(	O
<	B
=	I
7	I
days	I
prior	I
to	I
first	I
dose	I
of	I
study	I
treatment	I
)	O
.	O

Hematologic	O
function	O
,	O
as	O
follows	O
:	O
Absolute	B
neutrophil	I
count	I
(	I
ANC	I
)	I
>	B
=	I
1	I
.	I
5	I
x	I
10	I
^	I
9	I
/	I
Liter	I
(	I
L	I
)	I
,	O
Platelet	B
count	I
>	B
=	I
75	I
x	I
10	I
^	I
9	I
/	I
L	I
,	O
Hemoglobin	B
>	B
=	I
8	I
.	I
0	I
gram	I
/	I
deciliter	I
(	I
g	I
/	I
dL	I
)	I
.	O

Renal	O
function	O
,	O
as	O
follows	O
:	O
Creatinine	B
<	B
=	I
1	I
.	I
5	I
x	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
.	O

Hepatic	O
function	O
,	O
as	O
follows	O
:	O
Aspartate	B
aminotransferase	I
(	I
AST	I
)	I
<	B
=	I
3	I
x	I
ULN	I
,	O
Alanine	B
aminotransferase	I
(	I
ALT	I
)	I
<	B
=	I
3	I
x	I
ULN	I
,	O
Total	B
Bilirubin	I
<	B
=	I
1	I
.	I
5	I
x	I
ULN	I
.	O

Metabolic	O
function	O
,	O
as	O
follows	O
:	O
Serum	B
Magnesium	I
within	B
normal	I
limits	I
.	O

Serum	B
Calcium	I
within	B
normal	I
limits	I
.	O

Serum	B
Potassium	I
within	B
normal	I
limits	I
.	O

All	O
prior	O
treatment	O
related	O
toxicities	O
common	O
terminology	O
criteria	O
for	O
adverse	O
events	O
(	O
CTCAE	O
)	O
version	O
4	O
.	O
03	O
<	O
=	O
Grade	O
1	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Women	O
of	O
childbearing	O
potential	O
must	O
have	O
a	O
negative	O
serum	O
pregnancy	O
test	O
within	O
7	O
days	O
of	O
first	O
dose	O
of	O
study	O
treatment	O
and	O
agree	O
to	O
use	O
adequate	O
contraception	O
,	O
during	O
the	O
study	O
and	O
for	O
2	O
months	O
following	O
the	O
last	O
dose	O
of	O
study	O
treatment	O
.	O
Men	O
with	O
a	O
female	O
partner	O
of	O
childbearing	O
potential	O
must	O
have	O
either	O
had	O
a	O
prior	O
vasectomy	O
or	O
agree	O
to	O
use	O
adequate	O
contraception	O
,	O
from	O
time	O
of	O
signing	O
informed	O
consent	O
until	O
5	O
months	O
after	O
the	O
last	O
dose	O
of	O
study	O
treatment	O
.	O

Women	B
with	O
systemic	B
lupus	I
erythematosus	I
(	I
SLE	I
)	I

Women	B
with	O
active	B
thromboembolic	B
disorders	I

Women	B
with	O
history	B
of	O
previous	B
thromboembolic	B
disorders	I

Pregnant	B
women	B
with	O
APS	B
diagnosed	O
according	O
to	O
the	O
revised	B
classification	I
criteria	I
for	I
APS	I
in	I
2006	I
in	I
Sydney	I
,	I
Australia	I

Early	B
pregnancy	I
body	B
weight	I
is	O
50	B
-	I
90	I
Kg	I

Moderate	B
or	O
severe	B
endometriosis	B
.	O

Hydrosalpinx	B
.	O

Uterine	B
abnormalities	I
.	O

Myoma	B
.	O

Previous	B
uterine	B
surgery	I
.	O

Women	B
subjected	O
to	O
ICSI	B
through	O
controlled	B
ovarian	I
hyperstimulation	I
(	I
COH	I
)	I
with	O
pituitary	B
downregulation	I
by	I
GnRHa	I
.	O

Moderate	B
or	O
severe	B
endometriosis	B
.	O

Hydrosalpinx	B
.	O

Uterine	B
abnormalities	I
.	O

Myoma	B
.	O

Previous	O
uterine	B
surgery	I
.	O

Women	B
subjected	O
to	O
ICSI	B
through	O
controlled	O
ovarian	B
hyperstimulation	I
(	O
COH	B
)	O
with	O
pituitary	B
downregulation	I
by	O
GnRH	B
antagonist	I
.	O

Not	O
applicable	O
to	O
this	O
follow	O
up	O
study	O

Subject	O
was	O
previously	O
enrolled	O
in	O
a	O
selected	O
company	O
sponsored	O
feeder	O
trial	O
,	O
and	O
has	O
received	O
at	O
least	O
1	O
dose	O
of	O
radium	O
223	O
dichloride	O
or	O
placebo	O
in	O
the	O
feeder	O
trial	O

Dementia	B
.	O

Gastroscopy	B
planned	O
at	B
the	I
same	I
time	I
.	O

Allergies	B
to	O
propofol	B

All	O
cases	O
were	O
a	O
'	O
full	O
stomach	O
'	O
is	O
suspected	O
(	O
gastric	O
banding	O
)	O

Pregnancy	B

All	O
patients	O
subjected	O
to	O
deep	B
sedation	I
in	O
ambulant	O
care	O
,	O
having	O
a	O
colonoscopy	B

ASA	B
1	B
-	I
3	I

Contraindication	B
to	O
sitagliptin	B
or	O
metformin	B
or	O
thiazolidinedione	B

Pregnant	B
or	O
breast	B
feeding	O
women	O

Type	B
1	I
diabetes	I
,	O
gestational	B
diabetes	I
,	O
or	O
secondary	B
forms	I
of	I
diabetes	I

Not	B
appropriate	O
for	O
oral	B
antidiabetic	I
agent	I

Medication	B
which	O
affect	O
glycemic	O
control	O

Disease	B
which	O
affect	B
efficacy	I
and	O
safety	B
of	I
drugs	I

Any	O
major	B
illness	I
(	O
Liver	B
disease	I
,	O
Renal	B
failure	I
,	O
Heart	B
disease	I
,	O
Cancer	B
,	O
etc	O
)	O

HbA1c	B
>	B
13	I
.	I
0	I
%	I

No	B
treatment	B
with	O
insulin	B
or	O
oral	B
agents	I
for	B
6	I
months	I

20	B
=	I
Age	B
<	B
80	I
years	I

Patients	O
in	O
whom	O
the	O
preferred	O
treatment	O
is	O
CABG	B
(	O
Coronary	B
artery	I
bypass	I
grafting	I
)	O

Stented	B
lesion	B

Bypass	B
graft	I
lesion	B

The	O
patients	O
who	O
have	O
more	B
than	I
or	I
equal	I
to	I
3	I
target	B
lesions	I

2	B
target	B
lesions	I
in	B
the	I
same	I
coronary	I
territory	I

Heavily	B
calcified	I
or	O
angulated	B
lesion	B

Bifurcation	B
lesion	I
requiring	O
2	B
stenting	B
technique	I

Contraindication	B
to	O
or	O
planned	O
discontinuation	O
of	O
dual	B
antiplatelet	I
therapy	I
within	B
1	I
year	I

Life	O
expectancy	O
less	B
than	I
2	I
years	I

Planned	O
cardiac	B
surgery	I
or	O
planned	O
major	B
non	B
cardiac	I
surgery	I

Woman	B
who	O
are	O
breastfeeding	O
,	O
pregnant	B
or	O
planning	O
to	O
become	O
pregnant	B
during	B
the	I
course	I
of	I
the	I
study	I

Age	B
18	B
years	I
or	I
older	I

Symptomatic	B
or	O
asymptomatic	B
coronary	B
artery	I
disease	I
patients	O

MLA	B
(	O
minimal	B
luminal	I
area	I
)	O
<	B
4mm2	I

plaque	B
burden	I
>	B
70	I
%	I

Lipid	B
-	I
rich	I
plaque	I
on	O
NIRS	B
(	O
Intracoronary	B
Near	I
-	I
Infrared	I
Spectroscopy	I
)	O
(	O
defined	O
as	O
maxLCBI4mm	B
>	B
315	I
)	O

2	B
target	B
vulnerable	I
lesions	I

Eligible	O
for	O
percutaneous	B
coronary	I
intervention	I
with	O
Absorb	B
Bioresorbable	I
Vascular	I
Scaffold	I
or	O
Everolimus	B
Eluting	I
Stent	I

Willing	O
and	O
able	O
to	O
provide	O
informed	O
written	O
consent	O

Reference	B
vessel	I
diameter	I
2	B
.	I
75	I
-	I
4	I
.	I
0	I

Lesion	B
length	I
=	B
40	I

Pregnancy	B
and	O
lactation	B

Patients	O
with	O
diabetes	B
,	O
Ischemic	B
heart	I
disease	I
(	I
IHD	I
)	I
,	O
stroke	B
,	O
malignancy	B
and	O
psychiatric	B
diseases	I
are	O
excluded	O
from	O
study	O
.	O

The	O
patients	O
receiving	O
vitamin	B
supplements	I
or	O
who	O
had	O
clinical	O
evidence	O
for	O
an	O
acute	B
illness	I
,	O
renal	B
dysfunction	I
,	O
thyroid	B
dysfunction	I
,	O
chronic	B
inflammatory	I
diseases	I
,	O
inborn	B
errors	I
of	I
homocysteine	I
,	I
cobalamin	I
or	I
folate	I
metabolism	I
,	O
or	O
any	O
other	O
condition	B
known	I
to	I
interfere	I
with	I
homocysteine	I
metabolism	I
will	O
be	O
excluded	O

Patients	O
who	O
are	O
already	O
involved	O
in	O
any	O
other	O
trial	O
.	O

Patients	O
not	O
willing	O
to	O
fill	O
consent	O
/	O
assent	O
form	O
are	O
also	O
excluded	O
from	O
study	O
.	O

Diagnosed	O
epileptic	B
patients	O
of	O
either	O
sex	O
with	O
age	B
between	B
10	I
-	I
19	I
yrs	I
(	O
<	B
19yrs	I
)	O
,	O
coming	O
to	O
the	O
medicine	O
Out	O
Patient	O
/	O
In	O
Patient	O
Departments	O
and	O
undergoing	O
AED	B
therapy	I
for	B
more	I
than	I
6	I
months	I
.	O

Epileptics	O
with	O
high	B
homocysteine	B
levels	I
i	O
.	O
e	O
.	O
>	B
10	I
.	I
9	I
µmol	I
/	I
L	I
(	O
Normal	O
homocysteine	O
levels	O
are	O
4	O
.	O
3	O
-	O
9	O
.	O
9	O
µmol	O
/	O
L	O
for	O
male	O
and	O
3	O
.	O
3	O
-	O
7	O
.	O
2	O
µmol	O
/	O
L	O
for	O
female	O
adolescent	O
and	O
a	O
high	O
homocysteine	O
concentration	O
is	O
deaned	O
as	O
at	O
least	O
11	O
.	O
4	O
µmol	O
/	O
L	O
for	O
male	O
and	O
at	O
least	O
10	O
.	O
4	O
µmol	O
/	O
L	O
for	O
female	O
.	O
Gender	O
mean	O
of	O
high	O
homocysteine	O
concentration	O
is	O
10	O
.	O
9	O
µmol	O
/	O
L	O
)	O
[	O
5	O
]	O

Contraindication	O
for	O
hepatectomy	B
,	O
including	O
gastrointestinal	B
hemorrhage	I
,	O
severe	B
hemorrhagic	B
disorders	I
,	O
explicit	O
acute	B
nonspecific	B
infectious	B
lesion	I
,	O
overt	B
ascites	B
,	O
Child	B
-	I
Pugh	I
Score	I
C	B
,	O
indocyanine	B
green	I
retention	I
rate	I
at	I
15min	I
(	I
ICGR15	I
)	I
＞	B
30	I
%	I
(	O
12	O
)	O
,	O
serum	B
hepatitis	I
B	I
virus	I
(	I
HBV	I
)	I
-	I
DNA	I
＞	B
126	I
copies	I
/	I
ml	I
and	O
serum	B
alanine	I
aminotransferase	I
(	I
ALT	I
)	I
＞	B
2	I
×	I
ULN	I
,	O
serum	B
triglycerides	I
＞	B
2	I
.	I
0	I
mmol	I
/	I
L	I
,	O
circulatory	B
shock	I
,	O
stroke	B
,	O
acute	B
myocardial	I
infarction	I
,	O
renal	B
failure	I
,	O
coma	B
of	O
unknown	B
cause	I

Pregnancy	B

Age	B
of	O
＜	B
18y	I
or	I
＞	I
75y	I

Performed	O
intraoperative	B
ablation	I

Unresectable	B
tumor	I
during	O
operation	O

Allergic	B
reactions	I
against	O
fish	O
or	O
egg	B
proteins	I

The	O
cirrhotic	B
malnourished	B
patients	O
who	O
were	O
diagnosed	O
as	O
liver	B
cancer	I
preoperatively	B
and	O
underwent	O
hepatectomy	B
were	O
consecutively	O
enrolled	O
.	O

Total	B
lesion	I
area	I
of	O
>	B
12	I
DA	I
or	O
>	B
30	I
.	I
5	I
mm2	I

The	O
existence	O
of	O
subretinal	B
hemorrhage	I
area	I
constituting	O
=	B
50	I
%	I
of	I
total	I
lesion	I
area	I

The	O
existence	O
of	O
scar	O
or	O
fibrosis	B
area	I
constituting	O
=	B
50	I
%	I
of	I
total	I
lesion	I
area	I

The	O
existence	O
of	O
RPE	B
tear	I

Prior	B
treatment	B
for	O
wet	O
AMD	O

History	O
of	O
vitrectomy	B
surgery	I
,	O
submacular	B
surgery	I
,	O
or	O
other	B
surgical	B
intervention	I
for	O
AMD	B

The	O
pregnant	B
or	O
lactating	B
woman	B

Signed	O
informed	O
consent	O
form	O

Male	B
or	O
female	B
of	O
aged	B
50	B
years	I
or	I
older	I

Typical	O
AMD	B
and	O
PCV	B
patients	I

BCVA	B
of	O
24	B
letters	I
or	I
over	I

Subjects	O
taking	O
any	O
lipid	B
modification	I
therapy	I
,	O
including	O
but	O
not	O
limited	O
to	O
statins	B
,	O
fibrates	B
and	O
bile	B
acid	I
sequestrants	I
.	O

Subjects	O
taking	O
fish	B
oil	I
or	O
any	O
other	O
supplements	O
,	O
which	O
in	O
the	O
investigator	O
s	O
opinion	O
may	O
interfere	O
with	O
the	O
study	O
.	O

Subjects	O
with	O
acute	B
liver	I
disease	I
or	O
active	B
peptic	B
ulcer	I
disease	I
.	O

Subjects	O
with	O
elevated	B
uric	B
acid	I
levels	I
greater	B
than	I
10	I
mg	I
/	I
dL	I
or	O
gout	B

Pregnancy	B
or	O
women	B
currently	O
breastfeeding	O
.	O

Female	B
subjects	O
taking	O
hormonal	B
contraceptives	I
or	O
hormone	B
replacement	I
therapy	I
may	O
be	O
included	O
in	O
this	O
study	O
only	O
if	O
they	O
have	O
been	O
on	O
a	O
stable	B
dose	I
for	B
at	I
least	I
3	I
months	I
.	O

BMI	B
less	B
than	I
18	I
.	I
5	I

Subjects	O
with	O
weight	B
that	O
varies	B
greater	I
than	I
20	I
%	I
over	B
the	I
past	I
3	I
months	I
.	O

Subjects	O
taking	O
the	O
following	O
medications	O
for	B
at	I
least	I
six	I
weeks	I
,	O
which	O
may	O
interfere	O
with	O
the	O
study	O
,	O
will	O
be	O
excluded	O
:	O
BAS	B
,	O
antibiotics	B
,	O
anticoagulants	B
,	O
anticonvulsants	B
,	O
antiarrhythmic	B
,	O
Cyclosporine	B
,	O
Mycophenolate	B
and	O
Synthroid	B
.	O

Subjects	O
with	O
chronic	B
diarrhea	I
,	O
gastric	B
bypass	I
or	O
lap	B
band	I
procedures	I
,	O
ostomies	B
,	O
bowel	B
motility	I
problems	I
,	O
or	O
other	O
conditions	B
that	I
could	I
affect	I
intestinal	I
fat	I
absorption	I
.	O

Subjects	O
initiating	O
new	O
medications	O
or	O
patients	O
on	O
multiple	O
medications	O
may	O
also	O
be	O
excluded	O
.	O

Inability	B
to	I
swallow	I
capsules	I

Patients	O
with	O
a	O
history	B
of	O
type	O
I	O
or	O
type	B
II	I
diabetes	I
or	O
HbA1c	B
greater	B
than	I
6	I
.	I
5	I
%	I
.	O

Volunteers	O
may	O
also	O
be	O
excluded	O
,	O
if	O
in	O
the	O
opinion	O
of	O
the	O
study	O
investigators	O
,	O
they	O
have	O
some	O
other	O
condition	O
or	O
disorder	O
that	O
may	O
adversely	O
affect	O
the	O
outcome	O
of	O
the	O
study	O
or	O
the	O
safety	O
of	O
the	O
volunteer	O
.	O

Males	B
and	O
females	B
who	O
are	O
at	B
least	I
18	I
years	I
of	O
age	B
at	B
time	I
of	I
enrollment	I
.	O

Subject	O
understands	O
the	O
investigational	O
nature	O
of	O
the	O
study	O
and	O
provides	O
written	O
,	O
informed	O
consent	O
.	O

NA	O

Subject	O
'	O
s	O
age	B
is	O
between	B
=	I
12	I
and	I
16	I
years	I
,	O
inclusive	O

Subject	O
is	O
scheduled	O
for	O
a	O
procedure	B
that	O
requires	O
general	O
or	O
neuraxial	B
anesthesia	I

Subjects	O
must	O
have	O
normal	B
or	O
clinically	B
acceptable	I
physical	B
exam	I

Subjects	O
with	O
controlled	B
diabetes	B
prior	B
to	I
entry	I
must	O
have	O
a	O
mean	B
systolic	I
/	I
diastolic	I
office	I
blood	I
pressure	I
=	O
128	O
/	O
78	B
mmHg	I
(	O
sitting	B
,	O
after	B
5	I
minutes	I
of	I
rest	I
)	O

Females	O
must	O
have	O
a	O
urine	O
or	O
serum	B
pregnancy	I
test	I
(	O
Human	B
Chorionic	I
Gonadotropin	I
)	O
that	O
is	O
negative	B
at	B
Screening	I
and	O
Day	B
1	I

Subject	O
'	O
s	O
parent	O
or	O
legal	O
guardian	O
gives	O
informed	O
consent	O
and	O
subject	O
gives	O
assent	O
.	O

Advanced	B
male	B
factor	I
infertility	I
.	O

Polycystic	B
ovary	I
syndrome	I
(	I
PCOS	I
)	I
as	O
defined	O
by	O
the	O
Rotterdam	B
criteria	I
.	O

Endometriosis	B
.	O

Tubal	B
disease	I
.	O

Uterine	B
abnormalities	I
or	O
myoma	B
.	O

Previous	B
uterine	B
surgery	I
.	O

Metabolic	O
or	O
hormonal	B
abnormalities	I
.	O

Mild	B
male	B
factor	I
infertility	I
or	O
unexplained	B
infertility	I
.	O

PCOS	B
or	O
polycystic	B
ovary	I
on	O
ultrasound	B
scan	I
.	O

Moderate	B
or	O
severe	B
endometriosis	B
.	O

Hydrosalpinx	B
.	O

Uterine	B
abnormalities	I
or	O
myoma	B
.	O

Previous	B
uterine	B
surgery	I
.	O

Women	O
without	B
PCOS	B
as	O
defined	O
by	O
the	O
Rotterdam	B
criteria	I
.	O

Presence	O
of	O
at	B
least	I
2	I
cryopreserved	B
good	B
quality	I
cleavage	O
-	O
stage	O
embryo	O
(	O
good	B
quality	I
cleavage	O
-	O
stage	O
embryos	O
display	O
stage	B
-	I
specific	I
cell	I
division	I
,	O
have	B
blastomeres	I
of	I
fairly	I
equal	I
size	I
with	O
few	B
to	I
no	I
cytoplasmic	I
fragments	I
)	O
.	O

Current	O
or	O
past	O
diagnoses	O
of	O
other	B
Axis	B
I	I
psychiatric	I
disorders	I
,	O
except	B
for	I
generalized	B
anxiety	I
disorder	I
(	I
GAD	I
)	I
symptoms	O
occurring	O
during	O
a	O
depressive	B
episode	I

History	O
of	O
alcohol	O
or	O
drug	B
dependence	I
or	O
abuse	O
in	B
the	I
last	I
three	I
years	I

History	O
of	O
developmental	B
disorder	I
or	O
IQ	B
score	I
<	B
70	I

Presence	O
of	O
acute	B
suicidality	I

Acute	B
grief	I
(	O
<	B
1	I
month	I
)	O

Current	B
or	O
past	B
psychosis	B

Primary	B
neurological	I
disorder	I
,	O
including	O
but	O
not	O
limited	O
to	O
dementia	B
,	O
stroke	B
,	O
brain	B
tumors	I
,	O
epilepsy	B
,	O
Parkinson	B
'	I
s	I
disease	I
,	O
or	O
demyelinating	B
diseases	I

MRI	B
contraindications	B

Any	O
physical	O
or	O
intellectual	B
disability	I
adversely	O
affecting	O
ability	O
to	O
complete	O
assessments	O

Electroconvulsive	B
therapy	I
in	B
last	I
6	I
months	I

Use	O
of	O
antidepressant	B
medications	I
or	O
other	B
psychotropic	B
medications	I
in	B
the	I
last	I
4	I
weeks	I
(	O
or	O
the	O
last	O
6	O
weeks	O
for	O
fluoxetine	B
)	O
.	O

Occasional	B
use	I
of	O
benzodiazepines	O
or	O
non	B
-	I
benzodiazepine	I
sedatives	I
(	O
such	O
as	O
zolpidem	B
,	O
eszopiclone	B
,	O
or	O
zaleplon	B
)	O
during	O
this	O
period	O
is	B
allowable	I
.	O

A	O
failed	B
therapeutic	B
trial	I
of	O
escitalopram	B
in	O
the	O
current	O
depressive	B
episode	I
(	O
defined	O
as	O
at	B
least	I
6	I
weeks	I
of	I
treatment	I
at	O
a	O
daily	B
dose	I
of	I
10mg	I
or	I
higher	I
)	O

Known	O
allergy	B
or	O
hypersensitivity	B
to	O
escitalopram	B
or	O
bupropion	B

Current	B
or	O
planned	O
psychotherapy	B

Age	B
60	B
years	I
or	I
older	I
.	O

Current	O
diagnosis	O
of	O
major	B
depressive	I
disorder	I
(	O
DSM	B
-	I
IV	I
-	I
TR	I
)	O
,	O
single	B
episode	I
,	O
recurrent	B
or	O
chronic	B
,	O
without	B
psychotic	B
features	I
,	O
as	O
detected	O
by	O
MINI	B
and	O
clinical	B
exam	I
.	O

Minimum	O
MADRS	B
score	I
=	O
15	O
.	O

Mini	B
-	I
Mental	I
State	I
Exam	I
=	B
24	I
.	O

Fluent	O
in	O
English	O
.	O

Patients	O
with	O
a	O
contraindication	B
to	O
VCE	B
(	O
small	B
bowel	I
strictures	I
,	O
oropharyngeal	B
dysphagia	I
,	O
pregnancy	B
,	O
patients	O
who	O
are	O
not	B
surgical	O
candidates	O
)	O

Endoscopic	B
insertion	I
of	O
video	B
capsule	I
endoscope	I

Inpatient	B
procedures	I
for	O
active	B
GI	B
bleeding	I

Patients	O
with	O
fluid	O
restriction	O
or	O
who	O
are	O
unable	O
to	O
drink	O
up	O
to	O
900	O
ml	O
of	O
fluid	O
within	O
10	O
minutes	O
prior	O
to	O
the	O
VCE	B

Patients	O
undergoing	O
small	B
bowel	I
video	I
capsule	I
endoscopy	I

No	B
known	O
history	B
of	O
seizure	B
activity	I
.	O

Pregnant	B
or	O
breastfeeding	O
.	O

Renal	B
dysfunction	I
(	O
CrCl	B
<	B
30ml	I
/	I
min	I
)	O
.	O

Beck	B
'	I
s	I
Depression	I
Inventory	I
(	I
BDI	I
)	I
=	B
14	I

Allergy	B
to	O
levetiracetam	B
.	O

Adult	B
(	O
>	O
18	O
years	O
of	O
age	B
and	O
older	O
)	O
patients	O
who	O
have	O
or	O
will	O
have	O
undergone	O
surgical	B
resection	I
or	O
biopsy	B
of	O
a	O
supratentorial	B
brain	I
tumor	I
and	O
are	O
able	O
to	O
consent	O
for	O
themselves	O
.	O

Able	O
to	O
be	O
randomized	O
prior	O
to	O
or	O
up	O
to	O
48	O
hours	O
after	O
surgery	O
.	O

The	O
participant	O
has	O
Modified	B
Hoehn	I
&	I
Yahr	I
stage	B
5	I
(	O
or	O
stage	B
5	I
at	B
eather	I
on	I
-	I
time	I
or	O
off	O
-	O
time	O
for	O
the	O
participant	O
with	O
wearing	B
off	I
phenomenon	I
)	O
.	O

The	O
participant	O
has	O
severe	B
dyskinesia	B
.	O

The	O
participant	O
has	O
unstable	B
systemic	B
disease	I
.	O

The	O
participant	O
has	O
a	O
Mini	B
-	I
Mental	I
State	I
Examinations	I
(	I
MMSE	I
)	I
score	O
of	O
<	B
=	I
24	I
.	O
psychiatric	B
disease	I
.	O

The	O
participant	O
has	O
a	O
history	O
of	O
clinically	B
significant	I
hypertension	B
or	O
other	O
reactions	B
associated	I
with	I
ingestion	I
of	I
tyramine	I
-	I
rich	I
food	I
.	O

The	O
participant	O
has	O
received	O
neurosurgical	B
intervention	I
for	O
Parkinson	B
'	I
s	I
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
pallidotomy	B
,	O
thalamotomy	B
,	O
deep	B
brain	I
stimulation	I
)	O
.	O

The	O
participant	O
has	O
received	O
transcranial	B
magnetic	I
stimulation	I
within	B
6	I
months	I
.	O
The	O
participant	O
has	O
received	O
selegiline	B
,	O
pethidine	B
,	O
tramadol	B
,	O
reserpine	B
or	O
methyldopa	B
within	B
90	I
days	I
.	O

The	O
participant	O
has	O
received	O
levodopa	B
monotherapy	O
,	O
any	O
psychoneurotic	B
agent	I
or	O
antiemetic	B
medication	I
of	I
dopamine	I
agonist	I
within	B
14	I
days	I
.	O

However	O
,	O
the	O
participant	O
has	O
been	O
receiving	O
quetiapine	B
or	O
domperidone	B
with	O
a	O
stable	B
dose	I
regimen	O
for	O
>	B
=	I
14	I
days	I
may	O
be	O
included	O
in	O
the	O
study	O
.	O

The	O
participant	O
is	O
required	O
to	O
take	O
any	O
of	O
the	O
excluded	O
medications	O
or	O
treatments	O
.	O

The	O
participant	O
with	O
laboratory	O
data	O
meeting	O
any	O
of	O
the	O
following	O
:	O

Creatinine	B
>	B
=	I
2	I
x	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I

Total	B
bilirubin	I
>	B
=	I
2	I
x	I
ULN	I

ALT	B
or	O
AST	B
>	B
=	I
1	I
.	I
5	I
x	I
ULN	I

ALP	B
>	B
=	I
3	I
x	I
ULN	I

The	O
participant	O
has	O
received	O
any	O
of	O
the	O
excluded	O
medications	O
or	O
treatments	O
during	O
.	O

The	O
participant	O
has	O
a	O
diagnosis	O
of	O
Parkinson	B
'	I
s	I
disease	I
according	O
to	O
the	O
diagnostic	O
criteria	O
of	O
the	O
UK	B
Parkinson	I
'	I
s	I
Disease	I
Society	I
Brain	I
Bank	I
.	O

The	O
participant	O
has	O
received	O
a	O
levodopa	B
combination	I
drug	O
for	O
>	B
=	I
1	I
month	I
and	O
has	O
either	O
of	O
the	O
following	O
.	O

Wearing	B
off	I
phenomenon	I

Decreased	B
response	I
to	O
levodopa	B
combination	I
drugs	I

The	O
participant	O
has	O
received	O
a	O
levodopa	B
combination	I
drug	I
without	B
change	I
in	I
the	I
dose	I
regimen	I
.	O

The	O
participant	O
is	O
an	O
outpatient	O
of	O
either	O
sex	O
aged	B
>	B
=	I
30	I
and	I
<	I
80	I
years	I
.	O

Exclusion	O
Criteria	O
patients	O
:	O
Substance	B
abuse	I
on	O
a	O
daily	B
basis	I
during	B
the	I
last	I
3	I
month	I
or	O
patients	O
fulfilling	O
the	O
criteria	O
of	O
ongoing	B
substance	B
abuse	I
due	O
to	O
ICD	B
-	I
10	I
/	I
DSM	I
-	I
IV	I
/	I
V	I
,	O
Treatment	O
with	O
antidepressant	B
during	B
the	I
last	I
30	I
days	I
,	O
Head	B
injury	I
with	O
more	B
than	I
5	I
minutes	I
of	O
unconsciousness	B
,	O
Patients	O
involuntarily	O
admitted	O
or	O
treated	O
,	O
Components	B
of	I
metal	I
implanted	O
by	O
operation	O
,	O
Pacemaker	B
,	O
Pregnancy	B
,	O
Severe	B
physical	I
illness	I

Exclusion	O
criteria	O
controls	O
:	O
First	O
degree	O
relatives	O
with	O
psychiatric	B
disease	I
,	O
Substance	B
abuse	I
during	B
the	I
last	I
3	I
month	I
or	O
positive	B
screening	B
of	I
drugs	I
in	O
urine	B
-	I
sample	I
,	O
Head	B
injury	I
with	O
more	B
than	I
5	I
minutes	I
of	O
unconsciousness	B
,	O
Components	B
of	I
metal	I
implanted	O
by	O
operation	O
,	O
Pacemaker	B
,	O
Pregnancy	B
,	O
Severe	B
physical	I
illness	I

Inclusion	O
Criteria	O
Patients	O
:	O
Fulfilling	O
the	O
diagnostic	O
criteria	O
of	O
schizophrenia	B
or	O
schizoaffective	B
disorder	I
according	O
to	O
ICD	B
-	I
10	I
(	I
International	I
Classification	I
of	I
Diseases	I
version	I
10	I
)	I
or	O
DSM	B
-	I
IV	I
/	I
V	I
(	I
Diagnostic	I
and	I
Statistical	I
Manual	I
version	I
4	I
/	I
5	I
)	I
,	O
Age	B
18	B
-	I
45	I
years	I
,	O
Never	B
treated	O
with	O
antipsychotic	B
compounds	I
or	O
central	B
nervous	I
system	I
(	I
CNS	I
)	I
stimulants	I
,	O
Legally	O
competent	O

Inclusion	O
criteria	O
controls	O
:	O
Matching	O
patients	O
on	O
age	O
(	O
+	O
/	O
-	O
2	O
years	O
)	O
,	O
sex	O
and	O
parental	O
socioeconomic	O
status	O
,	O
Age	B
18	B
-	I
45	I
years	I
,	O
No	B
psychiatric	O
or	O
physical	B
disease	I
.	O

Heart	B
Team	I
assessment	I
of	I
operability	I
(	O
the	O
heart	B
team	I
considers	I
the	I
patient	I
to	I
be	I
a	I
good	I
surgical	I
candidate	I
)	O
.	O

Evidence	O
of	O
an	O
acute	B
myocardial	I
infarction	I
=	B
1	I
month	I
(	I
30	I
days	I
)	I
before	I
the	I
intended	I
treatment	I
[	O
defined	O
as	O
:	O
Q	O
wave	O
MI	O
,	O
or	O
non	O
-	O
Q	O
wave	O
MI	O
with	O
total	O
CK	O
elevation	O
of	O
CK	O
-	O
MB	O
=	O
twice	O
normal	O
in	O
the	O
presence	O
of	O
MB	O
elevation	O
and	O
/	O
or	O
troponin	O
level	O
elevation	O
(	O
WHO	O
definition	O
)	O
]	O
.	O

Untreated	B
,	O
severe	B
,	O
left	B
sided	I
valvular	B
heart	I
disease	I
including	O
mitral	B
regurgitation	I
or	O
stenosis	O
,	O
and	O
aortic	B
regurgitation	I
or	O
stenosis	O
.	O

Mean	B
pulmonary	I
artery	I
pressures	I
=	B
40mmHG	I
and	O
PVR	B
>	B
4	I
woods	I
units	I
as	O
assessed	O
by	O
right	B
heart	I
catheterization	I
.	O

Any	O
therapeutic	B
invasive	B
cardiac	B
procedure	I
resulting	O
in	O
a	O
permanent	B
implant	I
that	O
is	O
performed	O
within	B
30	I
days	I
of	I
the	I
index	I
procedure	I
.	O

Examples	O
of	O
permanent	O
implant	O
would	O
include	O
any	O
new	O
heart	B
valve	I
.	O

Implantation	O
of	O
a	O
permanent	B
pacemaker	I
is	O
excluded	B
.	O

Patients	O
with	O
planned	O
concomitant	B
surgical	O
or	O
transcatheter	B
ablation	I
for	O
Atrial	B
Fibrillation	I
.	O

Leukopenia	B
(	O
WBC	B
<	B
3000	I
cell	I
/	I
mL	I
)	O
,	O
acute	B
anemia	I
(	O
Hgb	B
<	B
9	I
g	I
/	I
dL	I
)	O
,	O
Thrombocytopenia	B
(	O
Plt	B
<	B
50	I
,	I
000	I
cell	I
/	I
mL	I
)	O
.	O

Hemodynamic	O
or	O
respiratory	B
instability	I
requiring	O
inotropic	B
support	I
,	O
mechanical	B
ventilation	I
or	O
mechanical	B
heart	I
assistance	I
within	B
30	I
days	I
of	I
screening	I
evaluation	I
.	O

Need	O
for	O
emergency	B
surgery	I
for	O
any	O
reason	O
.	O

Left	B
ventricular	I
ejection	I
fraction	I
<	B
40	I
%	I
.	O

Echocardiographic	B
evidence	O
of	O
intracardiac	B
mass	I
,	O
thrombus	O
or	O
vegetation	O
.	O

Active	B
upper	B
GI	I
bleeding	I
within	B
3	I
months	I
(	I
90	I
days	I
)	I
prior	I
to	I
procedure	I
.	O

A	O
known	O
contraindication	B
or	O
hypersensitivity	B
to	O
all	O
anticoagulation	B
regimens	I
,	O
or	O
inability	B
to	O
be	O
anticoagulated	B
for	B
the	I
study	I
procedure	I
.	O

Recent	O
CVA	B
clinically	B
confirmed	I
(	I
by	I
neurologist	I
)	I
or	O
neuroimaging	B
confirmed	B
stroke	B
or	O
transient	B
ischemic	I
attack	I
(	I
TIA	I
)	I
within	B
6	I
months	I
(	I
180	I
days	I
)	I
of	I
the	I
procedure	I
.	O

Estimated	O
life	O
expectancy	O
<	B
1	I
year	I
from	O
conditions	O
other	O
than	O
TR	O
.	O

Expectation	O
that	O
patient	O
will	O
not	O
improve	O
despite	O
treatment	O
of	O
tricuspid	O
regurgitation	O

Currently	O
participating	O
in	O
another	O
investigational	O
cardiac	O
device	O
study	O
or	O
any	O
other	O
clinical	O
trial	O
,	O
including	O
drugs	O
or	O
biologics	O
.	O
Note	O
:	O
Trials	O
requiring	O
extended	O
follow	O
-	O
up	O
for	O
products	O
that	O
were	O
investigational	O
,	O
but	O
have	O
since	O
become	O
commercially	O
available	O
,	O
are	O
not	O
considered	O
investigational	O
trials	O
.	O

Active	B
bacterial	B
endocarditis	I
within	B
6	I
months	I
(	I
180	I
days	I
)	I
of	I
procedure	I
.	O

Patients	O
with	O
signs	O
or	O
symptoms	O
of	O
SVC	B
syndrome	I
,	O
or	O
hepatic	B
cirrhosis	I
not	O
felt	O
due	O
to	O
passive	B
congestion	I
from	I
TR	I
.	O

Patients	O
must	O
be	O
at	B
least	I
21	I
years	I
old	B
.	O

The	O
patient	O
must	O
have	O
severe	B
,	O
symptomatic	B
(	O
ACC	B
/	I
AHA	I
Stage	B
D	I
symptoms	O
)	O
tricuspid	B
regurgitation	I
(	O
TR	B
)	O
as	O
assessed	O
by	O
2D	B
echocardiogram	I
with	O
evidence	O
of	O
peripheral	O
and	O
central	B
venous	I
congestion	I
(	O
specifically	O
lower	B
extremity	I
edema	I
and	O
abdominal	B
ascites	I
requiring	O
diuretics	B
.	O
)	O

The	O
patient	O
must	O
be	O
evaluated	O
by	O
a	O
"	O
heart	O
team	O
"	O
of	O
physicians	O
including	O
an	O
interventional	O
cardiologist	O
,	O
cardiothoracic	O
surgeon	O
,	O
heart	O
failure	O
specialist	O
,	O
and	O
imaging	O
specialist	O
,	O
and	O
presented	O
for	O
review	O
at	O
a	O
local	O
multi	O
-	O
disciplinary	O
conference	O
.	O
By	O
consensus	O
,	O
the	O
heart	O
team	O
must	O
agree	O
(	O
and	O
verify	O
in	O
the	O
case	O
review	O
process	O
)	O
that	O
valve	O
implantation	O
will	O
likely	O
benefit	O
the	O
patient	O
.	O

The	O
heart	O
team	O
must	O
agree	O
that	O
medical	O
factors	O
preclude	O
operation	O
,	O
based	O
on	O
a	O
conclusion	O
that	O
the	O
probability	O
of	O
death	O
or	O
serious	O
,	O
irreversible	O
morbidity	O
exceeds	O
the	O
probability	O
of	O
meaningful	O
improvement	O
.	O
Also	O
,	O
other	O
factors	O
which	O
may	O
increase	O
the	O
patients	O
perceived	O
surgical	O
risk	O
for	O
inclusion	O
in	O
the	O
trial	O
will	O
be	O
clearly	O
delineated	O
if	O
they	O
are	O
present	O
.	O
These	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
the	O
following	O
as	O
defined	O
by	O
VARC	O
2	O
:	O
Frailty	O
,	O
Hostile	O
chest	O
,	O
porcelain	O
aorta	O
,	O
IMA	O
or	O
other	O
critical	O
conduit	O
crossing	O
the	O
midline	O
or	O
adherent	O
to	O
the	O
posterior	O
table	O
of	O
sternum	O
,	O
severe	O
right	O
ventricular	O
(	O
RV	O
)	O
dysfunction	O
.	O
The	O
surgeons	O
'	O
consultation	O
notes	O
shall	O
specify	O
the	O
medical	O
or	O
anatomic	O
factors	O
leading	O
to	O
that	O
conclusion	O
.	O
At	O
least	O
one	O
of	O
the	O
cardiac	O
surgeon	O
assessors	O
must	O
have	O
interviewed	O
and	O
examined	O
the	O
patient	O
.	O

The	O
study	O
patient	O
provides	O
informed	O
consent	O
and	O
agrees	O
to	O
comply	O
with	O
all	O
required	O
post	O
-	O
procedure	O
follow	O
-	O
up	O
visits	O
,	O
including	O
annual	O
visits	O
up	O
to	O
5	O
years	O
.	O

Has	O
other	O
dermatological	O
conditions	O
that	O
may	O
interfere	O
with	O
clinical	O
assessments	O

Allergy	B
or	O
sensitivity	B
to	O
corticosteroids	B
or	O
any	O
drug	B
hypersensitivity	I
or	O
intolerance	O
that	O
would	O
compromise	O
patient	O
safety	O
or	O
study	O
results	O

History	O
of	O
an	O
adverse	B
reaction	I
to	O
Cortrosyn	B
™	O
or	O
similar	B
test	B
reagents	I

Chronic	O
infectious	O
disease	O
,	O
system	O
or	O
organ	O
disorder	O
or	O
other	O
medical	O
condition	O
that	O
would	O
place	O
patient	O
at	O
undue	O
risk	O
by	O
study	O
participation	O

Patients	O
aged	B
7	B
years	I
and	I
older	I
must	O
have	O
provided	O
written	O
assent	O
accompanied	O
by	O
written	O
informed	O
consent	O
from	O
patient	O
'	O
s	O
representative	O

Clinical	O
diagnosis	O
of	O
stable	B
plaque	B
psoriasis	I
with	O
involvement	O
of	O
=	B
10	I
%	I
body	B
surface	I
area	I
(	O
excluding	B
face	B
and	O
scalp	B
)	O

Physicians	B
Global	I
Assessment	I
score	I
of	O
3	B
or	O
4	B
at	B
baseline	I

Age	B
<	B
20	I
or	I
>	I
35	I
years	I
.	O

Body	B
mass	I
index	I
(	O
BMI	B
)	O
<	B
18	I
.	I
5	I
kg	I
/	I
m2	I
or	I
>	I
25	I
kg	I
/	I
m2	I
.	O

Presence	O
of	O
any	O
infertility	B
factor	I
other	B
than	I
anovulatory	B
PCOS	I
.	O

Previous	O
history	O
of	O
ovarian	B
surgery	I
or	O
surgical	B
removal	I
of	O
one	B
ovary	B
.	O

Previous	O
exposure	B
to	O
cytotoxic	B
drugs	I
or	O
pelvic	B
irradiation	I
.	O

Oral	B
hypoglycemic	O
or	O
hormonal	B
therapy	I
either	O
currently	O
or	O
in	O
the	O
preceding	B
3	I
months	I
.	O

Metabolic	O
or	O
hormonal	B
abnormalities	I

Infertile	B
lean	O
women	B
with	O
PCOS	B
as	O
defined	O
by	O
the	O
Rotterdam	B
criteria	I
.	O

CC	B
resistance	B
(	O
defined	O
as	O
failure	O
of	O
ovulation	O
after	O
receiving	O
150	O
mg	O
/	O
day	O
of	O
CC	O
for	O
5	O
consecutive	O
days	O
per	O
cycle	O
,	O
for	O
at	O
least	O
3	O
consecutive	O
cycles	O
)	O
.	O

Active	B
proliferative	I
diabetic	I
retinopathy	I
(	I
PDR	I
)	I
in	B
the	I
study	I
eye	I
such	O
as	O
NVE	B
,	O
NVD	B
,	O
vitreous	B
hemorrhage	I
,	O
or	O
neovascular	B
glaucoma	I
.	O

Uncontrolled	B
hypertension	I
defined	O
as	O
systolic	B
>	B
180	I
mmHg	I
or	O
>	B
160	I
mmHg	I
on	B
2	I
consecutive	I
measurements	I
or	O
diastolic	B
>	B
100	I
mmHg	I
on	O
optimal	B
medical	I
regimen	I

Screening	B
HgA1c	B
blood	I
test	I
>	B
10	I
.	I
0	I

Focal	B
laser	I
photocoagulation	I
or	O
intravitreal	B
/	I
periocular	I
steroids	I
of	O
any	O
type	O
in	B
the	I
study	I
eye	I
within	B
the	I
last	I
90	I
days	I
prior	I
to	I
study	I
enrollment	I
.	O

A	O
history	B
of	I
intravitreal	B
anti	B
-	I
VEGF	I
injection	I
of	O
any	O
type	O
in	B
the	I
study	I
eye	I
within	B
the	I
last	I
45	I
days	I
prior	I
to	I
study	I
enrollment	I
.	O

History	B
of	I
rhegmatogenous	B
retinal	I
detachment	I
,	O
retinal	B
tear	I
(	I
s	I
)	I
,	O
or	O
traction	B
retinal	I
detachments	I
in	B
the	I
study	I
eye	I
.	O

Epiretinal	O
membrane	O
and	O
/	O
or	O
vitreomacular	B
traction	I
in	B
the	I
study	I
eye	I
as	O
determined	O
by	O
the	O
central	O
reading	O
center	O
.	O

Previous	B
pars	B
plana	I
vitrectomy	I
in	B
the	I
study	I
eye	I

Any	O
intraocular	B
surgery	I
in	B
the	I
study	I
eye	I
within	B
the	I
last	I
90	I
days	I
prior	I
to	I
study	I
enrollment	I
.	O

YAG	B
laser	I
treatment	I
in	B
the	I
study	I
eye	I
in	B
last	I
30	I
days	I
prior	I
to	I
study	I
enrollment	I
.	O

High	B
myopia	I
in	B
the	I
study	I
eye	I
,	O
with	O
a	O
spherical	B
equivalent	I
of	O
>	B
8	I
.	I
00D	I
at	B
screening	I

Other	B
ocular	B
pathologies	I
that	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
would	O
interfere	O
with	O
the	O
subject	O
'	O
s	O
vision	O
in	O
the	O
study	O
eye	O
.	O

Chronic	B
or	O
recurrent	B
uveitis	B
.	O

Ongoing	B
ocular	B
infection	I
or	O
inflammation	O
in	B
either	I
eye	I
.	O

A	O
history	B
of	I
cataract	B
surgery	I
complications	O
/	O
vitreous	B
loss	I
in	B
the	I
study	I
eye	I
.	O

Congenital	B
eye	I
malformations	I
in	B
the	I
study	I
eye	I
.	O

A	O
history	B
of	I
penetrating	B
ocular	I
trauma	I
in	B
the	I
study	I
eye	I
.	O

Mentally	B
handicapped	I
.	O

Pregnant	B
female	B
,	O
as	O
determined	O
for	O
women	B
less	B
than	I
60	I
years	I
old	B
by	O
a	O
positive	B
urine	B
pregnancy	I
test	I
during	B
the	I
screening	I
window	I
.	O

Nursing	O
female	B
.	O

Currently	O
participating	O
in	O
any	O
other	O
clinical	O
research	O
study	O
.	O

Contraindication	B
to	O
the	O
study	B
medication	I
.	O

Male	B
or	O
female	B
,	O
18	O
years	O
of	O
age	B
or	O
older	O
.	O

Study	O
eye	O
with	O
clinically	B
significant	I
diabetic	B
macular	I
edema	I
(	I
DME	I
)	I
with	O
central	B
subfield	I
thickness	I
≥	B
350µm	I
on	O
spectral	B
domain	I
OCT	I

Best	B
corrected	I
visual	I
acuity	I
(	I
BCVA	I
)	I
of	O
20	B
/	I
50	I
to	I
20	I
/	I
320	I
ETDRS	I
equivalent	I
(	O
65	B
letters	I
to	I
23	I
letters	I
)	O
in	B
the	I
study	I
eye	I
,	O
with	O
BCVA	O
decrement	O
primarily	O
attributable	O
to	O
DME	O
.	O

Treatment	O
naïve	O
,	O
i	O
.	O
e	O
.	O
,	O
no	B
previous	B
anti	B
-	I
VEGF	I
treatment	I
in	B
the	I
study	I
eye	I
or	O
no	B
anti	B
-	I
VEGF	I
treatment	I
in	B
the	I
45	I
days	I
prior	I
to	I
study	I
enrollment	I
.	O

In	O
the	O
investigator	O
'	O
s	O
opinion	O
,	O
the	O
subject	O
still	O
has	O
significant	B
intraretinal	B
fluid	I
with	B
room	I
for	I
improvement	I
in	O
both	O
macular	B
edema	I
and	O
BCVA	B
.	O

Intra	B
-	I
Ocular	I
Pressure	I
(	I
IOP	I
)	I
is	O
under	B
control	I
(	O
i	O
.	O
e	O
.	O
,	O
IOP	B
≤	B
25	I
mm	I
in	B
the	I
study	I
eye	I
)	O
and	O
study	B
eye	I
is	O
not	B
receiving	O
any	O
IOP	B
lowering	I
drops	I
.	O

Willing	O
and	O
able	O
to	O
return	O
for	O
all	O
study	O
visits	O
.	O

Able	O
to	O
meet	O
the	O
extensive	O
post	O
-	O
op	O
evaluation	O
regimen	O
.	O

Understands	O
and	O
signs	O
the	O
informed	O
consent	O
form	O
.	O

1	O
.	O

Left	B
main	I
disease	I
(	O
angiographically	O
>	B
50	I
%	I
)	O

2	O
.	O

Cardiogenic	B
shock	I
/	O
hemodynamic	B
instability	I

3	O
.	O

Previous	B
CABG	B

4	O
.	O

Increased	B
risk	I
of	O
bradycardia	B
on	O
investigator	O
clinical	O
judgment	O

5	O
.	O

Severe	B
chronic	B
obstructive	I
pulmonary	I
disease	I

6	O
.	O

Coronary	B
vessels	I
with	I
tortuosity	I
or	O
extremely	O
calcified	O

7	O
.	O

Severe	B
left	B
ventricular	I
hypertrophy	I
or	O
severe	B
valvular	B
disease	I

8	O
.	O

STEMI	B
or	O
non	B
-	I
STEMI	I
within	B
the	I
past	I
five	I
days	I

9	O
.	O

Previous	B
myocardial	B
infarction	I
in	B
the	I
distribution	I
of	I
the	I
target	I
vessel	I
for	O
the	O
FFR	O

10	O
.	O

Acute	B
decompensated	I
heart	I
failure	I
.	O

1	O
.	O

Age	B
18	B
-	I
80	I
years	I

2	O
.	O

Patients	O
with	O
at	B
least	I
1	I
≥	B
50	I
%	I
stenosis	B
in	I
a	I
coronary	I
vessel	I
,	O
subjected	O
to	O
FFR	B
assessment	I
,	O
who	O
exhibit	O
variation	O
in	O
Pd	B
/	I
Pa	I
ratio	I
≥	B
0	I
.	I
05	I
(	O
e	O
.	O
g	O
.	O
difference	O
of	O
max	B
Pd	I
/	I
Pa	I
minus	O
min	B
Pd	I
/	I
Pa	I
)	O
during	O
steady	B
state	I
hyperaemia	B
(	O
determined	O
by	O
visual	B
assessment	I
)	O
.	O

3	O
.	O

Written	O
informed	O
consent	O

day	O
3	O
transfers	O

women	B
undergoing	O
IVF	B
/	O
ICSI	B
or	O
frozen	B
embryo	I
transfers	I
(	I
FET	I
)	I
that	O
less	B
than	I
40	I
years	I
old	B
.	O

Renal	B
impairment	I

Evidence	O
or	O
history	O
of	O
clinically	O
significant	O
allergic	B
reactions	O
to	O
varenicline	B

A	O
cardiovascular	B
event	I
in	B
the	I
past	I
month	I

History	O
of	O
alcohol	O
or	O
drug	B
dependence	I
in	O
the	B
past	I
year	I

Major	B
depressive	I
disorder	I
in	O
the	O
last	B
year	I
requiring	O
treatment	B

History	O
of	O
panic	B
disorder	I
,	O
psychosis	B
,	O
bipolar	B
disorder	I
,	O
or	O
eating	B
disorders	I

Use	O
of	O
tobacco	O
products	O
other	B
than	I
cigarettes	O
in	O
past	B
30	I
days	I

Use	O
of	O
pharmacotherapy	B
in	O
the	O
month	B
prior	I
to	I
enrollment	I
,	O
including	O
prior	O
use	O
of	O
varenicline	O

Pregnant	O
,	O
contemplating	O
getting	O
pregnant	O
,	O
or	O
breastfeeding	O

Plans	O
to	O
move	O
from	O
Kansas	O
City	O
during	O
the	O
treatment	O
and	O
follow	O
-	O
up	O
phase	O

Another	O
household	O
member	O
enrolled	O
in	O
the	O
study	O

Evidence	O
of	O
current	O
severe	B
major	B
depressive	I
disorder	I
or	O
suicidal	B
ideation	I

Self	O
-	O
identified	O
African	B
American	I

Smokes	O
=	B
1	I
cigarette	I
per	I
day	I
(	O
cpd	O
)	O

Smoke	O
on	O
=	B
25	I
days	I
of	I
the	I
past	I
30	I
days	I

Functioning	O
telephone	O

Interested	O
in	O
quitting	O
smoking	O

Interested	O
in	O
taking	O
3	O
months	O
of	O
varenicline	O

Willing	O
to	O
complete	O
all	O
study	O
visits	O

endometrial	B
hyperplasia	I
with	O
atypia	B
,	O

estrogen	B
-	I
progestin	I
therapy	I
in	B
the	I
2	I
months	I
before	I
enrollment	I
,	O

autoimmune	B
diseases	I
,	O

chronic	O
,	O
metabolic	O
,	O
systemic	O
and	O
endocrine	B
disorders	I
,	O
including	O
hyperandrogenism	B
,	O
hyperprolactinemia	B
,	O
diabetes	B
mellitus	I
and	O
thyroid	B
disease	I
,	O

hypogonadotropic	B
hypogonadism	I
,	O

majors	B
clinical	I
conditions	I

submucosal	B
,	O

intramural	O
or	O
subserosal	B
leiomyomas	I
,	O

symptoms	O
of	O
menometrorrhagia	B
,	O

menstrual	B
disorder	I
,	O

infertility	B
,	O

pelvic	B
pain	I

submucosal	B
leiomyoma	I
,	O

endometrial	B
hyperplasia	I
with	B
atypia	I
,	O

history	B
of	O
uterine	B
surgery	I

hypoechoic	B
uterine	B
leiomyoma	I
(	O
echogenicity	B
<	B
3	I
)	O
,	O

intramural	B
leiomyomas	I
with	O
an	O
ultrasonographic	B
size	I
<	B
20	I
cm	I
but	I
>	I
4cm	I
,	O

indication	O
to	O
surgery	B
(	O
symptoms	O
of	O
menometrorrhagia	B
,	O

menstrual	B
disorder	I
,	O

infertility	B
,	O

pelvic	B
pain	I
or	O
pelvic	B
pressure	I

History	B
of	O
cardiovascular	B
disease	I
;	O

Current	B
pregnancy	B
;	O

Uncontrolled	B
hypertension	B
;	O

Uncontrolled	B
hyperlipidemia	B
;	O

Current	B
hormone	B
replacement	I
therapy	I
;	O

Current	B
use	O
of	O
tobacco	O
products	O
;	O

Elevated	B
liver	I
enzymes	I
;	O

Current	B
autoimmune	B
disease	I
;	O

Daily	B
use	I
of	O
of	O
antioxidants	B
>	B
300mg	I

Stage	B
3	B
-	I
5	I
Chronic	B
Kidney	I
Disease	I

Unstable	B
medical	I
disease	I
of	O
comorbid	B
psychiatric	I
disease	I

Dementia	B

Subjects	O
with	O
less	B
than	I
one	I
year	I
duration	I
of	O
Parkinson	B
'	I
s	I

Current	B
treatment	O
with	O
a	O
dopamine	B
agonist	I

Diagnosis	O
of	O
DSM	B
5	I
Anxiety	I
Disorder	I

Stable	B
medical	I
history	I
and	O
general	O
health	O

On	O
stable	B
anti	B
-	I
parkinsonian	I
therapy	I
for	B
2	I
weeks	I
before	B
enrollment	I

Previous	B
or	O
concurrent	B
malignancy	B
,	O
except	B
for	O
adequately	B
treated	I
basal	O
cell	O
or	O
squamous	B
cell	I
skin	I
cancer	I
,	O
in	B
situ	I
cervical	B
cancer	I
,	O
or	O
any	O
other	O
cancer	O
for	O
which	O
the	O
patient	O
has	O
been	O
previously	O
treated	O
and	O
the	O
lifetime	O
recurrence	O
risk	O
is	O
less	O
than	O
30	O
%	O

Inflammatory	B
bowel	I
disease	I
that	O
is	O
uncontrolled	B
or	O
on	O
active	O
treatment	B
(	O
Crohn	B
'	I
s	I
disease	I
,	O
ulcerative	B
colitis	I
)	O

Diarrhea	B
,	O
grade	B
1	I
or	I
greater	I
by	O
the	O
National	B
Cancer	I
Institute	I
Common	I
Terminology	I
Criteria	I
for	I
Adverse	I
Events	I
(	O
NCI	B
-	I
CTCAE	I
,	I
version	I
[	I
v	I
]	I
4	I
.	I
0	I
)	O

Neuropathy	B
,	O
grade	B
2	I
or	I
greater	I
by	O
NCI	B
-	I
CTCAE	I
,	I
v	I
4	I
.	I
0	I

Serious	O
underlying	O
medical	O
or	O
psychiatric	O
illnesses	O
that	O
would	O
,	O
in	O
the	O
opinion	O
of	O
the	O
treating	O
physician	O
,	O
substantially	O
increase	O
the	O
risk	O
for	O
complications	O
related	O
to	O
treatment	O

Active	B
uncontrolled	B
bleeding	B

Pregnancy	O
or	O
breastfeeding	O

Major	B
surgery	I
within	B
4	I
weeks	I

Patients	O
with	O
any	O
polymorphism	O
in	O
UGT1A1	O
other	O
than	O
*	O
1	O
or	O
*	O
28	O
(	O
e	O
.	O
g	O
,	O
*	O
6	O
)	O
will	O
be	O
allowed	O
and	O
treated	O
as	O
in	O
the	O
*	O
28	O
/	O
*	O
28	O
dosing	O
group	O

Histologically	O
confirmed	O
locally	B
advanced	I
gastric	O
(	O
primary	O
endpoint	O
includes	O
proximal	O
and	O
mid	B
-	I
body	I
stomach	I
)	O
or	O
esophagogastric	B
adenocarcinoma	I
;	O
distal	B
gastric	I
(	O
antral	B
)	O
adenocarcinomas	B
are	O
eligible	O
for	O
enrolment	O
but	O
will	O
not	O
be	O
included	O
in	O
the	O
primary	O
analysis	O

Locally	B
advanced	I
disease	B
as	O
determined	O
by	O
endoscopic	B
ultrasound	I
(	O
EUS	B
)	O
stage	O
>	B
primary	I
tumor	I
(	I
T	I
)	I
3	I
and	I
/	I
or	I
any	I
T	I
,	I
lymph	I
nodes	I
(	I
N	I
)	I
+	I
disease	I
without	I
metastatic	I
disease	I
(	I
Mx	I
)	I

All	O
patients	O
must	O
have	O
diagnostic	B
laparoscopy	B
with	O
diagnostic	O
washings	B
for	I
cytology	I
;	O
both	O
cytology	B
positive	B
and	O
negative	B
patients	O
are	O
eligible	O
for	O
enrolment	O
,	O
but	O
only	O
cytology	O
negative	O
patients	O
will	O
be	O
included	O
in	O
the	O
primary	O
analyses	O
;	O
gross	O
peritoneal	O
disease	O
is	O
not	O
eligible	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	B
)	O
performance	O
status	O
=	B
<	I
1	I

Eligible	O
for	O
surgery	B
with	O
curative	B
intent	O

Absolute	B
neutrophil	I
count	I
(	O
ANC	B
)	O
>	B
=	I
1250	I
/	I
ul	I

Hemoglobin	B
>	B
=	I
9	I
g	I
/	I
dL	I

Platelets	B
>	B
=	I
100	I
,	I
000	I
/	I
ul	I

Total	B
bilirubin	I
<	B
1	I
.	I
5	I
x	I
upper	I
limit	I
of	I
normal	I

Serum	B
glutamic	I
oxaloacetic	I
transaminase	I
(	O
SGOT	B
)	O
and	O
serum	B
glutamate	I
pyruvate	I
transaminase	I
(	O
SGPT	B
)	O
<	B
2	I
.	I
5	I
x	I
upper	I
limit	I
of	I
normal	I
for	O
patients	O
without	B
liver	B
metastases	I
OR	O
SGOT	B
and	O
SGPT	B
<	B
5	I
x	I
upper	I
limit	I
of	I
normal	I
for	O
patients	O
with	O
liver	B
metastases	I

Creatinine	B
=	B
<	I
1	I
.	I
5	I
x	I
upper	I
limit	I
of	I
normal	I

Measurable	O
or	O
non	O
-	O
measurable	O
disease	O
by	O
Response	B
Evaluation	I
Criteria	I
in	I
Solid	I
Tumor	I
(	O
RECIST	B
)	O
1	B
.	I
1	I
will	O
be	O
allowed	O

Women	O
of	O
child	O
-	O
bearing	O
potential	O
and	O
men	O
must	O
agree	O
to	O
use	O
adequate	O
contraception	O
(	O
hormonal	O
or	O
barrier	O
method	O
of	O
birth	O
control	O
;	O
abstinence	O
)	O
prior	O
to	O
study	O
entry	O
and	O
for	O
the	O
duration	O
of	O
study	O
participation	O
,	O
up	O
until	O
30	O
days	O
after	O
final	O
study	O
treatment	O
;	O
should	O
a	O
woman	O
become	O
pregnant	O
or	O
suspect	O
that	O
she	O
is	O
pregnant	O
while	O
participating	O
in	O
this	O
study	O
,	O
she	O
should	O
inform	O
her	O
treating	O
physician	O
immediately	O

Patients	O
taking	O
substrates	O
,	O
inhibitors	O
,	O
or	O
inducers	O
of	O
cytochrome	O
P450	O
,	O
family	O
3	O
,	O
subfamily	O
A	O
,	O
polypeptide	O
4	O
(	O
CYP3A4	O
)	O
should	O
be	O
encouraged	O
to	O
switch	O
to	O
alternative	O
drugs	O
whenever	O
possible	O
,	O
given	O
the	O
potential	O
for	O
drug	O
-	O
drug	O
interactions	O
with	O
irinotecan	O

Signed	O
informed	O
consent	O

Patient	O
included	O
in	O
an	O
interventional	O
study	O
assessing	O
treatment	B
for	O
active	B
proctitis	I
or	O
distal	B
proctosigmoiditis	I
.	O

Patient	O
with	O
left	B
sided	I
,	O
colitis	B
or	O
pancolitis	B
.	O

Patient	O
with	O
severe	B
proctitis	B
(	O
MAYO	B
score	I
≥	B
11	I
at	B
inclusion	I
)	O
.	O

Patient	O
previously	B
treated	B
with	O
biologics	B
.	O

Patient	O
treated	O
with	O
immunosuppressive	B
within	B
1	I
month	I
before	I
study	I
inclusion	I
.	O

Patient	O
treated	O
with	O
corticosteroids	B
within	B
2	I
weeks	I
before	I
study	I
inclusion	I
.	O

Patient	O
aged	B
18	B
years	I
or	I
older	I
.	O

Patient	O
suffering	O
from	O
mild	B
to	I
moderate	I
active	B
proctitis	I
or	O
distal	B
proctosigmoiditis	I
(	O
MAYO	B
score	I
≥	B
3	I
and	I
≤	I
10	I
)	O
at	B
inclusion	I
based	O
on	O
clinical	O
and	O
endoscopic	O
findings	O
within	B
6	I
months	I
before	I
study	I
inclusion	I
.	O

Patient	O
with	O
evidence	O
of	O
endoscopic	B
active	B
proctitis	I
or	O
distal	B
proctosigmoiditis	I
(	O
Montreal	B
classification	I
E1	B
or	I
E2	I
defined	O
by	O
an	O
involvement	B
not	I
exceeding	I
25	I
cm	I
from	I
the	I
anal	I
margin	I
)	O
within	B
6	I
months	I
before	I
study	I
inclusion	I
.	O

Treatment	B
of	O
the	O
current	O
flare	B
with	O
Pentasa	B
®	O
to	O
induce	O
a	O
remission	O
initiated	O
by	O
the	O
patient	O
,	O
the	O
general	O
practitioner	O
or	O
the	O
gastroenterologist	O
,	O
during	B
the	I
inclusion	I
visit	I
or	O
during	B
the	I
week	I
before	I
the	I
inclusion	I
visit	I
.	O

Patient	O
having	O
received	O
oral	O
and	O
written	O
information	O
on	O
the	O
study	O
,	O
without	O
any	O
objections	O
for	O
the	O
use	O
of	O
his	O
/	O
her	O
personal	O
data	O
,	O
and	O
having	O
signed	O
a	O
written	O
Informed	O
Consent	O
Form	O
.	O

Chronic	B
opiate	B
use	O

Liver	B
disease	I
(	O
known	O
history	B
of	O
hepatitis	B
B	I
or	O
C	O
,	O
cirrhosis	B
,	O
nonalcoholic	B
steatohepatitis	I
,	O
history	B
of	O
alcoholism	B
,	O
ALT	B
/	I
AST	I
greater	B
than	I
3	I
times	I
upper	I
limit	I
of	I
normal	I
in	B
the	I
past	I
3	I
months	I
)	O

Allergy	B
/	O
hypersensitivity	B
to	O
acetaminophen	B

Patients	O
with	O
baseline	B
dementia	B

Chronic	B
diathesis	B

Chronic	B
kidney	B
disease	I

Patients	O
undergoing	O
robotic	B
-	I
assisted	I
laparoscopic	I
prostatectomy	I

=	O
18	O
years	B
old	O
males	B

ASA	B
class	I
1	B
-	I
4	I

immunization	B
with	O
PPV23	B
within	B
the	I
last	I
year	I

any	O
confirmed	B
or	O
suspected	B
immunodeficiency	B
condition	I
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	B
)	O
infection	O
,	O
haematological	B
malignancy	I
,	O
or	O
a	O
congenital	B
immunodeficiency	I

history	O
of	O
allergic	B
disease	I
or	O
reactions	O
likely	O
to	O
be	O
exacerbated	O
by	O
any	O
component	O
of	O
the	O
vaccine	B

history	O
of	O
allergic	B
disease	I
likely	O
to	O
be	O
stimulated	O
by	O
the	O
vaccination	B

history	O
or	O
records	O
of	O
immunosuppressive	B
therapy	I
(	O
with	O
the	O
exception	B
of	O
topical	B
corticosteroids	I
)	O
for	O
more	O
than	O
14	O
days	O
and	O
within	B
6	I
months	I
of	I
vaccination	I

history	O
or	O
evidence	O
of	O
administration	O
of	O
immunoglobulins	B
and	O
/	O
or	O
any	O
blood	B
products	I
during	B
the	I
study	I
period	I
or	O
within	B
the	I
three	I
months	I
preceding	I
the	I
study	I
vaccine	I

use	O
of	O
any	O
other	O
investigational	B
or	O
non	B
-	I
registered	I
drug	B
or	O
vaccine	B
during	B
the	I
study	I
period	I
or	O
within	B
30	I
days	I
preceding	I
the	I
study	I
vaccine	I

administration	O
of	O
a	O
vaccine	B
during	O
the	O
period	O
starting	O
one	O
month	O
before	O
the	O
dose	O
of	O
vaccine	B
and	O
ending	O
one	O
month	O
after	O

pregnancy	B

Males	B
and	O
females	B
of	O
18	O
years	O
of	O
age	B
or	O
older	O
at	O
the	O
time	O
of	O
the	O
vaccination	B

Severe	B
chronic	B
kidney	I
disease	I
(	O
Stage	O
4	O
and	O
5	O
)	O

1	O
.	O

Does	O
not	B
have	O
a	O
documented	O
history	B
of	O
generalized	B
seizures	I
.	O

2	O
.	O

Has	O
not	B
had	O
a	O
GTC	B
seizure	I
within	B
the	I
last	I
year	I
AND	O
is	O
not	B
expected	O
to	O
have	O
a	O
reduction	O
of	O
anti	B
-	I
epileptic	I
drugs	I
during	B
their	I
hospital	I
admission	I
.	O

3	O
.	O

Intracranial	B
EEG	I
electrodes	I
are	O
being	O
used	O

4	O
.	O

The	O
subject	O
'	O
s	O
upper	B
arm	I
circumference	I
not	B
adequate	B
for	I
proper	I
fit	I
of	I
the	I
EMG	I
monitor	I
(	O
less	B
than	I
14cm	I
)	O
.	O

5	O
.	O

Pregnant	B
female	B
.	O

6	O
.	O

Subject	O
/	O
Caregiver	O
is	O
unable	O
to	O
provide	O
consent	O
.	O

1	O
.	O

Subject	O
has	O
a	O
history	B
of	O
GTC	B
seizures	I
,	O
either	O
primary	B
GTC	I
or	O
partial	B
onset	I
seizures	I
with	O
secondary	B
generalization	I
.	O

2	O
.	O

Is	O
being	O
admitted	B
to	I
a	I
hospital	I
for	O
routine	O
vEEG	B
monitoring	I
related	O
to	O
seizures	B
.	O

3	O
.	O

Male	B
or	O
female	B
between	O
the	B
ages	I
of	O
2	O
-	O
99	O
.	O

4	O
.	O

Has	O
an	O
upper	B
arm	I
circumference	I
which	O
is	O
adequate	B
for	I
proper	I
fit	I
of	I
the	I
EMG	I
monitor	I
(	O
at	B
least	I
14cm	I
)	O
.	O

5	O
.	O

If	O
female	B
and	O
of	O
childbearing	B
potential	I
,	O
has	O
a	O
negative	B
pregnancy	B
test	I
.	O

6	O
.	O

Can	O
understand	O
and	O
sign	O
written	O
informed	O
consent	O
,	O
or	O
will	O
have	O
a	O
parent	O
or	O
a	O
legally	O
authorized	O
representative	O
(	O
LAR	O
)	O
who	O
can	O
do	O
so	O
,	O
prior	O
to	O
the	O
performance	O
of	O
any	O
study	O
assessments	O
.	O

7	O
.	O

Subject	O
and	O
/	O
or	O
Primary	O
Caregiver	O
must	O
be	O
competent	O
to	O
follow	O
all	O
study	O
procedures	O
.	O

8	O
.	O

Is	O
able	O
to	O
read	O
,	O
speak	O
,	O
and	O
understand	O
English	O
.	O

Patients	O
with	O
medical	B
comorbidities	I
preventing	O
them	O
from	O
definitive	B
surgical	I
therapy	I
.	O

Patients	O
with	O
persistent	B
stone	O
burden	O
following	O
definitive	B
surgical	I
therapy	I
.	O

Male	B
or	O
Female	B
.	O

No	O
age	O
restriction	O
.	O

Diagnosed	O
with	O
an	O
infection	B
related	I
stone	B
.	O

Medically	O
fit	O
for	O
definitive	B
surgical	I
management	I
of	O
stone	B
.	O

Life	O
expectancy	O
greater	B
than	I
one	I
year	I
.	O

Stone	B
free	B
after	O
definitive	B
surgical	I
therapy	I
defined	O
as	O
fragments	B
less	I
than	I
3mm	I
.	O

Evidence	O
of	O
sympathetic	O
integrity	O
below	B
the	I
lesion	I
level	I
by	O
the	O
skin	O
axon	O
-	O
reflex	O
vasodilatation	O
(	O
SkARV	B
)	O
test	O
;	O

Known	O
allergies	B
to	O
midodrine	B
hydrochloride	I
;	O

PMH	O
of	O
diagnosed	O
heart	O
,	O
kidney	O
,	O
peripheral	O
vascular	O
,	O
or	O
cerebral	B
vascular	I
disease	I
,	O
or	O
diabetes	B
mellitus	I
;	O

Hypertension	B
(	O
BP	B
>	B
140	I
/	I
90	I
mmHg	I
)	O
;	O

Untreated	B
thyroid	B
disease	I
;	O

Acute	B
illness	B
or	O
infection	B
;	O

Current	O
smoker	B
;	O

Pregnancy	B
.	O

Duration	O
of	O
SCI	B
=	B
1	I
year	I
;	O

Level	B
of	I
SCI	I
C3	B
-	I
T1	I
,	O
AIS	B
A	B
&	I
B	I
;	O

Age	B
between	B
18	I
and	I
65	I
years	I
.	O

known	O
hypersensitivity	B
or	O
contraindication	B
to	O
the	O
study	B
drugs	I

reversible	B
aetiology	I
for	O
agitation	B
(	O
e	O
.	O
g	O
.	O
hypotension	B
,	O
hypoxia	B
,	O
hypoglycaemia	B
)	O

known	O
pregnancy	B

acute	B
alcohol	I
withdrawal	I

patients	O
aged	B
>	B
75	I
years	I
.	O

Accident	O
&	O
Emergency	O
Department	O
patients	O
,	O
requiring	O
parenteral	B
drug	I
sedation	I
(	O
as	O
determined	O
by	O
an	O
emergency	O
clinician	O
)	O
will	O
be	O
enrolled	O
.	O

adequately	O
controlled	O
with	O
appropriate	O
therapy	O
or	O
would	O
compromise	O
the	O
patient	O
'	O
s	O
ability	O
to	O
tolerate	O
this	O
therapy	O
;	O
2	O
.	O

Treatment	O
with	O
any	O
systemic	B
anticancer	I
therapy	I
≤	B
3	I
weeks	I
prior	I
to	I
cycle	I
1	I
day	O
1	O
3	O
.	O

Uncontrolled	B
active	B
infection	B
(	O
Hepatitis	B
B	I
and	I
C	I
infection	I
are	O
NOT	B
exclusion	O
criteria	O
)	O
and	O
/	O
or	O
known	O
HIV	B
infection	I
;	O
4	O
.	O

Renal	B
failure	I
requiring	O
haemodialysis	B
or	O
peritoneal	B
dialysis	I
;	O
5	O
.	O

Patients	O
who	O
are	O
pregnant	B
or	O
breast	B
-	I
feeding	I
;	O
6	O
.	O

Patients	O
with	O
significantly	B
diseased	O
or	O
obstructed	B
gastrointestinal	I
tract	I
,	O
malabsorption	B
,	O
uncontrolled	B
vomiting	B
or	O
diarrhea	B
resulting	O
in	O
inability	B
to	I
swallow	I
oral	I
medications	I
;	O
7	O
.	O

Presence	O
of	O
symptomatic	B
CNS	B
metastasis	I
8	O
.	O

Unresolved	B
toxicity	I
from	O
previous	B
anti	B
-	I
cancer	I
therapy	I
or	O
incomplete	B
recovery	I
from	O
surgery	B
,	O
in	O
particular	O
oxaliplatin	B
-	O
induced	O
peripheral	B
neuropathy	I
>	O
grade	O
1	O
.	O

9	O
.	O

Any	O
of	O
the	O
following	O
within	B
the	I
12	I
months	I
prior	I
to	I
study	I
drug	I
administration	I
:	O
myocardial	B
infarction	I
,	O
severe	O
/	O
unstable	B
angina	I
,	O
coronary	O
/	O
peripheral	B
artery	I
bypass	I
graft	I
,	O
symptomatic	B
congestive	I
heart	I
failure	I
,	O
cerebrovascular	B
accident	I
or	O
transient	B
ischemic	I
attack	I
,	O
pulmonary	B
embolism	I
,	O
deep	B
vein	I
thrombosis	I
,	O
or	O
other	B
thromboembolic	I
event	I
.	O

1	O
.	O

Patients	O
with	O
histologically	B
confirmed	B
diagnosis	O
of	O
colorectal	B
cancer	I
presenting	O
with	O
unresectable	B
stage	O
IV	B
(	O
UICC	O
)	O
disease	B
(	O
primary	O
tumor	O
may	O
be	O
present	O
)	O

2	O
.	O

Patients	O
who	O
are	O
feasible	O
for	O
treatment	O
with	O
FOLFOX	B
(	O
prior	O
adjuvant	O
or	O
palliative	B
treatment	I
is	O
allowed	O
)	O

3	O
.	O

ECOG	B
Performance	I
status	I
≤	B
1	I

4	O
.	O

Life	O
expectancy	O
>	B
3	I
months	I

5	O
.	O

Age	B
≥	B
18	I
years	I

6	O
.	O

Haematologic	O
function	O
as	O
follows	O
(	O
5	O
%	O
deviation	O
allowed	O
)	O
:	O

ANC	B
≥	B
1	I
.	I
5	I
x	I
109	I
/	I
L	I

platelets	B
≥	B
100	I
x109	I
/	I
L	I

hemoglobin	B
≥	B
9	I
g	I
/	I
dl	I
or	O
5	O
.	O
59	O
mmol	O
/	O
l	O

7	O
.	O

Adequate	B
liver	B
function	I
as	O
follows	O
(	O
10	O
%	O
deviation	O
allowed	O
)	O

serum	B
alanine	I
transaminase	I
(	I
ALT	I
)	I
≤	B
2	I
.	I
5	I
x	I
ULN	I
(	O
in	O
case	O
of	O
liver	B
metastases	I
<	B
5	I
x	I
ULN	I
)	O

total	B
bilirubin	I
≤	B
1	I
.	I
5	I
x	I
ULN	I
(	O
patients	O
with	O
Gilbert	B
'	I
s	I
syndrome	I
total	B
bilirubin	I
≤	B
2	I
.	I
5	I
x	I
ULN	I
)	O

8	O
.	O

Adequate	B
renal	B
function	I
as	O
follows	O
(	O
10	O
%	O
deviation	O
allowed	O
)	O

·	O
creatinine	B
≤	B
1	I
.	I
5	I
x	I
ULN	I

9	O
.	O

Signed	O
written	O
informed	O
consent	O

10	O
.	O

Women	B
of	O
child	B
-	I
bearing	I
potential	I
must	O
have	O
a	O
negative	B
pregnancy	B
test	I

Patients	O
attending	O
for	O
a	O
therapeutic	B
endoscopic	I
procedure	I
e	O
.	O
g	O
.	O
variceal	B
banding	I
,	O
stent	B
insertion	I
,	O
balloon	B
dilatation	I
.	O

Patients	O
with	O
a	O
known	B
diagnosis	I
e	O
.	O
g	O
.	O
upper	B
gastrointestinal	I
cancer	I

Patients	O
previously	O
treated	O
with	O
HP	B
eradication	I
therapy	I

Patients	O
who	O
had	O
taken	O
PPI	B
,	O
H2	B
receptor	I
antagonists	I
and	O
antibiotics	B
within	B
4	I
weeks	I

Patients	O
with	O
acute	B
gastrointestinal	B
bleeding	I

Patients	O
who	O
'	O
d	O
had	O
previous	B
gastric	B
surgery	I

Patients	O
with	O
chronic	B
liver	B
disease	I

Patients	O
with	O
abnormal	B
coagulation	I
or	O
any	O
other	O
contra	B
-	I
indication	I
to	O
use	O
of	O
standard	B
biopsy	I
in	O
routine	O
diagnostic	B
endoscopic	I
procedures	I

Patients	O
who	O
are	O
unable	O
or	O
unwilling	O
to	O
give	O
informed	O
consent	O

Patients	O
under	O
the	O
age	B
of	O
18	O
years	O

•	O
All	O
patients	O
attending	O
for	O
a	O
routine	O
diagnostic	B
endoscopic	I
procedure	I
at	O
St	O
Mary	O
'	O
s	O
Hospital	O
NHS	O
Trust	O
for	O
dyspepsia	B
and	O
abdominal	B
pain	I

Operative	B
findings	I
not	B
suggestive	O
of	O
endometriotic	B
cyst	I

Contraindications	B
to	O
progestogens	B
or	O
oral	B
contraceptive	I
pills	I

Unwillingness	O
to	O
tolerate	O
menstrual	B
irregularity	I

Planning	O
pregnancy	B
within	B
2	I
years	I
of	I
study	I

Cannot	O
understand	O
English	O
,	O
Cantonese	O
or	O
Putonghua	O

Good	B
general	I
health	I

Older	O
than	O
the	O
age	B
of	O
legal	O
consent	O
(	O
i	O
.	O
e	O
.	O
18	B
years	I
old	I
)	O

Sonographic	B
diagnosis	O
of	O
ovarian	B
endometrioma	I
with	O
diameter	B
at	I
least	I
4cm	I
on	O
2	B
separate	I
scans	I
at	B
least	I
6	I
weeks	I
apart	I

No	B
contraindication	B
to	O
use	O
of	O
progesterone	B
or	O
combined	B
oral	I
contraceptive	I
pills	I

Not	B
attempting	O
to	O
conceive	B
either	O
at	B
the	I
time	I
of	I
study	I
entry	I
or	O
for	B
at	I
least	I
2	I
years	I
after	I
surgery	I

Willing	O
and	O
able	O
to	O
participate	O
after	O
the	O
study	O
has	O
been	O
explained	O

Patient	O
has	O
participated	O
in	O
a	O
combination	O
trial	O
where	O
ruxolitinib	O
was	O
dispensed	O
in	O
combination	O
with	O
another	O
study	O
medication	O
and	O
the	O
patient	O
is	O
still	O
receiving	O
combination	O
therapy	O
.	O

Pregnant	O
or	O
nursing	O
(	O
lactating	O
)	O
women	O
,	O
where	O
pregnancy	O
is	O
defined	O
as	O
the	O
state	O
of	O
a	O
female	O
after	O
conception	O
and	O
until	O
the	O
termination	O
of	O
gestation	O
,	O
confirmed	O
by	O
a	O
positive	O
hCG	O
laboratory	O
test	O
.	O

Women	O
of	O
child	O
-	O
bearing	O
potential	O
,	O
defined	O
as	O
all	O
women	O
physiologically	O
capable	O
of	O
becoming	O
pregnant	O
,	O
unless	O
they	O
are	O
using	O
highly	O
effective	O
methods	O
of	O
contraception	O
throughout	O
the	O
study	O
duration	O
inclusive	O
of	O
the	O
30	O
-	O
day	O
safety	O
follow	O
up	O
.	O

Patient	O
is	O
currently	O
enrolled	O
in	O
a	O
Novartis	O
OGD	O
or	O
GMA	O
-	O
sponsored	O
or	O
Incyte	O
-	O
sponsored	O
clinical	O
study	O
(	O
where	O
Incyte	O
can	O
delegate	O
the	O
sponsorship	O
to	O
a	O
preferred	O
CRO	O
,	O
if	O
applicable	O
)	O
that	O
is	O
approved	O
to	O
enroll	O
into	O
this	O
rollover	O
study	O
,	O
is	O
receiving	O
ruxolitinib	O
and	O
has	O
fulfilled	O
all	O
of	O
the	O
requirements	O
of	O
the	O
parent	O
protocol	O
.	O

Patient	O
is	O
currently	O
benefiting	O
from	O
the	O
treatment	O
with	O
ruxolitinib	B
,	O
as	O
determined	O
by	O
the	O
investigator	O

Patient	O
has	O
demonstrated	O
compliance	O
,	O
as	O
assessed	O
by	O
the	O
investigator	O
,	O
with	O
the	O
parent	O
study	O
protocol	O
requirements	O
Willingness	O
and	O
ability	O
to	O
comply	O
with	O
scheduled	O
visits	O
,	O
treatment	O
plans	O
and	O
any	O
other	O
study	O
procedures	O

Patient	O
currently	O
has	O
no	O
evidence	O
of	O
progressive	B
disease	I
,	O
as	O
determined	O
by	O
the	O
investigator	O
,	O
following	O
previous	O
treatment	O
with	O
ruxolitinib	B

Written	O
informed	O
consent	O
obtained	O
prior	O
to	O
enrolling	O
in	O
roll	O
-	O
over	O
study	O
and	O
receiving	O
study	O
medication	O
.	O
If	O
consent	O
cannot	O
be	O
expressed	O
in	O
writing	O
,	O
it	O
must	O
be	O
formally	O
documented	O
and	O
witnessed	O
,	O
ideally	O
via	O
an	O
independent	O
trusted	O
witness	O
.	O

pregnancy	B

past	O
esophageal	O
,	O
gastric	O
or	O
bariatric	B
surgery	I

irritable	B
bowel	I
,	O
unexplained	O
intermittent	B
vomiting	B
,	O
severe	B
abdominal	B
pain	I
,	O
chronic	B
diarrhea	B
or	O
constipation	B

history	O
of	O
gastric	O
or	O
duodenal	B
ulcers	I

pre	B
-	I
operatory	I
hypoalbuminemy	B

history	O
of	O
renal	O
,	O
hepatic	O
,	O
cardiac	O
or	O
pulmonary	O
severe	B
disease	O

taken	O
of	O
corticosteroid	B
in	O
the	O
last	B
month	I

evidence	O
of	O
psycological	O
problem	O
that	O
may	O
affect	O
the	O
capacity	O
to	O
understand	O
the	O
project	O
and	O
to	O
comply	O
with	O
the	O
medical	O
recommandations	O

history	O
of	O
drug	B
use	I
or	O
alcool	B
abuse	I
in	O
the	O
last	B
12	I
months	I

history	O
of	O
gastro	B
-	I
intestinal	I
inflammatory	I
diseases	I

BMI	B
=	B
35	I

type	B
2	I
diabetes	I

HbA1c	B
=	B
6	I
,	I
5	I
%	I
or	O
fasting	B
glycemia	I
=	B
7mmol	I
/	I
l	I
or	O
non	B
-	I
fasting	I
glycemia	I
=	B
11mmol	I
/	I
l	I

able	O
to	O
consent	O

1	O
.	O

Presence	O
of	O
other	B
neoplasia	B

2	O
.	O

Man	B

1	O
.	O

Age	B
≥	B
18	I
years	I

2	O
.	O

Patient	O
with	O
breast	B
cancer	I
,	O
histologically	B
proven	B
,	O
metastatic	B
or	O
locally	B
advanced	I

3	O
.	O

Patient	O
treated	O
by	O
Eribulin	B
between	B
January	I
and	I
October	I
2014	I
(	O
for	O
the	O
retrospective	O
part	O
)	O
or	O
between	B
November	I
2014	I
and	I
September	I
2015	I
(	O
for	O
the	O
prospective	O
part	O
)	O
.	O

4	O
.	O

Patient	O
with	O
at	O
least	O
an	O
assessment	B
of	I
the	I
response	I
to	O
Eribulin	B

Established	O
pre	O
-	O
existing	O
diabetes	B
(	O
including	O
unrecognised	O
diabetes	O
defined	O
as	O
a	O
fasting	B
plasma	I
glucose	I
=	B
7	I
.	I
0mmol	I
/	I
L	I
and	O
/	O
or	O
HbA1c	B
=	B
48mmol	I
/	I
mol	I
)	I
;	O
Contraindications	B
to	O
metformin	B
therapy	O
(	O
creatinine	B
=	B
130µmol	I
/	I
L	I
/	I
alanine	B
transaminase	I
=	B
2	I
.	I
0	I
x	I
upper	I
limit	I
normal	I
/	O
previous	O
intolerance	B
to	O
metformin	B
)	O

Planned	O
continued	O
antenatal	O
care	O
/	O
delivery	O
at	O
centre	O
not	O
included	O
in	O
trial	O

Planned	O
fast	O
for	O
cultural	O
/	O
religious	O
reasons	O
e	O
.	O
g	O
.	O
Ramadan	O

Singleton	B
pregnancy	I
;	O

8	B
-	I
22	I
weeks	I
gestation	B

Previous	O
pregnancy	B
complicated	O
by	O
gestational	B
diabetes	I

History	O
of	O
prostate	O
,	O
bladder	O
,	O
or	O
rectal	B
cancer	I

History	O
of	O
transurethral	B
resection	I
of	I
the	I
prostate	I
(	I
TURP	I
)	I
,	O
open	B
prostate	I
surgery	I
,	O
or	O
radiofrequency	B
or	O
microwave	B
therapies	I

History	O
of	O
open	O
bladder	O
,	O
rectosigmoid	O
colon	O
,	O
or	O
other	O
pelvic	B
surgery	I

Patient	O
is	O
unwilling	O
to	O
discontinue	O
alpha	B
blockers	I
1	B
month	I
after	I
study	I
treatment	I

Patient	O
is	O
unwilling	O
to	O
discontinue	O
5	B
-	I
alph	I
reductase	I
inhibitors	I
1	B
month	I
after	I
study	I
treatment	I

Neurogenic	B
bladder	I
or	O
other	O
neurologic	B
disorder	I
impacting	I
bladder	I
function	I
such	O
as	O
Parkinson	B
'	I
s	I
disease	I
,	O
multiple	B
sclerosis	I
,	O
cerebral	B
vascular	I
accident	I
or	O
diabetes	B

Any	O
other	O
confounding	O
bladder	O
or	O
urethral	B
pathology	I
,	O
including	O
urethral	B
stricture	I
,	O
bladder	B
neck	I
contracture	I
,	O
or	O
bladder	B
atonia	I

Active	B
prostatitis	B
or	O
urinary	B
tract	I
infection	I

Cystolithiasis	B
within	B
the	I
past	I
3	I
months	I

Serum	B
creatinine	I
>	B
1	I
.	I
7mg	I
/	I
dL	I

Inability	O
to	O
discontinue	O
oral	B
anticoagulant	I
2	B
-	I
5	I
days	I
prior	I
to	I
study	I
treatment	I

Coagulation	B
disturbances	I
not	B
normalized	B
by	O
medical	B
treatment	I

Iodinated	B
contrast	I
allergy	B
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
cannot	O
be	O
adequately	O
premedicated	O

Gelatin	B
allergy	B

Known	O
severe	B
peripheral	B
vascular	I
disease	I
or	O
major	B
iliac	B
arterial	I
occlusive	I
disease	I

Interest	O
in	O
future	O
fertility	O

Clinically	O
significant	O
cardiac	B
arrhythmia	I
or	O
other	O
cardiac	B
disease	I
(	O
including	O
congestive	B
heart	I
failure	I
)	O
,	O
uncontrolled	B
diabetes	B
mellitus	I
,	O
clinically	B
significant	I
respiratory	B
disease	I
,	O
or	O
known	O
immunosuppression	B

Other	O
condition	O
that	O
the	O
Investigator	O
believes	O
puts	O
the	O
patient	O
at	O
risk	O
for	O
a	O
complication	O
during	O
the	O
procedure	O

Patient	O
has	O
provided	O
signed	O
informed	O
consent	O

Patient	O
is	O
aged	B
greater	B
than	I
or	I
equal	I
to	I
40	I
and	O
less	B
than	I
or	I
equal	I
to	I
89	I
years	I
of	O
age	O

Patient	O
has	O
a	O
prostate	B
size	I
between	B
90g	I
and	I
200g	I
,	O
as	O
determined	O
by	O
MRI	B

Patient	O
has	O
experienced	O
lower	B
urinary	I
tract	I
symptoms	I
(	I
LUTS	I
)	I
for	O
at	B
least	I
6	I
months	I
prior	I
to	I
study	I
enrollment	I

Patient	O
has	O
an	O
IPSS	B
score	I
of	O
at	B
least	I
13	I
at	B
baseline	I

Patient	O
is	O
either	O
:	O
refractory	B
to	I
medical	I
treatment	I
,	O
contraindicated	B
to	I
medical	I
treatment	I
,	O
OR	O
refuses	B
medical	I
treatment	I

Patient	O
either	O
:	O
refuses	B
surgical	I
treatment	I
OR	O
is	O
contraindicated	B
for	I
surgical	I
treatment	I

Patient	O
meets	O
ONE	O
of	O
the	O
following	O
criteria	O
:	O
baseline	B
PSA	B
<	B
4	I
.	I
0ng	I
/	I
mL	I
(	O
no	O
prostate	O
biopsy	O
required	O
)	O
OR	O
baseline	B
PSA	B
>	B
/	I
=	I
4	I
ng	I
/	I
mL	I
AND	O
a	O
negative	B
prostate	B
biopsy	I
(	O
minimum	B
12	I
core	B
biopsy	I
)	O
within	B
the	I
prior	I
12	I
months	I

Presence	O
of	O
VTE	B
upon	B
admission	I

Pregnant	B
or	O
nursing	B

Inability	O
to	O
give	O
informed	O
consent	O
by	O
patient	O
or	O
healthcare	O
proxy	O

Contraindication	B
to	O
enoxaparin	B

Contraindication	B
to	O
aspirin	B

Epidural	O
or	O
subdural	B
hematoma	I

Presence	O
,	O
or	O
removal	O
within	B
the	I
last	I
12	I
hours	I
,	O
of	O
an	O
epidural	O
or	O
spinal	O
catheter	O
,	O
or	O
recent	B
(	O
within	B
the	I
last	I
12	I
hours	I
)	O
epidural	O
or	O
spinal	B
anesthesia	I
/	O
procedures	O

Age	B
18	B
years	I
or	I
older	I

Blunt	O
or	O
penetrating	B
trauma	I

Requires	O
VTE	B
thromboprophylaxis	B

High	O
-	O
risk	O
for	O
VTE	B

NA	O

Age	B
:	O
20	B
-	I
70	I
years	I
old	I
;	O

Gender	B
:	O
male	B
or	O
female	B
;	O

clinical	B
or	I
pathological	I
diagnosis	I
of	O
hepatocellular	B
carcinoma	I
(	O
HCC	B
)	O
in	O
previously	O
untreated	B
patients	O
;	O

The	O
expected	O
survival	O
>	B
3	I
months	I
;	O

Child	B
-	I
Pugh	I
grade	I
in	O
A	B
-	O
level	O
;	O

KPS	B
score	I
with	O
50	B
-	I
100	I
points	I
;	O

BCLC	B
stage	I
of	O
0	B
-	I
B	I
;	O

conform	O
to	O
the	O
indications	O
of	O
hepatectomy	B
;	O

Viable	O
tumor	O
resection	O
confirmed	O
by	O
two	O
highly	O
qualified	O
surgical	O
doctors	O
;	O

No	B
other	O
surgical	O
contraindications	O
.	O

women	B
in	O
the	O
reproductive	O
period	O
must	O
be	O
completely	O
contraception	B
in	B
28	I
days	I
before	I
treatment	I
,	O
during	B
the	I
treatment	I
process	I
and	O
in	B
28	I
days	I
after	I
treatment	I
;	O

Men	B
must	O
be	O
completely	O
contraception	B
and	O
prohibited	B
donation	B
and	O
sperm	B
donation	I
during	B
the	I
treatment	I
process	I
and	O
in	B
28	I
days	I
after	I
treatment	I
;	O

All	O
patients	O
must	O
be	O
prohibited	B
donation	B
during	B
the	I
treatment	I
process	I
and	O
in	B
28	I
days	I
after	I
treatment	I
;	O

In	O
addition	O
to	O
the	O
subjects	O
,	O
prohibitting	O
other	O
people	O
taking	O
this	O
product	O
.	O

patients	O
have	O
a	O
good	O
understanding	O
and	O
could	O
coordinate	O
with	O
investigators	O
for	O
the	O
trial	O
.	O

Patients	O
enrolled	O
in	O
the	O
trial	O
should	O
sign	O
an	O
informed	O
consent	O
form	O
,	O
to	O
indicate	O
understanding	O
the	O
purpose	O
and	O
procedure	O
of	O
the	O
trial	O
,	O
and	O
patients	O
volunteering	O
to	O
participate	O
in	O
the	O
trial	O
.	O

Is	O
not	O
a	O
habitual	O
wearer	O
of	O
Avaira	B
sphere	I
lenses	I

Has	O
a	O
CL	B
prescription	I
outside	B
the	I
range	I
of	I
the	I
available	I
parameters	I
of	I
the	I
study	I
lenses	I
.	O

Has	O
a	O
spectacle	B
cylinder	I
≥	B
1	I
.	I
00D	I
of	O
cylinder	O
in	O
either	O
eye	O
.	O

Has	O
a	O
history	B
of	O
not	B
achieving	O
comfortable	B
CL	I
wear	I
(	O
5	B
days	I
per	I
week	I
;	O
>	B
8	I
hours	I
/	I
day	I
)	O

Has	O
contact	B
lens	I
best	I
corrected	I
distance	I
vision	I
worse	B
than	I
20	I
/	I
25	I
(	I
0	I
.	I
10	I
logMAR	I
)	I
in	I
either	I
eye	I
.	O

Presence	O
of	O
clinically	B
significant	I
(	O
grade	O
2	B
-	I
4	I
)	O
anterior	B
segment	I
abnormalities	I

Presence	O
of	O
ocular	O
or	O
systemic	B
disease	I
or	O
need	B
of	I
medications	I
which	O
might	B
interfere	I
with	I
contact	I
lens	I
wear	I
.	O

Slit	B
lamp	I
findings	B
that	O
would	O
contraindicate	B
contact	I
lens	I
wear	O
such	O
as	O
:	O

Pathological	B
dry	I
eye	I
or	O
associated	B
findings	I

Pterygium	B
,	O
pinguecula	B
,	O
or	O
corneal	B
scars	I
within	B
the	I
visual	I
axis	I

Neovascularization	B
>	B
0	I
.	I
75	I
mm	I
in	I
from	I
of	I
the	I
limbus	I

Giant	B
papillary	I
conjunctivitis	I
(	I
GCP	I
)	I
worse	B
than	I
grade	I
1	I

Anterior	B
uveitis	I
or	O
iritis	B
(	O
past	B
or	O
present	B
)	O

Seborrheic	B
eczema	I
,	O
Seborrheic	B
conjunctivitis	I

History	B
of	O
corneal	B
ulcers	I
or	O
fungal	B
infections	I

Poor	B
personal	I
hygiene	I

Has	O
a	O
known	O
history	B
of	O
corneal	B
hypoesthesia	I
(	O
reduced	B
corneal	I
sensitivity	I
)	O

Has	O
aphakia	B
,	O
keratoconus	B
or	O
a	O
highly	B
irregular	I
cornea	I
.	O

Has	O
Presbyopia	B
or	O
has	O
dependence	B
on	I
spectacles	I
for	I
near	I
work	I
over	O
the	O
contact	O
lenses	O
.	O

Has	O
undergone	O
corneal	B
refractive	I
surgery	I
.	O

Is	O
participating	O
in	O
any	O
other	O
type	O
of	O
eye	O
related	O
clinical	O
or	O
research	O
study	O

Is	O
between	O
18	O
and	O
40	O
years	O
of	O
age	B
(	O
inclusive	O
)	O

Has	O
had	O
a	O
self	B
-	I
reported	I
visual	I
exam	I
in	B
the	I
last	I
two	I
years	I

Is	O
an	O
adapted	O
Avaira	B
sphere	I
contact	I
lens	I
wearer	O
(	O
at	O
least	O
1	O
week	O
in	O
Avaira	B
sphere	I
)	O

Has	O
a	O
contact	B
lens	I
spherical	B
prescription	O
between	O
+	B
2	I
.	I
25	I
to	I
-	I
8	I
.	I
00	I
(	I
inclusive	I
)	I

Has	O
a	O
spectacle	B
cylinder	I
up	B
to	I
0	I
.	I
75D	I
in	O
each	O
eye	O
.	O

Can	O
achieve	O
best	B
corrected	I
spectacle	I
distance	I
visual	I
acuity	I
of	O
20	O
/	O
25	O
(	O
0	B
.	I
10	I
logMAR	I
)	I
or	I
better	I
in	O
each	O
eye	O
.	O

Can	O
achieve	O
a	O
distance	B
visual	I
acuity	I
of	O
20	O
/	O
30	O
(	O
0	B
.	I
18	I
logMAR	I
)	I
or	I
better	I
in	O
each	O
eye	O
with	O
the	O
study	B
contact	I
lenses	I
.	O

Has	O
clear	B
corneas	I
and	O
no	B
active	B
ocular	B
disease	I

Has	O
read	O
,	O
understood	O
and	O
signed	O
the	O
information	O
consent	O
letter	O
.	O

Patient	O
contact	O
lens	O
refraction	O
should	O
fit	O
within	O
the	O
available	O
parameters	O
of	O
the	O
study	O
lenses	O
.	O

Is	O
willing	O
to	O
comply	O
with	O
the	O
wear	O
schedule	O
(	O
at	O
least	O
5	O
days	O
per	O
week	O
,	O
>	O
8	O
hours	O
/	O
day	O
assuming	O
there	O
are	O
no	O
contraindications	O
for	O
doing	O
so	O
)	O
.	O

Is	O
willing	O
to	O
comply	O
with	O
the	O
visit	O
schedule	O

History	O
of	O
documented	O
clotting	O
/	O
coagulation	B
disorder	I

History	O
of	O
cancer	B
(	O
within	O
the	O
last	B
year	I
)	O

Any	O
diagnosis	O
requiring	O
anti	B
-	I
coagulation	I

History	O
of	O
hypersensitivity	B
reaction	O
to	O
apixaban	B

Active	B
clinically	O
significant	B
bleeding	B

Creatinine	B
>	B
1	I
.	I
5	I
mg	I
/	I
dL	I

Participants	O
currently	O
receiving	O
any	O
type	O
of	O
anticoagulation	B
or	O
blood	B
thinning	I
medications	I
,	O
including	O
heparin	B
,	O
low	B
molecular	I
weight	I
heparins	I
,	O
Plavix	B
,	O
aspirin	B
,	O
NSAIDS	B

Combined	O
P	O
-	O
glycoprotein	O
and	O
strong	B
cytochrome	B
P450	I
(	I
CYP	I
)	I
3A4	I
inhibitor	I

Combined	O
P	O
-	O
glycoprotein	O
and	O
moderate	B
CYP	B
3A4	I
inhibitor	I

Combined	O
P	B
-	I
glycoprotein	I
inducer	I
and	O
strong	B
CYP	B
3A4	I
inducer	I

Inducers	B
of	I
p	I
-	I
glycoprotein	I

Strong	B
inducers	B
of	I
CYP	I
3A4	I

Men	B
or	O
women	B
,	O
18	B
to	I
65	I
years	I
old	B
with	O
a	O
BMI	B
of	O
35	B
kg	I
/	I
m2	I
or	I
greater	I
who	O
will	O
be	O
undergoing	O
bariatric	B
surgery	I
(	O
VSG	B
and	O
RYGB	B
)	O

Signed	O
written	O
informed	O
consent	O

Women	O
of	O
childbearing	O
potential	O
(	O
WOCBP	O
)	O
must	O
have	O
a	O
negative	O
serum	O
or	O
urine	O
pregnancy	O
test	O
(	O
minimum	O
sensitivity	O
25	O
IU	O
/	O
L	O
or	O
equivalent	O
units	O
of	O
HCG	O
)	O
within	O
24	O
hours	O
prior	O
to	O
the	O
start	O
of	O
study	O
drug	O

Women	O
must	O
not	O
be	O
breastfeeding	O

NA	O

Subjects	O
admitted	O
to	O
the	O
hospital	O
with	O
acute	B
or	O
chronic	B
medical	B
illnesses	I
or	O
for	O
elective	B
and	O
emergency	B
surgical	B
illness	I
or	O
trauma	B

Known	O
history	O
of	O
Type	B
2	I
diabetes	I
mellitus	I
for	O
>	B
3	I
months	I

Treated	O
with	O
either	O
diet	B
alone	O
,	O
any	O
combination	O
of	O
oral	B
antidiabetic	I
agents	I
,	O
non	O
-	O
insulin	O
injectables	O
or	O
insulin	B
therapy	O

Blood	B
glucose	I
levels	I
between	O
>	B
140	I
mg	I
and	I
<	I
400	I
mg	I
/	I
dL	I
without	B
laboratory	B
evidence	I
of	O
diabetic	B
ketoacidosis	I

Central	O
+	O
mixed	B
apneas	I
>	B
25	I
%	I
of	O
the	O
total	B
apnea	I
-	I
hypopnea	I
index	I
(	O
AHI	B
)	O

Any	O
anatomical	O
finding	O
that	O
would	O
compromise	O
the	O
performance	O
of	O
upper	O
airway	O
stimulation	O
,	O
such	O
as	O
the	O
presence	O
of	O
complete	O
concentric	O
collapse	O
of	O
the	O
soft	O
palate	O

Any	O
condition	O
or	O
procedure	O
that	O
has	O
compromised	O
neurological	O
control	O
of	O
the	O
upper	O
airway	O

Patients	O
who	O
are	O
unable	O
or	O
do	O
not	O
have	O
the	O
necessary	O
assistance	O
to	O
operate	O
the	O
patient	O
remote	O

Patients	O
who	O
are	O
pregnant	O
or	O
plan	O
to	O
become	O
pregnant	O

Patients	O
who	O
will	O
require	O
magnetic	B
resonance	I
imaging	I
(	O
MRI	B
)	O

Patients	O
with	O
an	O
implantable	O
device	O
that	O
may	O
be	O
susceptible	O
to	O
unintended	O
interaction	O
with	O
the	O
Inspire	O
system	O
.	O

Body	B
Mass	I
Index	I
(	O
BMI	B
)	O
of	O
>	B
32	I

Any	O
chronic	O
medical	O
illness	O
or	O
condition	O
that	O
contraindicates	B
a	O
surgical	B
procedure	I
under	O
general	B
anesthesia	I
,	O
as	O
judged	O
by	O
the	O
clinical	O
study	O
Investigator	O

Has	O
a	O
terminal	O
illness	O
with	O
life	O
expectancy	O
<	B
12	I
months	I

Active	O
psychiatric	B
disease	I
(	O
psychotic	B
illness	I
,	O
major	B
depression	I
,	O
or	O
acute	B
anxiety	I
attacks	I
)	O
which	O
prevents	O
subject	O
compliance	O
with	O
the	O
requirements	O
of	O
the	O
investigational	O
study	O
testing	O

Any	O
other	O
reason	O
the	O
investigator	O
deems	O
subject	O
is	O
unfit	O
for	O
participation	O
in	O
the	O
study	O

Likely	O
suffer	O
moderate	B
-	O
to	O
-	O
severe	B
OSA	B
based	O
on	O
history	O
and	O
physical	O
or	O
have	O
an	O
established	O
diagnosis	O
of	O
OSA	B
(	O
20	O
=	O
AHI	B
=	O
65	O
)	O
based	O
on	O
a	O
prior	O
in	O
-	O
lab	O
Polysomnography	O

Documentation	O
the	O
subject	O
not	B
effectively	O
treated	O
with	O
CPAP	B
therapy	I
.	O

(	O
Examples	O
include	O
non	O
-	O
compliance	O
,	O
discomfort	O
,	O
undesirable	O
side	O
effects	O
,	O
symptoms	O
persist	O
despite	O
use	O
)	O
.	O

Subjects	O
who	O
have	O
been	O
prescribed	O
,	O
but	O
refuse	O
to	O
try	O
CPAP	O
would	O
be	O
considered	O
intolerant	O
.	O

Age	B
22	B
or	I
above	I

Willing	O
and	O
capable	O
to	O
have	O
stimulation	O
hardware	O
permanently	O
implanted	O
,	O
and	O
to	O
use	O
the	O
patient	O
remote	O
to	O
activate	O
the	O
stimulation	O

Willing	O
and	O
capable	O
to	O
return	O
for	O
all	O
follow	O
-	O
up	O
visits	O
and	O
conduct	O
sleep	O
studies	O
at	O
home	O
,	O
including	O
the	O
evaluation	O
procedures	O
and	O
filling	O
out	O
questionnaires	O

Willing	O
and	O
capable	O
of	O
providing	O
informed	O
consent	O

Contraindication	B
to	O
azithromycin	B
use	O
and	O
other	B
prophylactic	B
antibiotic	I
use	I

Age	B
1	B
-	I
59	I
months	I
,	O

Plan	O
to	O
remain	O
in	O
study	O
area	O
greater	B
than	I
6	I
months	I

Discharged	B
from	I
hospital	I
following	O
non	B
-	I
trauma	I
related	I
admission	I

impaired	B
decision	I
making	I

neurofibromatosis	B

signs	O
for	O
central	B
dysfunction	I

remaining	B
vestibular	I
function	I

Patients	O
are	O
advised	O
not	O
to	O
participate	O
in	O
the	O
gentamicin	O
arm	O
if	O

hearing	B
is	O
better	B
than	I
30	I
deciBel	I
(	I
dB	I
)	I
in	O
pure	B
tone	I
average	I
(	O
500	B
,	I
1000	I
,	I
2000	I
,	I
3	I
-	I
4000	I
Hz	I
)	O
and	O
speech	B
discrimination	I
better	B
than	I
70	I
%	I

the	O
neurosurgeon	O
aim	O
at	O
hearing	O
preservation	O
surgery	O
and	O
do	O
not	O
want	O
to	O
risk	O
gentamicin	O
associated	O
hearing	O
loss	O

Vestibular	B
schwannoma	I
advised	O
to	O
surgical	B
treatment	I

No	B
measurable	O
remaining	B
vestibular	I
function	I

1	O
.	O

Clinically	O
significant	O
microvascular	B
complications	I
:	O
nephropathy	B
(	O
estimated	B
glomerular	I
filtration	I
rate	I
below	B
40	I
ml	I
/	I
min	I
)	O
,	O
neuropathy	B
(	O
especially	O
diagnosed	O
gastroparesis	B
)	O
or	O
severe	B
proliferative	I
retinopathy	I
as	B
judged	I
by	I
the	I
investigator	I
.	O

2	O
.	O

Recent	B
(	O
<	B
3	I
months	I
)	O
acute	B
macrovascular	I
event	I
e	O
.	O
g	O
.	O
acute	B
coronary	I
syndrome	I
or	O
cardiac	B
surgery	I
.	O

3	O
.	O

Ongoing	B
pregnancy	B
.	O

4	O
.	O

Severe	B
hypoglycemic	B
episode	I
within	B
1	I
month	I
of	I
screening	I
.	O

5	O
.	O

Agents	B
affecting	I
gastric	I
emptying	I
(	O
Motilium	B
®	O
,	O
Prandase	B
®	O
,	O
Victoza	B
®	O
,	O
Byetta	B
®	O
and	O
Symlin	B
®	O
)	O
as	O
well	O
as	O
oral	B
anti	I
-	I
diabetic	I
agents	I
(	O
Metformin	B
,	O
SGLT	B
-	I
2	I
inhibitors	I
and	O
DPP	B
-	I
4	I
inhibitors	I
)	O
if	O
not	B
at	O
a	O
stable	B
dose	I
for	B
3	I
months	I
.	O

Otherwise	O
,	O
these	O
medications	O
are	O
acceptable	O
and	O
will	O
be	O
kept	O
stable	O
during	O
the	O
entire	O
protocol	O
.	O

6	O
.	O

Oral	B
steroids	I
unless	B
patients	O
present	O
a	O
low	O
stable	B
dose	I
(	O
e	O
.	O
g	O
.	O
10	O
mg	O
or	O
less	O
of	O
prednisone	B
per	O
day	O
or	O
physiological	B
doses	I
,	O
less	B
than	I
35	I
mg	I
/	I
day	I
,	O
of	O
hydrocortisone	B
Cortef	B
®	O
)	O
.	O

Inhale	B
steroids	I
at	O
stable	B
dose	I
in	B
the	I
last	I
month	I
are	O
acceptable	O
.	O

7	O
.	O

Other	O
serious	B
medical	O
illness	O
likely	O
to	O
interfere	O
with	O
study	O
participation	O
or	O
with	O
the	O
ability	O
to	O
complete	O
the	O
trial	O
by	O
the	O
judgment	O
of	O
the	O
investigator	O
(	O
e	O
.	O
g	O
.	O
unstable	B
psychiatric	B
condition	I
)	O
.	O

8	O
.	O

Failure	O
to	O
comply	O
with	O
team	O
'	O
s	O
recommendations	O
(	O
e	O
.	O
g	O
.	O
not	O
willing	O
to	O
change	O
pump	O
parameters	O
,	O
follow	O
algorithm	O
'	O
s	O
suggestions	O
,	O
etc	O
)	O
.	O

9	O
.	O

Living	O
or	O
planned	O
travel	O
outside	O
Montreal	O
(	O
>	O
1h	O
of	O
driving	O
)	O
area	O
during	O
closed	B
-	I
loop	I
procedures	I
.	O

1	O
.	O

Males	B
and	O
females	B
≥	O
18	O
years	O
old	B
.	O

2	O
.	O

Clinical	O
diagnosis	O
of	O
type	B
1	I
diabetes	I
for	B
at	I
least	I
one	I
year	I
.	O

3	O
.	O

The	O
subject	O
will	O
have	O
been	O
on	O
insulin	B
pump	I
therapy	I
for	B
at	I
least	I
3	I
months	I
and	O
currently	B
using	O
a	O
fast	B
actin	I
insulin	I
analog	I
(	O
Lispro	B
,	O
Aspart	B
or	O
Guilisine	B
)	O
.	O

4	O
.	O

Last	B
(	I
less	I
than	I
3	I
months	I
)	I
HbA1c	B
≤	B
10	I
%	I
.	O

5	O
.	O

Currently	B
using	O
carbohydrate	B
counting	I
as	O
the	O
meal	B
insulin	I
dose	I
strategy	I
.	O

Heavy	B
tobacco	I
smokers	I

Drug	O
and	O
/	O
or	O
alcohol	B
abusers	I

Healthy	B
patients	I
(	O
ASA	B
I	B
)	O

Bilateral	B
symmetrically	I
impacted	I
lower	I
third	I
molars	I
according	O
to	O
Pel	B
-	I
Gregory	I
'	I
s	I
and	I
Winter	I
'	I
s	I
classification	I

Participation	B
in	O
another	O
clinical	O
trial	O
at	O
present	O
or	O
within	O
4	O
weeks	O
of	O
study	O
entry	O
.	O
There	O
may	O
be	O
exceptions	O
at	O
the	O
discretion	O
of	O
the	O
Investigator	O
.	O

Has	O
any	O
progressive	B
form	O
of	O
MS	B

Hypersensitivity	B
to	O
the	O
active	O
substance	O
,	O
or	O
to	O
any	O
of	O
the	O
excipients	O
of	O
Lemtrada	B
®	O

Medical	O
,	O
psychiatric	O
,	O
cognitive	O
,	O
or	O
other	O
conditions	O
that	O
,	O
in	O
the	O
Investigator	O
'	O
s	O
opinion	O
,	O
compromise	O
the	O
patient	O
'	O
s	O
ability	O
to	O
understand	O
the	O
patient	O
information	O
,	O
to	O
give	O
informed	O
consent	O
,	O
to	O
comply	O
with	O
the	O
trial	O
protocol	O
,	O
or	O
to	O
complete	O
the	O
study	O

Any	O
disability	O
acquired	O
from	O
trauma	O
or	O
another	O
illness	O
that	O
could	O
interfere	O
with	O
evaluation	O
of	O
disability	O
due	O
to	O
MS	O

Major	O
systemic	O
disease	O
or	O
other	O
illness	O
that	O
would	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
compromise	O
patient	O
safety	O
or	O
interfere	O
with	O
the	O
interpretation	O
of	O
study	O
results	O
,	O
e	O
.	O
g	O
.	O
,	O
current	O
peptic	O
ulcer	O
disease	O
or	O
other	O
conditions	O
that	O
may	O
predispose	O
to	O
hemorrhage	O

Known	O
bleeding	B
disorder	I
(	O
e	O
.	O
g	O
,	O
.	O
dysfibrinogenemia	B
,	O
factor	B
IX	I
deficiency	I
,	O
hemophilia	B
,	O
Von	B
Willebrand	I
'	I
s	I
disease	I
,	O
disseminated	B
intravascular	I
coagulation	I
(	O
DIC	B
)	O
,	O
fibrinogen	B
deficiency	I
,	O
or	O
clotting	B
factor	I
deficiency	I
)	O

Significant	O
autoimmune	B
disease	I
including	O
but	O
not	O
limited	O
to	O
immune	B
cytopenias	I
,	I
rheumatoid	B
arthritis	I
,	I
systemic	B
lupus	I
erythematosus	I
,	O
other	O
connective	B
tissue	I
disorders	I
,	O
vasculitis	B
,	O
inflammatory	B
bowel	I
disease	I
,	O
severe	B
psoriasis	B

History	O
of	O
malignancy	B
,	O
except	B
basal	B
skin	I
cell	I
carcinoma	I

Major	B
psychiatric	B
disorder	I
that	O
is	O
not	B
adequately	B
controlled	I
by	O
treatment	O

Epileptic	B
seizures	I
that	O
are	O
not	B
adequately	B
controlled	I
by	O
Treatment	O

Active	B
infection	B
,	O
e	O
.	O
g	O
.	O
,	O
deep	B
-	I
tissue	I
infection	I
,	O
that	O
the	O
Investigator	O
considers	O
sufficiently	O
serious	O
to	O
preclude	O
study	O
participation	O

In	O
the	O
Investigator	O
'	O
s	O
opinion	O
,	O
is	O
at	O
high	B
risk	O
for	O
infection	O
(	O
e	O
.	O
g	O
.	O
,	O
indwelling	B
catheter	I
,	O
dysphagia	B
with	O
aspiration	B
,	O
decubitus	B
ulcer	I
,	O
history	O
of	O
prior	O
aspiration	B
pneumonia	I
or	O
recurrent	B
urinary	B
tract	I
infection	I
)	O

Seropositivity	B
for	O
human	B
immunodeficiency	I
virus	I
(	O
HIV	B
)	O

Infection	B
with	O
hepatitis	B
C	I
Virus	I

Past	O
or	O
present	O
hepatitis	B
B	I
infection	I
(	O
positive	B
hepatitis	B
B	I
serology	I
)	O

Active	B
infection	B
with	O
human	B
cytomegaly	I
virus	I
(	O
HCMV	B
)	O
,	O
Epstein	B
-	I
Barr	I
virus	I
(	O
EBV	B
)	O
,	O
varicella	B
-	I
zoster	I
virus	I
(	O
VZV	B
)	O

Latent	B
tuberculosis	I
unless	B
effective	O
anti	B
-	I
tuberculosis	I
therapy	I
has	O
been	O
completed	B
,	O
or	O
active	B
tuberculosis	I
.	O

Invasive	B
fungal	B
infections	I
in	O
history	O
and	O
at	O
present	O

Cervical	B
cytology	I
other	B
than	O
PAP	B
I	I
or	O
PAP	B
II	I
(	O
Papanicolaou	B
)	O
or	O
cervical	B
high	I
risk	I
human	B
papillomavirus	I
(	O
HPV	B
)	O
positivity	B

Any	O
other	O
illness	B
or	O
infection	B
(	O
latent	B
or	O
active	B
)	O
that	O
,	O
in	O
the	O
Investigator	O
'	O
s	O
opinion	O
,	O
could	O
be	O
exacerbated	O
by	O
study	B
medication	I

Differential	B
blood	I
count	I
<	B
lower	I
limit	I
of	I
normal	I
(	I
LLN	I
)	I
at	B
Screening	I

Confirmed	B
platelet	B
count	I
<	B
the	I
LLN	I
of	I
the	I
evaluating	I
laboratory	I
at	B
Screening	I
or	O
documented	O
at	O
<	B
100	I
,	I
000	I
/	I
µL	I
within	B
the	I
past	I
year	I
on	O
a	O
sample	B
without	I
platelet	I
clumping	I

Presence	B
(	O
i	O
.	O
e	O
.	O
,	O
above	B
the	I
ULN	I
)	O
of	O
anti	B
-	I
thyroid	I
stimulating	I
hormone	I
receptor	I
antibodies	I
(	I
anti	I
-	I
TSHR	I
)	I
and	O
anti	B
-	I
thyroid	I
peroxidase	I
antibody	I
(	I
anti	I
-	I
TPO	I
)	I

Vaccination	B
less	O
than	O
6	O
weeks	O
prior	O
to	O
treatment	B
with	O
Lemtrada	B
.	O

Treatment	B
with	O
antineoplastic	O
or	O
immunosuppressive	B
drugs	I
within	B
8	I
weeks	I
prior	I
to	I
study	I
inclusion	I

Intolerance	B
of	O
pulsed	B
corticosteroids	I
,	O
especially	O
a	O
history	B
of	I
steroid	B
psychosis	I

Inability	O
to	O
undergo	O
MRI	B
with	O
gadolinium	B
administration	O

Of	O
childbearing	B
potential	I
with	O
a	O
positive	B
serum	B
pregnancy	I
test	I
,	O
pregnant	B
or	O
lactating	B

Female	B
patients	O
of	O
childbearing	B
potential	I
:	O
Unwilling	O
to	O
agree	O
to	O
use	O
a	O
reliable	O
and	O
acceptable	O
contraceptive	O
method	O
(	O
Pearl	O
index	O
<	O
1	O
)	O
throughout	O
the	O
study	O
period	O
.	O
These	O
methods	O
include	O
:	O
hormone	O
releasing	O
intrauterine	O
device	O
(	O
IUD	O
)	O
,	O
hormonal	O
-	O
based	O
contraception	O
,	O
surgical	O
sterilization	O
,	O
abstinence	O
,	O
or	O
double	O
-	O
barrier	O
contraception	O
(	O
condom	O
and	O
occlusive	O
cap	O
[	O
diaphragm	O
or	O
cervical	O
cap	O
combined	O
with	O
spermicide	O
]	O
)	O
.	O

Signed	O
informed	O
consent	O
form	O
(	O
ICF	O
)	O

Age	B
18	B
to	I
55	I
years	I
old	I
(	I
inclusive	O
)	O
as	O
of	O
the	O
date	O
the	O
ICF	O
is	O
signed	O

Diagnosis	O
of	O
MS	B
according	O
to	O
the	O
McDonald	B
criteria	I
2010	I
and	O
cranial	B
MRI	I
scan	I
demonstrating	O
white	O
matter	O
lesions	O
attributable	O
to	O
MS	O
within	B
10	I
years	I
before	I
Screening	I

Onset	O
of	O
MS	B
symptoms	I
(	O
as	O
determined	O
by	O
a	O
neurologist	O
,	O
either	O
at	O
present	O
or	O
retrospectively	O
)	O
within	B
10	I
years	I
of	O
the	O
date	O
the	O
ICF	O
is	O
signed	O

EDSS	B
score	I
0	B
.	I
0	I
to	I
5	I
.	I
0	I
(	O
inclusive	O
)	O
at	O
Screening	O

Patients	O
with	O
(	O
highly	O
)	O
active	B
RRMS	B
disease	O
course	O
indicated	O
to	O
receive	O
alemtuzumab	B
according	O
to	O
the	O
following	O
conditions	O
(	O
at	O
least	O
1	O
out	O
of	O
3	O
conditions	O
has	O
to	O
be	O
fulfilled	O
)	O
:	O
1	O
.	O

=	B
2	I
MS	B
relapses	I
within	B
24	I
months	I
,	I
2	O
.	O
clinical	O
(	O
=	B
1	I
relapse	B
)	O
or	O
MRI	B
(	O
new	B
gadolinium	B
enhancing	I
lesions	B
)	O
disease	O
activity	O
under	O
therapy	O
with	O
other	O
diseasemodifying	O
therapies	O
,	O
3	O
.	O
severe	B
relapse	B
with	O
high	O
disease	O
activity	O
(	O
=	B
9	I
T2	B
hyperintense	I
Lesions	B
and	O
=	B
1	I
gadolinium	B
enhancing	I
lesion	B
)	O
on	O
MRI	B
.	O

Completion	O
of	O
all	O
vaccinations	O
required	O
by	O
the	O
applicable	O
immunization	O
guidelines	O
published	O
by	O
"	O
ständige	O
Impfkommission	O
"	O
(	O
STIKO	O
)	O

History	O
of	O
chickenpox	B
or	O
positive	B
test	B
for	I
antibodies	I
against	O
varicella	B
zoster	I
virus	I
(	O
VZV	B
)	O

Have	O
a	O
history	O
of	O
myocardial	B
infarction	I
in	I
the	O
past	B
6	I
months	I

Have	O
a	O
contraindication	B
to	O
NRT	B
with	O
no	O
medical	O
clearance	O
from	O
the	O
primary	O
care	O
provider	O
or	O
study	O
physician	O

Use	O
and	O
unwillingness	O
to	O
stop	O
use	O
of	O
other	O
forms	O
of	O
nicotine	O
such	O
as	O
cigars	O
,	O
pipes	O
,	O
or	O
chewing	O
tobacco	O

Are	O
pregnant	B

Meet	O
criteria	O
for	O
a	O
current	O
manic	B
episode	I
based	O
on	O
structured	O
clinical	O
interview	O

Are	O
currently	O
enrolled	O
in	O
another	O
smoking	O
cessation	O
trial	O

Are	O
currently	O
imprisoned	B
or	O
in	O
psychiatric	O
hospitalization	O

Currently	O
smoke	O
at	B
least	I
ten	I
cigarettes	I
a	I
day	I

Have	O
been	O
smoking	O
for	O
at	B
least	I
one	I
year	I

Meet	O
criteria	O
for	O
schizophrenia	B
,	O
schizoaffective	B
disorder	I
,	O
or	O
another	O
psychotic	B
disorder	I
based	O
on	O
structured	O
clinical	O
interview	O

Can	O
speak	O
and	O
write	O
fluent	O
conversational	O
English	O

Are	O
between	B
18	I
and	I
70	I
years	I
of	O
age	B

Are	O
willing	O
to	O
make	O
a	O
smoking	O
cessation	O
attempt	O

Score	O
26	B
or	I
higher	I
on	O
the	O
Montreal	B
Cognitive	I
Assessment	I

adjuvant	B
radiotherapy	I

evident	O
intra	B
-	I
abdominal	I
inflammation	I
(	O
diagnosed	O
by	O
imaging	B
and	O
/	O
or	O
laboratory	B
results	O
,	O
including	O
an	O
abscess	B
or	O
cholecystitis	B
)	O

chronic	B
pancreatitis	B

pancreatic	B
polypeptide	I
producing	I
endocrine	I
tumor	I

American	B
Society	I
of	I
Anesthesiologists	I
physical	I
-	I
health	I
status	I
classification	I
(	I
ASA	I
-	I
PS	I
)	I
>	B
3	I

Poorly	B
regulated	I
diabetes	B
(	O
>	B
200	I
mg	I
/	I
dl	I
(	I
=	I
11	I
mmol	I
/	I
l	I
)	I
)	O

patients	O
undergoing	O
partial	O
or	O
full	B
resection	I
of	I
the	I
pancreas	I
due	O
to	O
a	O
benign	O
or	O
malignant	B
tumor	I

Subjects	B
with	O
poor	B
-	I
controlled	I
arterial	B
hypertension	I
(	O
systolic	B
blood	I
pressure	I
>	B
140	I
mmHg	I
and	O
diastolic	B
blood	I
pressure	I
>	B
90	I
mm	I
Hg	I
)	O
despite	O
standard	O
medical	O
management	O
;	O
Coronary	B
heart	I
disease	I
greater	B
than	I
ClassII	I
;	O
II	B
-	I
level	I
arrhythmia	B
(	O
including	O
QT	B
interval	I
prolongation	I
,	O
for	O
man	O
=	O
450	O
ms	O
,	O
for	O
woman	O
=	O
470	O
ms	O
)	O
together	O
with	O
Class	B
II	I
cardiac	B
dysfunction	I
;	O

Factors	O
that	O
could	O
have	O
an	O
effect	O
on	O
oral	O
medication	O
(	O
such	O
as	O
inability	B
to	I
swallow	I
,	O
chronic	B
diarrhea	I
and	O
intestinal	B
obstruction	I
)	O
;	O

Subjects	O
with	O
high	B
gastrointestinal	O
bleeding	O
risk	O
,	O
including	O
the	O
following	O
conditions	O
:	O
local	O
active	B
ulcer	B
lesions	I
with	O
positive	B
fecal	B
occult	I
blood	I
test	I
(	O
+	B
+	I
)	O
;	O
history	O
of	O
black	B
stool	I
,	O
or	O
vomiting	B
blood	I
in	O
the	O
past	B
3	I
months	I
;	O
unresected	O
primary	B
lesion	I
in	O
stomach	B
with	O
positive	B
fecal	B
occult	I
blood	I
test	I
(	O
+	B
)	O
,	O
ulcerated	B
gastric	I
carcinoma	I
with	O
massive	B
alimentary	B
tract	I
bleeding	O
risk	O
judged	O
by	O
PIs	O
based	O
on	O
gastric	O
endoscopy	O
result	O
;	O

Abnormal	B
Coagulation	I
(	O
INR	B
>	B
1	I
.	I
5	I
<	O
U	O
+	O
3001	O
>	O
APTT	B
>	B
1	I
.	I
5	I
UNL	I
)	O
,	O
with	O
tendency	B
of	I
bleed	I
;	O

Associated	O
with	O
CNS	O
(	O
central	O
nervous	O
system	O
)	O
metastases	O
;	O

Pregnant	O
or	O
lactating	O
women	O
;	O

Other	O
conditions	O
regimented	O
at	O
investigators	O
'	O
discretion	O
.	O

Age	B
:	O
18	B
to75	I
years	I
old	I
;	O

Pathologically	O
diagnosed	O
with	O
advanced	B
gastric	I
cancer	I
(	O
including	O
adenocarcinoma	B
of	O
the	O
gastroesophageal	B
junction	I
)	O
with	O
measurable	O
metastases	B
outside	B
the	O
stomach	B
(	O
measuring	O
=	O
10mm	O
on	O
spiral	O
CT	O
scan	O
,	O
satisfying	O
the	O
criteria	O
in	O
RECIST	O
1	O
.	O
1	O
)	O
;	O

Failure	B
of	O
prior	O
therapy	O
(	O
during	O
or	O
after	O
treatment	O
)	O
in	O
patients	O
who	O
have	O
received	O
at	B
least	I
two	I
prior	O
chemotherapy	B
regimens	O
;	O

ECOG	B
PS	I
of	O
0	B
-	I
2	I
;	O

HB	B
=	B
90g	I
/	I
L	I

ANC	B
=	B
1	I
.	I
5	I
×	I
109	I
/	I
L	I

PLT	B
=	B
80	I
×	I
109	I
/	I
L	I

Bilirubin	B
<	B
1	I
.	I
25	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
(	O
ULN	O
)	O

ALT	B
and	O
AST	B
<	B
2	I
.	I
5	I
×	I
ULN	I
;	O
liver	B
metastases	I
,	O
if	O
any	O
,	O
the	O
ALT	B
and	O
AST	B
<	B
5	I
×	I
ULN	I

Serum	B
Cr	I
=	B
1	I
×	I
ULN	I
endogenous	B
creatinine	I
clearance	I
>	B
50ml	I
/	I
min	I
(	O
Cockcroft	O
-	O
Gault	O
formula	O
)	O

An	O
expected	O
survival	O
of	O
=	B
3	I
months	I
;	O

Patient	O
received	O
apatinib	B
treatment	O
regimen	O
at	O
investigators	O
'	O
discretion	O
;	O

Patient	O
has	O
to	O
voluntarily	O
join	O
the	O
study	O
and	O
sign	O
the	O
Informed	O
Consent	O
Form	O
for	O
the	O
study	O
;	O

Pregnancy	O
test	O
(	O
serum	O
or	O
urine	O
)	O
has	O
to	O
be	O
performed	O
for	O
woman	O
of	O
childbearing	O
age	O
within	O
7	O
days	O
before	O
enrolment	O
and	O
the	O
test	O
result	O
must	O
be	O
negative	O
.	O
They	O
shall	O
take	O
appropriate	O
methods	O
for	O
contraception	O
during	O
the	O
study	O
until	O
the	O
8th	O
week	O
post	O
the	O
last	O
administration	O
of	O
study	O
drug	O
.	O
For	O
men	O
,	O
(	O
previous	O
surgical	O
sterilization	O
accepted	O
)	O
,	O
shall	O
agree	O
to	O
take	O
appropriate	O
methods	O
of	O
contraception	O
during	O
the	O
study	O
until	O
the	O
8th	O
week	O
post	O
the	O
last	O
administration	O
of	O
study	O
drug	O
.	O

thrombus	B
in	O
the	O
LA	B
or	O
LAA	B
;	O

mechanical	B
valve	I
prosthesis	I
;	O

mitral	B
stenosis	I
;	O

previous	O
LAA	B
ligation	I
during	O
cardiac	B
surgery	I
;	O

life	O
expectancy	O
less	B
than	I
2	I
years	I
;	O

comorbidities	B
other	B
than	I
AF	B
,	O
which	O
present	O
an	O
indication	B
for	O
anticoagulation	B
;	O

patent	B
foramen	I
ovale	I
with	O
atrial	B
septal	I
aneurysm	I

mobile	B
plaque	I
in	I
the	I
aorta	I
;	O

symptomatic	B
atherosclerosis	B
of	B
the	I
carotid	I
artery	I
;	O

pericardial	B
effusion	I
greater	B
than	I
10	I
mm	I
;	O

clinically	B
significant	I
bleeding	B
within	B
the	I
30	I
days	I
prior	I
to	I
the	I
scheduled	I
procedure	I
;	O

stroke	B
or	O
other	B
cardioembolic	B
event	I
within	B
the	I
30	I
days	I
prior	I
to	I
the	I
scheduled	I
procedure	I
;	O

acute	B
coronary	I
syndrome	I
within	B
the	I
90	I
days	I
prior	I
to	I
the	I
scheduled	I
procedure	I
,	O

gravidity	B
,	O

significant	B
valvular	B
disease	I
,	O

creatinine	B
clearance	I
less	B
than	I
30	I
ml	I
/	I
min	I

history	O
of	O
significant	B
bleeding	B
(	O
i	O
.	O
e	O
.	O
bleeding	B
which	O
required	O
intervention	B
or	O
hospitalization	B
)	O
,	O
even	O
in	O
the	O
absence	O
of	O
anticoagulation	O
treatment	O
at	O
the	O
time	O
of	O
the	O
bleeding	O
event	O
,	O
or	O

a	O
cardioembolic	B
event	I
,	O
which	O
occurred	O
on	O
anticoagulation	B
,	O
or	O

a	O
high	B
risk	I
profile	I
of	O
the	O
patient	O
,	O
defined	O
as	O
a	O
CHA2DS2	B
-	I
VASc	I
score	I
=	B
3	I
and	O
a	O
HAS	B
-	I
BLED	I
score	I
=	B
2	I

Severe	B
co	B
-	I
morbid	I
illness	I
such	O
as	O
untreatable	B
other	B
malignancy	B
and	O
/	O
or	O
active	B
infections	B
.	O

Pregnant	B
or	O
lactating	B
women	B

Hypersensitivity	B
to	O
Sandostatin	B
or	O
any	O
component	B
of	I
the	I
formulation	I
.	O

Age	B
18	B
or	I
older	I
.	O

Patients	O
diagnosed	O
with	O
acromegaly	B
with	O
GH	B
-	I
secreting	I
pituitary	I
adenoma	I
on	O
sellar	B
MRI	I
,	O
meeting	O
the	O
biochemical	B
criteria	I
outlined	I
above	I
(	O
refer	O
to	O
1	O
.	O
Diagnosis	O
of	O
acromegaly	O
)	O
and	O
with	O
typical	B
acromegalic	B
features	I
.	O

No	B
prior	B
use	O
of	O
somatostatin	B
analogues	I
.	O

Adequate	B
hepatic	I
and	I
renal	I
function	I

Provision	O
of	O
a	O
signed	O
written	O
informed	O
consent	O

Received	O
any	O
vaccine	B
within	B
a	I
month	I
prior	I
to	I
study	I
vaccine	I

Positive	B
serum	B
antibody	I
against	O
Hep	B
B	I
surface	I
antigen	I
and	O
/	O
or	O
core	B
Hep	I
B	I
core	I
antigen	I

HIV	B
positive	B

For	O
HCV	B
-	O
negative	B
,	O
healthy	O
volunteers	O
:	O
History	B
of	I
HCV	I
infection	I
or	O
positive	O
HCV	O
antibody	O
test	O

Participation	O
in	O
another	O
clinical	O
study	O
of	O
an	O
investigational	O
product	O
currently	O
or	O
within	O
the	O
past	O
90	O
days	O
,	O
or	O
expected	O
participation	O
during	O
this	O
study	O

In	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
the	O
volunteer	O
is	O
unlikely	O
to	O
comply	O
with	O
the	O
study	O
protocol	O

Any	O
clinically	O
significant	O
abnormality	O
or	O
medical	O
history	O
or	O
physical	O
examination	O
including	O
history	O
of	O
immunodeficiency	B
or	O
autoimmune	B
disease	I
(	O
in	B
addition	I
to	I
HCV	B
infection	I
,	O
for	O
HCV	O
group	O
)	O

Currently	O
taking	O
systemic	B
steroids	I
or	O
other	O
immunomodulatory	B
medications	I
including	O
anticancer	B
medications	I
and	O
antiviral	B
medications	I

Any	O
clinically	O
significant	O
acute	O
or	O
chronic	O
medical	O
condition	O
requiring	O
care	O
by	O
a	O
primary	O
care	O
provider	O
(	O
e	O
.	O
g	O
.	O
,	O
diabetes	B
,	O
coronary	B
artery	I
disease	I
,	O
rheumatologic	B
illness	I
,	O
malignancy	B
,	O
substance	B
abuse	I
)	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
preclude	O
participation	O

Unable	O
to	O
continue	O
participation	O
for	O
156	O
weeks	O

History	O
of	O
previous	O
Hepatitis	B
B	I
vaccination	I
(	O
s	O
)	O

Male	B
or	O
female	B
<	B
18	I
and	I
>	I
62	I
years	I
of	O
age	B

Is	O
pregnant	O
or	O
lactating	O

History	O
of	O
Hepatitis	B
B	I
infection	I

Clinical	O
,	O
laboratory	O
,	O
or	O
biopsy	O
evidence	O
of	O
cirrhosis	B

Willing	O
to	O
receive	O
three	O
doses	O
of	O
an	O
FDA	O
-	O
approved	O
Hepatitis	O
B	O
vaccine	O

Volunteer	O
chronically	B
infected	O
with	O
HCV	O
(	O
as	O
demonstrated	O
by	O
serology	O
and	O
/	O
or	O
viral	O
load	O
laboratory	O
studies	O
)	O

Healthy	B
volunteer	B
without	O
significant	O
medical	O
problems	O

A	O
diagnosis	O
of	O
sleep	B
disordered	I
breathing	I
;	O

Nocturnal	B
oxygen	I
therapy	I
.	O

Moderate	B
to	I
severe	I
COPD	B
(	O
post	B
-	I
bronchodilator	I
forced	B
expiratory	I
volume	I
in	I
1	I
s	I
(	I
FEV1	I
)	I
30	B
-	I
79	I
%	I
predicted	I
)	O
;	O

Resting	B
functional	I
residual	I
capacity	I
(	I
FRC	I
)	I
>	B
120	I
%	I
predicted	I
;	O

Clinically	B
stable	I
and	O
on	O
stable	B
triple	I
therapy	I
with	O
an	O
ICS	B
/	I
LABA	I
and	O
tiotropium	B
;	O

Symptomatic	O
:	O
Baseline	B
Dyspnea	I
Index	I
=	B
8	I
and	O
answer	O
"	O
in	B
the	I
morning	I
"	O
when	O
asked	O
about	O
what	O
time	O
of	O
day	O
their	O
COPD	O
symptoms	O
are	O
worst	O
.	O

polycystic	B
ovaries	I

untreated	B
thyroid	B
pathology	I

hypogonadotropic	B
hypogonadism	I

untreaed	B
hyperprolactinemia	B

study	B
drug	I
hypersensitivity	B

previous	B
OHSS	B

unilateral	B
ovariectomy	B

genital	B
malformation	I

BMI	B
>	B
40	I

female	B
infertile	B
patients	O
eligible	O
for	O
IVF	B
treatment	I

Fasting	B
blood	I
glucose	I
>	B
126	I
mg	I
/	I
dL	I
at	B
screening	I
.	O

Heterozygous	B
subjects	O
will	O
be	O
excluded	O
for	O
a	O
fasting	B
blood	I
glucose	I
>	B
140	I
mg	I
/	I
dL	I
.	O

Resting	B
heart	I
rate	I
<	B
45	I
bpm	I
or	O
>	B
90	I
bpm	I
at	B
screening	I
.	O

Abnormal	B
thyroid	B
stimulating	I
hormone	I
(	I
TSH	I
)	I
or	O
thyroxine	B
(	I
T4	I
)	I
levels	O
on	B
screening	I
.	O

Elevated	B
ALT	B
or	O
serum	B
creatinine	I
on	B
screening	I
or	O
any	O
clinically	O
significant	O
abnormalities	B
on	O
screening	O
laboratory	B
tests	I
as	O
determined	O
by	O
the	O
Investigator	O
.	O

History	B
of	O
medically	B
treated	O
diabetes	B
or	O
of	O
treated	B
or	O
medically	B
diagnosed	O
hypertension	B
.	O

Heterozygous	B
subjects	O
who	O
have	O
diagnosed	O
hypertension	B
and	O
are	O
well	B
controlled	I
on	O
treatment	B
(	O
Refer	O
to	O
Exclusion	O
Criteria	O
20	O
below	O
)	O
,	O
are	O
eligible	O
.	O

.	O

Presence	O
of	O
a	O
skin	B
lesion	I
suspicious	O
for	O
malignancy	B
,	O
unless	O
excised	B
prior	B
to	I
Day	I
1	I
.	O

History	B
of	O
malignancy	B
except	B
for	I
treated	B
cervical	B
carcinoma	I
in	I
situ	I
in	B
the	I
past	I
5	I
years	I
.	O

Active	B
or	O
history	B
of	O
any	O
clinically	B
significant	I
medical	B
condition	I
including	O
renal	O
,	O
hepatic	O
,	O
pulmonary	O
,	O
gastrointestinal	O
,	O
cardiovascular	O
,	O
genitourinary	O
,	O
endocrine	O
,	O
immunologic	O
,	O
metabolic	O
,	O
neurologic	O
,	O
psychiatric	O
or	O
hematological	B
disease	I
,	O
based	B
on	I
Investigator	I
judgment	I
.	O

Acute	O
illness	O
or	O
history	O
of	O
illness	O
,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
could	O
pose	O
a	O
threat	O
or	O
harm	O
to	O
the	O
subject	O
or	O
obscure	O
interpretation	O
of	O
laboratory	O
test	O
results	O
or	O
interpretation	O
of	O
study	O
data	O
.	O

Positive	B
hepatitis	B
B	I
surface	I
antigen	I
,	O
positive	B
hepatitis	B
C	I
antibody	I
or	O
positive	B
HIV	B
test	I
at	B
screening	I
or	O
a	O
history	B
of	O
positive	B
testing	B
(	O
e	O
.	O
g	O
.	O
liver	B
biopsy	I
,	O
serology	B
)	O
suggesting	O
acute	O
or	O
chronic	B
hepatitis	I
.	O

Abnormal	B
12	B
-	I
lead	I
electrocardiogram	I
(	I
ECG	I
)	I
at	B
screening	I
or	O
pre	O
-	O
dose	O
(	O
Day	B
-	I
1	I
or	O
Day	B
1	I
)	O
,	O
except	O
minor	O
deviations	O
deemed	O
to	O
be	O
of	O
no	O
clinical	O
significance	O
by	O
the	O
Investigator	O
.	O

Received	O
any	O
experimental	B
drugs	I
or	O
devices	O
within	B
30	I
days	I
or	O
5	O
half	O
lives	O
,	O
whichever	O
is	O
longer	O
,	O
prior	O
to	O
dosing	O
.	O

Ongoing	O
participation	O
in	O
a	O
prior	O
clinical	O
study	O
at	O
the	O
time	O
of	O
screening	O
.	O

Blood	B
donation	I
within	B
60	I
days	I
prior	I
to	I
screening	I
or	O
intent	O
to	O
donate	O
within	B
60	I
days	I
after	I
Final	I
Study	I
Visit	I
.	O

Hospitalization	B
for	O
major	B
surgery	B
including	O
but	O
not	O
limited	O
to	O
abdominal	O
,	O
thoracic	O
,	O
or	O
cardiovascular	B
surgery	I
within	B
the	I
past	I
3	I
months	I
prior	I
to	I
screening	I
,	O
or	O
for	O
a	O
clinically	B
significant	I
non	B
-	I
surgical	I
illness	I
,	O
based	O
on	O
Investigator	O
judgment	O
,	O
within	B
the	I
past	I
3	I
months	I
.	O

Planned	O
elective	B
surgery	I
within	B
30	I
days	I
of	I
the	I
Final	I
Study	I
Visit	I
.	O

Poor	B
venous	I
access	I
or	O
inability	O
to	O
tolerate	O
venipuncture	B
.	O

History	B
of	O
significant	B
drug	B
hypersensitivity	I
or	O
anaphylaxis	O
.	O

History	B
of	O
hypersensitivity	B
to	I
proteins	I
(	O
e	O
.	O
g	O
.	O
,	O
allergy	O
shots	O
)	O
.	O

Use	O
of	O
prescription	B
medications	I
on	O
a	O
regular	B
basis	I
.	O

The	O
last	O
use	O
of	O
any	B
prescription	I
medication	I
must	O
have	O
been	O
greater	O
than	O
5	O
half	O
-	O
lives	O
for	O
the	O
specific	O
medication	O
or	O
at	B
least	I
14	I
days	I
prior	I
to	I
admission	I
(	O
Day	O
-	O
1	O
)	O
,	O
whichever	O
is	O
longer	O
.	O

Hormonal	B
contraception	I
is	O
allowed	O
for	O
female	B
subjects	O
.	O

Heterozygous	O
cohorts	O
:	O
Use	O
of	O
prescription	O
medications	O
on	O
a	O
regular	O
basis	O
is	O
not	O
allowed	O
with	O
the	O
following	O
exceptions	O
:	O

Antihypertensives	B
(	O
<	B
3	I
medications	I
on	O
a	O
stable	B
dose	I
for	B
≥	I
30	I
days	I
)	O
;	O

Statins	B
(	O
dose	O
must	O
be	O
≤	B
half	I
the	I
maximum	I
dose	I
;	O
must	O
be	O
on	O
a	O
stable	B
dose	I
≥	B
3	I
months	I
)	O
;	O

Fibrates	B
(	O
must	O
be	O
on	O
stable	B
dose	I
for	O
≥	B
3	I
months	I
)	O
;	O

Niacin	B
(	O
must	O
be	O
on	O
stable	B
dose	I
for	O
≥	B
3	I
months	I
)	O
;	O

Thyroxin	B
(	O
stable	B
dose	I
for	O
≥	B
30	I
days	I
)	O
;	O
The	O
last	O
use	O
of	O
any	O
other	O
prescription	O
medication	O
will	O
need	O
follow	O
the	O
criteria	O
for	O
all	O
other	O
cohorts	O
,	O
as	O
outlined	O
above	O
.	O

Use	O
of	O
prescription	B
medications	I
not	O
listed	O
above	O
may	O
be	O
allowed	O
at	O
the	O
discretion	O
of	O
the	O
Investigator	O
upon	O
consultation	O
with	O
Rhythm	O
.	O

Use	O
of	O
a	O
non	B
-	I
prescription	I
drug	I
and	O
herbal	B
substances	I
during	B
the	I
study	I
(	O
through	O
the	O
Final	O
Study	O
Visit	O
)	O
.	O

The	O
last	O
dose	O
of	O
any	B
non	I
-	I
prescription	I
drug	I
must	O
have	O
been	O
taken	O
greater	B
than	I
5	I
half	I
-	I
lives	I
for	I
that	I
drug	I
before	I
receiving	I
study	I
drug	I
.	O

Inability	O
to	O
attend	O
all	O
study	O
visits	O
or	O
to	O
comply	O
with	O
protocol	O
requirements	O
including	O
fasting	O
and	O
restrictions	O
on	O
alcohol	O
,	O
caffeine	O
,	O
nicotine	O
and	O
concomitant	O
medication	O
intake	O
.	O

A	O
significant	O
history	B
of	O
drug	B
/	I
solvent	I
abuse	I
within	B
5	I
years	I
of	I
screening	I
or	O
a	O
positive	B
test	O
for	O
drugs	B
of	I
abuse	I
test	I
at	B
screening	I
or	O
on	O
Day	O
-	O
1	O
.	O

Positive	B
alcohol	O
(	O
breath	B
test	I
)	O
or	O
nicotine	B
screen	I
at	B
Screening	I
Visit	I
or	O
Day	O
1	O
(	O
positive	O
nicotine	O
screen	O
does	O
not	O
apply	O
to	O
heterozygous	O
cohort	O
)	O
.	O

History	B
of	O
alcohol	B
abuse	I
(	O
defined	O
as	O
average	O
intake	O
of	O
three	O
or	O
more	O
units	O
of	O
alcohol	B
per	O
day	O
)	O
within	B
5	I
years	I
of	I
the	I
Screening	I
Visit	I
.	O

History	B
of	O
tobacco	O
or	O
tobacco	B
product	I
use	I
unless	B
abstinent	B
for	B
at	I
least	I
one	I
year	I
prior	I
to	I
the	I
Screening	I
Visit	I
.	O

This	O
criterion	O
does	O
not	O
apply	O
to	O
heterozygous	O
subjects	O
.	O

Previously	O
randomized	O
and	O
dosed	O
in	O
this	O
study	O
.	O

This	O
criterion	O
does	O
not	O
apply	O
to	O
heterozygous	O
subjects	O
.	O

Any	O
other	O
reason	O
,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
would	O
confound	O
proper	O
evaluation	O
of	O
the	O
study	O
.	O

Able	O
to	O
provide	O
voluntary	O
,	O
written	O
informed	O
consent	O
with	O
comprehension	O
of	O
all	O
aspects	O
of	O
the	O
protocol	O
,	O
prior	O
to	O
any	O
study	O
procedures	O
.	O

Healthy	B
obese	B
male	B
and	O
female	B
volunteers	O
aged	B
18	B
to	I
55	I
years	I
,	I
inclusive	I
.	O

Heterozygous	B
subjects	O
may	O
be	O
18	B
to	I
65	I
years	I
inclusive	I
.	O

In	O
good	B
general	I
health	I
,	O
without	O
significant	O
medical	O
history	O
,	O
physical	O
examination	O
findings	O
,	O
or	O
clinical	O
laboratory	O
abnormalities	O
.	O

Body	B
Mass	I
Index	I
of	O
30	B
-	I
40	I
kg	I
/	I
m2	I
,	I
inclusive	I
.	O

Heterozygous	B
subjects	O
may	O
have	O
a	O
broader	O
BMI	O
range	O
;	O
to	O
be	O
eligible	O
heterozygous	B
subjects	O
may	O
have	O
a	O
BMI	B
27	B
-	I
55	I
kg	I
/	I
m2	I
,	I
inclusive	I
.	O

Stable	B
body	B
weight	I
during	B
the	I
previous	I
6	I
months	I
,	O
based	O
on	O
Investigator	O
judgment	O
.	O

Blood	B
pressure	I
<	B
140	I
/	I
90	I
mmHg	I
at	B
Screening	I
and	I
D	I
-	I
1	I
.	O

Measurement	O
may	O
be	O
repeated	O
within	O
24	O
hours	O
,	O
based	O
on	O
Investigator	O
judgment	O
.	O

Females	B
must	O
not	B
be	O
pregnant	B
and	O
must	O
have	O
a	O
negative	B
serum	B
pregnancy	I
test	I
result	O
at	B
the	I
Screening	I
Visit	I
and	I
Day	I
-	I
1	I
.	O

Females	O
of	O
childbearing	B
potential	I
must	O
agree	O
to	O
be	O
abstinent	O
or	O
else	O
use	O
any	O
two	O
of	O
the	O
following	O
medically	O
acceptable	O
forms	O
of	O
contraception	O
from	O
the	O
Screening	O
Period	O
through	O
the	O
Final	O
Study	O
Visit	O
:	O
hormonal	O
,	O
condom	O
with	O
spermicidal	O
jelly	O
,	O
diaphragm	O
or	O
cervical	O
cap	O
with	O
spermicidal	O
jelly	O
,	O
or	O
IUD	O
.	O

Hormonal	B
contraception	I
must	O
have	O
started	O
at	B
least	I
3	I
months	I
prior	I
to	I
screening	I
.	O

A	O
female	O
whose	O
male	O
partner	O
has	O
had	O
a	O
vasectomy	O
must	O
agree	O
to	O
use	O
one	O
additional	O
form	O
of	O
medically	O
acceptable	O
contraception	O
.	O

Subjects	O
must	O
agree	O
to	O
practice	O
the	O
above	O
birth	O
control	O
methods	O
for	O
30	O
days	O
from	O
the	O
final	O
visit	O
as	O
a	O
safety	O
precaution	O
.	O

Females	O
of	O
non	O
-	O
childbearing	O
potential	O
,	O
defined	O
as	O
surgically	O
sterile	O
(	O
status	O
post	O
hysterectomy	O
,	O
bilateral	O
oophorectomy	O
,	O
or	O
bilateral	O
tubal	O
ligation	O
)	O
or	O
post	O
-	O
menopausal	O
for	O
at	O
least	O
12	O
months	O
(	O
and	O
confirmed	O
with	O
a	O
screening	O
FSH	O
level	O
in	O
the	O
post	O
-	O
menopausal	O
range	O
)	O
,	O
do	O
not	O
require	O
contraception	O
during	O
the	O
study	O
.	O

Males	O
with	O
female	O
partners	O
of	O
childbearing	O
potential	O
must	O
agree	O
to	O
use	O
two	O
medically	O
acceptable	O
forms	O
of	O
contraception	O
as	O
described	O
above	O
,	O
with	O
one	O
of	O
the	O
two	O
forms	O
being	O
condom	O
with	O
spermicide	O
,	O
from	O
the	O
Screening	O
Period	O
through	O
the	O
Final	O
Study	O
Visit	O
.	O

Males	O
with	O
female	O
partners	O
of	O
childbearing	O
potential	O
who	O
themselves	O
are	O
surgically	O
sterile	O
(	O
status	O
post	O
vasectomy	O
)	O
must	O
agree	O
to	O
use	O
condoms	O
with	O
spermicide	O
over	O
the	O
same	O
period	O
of	O
time	O
.	O

Male	O
subjects	O
must	O
agree	O
to	O
practice	O
the	O
above	O
birth	O
control	O
methods	O
for	O
30	O
days	O
from	O
the	O
final	O
visit	O
as	O
a	O
safety	O
precaution	O
.	O

1	O
.	O

Prior	B
exposure	O
to	O
doxorubicin	B
,	O
PLD	B
or	O
any	O
other	O
anthracycline	B
,	O
motolimod	B
and	O
other	O
TLR	B
agonists	I
,	O
MEDI4736	B
or	O
checkpoint	B
inhibitors	I
,	O
such	O
as	O
anti	B
-	I
CTLA4	I
and	O
anti	O
-	O
PD1	O
/	O
anti	B
-	I
PD	I
-	I
L1	I
antibodies	I
.	O

2	O
.	O

Subjects	O
with	O
platinum	B
-	I
refractory	I
disease	I
,	O
defined	O
as	O
disease	B
progression	I
while	B
receiving	I
first	I
line	I
platinum	I
-	I
based	I
therapy	I
.	O

3	O
.	O

Clinically	B
significant	I
persistent	B
immune	B
-	I
related	I
adverse	I
events	I
following	B
prior	I
therapy	I
.	O

4	O
.	O

Subjects	O
with	O
history	O
or	O
evidence	O
upon	O
physical	O
examination	O
of	O
CNS	B
disease	I
,	O
including	O
primary	B
brain	I
tumor	I
,	O
seizures	B
not	B
controlled	B
with	O
standard	B
medical	I
therapy	I
,	O
any	O
brain	B
metastases	I
,	O
or	O
,	O
within	B
six	I
months	I
prior	I
to	I
Day	I
1	I
of	I
this	I
study	I
,	O
history	O
of	O
cerebrovascular	B
accident	I
(	O
CVA	B
,	O
stroke	B
)	O
,	O
transient	B
ischemic	I
attack	I
(	I
TIA	I
)	I
or	O
subarachnoid	B
hemorrhage	I
.	O

5	O
.	O

Subjects	O
with	O
clinically	B
significant	I
cardiovascular	B
disease	I
.	O

This	O
includes	O
:	O

1	O
.	O

Resisted	B
hypertension	I

2	O
.	O

Myocardial	B
infarction	I
or	O
unstable	B
angina	I
within	B
6	I
months	I
prior	I
to	I
Day	I
1	I
of	I
the	I
study	I
.	O

3	O
.	O

History	B
of	O
serious	B
ventricular	B
arrhythmia	I
(	O
i	O
.	O
e	O
.	O
,	O
ventricular	B
tachycardia	I
or	O
ventricular	B
fibrillation	I
)	O
or	O
cardiac	B
arrhythmias	I
requiring	O
anti	B
-	I
arrhythmic	I
medications	I
,	O
except	B
for	O
atrial	B
fibrillation	I
that	O
is	O
well	O
controlled	O
with	O
anti	B
-	I
arrhythmic	I
medication	I
.	O

4	O
.	O

Baseline	B
ejection	B
fraction	I
≤	B
50	I
%	I
as	O
assessed	O
by	O
echocardiogram	B
or	O
MUGA	B
.	O

5	O
.	O

New	B
York	I
Heart	I
Association	I
(	I
NYHA	I
)	I
Class	B
II	I
or	I
higher	I
congestive	B
heart	I
failure	I
.	O

6	O
.	O

Grade	O
2	B
or	I
higher	I
peripheral	B
ischemia	I
,	O
except	B
for	O
brief	B
(	O
<	B
24	I
hrs	I
)	O
episodes	O
of	O
ischemia	B
managed	O
non	B
-	O
surgically	B
and	O
without	B
permanent	B
deficit	I
.	O

6	O
.	O

History	B
of	O
pneumonitis	B
or	O
interstitial	B
lung	I
disease	I
.	O

7	O
.	O

Active	O
,	O
suspected	O
or	O
prior	O
documented	O
autoimmune	B
disease	I
(	O
including	O
inflammatory	B
bowel	I
disease	I
,	O
celiac	B
disease	I
,	O
Wegner	B
'	I
s	I
granulomatosis	I
,	O
active	O
Hashimoto	B
'	I
s	I
thyroiditis	I
,	O
rheumatoid	B
arthritis	I
,	O
lupus	B
,	O
scleroderma	B
and	O
its	O
variants	O
,	O
multiple	B
sclerosis	I
,	O
myasthenia	B
gravis	I
)	O
.	O

Vitiligo	B
,	O
type	B
I	I
diabetes	I
mellitus	I
,	O
residual	B
hypothyroidism	I
due	O
to	O
autoimmune	B
condition	I
only	O
requiring	O
hormone	B
replacement	I
,	O
psoriasis	B
not	B
requiring	O
systemic	B
treatment	I
,	O
or	O
conditions	B
not	B
expected	I
to	I
recur	I
in	O
the	O
absence	O
of	O
an	O
external	O
trigger	O
are	O
permitted	O
.	O

8	O
.	O

Other	O
malignancy	B
within	B
2	I
years	I
prior	I
to	I
Day	I
1	I
of	I
the	I
study	I
,	O
except	B
for	I
those	B
treated	O
with	O
surgical	B
intervention	I
only	O
.	O

9	O
.	O

Subjects	O
with	O
clinical	O
symptoms	O
or	O
signs	B
of	I
gastrointestinal	I
obstruction	I
and	O
/	O
or	O
who	O
require	O
drainage	B
gastrostomy	I
tube	I
and	O
/	O
or	O
parenteral	B
hydration	I
or	O
nutrition	O
.	O

10	O
.	O

Known	O
immunodeficiency	B
or	O
HIV	B
,	O
Hepatitis	B
B	I
or	O
Hepatitis	B
C	I
positivity	O
.	O

11	O
.	O

History	B
of	O
severe	B
allergic	B
reactions	I
to	B
any	I
unknown	I
allergens	I
or	I
components	I
of	I
the	I
study	I
drugs	I
.	O

12	O
.	O

Other	O
serious	B
illnesses	B
(	O
e	O
.	O
g	O
.	O
,	O
serious	B
infections	B
requiring	I
antibiotics	I
,	O
bleeding	B
disorders	I
)	O
.	O

13	O
.	O

Prior	B
treatment	B
in	O
any	O
other	O
interventional	O
clinical	O
trial	O
within	O
4	O
weeks	O
prior	O
to	O
Day	O
1	O
of	O
the	O
study	O
.	O

14	O
.	O

Mental	B
impairment	I
that	O
may	O
compromise	O
compliance	O
with	O
the	O
requirements	O
of	O
the	O
study	O
.	O

15	O
.	O

Lack	B
of	I
availability	O
for	O
immunological	O
and	O
clinical	B
follow	I
-	I
up	I
assessment	I
.	O

16	O
.	O

Women	B
who	O
are	O
breastfeeding	O
or	O
pregnant	B
as	O
evidenced	O
by	O
positive	B
serum	B
pregnancy	I
test	I

17	O
.	O

Subjects	O
unwilling	B
to	O
use	O
acceptable	B
methods	O
of	O
contraception	B
.	O

-	O
Female	B
subjects	O
should	O
refrain	B
from	I
breastfeeding	O
throughout	B
this	I
period	I
.	I

18	O
.	O

Any	O
condition	O
that	O
,	O
in	O
the	O
clinical	O
judgment	O
of	O
the	O
treating	O
physician	O
,	O
is	O
likely	O
to	O
prevent	O
the	O
subject	O
from	O
complying	O
with	O
any	O
aspect	O
of	O
the	O
protocol	O
or	O
that	O
may	O
put	O
the	O
subject	O
at	O
unacceptable	O
risk	O
.	O

19	O
.	O

Subjects	O
must	O
not	B
donate	B
blood	I
while	B
on	I
study	I
and	O
for	B
at	I
least	I
90	I
days	I
following	I
the	I
last	I
MEDI4736	I
treatment	I
.	O

20	O
.	O

History	B
of	O
allogeneic	B
organ	I
transplant	I

1	O
.	O

Subjects	O
must	O
have	O
recurrent	B
or	O
persistent	B
platinum	B
-	I
resistant	I
epithelial	O
ovarian	O
,	O
fallopian	O
tube	O
,	O
or	O
primary	B
peritoneal	I
carcinoma	I
with	O
measureable	B
disease	I
(	O
as	O
defined	O
by	O
RECIST	O
1	O
.	O
1	O
.	O
)	O
after	B
first	I
or	I
second	I
line	I
platinum	I
-	I
based	I
chemotherapy	I
,	O
for	O
which	O
treatment	O
with	O
PLD	B
is	O
indicated	B
.	O

Platinum	B
-	I
based	I
therapy	I
is	O
defined	O
as	O
treatment	O
with	O
carboplatin	B
,	O
cisplatin	B
or	O
another	B
organoplatinum	I
compound	I
.	O

Platinum	B
-	I
resistant	I
is	O
defined	O
as	O
having	O
a	O
platinum	B
-	I
free	I
interval	I
(	I
PFI	I
)	I
of	O
<	B
12	I
months	I
after	I
first	I
-	I
or	I
second	I
-	I
line	I
platinum	I
-	I
based	I
chemotherapy	I
,	O
or	O
having	O
disease	B
progression	I
while	O
receiving	O
second	B
-	I
line	I
platinum	I
-	I
based	I
chemotherapy	I
.	O

Subjects	O
are	O
allowed	O
to	O
have	O
received	O
,	O
but	O
are	O
not	O
required	O
to	O
have	O
received	O
:	O

one	B
additional	I
cytotoxic	B
regimen	I
and	O
/	O
or	O
PARP	B
inhibitor	I
for	O
management	O
of	O
recurrent	B
or	O
persistent	B
disease	B
.	O

biologic	B
therapy	I
(	O
e	O
.	O
g	O
.	O
,	O
bevacizumab	B
)	O
as	O
part	O
of	O
their	O
primary	B
treatment	I
regimen	I
or	O
part	O
of	O
their	O
treatment	B
for	O
management	O
of	O
recurrent	B
or	O
persistent	B
disease	B
.	O

2	O
.	O

Histologic	B
documentation	B
of	O
the	O
original	B
primary	I
tumor	I
.	O

3	O
.	O

Documented	O
radiographic	B
disease	B
progression	I
<	B
12	I
months	I
after	I
the	I
last	I
dose	I
of	I
first	I
-	I
or	I
second	I
-	I
line	I
platinum	I
-	I
based	I
chemotherapy	I
.	O

4	O
.	O

Subjects	O
in	O
Phase	O
2	O
must	O
have	O
disease	B
amenable	I
to	I
biopsy	I
and	O
must	O
be	O
willing	O
to	O
undergo	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
tumor	O
biopsies	O
.	O

Optional	O
for	O
Phase	O
1	O
.	O

Note	O
:	O
archival	O
tissue	O
will	O
be	O
requested	O
for	O
all	O
subjects	O
preferably	O
from	O
primary	O
tumor	O
site	O
prior	O
to	O
cancer	O
treatment	O
;	O
however	O
,	O
archival	O
tissue	O
is	O
not	O
a	O
requirement	O
for	O
study	O
entry	O
.	O

5	O
.	O

ECOG	B
performance	I
status	I
of	O
0	B
or	I
1	I
.	O

6	O
.	O

Laboratory	B
parameters	I
for	I
vital	I
functions	I
should	O
be	O
in	O
the	O
normal	B
range	I
.	O

Laboratory	O
abnormalities	O
that	O
are	O
not	O
clinically	O
significant	O
are	O
generally	O
permitted	O
,	O
except	O
for	O
the	O
following	O
laboratory	O
parameters	O
,	O
which	O
must	O
be	O
within	O
the	O
ranges	O
specified	O
,	O
regardless	O
of	O
clinical	O
significance	O
:	O

Hemoglobin	B
:	O
≥	B
9	I
g	I
/	I
dL	I

Neutrophil	B
count	I
:	O
≥	B
1	I
.	I
5	I
x	I
109	I
/	I
L	I

Platelet	B
count	I
:	O
≥	B
100	I
,	I
000	I
/	I
mm3	I

Serum	B
creatinine	I
,	O
≤	B
1	I
.	I
5x	I
Institutional	I
Upper	I
Limit	I
of	I
Normal	I
(	I
ULN	I
)	I
,	O
or	O
Creatinine	B
Clearance	I
≥	B
50	I
mL	I
/	I
min	I
(	O
by	O
Cockcroft	B
-	I
Gault	I
formula	I
)	O

Serum	B
bilirubin	I
:	O
≤	B
1	I
.	I
2	I
mg	I
/	I
dL	I

AST	B
/	I
ALT	I
:	O
≤	B
2	I
.	I
5	I
x	I
ULN	I

Alkaline	B
phosphatase	I
:	O
≤	B
2	I
.	I
5	I
x	I
ULN	I

7	O
.	O

Age	B
≥	B
18	I
years	I
.	O

8	O
.	O

Able	O
and	O
willing	O
to	O
give	O
valid	O
written	O
informed	O
consent	O
.	O

9	O
.	O

Body	B
weight	I
>	B
30	I
kg	I

Current	O
pregnancy	B

Desire	O
/	O
intent	O
to	O
become	O
pregnant	B
over	B
the	I
course	I
of	I
the	I
study	I

Women	B
who	O
are	O
less	B
than	I
6	I
weeks	I
postpartum	I

Contraindications	O
to	O
hormonal	B
contraceptive	I
use	O
per	O
package	O
insert	O
,	O
including	O
history	O
of	O
deep	B
vein	I
thrombosis	I
,	O
smoking	O
in	O
women	B
older	B
than	I
35	I
years	I

Current	O
IUD	B

Unable	O
to	O
comprehend	O
consent	O
material	O
because	O
of	O
language	O
barrier	O
or	O
psychological	O
difficulty	O

=	O
18	B
-	I
40	I
year	I
old	B
women	B

BV	B
+	O
by	O
Amsel	B
criteria	I
and	O
Nugent	B
score	I
OR	O
history	O
of	O
BV	B
in	B
the	I
prior	I
6	I
months	I

Willing	O
to	O
use	O
the	O
NuvaRing	B
as	O
directed	O

Not	O
intending	O
or	O
wishing	O
to	O
become	O
pregnant	O
over	O
the	O
course	O
of	O
the	O
study	O

Capable	O
of	O
providing	O
written	O
informed	O
consent	O

Patient	O
not	B
expected	O
to	O
survive	O
more	B
than	I
4	I
days	I

Patient	O
allergic	B
to	O
a	O
penicillin	B
or	O
a	O
carbapenem	B

Patient	O
with	O
significant	O
polymicrobial	B
bacteraemia	B
(	O
that	O
is	O
,	O
a	O
Gram	O
positive	O
skin	O
contaminant	O
in	O
one	O
set	O
of	O
blood	O
cultures	O
is	O
not	O
regarded	O
as	O
significant	O
polymicrobial	O
bacteraemia	O
)	O
.	O

Treatment	O
is	O
not	O
with	O
the	O
intent	O
to	O
cure	O
the	O
infection	O
(	O
that	O
is	O
,	O
palliative	O
care	O
is	O
an	O
exclusion	O
)	O
.	O

Pregnancy	O
or	O
breast	O
-	O
feeding	O
.	O

Use	O
of	O
concomitant	B
antimicrobials	B
in	O
the	O
first	B
4	I
days	I
after	I
enrolment	I
with	O
known	O
activity	O
against	O
Gram	O
-	O
negative	O
bacilli	O
(	O
except	B
trimethoprim	B
/	I
sulphamethoxazole	I
may	O
be	O
continued	O
as	O
Pneumocystis	O
prophylaxis	O
)	O
.	O

Severe	O
acute	O
illness	O
as	O
defined	O
by	O
Pitt	B
bacteraemia	I
score	I
of	O
>	B
4	I

Likely	O
source	O
to	O
be	O
from	O
(	O
proven	O
or	O
suspected	O
at	O
the	O
time	O
of	O
randomisation	O
)	O
the	O
central	O
nervous	O
system	O
,	O
e	O
.	O
g	O
.	O
brain	B
abscess	I
,	O
post	B
-	I
surgical	I
meningitis	B
,	O
shunt	B
infection	I
(	O
due	O
to	O
concerns	O
over	O
CNS	O
penetration	O
of	O
piperacillin	O
/	O
tazobactam	O
)	O

Bloodstream	B
infection	I
with	O
Enterobacter	B
spp	I
.	I
,	O
Serratia	B
marcescens	I
,	O
Providencia	B
spp	I
.	I
,	O
Morganella	B
morganii	I
or	O
Citrobacter	B
freundii	I
(	O
i	O
.	O
e	O
.	O
likely	O
AmpC	O
-	O
producer	O
)	O
,	O
and	O
susceptibility	O
to	O
3rd	B
generation	I
cephalosporins	I
(	I
i	O
.	O
e	O
.	O
ceftriaxone	B
,	O
cefotaxime	B
or	O
ceftazidime	B
)	O
,	O
meropenem	B
and	O
piperacillin	B
-	I
tazobactam	I
from	O
at	B
least	I
one	I
blood	B
culture	I
draw	O
.	O

This	O
will	O
be	O
determined	O
in	O
accordance	O
with	O
laboratory	O
methods	O
and	O
susceptibility	O
breakpoints	O
defined	O
by	O
protocols	O
used	O
in	O
the	O
recruiting	O
site	O
laboratories	O
.	O
.	O

No	O
more	O
than	O
72	O
hours	O
has	O
elapsed	O
since	O
the	O
first	O
positive	B
blood	B
culture	I
collection	I
.	O

Patient	O
is	O
aged	B
18	B
years	I
and	I
over	I
(	O
>	B
=	I
21y	I
in	O
Singapore	B
)	O
.	O

Less	B
than	I
30	I
yrs	I
of	O
age	B
or	O
>	B
65	I
yrs	I
of	O
age	B

Any	O
significant	B
co	B
-	I
morbidities	I
,	O
such	O
as	O
active	B
heart	O
,	O
kidney	O
,	O
or	O
liver	B
diseases	I
,	O
accelerated	B
or	O
malignant	B
hypertension	B
,	O
heart	B
failure	I
,	O
severe	B
anemia	I
.	O

Healthy	B
adults	B
30	O
-	O
65	O
years	O
old	B
,	O

BMI	B
25	B
-	I
35	I
kg	I
/	I
m2	I
,	O

nondiabetic	B
as	O
defined	O
by	O
fasting	B
plasma	I
glucose	I
<	B
126	I
mg	I
/	I
dL	I

Lipids	O
:	O
one	O
group	O
with	O
an	O
LDL	B
=	B
/	I
>	I
130	I
and	O
Triglycerides	B
<	B
150	I
mg	I
/	I
dL	I
The	O
2nd	O
group	O
will	O
have	O
and	O
LDL	O
=	O
/	O
>	O
130	O
mg	O
/	O
dL	O
and	O
Triglycerides	O
=	O
/	O
>	O
150	O
mg	O
/	O
dL	O
but	O
less	O
than	O
400	O
mg	O
/	O
dL	O
.	O

1	O
.	O

Orthopedic	B
injuries	I
that	O
are	O
unstable	B

2	O
.	O

Osteoporosis	B
with	O
high	B
risk	I
of	I
pathological	I
fracture	I

3	O
.	O

Cutaneous	B
lesions	I
and	O
/	O
or	O
pressure	B
ulcers	I

4	O
.	O

Joint	B
contractures	I

5	O
.	O

Cardiopulmonary	B
diseases	I

6	O
.	O

Body	B
weight	I
exceeding	B
150	I
Kg	I

1	O
.	O

Patients	O
≥	O
18	O
years	B
-	I
old	I
from	O
"	O
Instituto	O
Teletón	O
Santiago	O
"	O
and	O
"	O
Hospital	O
Clínico	O
Mutual	O
de	O
seguridad	O
"	O
.	O

2	O
.	O

C5	B
to	I
T12	I
spinal	B
cord	I
injury	I
,	O
classified	O
as	O
ISNCSCI	B
grades	B
C	I
and	I
D	I

3	O
.	O

Traumatic	B
and	O
non	B
-	I
traumatic	I
,	O
non	B
-	I
progressive	I
lesions	B

4	O
.	O

Onset	B
>	I
6	I
months	I

5	O
.	O

Ability	B
to	I
ambulate	I
with	I
or	I
without	I
assistive	I
devices	I

6	O
.	O

Ability	B
to	I
follow	I
verbal	I
or	I
visual	I
commands	I

7	O
.	O

Signed	O
informed	O
consent	O

History	O
of	O
severe	O
related	O
adverse	B
event	I
(	O
s	O
)	O
from	O
previous	O
participation	O
in	O
VA	O
-	O
001	O
or	O
VA	O
-	O
006	O
trials	O
or	O
to	O
any	O
smallpox	B
vaccination	I
.	O

Eczema	B
,	O
history	B
of	I
eczema	I
,	O
exfoliative	B
skin	I
conditions	I
,	O
wounds	B
,	O
burns	B
,	O
or	O
other	B
skin	I
conditions	I
at	O
the	O
investigator	O
'	O
s	O
discretion	O
.	O

A	O
history	B
of	I
immunodeficiency	I
.	O

Currently	O
or	O
has	O
recently	B
received	O
radiotherapy	B
or	O
chemotherapy	B
,	O
adrenocorticotropic	B
hormone	I
(	O
ACTH	B
)	O
,	O
corticosteroids	B
,	O
or	O
immunosuppressive	B
drugs	I
.	O

Eye	B
disease	I
treated	O
with	O
topical	B
steroids	I
.	O

Known	B
or	O
suspected	B
disorders	B
of	I
immunoglobulin	I
synthesis	I
.	O

Leukemia	B
,	O
lymphomas	B
of	O
any	O
type	O
,	O
melanoma	B
,	O
or	O
other	O
malignant	B
neoplasms	I
affecting	O
the	O
bone	B
marrow	I
or	O
lymphatic	B
systems	I
.	O

Has	O
been	O
diagnosed	B
with	I
cancer	I
and	O
who	O
will	O
be	O
undergoing	O
chemotherapy	B
or	O
radiation	B
therapy	I
during	B
the	I
vaccination	I
healing	I
time	I
.	O

Is	O
a	O
transplant	B
recipient	I
(	O
except	B
for	O
corneal	B
transplant	I
)	O
.	O

Is	O
pregnant	B
,	O
planning	O
pregnancy	O
or	O
breast	O
feeding	O
(	O
female	B
subjects	O
of	O
childbearing	O
potential	O
must	O
have	O
negative	B
pregnancy	B
test	I
prior	O
to	O
vaccination	B
)	O
.	O

Household	B
or	O
other	O
close	B
/	I
intimate	I
contact	I
(	I
s	I
)	I
under	O
the	O
age	B
of	O
12	O
months	O
.	O

History	O
of	O
allergies	B
to	O
phenol	B
,	O
any	O
of	O
the	O
antibiotics	B
listed	O
in	O
the	O
vaccine	B
content	O
,	O
or	O
any	O
other	O
component	O
of	O
ACAM2000	B
or	O
its	O
diluents	O
.	O

Subjects	O
with	O
kidney	B
disease	I
(	O
except	B
kidney	B
stones	I
)	O
.	O

Subjects	O
with	O
abnormal	B
EKG	B
at	B
screening	I
(	O
if	O
applicable	O
)	O
.	O

To	O
mitigate	O
the	O
risk	O
of	O
enrolling	O
at	O
risk	O
subjects	O
and	O
potentially	O
jeopardizing	O
subject	O
safety	O
an	O
EKG	O
will	O
be	O
performed	O
prior	O
to	O
vaccination	O
with	O
ACAM2000	O
smallpox	O
vaccine	O
in	O
all	O
potential	O
subjects	O
=	O
50	O
years	O
old	O
and	O
for	O
all	O
potential	O
subjects	O
<	O
50	O
with	O
two	O
cardiac	O
risk	O
factors	O
as	O
listed	O
immediately	O
below	O
including	O
;	O
severely	O
or	O
morbidly	O
obese	O
or	O
higher	O
obesity	O
classification	O
(	O
BMI	O
=	O
36	O
)	O
;	O
high	O
blood	O
pressure	O
;	O
high	O
blood	O
cholesterol	O
;	O
diabetes	O
or	O
high	O
blood	O
sugar	O
;	O
a	O
first	O
degree	O
relative	O
who	O
had	O
a	O
heart	O
condition	O
before	O
the	O
age	O
of	O
50	O
;	O
and	O
current	O
tobacco	O
smokers	O
.	O

Severely	B
or	O
morbidly	B
obese	B
or	O
higher	O
obesity	O
classification	O
(	O
BMI	B
=	B
36	I
)	O

High	B
blood	I
pressure	I
diagnosed	O
by	O
a	O
doctor	O

High	B
blood	I
cholesterol	I
diagnosed	O
by	O
a	O
doctor	O

Diabetes	B
or	O
high	B
blood	I
sugar	I
diagnosed	O
by	O
a	O
doctor	O

A	B
first	I
degree	I
relative	I
(	O
for	O
example	O
,	O
mother	B
,	O
father	B
,	O
brother	B
,	O
sister	B
)	O
who	O
had	O
a	O
heart	B
condition	I
before	O
the	O
age	B
of	O
50	B

Currently	O
smokes	O
tobacco	O
(	O
cigarettes	O
)	O

Arrhythmia	B

Syncope	B
related	O
to	O
cardiac	B
disease	I

Previous	B
myocardial	I
infarction	I

Angina	B

Coronary	B
artery	I
disease	I

Congestive	B
heart	I
failure	I

Cardiomyopathy	B

Stroke	B
or	O
transient	B
ischemic	I
attack	I

Myocarditis	B

Pericarditis	B

Chest	B
pain	I
or	O
shortness	B
of	I
breath	I
with	I
activity	I
(	O
such	O
as	O
climbing	O
stairs	O
)	O
,	O
peripheral	B
edema	I
,	O
heart	B
palpitations	I
,	O
dry	B
cough	I
,	O
irregular	B
heartbeat	I
,	O
excessive	B
fatigue	I
,	O
unexplained	O
syncope	B

Other	B
heart	I
conditions	I
being	O
treated	O
by	O
a	O
physician	O

Signed	O
written	O
informed	O
consent	O
.	O

Age	B
18	B
to	I
65	I
.	O

Normal	B
and	O
healthy	B
(	O
immune	O
competent	O
)	O
as	O
determined	O
by	O
medical	B
history	I
,	O
physical	B
exam	I
,	O
vital	B
signs	I
and	O
clinical	B
laboratory	I
tests	I
during	B
the	I
screening	I
period	I
.	O

If	O
all	O
lab	O
results	O
for	O
quantitative	B
IgA	I
immunoglobulin	I
level	I
are	O
lower	B
than	I
15	I
%	I
below	I
normal	I
range	I
,	O
the	O
subject	O
may	O
not	O
proceed	O
further	O
in	O
the	O
screening	O
process	O
.	O

Subject	O
must	O
meet	O
all	O
required	O
subject	O
suitability	O
criteria	O
that	O
pertain	O
to	O
normal	O
source	O
plasma	O
donors	O
.	O

Negative	B
HIV	B
serology	I
during	B
screening	I
period	I
.	O

Subject	O
must	O
have	O
been	O
previously	O
immunized	B
for	O
smallpox	B
,	O
at	O
=	O
3	B
years	I
prior	I
to	I
commencement	I
of	I
screening	I
assessments	I
,	O
and	O
vaccination	O
history	O
must	O
be	O
confirmed	O
by	O
oral	O
or	O
written	O
history	O
and	O
the	O
presence	O
of	O
a	O
visible	O
pathognomonic	O
smallpox	O
vaccination	O
scar	O
.	O

Female	B
subjects	O
of	O
childbearing	B
potential	I
must	O
agree	O
to	O
use	O
highly	O
effective	O
birth	B
control	I
methods	I
.	O

Patients	O
who	O
have	O
previous	B
prostate	B
surgery	I
Patients	O
who	O
have	O
muscle	B
invasive	I
bladder	B
cancer	I

Patients	O
who	O
have	O
non	B
muscle	I
invasive	I
bladder	I
cancer	I
male	B
patients	O
patients	O
between	B
40	I
-	I
80	I
years	I
old	B

Active	B
opioid	B
dependence	I

Acute	B
or	O
chronic	B
pain	B
requiring	O
opioid	B
treatment	I

Acute	B
liver	I
injury	I
(	O
liver	B
aminotransferase	I
concentrations	I
>	B
5	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
)	O

Health	B
condition	I
considered	B
unsafe	I
for	I
inclusion	I
(	O
at	O
discretion	O
of	O
PI	O
and	O
/	O
or	O
attending	O
physician	O
)	O

Lack	B
of	I
capacity	O
or	O
willingness	O
to	O
consent	O

Currently	B
prescribed	O
pharmacotherapy	B
for	O
alcohol	B
dependence	I
(	O
not	B
including	I
treatment	B
of	O
acute	B
alcohol	I
withdrawal	I
syndrome	I
)	O

Previous	B
significant	B
adverse	B
reaction	I
to	O
naltrexone	B
or	O
diluent	B

Pregnant	B
,	O
nursing	B
,	O
or	O
not	B
using	O
effective	B
methods	I
of	O
birth	B
control	I

Prisoners	B
(	O
as	O
defined	O
by	O
Office	B
of	I
Human	I
Research	I
Protection	I
)	O
at	B
the	I
time	I
of	I
enrollment	I
ARE	O
NOT	O
ELIGIBLE	O
for	O
study	O
entry	O
.	O

However	O
,	O
subjects	O
who	O
become	O
prisoners	O
after	O
being	O
enrolled	O
will	O
be	O
included	O
and	O
not	O
be	O
withdrawn	O
from	O
the	O
study	O
.	O
Patients	O
on	O
parole	O
or	O
probation	O
are	O
eligible	O
for	O
enrollment	O
.	O

English	O
or	O
Spanish	O
speaking	O
*	O

Emergency	O
Department	O
patient	O

Aged	B
18	B
-	I
80	I

Have	O
had	O
>	B
4	I
emergency	O
department	O
visits	O
within	B
12	I
months	I
for	O
2	B
consecutive	I
12	B
-	I
month	I
periods	I
.	O

Period	O
of	O
time	O
can	O
be	O
extended	B
by	I
up	I
to	I
6	I
months	I
if	O
incarcerated	B
or	O
institutionalized	B
for	O
≥	O
6	O
months	O
.	O

Meet	O
Diagnostic	B
and	I
Statistical	I
Manual	I
version	I
IV	I
(	I
DSM	I
-	I
IV	I
)	I
criteria	I
for	O
alcohol	B
dependence	I
or	O
&	O
DSM	B
-	I
V	I
criteria	I
for	O
alcohol	B
use	I
disorder	I
,	O
severe	B
.	O

Have	O
≥	B
2	I
days	I
/	I
week	I
of	O
heavy	B
drinking	I
(	O
>	B
4	I
drinks	B
/	I
day	I
)	O

Capable	O
of	O
giving	O
informed	O
consent	O
.	O

Parents	O
refusal	O

Cognitive	B
impairment	I

Difficulty	B
in	I
communication	I
due	O
to	O
language	B
issues	I

Psychiatric	B
disorder	I

Severe	B
systematic	I
disorder	I

Known	B
allergy	I
to	O
any	B
drug	I
used	I

Children	B
undergoing	B
ENT	B
surgery	I
under	O
general	B
anaesthesia	I
.	O

Incompletely	B
cured	I
pre	B
-	I
existing	I
diseases	I
for	O
which	O
it	O
can	O
be	O
assumed	O
that	O
the	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
elimination	O
or	O
effects	O
of	O
the	O
study	O
drugs	O
will	O
not	O
be	O
normal	O

Known	B
or	O
suspected	B
liver	B
diseases	I

Clinically	B
relevant	I
findings	B
(	O
e	O
.	O
g	O
.	O
blood	B
pressure	I
,	O
electrocardiogram	B
(	I
ECG	I
)	I
;	O
physical	O
and	O
gynecological	B
examination	I
,	O
laboratory	B
examination	I
)	O

Body	B
mass	I
index	I
(	I
BMI	I
)	I
:	O
18	B
≤	I
BMI	I
≤	I
32	I
kg	I
/	I
m²	I

Postmenopausal	B
state	I
revealed	O
by	O
:	O

Medical	O
history	O
,	O
if	O
applicable	O
(	O
natural	B
menopause	I
at	B
least	I
12	I
months	I
prior	I
to	I
first	I
study	I
drug	I
administration	I
;	O
or	O
surgical	B
menopause	I
by	O
bilateral	B
ovariectomy	I
at	B
least	I
3	I
months	I
prior	I
to	I
first	I
study	I
drug	I
administration	I
)	O
,	O
in	O
addition	O
:	O
in	O
women	B
<	O
65	O
years	B
old	I
,	O
follicle	B
stimulating	I
hormone	I
(	I
FSH	I
)	I
>	B
40	I
IU	I
/	I
L	I

acute	B
or	O
unstable	B
medical	B
disease	I
,	O

current	O
or	O
past	O
history	O
of	O
psychiatric	B
disease	I
,	O
alcoholism	B
or	O
drug	B
abuse	I
,	O
and	O
other	O
primary	B
sleep	I
disorders	I

DSM	B
-	I
5	I
diagnosis	O
of	O
insomnia	B

NA	O

ASA	B
physical	I
status	I
1	B
or	O
2	B

Written	O
informed	O
consent	O

Cardiovascular	B
disease	I

Pulmonary	B
disease	I

Liver	B
disease	I

CNS	B
disease	I

Alcohol	O
or	O
drug	B
abuse	I

Chronic	B
intake	I
of	O
CNS	B
active	I
drugs	I

Body	B
mass	I
index	I
>	B
35	I

Diabetes	B
mellitus	I

Hypersensitivity	B
or	O
allergy	B
to	O
one	O
of	O
the	O
study	B
drugs	I

Previous	B
antispastic	B
drugs	I

Contraindication	B
for	O
baclofen	B
or	O
toxin	B

Antecedent	B
of	O
epileptic	B
seizure	I

Psychiatric	B
antecedent	B

First	B
single	B
stroke	B
ischaemic	B
or	O
haemorrhagic	B
responsible	O
of	O
an	O
hemiplegia	B

Stoke	B
since	B
less	I
than	I
2	I
month	I

A	O
sufficient	O
understood	O

A	O
spasticity	B
:	O
a	O
Tardieu	B
score	I
upper	B
or	I
equal	I
to	I
2	I
on	O
at	B
least	I
one	I
of	O
the	O
following	O
muscle	B
-	I
triceps	I
surae	I
,	O
flexors	B
of	I
fingers	I
,	O
of	O
wrist	B
and	O
of	O
elbow	B

A	O
free	O
consent	O

Invasively	O
mechanically	B
ventilated	I
>	B
72	I
hours	I
at	O
the	O
time	O
of	O
screening	O
;	O

Patients	O
at	O
potential	O
increased	O
risk	O
of	O
iatrogenic	O
probiotic	O
infection	O
(	O
see	O
Section	O
2	O
.	O
6	O
for	O
detailed	O
explanation	O
)	O
including	O
specific	O
immunocompromised	B
populations	O
(	O
HIV	B
<	O
200	O
CD4	B
cells	O
/	O
µL	O
,	O
those	O
receiving	O
chronic	B
immunosuppressive	B
medications	I
(	O
e	O
.	O
g	O
.	O
,	O
azathioprine	B
,	O
cyclosporine	B
,	O
cyclophosphamide	B
,	O
tacrolimus	B
,	O
methotrexate	B
,	O
mycofenolate	B
,	O
Anti	B
-	I
IL2	I
)	O
,	O
previous	O
transplantation	B
(	O
including	O
stem	O
cell	O
)	O
at	O
any	O
time	O
,	O
malignancy	O
requiring	O
chemotherapy	B
in	O
the	O
last	B
3	I
months	I
,	O
neutropenia	B
[	O
absolute	B
neutrophil	I
count	I
<	B
500	I
]	I
)	O
.	O

However	O
,	O
patients	O
receiving	O
corticosteroids	O
previously	O
or	O
presently	O
or	O
projected	O
to	O
receive	O
corticosteroids	O
are	O
not	O
excluded	O
;	O

Patients	O
at	O
risk	O
for	O
endovascular	O
infection	O
(	O
previously	O
documented	O
rheumatic	B
heart	I
disease	I
,	O
congenital	B
valve	I
disease	I
,	O
surgically	B
repaired	I
congenital	B
heart	I
disease	I
,	O
unrepaired	B
cyanotic	B
congenital	I
heart	I
disease	I
,	O
any	O
intracardiac	B
repair	I
with	O
prosthetic	B
material	I
[	O
mechanical	O
or	O
bio	B
-	I
prosthetic	I
cardiac	I
valves	I
]	I
,	O
previous	O
or	O
current	O
endocarditis	B
,	O
permanent	B
endovascular	B
devices	I
(	O
e	O
.	O
g	O
.	O
,	O
endovascular	B
grafts	I
[	O
e	O
.	O
g	O
.	O
,	O
aortic	B
aneurysm	I
repair	I
,	O
stents	B
involving	O
large	B
arteries	I
such	O
as	O
aorta	O
,	O
femorals	O
and	O
carotids	O
]	O
,	O
inferior	B
vena	I
cava	I
filters	I
,	O
dialysis	B
vascular	I
grafts	I
)	O
,	O
tunnelled	O
(	O
not	O
short	O
-	O
term	O
)	O
hemodialysis	B
catheters	I
,	O
pacemakers	B
or	O
defibrillators	O
.	O

Patients	O
with	O
temporary	O
central	B
venous	I
catheters	I
,	O
central	B
venous	I
dialysis	I
catheters	I
or	O
peripherally	B
inserted	I
central	I
catheters	I
(	O
PICCs	B
)	O
are	O
not	B
excluded	O
and	O
patients	O
with	O
coronary	B
artery	I
stents	I
,	O
coronary	B
artery	I
bypass	I
grafts	I
(	O
CABG	O
)	O
or	O
neurovascular	B
coils	I
are	O
not	B
excluded	O
;	O
patients	O
with	O
mitral	B
valve	I
prolapse	I
or	O
bicuspid	B
aortic	I
valve	I
are	O
not	B
excluded	O
providing	O
they	O
have	O
no	O
other	O
exclusion	O
criteria	O
;	O

Patients	O
with	O
a	O
primary	O
diagnosis	O
of	O
severe	B
acute	B
pancreatitis	I
,	O
without	B
reference	O
to	O
a	O
Ranson	B
score	I
[	O
Ranson	O
1974	O
]	O
)	O
.	O

However	O
,	O
patients	O
with	O
mild	B
or	O
moderate	B
pancreatitis	B
are	O
not	B
excluded	O
;	O

Patients	O
with	O
percutaneous	O
gastric	O
or	O
jejunal	B
feeding	I
tubes	I
already	O
in	O
situ	O
as	O
per	O
Health	O
Canada	O
guidance	O
;	O

Strict	O
contraindication	B
or	O
inability	O
to	O
receive	O
enteral	B
medications	I
;	O

Intent	O
to	O
withdraw	O
advanced	O
life	O
support	O
as	O
per	O
the	O
ICU	O
physician	O
;	O

Previous	O
enrolment	O
in	O
this	O
or	O
current	O
enrolment	O
in	O
a	O
potentially	O
confounding	O
tria	O

Adults	B
=	B
18	I
years	I
of	O
age	B

Admitted	O
to	O
any	O
ICU	O
and	O
receiving	O
invasive	B
mechanical	B
ventilation	I

Anticipated	O
ventilation	B
of	O
=	B
72	I
hours	I
at	O
the	O
time	O
of	O
screening	O
,	O
as	O
per	O
the	O
ICU	O
physician	O
.	O

Other	O
spinal	B
pathology	I
or	O
other	O
associated	B
medical	I
condition	I

Major	B
neurologic	I
developmental	I
delay	I

Need	O
for	O
anterior	B
surgery	I
or	O
for	O
vertebral	B
column	I
resection	I
.	O

Preoperative	B
opioid	B
use	O

Inability	B
to	I
use	I
PCA	B

Adolescent	B
(	O
10	O
-	O
21	O
years	B
)	O
undergoing	O
spinal	B
fusion	I
for	O
idiopathic	B
scoliosis	I
,	O
spondylolisthesis	B
or	O
Scheuermann	B
kyphosis	I
.	O

Posterior	B
spinal	I
fusion	I

No	B
contraindication	B
for	O
Pregabalin	B
use	O

ASA	B
I	B
-	I
III	I

Written	O
informed	O
consent	O

pathological	B
obesity	I

chronic	B
diseases	I
e	O
.	O
g	O
.	O
cerebral	B
palsy	I
,	O
metabolic	B
disease	I
,	O
etc	O
.	O

diseases	B
of	I
red	I
blood	I
cells	I

on	O
medication	O
e	O
.	O
g	O
.	O
steroid	B
,	O
multivitamins	B
,	O
thiamine	B
-	I
containing	I
vitamins	I
,	O
diuretic	B
drugs	I

hemodialysis	B
or	O
peritoneal	B
dialysis	I

bariatric	B
surgery	I

obese	B
:	O
weight	B
for	I
height	I
>	B
median	I
+	I
3	I
standard	I
deviations	I

simple	B
obesity	I

With	O
severe	B
comorbidities	B
,	O
such	O
as	O
cardiovascular	B
disease	I
,	O
chronic	B
obstructive	I
pulmonary	I
disease	I
,	O
diabetes	B
mellitus	I
,	O
and	O
chronic	B
renal	I
dysfunction	I
.	O

With	O
bad	B
compliance	I
or	O
contraindication	B
to	I
enrollment	I
.	O

Pregnant	B
woman	B
or	O
lactating	B
woman	B
.	O

With	O
contraindication	B
to	O
receive	O
adjuvant	B
chemotherapy	I
.	O

The	O
informed	O
consent	O
has	O
been	O
obtained	O
from	O
the	O
patient	O
.	O

With	O
confirmed	O
diagnosis	O
of	O
stage	B
II	I
colon	B
cancer	I
.	O

With	O
moderate	B
/	I
good	I
ECOG	B
health	I
rating	I
(	I
PS	I
)	I
:	O
0	B
-	I
1	I
score	I
.	O

The	O
patient	O
receive	O
no	B
anti	B
-	I
cancer	I
treatment	I
before	O
primary	B
surgery	I
.	O

The	O
patient	O
receive	O
radical	O
operation	O
for	O
colon	B
cancer	I
with	O
negative	O
margin	O
.	O

Women	O
did	O
not	B
have	O
breast	B
cancer	I

do	O
not	B
use	O
tamoxifen	B
or	O
aromatase	B
inhibitor	I

not	B
in	O
menopause	B
and	O
not	B
have	O
hot	B
flashes	I

Menopausal	B
women	B
with	O
breast	B
cancer	I
treated	B
and	O
using	O
tamoxifen	B
or	O
aromatase	B
inhibitor	I
.	O

With	O
hot	B
flashes	I
and	O
with	O
or	O
without	O
active	O
sexual	O
life	O
.	O

Previous	B
thoracic	B
operation	I
in	O
the	O
same	B
side	I
.	O

Thoracoscopic	B
surgery	I
candidate	O
.	O

Over	O
18	O
years	O
old	B
.	O

No	B
known	O
allergy	B
to	O
Bupivacaine	B
.	O

Patient	O
is	O
able	O
to	O
read	O
understand	O
and	O
singe	O
an	O
inform	O
consent	O
.	O

Type	B
1	I
diabetes	I

Treatment	B
with	O
insulin	B

Body	B
weight	I
>	B
140	I
kg	I

HbA1c	B
>	B
75	I
mmol	I
/	I
mol	I

Treatment	O
with	O
GLP	B
-	I
1	I
analogues	I
,	O
Dipeptidyl	B
peptidase	I
-	I
4	I
inhibitors	I
,	O
or	O
glitazones	B

Chronic	B
kidney	I
disease	I

Hepatic	B
disease	I

Pancreatitis	B

Inflammatory	B
bowel	I
disease	I

Osteoporosis	B

Family	O
or	O
personal	B
history	I
of	O
medullary	B
thyroid	I
carcinoma	I

Treatment	B
with	O
glucocorticoids	B

Hormone	B
replacement	I
therapy	I

Diabetic	B
gastroparesis	I

Pregnancy	B
or	O
lactation	B

Informed	O
consent	O

Diagnosis	O
of	O
type	B
2	I
diabetes	I
(	O
HbA1c	B
>	B
48	I
mmol	I
/	I
mol	I
)	O

Age	B
older	B
than	I
30	I
years	I

previous	B
treated	B
dupuytrens	B
contracture	I
same	B
hand	I

more	B
than	I
tree	I
fingers	B
involvement	I

we	O
will	O
not	O
include	O
thumbs	O

other	B
things	I
affecting	B
hand	I
function	I

ASA	B
>	B
3	I

expected	O
to	O
live	O
under	B
five	I
years	I

Tetracycline	B
treatment	O
within	B
two	I
weeks	I

pregnancy	B

nursing	B

allergy	B
to	O
clostridium	O
histolyticum	O

participant	O
in	O
other	O
trial	O

symptomatic	B
Dupuytrens	B
contracture	I
with	O
palpable	B
cord	I
,	O
involving	B
MCP	I
,	O
total	B
contracture	I
size	I
over	B
30	I
degrees	I

Affected	O
by	O
alcohol	O
or	O
drugs	O
during	O
the	O
last	B
month	I
.	O

Untreated	B
severe	B
comorbid	B
psychiatric	O
or	O
somatic	B
illness	I
.	O

Bloodpressure	B
150	B
/	I
95	I
or	I
higher	I
.	O

Irregular	B
pulse	B
,	O
or	O
pulse	B
100	B
or	I
higher	I
.	O

No	O
counter	O
indications	O
according	O
to	O
the	O
Medikinet	O
pill	O
.	O

Concurrent	O
clinical	O
diagnosis	O
that	O
significantly	O
could	O
affect	O
test	O
performance	O
.	O

Concurrent	O
prescription	O
of	O
medicines	B
for	O
ADHD	B
or	O
medicines	O
that	O
significantly	O
could	O
affect	O
test	O
performance	O
.	O

18	O
years	O
old	B
or	O
older	O
.	O

ADHD	B
is	O
diagnosed	O
according	O
to	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
fifth	O
edition	O
(	O
DSM	B
-	I
5	I
criteria	O
)	O
.	O

Substance	B
Use	I
Disorder	I
is	O
diagnosed	O
according	O
to	O
DSM	B
-	I
5	I
criteria	O
.	O

Qb	B
-	I
score	I
1	B
.	I
3	I
or	I
higher	I
on	O
at	O
least	O
one	O
of	O
the	O
weighted	O
summary	O
parameters	O
QbActivity	O
,	O
QbInattention	O
or	O
QbImpulsivity	O
on	O
the	O
QbTest	O
.	O

Participants	O
are	O
given	O
their	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O
.	O

NA	O

Adult	B
patients	O
(	O
age	B
=	B
18	I
)	O

Diagnosed	O
by	O
preoperative	B
imaging	B
modalities	I
to	O
have	O
a	O
brain	B
tumor	I
(	O
including	O
metastatic	B
brain	I
tumors	I
)	O
or	O
vascular	B
lesions	I
(	O
aneurysm	B
,	O
arteriovenous	B
malformation	I
or	O
arteriovenous	B
fistula	I
)	O
requiring	O
surgical	B
intervention	I
.	O

The	O
patient	O
is	O
determined	O
by	O
a	O
board	O
certified	O
neurosurgeon	O
to	O
have	O
a	O
tumor	B
or	O
vascular	B
lesion	I
that	O
would	O
take	O
up	O
fluorescein	B

Patient	O
or	O
legally	O
authorized	O
representative	O
provides	O
written	O
informed	O
consent	O
to	O
enroll	O
in	O
this	O
study	O

Previous	O
treatment	O
with	O
anti	B
-	I
VEGF	I
drugs	I
or	O
corticosteroid	B
or	O
grid	B
laser	I
photocoagulation	I
(	I
study	O
eye	O
)	O

History	O
of	O
vitrectomy	B
surgery	I
,	O
submacular	B
surgery	I
,	O
or	O
other	O
surgical	B
intervention	I
for	O
RVO	B

Ocular	O
disorders	O
in	O
the	O
study	O
eye	O
that	O
may	O
confound	O
interpretation	O
of	O
study	O
results	O

BCVA	B
over	B
77	I
letters	I
between	O
screening	O
and	O
Day	O
0	O

The	O
pregnant	O
or	O
lactating	O
woman	O

Signed	O
informed	O
consent	O
form	O

Macula	B
edema	I
secondary	O
to	O
BRVO	B

BCVA	B
of	O
77	B
to	I
20	I
letters	I
assessed	O
with	O
the	O
use	O
of	O
ETDRS	O
charts	O

CRT	B
<	O
U	O
+	O
2267	O
>	O
250µm	B

Prior	O
treatment	O
with	O
cisplatin	B
before	B
randomization	I

Uncontrolled	B
concurrent	B
disease	I

Pregnancy	B

Age	B
>	B
18	I
years	I

Eastern	B
Cooperative	I
Oncology	I
Group	I
score	B
0	I
-	I
2	I

First	O
Diagnosed	O
Head	B
and	I
neck	I
cancer	I
and	O
plan	O
for	O
treatment	O
with	O
cisplatin	B

Serum	B
creatinine	I
=	B
1	I
.	I
5	I
mg	I
/	I
dl	I
or	O
eGFR	B
=	B
60	I
(	I
ml	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
)	I

pregnant	B
or	O
nursing	B
woman	B

serious	B
concomitant	B
illness	B
and	O
malignant	B
tumor	I
of	O
any	B
kind	I

history	B
of	I
hypersensitivity	B
to	O
test	B
drugs	I

serious	B
bleeding	B
during	B
the	I
course	I
of	I
the	I
ulcer	I

previous	B
gastric	B
surgery	I

receiving	O
bismuth	B
salts	I
,	O
PPIs	B
,	O
or	O
antibiotics	B
in	B
the	I
previous	I
month	I
.	O

Participants	O
having	O
H	B
.	I
pylori	I
related	I
chronic	B
gastritis	I
with	O
/	O
without	O
peptic	B
ulcers	I
who	O
are	O
aged	B
greater	B
than	I
20	I
years	I
old	I
and	O
are	O
willing	O
to	O
received	O
eradication	B
therapy	I
.	O

pregnant	B

30	B
min	I
or	I
more	I
of	O
moderate	O
to	O
vigorous	O
activity	O
more	B
than	I
3	I
times	I
per	I
week	I

cardiovascular	B
disease	I

physical	B
limitations	I
that	O
might	O
be	O
aggravated	O
by	O
moderate	B
physical	O
activity	O

planning	O
to	O
move	O
in	B
next	I
12	I
-	I
24	I
months	I

diabetic	B

Mexican	B
-	I
american	I

Female	B

BMI	B
30	B
-	I
42	I

willingness	O
to	O
complete	O
protocol	O

pre	B
-	I
diabetic	I

English	O
or	O
Spanish	O
literate	O

Females	B
who	O
are	O
pregnant	B
or	O
nursing	B
.	O

Patients	O
not	B
scheduled	O
for	O
trans	B
-	I
jugular	I
liver	I
biopsy	I

Patients	O
who	O
have	O
received	O
an	O
investigational	O
drug	O
in	O
the	O
30	O
days	O
before	O
study	O
drug	O
administration	O
,	O
or	O
will	O
receive	O
one	O
within	O
72	O
h	O
afterwards	O
,	O
.	O

Patients	O
with	O
known	O
or	O
suspected	O
right	O
-	O
to	O
-	O
left	O
,	O
bi	O
-	O
directional	O
,	O
or	O
transient	B
right	I
-	I
to	I
-	I
left	I
cardiac	I
shunts	I

Patients	O
with	O
pulmonary	B
hypertension	I
or	O
unstable	B
cardiopulmonary	I
conditions	I

Patients	O
currently	B
on	O
chemotherapy	B
or	O
with	O
other	B
primary	B
cancers	I
requiring	O
systemic	O
or	O
hepatic	B
loco	I
-	I
regional	I
treatment	I
.	O

Patients	O
who	O
are	O
medically	B
unstable	I
,	O
patients	O
who	O
are	O
seriously	O
or	O
terminally	B
ill	I
,	O
and	O
patients	O
whose	O
clinical	B
course	I
is	I
unpredictable	I
.	O

For	O
example	O
:	O

Patients	O
on	O
life	B
support	I
or	O
in	O
a	O
critical	O
care	O
unit	O
.	O

Patients	O
with	O
unstable	B
occlusive	I
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
crescendo	O
angina	O
)	O

Patients	O
with	O
clinically	B
unstable	I
cardiac	B
arrhythmias	I
,	O
such	O
as	O
recurrent	B
ventricular	B
tachycardia	I
.	O

Patients	O
with	O
uncontrolled	B
congestive	B
heart	I
failure	I
(	O
NYHA	B
Class	B
IV	I
)	O

Patients	O
with	O
recent	B
cerebral	B
hemorrhage	I
.	O

Patients	O
who	O
have	O
undergone	O
surgery	B
within	O
24	O
hours	O
prior	O
to	O
the	O
study	O
sonographic	B
examination	I
.	O

Patients	O
with	O
a	O
history	O
of	O
anaphylactic	B
allergy	I
to	O
eggs	B
or	O
egg	B
products	I
,	O
manifested	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
symptoms	O
:	O
generalized	B
urticaria	I
,	O
difficulty	B
in	I
breathing	I
,	O
swelling	B
of	I
the	I
mouth	I
and	O
throat	O
,	O
hypotension	B
,	O
or	O
shock	B
.	O

(	O
Subjects	O
with	O
nonanaphylactic	O
allergies	O
to	O
eggs	O
or	O
egg	O
products	O
may	O
be	O
enrolled	O
in	O
the	O
study	O
,	O
but	O
must	O
be	O
watched	O
carefully	O
for	O
1	O
h	O
following	O
the	O
administration	O
of	O
SONAZOID	O
)	O
.	O

Patients	O
with	O
congenital	B
heart	I
defects	I
.	O

Patients	O
with	O
severe	B
emphysema	B
,	O
pulmonary	B
vasculitis	I
,	O
or	O
a	O
history	O
of	O
pulmonary	B
emboli	I
.	O

Patients	O
with	O
respiratory	B
distress	I
syndrome	I

Patients	O
with	O
thrombosis	B
within	O
the	O
hepatic	O
,	O
portal	O
,	O
or	O
mesenteric	B
veins	I
.	O

Be	O
scheduled	O
for	O
trans	B
-	I
jugular	I
liver	I
biopsy	I
the	O
day	O
of	O
the	O
ultrasound	B
procedure	I
.	O

Be	O
at	B
least	I
21	I
years	I
of	O
age	B
.	O

Be	O
medically	B
stable	I
.	O

If	O
a	O
female	B
of	O
child	B
-	I
bearing	I
potential	I
,	O
must	O
have	O
a	O
negative	B
pregnancy	B
test	I
.	O

Be	O
conscious	O
and	O
able	O
to	O
comply	O
with	O
study	O
procedures	O
.	O

Have	O
read	O
and	O
signed	O
the	O
IRB	O
-	O
approved	O
Informed	O
Consent	O
form	O
for	O
participating	O
in	O
the	O
study	O
.	O

pregnant	B
or	O
nursing	B
woman	B

serious	B
concomitant	B
illness	B
and	O
malignant	B
tumor	I
of	O
any	B
kind	I

history	B
of	O
hypersensitivity	B
to	O
test	B
drugs	I

serious	B
bleeding	B
during	O
the	O
course	O
of	O
the	O
ulcer	B

previous	B
gastric	B
surgery	I

receiving	O
bismuth	B
salts	I
,	O
PPIs	B
,	O
or	O
antibiotics	B
in	B
the	I
previous	I
month	I
.	O

Participants	O
having	O
H	B
.	I
pylori	I
related	I
chronic	B
gastritis	I
with	O
/	O
without	O
peptic	B
ulcers	I
who	O
are	O
aged	B
greater	B
than	I
20	I
years	I
old	I
and	O
are	O
willing	O
to	O
received	O
eradication	B
therapy	I
.	O

Newborns	B
of	O
substance	B
abusing	I
mothers	B
.	O

Newborns	B
with	O
any	O
contraindications	B
to	O
routine	O
circumcision	B
,	O
anatomical	O
or	O
hematologic	O
.	O

Apgar	B
score	I
at	B
5	I
minutes	I
>	B
7	I

birthweight	B
greater	B
than	I
2	I
.	I
4	I
kg	I

Age	B
of	O
at	B
least	I
10	I
hours	I

At	B
least	I
one	I
void	O
.	O

Ongoing	O
acute	B
kidney	I
injury	I
Stage	B
2	B
/	I
3	I

History	B
of	O
kidney	B
transplant	I

=	B
18	I
years	I

High	B
risk	I
patients	O
:	O
General	B
Surgery	I
AKI	I
Risk	I
Index	I
Class	B
III	I
,	I
IV	I
or	I
V	I

Major	B
abdominal	I
surgery	I

A	O
history	B
of	O
life	B
-	I
threatening	I
asthma	B
defined	O
for	O
this	O
protocol	O
as	O
an	O
asthma	B
episode	I
that	O
required	O
intubation	B
,	O
hypercapnea	B
requiring	O
non	B
-	I
invasive	I
ventilatory	I
support	I
,	O
respiratory	B
arrest	I
,	O
hypoxic	B
seizures	I
or	O
asthma	B
-	I
related	I
syncopal	I
episode	I
(	O
s	O
)	O
.	O

Subjects	O
with	O
a	O
history	B
of	O
asthma	B
exacerbation	I
requiring	O
the	O
use	O
of	O
systemic	B
corticosteroids	I
(	O
tablets	O
,	O
suspension	O
,	O
or	O
injection	O
)	O
for	B
at	I
least	I
3	I
days	I
or	O
a	O
depot	B
corticosteroid	I
injection	I
or	O
emergency	B
room	I
attendance	I
(	O
within	B
3	I
months	I
)	O
or	O
requiring	O
hospitalization	B
for	O
asthma	B
(	O
within	B
6	I
months	I
)	O
prior	O
to	O
screening	O
.	O

Significant	B
,	O
non	B
-	I
reversible	I
active	B
pulmonary	B
disease	I
(	O
e	O
.	O
g	O
.	O
cystic	B
fibrosis	I
,	O
bronchiectasis	B
,	O
tuberculosis	B
)	O
.	O

Culture	B
-	O
documented	O
or	O
suspected	O
bacterial	O
or	O
viral	B
infection	I
of	I
the	I
upper	I
or	I
lower	I
respiratory	I
tract	I
,	O
sinus	O
or	O
middle	O
ear	O
that	O
is	O
not	B
resolved	B
within	B
4	I
weeks	I
of	I
Visit	I
1	I
and	O
led	O
to	O
a	O
change	O
in	O
asthma	B
management	I
or	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
is	O
expected	O
to	O
affect	O
the	O
subject	O
'	O
s	O
asthma	O
status	O
or	O
the	O
subject	O
'	O
s	O
ability	O
to	O
participate	O
in	O
the	O
study	O
.	O

Any	O
fracture	B
in	I
the	I
leg	I
to	O
be	O
measured	O
within	B
6	I
months	I
prior	I
to	I
the	I
screening	I
visit	I
.	O

Any	O
metabolic	B
disorders	I
or	O
other	B
diseases	I
that	O
may	B
impact	I
on	I
normal	I
growth	I
patterns	I
.	O

No	B
major	B
surgery	I
requiring	O
general	B
anaesthesia	I
for	B
at	I
least	I
3	I
months	I
prior	I
to	I
the	I
screening	I
visit	I
.	O

No	B
febrile	B
illnesses	I
with	O
temperature	B
>	B
39	I
degree	I
celsius	I
for	B
more	I
than	I
five	I
consecutive	I
days	I
within	B
the	I
week	I
preceding	I
the	I
Screening	I
Visit	I
.	O

Any	O
significant	B
abnormality	B
or	O
medical	B
condition	I
identified	O
at	O
the	O
screening	O
medical	O
assessment	O
(	O
including	O
serious	O
psychological	O
disorder	O
)	O
that	O
in	O
the	O
Investigator	O
'	O
s	O
opinion	O
,	O
preclude	O
entry	O
into	O
the	O
study	O
due	O
to	O
risk	O
to	O
the	O
subject	O
or	O
that	O
may	O
interfere	O
with	O
the	O
outcome	O
of	O
the	O
study	O
.	O

Clinical	O
visual	B
evidence	I
of	O
candidiasis	B
at	B
Visit	I
1	I
(	I
Screening	I
)	I
.	O

Use	O
of	O
any	O
of	O
the	O
prohibited	B
medications	I
listed	I
in	I
protocol	I
.	O

Strenuous	B
physical	I
exercise	I
within	B
3	I
hours	I
of	I
Visit	I
1	I
(	I
Screening	I
)	I

Drug	B
allergies	I
:	O
Any	O
adverse	B
reaction	I
including	O
immediate	O
or	O
delayed	B
hypersensitivity	I
to	O
any	O
intranasal	O
,	O
inhaled	O
,	O
or	O
systemic	B
corticosteroid	I
therapy	O
.	O

Known	O
or	O
suspected	O
sensitivity	B
to	O
the	O
constituents	B
of	I
the	I
ELLIPTA	I
Inhaler	I
(	O
i	O
.	O
e	O
.	O
,	O
lactose	B
,	O
FF	B
)	O
.	O

Milk	B
Protein	I
Allergy	I
:	O
History	O
of	O
severe	B
milk	B
protein	I
allergy	I
.	O

The	O
subject	O
has	O
participated	O
in	O
a	O
clinical	O
trial	O
and	O
has	O
received	O
an	O
investigational	O
product	O
within	O
the	O
following	O
time	O
period	O
prior	O
to	O
the	O
first	O
dosing	O
day	O
in	O
the	O
current	O
study	O
:	O
30	O
days	O
,	O
5	O
half	O
-	O
lives	O
or	O
twice	O
the	O
duration	O
of	O
the	O
biological	O
effect	O
of	O
the	O
investigational	O
product	O
(	O
whichever	O
is	O
longer	O
)	O
.	O

Exposure	O
to	O
more	B
than	I
4	I
investigational	B
medicinal	I
products	I
within	B
12	I
months	I
prior	I
to	I
the	I
first	I
dosing	I
day	I
.	O

Unable	O
to	O
use	O
the	O
ELLIPTA	B
inhaler	I
and	O
peak	B
flow	I
meter	I
correctly	O
.	O

An	O
affiliation	O
with	O
the	O
Investigator	O
site	O
:	O
the	O
parents	O
/	O
guardians	O
or	O
child	O
is	O
an	O
immediate	O
family	O
member	O
of	O
the	O
participating	O
Investigator	O
,	O
sub	O
-	O
Investigator	O
,	O
study	O
coordinator	O
,	O
or	O
employee	O
of	O
the	O
participating	O
Investigator	O
.	O

The	O
Parent	O
or	O
Guardian	O
has	O
a	O
history	O
of	O
psychiatric	O
disease	O
,	O
intellectual	O
deficiency	O
,	O
substance	O
abuse	O
or	O
other	O
condition	O
(	O
e	O
.	O
g	O
.	O
inability	O
to	O
read	O
,	O
comprehend	O
or	O
write	O
)	O
which	O
may	O
affect	O
:	O
validity	O
of	O
consent	O
to	O
participate	O
in	O
the	O
study	O
;	O
adequate	O
supervision	O
of	O
the	O
subject	O
during	O
the	O
study	O
;	O
compliance	O
of	O
subject	O
with	O
study	O
medication	O
and	O
study	O
procedures	O
(	O
e	O
.	O
g	O
.	O
completion	O
of	O
daily	O
diary	O
,	O
attending	O
scheduled	O
clinic	O
visits	O
)	O
;	O
subject	O
safety	O
and	O
well	O
-	O
being	O
.	O

Children	O
in	O
care	O
:	O
Children	O
who	O
are	O
wards	O
of	O
the	O
government	O
or	O
state	O
are	O
not	O
eligible	O
for	O
participation	O
in	O
this	O
study	O
.	O

Aged	B
5	B
years	I
to	I
less	I
than	I
12	I
years	I
at	B
Visit	I
1	I
.	O

At	O
least	O
15	O
(	O
25	O
%	O
)	O
children	O
of	O
the	O
total	O
study	O
population	O
must	O
be	O
aged	O
5	O
to	O
less	O
than	O
8	O
years	O
.	O

Male	B
or	O
pre	B
-	I
menarchial	I
female	B
subjects	O
.	O

Subjects	O
must	O
be	O
pre	B
-	I
adolescent	I
without	B
any	I
signs	B
of	I
puberty	I
(	O
Tanner	B
Stage	I
1	B
)	O
.	O

Normal	B
range	I
for	O
their	O
height	B
and	O
weight	B
.	O

Weight	B
and	O
height	B
measurements	O
should	O
fall	O
within	B
the	I
percentile	I
range	I
3	I
-	I
97	I
%	I
of	O
normal	O
values	O
for	O
age	O
according	O
to	O
Danish	O
growth	O
charts	O
.	O

Have	O
a	O
documented	O
diagnosis	O
of	O
persistent	B
asthma	I
,	O
as	B
defined	I
by	I
the	I
National	I
Institutes	I
of	I
Health	I
for	O
at	B
least	I
3	I
months	I
prior	I
to	I
the	I
Screening	I
Visit	I
.	O

A	O
pre	B
-	I
bronchodilatory	I
forced	B
expiratory	I
flow	I
in	I
1	I
second	I
(	I
FEV1	I
)	I
at	B
Visit	I
1	I
(	I
Screening	I
)	I
>	B
=	I
80	I
%	I
predicted	I
.	O

There	O
should	O
be	O
no	B
Short	B
acting	I
beta	I
-	I
agonist	I
(	I
SABA	I
)	I
use	O
within	B
4	I
hours	I
of	I
this	I
measurement	I
.	O

Using	O
one	O
of	O
the	O
following	O
asthma	B
therapies	I
prior	B
to	I
entry	I
into	I
the	I
study	I
:	O
SABA	B
inhaler	I
alone	O
(	O
e	O
.	O
g	O
.	O
salbutamol	B
)	O
on	O
an	O
as	O
required	O
basis	O
and	O
/	O
or	O
Regular	O
non	O
-	O
inhaled	O
corticosteroid	O
(	O
ICS	O
)	O
controller	O
medications	O
for	O
asthma	O
(	O
e	O
.	O
g	O
.	O
cromones	B
or	O
leukotriene	B
receptor	I
antagonists	I
)	O
and	O
/	O
or	O
Previously	O
treated	O
with	O
ICS	B
(	O
equipotent	O
to	O
inhaled	O
budesonide	B
<	B
=	I
400	I
micrograms	I
(	I
mcg	I
)	I
total	O
daily	O
dose	O
)	O
.	O

There	O
must	O
be	O
no	B
ICS	B
use	O
within	B
2	I
weeks	I
of	I
Visit	I
1	I
(	I
Screening	I
)	I
.	O

Able	O
to	O
replace	O
their	O
current	O
SABA	B
treatment	O
with	O
study	O
supplied	O
rescue	B
SABA	I
provided	O
at	O
Visit	O
1	O
for	O
use	O
as	O
needed	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Written	O
informed	O
consent	O
from	O
at	O
least	O
one	O
parent	O
/	O
care	O
giver	O
(	O
legal	O
guardian	O
)	O
and	O
accompanying	O
informed	O
assent	O
from	O
the	O
subject	O
(	O
where	O
the	O
subject	O
is	O
able	O
to	O
provide	O
assent	O
)	O
prior	O
to	O
admission	O
to	O
the	O
study	O
:	O
(	O
1	O
)	O
If	O
applicable	O
,	O
subject	O
must	O
be	O
able	O
and	O
willing	O
to	O
give	O
assent	O
to	O
take	O
part	O
in	O
the	O
study	O
according	O
to	O
the	O
local	O
requirement	O
.	O

The	O
study	O
investigator	O
is	O
accountable	O
for	O
determining	O
a	O
child	O
'	O
s	O
capacity	O
to	O
assent	O
to	O
participation	O
in	O
a	O
research	O
study	O
,	O
taking	O
into	O
consideration	O
any	O
standards	O
set	O
by	O
the	O
responsible	O
independent	O
ethics	O
committee	O
(	O
IEC	O
)	O
.	O

(	O
2	O
)	O
Subject	O
and	O
their	O
legal	O
guardian	O
(	O
s	O
)	O
understand	O
that	O
the	O
study	O
requires	O
them	O
to	O
be	O
treated	O
on	O
an	O
outpatient	O
basis	O
.	O

(	O
3	O
)	O
Subject	O
and	O
their	O
legal	O
guardian	O
(	O
s	O
)	O
understand	O
that	O
they	O
must	O
comply	O
with	O
study	O
medication	O
and	O
study	O
assessments	O
including	O
recording	O
of	O
peak	O
expiratory	O
flow	O
and	O
rescue	O
SABA	O
use	O
,	O
attending	O
scheduled	O
study	O
visits	O
,	O
and	O
being	O
accessible	O
by	O
a	O
telephone	O
call	O
.	O

NA	O

Children	O
born	O
outside	O
the	O
cluster	O
,	O
and	O
returning	O
more	O
than	O
72	O
hours	O
after	O
the	O
delivery	O

Children	O
that	O
the	O
nurse	O
evaluates	O
to	O
die	O
within	O
the	O
next	O
24	O
hours	O
.	O

Active	B
bleeding	B
without	O
control	O
;	O

Receiving	O
nasal	O
or	O
facial	B
surgery	I
recently	O
;	O

With	O
severe	B
cardio	B
-	I
pulmonary	I
dysfunction	I
,	O
such	O
as	O
left	B
heart	I
failure	I
,	O
unstable	B
arrhythmia	B
,	O
etc	O
.	O

With	O
other	O
respiratory	B
diseases	I
:	O
such	O
as	O
active	B
pulmonary	B
tuberculosis	I
,	O
non	O
-	O
tuberculosis	O
mycobacteria	O
(	O
NTM	B
)	O
pulmonary	O
disease	O
,	O
pulmonary	B
aspergillosis	I
,	O
etc	O
.	O

Be	O
allergic	B
to	O
amikacin	B

Age	B
=	B
18	I
years	I
and	I
=	I
80	I
years	I
;	O

Patients	O
with	O
non	B
-	I
cystic	I
fibrosis	I
bronchiectasis	I
diagnosed	O
by	O
high	B
-	I
resolution	I
CT	I
;	O

Are	O
sensitive	B
to	O
amikacin	B
;	O

Acute	B
exacerbation	I
of	I
bronchiectasis	I
;	O

Capable	O
of	O
the	O
completion	O
of	O
bronchoscopy	O
,	O
alveolar	O
lavage	O
,	O
pulmonary	O
function	O
testing	O
etc	O
;	O

Willing	O
to	O
join	O
in	O
and	O
sign	O
the	O
informed	O
consent	O
form	O
.	O

Patients	O
with	O
a	O
history	B
of	O
drug	B
abuse	I
;	O

preoperative	B
history	B
of	O
schizophrenia	B
,	O
epilepsy	B
,	O
parkinsonism	B
,	O
use	O
of	O
cholinesterase	B
inhibitor	I
,	O
inability	B
to	I
communicate	I
in	O
the	O
preoperative	O
period	O
(	O
coma	B
,	O
profound	B
dementia	I
,	O
or	O
language	B
barrier	I
)	O
.	O

age	B
>	B
17	I
and	I
<	I
60	I
years	I
;	O

American	B
Society	I
of	I
Anesthesiology	I
(	I
ASA	I
)	I
I	B
-	I
III	I
;	O

admitted	O
for	O
living	B
donor	I
renal	I
transplantation	I
.	O

1	O
.	O

Patients	O
with	O
other	B
uncontrolled	I
infections	I
(	O
see	O
2	O
.	O
3	O
.	O
2	O
for	O
definitions	O
)	O

2	O
.	O

Patients	O
who	O
received	O
ATG	B
,	O
Campath	B
,	O
or	O
other	O
T	B
cell	I
immunosuppressive	I
monoclonal	I
antibodies	I
in	B
the	I
last	I
28	I
days	I

3	O
.	O

Received	O
donor	B
lymphocyte	I
infusion	I
in	B
last	I
28	I
days	I

4	O
.	O

Diagnosis	O
of	O
Omenn	B
'	I
s	I
syndrome	I
or	O
MHC	B
class	I
I	I
deficiency	I

5	O
.	O

Active	B
and	O
uncontrolled	B
malignancy	B

6	O
.	O

Pregnant	B
or	O
lactating	B

7	O
.	O

Unable	B
to	O
wean	B
steroids	B
to	O
≤	B
0	I
.	I
5	I
mg	I
/	I
kg	I
/	I
day	I
prednisone	B
.	O

8	O
.	O

Patients	O
with	O
Grade	B
3	I
hyperbilirubinemia	B

1	O
.	O

Diagnosis	O
of	O
primary	B
immunodeficiency	I
with	O
established	O
plan	O
to	O
undergo	O
myeloablative	O
or	O
non	B
-	I
myeloablative	I
allogeneic	I
hematopoietic	I
stem	I
cell	I
transplant	I
for	O
treatment	O
thereof	O
or	O
diagnosis	O
of	O
a	O
form	O
of	O
primary	B
immunodeficiency	I
for	O
which	O
hematopoietic	B
stem	I
cell	I
transplantation	I
is	O
not	B
indicated	I
.	O

2	O
.	O

Active	O
infection	O
with	O
EBV	B
,	O
CMV	B
,	O
and	O
/	O
or	O
Adenovirus	B
,	O
unable	B
to	I
be	I
successfully	I
controlled	I
with	O
standard	B
therapy	I
.	O

3	O
.	O

Steroids	B
less	B
than	I
0	I
.	I
5	I
mg	I
/	I
kg	I
/	I
day	I
prednisone	B

4	O
.	O

Karnofsky	B
/	I
Lansky	I
score	I
of	O
≥	B
50	I

5	O
.	O

ANC	B
greater	B
than	I
500	I
/	I
µL	I
.	O

6	O
.	O

Bilirubin	B
<	B
2x	I
,	O
AST	B
<	B
3x	I
,	O
Serum	B
creatinine	I
<	B
2x	I
upper	I
limit	I
of	I
normal	I
,	O
Hgb	B
>	B
8	I
.	I
0	I

7	O
.	O

Pulse	O
oximetry	O
of	O
>	B
90	I
%	I
on	O
room	O
air	O

8	O
.	O

Negative	B
pregnancy	B
test	I
(	O
if	O
female	B
of	O
childbearing	B
potential	I
)	O

9	O
.	O

Patient	O
or	O
parent	O
/	O
guardian	O
capable	O
of	O
providing	O
informed	O
consent	O
.	O

no	B
confirmation	O
of	O
the	O
gestational	B
age	I

ruptured	B
membranes	I

painful	B
regular	I
uterine	I
contractions	I

major	B
fetal	B
abnormalities	I

gestational	B
age	I
between	B
20	I
weeks	I
and	I
23	I
weeks	I
and	I
6	I
days	I

singleton	B
pregnancies	I

Patients	O
will	O
be	O
excluded	O
if	O
they	O
have	O
had	O
exposure	O
to	O
a	O
total	O
daily	O
dose	O
of	O
MET	B
1000	B
mg	I
bid	I
for	O
at	B
least	I
2	I
weeks	I
in	I
the	I
past	I
3	I
months	I
;	O

Patients	O
will	O
be	O
excluded	O
if	O
they	O
could	O
not	B
tolerate	I
MET	B
during	O
the	O
recommended	O
titration	O
schedule	O
outlined	O
in	O
the	O
protocol	O
;	O

Major	O
neurological	O
or	O
medical	O
illnesses	O
that	O
affect	O
weight	O
gain	O
(	O
e	O
.	O
g	O
.	O
,	O
unstable	B
thyroid	B
disease	I
)	O
or	O
require	O
a	O
systemic	O
medication	O
that	O
might	O
impact	O
weight	O
or	O
glucose	O
regulation	O
(	O
e	O
.	O
g	O
.	O
,	O
diabetes	B
mellitus	I
[	O
insulin	B
]	O
,	O
chronic	B
renal	I
failure	I
[	O
steroids	B
]	O
)	O
;	O

Fasting	B
glucose	I
=	B
126	I
mg	I
/	I
dL	I
on	O
2	B
occasions	I
during	O
screening	O
indicating	O
need	O
for	O
prompt	O
treatment	O
;	O

If	O
lab	O
results	O
are	O
available	O
in	O
the	O
last	O
6	O
months	O
,	O
then	O
a	O
serum	B
creatinine	I
=	B
1	I
.	I
3	I
mg	I
/	I
dL	I
on	O
2	B
occasions	O
during	O
screening	O
and	O
/	O
or	O
follow	O
-	O
up	O
,	O
indicating	O
potential	O
impairment	O
of	O
renal	O
functioning	O
;	O

Pregnant	O
or	O
breast	O
feeding	O
;	O

Children	O
and	O
caregivers	O
who	O
are	O
unable	O
to	O
complete	O
assessments	O
for	O
any	O
reason	O
;	O

Inpatient	B
or	O
outpatient	B
age	B
8	B
-	I
19	I
years	I
inclusive	O
;	O
participants	O
must	O
live	O
with	O
a	O
parent	O
,	O
guardian	O
,	O
or	O
caregiver	O
;	O

Fluent	O
in	O
English	O
;	O

Diagnosed	O
or	O
told	O
by	O
a	O
clinician	O
that	O
they	O
have	O
any	O
of	O
the	O
following	O
bipolar	B
spectrum	I
disorders	I
(	O
BSD	B
)	O
:	O
bipolar	B
I	I
,	O
bipolar	B
II	I
,	O
unspecified	B
bipolar	I
and	I
related	I
disorders	I
,	O
Disruptive	B
Mood	I
Dysregulation	I
Disorder	I
(	O
DMDD	B
)	O
,	O
cyclothymic	B
disorder	I
,	O
other	B
specified	I
bipolar	I
and	I
related	I
disorders	I
,	O
as	O
well	O
as	O
mood	B
disorder	I
not	I
otherwise	I
specified	I
(	O
if	O
diagnosed	O
in	O
the	O
past	O
as	O
per	O
DSM	O
-	O
IV	O
)	O
;	O

Body	B
mass	I
index	I
>	B
85	I
%	I
ile	I
for	O
age	O
and	O
sex	O
by	O
standard	O
growth	O
charts	O
;	O

Received	O
a	O
new	O
or	O
ongoing	O
prescription	O
for	O
at	B
least	I
one	I
SGA	B
(	O
i	O
.	O
e	O
.	O
,	O
olanzapine	B
,	O
clozapine	B
,	O
risperidone	B
,	O
quetiapine	B
,	O
aripiprazole	B
,	O
ziprasidone	B
,	O
iloperidone	B
,	O
lurasidone	B
,	O
paliperidone	B
,	O
brexpiprazole	B
or	O
cariprazine	B
)	O
that	O
is	O
not	O
prescribed	O
as	O
a	O
PRN	O
medication	O
;	O

Major	B
depressive	I
disorder	I
with	O
psychotic	O
features	O

Traumatic	B
Brain	I
Injury	I
(	I
TBI	I
)	I
with	O
a	O
clear	O
impact	B
on	I
activities	I
of	I
daily	I
living	I

Developmental	B
delay	I
,	O
intellectual	B
deficit	I
,	O
and	O
/	O
or	O
severe	B
educational	I
disability	I
resulting	O
in	O
some	O
dependence	B
for	I
activities	I
of	I
daily	I
living	I

Ongoing	B
substance	B
use	I
disorder	I
with	O
significant	O
impact	B
on	I
activities	I
of	I
daily	I
living	I
.	O

Difficult	O
or	O
impossible	O
to	O
determine	O
whether	O
cognitive	O
or	O
functional	O
decline	O
is	O
due	O
to	O
substance	O
use	O
or	O
HIV	O
,	O
or	O
both	O

Evidence	O
of	O
intoxication	B
or	O
withdrawal	B
during	O
the	O
screening	O
evaluation	O

Central	B
nervous	I
system	I
(	I
CNS	I
)	I
infections	I
or	O
opportunistic	O
conditions	O
:	O
brain	B
abscess	I
(	O
bacterial	B
,	O
mycobacterial	B
,	O
fungal	B
or	O
Toxoplasma	B
)	O
,	O
meningitis	B
with	O
persistent	B
neurologic	B
impairment	I
,	O
primary	B
CNS	B
lymphoma	I
,	O
progressive	B
multifocal	I
leukoencephalopathy	I
(	I
PML	I
)	I
,	O
or	O
another	B
structural	B
brain	I
lesion	I
with	O
neurological	B
sequelae	I

Other	B
CNS	B
conditions	I
:	O
non	B
-	I
opportunistic	I
primary	B
or	O
metastatic	B
brain	B
tumors	I
,	O
uncontrolled	B
seizure	B
disorder	I
,	O
progressive	B
multiple	I
sclerosis	I
,	O
stroke	B
with	O
neurological	B
sequelae	I
,	O
or	O
dementia	B
due	O
to	O
causes	O
other	B
than	I
HIV	B
(	O
eg	O
,	O
Alzheimer	B
'	I
s	I
disease	I
)	O

Constitutional	B
illness	I
(	O
eg	O
,	O
persistent	B
unexplained	B
fever	I
,	O
diarrhea	B
,	O
significant	B
weight	B
loss	I
,	O
disabling	B
weakness	I
)	O
within	B
30	I
days	I
of	I
screening	I

Known	O
untreated	B
B12	B
deficiency	I
or	O
malnutrition	B
(	O
body	B
mass	I
index	I
[	I
BMI	I
]	I
less	B
than	I
18	I
)	O
at	B
screening	I

Evidence	O
of	O
current	B
hepatitis	B
C	I
virus	I
infection	I
(	I
HCV	I
)	I
(	O
ie	O
,	O
HCV	B
antibody	I
[	I
Ab	I
]	I
positive	B
within	B
90	I
days	I
prior	I
to	I
study	I
entry	I
unless	O
also	O
shown	O
to	O
be	O
plasma	B
HCV	I
RNA	I
negative	B
within	B
the	I
same	I
time	I
period	I
)	O

Unstable	B
and	O
advanced	B
liver	B
disease	I
(	O
as	O
defined	O
by	O
the	O
presence	O
of	O
at	B
least	I
one	I
of	O
the	O
following	O
:	O
ascites	B
,	O
encephalopathy	B
,	O
coagulopathy	B
,	O
hypoalbuminemia	B
,	O
esophageal	O
or	O
gastric	B
varices	I
,	O
or	O
persistent	B
jaundice	B
)	O

Prior	B
or	O
current	B
use	O
of	O
any	O
CCR5	B
antagonist	I
(	O
such	O
as	O
MVC	B
and	O
cenicriviroc	B
[	I
CVC	I
]	I
)	O
and	O
integrase	B
inhibitor	I
(	O
such	O
as	O
RAL	B
,	O
DTG	B
,	O
and	O
elvitegravir	B
[	I
EVG	I
]	I
)	O

Current	B
use	O
of	O
any	O
medication	B
,	O
including	O
antiretrovirals	B
,	O
prohibited	B
in	I
the	I
study	I
(	O
refer	O
to	O
the	O
A5324	O
protocol	O
-	O
specific	O
web	O
page	O
[	O
PSWP	O
]	O
for	O
the	O
prohibited	O
medications	O
)	O

Breastfeeding	O

Presence	O
of	O
an	O
AIDS	B
-	I
defining	I
opportunistic	I
infection	I
within	B
6	I
months	I
prior	I
to	I
entry	I
.	O

Note	O
:	O
Refer	O
to	O
the	O
A5324	O
Manual	O
of	O
Operations	O
(	O
MOPS	O
)	O
for	O
the	O
list	O
of	O
AIDS	O
-	O
defining	O
opportunistic	O
infections	O
.	O

Active	B
syphilis	B
or	O
treatment	B
for	O
syphilis	B
within	B
90	I
days	I
prior	I
to	I
study	I
entry	I
.	O

NOTE	O
:	O
Active	B
syphilis	B
is	O
defined	O
as	O
four	B
-	I
fold	I
increase	I
in	O
serum	B
rapid	I
plasma	I
reagin	I
(	I
RPR	I
)	I
or	O
venereal	B
disease	I
research	I
laboratory	I
(	I
VDRL	I
)	I
tests	O
in	O
an	O
individual	O
with	O
past	B
syphilis	B
,	O
or	O
newly	B
reactive	B
serum	B
RPR	I
or	O
VDRL	B
with	O
a	O
reactive	B
confirmatory	I
test	I
(	O
enzyme	B
immunoassays	I
[	I
EIA	I
]	I
or	O
chemiluminescent	B
assay	I
[	I
CIA	I
]	I
,	O
T	B
.	I
pallidum	I
particle	I
agglutination	I
[	I
TP	I
-	I
PA	I
]	I
,	O
or	O
fluorescent	B
treponemal	I
antibody	I
absorbed	I
[	I
FTA	I
-	I
ABS	I
]	I
)	O
.	O

Known	O
allergy	B
/	O
sensitivity	B
or	O
any	O
hypersensitivity	B
to	O
components	B
of	I
study	I
drugs	I
or	O
their	O
formulation	O

a	O
licensed	O
rapid	O
HIV	O
test	O
or	O
HIV	O
enzyme	O
or	O
chemiluminescence	O
immunoassay	O
(	O
E	O
/	O
CIA	O
)	O
test	O
kit	O
at	O
any	O
time	O
prior	O
to	O
study	O
entry	O
and	O
confirmed	O
by	O
a	O
licensed	O
Western	O
blot	O
or	O
a	O
second	O
antibody	O
test	O
by	O
a	O
method	O
other	O
than	O
the	O
initial	O
rapid	O
HIV	O
and	O
/	O
or	O
E	O
/	O
CIA	O
,	O
or	O
by	O
HIV	O
-	O
1	O
antigen	O
or	O
plasma	O
HIV	O
-	O
1	O
RNA	O
viral	O
load	O
.	O
NOTE	O
:	O
The	O
term	O
"	O
licensed	O
"	O
refers	O
to	O
a	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
-	O
approved	O
kit	O
,	O
which	O
is	O
required	O
for	O
all	O
IND	O
studies	O
,	O
or	O
for	O
sites	O
located	O
in	O
countries	O
other	O
than	O
the	O
United	O
States	O
,	O
a	O
kit	O
that	O
has	O
been	O
certified	O
or	O
licensed	O
by	O
an	O
oversight	O
body	O
within	O
that	O
country	O
and	O
validated	O
internally	O
.	O
Non	O
-	O
US	O
sites	O
are	O
encouraged	O
to	O
use	O
US	O
FDA	O
-	O
approved	O
methods	O
for	O
IND	O
studies	O
.	O
WHO	O
(	O
World	O
Health	O
Organization	O
)	O
and	O
CDC	O
(	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
)	O
guidelines	O
mandate	O
that	O
confirmation	O
of	O
the	O
initial	O
test	O
result	O
must	O
use	O
a	O
test	O
that	O
is	O
different	O
from	O
the	O
one	O
used	O
for	O
the	O
initial	O
assessment	O
.	O
A	O
reactive	O
initial	O
rapid	O
test	O
should	O
be	O
confirmed	O
by	O
either	O
another	O
type	O
of	O
rapid	O
assay	O
or	O
an	O
E	O
/	O
CIA	O
that	O
is	O
based	O
on	O
a	O
different	O
antigen	O
preparation	O
and	O
/	O
or	O
different	O
test	O
principle	O
(	O
eg	O
,	O
indirect	O
versus	O
competitive	O
)	O
,	O
or	O
a	O
Western	O
blot	O
or	O
a	O
plasma	O
HIV	O
-	O
1	O
RNA	O
.	O
OR	O

Documentation	O
of	O
HIV	B
diagnosis	I
in	O
the	O
medical	O
record	O
by	O
a	O
healthcare	O
provider	O
.	O

Tenofovir	B
disoproxil	I
fumarate	I
(	I
TDF	I
)	I
to	O
tenofovir	B
alafenamide	I
fumarate	I
(	I
TAF	I
)	I
/	O
TAF	B
-	I
containing	I
fixed	I
-	I
dose	I
combination	I
regimens	I

Ritonavir	B
(	I
RTV	I
)	I
to	O
cobicistat	B
(	I
COBI	I
)	I
/	O
COBI	B
-	I
containing	I
fixed	I
-	I
dose	I
combination	I
regimens	I

TDF	B
to	O
TAF	B
/	O
TAF	B
-	I
containing	I
fixed	I
-	I
dose	I
combination	I
regimens	I

RTV	B
to	O
COBI	B
/	O
COBI	B
-	I
containing	I
fixed	I
-	I
dose	I
combination	I
regimens	I

HIV	B
-	I
1	I
plasma	I
RNA	I
less	B
than	I
50	I
copies	I
/	I
mL	I
obtained	O
within	B
90	I
days	I
prior	I
to	I
study	I
entry	I
by	O
any	O
FDA	O
-	O
approved	O
assay	O
at	O
any	O
United	O
States	O
laboratory	O
that	O
has	O
a	O
Clinical	O
Laboratory	O
Improvement	O
Amendments	O
(	O
CLIA	O
)	O
certification	O
or	O
its	O
equivalent	O
,	O
or	O
at	O
any	O
network	O
-	O
approved	O
non	O
-	O
US	O
laboratory	O
that	O
operates	O
in	O
accordance	O
with	O
Good	O
Clinical	O
Laboratory	O
Practices	O
(	O
GCLP	O
)	O
and	O
participates	O
in	O
appropriate	O
external	O
quality	O
assurance	O
programs	O
.	O

No	B
more	I
than	I
one	I
HIV	B
-	I
1	I
plasma	I
RNA	I
greater	B
than	I
or	I
equal	I
to	I
50	I
and	I
less	I
than	I
200	I
copies	I
/	I
mL	I
(	O
only	O
one	O
"	O
blip	O
"	O
)	O
in	B
the	I
past	I
6	I
months	I
with	O
a	O
subsequent	B
HIV	B
-	I
1	I
plasma	I
RNA	I
less	B
than	I
50	I
copies	I
/	I
mL	I
.	O

NOTE	O
:	O
There	O
should	O
be	O
no	B
plasma	B
HIV	I
-	I
1	I
RNA	I
greater	B
than	I
200	I
copies	I
/	I
mL	I
within	B
the	I
6	I
months	I
prior	I
to	I
study	I
entry	I
.	O

HAND	B
diagnosis	O
(	O
ANI	B
,	O
MND	B
,	O
or	O
HAD	B
)	O
within	B
60	I
days	I
prior	I
to	I
study	I
entry	I
.	O

HAND	O
is	O
defined	O
as	O
at	B
least	I
mild	I
impairment	B
on	O
neurocognitive	B
testing	I
(	O
more	B
than	I
one	I
standard	I
deviation	I
below	I
appropriate	I
normative	I
data	I
in	B
two	I
domains	I
of	I
functioning	I
)	O
and	O
no	B
severely	B
confounding	I
factors	I
.	O

Absolute	B
neutrophil	I
count	I
(	I
ANC	I
)	I
greater	B
than	I
or	I
equal	I
to	I
500	I
/	I
mm	I
^	I
3	I

Hemoglobin	B
greater	B
than	I
or	I
equal	I
to	I
7	I
.	I
5	I
g	I
/	I
dL	I

Platelet	B
count	I
greater	B
than	I
or	I
equal	I
to	I
40	I
,	I
000	I
/	I
mm	I
^	I
3	I

Creatinine	B
less	B
than	I
or	I
equal	I
to	I
2	I
.	I
0	I
x	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I

Aspartate	B
transaminase	I
(	I
AST	I
)	I
less	B
than	I
or	I
equal	I
to	I
5	I
x	I
ULN	I

Alanine	B
transaminase	I
(	I
ALT	I
)	I
less	B
than	I
3	I
x	I
ULN	I

Alkaline	B
phosphatase	I
less	B
than	I
or	I
equal	I
to	I
5	I
x	I
ULN	I

Total	B
bilirubin	I
less	B
than	I
1	I
.	I
5	I
x	I
ULN	I
.	O

NOTE	O
:	O
If	O
the	O
potential	O
participant	O
is	O
taking	O
an	O
indinavir	B
(	I
IDV	I
)	I
-	O
or	O
atazanavir	B
(	I
ATV	I
)	I
-	O
containing	O
regimen	B
at	B
the	I
time	I
of	I
screening	I
,	O
total	B
bilirubin	I
less	B
than	I
or	I
equal	I
to	I
5	I
x	I
ULN	I
is	O
acceptable	O
.	O

Creatinine	B
clearance	I
(	I
CrCl	I
)	I
greater	B
than	I
or	I
equal	I
to	I
60	I
mL	I
/	I
min	I
,	O
either	O
measured	O
or	O
estimated	O
by	O
Cockcroft	B
-	I
Gault	I
equation	I
.	O

NOTE	O
:	O
A	O
calculator	O
for	O
estimating	O
the	O
CrCl	O
can	O
be	O
found	O
at	O
www	O
.	O
fstrf	O
.	O
org	O
/	O
ACTG	O
/	O
ccc	O
.	O
html	O

Females	O
of	O
reproductive	O
potential	O
(	O
women	O
who	O
have	O
not	O
been	O
post	O
-	O
menopausal	O
for	O
at	O
least	O
24	O
consecutive	O
months	O
,	O
ie	O
,	O
who	O
have	O
had	O
menses	O
within	O
the	O
preceding	O
24	O
months	O
,	O
or	O
women	O
who	O
have	O
not	O
undergone	O
surgical	O
sterilization	O
,	O
hysterectomy	O
or	O
bilateral	O
salpingectomy	O
or	O
bilateral	O
oophorectomy	O
or	O
tubal	O
ligation	O
)	O
must	O
have	O
a	O
negative	O
serum	O
or	O
urine	O
pregnancy	O
test	O
by	O
any	O
US	O
clinic	O
or	O
laboratory	O
that	O
has	O
a	O
CLIA	O
certification	O
or	O
its	O
equivalent	O
,	O
or	O
is	O
using	O
a	O
point	O
of	O
care	O
(	O
POC	O
)	O
/	O
CLIA	O
-	O
waived	O
test	O
,	O
or	O
at	O
any	O
network	O
-	O
approved	O
non	O
-	O
US	O
laboratory	O
or	O
clinic	O
that	O
operates	O
in	O
accordance	O
with	O
GCLP	O
and	O
participates	O
in	O
appropriate	O
external	O
quality	O
assurance	O
programs	O
within	O
48	O
hours	O
prior	O
to	O
study	O
entry	O

Females	O
of	O
reproductive	O
potential	O
must	O
agree	O
not	O
to	O
participate	O
in	O
the	O
conception	O
process	O
(	O
ie	O
,	O
active	O
attempt	O
to	O
become	O
pregnant	O
,	O
in	O
vitro	O
fertilization	O
)	O
,	O
and	O
if	O
participating	O
in	O
sexual	O
activity	O
that	O
could	O
lead	O
to	O
pregnancy	O
,	O
must	O
use	O
at	O
least	O
one	O
reliable	O
form	O
of	O
contraception	O
.	O
Female	O
participants	O
must	O
use	O
contraceptives	O
while	O
receiving	O
study	O
treatment	O
and	O
for	O
6	O
weeks	O
after	O
stopping	O
study	O
treatment	O
.	O
More	O
information	O
on	O
this	O
criterion	O
is	O
available	O
in	O
the	O
protocol	O
.	O

Men	B
and	O
women	B
18	O
years	O
of	O
age	B
and	O
older	O
who	O
are	O
able	O
to	O
complete	O
the	O
neuropsychological	B
tests	I

Ability	O
and	O
willingness	O
of	O
participant	O
or	O
a	O
legally	O
authorized	O
representative	O
(	O
see	O
protocol	O
for	O
more	O
information	O
)	O
to	O
provide	O
informed	O
consent	O

Ability	O
and	O
willingness	O
to	O
take	O
oral	O
study	O
medications	O

Patient	O
diagnosed	O
with	O
dementia	B
.	O

Patients	O
with	O
serious	B
and	O
unstable	B
illnesses	O
including	O
current	O
hepatic	B
,	O
renal	B
,	O
gastroenterologic	B
,	O
respiratory	B
,	O
cardiovascular	B
(	O
including	O
ischemic	B
heart	I
disease	I
and	O
congestive	B
heart	I
failure	I
)	O
,	O
endocrinologic	B
,	O
neurologic	B
(	O
including	O
stroke	B
,	O
transient	B
ischemic	I
attack	I
,	O
subarachnoidal	B
bleeding	I
,	O
brain	B
tumor	I
,	O
encephalopathy	B
,	O
and	O
meningitis	B
)	O
.	O

Patients	O
with	O
a	O
history	O
of	O
allergic	B
reactions	I
to	O
loxapine	B
or	O
amoxapine	B

Patients	O
who	O
have	O
received	O
an	O
investigational	O
drug	O
within	O
30	O
days	O
prior	O
to	O
the	O
current	O
agitation	O
episode	O
must	O
be	O
excluded	O
.	O

Patients	O
who	O
are	O
considered	O
by	O
the	O
investigator	O
,	O
for	O
any	O
reason	O
,	O
to	O
be	O
unable	O
to	O
self	O
-	O
administer	O
the	O
inhalation	O
device	O
.	O

Male	B
and	O
female	B
patients	O
between	O
the	O
ages	B
of	O
18	B
-	I
65	I
years	I
,	O
inclusive	O

Patients	O
(	O
or	O
legal	O
representative	O
)	O
willing	O
and	O
able	O
to	O
provide	O
written	O
Informed	O
Consent	O
Form	O
.	O

Psychiatric	O
patients	O
already	O
diagnosed	O
of	O
schizophrenia	B
or	O
bipolar	B
disorder	I
,	O
according	O
to	O
the	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
-	I
IV	I
,	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
-	I
V	I
or	O
International	B
Code	I
of	I
Disease	I
criteria	I
.	O

Patients	O
with	O
an	O
on	O
-	O
going	O
agitation	B
episode	I
,	O
or	O
with	O
a	O
previous	O
one	O
within	B
the	I
6	I
months	I
prior	I
to	I
screening	I
,	O
attended	O
and	O
managed	O
in	O
the	O
hospital	O
setting	O
.	O

Previously	O
treated	O
with	O
ADASUVE	B
®	O
with	O
a	O
positive	O
outcome	O
(	O
responders	O
)	O
according	O
to	O
(	O
CGI	O
-	O
I	O
)	O
scale	O
(	O
defined	O
as	O
having	O
a	O
CGI	B
-	I
I	I
score	I
of	O
1	B
or	I
2	I
at	O
2	B
hours	I
after	I
administration	I
of	I
the	I
inhalation	I
)	I

Patients	O
free	B
of	O
active	B
respiratory	B
disease	I
such	O
as	O
acute	B
respiratory	I
signs	I
/	O
symptoms	O
(	O
e	O
.	O
g	O
.	O
,	O
wheezing	B
)	O
or	O
with	O
active	B
airways	B
disease	I
(	O
asthma	B
,	O
chronic	B
obstructive	I
pulmonary	I
disease	I
or	O
emphysema	B
)	O
.	O

Requirement	O
of	O
family	O
or	O
other	O
caregiver	O
support	O
at	O
study	O
investigator	O
criteria	O
(	O
defined	O
as	O
a	O
patient	O
'	O
s	O
relative	O
or	O
caregiver	O
(	O
male	O
or	O
female	O
)	O
=	O
80	O
year	O
old	O
,	O
who	O
spend	O
=	O
3	O
consecutive	O
hours	O
with	O
patient	O
,	O
with	O
good	O
physical	O
and	O
psychological	O
health	O
status	O
and	O
without	O
physical	O
limitations	O
,	O
reading	O
and	O
writing	O
educational	O
level	O
and	O
able	O
to	O
understand	O
and	O
follow	O
the	O
study	O
procedures	O
)	O
.	O

Availability	O
of	O
patient	O
'	O
s	O
medical	O
records	O
data	O
about	O
the	O
previous	O
treatment	O
with	O
ADASUVE	O
®	O
at	O
hospital	O
setting	O
.	O

If	O
a	O
female	O
is	O
of	O
childbearing	O
potential	O
and	O
sexually	O
active	O
(	O
except	O
if	O
female	O
is	O
surgically	O
sterile	O
or	O
post	O
-	O
menopausal	O
with	O
history	O
of	O
no	O
menses	O
for	O
at	O
least	O
24	O
months	O
)	O
,	O
patient	O
must	O
be	O
non	O
-	O
lactating	O
and	O
non	O
-	O
pregnant	O
(	O
with	O
a	O
negative	O
pregnancy	O
test	O
result	O
at	O
baseline	O
visit	O
)	O
and	O
have	O
to	O
agree	O
to	O
use	O
a	O
medically	O
acceptable	O
and	O
effective	O
birth	O
control	O
method	O
throughout	O
the	O
study	O
and	O
for	O
one	O
week	O
following	O
the	O
end	O
of	O
the	O
study	O
.	O

Patients	B
with	O
severe	B
complications	B
or	O
severe	B
infection	B
;	O

Invasion	B
of	O
central	B
nervous	I
system	I
;	O

Patients	O
with	O
severe	B
heart	B
disease	I
history	O
,	O
including	O
ventricular	B
tachycardia	I
(	O
VT	B
)	O
,	O
atrial	B
fibrillation	I
(	O
AF	B
)	O
,	O
heart	B
block	I
,	O
myocardial	B
infarction	I
(	O
MI	B
)	O
,	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
,	O
coronary	B
heart	I
disease	I
patients	O
needed	O
therapy	O
;	O

patients	O
with	O
severe	B
allergic	B
constitution	O
,	O
or	O
those	O
who	O
are	O
allergic	B
to	O
or	O
intolerant	B
of	O
drug	O
composition	O
in	O
chemotherapy	B
regimens	I
;	O
with	O
other	B
malignant	B
tumors	I
in	O
the	O
past	B
5	I
years	I
;	O

patients	O
received	O
doxorubicin	B
therapy	O
,	O
total	B
cumulative	I
dose	I
of	O
adriamycin	B
was	O
more	B
than	I
300	I
mg	I
/	I
m2	I
,	O
total	B
cumulative	I
dose	I
of	O
epirubicin	B
was	O
more	B
than	I
450	I
mg	I
/	I
m2	I
;	O

Patients	O
participate	O
in	O
other	O
clinical	O
studies	O
;	O

Other	O
patients	O
who	O
are	O
not	O
suitable	O
for	O
the	O
study	O
.	O

Primary	B
B	I
-	I
NHL	I
,	O
PTCL	B
(	O
ALK	B
+	I
anaplastic	I
large	I
cell	I
lymphoma	I
and	I
NK	I
(	I
natural	I
killer	I
cell	I
)	I
/	I
T	I
cell	I
lymphoma	I
were	O
excluded	B
)	O
or	O
HL	B
patients	O
confirmed	O
by	O
histopathology	O
;	O

Ages	B
=	B
18	I
years	I
old	I
,	I
<	I
80	I
years	I
old	I
;	O

ECOG	B
(	I
Eastern	I
Cooperative	I
Oncology	I
Group	I
)	I
score	I
:	O
0	B
-	I
2	I

At	B
least	I
one	I
measurable	O
lesion	B
;	O

Expected	O
survival	O
time	O
=	O
3	B
months	I
;	O

Liver	O
function	O
:	O
transaminase	B
=	B
2	I
.	I
5	I
×	I
upper	I
limit	I
of	I
normal	I
value	I
,	O
bilirubin	B
=	B
1	I
.	I
5	I
×	I
upper	I
limit	I
of	I
normal	I
value	I
;	O

Renal	O
function	O
:	O
serum	B
creatinine	I
is	O
44	B
-	I
133	I
mmol	I
/	I
L	I
;	O

Routine	O
blood	O
test	B
:	I
WBC	I
=	B
3	I
.	I
0	I
×	I
109	I
/	I
L	I
,	O
Neutrophils	B
=	B
1	I
.	I
5	I
×	I
109	I
/	I
L	I
,	O
Hb	B
=	B
100g	I
/	I
L	I
,	O
Platelet	B
=	B
80	I
×	I
109	I
/	I
L	I
;	O
LVEF	B
=	B
50	I
%	I
;	O

New	O
York	O
Heart	O
Association	O
(	O
NYHA	B
)	O
heart	O
function	O
classification	O
is	O
I	B
-	I
II	I
grade	I

signed	O
informed	O
consent	O
.	O

Documented	O
renal	B
failure	I

documented	O
allergy	B
to	O
iodine	B
or	O
shellfish	B

previous	B
spine	B
fusion	I
surgery	I

undergoing	B
elective	B
posterior	B
spine	I
single	B
-	I
level	I
instrumentation	I
surgery	I

undergoing	B
anterior	B
spine	I
multi	B
-	I
level	I
instrumentation	I
surgery	I

current	B
antibiotic	B
use	I
.	O

Age	B
3	B
to	I
18	I
years	I
on	B
day	I
of	I
surgery	I

diagnosis	O
of	O
spinal	B
deformity	I

undergoing	B
elective	B
posterior	B
spine	I
multi	B
-	I
level	I
instrumentation	I
surgery	I

Patients	O
with	O
placenta	B
pathology	I
such	O
as	O
praevia	B
,	O
acreta	B
,	O
pre	B
-	I
eclampsia	I

Patients	O
with	O
bleeding	B
disorders	I
including	O
vonWillebrand	B
disease	I
type	I
I	I
.	O

Known	O
intolerance	B
to	O
one	B
of	I
the	I
two	I
drugs	B
.	O

Patients	O
with	O
prolonged	B
QT	I
-	I
time	I
or	O
other	B
serious	B
cardiac	I
diseases	I
.	O

Liver	O
or	O
kidney	B
failure	I
.	O

Epilepsy	B
.	O

Any	O
medical	O
reason	O
why	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
the	O
patient	O
should	O
not	O
participate	O

Healthy	B
pregnant	B
women	B
age	B
18	B
to	I
50	I

Singleton	B
pregnancy	I
at	O
gestational	B
age	I
36	B
weeks	I
or	I
more	I

Able	O
to	O
read	O
and	O
understand	O
Norwegian	O
.	O

Paroxysmal	B
atrial	I
fibrillation	I
.	O

Long	O
-	O
standing	O
persistent	B
or	O
permanent	B
atrial	B
fibrillation	I
.	O

Previous	O
pacemaker	B
implantation	I
.	O

Previous	O
atrial	B
ablation	I
.	O

Patient	O
is	O
unable	O
to	O
take	O
warfarin	B
or	O
other	O
oral	B
anti	I
-	I
coagulant	I
medication	I
.	O

Patient	O
is	O
suffering	O
with	O
unstable	B
angina	I
in	O
last	B
one	I
week	I
.	O

Patient	O
has	O
had	O
a	O
myocardial	B
infarction	I
within	O
last	B
two	I
months	I
.	O

Patient	O
is	O
expecting	O
or	O
has	O
had	O
major	B
cardiac	I
surgery	I
within	O
last	B
two	I
months	I
.	O

Patient	O
is	O
participating	O
in	O
a	O
conflicting	O
study	O
.	O

Patient	O
is	O
unable	O
to	O
perform	O
exercise	O
testing	O
.	O

Patient	O
is	O
mentally	O
incapacitated	O
and	O
cannot	O
consent	O
or	O
comply	O
with	O
follow	O
-	O
up	O
.	O

Patient	O
has	O
New	B
York	I
Heart	I
Association	I
(	O
NYHA	B
)	O
class	B
III	I
/	I
IV	I
heart	B
failure	I
.	O

Patient	O
has	O
left	B
ventricular	I
ejection	I
fraction	I
(	O
LVEF	B
)	O
less	B
than	I
35	I
%	I
not	O
secondary	O
to	O
tachycardia	B
.	O

Pregnancy	B
.	O

Patient	O
suffers	O
with	O
other	B
cardiac	B
rhythm	I
disorders	I
.	O

Recent	O
coronary	B
artery	I
intervention	I
or	O
other	O
factors	O
suggesting	O
clinical	O
instability	O
(	O
ECG	O
,	O
clinical	O
or	O
laboratory	O
findings	O
)	O
.	O

Patients	O
with	O
symptomatic	B
persistent	B
atrial	B
fibrillation	I
of	O
less	B
than	I
1	I
-	I
year	I
duration	O
.	O

Patients	O
must	O
be	O
over	B
65	I
years	I
old	B
.	O

Patients	O
give	O
informed	O
consent	O
prior	O
to	O
participating	O
in	O
this	O
study	O
.	O

Patients	O
minors	B

Patients	O
on	O
a	O
legal	B
protection	I
regime	I
type	I
guardianship	I

Respiratory	B
pathologies	I
,	O
cardiovascular	B
,	O
renal	B
,	O
diabetes	B

Claustrophobia	B

Contraindications	B
to	O
exposure	O
to	O
a	O
magnetic	B
field	I

Contraindications	B
to	O
injecting	O
Dotarem	B
®	O

Major	O
subjects	O
of	O
over	O
40	O
years	B
(	O
mean	O
age	O
of	O
Meniere	O
'	O
s	O
disease	O
40	O
to	O
50	O
years	O
)	O

Informed	O
consent	O
signed	O

Medical	B
examination	I
performed	O
prior	B
to	I
participation	I
in	I
research	I

Patients	O
without	B
history	B
of	O
inner	B
ear	I
disease	I

Recipient	O
of	O
a	O
French	O
social	O
security	O
scheme	O

Ongoing	B
treatment	B
with	O
inotropic	B
drugs	I
(	O
not	B
norepinephrine	B
)	O

Central	B
venous	I
oxygen	I
saturation	I
(	I
ScvO2	I
)	I
<	B
60	I
%	I
despite	O
optimization	B
of	I
hematocrit	I
and	O
volume	O
status	O

Need	O
of	O
renal	B
replacement	I
therapy	I

Ongoing	B
bleeding	B

Patient	O
or	O
next	O
of	O
kin	O
does	O
not	O
consent	O
with	O
study	O
participation	O

Patients	O
in	O
the	O
cardiothoracic	O
intensive	O
care	O
after	O
cardiac	B
surgery	I
with	O
cardiopulmonary	B
bypass	I

Acute	B
kidney	I
injury	I
,	O
defined	O
as	O
increase	B
in	I
S	I
-	I
creatinine	I
50	B
%	I
or	I
27	I
mol	I
/	I
L	I

Normal	B
S	B
-	I
creatinine	I
before	O
surgery	B

Women	O
who	O
are	O
pregnant	O
,	O
lactating	O
or	O
breast	O
feeding	O
or	O
have	O
a	O
positive	O
serum	O
pregnancy	O
test	O
at	O
enrollment	O
or	O
positive	O
urine	O
pregnancy	O
test	O
on	O
the	O
morning	O
of	O
the	O
first	O
day	O
of	O
any	O
study	O
session	O

Smokers	B
(	O
current	O
use	O
or	O
use	O
over	O
the	O
previous	O
2	O
months	O
of	O
nicotine	O
-	O
containing	O
substances	O
,	O
including	O
tobacco	O
products	O
(	O
e	O
.	O
g	O
.	O
cigarettes	O
,	O
cigars	O
,	O
chewing	O
tobacco	O
,	O
gum	O
,	O
patch	O
or	O
electronic	O
cigarettes	O
)	O

Participation	O
in	O
any	O
ongoing	O
investigational	O
drug	O
trial	O
/	O
study	O
or	O
clinical	O
drug	O
trial	O
/	O
study	O

History	O
of	O
chronic	B
obstructive	I
pulmonary	I
disease	I
or	O
cor	B
pulmonale	I
,	I
or	O
substantially	O
decreased	B
respiratory	I
reserve	I
,	O
hypoxia	B
,	O
hypercapnia	B
or	O
pre	O
-	O
existing	O
respiratory	B
depression	I

Active	O
positive	B
Hepatitis	O
B	O
,	O
C	O
and	O
HIV	B
serologies	I

Positive	B
urine	B
drug	I
screening	I
test	I

Use	O
of	O
any	O
prescription	O
medication	O
during	O
the	O
session	O
0	O
to	O
30	O
days	O
or	O
over	O
-	O
the	O
counter	O
medication	O
e	O
.	O
g	O
.	O
antihistamines	O
or	O
topical	O
corticosteroids	O
(	O
vitamin	O
,	O
herbal	O
supplements	O
and	O
birth	O
control	O
medications	O
not	O
included	O
)	O
during	O
the	O
session	O
0	O
to	O
3	O
days	O
before	O
entry	O
to	O
the	O
study	O

Use	O
of	O
medications	O
or	O
treatments	O
that	O
would	O
significantly	O
influence	O
or	O
exaggerate	O
responses	O
to	O
the	O
test	O
product	O
or	O
that	O
would	O
alter	O
inflammatory	O
or	O
immune	O
response	O
to	O
the	O
product	O
or	O
agents	O
deemed	O
to	O
be	O
immunosuppressive	O
as	O
determined	O
by	O
physician	O
investigator	O
with	O
72	O
hours	O
prior	O
to	O
dosing	O
(	O
e	O
.	O
g	O
.	O
antihistamines	O
,	O
systemic	O
or	O
topical	O
corticosteroids	O
(	O
within	O
3	O
weeks	O
prior	O
to	O
dosing	O
)	O
,	O
cyclosporine	O
,	O
tacrolimus	O
,	O
cytotoxic	O
drugs	O
,	O
immune	O
globulin	O
,	O
Bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
,	O
monoclonal	O
antibodies	O
,	O
radiation	O
therapy	O
)	O

Use	O
of	O
monoamine	B
oxidase	I
inhibitors	I
21	B
days	I
prior	I
to	I
study	I

Current	O
use	O
of	O
mixed	O
agonist	O
/	O
antagonist	O
(	O
such	O
as	O
pentazocine	B
,	O
nalbuphine	B
or	O
butorphanol	B
)	O
and	O
partial	O
agonist	O
(	O
buprenorphine	B
)	O
analgesics	O

Current	O
use	O
of	O
anticholinergics	B
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O

Consumption	O
of	O
beverages	O
containing	O
alcohol	O
,	O
grapefruit	O
juice	O
,	O
Seville	O
oranges	O
,	O
or	O
quinine	O
(	O
e	O
.	O
g	O
.	O
tonic	O
water	O
)	O
or	O
foods	O
containing	O
poppy	O
seeds	O
in	O
the	O
last	O
72	O
hours	O
.	O

Donation	O
or	O
loss	O
of	O
greater	O
than	O
one	O
pint	O
of	O
blood	O
within	O
60	O
days	O
of	O
entry	O
to	O
the	O
study	O

Any	O
prior	O
serious	O
adverse	O
reaction	O
or	O
hypersensitivity	B
to	O
fentanyl	B
,	O
morphine	B
,	O
codeine	B
,	O
hydrocodone	B
,	O
hydromorphone	B
,	O
oxycodone	B
,	O
oxymorphone	B
,	O
naltrexone	B
or	O
naloxone	B
or	O
any	O
of	O
the	O
inactive	O
ingredients	O
in	O
the	O
TDDS	B
(	O
polyester	B
/	I
ethyl	I
vinyl	I
acetate	I
,	O
polyacrylate	B
adhesive	I
,	O
silicone	B
adhesive	I
,	O
dimethicone	B
NF	I
,	O
or	O
polyolefin	B
)	O

Have	O
a	O
diagnosis	O
of	O
schizophrenia	B
or	O
other	O
major	B
psychiatric	I
diagnosis	I
or	O
mental	B
illness	I
(	O
e	O
.	O
g	O
.	O
major	B
depression	I
)	O

Medical	O
history	O
of	O
personal	O
drug	B
or	O
alcohol	B
addiction	B
or	O
abuse	B

Any	O
condition	O
that	O
would	O
,	O
in	O
the	O
opinion	O
of	O
the	O
MAI	O
,	O
place	O
the	O
subject	O
at	O
an	O
unacceptable	O
risk	O
of	O
injury	O
or	O
render	O
the	O
subject	O
unable	O
to	O
meet	O
the	O
requirements	O
of	O
the	O
protocol	O

Inability	O
to	O
communicate	O
or	O
cooperate	O
with	O
the	O
investigators	O

Subject	O
has	O
an	O
obvious	O
difference	O
in	O
skin	O
color	O
between	O
arms	O
or	O
the	O
presence	O
of	O
a	O
skin	O
condition	O
,	O
excessive	O
hair	O
at	O
the	O
application	O
site	O
(	O
upper	O
arm	O
)	O
,	O
sunburn	O
,	O
raised	O
moles	O
and	O
scars	O
,	O
open	O
sore	O
,	O
scar	O
tissue	O
,	O
tattoo	O
,	O
or	O
coloration	O
that	O
would	O
interfere	O
with	O
placement	O
of	O
test	O
articles	O
,	O
skin	O
assessment	O
,	O
or	O
reactions	O
to	O
drug	O

Failure	O
to	O
pass	O
opioid	O
dependence	O
challenge	O
test	O
on	O
the	O
first	O
day	O
study	O
day	O
of	O
any	O
study	O
session	O
(	O
i	O
.	O
e	O
.	O
,	O
before	O
taking	O
the	O
first	O
dose	O
of	O
naltrexone	O
hydrochloride	O
)	O
.	O
Each	O
subject	O
will	O
be	O
injected	O
subcutaneously	O
with	O
naloxone	O
hydrochloride	O
(	O
0	O
.	O
8	O
mg	O
injection	O
)	O
and	O
will	O
be	O
observed	O
for	O
45	O
minutes	O
for	O
signs	O
and	O
symptoms	O
of	O
opioid	O
withdrawal	O
.	O

Within	O
4	O
weeks	O
prior	O
to	O
dosing	O
,	O
use	O
of	O
medications	O
or	O
treatments	O
that	O
would	O
significantly	O
influence	O
or	O
exaggerate	O
responses	O
to	O
the	O
test	O
product	O
or	O
that	O
would	O
alter	O
inflammatory	O
or	O
immune	O
response	O
to	O
the	O
product	O
or	O
agents	O
deemed	O
to	O
be	O
immunosuppressive	O
as	O
determined	O
by	O
physician	O
investigator	O

Men	B
or	O
non	B
-	I
pregnant	I
women	B
of	O
any	O
ethnic	O
background	O
between	O
the	O
age	B
of	O
18	B
and	I
45	I
years	I
old	I

Subjects	O
must	O
be	O
non	B
-	I
smokers	I
(	O
must	O
have	O
refrained	O
from	O
the	O
use	O
of	O
nicotine	O
-	O
containing	O
substances	O
,	O
including	O
tobacco	O
products	O
(	O
e	O
.	O
g	O
.	O
cigarettes	O
,	O
cigars	O
,	O
chewing	O
tobacco	O
,	O
gum	O
,	O
patch	O
or	O
electronic	O
cigarettes	O
)	O
over	O
the	O
previous	O
2	O
months	O
and	O
are	O
not	O
currently	O
using	O
tobacco	O
products	O

Provide	O
written	O
informed	O
consent	O
before	O
initiation	O
of	O
any	O
study	O
procedures	O

Available	O
for	O
follow	O
-	O
up	O
for	O
the	O
planned	O
duration	O
of	O
the	O
study	O

Able	O
to	O
communicate	O
well	O
with	O
the	O
investigators	O

Able	O
to	O
adhere	O
to	O
the	O
study	O
protocol	O
schedule	O
,	O
study	O
restrictions	O
and	O
examination	O
schedule	O

Subjects	O
who	O
are	O
within	O
their	O
ideal	O
body	O
weight	O
(	O
BMI	B
between	B
>	I
17	I
and	I
=	I
28	I
kg	I
/	I
m2	I
)	O

Subjects	O
deemed	O
to	O
be	O
healthy	O
as	O
judged	O
by	O
the	O
Medically	O
Accountable	O
Investigator	O
(	O
MAI	O
)	O
and	O
determined	O
by	O
medical	O
history	O
,	O
physical	O
examination	O
and	O
medication	O
history	O

Subjects	O
have	O
no	B
history	O
of	O
the	O
following	O
:	O
ongoing	O
acute	B
or	O
intermittent	B
pain	B
,	O
postoperative	B
pain	B
,	O
respiratory	B
compromise	I
,	O
acute	B
or	O
severe	B
asthma	B
,	O
or	O
constipation	B
(	O
less	O
than	O
1	O
bowel	O
movement	O
every	O
2	O
days	O
)	O

Negative	B
urine	B
drug	I
screening	I
test	I
at	O
the	O
time	O
of	O
screening	O

Have	O
normal	B
screening	O
laboratories	O
for	O
white	B
blood	I
cells	I
(	O
WBC	B
)	O
,	O
hemoglobin	B
(	O
Hgb	B
)	O
,	O
platelets	B
,	O
sodium	B
,	O
potassium	B
,	O
chloride	B
,	O
bicarbonate	B
,	O
blood	B
urea	I
nitrogen	I
(	O
BUN	B
)	O
,	O
creatinine	B
,	O
ALT	B
(	O
liver	O
function	O
)	O
,	O
AST	B
(	O
liver	O
function	O
)	O
and	O
bilirubin	B

Have	O
normal	B
screening	O
laboratories	O
for	O
urine	B
protein	I
and	O
urine	B
glucose	I

Female	O
subjects	O
must	O
be	O
of	O
non	O
-	O
childbearing	O
potential	O
(	O
as	O
defined	O
as	O
surgically	O
sterile	O
[	O
i	O
.	O
e	O
.	O
history	O
of	O
hysterectomy	O
or	O
tubal	O
ligation	O
]	O
or	O
postmenopausal	O
for	O
more	O
than	O
1	O
year	O
[	O
no	O
bleeding	O
for	O
12	O
consecutive	O
months	O
]	O
,	O
or	O
if	O
of	O
childbearing	O
potential	O
must	O
be	O
non	O
-	O
pregnant	O
at	O
the	O
time	O
of	O
enrollment	O
and	O
on	O
the	O
morning	O
of	O
the	O
first	O
day	O
of	O
each	O
study	O
session	O
,	O
and	O
must	O
agree	O
to	O
use	O
hormonal	O
or	O
barrier	O
birth	O
control	O
such	O
as	O
implants	O
,	O
injectables	O
,	O
combined	O
oral	O
contraceptives	O
,	O
some	O
intrauterine	O
devices	O
(	O
IUDs	O
)	O
,	O
sexual	O
abstinence	O
or	O
a	O
vasectomized	O
parter	O

Agrees	O
not	O
to	O
participate	O
in	O
another	O
clinical	O
study	O
/	O
trial	O
during	O
the	O
study	O
period	O
or	O
to	O
participate	O
in	O
an	O
investigational	O
drug	O
study	O
for	O
at	O
least	O
one	O
month	O
after	O
last	O
study	O
session	O

Agrees	O
not	O
to	O
donate	O
blood	O
to	O
a	O
blood	O
bank	O
throughout	O
participation	O
in	O
the	O
study	O
and	O
for	O
at	O
least	O
3	O
months	O
after	O
last	O
study	O
day	O

Have	O
a	O
normal	B
ECG	B
;	O
must	O
not	B
have	O
the	O
following	O
to	O
be	O
acceptable	O
:	O
pathologic	O
Q	O
wave	O
abnormalities	O
,	O
significant	O
ST	O
-	O
T	O
wave	O
changes	O
,	O
left	B
ventricular	I
hypertrophy	I
,	O
right	B
bundle	I
branch	I
block	I
,	O
left	B
bundle	I
branch	I
block	I
.	O

(	O
sinus	O
rhythm	O
is	O
between	O
55	O
-	O
100	O
beats	O
per	O
minute	O
)	O

Temperature	B
35	B
-	I
37	I
.	I
9	I
°	I
C	I
(	O
95	B
-	I
100	I
.	I
3	I
°	I
F	I
)	O

Systolic	B
blood	I
pressure	I
90	B
-	I
140	I
mmHg	I

Diastolic	B
blood	I
pressure	I
60	B
-	I
90	I
mmHg	I

Heart	B
rate	I
55	B
-	I
100	I
beats	I
per	I
minute	I

Respiration	B
rate	I
12	B
-	I
18	I
breaths	I
per	I
minute	I

Type	B
1	I
diabetes	I
mellitus	I
,	O
presence	O
of	O
autoimmune	B
diabetes	I
indicated	O
by	O
antibodies	B
to	O
insulin	B
,	O
islet	B
cells	I
,	O
and	O
GAD	B
;	O

Gestational	B
diabetes	I
;	O

patients	O
with	O
heart	O
,	O
liver	O
,	O
or	O
renal	B
function	I
impairment	I
;	O
presence	O
of	O
severe	B
infections	B
or	O
cerebrovascular	B
disease	I
;	O

Newly	B
dignosised	I
type	B
2	I
diabetes	I
according	O
to	O
WHO	B
criteria	I
.	O
glycated	B
hemoglobin	I
(	I
HbA1c	I
)	I
was	O
more	B
than	I
10	I
%	I
;	O

Seronegative	B
for	O
antibodies	B
against	O
insulin	B
,	O
islet	B
cells	I
and	O
glutamic	B
acid	I
decarboxylase	I
(	I
GAD	I
)	I
;	O

Known	O
or	O
suspected	O
alcohol	O
or	O
substance	B
abuse	I
in	O
the	O
preceding	B
12	I
months	I
.	O

Women	O
who	O
are	O
pregnant	O
or	O
breastfeeding	O
.	O

Women	O
of	O
childbearing	O
potential	O
(	O
WOCP	O
)	O
who	O
are	O
not	O
using	O
at	O
least	O
one	O
method	O
of	O
contraception	O
.	O

Patients	O
with	O
severe	B
renal	B
impairment	I
(	O
CLcr	B
=	B
29	I
mL	I
/	I
min	I
,	O
or	O
eGFR	B
=	B
29	I
mL	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
)	O
,	O
or	O
moderate	B
or	O
severe	B
hepatic	B
impairment	I
(	O
Child	B
-	I
Pugh	I
classes	I
B	B
or	O
C	B
)	O
.	O

Patients	O
with	O
bladder	B
outlet	I
obstruction	I
(	O
BOO	B
)	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
urologist	O
,	O
would	O
expose	O
them	O
to	O
risk	O
of	O
urinary	O
retention	O
during	O
treatment	O
with	O
mirabegron	B
.	O

Patients	O
treated	O
with	O
drugs	O
metabolized	O
by	O
the	O
CYP2D6	O
pathway	O
.	O

Patients	O
with	O
supine	B
systolic	B
blood	I
pressure	I
(	O
SBP	B
)	O
=	B
180	I
mm	I
Hg	I
,	O
or	O
diastolic	B
blood	I
pressure	I
(	O
DBP	B
)	O
=	B
110	I
mm	I
Hg	I
.	O

Clinically	O
significant	O
,	O
uncontrolled	B
cardiac	B
arrhythmia	I
,	O
unstable	B
angina	I
,	O
congestive	B
heart	I
failure	I
(	O
NYHA	B
Class	I
3	B
or	O
4	B
)	O
,	O
or	O
history	O
of	O
myocardial	B
infarction	I
in	O
the	O
preceding	B
2	I
years	I
.	O

History	O
of	O
cancer	B
in	O
the	O
preceding	B
2	I
years	I
other	B
than	O
successfully	B
treated	I
,	O
non	B
-	I
metastatic	I
,	O
squamous	O
cell	O
or	O
basal	B
cell	I
carcinoma	I
,	O
or	O
cervical	B
cancer	I
in	I
situ	I
.	O

Any	O
major	B
urological	I
procedure	I
in	O
the	O
preceding	B
90	I
days	I
.	O

Any	O
major	B
surgical	I
procedure	I
in	O
the	O
preceding	B
30	I
days	I
.	O

Previously	O
treated	O
with	O
mirabegron	B
within	B
60	I
days	I
prior	I
to	I
the	I
baseline	I
visit	I
(	O
Visit	O
2	O
)	O
,	O
or	O
previously	O
having	O
failed	O
treatment	O
with	O
mirabegron	O
regardless	O
of	O
duration	O
and	O
timing	O
of	O
treatment	O
.	O

Current	O
or	O
previous	O
,	O
within	B
the	I
60	I
days	I
preceding	I
the	I
baseline	I
visit	I
(	O
Visit	O
2	O
)	O
,	O
treatment	O
with	O
antimuscarinic	B
agents	I
for	O
OAB	B
symptoms	I
;	O
and	O
,	O
willingness	O
to	O
not	O
use	O
antimuscarinic	O
agents	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Currently	O
receiving	O
any	O
other	O
investigational	O
drug	O
or	O
having	O
received	O
an	O
investigational	O
drug	O
within	O
the	O
60	O
days	O
preceding	O
the	O
baseline	O
visit	O
(	O
Visit	O
2	O
)	O
.	O

Any	O
condition	O
or	O
laboratory	O
test	O
result	O
,	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
or	O
the	O
Study	O
Urologist	O
,	O
might	O
result	O
in	O
an	O
increased	O
risk	O
to	O
the	O
patient	O
,	O
or	O
would	O
affect	O
their	O
participation	O
in	O
the	O
study	O
.	O

Any	O
patient	O
who	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
is	O
not	O
a	O
good	O
candidate	O
for	O
the	O
study	O
or	O
will	O
not	O
be	O
able	O
to	O
follow	O
study	O
procedures	O
.	O

Aged	B
25	B
-	I
80	I
at	O
screening	O
.	O

Subjects	O
older	O
than	O
80	O
will	O
be	O
allowed	O
at	O
the	O
discretion	O
of	O
the	O
PI	O
.	O

Ambulatory	B
(	O
defined	O
as	O
able	O
to	O
ambulate	O
at	O
least	O
10	O
meters	O
,	O
with	O
or	O
without	O
assistance	O
)	O
.	O

Clinical	O
Diagnosis	O
of	O
PD	B
based	O
on	O
the	O
United	B
Kingdom	I
Brain	I
Bank	I
diagnostic	I
criteria	I
for	O
PD	O
.	O

At	O
least	O
8	O
micturitions	B
per	O
24	O
hours	O
and	O

At	O
least	O
3	O
urgency	B
episodes	I
per	O
3	O
-	O
day	O
diary	O
.	O

A	O
MoCA	B
score	I
between	B
19	I
and	I
28	I
(	O
inclusive	O
)	O
at	O
screening	O
.	O

For	O
those	O
on	O
cognitive	B
enhancers	I
(	O
donepezil	B
,	O
rivastigmine	B
,	O
memantine	B
,	O
galantamine	B
)	O
a	O
MoCA	B
score	I
between	B
19	I
and	I
29	I
(	O
inclusive	O
)	O
at	O
screening	O
.	O

Provide	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O
and	O
understand	O
that	O
they	O
may	O
withdraw	O
their	O
consent	O
at	O
any	O
time	O
without	O
prejudice	O
to	O
their	O
future	O
medical	O
care	O
.	O

Be	O
cognitively	O
capable	O
,	O
in	O
the	O
opinion	O
of	O
investigator	O
,	O
to	O
understand	O
and	O
provide	O
such	O
informed	O
consent	O
.	O

Be	O
cognitively	O
capable	O
to	O
complete	O
the	O
required	O
questionnaires	O
and	O
assessments	O
,	O
OR	O
have	O
a	O
care	O
partner	O
who	O
is	O
willing	O
and	O
capable	O
to	O
assist	O
them	O
in	O
the	O
completion	O
of	O
these	O
tasks	O
.	O

Be	O
on	O
a	O
stable	O
regimen	O
of	O
antiparkinson	B
'	I
s	I
medications	I
at	B
least	I
30	I
days	I
prior	I
to	I
screening	I
,	O
and	O
be	O
expected	O
to	O
remain	O
on	O
a	O
stable	O
dose	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

If	O
taking	O
cognitive	B
enhancers	I
(	O
donepezil	B
,	O
rivastigmine	B
,	O
memantine	B
,	O
galantamine	B
)	O
,	O
must	O
be	O
on	O
stable	B
dose	I
at	B
least	I
30	I
days	I
prior	I
to	I
screening	I
,	O
and	O
be	O
expected	O
to	O
remain	O
on	O
a	O
stable	O
dose	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Non	B
survivable	I
injury	B

Multiple	B
significant	B
trauma	B
(	O
i	O
.	O
e	O
.	O
significant	O
intracranial	O
and	O
extracranial	B
injuries	I
including	O
limb	B
fractures	I
)	O
that	O
would	O
limit	O
observation	O
of	O
recovery	O
from	O
spinal	O
cord	O
injury	O

Other	O
conditions	O
that	O
would	O
limit	O
clinical	O
assessment	O
of	O
outcomes	O
(	O
e	O
.	O
g	O
.	O
dementia	B
,	O
demyelinating	B
disease	I
,	O
autoimmune	B
disease	I
,	O
etc	O
)	O

Refusal	O
of	O
treatment	O
or	O
contraindication	B
to	O
NeuroAiD	B

Male	B
or	O
female	B

Age	B
18	B
to	I
65	I
years	I

Diagnosed	O
with	O
spinal	B
cord	I
injury	I
between	B
3	I
days	I
and	I
4	I
weeks	I

American	B
Spinal	I
Injury	I
Association	I
Impairment	I
Scale	I
A	B
or	I
B	I

Informed	O
consent	O
for	O
inclusion	O
into	O
the	O
database	O
is	O
obtained	O

Prior	B
treatment	B
with	O
Acthar	B
in	B
the	I
past	I
2mos	I

Meet	O
one	B
of	I
the	O
above	O
RA	B
flare	I
requirements	I

Subjects	O
who	O
have	O
received	O
live	O
or	O
live	B
attenuated	I
vaccines	I
within	O
6	O
weeks	O
prior	O
to	O
the	O
first	B
dose	I
of	O
study	B
drug	I
(	O
or	O
the	O
zoster	B
vaccine	I
)	O

Patient	O
must	O
meet	O
1987	B
ACR	I
criteria	I

Age	B
>	B
18	I
years	I
of	I
age	I

Baseline	B
DAS28	B
/	I
Erythrocyte	I
Sedimentation	I
Rate	I
(	I
ESR	I
)	I
>	B
=	I
3	I
.	I
2	I

Stable	B
concomitant	B
Disease	B
Modifying	I
Anti	I
-	I
Rheumatic	I
Drugs	I
(	I
DMARDs	I
)	I

Stable	B
prednisone	B
<	B
10mg	I
or	O
equivalent	O

Power	B
Doppler	I
score	I
of	O
>	B
=	I
10	I

A	O
medical	O
condition	O
that	O
could	O
interfere	O
with	O
study	O
participation	O

Body	B
weight	I
less	B
than	I
50	I
kg	I

Participating	O
in	O
another	O
study	O
involving	O
an	O
investigational	O
medication	O

Undergoing	O
abdominoplasty	B
or	O
TRAM	B
flap	I
breast	I
reconstruction	I

Patients	O
who	O
will	O
not	B
get	O
surgical	B
treatment	I
for	O
their	O
endometrial	B
cancer	I

Patients	O
not	B
suffering	O
from	O
endometrial	O
or	O
epithelial	B
ovarian	I
cancer	I

Patients	O
who	O
do	O
not	B
agree	O
to	O
the	O
proposed	O
treatment	O
or	O
will	O
receive	O
(	O
part	O
of	O
)	O
the	O
treatment	B
in	O
a	O
non	O
-	O
participating	O
centre	O

Patients	O
who	O
cannot	B
or	O
do	B
not	I
want	I
to	I
give	O
informed	O
consent	O
(	O
including	O
language	O
barriers	O
)	O

All	O
patients	O
referred	O
to	O
a	O
participating	O
research	O
centre	O
with	O
suspicion	O
of	O
or	O
confirmed	B
endometrial	B
cancer	I
.	O

Patients	O
with	O
endometrial	O
or	O
epithelial	B
ovarian	I
cancer	I
who	O
following	O
routine	O
clinical	O
guidelines	O
are	O
offered	O
weekly	B
taxane	B
(	O
paclitaxel	B
)	O
treatment	B
.	O

This	O
will	O
often	O
be	O
a	O
third	O
or	O
fourth	O
line	O
treatment	O
,	O
i	O
.	O
e	O
.	O
patients	O
with	O
advanced	O
disease	O
.	O

Technical	O
possibility	O
to	O
obtain	O
a	O
new	O
tissue	B
biopsy	I
to	O
determine	O
stathmin	O
level	O
in	O
the	O
tumour	B
recurrence	I
.	O

Contraindications	B
for	O
BB	B
.	O

Living	O
in	O
a	O
nursing	O
home	O
.	O

Life	O
expectancy	O
<	B
6	I
months	I
.	O

Unable	B
to	I
self	I
-	I
care	I
or	O
mental	B
disease	I
without	B
caregiver	I
.	O

Unable	B
to	O
weight	B

Without	B
phone	O

Unable	O
to	O
go	O
to	O
clinic	O
visit	O
.	O

Patient	O
with	O
"	O
de	B
novo	I
"	O
heart	B
Failure	I
and	O
LVEF	B
<	B
=	I
40	I
%	I
admitted	B
in	O
hospital	O
,	O
without	B
contraindications	B
for	O
BB	B
prescription	O
with	O
cardiologist	O
up	O
-	O
titration	O
prescription	O
and	O
without	O
having	O
achieved	O
BB	O
target	O
dose	O
previous	O
discharge	O
and	O
signing	O
informed	O
consent	O
.	O

1	O
.	O

Patient	O
with	O
equivocal	B
diagnosis	O
of	O
rupture	B
of	I
membranes	I

2	O
.	O
advanced	B
labor	I

3	O
.	O
intrauterine	B
infection	I

4	O
.	O
vaginal	B
bleeding	I
or	O

5	O
.	O
non	B
reassuring	I
fetal	B
heart	I
rate	I
.	O

1	O
.	O

PPROM	B
with	O
gestational	B
age	I
between	B
27	I
to	I
34	I
weeks	I

2	O
.	O

Cephalic	B
presentation	I

3	O
.	O

Clear	O
amniotic	O
fluid	O

4	O
.	O

Oral	B
temperature	I
>	B
38	I
C	I

5	O
.	O

Near	O
distance	O
from	O
the	O
hospital	O
(	O
the	O
patient	O
can	O
reach	O
hospital	O
within	O
one	O
hour	O
)	O

6	O
.	O

Home	O
environment	O
safe	O
and	O
amenable	O
to	O
rest	O
,	O
availability	O
of	O
family	O
support	O
such	O
as	O
a	O
sister	O
or	O
mother	O
who	O
will	O
help	O
the	O
patient	O
at	O
home	O
.	O

7	O
.	O

Maternal	O
and	O
fetal	B
condition	I
remain	O
stable	B
after	B
hospitalization	I
for	I
72	I
hours	I

Babies	B
who	O
have	B
been	I
close	O
to	O
death	O

Seizure	B
occurred	O
by	O
metabolic	B
factors	I
(	O
hypoglycemia	B
,	O
hypocalcemia	B
,	O
electrolyte	B
disorder	I
)	O

Babies	B
who	O
have	O
received	O
phenobarbitone	B
or	O
any	B
other	I
anticonvulsive	B
medication	I
before	O
hospitalization	B

Abnormal	B
renal	B
function	I

Male	B
or	O
female	B
term	B
baby	B
with	O
gestational	B
>	B
37	I
weeks	I
and	O
postnatal	B
age	I
<	B
or	I
=	I
28	I
days	I

Birthweight	B
>	B
2500g	I

Written	O
informed	O
consent	O
of	O
parent	O
or	O
guardian	O

Has	O
previously	O
received	O
Dapsone	B
therapy	O
.	O

The	O
subject	O
or	O
any	O
of	O
their	O
healthcare	O
providers	O
is	O
aware	O
of	O
the	O
subjects	O
HLA	O
type	O
.	O

Has	O
been	O
diagnosed	O
with	O
Glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
or	O
methemoglobin	B
reductase	I
deficiency	I

Satisfies	O
any	O
contraindications	B
or	O
restrictions	O
to	O
Dapsone	B
therapy	O
as	O
listed	O
in	O
the	O
product	O
labels	O
.	O

Current	O
severe	O
illness	O
,	O
including	O
heart	O
,	O
liver	O
and	O
renal	B
failure	I
,	O
major	B
organ	I
allograft	I
,	O
malignancy	B
requiring	O
parenteral	O
chemotherapy	B
that	O
can	O
not	O
be	O
discontinued	O
for	O
the	O
duration	O
of	O
the	O
trial	O
,	O
or	O
any	O
other	O
conditions	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
would	O
make	O
the	O
patient	O
unsuitable	O
for	O
the	O
study	O
.	O

Any	O
laboratory	O
abnormality	O
at	O
Screening	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
should	O
preclude	O
the	O
subject	O
'	O
s	O
participation	O
in	O
the	O
study	O
[	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
,	O
glutamic	O
oxaloacetic	O
transaminase	O
(	O
ALT	O
)	O
,	O
et	O
al	O
)	O
.	O

Pregnant	O
women	O
or	O
women	O
who	O
are	O
breastfeeding	O
.	O

Subject	O
is	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
unable	O
to	O
complete	O
the	O
6	O
week	O
Observation	O
period	O
and	O
the	O
EPT	O
assessments	O
as	O
required	O
.	O

A	O
positive	B
result	O
for	O
HLA	B
-	I
B	I
*	I
1301	I
in	O
those	O
subjects	O
randomised	O
to	O
the	O
genetic	O
screening	O
arm	O
.	O

Diagnosed	O
with	O
cutaneous	B
vasculitis	I
,	O
urticaria	B
,	O
psoriasis	B
,	O
acne	B
,	O
bullous	B
skin	I
diseases	I
,	O
sterile	B
pustulosis	I
,	O
leprosy	B
,	O
pneumocystis	B
pneumonia	I
and	O
any	O
other	O
patients	O
who	O
need	O
dapsone	B
administration	O
.	O

Subjects	O
are	O
dapsone	B
-	O
naive	B
.	O

All	O
subjects	O
must	O
have	O
a	O
clinical	O
need	O
for	O
treatment	O
with	O
dapsone	O
that	O
precedes	O
the	O
decision	O
to	O
participate	O
in	O
the	O
study	O
.	O

All	O
subjects	O
are	O
willing	O
to	O
complete	O
the	O
6	O
-	O
weeks	O
period	O
clinical	O
trial	O
.	O

All	O
subjects	O
are	O
written	O
informed	O
consent	O
.	O

Do	O
not	O
sign	O
informed	O
consent	O

Pregnant	B
patients	O

Liver	B
cirrhosis	I

Undifferentiated	B
adenocarcinoma	B
.	O

cT4	B

Metastatic	B
disease	I
(	I
M1	I
)	I

chronic	B
renal	I
failure	I
on	O
dialysis	B

ASA	B
IV	B

BMI	B
<	B
18	I
and	I
>	I
35	I
kg	I
/	I
m2	I

Age	B
over	B
18	I
years	I

Patients	O
with	O
rectal	B
cancer	I
stage	B
:	O
cT1	B
-	B
2	I
-	I
3	I
,	O
cN0	B
-	B
1	I
,	O
cM0	B
.	O

Tumor	B
equal	B
or	I
below	I
10	I
cm	I
from	I
the	I
anal	I
verge	I
,	O
candidates	O
to	O
(	O
ETM	O
)	O
low	B
anterior	I
resection	I
and	O
anastomosis	O
,	O
with	O
or	O
without	O
preoperative	B
chemo	B
-	I
radiotherapy	I
.	O

Adenocarcinoma	B
of	O
low	B
or	I
moderate	I
differentiation	I

ASA	B
I	B
,	I
II	I
,	I
III	I
.	O

long	B
-	I
term	I
use	I
of	O
analgesics	B
,	O
sedatives	B
or	O
non	B
steroidal	I
anti	I
-	I
inflammatory	I
drugs	I
history	B
.	O

known	O
for	O
dexmedetomidine	B
or	O
other	B
drugs	B
allergy	B
in	O
this	O
study	O
.	O

cannot	O
communicate	O
.	O

preoperative	B
systolic	I
blood	I
pressure	I
<	B
90	I
mmHg	I
,	O
or	O
the	O
heart	B
rate	I
<	B
50	I
/	I
min	I
.	O

patients	O
undergoing	O
venous	B
malformation	I
embolization	I
operation	I
through	O
general	B
anesthesia	I
.	O

aged	B
18	B
-	I
65	I
years	I
old	I
.	O

operating	B
time	I
varies	O
1	B
-	I
4h	I
,	O
and	O
extubation	B
after	O
the	O
operation	B
.	O

Unable	O
to	O
read	O
and	O
understand	O
the	O
Danish	O
language	O
or	O
to	O
give	O
informed	O
consent	O

Cervical	B
dilatation	I
>	B
4	I
cm	I

Non	B
-	I
cephalic	I
presentation	I

Multiple	B
gestation	I

Pathological	B
fetal	I
heart	I
rate	I
pattern	I
(	O
cardiotocogram	B
,	O
CTG	B
)	O
before	O
Syntocinon	B
®	I
initiation	O

Fetal	B
weight	I
estimation	I
>	B
4500	I
g	I
(	O
clinical	B
or	O
ultrasonic	B
)	O

Subject	O
declines	O
participation	O

Gestational	B
age	I
less	B
than	I
37	I
completed	I
weeks	I

Women	B
stimulated	O
with	O
Syntocinon	B
®	I
infusion	O
for	O
induction	B
of	I
labour	I
(	O
with	O
or	O
without	O
cervical	B
priming	I
by	O
prostaglandin	B
)	O

Non	B
papillary	I
gross	I
features	I
of	O
the	O
tumor	B

Anteriorly	B
located	I
tumor	B

Patients	O
criteria	O

Poor	B
performance	O
status	O

History	B
of	O
BCG	B
sepsis	B

History	B
of	O
bladder	B
irradiation	I

Contracted	B
bladder	I

Patients	O
diagnosed	O
at	O
the	O
out	O
-	O
patient	O
cystoscopy	B
with	O
papillary	B
bladder	I
tumour	I
will	O
be	O
legible	O
for	O
inclusion	O

Chronic	B
pain	I
more	B
than	I
3	I
months	I

Drug	B
abuse	I

Chronic	B
use	O
of	O
analgesic	B
drugs	I
(	O
more	B
than	I
3	I
months	I
)	O

Psychiatric	B
illness	I

Peripheral	B
neuropathy	I

Drug	B
allergy	B

Severe	B
gastroesophageal	B
reflux	I
disease	I

Male	B
sex	O

ASA	B
status	I
I	B
or	I
II	I

BMI	B
between	B
20	I
and	I
34	I
kg	I
/	I
m2	I

Cruciate	B
ligament	I
of	I
the	I
knee	I
reconstructive	B
surgery	I

No	B
contraindications	B
to	O
general	O
and	O
regional	B
anesthesia	I

Apnea	B
-	I
hypopnea	I
index	I
of	O
less	B
than	I
5	I
h	I
-	I
1	I
or	I
greater	I
than	I
30	I
h	I
-	I
1	I
.	O

Predominance	B
of	O
central	B
apneas	I
and	I
hypopneas	I
,	O
defined	O
as	O
more	B
than	I
25	I
%	I
of	O
all	B
respiratory	I
events	I
.	O

Professional	B
drivers	I
,	O
risk	B
profession	I
or	O
respiratory	B
failure	I
(	O
according	O
to	O
criteria	B
of	I
the	I
clinical	I
pathway	I
for	I
diagnosis	I
and	I
treatment	I
of	I
sleep	I
-	I
disordered	I
breathing	I
)	O
.	O

Very	B
excessive	I
daytime	B
sleepiness	I
(	O
Epworth	B
Sleepiness	I
Scale	I
>	B
18	I
)	O
.	O

Morbid	B
obesity	I
(	O
BMI	B
>	B
40	I
kg	I
/	I
m2	I
)	O
.	O

Prior	B
treatment	O
with	O
CPAP	B
.	O

Diagnosis	O
of	O
dyslipidemia	B
:	O
The	O
existence	O
of	O
a	O
previous	O
clinical	O
diagnostic	O
of	O
dyslipidemia	B
associated	O
with	O
lipid	B
-	I
lowering	I
therapy	I
.	O

It	O
is	O
also	O
considered	O
patients	O
who	O
have	O
an	O
altered	B
analytical	I
,	O
using	O
the	O
following	O
cutoffs	O
:	O
total	B
cholesterol	I
=	B
200	I
mg	I
/	I
dl	I
,	O
triglycerides	B
=	B
180	I
mg	I
/	I
dl	I
,	O
HDL	B
-	I
cholesterol	I
=	B
40	I
mg	I
/	I
dl	I
or	O
LDL	B
-	I
cholesterol	I
=	B
150	I
mg	I
/	I
dl	I
.	O

Lipid	B
-	I
lowering	I
treatment	I
and	O
diet	O
,	O
stable	B
in	B
the	I
last	I
month	I
.	O

A	O
concentration	O
of	O
LDL	B
-	I
cholesterol	I
above	B
100	I
mg	I
/	I
dl	I
,	O
in	B
the	I
month	I
prior	I
to	I
inclusion	I
.	O

An	O
apnea	B
-	I
hypopnea	I
index	I
between	B
5	I
-	I
30	I
h	I
-	I
1	I

Aged	B
under	B
18	I
,	O

Lack	B
of	I
informed	O
consent	O
signed	O
,	O

Radiofrequency	B
treatment	I
history	B
,	O

on	B
going	I
neoplastic	B
history	B
with	O
a	O
short	B
prognosis	B
,	O

Concomitant	B
participation	O
in	O
another	O
clinical	O
study	O

Contraindication	B
to	O
general	B
anesthesia	I
,	O

Patient	O
with	O
an	O
esophageal	B
location	I
of	O
scleroderma	B

Presence	O
of	O
a	O
cardiac	B
pacemaker	I
or	O
stimulator	O

Pregnant	O
women	B
or	O
likely	O
to	O
be	O
in	B
the	I
absence	I
of	I
effective	I
contraception	I
,	O

Esophageal	B
stenosis	I
preventing	O
the	O
passage	O
of	O
an	O
endoscope	B
,	O

Histology	B
other	B
than	I
glandular	B
neoplasia	I
,	O

History	B
of	O
or	O
current	B
history	O
of	O
esophageal	B
cancer	I
invading	B
the	I
submucosal	I
layer	I
of	I
the	I
esophagus	I
or	O
more	O
,	O

Surgical	B
treatment	I
history	B
(	O
except	B
anti	B
-	I
reflux	I
treatment	I
)	O
or	O
esophageal	B
radiotherapy	I
,	O

previous	B
esophageal	B
treatment	I
by	O
another	B
method	I
ablation	B
:	O
photodynamic	B
therapy	I
,	O
argon	B
plasma	I
coagulation	I
,	O
laser	B
,	O
.	O
.	O
.	O
.	O

Esophageal	B
varices	I
observed	O
in	O
endoscopy	B
,	O

Coagulopathy	B
or	O
taking	O
anticoagulants	B
responsible	O
an	O
INR	B
>	B
1	I
.	I
3	I
or	O
a	O
platelet	B
count	I
<	B
75	I
,	I
000	I
per	I
microL	I
,	O

Life	B
expectancy	I
of	O
less	B
than	I
3	I
years	I
,	O
due	O
to	O
intercurrent	B
disease	I
,	O
especially	O
neoplastic	B
,	O

Liver	B
cirrhosis	I
(	O
Child	B
-	I
Pugh	I
all	B
stages	I
)	O

Respiratory	B
failure	I
:	O

Renal	B
failure	I
(	O
Cl	B
Cr	I
<	B
60	I
mL	I
/	I
min	I
/	I
1	I
,	I
73m	I
)	O
,	O

Heart	B
attack	I
within	B
the	I
last	I
six	I
months	I
or	O
progressive	B
coronary	I
artery	I
disease	I
,	O

Severe	B
distal	B
arteriopathie	I
>	B
stage	I
II	I
of	O
Leriche	O
and	O
Fontaine	O

Age	B
over	B
18	I
years	I
,	O

General	B
Condition	I
WHO	I
0	B
,	O
1	B
or	O
2	B
,	O

ASA	B
Class	I
I	B
and	O
II	B
,	O
eligible	O
for	O
endoscopic	O
or	O
surgical	B
treatment	I
with	B
curative	I
intent	I
,	O

Histological	B
diagnosis	I
of	O
high	B
grade	I
glandular	B
epithelial	I
neoplasia	I
(	O
Vienna	B
4	B
-	I
1	I
to	I
4	I
-	I
46	I
)	O
,	O
possibly	O
multifocal	B
or	O
stage	B
0	B
(	O
Tis	B
,	O
N0	B
,	O
M0	B
)	O
,	O

Endoscopic	B
and	O
histological	B
confirmed	O
diagnosis	O
of	O
intestinal	B
metaplasia	I
,	O

Histological	B
diagnosis	B
confirmed	O
by	O
two	B
endoscopies	B
with	O
biopsies	B
and	O
two	B
pathological	B
readings	I
;	O
biopsies	O
should	O
be	O
carried	O
out	O
according	O
to	O
the	O
protocol	O
of	O
the	O
SFED	O
(	O
four	O
-	O
quadrant	O
biopsies	O
every	O
cm	O
)	O
with	O
at	O
least	O
once	O
acetic	O
acid	O
for	O
staining	O
.	O

Operators	O
describe	O
Barrett	O
'	O
s	O
esophagus	O
using	O
he	O
SFED	O
planimetric	O
model	O
.	O

The	O
final	O
exam	O
will	O
be	O
no	O
more	O
than	O
two	O
months	O
before	O
the	O
date	O
of	O
treatment	O
and	O
should	O
have	O
been	O
achieved	O
in	O
investigator	O
establishment	O
,	O

Minimum	O
1	O
cm	O
,	O

Maximum	O
12	O
cm	O
.	O

the	O
resected	B
lesion	I
must	O
have	O
been	O
well	B
differentiated	I
and	O
confined	B
to	I
the	I
mucosa	I
(	O
m2	B
maximum	I
)	O
on	O
histological	B
analysis	I
,	O

resection	B
should	O
be	O
more	B
than	I
two	I
months	I
,	O

resection	B
must	O
have	O
been	O
macroscopically	B
complete	I
laterally	I
,	O

resection	B
must	O
have	O
been	O
histologically	B
complete	B
in	I
depth	I
,	O

resection	B
must	O
have	O
been	O
histologically	B
complete	B
laterally	I
with	O
regard	O
to	O
the	O
microinvasive	B
cancer	I
,	O
that	O
is	O
to	O
say	O
with	O
a	O
clear	O
margin	O
of	O
safety	O
(	O
margin	O
may	O
be	O
high	O
-	O
grade	O
dysplasia	O
provided	O
that	O
the	O
latter	O
has	O
not	O
macroscopic	O
translation	O
)	O
,	O

At	O
least	O
one	O
endoscopic	O
and	O
histologic	O
follow	O
-	O
up	O
should	O
be	O
conducted	O
with	O
dye	O
in	O
a	O
period	O
of	O
less	O
than	O
two	O
months	O
before	O
the	O
date	O
of	O
treatment	O
,	O
and	O
at	O
the	O
investigator	O
establishment	O
.	O

Patient	O
may	O
take	O
an	O
inhibitor	O
of	O
proton	O
pump	O
equivalent	O
to	O
2	O
times	O
40	O
mg	O
of	O
esomeprazole	O
,	O

No	B
mediastinal	B
or	O
celiac	B
,	O
or	O
suspected	O
metastatic	B
lymph	B
nodes	I
by	O
EUS	B
,	O

Affiliation	O
to	O
a	O
social	O
security	O
system	O
or	O
similar	O
,	O

Lack	B
of	I
participation	O
in	O
another	B
clinical	O
study	O
,	O

Informed	O
consent	O
signed	O
.	O

Claustrophobia	B
,	O
or	O
the	O
inability	O
to	O
lie	O
still	O
in	O
a	O
confined	O
space	O

Major	B
medical	B
disorders	I
(	O
e	O
.	O
g	O
.	O
,	O
HIV	B
,	O
cancer	B
)	O

Magnetic	B
metallic	I
implants	I
(	O
such	O
as	O
screws	B
,	O
pins	B
,	O
shrapnel	B
remnants	I
,	O
aneurysm	B
clips	I
,	O
artificial	B
heart	I
valves	I
,	O
inner	O
ear	O
(	O
cochlear	B
)	I
implants	I
,	O
artificial	B
joints	I
,	O
and	O
vascular	B
stents	I
)	O

Electronic	O
or	O
magnetic	B
implants	I
,	O
such	O
as	O
pacemakers	B

Permanent	O
makeup	O
or	O
tattoos	O
with	O
metallic	B
dyes	I

Currently	O
pregnant	B

A	O
self	B
-	I
reported	I
history	B
of	I
loss	I
of	I
consciousness	I
(	O
greater	B
than	I
10	I
minutes	I
)	O

Physical	O
disabilities	O
that	O
prohibit	O
task	O
performance	O
(	O
such	O
as	O
blindness	B
or	O
deafness	B
)	O

Psychotic	B
disorders	I
(	O
e	O
.	O
g	O
.	O
,	O
schizophrenia	B
)	O

Any	O
other	O
condition	O
that	O
the	O
investigator	O
believes	O
might	O
put	O
the	O
participant	O
at	O
risk	O

25	B
-	I
50	I
years	I
of	O
age	B

PTSD	B
related	O
to	O
physical	O
or	O
sexual	O
assault	O

Medically	O
healthy	O

English	O
speaking	O

History	O
of	O
a	O
primary	B
sleep	I
disorder	I
other	B
than	O
RLS	B
that	O
may	O
significantly	O
affect	O
the	O
symptoms	O
of	O
RLS	O
.	O

Serum	B
ferritin	I
level	O
<	B
20	I
ng	I
/	I
mL	I
at	O
screening	O
.	O

History	O
of	O
allergy	B
,	O
hypersensitivity	B
,	O
or	O
intolerance	B
to	O
HORIZANT	B
or	O
any	O
other	O
gabapentin	B
products	O
(	O
eg	O
,	O
Neurontin	B
®	O
,	O
Gralise	B
®	O
)	O
.	O

Suffering	O
from	O
a	O
movement	B
disorder	I
that	O
could	O
mimic	O
or	O
confound	O
the	O
accurate	O
diagnosis	O
of	O
RLS	O
(	O
eg	O
,	O
Tourette	B
'	I
s	I
syndrome	I
,	O
tic	B
disorder	I
,	O
periodic	B
limb	I
movement	I
disorder	I
[	O
PLMD	B
]	O
,	O
sleep	B
disorders	I
)	O
.	O

Currently	O
meet	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
-	I
Fifth	I
Edition	I
(	O
DSM	B
-	I
5	I
)	O
criteria	O
for	O
substance	B
use	I
disorder	I
,	O
or	O
history	O
thereof	O
,	O
within	B
12	I
months	I
before	O
dosing	O
.	O

Current	O
or	O
past	O
history	O
of	O
any	O
significant	B
psychiatric	B
disorder	I
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
depression	B
(	O
treatment	O
with	O
antidepressants	B
)	O
,	O
bipolar	B
disorder	I
,	O
or	O
schizophrenia	B
.	O

Diagnosis	O
of	O
attention	B
-	I
deficit	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
is	O
allowed	B
,	O
provided	O
the	O
patient	O
is	O
not	O
receiving	O
medication	O
(	O
s	O
)	O
known	O
to	O
affect	O
the	O
assessment	O
of	O
RLS	O
.	O

History	O
of	O
suicidal	O
behavior	O
or	O
suicidal	B
ideation	I
as	O
indicated	O
by	O
the	O
C	O
-	O
SSRS	O
,	O
administered	O
at	O
screening	O
(	O
the	O
questionnaire	O
is	O
provided	O
in	O
Appendix	O
4	O
)	O
,	O
and	O
as	O
per	O
investigator	O
'	O
s	O
judgment	O
.	O

History	O
of	O
seizure	B
disorder	I
or	O
at	O
increased	O
risk	O
for	O
development	O
of	O
a	O
seizure	O
disorder	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
complicated	B
febrile	I
seizure	I
and	O
history	O
of	O
significant	O
head	B
injury	I
.	O

Medical	O
condition	O
or	O
disorder	O
that	O
would	O
interfere	O
with	O
the	O
action	O
,	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
or	O
excretion	O
of	O
gabapentin	O
enacarbil	O
,	O
or	O
,	O
in	O
the	O
investigator	O
'	O
s	O
judgment	O
is	O
considered	O
to	O
be	O
clinically	O
significant	O
and	O
may	O
pose	O
a	O
safety	O
concern	O
,	O
or	O
,	O
could	O
interfere	O
with	O
the	O
accurate	O
assessment	O
of	O
safety	O
or	O
efficacy	O
,	O
or	O
could	O
potentially	O
affect	O
a	O
patient	O
'	O
s	O
safety	O
or	O
study	O
outcome	O
.	O

Clinically	O
significant	O
abnormal	O
laboratory	O
result	O
or	O
physical	O
examination	O
finding	O
not	O
resolved	O
by	O
the	O
time	O
of	O
baseline	O
assessments	O
.	O

Male	B
and	O
female	B
adolescent	B
patients	O
,	O
aged	B
13	B
to	I
17	I
years	I
,	O
diagnosed	O
with	O
RLS	B
based	O
on	O
the	O
IRLSSG	B
consensus	I
criteria	I
(	O
Allen	O
RP	O
2014	O
)	O
(	O
Appendix	O
2	O
)	O
.	O

Total	B
RLS	I
severity	I
score	I
of	O
15	B
or	I
greater	I
on	O
the	O
IRLS	O
rating	O
scale	O
at	O
Visit	O
1	O
(	O
screening	O
)	O
and	O
at	O
Visit	O
2	O
(	O
baseline	O
)	O
(	O
Appendix	O
8	O
)	O
.	O

RLS	B
symptoms	I
for	O
at	B
least	I
4	I
of	I
7	I
consecutive	I
evenings	I
/	I
nights	I
during	O
the	O
screening	O
period	O
.	O

Body	B
weight	I
greater	B
than	I
33	I
.	I
4	I
kg	I
and	O
a	O
healthy	O
weight	O
using	O
age	O
-	O
based	O
body	B
mass	I
index	I
(	O
BMI	B
)	O
range	O
5th	B
-	I
85th	I
percentile	I
at	O
screening	O
and	O
baseline	O
.	O

Appendix	O
3	O
contains	O
BMI	O
-	O
for	O
-	O
age	O
charts	O
that	O
can	O
be	O
consulted	O
.	O

Estimated	B
creatinine	I
clearance	I
of	O
at	B
least	I
60	I
mL	I
/	I
min	I
(	O
using	O
the	O
Cockcroft	O
-	O
Gault	O
equation	O
)	O
at	O
screening	O
only	O
.	O

Signed	O
patient	O
and	O
parent	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
-	O
approved	O
informed	O
consent	O
/	O
assent	O
form	O
(	O
as	O
applicable	O
)	O
before	O
any	O
study	O
-	O
related	O
procedures	O
are	O
performed	O
.	O

severe	B
behavioral	B
issues	I

presence	O
of	O
fistula	B
or	O
abscess	B
near	B
the	I
selected	I
tooth	I

presence	O
of	O
pulp	B
exposure	I
in	O
the	O
selected	B
tooth	I

presence	O
of	O
mobility	B
in	O
the	O
selected	B
tooth	I

Children	B
aging	B
between	B
3	I
and	I
6	I
years	I

presenting	O
good	B
health	I
conditions	I

whose	O
parents	O
or	O
legal	O
guardians	O
accept	O
and	O
sign	O
the	O
consent	O
form	O

with	O
at	B
least	I
one	I
occlusal	B
or	O
occlusal	B
proximal	I
caries	B
lesion	I
in	O
primary	B
molars	I

only	O
occlusal	O
and	O
/	O
or	O
occlusal	B
-	I
proximal	I
surfaces	I
with	O
caries	B
lesions	I
with	O
dentin	B
involvement	I

need	O
for	O
major	B
amputation	I
known	O
before	O
intervention	O

allergy	B
to	O
Paclitaxel	B

contraindication	B
for	O
combined	B
antiplatelet	I
treatment	I

life	O
expectancy	O
<	B
1	I
year	I

hypersensitivity	B
or	O
contraindication	B
to	O
one	B
of	I
the	O
study	B
drugs	I

lack	O
of	O
consent	O

age	B
>	B
18	I
years	I

critical	B
limb	B
ischemia	I
(	O
Rutherford	B
class	I
4	B
-	I
6	I
)	O

angiographic	B
stenosis	I
>	B
50	I
%	I
or	O
occlusion	B
of	O
at	B
least	I
one	I
tibial	B
vessel	I
of	O
at	B
least	I
40mm	I
for	O
which	O
an	O
interventional	B
treatment	I
is	O
scheduled	O

Subject	O
is	O
pregnant	O
,	O
or	O
lactating	O
,	O
or	O
of	O
childbearing	O
potential	O
(	O
to	O
be	O
considered	O
of	O
non	O
-	O
childbearing	O
potential	O
,	O
a	O
female	O
must	O
be	O
post	O
-	O
menopausal	O
for	O
at	O
least	O
1	O
year	O
,	O
surgically	O
sterile	O
,	O
or	O
using	O
an	O
effective	O
method	O
of	O
contraception	O
or	O
abstinence	O
from	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
the	O
first	O
vaccination	O
and	O
until	O
at	O
least	O
4	O
weeks	O
after	O
the	O
last	O
vaccination	O
.	O

Participation	O
in	O
the	O
4	O
weeks	O
preceding	O
the	O
first	O
trial	O
vaccination	O
,	O
or	O
planned	O
participation	O
during	O
the	O
present	O
trial	O
period	O
,	O
in	O
another	O
clinical	O
trial	O
investigating	O
a	O
vaccine	O
,	O
drug	O
,	O
medical	O
device	O
,	O
or	O
medical	O
procedure	O
.	O

Previous	B
history	I
of	O
receiving	O
the	O
rabies	B
vaccine	I
.	O

Previous	B
history	I
of	O
receiving	O
rabies	B
immune	I
globulin	I
.	O

Any	O
major	B
psychiatric	I
disorder	I
,	O
such	O
as	O
severe	B
depression	B
,	O
severe	B
anxiety	B
disorder	I
,	O
psychosis	B
,	O
schizophrenia	B
,	O
other	B
major	B
psychiatric	I
disorders	I
,	O
or	O
seizures	B
.	O

History	O
of	O
mild	B
depression	B
or	O
anxiety	B
disorder	I
that	O
are	O
well	B
controlled	I
are	O
not	B
exclusion	O
criteria	O
.	O

Use	O
of	O
any	O
immunosuppressive	B
drug	I
at	B
the	I
time	I
of	I
the	I
study	I
or	O
30	B
days	I
previously	I
.	O

Topical	B
steroids	I
will	O
not	B
be	O
considered	O
an	O
immunosuppressive	O
drug	O
and	O
their	O
use	O
will	O
not	O
be	O
considered	O
an	O
exclusion	O
criteria	O
.	O

Any	O
immunosuppressive	B
disorder	I
,	O
such	O
as	O
HIV	B
infection	I
,	O
common	B
variable	I
immunodeficiency	I
,	O
active	B
cancers	B
or	O
chemotherapy	B
.	O

History	B
of	O
renal	B
insufficiency	I
or	O
requiring	O
dialysis	B
.	O

Have	O
any	O
condition	O
that	O
would	O
,	O
in	O
the	O
opinion	O
of	O
the	O
site	O
investigator	O
,	O
place	O
the	O
subject	O
at	O
an	O
unacceptable	O
risk	O
of	O
injury	O
or	O
render	O
the	O
subject	O
unable	O
to	O
meet	O
the	O
requirements	O
of	O
the	O
protocol	O
.	O

Identified	O
as	O
an	O
employee	O
of	O
the	O
Investigator	O
or	O
study	O
center	O
,	O
with	O
direct	O
involvement	O
in	O
the	O
proposed	O
study	O
or	O
other	O
studies	O
under	O
the	O
direction	O
of	O
that	O
Investigator	O
or	O
study	O
center	O
,	O
as	O
well	O
as	O
family	O
members	O
(	O
i	O
.	O
e	O
.	O
,	O
immediate	O
,	O
husband	O
,	O
wife	O
and	O
their	O
children	O
,	O
adopted	O
or	O
natural	O
)	O
of	O
the	O
employee	O
or	O
the	O
Investigator	O
.	O

Previous	B
adverse	B
reaction	I
to	O
any	O
of	O
the	O
antimalarial	B
drugs	I
used	B
in	I
this	I
study	I
.	O

Provide	O
signed	O
and	O
dated	O
informed	O
consent	O
form	O
.	O

Willing	O
to	O
comply	O
with	O
all	O
study	O
procedures	O
and	O
be	O
available	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Male	B
or	O
female	B
,	O
aged	B
=	B
18	I
to	I
=	I
60	I
years	I
on	B
day	I
of	I
inclusion	I
.	O

In	O
good	B
general	I
health	I
based	O
on	O
medical	B
history	I
and	O
physical	B
exam	I

Have	O
not	B
received	O
influenza	B
vaccination	I
in	O
the	O
past	O
or	O
cannot	O
be	O
vaccinated	O
due	O
to	O
previous	O
severe	O
reaction	O
to	O
influenza	O
vaccine	O
,	O
egg	O
,	O
latex	O
,	O
or	O
thimerosol	O
allergies	O
,	O
or	O
refusal	O
of	O
vaccination	O

Participant	O
has	O
received	O
a	O
community	O
available	O
influenza	B
vaccine	I
within	B
<	I
6	I
months	I

History	O
of	O
Guillain	B
-	I
Barré	I
syndrome	I

Immunosuppressive	B
disorders	I
or	O
medications	O
(	O
including	O
oral	B
prednisone	I
>	B
10	I
mg	I
daily	I
,	O
recent	O
chemotherapy	B
treatment	O
)	O

Emergency	O
cases	O
as	O
determined	O
by	O
the	O
investigator	O
or	O
physician	O

Subjects	O
who	O
the	O
investigator	O
believes	O
can	O
and	O
will	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
(	O
i	O
.	O
e	O
.	O
return	O
for	O
follow	O
-	O
up	O
visits	O
,	O
and	O
able	O
to	O
converse	O
with	O
study	O
personnel	O
)	O

Age	B
18	B
years	I
or	I
older	I

Undergoing	O
major	B
cardiac	I
surgery	I
using	O
cardiopulmonary	B
bypass	I

planned	B
surgical	I
duration	I
more	B
than	I
3	I
hours	I

contraindication	B
to	O
spinal	B
anaesthesia	I

severe	B
respiratory	B
disease	I

patient	O
known	O
and	O
treated	B
for	O
sleep	B
apnea	I
syndrome	I

physical	B
status	I
I	B
-	I
III	I

patients	O
scheduled	O
to	O
undergo	O
hip	B
arthroplasty	I

patient	O
'	O
s	O
refusal	O

contraindications	B
to	O
dexmedetomidine	B

diseases	B
/	O
drugs	B
that	O
influence	B
on	I
autonomic	I
nervous	I
system	I
activity	I

patients	O
classified	O
with	O
American	O
Society	O
of	O
Anesthesiologists	O
Physical	O
Status	O
Classification	O
System	O
as	O
1	B
or	I
2	I
status	O

planned	O
eye	B
surgery	I
under	O
sedation	B

The	O
patient	O
is	O
unwilling	O
to	O
provide	O
informed	O
consent	O

acutely	B
sick	I
(	O
for	O
example	O
,	O
crying	B
,	O
wheezing	B
,	O
bleeding	B
,	O
screaming	B
or	O
shaken	B
)	O

unable	O
to	O
participate	O
in	O
a	O
discussion	O
about	O
the	O
study	O

between	B
7	I
to	I
70	I
years	I
of	O
age	B

fluent	O
in	O
English	O
or	O
Spanish	O

plans	O
to	O
receive	B
care	I
in	O
the	O
Community	O
Health	O
Center	O
during	B
the	I
next	I
year	I

presents	O
with	O
signs	B
and	O
symptoms	B
of	O
a	O
SSTI	B

willing	O
/	O
able	O
to	O
provide	O
informed	O
consent	O

Respiratory	B
exacerbation	I
within	B
the	I
2	I
months	I
preceding	I
the	I
study	I

Current	B
diagnostic	B
of	I
asthma	I

Significant	B
O2	B
desaturation	I
(	O
SpO2	B
<	B
85	I
%	I
)	O
at	B
rest	I
or	O
during	B
exercise	I

Presence	O
of	O
another	B
pathology	B
that	O
could	O
influence	B
exercise	I
tolerance	I

Use	O
of	O
home	B
oxygen	I

Age	B
>	B
50	I
years	I

Smoking	B
history	I
>	B
10	I
packs	I
/	I
year	I

FEV1	B
30	B
-	I
79	I
%	I
of	I
predicted	I
and	O
FEV1	B
/	I
FVC	I
<	B
70	I
%	I
(	O
GOLD	B
2	B
-	I
3	I
)	O

FRC	B
>	B
120	I
%	I
predicted	I

Borg	B
dyspnea	I
score	I
>	B
3	I
during	O
the	O
3	B
-	I
min	I
constant	I
rate	I
shuttle	I
walking	I
test	I
at	O
V3	B

allergy	B
to	O
morphine	B
or	O
ketamine	B

contraindicate	B
to	O
ketamine	B

remain	O
intubated	B
in	B
the	I
postoperative	I
period	I

ASA	B
physical	I
status	I
1	B
-	I
3	I

elective	B
thoracotomy	B

can	O
operate	O
patient	O
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
machine	O

Evidence	O
of	O
concomitant	B
infection	I
on	O
exam	O
or	O
gram	O
stain	O
(	O
i	O
.	O
e	O
.	O
herpes	O
,	O
both	O
bacteria	O
and	O
acanthamoeba	O
on	O
gram	O
stain	O
)	O

Impending	O
or	O
frank	O
perforation	B
at	O
recruitment	O

Involvement	B
of	I
sclera	I
at	O
presentation	O

Non	O
-	O
infectious	O
or	O
autoimmune	B
keratitis	I

History	O
of	O
corneal	B
transplantation	I
or	O
recent	O
intraocular	B
surgery	I

No	B
light	B
perception	I
in	O
the	O
affected	O
eye	O

Pinhole	B
visual	I
acuity	I
worse	B
than	I
20	I
/	I
200	I
in	O
the	O
unaffected	O
eye	O

Participants	O
who	O
are	O
decisionally	O
and	O
/	O
or	O
cognitively	B
impaired	I

Corneal	B
ulcer	I
that	O
is	O
smear	B
positive	B
for	O
either	O
bacteria	B
or	O
filamentous	B
fungus	I

Pinhole	B
visual	I
acuity	I
worse	B
than	I
20	I
/	I
70	I
in	O
the	O
affected	O
eye	O

Not	O
treated	O
already	O
with	O
antimicrobial	B
medications	I
at	O
presentation	O

Age	B
over	B
18	I
years	I

Basic	O
understanding	O
of	O
the	O
study	O
as	O
determined	O
by	O
the	O
physician	O

Commitment	O
to	O
return	O
for	O
follow	O
up	O
visits	O

Upper	B
limb	I
bites	B

Multiple	B
(	O
>	B
1	I
)	O
bites	B

Wound	O
manipulation	O

Extensive	B
local	I
necrosis	I
or	O
blebs	O

Seriously	B
-	I
ill	I
patients	O
with	O
hypotension	B
/	O
capillary	B
leak	I
/	O
life	B
threatening	I
bleeding	B
.	O

Suspected	O
cobra	B
bite	I
,	O
OR	O

Pregnant	B
/	O
breast	B
-	I
feeding	I
women	B

Age	B
18	B
-	I
65	I
years	I

History	O
of	O
snake	B
bite	I
with	O
features	O
of	O
local	B
envenomation	I
with	O
/	O
without	O
systemic	B
features	I

Less	O
than	O
24	O
hours	O
since	O
bite	B
,	O
AND	O

No	B
prior	B
antibiotic	B
treatment	I

a	O
disease	B
that	O
might	O
affect	B
hepatic	I
or	I
renal	I
function	I
,	O
contraindications	B
to	O
opioid	B
analgesics	I
,	O
fetal	B
growth	I
retardation	I
,	O
signs	O
of	O
fetal	B
asphyxia	I
by	O
cardiotocography	B
,	O
meconium	B
stained	I
amniotic	I
fluid	I
or	O
placental	B
insufficiency	I
.	O

The	O
subjects	O
should	O
not	B
have	O
received	O
fentanyl	B
during	B
the	I
previous	I
14	I
days	I
.	O

healthy	B
parturients	B
with	O
uncomplicated	B
,	O
single	B
gestation	I
pregnancies	B
,	O
full	B
term	I
(	O
38	B
-	I
42	I
weeks	B
of	I
gestation	I
)	O
pregnancy	B
,	O
agreed	O
to	O
participate	O

age	B
less	B
than	I
18	I
years	I

allergy	B
to	O
study	B
drugs	I

substance	B
misuse	I
other	O
contraindication	B
to	O
used	O
study	B
drugs	I
no	O
informed	O
consent	O

normal	B
full	B
term	I
single	B
pregnancy	B

age	B
18	B
years	I
or	I
more	I

BMI	B
20	B
-	I
35	I
kg	I
/	I
m2	I

written	O
informed	O
consent	O
obtained	O

Patients	O
posing	O
a	O
serious	O
suicidal	O
risk	O
and	O
/	O
or	O
violence	O
as	O
judged	O
by	O
the	O
investigator	O
;	O

Delirium	B

Dementia	B

Amnestic	O
and	O
other	O
cognitive	B
disorder	I
;	O

Patients	O
with	O
a	O
history	O
of	O
hypothyroidism	B
unless	B
taking	O
a	O
stable	O
dose	O
of	O
thyroid	B
medication	I
and	O
asymptomatic	O
or	O
euthyroid	O
for	O
6	O
months	O
;	O

Patients	O
who	O
meet	O
DSM	B
-	I
IV	I
-	I
TR	I
criteria	O
for	O
any	O
significant	O
current	O
substance	B
abuse	I
;	O

hepatic	B
insufficiency	I
(	O
three	B
times	I
the	I
upper	I
limit	I
of	I
normal	I
(	O
ULN	O
)	O
for	O
aspartate	B
aminotransferase	I
(	O
AST	B
)	O
and	O
/	O
or	O
alanine	B
aminotransferase	I
(	O
ALT	B
)	O
)	O
;	O
liver	B
transplant	I
recipient	O
;	O
cirrhosis	B
of	I
the	I
liver	I
;	O

malignancy	B
(	O
except	B
basal	B
cell	I
carcinoma	I
)	O
and	O
/	O
or	O
chemotherapy	B
within	B
1	I
year	I
prior	I
to	I
screening	I
;	O
malignancy	B
more	B
than	I
1	I
year	I
prior	O
to	O
screening	O
must	O
have	O
been	O
local	B
and	O
without	B
metastasis	B
and	O
/	O
or	O
recurrence	B
,	O
and	O
if	O
treated	O
with	O
chemotherapy	O
,	O
without	O
nervous	O
system	O
complications	O
;	O

significant	O
unstable	B
medical	B
condition	I
or	O
life	B
threatening	I
disease	I
with	O
anticipated	O
survival	O
of	O
less	B
than	I
6	I
months	I
;	O

need	O
for	O
therapies	O
that	O
may	O
obscure	O
the	O
results	O
of	O
treatment	O
and	O
/	O
or	O
of	O
the	O
study	O

Participation	O
in	O
another	O
clinical	O
trial	O
within	O
30	O
days	O
of	O
the	O
screening	O
visit	O
;	O

Anticipated	O
inability	O
to	O
attend	O
scheduled	O
study	O
visits	O
;	O

Patients	O
who	O
in	O
the	O
judgment	O
of	O
the	O
Investigator	O
may	O
be	O
unreliable	O
or	O
uncooperative	O
with	O
the	O
evaluation	O
procedure	O
outlined	O
in	O
this	O
protocol	O
;	O

Patients	O
with	O
a	O
history	O
of	O
prior	O
pharmacogenomic	O
testing	O
;	O

Any	O
change	O
in	O
psychotropic	B
medication	I
(	O
including	O
change	O
in	O
dosage	O
)	O
between	O
screening	O
and	O
baseline	O
;	O

Patients	O
who	O
are	O
known	O
to	O
be	O
pregnant	O
or	O
lactating	O
;	O

Patients	O
with	O
a	O
history	O
of	O
gastric	B
bypass	I
surgery	I
.	O

18	O
years	O
of	O
age	B
or	O
older	O
;	O

Suffer	O
from	O
schizophrenia	B
/	O
schizoaffective	B
disorder	I
meeting	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
Fourth	I
Edition	I
,	I
Text	I
Revision	I
(	O
DSM	B
-	I
IV	I
-	I
TR	I
)	O
criteria	O
;	O

Have	O
a	O
total	O
baseline	O
score	O
on	O
the	O
Brief	B
Psychiatric	I
Rating	I
Scale	I
(	O
BPRS	B
)	O
=	B
45	I
;	O

Be	O
capable	O
and	O
willing	O
to	O
provide	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
this	O
study	O
;	O

Agree	O
to	O
abide	O
by	O
the	O
study	O
protocol	O
and	O
its	O
restrictions	O
and	O
be	O
able	O
to	O
complete	O
all	O
aspects	O
of	O
the	O
study	O
,	O
including	O
all	O
visits	O
and	O
tests	O

<	B
37	I
weeks	I
gestation	B
,	O
H	O
/	O
o	O
Cesarean	B
Section	I
,	O
Multiple	B
Gestation	I
,	O
Pre	B
-	I
eclampsia	I
,	O
Narcotics	B
within	O
3	O
hours	O
prior	O
to	O
labor	B
epidural	I
placement	I
,	O
Chronic	B
Pain	I
(	O
as	O
defined	O
by	O
chronic	B
opiate	B
consumption	O
)	O
,	O
Women	O
who	O
are	O
participating	O
in	O
another	O
study	O
that	O
will	O
impact	O
protocol	O

ASA	B
I	B
&	I
II	I
,	O
Nulliparous	B
and	O
Multiparous	B
,	O
Spontaneous	O
/	O
Induced	O
/	O
Augmented	B
Labor	I
,	O
Early	B
active	I
labor	I
(	O
cervix	B
<	B
5	I
cm	I
(	O
if	O
known	O
)	O
)	O
,	O
Pain	B
(	I
VPS	I
)	I
>	B
3	I
,	O
18	B
-	I
45	I
years	I
of	O
age	B

Planned	O
surgery	B
under	O
regional	B
anesthesia	I

contraindication	B
to	O
the	O
study	B
drug	I

contraindication	B
to	O
the	O
lumbar	B
puncture	I

Contraindication	B
to	O
oxycodone	B

Pregnancy	B
or	O
lactation	B

no	O
informed	O
consent	O

Planned	O
gynecological	B
lower	I
abdomen	I
surgery	I
with	O
epidural	B
pain	I
treatment	I

Informed	O
consent	O
obtained	O

Inability	B
to	I
perform	I
exercise	B
tests	I

Diagnosed	O
psychiatric	O
or	O
cognitive	B
disorders	I

Progressive	O
neurological	O
or	O
neuromuscular	O
disorders	O
having	O
a	O
major	O
impact	B
on	I
exercise	I
capacity	I

Previous	O
diagnoses	O
of	O
COPD	B
and	O
HF	B
under	O
optimized	B
clinical	B
treatment	I
as	O
judged	O
by	O
the	O
accompanying	O
physician	O

Reduced	B
left	B
ventricular	I
ejection	I
fraction	I
(	O
<	B
50	I
%	I
)	O

Non	B
-	I
reversible	I
airway	B
obstruction	I
(	O
post	B
-	I
bronchodilator	I
FEV1	B
/	I
FVC	I
<	B
0	I
.	I
7	I
and	O
FEV1	B
<	B
80	I
%	I
)	O

Respiratory	B
muscle	I
weakness	I
(	O
Pi	B
,	I
max	I
<	B
70cmH2O	I
)	O

Persistent	B
dyspnea	B
on	I
daily	I
life	I
(	O
Baseline	B
Dyspnea	B
Index	I
focal	I
score	I
<	B
or	I
=	I
8	I
)	O
.	O

Patients	O
with	O
azathioprine	B
or	O
biologics	B
therapy	B

Ulcerative	B
colitis	I
patients	O
with	O
moderate	B
to	I
severe	I
activity	O
who	O
achieved	O
a	O
clinical	B
remission	I
by	O
the	O
first	B
course	I
of	O
corticosteroids	B

Newly	O
diagnosed	O
or	O
without	B
steroid	B
use	O
during	B
last	I
1	I
year	I

Endoscopic	B
Mayo	I
subscore	I
>	B
0	I

Current	B
inpatient	O
hospitalization	B
or	O
active	B
suicidal	B
ideation	I
requiring	O
referral	B
for	O
inpatient	O
hospitalization	O
for	O
safety	O
.	O

History	B
of	O
psychotic	B
disorder	I
or	O
manic	B
episode	I
diagnosed	O
by	O
MINI	B
-	I
KID	I

History	B
of	O
substance	B
dependence	I
diagnosis	O
by	O
MINI	B
-	I
KID	I
(	O
excluding	B
tobacco	B
)	O
or	O
positive	B
urine	B
toxicology	I
.	O

Pregnancy	B
(	O
urine	B
pregnancy	I
tests	I
on	B
the	I
day	I
of	I
scans	I
for	O
menstruating	B
girls	I
)	O
.	O

Inability	B
to	I
provide	I
written	O
informed	O
consent	O
according	O
to	O
the	O
Yale	B
Human	I
Investigation	I
Committee	I
(	I
HIC	I
)	I
guidelines	I
in	B
English	I
.	O

MDD	O
Cohort	O
:	O
Meet	O
DSM	B
-	I
5	I
criteria	I
for	O
Major	B
Depressive	I
Disorder	I
by	O
structured	B
interview	I
(	O
MINI	B
-	I
KID	I
)	O
;	O
CDRS	B
-	I
R	I
score	I
>	B
40	I
;	O
Failure	B
to	O
achieve	O
remission	B
with	O
at	B
least	I
1	I
adequate	B
prior	B
antidepressant	B
trial	O
(	O
e	O
.	O
g	O
.	O
SSRI	B
,	O
SNRI	B
,	O
or	O
TCA	B
)	O
,	O
meaning	O
at	B
least	I
8	I
weeks	I
at	O
therapeutic	B
dosing	I
,	O
including	O
at	B
least	I
4	I
weeks	I
of	O
stable	B
dosing	I
.	O

Anxiety	O
Cohort	O
:	O
Meet	O
DSM	B
-	I
5	I
criteria	I
for	O
any	O
of	O
the	O
following	O
anxiety	B
disorders	I
:	O
Social	B
Anxiety	I
Disorders	I
,	O
Generalized	B
Anxiety	I
Disorder	I
,	O
Separation	B
Anxiety	I
Disorder	I
and	O
/	O
or	O
Panic	B
Disorder	I
by	O
structured	B
interview	I
(	O
MINI	B
-	I
KID	I
)	O
;	O
ADIS	B
Clinical	I
Severity	I
Rating	I
≥	B
4	I
(	O
moderately	B
severe	I
)	O
for	O
any	O
of	O
the	O
4	O
included	O
anxiety	B
disorders	I
;	O
Failure	B
to	O
achieve	O
remission	B
with	O
at	B
least	I
1	I
adequate	B
prior	B
anxiolytic	B
medication	I
trial	O
(	O
e	O
.	O
g	O
.	O
SSRI	B
,	O
SNRI	B
,	O
or	O
TCA	B
)	O
,	O
meaning	O
at	B
least	I
8	I
weeks	I
at	O
therapeutic	B
dosing	I
,	O
including	O
at	B
least	I
4	I
weeks	I
of	O
stable	B
dosing	I
;	O
Failure	B
to	O
achieve	O
remission	B
with	O
previous	B
CBT	O
or	O
subject	O
declines	O
current	B
CBT	B
therapy	I

Stable	B
psychiatric	B
medications	I
and	O
doses	O
for	B
the	I
month	I
prior	I
to	I
enrollment	I
.	O

Subjects	O
may	O
continue	O
to	O
engage	O
in	O
any	O
ongoing	O
psychotherapy	O
.	O

Medically	O
and	O
neurologically	B
healthy	I
on	O
the	O
basis	O
of	O
physical	B
examination	I
and	O
medical	B
history	I
.	O

Parents	B
able	O
to	O
provide	O
written	O
informed	O
consent	O
and	O
adolescents	B
must	O
additionally	O
provide	O
assent	O
.	O

Earlier	O
operations	O
in	O
the	O
foot	O
and	O
leg	O
,	O
that	O
is	O
judged	O
to	O
complicate	O
training	O

known	O
arthritis	B
.	O

known	O
diabetes	B

Leg	B
ulcerations	I
or	O
infections	B
in	I
the	I
foot	I
.	O

Judged	O
unable	O
to	O
comply	O
with	O
the	O
training	O
protocol	O
.	O

Daily	B
use	O
of	O
pain	B
killers	I

Glucocorticosteroid	B
injection	B
to	O
the	O
diseased	B
achilles	I
tendon	I
within	B
the	I
last	I
6	I
months	I
.	O

Earlier	B
allergic	B
reactions	I
to	O
glucocorticosteroid	B
or	O
local	B
anesthetic	I
.	O

Pregnancy	B
or	O
planning	O
to	O
become	O
pregnant	B

BMI	B
above	B
30	I
.	O

Midsubstance	B
pain	I
in	O
the	O
achilles	B
tendon	I

Symptoms	B
for	B
at	I
least	I
3	I
months	I

Ultrasound	B
scanning	I
at	B
the	I
first	I
visit	I
shows	O
thickness	B
of	I
the	I
achilles	I
tendon	I
above	B
7	I
mm	I
or	O
20	B
%	I
thicker	I
than	I
the	I
contralateral	I
.	O

Patient	O
can	O
read	O
and	O
understand	O
danish	O

Pregnancy	B
at	B
enrollment	I
.	O

Any	O
condition	O
,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
provider	O
,	O
will	O
seriously	O
compromise	O
the	O
participant	O
'	O
s	O
ability	O
to	O
comply	O
with	O
the	O
protocol	O
,	O
including	O
adherence	O
to	O
PrEP	O
medication	O
dosing	O
,	O
such	O
as	O
active	O
,	O
untreated	O
or	O
unstable	O
major	O
mental	O
illness	O
(	O
i	O
.	O
e	O
.	O
untreated	O
psychotic	O
disorder	O
)	O
.	O

Use	O
of	O
prohibited	O
medications	O
,	O
in	O
particular	O
,	O
agents	B
known	O
to	O
be	O
nephrotoxic	B
or	O
drugs	B
slow	B
in	I
renal	I
excretion	I
.	O

Previous	B
participation	B
in	O
an	O
HIV	O
vaccine	O
trial	O
.	O

Participants	B
that	O
were	O
documented	O
to	O
have	O
received	O
only	O
placebo	B
are	O
not	O
excluded	O
.	O

Signs	B
or	O
symptoms	B
suspicious	O
for	O
Primary	B
HIV	I
Infection	I
(	O
PHI	B
)	O
.	O

Female	B
at	B
birth	I
and	O
identifies	O
as	O
female	B
gender	B

Age	B
18	B
years	I
or	I
older	I

Able	O
to	O
understand	O
and	O
provide	O
consent	O
in	O
English	O
or	O
Spanish	O

HIV	O
negative	B
by	O
4th	O
generation	O
test	O
(	O
Ag	B
/	I
Ab	I
test	I
)	O
or	O
combination	O
of	O
enzymeimmunoassay	B
(	O
EIA	B
)	O
and	O
HIV	B
RNA	I

Creatinine	B
clearance	I
=	B
60	I
ml	I
/	I
min	I
(	O
via	O
Cockcroft	B
-	I
Gault	I
formula	I
)	O

Condomless	O
sex	O
in	B
the	I
last	I
3	I
months	I
with	O
one	B
or	I
more	I
male	B
partners	I
of	O
unknown	B
HIV	I
status	I
known	O
to	O
be	O
at	O
substantial	O
risk	O
of	O
HIV	B
infection	I
(	O
IDU	O
,	O
bisexual	O
,	O
sex	O
for	O
goods	O
,	O
recently	O
incarcerated	O
,	O
from	O
a	O
country	O
with	O
HIV	O
prevalence	O
>	O
1	O
%	O
,	O
interpersonal	O
Partner	O
Violence	O
)	O
;	O

STI	B
(	O
rectal	O
or	O
vaginal	B
gonorrhea	I
or	O
syphilis	B
)	O
diagnosis	O
during	B
the	I
last	I
6	I
months	I
.	O

Previous	O
post	O
-	O
exposure	O
prophylaxis	O
(	O
PEP	B
)	O
use	O
during	B
the	I
last	I
12	I
months	I
.	O

Has	O
at	B
least	I
one	I
HIV	B
-	I
infected	I
sexual	O
partner	O
for	O
=	B
4	I
weeks	I
.	O

Sex	O
for	O
exchange	O
of	O
money	O
,	O
goods	O
or	O
services	O

adults	B
61	O
years	O
old	B
and	O
above	O

smokers	O

pregnant	B
women	B

taking	O
any	O
prescription	B
pain	I
/	I
insulin	I
medication	I

has	O
a	O
history	B
of	O
taste	O
or	O
smell	B
loss	I
or	O
other	B
oral	B
disorders	I
(	O
e	O
.	O
g	O
.	O
,	O
burning	B
mouth	I
syndrome	I
)	O

has	O
current	B
oral	B
lesions	I
,	O
canker	B
sores	I
,	O
or	O
piercings	B

has	O
a	O
history	B
of	O
food	B
allergy	I

self	B
-	I
reported	I
healthy	B
adults	B
between	O
the	O
ages	B
of	O
18	O
-	O
60	O
who	O
are	O
fluent	O
in	O
English	O
.	O

contra	B
-	I
indication	I
to	O
inhalational	B
induction	I
(	O
full	B
stomach	I
)	O

contra	B
-	I
indication	I
to	O
the	O
use	O
of	O
rocuronium	B

American	B
Society	I
of	I
Anesthesiologists	I
score	I
(	I
ASA	I
)	I
III	B
or	O
IV	B

intracranial	B
surgery	I

parental	O
refusal	O

absence	B
of	O
affiliation	O
to	O
social	O
security	O

age	B
<	B
2	I
years	I

indication	O
of	O
general	B
anesthesia	I
with	O
tracheal	B
intubation	I

inhalational	B
induction	I
scheduled	O

written	O
informed	O
consent	O
of	O
both	O
parents	O

Exclusion	O
Criteria	O
:	O
coronary	B
artery	I
disease	I
,	O
diabetes	B
mellitus	I
,	O
contraindications	B
to	O
cardiac	B
magnetic	I
resonance	I
imaging	I
(	I
CMR	I
)	I
,	O
weight	B
>	B
350	I
lbs	I
,	O
inability	O
to	O
lie	O
flat	O
for	O
imaging	O
,	O
anemia	B
,	O
contraindications	B
to	O
regadenoson	B
or	O
aminophylline	B

HEALTHY	B
:	O
known	O
cardiovascular	B
disease	I
,	O
cardiac	B
risk	I
factors	I
or	O
use	O
of	O
cardiac	B
medications	I

HYPERTENSIVE	B
:	O
known	O
cardiovascular	B
disease	I
or	O
risk	O
factors	O
aside	B
from	I
hypertension	O
or	O
use	O
of	O
cardiac	B
medications	I

HFpEF	B
:	O
prior	B
history	I
of	I
LVEF	B
below	B
50	I
%	I
,	O
acute	B
decompensated	B
HF	I
,	O
moderate	B
or	O
greater	B
valvular	B
disease	I
,	O
significant	B
cardiac	B
arrhythmias	I
,	O
pericardial	B
disease	I
,	O
congenital	B
heart	I
disease	I
,	O
primary	B
pulmonary	I
hypertension	I

estimated	B
glomerular	I
filtration	I
rate	I
(	I
eGFR	I
)	I
>	B
60	I
ml	I
/	I
min	I

preserved	B
left	B
ventricular	I
ejection	I
fraction	I
(	O
>	B
=	I
50	I
%	I
)	O
on	O
echocardiography	B

HEALTHY	B
:	O
normal	B
cardiac	I
structure	I
and	O
function	O
on	O
echocardiography	B
,	O
BP	B
<	B
140	I
/	I
90	I

HYPERTENSIVE	B
:	O
history	B
of	O
BP	B
>	B
140	I
/	I
90	I
,	O
1	B
or	I
more	I
antihypertensive	B
medications	I
,	O
LV	B
ejection	I
fraction	I
(	I
LVEF	I
)	I
at	B
least	I
50	I
%	I
,	O
current	B
BP	B
<	B
160	I
/	I
90	I

HFpEF	B
:	O
physician	B
-	I
confirmed	I
diagnosis	O
of	O
HF	B
,	O
symptomatic	B
HF	B
,	O
LVEF	B
at	B
least	I
50	I
%	I
,	O
elevated	B
LV	B
filling	I
pressure	I
by	O
catheterization	B
,	O
echocardiographic	O
criteria	O
or	O
B	B
-	I
type	I
-	I
natriuretic	I
peptide	I
>	B
100	I
,	O
current	B
BP	I
<	B
160	I
/	I
90	I

Personal	B
history	I
of	O
breast	B
cancer	I

A	O
terminal	B
illness	I

Patients	O
who	O
are	O
unable	O
to	O
give	O
informed	O
consent	O

Breast	B
implants	I

Asymptomatic	B
women	B
45	B
-	I
68	I
years	I
,	O
residents	O
in	O
the	O
Piedmont	O
Region	O
,	O
attending	O
the	O
regional	B
breast	I
cancer	I
screening	I
program	I

NA	O

Signed	O
Informed	O
Consent	O
Form	O

Patients	O
having	O
physical	O
and	O
mental	O
ability	O
to	O
participate	O
in	O
the	O
study	O

Patients	O
of	O
both	B
sexes	B
aged	B
35	B
to	I
65	I
years	I

Presence	O
of	O
documented	O
ST	B
-	I
elevation	I
myocardial	I
infarction	I
confirmed	O
by	O
ECG	B
,	O
as	O
well	O
as	O
troponin	B
I	I
and	O
CK	B
-	I
MB	I
levels	O
.	O

Presence	O
of	O
hemodynamically	B
relevant	I
stenosis	O
of	O
one	B
artery	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
infarct	B
-	I
related	I
artery	I
)	O
confirmed	O
by	O
coronary	B
angiography	I
(	O
CAG	B
)	O
,	O
with	O
the	O
occlusion	B
of	I
other	I
arteries	I
not	B
exceeding	I
30	I
%	I
.	O

•	O
Diabetes	B
duration	O
>	B
12	I
years	I

Currently	O
taking	O
more	B
than	I
three	I
glucose	B
lowering	I
therapies	I

Weight	O
-	O
loss	O
of	O
>	B
5kg	I
in	O
the	O
preceding	B
6	I
months	I

Stage	B
4	I
or	I
5	I
chronic	B
kidney	I
disease	I
(	O
eGFR	B
<	B
30ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I
)	O
,	O

Current	O
therapy	O
with	O
Insulin	B
,	O
thiazolidinediones	B
,	O
steroids	B
or	O
atypical	B
antipsychotic	I
medication	I

Untreated	B
thyroid	B
disease	I

Known	O
macrovascular	B
disease	I
including	O
coronary	B
artery	I
disease	I
,	O
stroke	B
/	O
TIA	B
or	O
peripheral	B
vascular	I
disease	I

Presence	O
of	O
arrhythmia	B
(	O
including	O
atrial	B
fibrillation	I
,	O
atrial	B
flutter	I
,	O
or	O
2nd	O
or	O
3rd	B
degree	I
atrioventricular	I
block	I
)	O

Known	O
heart	B
failure	I

Other	O
clinically	O
relevant	O
heart	B
disease	I

Inability	B
to	O
exercise	O
or	O
undertake	O
a	O
MRP	B

Absolute	O
contraindication	B
to	O
CMR	B

Cardiovascular	B
symptoms	I
(	O
angina	B
,	O
limiting	O
dyspnoea	B
during	O
normal	O
physical	O
activity	O
)	O

Inflammatory	B
condition	O
e	O
.	O
g	O
.	O
Connective	B
tissue	I
disorder	I
,	I
Rheumatoid	B
arthritis	I

Capacity	O
to	O
provide	O
informed	O
consent	O
before	O
any	O
trial	O
-	O
related	O
activities	O

Established	O
T2DM	B
(	O
=	B
3months	I
)	O

HbA1c	B
=	B
9	I
%	I
if	O
on	O
triple	O
therapy	O
or	O
=	B
10	I
%	I
on	O
diet	O
&	O
exercise	O
or	O
monotherapy	O
or	O
dual	O
therapy	O

Current	O
glucose	B
lowering	I
therapy	I
either	O
mono	O
,	O
dual	O
or	O
triple	O
of	O
any	O
combination	O
of	O
metformin	B
,	O
sulphonylurea	B
,	O
DPP	B
-	I
IV	I
inhibitor	I
,	I
GLP	B
-	I
1	I
therapy	I
or	O
an	O
SGLT2	B
+	O
/	O
-	O
diet	O
and	O
exercise	O

Poorly	O
managed	O
diet	O
controlled	O
diabetes	B
(	O
with	O
HbA1c	B
>	B
6	I
.	I
5	I
%	I
,	O
not	B
currently	O
taking	O
any	O
glucose	B
lowering	I
therapy	I
,	O
meeting	O
BMI	O
inclusion	O
range	O
)	O

Body	B
mass	I
index	I
>	B
30Kg	I
/	I
m2	I
or	O
>	B
27	I
.	I
5	I
Kg	I
/	I
m2	I
(	O
South	O
Asian	O
)	O
,	O

Diagnosis	O
of	O
T2DM	B
before	O
the	O
age	B
of	O
60	O
years	O
of	O
age	O

Age	B
=	B
18	I
and	I
=	I
65	I
years	I

Patients	O
will	O
not	O
be	O
included	O
if	O
they	O
have	O
reached	O
a	O
stable	B
dose	I
of	O
warfarin	B
,	O
liver	B
dysfunction	I
,	O
alcoholism	B
,	O
use	O
of	O
another	B
anticoagulant	B
,	O
use	O
of	O
chemotherapy	B
,	O
or	O
if	O
they	O
do	O
not	O
meet	O
the	O
inclusion	O
criteria	O

Only	O
patients	O
with	O
atrial	B
fibrillation	I
,	O
above	O
18	O
years	B
,	O
and	O
with	O
TTR	B
<	B
50	I
%	I
based	B
on	I
the	I
last	I
three	I
values	I
of	I
INR	I
will	O
be	O
included	O
in	O
this	O
study	O
.	O

HIV	B
infection	I
at	O
screening	O

participation	O
in	O
previous	O
or	O
concurrent	O
HIV	O
vaccine	O
trials	O

lactating	O
,	O
pregnant	O
or	O
planning	O
pregnancy	O

renal	B
function	I
impairment	I
(	O
serum	B
creatinine	I
>	B
1	I
.	I
5	I
mg	I
/	I
dl	I
)	O
,	O
Fanconi	B
syndrome	I

abnormal	B
liver	B
function	I
tests	I
(	O
AST	B
/	O
ALT	B
>	B
43	I
U	I
/	I
L	I
)	O
,	O
liver	B
disease	I
,	O
viral	B
hepatitis	I
,	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
infection	I

serum	B
phosphorus	I
<	B
2	I
.	I
2mg	I
/	I
dl	I
,	O
osteoporosis	B

known	O
sensitivity	B
to	O
components	O
of	O
the	O
Truvada	B
®	O
formulation	O

any	O
immunosuppressive	B
treatment	I
,	O
such	O
as	O
systemic	B
corticosteroids	I

assumption	O
of	O
medication	O
that	O
interacts	O
with	O
Truvada	O
®	O

high	O
likelihood	O
of	O
poor	O
adherence	O
to	O
PREP	O
and	O
clinic	O
attendance	O

any	O
condition	O
that	O
in	O
the	O
opinion	O
of	O
the	O
attending	O
physician	O
could	O
endanger	O
the	O
health	O
of	O
the	O
participant	O
or	O
render	O
her	O
unsuitable	O
to	O
participate	O
in	O
the	O
trial	O

age	B
=	B
18	I
at	O
screening	O

not	O
intending	O
to	O
move	O
away	O
from	O
the	O
clinic	O
'	O
s	O
catchment	O
area	O
for	O
the	O
next	O
2	O
years	O

HIV	B
-	I
1	I
antibody	I
negative	B

reports	O
commercial	O
sex	O
work	O

contact	O
information	O
is	O
provided	O

written	O
informed	O
consent	O

1	O
.	O

Patients	O
with	O
lumbar	B
common	I
diseases	I
(	O
e	O
.	O
g	O
.	O
,	O
Lumbar	B
disc	I
,	O
Lumbar	B
spinal	I
stenosis	I
,	O
Lumbar	B
slippage	I
,	O
etc	O
)	O

2	O
.	O

Researchers	O
think	O
that	O
Patients	O
with	O
disease	O
may	O
be	O
interference	O
results	O
(	O
e	O
.	O
g	O
.	O
,	O
Spinal	B
deformity	I
,	O
spine	B
fracture	I
,	I
ankylosing	B
spondylitis	I
,	O
spinal	B
tuberculosis	I
and	O
spinal	B
infection	I
,	O
spinal	B
tumor	I
,	O
pelvic	B
inflammatory	I
disease	I
and	O
other	O
disease	O
of	O
department	O
of	O
gynaecology	O
,	O
etc	O
)	O

3	O
.	O

Patients	O
with	O
other	O
nervous	B
system	I
diseases	I
(	O
e	O
.	O
g	O
.	O
,	O
cerebral	B
tumor	I
,	O
neurinoma	B
,	O
trigeminal	B
neuralgia	I
,	O
etc	O
)	O

4	O
.	O

Patients	O
with	O
Magnetic	B
resonance	I
imaging	I
contraindication	B
,	O
including	O
claustrophobic	B
syndrome	I
patients	O

5	O
.	O

Patients	O
with	O
recent	O
(	O
less	O
than	O
3	O
years	O
)	O
use	O
chemical	O
drugs	O
or	O
have	O
obvious	O
psychological	O
problems	O

6	O
.	O

In	O
the	O
past	O
2	O
months	O
involved	O
in	O
other	O
drugs	O
or	O
devices	O
clinical	O
trials	O

1	O
.	O

Diagnosed	O
with	O
symptomatic	B
sacral	B
perineurial	I
cysts	I
(	I
e	O
.	O
g	O
.	O
,	O
lumbosacral	O
or	O
perineal	B
pain	I
,	O
fecal	O
or	O
urinary	B
functions	I
change	I
,	O
sexual	B
function	I
change	I
,	O
lower	B
limb	I
radiation	I
pain	I
,	O
muscle	B
abate	I
,	O
paresthesia	B
,	O
etc	O
)	O

2	O
.	O

Visual	B
analog	I
scale	I
more	B
than	I
or	I
equal	I
to	I
4	I

3	O
.	O

Signed	O
the	O
informed	O
consent	O

4	O
.	O

Years	B
,	O
range	O
18	B
-	I
60	I

5	O
.	O

Self	B
-	I
rating	I
anxiety	I
scale	I
(	O
SAS	B
)	O
and	O
self	B
-	I
rating	I
depression	I
scale	I
(	O
SDS	B
)	O
scores	B
<	I
50	I

6	O
.	O

No	B
Congenital	O
,	O
Mental	O
and	O
other	O
Nervous	B
system	I
diseases	I

7	O
.	O

No	B
Serious	O
Cardiac	B
,	O
Pulmonary	B
,	O
Hepatic	B
and	O
Nephritic	B
disease	I

8	O
.	O

No	B
history	O
of	O
drug	B
allergy	B

9	O
.	O

No	B
pain	B
(	O
including	O
dysmenorrhea	B
)	O
or	O
drug	B
use	O
(	O
e	O
.	O
g	O
.	O
,	O
antipyretics	O
,	O
sleeping	O
pills	O
)	O
within	O
the	O
last	B
month	I

10	O
.	O

MRI	O
finding	O
of	O
sacral	O
perineurial	O
cysts	O
,	O
but	O
without	O
any	O
clinical	O
symptoms	O
,	O
included	O
in	O
the	O
negative	O
control	O
group	O

11	O
.	O

MRI	O
finding	O
healthy	O
volunteers	O
don	O
'	O
t	O
have	O
sacral	O
perineurial	O
cysts	O
,	O
included	O
in	O
the	O
negative	O
control	O
groupblank	O
control	O
group	O

Pregnancy	O
(	O
a	O
negative	O
serum	O
or	O
urine	O
pregnancy	O
test	O
should	O
be	O
available	O
for	O
women	O
of	O
child	O
-	O
bearing	O
potential	O
before	O
study	O
inclusion	O
)	O
or	O
lactation	O

Women	O
of	O
childbearing	O
potential	O
who	O
do	O
not	O
practice	O
a	O
medically	O
accepted	O
highly	O
effective	O
contraception	O
during	O
the	O
trial	O
and	O
one	O
month	O
beyond	O

History	O
of	O
hypersensitivity	O
to	O
the	O
investigational	O
medicinal	O
product	O
or	O
to	O
any	O
drug	O
with	O
similar	O
chemical	O
structure	O
or	O
to	O
any	O
excipient	O
present	O
in	O
the	O
pharmaceutical	O
form	O
of	O
the	O
investigational	O
medicinal	O
product	O

Participation	O
in	O
another	O
clinical	O
trial	O
during	O
the	O
present	O
clinical	O
trial	O
or	O
within	O
the	O
last	O
three	O
months	O

Medical	O
or	O
psychological	O
condition	O
that	O
would	O
not	O
permit	O
completion	O
of	O
the	O
trial	O
or	O
signing	O
of	O
informed	O
consent	O

Use	O
of	O
a	O
fibrinolytic	B
agent	I
,	O
surgical	B
thrombectomy	I
,	I
interventional	O
(	O
catheter	O
-	O
directed	O
)	O
thrombus	B
aspiration	I
or	O
lysis	O
,	O
or	O
use	O
of	O
a	O
cava	B
filter	I
to	O
treat	O
the	O
index	O
episode	O
of	O
PE	B

Treatment	O
with	O
any	O
therapeutically	B
dosed	O
anticoagulant	B
for	O
more	B
than	I
48	I
hours	I
prior	I
to	I
enrolment	I

Need	O
for	O
long	B
-	I
term	I
treatment	O
with	O
a	O
low	B
molecular	I
weight	I
heparin	I
,	O
vitamin	B
K	I
antagonists	I
or	O
NOAC	B
,	O
for	O
an	O
indication	O
other	B
than	O
the	O
index	B
PE	B
episode	I
,	O
or	O
for	O
antiplatelet	B
agents	I
except	B
acetylsalicylic	B
acid	I
at	O
a	O
dosage	O
=	B
100	I
mg	I
/	I
day	I
;	I

Active	B
bleeding	I
or	O
known	O
significant	B
bleeding	O
risk	O
(	O
e	O
.	O
g	O
.	O
,	O
gastrointestinal	B
ulcer	I
,	O
malignant	B
neoplasms	I
,	O
injuries	B
or	O
recent	O
surgeries	B
of	O
the	O
brain	B
,	O
spinal	B
cord	I
or	O
eyes	B
,	O
recent	O
intracranial	B
bleedings	I
,	O
known	O
or	O
suspected	O
esophagus	B
varices	I
,	O
aneurysms	B
or	O
intraspinal	B
or	O
intracranial	B
vascular	B
abnormalities	I
)	I

Artificial	B
heart	I
valves	I
requiring	O
treatment	O
with	O
an	O
anticoagulant	B

Renal	B
insufficiency	I
with	O
estimated	B
creatinine	I
clearance	I
<	B
30	I
ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I

Chronic	B
liver	I
disease	I
with	O
aminotransferase	B
levels	O
two	B
times	I
or	I
more	I
above	I
the	I
local	I
upper	I
limit	I
of	I
normal	I
range	I

Concomitant	O
administration	O
of	O
strong	O
inhibitors	B
of	I
P	I
-	I
glycoprotein	I
like	O
ketoconazole	B
,	O
cyclosporin	B
,	O
itraconazole	B
or	O
dronedarone	B

Unwillingness	O
or	O
inability	O
to	O
adhere	O
to	O
treatment	O
or	O
to	O
the	O
follow	O
-	O
up	O
visits	O

Life	O
expectancy	O
less	B
than	I
6	I
months	I

Age	B
=	B
18	I
years	I

Objectively	O
confirmed	O
diagnosis	O
of	O
acute	B
PE	B
by	O
multidetector	O
CT	B
angiography	I
,	O
ventilation	B
/	I
perfusion	I
lung	I
scan	I
,	O
or	O
selective	O
invasive	B
pulmonary	I
angiography	I
,	I
according	O
to	O
established	O
diagnostic	O
criteria	O
,	O
with	O
or	O
without	O
symptomatic	O
deep	B
vein	I
thrombosis	I

Absence	B
of	O
hemodynamic	B
collapse	I
,	O
or	O
decompensation	O
,	O
at	O
presentation	O
;	O
Hemodynamic	O
collapse	O
or	O
decompensation	O

At	B
least	I
one	I
sign	B
of	I
RV	I
pressure	I
overload	I
/	O
dysfunction	O
on	O
CT	B
angiography	I
or	O
echocardiography	B

Signs	O
of	O
myocardial	B
injury	I
as	O
indicated	O
by	O
elevated	B
troponin	B
levels	I

Signs	O
of	O
(	O
RV	B
)	I
failure	I
as	O
indicated	O
by	O
NT	B
-	I
proBNP	I
levels	I
>	B
600	I
pg	I
/	I
ml	I
at	O
baseline	O
.	O

Ability	O
of	O
the	O
subject	O
to	O
understand	O
the	O
character	O
and	O
individual	O
consequences	O
of	O
the	O
clinical	O
trial	O
;	O
signed	O
and	O
dated	O
informed	O
consent	O
of	O
the	O
subject	O
available	O
before	O
the	O
start	O
of	O
any	O
specific	O
trial	O
procedures	O

Unstable	B
angina	I
;	O

Myocardial	B
infarction	I
and	O
heart	B
surgery	I
up	B
to	I
three	I
months	I
before	I
the	I
survey	I
;	O

Chronic	B
respiratory	I
diseases	I
;	O

Hemodynamic	B
instability	I
;	O

Trauma	B
recent	O
face	O
,	O
nausea	B
and	O
vomiting	B
.	O

Orthopedic	B
and	O
neurological	B
diseases	I
that	O
may	O
preclude	B
the	I
achievement	I
of	I
the	I
cardiopulmonary	I
test	I
and	I
Cardiac	I
Rehabilitation	I
exercises	I
;	O

Psychological	O
and	O
/	O
or	O
cognitive	B
impairments	I
that	O
restrict	B
them	I
to	I
respond	I
to	I
questionnaires	I
;	O

Diagnosis	O
of	O
Heart	B
Failure	I
;	O

Lower	B
left	I
ventricular	I
ejection	I
fraction	I
45	B
%	I
(	O
LVEF	B
<	B
45	I
%	I
)	O
assessed	O
by	O
simple	O
and	O
recent	B
echocardiogram	B
;	O

Functional	O
Class	B
II	I
and	I
III	I
by	O
the	O
New	B
York	I
Heart	I
Association	I
(	I
NYHA	I
)	I

Clinically	B
stable	I
;	O

Ex	B
-	I
smokers	I
over	B
five	I
years	I
;	O

Maximal	B
inspiratory	I
pressure	I
(	I
MIP	I
)	I
<	B
70	I
%	I
of	I
predicted	I
;	O

Forced	B
expiratory	I
volume	I
/	I
Forced	I
vital	I
capacity	I
(	I
FEV1	I
/	I
FVC	I
)	I
>	B
70	I
%	I
of	I
predicted	I
;	O

1	O
.	O
High	B
risk	I
profiles	I
for	O
ischemic	B
adverse	I
events	I
such	O
as	O
A	O
.	O
ST	B
-	I
segment	I
elevation	I
myocardial	I
infarction	I
(	I
STEMI	I
)	I
B	O
.	O
Patients	O
with	O
cardiogenic	B
shock	I
or	O
concomitant	O
severe	B
decompensated	B
heart	B
failure	I
C	O
.	O
Myocardial	B
infarction	I
or	O
stent	B
thrombosis	I
in	O
spite	O
of	O
the	O
maintenance	O
of	O
antiplatelet	B
therapy	I
D	O
.	O
Restenosis	B
in	O
stented	O
segments	O
or	O
previous	O
sites	O
of	O
balloon	O
angioplasty	O
2	O
.	O
Patients	O
who	O
cannot	B
follow	I
allocated	I
DAPT	I
schedule	I
due	O
to	O
the	O
planned	O
surgery	B
or	O
elective	B
procedure	B
within	B
3	I
months	I
after	I
the	I
stenting	I
3	O
.	O
Recent	O
history	O
of	O
major	B
surgery	I
or	O
evident	O
events	B
of	I
gastrointestinal	I
bleeding	I
within	B
1	I
month	I
from	I
the	I
procedure	I
4	O
.	O
Patients	O
on	O
anticoagulation	B
therapy	I
with	O
warfarin	B
or	O
other	B
anticoagulants	B
5	O
.	O
Life	O
expectancy	O
less	B
than	I
1	I
year	I
(	O
such	O
as	O
malignancies	B
or	O
other	B
chronic	B
systemic	I
diseases	I
)	O
6	O
.	O
Pregnant	B
women	B
7	O
.	O
Past	O
history	O
of	O
allergy	B
or	O
other	B
contraindications	B
for	O
the	O
following	O
medications	O
/	O
materials	O
:	O
aspirin	B
,	O
clopidogrel	B
,	O
heparin	B
,	O
cobalt	B
chromium	I
,	O
sirolimus	B

Patients	O
with	O
de	B
novo	I
stenotic	B
lesions	I
who	O
are	O
suitable	O
for	O
coronary	B
stenting	I
with	O
drug	B
-	I
eluting	I
stent	I

Inability	O
to	O
follow	O
directions	O
or	O
comprehend	O
the	O
English	O
language	O

Severe	B
uncorrected	B
visual	O
or	O
auditory	B
handicaps	I

Delirium	B
at	B
screening	I
or	O
baseline	O

Emergency	B
surgery	I

Subject	O
or	O
legal	O
representative	O
has	O
voluntarily	O
signed	O
the	O
informed	O
consent	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
,	O

Hip	B
fracture	I
surgery	I
scheduled	O
under	O
general	B
anesthesia	I

Subject	O
is	O
65	O
years	O
or	O
older	B
on	O
the	O
day	O
of	O
surgery	B

Newborns	B
with	O
severe	B
congenital	I
anomalies	I

Newborns	B
with	O
infection	B
of	I
the	I
umbilical	I
cord	I
at	B
birth	I

Newborns	B
weighing	B
1	B
.	I
5kg	I
or	I
more	I
at	B
birth	I

NA	O

the	O
patients	O
undergoing	O
ascending	O
,	O
arch	O
and	O
/	O
or	O
proximal	B
descending	I
aorta	I
surgery	I
with	O
cardiopulmonary	B
bypass	I

20	B
-	I
100	I
yrs	I
old	B

Evidence	O
of	O
low	B
ovarian	I
reserve	I
by	O
at	O
least	O
one	O
of	O
the	O
following	O
:	O
AMH	B
=	B
1	I
,	I
5	I
ng	I
/	I
mL	I
and	O
/	O
or	O
basal	B
CD	I
3	I
FSH	I
=	B
10	I
mIU	I
/	I
mL	I
and	O
/	O
or	O
basal	B
CD	I
3	I
Estradiol	I
=	B
60	I
ng	I
/	I
mL	I
and	O
/	O
or	O
previous	O
egg	B
collection	I
yield	I
=	B
3	I
oocytes	I
.	O

Preexisting	O
medical	O
condition	O
(	O
thyroid	B
disease	I
,	O
diabetes	B
mellitus	I
,	O
hypertension	B
,	O
pulmonary	B
conditions	I
,	O
cardiac	B
condition	I
…	O
)	O
.	O

Severe	B
male	B
factor	I
infertility	I
(	O
Total	B
motile	I
sperm	I
count	I
<	B
5	I
million	I
/	I
ml	I
and	O
/	O
or	O
normal	B
WHO	I
morphology	I
<	B
20	I
%	I
)	O
.	O

Hypersensitivity	B
to	O
Heparin	B
or	O
its	O
derivatives	O
.	O

Acquired	B
thrombophilia	B
.	O

Active	B
hemorrhage	I
or	O
increased	B
risk	O
of	O
bleeding	O
due	O
to	O
impairment	B
of	I
homeostasis	I
.	O

Severe	B
impairment	B
of	I
liver	I
or	O
pancreatic	O
function	O
.	O

Severe	B
renal	B
insufficiency	I
(	O
Creatinine	B
Clearance	I
<	B
30	I
ml	I
/	I
min	I
)	O
.	O

Injuries	B
to	O
or	O
operations	B
on	O
the	O
central	B
nervous	I
system	I
,	O
eyes	B
and	O
ears	B
within	O
the	O
last	B
2	I
months	I
.	O

Disseminated	B
Intravascular	I
Coagulation	I
(	O
DIC	B
)	O
attributable	O
to	O
heparin	B
-	I
induced	I
thrombocytopenia	I
.	O

Acute	B
bacterial	I
endocarditis	I
and	O
endocarditis	B
lenta	I
.	O

Any	O
organic	B
lesion	I
with	O
high	B
risk	O
of	O
bleeding	O
(	O
e	O
.	O
g	O
.	O
:	O
active	B
peptic	I
ulcer	I
,	O
hemorrhagic	B
stroke	I
,	O
cerebral	B
aneurysm	I
or	O
cerebral	B
neoplasms	I
)	O
.	O

History	O
of	O
three	B
or	I
more	I
consecutively	B
failed	I
In	B
Vitro	I
Fertilization	I
(	O
IVF	B
)	O
cycles	O
after	B
embryo	I
transfer	I
.	O

Normal	B
uterine	O
cavity	O
(	O
as	O
assessed	O
by	O
hysteroscopy	B
or	O
HSG	B
)	O
.	O

Normal	B
hormonal	B
investigation	I
:	I
TSH	B
,	O
PRL	B
,	O
FBS	B
.	O

Normal	B
acquired	O
/	O
inherited	O
thrombophilia	B
profile	I
:	O
LAC	B
,	O
ACA	B
IgG	I
/	O
IgM	O
,	O
Prot	B
S	I
,	O
Antithrombin	B
III	I
,	O
beta	B
-	I
2	I
glycoprotein	I
,	O
Factors	B
V	I
,	O
II	O
,	O
MTHFR	B
.	O

Normal	O
semen	B
analysis	I
and	O
mild	B
/	O
moderate	B
male	B
factor	I
(	O
Total	B
motile	I
sperm	I
count	I
>	B
5	I
million	I
/	I
ml	I
and	O
/	O
or	O
normal	B
WHO	I
morphology	I
>	B
20	I
%	I
.	O

Patient	O
provides	O
written	O
informed	O
consent	O
.	O

Age	B
<	B
18	I
years	I

Creatinine	B
>	B
1	I
.	I
5	I
mg	I
/	I
dL	I

History	O
of	O
severe	O
allergy	B
to	O
Iodine	B
contrast	I
agents	I

Pregnancy	B

Active	O
atrial	B
fibrillation	I

Multiple	B
premature	I
ventricular	I
or	I
atrial	I
contractions	I

Ejection	B
fraction	I
<	B
35	I
%	I

Class	B
III	I
congestive	B
heart	I
failure	I

Acute	B
Coronary	I
Syndrome	I
group	O
:	O
40	O
patients	O
with	O
type	O
1	O
myocardial	O
infarction	O
within	O
21	O
days	O
prior	O
to	O
the	O
imaging	O
visit	O
and	O
invasive	O
coronary	O
angiography	O
with	O
angiographic	O
evidence	O
of	O
at	O
least	O
a	O
50	O
%	O
stenosis	O
in	O
one	O
or	O
more	O
coronary	O
arteries	O
.	O
Only	O
patients	O
undergoing	O
PCI	O
will	O
be	O
included	O
in	O
the	O
study	O
.	O

Stable	O
Ischemic	O
Heart	O
Disease	O
group	O
:	O
40	O
patients	O
who	O
have	O
undergone	O
invasive	O
coronary	O
angiography	O
within	O
21	O
days	O
prior	O
to	O
the	O
imaging	O
visit	O
,	O
with	O
history	O
of	O
typical	O
angina	O
prior	O
to	O
the	O
angiogram	O
,	O
but	O
no	O
prior	O
myocardial	O
infarction	O
or	O
coronary	O
revascularization	O
.	O

have	O
no	B
prior	O
CAD	B
associated	O
event	O
(	O
no	O
prior	O
myocardial	B
infarction	I
,	O
acute	B
coronary	I
syndrome	I
,	O
coronary	B
angiogram	I
,	O
or	O
PCI	B
)	O
,	O

have	O
CAC	B
between	B
10	I
to	I
<	I
1000	I
,	O
and	O

match	O
to	O
patients	O
in	O
the	O
ACS	O
group	O
by	O
gender	O
,	O
age	O
by	O
decile	O
,	O
and	O
CAC	O
category	O
(	O
using	O
CAC	O
categories	O
of	O
10	O
to	O
<	O
100	O
,	O
100	O
to	O
<	O
400	O
,	O
400	O
to	O
<	O
1000	O
)	O
.	O

1	O
.	O

A	O
medical	B
condition	I
,	O
other	B
than	I
PBC	B
,	O
that	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
would	O
preclude	O
full	O
participation	O
in	O
the	O
study	O
or	O
confound	O
its	O
results	O
(	O
e	O
.	O
g	O
.	O
,	O
cancer	O
on	O
active	O
treatment	O
)	O

2	O
.	O

AST	B
or	O
ALT	B
>	B
3	I
×	I
ULN	I

3	O
.	O

Total	B
bilirubin	I
>	B
2	I
×	I
ULN	I

4	O
.	O

Auto	B
-	I
immune	I
hepatitis	I

5	O
.	O

Primary	B
sclerosing	I
cholangitis	I

6	O
.	O

Known	O
history	B
of	O
alpha	B
-	I
1	I
-	I
Antitrypsin	I
deficiency	I

7	O
.	O

Known	O
history	B
of	O
chronic	B
viral	B
hepatitis	I

8	O
.	O

Creatine	B
kinase	I
above	B
ULN	I

9	O
.	O

Serum	B
creatinine	I
above	B
ULN	I

10	O
.	O

For	O
females	B
,	O
pregnancy	B
or	O
breast	B
-	I
feeding	I

11	O
.	O

Use	O
of	O
colchicine	B
,	O
methotrexate	B
,	O
azathioprine	B
,	O
or	O
systemic	B
steroids	I
in	B
the	I
two	I
months	I
preceding	I
screening	I

12	O
.	O

Current	B
use	O
of	O
fibrates	B
,	O
including	O
fenofibrates	B
,	O
or	O
simvastatin	B

13	O
.	O

Use	O
of	O
an	O
experimental	B
treatment	I
for	I
PBC	I

14	O
.	O

Use	O
of	O
experimental	B
or	O
unapproved	B
immunosuppressant	B

15	O
.	O

Any	O
other	O
condition	O
(	O
s	O
)	O
that	O
would	O
compromise	O
the	O
safety	O
of	O
the	O
subject	O
or	O
compromise	O
the	O
quality	O
of	O
the	O
clinical	O
study	O
,	O
as	O
judged	O
by	O
the	O
Investigator	O

1	O
.	O

Must	O
have	O
given	O
written	O
informed	O
consent	O
(	O
signed	O
and	O
dated	O
)	O
and	O
any	O
authorizations	O
required	O
by	O
local	O
law	O

2	O
.	O

18	O
to	O
75	O
years	B
old	I
(	O
inclusive	O
)	O

3	O
.	O

Male	B
or	O
female	B
with	O
a	O
diagnosis	O
of	O
PBC	B
,	O
by	O
at	B
least	I
two	I
of	O
the	O
following	B
criteria	I
:	O

History	O
of	O
AP	B
above	B
ULN	I
for	B
at	I
least	I
six	I
months	I

Positive	B
Anti	I
-	I
Mitochondrial	I
Antibodies	I
(	I
AMA	I
)	I
titers	I
(	O
>	B
1	I
/	I
40	I
on	O
immunofluorescence	B
or	O
M2	B
positive	I
by	O
enzyme	B
linked	I
immunosorbent	I
assay	I
(	I
ELISA	I
)	I
or	O
positive	B
PBC	B
-	I
specific	I
antinuclear	I
antibodies	I

Documented	O
liver	B
biopsy	I
result	O
consistent	O
with	O
PBC	B

4	O
.	O

On	O
a	O
stable	O
and	O
recommended	B
dose	I
of	O
UDCA	B
for	B
the	I
past	I
twelve	I
months	I

5	O
.	O

AP	B
≥	B
1	I
.	I
67	I
×	I
ULN	I

6	O
.	O

For	O
females	B
of	O
reproductive	B
potential	I
,	O
use	O
of	O
at	B
least	I
one	I
barrier	B
contraceptive	I
and	O
a	O
second	B
effective	B
birth	B
control	I
method	I
during	B
the	I
study	I
and	O
for	B
at	I
least	I
two	I
weeks	I
after	I
the	I
last	I
dose	I
.	O

For	O
male	B
subjects	O
,	O
use	O
of	O
appropriate	B
contraception	B
(	O
e	O
.	O
g	O
.	O
,	O
condoms	B
)	O
,	O
so	O
their	O
female	B
partners	O
of	O
reproductive	B
potential	I
do	O
not	B
become	I
pregnant	B
during	B
the	I
study	I
and	O
for	B
at	I
least	I
two	I
weeks	I
after	I
the	I
last	I
dose	I

Any	O
patient	O
with	O
esophageal	B
cancer	I
who	O
is	O
not	B
deemed	O
a	O
surgical	B
candidate	O
or	O
who	O
is	O
not	B
deemed	O
a	O
candidate	O
for	O
the	O
Ivor	B
Lewis	I
technique	I
of	O
esophagectomy	B
(	O
with	O
intrathoracic	B
anastomosis	I
)	O
.	O

Any	O
patient	O
less	B
than	I
18	I
years	I
of	O
age	B

All	O
patients	O
with	O
esophageal	B
cancer	I
who	O
are	O
deemed	O
candidates	O
for	O
minimally	B
invasive	I
robot	B
assisted	I
Ivor	B
Lewis	I
esophagogastrectomy	B
.	O

Patients	O
who	O
provide	O
written	O
informed	O
consent	O
for	O
the	O
study	O
.	O

Patients	O
with	O
any	O
contraindications	B
or	O
hypersensitivity	B
related	O
to	O
antiplatelet	B
therapy	I

Patients	O
with	O
Acute	B
Myocardial	I
Infarction	I
(	O
ST	B
elevation	I
myocardial	I
infarction	I
,	O
Non	B
ST	I
elevation	I
myocardial	I
infarction	I
)	O

Patients	O
who	O
are	O
anticipated	O
to	O
receive	O
treatment	B
or	O
surgery	B
that	O
may	O
require	O
desisting	O
the	O
administration	O
of	O
antiplatelet	B
therapy	I
for	B
2	I
weeks	I
or	I
longer	I
during	O
the	O
period	O
of	O
the	O
clinical	O
trial	O

Chronic	B
total	I
occlusion	I
(	O
CTO	B
)	O
lesions	O
,	O
in	B
-	I
stent	I
restenosis	I
(	O
ISR	B
)	O

Patients	O
experiencing	O
cardiogenic	B
shock	I

Women	O
who	O
are	O
breastfeeding	O
,	O
pregnant	O
,	O
or	O
desiring	O
pregnancy	O

Patients	O
with	O
findings	O
of	O
hemorrhage	B

Patients	O
with	O
a	O
life	O
expectancy	O
of	O
less	B
than	I
1	I
year	I

Patients	O
who	O
have	O
received	O
a	O
drug	O
-	O
eluting	O
stent	O
(	O
DES	B
)	O
procedure	O
within	O
the	O
past	B
6	I
months	I

Any	O
other	O
patients	O
judged	O
by	O
the	O
investigator	O
to	O
be	O
unsuitable	O
for	O
the	O
trial	O

Patients	O
aged	B
19	B
or	I
older	I

Patients	O
who	O
have	O
submitted	O
a	O
written	O
consent	O
to	O
participate	O
in	O
the	O
clinical	O
trial	O

De	B
novo	I
lesion	I

Patients	O
scheduled	O
for	O
elective	O
intervention	O
to	O
treat	O
ischemic	O
cardiovascular	O
disease	O

Age	B
<	B
18	I

Pregnancy	B

Bradycardia	B
(	O
HR	B
<	B
55bpm	I
)	O

Systolic	B
Blood	I
Pressure	I
<	B
80	I
mmHg	I
/	O
Mean	B
arterial	I
pressure	I
<	B
50	I
mmHg	I
on	O
maximal	O
support	B

Death	B
imminent	B

Unlikely	O
to	O
survive	O
90	O
days	O

Acute	B
liver	I
failure	I

Dementia	B

High	B
-	I
grade	I
block	I
in	B
the	I
absence	I
of	I
a	O
functioning	B
pacemaker	B
.	O

Septic	B
shock	I
patients	O
despite	O
early	B
goal	I
directed	I
therapy	I

Agree	O
to	O
participate	O
this	O
study	O

Participation	O
in	O
another	O
clinical	O
trial	O
.	O

Known	O
or	O
suspected	O
(	O
or	O
history	B
of	I
)	O
malignancy	B
or	O
chronic	B
illness	I
.	O

Serious	O
organic	O
or	O
mental	B
disease	I
diagnosed	B
by	I
a	I
psychiatrist	I
(	O
e	O
.	O
g	O
.	O
,	O
major	B
depression	I
currently	B
treated	B
with	O
antidepressant	B
medication	I
)	O
suspected	O
on	O
the	O
basis	O
of	O
the	O
medical	B
history	I
and	O
/	O
or	O
clinical	B
examination	I
.	O

Conditions	O
that	O
may	O
affect	O
the	O
compliance	O
to	O
the	O
study	O
.	O

Contraindications	O
to	O
therapy	O
with	O
the	O
study	O
drug	O
or	O
hypersensitivity	O
to	O
the	O
study	O
drug	O
(	O
active	O
ingredient	O
or	O
excipients	O
of	O
the	O
formulation	O
)	O
.	O

Female	B
subjects	O
aged	B
=	B
/	I
>	I
18	I
years	I
and	O
of	O
reproductive	B
age	I
.	O

Capacity	O
to	O
give	O
consent	O
for	O
study	O
participation	O
,	O
after	O
being	O
adequately	O
informed	O
of	O
the	O
aims	O
,	O
benefits	O
,	O
risks	O
,	O
time	O
and	O
motion	O
of	O
the	O
study	O
.	O

Immunosuppresant	B
host	I

Chronic	B
cardiovascular	O
/	O
pulmonary	B
disease	I

Hospital	B
acquired	I
infection	I

Evidence	O
of	O
Mycoplasma	B
pneumoniae	I
infection	I

Lobar	B
pneumonia	I
or	O
pneumoniae	B
with	O
pleural	B
effusion	I

NA	O

Intrauterine	B
fetal	I
death	I
as	O
confirmed	O
by	O
absence	B
of	I
cardiac	I
motion	I
on	O
ultrasound	B
by	O
Attending	O
physician	O
at	B
the	I
time	I
of	I
admission	I
to	I
the	I
hospital	I
.	O

Estimated	B
gestational	I
age	I
greater	B
than	I
20	I
weeks	I

Hemodynamically	B
stable	I
and	O
appropriate	O
for	O
induction	B
of	I
labor	I
as	O
per	O
primary	O
clinical	O
health	O
team	O
in	O
house	O

Women	B
with	O
one	B
prior	O
low	B
transverse	I
cesarean	I
delivery	I

Type	B
1	I
diabetes	I
(	O
autoantibody	B
positive	B
)	O
.	O

Any	O
history	O
of	O
receiving	O
GLP	B
-	I
1	I
analogues	I
or	O
dipeptidyl	B
peptidase	I
inhibitors	I
within	B
6	I
months	I

Known	O
severe	B
heart	B
failure	I
,	O
classified	O
as	O
NYHA	B
4	B
.	O

Active	B
myocarditis	I
;	O
malfunctioning	B
artificial	B
heart	I
valve	I
.	O

History	O
of	O
ventricular	B
tachycardia	I
within	B
3	I
months	I
before	O
study	O
entry	O
;	O
second	O
-	O
or	O
third	B
-	I
degree	I
atrioventricular	I
block	I
.	O

Supine	B
systolic	B
blood	I
pressure	I
<	B
85	I
mm	I
Hg	I
or	O
>	B
200	I
mm	I
Hg	I
at	O
screening	O
.	O

Primary	B
renal	I
impairment	I
,	O
creatinine	B
clearance	I
<	B
45	I
ml	I
/	I
min	I
if	O
treated	O
with	O
metformin	B
.	O

Uncorrected	O
hypokalemia	B
or	O
hyperkalemia	B
(	O
potassium	B
<	B
3	I
.	I
5	I
mmol	I
/	I
l	I
or	O
>	B
5	I
.	I
5	I
mmol	I
/	I
l	I
)	O
.	O

Significant	B
anemia	B
(	O
Hb	B
<	B
90	I
g	I
/	I
l	I
)	O

Severe	B
gastrointestinal	B
disease	I
,	O
including	O
gastroparesis	B
.	O

As	O
judged	O
by	O
the	O
Investigator	O
.	O

Body	B
mass	I
index	I
(	O
BMI	B
)	O
>	B
45	I
kg	I
/	I
m2	I
.	O

Malignant	B
neoplasm	I
requiring	O
chemotherapy	B
,	O
surgery	B
,	O
radiation	B
or	O
palliative	B
therapy	I
in	O
the	O
previous	B
5	I
years	I
.	I

Patients	O
with	O
intraepithelial	B
squamous	I
cell	I
carcinoma	I
of	O
the	O
skin	B
treated	O
with	O
topical	B
5FU	I
and	O
subjects	O
with	O
basal	B
cell	I
skin	I
cancer	I
are	O
allowed	B
to	O
enter	O
the	O
trial	O
.	O

Females	O
of	O
child	O
bearing	O
potential	O
who	O
are	O
pregnant	O
,	O
breast	O
-	O
feeding	O
or	O
intend	O
to	O
become	O
pregnant	O
.	O

Current	O
drug	O
and	O
alcohol	B
abuse	I
.	O

History	O
of	O
acute	O
or	O
chronic	B
pancreatitis	I

Subjects	O
considered	O
by	O
the	O
Investigator	O
to	O
be	O
unsuitable	O
for	O
the	O
study	O
.	O

Patients	O
eligible	O
for	O
PCI	B
with	O
application	O
of	O
DES	B
,	O
due	O
to	O
ACS	B
.	O

Patients	O
with	O
known	O
or	O
newly	O
diagnosed	O
T2D	B
(	O
type	O
2	O
diabetes	O
is	O
diagnosed	O
according	O
to	O
current	O
WHO	O
criteria	O
or	O
by	O
the	O
use	O
of	O
anti	O
-	O
diabetic	O
drugs	O
)	O

Male	B
and	O
female	B
subjects	O
18	B
-	I
80	I
years	B
.	O

HbA1c	B
(	O
accordingly	O
to	O
IFCC	O
)	O
47	B
mmol	I
/	I
mol	I
-	I
110	I
mmol	I
/	I
mol	I
.	O

Signed	O
informed	O
consent	O
form	O
.	O

vulnerable	B
study	O
subjects	O
such	O
as	O
described	O
in	O
Finnish	B
law	I
concerning	I
clinical	I
studies	I
(	O
disabled	B
,	O
children	B
,	O
pregnant	B
or	O
breast	B
-	I
feeding	I
women	B
,	O
prisoners	O
)	O
will	O
not	O
be	O
included	O
.	O

suspicion	O
of	O
nonfunctional	B
P	I
-	I
NET	I
on	O
primary	B
CT	I
(	O
i	O
.	O
e	O
hypervascularity	B
)	O
or	O
MRI	B

signed	O
informed	O
consent	O

Type	B
1	I
diabetes	I

Known	O
peripheral	B
artery	I
disease	I

Liver	B
enzymes	I
equal	B
or	I
more	I
than	I
1	I
.	I
5	I
times	I
the	I
upper	I
limit	I
of	I
normal	I

Chronic	B
heart	I
failure	I
NYHA	B
class	B
III	I
or	I
IV	I

Current	B
haemodialysis	B
or	O
peritoneal	B
dialysis	I

End	B
stage	I
liver	I
disease	I
,	O
defined	O
as	O
acute	O
or	O
chronic	B
liver	I
disease	I
and	O
recent	B
history	O
of	O
one	O
of	O
the	O
following	O
:	O
ascites	B
,	O
encephalopathy	B
,	O
variceal	B
bleeding	I
,	O
bilirubin	B
equal	B
or	I
greater	I
than	I
2	I
.	I
0	I
mg	I
/	I
dL	I
,	O
albumin	B
equal	B
or	I
less	I
than	I
3	I
.	I
5	I
g	I
/	I
dL	I
,	O
prothrombin	B
time	I
greater	B
or	I
equal	I
to	I
4	I
seconds	I
,	O
INR	B
greater	B
than	I
or	I
equal	I
to	I
1	I
.	I
7	I
or	O
prior	B
liver	B
transplant	I

Known	O
or	O
suspected	O
hypersensitivity	B
to	O
trial	B
products	I
or	O
related	B
products	I

Female	O
of	O
child	O
-	O
bearing	O
potential	O
who	O
is	O
pregnant	O
,	O
breast	O
-	O
feeding	O
or	O
intends	O
to	O
become	O
pregnant	O
or	O
is	O
not	O
using	O
adequate	O
contraceptive	O
methods	O
as	O
required	O
by	O
law	O
or	O
local	O
practice	O
.	O

Expected	O
simultaneous	O
participation	O
in	O
any	O
other	O
clinical	O
trial	O
of	O
an	O
investigational	O
medicinal	O
product	O
.	O

Receipt	O
of	O
any	O
investigational	O
medicinal	O
product	O
within	O
30	O
days	O
before	O
randomization	O

Current	B
or	O
past	B
(	O
within	B
the	I
last	I
5	I
years	I
)	O
malignant	B
neoplasms	I
(	O
except	B
basal	O
cell	O
and	O
squamous	B
cell	I
skin	I
carcinoma	I
)	O

Any	O
condition	O
that	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
would	O
make	O
the	O
subject	O
unable	O
to	O
adhere	O
to	O
the	O
trial	O
visit	O
schedule	O
and	O
procedures	O

Known	O
history	O
of	O
non	O
-	O
compliance	O
to	O
treatment	O
.	O

use	O
of	O
basal	B
-	I
bolus	I
insulin	I

onset	B
of	I
diabetes	I
after	B
age	I
30	I

BMI	B
less	B
than	I
35	I

eGFR	B
at	B
least	I
60	I
ml	I
/	I
mn	I

Hb	B
A1c	I
7	B
.	I
0	I
-	I
10	I
.	I
0	I
%	I

willingness	O
to	O
perform	O
home	O
glucose	O
monitoring	O

willingness	O
to	O
transmit	O
glucose	O
and	O
medication	O
information	O
weekly	O

Anticoagulation	B
therapy	I

Prior	B
CABG	B
.	O

Active	B
bleeding	B
or	O
at	B
high	I
risk	I
of	O
bleeding	B

Severe	B
liver	O
or	O
renal	B
disease	I
.	O

Hypersensitivity	B
to	O
ticagrelor	B

History	B
of	O
intracranial	B
hemorrhage	I

Accepted	O
for	O
CABG	B
surgery	I

Treatment	B
with	O
Ticagrelor	B
within	B
48	I
hours	I

pregnant	B
or	O
breastfeeding	O

known	O
thromboembolic	B
disease	I
or	O
with	O
high	O
risk	O
of	O
thromboembolism	B
,	O
warranting	O
extra	B
anticoagulation	I
in	O
connection	O
with	O
the	O
procedure	O

known	O
allergy	B
to	O
tranexamic	B
acid	I
/	O
Cyklokapron	B
®	O

breast	B
cancer	I

undergoing	B
unilateral	B
mastectomy	I
with	O
or	O
without	O
axillary	B
node	I
dissection	I

received	O
adequate	O
oral	O
and	O
written	O
information	O
about	O
the	O
study	O
and	O
signed	O
an	O
informed	O
-	O
consent	O
form	O

Renal	B
disease	I
unrelated	B
to	O
SLE	B
(	O
e	O
.	O
g	O
.	O
diabetes	B
mellitus	I
,	O
other	O
glomerular	O
or	O
tubulointerstitial	B
disease	I
,	O
renovascular	B
disease	I
)	O
,	O
or	O
transplanted	B
kidney	I
.	O

Estimated	B
glomerular	I
filtration	I
rate	I
(	O
eGFR	B
by	O
MDRD	O
)	O
=	B
20	I
mL	I
/	I
min	I
per	I
1	I
.	I
73	I
m2	I
or	O
serum	B
creatinine	I
>	B
300	I
micromol	I
/	I
L	I
(	O
3	B
.	I
39	I
mg	I
/	I
dL	I
)	O
at	O
screening	O
.	O

Renal	B
biopsy	I
showing	O
cellular	O
or	O
fibrocellular	B
crescent	I
in	O
more	B
than	I
25	I
%	I
of	I
glomeruli	I
.	O

CNS	B
or	O
other	O
severe	O
organ	B
manifestation	I
of	O
lupus	B
that	O
necessitate	O
aggressive	O
immunosuppressive	B
therapy	I
on	O
its	O
own	O
.	O

Co	B
-	I
morbidities	I
that	O
require	O
corticosteroid	B
therapy	I
(	O
e	O
.	O
g	O
.	O
asthma	B
,	O
inflammatory	B
bowel	I
disease	I
)	O
.	O

Treatment	O
with	O
prednisolone	B
(	O
or	O
prednisone	B
,	O
or	O
equivalent	O
)	O
at	O
>	B
20	I
mg	I
/	I
D	I
for	I
over	I
4	I
weeks	I
within	O
the	O
past	B
3	I
months	I
.	O

Treatment	O
with	O
MMF	B
at	O
>	B
1	I
.	I
5	I
g	I
/	I
D	I
for	I
over	I
4	I
weeks	I
within	O
the	O
past	B
3	I
months	I
.	O

Known	O
hypersensitivity	B
or	O
intolerability	B
to	O
prednisolone	B
(	O
or	O
prednisone	B
,	O
or	O
equivalent	O
)	O
,	O
TAC	B
,	O
or	O
MMF	B
at	O
a	O
dose	O
of	O
1	B
.	I
25	I
g	I
or	I
below	I
per	I
day	I
.	O

Subjects	O
who	O
are	O
already	O
on	O
treatment	O
with	O
TAC	B
,	O
cyclosporine	B
or	O
any	O
other	O
calcineurin	B
inhibitor	I
for	O
over	B
4	I
weeks	I
within	O
the	O
past	B
12	I
months	I
.	I

Treatment	O
with	O
cyclophosphamide	B
,	O
leflunomide	B
,	O
or	O
methotrexate	B
for	O
over	O
2	B
weeks	I
,	O
or	O
use	O
of	O
biological	B
agent	I
(	O
s	O
)	O
regardless	O
of	O
duration	O
,	O
within	O
the	O
past	B
6	I
months	I
(	O
Note	O
:	O
prior	O
use	O
of	O
azathioprine	B
,	O
mizoribine	B
,	O
intravenous	O
immunoglobulins	B
and	O
anti	B
-	I
malarials	I
is	O
allowed	B
)	O
.	O

Uncontrolled	B
hypertension	B
with	O
systolic	B
BP	I
>	B
160	I
mmHg	I
or	O
diastolic	B
BP	I
>	B
95	I
mmHg	I
.	O

Women	O
who	O
are	O
pregnant	O
or	O
breastfeeding	O
.	O

Women	O
with	O
childbearing	O
potential	O
or	O
their	O
male	O
partners	O
,	O
who	O
refuse	O
to	O
use	O
an	O
effective	O
birth	O
control	O
method	O

Biopsy	O
-	O
proven	O
LN	B
Class	B
III	I
/	I
IV	I
±	I
V	I
(	O
ISN	O
/	O
RPS	O
2003	O
)	O
,	O
with	O
biopsy	B
performed	O
within	B
12	I
weeks	I
of	O
randomization	O
.	O

Positive	B
anti	B
-	I
dsDNA	I
.	O

Active	B
LN	B
with	O
proteinuria	B
(	O
urine	B
protein	I
/	I
creatinine	I
ratio	I
>	B
1	I
.	I
0	I
or	O
24	B
-	I
hr	I
urine	I
protein	I
>	B
1	I
.	I
0	I
g	I
at	O
baseline	O
)	O
,	O
with	O
or	O
without	O
hematuria	B
.	O

Both	O
'	O
incident	O
'	O
(	O
i	O
.	O
e	O
.	O
new	O
)	O
patients	O
and	O
'	O
flare	O
'	O
patients	O
can	O
be	O
included	O
.	O

Ulcers	B
due	O
to	O
non	B
-	I
diabetic	I
etiology	O
.	O

Uncontrolled	B
diabetes	I
defined	O
as	O
HbA1c	B
above	B
70	I
mmol	I
/	I
mol	I
and	O
insufficient	B
nutritional	I
status	I
.	O

Ulcers	B
older	B
than	I
1	I
year	I
.	O

Any	B
of	I
gangrene	B
,	O
osteomyelitis	B
,	O
cellulitis	B
,	O
or	O
Charcot	B
osteoarthropathy	I
.	O

Type	B
I	I
or	I
II	I
diabetes	I
mellitus	I
.	O

Target	B
ulcer	I
area	I
between	B
0	I
.	I
5	I
and	I
5	I
sqcm	I
,	O
and	O
more	B
than	I
4	I
weeks	I
old	I
.	O

Ankle	B
-	I
brachial	I
pressure	I
index	I
above	B
0	I
.	I
7	I
.	O

Newborn	B
infants	I
<	B
28	I
weeks	I
and	I
>	I
34	I
weeks	I
gestation	B
,	O
those	O
with	O
life	B
threatening	I
illness	I
,	O
congenital	O
and	O
chromosomal	B
anomalies	I
,	O
gastrointestinal	B
anomalies	I
or	O
necrotizing	B
enterocolitis	I
and	O
fed	O
premature	O
formula	O

Inborn	B
preterm	B
infants	B
born	O
between	B
28	I
0	I
/	I
7	I
and	I
34	I
0	I
/	I
7	I
weeks	I
gestation	B
and	O
fed	O
either	O
mother	O
'	O
s	O
own	O
milk	O
or	O
donor	O
human	O
milk	O

Regular	O
cigarette	O
smoker	O

Alcohol	O
abuse	O

Drug	O
abuse	O

History	O
of	O
falls	B
or	O
dizziness	B
at	B
exit	I
from	I
bed	I
in	I
the	I
morning	I
(	O
at	B
least	I
two	I
incidents	B
in	B
the	I
past	I
year	I
)	O

At	B
least	I
20	I
/	I
200	I
corrected	B
visual	I
acuity	I

Stable	B
health	I

Normal	B
hearing	I

Pregnancy	B

Known	O
hypersensitivity	B
to	O
study	B
drug	I
(	O
ferric	B
carboxymaltose	I
or	O
equivalent	O
)	O
or	O
its	O
excipients	O

Known	O
or	O
suspected	O
haemoglobinopathy	B
/	O
thalassaemia	B

Bone	B
marrow	I
disease	I

Haemochromatosis	B

Renal	B
dialysis	I

Erythropoietin	B
or	O
IV	B
iron	I
in	B
the	I
previous	I
4	I
weeks	I

Patients	O
with	O
anaemia	B
(	O
males	B
Hb	B
<	B
130	I
g	I
/	I
L	I
,	O
females	B
<	B
120	I
g	I
/	I
L	I
)	O
undergoing	O
elective	B
cardiac	B
surgery	I
,	O
and	O
available	O
to	O
receive	O
trial	B
drug	I
1	O
-	O
10	O
weeks	O
prior	O
to	O
surgery	B

Psoriasis	B
or	O
psoriasis	B
arthropathy	I

Inflammatory	B
bowel	I
disease	I

Unwillingness	O
to	O
participate	O
in	O
the	O
study	O
with	O
additional	O
imaging	O
protocols	O

Expected	O
life	O
-	O
span	O
less	B
than	I
<	I
1	I
year	I

Diabetes	B
(	O
to	O
improve	O
the	O
PET	B
imaging	I
quality	I
)	O

Probable	B
noncompliance	B

Pregnancy	B

Age	B
<	B
18	I
years	I
or	O
>	B
75	I
years	I

Contraindication	B
for	O
adalimumab	B

Methotrexate	B
used	O
within	B
the	I
previous	I
6	I
months	I

A	O
biologic	B
medicine	I
used	O
within	B
the	I
previous	I
6	I
months	I

Axial	B
spondyloarthritis	I
(	O
ASAS	B
criteria	I
)	O
and	O
radiologic	B
sacroiliitis	B
as	O
detected	O
either	O
by	O
MRI	B
or	O
X	B
-	I
ray	I
.	O

Uncontrolled	B
medical	B
problems	I
including	O
pulmonary	O
,	O
cardiovascular	O
or	O
orthopedic	B
disease	I
,	O

Any	O
debilitating	B
disease	I
prior	B
to	I
the	I
SCI	I
that	O
caused	O
exercise	B
intolerance	I

Premorbid	B
,	O
ongoing	B
major	B
depression	I
or	O
psychosis	B
,	O
altered	B
cognitive	I
status	I

History	B
of	I
head	B
injury	I
or	O
stroke	B
,	O

Metal	B
plate	I
in	I
skull	I

History	O
of	O
seizures	B

Receiving	O
drugs	B
acting	I
primarily	I
on	I
the	I
central	I
nervous	I
system	I
,	O
which	O
lower	B
the	I
seizure	I
threshold	I
such	O
as	O
antipsychotic	B
drugs	I
(	O
chlorpromazine	B
,	O
clozapine	B
)	O
or	O
tricyclic	B
antidepressants	I
.	O

Pregnant	B
females	B
,	O
and	O

Ongoing	O
cord	B
compression	I
or	O
a	O
syrinx	B
in	O
the	O
spinal	B
cord	I
or	O
who	O
suffer	O
from	O
a	O
spinal	B
cord	I
disease	I
such	O
as	O
spinal	B
stenosis	I
,	O
spina	B
bifida	I
or	O
herniated	B
cervical	I
disk	I
.	O

Uncontrolled	B
medical	B
problems	I
including	O
pulmonary	O
,	O
cardiovascular	O
or	O
orthopedic	B
disease	I
,	O

Any	O
debilitating	B
disease	I
that	O
causes	O
exercise	B
intolerance	I

Premorbid	B
,	O
ongoing	B
major	B
depression	I
or	O
psychosis	B
,	O
altered	B
cognitive	I
status	I

History	B
of	O
head	B
injury	I
or	O
stroke	B
,	O

Metal	B
plate	I
in	I
skull	I

History	B
of	I
seizures	B

Receiving	O
drugs	B
acting	I
primarily	I
on	I
the	I
central	I
nervous	I
system	I
,	O
which	O
lower	B
the	I
seizure	I
threshold	I
such	O
as	O
antipsychotic	B
drugs	I
(	O
chlorpromazine	B
,	O
clozapine	B
)	O
or	O
tricyclic	B
antidepressants	I
.	O

Pregnant	B
females	B
,	O
and	O

Ongoing	O
cord	B
compression	I
or	O
a	O
syrinx	B
in	O
the	O
spinal	B
cord	I
or	O
who	O
suffer	O
from	O
a	O
spinal	B
cord	I
disease	I
such	O
as	O
spinal	B
stenosis	I
,	O
spina	B
bifida	I
or	O
herniated	B
cervical	I
disk	I
.	O

Male	B
and	O
females	B
between	O
ages	B
18	O
-	O
85	O
years	O
of	O
age	O

SCI	B
(	O
=	B
1	I
month	I
of	I
injury	I
)	O

ASIA	B
A	B
,	I
B	I
,	I
C	I
and	I
D	I

SCI	B
above	B
L5	I

Able	O
to	O
perform	O
a	O
visible	O
contraction	O
with	O
dorsiflexor	O
and	O
hip	O
flexor	O
muscles	O
(	O
allowing	O
testing	O
of	O
largely	O
impaired	O
patients	O
)	O

Able	B
to	I
ambulate	I
a	I
few	I
steps	I
with	O
or	O
without	B
an	I
assistive	I
device	I

Male	B
and	O
females	B
between	O
ages	B
18	O
-	O
85	O
years	O
of	O
age	O

Able	B
to	I
walk	I
and	O
complete	O
lower	O
-	O
limb	O
tests	O
with	B
both	I
legs	I

use	O
of	O
any	O
sedative	B
hypnotics	I
,	O
tranquilizers	B
,	O
anticonvulsants	B
,	O
antihistamines	B
(	O
except	B
non	B
-	I
sedating	I
)	O
,	O
benzodiazepines	B
,	O
clonidine	B
or	O
any	O
medication	B
known	I
to	I
affect	I
dopamine	I
at	B
start	I
of	I
baseline	I
period	I

significant	B
unstable	B
or	O
uncontrolled	B
medical	O
/	O
psychiatric	B
disease	I

significant	B
history	B
of	O
head	B
trauma	I
/	O
surgery	O
or	O
seizure	B
disorder	I

radiation	B
exposure	I
exceeding	B
20mSv	I
in	B
last	I
12	I
months	I

pregnancy	B

substance	B
abuse	I
/	O
dependence	O
(	O
including	O
alcohol	B
)	O

have	O
sleep	B
apnea	I
,	O
or	O
are	O
shift	B
workers	I

on	O
a	O
sodium	B
-	I
restricted	I
diet	I

has	O
ever	B
taken	O
Xyrem	B
/	O
sodium	B
oxybate	I
/	O
GHB	B
at	O
any	O
time	O

claustrophobia	B

metal	B
implants	I
/	O
objects	O
in	O
the	O
body	O
that	O
may	O
interfere	O
with	O
MRI	B

succinic	B
semialdehyde	I
dehydrogenase	I
deficiency	I

current	O
diagnosis	O
of	O
narcolepsy	B
with	O
cataplexy	B
OR	O
healthy	B
control	O

With	O
acute	B
diseases	I
,	O
such	O
as	O
acute	B
phase	I
after	O
myocardial	B
infarction	I
(	O
within	B
3	I
months	I
)	O
,	O
within	B
3	I
months	I
after	O
acute	B
heart	I
failure	I
or	O
new	O
cerebral	B
infarction	I
;	O

In	O
the	O
list	O
of	O
heart	B
transplantation	I
;	O

Expected	O
survival	O
less	B
than	I
1	I
year	I
;	O

With	O
other	B
hemorrhagic	B
diseases	I
and	O
anticoagulant	B
therapy	I
is	O
not	B
allowed	I
;	O

Thrombosis	B
in	O
left	B
atrium	I
;	O

Heart	B
failure	I
,	O
New	B
York	I
Heart	I
Association	I
(	I
NYHA	I
)	I
III	B
/	I
IV	I
or	O
eject	B
fraction	I
(	I
EF	I
)	I
<	B
40	I
%	I
;	O

Patients	O
with	O
uncontrolled	B
cancer	B
;	O

Significant	B
hepatic	O
or	O
renal	B
impairment	I
(	O
and	O
/	O
or	O
alanine	B
transaminase	I
(	I
ALT	I
)	I
or	O
Aspartate	B
transaminase	I
(	I
AST	I
)	I
>	B
2	I
times	I
upper	I
limit	I
of	I
normal	I
,	O
creatinine	B
clearance	I
rate	I
(	I
CCr	I
)	I
<	B
50	I
%	I
)	O
;	O

Previous	O
catheter	B
radiofrequency	I
ablation	I
for	O
AF	B
or	O
cardiac	B
surgery	I
;	O

Pregnant	O
and	O
lactating	O
women	O
,	O
women	O
who	O
plan	O
to	O
become	O
pregnant	O
,	O
or	O
women	O
of	O
child	O
bearing	O
age	O
not	O
using	O
reliable	O
contraceptive	O
measures	O
.	O

No	B
response	B
to	O
more	B
than	I
one	I
antiarrhythmic	B
drug	I
,	O
or	O
unwilling	O
to	O
receive	O
long	O
-	O
term	O
drug	O
treatment	O
.	O

Can	O
provide	O
informed	O
consent	O
form	O
expressing	O
willingness	O
to	O
participate	O
in	O
the	O
study	O
and	O
comply	O
with	O
follow	O
-	O
up	O
tests	O
and	O
evaluation	O
procedures	O
.	O

Aged	B
18	B
-	I
80	I
years	I
.	O

Pregnant	B
or	O
lactating	B
women	B

Women	B
with	O
breast	B
implants	I
on	O
the	O
same	B
side	I
as	I
the	I
lesion	I

Women	B
that	O
underwent	O
local	B
radiation	I
or	O
chemotherapy	B
within	B
the	I
last	I
12	I
months	I

Women	B
with	O
history	O
of	O
breast	B
cancer	I
or	O
breast	B
surgery	I
in	O
the	O
same	B
quadrant	I

Lesions	B
in	B
or	I
close	I
to	I
scar	I
tissue	I
(	O
<	B
1cm	I
)	O

Skin	B
lesions	I
or	O
lesions	B
that	O
have	O
been	O
biopsied	B
previously	B

Lesion	B
larger	B
than	I
4	I
cm	I
in	O
the	O
longest	B
dimension	I

No	O
lesion	B
should	O
be	O
included	O
when	O
more	B
than	I
50	I
%	I
of	I
the	I
lesion	I
is	O
further	B
down	I
than	I
4	I
cm	I
beneath	B
the	I
skin	I
level	I
.	O

Female	B

Age	B
≥	B
18	I
years	I

Patients	O
with	O
a	O
lesion	B
>	B
0	I
.	I
5	I
cm	I
in	O
largest	B
diameter	I
size	I
,	O
initially	O
scored	O
BI	B
-	I
RADS	I
®	I
3	B
,	I
4a	I
,	I
4b	I
or	I
4c	I
in	O
B	B
-	I
mode	I
ultrasound	I

Informed	O
consent	O
about	O
histological	B
examination	I
(	O
core	B
cut	I
biopsy	I
(	I
CCB	I
)	I
,	O
vacuum	B
-	I
assisted	I
biopsy	I
(	I
VAB	I
)	I
,	O
fine	B
needle	I
aspiration	I
(	I
FNA	I
)	I
or	O
surgery	B
)	O
has	O
already	O
been	O
given	O
in	O
the	O
course	O
of	O
clinical	O
routine	O

Signed	O
informed	O
consent	O
of	O
study	O
participation	O

Children	B
(	O
<	B
18	I
years	I
old	B
)	O
.	O

Women	B
who	O
are	O
known	O
to	O
be	O
pregnant	B
.	O

Any	O
patient	O
who	O
has	O
been	O
previously	B
randomized	B
in	O
the	O
EvK	O
Trial	O
.	O

Patients	O
who	O
require	O
endotracheal	B
intubation	I
without	B
sedative	B
medication	I
.	O

For	O
example	O
,	O
patients	O
in	O
full	B
cardiac	I
arrest	I
.	O

Patients	O
with	O
a	O
known	O
allergy	B
to	O
ketamine	B
or	O
etomidate	B
.	O

Any	B
individual	I
wearing	I
a	I
MedAlert	I
bracelet	I
indicating	I
that	I
he	I
/	I
she	I
has	I
formally	I
opted	I
out	I
of	I
the	I
EvK	I
Trial	I
.	O

Adult	B
patient	O
(	O
male	B
or	O
female	B
)	O
requiring	O
emergency	B
endotracheal	I
intubation	I
.	O

Active	B
or	O
past	B
psychotic	B
disorder	I
,	O
including	O
a	O
history	O
of	O
psychotic	B
affective	I
state	I

Mental	B
Retardation	I
or	O
Autistic	B
Spectrum	I
Disorder	I

Prominent	B
personality	I
disorder	I

Cardiac	O
or	O
neurologic	B
active	I
medical	I
condition	I
,	O
including	O
past	B
CVA	B
/	O
TIA	B
(	O
Cardiovascular	B
Accident	I
/	O
Transient	B
Ischemic	I
Attack	I
)	O
or	O
any	O
other	O
unstable	B
medical	B
condition	I
.	O

Chronic	B
nasal	B
congestion	I

Active	B
or	O
recent	B
drug	O
or	O
alcohol	B
abuse	I

Substantial	B
suicidality	B
in	O
a	O
patient	O
requiring	O
admission	B
but	O
refuses	O
to	O
do	O
so	O
,	O
and	O
signs	O
an	O
"	O
against	O
medical	O
advice	O
"	O
release	O
form	O
as	O
part	O
of	O
clinical	O
evaluation	O
,	O
and	O
does	O
not	O
answer	O
the	O
terms	O
for	O
involuntary	O
admission	O
.	O

Age	B
18	B
-	I
65	I

Diagnosis	O
of	O
MDD	B
(	O
Major	B
Depressive	I
Disorder	I
)	O
,	O
made	O
or	O
affirmed	O
by	O
a	O
senior	O
psychiatrist	O
in	O
Shalvata	O

MADRS	B
score	I
>	B
20	I

Treated	B
with	O
conventional	B
anti	I
-	I
depressant	I
,	O
administered	O
within	O
a	O
formal	O
psychiatric	O
clinic	O
or	O
by	O
a	O
certified	O
psychiatrist	O
.	O

patients	O
'	O
refusal	O

contraindication	B
to	O
regional	B
anaesthesia	I
(	I
coagulopathies	B
,	O
concurrent	O
anticoagulant	B
therapy	I
,	O
allergy	B
to	O
local	B
anaesthetics	I
,	O
infection	B
at	O
puncture	B
site	I
)	O

adult	B
patients	O

ASA	B
class	I
1	B
to	I
3	I
patients	O

patients	O
scheduled	O
for	O
elective	B
breast	O
mastectomy	B
or	O
quadrantectomy	O

ASA	B
>	B
3	I
;	O

Coagulopathy	B
;	O

Renal	B
disease	I
,	O

Liver	B
disease	I
,	O

History	O
of	O
recent	B
gastro	B
-	I
intestinal	I
bleeding	I

Pregnancy	B
.	O

Diagnosis	O
of	O
chronic	B
pain	I
currently	O
taking	O
opioid	B
pain	I
medication	I
or	O
with	O
a	O
history	B
of	I
drug	B
abuse	I
.	O

Patients	O
with	O
a	O
self	O
-	O
described	O
allergy	B
to	O
ASA	B
,	O
acetaminophen	B
,	O
NSAIDS	B
and	O
codeine	B
.	O

All	O
patients	O
receiving	O
a	O
brachial	B
plexus	I
block	I
for	O
anesthesia	O
and	O
/	O
or	O
analgesia	O

Patients	O
undergoing	O
ambulatory	B
hand	B
surgery	I
for	O
carpal	B
tunnel	I
and	O
trigger	B
finger	I
,	O
under	O
local	B
anesthesia	I
with	O
or	O
without	O
sedation	O
.	O

current	B
suicidal	B
risk	I

current	B
psychosis	B

ongoing	B
trauma	B
(	O
e	O
.	O
g	O
.	O
current	B
involvement	B
in	I
an	I
abusive	I
relationship	I
)	O
.	O

satisfying	B
DSM	B
-	I
V	I
criteria	I
for	O
ED	B
and	O
for	O
half	O
of	O
the	O
patients	O
in	O
addition	O

have	O
a	O
history	B
of	O
childhood	B
trauma	I
.	O

Amiodarone	B

P	B
-	I
glycoprotein	I
(	I
P	I
-	I
gp	I
)	I
inducers	I
(	O
e	O
.	O
g	O
.	O
,	O
rifampin	B
,	O
St	B
.	I
John	I
'	I
s	I
wort	I
)	O

Liver	B
biopsy	I
at	O
any	B
time	I
showing	O
mHAI	B
stage	I
4	B
or	I
higher	I
fibrosis	O
OR	O

FibroScan	B
within	B
12	I
months	I
demonstrating	O
liver	B
stiffness	I
of	O
=	B
9	I
.	I
5	I
kilo	I
Pascal	I
or	O

AST	B
to	I
platelet	I
ratio	I
index	I
(	I
APRI	I
)	I
=	B
2	I
.	I
0	I
and	O
Fibrosis	B
-	I
4	I
(	I
FIB	I
-	I
4	I
)	I
=	B
3	I
.	I
25	I

NOTE	O
:	O
If	O
APRI	O
and	O
FIB	O
-	O
4	O
are	O
discordant	O
one	O
of	O
the	O
other	O
forms	O
of	O
fibrosis	O
staging	O
must	O
be	O
used	O
.	O

Known	O
allergy	B
/	O
sensitivity	B
or	O
any	O
hypersensitivity	B
to	O
components	B
of	I
study	I
drugs	I
or	O
their	O
formulation	O
.	O

Hemochromatosis	B

Alpha	B
-	I
1	I
antitrypsin	I
deficiency	I

Wilson	B
'	I
s	I
disease	I

Autoimmune	B
hepatitis	I

Alcoholic	B
liver	I
disease	I

Drug	B
-	I
related	I
liver	I
disease	I

Severe	O
NC	B
confounding	I
conditions	I
(	O
stroke	B
,	O
head	B
injury	I
,	O
or	O
developmental	B
learning	I
disability	I
)	O
.	O

Regular	O
use	O
of	O
anti	B
-	I
inflammatory	I
drugs	I
.	O

Current	B
or	O
recent	B
treatment	B
with	O
pegylated	B
interferon	I
(	O
PEG	B
-	I
IFN	I
)	O
.	O

Other	B
active	B
inflammatory	I
process	I
(	O
major	B
infection	I
,	O
malignancy	B
,	O
rheumatoid	B
arthritis	I
/	O
autoimmune	B
disorder	I
)	O
within	B
the	I
prior	I
28	I
days	I
.	O

Contraindications	B
to	O
magnetic	B
resonance	I
imaging	I
(	I
MRI	I
)	I
.	O

Bleeding	B
diathesis	I
,	O
thrombocytopenia	B
,	O
or	O
use	O
of	O
anticoagulants	B
that	O
would	O
contraindicate	B
lumbar	B
puncture	I
.	O

Uncontrolled	B
or	O
active	B
depression	B
or	O
other	B
psychiatric	B
disorder	I
that	O
in	O
the	O
opinion	O
of	O
the	O
site	O
investigator	O
might	O
preclude	O
adherence	O
to	O
study	O
requirements	O
or	O
impact	O
NC	O
functioning	O
and	O
assessments	O
.	O

Active	B
drug	O
or	O
alcohol	B
use	I
or	I
dependence	I
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
site	O
investigator	O
,	O
would	O
interfere	O
with	O
adherence	O
to	O
study	O
requirements	O
.	O

Presence	O
of	O
active	B
or	O
acute	B
AIDS	B
-	I
defining	I
opportunistic	I
infections	I
within	B
12	I
weeks	I
prior	I
to	I
study	I
entry	I
.	O

Adult	B
(	O
=	O
18	O
years	O
old	B
)	O
subjects	O
with	O
chronic	B
genotype	B
1	I
HCV	B
and	O
NCI	B
with	O
a	O
GDS	B
greater	B
than	I
or	I
equal	I
to	I
0	I
.	I
5	I
(	O
n	O
=	O
60	O
)	O
.	O

Presence	O
of	O
chronic	B
HCV	B
infection	I
based	O
on	O
chart	O
review	O
will	O
be	O
defined	O
as	O
positive	B
for	O
anti	B
-	I
HCV	I
antibody	I
or	O
HCV	B
RNA	I
at	B
least	I
6	I
months	I
before	I
screening	I
.	O

For	O
the	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
group	O
only	O
,	O
subjects	O
must	O
have	O
HIV	O
.	O
HIV	O
status	O
will	O
be	O
obtained	O
through	O
self	O
report	O
.	O
Self	O
report	O
will	O
be	O
confirmed	O
at	O
screening	O
using	O
a	O
HIV	O
-	O
1	O
point	O
of	O
care	O
test	O
.	O
In	O
the	O
event	O
that	O
point	O
of	O
care	O
test	O
and	O
self	O
-	O
report	O
are	O
discordant	O
,	O
then	O
HIV	O
status	O
will	O
be	O
confirmed	O
by	O
a	O
licensed	O
Western	O
blot	O
or	O
a	O
second	O
antibody	O
test	O
.	O

HIV	B
/	O
HCV	B
co	B
-	I
infected	I
subjects	O
(	O
n	O
=	O
12	O
)	O
must	O
also	O
have	O
a	O
HIV	B
RNA	I
measurement	I
<	B
50	I
copies	I
/	I
mL	I
at	B
the	I
pre	I
-	I
treatment	I
visit	I
.	O

Platelets	B
>	B
150	I
,	I
000	I

Aspartate	B
aminotransferase	I
(	I
AST	I
)	I
/	O
Alanine	B
aminotransferase	I
(	I
ALT	I
)	I
<	B
10x	I
upper	I
limit	I
of	I
normal	I

Creatinine	B
clearance	I
>	B
30	I
milliliters	I
/	I
minute	I
/	I
1	I
.	I
73	I
centimeter	I
squared	I

Died	O
before	B
TAVI	I

Not	O
willing	O
to	O
participate	O

Age	B
=	B
75	I
years	I
,	O

Severe	B
,	O
symptomatic	B
aortic	B
stenosis	I
,	O

High	B
risk	I
for	O
cardiac	B
surgery	I
(	O
STS	B
and	O
logistic	B
Euroscore	I
)	O
,	O

According	O
multidisciplinary	O
(	O
heart	O
)	O
team	O
decision	O
TAVI	O
is	O
preferable	O
,	O

Willing	O
to	O
participate	O

1	O
.	O

Decrease	B
in	I
size	I
of	O
the	O
designated	O
target	B
ulcer	I
(	O
s	O
)	O
by	O
≥	B
30	I
%	I
during	B
the	I
7	I
-	I
day	I
screening	I
period	I

2	O
.	O

Cannot	O
tolerate	O
or	O
comply	O
with	O
compression	B
therapy	I
.	O

3	O
.	O

An	O
ulcer	B
which	O
shows	O
signs	O
of	O
severe	B
clinical	I
infection	I
,	O
defined	O
as	O
pus	B
oozing	O
from	O
the	O
ulcer	O
site	O

4	O
.	O

An	O
ulcer	B
positive	B
for	I
β	I
-	I
hemolytic	I
streptococci	I
upon	O
culture	O

5	O
.	O

The	O
ulcer	B
has	O
>	B
50	I
%	I
slough	B
,	O
significant	O
necrotic	O
tissue	O
,	O
bone	O
,	O
tendon	O
,	O
or	O
capsule	O
exposure	O
or	O
avascular	O
ulcer	O
beds	O

6	O
.	O

Is	O
highly	B
exuding	I
(	O
i	O
.	O
e	O
.	O
requires	O
daily	B
change	B
of	I
dressing	I
)	O

7	O
.	O

Ankle	B
brachial	I
pressure	I
index	I
<	B
0	I
.	I
65	I

8	O
.	O

Patients	O
with	O
active	B
systemic	B
infections	I

9	O
.	O

Patients	O
with	O
clinically	B
significant	I
medical	B
conditions	I
as	O
determined	O
by	O
the	O
investigator	O
including	O
renal	O
,	O
hepatic	O
,	O
hematologic	O
,	O
neurologic	O
or	O
immune	B
disease	I
.	O

Examples	O
include	O
but	O
are	O
not	O
limited	O
to	O
:	O

1	O
.	O

Renal	B
insufficiency	I
as	O
an	O
estimated	B
GFR	I
which	O
is	O
<	B
30	I
mL	I
/	I
min	I
/	I
1	I
.	I
7m2	I

2	O
.	O

Abnormal	B
blood	B
biochemistry	I
defined	O
as	O
3	B
times	I
that	I
of	I
the	I
upper	I
limit	I
of	I
the	I
normal	I
range	I
.	O

3	O
.	O

Hepatic	B
insufficiency	I
defined	O
as	O
total	B
bilirubin	I
>	B
2	I
mg	I
/	I
dL	I
or	O
serum	B
albumin	I
<	B
25	I
g	I
/	I
L	I

4	O
.	O

HbA1c	B
>	B
9	I
%	I

5	O
.	O

Hemoglobin	B
<	B
10	I
g	I
/	I
dL	I

6	O
.	O

Hematocrit	B
<	B
0	I
.	I
30	I

7	O
.	O

Platelet	B
count	I
<	B
100	I
,	I
000	I

10	O
.	O

Presence	O
of	O
an	O
active	B
systemic	O
or	O
local	B
cancer	I
or	O
tumor	B
of	I
any	I
kind	I
(	O
with	B
the	I
exception	I
of	I
non	B
-	I
melanoma	I
skin	I
cancer	I
)	O

11	O
.	O

Patients	O
with	O
severe	B
rheumatoid	B
arthritis	I
(	O
with	O
more	B
than	I
20	I
persistently	B
inflamed	B
joints	I
,	O
or	O
below	B
lower	I
normal	I
limit	I
blood	B
albumin	I
level	I
,	O
or	O
evidence	O
of	O
bone	B
and	I
cartilage	I
damage	I
on	O
x	B
-	I
ray	I
,	O
or	O
inflammation	B
in	I
tissues	I
other	I
than	I
joints	I
)	O
and	O
other	O
collagen	B
vascular	I
diseases	I
.	O

12	O
.	O

Patients	O
with	O
active	B
connective	B
tissue	I
disease	I

13	O
.	O

Treatment	B
with	O
systemic	B
corticosteroids	I
(	O
>	B
15	I
mg	I
/	I
day	I
)	O
,	O
or	O
current	B
immunosuppressive	B
agents	I

14	O
.	O

Previous	B
or	O
current	B
radiation	B
therapy	I
or	O
likelihood	O
to	O
receive	O
this	O
therapy	O
during	O
study	O
participation	O

15	O
.	O

Pregnant	B
or	O
nursing	B
patients	O

16	O
.	O

Known	O
prior	O
inability	O
or	O
unavailability	O
to	O
complete	O
required	O
study	O
visits	O
during	O
study	O
participation	O

17	O
.	O

Significant	B
peripheral	B
edema	I
as	O
per	O
investigator	O
'	O
s	O
discretion	O

18	O
.	O

A	O
psychiatric	B
condition	I
(	O
e	O
.	O
g	O
.	O
,	O
suicidal	B
ideation	I
)	O
or	O
chronic	O
alcohol	O
or	O
drug	B
abuse	I
problem	I
,	O
determined	O
from	O
the	O
patient	O
'	O
s	O
medical	O
history	O
,	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
may	B
pose	I
a	I
threat	I
to	I
patient	I
compliance	I

19	O
.	O

Use	O
of	O
a	O
platelet	B
-	I
derived	I
growth	I
factor	I
within	B
28	I
days	I
before	I
screening	I

20	O
.	O

Use	O
of	O
any	O
investigational	B
drug	I
or	O
therapy	O
within	B
28	I
days	I
before	I
screening	I

21	O
.	O

Has	O
any	O
other	O
factor	O
which	O
may	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
compromise	O
participation	O
and	O
/	O
or	O
follow	O
-	O
up	O
in	O
the	O
study	O

1	O
.	O

Age	B
18	B
years	I
or	I
older	I

2	O
.	O

Diagnosis	O
of	O
venous	B
leg	I
ulcer	I
(	I
s	I
)	I
,	O
as	O
clinically	O
determined	O
by	O
the	O
investigator	O
by	O
a	O
positive	B
venous	B
reflux	I
test	I
(	O
venous	B
refilling	I
<	B
20	I
seconds	I
)	O
using	O
Doppler	B
ultrasound	I
for	O
at	B
least	I
4	I
weeks	I
prior	I
to	I
screening	I
day	I
,	O
which	O
have	O
not	B
adequately	B
responded	O
to	O
conventional	B
ulcer	I
therapy	I
.	O

3	O
.	O

Designated	O
venous	B
leg	I
ulcer	I
meets	O
the	O
following	O
criteria	O
at	O
both	O
the	O
screening	O
and	O
baseline	O
visits	O
.	O

If	O
the	O
patient	O
has	O
multiple	B
ulcers	B
,	O
at	B
least	I
one	I
ulcer	B
must	O
meet	O
the	O
following	O
criteria	O
at	O
both	O
the	O
screening	O
and	O
baseline	O
visits	O
:	O

1	O
.	O

Present	B
for	O
at	B
least	I
4	I
weeks	I

2	O
.	O

CEAP	B
Classification	I
Stage	B
6	I

3	O
.	O

Surface	B
ulcer	I
with	O
an	O
area	O
>	B
15cm2	I
post	O
debridement	O

4	O
.	O

Viable	B
,	O
granulating	B
wound	B
(	O
investigator	O
discretion	O
)	O

4	O
.	O

Ulcers	B
that	O
extend	B
through	I
the	I
epidermis	I
but	O
not	B
through	O
the	O
muscle	O
,	O
tendon	O
,	O
or	O
bone	O
(	O
Stage	B
II	I
or	I
III	I
ulcers	B
as	O
defined	O
by	O
the	O
IAET	B
)	O
.	O

5	O
.	O

Female	B
patients	O
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
pregnancy	B
test	I
at	B
screening	I
and	O
must	O
agree	O
to	O
use	O
hormonal	B
contraceptive	I
,	O
intrauterine	B
device	I
,	O
diaphragm	B
with	I
spermicide	I
,	O
condom	B
with	I
spermicide	I
,	O
or	O
abstinence	O
throughout	B
until	I
2	I
weeks	I
after	I
the	I
last	I
administration	I
of	I
study	I
drug	I

6	O
.	O

Signed	O
informed	O
consent	O

Emergency	B
surgery	I
needed	O

Bowel	B
obstruction	I

Colonoscopy	B
scheduled	O
to	O
be	O
undertaken	B
peroperatively	B

Other	O
reason	O
indicating	O
mechanical	B
preparation	I
or	O
contradicting	B
it	O

Allergy	B
to	O
used	O
drugs	B
(	O
PEG	B
,	O
neomycin	B
,	O
metronidazole	B
)	O

Patients	O
undergoing	B
colon	B
resection	I

HPN	B
<	B
12	I
months	I

metabolically	B
unstable	I

cancer	B
as	O
the	O
reason	O
for	O
intestinal	B
failure	I

patients	O
receiving	O
home	B
parenteral	I
nutrition	I
(	I
HPN	I
)	I
because	O
of	O
short	B
bowel	I
syndrome	I
for	B
at	I
least	I
12	I
months	I

stable	B
metabolic	B
status	I

benign	B
disease	I

contraindications	B
from	O
manufacturer	O
for	O
medications	O
including	O
currently	O
taking	O
haloperidol	B
,	O
artane	B
,	O
Phenergan	B
(	O
Promethazine	B
)	O
,	O
chlorpromazine	B
,	O
erythromycin	B
,	O
Azithromycin	B
,	O
clarithromycin	B
,	O
Ketoconazole	B
,	O
fluconazole	B
,	O
mefloquine	B
(	O
as	O
prophylaxis	O
)	O
,	O
lumefantrine	B
(	O
in	O
Coartem	B
)	O
,	O
quinine	B
,	O
Septrin	B

anyone	O
seriously	B
ill	I

currently	O
taking	O
antimalarial	B
medicines	I

allergy	B
to	O
artemisinin	B
drugs	I

pregnant	B
women	B
in	O
first	B
trimester	O

children	B
under	B
3	I
months	I
of	O
age	B

reported	O
heart	B
condition	I

anyone	O
not	O
excluded	O
and	O
consenting	O

1	O
.	O

Comorbidity	O
with	O
other	O
severe	O
or	O
chronic	O
eye	B
conditions	I
that	O
in	O
the	O
judgment	O
of	O
the	O
investigator	O
will	B
interfere	I
with	I
study	I
assessments	I
,	O
such	O
as	O
corneal	B
opacities	I
and	O
scars	O
,	O
dystrophies	B
,	O
epithelial	B
scarring	I
,	O
infections	B
,	O
blood	B
clots	I
,	O
etc	O
.	O

2	O
.	O

Best	B
corrected	I
visual	I
acuity	I
(	I
BCVA	I
)	I
at	B
baseline	I
<	B
20	I
/	I
200	I
.	O

3	O
.	O

Has	O
a	O
condition	O
or	O
history	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
may	O
interfere	O
significantly	O
with	O
the	O
subject	O
'	O
s	O
participation	O
in	O
the	O
study	O
.	O

4	O
.	O

A	O
woman	B
who	O
is	O
pregnant	B
,	O
nursing	B
an	O
infant	O
,	O
or	O
planning	O
a	O
pregnancy	B
.	O

5	O
.	O

Has	O
a	O
known	O
adverse	O
reaction	O
and	O
/	O
or	O
sensitivity	B
to	I
the	I
study	I
drug	I
or	I
its	I
components	I
.	O

6	O
.	O

Routine	B
use	I
(	O
more	B
than	I
twice	I
a	I
week	I
)	O
of	O
a	O
chlorinated	O
swimming	O
pool	O
.	O

7	O
.	O

Unwilling	O
or	O
unable	O
to	O
cease	O
using	O
the	O
following	O
medications	O
during	B
the	I
study	I
period	I
:	O
Topical	B
ocular	I
cyclosporine	I
(	O
e	O
.	O
g	O
.	O
Restasis	B
®	I
)	O
,	O
anti	B
-	I
histamines	I
,	O
antipsychotics	B
,	O
or	O
eye	B
gels	I
.	O

8	O
.	O

Currently	O
enrolled	O
in	O
an	O
investigational	B
drug	I
or	O
device	O
study	O
or	O
have	O
used	O
an	O
investigational	B
drug	I
or	O
device	O
within	B
30	I
days	I
prior	I
to	I
Visit	I
1	I
.	O

1	O
.	O

Male	B
or	O
female	B
of	O
any	O
race	O
,	O
at	B
least	I
18	I
years	I
of	O
age	B
at	B
Visit	I
1	I
Screening	I
.	O

2	O
.	O

Has	O
provided	O
verbal	O
and	O
written	O
informed	O
consent	O
.	O

3	O
.	O

Be	O
able	O
and	O
willing	O
to	O
follow	O
instructions	O
,	O
including	O
participation	O
in	O
all	O
study	O
assessments	O
and	O
visits	O
.	O

4	O
.	O

Currently	B
being	O
treated	B
for	O
glaucoma	B
using	O
at	B
least	I
two	I
medications	B
,	O
and	O
be	O
willing	O
to	O
continue	O
on	O
the	O
same	O
regime	O
.	O

5	O
.	O

Suffers	O
from	O
at	B
least	I
two	I
of	O
the	O
symptoms	B
in	O
the	O
GLIA	B
™	I
Glaucoma	I
Medication	I
Ocular	I
Side	I
Effect	I
Symptoms	I
Questionnaire	I
at	O
a	O
severity	O
of	O
2	O
(	O
moderate	B
)	O
or	O
more	O
.	O

6	O
.	O

If	O
a	O
woman	B
of	O
childbearing	B
potential	I
,	O
have	O
a	O
negative	B
urine	B
pregnancy	I
test	I
at	B
Visit	I
1	I
and	O
be	O
using	O
an	O
adequate	B
method	B
of	I
birth	I
control	I
throughout	B
the	I
study	I
period	I
.	O

Exclusions	O
Related	O
to	O
Cardiovascular	O
Disease	O

1	O
.	O

History	B
of	O
uncontrolled	B
hypertension	B

2	O
.	O

Persistent	B
hypotension	I
at	B
Screening	I
.	O

3	O
.	O

Evidence	O
or	O
history	B
of	O
left	B
-	I
sided	I
heart	I
disease	I
and	O
/	O
or	O
clinically	B
significant	I
cardiac	B
disease	I
in	O
which	O
pulmonary	B
hypertension	I
is	O
more	O
likely	O
WHO	B
Group	I
2	B
.	O

4	O
.	O

Acute	B
decompensated	B
heart	B
failure	I
within	B
1	I
month	I
of	I
Screening	I
.	O

5	O
.	O

Recent	B
initiation	O
(	O
<	B
8	I
weeks	I
from	I
Screening	I
)	O
or	O
planned	B
initiation	O
of	O
cardiopulmonary	B
rehabilitation	I
exercise	I
program	I
.	O

Exclusions	O
Related	O
to	O
Pulmonary	O
Disease	O

6	O
.	O

Newly	B
diagnosed	I
with	O
PAH	B
and	O
not	B
on	O
PAH	B
-	I
specific	I
therapy	I
.	O

7	O
.	O

Pulmonary	O
hypertension	O
due	O
to	O
:	O

1	O
.	O

Uncorrected	B
congenital	B
systemic	I
-	I
to	I
-	I
pulmonary	I
shunt	I
.	O

2	O
.	O

Pulmonary	B
veno	I
-	I
occlusive	I
disease	I
and	O
/	O
or	O
pulmonary	B
capillary	I
hemangiomatosis	I

3	O
.	O

Persistent	B
pulmonary	B
hypertension	I
of	I
the	I
newborn	I

4	O
.	O

WHO	B
clinical	I
classification	I
Groups	B
2	I
-	I
5	I

8	O
.	O

Evidence	O
of	O
significant	B
airway	O
and	O
/	O
or	O
parenchymal	B
lung	I
disease	I
.	O

9	O
.	O

Chronic	B
infection	B
related	O
to	O
tuberculosis	B
or	O
fungal	O
or	O
mycobacterial	B
disease	I
.	O

Exclusions	O
Based	O
on	O
Other	O
Medical	O
Conditions	O

10	O
.	O

Chronic	B
infections	B
including	O
,	O
but	O
not	O
limited	O
to	O
tuberculosis	B
(	I
TB	I
)	I
,	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
or	O
hepatitis	B
C	I
virus	I
(	I
HCV	I
)	I
.	O

11	O
.	O

History	O
of	O
portal	B
hypertension	I
or	O
chronic	B
liver	I
disease	I
,	O
including	O
positive	B
serology	B
for	I
infection	I
with	I
HCV	I
and	O
/	O
or	O
HBV	O
.	O

12	O
.	O

Evidence	O
of	O
active	O
infection	B
requiring	I
intravenous	I
or	I
oral	I
antibiotics	I
within	B
4	I
weeks	I
of	I
Screening	I
.	O

13	O
.	O

Body	B
mass	I
index	I
≥	B
35	I
.	I
0	I
at	B
Screening	I
.	O

14	O
.	O

History	B
of	O
obstructive	B
sleep	I
apnea	I
.	O

15	O
.	O

History	B
of	O
malignancy	B
within	B
the	I
last	I
5	I
years	I
,	O
except	B
nonmelanoma	B
skin	I
cancer	I
and	O
cervical	B
carcinoma	I
in	I
situ	I
treated	B
with	O
curative	B
intent	I
.	O

16	O
.	O

Neuropsychiatric	B
disorders	I
/	O
symptoms	O
or	O
psychological	B
conditions	I
.	O

17	O
.	O

Pregnancy	B
or	O
breast	B
-	I
feeding	I

18	O
.	O

Prior	B
treatment	O
with	O
B	O
cell	O
or	O
lymphocyte	B
-	I
depleting	I
agents	I
(	O
eg	O
,	O
rituximab	B
,	O
Campath	B
)	O

Exclusions	O
Based	O
on	O
Concomitant	O
Medication	O
Use	O

19	O
.	O

Concurrent	B
regular	B
use	I
of	O
another	B
leukotriene	B
pathway	I
inhibitor	I
,	O
including	O
over	O
-	O
the	O
-	O
counter	O
medications	O
or	O
herbal	O
remedies	O
.	O

Exclusions	O
Based	O
on	O
Laboratory	O
Values	O

20	O
.	O

Significant	B
/	O
chronic	B
renal	I
insufficiency	I
.	O

21	O
.	O

Transaminases	O
(	O
alanine	B
transaminase	I
,	O
aspartate	B
transaminase	I
)	O
levels	O
>	B
3	I
×	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
and	O
/	O
or	O
bilirubin	B
level	I
>	B
2	I
×	I
ULN	I
.	O

22	O
.	O

Absolute	B
neutrophil	I
count	I
<	B
1500	I
mm3	I
.	O

23	O
.	O

Hemoglobin	B
concentration	I
<	B
9	I
g	I
/	I
dL	I
at	B
Screening	I
.	O

24	O
.	O

Hepatic	B
dysfunction	I
as	O
defined	O
by	O
Child	B
-	I
Pugh	I
Class	B
B	I
or	I
C	I

1	O
.	O

Male	B
or	O
female	B
,	O
18	O
-	O
75	O
years	B
old	I
.	O

2	O
.	O

Has	O
a	O
diagnosis	O
of	O
WHO	B
Group	I
1	B
PAH	B
.	O

3	O
.	O

Right	B
heart	I
catheterization	I
performed	B
at	I
Screening	I
with	O
results	O
that	O
are	O
:	O

1	O
.	O

Mean	B
pulmonary	I
arterial	I
pressure	I
≥	B
25	I
mmHg	I
(	O
at	B
rest	I
)	O
and	O

2	O
.	O

Pulmonary	B
venous	I
hypertension	I
(	O
measured	O
as	O
pulmonary	B
capillary	I
wedge	I
pressure	I
(	I
PCWP	I
)	I
≤	B
15	I
mmHg	I
.	O

If	O
PCWP	O
is	O
not	O
available	O
,	O
then	O
mean	B
left	I
atrial	I
pressure	I
or	O
left	B
ventricular	I
end	I
-	I
diastolic	I
pressure	I
≤	B
15	I
mmHg	I
in	O
the	O
absence	B
of	O
left	B
atrial	I
obstruction	I
.	O
and	O

3	O
.	O

Pulmonary	B
vascular	I
resistance	I
(	I
PVR	I
)	I
≥	B
300	I
dyn	I
•	I
s	I
/	I
cm5	I
(	O
3	B
.	I
75	I
Wood	I
units	I
)	O

4	O
.	O

Has	O
WHO	B
/	I
NYHA	I
-	I
FC	I
of	O
II	B
or	O
III	B
.	O

5	O
.	O

Be	O
on	O
stable	B
dose	I
of	O
at	B
least	I
one	I
of	O
the	O
following	O
PAH	B
-	I
specific	I
therapies	I
:	O
endothelin	B
receptor	I
antagonist	I
,	O
an	O
agent	B
acting	I
on	I
the	I
nitric	I
oxide	I
pathway	I
(	O
phosphodiesterase	B
type	I
5	I
inhibitor	I
or	O
soluble	B
guanylate	I
cyclase	I
stimulator	I
)	O
,	O
and	O
/	O
or	O
a	O
prostacyclin	O
or	O
prostacyclin	B
analog	I
.	O

6	O
.	O

Has	O
a	O
6	B
-	I
minute	I
walk	I
distance	I
that	O
is	O
≥	B
150	I
and	I
≤	I
500	I
meters	I
.	O

7	O
.	O

Have	O
a	O
ventilation	B
-	I
perfusion	I
scan	I
that	O
rules	B
out	I
thromboembolic	B
disease	I
.	O

Diagnosis	O
of	O
ankle	B
fracture	I
or	O
ligament	B
rupture	I

Has	O
planned	O
release	O
from	O
the	O
Canadian	O
Armed	O
Forces	O
within	B
one	I
year	I
;	O

Documented	O
restrictions	O
on	O
military	O
duties	O

Has	O
known	O
intolerance	B
or	O
documented	O
adverse	B
reaction	I
to	O
acetaminophen	B
or	O
naproxen	B
or	O
celecoxib	B

Documented	O
history	B
of	O
liver	O
or	O
kidney	B
problems	I

pregnant	B
or	O
breastfeeding	O

Acquired	B
acute	B
ankle	I
injury	I
(	O
injured	O
less	B
than	I
48	I
hours	I
ago	I
)	O
;	O

Clinical	O
diagnosis	O
of	O
a	O
Grade	B
I	I
or	O
II	O
ankle	B
sprain	I

Is	O
eligible	O
to	O
receive	O
comprehensive	O
medical	O
care	O
from	O
Garrison	O
Petawawa	O

History	O
of	O
neuropathy	B

Regularly	B
taking	O
prescribed	O
analgesia	B

History	O
of	O
a	O
chronic	B
pain	I
condition	O

History	O
of	O
severe	B
mental	B
illness	I
(	O
as	O
their	O
experience	O
of	O
symptoms	O
may	O
already	O
be	O
altered	O
)	O

Current	O
use	O
of	O
fibrates	B
(	O
because	O
of	O
the	O
risk	O
of	O
interaction	O
with	O
statins	O
but	O
will	O
not	O
exclude	O
participants	O
taking	O
ezetimibe	O
)	O
.	O

Severe	O
previous	O
reaction	O
or	O
reaction	O
considered	O
immunological	O
,	O
such	O
as	O
anaphylaxis	B
,	O
facial	B
swelling	I
,	I
severe	B
rash	I
,	O
muscle	B
ache	I
with	O
rise	B
in	O
serum	B
creatine	I
kinase	I
,	O
inflammatory	B
myopathy	I
,	O
rhabdomyolysis	B
or	O
liver	B
function	I
abnormalities	I
(	O
aspartate	B
transaminase	I
(	O
AST	B
)	O
or	O
alanine	B
transaminase	I
(	O
ALT	B
)	O
greater	B
than	I
3	I
times	I
upper	I
limit	I
or	I
normal	I
)	O
.	O

Side	O
-	O
effects	O
taking	O
longer	O
than	O
2	O
weeks	O
to	O
develop	O
(	O
because	O
in	O
such	O
participants	O
much	O
longer	O
blocks	O
of	O
treatment	O
would	O
be	O
required	O
,	O
if	O
the	O
present	O
study	O
is	O
positive	O
such	O
studies	O
will	O
be	O
planned	O
for	O
the	O
future	O
)	O
*	O
.	O

History	O
of	O
statin	B
intolerance	B
with	O
drug	O
interaction	O
to	O
antiretroviral	B
drugs	I
.	O

History	O
of	O
statin	B
intolerance	B
to	O
any	O
other	O
drug	O
.	O

Pregnant	O
or	O
breast	O
feeding	O
.	O

Side	O
effects	O
taking	O
longer	O
than	O
2	O
weeks	O
to	O
present	O
.	O

In	O
clinical	O
judgement	O
of	O
study	O
doctor	O
,	O
participant	O
should	O
not	O
participate	O
.	O

Aged	B
18	B
years	I
or	I
older	I

Previously	O
taken	O
one	B
or	I
more	I
statins	B

Withdrawn	O
from	O
statins	O
because	O
of	O
perceived	O
side	O
effects	O

Developed	O
side	B
effects	I
within	B
2	I
weeks	I
of	I
initiation	I

Clinical	O
indication	B
for	O
statins	B
for	O
primary	B
or	O
secondary	B
prevention	O
of	O
cardiovascular	O
disease	O
or	O
dyslipidaemia	B
,	O
on	O
either	O
no	O
medication	O
or	O
non	O
-	O
statin	O
lipid	O
lowering	O
therapy	O
(	O
e	O
.	O
g	O
,	O
ezetimibe	O
)	O

Traumatic	B
pulmonary	B
contusion	I
or	O
laceration	B

Lung	B
reduction	I
surgery	I

Planned	O
removal	B
of	O
more	B
than	I
10	I
lung	B
lesions	I

Pneumonectomy	B

Known	O
hypersensitivity	B
to	O
bovine	B
protein	I

Known	O
hypersensitivity	B
to	O
Brilliant	B
Blue	I
FCF	I
(	I
E133	I
)	I

Presence	O
of	O
active	B
infection	I

Patients	O
over	B
the	I
age	I
of	I
18	I
years	I
who	O
are	O
able	O
to	O
give	O
their	O
informed	O
consent	O

Lobar	O
and	O
sublobar	B
resections	I

Open	O
,	O
video	B
-	I
assisted	I
thoracoscopic	O
or	O
robotic	B
surgeries	I

Diagnostic	O
or	O
therapeutic	B
procedures	I

Re	B
-	I
transplant	I
;	O

Patients	O
with	O
any	O
panel	B
reactive	I
antibody	I
(	O
PRA	B
)	O
equal	B
to	I
or	I
above	I
50	I
%	I
,	O
class	B
I	I
or	O
class	B
II	I
;	O

Acute	B
rejection	I
episode	I
in	O
the	O
last	B
30	I
days	I
,	O
or	O
episode	O
>	B
2A	I
in	O
the	O
Banff	B
criteria	I
;	O

GFR	B
(	O
MDRD	O
)	O
<	B
40	I
ml	I
/	I
min	I
;	O

Proteinuria	B
>	B
0	I
,	I
5	I
g	I
/	I
l	I
;	O

Hemoglobin	B
<	B
10	I
g	I
/	I
l	I
and	O
/	O
or	O
leucocytes	B
<	B
4000	I
cels	I
/	I
mm3	I
and	O
/	O
or	O
platelets	B
<	B
150	I
.	I
000	I
cels	I
/	I
mm3	I
;	O

Triglycerides	B
>	B
500	I
mg	I
/	I
dl	I
with	O
or	O
without	O
use	O
of	O
fibrate	B
;	O

Cholesterol	B
total	I
>	B
300	I
mg	I
/	I
dl	I
with	O
or	O
without	O
use	O
of	O
statin	B
;	O

Hepatic	B
abnormalities	I
;	O

Significant	B
periphery	B
edema	I
;	O

Pulmonary	B
abnormalities	I
or	O
breast	B
x	I
-	I
ray	I
abnormalities	B
;	O

Hyper	B
sensibility	I
to	O
sirolimus	B
formula	O
;	O

Adult	B
kidney	B
transplant	I
recipients	O
>	B
18	I
y	B
.	I
o	I
.	I

Kidney	O
Transplant	O
recipients	O
,	O
after	O
the	O
first	O
episode	O
of	O
cytomegalovirus	B
infection	I
,	O
using	O
the	O
current	O
immunosuppressive	B
regimen	I
:	O
azathioprine	B
or	O
mycophenolate	B
,	O
tacrolimus	B
and	O
prednisone	B
.	O

Age	B
<	B
20	I
or	O
>	B
35	I
years	I
.	O

Congenital	B
uterine	I
malformation	I
.	O

Multifetal	B
pregnancy	I
.	O

Known	O
major	B
fetal	B
structural	I
or	O
chromosomal	B
abnormality	I
.	O

Known	O
allergy	B
or	O
contraindication	B
(	O
relative	B
or	O
absolute	B
)	O
to	O
progesterone	B
therapy	I
.	O

Presence	O
of	O
contraindication	B
to	O
cervical	B
cerclage	I
.	O

Medical	B
conditions	I
complicating	B
pregnancy	I
.	O

Vaginal	B
bleeding	I
.	O

Women	B
with	O
singleton	B
pregnancy	I
.	O

History	O
of	O
preterm	B
labor	I
and	O
/	O
or	O
midtrimester	B
miscarriage	I
in	O
a	O
previous	B
pregnancy	B
.	O

Cervical	B
length	I
of	O
15	B
-	I
25	I
mm	I
by	O
transvaginal	B
sonography	I
(	I
TVS	I
)	I
at	O
16	B
-	I
24	I
weeks	I
of	O
gestation	B
.	O

Allergic	B
to	O
sirolimus	B
or	O
serious	B
side	B
effects	I

Need	O
emergency	B
surgery	I

Accompanied	O
with	O
other	O
severe	B
disease	I
(	O
involve	O
C	B
.	I
diff	I
infection	I
)	O

Follow	B
-	I
up	I
less	B
than	I
1	I
year	I

moderate	B
to	I
severe	I
Crohn	B
'	I
s	I
Disease	I
(	O
basic	B
HBI	I
=	B
7	I
)	O
with	O
stenosis	B

History	O
of	O
recurrent	B
UTI	I
(	O
defined	O
as	O
three	B
culture	B
proven	O
UTIs	O
within	B
last	I
12	I
months	I
)	O

Systemic	O
neuromuscular	B
disease	I
known	O
to	O
affect	O
the	O
lower	O
urinary	O
tract	O

Undergoing	O
concomitant	O
prolapse	B
surgery	I

Previous	O
incontinence	B
surgery	I

Treatment	O
with	O
anticholinergic	B
medication	I
in	O
the	O
last	B
2	I
months	I

Previous	O
bladder	B
injection	I
with	O
onabotulinumtoxinA	B

Prisoner	B
Status	O

Pregnancy	B

Undergoing	O
mid	B
-	I
urethral	I
sling	I
surgery	I

Have	O
symptoms	O
of	O
both	O
stress	O
and	O
urgency	B
urinary	I
incontinence	I

Able	O
to	O
consent	O
,	O
fill	O
out	O
study	O
documents	O
,	O
and	O
complete	O
all	O
study	O
procedures	O
and	O
follow	O
-	O
up	O
visits	O

At	B
least	I
18	I
years	I
of	O
age	B

English	O
speaking	O

Be	O
able	O
and	O
willing	O
to	O
learn	O
clean	O
intermittent	O
self	O
catheterization	O
technique	O

Anticoagulant	B
therapy	O
during	B
the	I
past	I
1	I
week	I
of	O
the	O
procedure	B

Known	O
coagulopathy	B

History	B
of	O
liver	B
cirrhosis	I
,	O
chronic	B
kidney	I
disease	I
,	O
malignancy	B
,	O
inflammatory	B
bowel	I
disease	I
,	O
significant	B
infectious	I
disease	I
,	O
polyposis	B
syndrome	I

Subjects	O
over	O
the	O
age	B
of	O
18	O
years	O
who	O
agree	O
informed	O
consent	O
and	O
who	O
have	O
at	B
least	I
one	I
polyp	B
of	O
eligible	B
size	I
(	O
6	B
-	I
10mm	I
)	O

Unstable	B
vital	B
sign	I
before	O
surgery	B

Severe	B
pulmonary	B
disease	I
requiring	O
consistent	B
treatment	I

Illiterate	O

Pregnancy	B

Patients	O
undergoing	O
thoracic	B
aorta	I
surgery	B
with	O
hypothermic	B
circulatory	I
arrest	I
,	O
over	B
20	I
-	O
of	O
age	B

Preexisting	B
ocular	B
diseases	I
or	O
conditions	B
other	B
than	I
age	B
related	I
cataracts	B
,	O
have	O
contraindications	B
for	O
cataract	B
surgery	I
;	O

Preexisting	B
systemic	B
diseases	I
or	O
conditions	B
that	O
may	B
confound	I
the	I
results	I
of	I
the	I
study	I
;	O

Previous	B
ocular	B
surgery	I
history	O
or	O
ocular	B
trauma	I
that	O
may	B
confound	I
the	I
results	I
of	I
the	I
study	I
;	O

Require	O
combined	B
surgery	I
that	O
may	B
confound	I
the	I
results	I
of	I
the	I
study	I
;	O

Previous	O
participation	O
in	O
other	O
clinical	O
trial	O
within	O
30	O
days	O
of	O
this	O
study	O
start	O
;	O

Systemic	O
or	O
ocular	B
medications	I
that	O
may	B
confound	I
the	I
outcome	I
of	I
the	I
intervention	I

Pregnant	B
,	O
lactating	B
,	O
or	O
planning	O
to	O
become	O
pregnant	B
during	B
the	I
course	I
of	I
the	I
trial	I
;	O

Age	B
from	B
40	I
to	I
80	I
years	I
old	I
,	O
either	O
gender	O
;	O

Patients	O
with	O
bilateral	B
age	B
related	I
cataracts	B
,	O
require	O
bilateral	B
cataract	B
phacoemulsification	I
combined	O
Intraocular	B
Lens	I
implantation	I
;	O

Willing	O
to	O
undergo	O
second	O
eye	O
surgery	O
within	O
7	O
days	O
after	O
first	O
eye	O
surgery	O
;	O

The	O
potential	O
postoperative	O
visual	O
acuity	O
of	O
20	O
/	O
40	O
or	O
better	O
in	O
both	O
eyes	O
;	O

Preoperative	B
measurement	B
of	I
corneal	I
astigmatism	I
indicate	O
the	O
subjects	O
are	O
suitable	B
for	O
multifocal	B
intraocular	I
lenses	I
implantation	I
;	O

Capability	O
to	O
understand	O
the	O
informed	O
consent	O
and	O
willing	O
and	O
able	O
to	O
attend	O
study	O

HbA1c	B
greater	B
than	I
75	I
mmol	I
/	I
mol	I
(	O
9	B
.	I
0	I
%	I
)	O

Child	O
unwilling	O
to	O
agree	O
to	O
second	O
insulin	O
injection	O
at	O
a	O
meal	O
-	O
time	O

Untreated	B
coeliac	B
disease	I
or	O
other	O
concomitant	O
condition	O
likely	O
to	O
affect	O
BG	O
control	O

Food	B
allergies	I
(	O
other	B
than	O
controlled	O
Coeliac	B
Disease	I
)	O

Vegetarians	B
,	O
vegans	O
or	O
patients	O
with	O
religious	O
dietary	O
restrictions	O
(	O
as	O
the	O
standard	O
meal	O
contains	O
meat	O
)	O

Participant	O
taking	O
any	O
glucose	B
-	I
containing	I
medication	I
concurrently	O

Diagnosis	O
of	O
Type	B
1	I
diabetes	I
(	O
for	O
at	B
least	I
a	I
year	I
)	O

On	O
multiple	O
daily	B
insulin	B
injections	O
,	O
including	O
basal	B
long	I
-	I
acting	I
insulin	B
and	O
rapid	B
-	I
acting	I
insulin	B
before	O
each	O
meal	O
.	O

HbA1c	B
<	B
75	I
mmol	I
/	I
mol	I
(	O
9	B
.	I
0	I
%	I
)	O

Participant	O
and	O
/	O
or	O
parent	O
/	O
legal	O
guardian	O
willing	O
and	O
able	O
to	O
give	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
study	O
.	O

Family	O
have	O
a	O
freezer	O
in	O
which	O
to	O
safely	O
store	O
the	O
test	O
meals	O
.	O

In	O
the	O
Investigator	O
'	O
s	O
opinion	O
,	O
is	O
able	O
and	O
willing	O
to	O
comply	O
with	O
all	O
trial	O
requirements	O
.	O

simultaneous	B
both	B
sided	I
extraction	O
or	O
only	B
upper	I
third	I
molar	B
extraction	I

general	B
anesthesia	I

known	B
or	O
presumed	B
abnormal	B
coagulation	I
status	I

known	B
or	O
presumed	B
liver	O
or	O
renal	B
dysfunction	I

contraindication	B
against	O
metamizole	B
known	B
or	O
suspected	B
(	O
known	B
or	O
suspected	B
allergy	B
against	O
novalgin	B
or	O
other	B
pyrazolones	B
,	O
anaphylactic	B
reaction	I
against	O
NSAIDS	B
,	O
decreased	B
bone	B
marrow	I
function	I
or	O
hematopoesis	B
,	O
hepatic	B
porphyria	I
,	O
glucose	B
-	I
6	I
-	I
phosphate	I
dehydrogenase	I
deficiency	I
,	O
and	O
pregnancy	B
/	O
breastfeeding	O
)	O

contraindication	B
against	O
ibuprofen	B
(	O
known	B
or	O
suspected	B
allergy	B
against	O
ibuprofen	B
,	O
anaphylactic	B
reaction	I
against	O
Nonsteroidal	B
anti	I
-	I
inflammatory	I
drugs	I
(	I
NSAID	I
)	I
,	O
active	B
or	O
recurrent	B
stomach	B
or	O
duodenal	B
ulcera	B
or	O
bleeding	B
,	O
severe	B
liver	I
or	I
renal	I
insufficiency	I
,	O
inflammatory	B
bowel	I
syndrome	I
,	O
and	O
pregnancy	B
/	O
breastfeeding	O
)	O

pregnancy	B
and	O
breast	O
feeding	O
mothers	O

planned	O
sequential	B
both	B
-	I
sided	I
lower	B
third	I
molar	I
extraction	I
(	O
split	B
-	I
mouth	I
)	O
with	O
osteotomy	B
(	O
with	O
or	O
without	O
upper	B
molar	I
extraction	I
in	O
local	B
anesthesia	I
)	O

able	O
to	O
understand	O
the	O
study	O
and	O
the	O
NRS	O
scale	O

diabetes	B
mellitus	I

secondary	B
hypertension	I

pregnancy	B

Caucasian	B
patients	O
affected	O
by	O
uncomplicated	B
,	O
essential	B
hypertension	I
,	O
not	B
well	I
controlled	I
by	O
concomitant	O
administration	O
of	O
ACE	B
-	I
I	I
or	O
ARBs	B
and	O
diuretics	B
at	O
the	O
maximum	B
dosage	I
.	O

Female	O
subjects	O
who	O
are	O
pregnant	O
or	O
breast	O
-	O
feeding	O
or	O
considering	O
becoming	O
pregnant	O
during	O
the	O
study	O

Patients	O
aged	B
<	B
18	I
years	I
of	I
age	I

Patients	O
who	O
cannot	O
give	O
informed	O
consent	O
,	O

Pregnant	O
patients	O
or	O
those	O
who	O
are	O
breastfeeding	O
will	O
be	O
deemed	O
ineligible	O
.	O

Prior	B
treatment	B
with	O
any	O
anti	B
-	I
TNF	I
agent	I

Contra	B
-	I
indication	I
to	O
use	O
of	O
GLM	B
(	O
Hypersensitivity	B
to	O
the	O
active	B
substance	I
or	O
to	O
any	O
of	O
the	O
excipients	B
;	O
Active	B
tuberculosis	B
(	I
TB	I
)	I
,	O
acute	B
or	O
chronic	B
Hepatitis	B
B	I
infection	I
or	O
other	O
severe	B
infections	I
such	O
as	O
sepsis	B
and	O
/	O
or	O
opportunistic	B
infections	I
including	O
HIV	B
infection	I
;	O
Moderate	B
or	O
severe	B
heart	B
failure	I
(	O
NYHA	B
class	B
III	I
/	I
IV	I
)	O

Have	O
symptoms	O
or	O
signs	O
suggestive	O
of	O
current	B
active	B
or	O
latent	B
TB	B
upon	O
medical	B
history	I
,	O
physical	B
examination	I
and	O
/	O
or	O
chest	B
radiograph	I
,	O
or	O
positive	B
Mycobacterium	B
tuberculosis	I
antigen	I
-	I
specific	I
interferon	I
-	I
gamma	I
release	I
assay	I
(	I
IGRA	I
)	I

Patients	O
with	O
a	O
history	B
of	I
,	O
or	O
at	O
imminent	O
risk	O
for	O
,	O
colectomy	B
;	O
who	O
required	O
gastrointestinal	B
surgery	I
within	B
2	I
months	I
before	I
screening	I
;	O

History	O
of	O
colonic	B
mucosal	I
dysplasia	I
or	O
adenomatous	B
colonic	I
polyps	I
that	O
were	O
not	B
removed	B

Screening	O
stool	B
study	I
positive	B
for	O
enteric	B
pathogens	I
or	O
Clostridium	B
difficile	I
toxin	I
.	O

Oral	B
corticosteroids	I
at	O
a	O
dose	O
>	B
40	I
mg	I
prednisone	I
or	I
its	I
equivalent	I
per	I
day	I
;	O
receipt	O
of	O
cyclosporine	B
,	O
tacrolimus	B
,	O
sirolimus	B
,	O
or	O
mycophenolate	B
mofetil	I
within	B
8	I
weeks	I
before	I
the	I
first	I
study	I
agent	I
injection	I
;	O
or	O
use	O
of	O
an	O
investigational	B
agent	I
within	B
5	I
half	I
-	I
lives	I
of	O
that	O
agent	O
before	B
the	I
first	I
study	I
agent	I
injection	I
.	O

Patients	O
in	O
recent	O
receipt	O
of	O
live	B
vaccinations	I
within	B
4	I
weeks	I
prior	I
to	I
enrolment	I

Patients	O
=	B
18	I
years	I
of	O
age	B

Subjects	O
must	O
be	O
able	O
and	O
willing	O
to	O
give	O
written	O
informed	O
consent	O
and	O
to	O
comply	O
with	O
the	O
requirements	O
of	O
this	O
study	O
protocol	O

Established	O
diagnosis	O
of	O
UC	B
and	O
moderate	B
-	I
to	I
-	I
severe	I
disease	O
activity	O
,	O
defined	O
as	O
a	O
Mayo	B
score	I
of	O
6	B
-	I
12	I
,	O
with	O
an	O
endoscopic	B
subscore	I
=	B
2	I
.	O

Patients	O
had	O
an	O
inadequate	B
response	I
to	O
,	O
or	O
had	O
failed	B
to	I
tolerate	I
,	O
1	B
or	I
more	I
of	O
the	O
following	O
conventional	O
therapies	O
:	O
oral	B
5	I
-	I
aminosalicylates	I
,	O
oral	B
corticosteroids	I
,	O
azathioprine	B
(	I
AZA	I
)	I
,	O
and	O
/	O
or	O
6	B
-	I
mercaptopurine	I
(	I
6MP	I
)	I
;	O
or	O
corticosteroid	B
dependent	B
(	O
ie	O
,	O
an	O
inability	O
to	O
taper	O
corticosteroids	O
without	O
recurrence	O
of	O
UC	O
symptoms	O
)	O
.	O

Patients	O
concurrently	O
treated	B
with	O
oral	B
5	I
-	I
aminosalicylates	I
or	O
corticosteroids	B
were	O
to	O
receive	O
a	O
stable	B
dose	I
for	B
at	I
least	I
2	I
weeks	I
before	I
baseline	I
,	O
and	O
patients	O
receiving	O
AZA	B
and	O
/	O
or	O
6MP	B
were	O
to	O
receive	O
a	O
stable	B
dose	I
for	B
at	I
least	I
4	I
weeks	I
before	I
baseline	I
.	O

Patients	O
were	O
required	O
to	O
maintain	O
stable	O
doses	O
of	O
their	O
concomitant	O
UC	O
medications	O
during	O
the	O
study	O
.	O

Female	O
subjects	O
of	O
child	O
bearing	O
potential	O
must	O
be	O
willing	O
to	O
ensure	O
that	O
they	O
or	O
their	O
partner	O
use	O
effective	O
contraception	O
during	O
the	O
study	O
and	O
for	O
6	O
months	O
thereafter	O
OR	O

Surgical	O
sterilized	O
female	O
patients	O
with	O
documentation	O
of	O
prior	O
hysterectomy	O
,	O
tubal	O
ligation	O
or	O
complete	O
bilateral	O
oophorectomy	O
OR	O

Postmenopausal	O
women	O
with	O
postmenopausal	O
defined	O
as	O
permanent	O
cessation	O
>	O
1	O
year	O
of	O
previously	O
occurring	O
menses	O
.	O

Female	O
subjects	O
'	O
serum	O
pregnancy	O
test	O
performed	O
at	O
the	O
screening	O
visit	O
and	O
urine	O
pregnancy	O
test	O
performed	O
at	O
the	O
baseline	O
visit	O
must	O
be	O
negative	O
.	O

Subjects	O
have	O
following	O
investigations	O
within	B
1	I
month	I
prior	I
to	I
enrolment	I
.	O

Routine	B
bloods	I
including	O
U	B
&	I
E	I
,	O
FBC	B
,	O
LFTs	B
,	O
inflammatory	B
markers	I
(	I
CRP	I
)	I
and	O
albumin	B
will	O
be	O
measured	O
.	O

Medical	O
history	O
,	O
concomitant	O
medications	O

Intradermal	B
reaction	I
to	I
Tuberculin	I
(	I
PPD	I
skin	I
test	I
)	I
or	O
Mycobacterium	B
tuberculosis	I
antigenspecific	I
interferon	I
-	I
gamma	I
release	I
assay	I
(	I
IGRA	I
)	I

TB	B
screening	I
:	O
chest	B
X	I
-	I
Ray	I
unless	O
performed	O
in	O
the	O
last	O
6	O
months	O

Stool	B
examination	I
for	B
enteric	I
pathogens	I
including	I
Clostridium	I
difficile	I

Inclusion	O
/	O
exclusion	O
criteria	O

Informed	O
consent	O

Mayo	B
score	I
(	O
including	O
sigmoidoscopy	B
unless	O
performed	O
in	O
previous	O
3	O
months	O
)	O

Patient	O
'	O
s	O
weight	B
and	O
height	B
and	O
abdominal	B
circumference	I

multiple	B
injuries	I
(	O
polytrauma	B
patients	O
)	O

previous	O
adverse	B
reaction	I
or	O
known	O
allergy	B
to	O
local	B
anaesthetics	I
or	O
opioids	B
or	O
paracetamol	B

skin	B
infection	I
in	O
proximity	O
of	O
injection	B
site	I

delirious	B
state	O
at	O
presentation	O
in	O
the	O
ED	O

adult	B
patients	O
aged	B
=	B
55	I
years	I
with	O

a	O
radiographically	B
confirmed	O
hip	B
fracture	I

Suspected	O
or	O
confirmed	O
active	B
TB	I
disease	O

Known	O
allergies	B
to	O
any	O
of	O
the	O
study	O
medications	O
by	O
participant	O
self	O
-	O
report	O

have	O
a	O
positive	O
pregnancy	O
test	O
at	O
screening	O
,	O
or	O

are	O
not	O
willing	O
to	O
use	O
a	O
reliable	O
method	O
of	O
barrier	O
contraception	O
during	O
the	O
study	O
,	O
or	O

are	O
breastfeeding	O

hormonal	B
contraception	I

HIV	B
infected	I
participants	O
who	O
are	O
on	O
anti	B
-	I
retroviral	I
drugs	I

other	O
drugs	O
that	O
interact	O
with	O
3HP	O
(	O
see	O
Table	O
1	O
)	O

Known	O
contact	O
with	O
an	O
INH	B
or	O
rifampin	B
resistant	B
case	O

Weight	B
<	B
10	I
kg	I

Evidence	O
of	O
possible	O
liver	B
damage	I
defined	O
by	O
an	O
aspartate	B
transaminase	I
(	O
AST	B
)	O
level	O
that	O
is	O
more	B
than	I
3x	I
the	I
upper	I
limit	I
of	I
normal	I
in	O
an	O
asymptomatic	O
patient	O

Porphyria	B
reported	O
by	O
patient	O

Inability	O
to	O
adhere	O
to	O
protocol	O
.	O

Patients	O
may	O
be	O
excluded	O
from	O
the	O
study	O
for	O
other	O
reasons	O
,	O
at	O
the	O
investigator	O
'	O
s	O
discretion	O
with	O
detailed	O
documentation	O
.	O

Males	B
or	O
non	O
-	O
pregnant	O
,	O
non	O
-	O
nursing	O
females	B
between	O
the	O
ages	B
of	O
2	B
-	I
65	I
years	I

LTBI	B
diagnosis	O
as	O
per	O
Canadian	O
TB	O
Standards	O
using	O
either	O
the	O
Tuberculin	B
Skin	I
Test	I
(	O
TST	B
)	O
or	O
the	O
Interferon	B
Gamma	I
Release	I
Assay	I
(	O
IGRA	B
)	O

Children	B
2	B
-	I
5	I
years	B
with	O
negative	B
TSTs	B
who	O
have	O
been	O
in	O
close	O
contact	O
with	O
a	O
case	O
of	O
active	O
TB	O
disease	O
recently	O

Able	O
and	O
willing	O
to	O
provide	O
fully	O
informed	O
consent	O
or	O
parent	O
/	O
guardian	O
able	O
to	O
provide	O
consent	O

Existing	O
sacral	B
pressure	I
ulcer	I
,	O
undergoing	O
a	O
cardiac	B
procedure	I
,	O
or	O
inability	B
to	I
provide	I
informed	I
consent	I
.	O

Patients	O
undergoing	O
an	O
operation	B
that	O
is	O
scheduled	O
to	O
last	B
more	I
than	I
2	I
hours	I

Patients	O
with	O
second	B
primary	B
cancer	I
,	I
except	B
:	O
adequately	O
treated	O
non	B
-	I
melanoma	I
skin	I
cancer	I
,	O
curatively	O
treated	O
in	B
-	I
situ	I
cancer	I
of	I
the	I
cervix	I
,	O
or	O
other	O
solid	B
tumor	I
curatively	O
treated	O
with	O
no	O
evidence	O
of	O
disease	O
for	O
<	O
=	O
5	O
years	O
.	O

Has	O
known	O
active	O
central	B
nervous	I
system	I
(	O
CNS	B
)	O
metastases	B

Has	O
an	O
active	B
infection	I
requiring	O
systemic	O
therapy	O

Pregnancy	O
or	O
breast	O
feeding	O

Patients	O
with	O
cardiac	B
problem	I

Any	O
previous	O
treatment	O
with	O
sunitinib	B

Provision	O
of	O
fully	O
informed	O
consent	O
prior	O
to	O
study	O
specific	O
procedures	O
.	O

Patients	O
must	O
be	O
>	B
=	I
19	I
years	I
of	O
age	B

RET	B
fusion	I
positive	B
or	O
FGFR2	B
fusion	I
/	O
other	O
FGFR	B
mutation	I
Refractory	B
solid	B
tumor	I
and	O
/	O
or	O
specific	O
sensitivity	B
to	O
Sunitinib	B
by	O
Avatar	O
scan	O
that	O
has	O
progressed	O
following	O
standard	O
therapy	O
or	O
that	O
has	O
not	O
responded	O
to	O
standard	O
therapy	O
or	O
for	O
which	O
there	O
is	O
no	O
standard	O
therapy	O
.	O

ECOG	B
Performance	I
status0	I
-	B
2	I

Have	O
measurable	O
or	O
evaluated	O
disease	O
based	O
on	O
RECIST	O
1	O
.	O
1	O
as	O
determined	O
by	O
investigator	O
.	O

Absolute	B
neutrophil	I
count	I
>	B
=	I
1	I
.	I
5	I
x	I
109	I
/	I
L	I
,	O
Hemoglobin	B
>	B
=	I
9g	I
/	I
dL	I
,	I
Platelets	B
>	B
=	I
100	I
x	I
109	I
/	I
L	I
Bilirubin	B
<	B
=	I
1	I
.	I
5	I
x	I
upper	I
limit	I
of	I
normal	I
AST	B
/	O
ALT	B
<	B
=	I
2	I
.	I
5	I
X	I
upper	I
limit	I
of	I
normal	I
(	I
5	B
.	I
0	I
x	I
upper	I
limit	I
of	I
normal	I
,	O
for	O
subject	O
with	O
liver	B
metastases	I
)	O
Creatinine	B
<	B
=	I
1	I
.	I
5	I
X	I
UNL	I

Patients	O
of	O
child	O
-	O
bearing	O
potential	O
should	O
be	O
using	O
adequate	B
contraceptive	I
measures	I
should	O
not	B
be	I
breast	B
feeding	I
and	O
must	O
have	O
a	O
negative	B
pregnancy	B
test	I
prior	B
to	I
start	I
of	I
dosing	I

Adequate	B
heart	B
function	I

Patients	O
with	O
severe	O
-	O
complicated	O
disease	O
that	O
would	O
compromise	O
oral	O
therapy	O
(	O
hypotenstion	B
or	O
shock	B
,	O
ileus	B
or	O
bowel	B
obstruction	I
,	O
megacolon	B
)	O
.	O

Patients	O
with	O
an	O
allergy	B
to	O
oral	B
vancomycin	B
or	O
fidaxomicin	B
.	O

Patients	O
anticipated	O
to	O
receive	O
metronidazole	B
after	O
enrollment	O
.	O

Patients	O
who	O
already	O
received	O
oral	B
vancomycin	B
or	O
metronidazole	B
(	O
either	O
oral	O
or	O
intravenous	O
)	O
for	O
>	B
24	I
hours	I
within	O
the	O
preceding	B
72	I
hours	I
at	I
the	I
time	I
of	I
enrollment	I
.	I

Patients	O
anticipated	O
to	O
receive	O
adjunctive	O
C	B
.	I
difficile	I
therapy	I
(	O
rifaxamin	B
,	O
nitazoxanide	B
,	O
tigecycline	B
)	O
after	O
enrollment	O
.	O

Patients	O
18	O
years	O
of	O
age	B
or	O
older	O
with	O
>	B
3	I
unformed	O
stools	O
/	O
24	B
hours	I
with	O
positive	B
stool	B
test	I
for	O
C	B
.	I
difficile	I
.	O

Patients	O
receiving	O
=	O
1	O
high	O
or	O
medium	O
risk	O
antibiotic	O
for	O
treatment	O
of	O
an	O
infection	O
other	O
than	O
CDI	O
,	O
for	O
an	O
anticipated	O
duration	O
of	O
=	O
5	O
days	O
from	O
the	O
time	O
of	O
enrollment	O
.	O

Congestive	B
heart	I
failure	I

Ischemic	B
heart	I
disease	I

Hypotension	B
(	O
Systolic	B
blood	I
pressure	I
<	B
100	I
mmHg	I
)	O

Treatment	O
with	O
class	B
I	I
or	O
III	O
antiarrhythmic	B
drugs	I

Severe	B
hepatic	O
or	O
renal	B
failure	I

Pregnancy	B
or	O
lactation	B

Hypersensitivity	B
or	O
contradictions	B
to	O
study	B
drugs	I

Atrio	B
-	I
ventricular	I
conduction	I
disturbances	I

Thyrotoxicosis	B

Life	B
limiting	I
disease	I
or	O
substance	B
abuse	I
which	O
may	B
affect	I
participation	I

Above	B
18	I
years	I
of	O
age	B

Symptomatic	B
,	O
permanent	B
AF	B
of	O
at	B
least	I
three	I
months	I
duration	I

Resting	B
heart	I
rate	I
=	B
80	I
bpm	I

Signed	O
informed	O
consent	O

Clinical	B
diagnosis	I
of	O
hepatic	O
or	O
renal	B
disease	I

Clinical	B
diagnosis	I
of	O
chronic	B
or	O
acute	B
alcoholism	B

History	B
of	O
allergy	B
or	O
hypersensitivity	B
to	O
Sugammadex	B
and	O
/	O
or	O
atropine	B
or	O
Neostigmine	B

Current	O
medications	B
with	O
CNS	B
effects	I

History	B
of	O
neurologic	B
disease	I

Diaphragmatic	B
palsy	I

Pregnancy	B
or	O
nursing	B

History	B
of	O
malignant	B
arrhythmias	I

ASA	B
physical	I
status	I
I	B
-	I
II	I

age	B
between	B
18	I
-	I
80	I
years	I
old	O

dNMB	B
with	I
rocuronium	I
during	O
ear	B
nose	I
and	I
throat	I
(	I
ENT	I
)	I
surgery	I

Uncontrolled	B
medical	B
problems	I
including	O
pulmonary	O
,	O
cardiovascular	O
or	O
orthopedic	B
disease	I

Any	O
debilitating	B
disease	I
prior	B
to	I
the	I
SCI	I
that	O
caused	O
exercise	B
intolerance	I

Premorbid	B
,	O
ongoing	B
major	B
depression	I
or	O
psychosis	B
,	O
altered	B
cognitive	I
status	I

History	B
of	O
head	B
injury	I
or	O
stroke	B

Metal	B
plate	I
in	I
skull	I

History	B
of	O
seizures	B

Receiving	O
drugs	B
acting	I
primarily	I
on	I
the	I
central	I
nervous	I
system	I
,	O
which	O
lower	B
the	I
seizure	I
threshold	I
(	O
see	O
appendix	O
2	O
)	O

Pregnant	B
females	B

Ongoing	O
cord	B
compression	I
or	O
a	O
syrinx	B
in	O
the	O
spinal	B
cord	I
or	O
who	O
suffer	O
from	O
a	O
spinal	B
cord	I
disease	I
such	O
as	O
spinal	B
stenosis	I
,	O
spina	B
bifida	I
,	O
MS	B
,	O
or	O
herniated	B
disk	I

Individuals	O
with	O
scalp	B
shrapnel	I
,	O
cochlear	B
implants	I
,	O
or	O
aneurysm	B
clips	I
.	O

Male	B
and	O
females	B
between	O
ages	B
18	O
-	O
85	O
years	O

Right	B
handed	I

Able	O
to	O
complete	B
precision	I
grips	I
with	I
both	I
hands	I

Able	O
to	O
complete	B
full	I
wrist	I
flexion	I
-	I
extension	I
bilaterally	I

Able	O
to	O
walk	B
unassisted	I

Able	O
to	O
complete	B
full	I
ankle	I
flexion	I
-	I
extension	I
bilaterally	I

Male	B
and	O
females	B
between	O
ages	B
18	O
-	O
85	O
years	O

SCI	B
(	O
2	B
months	I
of	I
injury	I
)	O

Spinal	B
Cord	I
injury	I
at	B
or	I
above	I
L5	I

The	O
ability	O
to	O
produce	B
a	I
visible	I
precision	I
grip	I
force	I
with	I
one	I
hand	I

Able	O
to	O
perform	O
some	O
small	B
wrist	I
flexion	I
and	I
extension	I

The	O
ability	O
to	O
perform	O
a	O
small	B
visible	I
contraction	I
with	I
dorsiflexion	I
and	I
hip	I
flexor	I
muscles	I

No	O
subjects	O
will	O
be	O
excluded	O
based	O
on	O
their	O
race	O
,	O
religion	O
,	O
ethnicity	O
,	O
gender	O
or	O
HIV	O
status	O
.	O

ASIA	B
A	B
,	I
B	I
,	I
C	I
,	I
or	I
D	I

Acute	B
critical	B
limb	B
ischemia	I

Severe	B
critical	B
limb	B
ischemia	I
(	O
Rutherford	B
category	I
6	B
)	O

Major	B
bleeding	I
history	I
within	B
prior	I
2	I
months	I

Known	O
hypersensitivity	B
or	O
contraindication	B
to	O
any	O
of	O
the	O
following	O
medications	O
:	O
heparin	B
,	O
aspirin	B
,	O
clopidogrel	B
or	O
contrast	B
agents	I

Age	B
>	B
85	I
years	I

Severe	B
hepatic	B
dysfunction	I
(	O
>	O
3	O
times	O
normal	O
reference	O
values	O
)	O

Significant	B
renal	B
dysfunction	I
(	O
Serum	B
creatinine	I
>	B
2	I
.	I
0	I
mg	I
/	I
dl	I

Significant	B
leucopenia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
anemia	B
,	O
or	O
known	O
bleeding	B
diathesis	I

LVEF	B
<	B
40	I
%	I
or	O
clinically	B
overt	I
congestive	B
heart	I
failure	I

Pregnant	B
women	B
or	O
women	B
with	O
potential	B
childbearing	I

Life	O
expectancy	O
<	B
1	I
year	I
due	O
to	O
comorbidity	B

Previous	B
bypass	B
surgery	I
or	O
stenting	B
of	I
the	I
superficial	I
femoral	I
artery	I

Untreated	B
inflow	B
disease	I
of	O
the	O
ipsilateral	B
pelvic	I
arteries	I
(	O
more	B
than	I
50	I
%	I
stenosis	B
or	O
or	O
occlusion	B

Popliteal	B
artery	I
stenosis	I
>	B
50	I
%	I
at	O
P2	B
or	I
P3	I
segment	I

Age	B
19	B
years	I
of	I
older	I

Moderate	B
or	O
severe	B
claudication	B
(	O
Rutherford	B
category	I
2	B
or	I
3	I
)	O

Critical	B
limb	B
ischemia	I
(	O
Rutherford	B
category	I
4	B
or	I
5	I
)	O

Patients	O
with	O
signed	O
informed	O
consent	O

Target	B
lesion	I
length	B
=	B
150	I
mm	I
by	O
angiographic	B
estimation	O

Stenosis	B
of	O
more	B
than	I
50	I
%	I
in	O
femoropopliteal	B
artery	I

At	B
least	I
one	I
patent	B
(	I
less	I
than	I
50	I
percent	I
stenosed	I
)	I
tibioperoneal	I
runoff	I
vessel	I
.	O

pregnancy	B

menopause	B

interstitial	B
cystitis	I

irritable	B
bowel	I
syndrome	I

untreated	B
vaginitis	I

cervicitis	B

pelvic	B
inflammatory	I
disease	I

any	O
other	O
pelvic	B
pathology	I
causing	B
pain	I

concomitant	B
physical	B
therapy	I

concomitant	B
biofeedback	B

concomitant	B
massage	B

additional	O
acupuncture	B

women	B
previously	O
diagnosed	O
with	O
generalized	B
vulvodynia	I

women	B
previously	O
diagnosed	O
with	O
localized	B
vestibulodynia	I
,	O

Psychiatric	B
disorders	I
other	B
than	O
insomnia	B
,	O
PTSD	B
and	O
specific	O
phobias	B
;	O
including	O
bipolar	B
and	O
psychotic	B
disorders	I
and	O
meeting	O
criteria	O
for	O
DSM	B
-	I
5	I
moderate	B
alcohol	O
or	O
drug	B
use	I
disorders	I
within	O
the	O
past	B
year	I
.	O

Diagnosis	O
of	O
a	O
sleep	B
disorder	I
other	B
than	O
insomnia	B
including	O
PSG	B
findings	O
of	O
apnea	B
/	O
hypopnea	B
or	O
periodic	B
limb	I
movement	I
indices	I
>	B
10	I
/	I
hour	I
;	O

Medical	O
conditions	O
that	O
require	O
consistent	O
use	O
of	O
medication	O
or	O
compromise	O
sleep	O
;	O

History	O
of	O
moderate	B
to	O
severe	B
traumatic	B
brain	I
injury	I
or	O
mild	B
traumatic	B
brain	I
injury	I
with	O
ongoing	O
post	B
-	I
concussive	I
symptoms	I
;	O

Suicidal	B
ideation	I
with	O
intent	O
to	O
act	O
or	O
with	O
specific	O
plan	O
and	O
intent	O
in	O
the	O
past	B
6	I
months	I
(	O
Type	B
4	I
-	I
5	I
ideation	I
on	O
the	O
Columbia	B
Suicide	I
Severity	I
Rating	I
Scale	I
)	O
or	O
a	O
concerning	O
history	O
of	O
prior	O
suicidal	B
behavior	I
.	I

Caffeine	B
use	O
exceeding	O
5	O
cups	O
of	O
coffee	O
per	O
day	O
or	O
its	O
equivalent	O
;	O

Habitual	O
bedtimes	O
after	O
3	O
AM	O
,	O
habitual	O
rise	O
times	O
after	O
10	O
AM	O
,	O
or	O
habitual	O
napping	O
>	O
1hour	O
/	O
day	O
;	O

Pregnancy	O
or	O
breastfeeding	O
,	O
or	O
expecting	O
to	O
conceive	O
while	O
in	O
study	O
;	O

Positive	B
urine	B
toxicology	I
.	O

Physically	O
healthy	B
adults	B
age	B
18	B
-	I
55	I
who	O
meet	O
DSM	B
-	I
5	I
criteria	O
for	O
insomnia	B
and	O
Criterion	B
A	I
(	O
exposure	O
to	O
a	O
traumatic	O
event	O
)	O
for	O
PTSD	B
.	O

The	O
index	B
trauma	B
must	O
have	O
occurred	O
within	O
the	B
past	I
5	I
years	I
and	I
at	I
least	I
3	I
months	I
before	O
enrolling	O
,	O
and	O
insomnia	O
symptoms	O
must	O
have	O
started	O
or	O
worsened	O
after	O
the	O
exposure	O
to	O
the	O
index	O
trauma	O

Age	B
<	B
45	I
or	I
>	I
55	I
years	I
.	O

Blood	B
disorders	I
or	O
coagulopathy	B
.	O

Diagnosed	O
or	O
suspected	O
local	B
gynecologic	I
lesion	I
(	O
polyp	B
,	O
adenomyosis	B
,	O
myoma	B
,	O
malignancy	B
or	O
cervical	B
pathology	I
)	O
.	O

Use	O
intrauterine	B
contraceptive	I
device	I
.	O

Pregnancy	B
related	O
conditions	B
.	O

Perimenopausal	B
women	B
complaining	O
of	O
abnormal	B
uterine	I
bleeding	I
(	O
menorrhagia	B
,	O
metrorrhagia	B
,	O
polymenorrhoea	B
or	O
polymenorrhagia	B
)	O
without	B
local	B
gynecological	I
cause	I
.	O

Failure	O
of	O
medical	B
treatment	I
for	B
at	I
least	I
3	I
months	I
.	O

allergic	B
history	B
to	O
dexmedetomidine	B

refractory	B
bradycardia	B
<	B
60	I
bpm	I
despite	O
treatment	B

severe	B
atrioventricular	B
block	I
(	O
2nd	O
and	O
3rd	B
degree	I
)	O

previous	B
operation	B
of	I
tongue	I

kidney	B
transplant	I
recipient	O

Patients	O
who	O
undergo	O
iliac	B
crest	I
bone	I
graft	I
harvesting	I
as	O
part	O
of	O
their	O
surgery	O

Preexisting	O
neurological	B
deficits	I
or	O
peripheral	B
neuropathy	I
in	O
the	O
distribution	O
of	O
the	O
sciatic	B
nerve	I

Local	B
infection	I

Contraindication	B
to	O
regional	B
anesthesia	I
e	O
.	O
g	O
.	O
bleeding	B
diathesis	I
,	O
coagulopathy	B

Chronic	B
pain	I
disorders	O

History	O
of	O
use	O
of	O
over	O
30mg	O
oxycodone	B
or	O
equivalent	O
per	O
day	O

Allergy	B
to	O
local	B
anesthetics	I

History	O
of	O
significant	O
psychiatric	O
conditions	O
that	O
may	O
affect	O
patient	O
assessment	O

Pregnancy	B

Inability	O
to	O
provide	O
informed	O
consent	O

Inpatients	O
having	O
major	B
foot	I
and	I
ankle	I
surgery	I
that	O
will	O
benefit	O
from	O
continuous	B
popliteal	B
sciatic	I
nerve	I
block	I
with	O
an	O
indwelling	B
catheter	I

American	O
Society	O
Anesthesiologists	O
(	O
ASA	B
)	O
physical	O
status	O
I	B
-	I
III	I

18	B
-	I
85	I
years	I
of	O
age	B
,	O
inclusive	O

40	B
-	I
120	I
kg	B
,	O
inclusive	O

150	O
cm	O
of	O
height	B
or	O
greater	O

Age	B
younger	B
than	I
18	I
yrs	I
.	I
or	I
older	I
than	I
75	I
yrs	I
.	I

Pregnancy	B
or	O
nursing	B
(	O
negative	B
pregnancy	B
blood	I
test	I
)	O

History	B
of	O
allergic	B
reactions	I
to	O
phenylephrine	B
or	O
ephedrine	B

eGFR	B
<	B
60ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I

Patients	O
scheduled	O
for	O
supine	B
-	I
positioned	I
elective	I
craniotomy	I
for	O
supratentorial	B
malignant	B
and	O
non	B
-	O
malignant	B
brain	B
tumors	I
3	B
cm	I
or	I
larger	I
(	O
measured	O
as	O
the	O
largest	B
diameter	I
in	I
any	I
plane	I
on	O
MR	B
images	O
)	O

ASA	O
(	O
American	B
Society	I
of	I
Anesthesiologist	I
)	I
status	I
1	B
-	I
3	I
(	O
27	B
)	O

Written	O
informed	O
consent	O
from	O
participating	O
patients	O

Patient	O
refusal	O
.	O

Emergency	B
surgeries	I

Redo	B
surgeries	I

Pregnancy	B

Vasculitis	B

Inflammation	B
or	O
infection	B
at	O
the	O
study	B
site	I

History	O
of	O
allergic	B
reaction	O
to	O
study	O
medications	O

Adult	O
patients	O
aged	B
(	O
>	B
18	I
)	O
,	O
males	B
and	O
females	B
,	O
undergoing	O
elective	B
coronary	O
artery	O
bypass	O
graft	O
(	O
CABG	B
)	O
surgery	O
with	O
cardiopulmonary	B
bypass	I
(	O
CPB	B
)	O
.	O

Administration	O
of	O
HES	B
,	O
dextrane	B
solutions	I
or	O
>	B
500	I
ml	I
of	O
Gelatin	B
solutions	I
within	B
the	I
24	I
h	I
prior	I
to	I
randomization	I

Death	O
expected	O
within	B
the	I
next	I
48	I
h	I
(	O
moribund	B
patients	O
as	O
defined	O
by	O
ASA	B
=	B
class	I
V	I
)	O

Patients	O
whose	O
medical	O
condition	O
does	O
preclude	O
the	O
PLR	O
manoeuvre	O

Patients	O
for	O
whom	O
the	O
need	O
of	O
pressure	O
infusions	O
are	O
expected	O

Requirement	O
for	O
renal	B
support	I
(	O
either	O
continuous	O
or	O
discontinuous	O
techniques	O
,	O
including	O
intermittent	O
haemodialysis	O
,	O
haemofiltration	O
and	O
haemodiafiltration	O
)	O

Patients	O
receiving	O
therapeutic	O
heparin	B
medication	O
due	O
to	O
chronic	B
coagulation	I
disease	I
/	O
anticoagulation	B
medication	I
(	O
i	O
.	O
e	O
.	O
partial	B
thromboplastin	I
time	I
>	B
60	I
sec	I
)	O

Acutely	B
burned	I
patients	O

Contraindications	O
according	O
to	O
summary	O
of	O
product	O
characteristics	O
of	O
investigational	O
test	O
and	O
reference	O
product	O

Simultaneous	O
participation	O
in	O
another	O
interventional	O
clinical	O
trial	O
(	O
drugs	O
or	O
medical	O
devices	O
studies	O
)	O

Male	B
or	O
female	B
patients	O
=	B
18	I
and	I
=	I
85	I
years	I
of	O
age	B

Women	B
of	O
child	B
bearing	I
potential	I
must	O
test	O
negative	B
on	O
standard	B
pregnancy	I
test	I
(	O
urine	B
or	O
serum	B
)	O

Patients	O
with	O
body	B
weight	I
=	B
55	I
kg	I
and	I
=	I
140	I
kg	I
and	O
body	B
mass	I
index	I
(	I
BMI	I
)	I
=	B
18	I
kg	I
/	I
m2	I

Patients	O
diagnosed	O
severe	B
sepsis	I
/	O
septic	B
shock	I
at	B
admission	I
on	I
Intensive	I
Care	I
Unit	I
who	O
can	O
be	O
enrolled	O
within	O
90	O
min	O
after	O
admission	O
OR	O
patients	O
diagnosed	O
severe	O
sepsis	O
/	O
septic	O
shock	O
during	O
Intensive	O
Care	O
Unit	O
stay	O
who	O
can	O
be	O
enrolled	O
within	O
90	O
min	O
after	O
diagnosis	O

Patients	O
where	O
antibiotic	B
therapy	I
has	O
already	O
been	O
started	O
(	O
prior	B
to	I
randomization	I
)	O

Patient	O
who	O
are	O
fluid	B
responsive	I
.	O

Fluid	O
responsiveness	O
is	O
defined	O
as	O
increase	O
of	O
>	B
10	I
%	I
in	O
mean	B
arterial	I
pressure	I
(	I
MAP	I
)	I
after	B
passive	I
leg	I
raising	I
(	I
PLR	I
)	I

Signed	O
informed	O
consent	O
by	O
patient	O
,	O
legal	O
representative	O
or	O
authorized	O
person	O
or	O
deferred	O
consent	O

NA	O

Symptoms	O
of	O
ischaemia	B
.	O

New	B
or	O
presumed	B
new	I
significant	B
ST	B
-	I
T	I
wave	I
changes	I

Development	O
of	O
pathological	B
Q	I
waves	I
on	O
ECG	B
.	O

Imaging	B
evidence	B
of	O
new	B
or	O
presumed	B
new	I
loss	B
of	I
viable	I
myocardium	I
or	O
regional	B
wall	I
motion	I
abnormality	I
.	O

age	B
less	B
than	I
13	I
years	I
at	B
time	I
of	I
procedure	I

use	O
of	O
pain	B
medication	I
prior	B
to	I
procedure	I

pectus	B
carinatum	I
,	O
Poland	B
'	I
s	I
syndrome	I
,	O
or	O
any	O
chest	B
wall	I
anomaly	I
other	B
than	I
pectus	B
excavatum	I

previous	B
repair	B
of	I
pectus	I
excavatum	I
by	O
any	O
technique	O

previous	B
thoracic	B
surgery	I

congenital	B
heart	I
disease	I

bleeding	B
dyscrasia	I

major	B
anesthetic	B
risk	I
factors	I
or	O
history	O
of	O
previous	B
problem	B
with	I
anesthesia	I

pregnancy	B

inability	B
to	I
communicate	I
in	I
English	I

scheduled	O
for	O
Nuss	B
procedure	I
for	O
pectus	B
excavatum	I
correction	O

at	B
least	I
13	I
years	I
old	B
at	B
the	I
time	I
of	I
the	I
procedure	I

Previous	O
or	O
concurrent	O
hormonal	B
management	I
of	O
prostate	B
cancer	I

Contraindication	B
for	O
prescription	O
of	O
Firmagon	B
®	O

Concurrent	O
treatment	O
with	O
a	O
5	B
-	I
a	I
-	I
reductase	I
inhibitor	I

Considered	O
as	O
a	O
candidate	O
for	O
curative	B
therapy	I

History	O
of	O
severe	B
untreated	B
asthma	B
,	O
anaphylactic	B
reactions	I
or	O
severe	B
urticaria	B
and	O
/	O
or	O
angioedema	B

QTc	B
interval	I
over	B
450	I
msec	I
or	O
risk	O
factors	O
for	O
torsades	O
de	O
pointes	O
or	O
on	O
Class	O
IA	O
and	O
Class	B
III	I
anti	I
arrhythmic	I
medications	I

Cancer	B
within	O
the	O
last	B
5	I
years	I
except	B
prostate	B
cancer	I
and	O
surgically	B
removed	O
basal	O
or	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
skin	I

Known	O
or	O
suspected	O
hepatic	O
,	O
symptomatic	O
biliary	B
disease	I
(	O
this	O
includes	O
moderate	B
to	O
severe	B
chronic	B
hepatic	I
impairment	I
)	O

Patients	O
with	O
clinically	O
significant	O
laboratory	O
abnormalities	O
/	O
disorders	O
other	O
than	O
prostate	O
cancer	O

Patient	O
with	O
Hepatitis	O
B	O
Virus	O
(	O
HBV	B
)	O
,	O
Hepatitis	O
C	O
Virus	O
(	O
HCV	B
)	O
and	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	B
)	O
infections	O

Has	O
given	O
written	O
informed	O
consent	O
before	O
any	O
study	O
-	O
related	O
activity	O
is	O
performed	O

Advanced	B
hormone	B
-	I
dependent	I
prostate	B
cancer	I
for	O
which	O
androgen	B
deprivation	I
therapy	I
is	O
indicated	O
,	O
and	O
independently	O
from	O
this	O
trial	O
,	O
Firmagon	B
®	O
is	O
intended	O
to	O
be	O
used	O
for	O
treatment	O

Age	B
greater	B
than	I
or	I
equal	I
to	I
18	I
years	I
and	I
less	I
than	I
80	I
years	I

Advanced	B
hormone	B
-	I
dependent	I
prostate	B
cancer	I
without	O
any	O
other	O
clinically	O
significant	O
disorder	O

Easten	B
Cooperative	I
Oncology	I
Group	I
score	I
=	B
2	I

PSA	B
=	B
2	I
ng	I
/	I
mL	I
at	O
screening	O

Life	O
expectancy	O
of	O
at	B
least	I
12	I
months	I
as	O
per	O
the	O
investigator	O
'	O
s	O
judgement	O

myocardial	B
infarction	I
within	B
the	I
preceding	I
4	I
weeks	I

severe	B
valve	B
disease	I
requiring	O
valve	B
replacement	I

cardiac	B
reoperations	I

patients	O
with	O
severe	B
left	B
ventricle	I
dysfunction	I
with	O
an	O
ejection	B
fraction	I
(	I
EF	I
)	I
=	B
40	I
%	I
,	O
being	O
scheduled	O
for	O
revascularization	B
.	O

Recanalized	B
(	O
TIMI	B
I	I
-	I
III	I
flow	I
)	O
IRA	B
at	O
coronary	B
angiography	I
.	O

Patients	O
in	O
whom	O
TIMI	O
-	O
3	O
flow	O
was	O
not	O
able	O
to	O
be	O
established	O
after	O
wire	O
crossing	O
,	O
balloon	O
angioplasty	O
or	O
thrombectomy	O
.	O

STEMI	B
due	O
to	O
bypass	B
-	I
graft	I
occlusion	B

Severe	B
heart	B
failure	I
or	O
cardiogenic	B
shock	I

Patients	O
presenting	O
with	O
ST	B
-	I
elevation	I
acute	I
myocardial	I
infarction	I
(	I
STEMI	I
)	I
within	B
12	I
hours	I
of	I
their	I
symptom	I
onset	I
in	O
whom	O
TIMI	O
-	O
3	O
flow	O
was	O
established	O
in	O
infarct	B
related	I
artery	I
(	I
IRA	I
)	I
after	O
balloon	B
angioplasty	I
or	O
thrombectomy	B
.	O

Untreated	B
symptomatic	B
brain	I
or	I
leptomeningeal	I
metastatic	I
disease	I
.	O

Medical	O
or	O
psychiatric	B
conditions	I
comprising	O
informed	O
consent	O
.	O

Any	O
medical	O
condition	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
would	O
compromise	O
the	O
ability	O
of	O
the	O
patient	O
to	O
participate	O
in	O
the	O
trial	O
or	O
which	O
would	O
jeopardise	O
compliance	O
with	O
the	O
protocol	O
.	O

Radiotherapy	B
within	B
4	I
weeks	I
of	I
trial	I
entry	I
.	O

Active	B
autoimmune	B
disease	I
that	O
has	O
required	O
systemic	B
treatment	I
in	B
past	I
2	I
years	I

Chronic	B
usage	I
of	O
steroids	B
or	O
other	O
immunosuppressant	B
medication	I
.	O

Previous	O
history	B
of	O
pneumonitis	B
.	O

Any	O
evidence	O
of	O
clinical	O
autoimmunity	B
.	O

Histologically	O
confirmed	O
PD	B
-	I
L1	I
status	I
defined	O
NSCLC	B
.	O

Biopsy	B
must	O
be	O
within	B
70	I
days	I
of	I
first	I
treatment	I
with	O
pembrolizumab	B
.	O

ECOG	B
performance	I
status	I
2	B
.	O

Life	O
expectancy	O
>	O
12	O
weeks	O
.	O

Uni	B
-	I
dimensionally	I
measurable	I
disease	B
according	O
to	O
Response	B
Evaluation	I
Criteria	I
in	I
Solid	I
Tumours	I
(	I
RECIST	I
)	I
v1	I
.	I
1	I

Computerised	B
Tomography	I
(	I
CT	I
)	I
scan	I
of	I
chest	I
and	I
abdomen	I
within	O
28	O
days	O
of	O
starting	O
pembrolizumab	B
.	O

Adequate	O
haematological	O
function	O
:	O

Platelet	B
count	I
≥	B
100	I
x	I
109	I
/	I
L	I
.	O

Neutrophils	B
≥	B
1	I
.	I
5	I
x	I
109	I
/	I
L	I
.	O

Haemoglobin	B
≥	B
9g	I
/	I
dL	I
.	O

Adequate	O
hepatic	O
function	O
:	O

Serum	B
bilirubin	I
≤	B
1	I
.	I
5	I
x	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
.	O

Serum	B
transaminases	I
≤	B
2	I
.	I
5	I
x	I
ULN	I
.	O

Adequate	B
renal	B
function	I
:	O
Creatinine	B
clearance	I
<	B
1	I
.	I
5	I
times	I
ULN	I
concurrent	B
with	O
creatinine	B
clearance	I
>	B
50	I
ml	I
/	I
min	I
.	O

Provision	O
of	O
signed	O
and	O
dated	O
,	O
written	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
specific	O
procedures	O
,	O
sampling	O
and	O
analyses	O
.	O

<	B
18	I
years	I
old	B

Evidence	O
of	O
decompensated	B
liver	B
disease	I

HOMA	B
IR	I
<	B
2	I
.	I
0	I

HIV	B
seropositivity	B

Chronic	O
HBV	O
/	O
HIV	O
infection	O

Use	O
of	O
immune	B
suppressing	I
medications	I

Active	B
malignancy	B

HCV	B
RNA	I
evidence	O
of	O
HCV	B
infection	I

Documented	O
history	O
of	O
chronic	B
HCV	I
RNA	I
infection	I
with	O
Genotype	B
1	I

Able	O
to	O
provide	O
informed	O
consent	O

Available	O
for	O
ongoing	O
follow	O
-	O
up	O
if	O
required	O

Risk	O
of	O
severe	B
alcohol	B
withdrawal	I
(	O
e	O
.	O
g	O
.	O
history	B
of	O
seizures	B
or	O
delirium	B
tremens	I
)	O

Current	B
Moderate	B
or	O
Severe	B
Substance	B
Use	I
Disorder	I
,	O
other	B
than	I
Alcohol	O
,	O
Nicotine	O
or	O
Caffeine	B
Use	I
Disorders	I

Lifetime	B
history	I
of	O
Bipolar	B
Disorder	I
,	O
Schizophrenia	B
or	O
Schizoaffective	B
Disorder	I

Any	O
current	B
psychiatric	B
disorder	I
,	O
other	B
than	I
Alcohol	B
Use	I
Disorder	I
,	O
that	O
,	O
in	O
the	O
judgment	O
of	O
the	O
investigator	O
,	O
will	O
require	O
treatment	O
that	O
will	O
interfere	O
with	O
study	O
participation	O
.	O

Current	B
severe	B
depression	B
(	O
HAM	B
-	I
D	I
>	B
24	I
)	O
or	O
anxiety	B
(	O
HAM	B
-	I
A	I
>	B
24	I
)	O

Significant	B
suicide	O
or	O
violence	B
risk	I

Currently	B
taking	O
any	O
psychotropic	B
medications	I

Legally	O
mandated	O
to	O
participate	O
in	O
treatment	O

History	B
of	I
prior	I
treatment	I
with	O
disulfiram	B

Sufficiently	B
socially	B
unstable	I
as	O
to	O
preclude	O
participation	O
(	O
e	O
.	O
g	O
.	O
homeless	O
)	O

Contraindications	B
to	O
disulfiram	B
treatment	O
(	O
liver	B
disease	I
,	O
kidney	B
disease	I
,	O
cardiac	B
disease	I
,	O
seizure	B
disorder	I
,	O
hypothyroidism	B
,	O
diabetes	B
mellitus	I
,	O
pregnancy	B
or	O
lactation	B
,	O
allergy	B
to	O
disulfiram	B
or	O
thiuran	B
derivatives	I
)	O

Neurological	O
or	O
medical	B
conditions	I
that	O
would	O
interfere	B
with	O
MRI	B
scanning	I
(	O
e	O
.	O
g	O
.	O
history	O
of	O
stroke	B
,	O
seizure	B
,	O
brain	B
tumor	I
,	O
brain	B
infection	I
,	O
traumatic	B
brain	I
injury	I
,	O
multiple	B
sclerosis	I
,	O
dementia	B
,	O
metal	B
device	I
in	I
body	I
,	O
pregnancy	B
,	O
claustrophobia	B
,	O
color	B
blindness	I
,	O
severe	B
hearing	B
impairment	I
,	O
weight	B
>	B
300	I
lbs	I
.	I
,	O
wheelchair	B
-	I
bound	I
)	O

Currently	B
taking	O
medications	O
containing	O
alcohol	B
,	O
metronidazole	B
,	O
isoniazid	B
,	O
paraldehyde	B
,	O
phenytoin	B
,	O
warfarin	B
,	O
or	O
theophylline	B
.	O

Significant	B
alcohol	B
withdrawal	I
(	O
CIWA	B
>	B
8	I
)	O
at	B
screening	I
,	O
after	O
confirming	O
a	O
blood	B
alcohol	I
level	I
of	O
zero	B
.	O

Between	O
the	O
ages	B
of	O
21	O
-	O
60	O

Right	B
-	I
handed	I

Capable	O
of	O
giving	O
informed	O
consent	O
and	O
complying	O
with	O
study	O
procedures	O

Reports	O
drinking	B
a	O
minimum	O
of	O
5	O
standard	O
drinks	O
for	O
men	B
or	O
4	O
standard	O
drinks	O
for	O
women	B
on	O
at	O
least	O
4	O
days	O
per	O
week	O
on	O
average	O
over	B
the	I
past	I
28	I
days	I

Meets	B
DSM	B
-	I
V	I
criteria	I
for	O
current	O
Alcohol	B
Use	I
Disorder	I

Seeking	O
treatment	B
for	O
Alcohol	B
Use	I
Disorder	I

Agree	O
to	O
not	O
seek	O
additional	O
treatment	O
,	O
apart	O
from	O
Alcoholics	O
Anonymous	O

Willing	O
to	O
attempt	O
to	O
abstain	B
from	I
alcohol	I
completely	B
for	O
the	O
duration	O
of	O
the	O
study	O

Willing	O
to	O
be	O
hospitalized	O
on	O
a	O
research	O
unit	O
for	O
24	O
hours	O
,	O
longer	O
if	O
detoxification	O
is	O
needed	O
.	O

The	O
patient	O
is	O
participating	O
in	O
another	O
study	O

The	O
patient	O
is	O
in	O
an	O
exclusion	O
period	O
determined	O
by	O
a	O
previous	O
study	O

The	O
patient	O
or	O
his	O
/	O
her	O
representative	O
refuses	O
to	O
sign	O
the	O
consent	O

It	O
is	O
impossible	O
to	O
correctly	O
inform	O
the	O
patient	O
or	O
his	O
/	O
her	O
representative	O

The	O
patient	O
is	O
pregnant	O
or	O
breastfeeding	O

The	O
patient	O
has	O
a	O
contraindication	B
(	O
or	O
an	O
incompatible	O
drug	O
association	O
)	O
for	O
a	O
treatment	O
used	O
in	O
this	O
study	O

The	O
patient	O
had	O
a	O
coronary	B
stent	I
for	O
less	B
than	I
12	I
months	I

The	O
patient	O
does	O
not	B
require	O
treatment	B
with	O
aspirin	B
or	O
any	O
other	B
antiplatelet	B
agent	I

The	O
patient	O
has	O
a	O
history	B
of	I
aspirin	B
allergy	B

High	B
bleeding	O
risk	O
;	O
such	O
as	O
platelets	B
<	B
50	I
,	I
000	I
/	I
mm3	I
during	O
screening	O
,	O
Hb	B
<	B
8	I
.	I
5	I
g	I
/	I
dL	I
,	O
history	O
of	O
intracranial	B
hemorrhage	I
or	O
subdural	B
hematoma	I
,	O
major	B
surgery	I
,	I
parenchymal	B
organ	I
biopsy	I
or	O
severe	B
trauma	B
within	B
30	I
days	I
before	O
inclusion	O
,	O
active	B
gastrointestinal	B
ulcer	I
in	O
the	O
last	B
3	I
months	I
;	O

History	B
of	I
Stroke	B
in	B
the	I
last	I
3	I
months	I
;	O

Moderate	B
or	O
severe	B
liver	B
affection	I
associated	O
with	O
coagulopathy	B

Active	B
infectious	B
endocarditis	I

Active	B
tumor	B
treated	B
at	B
the	I
time	I
of	I
inclusion	I
associated	O
with	O
expected	B
survival	I
less	B
than	I
one	I
year	I

The	O
patient	O
or	O
his	O
/	O
her	O
representative	O
must	O
have	O
given	O
free	O
and	O
informed	O
consent	O
and	O
signed	O
the	O
consent	O

The	O
patient	O
must	O
be	O
insured	O
or	O
beneficiary	O
of	O
a	O
health	O
insurance	O
plan	O

The	O
patient	O
is	O
available	O
for	O
12	O
months	O
of	O
follow	O
-	O
up	O

The	O
patient	O
underwent	O
a	O
successful	O
transcutaneous	B
implant	I
procedure	I
for	O
an	O
aortic	B
valve	I
within	O
the	O
past	B
24	I
hours	I

The	O
patient	O
was	O
receiving	O
anti	B
-	I
vitamin	I
K	I
(	O
AVK	B
)	O
treatment	O
before	B
percutaneous	I
implantation	I
of	I
the	I
aortic	I
valve	I

Toxic	B
epidermal	I
necrolysis	I
with	O
SCORTEN	B
6	B
or	I
7	I
at	B
admission	I

Hypercoagulable	B
state	I

Cardiac	O
or	O
peripheral	B
arterial	I
disease	I

Active	B
malignancy	B

Myelodysplastic	B
syndrome	I
or	O
hematological	B
malignancy	I

Fructose	B
intolerance	O

Pregnancy	O

Patient	O
refusal	O

Toxic	B
epidermal	I
necrolysis	I
with	O
SCORTEN	B
1	B
to	I
5	I
at	B
admission	I

Uncontrolled	B
diabetes	B

Ulcer	B
infection	I

Non	B
-	I
diabetic	I
ulcers	B
Orthopedic	O
or	O
neuromuscular	B
pathologic	I
conditions	I

Diagnosis	O
of	O
diabetes	B
mellitus	I
according	O
to	O
World	B
Health	I
Organization	I
criteria	I
(	O
treatment	B
with	O
insulin	B
or	O
an	O
oral	B
hypoglycemic	I
agent	I
,	O
twice	B
random	B
glucose	I
measurements	I
major	B
than	I
200	I
mg	I
/	I
dl	I
,	O
or	O
a	O
fasting	B
glucose	I
major	B
than	I
140	I
mg	I
/	I
dl	I
)	O

Ulcer	B
located	O
on	O
the	O
legs	B
or	O
feet	B
,	O
stage	B
III	B
or	I
IV	I
(	O
Wagner	B
Classification	I
System	I
)	O

The	O
subject	O
agrees	O
to	O
comply	O
with	O
study	O
protocol	O
requirements	O
and	O
all	O
follow	O
up	O
visit	O
requirements	O
.	O

Personal	O
or	O
family	O
history	O
of	O
pancreatitis	B

Medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
or	O
Multiple	B
Endocrine	I
Neoplasia	I
Syndrome	I
Type	I
2	I
(	O
MEN	B
2	I
)	O

Gastroparesis	B

Allergy	B
to	O
liraglutide	B
or	O
any	O
of	O
the	O
active	O
ingredients	O
in	O
liraglutide	O
or	O
other	O
GLP	B
-	I
1	I
analogue	I

Weight	O
loss	O
drugs	O
other	B
than	O
metformin	B

Type	B
1	I
diabetes	I
mellitus	I
or	O
diabetic	B
ketoacidosis	I

Known	O
major	O
cognitive	B
deficit	I
dementia	B
,	O
history	O
of	O
head	B
trauma	I
with	O
loss	B
of	I
consciousness	I
>	B
30	I
min	I
,	O
history	O
of	O
stroke	B
,	O
current	O
central	B
nervous	I
system	I
(	I
CNS	I
)	I
disorder	I
such	O
as	O
seizures	B
or	O
opportunistic	B
CNS	I
infection	I

Renal	B
insufficiency	I
defined	O
as	O
creatinine	B
clearance	I
<	B
60	I
mL	I
/	I
min	I

Active	B
opportunistic	B
infections	I

Pregnancy	O
or	O
breastfeeding	O

Unstable	O
cardiovascular	O
disease	O
with	O
hospitalization	O
within	B
1	I
year	I
for	O
acute	B
coronary	I
syndrome	I

Decompensated	B
heart	I
failure	I

Substance	B
abuse	I

Active	O
alcohol	O
or	O
opioid	B
substitution	I
therapy	I

Serious	O
or	O
unstable	O
medical	O
or	O
psychological	O
conditions	O
that	O
would	O
compromise	O
the	O
subject	O
'	O
s	O
safety	O
for	O
successful	O
participation	O

HIV	B
controlled	B
on	O
therapy	O
for	O
at	B
least	I
12	I
weeks	I

Viral	B
load	I
<	B
200	I
copies	I

BMI	B
>	B
27	I
to	I
45	I

Diagnosis	O
of	O
DM	B
type	I
2	I
with	O
A1	B
-	I
C	I
>	B
7	I
to	I
15	I

Participants	O
must	O
be	O
willing	O
to	O
comply	O
with	O
all	O
study	O
related	O
procedures	O

cardiac	O
or	O
non	B
-	I
cardiac	I
illness	I
with	O
life	O
expectancy	O
of	O
less	B
than	I
two	I
years	I
;	O

failure	B
to	O
advance	O
the	O
IVUS	B
catheter	I
through	O
the	O
culprit	B
lesion	I
;	O

acute	B
coronary	I
syndrome	I

congestive	B
heart	I
failure	I
NYHA	B
III	B
-	I
IV	I

diabetes	B
mellitus	I

chronic	B
kidney	I
disease	I

previous	B
PCI	B
in	O
the	O
target	B
vessel	I

heavily	B
calcified	I
vessels	I

allergy	B
to	O
metformin	B

age	B
=	B
18	I
and	I
<	I
75	I
years	I
;	O

patients	O
with	O
stable	B
coronary	B
artery	I
disease	I
referred	O
to	O
PCI	B
in	O
an	O
artery	B
suitable	I
for	I
IVUS	I
pullback	I
;	O

signed	O
informed	O
consent	O
before	O
PCI	O
.	O

Patients	O
with	O
liver	B
cirrhosis	I
,	O
Hepatocellular	B
Carcinoma	I
or	O
other	O
malignancies	B
.	O

Patients	O
with	O
other	O
factors	O
causing	O
liver	O
diseases	O
.	O

Pregnant	O
and	O
lactating	O
women	O
.	O

Patients	O
with	O
concomitant	B
HIV	B
infection	I
or	O
congenital	B
immune	I
deficiency	I
diseases	I
.	I

Patients	O
with	O
diabetes	B
,	O
autoimmune	B
diseases	I
.	O

Patients	O
with	O
important	O
organ	B
dysfunctions	I
.	O

Patients	O
with	O
serious	B
complications	B
(	O
e	O
.	O
g	O
.	O
,	O
infection	B
,	O
hepatic	B
encephalopathy	I
,	O
hepatorenal	B
syndrome	I
,	O
gastrointestinal	B
bleeding	I
.	O
)	O

Patients	O
who	O
receive	O
antineoplastic	O
or	O
immunomodulatory	B
therapy	I
in	O
the	O
past	B
12	I
months	I
.	O

Patients	O
who	O
can	O
'	O
t	O
come	O
back	O
to	O
clinic	O
for	O
follow	O
-	O
up	O
on	O
schedule	O
.	O

CHB	B
patients	O
who	O
had	O
received	O
NAs	B
for	O
more	B
than	I
12	I
months	I
.	I

Hepatitis	B
B	I
e	I
antigen	I
(	O
HBeAg	B
)	O
-	O
negative	B
and	O
anti	B
-	I
HBeAg	I
positive	B
.	O

Hepatitis	B
B	I
surface	I
antigen	I
(	O
HBsAg	B
)	O
positive	B
and	O
<	B
1500	I
IU	I
/	I
mL	I
.	O

Hepatitis	B
B	I
virus	I
DNA	I
not	B
detectable	I
(	O
Roche	O
Cobas	O
)	O
.	O

Multiple	B
pregnancy	I

Prior	B
spontaneous	B
preterm	I
birth	I
or	O
second	B
trimester	I
losses	B
between	B
16	I
(	I
0	I
)	I
and	I
36	I
(	I
6	I
)	I
weeks	I

Cerclage	B
in	I
situ	I

Painful	B
regular	I
uterine	I
contraction	I
and	O
/	O
or	O
preterm	B
labor	I

Ruptured	B
membranes	I

Major	B
fetal	I
defects	I

Active	B
vaginal	I
bleeding	I

Placenda	B
previa	I
and	O
/	O
or	O
accreta	B

Cervical	B
dilation	I
>	B
1	I
.	I
5	I
cm	I
and	O
/	O
or	O
visible	B
membranes	I
by	O
pelvic	B
exam	I

Suspicion	O
of	O
chorioamnionitis	B

18	B
-	I
50	I
ages	B

Singleton	B
pregnancy	I

Cervical	B
length	I
<	B
=	I
25mm	I
between	B
18	I
(	I
0	I
)	I
and	I
23	I
(	I
6	I
)	I
weeks	I

history	O
of	O
major	B
systemic	B
illness	I
,	O
including	O
uncontrolled	B
hypertension	B
,	O
diabetes	B
,	O
chronic	B
renal	I
insufficiency	I
,	I
autoimmune	B
diseases	I
or	O
malignancies	B

history	O
of	O
neurological	B
disorders	I
which	O
might	O
affect	B
sensation	I
such	O
as	O
previous	O
stroke	B
or	O
peripheral	B
neuropathy	I

history	O
of	O
substance	B
abuse	I
(	O
except	B
painkillers	B
)	O

heavy	B
smokers	B
(	O
with	O
a	O
daily	B
consumption	I
>	I
20	I
cigarettes	O
)	O

pregnancy	O
or	O
lactation	O

any	O
contraindication	B
for	O
magnetic	B
resonance	I
imaging	I
(	O
MRI	B
)	O

and	O
any	O
obvious	B
infection	B
or	O
inflammation	B
over	O
a	O
period	O
of	O
at	B
least	I
1	I
month	I
before	I
the	I
study	I
.	O

Control	O
:	O
devoid	B
of	O
any	O
systemic	O
or	O
neurological	B
diseases	I

Chronic	B
migraine	I
:	O
by	O
ICHD	B
-	I
III	I
(	O
International	B
Classification	I
of	I
Headache	I
Disorder	I
)	O
criteria	O

Fibromyalgia	B
:	O
by	O
ACR	O
(	O
American	B
College	I
of	I
Rheumatology	I
)	O
2010	O
criteria	O

NA	O

Provision	O
of	O
written	O
informed	O
consent	O
(	O
by	O
patient	O
or	O
appropriate	O
designee	O
according	O
to	O
local	O
regulations	O
)	O
prior	O
to	O
any	O
study	O
specific	O
procedures	O
.	O

Aged	B
18	B
years	I
or	I
older	I
,	O
male	B
or	O
female	B
.	O

History	O
of	O
stable	B
angina	I
pectoris	I
with	O
angiographic	B
evidence	I
of	O
CAD	B
(	O
diameter	O
stenosis	O
=	B
50	I
%	I
)	O
in	O
major	O
,	O
i	O
.	O
e	O
.	O
,	O
left	O
main	O
,	O
left	O
anterior	O
descending	O
,	O
left	O
circumflex	O
,	O
and	O
right	B
coronary	I
arteries	I
.	O

History	O
of	O
previous	O
myocardial	B
infarction	I
(	O
MI	B
)	O

History	O
of	O
coronary	B
revascularization	I
,	O
i	O
.	O
e	O
.	O
,	O
percutaneous	B
coronary	I
intervention	I
(	O
PCI	B
)	O
or	O
coronary	B
artery	I
bypass	I
graft	I
(	O
CABG	B
)	O
,	O
not	B
including	O
the	O
elective	B
PCI	B
during	B
the	I
index	I
hospitalization	I

Documented	O
history	O
of	O
type	B
2	I
diabetes	I
mellitus	I
.	O

Post	O
-	O
procedural	O
residual	O
diameter	O
stenosis	O
of	O
the	O
treated	B
lesions	B
<	B
20	I
%	I
in	O
patients	O
with	O
stent	B
implantation	I
or	O
<	B
50	I
%	I
in	O
those	O
with	O
balloon	B
angioplasty	I

Post	B
-	I
procedural	I
thrombolysis	I
in	O
myocardial	B
infarction	I
(	O
TIMI	B
)	O
grade	O
3	B
flow	O
in	O
treated	B
vessels	I

Negative	B
cardiac	B
troponin	I
test	I
before	O
the	O
index	O
elective	O
PCI	B
.	O

Taking	O
Clopidogrel	B
75	B
mg	I
daily	B
dose	O
for	B
at	I
least	I
7	I
days	I
or	O
taking	O
Clopidogrel	B
75	B
mg	I
daily	B
dose	O
for	B
less	I
than	I
7	I
days	I
but	O
with	O
300	B
to	I
600	I
mg	I
Clopidogrel	B
loading	O
dose	O
before	O
PCI	B
.	O

Taking	O
acetylsalicylic	B
acid	I
(	O
ASA	B
)	O
100	B
mg	I
daily	B
treatment	O
for	B
at	I
least	I
7	I
days	I
or	O
taking	O
ASA	B
100	B
mg	I
daily	B
dose	O
for	B
less	I
than	I
7	I
days	I
but	O
with	O
300	B
mg	I
ASA	B
loading	O
dose	O
before	O
PCI	B
.	O

have	O
a	O
negative	O
urine	O
or	O
blood	O
pregnancy	O
test	O
at	O
enrolment	O
and	O
prior	O
to	O
randomization	O
;	O

currently	O
be	O
using	O
a	O
hormonal	O
contraceptive	O
and	O
agree	O
to	O
continue	O
its	O
use	O
in	O
addition	O
to	O
using	O
double	O
-	O
barrier	O
local	O
contraception	O
(	O
i	O
.	O
e	O
.	O
,	O
intra	O
-	O
uterine	O
device	O
plus	O
spermicidal	O
and	O
condom	O
for	O
male	O
partner	O
)	O
from	O
screening	O
through	O
study	O
completion	O
.	O

Concomitant	B
antiplatelet	B
or	O
anticoagulant	B
use	O

Calculated	B
creatinine	I
clearance	I
<	B
30	I
mL	I
/	I
min	I
by	O
Cockcroft	B
-	I
Gault	I
formula	I

Alanine	B
aminotransferase	I
(	I
ALT	I
)	I
or	O
aspartate	B
aminotransferase	I
(	I
AST	I
)	I
>	B
3	I
times	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I

Total	B
bilirubin	I
>	B
2	I
x	I
ULN	I

Thrombocytopenia	B
<	B
50	I
x	I
10	I
gigalitres	I
(	I
Gl	I
)	I

High	B
bleeding	I
risk	I
or	O
spontaneously	B
prolonged	B
prothrombin	I
time	I
or	O
activated	B
partial	I
thromboplastin	I
time	I
>	B
1	I
.	I
5	I
x	I
ULN	I

Body	B
weight	I
<	O
50	O
or	O
>	B
120	I
kg	I

Concomitant	B
use	O
of	O
CYP3A4	B
or	O
p	B
-	I
glycoprotein	I
inducers	I
or	O
inhibitors	O

Use	O
of	O
Ginkgo	B
biloba	I
or	O
St	B
.	I
John	I
'	I
s	I
Wort	I
within	O
14	O
days	O
before	O
first	B
dose	I
of	O
study	B
drug	I

Dexamethasone	B
use	O
within	B
last	I
3	I
months	I

Women	B
of	O
Childbearing	B
potential	I
without	B
proper	O
contraceptive	B
measures	I
,	O
pregnancy	B
or	O
breast	O
feeding	O

Life	O
expectancy	O
less	B
than	I
3	I
months	I

Inability	B
to	I
swallow	I
or	O
issues	B
with	I
malabsorption	I

Any	O
other	O
medical	O
,	O
social	O
,	O
logistical	O
,	O
geographical	O
or	O
psychological	O
factors	O
,	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
prohibit	O
follow	O
-	O
up	O
,	O
compliance	O
and	O
study	O
completion	O

Patients	O
with	O
diagnosis	O
of	O
multiple	B
myeloma	I
according	O
to	O
criteria	B
of	I
the	I
International	I
Myeloma	I
Working	I
Group	I

Patients	O
in	O
whom	O
a	O
LEN	B
-	O
DEX	B
-	O
based	O
treatment	B
regimen	I
is	O
indicated	O

Adult	B
patients	O
≥	B
19	I
years	I
of	O
age	B
who	O
are	O
able	O
to	O
freely	O
provide	O
informed	O
consent	O

School	O
districts	O
that	O
are	O
too	O
difficult	O
to	O
reach	O
(	O
more	B
than	I
a	I
3	I
-	I
hour	I
walk	B
from	I
the	I
farthest	I
place	I
reachable	I
by	I
a	I
four	I
-	I
wheel	I
drive	I
vehicle	I
)	O

School	O
districts	O
in	O
the	O
2	O
urban	O
regions	O
of	O
the	O
study	O
area	O

Refusal	O
of	O
village	O
chief	O

All	O
residents	O
residing	O
near	O
to	O
the	O
well	O
sites	O
that	O
are	O
randomly	O
selected	O
for	O
this	O
study	O
.	O

Refusal	O
of	O
participant	O
[	O
or	O
parent	O
/	O
guardian	O
]	O

Community	O
in	O
a	O
school	O
district	O
that	O
is	O
within	O
the	O
study	O
area	O

Area	O
within	O
each	O
school	O
district	O
that	O
is	O
in	O
need	O
of	O
a	O
well	O

Child	B
-	I
Pugh	I
score	I
>	B
12	I

Having	O
been	O
diagnosed	O
as	O
HCC	B
within	O
the	O
past	B
5	I
years	I

Serum	B
creatinine	I
>	B
1	I
.	I
5mg	I
/	I
dl	I

Serum	B
bilirubin	I
>	B
5	I
.	I
0mg	I
/	I
dl	I

Presence	O
of	O
such	O
complications	B
as	O
SBP	B
,	O
or	O
hepatic	B
encephalopathy	I
(	O
West	B
Haven	I
grade	I
=	B
3	I
)	O

Patients	O
who	O
experienced	O
organ	B
failure	I
by	O
acute	B
exacerbation	I
of	I
liver	I
cirrhosis	I
within	O
the	O
past	B
1	I
month	I

Presence	O
of	O
serious	B
cardiac	O
or	O
respiratory	B
disease	I

Contraindicated	B
to	O
either	O
diuretics	B
or	O
BCAA	B

Having	O
commenced	O
anti	B
-	I
viral	I
treatment	I
against	O
hepatitis	B
C	I
,	O
B	O
within	O
the	O
past	B
1	I
month	I

Pregnant	O
or	O
lactating	O
women	O

Chronic	B
alcohol	B
taker	I

Woman	O
patients	O
who	O
do	O
not	O
agree	O
to	O
the	O
contraception	O
from	O
baseline	O
to	O
12	O
month	O

Unsuitable	O
patients	O
judged	O
by	O
investigator	O

Patients	O
participating	O
in	O
another	O
clinical	O
trial	O
within	O
1	O
month	O

Age	B
=	B
19	I
and	I
=	I
70	I
years	I
;	O

Presence	O
of	O
liver	B
cirrhosis	I

Serum	B
albumin	I
level	O
=	B
3	I
.	I
5g	I
/	I
dl	I
,	O
ultrasound	B
or	O
CT	B
scan	I
confirmed	O
ascites	B
(	O
=	O
Grade	B
1	I
)	O

No	B
administration	O
of	O
diuretics	B
and	O
BCAA	B
within	O
the	O
past	B
1	I
week	I

Voluntary	O
consent	O
to	O
take	O
part	O
in	O
this	O
trial	O

Pregnant	O
women	O
and	O
nursing	O
mothers	O
are	O
ineligible	O
due	O
to	O
the	O
possible	O
risk	O
of	O
adverse	O
effects	O
in	O
the	O
newborn	O
.	O
Eligible	O
patients	O
of	O
reproductive	O
potential	O
should	O
use	O
adequate	O
contraception	O
if	O
sexually	O
active	O
.	O

Serious	O
concurrent	O
medical	O
illness	O
which	O
would	O
jeopardize	O
the	O
ability	O
of	O
the	O
subject	O
to	O
receive	O
the	O
therapy	O
as	O
outlined	O
in	O
this	O
protocol	O
with	O
reasonable	O
safety	O
.	O

Malignancy	B
diagnosed	O
or	O
treated	O
within	B
5	I
years	I
(	O
recent	B
localized	B
treatment	B
of	O
squamous	O
or	O
non	B
-	I
invasive	I
basal	I
cell	I
skin	I
cancers	I
is	O
permitted	B
;	O
cervical	B
carcinoma	I
in	I
situ	I
is	O
allowed	B
if	O
appropriately	B
treated	B
prior	B
to	I
screening	I
)	O
;	O
subjects	O
under	O
evaluation	O
for	O
a	O
malignancy	O
are	O
not	O
eligible	O
.	O

Infection	O
with	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
or	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I

Use	O
of	O
any	O
prohibited	O
concomitant	O
medications	O
within	O
30	O
days	O
of	O
the	O
Baseline	O
/	O
Day	O
1	O
visit	O
.	O

Known	O
hypersensitivity	B
to	O
LDV	B
/	O
SOF	B

The	O
subject	O
must	O
be	O
willingly	O
and	O
able	O
to	O
provide	O
written	O
informed	O
consent	O

Age	B
19	B
years	I
of	I
age	I
or	I
older	I
(	O
The	O
age	O
of	O
consent	O
in	O
Nebraska	O
)	O

HCV	B
treatment	B
-	O
naïve	B
,	O
as	O
defined	O
as	O
no	B
prior	B
exposure	O
to	O
any	O
Interferon	B
(	I
IFN	I
)	I
,	O
RBV	B
,	O
or	O
other	O
FDA	O
approved	O
or	O
experimental	O
HCV	O
-	O
specific	O
direct	O
-	O
acting	O
antiviral	O
agent	O

HCV	B
RNA	I
level	I
at	B
most	I
6	I
months	I
prior	I
to	I
the	I
Baseline	I
/	I
Day	I
1	I
visit	I
.	O

HCV	B
genotyping	I
1a	B
,	I
1b	I
,	I
or	I
mixed	I
1a	I
/	I
ab	I
.	O

Any	O
non	O
-	O
definitive	O
results	O
will	O
exclude	O
the	O
subject	O
from	O
study	O
participation	O
.	O

Alcohol	B
misuse	I
as	O
defined	O
by	O
the	O
Alcohol	B
Use	I
Disorders	I
Identification	I
Test	I
(	I
AUDIT	I
)	I
score	I
subjects	O
must	O
score	O
>	B
8	I
(	O
associated	O
with	O
harmful	O
or	O
hazardous	O
drinking	O
)	O

History	O
of	O
a	O
liver	B
biopsy	I
showing	O
cirrhosis	B
(	O
e	O
.	O
g	O
.	O
Metavir	B
score	I
=	B
4	I
or	O
Ishak	B
score	I
>	B
5	I
)	O

Fibroscan	B
showing	O
cirrhosis	B
or	O
results	O
>	B
12	I
.	I
5	I
kPa	I

FIBRO	B
Spect	I
II	I
index	I
consistent	O
with	O
F3	B
or	I
F4	I
AND	O
an	O
AST	B
:	O
platelet	B
ration	I
index	I
(	I
APRI	I
)	I
of	O
>	B
2	I
during	B
Screening	I

Liver	B
biopsy	I
within	B
2	I
years	I
of	I
Screening	I
showing	O
absence	B
of	O
cirrhosis	B

Fibroscan	B
within	B
6	I
months	I
of	I
Baseline	I
/	I
Day1	I
with	O
a	O
result	O
of	O
=	B
12	I
.	I
5	I
kPa	I

FIBRO	B
Spect	I
II	I
Index	I
consistent	O
with	O
F0	B
-	I
F2	I
AND	O
APRI	B
of	O
=	B
1	I
during	B
Screening	I

Liver	B
imaging	I
within	B
6	I
months	I
of	I
Baseline	I
/	I
Day	I
1	I
to	O
exclude	B
hepatocellular	B
carcinoma	I
HCC	I
)	I
is	O
required	O

ALT	B
<	B
10	I
x	I
the	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I

AST	B
<	B
10	I
x	I
ULN	I

Direct	B
bilirubin	I
<	B
2	I
.	I
0	I
x	I
ULN	I

Platelets	B
>	B
50	I
,	I
000	I

HbA1c	B
<	B
8	I
.	I
5	I
%	I

Creatinine	B
clearance	I
(	I
CLcr	I
)	I
=	B
60	I
mL	I
/	I
min	I
,	O
as	O
calculated	O
by	O
the	O
Cockcroft	B
-	I
Gault	I
equation	I

Hemoglobin	B
=	B
11	I
g	I
/	I
dL	I
for	O
female	B
subjects	O
;	O
=	B
12	I
g	I
/	I
dL	I
for	O
male	B
subjects	O
.	O

Albumin	B
=	B
2	I
.	I
5	I
g	I
/	I
dL	I

INR	B
=	B
1	I
.	I
5	I
x	I
ULN	I
unless	B
subject	O
has	O
known	O
hemophilia	B
or	O
is	O
stable	B
on	I
an	I
anticoagulant	I
regimen	I
affecting	I
INR	I
.	O

Subject	O
has	O
not	O
been	O
treated	O
with	O
any	O
investigational	O
drug	O
or	O
device	O
within	O
30	O
days	O
of	O
the	O
screening	O
visit	O
.	O

Adults	B
older	B
than	I
45	I
and	O
children	B
younger	B
than	I
18	I
years	I

Platelet	B
count	I
higher	B
than	I
30x109	I
/	I
l	I
at	B
time	I
of	I
screening	I

Suspicion	O
of	O
secondary	B
ITP	I

Positive	O
family	O
history	O
for	O
ITP	O

Presence	O
or	O
history	O
of	O
autoimmune	B
disease	I
as	O
judged	O
by	O
the	O
investigator	O

Hepatosplenomegaly	B

Presence	O
or	O
history	O
of	O
relevant	B
hepatic	B
disease	I
as	O
judged	O
by	O
the	O
investigator	O

Presence	O
or	O
history	O
of	O
thromboembolic	B
disease	I
as	O
judged	O
by	O
the	O
investigator	O

Patients	O
with	O
splenectomy	B

Women	O
who	O
are	O
pregnant	O
or	O
breast	O
feeding	O

Intention	O
to	O
become	O
pregnant	O
during	O
the	O
course	O
of	O
the	O
study	O

Lack	O
of	O
safe	O
double	O
contraception	O
(	O
see	O
7	O
.	O
1	O
)	O

Any	O
vaccination	B
2	B
weeks	I
prior	I
start	I
of	I
the	I
study	I

Drugs	O
with	O
a	O
known	O
impact	O
on	O
the	O
immune	O
system	O
or	O
on	O
platelet	O
function	O
must	O
be	O
recorded	O
and	O
an	O
exclusion	O
of	O
the	O
study	O
should	O
be	O
discussed	O
with	O
the	O
study	O
center	O

Known	O
or	O
suspected	O
non	B
-	I
compliance	I
,	O
drug	O
or	O
alcohol	B
abuse	I

Inability	O
to	O
follow	O
the	O
procedures	O
of	O
the	O
study	O
,	O
e	O
.	O
g	O
.	O
due	O
to	O
language	O
problems	O
,	O
psychological	O
disorders	O
,	O
dementia	O
of	O
the	O
study	O
subject	O

Participation	O
in	O
another	O
study	O
with	O
investigational	O
drug	O
within	O
the	O
30	O
days	O
preceding	O
and	O
during	O
the	O
present	O
study	O

Previous	O
enrolment	O
into	O
the	O
current	O
study	O

Previous	O
treatment	O
with	O
romiplostim	B
or	O
eltrombopag	B

Hypersensitivity	B
to	O
the	O
active	O
substance	O
or	O
to	O
any	O
of	O
the	O
excipients	O
or	O
to	O
E	O
.	O
coli	O
derived	O
proteins	O

Enrolment	O
of	O
the	O
investigator	O
,	O
his	O
/	O
her	O
family	O
members	O
,	O
employees	O
and	O
other	O
dependent	O
persons	O

Informed	O
consent	O
as	O
documented	O
by	O
signature	O
(	O
see	O
informed	O
consent	O
form	O
)	O

Primary	B
ITP	I
according	O
to	O
the	O
definition	B
of	I
Rodeghiero	I
et	O
al	O
.	O

(	O
52	O
)	O
and	O
a	O
platelet	B
count	I
of	O
<	B
30x109	I
/	I
l	I

Age	B
range	O
:	O
18	B
-	I
45	I
years	I

Previously	O
treated	O
patients	O
,	O
with	O
failure	B
or	O
intolerance	B
to	O
first	B
-	I
line	I
therapy	I
,	O
or	O
relapse	B
after	O
first	B
-	I
line	I
therapy	I
,	O
i	O
.	O
e	O
.	O
corticosteroids	B
,	O
intravenous	B
immunoglobulin	I
(	O
IVIG	B
)	O
,	O
or	O
anti	B
-	I
D	I
immunoglobulins	I

History	O
of	O
active	B
rheumatic	B
diseases	I

History	O
of	O
previous	O
musculoskeletal	B
injury	I
of	O
the	O
same	O
knee	B
for	O
excluding	O
patients	O
with	O
secondary	B
knee	I
osteoarthritis	I

History	O
of	O
previous	O
surgery	B
on	O
the	O
same	O
knee	B

History	O
of	O
adverse	O
effects	O
from	O
medications	O
to	O
be	O
used	O
in	O
this	O
study	O

Contraindication	B
to	O
spinal	B
anesthesia	I

History	O
of	O
psychiatric	B
disorders	I
or	O
cognitive	B
impairment	I

Contraindication	B
to	O
corticosteroid	B
agents	O

Poorly	B
controlled	I
diabetes	B
mellitus	I
(	O
HbA1C	B
>	B
7	I
.	I
5	I
)	O

Poorly	B
controlled	I
hypertension	B

History	O
of	O
ischemic	B
heart	I
disease	I
or	O
peripheral	B
arterial	I
disease	I
or	O
cerebrovascular	B
disease	I

Hepatic	B
insufficiency	I
(	O
Child	B
-	I
Pugh	I
score	I
>	B
5	I
)	O

Renal	B
insufficiency	I
(	O
Creatinine	B
clearance	I
<	B
30	I
mL	I
/	I
min	I
)	O

History	O
of	O
cataracts	B
or	O
glaucoma	B
or	O
ocular	B
hypertension	I

History	O
of	O
steroid	B
or	O
immunosuppressive	B
drug	I
use	O
within	B
6	I
months	I
of	I
surgery	I

Age	B
>	B
40	I
years	I
(	O
45	O
)	O

Primary	B
knee	I
osteoarthritis	I
diagnosed	O
using	O
the	O
American	B
College	I
of	I
Rheumatology	I
criteria	I
(	O
46	O
)	O

Undergoing	O
elective	B
,	O
primary	B
and	O
unilateral	B
total	B
knee	I
arthroplasty	I

American	O
Society	O
of	O
Anesthesiology	O
(	O
ASA	B
)	O
physical	O
status	O
class	O
1	B
-	I
3	I

BMI	B
<	B
40	I
kg	I
/	I
m2	I

Anaphylactic	B
reaction	I
to	O
a	O
previous	O
dose	O
of	O
TIV	B
(	O
trivalent	B
influenza	I
vaccine	I
)	O

Known	O
IgE	B
(	I
Immunoglobulin	I
E	I
)	I
-	I
mediated	I
hypersensitivity	I
to	O
eggs	B
manifested	O
as	O
hives	B
,	O
swelling	B
of	I
the	I
mouth	I
and	I
throat	I
,	O
difficulty	B
in	I
breathing	I
,	O
hypotension	B
,	O
or	O
shock	B

Guillain	B
-	I
Barré	I
syndrome	I
within	O
eight	O
weeks	O
of	O
a	O
previous	B
influenza	B
vaccine	I

Anaphylactic	B
reaction	I
to	O
neomycin	B

Patients	O
who	O
have	O
had	O
influenza	B
vaccine	I
in	B
two	I
of	I
the	I
three	I
previous	I
years	I

Age	B
=	B
18	I
years	I
and	O
NYHA	B
(	I
New	I
York	I
Heart	I
Association	I
)	I
functional	I
class	I
II	B
,	I
III	I
and	I
IV	I

eGFR	B
(	O
Epidermal	B
growth	I
factor	I
receptor	I
)	O
<	B
50mL	I
/	I
min	I

AST	B
(	O
aspartate	B
aminotransferase	I
)	O
/	O
ALT	B
(	O
alanine	B
aminotransaminase	I
)	O
>	B
2	I
.	I
5	I
upper	I
limit	I
of	I
normal	I

Pregnant	O
or	O
lactating	O
women	O

Subject	O
who	O
the	O
investigator	O
deems	O
inappropriate	O
to	O
participate	O
in	O
this	O
study	O

Patients	O
with	O
a	O
history	O
of	O
bladder	B
cancer	I
or	O
patients	O
with	O
active	B
bladder	B
cancer	I

Patients	O
with	O
uninvestigated	B
macroscopic	B
hematuria	I

Patients	O
with	O
cardiac	B
failure	I
or	O
a	O
history	B
of	I
cardiac	I
failure	I
(	O
New	O
York	O
Heart	O
Association	O
[	O
NYHA	B
]	O
Stages	O
3	B
to	I
4	I
)	O

Patients	O
with	O
genetic	B
problems	I
such	O
as	O
galactose	B
intolerance	I
,	O
Lapp	B
lactase	I
deficiency	I
or	O
glucose	B
-	I
galactose	I
malabsorption	I
,	O
since	O
this	O
study	O
drug	O
contains	O
lactose	O

Completed	O
"	O
ALO	O
-	O
IIT	O
-	O
012	O
(	O
PEAK	O
study	O
)	O
"	O
,	O
without	O
major	O
protocol	O
deviations	O
.	O

Male	B
,	O
or	O
female	B
,	O
19	B
years	I
to	I
75	I
years	B
.	O

Female	O
with	O
childbearing	O
potential	O
who	O
has	O
a	O
negative	O
urine	O
pregnancy	O
test	O
result	O
at	O
study	O
start	O
and	O
willing	O
to	O
continue	O
practice	O
appropriate	O
birth	O
control	O
during	O
the	O
entire	O
duration	O
of	O
study	O

Subjects	O
completed	O
PEAK	O
can	O
be	O
included	O
within	O
30	O
days	O
after	O
End	O
Of	O
the	O
Study	O

Subjects	O
completed	O
PEAK	O
can	O
be	O
included	O
if	O
their	O
treatment	O
is	O
the	O
same	O
as	O
randomized	O
even	O
after	O
30	O
days	O
of	O
End	O
Of	O
the	O
Study	O
.	O

Nonfluency	O
or	O
inability	O
to	O
communicate	O
in	O
English	O
spoken	O
language	O

Inability	O
to	O
participate	O
or	O
attend	O
biweekly	O
30	O
minute	O
session	O
over	O
14	O
weeks	O

Frank	B
psychosis	B

Active	B
self	B
harm	I
urges	I

Serious	B
medical	B
illness	I

Active	O
substance	O
or	O
alcohol	B
use	I
or	I
dependence	I
that	O
could	O
interfere	O
with	O
participation	O

Diagnoses	O
of	O
mental	B
retardation	I
,	O
dementia	B
or	O
delirium	B

Pregnant	B
women	B

Adults	B
18	B
-	I
65	I
years	I
,	O
who	O
are	O
diagnosed	O
with	O
functional	B
neurologic	I
symptom	I
or	O
conversion	B
disorder	I
.	O

If	O
diagnosis	O
of	O
seizure	B
type	I
then	O
video	B
EEG	I
with	O
diagnosis	O
confirmed	O
by	O
board	O
-	O
certified	O
neurologist	O
with	O
subspecialty	O
training	O
in	O
epilepsy	O
and	O
clinical	O
neurophysiology	O
using	O
the	O
criteria	B
of	I
the	I
International	I
Classification	I
of	I
the	I
Epilepsies	I
is	O
required	O
.	O

If	O
diagnosis	O
of	O
motor	B
type	I
,	O
documented	O
and	O
clinically	O
established	O
levels	O
of	O
diagnostic	O
certainty	O
(	O
Williams	O
,	O
1995	O
)	O
confirmed	O
by	O
2	O
neurologists	O
is	O
required	O
.	O

Participants	O
must	O
have	O
at	O
least	O
one	O
symptom	B
per	O
month	O
in	B
the	I
month	I
prior	I
to	I
enrollment	I

Fluency	O
in	O
English	O
spoken	O
language	O

Person	O
is	O
under	B
18	I
years	I
of	O
age	B
.	O

Person	O
who	O
weighs	B
more	B
than	I
136kg	I
.	O

Person	O
who	O
weighs	B
less	B
than	I
50kg	I
.	O

Person	O
who	O
is	O
pregnant	B
.	O

Person	O
has	O
a	O
history	O
of	O
chronic	B
skin	B
breakdown	I
on	O
the	O
residual	B
limb	I
.	O

Person	O
has	O
conditions	O
that	O
would	O
prevent	O
participation	O
and	O
pose	O
increased	O
risk	O
(	O
e	O
.	O
g	O
.	O
unstable	O
cardiovascular	O
conditions	O
that	O
preclude	O
physical	O
activity	O
such	O
as	O
walking	O
)	O
.	O

Person	O
falls	O
=	O
once	B
a	I
week	I
due	O
to	O
the	O
reasons	O
that	O
could	O
not	O
be	O
corrected	O
by	O
the	O
new	O
prosthesis	O
(	O
for	O
ex	O
.	O
problems	O
with	O
vestibular	O
system	O
)	O
.	O

Person	O
is	O
using	O
under	B
arm	I
axillary	I
crutches	I
or	O
walker	B
.	O

Person	O
in	O
an	O
emergency	O
,	O
life	O
threatening	O
situation	O
.	O

Person	O
is	O
unwilling	O
/	O
unable	O
to	O
follow	O
instructions	O
.	O

Person	O
who	O
is	O
not	O
available	O
to	O
follow	O
the	O
entire	O
study	O
protocol	O
.	O

Person	O
who	O
is	O
participating	O
in	O
another	O
study	O
or	O
intends	O
to	O
participate	O
in	O
another	O
study	O
during	O
this	O
study	O
duration	O
.	O

Person	O
who	O
cannot	O
personally	O
provide	O
their	O
consent	O
.	O

Person	O
who	O
is	O
not	B
wearing	O
prosthesis	B
8hours	B
/	I
day	I
on	O
average	O
.	O

Person	O
who	O
has	O
a	O
score	O
on	O
10m	B
walk	I
test	I
less	B
than	I
3km	I
/	I
h	I
(	O
~	O
0	B
.	I
8m	I
/	I
s	I
)	I
(	O
based	O
on	O
10m	O
walk	O
test	O
conducted	O
during	O
recruiting	O
)	O
.	O

Person	O
who	O
walks	O
on	O
average	O
less	B
than	I
1km	I
per	I
day	I
.	O

Person	O
who	O
is	O
not	O
able	O
to	O
walk	O
on	O
level	O
ground	O
in	O
a	O
step	O
over	O
step	O
manner	O
.	O

Person	O
is	O
>	B
18	I
years	I
old	B
.	O

Person	O
is	O
a	O
unilateral	O
transfemoral	O
or	O
knee	O
-	O
disarticulation	O
amputee	O
with	O
stabilized	O
residual	O
limb	O
.	O

Person	O
is	O
a	O
K2	B
,	I
K3	I
or	I
K4	I
ambulator	O
based	O
on	O
Medicare	B
Functional	I
Classification	I
Level	I
(	O
MFCL	B
)	O
.	O

Person	O
is	O
currently	O
fitted	O
with	O
a	O
prosthesis	B
using	O
a	O
non	B
-	I
microprocessor	I
controlled	I
prosthetic	B
knee	I
for	O
at	B
least	I
6	I
months	I
.	O

Person	O
was	O
never	B
fitted	O
with	O
microprocessor	B
controlled	I
prosthetic	B
knee	I
joint	I
.	O

Person	O
is	O
willing	O
and	O
able	O
to	O
independently	O
provide	O
informed	O
consent	O
.	O

Person	O
is	O
willing	O
to	O
comply	O
with	O
study	O
procedures	O
.	O

Person	O
wears	O
prosthesis	B
daily	B
and	I
=	I
8	I
hours	I
/	I
day	I
.	O

Person	O
is	O
walking	O
on	O
average	O
1km	B
/	I
day	I
.	O

Person	O
is	O
walking	O
not	B
slower	I
than	I
3km	I
/	I
h	I
(	O
~	O
0	O
.	O
8m	O
/	O
s	O
)	O
(	O
based	O
on	O
10m	O
walk	O
test	O
conducted	O
during	O
recruiting	O
)	O
.	O

Person	O
is	O
walking	O
on	O
level	O
ground	O
in	O
a	O
step	O
over	O
step	O
manner	O
.	O

Receiving	O
antibiotic	B
and	O
/	O
or	O
probiotic	B
,	O
8	B
weeks	I
before	I
the	I
study	I

Chronic	B
gastrointestinal	I
system	I
disorders	I

Congenital	B
anomalies	I

Chronic	B
diseases	I

Chemotherapy	B
and	O
radiotherapy	B

Pregnancy	B

Children	B
receiving	O
amoxicilline	B
-	I
clavulanic	I
acid	I
(	O
50	B
-	I
90	I
mg	I
/	I
kg	I
/	I
day	I
,	O
twice	B
daily	I
)	O
due	O
to	O
acute	B
otitis	I
media	I
or	O
acute	B
sinusitis	I

Estimated	B
GFR	I
(	O
eGFR	B
)	O
<	B
60	I
mL	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
and	O
blood	B
glucose	I
>	B
135	I
mg	I
/	I
dl	I
;	O
Past	O
or	O
present	O
history	O
of	O
acute	B
renal	I
failure	I
,	O
renal	B
dialysis	I
,	O
diabetes	B
mellitus	I
.	O

Women	B
who	O
received	O
metallic	B
fixation	I
,	O
coronary	B
artery	I
stent	I
in	O
recent	B
3	I
months	I
;	O
or	O
women	B
who	O
received	O
mechanical	B
valve	I
replacement	I
that	O
is	O
not	O
compatible	O
with	O
MR	O
magnet	O
;	O
or	O
women	B
with	O
aneurysmal	B
clips	I
,	O
pacemakers	B
.	O

Past	O
history	O
of	O
claustrophobia	B
.	O

Women	O
who	O
are	O
pregnant	O
or	O
who	O
are	O
planning	O
to	O
be	O
pregnant	O
,	O
or	O
who	O
are	O
lactating	O
(	O
though	O
the	O
possibility	O
in	O
our	O
target	O
population	O
should	O
be	O
very	O
low	O
)	O

Past	O
history	O
of	O
breast	B
cancer	I
within	O
recent	B
5	I
years	I
before	I
the	I
currently	I
diagnosed	I
breast	I
cancer	I
.	O

Women	O
who	O
received	O
chemotherapy	B
for	O
other	O
disease	O
entity	O
in	O
recent	B
1	I
year	I
.	O

Women	O
who	O
cannot	O
cooperate	O
with	O
the	O
examinations	O
.	O

Women	B
aged	B
25	B
-	I
75	I
years	I
old	I
.	O

Women	B
with	O
recently	O
diagnosed	O
breast	B
cancer	I
and	O
who	O
will	O
receive	O
NAC	B
to	O
reduce	B
tumor	I
burden	I
before	B
surgery	I
.	O

(	O
including	O
locally	O
advanced	O
breast	O
cancer	O
(	O
LABC	O
)	O
according	O
to	O
clinical	O
assessment	O
;	O
or	O
tumor	O
size	O
>	O
2cm	O
,	O
that	O
is	O
,	O
at	O
least	O
T2	O
in	O
TNM	O
staging	O
)	O
.	O

Emergency	B
surgery	I

Pregnancy	B
or	O
lactation	B

Immune	B
disorders	I

Kidney	O
or	O
liver	B
disease	I
or	O
advanced	B
-	I
stage	I
cardiopulmonary	I

Patient	O
refusal	O
to	O
participate	O
in	O
the	O
study	O

Patients	O
under	B
18	I
years	B
or	O
inability	B
to	I
consent	I

Associated	O
neuromuscular	B
disorders	I
,	O
contraindication	B
for	O
the	O
use	O
of	O
rocuronium	B
/	O
sugammadex	B
,	O
allergy	B
or	O
hypersensitivity	B
to	O
rocuronium	B
/	O
sugammadex	B

Patients	O
older	B
than	I
18	I
years	B

Classification	B
of	I
the	I
American	I
Society	I
of	I
Anesthesiologists	I
(	O
ASA	B
I	B
-	I
III	I
)	O

No	B
cognitive	B
deficits	I

Signed	O
informed	O
consent	O
prior	O
to	O
surgery	O

Patients	O
who	O
are	O
being	O
prepared	O
for	O
surgery	B
,	O
or	O
during	O
or	O
after	B
surgery	I
.	O

Patients	O
with	O
congenital	B
anomalies	I
,	O
chromosomal	B
anomalies	I
,	O
or	O
heart	B
defects	I
.	O

Patients	O
whose	O
parents	O
refuse	O
to	O
consent	O
.	O

Nonsurgical	B
neonates	B
and	O
babies	B
up	O
to	O
age	B
6	O
months	O
with	O
INR	B
1	B
.	I
5	I
or	I
more	I
who	O
are	O
deemed	O
clinically	O
to	O
need	B
plasma	B
infusion	I
.	O

Concomitant	B
use	O
with	O
oral	B
anticoagulant	I
drugs	I

Acquired	B
deficiency	I
of	I
coagulation	I
factors	I
whose	B
treatment	I
is	I
established	I

Hypersensitivity	B
to	O
a	O
PCC	B

History	O
of	O
thrombocytopenia	B
induced	O
by	O
heparin	B

Disseminated	B
intravascular	I
coagulation	I

Extracranial	O
active	B
bleeding	O

Hypersensitivity	B
to	O
vitamin	B
K	I

Patient	O
with	O
spontaneous	B
intracranial	I
hemorrhage	I
or	O
traumatic	B
intracranial	I
hemorrhage	I
or	O
patient	O
requiring	O
neurological	B
surgery	I

Coagulation	B
disorder	I
defined	O
by	O
PT	B
less	B
than	I
60	I
%	I

1	O
.	O

Expected	O
performance	O
of	O
PCI	B
<	B
60	I
minutes	I
from	I
diagnosis	I
(	O
qualifying	O
ECG	O
)	O
or	O
inability	O
to	O
arrive	O
at	O
the	O
catheterisation	O
laboratory	O
within	O
3	O
hours	O

Previous	O
CABG	B

Left	B
bundle	I
branch	I
block	I
or	O
ventricular	B
pacing	I

Patients	O
with	O
cardiogenic	B
shock	I
-	O
Killip	B
Class	I
4	B

Patients	O
with	O
a	O
body	B
weight	I
<	B
55	I
kg	I
(	O
known	O
or	O
estimated	O
)	O

Uncontrolled	B
hypertension	B
,	O
defined	O
as	O
sustained	O
blood	B
pressure	I
=	B
180	I
/	I
110	I
mm	I
Hg	I
(	O
systolic	B
BP	I
=	B
180	I
mm	I
Hg	I
and	O
/	O
or	O
diastolic	B
BP	I
=	B
110	I
mm	I
Hg	I
)	O
prior	O
to	O
randomisation	O

Known	O
prior	O
stroke	B
or	O
TIA	B

Recent	O
administration	O
of	O
any	O
i	O
.	O
v	O
.	O
or	O
s	O
.	O
c	O
.	O
anticoagulation	B
within	B
12	I
hours	I
,	O
including	O
unfractionated	B
heparin	I
,	O
enoxaparin	B
,	O
and	O
/	O
or	O
bivalirudin	B
or	O
current	O
use	O
of	O
oral	B
anticoagulation	I
(	O
i	O
.	O
e	O
.	O
warfarin	B
or	O
a	O
NOACs	B
)	O

Active	B
bleeding	I
or	O
known	O
bleeding	B
disorder	I
/	O
diathesis	B

Known	O
history	O
of	O
central	B
nervous	I
system	I
damage	I
(	O
i	O
.	O
e	O
.	O
neoplasm	B
,	O
aneurysm	B
,	O
intracranial	O
or	O
spinal	B
surgery	I
)	O
or	O
recent	O
trauma	B
to	O
the	O
head	B
or	O
cranium	B
(	O
i	O
.	O
e	O
.	O
<	B
3	I
months	I
)	O

Major	B
surgery	I
,	O
biopsy	B
of	O
a	O
parenchymal	B
organ	I
,	O
or	O
significant	B
trauma	B
within	O
the	O
past	B
2	I
months	I
(	O
this	O
includes	O
any	O
trauma	O
associated	O
with	O
the	O
current	O
myocardial	B
infarction	I
)	O

Clinical	O
diagnosis	O
associated	O
with	O
increased	B
risk	O
of	O
bleeding	O
including	O
known	O
active	B
peptic	B
ulceration	I
and	O
/	O
or	O
neoplasm	B
with	O
increased	O
bleeding	O
risk	O

Prolonged	B
cardiopulmonary	B
resuscitation	I
(	O
>	O
2	O
minutes	O
)	O
within	O
the	O
past	B
2	I
weeks	I

Known	O
acute	B
pericarditis	I
and	O
/	O
or	O
subacute	B
bacterial	I
endocarditis	I

Known	O
acute	B
pancreatitis	I
or	O
known	O
severe	B
hepatic	B
dysfunction	I
,	O
including	O
hepatic	B
failure	I
,	O
cirrhosis	B
,	O
portal	B
hypertension	I
(	O
oesophageal	B
varices	I
)	O
and	O
active	B
hepatitis	I

Dementia	B

Known	O
severe	B
renal	B
insufficiency	I

Previous	O
enrolment	O
in	O
this	O
study	O
or	O
treatment	O
with	O
an	O
investigational	O
drug	O
or	O
device	O
under	O
another	O
study	O
protocol	O
in	O
the	O
past	O
7	O
days	O

Known	O
allergic	B
reactions	I
to	O
tenecteplase	B
,	O
clopidogrel	B
,	O
enoxaparin	B
and	O
aspirin	B

Inability	O
to	O
follow	O
the	O
protocol	O
and	O
comply	O
with	O
follow	O
-	O
up	O
requirements	O
or	O
any	O
other	O
reason	O
that	O
the	O
investigator	O
feels	O
would	O
place	O
the	O
patient	O
at	O
increased	O
risk	O
if	O
the	O
investigational	O
therapy	O
is	O
initiated	O
.	O

Age	B
equal	B
or	I
greater	I
than	I
70	I
years	I

Onset	O
of	O
symptoms	O
<	B
3	I
hours	I
prior	I
to	I
randomisation	I

=	O
2	O
mm	O
ST	O
-	O
elevation	O
across	O
2	O
contiguous	O
precordial	O
leads	O
(	O
V1	O
-	O
V6	O
)	O
or	O
leads	O
I	O
and	O
aVL	O
for	O
a	O
minimum	O
combined	O
total	O
of	O
=	O
4	O
mm	O
ST	O
-	O
elevation	O
or	O

=	O
2	O
mm	O
ST	O
-	O
elevation	O
in	O
2	O
contiguous	O
inferior	O
leads	O
(	O
II	O
,	O
III	O
,	O
aVF	O
)	O
for	O
a	O
minimum	O
combined	O
total	O
of	O
=	O
4	O
mm	O
ST	O
-	O
elevation	O

Informed	O
consent	O
received	O

Abnormal	B
karyotype	I

Previous	B
pelvic	O
or	O
abdominal	B
radiotherapy	I

Previous	B
surgical	B
management	I
of	O
ovarian	B
pathology	I

Chronic	B
disease	I
:	O
renal	O
,	O
liver	O
,	O
cardiac	B
,	I
malignancy	I

Women	B
with	O
POI	B
:	O
For	O
the	O
purpose	O
of	O
the	O
research	O
women	O
is	O
considered	O
to	O
have	O
POI	O
if	O
she	O
is	O
aged	B
less	B
than	I
40	I
years	I
and	O
has	O
amenorrhea	B
of	O
at	B
least	I
4	I
month	I
with	O
FSH	B
level	I
above	B
25	I
IU	I
/	I
L	I
(	O
repeated	B
twice	I
>	B
4	I
weeks	I
apart	I
)	O
.	O

Known	O
allergy	B
or	O
hypersensitive	B
reaction	O
to	O
dexmedetomidine	B

Organ	B
dysfunction	I
,	O
and	O
significant	B
developmental	B
delays	I
or	O
behavior	B
problems	I

Cardiac	B
arrhythmia	I

Known	O
.	O
acyanotic	B
congenital	I
heart	I
disease	I
or	O
children	B
after	O
cardiac	B
interventional	I
procedures	I
for	O
follow	B
-	I
up	I
examination	I
.	O

Children	B
,	O
aged	B
between	B
one	I
and	I
24	I
months	I
.	O
classified	O
as	O
(	O
American	B
Society	I
of	I
Anesthesiologists	I
)	O
ASA	B
physical	I
status	I
I	B
or	I
II	I
,	O
undergoing	O
TEE	B
were	O
enrolled	O
in	O
the	O
study	O
.	O

Previous	O
randomization	O
in	O
this	O
study	O

Treatment	O
with	O
IV	B
antibiotics	I
in	B
the	I
6	I
weeks	I
prior	I
to	I
Visit	I
1	I

Admission	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
current	O
pulmonary	B
exacerbation	I
in	B
the	I
two	I
weeks	I
prior	I
to	I
Visit	I
2	I
,	O
unless	B
admission	O
was	O
due	O
to	O
a	O
desensitization	B
protocol	I

Pneumothorax	B
in	B
the	I
two	I
weeks	I
prior	I
to	I
Visit	I
2	I

Primary	B
diagnosis	I
for	O
current	O
hospitalization	O
is	O
unrelated	B
to	O
worsening	B
lower	B
respiratory	I
symptoms	I
(	O
e	O
.	O
g	O
.	O
,	O
pulmonary	B
clean	I
out	I
,	O
distal	B
intestinal	I
obstruction	I
syndrome	I
(	O
DIOS	B
)	O
,	O
sinusitis	B
)	O

Massive	B
hemoptysis	B
defined	O
as	O
>	B
250	I
cc	I
in	B
a	I
24	I
hour	I
period	I
or	O
100	B
cc	I
/	I
day	I
over	B
4	I
consecutive	I
days	I
occurring	O
in	B
the	I
two	I
weeks	I
prior	I
to	I
Visit	I
2	I

Current	O
pulmonary	B
exacerbation	I
thought	O
to	O
be	O
due	O
to	O
allergic	B
bronchopulmonary	I
aspergillosis	I
(	O
ABPA	B
)	O

At	B
Visit	I
1	I
,	I
receiving	I
ongoing	I
treatment	I
with	I
a	I
duration	I
of	I
more	I
than	I
2	I
weeks	I
with	O
prednisone	B
equivalent	O
to	O
>	B
10mg	I
/	I
day	I

History	O
of	O
solid	B
organ	I
transplantation	I

Receiving	O
antimicrobial	B
therapy	I
to	O
treat	O
non	B
-	I
tuberculous	I
mycobacterium	I
(	O
e	O
.	O
g	O
.	O
,	O
M	B
.	I
abscessus	I
,	O
M	B
.	I
avium	I
complex	I
)	O
in	B
the	I
two	I
weeks	I
prior	I
to	I
Visit	I
2	I

Male	B
or	O
female	B
=	B
18	I
years	I
of	O
age	B
at	B
Visit	I
1	I

Documentation	O
of	O
a	O
CF	B
diagnosis	O

Enrolled	O
in	O
the	O
Cystic	O
Fibrosis	O
Foundation	O
National	O
Patient	O
Registry	O
(	O
CFFNPR	O
)	O
prior	B
to	I
Visit	I
1	I
(	O
US	O
sites	O
only	O
)	O

At	B
the	I
time	I
of	I
Visit	I
1	I
,	O
there	O
is	O
a	O
plan	O
to	O
initiate	O
IV	B
antibiotics	I
for	O
a	O
pulmonary	B
exacerbation	I

Performed	O
spirometry	B
at	B
Visit	I
1	I
and	O
Visit	O
2	O
and	O
willing	O
to	O
perform	O
spirometry	B
at	B
Visit	I
3	I

Completed	O
the	O
CRISS	B
questionnaire	I
at	B
Visit	I
1	I
and	O
Visit	O
2	O
and	O
willing	O
to	O
complete	O
the	O
Cystic	B
Fibrosis	I
Respiratory	I
Symptoms	I
Diary	I
(	I
CFRSD	I
)	I
questionnaire	I
at	B
Visit	I
3	I

Willing	O
to	O
adhere	O
to	O
a	O
specific	O
treatment	O
duration	O
determined	O
by	O
initial	O
response	O
to	O
treatment	O
and	O
subsequent	O
randomization	O

Willing	O
to	O
return	O
for	O
follow	B
up	I
Visit	I
3	I

Written	O
informed	O
consent	O
obtained	O
from	B
the	I
subject	I
or	O
subject	O
'	O
s	O
legal	O
representative	O

Hypersensibility	B
to	O
toxin	B
or	O
excipients	B

Myastheny	B

Deglutition	B
'	I
s	I
problems	I

Past	B
medical	I
history	I
of	O
dysphagia	B
or	O
aspiration	B
pneumonia	I

Pregnancy	B
(	O
positive	B
B	B
-	I
HCG	I
test	I
performed	O
a	B
maxima	I
72h	I
before	I
)	O
or	O
breastfeeding	O

Mental	O
,	O
physical	B
incapacity	I
to	O
fill	B
in	I
the	I
questionnaires	I

Guardianship	O
patients	O

Skin	B
infections	I
at	B
the	I
inclusion	I
visit	I

Application	O
in	B
the	I
last	I
7	I
days	I
at	O
the	O
site	O
of	O
injection	O
of	O
local	O
treatments	O
(	O
apart	B
emollients	B
or	O
antiseptics	B
)	O
or	O
injections	B
of	O
botulism	B
toxin	I
or	O
dynamic	B
phototherapy	I
or	O
laser	B
in	B
the	I
last	I
6	I
months	I
.	O

Systemic	B
treatment	I
with	O
aminosides	B
in	B
the	I
last	I
15	I
days	I

Inclusion	B
in	I
another	I
study	I
in	B
the	I
last	I
2	I
months	I
.	O

Confirmed	O
diagnosis	O
(	O
clinical	O
and	O
histological	B
features	O
)	O
of	O
Hailey	O
Hailey	O
or	O
Darier	B
diseases	I
.	O

Moderate	O
to	O
very	B
severe	I
lesions	B
located	O
in	O
large	O
folds	O

Patient	O
aged	B
18	B
ans	I
or	I
more	I

Patient	O
with	O
health	O
coverage	O

Patient	O
who	O
have	O
signed	O
the	O
consent	O
form	O

Patient	O
proficient	O
into	O
filling	O
out	O
the	O
questionnaires	O
.	O

Current	O
wheeze	B

Underlying	O
chronic	B
illness	I
other	B
than	O
asthma	B
(	O
e	O
.	O
g	O
.	O
bronchiectasis	B
,	O
cyanotic	B
congenital	I
heart	I
disease	I
or	O
cardiac	B
failure	I
,	O
neuromuscular	B
disorders	I
,	O
immunodeficiency	B
)	O
that	O
could	O
potentially	O
influence	O
the	O
current	O
illness	O

Severe	B
malnutrition	B
(	O
weight	B
-	I
for	I
-	I
height	I
Z	I
-	I
score	I
<	B
-	I
3	I
)	O

Complicated	O
(	O
effusion	B
,	O
empyema	B
or	O
abscess	B
)	O
pneumonia	O
,	O
including	O
tuberculosis	B

Extra	B
-	I
pulmonary	I
infection	B
requiring	O
antibiotic	B
therapy	I
(	O
e	O
.	O
g	O
.	O
meningitis	B
)	O

Beta	B
-	I
lactam	I
allergy	B

Previously	O
enrolled	O

Lack	O
a	O
mobile	O
phone	O
and	O
/	O
or	O
unable	O
to	O
return	O
for	O
follow	O
-	O
up	O
clinic	O
visits	O
during	O
the	O
next	O
24	O
months	O

Hospitalised	O
children	B
aged	B
3	B
-	I
mo	I
to	I
5	I
-	I
yrs	I
(	O
in	O
Darwin	O
,	O
children	O
have	O
to	O
be	O
Indigenous	O
)	O

Have	O
features	O
of	O
severe	B
pneumonia	B
on	O
admission	O
(	O
temperature	B
>	B
37	I
.	I
5	I
celsius	I
or	O
a	O
history	O
of	O
fever	O
at	O
home	O
or	O
observed	O
at	O
the	O
referring	O
clinic	O
,	O
age	B
-	O
adjusted	O
tachypnoea	B
[	O
respiratory	B
rate	I
>	B
50	I
if	O
<	B
12	I
-	I
months	I
;	O
respiratory	B
rate	I
>	B
40	I
if	O
>	B
12	I
-	I
months	I
]	O
with	O
chest	B
wall	I
recession	I
and	O
/	O
or	O
oxygen	B
saturation	I
<	B
92	I
%	I
in	I
air	I
)	O
,	O
and	O
consolidation	B
on	O
chest	B
X	I
-	I
ray	I
as	O
diagnosed	O
by	O
treating	O
clinician	O

After	O
1	O
-	O
3	O
days	O
of	O
IV	O
antibiotics	O
,	O
are	O
afebrile	O
,	O
with	O
improved	O
respiratory	O
symptoms	O
and	O
signs	O
,	O
oxygen	O
saturation	O
>	O
90	O
%	O
in	O
air	O
and	O
are	O
ready	O
to	O
be	O
switched	O
to	O
oral	O
amoxicillin	O
-	O
clavulanate	O
,	O
and	O

Have	O
symptoms	B
of	O
no	B
longer	I
than	I
7	I
days	I
at	I
point	I
of	I
hospitalisation	I
.	O

NA	O

Patient	O
'	O
s	O
written	O
informed	O
consent	O
.	O
Adequate	O
cognitive	O
capacity	O
.	O

Adequate	O
family	O
support	O

No	O
acute	B
diverticulitis	B
episode	O
in	B
the	I
last	I
3	I
months	I

mNeff	B
0	B
acute	B
diverticulitis	B
(	O
abdominal	B
computed	I
tomography	I
scan	I
)	O

No	B
antibiotic	B
treatment	I
in	B
the	I
last	I
2	I
weeks	I

Immunocompetence	B
*	O

No	B
significant	B
comorbidities	B
*	O
*	O

Good	B
oral	B
tolerance	I

Good	B
symptom	B
control	I

Maximum	O
one	O
of	O
the	O
following	O
SIRS	B
criteria	I
(	O
*	O
T	B
>	B
38	I
ºC	I
or	O
<	B
36ºC	I
,	O
L	B
>	O
12	O
,	O
000	O
or	O
<	B
4000	I
/	I
uL	I
,	O
HR	B
>	B
90	I
bpm	I
,	O
RR	B
<	B
20	I
rpm	I
)	O
or	O
CRP	B
>	B
15	I
mg	I
/	I
dL	I

General	O
danger	O
signs	O
or	O
symptoms	O
of	O
severe	B
malaria	B

Anaemia	B
,	O
defined	O
as	O
Hb	B
<	B
9g	I
/	I
dl	I

G6PD	B
deficiency	I
(	O
as	O
determined	O
by	O
FST	O
)	O

Pregnant	O
women	O
as	O
determined	O
by	O
Urine	O
ß	O
-	O
HCG	O
pregnancy	O
test	O

Known	O
hypersensitivity	B
to	O
any	O
of	O
the	O
drugs	B
given	O

Infection	B
with	O
Plasmodium	B
falciparum	I
or	O
P	B
.	I
vivax	I
either	O
alone	O
or	O
mixed	O

Age	B
>	B
12	I
months	I

Weight	B
>	B
5kg	I

Living	O
in	O
the	O
study	O
clusters	O

Vaccination	B
against	O
pneumococcal	B
infection	I
in	O
anamnesis	O
;	O

Application	O
of	O
preparations	B
of	I
immune	I
globulin	I
or	O
blood	B
transfusion	I
within	B
last	I
three	I
months	I
prior	I
to	I
clinical	I
studies	I
;	O

Prolonged	B
use	I
(	O
more	B
than	I
14	I
days	I
)	O
immunosuppressants	B
or	O
other	B
immunosuppressive	B
drugs	I
within	B
6	I
months	I
prior	I
to	I
the	I
start	I
of	I
the	I
study	I
;	O

Any	O
confirmed	O
or	O
suspected	O
immunosuppressive	O
or	O
immunodeficient	B
condition	I
,	O
including	O
HIV	B
infection	I
;	O

A	O
history	O
or	O
currently	O
hematologic	O
and	O
other	O
cancers	O
;	O

A	O
positive	B
reaction	B
for	I
HIV	I
infection	I
,	O
viral	O
hepatitis	O
B	O
and	O
hepatitis	O
C	O
;	O

The	O
presence	O
of	O
respiratory	O
,	O
cardio	B
-	I
vascular	I
insufficiency	I
,	O
impaired	B
liver	I
and	O
kidney	O
function	O
,	O
established	O
during	O
a	O
physical	O
examination	O
at	B
visit	I
number	I
1	I
;	O

Pronounced	O
congenital	B
defects	I
or	O
serious	B
chronic	B
diseases	I
in	O
the	O
acute	B
stage	I
,	O
including	O
any	O
clinically	B
important	I
exacerbation	B
of	O
chronic	B
diseases	B
of	I
the	I
liver	I
,	O
kidney	O
,	O
cardiovascular	O
,	O
nervous	O
system	O
,	O
mental	B
diseases	I
or	O
metabolic	B
disorders	I
,	O
confirmed	O
by	O
the	O
history	O
or	O
objective	O
examination	O
(	O
pulmonary	O
:	O
cystic	B
fibrosis	I
,	O
lung	B
abscess	I
,	O
empyema	B
,	O
active	B
tuberculosis	B
;	O
extra	O
-	O
pulmonary	O
:	O
congestive	B
heart	I
failure	I
,	O
malabsorption	B
,	O
chronic	B
renal	O
and	O
hepatic	B
failure	I
,	O
cirrhosis	B
,	O
malignancy	B
,	O
immunodeficiency	B
,	O
cirrhosis	B
of	I
the	I
liver	I
)	O
;	O

Severe	B
allergic	B
reactions	I
in	O
anamnesis	O
of	O
autoimmune	O
disease	O
;	O

The	O
presence	O
of	O
acute	B
infectious	O
and	O
/	O
or	O
communicable	B
illnesses	I
within	B
1	I
month	I
prior	I
to	I
study	I
;	O

History	O
of	O
chronic	B
alcohol	B
abuse	I
and	O
/	O
or	O
drug	B
use	I
;	O

Exacerbation	B
of	O
chronic	B
diseases	I
;	O

Breastfeeding	O
;	O

Pregnancy	B
;	O

Participation	O
in	O
any	B
other	I
clinical	O
study	O
within	B
the	I
last	I
3	I
months	I
.	O

Individuals	O
of	O
both	B
sexes	I
from	B
18	I
years	I
with	O
a	O
diagnosis	O
of	O
community	B
-	I
acquired	I
pneumonia	I
,	O
COPD	B
or	O
Bronchial	B
Asthma	I
;	O

The	O
presence	O
of	O
signed	O
and	O
dated	O
informed	O
consent	O
to	O
participate	O
in	O
a	O
clinical	O
study	O
;	O

The	O
ability	O
to	O
perform	O
the	O
requirements	O
of	O
the	O
Protocol	O
;	O

For	O
women	O
of	O
childbearing	O
age	O
is	O
a	O
negative	O
result	O
of	O
a	O
pregnancy	O
test	O
before	O
vaccination	O
.	O

community	B
-	I
acquired	I
pneumonia	I
:	O
the	O
presence	O
of	O
radiologically	B
confirmed	O
infiltration	B
of	I
the	I
lung	I
tissue	I
;	O
the	O
presence	O
of	O
at	B
least	I
two	I
of	O
the	O
following	O
clinical	O
signs	O
:	O
acute	B
fever	I
early	B
in	I
the	I
disease	I
(	O
temperature	B
>	B
38	I
.	I
0	I
°	I
C	I
)	O
,	O
cough	B
with	I
sputum	I
,	O
the	O
physical	B
signs	I
of	O
pneumonia	B
(	O
focus	O
of	O
crepitate	O
and	O
/	O
or	O
fine	B
bubble	I
rales	I
,	O
bronchial	B
breathing	I
hard	I
,	O
shortening	B
of	I
percussion	I
sounds	I
)	O
,	O
leukocytosis	B
>	B
10	I
*	I
10	I
9	I
/	I
l	I
and	O
/	O
or	O
stab	B
shift	I
>	B
10	I
%	I
;	O
the	O
occurrence	O
of	O
the	O
disease	O
outside	O
the	O
hospital	O
and	O
the	O
organized	O
groups	O
(	O
such	O
as	O
nursing	O
homes	O
,	O
sanatoriums	O
,	O
etc	O
.	O
)	O
.	O

COPD	B
:	O
dyspnea	B
:	O
progressive	B
(	O
worsens	B
over	I
time	I
)	O
,	O
increases	B
with	I
exertion	I
,	O
persistent	B
;	O
chronic	B
cough	I
(	O
may	O
appear	O
sporadically	O
and	O
may	O
be	O
unproductive	O
)	O
;	O
chronic	B
expectoration	I
;	O
the	O
impact	O
of	O
risk	B
factors	I
in	O
the	O
medical	O
history	O
(	O
Smoking	B
,	O
occupational	B
dust	I
pollutants	I
and	I
chemicals	I
)	O
;	O
widespread	B
wheeze	B
on	I
auscultation	I
of	I
the	I
chest	I
and	O
/	O
or	O
distant	B
wheezing	I
in	I
the	I
chest	I
;	O
family	O
history	O
of	O
COPD	B
;	O
spirometric	B
data	O
confirming	O
the	O
presence	O
of	O
fixed	B
bronchial	I
obstruction	I
.	O

Has	O
chronic	B
hepatitis	I
B	I
(	O
measured	O
by	O
hepatitis	B
B	I
surface	I
antigen	I
test	I
)	O
or	O
active	B
hepatitis	I
C	I
(	O
measured	O
by	O
hepatitis	B
C	I
virus	I
[	I
HCV	I
]	I
Ab	I
test	I
;	O
if	O
positive	B
,	O
HCV	B
ribonucleic	I
acid	I
[	I
RNA	I
]	I
PCR	I
test	I
will	O
be	O
used	O
to	O
confirm	O
active	O
versus	O
past	O
HCV	O
infection	O
)	O
,	O
active	B
syphilis	B
infection	I
,	O
chlamydia	B
,	O
gonorrhea	B
,	O
or	O
trichomonas	B
.	O

Active	B
syphilis	B
documented	O
by	O
serology	B
unless	B
positive	B
serology	B
is	O
due	O
to	O
past	O
treated	B
infection	I

Has	O
had	O
a	O
thyroidectomy	B
or	O
active	B
thyroid	B
disease	I
requiring	O
medication	B
during	B
the	I
last	I
12	I
months	I
(	O
not	B
excluded	I
:	O
a	O
stable	B
thyroid	B
supplementation	I
)	O

Has	O
had	O
major	B
psychiatric	B
illness	I
and	O
/	O
or	O
substance	B
abuse	I
problems	O
during	B
the	I
past	I
12	I
months	I
(	O
including	O
hospitalization	B
or	O
periods	O
of	O
work	B
disability	I
)	O
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
would	O
preclude	O
participation	O

Has	O
been	O
in	O
receipt	O
of	O
any	O
licensed	B
vaccine	I
within	B
14	I
days	I
prior	I
to	O
the	O
first	O
dose	O
of	O
study	B
vaccine	I
/	O
placebo	B
,	O
plans	O
to	O
receive	O
within	B
14	I
days	I
after	I
the	O
first	O
study	B
vaccination	I
,	O
or	O
plans	O
to	O
receive	O
within	B
14	I
days	I
before	I
or	I
after	I
the	O
second	O
,	O
third	O
or	O
fourth	O
vaccination	B

Is	O
a	O
recipient	O
of	O
a	O
prophylactic	B
or	O
therapeutic	B
HIV	B
vaccine	I
candidate	I
at	B
any	I
time	I
,	O
or	O
a	O
recipient	O
of	O
other	B
experimental	I
vaccine	I
(	I
s	I
)	I
within	B
the	I
last	I
12	I
months	I
.	O

For	O
participants	O
who	O
received	O
an	O
experimental	B
vaccine	I
(	O
except	B
HIV	B
vaccine	I
)	O
more	B
than	I
12	I
months	I
ago	I
,	O
documentation	O
of	O
the	O
identity	O
of	O
the	O
experimental	O
vaccine	O
must	O
be	O
provided	O
to	O
the	O
sponsor	O
,	O
who	O
will	O
determine	O
eligibility	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O

Are	O
negative	B
for	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
infection	O
at	B
screening	I

Is	O
healthy	B
on	O
the	O
basis	O
of	O
physical	B
examination	I
,	O
medical	B
history	I
,	O
electrocardiogram	B
(	I
ECG	I
)	I
,	O
and	O
vital	B
signs	I
measurement	I
performed	O
at	B
screening	I

Are	O
willing	O
/	O
able	O
to	O
adhere	O
to	O
the	O
prohibitions	O
and	O
restrictions	O
specified	O
in	O
the	O
protocol	O
and	O
study	O
procedures	O

Female	B
participants	O
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
serum	B
pregnancy	I
test	I
(	O
beta	B
human	I
chorionic	I
gonadotropin	I
[	I
beta	I
hCG	I
]	I
)	O
at	B
the	I
Screening	I
visit	I
,	O
and	O
a	O
negative	B
urine	B
pregnancy	I
test	I
pre	B
-	I
dose	I
on	I
Day	I
1	I

Are	O
assessed	O
by	O
the	O
clinic	O
staff	O
as	O
being	O
at	O
low	B
risk	I
for	O
HIV	B
infection	I

More	B
than	I
three	I
doses	I
of	O
any	O
opioid	B
within	B
one	I
week	I
of	I
surgery	I

Pregnancy	B

Prisoners	B

Unable	O
to	O
provide	O
consent	O

Emergency	B
surgery	I

Chronic	B
kidney	I
disease	I
stage	B
5	I
(	O
GFR	B
<	B
15	I
ml	I
/	I
min	I
)	I

Severe	B
hepatic	B
impairment	I

Recent	O
myocardial	B
infarction	I
(	O
within	O
the	B
last	I
3	I
months	I
)	O

Major	B
spine	I
surgery	I
scheduled	O
as	O
part	O
of	O
clinical	O
care	O

18	B
-	I
80	I
years	B

Age	B
less	B
than	I
18	I
years	I

Significant	B
arterial	B
disease	I
(	O
Ankle	B
Brachial	I
Pressure	I
Index	I
<	B
0	I
•	I
9	I
or	O
evidence	O
on	O
Arterial	B
Duplex	I
)	O

Acute	B
Deep	I
Vein	I
Thrombosis	I

Patient	O
unable	O
or	O
unwilling	O
to	O
have	O
high	O
compression	O
(	O
30mmHg	O
minimum	O
)	O

Patients	O
with	O
dexterity	B
insufficiency	I
of	I
hands	I

Patients	O
with	O
peripheral	B
neuropathy	I

Leg	B
ulcers	I
of	O
another	B
underlying	B
cause	I

Leg	B
ulcers	I
of	O
greater	B
than	I
1	I
year	I
duration	I

Patients	O
unable	O
or	O
unwilling	O
to	O
provide	O
written	O
,	O
informed	O
consent	O

Age	B
>	B
18	I
years	I
old	I

1cm	B
squared	I
surface	B
area	I

Venous	B
incompetence	I
confirmed	O
by	O
clinical	B
assessment	I
and	O
duplex	B
ultrasound	I
scan	I

No	B
evidence	O
of	O
arterial	B
disease	I
(	O
Arterial	B
Duplex	I
or	O
Ankle	B
Brachial	I
Pressure	I
Index	I
>	B
0	I
.	I
9	I
)	O

Patients	O
able	O
to	O
complete	O
trial	O
procedures	O

Patients	O
with	O
a	O
life	O
expectancy	O
of	O
greater	B
than	I
1	I
year	I

Cholesterol	B
-	I
lowering	I
drugs	I

Diabetes	B
Mellitus	I

Cardiovascular	B
disease	I
such	O
as	O
arrythmia	B
,	O
ischaemic	B
heart	I
disease	I
.	O

Musculoskeletal	B
disorders	I
preventing	B
the	I
subject	I
to	I
perform	I
physical	I
training	I

Mental	B
disorders	I
preventing	B
the	I
subject	I
to	I
understand	I
the	I
project	I
description	I
.	O

Elevated	B
blood	B
-	I
cholesterol	I

Acute	B
coronary	I
syndrome	I
within	B
1	I
month	I

Heart	B
failure	I
NYHA	B
III	B
to	I
IV	I

Contraindication	B
to	O
Aspirin	B

On	O
anticoagulant	B
therapy	I

Emergent	B
surgery	I

Cardiac	B
surgery	I

High	B
bleeding	I
risk	I
surgeries	I
,	O
e	O
.	O
g	O
.	O
,	O
Intra	B
-	I
cranial	I
surgery	I
,	O
Intra	B
-	I
spinal	I
surgery	I
,	O
Retinal	B
surgery	I

Pregnancy	B
or	O
breast	B
-	I
feeding	I

Life	O
expectancy	O
less	B
than	I
1year	I

Planned	O
non	B
-	I
cardiac	I
surgery	I
at	O
least	O
after	O
12	O
months	O
of	O
implantation	B
of	O
drug	B
eluting	I
stent	I

Low	O
or	O
intermediate	B
risk	I
level	I
surgery	I

Written	O
informed	O
consent	O

cognitive	B
impairment	I
(	O
Mini	B
-	I
Mental	I
Status	I
Examination	I
score	I
:	O
illiterate	O
13	B
points	I
;	O
elementary	O
and	O
middle	O
school	O
18	B
points	I
;	O
and	O
high	O
-	O
school	O
26	B
points	I
;	O
or	O
inability	B
to	I
respond	I
to	I
verbal	I
command	I
)	O
;	O

inability	B
to	I
walk	I
independently	I
for	O
at	B
least	I
10	I
minutes	I
,	O
with	O
or	O
without	O
walking	B
devices	I
;	O

pain	B
or	O
other	B
disorders	I
precluding	B
their	I
participation	I
.	O

=	B
20years	I
of	O
age	B
;	O

diagnosis	O
of	O
stroke	B
(	O
>	B
6months	I
)	O
;	O

sedentary	O
or	O
insufficiently	O
active	O
;	O

have	O
a	O
writing	O
medical	O
permission	O
to	O
participate	O
in	O
the	O
training	O
program	O
.	O

Left	B
main	I
disease	I

Known	O
hypersensitivity	B
or	O
contraindication	B
to	O
any	O
of	O
the	O
following	O
medications	O
:	O
Heparin	B
,	O
aspirin	B
,	O
clopidogrel	B
,	O
sirolimus	B
,	O
siptagliptin	B
and	O
statin	B

Congestive	B
heart	I
failure	I
(	O
patients	O
with	O
LVEF	B
<	B
30	I
%	I
or	O
cardiogenic	B
shock	I
)	O

Uncontrolled	B
myocardial	B
ischemia	I
(	O
repeated	B
chest	B
pain	I
or	O
dyspnea	B
after	O
revascularization	B
)	O

Uncontrolled	B
ventricular	B
arrhythmia	I

History	O
of	O
malignancy	B
with	O
chemotherapy	B

Serious	B
hematologic	B
disease	I
(	O
e	O
.	O
g	O
.	O
CML	B
,	O
MDS	B
)	O

Current	O
infectious	B
disease	I
needs	O
antibiotics	B
therapy	O

Creatinine	B
level	I
>	B
1	I
.	I
5	I
mg	I
/	I
dL	I
or	O
dependence	O
on	O
dialysis	B

Other	O
severe	B
concurrent	B
illness	B
(	O
e	O
.	O
g	O
.	O
active	B
infection	I
,	O
malignancy	B
)	O
.	O

Life	O
expectancy	O
of	O
less	B
than	I
one	I
year	I

Pregnancy	O
or	O
women	O
with	O
potential	O
childbearing	O

Type	B
I	I
DM	I

Treatment	O
with	O
insulin	B

History	O
of	O
pancreatitis	B

Who	O
cannot	O
read	O
the	O
informed	O
consent	O
form	O
(	O
e	O
.	O
g	O
.	O
illiteracy	O
,	O
foreigner	O
)	O

Non	B
-	I
ST	I
segement	I
elevation	I
acute	B
coronary	I
syndrome	I

coagulopathy	B

allergy	B
to	O
to	O
local	B
anesthetics	I

depression	B
,	O
antidepressant	B
drugs	I
treatment	O

epilepsy	B

usage	O
of	O
painkiller	B
before	B
surgery	I

addiction	B
to	I
alcohol	I
or	O
recreational	O
drugs	O

obtained	O
consent	O

singleton	B
pregnancy	B

subarachnoid	B
anaesthesia	I

1	O
)	O
pregnancy	O
,	O
breast	O
-	O
feeding	O
women	O
,	O
or	O
female	O
patients	O
of	O
childbearing	O
potential	O
but	O
did	O
not	O
take	O
contraceptive	O
measures	O
;	O
2	O
)	O
existing	O
severe	B
acute	B
infection	B
and	O
is	O
not	B
controlled	I
;	O
or	O
purulent	B
and	O
chronic	B
infection	B
,	O
delayed	B
healing	I
wounds	I
;	O
3	O
)	O
the	O
original	O
severe	B
heart	B
disease	I
,	O
including	O
congestive	B
heart	I
failure	I
,	O
uncontrolled	B
high	B
-	I
risk	I
arrhythmias	B
,	O
unstable	B
angina	I
,	O
myocardial	B
infarction	I
,	O
severe	B
heart	B
valve	I
disease	I
and	O
resistant	B
hypertension	B
;	O
4	O
)	O
suffering	O
from	O
neurological	O
and	O
psychiatric	B
diseases	I
or	O
mental	B
disorders	I
is	O
not	O
easy	O
to	O
control	O
,	O
poor	B
compliance	I
,	O
and	O
can	O
not	O
be	O
described	O
with	O
treatment	O
responders	O
;	O
primary	O
brain	O
or	O
central	B
nervous	I
metastasis	I
disease	I
has	O
not	B
been	O
controlled	B
,	O
with	O
significant	B
cranial	B
hypertension	I
or	O
neuropsychiatric	B
symptoms	I
;	O
5	O
)	O
have	O
bleeding	B
tendencies	I
;	O
6	O
)	O
other	O
researchers	O
believe	O
that	O
patients	O
should	O
not	O
participate	O
in	O
the	O
present	O
trial	O
.	O

1	O
)	O
histologically	B
confirmed	I
(	O
patients	O
not	O
receiving	O
a	O
single	O
sputum	O
cytology	O
diagnosis	O
)	O
non	B
-	I
small	I
cell	I
lung	I
cancer	I
patients	O
,	O
with	O
wild	B
-	I
type	I
EGFR	I
and	O
ALK	B
-	I
negative	I
;	O
2	O
)	O
According	O
to	O
IASLC2009	B
new	I
TNM	I
staging	I
of	O
lung	B
cancer	I
stage	B
<	I
U	I
+	I
2162	I
>	I
B	I
or	I
<	I
U	I
+	I
2163	I
>	I
,	O
previously	O
untreated	B
or	O
relapsed	B
after	B
1	I
year	I
of	I
lung	I
cancer	I
resection	I
;	O
3	O
)	O
have	O
at	B
least	I
one	I
evaluable	B
lesions	I
,	O
according	O
to	O
version	O
1	O
.	O
1	O
of	O
the	O
standard	O
in	O
accordance	O
with	O
a	O
judgment	O
RECIST	O
(	O
longest	B
diameter	I
on	O
a	O
spiral	B
CT	I
at	B
least	I
10mm	I
,	O
on	O
a	O
regular	B
CT	I
longest	B
diameter	I
at	B
least	I
20mm	I
)	O
;	O
4	O
)	O
Male	B
or	O
female	B
,	O
aged	B
18	B
to	I
75	I
years	I
;	O
5	O
)	O
ECOG	B
PS	I
0	B
or	I
1	I
;	O
6	O
)	O
expected	O
survival	O
at	B
least	I
3	I
months	I
;	O
7	O
)	O
adequate	B
hematological	I
function	I
:	O
absolute	B
neutrophil	I
count	I
(	I
ANC	I
)	I
at	B
least	I
2	I
×	I
10	I
^	I
9	I
/	I
L	I
and	O
platelet	B
count	I
at	B
least	I
100	I
×	I
10	I
^	I
9	I
/	I
L	I
and	O
hemoglobin	B
at	B
least	I
9	I
g	I
/	I
dL	I
;	O
8	O
)	O
adequate	B
liver	I
function	I
:	O
total	B
bilirubin	I
less	B
than	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
;	O
AST	B
and	O
ALT	B
less	B
than	I
2	I
.	I
5	I
times	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
;	O
alkaline	B
phosphatase	I
less	B
than	I
5	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
;	O
9	O
)	O
adequate	B
renal	I
function	I
:	O
serum	B
creatinine	I
less	B
than	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
or	O
calculated	B
creatinine	I
clearance	I
at	B
least	I
60	I
mL	I
/	I
min	I
;	O
10	O
)	O
ECG	B
is	O
normal	B
,	O
there	O
is	O
no	B
non	B
-	I
healing	I
wounds	I
on	I
the	I
body	I
;	O
11	O
)	O
had	O
not	B
received	I
previous	O
treatment	O
anticancer	B
drugs	I
,	O
or	O
had	O
only	O
received	O
for	O
previous	B
non	B
-	I
metastatic	I
tumors	I
adjuvant	B
or	O
neoadjuvant	B
chemotherapy	B
,	O
but	O
when	O
you	O
start	O
to	O
study	O
treatment	O
has	O
ended	B
more	I
than	I
6	I
months	I
;	O
12	O
)	O
have	O
conducted	O
previous	O
surgery	O
patients	O
required	O
to	O
study	O
treatment	O
was	O
started	O
more	O
than	O
four	O
weeks	O
,	O
and	O
the	O
patient	O
had	O
recovered	O
;	O
13	O
)	O
have	O
an	O
intact	O
uterus	O
in	O
women	O
prior	O
to	O
enrollment	O
in	O
the	O
study	O
must	O
have	O
a	O
negative	O
pregnancy	O
test	O
result	O
(	O
unless	O
it	O
is	O
already	O
24	O
months	O
of	O
amenorrhea	O
)	O
within	O
28	O
days	O
.	O
If	O
the	O
pregnancy	O
test	O
from	O
the	O
first	O
administration	O
more	O
than	O
seven	O
days	O
,	O
urine	O
pregnancy	O
test	O
is	O
required	O
for	O
authentication	O
(	O
less	O
than	O
7	O
days	O
before	O
the	O
first	O
dose	O
)	O
;	O
14	O
)	O
previous	O
to	O
biological	O
agents	O
,	O
particularly	O
E	O
.	O
coli	O
genetically	O
engineered	O
products	O
without	O
serious	O
allergic	O
reactions	O
;	O
15	O
)	O
signed	O
informed	O
consent	O
.	O

Pregnant	B
and	O
/	O
or	O
nursing	B
mothers	O
.	O

Allergy	B
to	O
bupivacaine	B
.	O

History	B
of	O
drug	B
/	I
alcohol	I
abuse	I
.	O

Severe	O
cardiovascular	O
,	O
hepatic	O
,	O
renal	B
disease	I
or	O
neurological	B
impairment	I
.	O

Patients	O
undergoing	O
urologic	B
surgery	I
.	O

Use	O
of	O
investigational	O
drugs	O
either	O
within	O
5	O
half	O
-	O
lives	O
of	O
enrollment	O
,	O
or	O
within	O
30	O
days	O
,	O
or	O
until	O
the	O
expected	O
pharmacodynamic	O
effect	O
has	O
returned	O
to	O
baseline	O
,	O
whichever	O
is	O
longer	O
.	O

Major	B
surgery	I
in	O
the	O
last	B
3	I
months	I
prior	I
to	I
baseline	I
or	I
planned	I
major	I
surgery	I
or	I
cardiac	I
intervention	I
during	I
the	I
study	I
.	O

Cancer	B
or	O
other	O
significant	O
co	B
-	I
morbidities	I
implying	O
that	O
the	O
patient	O
'	O
s	O
condition	O
is	O
unstable	O
.	O

Comorbidities	B
that	O
can	O
be	O
associated	O
with	O
elevated	B
natriuretic	O
peptide	O
(	O
NP	B
)	O
levels	O
:	O
renal	B
insufficiency	I
,	O
(	O
eGFR	B
<	B
25	I
ml	I
/	I
min	I
/	I
1	I
.	I
73	I
m²	I
calculated	O
according	O
to	O
MDRD	O
formula	O
)	O
,	O
recent	O
(	O
less	B
than	I
3	I
months	I
)	O
cerebral	B
trauma	I
or	O
recent	O
(	O
less	B
than	I
3	I
months	I
)	O
cerebrovascular	B
incident	I
,	O
novel	O
diagnosis	O
or	O
acute	B
exacerbation	I
of	I
COPD	I
within	O
the	O
last	B
3	I
months	I
.	O

Patients	O
who	O
are	O
primarily	O
managed	O
and	O
regularly	O
followed	O
-	O
up	O
by	O
a	O
cardiologist	O
for	O
their	O
HF	O

Highly	O
frail	O
patients	O
whose	O
estimated	O
lifespan	O
due	O
to	O
comorbidities	O
by	O
the	O
judgement	O
of	O
the	O
investigator	O
is	O
less	B
than	I
6	I
months	I
.	O

Willing	O
and	O
able	O
to	O
provide	O
written	O
informed	O
consent	O
and	O
accept	O
study	O
procedures	O
and	O
time	O
schedule	O
.	O

Age	B
=	B
18	I
years	I
.	O

Patients	O
suffering	O
from	O
chronic	B
heart	I
failure	I
(	O
the	O
heart	O
failure	O
diagnosis	O
must	O
have	O
been	O
made	O
or	O
confirmed	O
by	O
a	O
cardiologist	O
and	O
/	O
or	O
hospital	O
physician	O
at	O
any	O
time	O
in	O
the	O
patient	O
'	O
s	O
medical	O
history	O
)	O
.	O

Patients	O
with	O
reduced	O
ejection	B
fraction	I
(	O
=	B
40	I
%	I
)	O
as	O
confirmed	O
at	O
any	O
time	O
point	O
in	O
the	O
patient	O
'	O
s	O
medical	O
history	O
.	O

Patients	O
undergoing	O
bilateral	B
hip	O
or	O
knee	B
replacement	I
;	O

Patients	O
undergoing	O
total	B
hip	I
or	I
knee	I
replacement	I
who	O
have	O
been	O
enrolled	O
in	O
this	O
study	O
for	O
a	O
prior	O
hip	O
or	O
knee	O
replacement	O
;	O

Patients	O
who	O
are	O
concurrently	O
enrolled	O
in	O
another	O
active	O
interventional	O
clinical	O
trial	O
testing	O
a	O
drug	O
or	O
intervention	O
known	O
or	O
believed	O
to	O
interact	O
with	O
aspirin	O
,	O
warfarin	O
,	O
or	O
rivaroxaban	O
;	O

Patients	O
who	O
have	O
a	O
contraindication	B
to	O
two	O
or	O
more	O
of	O
the	O
three	O
study	O
prophylaxis	O
regimens	O
;	O

Women	O
who	O
are	O
pregnant	O
or	O
breastfeeding	O
,	O
as	O
well	O
as	O
those	O
of	O
reproductive	O
potential	O
unless	O
there	O
is	O
a	O
negative	O
urine	O
pregnancy	O
test	O
on	O
the	O
day	O
of	O
surgery	O
;	O

Patients	O
on	O
chronic	O
(	O
longer	B
than	I
the	I
prior	I
6	I
months	I
)	O
anticoagulation	B
other	B
than	I
with	O
antiplatelet	B
medications	O
;	O

Patients	O
with	O
documented	O
gastrointestinal	O
,	O
cerebral	O
,	O
or	O
other	O
hemorrhage	B
within	B
3	I
months	I
of	I
the	I
operation	I
;	O

Patients	O
with	O
a	O
known	O
diagnosis	O
of	O
defective	B
hemostasis	B
and	O
past	O
history	O
of	O
clinical	O
bleeding	B
requiring	O
transfusion	B
and	O
treatment	B
;	O

Patients	O
who	O
have	O
had	O
an	O
operative	B
procedure	I
involving	O
the	O
eye	B
,	O
ear	B
,	O
or	O
central	B
nervous	I
system	I
within	B
one	I
month	I
;	O

Patients	O
with	O
severe	B
uncontrolled	B
hypertension	B
with	O
systolic	B
BP	I
>	B
220mmHg	I
or	O
diastolic	B
BP	I
>	B
120mmHg	I
;	O

Patients	O
with	O
an	O
absolute	O
body	B
weight	I
of	O
less	B
than	I
41	I
kilograms	I
(	O
90	B
.	I
4	I
lbs	I
)	O
at	O
baseline	O
visit	O
;	O

Vulnerable	O
patient	O
populations	O
including	O
prisoners	B
and	O
institutionalized	O
individuals	O
.	O

Males	B
and	O
females	B
21	O
years	O
of	O
age	B
or	O
older	O
;	O

Undergoing	O
elective	B
primary	B
,	O
resurfacing	B
arthroplasty	I
,	O
revision	B
,	O
or	O
second	B
stage	I
re	I
-	I
implantation	I
total	B
hip	I
replacement	I
;	O

Undergoing	O
elective	B
primary	B
,	O
revision	B
,	O
or	O
second	B
stage	I
re	I
-	I
implantation	I
total	I
or	O
uni	B
compartmental	I
knee	B
replacement	I
;	O

Patient	O
has	O
necessary	O
mental	O
capacity	O
to	O
participate	O
and	O
is	O
able	O
to	O
comply	O
with	O
study	O
protocol	O
requirements	O
;	O

Patient	O
is	O
willing	O
and	O
able	O
to	O
give	O
informed	O
consent	O
;	O
and	O

Patient	O
is	O
willing	O
to	O
be	O
randomized	O
and	O
participate	O
.	O

Contraindication	B
to	O
Filgrastim	B

Histologically	B
confirmed	O
primary	B
breast	I
cancer	I

Planned	O
to	O
start	O
docetaxel	B
component	O
of	O
FEC	B
-	I
D	I
or	O
AC	B
-	I
D	I
,	O
or	O
first	B
cycle	I
of	I
;	O
dose	B
-	I
dense	I
AC	I
-	I
T	I
,	O
TC	B
,	O
FEC	B
-	I
D	I
or	O
TAC	B
chemotherapy	I

=	B
19	I
years	I
of	O
age	B

Able	O
to	O
provide	O
verbal	O
consent	O

Non	B
diabetic	I
nephropathy	I
(	O
confirmed	O
by	O
biopsy	B
)	O
.	O

Dialysis	B
for	O
acute	B
renal	I
failure	I
within	B
the	I
6	I
previous	I
months	I
.	O

Evidence	O
in	O
the	O
clinic	O
history	O
of	O
relevant	B
bilateral	B
stenosis	B
of	I
renal	I
artery	I
(	O
>	B
75	I
%	I
)	O

Urinary	B
albumin	I
/	I
creatinine	I
ratio	I
higher	B
than	I
3000	I
mg	I
/	I
g	I
,	O
at	B
the	I
baseline	I
visit	I
.	O

Systolic	B
blood	I
pressure	I
=	B
180	I
mmHg	I
or	O
diastolic	B
blood	I
pressure	I
=	B
110	I
mm	I
Hg	I
at	B
the	I
baseline	I
visit	I
.	O

Stroke	B
,	O
transient	B
ischemic	I
attack	I
,	O
acute	B
coronary	I
syndrome	I
,	O
or	O
hospitalization	B
for	O
heart	B
failure	I
worsening	B
,	O
within	B
the	I
previous	I
30	I
days	I
.	O

Professional	B
drivers	I
,	O
risk	B
profession	I
or	O
respiratory	B
failure	I
.	O

Severe	B
daytime	B
sleepiness	I
(	O
Epworth	B
sleepiness	I
scale	I
>	B
18	I
)	O

Concomitant	B
treatment	B
with	O
high	B
doses	I
of	O
acetylsalicylic	B
acid	I
(	O
>	B
500	I
mg	I
/	I
day	I
)	O
or	O
continuous	B
treatment	B
with	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drugs	I

Previous	B
treatment	B
with	O
CPAP	B

Participation	O
in	O
another	O
clinical	O
trial	O
within	O
the	O
30	O
days	O
prior	O
to	O
randomization	O
.	O

Subjects	O
aged	B
18	B
to	I
80	I
years	I
old	I

Overweight	B
or	O
obesity	B
(	O
BMI	B
=	B
25	I
kg	I
/	I
m2	I
)	O

Previous	B
diagnosis	O
of	O
type	B
2	I
diabetes	I
,	O
fulfilling	O
at	B
least	I
one	I
of	O
the	O
following	O
criteria	O
:	O
1	O
)	O
current	B
treatment	O
with	O
oral	B
antidiabetic	I
drugs	I
and	O
/	O
or	O
insulin	B
;	O
2	O
)	O
a	O
fasting	B
glucose	I
value	O
above	B
126	I
mg	I
/	I
dl	I
on	B
at	I
least	I
2	I
occasions	I
;	O
3	O
)	O
blood	B
glucose	I
level	I
at	O
2	O
hours	O
after	O
an	O
oral	B
glucose	I
tolerance	I
test	I
is	O
equal	B
to	I
or	I
more	I
than	I
200	I
mg	I
/	I
dl	I
;	O
or	O
4	O
)	O
a	O
glycated	B
hemoglobin	I
(	I
HbA1c	I
)	I
level	I
>	B
6	I
.	I
5	I
%	I

Clinical	O
diagnosis	O
of	O
diabetic	B
nephropathy	I
,	O
with	O
a	O
urinary	B
albumin	I
/	I
creatinine	I
ratio	I
>	B
30	I
mg	I
/	I
g	I
and	O
an	O
estimated	B
glomerular	I
filtration	I
rate	I
more	B
than	I
20	I
ml	I
/	I
min	I
per	I
1	I
.	I
73	I
m2	I
.	O

Treatment	O
with	O
stable	B
doses	I
of	O
angiotensin	B
-	I
converting	I
enzyme	I
inhibitors	I
,	O
angiotensin	B
II	I
receptor	I
blockers	I
or	O
anti	B
-	I
aldosterone	I
agents	I
in	B
the	I
last	I
four	I
weeks	I
.	O

Patients	O
having	O
had	O
an	O
ophthalmic	B
surgical	I
procedure	I
within	B
6	I
months	I
of	I
the	I
beginning	I
of	I
the	I
study	I
.	O

Patients	O
with	O
a	O
diagnosis	O
of	O
glaucoma	B

Any	O
abnormality	B
of	O
the	O
cornea	B
which	O
may	O
prevent	O
reliable	O
applanation	O
tonometry	O

Known	O
allergy	B
/	O
hypersensitivity	B
reaction	O
to	O
Brimonidine	B

Contra	B
-	I
indication	I
to	O
Brimonidine	B
including	O
patients	O
on	O
monoamine	B
oxidase	I
inhibitors	I
(	O
MOA	B
)	O

Patients	O
unwilling	O
or	O
unable	O
to	O
provide	O
informed	O
consent	O

Patients	O
with	O
anticipated	O
difficult	O
airway	O
management	O
(	O
as	O
this	O
may	O
require	O
medications	O
and	O
/	O
or	O
airway	O
manipulations	O
resulting	O
in	O
increased	O
IOP	O
)	O

Males	B
aged	B
18	B
years	I
and	I
above	I

Patients	O
with	O
a	O
diagnosis	O
of	O
prostatic	B
carcinoma	I
requiring	O
prostate	B
surgery	I

PCOS	B
patients	O

Allergy	B
to	O
gonadotrophins	B

Concomitant	O
participation	O
in	O
other	O
trial	O

Premenopausal	B
women	B

18	B
-	I
35	I
years	I
old	B

FSH	B
levels	I
<	B
10	I
mIU	I
/	I
ml	I

AFC	B
>	B
10	I

Regular	B
cycles	I

BMI	B
<	B
28	I

Signed	O
informed	O
consent	O

Patients	O
unable	O
to	O
give	O
informed	O
consent	O
.	O

Any	O
patient	O
whose	O
condition	B
will	O
not	B
allow	O
for	O
placement	B
of	O
the	O
electrode	B
PadSet	I
.	O

Patients	O
whose	O
tracheas	B
were	O
not	B
extubated	B
in	O
OR	O
or	O
PACU	O
.	O

Patients	O
with	O
Impaired	B
Renal	I
Function	I
with	O
a	O
have	O
a	O
known	O
estimated	B
CrCl	I
<	B
30	I
ml	I
/	I
min	I

Patients	O
using	O
oral	B
contraception	I
.	O

Patients	O
undergoing	B
surgery	B
with	O
general	B
anesthesia	I
,	O

Patients	O
weighing	B
=	B
80	I
pounds	I
who	O
are	O
not	B
-	O
intubated	B
prior	O
to	O
surgery	B
,	O

Patients	O
who	O
are	O
able	O
to	O
give	O
informed	O
consent	O
.	O

The	O
use	O
of	O
weight	B
-	I
lowering	I
drugs	B
,	O
any	O
investigational	B
blood	B
-	I
glucose	I
or	O
lipid	B
-	I
lowering	I
agent	B
(	O
other	B
than	O
statins	B
or	O
ezetimibe	B
)	O
within	O
the	O
past	B
3	I
months	I

Previous	O
treatment	O
with	O
systemic	B
corticosteroids	I
or	O
a	O
change	B
in	I
dosage	I
of	O
thyroid	B
hormones	I
in	O
the	O
previous	B
6	I
weeks	I

The	O
use	O
of	O
insulin	B
within	B
the	I
3	I
months	I
prior	I
to	I
screening	I

Others	O

Type	B
2	I
Diabetes	I
Mellitus	I
patients	O

Patient	O
who	O
had	O
been	O
diagnosed	O
within	O
the	O
previous	B
12	I
months	I
with	O
HbA1c	B
levels	O
of	O
8	B
.	I
0	I
-	I
12	I
.	I
0	I
%	I
,	O
did	O
not	B
have	O
a	O
medical	B
history	I
related	I
to	I
diabetes	I
,	O
and	O
did	O
not	B
display	O
proliferative	B
retinopathy	I

PGD	B
patients	O

More	B
than	I
4	I
previous	B
embryo	B
transfers	I

20	B
-	I
40	I
years	I
old	B
women	B

Spontaneously	B
ovulating	I
women	B

Treated	O
in	O
our	O
IVF	O
unit	O
for	O
frozen	B
-	I
thawed	I
embryo	I
transfer	I

At	B
least	I
one	I
top	B
quality	I
embryo	I

Previous	B
vaginal	B
delivery	I
.	O

Submucous	B
myoma	I
.	O

Uterine	B
anomalies	I
.	O

Undiagnosed	B
vaginal	B
bleeding	I
.	O

Pelvic	B
inflammatory	I
disease	I
.	O

Women	B
with	O
expected	O
difficult	B
IUD	B
insertion	I
like	O
nulliparous	O
women	B
and	O
women	B
with	O
previous	B
cesarean	B
section	I
.	O

Preoperative	B
renal	B
failure	I
(	O
defined	O
as	O
a	O
serum	B
creatinine	I
>	B
2	I
.	I
0	I
mg	I
/	I
dL	I
.	O
)	O

American	B
Society	I
of	I
Anesthesiologists	I
Physical	I
Status	I
IV	B
or	I
V	I

Pulmonary	B
disease	I
necessitating	O
home	B
oxygen	I
therapy	I

Allergy	O
to	O
methadone	B
,	O
hydromorphone	B
,	O
or	O
ketamine	B

Preoperative	B
recent	B
history	B
of	O
opioid	O
or	O
alcohol	B
abuse	I

Significant	B
liver	B
disease	I

Inability	O
to	O
use	O
a	O
PCA	B
device	I
or	O
speak	O
the	O
English	O
language	O

Patients	O
presenting	O
for	O
elective	B
posterior	B
spinal	I
fusion	I
surgery	I
(	O
lower	B
thoracic	I
,	O
lumbar	B
,	O
sacral	B
)	O

Ages	B
18	B
-	I
80	I

Unable	O
or	O
unwilling	O
to	O
provide	O
informed	O
consent	O
.	O

Active	B
ischemia	B
(	O
acute	B
thrombus	I
diagnosed	O
by	O
coronary	B
angiography	I
,	O
or	O
dynamic	O
ST	B
segment	I
changes	I
demonstrated	O
on	O
ECG	B
)	O
or	O
another	O
reversible	B
cause	O
of	O
VT	B
(	O
e	O
.	O
g	O
.	O
drug	B
-	I
induced	I
arrhythmia	I
)	O
,	O
had	O
recent	O
acute	B
coronary	I
syndrome	I
within	B
30	I
days	I
,	I
coronary	B
revascularization	I
(	O
<	B
90	I
days	I
bypass	B
surgery	I
,	O
<	B
30	I
days	I
percutaneous	B
coronary	I
intervention	I
)	O
,	O
or	O
have	O
CCS	B
functional	I
class	I
IV	B
angina	B
.	O

Note	O
that	O
biomarker	O
level	O
elevation	O
alone	O
after	O
ventricular	O
arrhythmias	O
does	O
not	O
denote	O
acute	O
coronary	O
syndrome	O
or	O
active	O
ischemia	O
.	O

Are	O
ineligible	O
to	O
take	O
the	O
antiarrhythmic	B
drug	I
to	O
which	O
they	O
would	O
be	O
assigned	O
due	O
to	O
allergy	B
,	O
intolerance	B
or	O
contraindication	B

Are	O
known	O
to	O
have	O
protruding	O
left	B
ventricular	I
thrombus	I
or	O
mechanical	B
aortic	I
and	I
mitral	I
valves	I

Have	O
had	O
a	O
prior	O
catheter	B
ablation	I
procedure	I
for	O
VT	B

Are	O
in	O
renal	B
failure	I
(	O
Creatinine	B
clearance	I
<	B
15	I
mL	I
/	I
min	I
)	O
,	O
have	O
NYHA	B
Functional	I
class	I
IV	B
heart	B
failure	I
,	O
or	O
a	O
systemic	B
illness	I
likely	O
to	O
limit	O
survival	O
to	O
<	B
1	I
year	I

Have	O
had	O
recent	O
ST	B
elevation	I
myocardial	I
infarction	I
or	O
non	B
-	I
ST	I
elevation	I
MI	I
(	O
<	B
30	I
days	I
)	O
;	O
note	O
that	O
biomarker	O
elevation	O
alone	O
after	O
ventricular	O
arrhythmias	O
does	O
not	O
denote	O
MI	O
.	O

Are	O
pregnant	B
.	O

Prior	O
Myocardial	B
Infarction	I
and	O

Sustained	B
monomorphic	B
VT	I
documented	O
on	O
12	B
-	I
lead	I
ECG	I
or	O
rhythm	B
strip	I
terminated	O
by	O
pharmacologic	B
means	I
or	O
DC	B
cardioversion	I

=	O
3	B
episodes	I
of	O
VT	B
treated	O
with	O
antitachycardia	B
pacing	I
(	O
ATP	B
)	O
,	O
at	B
least	I
one	I
of	O
which	O
was	O
symptomatic	B

=	O
5	B
episodes	I
of	O
VT	B
treated	O
with	O
antitachycardia	B
pacing	I
(	O
ATP	B
)	O
regardless	O
of	O
symptoms	O

=	B
1	I
appropriate	O
ICD	B
shocks	I
,	O

=	O
3	O
VT	B
episodes	O
within	B
24	I
hours	I

Less	B
than	I
18	I
years	I
of	O
age	B
;	O

Pregnancy	B
;	O

Chronic	B
use	O
of	O
vitamin	B
K	I
antagonists	I
or	O
direct	B
thrombin	I
inhibitors	I
,	O
or	O
oral	B
Xa	I
-	I
factor	I
antagonists	I
;	O

Hypersensitivity	B
to	O
antiplatelet	O
and	O
/	O
or	O
anticoagulant	B
drugs	I
;	O

Active	B
bleeding	B
or	O
high	B
bleeding	I
risk	I
(	O
severe	B
liver	B
failure	I
,	O
active	B
peptic	B
ulcer	I
,	O
creatinine	B
clearance	I
<	B
30	I
mL	I
/	I
min	I
,	O
platelets	B
count	I
<	B
100	I
.	I
000	I
mm3	I
)	O
;	O

Uncontrolled	B
systemic	B
hypertension	I
;	O

Cardiogenic	B
shock	I
;	O

Previous	B
myocardial	B
revascularization	I
surgery	I
with	O
=	B
1	I
internal	O
mammary	O
or	O
radial	B
artery	I
graft	I
;	O

Documented	O
chronic	B
peripheral	B
arterial	I
disease	I
preventing	B
the	O
use	O
of	O
the	O
femoral	B
technique	I
;	O

Severe	B
concomitant	B
disease	B
with	O
life	O
expectancy	O
below	B
12	I
months	I
;	O

Participation	O
in	O
drug	O
or	O
devices	O
investigative	O
clinical	O
trials	O
in	O
the	O
last	O
30	O
days	O
;	O

Medical	O
,	O
geographic	O
or	O
social	O
conditions	O
impairing	O
the	O
participation	O
in	O
the	O
study	O
or	O
inability	O
to	O
understand	O
and	O
sign	O
the	O
informed	O
consent	O
term	O
.	O

ST	B
-	I
segment	I
elevation	I
acute	B
myocardial	I
infarction	I
patients	O
during	B
the	I
first	I
12	I
hours	I
of	I
sympton	I
onset	I
;	O

Intention	O
to	O
perform	O
primary	B
percutaneous	B
coronary	I
intervention	I
;	O

Signed	O
informed	O
consent	O
;	O

Patient	O
eligible	O
for	O
transradial	B
and	O
transfemoral	B
primary	B
percutaneous	B
coronary	I
intervention	I
,	O
being	O
pre	O
-	O
requisites	O
:	O
(	O
a	O
)	O
familiarity	O
of	O
the	O
operator	O
with	O
the	O
radial	O
and	O
femoral	O
techniques	O
using	O
vascular	O
closure	O
devices	O
,	O
(	O
b	O
)	O
agreement	O
of	O
the	O
operator	O
to	O
use	O
the	O
access	O
route	O
determined	O
by	O
the	O
randomization	O
process	O
.	O

Patients	O
with	O
high	B
intracranial	B
pressure	I
.	O

Patients	O
with	O
Multiple	B
Sclerosis	I
.	O

Patients	O
with	O
Guillain	B
-	I
Barré	I
syndrome	I
radiculopathy	I
of	O
vascular	B
origin	O
.	O

Patients	O
with	O
previous	O
lumbar	B
surgery	I
.	I

Patients	O
pregnant	O
or	O
lactating	O
.	O

Patients	O
with	O
allergy	B
or	O
intolerance	B
to	O
any	O
of	O
the	O
drugs	B
used	O
.	O

Patients	O
with	O
severe	B
cognitive	B
impairment	I
.	O

Patients	O
with	O
intrathecal	B
injectio	I
radiculalgia	I
.	O

Patients	O
with	O
poorly	B
controlled	I
major	B
psychiatric	B
pathology	I
.	O

Patients	O
with	O
type	B
I	I
diabetes	I
or	O
poorly	B
controlled	I
type	B
II	I
diabetes	I
(	O
Hb1Ac	B
>	B
8	I
.	I
5	I
)	O
.	O

Patients	O
with	O
glaucoma	B
.	O

Patients	O
with	O
caudal	B
equine	I
syndrome	I
.	O

Patients	O
with	O
pre	O
-	O
treatment	O
with	O
steroid	B
injections	I
/	O
or	O
local	B
anesthetics	I
.	O

Patients	O
with	O
central	B
canal	I
stenosis	I
.	O

patients	O
with	O
chronic	O
treatment	O
with	O
oral	B
corticosteroids	I
without	O
stabilized	O
pattern	O
.	O

Unilateral	B
leg	I
pain	I
secondary	O
to	O
lateral	B
stenosis	I
,	O
disc	B
protrusion	I
or	O
herniated	B
disc	I
.	O

Age	B
between	B
18	I
and	I
80	I
years	I
.	O

Moderate	B
to	O
severe	B
pain	B
(	O
NVS	B
>	B
4	I
)	I
.	O

Right	O
proficient	O
oral	O
and	O
written	O
language	O
.	O

advanced	O
chronic	O
disease	O
that	O
would	O
not	O
allow	O
the	O
patient	O
to	O
complete	O
the	O
treatment	O
or	O
follow	O
-	O
up	O
or	O
attend	O
visits	O

allergy	O
to	O
any	O
of	O
the	O
drugs	O
used	O
in	O
this	O
study	O

previous	O
Helicobacter	B
Pylori	I
eradication	I
treatment	I

pregnancy	O
or	O
breastfeeding	O
(	O
female	O
participants	O
with	O
childbearing	O
potential	O
were	O
required	O
to	O
use	O
medically	O
accepted	O
contraception	O
for	O
the	O
duration	O
of	O
the	O
study	O
)	O

taking	O
antibiotics	B
or	O
PPIs	B
or	O
bismuth	B
salts	I
within	B
four	I
weeks	I

previous	O
gastrointestinal	B
surgery	I

outpatients	O
aged	B
18	B
-	I
70	I
years	I

confirmed	O
diagnosis	O
of	O
H	B
.	I
pylori	I
infection	I
by	O
at	O
least	O
one	O
of	O
the	O
following	O
methods	O
:	O
13C	B
-	I
urea	I
breath	I
test	I
,	O
histology	B
,	O
rapid	B
urease	I
test	I
or	O
bacterial	B
culture	I

an	O
intention	O
of	O
H	O
.	O
pylori	O
eradication	O
treatment	O
and	O
have	O
written	O
inform	O
consent	O

ability	O
to	O
read	O
short	O
messages	O
on	O
the	O
mobile	O
phone	O

Sensitivity	B
to	O
pilocarpine	B

Secondary	B
Sjögren	B
'	I
s	I
syndrome	I
;	O

Type	B
II	I
diabetes	I
mellitus	I
;	O

AIDS	B
;	O

pregnant	O
or	O
lactating	O
women	O
;	O

Glaucoma	B
;	O

Uncontrolled	B
asthma	B
;	O

Chronic	B
obstructive	I
pulmonary	I
disease	I
;	O

Renal	B
diseases	I
;	O

Severe	B
cardiovascular	B
diseases	I
;	O

Gastrointestinal	B
disorders	I
;	O

Hepatic	B
insufficiency	I
.	O

Age	B
equal	B
or	I
superior	I
to	I
18	I
years	I
;	O

Both	O
genders	B
;	O

Lucid	B
and	O
without	B
diagnosis	O
of	O
any	O
psychiatric	B
disorder	I
;	O

Diagnosed	O
with	O
head	B
and	I
neck	I
cancer	I
and	O
treated	O
for	O
a	O
period	O
of	O
up	O
to	O
5	B
years	I
with	O
radiotherapy	B
where	O
the	O
major	B
salivary	I
glands	I
(	O
parotid	B
,	O
submandibular	B
and	O
sublingual	B
)	O
were	O
included	O
in	O
the	O
radiation	O
field	O
;	O

Primary	B
Sjögren	I
'	I
s	I
syndrome	I
with	O
the	O
diagnosis	O
made	O
by	O
the	O
American	B
-	I
European	I
criteria	I
.	O

Congestive	B
heart	I
failure	I
,	O
history	B
of	I
ventricular	B
tachycardia	I
,	O
ventricular	B
fibrillation	I
or	O
multifocal	B
ventricular	I
extrasystoles	I
or	O
QTc	B
prolongation	I
.	O

Patients	O
with	O
atrial	B
fibrillation	I
taking	O
any	O
anticoagulant	B
therapy	I
or	O
patients	O
with	O
a	O
history	B
of	I
cardioembolic	B
ischemic	B
stroke	I
or	O
hemorrhagic	B
stroke	I
.	O

Patients	O
with	O
a	O
history	B
(	O
=	B
12	I
months	I
)	O
of	O
acute	B
coronary	I
syndrome	I
receiving	O
dual	B
antiplatelet	I
therapy	I
,	O
or	O
patients	O
receiving	O
monotherapy	B
with	O
aspirin	B
.	O

Patients	O
with	O
hepatic	B
impairment	I
(	O
child	B
-	I
Pugh	I
staging	I
,	O
calibration	B
=	I
5	I
)	O
or	O
renal	B
impairment	I
(	O
creatinine	B
clearance	I
=	B
30ml	I
/	I
min	I
)	O
,	O
recent	B
peptic	B
ulcer	I
,	O
a	O
history	B
of	I
hypersensitivity	B
to	O
cilostazol	B
,	O
cancer	B
patients	O
undergoing	O
treatment	B
.	O

Patients	O
aged	B
=	B
50	I
years	I
with	O
DM2	B
and	O
symptomatic	B
PAD	B
diagnosed	O
clinically	O
(	O
according	O
to	O
Fontaine	B
criteria	I
,	O
stage	B
IIa	I
or	I
IIb	I
and	I
III	I
)	O
and	O
by	O
measuring	O
the	O
<	O
U	O
+	O
0391	O
>	O
<	O
U	O
+	O
0392	O
>	O
<	O
U	O
+	O
0399	O
>	O
.	O

Non	O
-	O
English	O
speaking	O
/	O
illiterate	O

Painful	B
active	O
,	O
concurrent	O
cervical	B
spine	I
conditions	I

Current	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drug	I
(	O
NSAID	B
)	O
use	O

History	O
of	O
taking	O
coumadin	B
or	O
similar	O
anticoagulant	B
,	O
have	O
a	O
known	O
coagulopathy	B
,	O
bleeding	B
dyscrasia	I
,	O
or	O
platelet	B
count	I
<	B
150	I
,	I
000	I
/	I
cubic	I
mm	I

Allergic	B
reaction	I
to	O
poultry	O
or	O
previous	O
viscosupplementation	O

Involved	O
in	O
workers	O
'	O
compensation	O
or	O
active	O
litigation	O
involving	O
affected	O
shoulder	O

Inability	O
to	O
refrain	O
from	O
NSAID	B
use	O
for	O
5	B
days	I
prior	I
to	I
and	I
6	I
weeks	I
after	I
injection	I

History	B
of	I
corticosteroid	B
injection	I
to	O
affected	O
shoulder	B
within	O
the	O
last	B
3	I
months	I

History	B
of	I
viscosupplementation	B
or	O
platelet	B
-	I
rich	I
plasma	I
to	O
affected	O
shoulder	B
within	O
the	O
last	B
6	I
months	I

Presence	O
of	O
acute	B
fracture	B

History	B
of	I
shoulder	B
tumor	I

Known	O
uncontrolled	B
systemic	B
illness	I
(	O
uncontrolled	B
diabetes	B
,	O
human	B
immunodeficiency	I
virus	I
,	O
vasculitis	B
,	O
autoimmune	B
/	O
inflammatory	B
disease	I
)	O

Psychiatric	O
and	O
somatoform	B
disorders	I

English	O
speaking	O
/	O
literate	O

Age	B
18	B
-	I
100	I
years	I

Visual	B
analog	I
score	I
pain	I
>	B
=	I
5	I

Greater	B
than	I
or	I
equal	I
to	I
3	I
months	I
of	O
pain	B
after	B
onset	I
of	I
symptoms	I
that	O
has	O
failed	O
conservative	B
treatments	I

Confirmation	O
of	O
glenohumeral	B
OA	I
via	O
imaging	B

Transient	B
relief	B
of	I
symptoms	I
after	O
diagnostic	O
intra	B
-	I
articular	I
injection	I
into	O
the	O
glenohumeral	B
joint	I

Patients	O
with	O
renal	B
impairment	I
(	O
serum	B
creatinine	I
more	B
than	I
twice	I
the	I
upper	I
limit	I
of	I
normal	I
)	O
.	O

Patients	O
with	O
heart	B
failure	I
.	O

Patients	O
with	O
sepsis	B
or	O
active	B
infection	I
.	O

Patients	O
with	O
diabetes	B
mellitus	I
(	O
either	O
primary	B
or	O
secondary	B
to	I
thalassemia	I
)	O
.	O

regular	O
consumption	O
of	O
medication	B
with	O
potential	O
hepatotoxicity	B
.	O

regular	O
herbal	B
medicine	I
or	O
antioxidant	B
supplementation	I
.	O

patients	O
with	O
gastrointestinal	O
conditions	O
preventing	O
adsorption	O
of	O
oral	O
medication	O
.	O

Diagnosed	O
with	O
Beta	B
-	I
Thalassemia	I
Major	I
and	O
receiving	O
regular	B
blood	B
transfusion	I
and	O
on	O
iron	B
chelating	I
therapy	I
.	O

Weight	B
:	O
equal	B
to	I
or	I
over	I
35	I
kg	I
.	O

Normal	B
renal	B
function	I
.	O

Type	B
1	I
diabetes	I

uncontrolled	B
diabetes	B
mellitus	I
type	I
2	I
with	O
fasting	B
glucose	I
>	B
13	I
.	I
3	I
mmol	I
/	I
l	I
confirmed	O
on	O
a	O
second	O
day	O

known	O
or	O
suspected	O
hypersensitivity	B
to	O
empagliflozin	B
,	O
glimepiride	B
,	O
or	O
any	O
excipients	O
;	O
and	O
/	O
or	O
known	O
or	O
suspected	O
hypersensitivity	B
to	O
sulfonylureas	B
,	O
sulfonamides	B
or	O
SGLT2	B
inhibitors	I
in	O
general	O

history	O
of	O
multiple	B
severe	B
hypoglycemic	B
episodes	I
within	O
the	O
last	B
two	I
years	I

use	O
of	O
Insulin	B
,	O
SGLT2	B
-	I
inhibitor	I
,	O
sulfonylurea	B
derivate	I
or	O
a	O
glinide	B
within	O
past	B
3	I
months	I

clinical	O
significant	O
macular	B
edema	I
in	O
both	B
eyes	I
and	O
indication	O
for	O
intravitreal	B
anti	I
-	I
VEGF	I
treatment	I
for	O
both	B
eyes	I
at	O
screening	O
or	O
baseline	O
visit	O
.	O

Eyes	O
with	O
a	O
small	O
amount	O
of	O
intraretinal	O
or	O
subretinal	O
fluid	O
(	O
seen	O
in	O
OCT	O
)	O
but	O
no	O
need	O
for	O
intravitreal	O
treatment	O
as	O
judged	O
by	O
the	O
investigator	O
(	O
according	O
to	O
current	O
practice	O
patterns	O
)	O
may	O
be	O
included	O
.	O
Eyes	O
with	O
a	O
history	O
of	O
intravitreal	O
treatment	O
of	O
macular	O
edema	O
which	O
do	O
not	O
need	O
ongoing	O
intravitreal	O
treatment	O
at	O
the	O
time	O
of	O
screening	O
may	O
be	O
included	O
.	O

eye	O
diseases	O
or	O
pathologies	O
that	O
prevent	B
clear	O
ophthalmoscopy	B
and	O
evaluation	O
of	O
study	O
parameters	O
,	O
thus	O
not	O
allowing	O
study	O
participation	O
according	O
to	O
the	O
investigator	O
´	O
s	O
judgment	O
,	O
such	O
as	O
(	O
but	O
not	O
only	O
)	O
vitreous	B
hemorrhage	I
,	O
mature	B
cataract	I
,	O
macular	B
pathologies	I
other	B
than	O
diabetic	B
maculopathy	I

history	O
of	O
ketoacidosis	B
or	O
metabolic	B
acidosis	I

use	O
of	O
loop	B
diuretics	I

history	O
of	O
>	O
1	O
urogenital	B
infection	I
/	O
year	O

any	O
history	O
of	O
stroke	B
,	O
transient	B
ischemic	I
attack	I
(	O
TIA	B
)	O
,	O
instable	B
angina	B
pectoris	I
or	O
myocardial	B
infarction	I
within	O
last	B
3	I
months	I
prior	I
to	I
baseline	I
visit	I

congestive	B
heart	I
failure	I
New	B
York	I
Heart	I
Association	I
(	O
NYHA	B
)	O
III	B
and	I
IV	I

severe	B
valvular	O
or	O
left	B
ventricular	I
outflow	I
obstruction	I
disease	O
needing	O
intervention	B
;	O

atrial	B
fibrillation	I
/	O
flutter	O
with	O
a	O
mean	B
ventricular	I
response	I
rate	I
at	B
rest	I
>	B
100	I
beats	I
per	I
minute	I

chronic	B
lower	B
urinary	I
tract	I
infections	I
(	O
but	O
not	B
simple	O
asymptomatic	B
bacteriuria	I
)	O

eGFR	B
<	B
60	I
ml	I
/	I
min	I
/	I
1	I
,	I
73	I
m2	I
(	O
MDRD	O
-	O
formula	O
,	O
confirmed	O
on	O
a	O
second	O
day	O
)	O

chronic	B
diarrhea	I
,	O
any	O
clinical	O
signs	O
of	O
volume	B
depletion	I
or	O
a	O
hematocrit	B
>	B
48	I
%	I
(	O
women	B
)	O
and	O
>	B
53	I
%	I
(	O
men	B
)	O

elevated	B
risk	O
for	O
volume	O
depletion	O
,	O
e	O
.	O
g	O
.	O
history	O
of	O
severe	O
volume	O
depletion	O
that	O
required	O
medical	O
therapy	O

chronic	B
liver	I
disease	I
(	O
including	O
known	O
active	B
hepatitis	I
)	O
and	O
/	O
or	O
screening	O
alanine	B
transaminase	I
(	O
ALT	B
)	O
or	O
aspartate	B
transaminase	I
(	O
AST	B
)	O
>	B
3	I
x	I
upper	I
limit	I
of	I
normal	I
(	O
ULN	O
)	O
(	O
confirmed	O
on	O
a	O
second	O
day	O
)	O

Subjects	O
with	O
known	O
seropositivity	B
to	O
human	B
immunodeficiency	I
virus	I
.	O

acute	O
illness	O
at	O
screening	O
or	O
randomization	O
according	O
to	O
judgement	O
by	O
the	O
investigator	O
or	O
patient	O

drug	O
or	O
alcohol	B
abuse	I

psychosomatic	O
or	O
psychiatric	B
diseases	I
requiring	O
hospitalization	O
during	O
the	O
last	B
12	I
months	I

clinical	O
evidence	O
of	O
current	O
malignancy	B
with	O
exception	B
of	O
basal	O
cell	O
or	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
skin	I
,	O
and	O
cervical	B
intraepithelial	I
neoplasia	I
(	O
5	B
years	I
prior	I
to	I
randomization	I
)	O

any	O
medical	O
or	O
surgical	O
intervention	O
planned	O
for	O
the	O
next	O
13	O
months	O
after	O
randomization	O
not	O
allowing	O
study	O
participation	O
according	O
to	O
the	O
investigator	O
´	O
s	O
judgment	O

current	O
participation	O
in	O
any	O
other	O
clinical	O
trial	O
or	O
participation	O
in	O
another	O
clinical	O
trial	O
within	O
30	O
days	O
before	O
screening	O

women	B
and	O
men	B
between	B
18	I
-	I
80	I
years	I
of	O
age	B

type	B
2	I
diabetes	I
mellitus	I

early	B
to	O
moderate	B
stage	I
diabetic	B
retinopathy	I
(	O
ETDRS	B
:	O
20	B
(	O
microaneurysms	O
only	O
)	O
to	O
35	B
(	O
microaneurysms	O
/	O
hemorrhages	O
and	O
/	O
or	O
hard	O
exsudates	O
)	O
)	O
in	O
one	O
or	O
both	O
eyes	B

stable	O
HbA1c	B
(	O
±	B
0	I
.	I
5	I
%	I
)	O
for	O
at	B
least	I
12	I
weeks	I

antidiabetic	B
treatment	I
with	O
either	O
diet	O
,	O
metformin	B
,	O
DPP4	B
,	O
GLP1	B
,	O
pioglitazone	B
,	O
acarbose	B
,	O
or	O
respective	O
combinations	O

HbA1c	B
=	B
6	I
.	I
5	I
and	I
=	I
10	I
.	I
0	I
%	I

body	B
mass	I
index	I
<	B
46	I
kg	I
/	I
m2	I

office	O
blood	B
pressure	I
=	B
150	I
/	I
95	I
mmHg	I
(	O
confirmed	O
on	O
a	O
second	O
day	O
;	O
24h	O
ambulatory	O
blood	O
pressure	O
measurement	O
(	O
ABPM	O
)	O
is	O
allowed	O
to	O
check	O
accuracy	O
of	O
office	O
values	O
;	O
inclusion	O
with	O
24h	O
mean	O
blood	O
pressure	O
=	O
145	O
/	O
90	O
mm	O
Hg	O
is	O
possible	O
)	O
;	O
patients	O
with	O
hypertension	O
should	O
be	O
treated	O
according	O
to	O
current	O
treatment	O
guidelines	O

at	B
least	I
6	I
weeks	I
after	O
surgical	B
sterilization	I
by	O
bilateral	B
tubal	I
ligation	I
or	O
bilateral	B
oophorectomy	I

hysterectomy	B

=	B
50	I
years	B
and	O
in	O
postmenopausal	O
state	O
>	B
1	I
year	I

<	O
50	O
years	O
and	O
in	O
postmenopausal	O
state	O
>	O
1	O
year	O
with	O
serum	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
>	O
40	O
IU	O
/	O
l	O
and	O
serum	O
estrogen	O
<	O
30	O
ng	O
/	O
l	O
or	O
a	O
negative	O
estrogen	O
test	O
,	O
both	O
at	O
screening	O
or	O
women	O
of	O
childbearing	O
potential	O
with	O
a	O
negative	O
serum	O
beta	O
human	O
chorionic	O
gonadotropin	O
(	O
ß	O
-	O
hCG	O
)	O
pregnancy	O
test	O
at	O
screening	O
who	O
agree	O
to	O
meet	O
one	O
of	O
the	O
following	O
criteria	O
from	O
the	O
time	O
of	O
screening	O
,	O
during	O
the	O
study	O
and	O
for	O
a	O
period	O
of	O
4	O
days	O
following	O
the	O
last	O
administration	O
of	O
study	O
medication	O
:	O

correct	O
use	O
of	O
one	O
of	O
the	O
following	O
accepted	O
contraception	O
methods	O
:	O
hormonal	O
contraceptives	O
(	O
combined	O
oral	O
contraceptives	O
,	O
implants	O
,	O
transdermal	O
patches	O
,	O
hormonal	O
vaginal	O
devices	O
or	O
injections	O
with	O
prolonged	O
release	O
)	O
,	O
intrauterine	O
device	O
(	O
IUD	O
/	O
IUS	O
)	O
or	O
a	O
double	O
barrier	O
method	O
,	O
e	O
.	O
g	O
.	O
condom	O
and	O
occlusive	O
cap	O
(	O
diaphragm	O
or	O
cervical	O
/	O
vault	O
caps	O
)	O
with	O
spermicide	O
(	O
foam	O
,	O
gel	O
,	O
film	O
,	O
cream	O
or	O
suppository	O
)	O

true	O
abstinence	O
(	O
periodic	O
abstinence	O
and	O
withdrawal	O
are	O
not	O
acceptable	O
methods	O
of	O
contraception	O
)	O

sexual	O
relationship	O
only	O
with	O
female	O
partners	O

sterile	O
male	O
partners	O

signed	O
written	O
informed	O
consent	O
and	O
willingness	O
to	O
comply	O
with	O
treatment	O
and	O
follow	O
-	O
up	O
procedures	O

capability	O
of	O
understanding	O
the	O
investigational	O
nature	O
,	O
potential	O
risks	O
and	O
benefits	O
of	O
the	O
clinical	O
trial	O

Subjects	O
with	O
cognitive	O
,	O
psychiatric	B
,	I
or	I
other	I
problems	I
that	O
preclude	O
informed	O
consent	O
.	O

Patients	O
with	O
history	B
of	O
glucose	B
intolerance	I
or	O
diabetes	B
.	O

Patient	O
on	O
chemotherapy	B

People	O
with	O
any	O
open	O
or	O
bleeding	B
wounds	I
at	B
any	I
sensor	I
plate	I
contact	I
surface	I
location	I

People	O
with	O
any	O
type	O
of	O
implantable	B
device	I

People	O
with	O
missing	B
hand	I
(	O
s	O
)	O
and	O
/	O
or	O
leg	O
(	O
s	O
)	O

Pregnant	B
women	O
or	O
women	O
who	O
are	O
uncertain	O
about	O
a	O
possible	O
pregnancy	O

Patients	O
sensitive	B
to	I
chemicals	I
used	I
to	I
induce	I
sweating	I

Patients	O
with	O
heat	B
intolerance	I

Patients	O
with	O
bleeding	B
disorders	I

Patients	O
on	O
current	B
anticoagulant	B
therapy	I

Patients	O
with	O
keloids	B
on	B
the	I
intended	I
biopsy	I
site	I

People	O
with	O
hypersensitivity	B
to	O
local	B
amide	I
-	I
type	I
anesthetics	I

Males	B
and	O
females	B
with	O
confirmed	B
disease	I
:	O
Fabry	O
(	O
by	O
GLA	B
enzymes	I
and	O
/	O
or	O
DNA	B
testing	I
)	O
naïve	O
and	O
on	O
ERT	B
,	O
Mitochondrial	B
diseases	I
(	O
electron	B
transport	I
chain	I
and	O
/	O
or	O
DNA	B
testing	I
)	O
or	O
connective	B
tissue	I
diseases	I
(	O
clinical	O
criteria	O
and	O
/	O
or	O
DNA	B
testing	I
when	O
available	O
)	O

Consenting	O
adults	O
(	O
18	O
years	O
and	O
older	O
)	O
who	O
agrees	O
and	O
consents	O
to	O
skin	O
biopsy	O
and	O
QSART	O
procedure	O

eGFR	B
<	B
45	I

Type	B
2	I
diabetes	I
(	O
HbA1c	B
>	B
6	I
.	I
5	I
)	O
or	O
type	B
1	I
diabetes	I

Any	O
tobacco	O
or	O
nicotine	O
product	O
use	O
in	O
the	O
past	B
year	I

Low	O
vitamin	B
B12	I
Levels	I
(	O
<	B
300	I
pg	I
/	I
mL	I
)	O

Self	O
-	O
reported	O
severe	O
difficulty	O
or	O
inability	O
to	O
walk	O
400m	O
or	O
climb	O
10	O
steps	O
(	O
from	O
Q	O
2	O
and	O
19	O
on	O
PAT	O
-	O
D	O
)	O

Self	O
-	O
reported	O
difficulty	O
or	O
inability	O
to	O
perform	O
basic	O
ADL	O
functions	O
(	O
from	O
Q	O
10	O
,	O
13	O
,	O
14	O
,	O
16	O
on	O
PAT	O
-	O
D	O
)	O

Excessive	O
alcohol	O
use	O
(	O
>	B
14	I
drinks	I
/	I
week	I
)	O

Cancer	B
requiring	O
treatment	B
in	O
past	B
year	I
(	O
except	O
skin	O
)	O

Dementia	B
-	O
diagnosed	O
and	O
/	O
or	O
MoCA	B
score	I
<	B
18	I

Parkinson	B
'	I
s	I
or	O
other	O
neurological	B
disease	I

Chronic	B
liver	I
disease	I
or	O
cirrhosis	B

End	B
stage	I
renal	I
disease	I
or	O
on	O
dialysis	B

Rheumatic	B
conditions	I
(	O
Rheumatoid	B
arthritis	I
,	O
lupus	B
,	O
and	O
any	O
other	O
autoimmune	B
disease	I
the	O
-	O
PI	O
deems	O
them	O
to	O
be	O
ineligible	O
for	O
)	O

Thyroid	B
problems	I
the	O
PI	O
deems	O
them	O
to	O
be	O
ineligible	O
for	O

Gout	B

Involved	O
in	O
another	O
interventional	O
study	O

Hemoglobin	B
<	B
8	I
or	O
diagnosed	O
with	O
anemia	B

Recent	O
unintentional	O
weight	B
change	O
(	O
+	B
/	I
-	I
10	I
lbs	I
.	I
in	O
the	O
last	B
12	I
months	I
)	O

BMI	B
<	B
18	I
.	I
5	I

Likely	O
to	O
not	O
follow	O
the	O
protocol	O

PI	O
deems	O
unfit	O
to	O
participate	O

Already	O
taking	O
Metformin	B
or	O
any	O
other	O
drug	B
intended	O
to	O
treat	O
diabetes	B

Age	B
65	B
-	I
79	I

History	B
of	O
coronary	B
artery	I
disease	I
(	O
MI	B
/	O
heart	B
attack	I
,	O
stroke	B
,	O
heart	B
failure	I
,	O
or	O
peripheral	B
artery	I
disease	I
)	O

Cancer	B
,	O
with	O
no	B
active	B
treatment	I
in	B
the	I
last	I
year	I

MCI	B
(	O
MoCA	B
>	B
18	I
<	I
26	I
-	O
inclusive	O
of	O
1	O
point	O
if	O
<	O
12	O
years	O
of	O
education	O
Group	O
2	O

Decline	B
physical	I
function	I
(	O
walking	B
speed	I
<	B
1	I
m	I
/	I
s	I
)	O
Group	O
3	O
(	O
Either	O
or	O
both	O
)	O

Abdominal	B
obesity	O
(	O
>	B
88cm	I
women	B
,	O
>	B
102cm	I
men	B
)	O
AND	O
hypertension	B
(	O
treated	B
or	O
resting	B
blood	I
pressure	I
>	B
140	I
/	I
90	I

Abdominal	B
obesity	I
(	O
>	B
88cm	I
women	B
,	O
>	B
102cm	I
men	B
)	O
AND	O
hyperlipidemia	B
(	O
treated	B
or	O
fasting	B
total	I
cholesterol	I
>	B
240	I
English	O
literacy	O
Willing	O
to	O
provide	O
informed	O
consent	O

having	O
experienced	O
severe	B
allergies	B
,	O
trauma	B
history	B
and	O
/	O
or	O
operation	B
history	B
within	B
3	I
months	I
.	O

with	O
a	O
history	B
of	O
mental	B
illness	I
and	O
/	O
or	O
family	O
history	O
of	O
mental	B
illness	I
limb	B
disabled	I
.	O

taking	O
medicine	B
within	B
one	I
month	I
.	O

suffering	O
major	B
events	I
or	O
having	O
mood	B
swings	I
.	O

having	O
internal	O
and	O
surgical	B
disease	O
(	O
after	O
having	O
variety	O
of	O
physical	B
examination	I
such	O
as	O
electrocardiogram	B
/	O
hepatic	O
and	O
renal	B
function	I
/	O
blood	B
routine	I
and	O
urine	B
routine	I
)	O

chromosome	B
aberrations	I
in	O
anyone	B
of	I
the	I
couple	I
.	O

patients	O
who	O
have	O
drugs	B
contraindications	B

Woman	B
who	O
had	O
2	B
miscarriage	B
before	B
12	I
(	I
th	I
)	I
week	I
of	I
gestation	I
.	O
The	O
patient	O
who	O
is	O
diagnosed	O
as	O
thrombophilia	B
with	O
recurrent	B
pregnancy	B
loss	I
.	O

Signed	O
consent	O
form	O
.	O

age	B
<	B
45	I
or	I
>	I
80	I

allergies	B
to	O
medications	B
used	B
in	I
the	I
study	I

history	B
of	O
renal	B
diseases	I
,	O
a	O
coagulation	B
abnormality	I
,	O
a	O
hepatic	B
disease	I
,	O
or	O
drug	B
abuse	I

definite	B
radiographic	B
evidence	O
of	O
osteoarthritis	B
of	O
the	O
glenohumeral	B
joint	I

inflammatory	B
arthritis	I
including	O
rheumatoid	B
arthritis	I

a	O
history	B
of	O
acute	B
trauma	I

systemic	B
conditions	I
associated	O
with	O
chronic	B
pain	I

a	O
history	B
of	O
infection	B

an	O
inability	O
to	O
understand	O
the	O
questionnaires	O

Rotator	B
cuff	I
tear	I
patients	O
undergoing	O
arthroscopic	B
rotator	I
cuff	I
tear	I

Patients	O
ASA	B
III	B
y	I
IV	I

Chronic	B
pain	I
history	O

Drug	O
and	O
alcohol	B
abuse	I

Chronic	B
use	I
of	O
opioid	B
and	O
sedatives	B

Neuropsychiatric	B
illness	I

NSAID	B
and	O
other	B
analgesics	B
used	O
the	O
48	B
hours	I
previous	I
to	I
the	I
surgery	I

CMI	B
>	B
30	I

Patients	O
scheduled	O
for	O
thyroidectomy	B
with	O
general	B
anesthesia	I
in	O
the	O
University	O
of	O
Chile	O
Clinical	O
Hospital	O

contra	B
-	I
indications	I
for	O
regular	B
dental	I
treatment	I

medical	B
history	I
that	O
contraindicates	B
the	O
use	O
of	O
epinephrine	B

participant	O
taken	O
an	O
opioid	B
or	O
an	O
opioid	B
like	I
analgesic	I
within	B
24	I
hours	I

pregnant	B

18	O
years	O
of	O
age	B
or	O
older	O

capable	O
of	O
providing	O
informed	O
consent	O

Secondary	B
hypertension	I
or	O
malignant	B
hypertension	I

Diabetes	B
mellitus	I

History	B
or	O
evidence	O
of	O
a	O
stroke	B

Hepatic	O
or	O
hematologic	B
abnormality	I

Mild	B
Cognitive	I
Impairment	I
or	O
Dementia	B

Serum	B
potassium	I
level	I
=	B
5	I
.	I
5	I
mEq	I
/	I
L	I

Serum	B
creatinine	I
level	I
=	B
3	I
.	I
0	I
mg	I
/	I
dL	I

Acute	O
or	O
chronic	B
disease	I

Allergy	B
to	O
any	B
drugs	I

Pregnancy	B

Written	O
informed	O
consent	O
obtained	O

Male	B
and	O
female	B
subjects	O
aged	B
20	B
years	I
or	I
older	I
at	B
informed	I
consent	I

Essential	B
hypertension	I
who	O
had	O
never	B
received	O
angiotensin	B
II	I
receptor	I
antagonists	I
and	O
calcium	B
channel	I
blockers	I

Open	B
surgery	I
;	O

Patients	O
allergic	B
to	O
lidocaine	B
or	O
other	B
local	B
anesthetics	I
;	O

Drug	B
abuser	I
.	O

American	B
Society	I
of	I
Anesthesiologist	I
(	I
ASA	I
)	I
status	B
I	I
-	I
II	I
adult	B
patients	O
undergoing	O
elective	B
laparoscopic	B
cholecystectomy	I
.	O

Hemoglobin	B
>	B
12g	I
/	I
dL	I

Hematochrit	B
>	B
36	I
%	I

Thrombocytosis	B
>	B
750K	I

AST	B
or	O
ALT	B
>	B
120	I

HIV	B
(	I
+	I
)	I

Allergic	B
reaction	O
upon	O
erythropoietin	B

Uncontrolled	B
hypertension	I

mRS	B
before	O
the	O
autoimmune	B
encephalitis	I
>	B
3	I

Breast	O
feeding	O
or	O
pregnancy	B

History	B
of	O
ischemic	B
stroke	I
or	O
pulmonary	B
thrombosis	I

Refuse	O
to	O
be	O
enrolled	O

Clinically	B
diagnosed	I
autoimmune	B
encephalitis	I

Ineffective	B
1st	B
line	I
treatment	I
(	O
e	O
.	O
g	O
.	O
steroid	B
IV	I
,	O
IVIg	B
)	O
and	O
2nd	B
line	I
treatment	I
(	O
e	O
.	O
g	O
.	O
Rituximab	B
or	O
cyclophosphamide	B
)	O

Patients	O
receiving	O
prednisone	B
=	B
1mg	I
/	I
kg	I
/	I
d	I
for	O
the	O
treatment	O
of	O
acute	B
GVHD	I
or	O
mild	B
,	O
severe	B
chronic	B
GVHD	B
.	O

Recipient	O
<	B
14years	I
of	O
age	B

Donor	O
is	O
sero	B
-	I
positive	I
in	I
HBV	I
/	O
HCV	O
/	O
HIV	O
or	O
RPR	O
.	O

Any	O
allogeneic	B
stem	I
cell	I
transplant	I
recipient	O
=	B
14	I
years	I
of	O
age	B
and	O
=	B
60	I
years	I
of	O
age	B

Bilirubin	B
/	O
SGOT	B
/	O
SGPT	B
<	B
5	I
×	I
upper	I
normal	I
limits	I
.	O

Creatinine	B
<	B
2	I
×	I
upper	I
normal	I
limits	I
.	O

Ejection	B
fraction	I
=	B
50	I
%	I
,	O
no	B
severe	B
arrhythmia	B
.	O

Estimated	O
life	O
expectancy	O
=	B
6	I
months	I
.	O

Patients	O
'	O
CMV	B
-	I
DNA	I
=	B
1000cp	I
/	I
ml	I
in	O
treatment	B
group	I
and	O
being	O
negative	B
in	O
prophylactic	B
group	I
.	O

clinically	B
significant	I
medical	O
or	O
neurologic	B
condition	I
or	O
neurocognitive	B
dysfunction	I
that	O
would	O
affect	O
function	O
and	O
/	O
or	O
task	O
performance	O
and	O
/	O
or	O
interfere	O
with	O
the	O
study	O
protocol	O

any	O
current	B
(	O
or	O
within	B
past	I
2	I
months	I
)	O
medical	B
condition	I
requiring	O
medication	B
that	O
would	O
interact	O
with	O
dronabinol	B
or	O
interfere	O
with	O
the	O
study	O
protocol	O

risk	O
of	O
harm	O
to	O
self	O
or	O
others	O
that	O
requires	O
immediate	O
intervention	O

presence	O
of	O
contraindications	B
,	O
current	B
or	O
past	B
allergic	O
or	O
adverse	B
reaction	I
,	O
or	O
known	O
sensitivity	B
to	O
cannabinoid	B
-	I
like	I
substances	I
(	O
dronabinol	B
/	O
marijuana	B
/	O
cannabis	B
/	O
THC	B
,	O
cannabinoid	B
oil	I
,	O
sesame	B
oil	I
,	O
gelatin	B
,	O
glycerin	B
,	O
and	O
titanium	B
dioxide	I
)	O

lack	O
of	O
fluency	O
in	O
English	O

positive	B
drug	B
screen	I
or	O
alcohol	B
breathalyzer	I

unwilling	O
/	O
unable	O
to	O
sign	O
informed	O
consent	O
document	O

currently	B
pregnant	B
(	O
positive	B
pregnancy	B
test	I
)	O
,	O
planning	O
pregnancy	B
,	O
or	O
lactating	B
(	O
women	O
)	O

under	B
18	I
or	I
over	I
50	I
years	I
of	O
age	B

traumatic	B
brain	I
injury	I
(	O
as	O
defined	O
by	O
The	O
American	O
Congress	O
of	O
Rehabilitation	O
as	O
a	O
person	O
who	O
has	O
had	O
a	O
traumatically	O
induced	O
physiological	O
disruption	O
of	O
brain	O
function	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
head	O
being	O
struck	O
,	O
the	O
head	O
striking	O
an	O
object	O
,	O
and	O
/	O
or	O
the	O
brain	O
undergoing	O
an	O
acceleration	O
/	O
deceleration	O
movement	O
(	O
i	O
.	O
e	O
.	O
,	O
whiplash	O
)	O
without	O
direct	O
external	O
trauma	O
to	O
the	O
head	O
)	O
,	O
as	O
manifested	O
by	O
at	O
least	O
one	O
of	O
the	O
following	O
:	O
any	O
loss	O
of	O
consciousness	O
;	O
any	O
loss	O
of	O
memory	O
for	O
events	O
immediately	O
before	O
or	O
after	O
the	O
injury	O
;	O
any	O
alteration	O
in	O
mental	O
status	O
at	O
the	O
time	O
of	O
the	O
incident	O
;	O
or	O
focal	O
neurological	O
deficits	O
that	O
may	O
or	O
may	O
not	O
be	O
transient	O
)	O

inability	B
to	O
tolerate	B
small	I
,	I
enclosed	I
spaces	I
without	I
anxiety	I
(	O
e	O
.	O
g	O
.	O
claustrophobia	B
)	O
,	O
as	O
determined	O
by	O
self	B
-	I
report	I
and	O
/	O
or	O
a	O
preliminary	O
session	O
in	O
a	O
mock	O
scanner	O

left	B
-	I
handed	I
;	O

presence	O
of	O
ferrous	B
-	I
containing	I
metals	I
within	O
the	O
body	O
(	O
e	O
.	O
g	O
.	O
,	O
aneurysm	B
clips	I
,	O
shrapnel	B
/	O
retained	B
particles	I
)	O

anticipation	O
of	O
a	O
required	O
drug	B
test	I
in	B
the	I
4	I
weeks	I
following	I
the	I
study	I
.	O

current	O
diagnosis	O
of	O
a	O
mood	O
,	O
anxiety	O
,	O
or	O
other	B
disorder	B
that	O
is	O
more	O
clinically	O
salient	O
than	O
PTSD	B

current	O
moderate	B
or	O
severe	B
alcohol	O
/	O
drug	B
use	I
disorder	I
or	O
in	B
the	I
past	I
8	I
weeks	I

current	O
or	O
past	O
diagnosis	O
of	O
bipolar	B
and	O
other	B
related	B
disorders	I
,	O
schizophrenia	B
spectrum	I
,	O
or	O
other	O
psychotic	B
disorders	I

concomitant	O
treatments	B
with	O
medication	B
known	O
to	O
have	O
drug	B
interactions	I
with	O
dronabinol	B
,	O
such	O
as	O
,	O
central	B
nervous	I
system	I
depressants	I
(	O
barbiturates	B
,	O
benzodiazepines	B
,	O
buspirone	B
,	O
lithium	B
,	O
etc	O
)	O
and	O
anticholinergic	B
agents	I
(	O
atropine	B
,	O
scopolamine	B
,	O
antihistamines	B
,	O
etc	O
)	O
.	O

Able	O
to	O
give	O
informed	O
consent	O

Right	B
-	I
handed	I

Age	B
between	B
18	I
-	I
50	I
years	I
old	I
,	O

Physically	O
and	O
neurologically	B
healthy	I
[	O
confirmed	O
by	O
a	O
comprehensive	B
medical	I
history	I
]	O

Current	B
PTSD	B
diagnosis	O

NA	O

Patients	O
who	O
are	O
19	O
years	B
or	O
older	O
on	B
screening	I

Patients	O
with	O
type	B
2	I
diabetes	I
mellitus	I

Patients	O
with	O
7	O
.	O
0	O
%	O
=	O
HbA1c	B
=	O
11	O
.	O
0	O
%	O
at	B
the	I
screening	I
visit	I

Patients	O
with	O
Fasting	B
Plasma	I
Glucose	I
<	B
15mmol	I
/	I
L	I
(	O
270mg	B
/	I
dL	I
)	O
on	B
screening	I

Significant	B
motor	B
complication	I
affecting	O
daily	O
activities	O

Drugs	B
related	O
to	O
acetylcholine	B
metabolism	O

Parkinson	B
disease	I
diagnosed	O
by	O
United	B
Kingdom	I
Parkinson	I
'	I
s	I
disease	I
Society	I
Brain	I
Bank	I
Criteria	I

Postural	B
instability	I
and	O
gait	B
disturbance	I
phenotype	O

Hoehn	B
and	I
Yahr	I
stage	B
=	I
3	I

Mini	B
-	I
Mental	I
status	I
examination	I
=	B
24	I

Preoperative	B
history	B
of	O
schizophrenia	B
,	O
epilepsy	B
,	O
parkinsonism	B
or	O
myasthenia	B
gravis	I
;	O

Preoperative	B
radio	O
-	O
or	O
chemotherapy	B
;	O

Inability	B
to	I
communicate	I
in	O
the	O
preoperative	B
period	I
because	O
of	O
coma	B
,	O
profound	B
dementia	B
or	O
language	O
barrier	O
;	O

Preoperative	B
obstructive	B
sleep	I
apnea	I
(	O
previously	O
diagnosed	O
as	O
obstructive	B
sleep	I
apnea	I
,	O
or	O
a	O
STOP	B
-	I
Bang	I
score	I
>	B
=	I
3	I
)	O
;	O

Brain	B
trauma	I
or	O
neurosurgery	B
;	O

Preoperative	B
left	B
ventricular	I
ejection	I
fraction	I
<	B
30	I
%	I
,	O
sick	B
sinus	I
syndrome	I
,	O
severe	B
sinus	B
bradycardia	I
(	O
<	B
50	I
beats	I
per	I
minute	I
)	O
,	O
or	O
second	B
-	I
degree	I
or	I
above	I
atrioventricular	B
block	I
without	B
pacemaker	B
;	O

Severe	B
hepatic	B
dysfunction	I
(	O
Child	B
-	I
Pugh	I
class	B
C	I
)	O
or	O
severe	B
renal	B
dysfunction	I
(	O
requirement	O
of	O
renal	B
replacement	I
therapy	I
before	O
surgery	B
)	O
;	O

ASA	B
classification	I
>	B
=	I
IV	I
.	O

Age	B
>	B
=	I
65	I
years	I
,	I
<	I
90	I
years	I
;	O

Scheduled	O
to	O
undergo	O
surgery	B
for	O
primary	B
solid	B
organ	I
cancer	I
under	O
general	B
anesthesia	I
,	O
with	O
an	O
expected	O
duration	O
of	O
surgery	O
>	O
=	O
2	O
hours	O
;	O

Planned	O
to	O
use	O
patient	B
-	I
controlled	I
intravenous	B
analgesia	I
after	O
surgery	B
;	O

Provide	O
written	O
informed	O
consent	O
.	O

Patients	O
with	O
head	B
trauma	I
or	O
Neurosurgical	B
intervention	I

Patients	O
<	B
65	I
years	I
of	O
age	B

Patients	O
with	O
an	O
expected	O
life	O
expectancy	O
<	B
48	I
hours	I

Blind	B
patients	O

Patients	O
with	O
a	O
seizure	B
history	B

Patients	O
with	O
uncontrolled	B
hypertension	I

Patients	O
with	O
a	O
supratheraputic	B
(	O
>	B
3	I
.	I
0	I
)	O
INR	B

Patients	O
on	O
strong	B
CYP1A2	I
inhibitors	I
:	O
ciprofloxacin	B
,	O
fluvoxamine	B
,	O
methoxsalen	B
,	O
ofloxacin	B
,	O
primaquine	B

Patients	O
who	O
do	O
not	B
speak	O
English	O
or	O
Spanish	O

Non	B
-	O
ventilated	B
Patients	O
over	O
the	O
age	B
of	O
65	O

Inability	O
to	O
give	O
informed	O
consent	O

Pregnancy	B

Concurrent	B
antibiotherapy	B

Certain	B
infectious	B
endocarditis	I

Concurrent	B
anti	B
-	I
inflammatory	I
therapy	O
,	O
including	O
corticosteroid	B
therapy	O

age	B
>	B
18	I

written	O
informed	O
consent	O

SVD	B
defined	O
on	O
echocardiography	B
by	O
an	O
alteration	B
of	I
bioprosthesis	I
leaflets	I
function	I
with	O
a	O
mean	B
transvalvular	I
gradient	I
>	B
20	I
mmHg	I
and	O
maximal	B
velocity	I
=	B
3	I
m	I
/	I
s	I
and	O
effective	B
orifice	I
area	I
=	B
1	I
.	I
2	I
cm²	I
,	O
and	O
/	O
or	O
an	O
aortic	B
regurgitation	I
more	O
or	O
equal	O
to	O
grade	B
2	O
on	O
4	O
.	O

Prior	O
treatment	B
with	O
enzalutamide	B
or	O
abiraterone	B
acetate	I
for	B
>	I
14	I
days	I
prior	B
to	I
enrollment	I
and	O
completion	O
of	O
baseline	O
tests	O
.	O

Receipt	O
of	O
chemotherapy	B
for	O
prostate	O
or	O
other	B
cancer	B
within	B
the	I
past	I
12	I
months	I
with	O
residual	B
cognitive	I
deficits	I
,	O
or	O
receipt	O
of	O
chemotherapy	B
for	O
mCRPC	B
.	O

Patients	O
/	O
physicians	O
planning	O
treatment	O
with	O
chemotherapy	O
during	O
the	O
12	O
month	O
period	O
of	O
the	O
investigation	O
are	O
also	O
ineligible	O
.	O

History	O
of	O
cognitive	B
impairment	I
or	O
dysfunction	O
,	O
including	O
a	O
history	O
of	O
dementia	B
,	O
Alzheimer	B
'	I
s	I
disease	I
,	O
stroke	B
with	O
residual	B
cognitive	I
deficits	I
,	O
cognitive	B
dysfunction	I
related	O
to	O
alcohol	O
or	O
substance	B
abuse	I
,	O
or	O
cognitive	B
dysfunction	I
related	O
to	O
prior	B
treatment	B
for	O
any	B
cancer	B
.	O

Patients	O
with	O
a	O
seizure	B
history	B
,	O
history	B
of	I
recurrent	B
falls	I
,	O
or	O
known	O
brain	B
metastases	I
are	O
excluded	O
from	O
this	O
clinical	O
trial	O
because	O
of	O
their	O
poor	O
prognosis	O
and	O
because	O
of	O
their	O
heightened	O
risk	O
of	O
seizure	O
or	O
progressive	O
cognitive	O
and	O
/	O
or	O
neurologic	O
dysfunction	O
that	O
would	O
confound	O
the	O
evaluation	O
.	O

Uncontrolled	B
intercurrent	B
illness	I
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
uncontrolled	B
diabetes	B
,	O
ongoing	B
or	O
active	B
infection	B
,	O
symptomatic	B
congestive	B
heart	I
failure	I
(	O
New	B
York	I
Heart	I
Association	I
Class	B
III	I
and	I
IV	I
heart	B
failure	I
)	O
,	O
unstable	B
angina	I
pectoris	I
,	O
cardiac	B
arrhythmia	I
,	O
or	O
psychiatric	B
illness	I
/	O
social	B
situations	I
/	O
substance	B
abuse	I
that	O
would	O
limit	O
compliance	O
with	O
study	O
requirements	O
.	O

Patients	O
with	O
a	O
"	O
currently	B
active	I
"	O
second	B
malignancy	B
other	B
than	I
non	B
-	I
melanoma	I
skin	I
cancers	I
are	O
not	O
eligible	O
.	O

Patients	O
are	O
not	O
considered	O
to	O
have	O
a	O
"	O
currently	O
active	O
"	O
malignancy	O
if	O
they	O
have	O
completed	O
all	O
therapy	O
and	O
are	O
now	O
considered	O
without	O
evidence	O
of	O
disease	O
for	O
1	O
year	O
.	O

Patients	O
with	O
cognitive	B
dysfunction	I
related	O
to	O
treatment	B
of	O
another	B
malignancy	B
,	O
including	O
a	O
history	O
of	O
"	O
chemo	O
-	O
brain	O
"	O
,	O
are	O
ineligible	O
.	O

Patients	O
taking	O
psychotropic	B
medications	I
or	O
illicit	B
drugs	I
that	O
may	O
alter	B
cognition	I
,	O
concentration	O
,	O
or	O
behavior	O
.	O

Appropriate	O
treatment	O
by	O
a	O
licensed	O
provider	O
with	O
medications	O
for	O
depression	O
or	O
anxiety	O
,	O
including	O
but	O
not	O
limited	O
to	O
SSRIs	O
,	O
SNRIs	O
,	O
and	O
standard	O
dose	O
benzodiazepines	O
at	O
a	O
stable	O
dose	O
,	O
is	O
permitted	O

Have	O
diagnosis	O
of	O
prostate	B
cancer	I
and	O
have	O
received	O
treatment	B
with	O
GnRH	B
agonist	I
or	O
antagonist	O
therapy	O
for	B
at	I
least	I
1	I
month	I
prior	B
to	I
enrollment	I
.	O

Willing	O
and	O
able	O
to	O
complete	O
survey	O
questionnaires	O
in	O
English	O
without	O
assistance	O
through	O
the	O
duration	O
of	O
the	O
study	O
.	O
This	O
stipulation	O
is	O
in	O
place	O
because	O
not	O
all	O
of	O
the	O
proposed	O
quality	O
of	O
life	O
or	O
cognitive	O
tests	O
are	O
available	O
or	O
validated	O
in	O
other	O
languages	O
.	O

Age	B
=	B
18	I
years	I
.	O

Ability	O
to	O
understand	O
and	O
the	O
willingness	O
to	O
sign	O
a	O
written	O
informed	O
consent	O
document	O
written	O
in	O
English	O
that	O
is	O
approved	O
by	O
an	O
institutional	O
review	O
board	O
.	O

Have	O
either	O
newly	O
diagnosed	O
metastatic	B
hormone	B
sensitive	I
prostate	B
cancer	I
(	O
mHSPC	B
)	O
or	O
castration	B
-	I
resistant	I
metastatic	B
prostate	B
cancer	I
(	O
mCRPC	B
)	O
and	O
eligible	O
to	O
undergo	O
treatment	B
with	O
abiraterone	B
acetate	I
(	O
mHSPC	B
or	O
mCRPC	B
)	O
or	O
enzalutamide	B
(	O
mCRPC	B
)	O

Patients	O
may	O
have	O
received	O
the	O
following	O
prior	O
AR	O
directed	O
therapy	O
prior	O
to	O
enrollment	O
:	O
bicalutamide	O
,	O
ketoconazole	O
.	O

Prior	O
to	O
enrollment	O
,	O
patients	O
may	O
have	O
received	O
treatment	O
with	O
abiraterone	O
acetate	O
or	O
enzalutamide	O
for	O
no	O
more	O
than	O
14	O
days	O
before	O
completing	O
baseline	O
studies	O
.	O

Patients	O
may	O
have	O
received	O
chemotherapy	B
for	O
hormone	B
-	I
sensitive	I
metastatic	B
prostate	B
cancer	I
only	O
,	O
but	O
it	O
must	O
not	B
have	O
lasted	B
for	I
more	I
than	I
6	I
months	I
.	O

At	O
least	O
12	O
months	O
must	O
have	O
elapsed	O
since	O
completion	O
of	O
chemotherapy	B
.	O

Patients	O
may	O
have	O
received	O
prior	B
definitive	B
radiation	B
therapy	I
or	O
surgery	B
.	O

At	O
least	O
60	O
days	O
must	O
have	O
elapsed	O
since	O
completion	O
of	O
definitive	B
radiation	B
therapy	I
or	O
surgery	B
and	O
patient	O
must	O
have	O
only	O
grade	B
2	I
or	I
less	I
adverse	B
effects	I
at	B
the	I
time	I
of	I
registration	I
.	O

Enrollment	O
during	O
palliative	O
radiation	O
of	O
=	O
10	O
days	O
,	O
or	O
radiation	O
of	O
=	O
10	O
days	O
during	O
the	O
duration	O
of	O
the	O
study	O
is	O
allowed	O
.	O

Patients	O
must	O
be	O
able	O
to	O
take	O
oral	O
medication	O
.	O

Inability	O
to	O
provide	O
an	O
informed	O
consent	O

Evidence	O
of	O
oral	B
distant	B
metastasis	B
or	O
other	B
malignancies	B

The	O
patient	O
has	O
received	O
prior	B
surgery	B
for	O
primary	B
tumor	B
or	O
lymph	B
node	I
(	O
except	B
for	I
biopsy	B
)	O

Prior	B
radiotherapy	B
for	O
primary	B
tumor	B

The	O
patient	O
has	O
previously	B
received	O
anti	B
-	I
tumor	I
biological	I
targeted	I
therapy	I

The	O
patient	O
has	O
received	O
chemotherapy	B
or	O
immunotherapy	B
for	O
primary	B
tumors	I

Prior	B
malignancy	B
within	B
the	I
previous	I
5	I
years	I
(	O
except	B
for	I
cured	B
skin	I
basal	I
cell	I
carcinoma	I
or	O
cervical	B
carcinoma	I
in	I
situ	I
)	O

With	O
3	B
-	I
4	I
grad	I
Allergy	B
to	O
any	B
drug	B
in	O
the	O
treatment	O

Peripheral	B
neuropathy	I
>	B
1	I
grade	I

Any	O
unstable	B
systematic	B
disease	I
(	O
including	O
active	O
infection	B
,	O
uncontrolled	B
high	B
blood	I
pressure	I
,	O
unstable	B
angina	I
,	O
onset	B
of	O
angina	B
within	B
the	I
last	I
3	I
months	I
,	O
congestive	B
heart	I
failure	I
,	O
myocardial	B
infarction	I
within	B
the	I
previous	I
12	I
months	I
,	O
severe	B
arrhythmia	B
needing	O
drug	B
treatment	B
,	O
liver	O
,	O
kidney	O
or	O
metabolic	B
disease	I
)	O

HIV	B
positive	I

Chronic	B
diseases	I
requiring	O
immune	B
agents	I
or	O
hormone	B
therapy	I

Pregnant	B
or	O
lactating	B
women	B

Drug	O
/	O
alcohol	O
abuse	O
,	O
psychological	O
or	O
spiritual	O
illness	O
that	O
may	O
interfere	O
compliance	O
to	O
the	O
study	O

Patients	O
with	O
epilepsy	B
requiring	O
medications	B
(	O
such	O
as	O
steroids	B
or	O
antiepileptic	B
drugs	I
)	O

The	O
patient	O
has	O
participated	O
in	O
other	O
experimental	O
therapy	O
studies	O
within	O
30	O
days	O

Researchers	O
believe	O
that	O
the	O
situation	O
is	O
unsuitable	O
for	O
participation	O
in	O
the	O
group	O

Ability	O
to	O
understand	O
and	O
the	O
willingness	O
to	O
sign	O
a	O
written	O
informed	O
consent	O
document	O

Age	B
=	B
18	I
and	I
=	I
75	I
years	I

Clinical	O
/	O
Histological	O
/	O
cytological	O
/	O
Imaging	B
examination	I
proven	O
Oral	B
/	O
Oropharynx	B
Squamous	B
-	I
cell	I
carcinoma	I
(	O
Tongue	B
,	O
buccal	B
mucosa	I
,	O
mouth	B
floor	I
,	O
hard	B
palate	I
,	O
Molar	B
area	I
)	O
,	O
the	O
depth	B
of	I
invasion	I
>	B
4mm	I
in	O
preoperative	B
assessment	I

In	O
line	O
with	O
clinical	B
stage	I
I	I
/	O
II	O
stage	O
(	O
T1	B
-	B
2	I
N0	B
M0	B
;	O
AJCC	O
2010	O
)	O
and	O
receiving	O
surgical	B
resection	I

KPS	B
=	B
70	I

Normal	B
bone	B
marrow	I
reserve	I
function	I
and	O
normal	B
liver	O
,	O
kidney	B
function	I

Expected	O
survival	O
period	O
=	B
6	I
months	I

Suspect	O
or	O
certainty	O
of	O
fetal	B
malformation	I
,	O

Presence	O
of	O
conditions	O
such	O
as	O
preeclampsia	B
,	O
multiparity	B
,	O
preterm	B
labor	I

History	O
of	O
adverse	B
reaction	I
to	O
a	B
-	I
2	I
adrenergic	I
agonists	I

Nicotine	B
addiction	I

Chronic	B
use	I
of	O
opioid	B

Written	O
maternal	O
informed	O
consent	O

Singleton	B
pregnancy	I

Gestational	B
age	I
=	B
37	I
weeks	I
,	O

ASA	B
I	B

BMI	B
<	B
30	I

fetus	O
in	O
cephalic	B
presentation	I

Allergic	B
to	O
study	B
drugs	I

Patient	O
with	O
asthma	B
or	O
COPD	B
,	O
patient	O
who	O
is	O
severely	B
respiratory	B
depressed	I

Renal	O
of	O
hepatic	B
insufficiency	I

Epileptic	B
status	I

Intracranial	B
lesion	I
associated	O
with	O
increased	B
intracranial	B
pressure	I

Acute	B
abdomen	I
,	O
patient	O
who	O
has	O
diagnosed	O
paralytic	B
ileus	I
or	O
suspicious	B
ileus	I

Pregnant	B
or	O
lactating	B
women	B

19	B
-	I
65	I
years	I
of	O
age	B

ASA	B
physical	I
status	I
classification	I
I	B
or	I
II	I

Scheduled	O
for	O
total	B
hip	I
replacement	I
surgery	I

Patients	O
unable	O
to	O
understand	O
the	O
objectives	O
of	O
the	O
dietary	O
intervention	O

Patients	O
in	O
paliative	O
care	O

Patients	O
receiving	O
supplement	O
diets	O

Elderly	B
patients	O
over	B
65	I
years	I
old	B
exhibiting	O
clinical	O
indices	O
of	O
cardiovascular	O
disease	O

Male	B
or	O
female	B

Subjects	O
who	O
were	O
hospitalized	O
in	O
the	O
Geriatric	O
Unit	O
of	O
the	O
Emile	O
Roux	O
Hospital	O
(	O
AP	O
-	O
HP	O
)	O

MMSE	B
(	I
Mini	I
Mental	I
State	I
Examination	I
)	I
score	B
>	I
or	I
=	I
15	I

Supervision	O
available	O
for	O
study	O
medication	O

Able	B
to	I
ingest	I
oral	I
diet	I

Acute	B
coronary	I
syndrome	I
(	O
ACS	B
)	O
within	B
3	I
months	I
.	O

Under	O
beta	B
-	I
blocker	I
treatment	O
for	B
the	I
last	I
2	I
weeks	I
.	O

Under	O
other	O
medicine	O
treatment	O
which	O
may	O
affect	O
heart	O
rate	O
,	O
like	O
Non	B
-	I
dihydropyridine	I
calcium	I
channel	I
blockers	I
(	O
NDHP	B
-	I
CCBs	I
)	O
or	O
ivabradine	B
for	B
the	I
last	I
2	I
weeks	I
;	O
Under	O
Digoxin	B
treatment	O
[	O
more	O
than	O
(	O
>	B
)	I
0	I
.	I
125	I
milligram	I
(	I
mg	I
)	O
]	O
.	O

Uncontrolled	B
Diabetes	B
[	O
hemoglobin	B
A1c	I
,	O
(	O
HbA1c	B
)	O
>	B
7	I
.	I
5	I
%	I
]	O
.	O

Severe	B
or	O
uncontrolled	B
hypertension	B
[	O
resting	B
Systolic	B
Blood	I
Pressure	I
(	O
SBP	B
)	O
>	B
180	I
millimeters	I
of	I
mercury	I
(	O
mmHg	O
)	O
,	O
or	O
resting	B
Diastolic	B
Blood	I
Pressure	I
(	O
DBP	B
)	O
>	B
110mmHg	I
at	B
screening	I
period	I
]	O
.	O

Severe	B
hypotension	B
[	O
resting	B
SBP	B
less	B
than	I
(	I
<	I
)	I
90mmHg	I
,	O
or	O
resting	B
DBP	B
<	B
50mmHg	I
]	O
.	O

Resting	B
heart	B
rate	I
<	B
60	I
beat	I
per	I
minute	I
(	O
bpm	O
)	O
.	O

Any	O
contradiction	B
to	O
Bisoprolol	B
according	O
to	O
label	O
,	O
including	O
:	O

Acute	B
heart	I
failure	I
or	O
during	O
episodes	O
of	O
heart	B
failure	I
decompensation	I
requiring	O
intravenous	B
inotropic	I
therapy	I
.	O

Cardiogenic	B
shock	I
.	O

Atrioventricular	B
block	I
of	I
second	I
or	I
third	I
degree	I
(	O
without	B
a	O
pacemaker	B
)	O
.	O

Sick	B
sinus	I
syndrome	I
.	O

Sinoatrial	B
block	I
.	O

Slowed	B
heart	B
rate	I
,	O
causing	O
symptoms	B
(	O
symptomatic	B
bradycardia	B
)	O
,	O

Decreased	B
blood	B
pressure	I
,	O
causing	O
symptoms	B
(	O
symptomatic	B
hypotension	B
)	O
,	O

Severe	B
bronchial	B
asthma	I
or	O
severe	B
chronic	B
obstructive	I
pulmonary	I
disease	I
.	O

Sever	B
forms	O
of	O
peripheral	B
arterial	I
occlusive	I
disease	I
and	O
Raynaud	B
'	I
s	I
syndrome	I
.	O

Untreated	B
phaeochromocytoma	B
.	O

Metabolic	B
acidosis	I
.	O

Hypersensitivity	B
to	O
bisoprolol	B
or	O
to	O
any	B
of	O
the	O
excipients	B
.	O

Severe	B
Arrhythmia	B
including	O
atrial	B
fibrillation	I
,	O
atrial	B
flutter	I
,	O
ventricular	B
fibrillation	I
,	O
ventricular	B
flutter	I
or	O
ventricular	B
tachycardia	I
.	O

Significant	B
valvular	B
heart	I
disease	I
,	O
congenital	B
heart	I
disease	I
,	O
pulmonary	B
heart	I
disease	I
or	O
perinatal	B
heart	I
disease	I
.	O

Acute	B
pulmonary	I
edema	I
.	O

Severe	B
hepatic	B
dysfunction	I
,	O
defined	O
as	O
:	O

Serum	B
Alanine	I
Aminotransferase	I
(	O
ALT	B
)	O
>	B
triple	I
the	I
upper	I
limit	I
of	I
the	I
normal	I
range	I
;	O
and	O
/	O
or	O

Serum	B
Aspartate	I
Aminotransferase	I
(	O
AST	B
)	O
>	B
triple	I
the	I
upper	I
limit	I
of	I
the	I
normal	I
value	I
range	I
and	O
/	O
or	O

Severe	B
renal	B
dysfunction	I
,	O
defined	O
as	O
:	O

Serum	B
creatinine	I
>	B
twice	I
the	I
upper	I
limit	I
of	I
the	I
normal	I
range	I

Chronic	B
Kidney	I
Disease	I
(	O
glomerular	B
filtration	I
rate	I
<	B
45	I
Milliliter	I
per	I
minute	I
)	O
.	O

Hyperthyroidism	B
or	O
hypothyroidism	B
.	O

Severe	B
infectious	B
disease	I
,	O
example	O
(	O
eg	O
)	O
Human	B
Immunodeficiency	I
Virus	I
positive	I
or	O
active	B
tuberculosis	B
.	O

Severe	B
autoimmune	B
disease	I
,	O
e	O
.	O
g	O
.	O
lupus	B
erythematosus	I
,	O
multiple	B
sclerosis	I
.	O

Severe	B
respiratory	O
,	O
digestive	O
,	O
hematological	B
disease	I
(	O
including	O
Anemia	B
of	O
Hb	B
<	B
100	I
gram	I
per	I
litre	I
)	O
or	O
tumor	B
.	O

Known	O
to	O
be	O
hypersensitivity	B
to	O
Bisoprolol	B
,	O
or	O
any	B
of	O
the	O
excipient	B
.	O

Substance	O
or	O
alcohol	B
abuse	I
.	O

Received	O
heart	B
transplantation	I
or	O
pacemaker	B
implantation	I
;	O
revascularization	B
treatment	O
within	B
3	I
months	I
;	O
or	O
plan	O
to	O
receive	O
above	O
treatment	O
in	B
6	I
months	I
.	O

Currently	O
undertaking	O
other	O
treatment	O
that	O
may	O
affect	O
the	O
safety	O
and	O
/	O
or	O
efficacy	O
evaluation	O
,	O
e	O
.	O
g	O
.	O
beta	B
receptors	I
agonists	I
,	O
et	O
cetera	O
.	O

No	O
legal	O
ability	O
or	O
legal	O
ability	O
is	O
limited	O
.	O

Subjects	O
unlikely	O
to	O
cooperate	O
in	O
the	O
study	O
or	O
with	O
inability	O
or	O
unwillingness	O
to	O
give	O
informed	O
consent	O
.	O

Child	O
-	O
bearing	O
period	O
women	O
without	O
effective	O
contraceptive	O
measures	O
,	O
pregnancy	O
and	O
lactation	O
.	O

Participation	O
in	O
another	O
clinical	O
trial	O
within	O
the	O
past	O
90	O
days	O
.	O

Other	O
significant	O
condition	O
that	O
in	O
the	O
Investigator	O
'	O
s	O
opinion	O
would	O
exclude	O
the	O
subject	O
from	O
the	O
trial	O
.	O

18	B
-	I
80	I
year	B
,	O
male	B
or	O
female	B
.	O

Chronic	B
Heart	I
failure	I
subjects	O
with	O
medical	O
history	O
of	O
cardiac	B
disease	I
or	O
other	O
related	B
cardiovascular	B
disease	I
.	O

Left	B
ventricular	I
ejection	I
fraction	I
(	O
LVEF	B
)	O
less	O
than	O
or	O
equal	O
to	O
(	O
=	B
<	I
)	I
40	I
percent	I
(	I
%	I
)	O
.	O

New	O
York	O
Heart	O
Association	O
(	O
NYHA	B
)	O
class	O
of	O
II	B
-	I
IV	I

NYHA	O
II	O
:	O
Slight	O
limitation	O
of	O
physical	O
activity	O
.	O
Comfortable	O
at	O
rest	O
,	O
but	O
ordinary	O
physical	O
activity	O
results	O
in	O
undue	O
breathlessness	O
,	O
fatigue	O
or	O
palpitation	O
.	O

NYHA	O
III	O
:	O
Marked	O
limitation	O
of	O
physical	O
activity	O
.	O
Comfortable	O
at	O
rest	O
,	O
but	O
less	O
than	O
ordinary	O
activity	O
causes	O
undue	O
breathlessness	O
,	O
fatigue	O
or	O
palpitation	O
.	O

NYHA	O
IV	O
:	O
Unable	O
to	O
carry	O
on	O
any	O
physical	O
activity	O
without	O
discomfort	O
.	O
Symptoms	O
at	O
rest	O
can	O
be	O
present	O
.	O
If	O
any	O
physical	O
activity	O
is	O
undertaken	O
,	O
discomfort	O
increased	O
.	O

Signed	O
Informed	O
Consent	O
Form	O
(	O
ICF	O
)	O
.	O

Target	B
lesion	I
located	O
in	O
the	O
left	B
main	I
stem	I

STEMI	B

Restenosis	B

Cardiogenic	B
shock	I

Malignancies	B
or	O
other	B
comorbid	B
conditions	I
with	O
life	O
expectancy	O
less	B
than	I
12	I
months	I
or	O
that	O
may	O
result	O
in	O
protocol	O
noncompliance	O

Known	O
allergy	B
to	O
the	O
study	B
medications	I
(	O
probucol	B
,	O
sirolimus	B
,	O
zotarolimus	B
)	O

Pregnancy	B
(	O
present	B
,	O
suspected	O
,	O
or	O
planned	O
)	O

Patients	O
older	B
than	I
18	I
years	B

Ischemic	B
symptoms	I
or	O
evidence	O
of	O
myocardial	B
ischemia	I
(	O
inducible	B
or	O
spontaneous	B
)	O
in	O
the	O
presence	O
of	O
>	B
50	I
%	I
de	B
novo	I
stenosis	B
located	O
in	O
native	B
coronary	I
vessels	I

Intolerability	B
of	O
tamsulosin	B
or	O
related	B
drugs	I

Investigator	O
discretion	O

Unwillingness	O
or	O
inability	O
to	O
comply	O
with	O
protocol	O
procedures	O
and	O
assessments	O

Male	B

18	B
years	I
of	O
age	B

Presenting	O
with	O
hernia	B
requiring	O
surgical	B
intervention	I

Pregnant	B
woman	B
or	O
breastfeeding	O

immunosuppression	B
including	O
AIDS	B
,	O
corticosteroids	B
over	B
60mg	I
/	I
day	I

ongoing	O
antibiotic	B
treatment	B
at	B
the	I
day	I
of	I
inclusion	I

impossibility	B
to	I
obtain	I
a	O
signed	O
consent	O
form	O
.	O

Patient	O
harboring	O
a	O
GRE	O
or	O
CRE	B
bacteria	I

Colonization	B
confirmed	B
by	I
our	I
microbiology	I
department	I
,	O
including	O
at	B
least	I
3	I
positives	B
swabs	B
in	B
the	I
last	I
month	I

Ongoing	O
serious	B
bacterial	B
infections	I
at	B
the	I
time	I
of	I
screening	I
.	O

Other	O
significant	O
medical	O
conditions	O
that	O
could	O
increase	O
the	O
risk	O
to	O
the	O
subject	O
.	O

Females	O
who	O
are	O
pregnant	O
,	O
breast	O
feeding	O
,	O
or	O
planning	O
a	O
pregnancy	O
during	O
the	O
course	O
study	O
.	O

Participation	O
in	O
a	O
study	O
with	O
an	O
Investigational	O
Medicinal	O
Product	O
(	O
IMP	O
)	O
other	O
than	O
IgPro20	O
within	O
three	O
months	O
prior	O
to	O
enrollment	O
.	O

Male	B
or	O
female	B
on	O
stable	B
dose	I
of	O
IgPro20	B
(	O
Hizentra	B
)	O
therapy	O
.	O

Women	O
of	O
childbearing	O
potential	O
must	O
be	O
using	O
and	O
agree	O
to	O
continue	O
using	O
medically	O
approved	O
contraception	O
(	O
which	O
must	O
be	O
discussed	O
with	O
the	O
study	O
doctor	O
)	O
and	O
must	O
have	O
a	O
negative	O
pregnancy	O
test	O
at	O
screening	O
.	O

Subjects	O
with	O
PID	B
,	O
eg	O
,	O
with	O
a	O
diagnosis	O
of	O
common	B
variable	I
immunodeficiency	I
or	O
X	B
-	I
linked	I
agammaglobulinemia	I
,	O
as	O
defined	O
by	O
the	O
Pan	B
American	I
Group	I
for	I
Immune	I
Deficiency	I
and	O
the	O
European	B
Society	I
of	I
Immune	I
Deficiencies	I
.	O

With	O
infusion	O
parameters	O
as	O
specified	O
below	O
:	O

Experience	O
with	O
pump	B
-	I
assisted	I
infusions	I
of	O
IgPro20	B
at	O
the	O
tolerated	B
flow	B
rate	I
of	I
25	I
mL	I
/	I
h	I
per	I
injection	I
site	I
for	B
at	I
least	I
1	I
month	I
prior	I
to	I
Day	I
1	I
.	O

Total	O
weekly	B
IgPro20	B
dose	O
of	O
=	B
50	I
mL	I
(	O
=	B
10	I
g	I
)	O
.	O

Experience	O
with	O
pump	B
-	I
assisted	I
infusions	I
of	O
IgPro20	B
at	O
tolerated	B
volumes	B
of	I
25	I
mL	I
/	I
injection	I
site	I
for	B
at	I
least	I
1	I
month	I
prior	I
to	I
Day	I
1	I
.	O

Experience	O
with	O
frequent	B
(	O
2	B
-	I
7	I
times	I
per	I
week	I
)	O
infusions	O
of	O
IgPro20	B
at	O
the	O
tolerated	O
flow	O
rate	O
of	O
approximately	O
0	O
.	O
5	O
mL	O
/	O
min	O
(	O
equivalent	O
of	O
25	B
-	I
30	I
mL	I
/	I
h	I
)	O
per	O
injection	O
site	O
for	B
at	I
least	I
1	I
month	I
prior	I
to	I
Day	I
1	I
.	O

The	O
dose	O
(	O
volume	O
)	O
per	O
injection	O
site	O
should	O
not	B
exceed	B
25	I
mL	I
.	I

Age	B
less	B
than	I
18	I
years	I

American	B
Society	I
of	I
Anesthesiologist	I
Class	I
5	B

Projected	O
life	O
expectancy	O
less	B
than	I
30	I
days	I

Known	O
or	O
suspected	O
hypersensitivity	B
to	O
either	O
propofol	B
,	O
e	O
.	O
g	O
.	O
egg	B
or	O
soy	B
allergy	B
,	O
or	O
volatile	B
general	I
anesthetic	I
agents	I

Known	O
or	O
suspected	O
history	B
of	O
malignant	B
hyperthermia	I

Lobectomy	B
or	O
pneumonectomy	B

Esophagectomy	B

Radical	O
(	O
total	B
)	I
cystectomy	I

Pancreatectomy	B

Partial	B
hepatectomy	I

Hyperthermic	B
intraperitoneal	I
chemotherapy	I
(	O
HIPEC	B
)	O

Gastrectomy	B
(	O
subtotal	B
or	O
total	B
)	O

Cholecystectomy	B
or	O
bile	B
duct	I
resection	I

severe	B
coronary	B
artery	I
disease	I
,	O
heart	B
failure	I
,	O
kidney	B
failure	I

insulin	B
-	I
dependent	I
DM	I
(	O
diabetes	B
mellitus	I
)	O
,	O
poorly	B
controlled	I
type	B
II	I
DM	I

gastric	O
/	O
duodenal	B
ulcer	I

allergy	B
/	O
contra	B
-	I
indication	I
for	O
any	O
drug	B
used	I
in	I
the	I
study	I

corticosteroid	B
use	O
during	B
last	I
3	I
months	I

preoperative	B
use	O
of	O
opioid	B
drugs	I
(	O
excl	B
.	I
codeine	B
,	O
tramadol	B
)	O

neuropathy	B
/	O
sensory	B
impairment	I
of	O
lower	B
limbs	I

lack	O
of	O
co	O
-	O
operation	O
,	O
e	O
.	O
g	O
.	O
inability	B
to	I
use	I
a	O
PCA	B
(	I
patient	I
controlled	I
analgesia	I
)	I
-	I
device	I

primary	B
total	B
knee	I
replacement	I
surgery	I

ASA	O
(	O
american	B
society	I
of	I
anesthesiologists	I
)	O
class	O
1	B
-	I
3	I

Can	O
not	B
cooperate	O
with	O
the	O
treatment	O

Can	O
not	B
obtain	O
the	O
child	O
'	O
s	O
parental	O
consent	O

generally	B
healthy	I
grade	O
1	O
-	O
2	O
school	O
children	B

with	O
written	O
parental	O
consent	O

with	O
at	B
least	I
1	I
sound	B
and	O
fully	B
erupted	I
permanent	B
first	I
molar	I

Hypersensitivity	B
to	O
the	O
active	B
substance	I
,	O
to	O
FCM	B
or	O
any	O
of	O
its	O
excipients	B

Known	O
serious	B
hypersensitivity	B
to	O
other	O
parenteral	B
iron	I
products	I

Anaemia	B
not	B
attributed	O
to	O
iron	B
deficiency	I
,	O
e	O
.	O
g	O
.	O
other	B
microcytic	B
anaemia	I

Evidence	O
of	O
iron	B
overload	O
or	O
disturbances	O
in	O
the	O
utilisation	O
of	O
iron	B

Patients	O
aged	B
at	B
least	I
18	I
years	I

Patients	O
with	O
chronic	B
heart	I
failure	I
present	O
for	B
at	I
least	I
12	I
months	I

Confirmed	O
presence	O
of	O
iron	B
deficiency	O

Serum	B
haemoglobin	I
of	O
9	B
.	I
5	I
to	I
14	I
.	I
0	I
g	I
/	I
dL	I

Emergency	B
surgery	I

Monitored	B
Anesthesia	I
Care	I
(	O
i	O
.	O
e	O
.	O
,	O
regional	B
anesthesia	I
alone	B
without	B
plans	O
for	O
general	B
anesthesia	I
)	O

Surgery	B
involving	O
the	O
eye	B
,	O
eyebrow	B
,	O
forehead	B
,	O
or	O
frontal	B
scalp	I
near	O
the	O
sensor	O
placement	O

Poor	O
health	O
literacy	O

Allergy	B
,	O
or	O
have	O
experienced	O
any	O
drug	B
reaction	I
to	O
ketamine	B

Pregnant	B
or	O
lactating	B

Currently	B
in	O
active	B
alcohol	B
withdrawal	I

Current	O
diagnosis	O
of	O
otolaryngeal	B
cancer	I
and	O
undergoing	B
surgery	B
with	O
general	B
anesthesia	I

Competent	O
to	O
provide	O
informed	O
consent	O

Coagulopathies	B
(	O
with	O
prothrombin	B
concentration	I
less	B
than	I
60	I
%	I
or	O
INR	B
more	B
than	I
1	I
.	I
5	I
)	O

In	O
-	O
ability	O
to	O
postpone	O
anti	B
-	I
coagulation	I
medications	I
.	O

Infection	B
or	O
injury	B
or	O
a	O
lesion	B
at	B
the	I
block	I
site	I
.	O

Suspected	O
cervical	B
vertebral	I
column	I
injury	I
necessitating	O
using	O
a	O
neck	O
collar	O
.	O

A	O
compromised	B
lung	I
on	O
the	O
contralateral	B
side	I
of	I
the	I
block	I
(	O
Pneumothorax	B
,	O
hemothorax	B
or	O
Pneumonectomy	B
)	O
.	O

Traumatic	B
vascular	I
injuries	I
or	O
operative	B
interventions	I
(	O
Surgical	B
harvesting	I
)	O
involving	O
arteries	B
of	I
the	I
upper	I
limb	I
on	I
the	I
operative	I
side	I
.	O

Patients	O
with	O
communication	B
difficulties	I
.	O

Hypersensitivity	B
to	O
local	B
anesthetics	I
and	O
/	O
or	O
Dexamethasone	B
.	O

Patients	O
on	O
perioperative	B
intravenous	B
(	I
IV	I
)	I
steroids	I
.	O

Patients	O
undergoing	O
surgeries	B
in	O
the	O
upper	B
limb	I
(	O
arm	B
,	O
forearm	B
or	O
hand	B
)	O

hematology	B
diseases	I

clotting	B
factor	I
deficiency	I

healthy	B

no	B
allergy	B
known	O
to	O
these	B
drugs	I

second	B
trimester	I
abortion	B

(	O
1	O
)	O
Uterine	B
abnormalities	I
(	O
e	O
.	O
g	O
.	O
septate	O
,	O
bicornuate	O
and	O
fibroid	B
uterus	I
,	O
Asherman	B
Syndrome	I
)	O
.	O

Concurrent	B
use	O
of	O
organic	B
nitrites	I
and	O
nitrates	B
.	O

Severe	B
hepatic	B
impairment	I
.	O

Severe	B
renal	B
impairment	I
.	O

Hypotension	B
.	O

Recent	B
stroke	B
or	O
heart	B
attack	I
.	O

(	O
1	O
)	O
cases	O
of	O
infertility	B
,	O
older	B
than	I
20	I
years	I
of	O
age	B
and	O
not	B
older	I
than	I
40	I
years	I
.	O

(	O
2	O
)	O
Body	B
mass	I
index	I
(	O
BMI	B
)	O
:	O
20	B
-	I
29	I
.	O

(	O
3	O
)	O
women	B
have	O
experienced	O
two	B
or	I
more	I
implantation	B
failure	B
attributed	O
to	O
inadequate	B
endometrial	I
development	I
.	O

NA	O

Informed	O
consent	O
must	O
be	O
obtained	O
prior	O
to	O
any	O
study	O
procedure	O
.	O

Age	B
>	B
18	I
years	I
.	I

Subjects	O
of	O
STEMI	B
who	O
underwent	O
primary	B
PCI	I
within	B
the	I
first	I
12	I
hours	I
.	I

Contraindication	B
for	O
the	O
use	O
of	O
corticosteroids	B
or	O
local	B
anesthetics	I

Presence	O
of	O
inflammatory	B
arthropathy	I
or	O
neuropathy	O

Skin	B
lesions	I
in	O
the	O
area	O

diabetes	B
mellitus	I

Infiltration	B
or	O
previous	B
surgery	I
in	O
the	O
area	O

Refusal	O
to	O
participate	O
in	O
the	O
study	O

Clinical	O
suspicion	O
of	O
Morton	B
neuroma	I
confirmed	O
in	O
ultrasound	B
scan	I

Symptoms	B
present	O
more	B
than	I
six	I
months	I

The	O
thickness	O
of	O
the	O
nerve	O
must	O
be	O
at	B
least	I
2	I
mm	I
in	O
short	O
axis	O
and	O
at	B
least	I
5	I
mm	I
in	O
the	O
longitudinal	O
axis	O
.	O

hypersensitivity	B
to	O
perindopril	B
or	O
to	O
other	B
ACE	B
inhibitors	I
,	O
amlodipine	B
,	O
atorvastatin	B
,	O
dihydropyridines	B
or	O
to	O
or	O
statins	B

angioneurotic	B
edema	I
in	O
medical	O
history	O
(	O
hereditary	B
/	O
idiopathic	B
or	O
associated	B
with	O
prior	B
treatment	B
with	O
ACE	B
inhibitors	I
)	O

severe	B
hypotension	B
,	O
shock	B
,	O
including	O
cardiogenic	B
shock	I

hemodynamically	B
unstable	I
heart	B
failure	I

Active	O
liver	B
disease	I
or	O
unexplained	B
persistent	B
elevations	B
of	O
serum	B
transaminases	I
more	B
than	I
three	I
times	I
normal	I

Women	B
of	O
childbearing	B
age	I
without	B
reliable	B
contraception	B

pregnancy	B

breastfeeding	O

Patients	O
with	O
contraindications	B
listed	B
in	I
the	I
currently	I
valid	I
SP	I

a	O
very	B
high	I
cardiovascular	B
risk	I
and	O
LDL	B
-	I
cholesterol	I
>	B
1	I
.	I
8	I
mmol	I
/	I
l	I

a	O
high	B
cardiovascular	B
risk	I
and	O
LDL	B
-	I
cholesterol	I
>	B
2	I
.	I
5	I
mmol	I
/	I
l	I

Patient	O
with	O
a	O
high	B
or	O
very	B
high	I
cardiovascular	B
risk	I
treated	O
by	O
lipidlowering	B
therapy	I
with	O
statin	B

1	O
.	O

Unable	B
to	I
ambulate	I
at	I
least	I
150	I
feet	I
prior	B
to	O
stroke	B
,	O
or	O
experienced	O
intermittent	B
claudication	I
while	B
walking	I
;	O

2	O
.	O
history	B
of	O
congestive	B
heart	I
failure	I
,	O
unstable	B
cardiac	I
arrhythmias	I
,	O
hypertrophic	B
cardiomyopathy	I
,	O
severe	B
aortic	I
stenosis	I
,	O
angina	B
or	O
dyspnea	B
at	I
rest	I
or	O
during	O
ADL	O
'	O
s	O
;	O

3	O
.	O

History	B
of	O
oxygen	B
dependence	I
;	O

4	O
.	O

Preexisting	B
neurological	B
disorders	I
,	O
dementia	B
or	O
previous	B
stroke	B
;	O

5	O
.	O

History	B
of	O
major	B
head	I
trauma	I
;	O

6	O
.	O

Legal	B
blindness	I
or	O
severe	B
visual	I
impairment	I
;	O

7	O
.	O
history	B
of	O
psychosis	B
or	O
other	O
Axis	B
I	I
disorder	I
that	O
is	O
primary	B
;	O

8	O
.	O

Life	O
expectancy	O
<	B
1	I
yr	I
.	O
;	O

9	O
.	O

Severe	B
arthritis	I
or	O
other	O
problems	B
that	I
limit	I
passive	I
range	I
of	I
motion	I
;	O

10	O
.	O

History	B
of	O
DVT	B
or	O
pulmonary	B
embolism	I
within	B
6	I
months	I
;	O

11	O
.	O

Uncontrolled	B
diabetes	B
with	O
recent	O
weight	B
loss	I
,	O
diabetic	B
coma	I
,	O
or	O
frequent	B
insulin	B
reactions	I
;	O

12	O
.	O

Severe	B
hypertension	I
with	O
systolic	B
>	B
200	I
mmHg	I
and	O
diastolic	B
>	B
110	I
mmHg	I
at	O
rest	O
;	O

13	O
.	O
attempt	B
of	I
suicide	I
in	B
the	I
last	I
2	I
years	I
or	O
at	B
suicidal	I
risk	I
assessed	O
by	O
SCID	B
interview	I
;	O

14	O
.	O

Previous	O
or	O
current	O
enrollment	O
in	O
a	O
clinical	O
trial	O
to	O
enhance	O
motor	O
recovery	O
;	O
15	O
)	O
currently	O
exercising	O
≥	O
2	O
times	O
per	O
week	O
(	O
≥	O
20	O
minutes	O
)	O
;	O

16	O
)	O
Presence	O
of	O
non	B
-	I
MR	I
compatible	I
implants	I
,	O
pregnancy	B
or	O
severe	B
claustrophobia	B
.	O

1	O
)	O
age	B
50	B
-	I
70	I

2	O
)	O
stroke	B
within	B
the	I
past	I
6	I
to	I
60	I
months	I
,	O

3	O
)	O
major	B
depressive	I
disorder	I
(	O
PHQ	B
-	I
9	I
>	B
10	I
)	O
and	O
diagnosed	O
using	O
the	O
Structured	B
Clinical	I
Interview	I
for	I
Depression	I
(	I
SCID	I
)	I
according	I
to	I
the	I
Diagnostic	I
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
Fourth	I
Edition	I
(	I
DSM	I
-	I
IV	I
)	I
,	O

4	O
)	O
residual	B
paresis	I
in	O
the	O
lower	B
extremity	I
(	O
Fugl	B
-	I
Meyer	I
LE	I
motor	I
score	I
<	B
34	I
)	O
,	O

5	O
)	O
ability	B
to	I
walk	I
without	I
assistance	I
and	O
without	B
an	O
AFO	B
on	I
the	I
treadmill	I
≥	B
30	I
seconds	I
at	O
speeds	B
ranging	O
from	B
0	I
.	I
2	I
-	I
0	I
.	I
8	I
m	I
/	I
s	I
,	O

6	O
)	O
no	B
antidepressant	B
medications	O
or	O
clinically	B
able	I
to	I
discontinue	I
medications	I
,	O

7	O
)	O
HRSD	B
question	I
#	I
9	I
regarding	O
suicide	O
<	B
2	I
,	O

8	O
)	O
provision	O
of	O
informed	O
consent	O
.	O

In	O
addition	O
,	O
all	O
subjects	O
who	O
meet	O
criteria	O
for	O
the	O
training	O
portion	O
must	O
complete	O
an	O
exercise	O
tolerance	O
test	O
and	O
be	O
cleared	O
for	O
participation	O
by	O
the	O
study	O
cardiologist	O
.	O

1	O
.	O

Patient	O
or	O
relatives	O
unable	O
or	O
unwilling	O
to	O
give	O
informed	O
consent	O

2	O
.	O

Contraindication	B
or	O
allergy	B
to	O
paracetamol	B
or	O
artesunate	B
therapy	O

3	O
.	O

Known	O
cirrhosis	B
,	O
or	O
>	B
6	I
standard	I
alcoholic	I
drinks	I
/	I
day	I

4	O
.	O

Pregnancy	B

1	O
.	O

Patient	O
age	B
≥	B
12	I
years	I

2	O
.	O

Presence	O
of	O
P	B
.	I
knowlesi	I
malaria	I
,	O
confirmed	O
by	O
positive	B
blood	B
smear	I
with	B
asexual	I
forms	I
of	I
P	I
.	I
knowlesi	I
.	O

3	O
.	O

Temperature	B
>	B
38C	I
on	O
admission	O
or	O
fever	O
during	O
the	O
preceding	O
48	O
hours	O

4	O
.	O

Enrolled	O
within	B
18	I
hours	I
of	O
commencing	O
antimalarial	B
treatment	I

5	O
.	O

Written	O
informed	O
consent	O
from	O
patient	O
or	O
attending	O
relative	O
able	O
to	O
and	O
willing	O
to	O
give	O
informed	O
consent	O
.	O

Consent	O
form	O
and	O
information	O
sheets	O
will	O
be	O
translated	O
into	O
Malay	O
and	O
copies	O
provided	O
to	O
the	O
patient	O
.	O

Active	O
alcohol	O
or	O
drug	O
use	O
or	O
dependence	O
which	O
may	O
interfere	O
with	O
adherence	O
to	O
study	O
requirements	O

HIV	B
-	I
infected	I
at	B
screening	I
or	O
enrollment	O

Estimated	B
CrCl	I
<	B
60	I
mL	I
/	I
min	I

Past	O
participation	O
in	O
an	O
HIV	O
vaccine	O
study	O

Positive	B
Hepatitis	B
B	I
surface	I
antigen	I
test	I

Underlying	O
medical	B
condition	I
with	O
survival	B
unlikely	I
during	O
follow	O
-	O
up	O
period	O

Any	O
condition	B
that	O
in	O
the	O
opinion	O
of	O
study	O
staff	O
would	O
make	B
participation	I
in	I
the	I
study	I
unsafe	I
or	O
interfere	B
with	I
achieving	I
study	I
objectives	I

Pregnant	B
or	O
breast	O
feeding	O

Actively	O
trying	O
to	O
achieve	O
pregnancy	O

18	B
-	I
64	I
years	I
old	B

Able	O
to	O
give	O
consent	O

unprotected	O
sex	O
(	O
in	B
past	I
6	I
months	I
)	O
with	O
1	B
or	I
more	I
men	B
of	I
unknown	I
HIV	I
status	I

evaluated	B
for	I
an	I
STI	I
within	B
6	I
months	I
prior	I
to	I
screening	I

sex	O
in	B
last	I
6	I
months	I
with	O
an	O
HIV	B
-	I
infected	I
partner	I

IDU	B
with	O
report	O
of	O
using	O
previously	O
used	O
or	O
shared	O
needles	O
in	B
past	I
6	I
months	I
or	O
has	O
been	O
in	O
a	O
methadone	B
,	O
buprenorphine	B
,	O
or	O
suboxone	B
treatment	B
program	I
in	B
past	I
6	I
months	I
or	O
engaging	O
in	O
high	O
-	O
risk	O
sexual	O
behaviors	O

individuals	O
engaging	O
in	O
transactional	O
sex	O
(	O
i	O
.	O
e	O
sex	O
for	O
money	O
,	O
drugs	O
,	O
or	O
housing	O
)	O

Infrequently	O
uses	O
condoms	O
during	O
sex	O
with	O
1	B
or	I
more	I
partners	B
of	I
unknown	I
HIV	I
status	I
who	O
are	O
known	O
to	O
be	O
at	O
substantial	O
risk	O
of	O
HIV	O
infection	O
(	O
IDU	B
or	O
bisexual	B
male	I
partner	I
)	O

CrCl	B
=	B
60	I
ml	I
/	I
min	I

HIV	B
-	I
uninfected	I
women	B
desiring	O
PrEP	B

Type	B
1	I
diabetes	I
,	O
Secondary	B
diabetes	I
,	O
gestational	B
diabetes	I

Ongoing	B
dementia	B
treatment	B
or	O
anti	B
-	I
depressive	I
disorder	I
medication	I

Uncontrolled	B
psychiatric	O
disorder	O

BDI	B
=	B
30	I
points	I

Heavy	B
alcoholics	B

Underlying	O
chronic	B
liver	I
disease	I
(	O
hemochromatosis	B
,	O
liver	B
cell	I
carcinoma	I
,	O
autoimmune	B
liver	I
disease	I
,	O
liver	B
cirrhosis	I
,	O
chronic	B
viral	I
hepatitis	I
)	O

Allergy	B
or	O
hypersensitivity	B
to	O
target	B
medication	I
or	O
any	O
of	O
its	O
components	O

Renal	B
failure	I
,	O
moderate	B
or	O
severe	B
renal	B
impairment	I
(	O
estimated	B
glomerular	I
filtration	I
rate	I
<	B
30	I
mL	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
)	O
,	O
or	O
ongoing	B
dialysis	B

Abnormal	B
liver	B
function	I
(	O
AST	B
/	I
ALT	I
>	B
x3	I
upper	I
normal	I
limit	I
)	O

History	O
of	O
alcohol	O
or	O
drug	B
abuse	I
in	B
the	I
previous	I
3	I
months	I

Premenopausal	B
women	B
who	O
are	O
nursing	B
or	O
pregnant	B

Human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
or	O
human	B
immunodeficiency	I
virus	I
(	I
AIDS	I
)	I

chronic	B
pancreatitis	I
or	O
pancreatic	B
cancer	I

Type	B
2	I
diabetic	I
patients	O

Age	B
=	B
50	I

Glycemic	O
control	O
:	O
HbA1c	B
=	B
10	I
.	I
0	I
%	I

10	O
=	O
Beck	B
Depression	I
Inventory	I
(	I
BDI	I
)	I
<	B
30	I
points	I

Participants	O
who	O
can	O
undergo	O
contraception	O
in	O
case	O
of	O
being	O
in	O
childbearing	O
period	O

Understands	O
the	O
study	O
procedure	O
,	O
alternatives	O
,	O
and	O
risks	O
and	O
voluntarily	O
agrees	O
to	O
participate	O
by	O
giving	O
written	O
informed	O
concent	O

Is	O
currently	O
participating	O
or	O
has	O
participated	O
in	O
a	O
study	O
with	O
an	O
investigational	O
agent	O
or	O
using	O
an	O
investigational	O
device	O
within	O
4	O
weeks	O
of	O
the	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
received	O
sorafenib	B
or	O
oxaliplatin	B
-	O
based	O
chemotherapy	B
within	B
14	I
days	I
of	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
had	O
esophageal	O
or	O
gastric	B
variceal	I
bleeding	I
within	B
the	I
last	I
6	I
months	I

Has	O
clinically	O
apparent	O
ascites	B
on	O
physical	O
examination	O

Has	O
portal	B
vein	I
invasion	I
at	O
the	O
main	B
portal	I
branch	I
(	I
Vp4	I
)	I
,	O
inferior	B
vena	I
cava	I
,	O
or	O
cardiac	B
involvement	I
of	O
HCC	B
based	O
on	O
imaging	B

Has	O
had	O
clinically	O
diagnosed	O
hepatic	B
encephalopathy	I
in	B
the	I
last	I
6	I
months	I

Has	O
had	O
a	O
solid	O
organ	O
or	O
hematologic	B
transplant	I

Has	O
had	O
prior	O
systemic	B
therapy	I
for	O
HCC	B
in	O
the	O
advanced	O
(	O
incurable	O
)	O
setting	O
other	B
than	I
sorafenib	B
or	O
oxaliplatin	B
-	O
based	O
chemotherapy	B
,	O
prior	B
to	O
start	O
of	O
study	O
medication	O

Has	O
an	O
active	B
autoimmune	B
disease	I
that	O
has	O
required	O
systemic	B
treatment	I
in	B
the	I
past	I
2	I
years	I
.	O

Replacement	O
therapy	O
is	O
not	O
considered	O
a	O
form	O
of	O
systemic	O
treatment	O
.	O

Has	O
a	O
diagnosis	O
of	O
immunodeficiency	B
or	O
is	O
receiving	O
systemic	B
steroid	I
therapy	I
or	O
any	O
other	O
form	O
of	O
immunosuppressive	B
therapy	I
within	B
7	I
days	I
prior	I
to	O
the	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
received	O
locoregional	B
therapy	I
to	O
liver	B
(	O
transcatheter	B
chemoembolization	I
[	I
TACE	I
]	I
,	O
transcatheter	B
embolization	I
[	I
TAE	I
]	I
,	O
hepatic	B
arterial	I
infusion	I
[	I
HAI	I
]	I
,	O
radiation	B
,	O
radioembolization	B
,	O
or	O
ablation	B
)	O
or	O
other	B
site	I
within	B
4	I
weeks	I
prior	I
to	O
the	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
had	O
major	B
surgery	I
to	O
liver	B
or	O
other	B
site	I
within	B
4	I
weeks	I
prior	I
to	O
the	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
had	O
a	O
minor	B
surgery	I
≤	B
7	I
days	I
prior	I
to	O
the	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
not	O
recovered	O
adequately	O
(	O
i	O
.	O
e	O
.	O
,	O
Grade	O
≤	O
1	O
or	O
baseline	O
)	O
from	O
the	O
toxicity	O
and	O
/	O
or	O
complications	O
from	O
any	O
intervention	O
prior	O
to	O
study	O
start	O

Has	O
a	O
diagnosed	O
additional	B
malignancy	B
within	B
3	I
years	I
prior	I
to	I
first	I
dose	I
of	I
study	I
medication	I
with	B
the	I
exception	I
of	I
curatively	B
treated	B
basal	B
cell	I
carcinoma	I
of	I
the	I
skin	I
,	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
skin	I
and	O
/	O
or	O
curatively	B
resected	B
in	B
situ	I
cancers	I

Has	O
a	O
known	O
history	B
of	O
,	O
or	O
any	O
evidence	O
of	O
,	O
central	B
nervous	I
system	I
(	I
CNS	I
)	I
metastases	I
and	O
/	O
or	O
carcinomatous	B
meningitis	I

Has	O
a	O
history	B
of	O
(	O
non	B
-	I
infectious	I
)	I
pneumonitis	I
that	O
required	O
steroids	B
or	O
current	B
pneumonitis	B

Has	O
an	O
active	B
infection	B
requiring	O
systemic	B
therapy	I

Is	O
pregnant	B
or	O
breast	O
feeding	O
or	O
expecting	O
to	O
conceive	O
or	O
father	O
starting	B
from	I
the	I
first	I
dose	I
of	I
study	I
medication	I
,	O
throughout	B
the	I
study	I
period	I
,	O
and	O
for	B
up	I
to	I
120	I
days	I
after	I
the	I
last	I
dose	I
of	I
study	I
medication	I

Has	O
received	O
prior	O
immunotherapy	B
with	O
an	O
anti	B
-	I
Programmed	I
Cell	I
Death	I
Receptor	I
1	I
(	I
PD	I
-	I
1	I
)	I
,	O
Programmed	B
Cell	I
Death	I
Receptor	I
Ligand	I
1	I
(	I
anti	I
-	I
PD	I
-	I
L1	I
)	I
,	O
or	O
anti	B
-	I
Programmed	I
Cell	I
Death	I
Receptor	I
Ligand	I
2	I
(	I
PD	I
-	I
L2	I
)	I
or	O
has	O
previously	O
participated	O
in	O
clinical	O
studies	O
with	O
pembrolizumab	B

Has	O
a	O
known	O
history	B
of	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I

Has	O
untreated	B
active	B
Hepatitis	B
B	I

Has	O
hepatitis	B
C	I
in	O
which	O
participants	O
received	O
therapy	B
for	I
HCV	I
<	B
4	I
weeks	I
prior	I
to	O
receiving	O
pembrolizumab	B

Has	O
received	O
a	O
live	B
vaccine	I
within	O
30	B
days	I
prior	I
to	O
the	O
first	O
dose	O
of	O
study	O
therapy	O

Has	O
a	O
HCC	B
diagnosis	O
confirmed	O
by	O
radiology	B
,	O
histology	B
,	O
or	O
cytology	B
(	O
fibrolamellar	O
,	O
and	O
mixed	B
hepatocellular	I
/	I
cholangiocarcinoma	I
subtypes	I
are	O
not	B
eligible	I
)	O

Has	O
Barcelona	B
Clinic	I
Liver	I
Cancer	I
(	I
BCLC	I
)	I
Stage	B
C	I
disease	B
or	O
BCLC	B
Stage	B
B	I
disease	B
not	B
amenable	B
to	I
locoregional	I
therapy	I
or	O
refractory	B
to	I
locoregional	I
therapy	I
and	O
not	B
amenable	B
to	I
a	I
curative	I
treatment	I
approach	I

Has	O
a	O
Child	O
-	O
Pugh	O
A	B
liver	O
score	O
within	B
7	I
days	I
prior	I
to	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
a	O
life	O
expectancy	O
of	O
>	B
3	I
months	I

Has	O
at	B
least	I
one	I
measurable	B
lesion	B
based	O
on	O
RECIST	B
version	I
1	I
.	I
1	I
as	O
determined	O
by	O
investigator	O

Has	O
Eastern	B
Cooperative	I
Oncology	I
Group	I
(	I
ECOG	I
)	I
performance	I
status	I
of	O
0	B
or	I
1	I
performed	O
within	B
7	I
days	I
prior	I
to	O
receiving	O
the	O
first	O
dose	O
of	O
study	O
medication	O

Has	O
documented	O
objective	O
radiographic	B
progression	O
during	B
or	I
after	I
treatment	O
with	O
sorafenib	B
or	O
oxaliplatin	B
-	O
based	O
chemotherapy	B
,	O
or	O
else	O
intolerance	B
to	O
sorafenib	B
or	O
oxaliplatin	B
-	O
based	O
chemotherapy	B

Female	B
participants	O
of	O
childbearing	B
potential	I
must	O
have	O
a	O
negative	B
urine	O
or	O
serum	B
pregnancy	I
test	I
within	B
72	I
hours	I
prior	I
to	O
receiving	O
the	O
first	O
dose	O
of	O
study	O
therapy	O

Female	B
and	O
male	B
participants	O
of	O
reproductive	B
potential	I
must	O
agree	O
to	O
use	O
adequate	B
contraception	I
starting	O
from	O
the	O
first	O
dose	O
of	O
study	O
medication	O
,	O
throughout	O
the	O
study	O
period	O
,	O
and	O
for	O
up	O
to	O
120	O
days	O
after	O
the	O
last	O
dose	O
of	O
study	O
medication	O

Emergent	B
condition	I
like	O
hematemesis	B
.	O

Patients	O
with	O
moderate	B
to	O
severe	B
hepatic	B
encephalopathy	I
.	O

Patients	O
with	O
hepatopulmonary	B
syndrome	I
.	O

Patients	O
with	O
known	O
or	O
suspected	O
hypersensitivity	B
to	O
the	O
used	B
medication	I
were	O
also	O
excluded	O
from	O
the	O
study	O
.	O

Patients	O
aged	B
between	B
40	I
and	I
60	I
years	I
old	I
.	O

With	O
Child	B
score	I
B	B
or	O
C	B

Presented	O
for	O
elective	B
gastrointestinal	B
endoscopy	I

Patient	O
with	O
contraindication	B
to	O
misoprostol	B
or	O
vasopressin	B
,	O
personal	B
history	I
or	O
cardiac	O
or	O
pulmonary	B
disease	I
,	O
history	B
of	O
prior	B
myomectomy	B

Female	B
age	B
20	B
-	I
50	I
y	I
/	I
o	I
who	O
plan	O
to	O
undergo	O
abdominal	B
myomectomy	I
for	O
symptomatic	B
myomatous	B
uterus	I

Prior	O
treatment	O
toxicities	O
have	O
not	O
resolved	O
to	O
<	O
Grade	O
2	O
according	O
to	O
NCI	O
CTCAE	O
Version	O
4	O
.	O
0	O
(	O
except	O
clinically	O
insignificant	O
toxicities	O
such	O
as	O
alopecia	O
)	O
.	O

Subjects	O
receiving	O
any	O
other	O
investigational	O
agents	O
.	O

Patients	O
with	O
active	O
tumor	B
lysis	I
syndrome	I
(	I
TLS	I
)	I
either	O
from	O
laboratory	O
or	O
clinical	O
changes	O
.	O

Patients	O
with	O
active	O
central	B
nervous	I
system	I
(	I
CNS	I
)	I
disease	I
defined	O
as	O
symptomatic	B
meningeal	B
lymphoma	I
or	O
known	O
CNS	B
parenchymal	I
lymphoma	I
.	O

History	O
of	O
severe	B
allergic	B
reactions	I
attributed	O
to	O
compounds	B
of	I
similar	I
chemical	I
or	I
biologic	I
composition	I
to	I
rituximab	I
or	O
other	O
agents	O
used	O
in	O
this	O
study	O
.	O

Subjects	O
with	O
uncontrolled	O
intercurrent	O
illness	O
.	O

HIV	B
-	I
positive	I
subjects	O
on	O
combination	B
antiretroviral	I
therapy	I
are	O
ineligible	O
because	O
of	O
the	O
potential	O
for	O
pharmacokinetic	O
interactions	O
with	O
Venetoclax	O
.	O

In	O
addition	O
,	O
these	O
subjects	O
are	O
at	O
increased	O
risk	O
of	O
lethal	O
infections	O
when	O
treated	O
with	O
marrow	O
suppressive	O
therapy	O
.	O

Appropriate	O
studies	O
will	O
be	O
undertaken	O
in	O
subjects	O
receiving	O
combination	O
antiretroviral	O
therapy	O
when	O
indicated	O
.	O

HIV	O
testing	O
prior	O
to	O
enrollment	O
is	O
not	O
required	O
for	O
screening	O
but	O
strongly	O
encouraged	O
for	O
patients	O
with	O
no	O
documented	O
prior	O
HIV	O
assessment	O
.	O

Presence	O
of	O
positive	B
test	O
results	O
for	O
hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
,	O
hepatitis	B
B	I
surface	I
antigen	I
(	I
HBsAg	I
)	I
,	O
or	O
hepatitis	B
C	I
(	I
HCV	I
)	I
antibody	I
.	O

Patients	O
who	O
are	O
positive	B
for	O
HCV	B
antibody	I
must	O
be	O
negative	B
for	O
HCV	B
by	O
polymerase	B
chain	I
reaction	I
(	I
PCR	I
)	I
to	O
be	O
eligible	O
for	O
study	O
participation	O

Patients	O
with	O
occult	O
or	O
prior	O
HBV	B
infection	I
(	O
defined	O
as	O
positive	B
total	B
hepatitis	I
B	I
core	I
antibody	I
[	I
HBcAb	I
]	I
and	O
negative	B
HBsAg	B
)	O
may	O
be	O
included	O
if	O
HBV	B
DNA	I
is	O
undetectable	B
.	O

These	O
patients	O
must	O
be	O
willing	O
to	O
undergo	O
monthly	O
DNA	O
testing	O
.	O

Women	B
who	O
are	O
pregnant	B
or	O
lactating	B

Malabsorption	B
syndrome	I
or	O
other	O
condition	B
that	I
precludes	I
enteral	I
route	I
of	I
administration	I

Chemotherapy	B
or	O
radiation	B
within	B
3	I
weeks	I
of	I
the	I
first	I
scheduled	I
study	I
treatment	I
.	O

Less	B
than	I
2	I
-	I
year	I
disease	B
free	I
from	O
another	B
primary	B
malignancy	I
(	O
other	B
than	I
squamous	B
or	I
basal	I
cell	I
carcinoma	I
of	I
the	I
skin	I
,	O
"	B
in	I
-	I
situ	I
"	I
carcinoma	I
of	I
the	I
cervix	I
or	O
breast	O
,	O
superficial	B
bladder	I
carcinoma	I
,	O
or	O
previously	O
treated	O
localized	B
prostate	I
cancer	I
with	O
normal	B
prostate	B
specific	I
antigen	I
(	I
PSA	I
)	I
levels	I
)	O
.	O

Patients	O
who	O
have	O
had	O
completed	O
all	O
anti	B
-	I
cancer	I
treatment	I
for	O
another	B
primary	B
malignancy	I
more	B
than	I
2	I
years	I
prior	I
to	O
screening	O
are	B
eligible	I
if	O
they	O
are	O
not	O
considered	O
to	O
have	O
a	O
"	O
currently	O
active	O
"	O
malignancy	O
based	O
on	O
having	O
less	O
than	O
a	O
30	O
%	O
risk	O
of	O
relapse	O
.	O

Major	B
surgery	I
,	O
other	B
than	I
diagnostic	B
surgery	I
,	O
within	B
2	I
weeks	I
.	O

Medical	B
condition	I
requiring	O
chronic	B
use	O
of	O
high	B
dose	I
systemic	B
corticosteroids	I
(	O
i	O
.	O
e	O
.	O
,	O
doses	O
of	O
prednisone	B
higher	B
than	I
10	I
mg	I
/	I
day	I
or	O
equivalent	O
)	O
.	O

Brief	O
(	O
<	B
15	I
days	I
)	O
treatment	O
with	O
glucocorticoids	B
(	O
prednisone	B
100	B
mg	I
by	I
mouth	I
daily	I
,	O
or	O
equivalent	O
)	O
is	O
acceptable	O
.	O

Known	O
allergy	B
to	O
both	O
xanthine	B
oxidase	I
inhibitors	I
and	O
rasburicase	B
.	O

Use	O
of	O
warfarin	B
is	O
prohibited	O
.	O

Anticoagulation	B
with	O
low	B
-	I
molecular	I
weight	I
heparin	I
(	O
i	O
.	O
e	O
.	O
enoxaparin	B
)	O
or	O
direct	B
thrombin	I
inhibitors	I
is	O
permitted	O
.	O

The	O
following	O
concomitant	O
medications	O
are	O
not	O
allowed	O
from	O
7	B
days	I
prior	I
to	O
the	O
first	O
dose	O
of	O
study	O
drug	O
and	O
during	O
venetoclax	B
administration	O
:	O
Strong	B
CYP3A4	I
inhibitors	I
including	O
but	O
not	O
limited	O
to	O
fluconazole	B
,	O
ketoconazole	B
,	O
and	O
clarithromycin	B
or	O
strong	B
CYP3A4	I
inducers	I
included	O
but	O
not	O
limited	O
to	O
rifampin	B
,	O
carbamazepine	B
.	O

Receipt	O
of	O
live	B
-	I
virus	I
vaccines	I
within	B
28	I
days	I
prior	I
to	O
the	O
initiation	O
of	O
study	O
treatment	O
or	O
need	O
for	O
live	B
-	I
virus	I
vaccines	I
at	O
any	B
time	I
during	I
study	O
treatment	O
.	O

Concomitant	O
medications	O
that	O
fall	O
into	O
the	O
categories	O
below	O
could	O
potentially	O
lead	O
to	O
adverse	O
reactions	O
and	O
should	O
be	O
considered	O
cautionary	O
.	O

Moderate	O
/	O
Weak	B
CYP3A	I
inducers	I
such	O
as	O
efavirenz	B
and	O
oxcarbazepine	B

CYP2C8	B
substrates	I
such	O
as	O
thiazolidinediones	B
(	O
glitazones	B
)	O
and	O
select	B
statins	B
(	O
because	O
of	O
expected	O
inhibition	O
of	O
the	O
metabolism	O
of	O
CYP2C8	O
substrates	O
)	O
by	O
venetoclax	O

CYP2C9	B
substrates	I
such	O
as	O
tolbutamide	B
(	O
because	O
of	O
expected	O
inhibition	O
of	O
the	O
metabolism	O
of	O
CYP2C9	O
substrates	O
by	O
venetoclax	O
.	O

It	O
is	O
recommended	O
to	O
exclude	O
CYP2C9	B
substrates	I
with	O
a	O
narrow	B
therapeutic	I
index	I
such	O
as	O
phenytoin	B
.	O

Histological	B
confirmation	B
of	O
relapsed	O
/	O
refractory	O
diffuse	B
large	B
B	B
-	I
cell	I
lymphoma	I
after	B
prior	O
rituximab	B
and	O
anthracycline	B
-	O
containing	O
systemic	O
treatment	O
regimen	O
such	O
as	O
R	B
-	I
CHOP	I
(	O
rituximab	B
,	O
cyclophosphamide	B
,	O
doxorubicin	B
,	O
vincristine	B
,	O
and	O
prednisone	B
)	O
,	O
R	B
-	I
EPOCH	I
(	O
rituximab	B
,	O
etoposide	B
phosphate	I
,	O
prednisone	B
,	O
vincristine	B
sulfate	I
,	O
cyclophosphamide	B
,	O
doxorubicin	B
hydrochloride	I
)	O
,	O
R	B
-	I
HyperCVAD	I
(	O
rituximab	B
,	O
cyclophosphamide	B
,	O
vincristine	B
sulfate	I
,	O
doxorubicin	B
hydrochloride	I
,	O
dexamethasone	B
)	O
etc	O
.	O

Subjects	O
must	O
have	O
received	O
no	B
more	I
than	I
2	I
prior	B
systemic	B
therapies	I
for	I
lymphoma	I
.	O

Prior	B
therapy	O
with	O
systemic	O
rituximab	B
monotherapy	O
or	O
conventional	B
chemotherapy	I
(	O
i	O
.	O
e	O
.	O
bendamustine	B
,	O
CVP	B
(	O
Cyclophosphamide	B
,	O
Vincristine	B
Sulfate	I
,	O
Prednisone	B
)	O
or	O
other	O
)	O
±	O
rituximab	B
for	O
indolent	B
non	B
-	I
Hodgkin	I
'	I
s	I
lymphoma	I
(	I
NHL	I
)	I
±	O
maintenance	B
/	O
extended	B
-	I
use	I
rituximab	B
will	O
count	O
as	O
1	O
line	O
of	O
systemic	O
therapy	O
.	O

Eastern	B
Cooperative	I
Oncology	I
Group	I
(	I
ECOG	I
)	I
Performance	I
status	I
≤	B
2	I

Subjects	O
must	O
have	O
normal	B
organ	I
and	I
marrow	I
function	I
as	O
defined	O
below	O
:	O

Hemoglobin	B
≥	B
8	I
.	I
0	I
g	I
/	I
dl	I

Absolute	B
neutrophil	I
count	I
≥	B
1	I
,	I
000	I
/	I
mcL	I

Platelet	B
count	I
≥	B
75	I
,	I
000	I
/	I
mcL	I

Total	B
bilirubin	I
≤	B
1	I
.	I
5	I
X	I
the	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
unless	O
a	O
known	O
history	O
of	O
impaired	B
bilirubin	I
conjugation	I
such	O
as	O
Gilbert	B
'	I
s	I
,	O
for	O
whom	O
the	O
maximum	B
will	I
be	I
2	I
.	I
5	I
ULN	I
.	O

Aspartate	B
transaminase	I
(	I
AST	I
)	I
(	I
SGOT	I
)	I
≤	B
2	I
.	I
5	I
X	I
institutional	I
ULN	I

Alanine	B
transaminase	I
(	I
ALT	I
)	I
(	I
SGPT	I
)	I
≤	B
2	I
.	I
5	I
X	I
institutional	I
ULN	I

International	B
normalized	I
ratio	I
(	I
INR	I
)	I
>	B
1	I
.	I
5	I
×	I
ULN	I

Patients	O
must	O
have	O
a	O
calculated	O
serum	B
creatinine	I
clearance	I
>	B
50	I
mL	I
/	I
min	I
using	O
Cockcroft	B
-	I
Gault	I
calculation	I
or	O
based	O
on	O
24	B
-	I
hour	I
urine	I
collection	I
performed	O
within	B
7	I
days	I
prior	I
to	O
treatment	O
.	O

Specific	O
guidelines	O
will	O
be	O
followed	O
regarding	O
inclusion	O
of	O
relapsed	O
/	O
refractory	O
DLBCL	O
based	O
on	O
Hepatitis	O
B	O
serological	O
testing	O
as	O
follow	O
:	O

HBsAg	B
negative	B
,	O
HBcAb	B
negative	B
,	O
HBsAb	B
positive	B
patients	O
are	O
eligible	O
.	O

Patients	O
who	O
test	O
positive	B
for	O
HBsAg	B
are	O
ineligible	O

Patients	O
with	O
HBsAg	B
negative	B
,	O
but	O
HBcAb	B
positive	B
(	O
regardless	O
of	O
HBsAb	O
status	O
)	O
should	O
have	O
a	O
HBV	B
DNA	I
testing	I
performed	O
and	O
protocol	O
eligibility	O
determined	O
as	O
follow	O
:	O

If	O
HBV	B
DNA	I
is	O
positive	B
,	O
the	O
subject	O
is	O
ineligible	O
.	O

If	O
HBV	B
DNA	I
is	O
negative	B
,	O
the	O
subject	O
may	O
be	O
included	O
but	O
must	O
undergo	O
HBV	O
DNA	O
PCR	O
testing	O
monthly	O
x	O
3	O
months	O
beginning	O
from	O
the	O
start	O
of	O
treatment	O

Subjects	O
must	O
have	O
the	O
ability	O
to	O
understand	O
and	O
the	O
willingness	O
to	O
sign	O
a	O
written	O
informed	O
consent	O
document	O
.	O

For	O
women	O
of	O
childbearing	O
potential	O
:	O
agreement	O
to	O
remain	O
abstinent	O
(	O
refrain	O
from	O
heterosexual	O
intercourse	O
)	O
or	O
use	O
a	O
contraceptive	O
method	O
with	O
a	O
failure	O
rate	O
of	O
<	O
1	O
%	O
per	O
year	O
during	O
the	O
treatment	O
period	O
and	O
for	O
at	O
least	O
30	O
days	O
after	O
the	O
last	O
dose	O
of	O
venetoclax	O
or	O
18	O
months	O
after	O
the	O
last	O
dose	O
of	O
rituximab	O
,	O
whichever	O
is	O
longer	O
.	O

A	O
woman	O
is	O
considered	O
to	O
be	O
of	O
childbearing	O
potential	O
if	O
she	O
is	O
postmenarcheal	O
,	O
has	O
not	O
reached	O
a	O
postmenopausal	O
state	O
(	O
<	O
12	O
continuous	O
months	O
of	O
amenorrhea	O
with	O
no	O
identified	O
cause	O
other	O
than	O
menopause	O
)	O
,	O
and	O
has	O
not	O
undergone	O
surgical	O
sterilization	O
(	O
removal	O
of	O
ovaries	O
and	O
/	O
or	O
uterus	O
)	O
.	O

For	O
men	O
:	O
agreement	O
to	O
remain	O
abstinent	O
(	O
refrain	O
from	O
heterosexual	O
intercourse	O
)	O
or	O
use	O
contraceptive	O
measures	O
,	O
and	O
agreement	O
to	O
refrain	O
from	O
donating	O
sperm	O
,	O
as	O
defined	O
below	O
:	O

With	O
female	O
partners	O
of	O
childbearing	O
potential	O
,	O
men	O
must	O
remain	O
abstinent	O
or	O
use	O
a	O
condom	O
plus	O
an	O
additional	O
contraceptive	O
method	O
that	O
together	O
result	O
in	O
a	O
failure	O
rate	O
of	O
<	O
1	O
%	O
per	O
year	O
during	O
the	O
treatment	O
period	O
and	O
for	O
at	O
least	O
6	O
months	O
after	O
the	O
last	O
dose	O
of	O
rituximab	O
.	O

Men	O
must	O
refrain	O
from	O
donating	O
sperm	O
during	O
this	O
same	O
period	O
.	O

With	O
pregnant	O
female	O
partners	O
,	O
men	O
must	O
remain	O
abstinent	O
or	O
use	O
a	O
condom	O
during	O
the	O
treatment	O
period	O
and	O
for	O
at	O
least	O
6	O
months	O
after	O
the	O
last	O
dose	O
of	O
rituximab	O
to	O
avoid	O
exposing	O
the	O
embryo	O
.	O

Age	B
>	B
18	I
Years	I

Physician	O
discretion	O

Septic	O
or	O
hypovolemic	B
shock	I

Signs	O
of	O
life	B
-	I
threatening	I
cerebral	B
edema	I
or	O
multi	B
-	I
organ	I
failure	I
upon	B
presentation	I
to	I
the	I
emergency	I
room	I
or	I
pediatric	I
intensive	I
care	I
unit	I

Enrollment	O
time	O
more	B
than	I
1	I
hr	I
since	I
arrival	I
to	I
emergency	I
room	I
or	I
PICU	I

Pregnancy	B

Age	B
between	B
0	I
and	I
18	I
years	I

Venous	B
pH	I
less	B
than	I
7	I
.	I
25	I

Ketonuria	B
as	O
confirmed	O
on	O
urine	B
point	I
-	I
of	I
-	I
care	I
testing	I
or	O
urinalysis	B

Hyperglycemia	B
(	O
Serum	B
glucose	I
>	B
200	I
mg	I
/	I
dl	I
)	O

Serum	B
bicarbonate	I
<	B
15	I
mmol	I
/	I
L	I

PICU	O
admission	B

The	O
diagnosis	O
of	O
developmental	B
delay	I
,	O
attention	B
deficit	I
disorder	I
,	O
chronic	B
pain	I
,	O
psychiatric	B
illness	I
,	O
previous	B
open	B
abdominal	I
surgery	I
,	O
the	O
presence	O
of	O
a	O
gastrostomy	B
,	O
ventricular	B
-	I
peritoneal	I
shunt	I
or	O
other	O
abdominal	B
prosthesis	I
,	O
immunosuppression	B
,	O
and	O
those	O
allergic	B
to	O
any	B
of	I
the	I
medications	I
.	O

Patients	O
are	O
of	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	B
)	O
physical	O
status	O
I	B
and	I
II	I
,	O
aged	B
8	B
-	I
14	I
years	I
old	I
,	O
of	O
both	B
gender	I
,	O
with	O
suspected	O
acute	B
appendicitis	I
scheduled	O
for	O
laparoscopic	B
appendicectomy	I
.	O

Not	O
available	O
for	O
follow	O
-	O
up	O

Pregnant	B
or	O
breast	B
-	I
feeding	I

Chronic	B
pain	I
syndrome	I
defined	O
as	O
use	O
of	O
any	B
analgesic	B
medication	I
on	B
a	I
daily	I
or	I
near	I
-	I
daily	I
basis	I

Allergic	B
to	O
or	O
intolerant	B
of	O
investigational	B
medications	I

Contra	B
-	I
indications	I
to	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drugs	I
:	O
1	O
)	O
history	B
of	O
hypersensitivity	B
to	O
NSAIDs	B
or	O
aspirin	B
2	O
)	O
active	B
or	O
history	B
of	O
peptic	B
ulcer	I
disease	I
,	O
chronic	B
dyspepsia	I
,	O
or	O
active	B
or	O
history	B
of	O
gastrointestinal	B
bleed	I
3	O
)	O
Severe	B
heart	B
failure	I
(	O
NYHA	B
2	B
or	I
worse	I
)	O
4	O
)	O
hypertension	B
(	O
JNC7	B
stage	I
2	B
or	I
worse	I
)	O
5	O
)	O
Chronic	B
kidney	I
disease	I
3	O
or	O
worse	O
6	O
)	O
Current	B
use	O
of	O
anti	B
-	I
coagulants	I
7	O
)	O
Hepatitis	B
8	O
)	O
Alcoholism	B

Contra	B
-	I
indications	I
to	O
muscle	B
relaxants	I
:	O
1	O
)	O
Concurrent	B
use	O
of	O
centrally	B
acting	I
opioids	I
;	O
2	O
)	O
Renal	B
impairment	I
;	O
3	O
)	O
Liver	B
abnormality	I
including	O
cirrhosis	B
or	O
elevated	B
enzymes	I
4	O
)	O
Use	O
of	O
any	O
of	O
the	O
following	O
medications	O
:	O
fluvoxamine	B
,	O
fluoroquinolones	B
,	O
amiodarone	B
,	O
mexiletine	B
,	O
propafenone	B
,	O
verapamil	B
,	O
cimetidine	B
,	O
famotidine	B
,	O
acyclovir	B
,	O
ticlopidine	B
,	O
oral	B
contraceptive	I
pills	I

Present	O
to	O
ED	O
primary	O
for	O
management	O
of	O
LBP	B
,	O
defined	O
as	O
pain	B
originating	O
between	B
the	I
lower	I
border	I
of	I
the	I
scapulae	I
and	I
the	I
upper	I
gluteal	I
folds	I
.	O

Flank	B
pain	I
,	O
that	O
is	O
pain	B
originating	O
from	O
tissues	B
lateral	I
to	I
the	I
paraspinal	I
muscles	I
,	O
will	O
not	B
be	O
included	O
.	O

Musculoskeletal	B
etiology	B
of	O
low	B
back	I
.	O

Patients	O
with	O
non	B
-	O
musculoskeletal	B
etiologies	B
such	O
as	O
urinary	B
tract	I
infection	I
,	O
ovarian	B
cysts	I
,	O
or	O
influenza	B
like	I
illness	I
will	O
be	O
excluded	B
.	O

The	O
primary	O
clinical	O
diagnosis	O
,	O
at	O
the	O
conclusion	O
of	O
the	O
ED	O
visit	O
,	O
must	O
be	O
a	O
diagnosis	O
consistent	O
with	O
non	B
-	I
traumatic	I
,	O
non	B
-	I
radicular	I
,	O
musculoskeletal	B
LBP	B
.	O

Patient	O
is	O
to	O
be	O
discharged	O
home	O
.	O
Patients	O
admitted	O
to	O
the	O
hospital	O
are	O
more	O
likely	O
to	O
be	O
treated	O
with	O
parenteral	O
medication	O
and	O
therefore	O
are	O
not	O
appropriate	O
for	O
this	O
study	O
.	O

Age	B
18	B
-	I
64	I
Enrollment	O
will	O
be	O
limited	O
to	O
adults	B
younger	B
than	I
65	I
years	I
because	O
of	O
the	O
increased	O
risk	O
of	O
adverse	O
medication	B
effects	O
in	O
the	O
elderly	B
.	O

Non	B
-	O
radicular	B
pain	B
.	O

Patients	O
will	O
be	O
excluded	B
if	O
the	O
pain	B
radiates	O
below	B
the	I
gluteal	I
folds	I
in	I
a	I
radicular	I
pattern	I
.	O

Pain	B
duration	B
<	I
2	I
weeks	I
(	O
336	O
hours	O
)	O
.	O

Patients	O
with	O
more	O
than	O
two	O
weeks	O
of	O
pain	O
are	O
at	O
increased	O
risk	O
of	O
poor	O
pain	O
and	O
functional	O
outcomes	O
.	O
(	O
9	O
)	O

Prior	O
to	O
the	O
acute	B
attack	B
of	I
LBP	I
,	O
back	B
pain	I
cannot	B
occur	O
more	B
frequently	I
than	I
once	I
per	I
month	I
.	O

Patients	O
with	O
more	O
frequent	O
back	O
pain	O
are	O
at	O
increased	O
risk	O
of	O
poor	O
pain	O
and	O
functional	O
outcomes	O
.	O
(	O
9	O
)	O

Non	B
-	I
traumatic	I
LBP	B
:	O
no	B
substantial	B
and	O
direct	B
trauma	B
to	O
the	O
back	B
within	B
the	I
previous	I
month	I

Functionally	B
impairing	I
back	B
pain	I
:	O
A	O
baseline	B
score	B
of	I
>	I
5	I
on	O
the	O
Roland	B
-	I
Morris	I
Disability	I
Questionnaire	I

pregnancy	B

known	O
allergies	B
for	O
tranexamic	B
acid	I
or	O
any	O
other	O
substance	O
in	O
Exacyl	B

deep	B
vein	I
thrombosis	I

Hormone	B
Replacement	I
Therapy	I
or	O
oral	B
contraceptive	I
usage	O

anticoagulants	B
usage	O

obesity	B
-	O
BMI	B
(	O
body	B
mass	I
index	I
)	O
>	B
30	I
kg	I
/	I
m2	I

renal	B
disease	I
,	O
as	O
glomerular	B
filtration	I
rate	I
(	O
GFR	B
)	O
<	B
60	I
ml	I
/	I
min	I
/	I
1	I
,	I
73	I
m	I
*	I
m	I

seizures	B
or	O
epilepsy	B
in	B
the	I
past	I

age	B
>	B
18	I
y	I
.	I
o	I
.	O

American	B
Society	I
of	I
Anesthesiologists	I
Physical	I
Status	I
Classification	I
(	O
ASA	B
)	O
1	B
-	I
2	I

signed	O
informed	O
consent	O
form	O
after	O
reading	O
the	O
information	O
about	O
the	O
study	O
and	O
talking	O
with	O
one	O
of	O
the	O
investigators	O

Any	O
MS	B
relapse	B
in	B
the	I
last	I
five	I
years	I
,	O
as	O
determined	O
at	O
the	O
screen	O
visit	O
by	O
the	O
PI	O

Any	O
new	O
or	O
definitely	O
enlarging	O
T2	B
/	I
FLAIR	I
lesion	I
or	O
new	O
gadolinium	B
-	O
enhancing	O
lesion	B
within	B
the	I
past	I
three	I
years	I
(	O
at	B
least	I
two	I
scans	B
separated	B
by	I
at	I
least	I
three	I
years	I
must	O
be	O
reviewed	O
)	O
on	O
brain	O
or	O
spine	B
MRI	I
scan	I
.	O

Lesions	B
must	O
be	O
3mm	B
or	I
larger	I
to	O
be	O
exclusionary	O
.	O

Significant	B
(	O
as	O
defined	O
by	O
the	O
PI	O
)	O
intolerance	B
of	O
presently	B
-	I
used	I
DMT	B

Use	O
of	O
inhaled	O
or	O
topical	B
steroids	I
are	O
not	B
an	O
exclusion	O
criteria	O
.	O

Use	O
of	O
oral	B
steroids	I
for	O
no	B
greater	I
than	I
14	I
days	I
given	O
for	O
a	O
non	B
-	I
MS	I
condition	I
is	O
not	B
exclusionary	O
.	O

alemtuzumab	B
,	O

mitoxantrone	B
,	O

cyclophosphamide	B
,	O

methotrexate	B
,	O

cyclosporine	B
,	O
or	O

rituximab	B

Prior	O
use	O
of	O
any	O
experimental	O
agent	O
used	O
as	O
a	O
DMT	O
for	O
MS	O
in	O
the	O
last	O
five	O
years	O

uncontrolled	B
hypertension	B
,	O

uncontrolled	B
diabetes	B
,	O

uncontrolled	B
asthma	B
,	O
or	O

uncontrolled	B
depression	B

Cancers	B
other	B
than	I
basal	B
cell	I
skin	I
cancers	I
within	B
the	I
last	I
5	I
years	I

Unable	O
to	O
give	O
informed	O
consent	O
or	O
follow	O
the	O
protocol	O

Unable	O
to	O
undergo	O
brain	B
MRI	I

Unwilling	O
to	O
be	O
randomized	O
per	O
this	O
protocol	O

History	B
of	I
other	O
chronic	B
neurological	I
illnesses	I
that	O
might	O
mimic	B
MS	I
with	O
chronic	O
or	O
intermittent	O
symptoms	O
(	O
i	O
.	O
e	O
.	O
ALS	B
,	O
myasthenia	B
gravis	I
,	O
chronic	B
neuropathy	I
,	O
etc	O
.	O
)	O

Patients	O
with	O
either	O
Relapsing	B
-	I
remitting	I
MS	I
(	I
RRMS	I
)	I
,	O
Secondary	B
progressive	I
MS	I
(	I
SPMS	I
)	I
,	O
or	O
Primary	B
progressive	I
MS	I
(	I
PPMS	I
)	I
by	O
McDonald	O
2010	O
criteria	O
.	O

Patients	O
defined	O
by	O
subtype	O
based	O
on	O
2013	O
updated	O
phenotypic	O
criteria	O
.	O

prospectively	O
with	O
an	O
EDSS	B
change	I
of	O
at	B
least	I
1	I
.	I
0	I
points	I
over	B
the	I
last	I
two	I
years	I
,	O
or	O

retrospectively	O
,	O
with	O
any	O
significant	B
change	B
in	I
motor	I
function	I
over	B
at	I
least	I
one	I
year	I
,	O
unrelated	B
to	I
relapse	I
.	O

55	O
years	O
of	O
age	B
or	O
older	O
at	B
time	I
of	I
randomization	I
;	O

No	B
evidence	O
of	O
recent	O
new	B
inflammatory	B
disease	I
activity	O
(	O
inactive	B
by	O
the	O
Lublin	B
criteria16	I
)	O
with	O
no	B
new	B
relapse	B
for	B
at	I
least	I
five	I
years	I
and	O
no	B
new	B
MRI	B
lesion	B
for	B
at	I
least	I
three	I
years	I

interferon	B
ß	I
-	I
1a	I
,	O

interferon	B
ß	I
-	I
1b	I
,	O

glatiramer	B
acetate	I
,	O

natalizumab	B
,	O

fingolimod	B
,	O

dimethyl	B
fumarate	I
,	O
or	O

teriflunomide	B
;	O
continuously	B
for	B
no	I
less	I
than	I
5	I
years	I
.	O

Taking	O
most	O
recent	O
DMT	B
continuously	B
*	O
for	B
no	I
less	I
than	I
two	I
years	I
.	O

Willing	O
to	O
be	O
randomized	O
per	O
this	O
protocol	O
;	O
each	O
patient	O
will	O
be	O
questioned	O
as	O
to	O
their	O
willingness	O
to	O
stay	O
in	O
the	O
trial	O
regardless	O
of	O
the	O
group	O
to	O
which	O
group	O
they	O
are	O
randomized	O
.	O

Willing	O
to	O
follow	O
the	O
protocol	O

Continuously	O
will	O
be	O
defined	O
as	O
no	O
less	O
than	O
75	O
%	O
of	O
all	O
prescribed	O
doses	O
,	O
with	O
no	O
time	O
of	O
greater	O
than	O
four	O
weeks	O
from	O
last	O
intended	O
dose	O
to	O
have	O
missed	O
a	O
dose	O
(	O
8	O
weeks	O
for	O
natalizumab	O
,	O
i	O
.	O
e	O
.	O
one	O
missed	O
dose	O
)	O
.	O

NA	O

Age	B
>	B
18	I
years	I

Scheduled	O
1	O
or	O
2	B
-	I
level	I
ACDF	B
spine	I
surgery	I

The	O
capacity	O
to	O
provide	O
informed	O
consent	O
.	O

Degenerative	B
Disc	I
Disease	I
(	O
as	O
defined	O
by	O
neck	B
pain	I
of	O
discogenic	B
origin	I
with	O
degeneration	B
of	I
the	I
disc	I
confirmed	O
by	O
patient	B
history	I
and	O
radiographic	B
studies	I
)	O

Trauma	B
(	O
including	O
fractures	B
)	O

Tumors	B

Deformities	B
or	O
curvatures	B
(	O
including	O
kyphosis	B
,	O
lordosis	B
,	O
or	O
scoliosis	B
)	O

Pseudoarthrosis	B

Failed	B
previous	B
fusion	B

Decompression	B
of	I
the	I
spinal	I
cord	I
following	O
total	O
or	O
partial	B
cervical	I
vertebrectomy	I

Spondylolisthesis	B

Spinal	B
stenosis	I

Patients	O
with	O
current	B
or	O
recent	B
history	B
of	O
malignancy	B
or	O
infectious	B
disease	I
.	O

The	O
inability	O
to	O
provide	O
informed	O
consent	O
.	O

Subject	O
has	O
marked	B
local	B
inflammation	I

Subject	O
has	O
any	O
mental	O
or	O
neuromuscular	B
disorder	I
which	O
would	O
create	O
an	O
unacceptable	B
risk	O
of	O
fixation	B
failure	I
or	O
complications	B
in	O
postoperative	O
care	O
.	O

Subject	O
has	O
a	O
bone	B
stock	I
compromised	I
by	O
disease	B
,	O
infection	B
or	O
prior	B
implantation	B
which	O
cannot	B
provide	O
adequate	O
support	O
and	O
/	O
or	O
fixation	B
to	I
the	I
devices	I
.	O

Subject	O
has	O
bone	B
abnormalities	I
preventing	B
safe	B
screw	B
fixation	I
.	O

Subject	O
has	O
any	O
open	B
wounds	I
.	O

Subject	O
has	O
rapid	B
joint	I
disease	I
,	O
bone	B
absorption	I
,	O
osteopenia	B
,	O
osteomalacia	B
,	O
and	O
/	O
or	O
osteoporosis	B
.	O

Osteoporosis	B
or	O
osteopenia	B
are	O
relative	B
contraindications	B
,	O
since	O
this	O
condition	O
may	O
limit	O
the	O
degree	O
of	O
obtainable	O
correction	O
and	O
/	O
or	O
the	O
amount	O
of	O
mechanical	O
fixation	O
.	O

Subject	O
has	O
a	O
documented	O
or	O
suspected	O
metal	B
sensitivity	B
.	O

Subject	O
is	O
pregnant	B
.	O

Subject	O
has	O
anatomical	O
structures	O
or	O
physiological	O
performance	O
that	O
would	O
interfere	O
with	O
implant	B
utilization	O
.	O

Subject	O
has	O
inadequate	B
tissue	I
coverage	I
over	O
the	O
operative	B
site	I
.	O

Subject	O
has	O
other	O
medical	O
or	O
surgical	B
conditions	I
which	O
would	O
preclude	B
the	O
potential	O
benefit	O
of	O
surgery	B
,	O
such	O
as	O
congenital	B
abnormalities	I
,	O
immunosuppressive	B
disease	I
,	O
elevation	B
of	O
sedimentation	B
rate	I
unexplained	B
by	I
other	I
diseases	I
,	O
elevation	B
of	O
white	B
blood	I
count	I
(	I
WBC	I
)	I
,	O
or	O
marked	O
left	B
shift	I
in	O
the	O
WBC	B
differential	I
count	I
.	O

Note	O
:	O
The	O
Aviator	O
Anterior	O
Cervical	O
Plating	O
System	O
is	O
not	O
approved	O
or	O
intended	O
for	O
screw	O
attachment	O
to	O
the	O
posterior	O
elements	O
(	O
pedicles	O
)	O
of	O
the	O
cervical	O
,	O
thoracic	O
,	O
or	O
lumbar	O
spine	O
.	O
The	O
surgeon	O
must	O
consider	O
the	O
levels	O
of	O
implantation	O
,	O
patient	O
weight	O
,	O
patient	O
activity	O
level	O
,	O
and	O
other	O
patient	O
conditions	O
which	O
may	O
impact	O
on	O
the	O
performance	O
of	O
the	O
system	O
.	O

Any	O
previous	B
treatments	B
for	O
active	B
CSC	B
;	O

Previous	B
prescription	O
of	O
mineralocorticoid	B
receptor	I
antagonists	I
,	O
for	O
cCSC	B
or	O
for	O
other	B
diseases	I
;	O

Current	B
treatment	O
with	O
corticosteroids	B
(	O
topical	B
or	O
systemic	B
)	O
,	O
corticosteroid	B
use	I
within	B
3	I
months	I
before	I
possible	I
start	I
of	I
trial	I
treatment	I
,	O
or	O
anticipated	O
start	O
of	O
corticosteroid	B
treatment	I
within	B
the	I
first	I
2	I
years	I
from	I
the	I
start	I
of	I
the	I
trial	I
period	I
;	O

Evidence	O
of	O
another	O
diagnosis	O
that	O
can	O
explain	O
serous	O
SRF	O
or	O
visual	O
loss	O
;	O

Best	B
-	I
corrected	I
visual	I
acuity	I
<	B
20	I
/	I
200	I
(	O
Snellen	O
equivalent	O
)	O
;	O

Profound	B
chorioretinal	B
atrophy	I
in	O
central	B
macular	I
area	I
on	O
ophthalmoscopy	B
and	O
OCT	B
;	O

Myopia	B
>	B
6D	I
;	O

Visual	B
loss	I
and	O
/	O
or	O
serous	B
detachment	I
on	O
OCT	B
<	B
6	I
weeks	I
;	O

Continuous	B
and	O
/	O
or	O
progressive	B
visual	B
loss	I
>	B
18	I
months	I
or	O
serous	B
detachment	I
on	O
OCT	B
>	B
18	I
months	I
;	O

No	B
hyperfluorescence	B
on	O
ICGA	B
;	O

Intraretinal	B
edema	I
on	O
OCT	B
;	O

(	O
relative	O
)	O
Contraindications	B
for	O
FA	B
or	O
ICGA	B
;	O

(	O
relative	O
)	O
Contraindications	B
for	O
photodynamic	B
treatment	I
(	O
pregnancy	B
,	O
porphyria	B
,	O
severely	B
disturbed	B
liver	I
function	I
)	O
.	O

Pregnancy	O
will	O
not	O
be	O
routinely	O
tested	O
in	O
female	O
patients	O
,	O
but	O
the	O
possibility	O
of	O
pregnancy	O
will	O
be	O
discussed	O
during	O
screening	O

(	O
relative	O
)	O
Known	O
contraindications	B
for	O
initiation	O
of	O
eplerenone	B
treatment	O
(	O
hyperkalemia	B
,	O
abnormal	B
renal	B
clearance	I
,	O
severe	B
hepatic	I
insufficiency	I
(	O
Child	B
-	I
Pugh	I
C	B
)	O
,	O
type	B
2	I
diabetes	I
mellitus	I
with	O
microalbuminuria	B
,	O
concomitant	B
use	O
of	O
potassium	B
supplements	I
,	O
potassium	B
-	I
sparing	I
diuretics	I
,	O
strong	B
CYP3A4	I
inhibitors	I
,	O
or	O
the	O
combination	O
of	O
an	O
ACE	B
-	I
inhibitor	I
and	O
an	O
angiotensin	B
receptor	I
blocking	I
agent	I
)	O
.	O

Pregnancy	O
will	O
not	O
be	O
routinely	O
tested	O
in	O
female	O
patients	O
,	O
but	O
the	O
possibility	O
of	O
pregnancy	O
will	O
be	O
discussed	O
during	O
screening	O
;	O

Soft	B
drusen	I
in	O
treated	B
eye	I
or	O
fellow	B
eye	I
,	O
signs	O
of	O
choroidal	B
neovascularization	I
on	O
ophthalmoscopy	B
and	O
/	O
or	O
FA	B
/	O
ICGA	B
of	O
the	O
study	B
eye	I
.	O

Age	B
of	O
=	B
18	I
years	I
of	O
age	O
and	O
able	O
to	O
give	O
written	O
informed	O
consent	O
;	O

Active	B
chronic	B
central	B
serous	I
chorioretinopathy	I
(	I
cCSC	I
)	I
;	O

Subjective	B
visual	I
loss	I
>	B
6	I
weeks	I
,	O
interpreted	O
as	O
onset	O
of	O
active	O
disease	O
;	O

Foveal	B
subretinal	I
fluid	I
(	I
SRF	I
)	I
,	O
on	O
optical	B
coherence	I
tomography	I
(	I
OCT	I
)	I
,	O
at	B
Baseline	I
Examination	I
;	O

=	B
1	I
ill	B
-	I
defined	I
hyperfluorescent	B
leakage	I
areas	I
on	O
fluorescein	B
angiography	I
(	I
FA	I
)	I
with	O
retinal	B
pigment	I
epithelial	I
window	I
defect	I
(	I
s	I
)	I
that	O
are	O
compatible	O
with	O
cCSC	O
;	O

Hyperfluorescent	B
areas	I
on	O
indocyanine	B
green	I
angiography	I
(	I
ICGA	I
)	I
.	O

Current	B
use	O
of	O
gabapentin	B
or	O
pregabalin	B

Allergy	B
to	O
gabapentin	B
,	O
acetaminophen	B
,	O
codeine	B
,	O
or	O
ibuprofen	B

Self	B
reported	I
renal	B
disease	I
(	O
severe	B
impaired	B
renal	I
function	I
)	O

Self	B
reported	I
current	B
or	O
chronic	B
narcotic	B
use	I
(	O
typical	O
daily	B
use	I
)	O

Women	O
with	O
any	O
issue	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
interfere	O
with	O
study	O
participation	O
or	O
generating	O
accurate	O
study	O
data	O

15	O
weeks	O
0	O
days	O
gestational	B
age	I
-	O
23	O
weeks	O
5	O
days	O
gestational	O
age	O
at	B
time	I
of	I
dilator	I
insertion	I

Able	O
to	O
read	O
and	O
write	O
in	O
English	O

Active	O
cell	O
phone	O
with	O
text	O
messaging	O
capability	O

Ride	O
home	O
from	O
dilator	B
insertion	I
clinic	O
appointment	O

NA	O

Fluent	O
in	O
reading	O
and	O
writing	O
in	O
English	O
language	O
.	O

=	B
21	I
years	I
of	O
age	B
at	B
the	I
time	I
of	I
participation	I
.	O

Known	O
hypersensitivity	B
to	O
tetracycline	B
,	O
doxycycline	B
or	O
azithromycin	B

Administration	O
of	O
doxycycline	B
,	O
azithromycin	B
,	O
chloramphenicol	B
,	O
rifampicin	B
,	O
or	O
tetracycline	B
during	B
the	I
preceding	I
7	I
days	I

Pregnancy	B
or	O
breast	O
-	O
feeding	O

Patients	O
with	O
myasthenia	B
gravis	I
or	O
systemic	B
lupus	I
erythematosus	I

Patients	O
with	O
an	O
established	O
infection	B
(	O
diagnostic	B
test	I
required	O
)	O
e	O
.	O
g	O
.	O
acute	B
malaria	I
,	O
dengue	B
,	O
leptospirosis	B
,	O
typhoid	B
,	O
Japanese	B
encephalitis	I
etc	O
.	O

Current	O
TB	B
or	O
TB	B
treatment	I
in	B
=	I
6	I
months	I
(	O
contain	O
active	O
antibiotics	O
against	O
Orientia	O
spp	O
.	O
)	O

Current	O
HAART	B
use	O
for	O
HIV	B
,	O
long	B
term	I
use	I
of	O
immunosuppressants	B
(	O
e	O
.	O
g	O
.	O
steroids	B
,	O
chemotherapy	B
,	O
TNF	B
-	I
inhibitors	I
and	O
related	O
agents	O
)	O

Patients	O
with	O
severe	O
disease	O
whom	O
the	O
clinical	O
team	O
feel	O
their	O
condition	O
necessitates	O
the	O
need	O
for	O
additional	O
scrub	O
typhus	O
treatment	O
beyond	O
the	O
allocated	O
antibiotic	O
treatment	O
assigned	O
at	O
randomization	O
(	O
e	O
.	O
g	O
.	O
IV	O
chloramphenicol	O
and	O
/	O
or	O
PO	O
/	O
NG	O
rifampicin	O
)	O

Age	B
=	B
15	I
years	I
old	I

Hospitalization	B
with	O
acute	B
undifferentiated	I
fever	I
(	O
temperature	B
>	B
37	I
.	I
5	I
C	I
,	O
tympanic	B
)	O
=	B
14	I
days	I
or	O
patients	O
admitted	B
to	I
hospital	I
with	O
a	O
history	B
of	O
fever	B
=	B
14	I
days	I
who	O
subsequently	O
develop	O
fever	B
within	B
24	I
hours	I
of	I
admission	I

Clinically	O
suspected	O
scrub	B
typhus	I
:	O
defined	O
as	O
acute	B
undifferentiated	I
fever	I
with	O
no	B
clear	I
focus	B
of	I
infection	I
and	O
negative	B
malaria	B
blood	I
smear	I
and	O
/	O
or	O
negative	B
malaria	B
RDT	I
.	O

Patients	O
may	O
have	O
one	B
,	O
none	B
,	O
or	O
a	B
combination	I
of	I
other	O
clinical	O
findings	O
such	O
as	O
eschar	B
,	O
rash	B
,	O
lymphadenopathy	B
,	O
headache	B
,	O
myalgia	B
,	O
cough	B
,	O
nausea	B
and	O
abdominal	B
discomfort	I
.	O

A	O
positive	B
scrub	B
typhus	I
RDT	I
(	O
Scrub	B
Typhus	I
IgM	I
RDT	I
,	O
InBios	O
International	O
,	O
Seattle	O
,	O
WA	O
,	O
USA	O
)	O
and	O
/	O
or	O
positive	B
PCR	B
-	O
based	O
detection	O
of	O
O	B
.	I
tsutsugamushi	I
DNA	I
from	O
the	O
admission	B
blood	I
sample	I

Written	O
informed	O
consent	O
and	O
/	O
or	O
,	O
written	O
informed	O
assent	O
as	O
required	O

Able	O
to	O
take	O
oral	B
medication	I

Preoperative	B
renal	B
failure	I
requiring	O
dialysis	B

Poorly	B
controlled	I
pulmonary	B
disease	I
(	O
severe	B
asthma	B
or	O
COPD	B
)	O
-	O
Contraindication	B
to	O
regional	B
anesthesia	I
(	O
recent	B
anticoagulant	B
use	O
)	O

Sleep	B
apnea	I
or	O
morbid	B
obesity	I
with	O
possible	O
sleep	B
apnea	I

Allergy	B
to	O
methadone	B

Significant	B
preoperative	B
pain	I
requiring	O
treatment	O
with	O
high	B
doses	I
of	O
opioids	B
(	O
more	O
than	O
6	O
-	O
8	O
Norco	B
tablets	I
or	O
equivalence	B
per	O
day	O
)	O
or	O
recent	B
history	B
of	O
opioid	B
abuse	I

All	O
patients	O
presenting	O
for	O
elective	B
shoulder	B
arthroscopic	I
procedures	I
will	O
be	O
eligible	O
for	O
enrollment	O
.	O

PRA	B
>	B
50	I
%	I

DSA	B
>	B
1500	I
MFI	I

Retransplantation	B

Patients	O
who	O
are	O
planning	O
to	O
receive	O
mycophenolate	B
instead	B
of	I
everolimus	B

Patients	O
who	O
have	O
planning	O
for	O
follow	B
-	I
up	I
in	O
another	O
center	O

Primary	B
kidney	B
transplant	I
recipients	O
,	O
adults	B

NA	O

NA	O

Previous	B
anaphylaxis	B
following	O
any	O
component	O
of	O
Bexsero	B
vaccine	I

Previous	B
receipt	O
of	O
meningococcal	B
B	I
vaccine	I
(	O
Bexsero	B
)	O

Known	O
pregnancy	B

South	O
Australian	O
secondary	O
school	O
students	O
in	O
years	B
10	I
,	O
11	O
,	O
and	O
12	O
in	B
2017	I

Written	O
parental	O
consent	O
for	O
those	O
under	O
the	O
age	O
of	O
18	O

Written	O
student	O
consent	O
assent	O
for	O
those	O
under	O
the	O
age	O
of	O
18	O
(	O
or	O
if	O
18	O
years	O
old	O
and	O
older	O
consent	O
for	O
themselves	O
)	O

Available	O
at	O
school	O
for	O
at	O
least	O
the	O
first	B
pharyngeal	B
swab	I
and	O
willing	O
to	O
comply	O
with	O
study	O
procedures	O

Contraindications	B
for	O
spinal	B
anesthesia	I
(	O
like	O
bleeding	B
diathesis	I
or	O
regional	B
infection	I
at	O
site	B
of	I
neuroaxial	I
block	I
)	O

Known	O
allergy	B
to	O
Granisetron	B
or	O
local	B
anaesthetic	I
(	O
heavy	B
bupivacaine	I
,	O
Marcaine	B
Spinal	I
0	I
.	I
5	I
%	I
Heavy	I
,	O
5mg	B
/	I
ml	I
,	O
AstraZeneca	B
ampule	I
)	O

Pregnancy	B
induced	O
hypertension	B

Congenital	B
or	O
rheumatic	B
heart	B
diseases	I

Antepartum	B
haemorrhage	I

Fetal	B
destress	I
or	O
gestational	B
age	I
<	B
36	I
week	I

Type	B
I	I
diabetic	I
patients	O

Parturients	B
presented	O
for	O
Cesarean	B
section	I

Acute	B
heart	I
failure	I
or	O
acute	B
exacerbation	B
of	O
chronic	B
heart	I
failure	I
within	B
the	I
past	I
2	I
weeks	I
.	O

Scheduled	O
cardiac	B
resynchronization	I
therapy	I
or	O
heart	B
transplantation	I
.	O

History	O
of	O
malignant	B
tumor	I
or	O
life	B
expectancy	I
under	B
12	I
months	I
.	O

Already	O
on	O
medications	B
that	O
may	O
affect	B
thyroid	B
function	I
(	O
L	B
-	I
T4	I
,	O
carbimazole	B
,	O
propylthiouracil	B
,	O
amiodarone	B
,	O
lithium	B
)	O
.	O

Pregnancy	B
and	O
lactation	B
period	I
.	O

Participation	O
in	O
another	O
clinical	O
trial	O
within	O
the	O
past	O
30	O
days	O
.	O

Contraindication	B
or	O
intolerance	B
to	O
evidence	B
-	I
based	I
therapy	I
for	O
CHF	B
,	O
such	O
as	O
beta	B
-	I
blocker	I
,	O
angiotensin	B
-	I
converting	I
enzyme	I
inhibitor	I
or	O
angiotensin	B
receptor	I
blocker	I
.	O

Known	O
hypersensitivity	B
to	O
the	O
trial	B
treatment	I
(	I
s	I
)	I
or	O
diluents	O
(	O
when	O
applicable	O
)	O
,	O
including	O
placebo	B
or	O
other	B
comparator	B
drug	I
(	I
s	I
)	I
.	O

Untreated	B
adrenal	B
insufficiency	I
.	O

Untreated	B
pituitary	B
insufficiency	I
.	O

Untreated	B
thyrotoxicosis	B
.	O

Treatment	B
with	O
levothyroxine	B
must	O
not	B
be	I
initiated	I
in	O
patients	O
with	O
acute	B
myocardial	I
infarction	I
,	O
acute	B
myocarditis	I
,	O
or	O
acute	B
pancarditis	I
.	O

Severe	B
renal	B
dysfunction	I
(	O
eGFR	B
=	B
30	I
ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I
)	O
.	O

Significant	B
hepatic	B
impairment	I
(	O
Serum	B
GPT	I
>	B
120	I
U	I
/	I
L	I
)	O
.	O

Any	O
disorder	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
might	O
jeopardise	O
subject	O
'	O
s	O
safety	O
or	O
compliance	O
with	O
the	O
protocol	O
.	O

Aged	B
18	B
years	I
or	I
older	I
,	O
male	B
or	O
female	B
.	O

Systolic	B
heart	I
failure	I
with	O
New	B
York	I
Heart	I
Association	I
(	I
NYHA	I
)	I
class	B
II	I
-	I
III	I
.	O

Left	B
ventricular	I
ejection	I
fraction	I
(	I
LVEF	I
)	I
less	B
than	I
40	I
%	I
by	O
echocardiography	B
during	B
screening	I
and	I
randomization	I
.	O

SCH	B
(	O
TSH	B
:	O
upper	B
limits	I
of	I
normal	I
(	I
ULN	I
)	I
-	I
10mIU	I
/	I
L	I
,	O
and	O
FT4	B
level	I
within	B
reference	I
range	I
)	O
.	O

Having	O
received	O
standard	B
HF	I
therapy	I
for	B
at	I
least	I
2	I
weeks	I
,	O
having	O
reached	O
target	B
dose	I
or	O
max	B
tolerable	I
dose	I
.	O

Provided	O
informed	O
consent	O
.	O

History	O
of	O
anti	B
-	I
vascular	I
endothelial	I
growth	I
factor	I
treatment	O
in	B
the	I
past	I
12	I
months	I

Any	O
diabetic	B
macular	I
edema	I
treatment	B
in	B
the	I
past	I
4	I
months	I

Heart	B
attack	I
,	O
stroke	B
,	O
transient	B
ischemic	I
attack	I
or	O
acute	B
congestive	I
heart	I
failure	I
within	B
4	I
months	I

Diagnosis	O
of	O
diabetes	B
mellitus	I

Best	B
corrected	I
visual	I
acuity	I
20	B
/	I
32	I
-	I
20	I
/	I
320	I

Diabetic	B
macular	I
edema	I
involving	O
the	O
center	B
of	I
the	I
macula	I

Optical	B
coherence	I
tomography	I
central	I
subfield	I
thickness	I
of	O
at	B
least	I
250	I
microns	I

Presence	O
of	O
another	B
vaginal	B
infection	I
or	O
STD	B

Allergy	B
to	O
metronidazole	B

Pregnant	B
or	O
nursing	B

Use	O
of	O
oral	O
or	O
intravaginal	B
antibiotics	I
within	B
the	I
past	I
2	I
weeks	I

HIV	B
or	O
other	B
chronic	B
disease	I

Inability	O
to	O
keep	O
return	O
appointments	O

Contraindications	B
for	O
Lactobacillus	B
Vaginal	I
Suppositories	I
(	O
those	O
without	B
sexual	B
history	I
)	O

Women	B
be	O
at	B
least	I
18	I
years	I
of	O
age	B

Have	O
symptoms	O
of	O
vaginal	B
odor	I
and	O
or	O
/	O
discharge	O

Meet	O
the	O
clinical	O
(	O
Amsel	B
)	I
criteria	I
for	O
BV	B

Willing	O
to	O
participate	O
in	O
research	O

Surgeries	O
that	O
include	O
:	O
intradetrusor	B
Botox	B
,	O
vaginal	B
mesh	I
excision	O
,	O
and	O
fistula	B
repair	I

Pregnancy	B

History	B
of	O
nephrolithiasis	B

Allergy	B
to	O
study	B
medications	I

Congenital	B
urogenital	B
anomaly	I

Neurogenic	B
bladder	I

Adult	B
women	B
at	B
least	I
18	I
years	I
of	O
age	B

Elective	B
Female	B
Pelvic	I
Medicine	B
and	O
Reconstructive	B
Surgery	I
or	O
Gynecologic	B
Minimally	B
Invasive	I
surgeries	B
including	O
hysterectomy	B
,	O
suburethral	B
sling	I
,	O
and	O
pelvic	B
organ	I
prolapse	I
repair	I
that	O
require	O
cystoscopy	B
.	O

Patients	O
with	O
active	B
GIT	B
bleeding	I
.	O

Patients	O
with	O
history	B
of	O
bowel	B
obstruction	I
,	O
perforation	O
.	O

Patients	O
with	O
history	B
of	O
allergy	B
to	O
PEG	B
.	O

Treatment	O
with	O
rifaximin	B
or	O
neomycin	B
in	B
the	I
previous	I
7	I
days	I
.	O

Patients	O
with	O
major	B
psychiatric	I
illness	I
.	O

Patients	O
receiving	O
benzodiazepines	B
and	O
narcotics	B
.	O

Patients	O
with	O
compromised	B
renal	I
.	O

Patients	O
receiving	O
medications	B
highly	I
bound	I
to	I
plasma	I
proteins	I
eg	O
.	O

Warfarin	B
.	O

Pregnant	B
or	O
lactating	B
women	B
.	O

Fulminant	B
hepatic	B
failure	I
.	O

Adult	B
Patients	O
with	O
Overt	B
Hepatic	I
Encephalopathy	I
.	O

Systemic	B
diseases	I
(	O
diabetes	O
,	O
renal	O
diseases	O
,	O
rheumatic	O
diseases	O
,	O
osteoporosis	O
and	O
cardiovascular	O
diseases	O
)	O

Pregnant	B
and	O
lactating	B
women	B

HIV	B
/	O
AIDS	B

periodontal	B
treatment	I
in	B
the	I
last	I
year	I
(	O
before	O
baseline	B
appointment	I
)	O

Medication	O
:	O
Immunosuppressive	B
drugs	I
,	O
antibiotics	B
in	B
the	I
past	I
three	I
months	I
(	O
before	O
baseline	B
appointment	I
)	O
)	O

orthodontic	B
appliance	I

Moderate	B
to	I
advanced	I
generalized	B
chronic	I
periodontitis	I

Body	B
mass	I
index	I
:	O
>	B
18	I
.	I
5	I
kg	I
/	I
m2	I

Minimum	B
of	I
12	I
natural	O
teeth	O

Smokers	B
,	O
non	B
-	I
smokers	I
or	O
former	B
-	I
smokers	I

Patients	O
requiring	O
surgery	B
for	O
neoplastic	B
processes	I

Allergy	B
to	O
acetaminophen	B

Liver	B
dysfunction	I
and	O
elevated	B
Liver	B
Function	I
Tests	I
(	O
LFTs	B
)	O

Alcohol	O
or	O
drug	B
dependency	I

Mental	B
retardation	I

Less	B
than	I
50	I
kg	I
of	O
weight	B

regnant	B
women	B

Patients	O
requiring	O
long	B
-	I
acting	I
opioid	I
pain	O
management	O
(	O
including	O
fentanyl	B
patch	I
,	O
oxycontin	B
,	O
etc	O
)	O
for	B
over	I
3	I
weeks	I
immediately	B
prior	I
to	I
surgery	I

ASA	B
I	B
-	I
III	I
patients	O
scheduled	O
for	O
elective	B
one	O
or	O
two	B
level	I
minimally	B
invasive	I
lumbar	I
fusions	I

NA	O

NA	O

Subjects	O
with	O
a	O
history	B
of	O
hypercoagulopathy	B
,	O
deep	B
vein	I
thrombosis	I
(	O
DVT	B
)	O
,	O
pulmonary	B
embolism	I

Renal	B
impairment	I

Subjects	O
with	O
known	O
hypersensitivity	B
to	O
tranexamic	B
acid	I

Consecutive	O
fibrinolytic	B
states	I
to	O
coagulopathy	B

History	B
of	O
convulsions	B

Subjects	O
undergoing	B
burn	B
excision	I
surgery	I
for	O
standard	O
of	O
care	O
purposes	O

Male	B
or	O
female	B
>	B
=	I
18	I
years	I
of	O
age	B

Subject	O
or	O
subject	O
'	O
s	O
medical	O
decision	O
maker	O
agrees	O
to	O
participate	O
in	O
this	O
study	O
and	O
provides	O
informed	O
consent	O

Baseline	O
cognitive	O
deficits	O
sufficient	O
to	O
make	O
objective	O
pain	O
self	O
-	O
assessments	O
unreliable	O
in	O
the	O
estimation	O
of	O
the	O
Study	O
Investigators	O
.	O

Immunocompromised	B
subject	O

Coagulopathy	B

Severe	B
liver	O
and	O
renal	B
dysfunction	I

Preoperative	B
neurological	B
deficits	I

The	O
dura	O
damage	O
during	O
surgery	B

Inability	O
to	O
follow	O
directions	O
or	O
comprehend	O
the	O
English	O
language	O
.	O

Females	O
who	O
are	O
pregnant	O
as	O
determined	O
by	O
positive	O
pregnancy	O
test	O
on	O
or	O
before	O
the	O
day	O
of	O
surgery	O
.	O

Prisoners	B
.	O

Patient	O
refusal	O
to	O
provide	O
informed	O
consent	O
.	O

Allergy	B
to	O
amide	B
local	I
anesthetics	I
(	O
lidocaine	B
,	O
bupivacaine	B
,	O
ropivacaine	B
)	O
or	O
opioid	B
(	O
fentanyl	B
)	O
.	O

Adult	B
subjects	O
aged	B
18	B
years	I
or	I
older	I

Scheduled	O
for	O
elective	B
posterior	B
lumbar	I
spinal	I
fusion	I
surgery	I
between	B
1	I
and	I
3	I
levels	I

-	O
Irregular	B
menstrual	I
cycle	I
demanding	O
preparing	B
endometrium	I
with	I
hormones	I
for	I
frozen	I
-	I
thawed	I
embryo	I

No	B
frozen	O
embryos	O
after	O
IVF	B
cycle	I

Allergy	B
to	O
Pregnyl	B
®	O
or	O
some	B
of	I
its	I
ingredients	I
in	O
the	O
medication	O
or	O
other	O
contraindications	B
due	O
to	O
Pregnyl	B
®	O

-	O
Patient	O
with	O
IVF	B
cycle	I
and	O
therefore	O
having	O
frozen	B
-	I
thawed	I
embryos	I

Regular	B
menstruation	I
cycle	I

Patient	O
'	O
s	O
willingness	O
to	O
participate	O
in	O
the	O
study	O

Patients	O
incapable	O
to	O
understanding	O
and	O
will	O
;	O

Patients	O
participating	O
in	O
previous	B
,	O
concurrent	O
or	O
not	O
,	O
trials	O
(	O
ongoing	B
or	O
completed	B
within	B
three	I
months	I
)	O
;	O

Patients	O
surgically	B
treated	I
for	O
the	B
same	I
defect	I
within	B
one	I
year	I
;	O

Patients	O
affected	O
by	O
malignancy	B
;	O

Patients	O
affected	O
by	O
metabolic	O
or	O
thyroid	B
disorders	I
;	O

Patients	O
used	O
to	O
alcohol	O
or	O
drug	O
(	O
medication	B
)	I
abuse	I
;	O

Patients	O
affected	O
by	O
synovitis	B
;	O

Varus	O
or	O
valgus	B
misalignment	I
exceeding	B
15	I
°	I
;	O

Body	B
Mass	I
Index	I
>	B
40	I
;	O

Patients	O
with	O
trauma	B
within	O
6	O
months	O
pre	O
-	O
operative	B
.	O

Patients	O
provided	O
written	O
informed	O
consent	O
;	O

Patients	O
aged	B
between	B
18	I
and	I
75	I
years	I
;	O

Knee	O
symptomatic	B
OA	O
(	O
Kellgren	B
-	I
Lawrence	I
grade	I
1	B
-	I
4	I
)	O

Failure	O
of	O
conservative	B
treatment	I
for	B
at	I
least	I
3	I
months	I
;	O

Patients	O
agreed	O
to	O
actively	O
participate	O
in	O
the	O
rehabilitation	O
protocol	O
and	O
follow	O
-	O
up	O
program	O
;	O

Male	B
or	O
female	B
patients	O
;	O

Women	B
of	O
childbearing	O
age	O
had	O
to	O
use	O
a	O
proven	O
method	O
to	O
prevent	O
pregnancy	O
,	O
before	O
the	O
surgical	B
treatment	I
.	O

Nursing	O
homes	O
will	O
not	O
be	O
eligible	O
to	O
participate	O
if	O
they	O
meet	O
the	O
following	O
criteria	O
:	O

Facilities	O
routinely	B
using	O
decolonization	B

Dedicated	O
psychiatric	O
nursing	O
homes	O

Facilities	O
with	O
a	O
resident	B
population	I
with	O
>	B
=	I
20	I
%	I
combative	O
patients	O

Pediatric	O
facilities	O

Nursing	O
homes	O
will	O
be	O
eligible	O
to	O
participate	O
if	O
they	O
meet	O
the	O
following	O
criteria	O
:	O

Licensed	O
nursing	O
home	O
in	O
Orange	O
County	O
or	O
Southern	O
Los	O
Angeles	O
County	O
serving	B
adults	I

Minimal	B
use	I
of	O
chlorhexidine	B
bathing	O
*	O

Minimal	B
use	I
of	O
nasal	B
decolonization	I
*	O
*	O
Minimal	B
use	I
defined	O
as	O
<	B
15	I
%	I
of	O
residents	O
receiving	O
at	B
least	I
one	I
chlorhexidine	B
bath	O
or	O
nasal	B
decolonization	I
treatment	I
during	B
their	I
nursing	I
home	I
stay	I
.	O

Organic	B
diseases	I
of	O
the	O
digestive	B
system	I
(	O
gastro	B
-	I
oesophageal	I
reflux	I
disease	I
(	I
GERD	I
)	I
,	O
ulcer	B
,	O
chronic	B
pancreatitis	I
,	O
cholelithiasis	B
,	O
fatty	B
liver	I
disease	I
,	O
hepatitis	B
,	O
cirrhosis	B
of	I
liver	I
,	O
etc	O
.	O
)	O
.	O

Diagnosis	O
of	O
other	O
functional	B
diseases	I
of	O
the	O
digestive	B
system	I
,	O
such	O
as	O
dyskinesia	B
of	I
cystic	I
duct	I
or	O
gallbladder	O
,	O
irritable	B
bowel	I
syndrome	I
,	O
etc	O
.	O

Discontinuation	O
of	O
proton	B
pump	I
inhibitors	I
,	O
propulsives	B
,	O
antispasmodics	B
,	O
antacids	B
,	O
or	O
bismuth	B
preparations	I
less	B
than	I
7	I
days	I
prior	I
to	I
randomization	I
.	O

H	B
.	I
Pylori	I
eradication	I
within	B
2	I
months	I
before	I
study	I
entry	I
.	O

Intestinal	B
infection	I
within	B
2	I
months	I
before	I
study	I
entry	I
.	O

Known	O
history	B
of	I
/	O
suspected	O
malignant	B
neoplasm	I
of	O
various	B
sites	I
.	O

Prior	O
diagnosis	O
of	O
a	O
class	B
IV	I
cardiovascular	B
disease	I
(	O
according	O
to	O
the	O
New	B
York	I
Heart	I
Association	I
,	O
1964	O
)	O
,	O
hypothyroidism	B
,	O
diabetes	B
mellitus	I
,	O
chronic	B
kidney	I
disease	I
(	O
С3	B
-	B
5	I
)	O
,	O
or	O
disease	B
of	I
liver	I
with	O
portal	B
hypertension	I
and	O
/	O
or	O
severe	B
decompensation	I
(	O
Child	B
-	I
Pugh	I
score	I
>	B
6	I
)	O
.	O

Other	O
severe	O
coexisting	B
morbidity	B
which	O
,	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
,	O
can	O
prevent	O
the	O
patient	O
from	O
participating	O
in	O
the	O
study	O
.	O

Allergy	B
/	O
intolerance	B
to	O
any	O
of	O
the	O
components	B
of	I
medications	I
used	I
in	I
the	I
treatment	I
.	O

Pregnancy	B
,	O
breast	O
-	O
feeding	O
.	O

Patients	O
who	O
,	O
from	O
investigator	O
'	O
s	O
point	O
of	O
view	O
,	O
will	O
fail	O
to	O
comply	O
with	O
the	O
observation	O
requirements	O
of	O
the	O
trial	O
or	O
with	O
the	O
dosing	O
regimen	O
of	O
the	O
investigational	O
drugs	O
.	O

Planned	O
hospitalization	B
during	B
the	I
study	I
period	I
,	O
for	O
any	O
diagnostic	O
or	O
treatment	B
procedures	I
.	O

Drug	B
addiction	I
,	O
alcohol	B
use	I
in	O
the	O
amount	O
over	B
2	I
units	I
of	I
alcohol	I
a	I
day	I
,	O
mental	B
diseases	I
.	O

Intake	O
of	O
medicines	B
listed	B
in	I
the	I
section	I
'	I
Prohibited	I
concomitant	I
treatment	I
'	I
for	O
1	B
month	I
prior	I
to	I
the	I
enrollment	I
in	I
the	I
trial	I
.	O

Participation	O
in	O
other	O
clinical	O
trials	O
within	O
3	O
months	O
to	O
the	O
enrollment	O
in	O
this	O
study	O
.	O

Patient	O
is	O
related	O
to	O
the	O
research	O
staff	O
of	O
the	O
clinical	O
investigative	O
site	O
who	O
are	O
directly	O
involved	O
in	O
the	O
trial	O
or	O
is	O
the	O
immediate	O
family	O
member	O
of	O
the	O
investigator	O
.	O
The	O
immediate	O
family	O
members	O
include	O
husband	O
/	O
wife	O
,	O
parents	O
,	O
children	O
or	O
brothers	O
(	O
or	O
sisters	O
)	O
,	O
regardless	O
of	O
whether	O
they	O
are	O
natural	O
or	O
adopted	O
.	O

Patient	O
works	B
for	I
OOO	I
"	I
NPF	I
"	I
MATERIA	I
MEDICA	I
HOLDING	I
"	I
(	O
i	O
.	O
e	O
.	O
,	O
is	O
the	O
company	B
'	I
s	I
employee	I
,	O
temporary	B
contract	I
worker	I
or	O
appointed	B
official	I
responsible	O
for	O
carrying	O
out	O
the	O
research	O
or	O
their	O
immediate	O
family	O
)	O
.	O

Men	B
and	O
women	B
aged	B
18	B
-	I
45	I
years	I
.	O

Diagnosis	O
of	O
functional	B
dyspepsia	I
,	O
based	O
on	O
the	O
Rome	B
IV	I
criteria	I
(	I
2016	I
)	I
.	O

GIS	B
score	I
of	O
at	B
least	I
6	I
.	O

Negative	B
H	B
.	I
pylori	I
test	I
.	O

Availability	O
of	O
a	O
signed	O
patient	O
information	O
sheet	O
(	O
Informed	O
Consent	O
form	O
)	O
for	O
participation	O
in	O
the	O
clinical	O
trial	O
.	O

Patients	O
who	O
agree	O
to	O
use	O
an	O
effective	O
method	O
of	O
contraception	O
throughout	O
the	O
clinical	O
trial	O
.	O

Healthy	O
Volunteers	O

Treprostinil	B
contraindications	B
:	O
Known	O
hypersensitivity	B
to	O
treprostinil	B
or	O
any	B
of	I
the	I
excipients	I
,	O
Pulmonary	B
arterial	I
hypertension	I
related	O
to	O
veno	B
-	I
occlusive	I
disease	I
,	O
Congestive	B
heart	I
failure	I
due	O
to	O
severe	B
left	B
ventricular	I
dysfunction	I
,	O
Severe	B
hepatic	B
insufficiency	I
(	O
Child	B
-	I
Pugh	I
stage	B
C	I
)	O
,	O
Evolving	B
gastrointestinal	B
ulcer	I
,	O
intracranial	B
hemorrhage	I
,	O
recent	B
trauma	B
or	O
other	O
clinical	B
condition	I
that	I
may	I
lead	I
to	I
bleeding	I
,	O
Congenital	O
or	O
acquired	B
valvular	I
abnormalities	I
with	B
cardiac	I
repercussions	I
,	O
Severe	B
ischemic	B
heart	I
disease	I
or	O
unstable	B
angina	I
;	O
Myocardial	B
infarction	I
in	B
the	I
last	I
six	I
months	I
;	O
Decompensated	B
cardiac	I
insufficiency	I
not	B
medically	I
controlled	I
;	O
Severe	B
arrhythmias	B
;	O
Cerebrovascular	B
lesions	I
(	O
such	O
as	O
transient	B
ischemic	I
attack	I
,	O
stroke	B
)	O
that	O
occurred	O
within	B
the	I
last	I
three	I
months	I
.	O

Persons	O
referred	O
to	O
in	O
Articles	O
L1121	O
-	O
5	O
to	O
L1121	O
-	O
8	O
of	O
the	O
French	O
Public	O
health	O
Code	O
:	O
pregnant	B
woman	B
,	O
parturient	B
,	O
nursing	B
mother	O
,	O
person	O
deprived	O
of	O
liberty	O
by	O
judicial	O
or	O
administrative	O
decision	O
,	O
person	O
subject	O
to	O
a	O
legal	O
protection	O
measure	O
,	O
can	O
not	O
Be	O
included	O
in	O
clinical	O
trials	O
.	O

Subject	O
in	O
an	O
exclusion	O
period	O
from	O
another	O
study	O
,	O

Subject	O
who	O
would	O
receive	O
more	O
than	O
4500	O
euros	O
of	O
compensation	O
due	O
to	O
his	O
participation	O
in	O
other	O
biomedical	O
research	O
in	O
the	O
12	O
months	O
preceding	O
this	O
study	O

Systemic	B
sclerosis	I
patients	O
:	O

Iloprost	B
cure	O
carried	O
out	O
in	B
the	I
previous	I
month	I
or	O
planned	O
in	B
the	I
following	I
month	I
.	O

Initiation	O
or	O
change	O
of	O
dosage	O
of	O
bosentan	B
,	O
sildenafil	B
or	O
calcium	B
channel	I
blockers	I
in	B
the	I
previous	I
month	I
or	O
in	B
the	I
following	I
month	I

Digital	B
Sympathectomy	I
or	O
botulinum	B
toxin	I
injection	I
planned	O
in	B
the	I
following	I
month	I
.	O

Clinically	O
superinfected	O
digital	B
ulcers	I

Treprostinil	B
contraindications	B
:	O
Known	O
hypersensitivity	B
to	O
treprostinil	B
or	O
any	B
of	I
the	I
excipients	I
,	O
Pulmonary	B
arterial	I
hypertension	I
related	O
to	O
veno	B
-	I
occlusive	I
disease	I
,	O
Congestive	B
heart	I
failure	I
due	O
to	O
severe	B
left	B
ventricular	I
dysfunction	I
,	O
Severe	B
hepatic	B
insufficiency	I
(	O
Child	B
-	I
Pugh	I
stage	B
C	I
)	O
,	O
Evolving	O
gastrointestinal	B
ulcer	I
,	O
intracranial	B
hemorrhage	I
,	O
recent	B
trauma	B
or	O
other	O
clinical	B
condition	I
that	I
may	I
lead	I
to	I
bleeding	I
,	O
Congenital	O
or	O
acquired	B
valvular	I
abnormalities	I
with	B
cardiac	I
repercussions	I
,	O
Severe	B
ischemic	B
heart	I
disease	I
or	O
unstable	B
angina	I
;	O
Myocardial	B
infarction	I
in	B
the	I
last	I
six	I
months	I
;	O
Decompensated	B
cardiac	I
insufficiency	I
not	O
medically	O
controlled	O
;	O
Severe	B
arrhythmias	B
;	O
Cerebrovascular	B
lesions	I
(	O
such	O
as	O
transient	B
ischemic	I
attack	I
,	O
stroke	B
)	O
that	O
occurred	O
within	B
the	I
last	I
three	I
months	I
.	O

Persons	O
referred	O
to	O
in	O
Articles	O
L1121	O
-	O
5	O
to	O
L1121	O
-	O
8	O
of	O
the	O
French	O
Public	O
health	O
Code	O
:	O
pregnant	B
woman	B
,	O
parturient	B
,	O
nursing	B
mother	O
,	O
person	O
deprived	O
of	O
liberty	O
by	O
judicial	O
or	O
administrative	O
decision	O
,	O
person	O
subject	O
to	O
a	O
legal	O
protection	O
measure	O
,	O
can	O
not	O
Be	O
included	O
in	O
clinical	O
trials	O
.	O

Subject	O
in	O
an	O
exclusion	O
period	O
from	O
another	O
study	O
,	O

Subject	O
who	O
would	O
receive	O
more	O
than	O
4500	O
euros	O
of	O
compensation	O
due	O
to	O
his	O
participation	O
in	O
other	O
biomedical	O
research	O
in	O
the	O
12	O
months	O
preceding	O
this	O
study	O

Healthy	O
Volunteers	O
:	O

Age	B
of	O
at	B
least	I
18	I
years	I

Existence	O
of	O
a	O
contraceptive	B
method	I
for	O
women	B
of	O
child	B
-	I
bearing	I
age	B

Person	O
affiliated	O
to	O
social	O
security	O
or	O
beneficiary	O
of	O
such	O
a	O
scheme	O

Signed	O
consent	O
form	O

Systemic	O
sclerosis	O
patients	O
:	O

Systemic	B
sclerosis	I
meeting	B
the	O
EULAR	B
criteria	I
.	O

Presence	O
of	O
at	O
least	O
2	O
ischemic	B
digital	I
cutaneous	I
ulcerations	I
on	O
two	O
different	O
fingers	O
,	O
with	O
digital	B
ulcers	I
classified	O
as	O
"	O
active	B
ulcers	O
"	O
according	O
to	O
the	O
North	B
American	I
working	I
group	I
definition	I
:	O
epithelial	B
denudation	I
is	I
clearly	I
Visible	I
at	I
one	I
place	I
and	I
the	I
bed	I
of	I
de	I
-	I
epithelialized	I
ulcer	I
can	I
be	I
seen	I
;	I
Ulcerations	I
distal	I
to	I
the	I
proximal	I
interphalangeal	I
joint	I
,	I
not	I
associated	I
with	I
calcinosis	I
or	I
bony	I
relief	I
.	O

Ulcers	B
whose	O
major	B
axis	I
measured	B
with	I
the	I
electronic	I
caliper	I
is	O
≥	B
2	I
mm	I

Age	B
greater	B
than	I
or	I
equal	I
to	I
18	I
years	I

Existence	O
of	O
a	O
contraceptive	B
method	O
for	O
women	B
of	O
reproductive	B
age	B

A	O
person	O
who	O
is	O
or	O
is	O
a	O
beneficiary	O
of	O
social	O
security	O

Informed	O
and	O
signed	O
consent	O
signed	O
by	O
the	O
patient	O
or	O
his	O
/	O
her	O
legal	O
representative	O
.	O

Currently	B
pregnant	B
or	O
breastfeeding	O

Severe	B
pelvic	B
organ	I
prolapse	I
or	O
prolapse	B
to	O
any	O
degree	O
that	O
may	B
prevent	I
retention	I
of	I
the	I
vaginal	I
ring	I
after	I
insertion	I

Use	O
of	O
oral	B
contraceptive	I
pills	I
,	O
patches	B
,	O
implants	B
or	O
hormonal	B
intrauterine	I
contraception	I
in	B
the	I
month	I
prior	I
to	I
screening	I

Use	O
of	O
depo	B
medroxyprogesterone	I
within	B
6	I
months	I
of	I
screening	I

Use	O
of	O
medications	B
that	O
interact	O
with	O
contraceptive	B
steroid	I
hormones	I
:	O
anti	B
-	I
epileptic	I
medications	I
,	O
rifampin	B
,	O
rifabutin	B
,	O
fosamprenavir	B
,	O
etc	O

Medical	B
condition	I
with	O
safety	B
deemed	I
to	I
be	I
category	I
3	B
or	I
4	I
when	O
using	O
a	O
combined	B
hormonal	I
contraceptive	I
,	O
as	O
determined	O
by	O
the	O
Center	B
for	I
Disease	I
Control	I
Medical	I
Eligibility	I
Criteria	I
:	O
current	B
or	O
past	B
history	B
of	O
breast	B
cancer	I
,	O
severe	B
decompensated	B
cirrhosis	B
,	O
history	B
of	O
deep	B
vein	I
thrombosis	I
or	O
pulmonary	B
embolus	I
,	O
diabetes	B
with	O
nephropathy	B
/	O
retinopathy	B
/	O
neuropathy	B
or	O
other	B
vascular	B
disease	I
diagnosed	O
more	B
than	I
20	I
years	I
ago	I
,	O
current	B
symptomatic	B
gallbladder	B
disease	I
,	O
hypertension	B
,	O
ischemic	B
heart	I
disease	I
,	O
known	O
thrombogenic	B
mutations	I
,	O
hepatocellular	B
adenoma	I
,	O
malignant	B
hepatoma	I
,	O
multiple	B
risk	O
factors	O
for	O
atherosclerotic	B
cardiovascular	I
disease	I
,	O
multiple	B
sclerosis	I
with	O
prolonged	B
immobility	I
,	O
history	B
of	O
peripartum	B
cardiomyopathy	I
,	O
cigarette	O
smoking	O
and	O
=	O
35yo	B
,	O
history	B
of	O
complicated	B
solid	I
organ	I
transplant	I
,	O
history	B
of	O
stroke	B
,	O
history	B
of	O
superficial	B
venous	I
thrombosis	I
not	B
associated	I
with	O
catheter	B
,	O
systemic	B
lupus	I
erythematosus	I
with	O
positive	B
antiphospholipid	B
antibodies	I
,	O
valvular	B
heart	I
disease	I
complicated	O
by	O
pulmonary	B
hypertension	I
or	O
atrial	B
fibrillation	I
or	O
bacterial	B
endocarditis	I
,	O
and	O
acute	B
viral	I
hepatitis	I

Healthy	B
,	O
women	B
ages	B
18	B
to	I
39yo	I
with	O
BMI	B
<	B
30	I

Regular	B
menstrual	I
cycles	I
with	O
duration	B
between	B
24	I
-	I
35	I
days	I

Completion	O
of	O
screening	O
visit	O
where	O
ovulation	O
will	O
be	O
assessed	O
with	O
blood	O
draw	O
for	O
progesterone	B
level	I
(	O
must	O
be	O
5ng	B
/	I
mL	I
or	I
greater	I
)	O

Not	O
seeking	O
pregnancy	O
during	O
the	O
study	O
period	O

Use	O
of	O
a	O
non	B
-	I
hormonal	I
form	I
of	I
contraception	I
,	O
such	O
as	O
:	O
sterilization	B
(	O
tubal	B
ligation	I
,	O
Essure	B
)	O
,	O
copper	B
IUD	I
(	O
intrauterine	B
device	I
)	O
,	O
barrier	B
methods	I
or	O
abstinence	O

Must	O
speak	O
English	O
or	O
Spanish	O

Patients	O
under	O
the	O
age	B
of	O
18	O
(	O
Subjects	O
under	O
the	O
age	O
of	O
18	O
will	O
not	O
be	O
included	O
in	O
this	O
study	O
due	O
to	O
the	O
continued	O
growth	O
and	O
development	O
of	O
their	O
joints	O
and	O
unstudied	O
effects	O
on	O
children	O
.	O
)	O

Over	O
the	O
age	B
of	O
80	O

Multiple	B
pain	I
sources	I
and	O
multifactorial	B
pain	I
sources	I
that	O
complicated	O
or	O
confound	O
diagnosing	O
the	O
SI	O
joint	O
as	O
the	O
primary	O
and	O
predominant	O
pain	O
generator	O
that	O
may	O
contribute	O
to	O
low	O
back	O
pain	O
(	O
including	O
but	O
not	O
limited	O
to	O
:	O
lumbar	B
diagnosis	I
,	O
lumbar	B
radiculopathy	I
,	O
intra	O
or	O
extra	B
-	I
articular	I
hip	I
pathology	I
to	O
include	O
acetabulum	O
and	O
femoral	O
head	O
,	O
lumbo	B
-	I
sacral	I
joint	I
pathology	I
,	O
intervertebral	B
disk	I
disease	I
,	O
spondylolisthesis	B
/	O
spondylosis	B
/	O
spondylolysis	B
of	I
lumbar	I
vertebra	I
)	O

Immunosuppressed	B
/	O
immune	B
compromised	I

Underlying	B
comorbidities	I
that	O
contraindicate	B
the	O
procedure	B
(	O
including	O
but	O
not	O
limited	O
to	O
polycythemia	B
,	O
coagulation	B
disorder	I
,	O
or	O
malignancy	B
)	O
.	O

Diagnosis	O
of	O
sacroiliitis	B

Age	B
18	B
to	I
80	I
years	I
old	O

Chronic	B
low	I
back	I
pain	I

SI	B
joint	I
pathology	I
is	O
the	O
predominant	O
source	O
of	O
pain	O

Positive	B
Fortin	B
Finger	I
Test	I
(	I
PMT	I
)	I

Joint	O
anatomy	O
is	O
identifiable	O
using	O
ultrasonography	O

Patient	O
has	O
no	B
other	B
comorbidities	B
that	I
contraindicate	I
the	I
procedure	I

Patient	O
has	O
attempted	O
physical	B
therapy	I
and	O
corticosteroid	B
injections	I
with	O
local	B
anesthetic	I
-	O
Previous	O
injections	O
of	O
lidocaine	O
and	O
corticosteroid	O
provided	O
at	O
least	O
minor	O
immediate	O
relief	O

Patient	O
must	O
not	B
have	O
had	O
a	O
corticosteroid	B
injection	I
in	O
the	O
SI	B
joint	I
within	B
the	I
last	I
three	I
months	I

Patient	O
must	O
consent	O
to	O
the	O
procedure	O

Epilepsy	B

Hydrocephalus	B
with	O
ventricular	B
drain	I

Coagulation	B
disorders	I

Allergy	B
to	O
anesthetic	B
agents	I

Severe	B
health	I
conditions	I
such	O
as	O
cancer	B
,	O
failure	B
of	I
heart	I
,	O
lung	O
,	O
liver	O
or	O
kidney	O

Active	B
infections	B

Cerebral	B
palsy	I
of	O
any	O
types	O
caused	O
by	O
Neonatal	B
Jaundice	I

Molar	B
teeth	I

Milller	B
Class	B
4	I
recession	B
defects	I

Pregnancy	B
(	O
Self	O
-	O
reported	O
)	O

Smoking	B

Uncontrolled	B
local	O
or	O
systemic	B
diseases	I
that	B
affects	I
wound	I
healing	I
(	O
diabetes	B
,	O
autoimmune	O
or	O
inflammatory	B
disorders	I
)	O

Past	B
history	I
of	O
systemic	B
steroid	I
use	O
over	B
2	I
weeks	I
within	B
the	I
last	I
2	I
years	I

Poor	B
oral	I
hygiene	I
on	O
a	O
non	O
-	O
compliant	O
individual	O

Ibuprofen	B
Allergy	B
/	O
interlerance	B

Anticoagulant	B
therapy	I
(	O
e	O
.	O
g	O
.	O
Warfarin	B
,	O
Plavix	B
,	O
etc	O
.	O
)	O
,	O
will	O
not	O
be	O
automatic	O
exclusion	O
but	O
patients	O
will	O
be	O
required	O
to	O
have	O
INR	B
test	I
performed	O
and	O
have	O
values	O
between	B
2	I
.	I
0	I
to	I
3	I
.	O

Physician	O
consultation	O
will	O
be	O
requested	O
to	O
determine	O
whether	O
anticoagulant	B
therapy	I
can	O
be	O
discontinued	O
for	O
3	O
days	O
prior	O
to	O
surgery	O
.	O

Objection	O
to	O
blood	O
draw	O
or	O
application	O
of	O
blood	O
products	O

Students	O
and	O
staff	O
from	O
USC	O
Ostrow	O
school	O
of	O
Dentistry	O
will	O
not	O
be	O
recruited	O
for	O
this	O
study	O

Male	O
and	O
female	O
individuals	O
between	O
ages	B
of	O
18	O
to	O
70	O
years	O
old	O

Multiple	B
contiguous	O
gingival	B
recession	I
defects	I
on	O
a	O
minimum	B
of	I
two	I
adjacent	O
teeth	O
,	O
exhibiting	O
3mm	B
or	I
more	I
recession	B
on	O
at	B
least	I
one	I
of	O
those	O
teeth	O

No	B
prior	O
surgical	B
treatment	I
in	O
the	O
sites	O
planned	O
for	O
therapy	O

Minimum	B
of	I
2	I
mm	I
of	O
keratinized	B
gingiva	I

Absence	B
of	O
cervical	O
restorations	O
extending	O
to	O
the	O
CEJ	O

Miller	B
class	B
1	I
,	I
2	I
and	I
3	I
recession	B
defects	I
will	O
be	O
included	O

Availability	O
to	O
undergo	O
treatment	O
and	O
return	O
for	O
follow	O
up	O
visits	O
at	O
specified	O
post	O
-	O
operative	O
intervals	O

Therapy	O
area	O
located	O
outside	O
of	O
head	O
and	O
neck	O
;	O

Other	O
skin	B
diseases	I
that	O
might	O
interfere	B
with	I
the	I
efficacy	I
evaluation	I
;	O

Therapy	O
area	O
was	O
previously	O
received	O
isotope	B
or	O
PDT	B
or	O
other	O
treatment	B
which	O
might	B
interfere	I
with	I
the	I
efficacy	I
evaluation	I
;	O

Allergy	B
to	O
porphyrins	B
and	O
analogues	B
;	O
Photosensitivity	B
;	O
Porphyria	B
;	O
Allergic	B
constitution	I
;	O

Scar	B
diathesis	I
;	O

Immunocompromised	B
conditions	I
;	O

Electrocardiographic	B
abnormalities	O
or	O
organic	B
heart	B
diseases	I
;	O

Coagulation	B
disorders	I
;	O

Hepatic	O
or	O
renal	B
functions	I
abnormal	B
(	O
alanine	B
aminotransferase	I
or	O
aspartate	B
transaminase	I
or	O
total	B
bilirubin	I
>	B
1	I
.	I
5	I
upper	I
limit	I
of	I
normal	I
[	I
ULN	I
]	I
,	O
or	O
serum	B
creatinine	I
or	O
blood	B
urea	I
nitrogen	I
>	B
1	I
.	I
5	I
ULN	I
)	O
;	O

Psychiatric	B
diseases	I
;	O
Severe	B
endocrinopathies	B
;	O

Previous	B
therapy	B
of	O
PWS	B
within	B
the	I
last	I
4	I
weeks	I
;	O

Participation	O
in	O
any	O
clinical	O
studies	O
within	B
the	I
last	I
4	I
weeks	I
;	O

Be	O
judged	O
not	O
suitable	O
to	O
participate	O
the	O
study	O
by	O
the	O
investigators	O

Children	B
with	O
clinical	B
diagnosis	I
of	O
PWS	B
;	O

Age	B
range	O
:	O
7	B
to	I
14	I
years	I
-	I
old	I
;	O

Voluntarily	O
participated	O
and	O
Written	O
informed	O
consent	O
signed	O

Uncontrolled	B
hypertension	B
(	O
defined	O
as	O
average	B
SBP	I
=	B
160	I
mmHg	I
[	O
2	B
readings	I
taken	O
at	B
time	I
of	I
screening	I
]	O
)	O
.	O

End	B
stage	I
renal	I
disease	I
(	O
CrCl	B
<	B
15	I
ml	I
/	I
min	I
)	O

Valvular	B
Heart	I
Disease	I
including	O
those	O
with	O
prosthetic	B
valve	I
,	O
mitral	B
stenosis	I
(	O
moderate	B
to	O
severe	B
)	O
or	O
valve	B
repair	I
.	O

Excess	B
alcohol	B
intake	I
(	O
males	B
:	O
=	B
28	I
units	I
/	I
week	I
,	O
females	B
:	O
=	B
21	I
units	I
/	I
week	I
.	O
One	O
unit	O
of	O
alcohol	O
=	O
8	O
oz	O
beer	O
,	O
1	O
oz	O
hard	O
liquor	O
or	O
4	O
oz	O
wine	O
)	O
.	O

Intracranial	B
bleed	I
at	B
any	I
point	I
.	O

History	B
of	O
"	O
Major	B
Bleeding	I
"	O
at	B
any	I
point	I
(	O
defined	O
as	O
overt	B
bleeding	I
at	O
a	O
critical	B
site	I
including	O
intracranial	B
,	O
intraspinal	B
,	O
intraocular	B
,	O
pericardial	B
,	O
or	O
retroperitoneal	B
;	O
or	O
bleed	B
requiring	O
hospitalization	B
)	O
.	O

Foreshortened	B
life	O
-	O
expectancy	O
or	O
severe	B
comorbidities	I
precluding	O
study	O
follow	O
-	O
up	O
period	O

Unable	O
to	O
read	O
/	O
understand	O
English	O

Severe	B
cognitive	B
impairment	I
(	O
defined	O
as	O
score	O
=	B
5	I
on	O
the	O
Short	B
Portable	I
Mental	I
Status	I
Questionnaire	I
)	O

Age	B
=	B
65	I
years	I
with	O
one	B
additional	I
stroke	B
risk	B
factor	I
(	O
hypertension	B
,	O
diabetes	B
,	O
heart	B
failure	I
history	B
of	O
or	O
left	B
ventricular	I
ejection	I
fraction	I
<	B
0	I
.	I
40	I
)	O
,	O
previous	B
stroke	B
or	O
transient	B
ischemic	I
attack	I
)	O
.	O

Atrial	B
fibrillation	I
and	O
not	B
on	O
oral	B
anticoagulation	I
(	I
OAC	I
)	I
therapy	I
but	O
eligible	O

Atrial	B
fibrillation	I
on	O
sub	B
-	I
optimal	I
OAC	B

A	O
prescription	O
of	O
a	O
NOAC	B
within	O
90	O
days	O
prior	O
to	O
hospitalization	B
or	O
outpatient	B
clinic	I
visit	I
for	O
VTE	B
.	O

Patients	O
with	O
NOAC	B
preference	O
apart	O
from	O
preference	O
consistent	O
with	O
current	O
cluster	O
randomized	O
NOAC	O
.	O

Other	B
contraindications	B
mentioned	O
in	O
the	O
"	O
Summary	B
of	I
Product	I
Characteristics	I
"	O
for	O
the	O
respective	O
NOAC	B
.	O

A	O
diagnosis	O
of	O
VTE	B
in	O
outpatient	O
clinic	O
or	O
as	O
discharge	B
diagnosis	I
after	O
hospitalization	B
.	O

A	O
claimed	B
prescription	B
of	O
a	O
NOAC	B
from	O
a	O
Danish	B
pharmacy	I
within	O
14	O
days	O
of	O
discharge	B
or	O
outpatient	B
clinic	I
visit	I
.	O

Currently	O
enrolled	O
in	O
,	O
or	O
discontinued	O
within	O
the	O
last	O
30	O
days	O
from	O
,	O
a	O
clinical	O
trial	O
involving	O
an	O
off	O
-	O
label	O
use	O
of	O
an	O
investigational	O
drug	O
.	O

Current	O
Axis	B
I	I
primary	B
psychiatric	B
diagnosis	I
other	B
than	I
major	B
depressive	I
disorder	I
.	O

Organic	B
mental	I
disease	I
,	O
including	O
mental	B
retardation	I
.	O

History	O
of	O
clinically	B
significant	I
disease	B
,	O
including	O
any	O
cardiovascular	O
,	O
hepatic	O
,	O
renal	O
,	O
respiratory	O
,	O
hematologic	O
,	O
endocrinologic	O
,	O
or	O
neurologic	B
disease	I
,	O
or	O
clinically	B
significant	I
laboratory	B
abnormality	I
that	O
is	O
not	B
stabilized	B
or	O
is	O
anticipated	O
to	O
require	O
treatment	B
during	B
the	I
study	I
.	O

Subjects	O
receiving	O
an	O
investigational	O
agent	O
(	O
including	O
different	O
formulation	O
and	O
generic	O
agents	O
of	O
investigational	O
drug	O
)	O
in	O
the	O
previous	O
3	O
months	O
prior	O
to	O
screening	O
.	O

Women	O
in	O
pregnancy	O
or	O
lactation	O
,	O
or	O
female	O
of	O
child	O
bearing	O
potential	O
without	O
appropriate	O
birth	O
control	O
measures	O
.	O

Use	O
of	O
antipsychotics	B
or	O
mood	B
stabilizers	I
within	B
5	I
days	I
prior	I
to	I
screening	I
.	O

Has	O
received	O
depot	B
antipsychotic	I
medication	I
within	B
one	I
cycle	I
prior	I
to	I
screening	I
.	O

Known	O
allergy	B
or	O
lack	B
of	I
response	I
to	O
mirtazapine	B
.	O

Has	O
received	O
ECT	B
or	O
MECT	B
within	B
3	I
months	I
prior	I
to	I
screening	I
.	O

History	O
of	O
anticholinergic	B
drug	I
allergy	B
or	O
complications	O
(	O
allergic	B
reaction	I
,	O
skin	B
rash	I
,	O
urticaria	B
and	O
other	B
allergic	B
reactions	I
which	O
caused	O
by	O
drugs	B
)	O
.	O

Smokers	O
.	O

Significant	O
risk	O
of	O
suicidal	O
and	O
/	O
or	O
self	O
-	O
harm	O
behaviors	O

Has	O
given	O
written	O
informed	O
consent	O
.	O

Male	B
or	O
female	B
outpatients	O
aged	B
at	B
least	I
18	I
years	I
and	I
not	I
more	I
than	I
45	I
years	I
.	O

Has	O
a	O
diagnosis	O
of	O
major	B
depressive	I
disorder	I
by	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
Fourth	I
Edition	I
(	I
DSM	I
-	I
IV	I
)	I
criteria	I
.	O

Current	B
HAMD	B
-	I
17	I
score	B
=	I
20	I
and	O
the	O
duration	O
of	O
the	O
index	B
episode	I
is	O
greater	B
than	I
or	I
equal	I
to	I
four	I
weeks	I
.	O

GCS	B
less	B
than	I
15	I

Preoperative	B
Heart	I
Rate	I
less	B
than	I
50	I
beat	I
/	I
min	I

No	B
Beta	B
-	I
Blockers	I

Pregnant	B
patients	O

Take	O
any	O
Alpha	B
-	I
Methyldopa	I
,	O
Clonodine	B
,	O
Other	B
Alpha	B
-	I
2	I
Adrenergic	I
Agonist	I

Hemodynamic	B
unstable	I

Systolic	B
BP	I
more	B
than	I
160mmHg	I

CAD	B

Renal	B
insuffuciency	I

Allergy	B
in	O
dexmedethomidine	B
and	O
opioid	B

BMI	B
more	B
than	I
30	I

Denied	O
consent	O

Age18	B
-	B
65	I

ASA	B
1	B
-	I
2	I

Elective	B
TNTS	B
resection	I
of	O
Pituitary	B
Tumor	I

No	B
narcotic	B
before	O
surgery	B
as	O
premedication	O

Able	O
to	O
Extubate	B

NA	O

NA	O

Patients	O
refuse	O
to	O
follow	O
the	O
research	O

Patient	O
has	O
had	O
previous	B
eradication	B
therapy	I
of	O
Helicobacter	B
pylori	I
infection	I
.	O

The	O
patient	O
is	O
pregnant	B
or	O
breastfeeding	O

Patients	O
have	O
a	O
history	B
of	O
allergy	B
to	O
one	O
component	B
of	I
triple	I
therapy	I
regimen	I
(	O
proton	B
pump	I
inhibitor	I
,	O
penicillin	B
,	O
and	O
/	O
or	O
macrolide	B
)	O
before	O
.	O

Patients	O
are	O
known	O
to	O
have	O
impaired	B
liver	B
function	I
,	O
evidenced	O
by	O
ALT	B
values	I
within	B
normal	I
limits	I
,	O
and	O
no	B
previous	B
liver	B
disease	I
.	O

Patients	O
were	O
found	O
to	O
have	O
arrhythmias	B
or	O
obtained	O
QT	B
wave	I
elongation	I
on	O
electrocardiographic	B

18	O
years	O
or	O
older	B
patients	O
who	O
are	O
proven	O
to	O
be	O
infected	B
by	I
Helicobacter	I
pylori	I
based	O
on	O
positive	B
in	O
Urea	B
Breath	I
Test	I
or	O
positive	B
in	O
histopathologic	B
examination	I
of	I
biopsy	I
in	O
antrum	O
and	O
corpus	B
of	I
gaster	I
through	O
esophagoduodenoscopy	B
.	O

Patient	O
refusal	O
for	O
supraclavicular	B
block	I

Inability	O
to	O
give	O
informed	O
consent	O

Allergy	B
to	O
local	B
anesthetics	I

Hemidiaphragmatic	B
dysfunction	I
,	O
suspected	B
or	O
known	B
PNP	B

Neuromuscular	B
disease	I

Obstructive	O
or	O
restrictive	B
pulmonary	I
disease	I

Medical	B
or	O
anatomic	B
contraindication	B
to	O
supraclavicular	B
blockade	I
as	O
judged	O
by	O
clinician	O

Pregnancy	B

Undergoing	B
right	B
upper	I
extremity	I
surgery	I
with	O
supraclavicular	B
block	I
as	O
the	O
primary	B
anesthetic	I

Age	B
greater	B
than	I
or	I
equal	I
to	I
18	I
years	I
of	O
age	O

American	B
Society	I
of	I
Anesthesiologists	I
(	I
ASA	I
)	I
physical	I
status	I
1	B
to	I
3	I

Able	O
to	O
give	O
informed	O
consent	O

Exclusion	O
criteria	O
includes	O
ICUs	O
with	O
an	O
average	B
length	I
of	I
stay	I
of	O
less	B
than	I
2	I
days	I
;	O

HCA	O
hospitals	O
that	O
are	O
not	O
able	O
to	O
transfer	O
or	O
merge	O
data	O
into	O
the	O
centralized	O
data	O
warehouse	O
for	O
the	O
baseline	O
and	O
intervention	O
periods	O
of	O
the	O
study	O
are	O
also	O
excluded	O
.	O

Inclusion	O
criteria	O
includes	O
all	O
U	O
.	O
S	O
.	O

HCA	O
hospitals	O
with	O
an	O
adult	B
ICU	O
;	O

Note	O
:	O
Unit	O
of	O
randomization	O
is	O
the	O
hospital	O
,	O
but	O
the	O
participants	O
are	O
hospital	O
adult	O
ICUs	O

All	O
patients	O
within	O
adult	B
ICUs	O
are	O
included	O
,	O
including	O
rare	B
patients	I
<	O
18	O
years	B
and	O
>	O
=	O
12	O
years	O
.	O

Non	B
-	I
reassuring	I
fetal	B
assessment	I
at	B
the	I
time	I
of	I
recruitment	I

Previous	B
cervical	B
ripening	I
agents	I
(	O
cytotec	B
,	O
cervidil	B
,	O
cervical	B
Foley	I
Balloon	I
)	O

<	B
18	I
years	I
of	O
age	B

Prisoners	B

Any	O
patients	O
contraindicated	B
for	O
vaginal	B
delivery	I

Multiple	O
gestations	O

History	B
of	O
previous	B
cesarean	B
delivery	I

Patients	O
with	O
history	B
of	O
significant	B
cardiac	B
disease	I

Fetal	B
demise	I

Estimated	B
fetal	I
weight	I
greater	B
than	I
4500	I
grams	I
in	O
diabetic	B
and	O
5000	B
grams	I
in	O
non	B
-	I
diabetic	B
mother	O

Ruptured	B
membranes	I

Spontaneous	B
labor	I
(	O
latent	O
or	O
active	B
phase	I
)	O

Augmentation	B
of	I
labor	I
(	O
latent	O
or	O
active	B
phase	I
)	O

Singleton	B
pregnancy	I
=	B
37	I
weeks	I
gestation	B

Patient	O
presented	O
for	O
induction	B
of	I
labor	I
who	O
is	O
determined	O
to	O
be	O
a	O
candidate	O
for	O
oxytocin	B

Cephalic	O
presentation	O

Reassuring	B
fetal	B
health	I
assessment	I
(	O
no	B
abnormal	B
findings	I
in	O
fetal	B
assessment	I
,	O
see	O
below	O
)	O

Meeting	O
one	O
of	O
the	O
following	O
BMI	O
category	O
:	O

Smoker	B
or	O
former	B
smoker	I
.	O

Presence	O
of	O
dental	B
prostheses	I
.	O

Presence	O
of	O
orthodontic	B
devices	I
.	O

Antibiotic	B
treatment	O
or	O
routine	B
use	I
of	O
oral	B
antiseptics	I
in	B
the	I
previous	I
3	I
months	I
.	O

Presence	O
of	O
any	O
systemic	B
disease	I
that	O
could	B
alter	I
the	I
production	I
or	I
composition	I
of	I
saliva	I
.	O

Systemically	B
healthy	B
adults	B
.	O

Minimum	B
of	I
24	I
permanent	O
teeth	O
.	O

No	B
gingivitis	B
(	O
Community	B
Periodontal	I
Index	I
score	I
=	B
0	I
)	O
.	O

No	B
periodontitis	B
(	O
Community	B
Periodontal	I
Index	I
score	I
=	B
0	I
)	O
.	O

Absence	B
of	O
untreated	B
caries	B
.	O

Upper	B
urinary	I
tract	I
deterioration	I

Uncontrolled	B
diabetes	B
mellitus	I

Evident	O
local	O
or	O
pelvic	B
recurrence	I

Adjuvant	B
chemotherapy	I

Chronic	B
retention	I

Pouch	B
stones	I

Urethral	B
stricture	I
or	O
urethro	B
-	I
ileal	I
maldirection	I

Sensitivity	B
to	O
Mebeverine	B

Untreated	B
chronic	B
constipation	I

Active	B
symptomatic	B
urinary	B
infection	I

Men	B
18	B
years	I
or	I
older	I

ONB	B
within	O
1	O
year	O
post	O
-	O
surgery	B
.	O

Pregnancy	B
,	O
coagulopathy	B
,	O
allergy	B
to	O
bupivacaine	B
,	O
renal	B
failure	I
,	O
hepatic	B
insufficiency	I
,	O
and	O
/	O
or	O
inappropriate	B
candidate	I
for	O
usual	B
therapy	I
(	O
specifically	O
,	O
if	O
unable	O
to	O
receive	O
the	O
usual	O
preoperative	B
interscalene	I
nerve	I
block	I
:	O
preexisting	B
nerve	B
injury	I
on	O
side	B
of	I
surgery	I
,	O
refusal	B
of	I
nerve	I
block	I
,	O
infection	B
at	O
site	B
of	I
nerve	I
block	I
)	O
.	O

Adult	B
patients	O
up	O
to	O
age	B
75	O
years	O
,	O
undergoing	O
elective	B
,	O
ambulatory	O
,	O
arthroscopic	B
rotator	I
cuff	I
repair	I
.	O

signs	O
of	O
complicated	B
UTI	I
(	O
e	O
.	O
g	O
.	O
temperature	B
>	B
38	I
°	I
C	I
,	O
loin	B
tenderness	I
)	O

conditions	B
that	O
may	O
lead	O
to	O
complicated	B
infections	I
(	O
i	O
.	O
e	O
.	O
renal	B
diseases	I
,	O
patients	B
with	O
urinary	B
catheter	I
)	O

pregnancy	O
/	O
breastfeeding	O

current	O
self	B
-	I
medication	I
with	O
UU	B
preparations	I
e	O
.	O
g	O
.	O
z	B
.	I
B	I
.	I
Cystinol	I
®	I
,	O
Uvalysat	B
®	I
,	O
Arctuvan	B
®	I

antibiotic	B
use	O
in	O
the	O
last	B
7	I
days	I

previous	O
UTI	B
in	O
the	O
past	B
2	I
weeks	I

history	O
of	O
pyelonephritis	B

contraindications	O
for	O
trial	B
drugs	B

serious	B
diseases	B

inability	O
to	O
understand	O
trial	O
Information	O

current	O
participation	O
in	O
another	O
clinical	O
trial	O
or	O
participation	O
in	O
another	O
clinical	O
trial	O
within	O
the	O
last	O
4	O
weeks	O

Women	B
(	O
18	B
-	I
75	I
years	B
)	O
with	O
suspected	B
UTI	B

at	B
least	I
two	I
symptoms	B
of	I
UTI	I
(	O
dysuria	B
,	O
urgency	B
of	I
micturition	I
,	O
frequency	B
,	O
lower	B
abdominal	I
pain	I
)	O

Written	O
informed	O
consent	O

Suicidal	B
patients	O
and	O
/	O
or	O
severe	B
automutilation	B
behavior	I
and	O
/	O
or	O
psychotic	B
symptoms	I
and	O
/	O
or	O
lack	B
of	I
event	I
memory	I
.	O

Clinical	B
Administered	I
PTSD	I
Scale	I
5	O
Monthly	O
version	O
Criteria	B
A	I
and	O
>	B
30	I
points	I

NA	O

children	B
and	O
teenagers	B
aged	B
less	B
than	I
20	I
years	I
,	O

history	B
of	O
gastrectomy	B
,	O

gastric	B
malignancy	I
,	O
including	O
adenocarcinoma	B
and	O
lymphoma	B
,	O

previous	B
allergic	B
reaction	I
to	O
antibiotics	B
(	O
bismuth	B
,	O
amoxicillin	B
,	O
metronidazole	B
,	O
clarithromycin	B
,	O
tetracycline	B
)	O
and	O
PPI	B
(	O
esomeprazole	B
)	O
,	O

contraindication	B
to	O
treatment	B
drugs	I
,	O

pregnant	B
or	O
lactating	B
women	B
,	O

severe	B
concurrent	B
disease	B
,	O

concomitant	B
use	O
of	O
clopidogrel	B
,	O
or	O
(	O
9	O
)	O
Unwilling	O
to	O
accept	O
random	O
assignment	O
of	O
subjects	O

Allergy	B
known	O
to	O
fish	B

Pregnant	B
women	B
who	O
breast	B
-	I
feed	I
or	O
test	O
positive	B
for	O
pregnancy	O

Participant	O
aged	B
19	B
or	I
over	I

Available	O
for	O
the	O
entire	O
duration	O
of	O
the	O
study	O
and	O
willing	O
to	O
participate	O
on	O
the	O
basis	O
of	O
the	O
information	O
provided	O
in	O
the	O
FIU	O
duly	O
read	O
and	O
signed	O
.	O

Patients	O
with	O
coagulopathy	B
or	O
under	O
anti	B
-	I
coagulation	I
therapy	I
.	O

Gastrointestinal	B
disease	I
,	O

motion	B
sickness	I
.	O

diabetes	B
mellitus	I
.	O

Patients	O
with	O
preeclampsia	B
,	O

adult	B
female	B
partner	O

aged	B
18	B
to	I
40	I
years	I
.	O

scheduled	O
for	O
elective	B
cesarean	B
section	I
.	O

Women	B
with	O
Non	B
-	I
proteinuric	I
hypertension	I

severe	B
renal	B
impairment	I

Myasthenia	B
gravis	I

High	B
amount	I
of	O
magnesium	B
in	I
blood	I

Low	O
or	O
high	B
amount	I
of	O
calcium	B
in	I
blood	I

Myocardial	B
damage	I
,	O
diabetic	B
coma	I
,	O
heart	B
block	I

Pregnant	B
women	B
admitted	B
to	I
Women	O
health	O
hospital	O
with	O
a	O
diagnosis	O
of	O
severe	B
pre	B
-	I
eclampsia	I

Known	O
fetal	B
anomaly	I

Other	O
indication	B
for	O
intrapartum	B
antibiotics	I
(	O
endocarditis	B
prophylaxis	I
,	O
other	O
known	O
maternal	B
infection	I
)	O

Pregnant	B
women	B
between	B
34	I
-	I
42	I
weeks	I
gestation	B

Singleton	B
fetus	I

Admitted	O
for	O
labor	B
management	I
&	O
develops	O
a	O
fever	B
of	O
100	B
.	I
4	I
F	I
or	I
greater	I

small	B
bowel	I
resection	I

right	B
sided	I
hemicolectomy	I

known	O
chronic	B
diarrheal	I
disease	I
(	O
celiac	B
disease	I
,	O
lactose	B
malabsorption	I
,	O
Inflammatory	B
bowel	I
diseases	I
,	O
incl	O
microscopic	B
colitis	I
)	O

pregnancy	B

wish	O
for	O
pregnancy	B
within	B
next	I
three	I
months	I

allergy	B
to	O
eggs	B

allergy	B
to	O
constituents	B
in	I
Xenbilox	I
(	O
capsules	O
with	O
chenodeoxycholic	B
acid	I
)	O

acute	B
cholecystitis	I
within	B
two	I
months	I

chronic	B
cholecystitis	I

cirrhosis	B
of	I
the	I
liver	I

suspected	O
obstructive	B
choledocholithiasis	I

icterus	B

planned	O
elective	B
cholecystectomy	B

Presence	O
of	O
systemic	B
diseases	I
;	O

Presence	O
of	O
local	B
inflammation	I
and	O
/	O
or	O
infection	O
;	O

Any	O
history	B
of	O
allergic	B
reaction	I
to	O
local	B
anesthetics	I
,	O
gastrointestinal	B
bleeding	I
or	O
ulceration	O
;	O

Cardiovascular	O
,	O
kidney	O
or	O
hepatic	B
diseases	I
;	O

Patients	O
who	O
are	O
making	O
use	O
of	O
antidepressants	B
,	O
diuretics	B
or	O
anticoagulants	B
;	O

Asthma	B
and	O
allergy	B
to	O
aspirin	B
,	O
ibuprofen	B
or	O
any	B
other	I
nonsteroidal	B
antiinflammatory	I
drug	I
;	O

Regular	B
use	I
of	O
any	O
nonsteroidal	B
antiinflammatory	I
drug	I
,	O

Pregnancy	B
or	O
breast	O
feeding	O
.	O

Need	O
of	O
lower	B
third	I
molar	I
surgeries	B

Known	O
or	O
suspected	O
serious	B
spinal	B
pathology	I
and	O
spinal	B
implants	I

Lumbar	B
spinal	I
surgery	I
within	B
the	I
preceding	I
six	I
months	I

Serious	B
comorbidities	B
preventing	B
prescription	O
of	O
paracetamol	B

Alternative	B
treatment	B
for	O
low	B
back	I
pain	I
in	B
previous	I
two	I
weeks	I

Chronic	B
neurological	I
lesion	I

Chronic	B
musculoskeletal	I
lesion	I

Active	B
cancer	B

Pregnancy	B

Use	O
of	O
pain	B
medication	I
(	O
except	B
paracetamol	B
)	O
within	B
3	I
days	I

Treatment	O
site	O
has	O
active	B
skin	B
lesion	I
or	O
inflammation	B

Known	O
allergy	B
to	O
skin	B
patch	I

All	O
subjects	O
underwent	O
a	O
detailed	O
history	O
and	O
systemic	O
physical	O
examination	O
including	O
neurologic	O
and	O
musculoskeletal	O
evaluations	O
.	O

To	O
rule	O
out	O
any	O
confounding	O
etiologies	O
,	O
basic	O
diagnostic	B
laboratory	I
tests	I
including	O
complete	B
blood	I
count	I
and	O
acute	B
phase	I
reactants	I
(	O
erythrocyte	B
sedimentation	I
rate	I
and	O
C	B
-	I
reactive	I
protein	I
)	O
were	O
performed	O
.	O

The	O
patients	O
diagnosed	O
as	O
having	O
acute	B
non	B
-	I
specific	I
low	I
back	I
pain	I
according	O
to	O
history	B
and	O
physical	B
examinations	I
were	O
invited	O
to	O
participate	O
and	O
will	O
be	O
informed	O
about	O
the	O
purpose	O
and	O
course	O
of	O
the	O
study	O
.	O

A	O
primary	O
complaint	O
of	O
pain	B
in	O
the	O
area	B
between	I
the	I
12th	I
rib	I
and	I
buttock	I
crease	I
without	B
leg	B
pain	I

Female	B
or	O
male	B
,	O
20	B
-	I
80	I
years	I
of	O
age	B

Low	B
back	I
pain	I
of	O
less	B
than	I
six	I
weeks	I
'	I
duration	I
;	O
and	O
at	B
least	I
moderate	I
pain	B
intensity	I
(	O
NRS	B
<	O
U	O
+	O
2267	O
>	O
4	B
)	O

Failure	B
to	O
have	O
fully	B
recovered	I
(	O
that	O
is	O
,	O
less	B
than	I
or	I
equal	I
to	I
[	I
<	I
=	I
]	I
Grade	I
1	I
toxicity	B
)	O
from	O
the	O
reversible	O
effects	O
of	O
prior	O
chemotherapy	B
.	O

Major	B
surgery	I
within	B
14	I
days	I
before	I
enrollment	I
.	O

Radiotherapy	B
within	B
14	I
days	I
before	I
enrollment	I
(	O
if	O
the	O
involved	O
field	O
is	O
small	O
,	O
7	B
days	I
will	O
be	O
considered	O
a	O
sufficient	O
interval	O
between	O
treatment	O
and	O
administration	O
of	O
the	O
ixazomib	O
.	O
)	O

Central	B
nervous	I
system	I
involvement	I
.	O

Infection	B
requiring	O
systemic	B
antibiotic	I
therapy	I
or	O
other	B
serious	B
infection	B
within	B
14	I
days	I
before	I
study	I
enrollment	I
.	O

Evidence	O
of	O
current	B
uncontrolled	B
cardiovascular	B
conditions	I
,	O
including	O
uncontrolled	B
hypertension	B
,	O
uncontrolled	B
cardiac	B
arrhythmias	I
,	O
symptomatic	B
congestive	B
heart	I
failure	I
,	O
unstable	B
angina	I
,	O
or	O
myocardial	B
infarction	I
within	B
the	I
past	I
6	I
months	I
.	O

Systemic	B
treatment	I
,	O
within	O
14	O
days	O
before	O
the	O
first	O
dose	O
of	O
ixazomib	B
,	O
with	O
strong	B
cytochrome	I
P450	I
3A	I
(	I
CYP3A	I
)	I
inducers	I
(	O
rifampin	B
,	O
rifapentine	B
,	O
rifabutin	B
,	O
carbamazepine	B
,	O
phenytoin	B
,	O
phenobarbital	B
)	O
,	O
or	O
use	O
of	O
Ginkgo	B
biloba	I
or	O
St	B
.	I
John	I
'	I
s	I
wort	I
.	O

Ongoing	B
or	O
active	B
systemic	B
infection	I
,	O
active	B
hepatitis	O
B	O
or	O
C	B
virus	I
infection	I
,	O
or	O
known	O
human	B
immunodeficiency	I
virus	I
positive	B
.	O

Diagnosed	O
or	O
treated	O
for	O
another	O
malignancy	B
within	B
2	I
years	I
before	I
study	I
enrollment	I
or	O
previously	B
diagnosed	O
with	O
another	B
malignancy	B
and	O
have	O
any	O
evidence	O
of	O
residual	B
disease	I
.	O

Participants	O
with	O
non	B
-	I
melanoma	I
skin	I
cancer	I
or	O
carcinoma	B
in	I
situ	I
of	O
any	B
type	I
are	O
not	B
excluded	I
if	O
they	O
have	O
undergone	O
complete	B
resection	I
.	O

Has	O
greater	B
than	I
or	I
equal	I
to	I
(	I
>	I
=	I
)	I
Grade	I
2	I
peripheral	B
neuropathy	I
,	O
or	O
Grade	B
1	I
with	O
pain	B
on	O
clinical	O
examination	O
during	O
the	O
screening	O
period	O
.	O

PD	B
on	O
first	B
-	I
line	I
therapy	I
.	O

Participation	O
in	O
other	O
interventional	O
clinical	O
trials	O
,	O
including	O
those	O
with	O
other	O
investigational	O
agents	O
not	O
included	O
in	O
this	O
trial	O
,	O
within	B
30	I
days	I
of	I
the	I
start	I
of	I
this	I
trial	I
and	O
throughout	B
the	I
duration	I
of	I
this	I
trial	I
.	O

Non	O
-	O
interventional	O
trials	O
(	O
that	O
is	O
,	O
observational	O
trials	O
)	O
are	O
permitted	O
at	O
any	O
time	O
point	O
.	O

Participants	O
must	O
have	O
completed	O
3	B
cycles	I
of	O
a	O
bortezomib	B
-	O
based	O
induction	B
regimen	I
(	O
as	O
defined	O
by	O
current	O
NCCN	B
guidelines	I
)	O
and	O
have	O
no	B
evidence	I
of	I
disease	I
progression	I
as	O
defined	O
by	O
IMWG	B
criteria	I
.	O

Participants	O
with	O
light	B
chain	I
and	I
free	I
light	I
chain	I
(	I
FLC	I
)	I
only	O
may	O
be	O
enrolled	O
if	O
they	O
meet	O
all	B
the	O
criteria	B
for	I
a	I
diagnosis	I
of	I
MM	I
.	O

Participants	O
must	O
be	O
considered	O
by	O
their	O
physician	O
eligible	O
to	O
receiving	O
the	O
IRD	B
regimen	I
.	O

Eastern	B
Cooperative	I
Oncology	I
Group	I
(	I
ECOG	I
)	I
performance	I
status	I
and	O
/	O
or	O
other	O
performance	O
status	O
0	B
,	I
1	I
,	I
or	I
2	I
at	B
time	I
of	I
enrollment	I
.	O

Pregnancy	B
,	O
age	B
<	B
18	I
,	O
nursing	B
,	O
or	O
documented	O
allergy	B
to	O
naloxone	B

Patients	O
will	O
be	O
included	O
if	O
they	O
are	O
having	O
an	O
in	O
-	O
patient	O
spinal	B
fusion	I
procedure	I
,	O
are	O
18	O
years	B
or	O
older	O
,	O
post	O
and	O
post	B
-	I
operative	I
pain	B
control	I
plan	I
includes	O
opioid	B
medications	O
.	O

COPD	B
exacerbation	I
,	O
very	B
severe	I
COPD	B
with	O
hypoxemia	B
at	O
low	B
altitude	I
(	O
FEV1	B
/	I
FVC	I
<	B
0	I
.	I
7	I
,	O
FEV1	B
<	B
40	I
%	I
predicted	I
,	O
oxygen	B
saturation	I
on	O
room	B
air	I
<	B
92	I
%	I
at	I
750	I
m	I
)	O
.	O

Comorbidities	B
such	O
as	O
uncontrolled	B
cardiovascular	B
disease	I
,	O
i	O
.	O
e	O
.	O
,	O
unstable	B
systemic	B
arterial	I
hypertension	I
,	O
coronary	B
artery	I
disease	I
;	O
previous	B
stroke	B
;	O
OSA	B
;	O
pneumothorax	B
in	B
the	I
last	I
2	I
months	I
.	O

Internal	O
,	O
neurologic	O
,	O
rheumatologic	O
or	O
psychiatric	B
disease	I
including	O
current	O
heavy	O
smoking	O
(	O
>	B
20	I
cigarettes	I
per	I
day	I
)	O

Known	O
renal	B
failure	I
or	O
allergy	B
to	O
acetazolamide	B
and	O
other	O
sulfonamides	B

Male	B
and	O
female	B
patients	O
,	O
age	B
18	B
-	I
75	I
yrs	I
.	O

COPD	B
diagnosed	O
according	O
to	O
GOLD	B
,	O
FEV1	B
40	B
-	I
80	I
%	I
predicted	I
,	O
SpO2	B
=	B
92	I
%	I
at	I
750	I
m	I
.	O

Born	O
,	O
raised	O
and	O
currently	O
living	O
at	O
low	O
altitude	O
(	O
<	O
800m	O
)	O
.	O

Written	O
informed	O
consent	O
.	O

COPD	B
exacerbation	I
,	O
very	B
severe	I
COPD	B
with	O
hypoxemia	B
at	O
low	B
altitude	I
(	O
FEV1	B
/	I
FVC	I
<	B
0	I
.	I
7	I
,	O
FEV1	B
<	B
40	I
%	I
predicted	I
,	O
oxygen	B
saturation	I
on	O
room	B
air	I
<	B
92	I
%	I
at	O
750	B
m	I
)	O
.	O

Comorbidities	B
such	O
as	O
uncontrolled	B
cardiovascular	B
disease	I
,	O
i	O
.	O
e	O
.	O
,	O
unstable	B
systemic	B
arterial	I
hypertension	I
,	O
coronary	B
artery	I
disease	I
;	O
previous	B
stroke	B
;	O
OSA	B
;	O
pneumothorax	B
in	B
the	I
last	I
2	I
months	I
.	O

Internal	B
,	O
neurologic	B
,	O
rheumatologic	B
or	O
psychiatric	B
disease	B
including	O
current	B
heavy	B
smoking	O
(	O
>	B
20	I
cigarettes	B
per	I
day	I
)	O

Known	O
renal	B
failure	I
or	O
allergy	B
to	O
acetazolamide	B
and	O
other	B
sulfonamides	B

Male	B
and	O
female	B
patients	O
,	O
age	B
18	B
-	I
75	I
yrs	I
.	O

COPD	B
diagnosed	O
according	O
to	O
GOLD	B
,	O
FEV1	B
40	B
-	I
80	I
%	I
predicted	I
,	O
SpO2	B
=	B
92	I
%	I
at	O
750	B
m	I
.	O

Born	O
,	O
raised	O
and	O
currently	O
living	O
at	O
low	O
altitude	O
(	O
<	B
800m	I
)	O
.	O

Written	O
informed	O
consent	O
.	O

Allergy	B
to	O
porphyrins	B
and	O
analogues	O
;	O
Photosensitivity	B
;	O
Porphyria	B
;	O
Allergic	B
constitution	I
;	O

Scar	B
diathesis	I
;	O

Pregnancy	O
or	O
unwilling	O
to	O
adopt	O
reliable	O
contraceptive	O
measures	O
during	O
the	O
month	O
after	O
drug	O
application	O
;	O

Be	O
judged	O
not	O
suitable	O
to	O
participate	O
the	O
study	O
by	O
the	O
investigators	O

Age	B
range	O
:	O
14	B
to	I
65	I
years	I
-	I
old	I
;	O

Clinically	O
diagnosed	O
of	O
Port	B
-	I
wine	I
Stain	I
;	O

Patients	O
receiving	O
hemoporfin	B
based	O
upon	O
the	O
clinical	O
judgment	O
of	O
the	O
investigator	O
;	O

Written	O
informed	O
consent	O
signed	O
and	O
agreed	O
to	O
receive	O
periodic	O
follow	O
-	O
up	O

Cardiac	B
morbidities	I

hypertensive	B
disorders	I
of	I
pregnancy	I

peripartum	B
bleeding	I

baseline	B
systolic	B
blood	I
pressure	I
(	O
SBP	B
)	O
<	B
100	I
mmHg	I

body	B
mass	I
index	I
>	B
35	I

full	B
term	I

singleton	B
pregnant	B
women	B

scheduled	O
for	O
elective	B
cesarean	B
delivery	I

Pregnant	B

Meningeal	B
signs	I
are	O
present	O

Acute	B
angle	I
closure	I
glaucoma	I
is	O
suspected	O

Head	B
trauma	I
within	B
the	I
previous	I
two	I
weeks	I

Lumbar	B
puncture	I
within	B
the	I
previous	I
two	I
weeks	I

Thunderclap	B
onset	I
of	O
the	O
headache	B

Known	O
allergy	B
to	O
one	O
of	O
the	O
study	B
drugs	I

History	B
of	O
intracranial	B
hypertension	I

Is	O
a	O
prisoner	B

Patient	O
declined	B
informed	O
consent	O

Non	O
-	O
English	O
speaking	O
patient	O
or	O
parent	O
/	O
guardian	O
for	O
pediatric	O
patients	O

Attending	O
provider	O
excludes	O
patient	O

Severe	B
Dehydration	B

Age	B
10	B
to	I
65	I
years	I

Temperature	B
less	B
than	I
100	I
.	I
4	I
F	I

Normal	B
neurologic	B
exam	I
and	O
normal	B
mental	B
status	I

age	B
<	B
18	I
years	I

previous	B
history	B
of	O
roux	B
-	I
en	I
-	I
y	I
gastric	I
bypass	I

patients	O
undergoing	B
other	B
bariatric	B
procedures	I

pre	B
-	I
operative	I
opioid	B
analgesics	I

bariatric	B
surgery	I
patients	O

laparoscopic	B
roux	B
-	I
en	I
-	I
y	I
gastric	I
bypass	I

use	O
of	O
EEA	B
stapler	I
anastomosis	I

Atrial	B
fibrillation	I
of	O
new	B
onset	I
or	O
when	O
rate	B
control	I
has	I
been	I
difficult	I

Known	O
bigemini	B
/	O
trigeminy	B

Prior	B
CABG	B
surgery	I

Allergic	B
to	O
contrast	B

Advanced	B
renal	I
impairment	I

Significant	O
valve	B
disease	I
(	O
severe	B
aortic	B
stenosis	I
or	O
regurgitation	B
;	O
severe	B
mitral	B
regurgitation	I
)	O

Life	O
expectancy	O
<	B
12	I
months	I

Inclusion	O
in	O
another	O
trial	O
without	O
prior	O
agreement	O
with	O
CI	O

Aged	B
over	B
18	I

Primary	B
symptom	I
of	O
chest	B
pain	I

No	B
contraindication	B
to	O
CTA	B

Willing	O
and	O
able	O
to	O
provide	O
written	O
informed	O
consent	O

History	O
of	O
hypersensitivity	B
or	O
allergy	B
to	O
any	O
of	O
the	O
study	B
drugs	I
,	O
drugs	O
of	O
similar	O
chemical	O
classes	O
,	O
ACE	B
inhibitors	I
(	I
ACEIs	I
)	I
,	O
angiotensin	B
II	I
receptor	I
blockers	I
(	I
ARBs	I
)	I
,	O
or	O
neprilysin	B
inhibitors	I
,	O
as	O
well	O
as	O
known	O
or	O
suspected	O
contraindications	B
to	O
the	O
study	B
drugs	I
.	O

Previous	B
history	B
of	O
intolerance	B
to	O
recommended	O
target	O
doses	O
of	O
ACEIs	B
or	O
ARBs	B
.	O

Known	O
history	B
of	O
angioedema	B
.	O

Requirement	O
for	O
treatment	B
with	O
both	O
ACEIs	B
and	O
ARBs	B
.	O

Current	O
acute	B
decompensated	B
heart	B
failure	I
(	O
exacerbation	B
of	O
chronic	B
heart	I
failure	I
manifested	O
by	O
signs	B
and	O
symptoms	B
that	O
may	O
require	O
intravenous	B
therapy	I
)	O
.	O

Symptomatic	B
hypotension	B
.	O

Estimated	B
glomerular	I
filtration	I
rate	I
(	I
eGFR	I
)	I
<	B
30	I
%	I
.	O

Serum	B
potassium	I
>	B
5	I
.	I
4	I
mmol	I
/	I
L	I
.	O

Acute	B
coronary	I
syndrome	I
,	O
stroke	B
,	O
transient	B
ischaemic	I
attack	I
,	O
cardiac	B
,	O
carotid	B
,	O
or	O
other	O
major	B
cardiovascular	I
surgery	I
,	O
percutaneous	B
coronary	I
intervention	I
,	O
or	O
carotid	B
angioplasty	I
within	B
the	I
3	I
months	I
.	O

Coronary	O
or	O
carotid	B
artery	I
disease	I
likely	O
to	O
require	O
surgical	O
or	O
percutaneous	B
intervention	I
within	B
the	I
6	I
months	I
.	O

Implantation	B
of	O
a	O
cardiac	B
resynchronization	I
therapy	I
(	I
CRT	I
)	I
device	I
within	B
3	I
months	I
or	O
intent	O
to	O
implant	B
a	O
CRT	B
.	O

History	B
of	O
heart	B
transplant	I
or	O
on	O
a	O
transplant	O
list	O
or	O
with	O
left	B
ventricular	I
(	I
LV	I
)	I
assistance	I
device	I
.	O

History	B
of	O
severe	B
pulmonary	I
disease	I
.	O

Diagnosis	O
of	O
peripartum	B
-	O
or	O
chemotherapy	B
-	O
induced	O
cardiomyopathy	B
within	B
the	I
12	I
months	I
.	O

Documented	O
untreated	B
ventricular	B
arrhythmia	I
with	O
syncopal	B
episodes	I
within	B
the	I
3	I
months	I
.	O

Symptomatic	O
bradycardia	B
or	O
second	O
-	O
or	O
third	B
-	I
degree	I
atrioventricular	B
block	I
without	B
a	O
pacemaker	B
.	O

Presence	O
of	O
haemodynamically	B
significant	I
mitral	O
and	O
/	O
or	O
aortic	B
valve	I
disease	I
,	O
except	B
mitral	B
regurgitation	I
secondary	O
to	O
LV	B
dilatation	I
.	O

Presence	O
of	O
other	O
haemodynamically	B
significant	I
obstructive	B
lesions	I
of	O
the	O
LV	B
outflow	I
tract	I
,	O
including	O
aortic	O
and	O
subaortic	B
stenosis	I
.	O

Any	O
surgical	O
or	O
medical	B
condition	I
which	O
might	O
significantly	O
alter	B
the	I
absorption	I
,	I
distribution	I
,	I
metabolism	I
,	I
or	I
excretion	I
of	O
study	B
drugs	I
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
any	O
of	O
the	O
following	O
:	O
History	O
of	O
active	B
inflammatory	B
bowel	I
disease	I
during	B
the	I
12	I
months	I
.	O

Active	B
duodenal	O
or	O
gastric	B
ulcers	I
during	B
the	I
3	I
months	I
.	O

Evidence	O
of	O
hepatic	B
disease	I
as	O
determined	O
by	O
any	O
one	O
of	O
the	O
following	O
:	O
aspartate	B
aminotransferase	I
or	O
alanine	B
aminotransferase	I
values	O
exceeding	B
2x	I
upper	I
limit	I
of	I
normal	I
,	O
history	B
of	O
hepatic	B
encephalopathy	I
,	O
history	B
of	O
oesophageal	B
varices	I
,	O
or	O
history	B
of	O
porto	B
-	I
caval	I
shunt	I
.	O

Current	B
treatment	B
with	O
cholestyramine	O
or	O
colestipol	B
resins	I
.	O

Presence	O
of	O
any	B
other	I
disease	B
with	O
a	O
life	O
expectancy	O
of	O
<	B
5	I
years	I
.	O

Symptomatic	B
patients	O
with	O
heart	B
failure	I
(	O
men	B
and	O
women	B
)	O
aged	B
>	B
18	I
years	I
,	O

Functional	B
class	I
II	I
,	I
III	I
or	I
IV	I
by	O
the	O
New	B
York	I
Heart	I
Association	I
(	I
NYHA	I
)	I

Left	B
ventricular	I
ejection	I
fraction	I
<	B
35	I
%	I

Ischemic	O
and	O
nonischemic	B
etiology	I

Type	B
B	I
natriuretic	I
peptide	I
(	I
BNP	I
)	I
>	B
150	I
pg	I
/	I
ml	I
(	O
or	O
pro	B
-	I
BNP	I
[	I
N	I
-	I
terminal	I
-	I
proBNP	I
]	I
=	B
600	I
pg	I
/	I
ml	I
)	O
or	O
if	O
the	O
patient	O
was	O
hospitalized	B
for	O
cardiac	B
decompensation	I
within	B
the	I
preceding	I
12	I
months	I
,	O
BNP	B
>	B
100	I
pg	I
/	I
ml	I
(	O
or	O
N	B
-	I
terminal	I
-	I
proBNP	I
=	B
400	I
pg	I
/	I
ml	I
)	O

recurrent	B
contracture	B
in	O
the	O
finger	B
to	I
be	I
treated	I

neurologic	B
condition	I
causing	O
the	O
loss	B
of	I
function	I
of	O
the	O
finger	B
to	I
be	I
treated	I

contraindication	B
for	O
collagenase	B
clostridium	I
histolyticym	I
(	O
Xiapex	B
/	O
Xiaflex	B
®	O
)	O

pregnant	B
or	O
breast	O
feeding	O

TPED	B
>	B
135	I
°	I
(	O
Tubiana	B
stage	B
4	I
)	O
in	O
finger	B
to	I
be	I
treated	I

rheumatoid	B
arthritis	I

previous	B
fracture	B
in	O
finger	B
to	I
be	I
treated	I
,	O
which	O
affects	B
range	I
of	I
motion	I
of	O
MP	O
or	O
PIP	B
joint	I

age	B
>	B
80	I
years	I

patients	O
with	O
=	B
20	I
°	I
passive	B
extension	I
deficit	I
(	I
PED	I
)	I
in	O
metacarpophalangeal	O
(	O
MP	O
)	O
or	O
proximal	B
interphalangeal	I
(	I
PIP	I
)	I
joint	I
,	O
or	O
TPED	B
of	O
=	B
30	I
°	I
in	O
MP	B
and	O
PIP	B
joints	I
of	O
finger	B
/	I
fingers	I
II	I
-	I
V	I

age	B
>	B
18	I
years	I

palpable	B
cord	I

provision	O
of	O
informed	O
consent	O

ability	O
to	O
fill	O
the	O
Finnish	O
versions	O
of	O
questionnaires	O
.	O

eGFR	B
<	B
60	I
T2DM	B
patients	O
on	O
insulin	B
,	O
GLP	B
-	I
1	I
RA	B
or	O
SGLT2	B
treatment	O
Major	B
organ	I
disease	I
type	B
1	I
diabetes	I

eGFR	B
>	B
60	I
ml	I
/	I
min	I
healthy	B
volunteers	O
type	B
2	I
diabetes	I
patients	O
who	O
otherwise	O
healthy	O

Patients	O
with	O
cardiac	O
,	O
pulmonary	O
,	O
hepatic	O
,	O
or	O
renal	B
dysfunction	I
,	O
epilepsy	B
,	O
or	O
uncontrolled	B
hypertension	B
,	O
or	O
those	O
taking	O
medications	B
that	I
influence	I
the	I
central	I
nervous	I
system	I
,	O
are	O
excluded	O
from	O
the	O
study	O
.	O

Patients	O
who	O
show	O
obvious	O
alteration	B
of	I
mental	I
status	I
,	O
or	O
refuse	O
to	O
participate	O
,	O
are	O
also	O
excluded	O
from	O
the	O
study	O
.	O

Patients	O
scheduled	O
for	O
laser	B
laryngeal	I
surgery	I
under	O
general	B
anesthesia	I
with	O
either	O
Propofol	B
or	O
desflurane	B
based	O
technique	O
.	O

not	B
diabetic	B
patient	O
;	O

patients	O
in	O
dual	B
antiplatelet	I
therapy	I
;	O

patient	O
with	O
severe	B
renal	B
failure	I
;	O

patient	O
poor	B
responders	I

diabetic	B
patient	O
;	O

therapy	O
with	O
aspirin	B
and	O
insulin	B
;	O

patient	O
well	B
responders	I

Patients	O
with	O
a	O
history	B
of	O
any	B
other	I
malignancy	B
.	O

Concomitant	B
treatment	B
with	O
any	B
other	I
anticancer	B
therapy	I
.	O

Patient	O
have	O
contraindication	B
to	O
chemotherapy	B
(	O
eg	O
.	O
uncontrolled	B
coronarism	B
and	O
heart	B
failure	I
;	O
History	B
of	O
myocardial	B
infarction	I
within	B
the	I
past	I
6	I
months	I
,	O
Chronic	B
obstructive	I
pulmonary	I
,	O
uncontrolled	B
epileptic	B
attack	I
and	O
other	B
disease	B
that	O
investigator	O
consider	O
it	O
unsuitable	O
for	O
the	O
chemotherapy	B
)	O

Before	O
participate	O
in	O
the	O
study	O
,	O
patients	O
must	O
understand	O
the	O
treatment	O
plan	O
and	O
willing	O
to	O
participate	O
in	O
the	O
study	O
.	O
Patients	O
must	O
have	O
signed	O
an	O
approved	O
informed	O
consent	O
.	O

Histopathologic	B
confirmed	O
squamous	B
cell	I
carcinoma	I
of	O
head	B
and	I
neck	I
,	O
including	O
oral	B
cavity	I
,	O
oropharynx	B
,	O
larynx	B
,	O
or	O
hypopharynx	B
.	O

Ages	B
=	B
65	I
years	I
,	O
Not	O
limited	O
to	O
gender	O
.	O

ECOG	B
performance	I
status	I
=	B
2	I
.	O

Patients	O
with	O
surgical	B
contraindication	B
or	O
reject	O
to	O
surgery	B
.	O

Postoperative	B
TNM	B
(	I
primary	I
tumor	I
,	I
regional	I
nodes	I
,	I
metastasis	I
)	I
staging	I
III	B
~	I
IV	I
,	I
positive	B
surgical	B
margin	I
.	O

without	B
evidence	O
of	O
distant	B
metastases	I
.	O

No	B
contraindication	B
to	O
chemoradiotherapy	B
.	O

Life	O
expectancy	O
>	B
3	I
months	I
.	O

Available	O
Organ	O
function	O
:	O
white	B
blood	I
cell	I
=	B
3	I
.	I
5	I
×	I
109	I
/	I
L	I
,	O
Neutrophils	B
=	B
1	I
.	I
5	I
×	I
109	I
/	I
L	I
,	O
Hemoglobin	B
=	B
80g	I
/	I
L	I
,	O
Blood	B
platelet	I
>	B
100	I
×	I
109	I
/	I
L	I
;	O
Alanine	B
aminotransferase	I
(	I
ALT	I
)	I
and	O
Aspartate	B
aminotransferase	I
(	I
AST	I
)	I
=	B
2	I
.	I
5	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
;	O
Total	B
bilirubin	I
(	I
TBIL	I
)	I
<	B
1	I
.	I
5	I
ULN	I
;	O
serum	B
creatinine	I
=	B
1	I
.	I
5	I
ULN	I
;	O
creatinine	B
clearance	I
of	O
=	B
50ml	I
/	I
min	I

Patients	O
with	O
pulmonary	B
arterial	I
hypertension	I
(	I
PAH	I
)	I

Patients	O
with	O
chronic	B
thromboembolic	I
pulmonary	I
hypertension	I
(	I
CTEPH	I
)	I

All	O
prevalent	O
patients	O
(	O
diagnosed	O
>	B
12	I
month	I
ago	I
)	O
with	O
PAH	B
or	O
distal	B
CTEPH	B
who	O
had	O
a	O
consultation	O
at	O
the	O
PH	O
centre	O
in	O
Zurich	O
between	B
November	I
2015	I
and	I
November	I
2016	I
)	O

Women	B
under	O
the	O
age	B
of	O
18	O
,	O

Clinically	O
positive	B
axillary	B
nodes	I

Neoadjuvant	B
therapy	I
for	O
current	O
breast	B
cancer	I
diagnosis	O

Women	B
with	O
previous	B
SLNBx	B
or	O
axillary	B
node	I
dissection	I

Pregnant	O
women	O

Women	B
with	O
previous	B
radiation	B
above	B
the	I
diaphragm	I
,	O
and	O
below	B
the	I
neck	I

Women	B
above	B
18	I
years	I
of	O
age	B
with	O
biopsy	B
proven	O
,	O
clinically	O
stage	B
1	I
or	O
2	O
breast	B
cancer	I
who	O
will	O
be	O
undergoing	O
partial	B
mastectomy	I
with	O
SLNBx	B
at	O
Memorial	O
Health	O

Pregnant	B
or	O
nursing	O
(	O
lactating	O
)	O
women	B

HIV	B
positivity	B

Need	O
for	O
dual	B
organ	I
transplant	I

Any	O
contra	B
-	I
indication	I
to	O
liver	B
transplantation	I
per	O
center	O
protocol	O

Recipient	O
is	O
Age	B
=	B
18	I
years	I

Met	O
MGH	B
transplant	I
center	I
criteria	I
,	O
listed	O
for	O
liver	B
transplant	I

HCV	B
naive	B

Able	O
to	O
sign	O
informed	O
consent	O

Sensitization	B
(	O
i	O
.	O
e	O
.	O
PRA	B
>	B
20	I
%	I
)	O

Any	O
liver	B
disease	I
in	O
recipient	O

Albumin	B
<	B
3g	I
/	I
dl	I
or	O
platelet	B
count	I
<	B
75	I
x	I
103	I
/	I
mL	I

Need	O
for	O
dual	B
organ	I
transplant	I

Recipient	O
is	O
Age	B
=	B
18	I
years	I

Serum	B
ALT	I
within	B
normal	I
limits	I
with	O
no	B
history	B
of	O
liver	B
disease	I

Lack	B
of	I
sensitization	B
(	O
i	O
.	O
e	O
.	O
PRA	B
<	B
20	I
%	I
)	O
that	O
would	O
be	O
expected	O
to	O
result	O
in	O
a	O
high	O
likelihood	O
of	O
needing	O
aggressive	O
immunosuppression	O
to	O
treat	O
rejection	O

Contraindications	B
to	O
empagliflozin	B
,	O
Sitagliptin	B

DPP4	B
inhibitors	I
or	O
Sodium	B
-	I
glucose	I
cotransporter	I
-	I
2	I
(	I
SGLT2	I
)	I
inhibitors	I
within	B
the	I
previous	I
4	I
weeks	I

Insulin	B
requiring	O
diabetes	B

Poor	B
glucose	I
control	I
(	O
HbA1C	B
>	B
10	I
%	I
)	O

Acute	B
coronary	I
syndrome	I

Stent	B
placement	B
within	B
the	I
previous	I
6	I
months	I

Previous	B
coronary	B
artery	I
bypass	I
graft	I
surgery	I
within	B
the	I
previous	I
6	I
months	I

Planned	O
revascularization	B
within	B
6	I
months	I

Heart	B
failure	I
requiring	O
loop	B
diuretics	I

Severe	B
left	B
ventricular	I
hypertrophy	I
(	O
left	B
ventricular	I
septal	I
wall	I
thickness	I
>	B
13mm	I
)	O

Significant	B
renal	B
disease	I
manifested	O
by	O
creatinine	B
clearance	I
of	O
<	B
30	I
ml	I
/	I
min	I
)	O

Hepatic	B
disease	I
or	O
biliary	B
tract	I
obstruction	I
,	O
or	O
significant	B
hepatic	B
enzyme	I
elevation	I
(	O
alanine	B
transaminase	I
or	O
Aspartate	B
Aminotransferase	I
>	B
3	I
times	I
upper	I
limit	I
of	I
normal	I
)	O

Radiopaque	B
material	I
implanted	O
in	O
the	O
chest	B
wall	I
(	O
metal	O
,	O
silicone	O
,	O
etc	O
.	O
)	O

Contraindication	B
to	O
adenosine	B
stress	I
test	I

Any	O
clinically	O
significant	O
abnormality	O
identified	O
at	O
the	O
screening	O
visit	O
,	O
physical	O
examination	O
,	O
laboratory	O
tests	O
,	O
or	O
electrocardiogram	O
which	O
,	O
in	O
the	O
judgment	O
of	O
the	O
Investigator	O
,	O
would	O
preclude	O
safe	O
completion	O
of	O
the	O
study	O
.	O

Patient	O
'	O
s	O
pregnant	B
or	O
breast	B
-	I
feeding	I
or	O
child	B
-	I
bearing	I
potential	I

Expected	O
life	O
expectancy	O
<	B
1	I
year	I

Unwillingness	O
or	O
inability	O
to	O
comply	O
with	O
the	O
procedures	O
described	O
in	O
this	O
protocol	O

Men	B
or	O
women	B
at	B
least	I
19	I
years	I
of	O
age	B

Type	B
2	I
diabetes	I
mellitus	I

Stable	B
coronary	B
artery	I
disease	I

Global	B
myocardial	I
perfusion	I
reserve	I
(	I
MPR	I
)	I
index	I
<	B
2	I
.	I
5	I

The	O
patient	O
or	O
guardian	O
agrees	O
to	O
the	O
study	O
protocol	O
and	O
the	O
schedule	O
of	O
clinical	O
and	O
dynamic	O
SPECT	O
follow	O
-	O
up	O
,	O
and	O
provides	O
informed	O
,	O
written	O
consent	O
,	O
as	O
approved	O
by	O
the	O
appropriate	O
Institutional	O
Review	O
Board	O
/	O
Ethical	O
Committee	O
of	O
the	O
respective	O
clinical	O
site	O
.	O

Active	B
consumption	B
of	I
alcohol	I
and	O
/	O
or	O
drugs	O

Co	O
-	O
infection	O
with	O
human	B
immunodeficiency	I
virus	I
,	O
hepatitis	B
C	I
virus	I
,	O
or	O
hepatitis	B
D	I
virus	I

History	O
of	O
autoimmune	B
hepatitis	I

Psychiatric	B
disease	I

Evidence	O
of	O
neoplastic	B
diseases	I
of	O
the	O
liver	B

HBsAg	O
and	O
HBeAg	B
positive	I
for	B
more	I
than	I
6	I
months	I
,	O
HBV	B
DNA	I
detectable	I
with	O
ALT	B
level	I
abnormal	B
lasted	B
for	I
three	I
months	I
and	O
at	B
least	I
time190	I
IU	B
/	I
L	I
or	O
liver	B
puncture	I
biopsy	I
demonstrated	O
apparent	O
inflammation	B
,	O
never	B
treated	B
before	O
enrolled	B
.	O

Active	B
consumption	B
of	I
alcohol	I
and	O
/	O
or	O
drugs	O

Co	O
-	O
infection	O
with	O
human	B
immunodeficiency	I
virus	I
,	O
hepatitis	B
C	I
virus	I
,	O
or	O
hepatitis	B
D	I
virus	I

History	B
of	O
autoimmune	B
hepatitis	I

Psychiatric	B
disease	I

Evidence	O
of	O
neoplastic	B
diseases	I
of	O
the	O
liver	B

HBsAg	O
and	O
HBeAg	B
positive	I
for	B
more	I
than	I
6	I
months	I
,	O
HBV	B
DNA	I
detectable	I
with	O
ALT	B
level	I
abnormal	B
lasted	B
for	I
three	I
months	I
and	O
at	B
least	I
time190	I
IU	B
/	I
L	I
or	O
liver	B
puncture	I
biopsy	I
demonstrated	O
apparent	O
inflammation	B
,	O
never	B
treated	B
before	B
enrolled	I
.	O

Females	B
who	O
have	O
high	B
response	I
(	O
estradiol	B
at	B
time	I
of	I
ovulation	I
trigger	I
is	O
>	B
5000	I
pg	I
/	I
ml	I
or	O
more	B
than	I
15	I
oocytes	B
are	I
retrieved	I
)	O

Females	B
undergoing	B
Intra	B
-	I
Cytoplasmic	I
Sperm	I
Injection	I
(	I
ICSI	I
)	I
cycles	I

Age	B
between	B
20	I
and	I
40	I
years	I

Women	B
who	O
are	O
pregnant	B
or	O
breastfeeding	O
(	O
pregnancy	O
defined	O
as	O
the	O
state	O
of	O
a	O
female	O
after	O
conception	O
until	O
the	O
termination	O
of	O
gestation	O
,	O
confirmed	O
by	O
a	O
positive	B
human	B
chorionic	I
gonadotropin	I
laboratory	O
test	O
(	O
>	B
5mIU	I
/	I
mL	I
)	O

Women	B
of	O
child	B
bearing	I
potential	I
must	O
be	O
practicing	O
effective	B
contraception	B
implemented	O
during	B
the	I
trial	I
and	O
for	O
at	O
least	O
28	O
days	O
following	O
the	O
last	B
dose	I
of	O
study	B
medication	I

Tromboembolic	B
event	I
(	O
CVA	B
or	O
transient	B
ischemic	I
attack	I
,	O
AMI	B
)	O
less	O
than	O
3	O
months	O
prior	O
to	O
the	O
intravitreal	B
injection	I
of	O
bevacizumab	B

History	B
of	O
hypersensitivity	B
for	O
bevacizumab	B
.	O

Age	B
=	B
18	I
years	I
of	O
either	B
gender	I

Written	O
informed	O
consent	O
must	O
be	O
obtained	O
before	O
any	O
intravitreal	O
injection	O
of	O
bevacizumab	O
is	O
performed	O

Visual	B
impairment	I
predominantly	O
due	O
to	O
abnormal	B
new	I
vessel	I
ingrowth	I
and	O
/	O
or	O
macular	B
edema	I
.	O

The	O
presence	O
of	O
fluid	B
(	O
intraretinal	B
,	O
subretinal	B
or	O
sub	B
-	I
RPE	I
)	O
detected	O
clinically	O
or	O
on	O
the	O
ocular	B
coherence	I
tomography	I
.	O

Patient	O
does	O
not	O
meet	O
inclusion	O
criteria	O
,	O
discovered	O
after	O
randomization	O

Inability	O
to	O
give	O
informed	O
consent	O

Known	O
clotting	B
disorder	I
or	O
use	O
of	O
anticoagulants	B

Known	O
risk	O
factors	O
for	O
,	O
or	O
presence	O
of	O
,	O
a	O
cardiovascular	B
disease	I

Language	O
barrier	O

a	O
crown	B
-	I
rump	I
length	I
=	B
6mm	I
and	O
no	B
cardiac	O
activity	O
OR	O

a	O
crown	B
-	I
rump	I
length	I
<	B
6mm	I
and	O
no	B
fetal	O
growth	O
at	B
least	I
one	I
week	I
later	I
OR	O

At	B
least	I
one	I
week	I
after	I
diagnosis	I
OR	O
a	O
discrepancy	B
of	O
at	B
least	I
one	I
week	I
between	I
crown	I
-	I
rump	I
length	I
and	I
calendar	I
gestational	I
age	I

Intra	B
-	I
uterine	I
pregnancy	I

Women	B
aged	B
above	B
16	I
years	I

Hemodynamic	B
stable	I
patient	O

No	B
signs	B
of	I
infection	I

No	B
signs	B
of	I
incomplete	I
abortion	I

No	B
contraindications	O
for	O
mifepristone	B
or	O
misoprostol	B

age	B
<	B
18	I
years	I
;	O

Pregnancy	B

inability	O
to	O
give	O
informed	O
written	O
consent	O
;	O

previous	B
thoracic	B
surgery	I
or	O
thrombolytic	B
therapy	I
for	O
pleural	B
infection	I
;	O

medical	B
thoracoscopy	I
cannot	B
be	O
performed	O
within	B
48	I
hours	I
;	O

inability	B
to	I
tolerate	I
procedure	B
due	O
to	O
hemodynamic	B
instability	I
or	O
severe	B
hypoxemia	B
;	O

inability	O
to	O
correct	B
coagulopathy	B
;	O

presence	O
of	O
a	O
homogeneously	B
echogenic	I
effusion	I
on	O
pleural	B
US27	I
-	O

CPPE	B
along	O
with	O
evidence	O
of	O
septated	B
pleural	I
effusion	I
on	O
pleural	B
ultrasonography	I
and	O
/	O
or	O
chest	B
CT	I
scan	I

empyema	B
.	O

Patient	O
has	O
previously	O
received	O
or	O
is	O
receiving	O
an	O
organ	B
transplant	I
other	B
than	I
a	O
liver	B
.	O

Patient	O
currently	O
requires	O
dialysis	B

Recipient	B
or	O
donor	B
is	O
known	O
to	O
be	O
seropositive	B
for	O
human	B
immunodeficiency	I
virus	I
(	O
HIV	B
)	O

Patient	O
has	O
received	O
a	O
liver	B
transplant	I
from	O
a	O
non	B
-	O
heart	B
beating	I
donor	B

Patient	O
who	O
is	O
HCV	B
negative	B
has	O
received	O
an	O
HCV	B
positive	B
(	O
HCV	B
RNA	I
by	O
PCR	B
or	O
HCV	B
antibody	I
)	O
donor	B
liver	B

Patient	O
who	O
is	O
HbsAg	B
negative	B
has	O
received	O
an	O
HbsAg	B
positive	B
(	O
HBV	B
DNA	I
by	O
PCR	B
or	O
HBV	B
antibody	I
)	O
donor	B
liver	B

Patient	O
has	O
received	O
a	O
liver	B
transplant	I
from	O
a	O
decrease	O
donor	B
>	B
70	I
years	I
of	O
age	B

Patient	O
has	O
a	O
current	O
malignancy	B
or	O
a	O
history	B
of	I
malignancy	I
(	O
within	B
the	I
past	I
5	I
years	I
)	O
,	O
except	B
hepatocellular	B
carcinoma	I
within	O
UCSF	B
Criteria	I
and	O
basal	O
or	O
non	B
-	I
metastatic	I
squamous	B
cell	I
carcinoma	I
of	I
skin	I
that	O
has	O
been	O
treated	O
successfully	O
.	O

Patient	O
is	O
hemodynamically	B
unstable	I
on	O
POD	B
15	I

Patient	O
has	O
been	O
fully	O
informed	O
and	O
has	O
signed	O
an	O
IRB	O
approved	O
informed	O
consent	O
form	O
within	O
7	O
days	O
(	O
Day	O
7	O
-	O
13	O
)	O
prior	O
to	O
POD	O
15	O
and	O
is	O
willing	O
and	O
able	O
to	O
follow	O
study	O
procedure	O

Patient	O
is	O
a	O
primary	B
liver	I
transplant	I
recipient	B

Patient	O
is	O
20	B
to	I
70	I
years	I
of	O
age	B

Patient	O
should	O
be	O
clearly	O
conscious	O
,	O
fully	O
understand	O
and	O
able	O
to	O
answer	O
questionnaire	O

Known	O
proved	B
BKV	B
nephropathy	I

Hypersensitivity	B
to	O
everolimus	B
,	O
sirolimus	B
or	O
excipient	B

Concomitant	B
treatment	O
by	O
leflunomide	B
,	O
cidofovir	B
,	O
sirolimus	B
,	O
Millepertuis	B
(	O
Hypericum	B
Perforatum	I
)	O

Pregnant	B
or	O
lactating	B
women	B

Women	B
of	O
child	B
bearing	I
potential	I
unless	B
they	O
are	O
using	O
a	O
birth	B
control	I
method	I

Adult	B
patients	O

Kidney	B
transplant	I
recipients	O

Patients	O
treated	O
by	O
a	O
calcineurin	B
inhibitor	I
and	O
mycophenolic	B
acid	I

Viremia	B
>	B
=	I
3	I
log	I
UI	I
/	I
ml	I

Patients	O
who	O
have	O
given	O
written	O
informed	O
consent	O

Negative	B
pregnancy	B
test	I
(	O
blood	B
ß	I
-	I
HCG	I
dosage	I
)	O

Subjects	O
with	O
hypersensitivity	B
reaction	O
to	O
Statin	B
and	O
Ezetimibe	B

Subjects	O
with	O
severe	B
kidney	B
disease	I

Subjects	O
with	O
HIV	B
positive	I
result	O
at	B
the	I
screening	I

Pregnant	B
or	O
breast	B
-	I
feeding	I
subjects	O

Subjects	O
with	O
taking	O
any	O
medication	B
affecting	B
level	O
of	O
LDL	B
(	O
Fenofibrate	B
,	O
Omega	B
3	I
fatty	I
aicd	I
etc	O
.	O
)	O

Insulin	B
-	O
treated	O
Subjects	O

Other	O
exclusions	O
applied	O

Subjects	O
=	B
19	I
or	I
=	I
75	I
years	I
of	O
age	B

Subjects	O
undergoing	O
treatment	B
for	O
type	B
2	I
diabetes	I

Subjects	O
undergoing	O
treatment	B
of	O
statin	B
for	O
hypercholesterolemia	B

Fasting	B
LDL	I
-	I
C	I
=	B
250mg	I
/	I
dL	I
at	B
the	I
screening	I
visit	I

Fasting	B
LDL	I
-	I
C	I
=	B
70mg	I
/	I
dL	I
or	O
=	B
160mg	I
/	I
dL	I
at	B
the	I
randomization	I
visit	I

Fasting	B
TG	I
<	B
500mg	I
/	I
dL	I

Currently	O
dependent	B
on	O
any	O
substance	B
other	B
than	I
cannabis	B
,	O
alcohol	B
or	O
nicotine	B
;	O

History	O
of	O
any	O
major	B
internal	I
disease	I
(	O
including	O
diabetes	B
,	O
cardiovascular	B
disease	I
,	O
lung	B
disease	I
,	O
liver	O
or	O
kidney	B
disease	I
)	O
;	O

An	O
active	B
or	O
any	O
history	B
of	O
neurological	B
disorder	I
,	O
including	O
but	O
not	O
limited	O
to	O
seizure	B
disorder	I
,	O
epilepsy	B
,	O
stroke	B
,	O
neurological	B
disease	I
,	O
cognitive	B
impairment	I
,	O
head	B
trauma	I
with	O
prolonged	B
loss	I
of	I
consciousness	I
(	O
>	B
10	I
minutes	I
)	O
,	O
or	O
migraine	B
headaches	I
;	O

An	O
active	B
or	O
a	O
history	B
of	O
a	O
psychiatric	B
disorder	I
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
depression	B
,	O
schizophrenia	B
,	O
bipolar	B
disorder	I
,	O
anxiety	B
,	O
or	O
other	B
psychiatric	B
disorders	I
;	O

Asthma	B
;	O

Known	O
hypersensitivity	B
or	O
allergy	B
to	O
n	B
-	I
acetylcysteine	I
,	O
or	O
receiving	O
chronic	B
therapy	I
with	O
medication	O
that	O
could	O
interact	O
adversely	O
with	O
n	B
-	I
acetylcysteine	I
within	B
30	I
days	I
prior	I
to	I
randomization	I
(	O
i	O
.	O
e	O
.	O
,	O
nitroglycerin	B
,	O
ACE	B
inhibitors	I
or	O
antihypertensive	B
drugs	I
,	O
anti	B
-	I
coagulants	I
)	O
;	O

Exclusion	B
criteria	I
for	I
MRI	I
:	O
having	O
metal	B
in	I
the	I
body	I
and	O
/	O
or	O
having	O
claustrophobia	B

Current	O
DSM	B
-	I
IV	I
diagnosis	O
of	O
cannabis	B
dependence	I
,	O
>	B
1	I
week	I
detoxified	B
and	O
abstinent	B
;	O

Able	O
to	O
provide	O
written	O
informed	O
consent	O
and	O
to	O
comply	O
with	O
study	O
procedures	O
.	O

Dutch	O
speaking	O
(	O
Dutch	O
as	O
primary	O
language	O
)	O
.	O

Subjects	O
with	O
topical	O
and	O
/	O
or	O
systemic	B
medication	I
or	O
mechanical	B
devices	I
that	O
interfere	O
determinedly	O
on	O
the	O
results	O
of	O
the	O
study	O
(	O
such	O
as	O
topical	B
immunomodulators	I
,	O
punctal	B
plugs	I
,	O
corticosteroids	B
,	O
preservative	B
artificial	I
tears	I
,	O
contact	B
lenses	I
)	O
.	O

Subjects	O
(	O
females	B
)	O
with	O
active	O
sexual	O
life	O
that	O
do	O
not	B
use	O
a	O
contraceptive	B
method	I
.	O

Female	B
subjects	O
who	O
are	O
pregnant	B
or	O
lactating	B

Female	B
subjects	O
with	O
a	O
positive	B
urine	B
pregnancy	I
test	I

Positive	B
drug	I
addictions	I
*	O
(	O
verbal	B
interrogatory	I
)	O

Subjects	O
who	O
have	O
participated	O
on	O
any	O
other	O
research	O
clinical	O
trials	O
on	O
the	O
last	O
40	O
days	O

Subjects	O
legal	O
or	O
mentally	B
disabled	I
to	O
give	O
an	O
informed	O
consent	O
for	O
participating	O
on	O
this	O
study	O

Subjects	O
who	O
can	O
'	O
t	O
comply	O
with	O
the	O
appointments	O
or	O
with	O
every	O
protocol	O
requirement	O
.	O

Serious	B
tear	I
film	I
dysfunction	I
syndrome	I
TBUT	B
<	B
5	I
s	I
Schirmer	B
:	O
<	B
4	I
mm	I
OSDI	B
>	B
30	I
pints	I
Corneal	B
staining	I
>	B
grade	I
III	I
on	O
the	O
Oxford	B
scale	I

Non	B
perforated	I
corneal	B
ulcer	I

Perforated	B
corneal	B
ulcer	I

Autoimmune	B
corneal	B
ulcer	I

Ocular	B
surface	I
scarring	I
diseases	I

Ocular	O
surface	O
or	O
annexes	O
metaplastic	O
lesions	O

Fibro	B
vascular	I
proliferation	I
lesions	I
on	O
the	O
conjunctival	B
and	O
/	O
or	O
corneal	B
surface	I
(	O
i	O
.	O
e	O
.	O
:	O
pterygium	B
)	O

Concomitant	B
chronic	B
inflammatory	I
diseases	I
on	O
any	O
ocular	B
structure	I

Acute	B
or	O
infectious	B
inflammatory	B
disease	I

Corneal	B
disease	I
potentially	O
requiring	O
a	O
treatment	B
during	B
the	I
following	I
3	I
months	I

Use	O
of	O
topical	O
or	O
systemic	O
drug	O
products	O
classified	O
as	O
forbidden	O

Ocular	B
surgical	I
procedures	I
3	B
months	I
before	I
the	I
protocol	I
inclusion	I

Treatments	B
or	O
procedures	B
indicated	O
on	O
the	O
tear	B
film	I
dysfunction	I
treatment	I
,	O
as	O
punctal	B
silicone	I
plugs	I
.	O

Posterior	B
segment	I
diseases	I
requiring	O
a	O
treatment	B
or	O
threatening	B
the	I
visual	I
prognosis	I

Retinal	B
diseases	I
potentially	O
requiring	O
treatment	B
during	B
the	I
following	I
3	I
months	I

History	B
of	O
penetrating	B
keratoplasty	I
.	O

Soft	O
or	O
hard	B
contact	I
lenses	I
use	O
during	B
the	I
last	I
month	I
from	I
inclusion	I
day	I

>	B
18	I
to	I
<	I
90	I
years	I
old	B

Both	B
sexes	I

Mild	B
to	O
moderate	B
tear	B
film	I
dysfunction	I
clinical	O
diagnose	O

TBUT	B
>	B
5	I
sec	I
.	I
and	I
<	I
10	I
sec	I
.	O

Schirmer	B
:	O
>	B
4	I
mm	I
and	I
<	I
14	I
mm	I

OSDI	B
<	B
30	I
points	I

Corneal	B
staining	I
<	B
grade	I
III	I
on	O
the	O
Oxford	B
scale	I

Availability	O
to	O
go	O
to	O
each	O
revision	O
when	O
indicated	O
.	O

1	O
.	O

History	B
of	O
colorectal	B
surgery	I

2	O
.	O

Suspected	O
or	O
known	O
digestive	B
tract	I
obstruction	I
,	O
stricture	O
,	O
or	O
perforation	O

3	O
.	O

Serious	B
status	I
of	I
illness	I
,	O
such	O
as	O
severe	B
renal	B
failure	I
whose	O
creatinine	B
clearance	I
<	B
30	I
ml	I
/	I
min	I
,	O
New	B
York	I
Heart	I
Association	I
grade	B
III	I
or	I
grade	I
IV	I
congestive	B
heart	I
failure	I
,	O
or	O
hemodynamic	B
instability	I
,	O
etc	O
.	O

4	O
.	O

Incapable	B
of	I
completing	I
bowel	I
preparation	I
，	O
such	O
as	O
dysphagia	B
,	O
allergy	B
to	O
purgatives	B
,	O
or	O
impaired	B
mental	I
status	I
,	O
etc	O
.	O

5	O
.	O

Pregnancy	B
or	O
breastfeeding	O

6	O
.	O

Incomplete	B
colonoscopy	B
due	O
to	O
causes	O
except	B
poor	B
bowel	I
preparation	I

7	O
.	O

Unable	O
to	O
give	O
informed	O
consent	O

8	O
.	O

Have	O
participated	O
in	O
the	O
study	O
before	O
.	O

1	O
.	O

Individuals	O
scheduled	O
for	O
undergoing	O
colonoscopy	B
at	O
the	O
Endoscopy	O
Center	O
of	O
Wuxi	O
people	O
'	O
s	O
Hospital	O
in	O
China	O

2	O
.	O

Greater	O
than	O
the	O
age	B
of	O
18	O

3	O
.	O

Individuals	O
living	O
with	O
other	O
family	O
members	O

4	O
.	O

Outpatients	O

Inability	O
to	O
consent	O
/	O
refusal	O
Allergy	B
to	O
any	O
of	O
the	O
study	B
medications	I
Multiple	B
traumatic	I
injuries	I
Contraindication	B
to	O
neuraxial	O
or	O
general	B
anesthesia	I
Pregnancy	B

ASA	B
I	B
-	I
IV	I
Age	B
55	B
or	I
older	I
Scheduled	O
for	O
operative	B
repair	I
of	O
isolated	B
intertrochanteric	B
hip	I
fracture	I

Unable	O
to	O
speak	O
Spanish	O
or	O
English	O

Active	B
smoking	O
(	O
within	B
the	I
past	I
year	I
)	O

Autoimmune	O
,	O
rheumatologic	O
or	O
inflammatory	B
disease	I
which	O
are	O
not	B
psoriasis	B
or	O
psoriatic	B
arthritis	I

Known	O
active	B
cancer	B
receiving	O
treatment	B

Pregnancy	B

Anemia	B
(	O
hemoglobin	B
<	B
9	I
mg	I
/	I
dl	I
)	O
or	O
thrombocytopenia	B
(	O
Platelet	B
count	I
<	B
75	I
)	O
,	O
or	O
thrombocytosis	B
(	O
Platelet	B
count	I
>	B
600	I
)	O

A	O
history	B
of	O
severe	B
bleeding	B
or	O
bleeding	B
disorders	I

Current	B
medication	B
use	O
which	O
interact	B
with	O
either	O
aspirin	B
or	O
atorvastatin	B

Chronic	B
kidney	I
disease	I
(	O
CrCl	B
<	B
30ml	I
/	I
min	I
)	O

Congestive	B
heart	I
failure	I

Currently	O
taking	O
aspirin	B
or	O
a	O
statin	B
.	O

NSAID	B
use	O
within	B
the	I
past	I
48	I
hours	I

Subjects	O
with	O
a	O
history	B
of	O
moderate	B
to	O
severe	B
psoriatic	B
disease	I

Group	O
2	O
:	O
Healthy	B
subjects	O
without	B
known	O
psoriatic	B
disease	I
or	O
cardiovascular	B
disease	I

NA	O

Subject	O
must	O
be	O
at	B
least	I
30	I
years	I
of	O
age	B
.	O

Subject	O
is	O
able	O
to	O
verbally	O
confirm	O
understandings	O
of	O
risks	O
,	O
benefits	O
and	O
treatment	O
alternatives	O
of	O
receiving	O
the	O
Vitamin	O
C	O
+	O
E	O
or	O
Statin	O
or	O
Dual	O
,	O
and	O
he	O
/	O
she	O
or	O
his	O
/	O
her	O
legally	O
authorized	O
representative	O
provides	O
written	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
related	O
procedure	O
.	O

Subject	O
must	O
have	O
symptoms	B
that	O
are	O
consistent	O
with	O
vasospastic	B
angina	I
with	O
planned	O
Coronary	B
angiography	I
and	O
Provocation	B
test	I
.	O

1	O
.	O

Absence	B
of	O
objectionable	B
cognitive	B
impairment	I
or	O
presence	O
of	O
dementia	B
of	O
severe	B
degree	I
defined	O
by	O
CDR	B
score	I
>	B
2	I
.	I
0	I
.	O

2	O
.	O

Unavailability	B
of	O
brain	B
MRI	I
(	O
in	O
case	O
of	O
absolute	B
contraindications	I
,	O
the	O
use	O
of	O
cranial	B
CT	I
is	O
allowed	O
)	O
.	O

3	O
.	O

Expected	O
poor	O
compliance	O
with	O
the	O
study	O
protocol	O
.	O

4	O
.	O

Past	O
diagnosis	O
of	O
major	B
depression	I
,	O
schizophrenia	B
,	O
major	B
anxiety	I
syndrome	I
,	O
or	O
manic	B
-	I
depressive	I
illness	I
.	O

5	O
.	O

Diagnosis	O
of	O
degenerative	B
cognitive	I
impairment	I
based	O
on	O
clinical	B
and	I
/	I
or	I
neuroradiological	I
findings	I
(	O
i	O
.	O
e	O
.	O
,	O
patients	O
with	O
prevailing	O
memory	B
impairment	I
,	O
or	O
with	O
medial	B
temporal	I
atrophy	I
on	O
brain	B
MRI	I
in	O
absence	B
of	O
evident	O
vascular	B
abnormalities	I
;	O
i	O
.	O
e	O
.	O
,	O
Alzheimer	B
disease	I
as	O
defined	O
using	O
the	O
National	B
Institute	I
of	I
Neurological	I
and	I
Communicative	I
Disorders	I
and	I
Stroke	I
/	I
Alzheimer	I
'	I
s	I
Disease	I
and	I
Related	I
Disorders	I
Association	I
criteria	I
,	O
Parkinson	B
disease	I
,	O
Huntington	B
disease	I
,	O
frontotemporal	B
dementia	I
)	O
.	O

6	O
.	O

Diagnosis	O
of	O
cognitive	B
impairment	I
from	O
other	B
causes	I
(	O
i	O
.	O
e	O
.	O
,	O
vitamine	O
B12	O
and	O
folic	B
acid	I
deficiency	I
,	O
thyroid	B
disorders	I
,	O
metabolic	B
diseases	I
,	O
head	B
trauma	I
,	O
tumor	O
or	O
infections	B
of	I
the	I
central	I
nervous	I
system	I
,	O
normal	B
pressure	I
hydrocephalus	I
)	O
.	O

7	O
.	O

Medical	O
conditions	O
expected	O
to	O
progress	O
,	O
recur	O
,	O
or	O
change	O
to	O
such	O
a	O
degree	O
to	O
interfere	O
with	O
the	O
assessment	O
of	O
the	O
clinical	O
and	O
mental	O
status	O
.	O

8	O
.	O

Clinically	B
relevant	I
cardiac	O
or	O
pulmonary	B
insufficiency	I
.	O

9	O
.	O

Relevant	B
electrocardiograph	B
abnormalities	B
;	O
bradycardia	B
(	O
50	B
bpm	I
)	O
or	O
tachycardia	B
(	O
120	B
bpm	I
)	O
under	B
resting	I
conditions	I
.	O

10	O
.	O

Myocardial	B
infarction	I
within	B
the	I
past	I
6	I
months	I
.	O

11	O
.	O

Stroke	B
still	O
requiring	B
neurological	B
rehabilitation	I
.	O

12	O
.	O

Severe	B
/	O
untreated	B
blood	B
pressure	I
(	O
systolic	B
180	B
mm	I
Hg	I
,	O
diastolic	B
95	B
mm	I
Hg	I
)	O
.	O

13	O
.	O

Clinically	B
relevant	I
liver	B
function	I
impairment	I
.	O

14	O
.	O

Insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
.	O

15	O
.	O

Idiopathic	B
epilepsy	I
and	O
anti	B
-	I
epileptic	I
treatment	I
.	O

16	O
.	O

Severe	B
anemia	B
(	O
Hb	B
<	B
10	I
mg	I
/	I
dL	I
)	O
.	O

17	O
.	O

Severe	B
gastrointestinal	B
disease	I
.	O

18	O
.	O

Cancer	B
.	O

19	O
.	O

Known	O
intolerance	B
to	O
study	B
drugs	I
.	O

20	O
.	O

Coexistent	O
serious	O
illnesses	O
that	O
would	O
imply	O
a	O
drop	O
-	O
out	O
before	O
the	O
end	O
of	O
the	O
trial	O
.	O

1	O
.	O

Cognitive	B
impairment	I
from	O
mild	B
to	I
moderate	I
degree	O
defined	O
by	O
a	O
Clinical	B
Deterioration	I
Rating	I
(	I
CDR	I
)	I
score	I
range	B
between	I
0	I
.	I
5	I
and	I
2	I
.	I
0	I
.	O

2	O
.	O

Evidence	O
on	O
brain	B
MRI	I
of	O
white	O
matter	O
hyperintensities	O
(	O
leukoaraiosis	B
of	O
moderate	B
or	I
severe	I
degree	I
according	O
to	O
the	O
modified	B
Fazekas	I
visual	I
scale	I
and	O
/	O
or	O
presence	O
of	O
lacunar	B
infarcts	I
)	O
.	O

3	O
.	O

Consent	O
to	O
participation	O
in	O
the	O
study	O
.	O

Suspected	O
or	O
known	O
gynecological	B
malignancy	I
.	O

uterine	B
size	I
>	B
12	I
weeks	I
.	O

Endometriosis	B

Presence	O
of	O
adnexal	B
mass	I
.	O

cervix	B
flushed	I
with	I
the	I
vagina	I
.	O

presence	O
of	O
significant	B
scarring	I
in	O
the	O
pelvic	B
area	I
from	O
previous	B
surgery	B
.	O

uterine	B
size	I
<	B
12	I
weeks	I
.	O

presence	O
of	O
benign	B
cause	I
for	O
the	O
hysterectomy	B
e	O
.	O
g	O
.	O
fibroid	B
uterus	I
,	O
perimenopausal	B
beeding	I
not	B
responding	O
to	O
medical	B
treatment	I
or	O
complex	B
endometrial	I
hyperplasia	I
without	B
atypia	B
.	O

Absence	B
of	O
significant	B
scarring	I
in	O
the	O
pelvis	B
from	O
previous	B
surgeries	B
.	O

The	O
difference	B
in	I
blood	I
pressure	I
between	O
the	O
selected	B
arm	I
versus	I
non	I
-	I
selected	I
arm	I
is	O
=	B
20	I
mmHg	I
for	O
siSBP	B
and	O
=	B
10	I
mmHg	I
for	O
siDBP	B
at	B
Visit	I
1	I
(	O
screening	O
)	O
.	O

Blood	B
pressure	I
taken	O
at	B
screening	I
and	O
randomization	O
is	O
=	B
180	I
mmHg	I
for	O
siSBP	B
or	O
=	B
110	I
mmHg	I
for	O
siDBP	B
.	O

Diagnosed	O
with	O
secondary	B
hypertension	B
or	O
suspected	O
of	O
secondary	B
hypertension	B
[	O
e	O
.	O
g	O
.	O
,	O
renovascular	B
disease	I
,	O
adrenal	O
medullary	O
and	O
cortical	B
hyperfunction	I
,	O
coarctation	B
of	I
the	I
aorta	I
,	O
hyperaldosteronism	B
,	O
unilateral	B
or	O
bilateral	B
renal	B
artery	I
stenosis	I
,	O
Cushing	B
'	I
s	I
syndrome	I
,	O
pheochromocytoma	B
,	O
polycystic	B
kidney	I
disease	I
,	O
etc	O
.	O
]	O

Patients	O
with	O
symptomatic	B
orthostatic	B
hypertension	I
(	O
the	O
difference	B
in	I
the	I
blood	I
pressures	I
between	O
measured	B
at	I
supine	I
position	I
and	I
measured	I
at	I
standing	I
position	I
is	O
=	B
20	I
mmHg	I
for	O
siSBP	B
and	O
=	B
10	I
mmHg	I
for	O
siDBP	B
)	O

Diagnosis	O
of	O
type	B
1	I
diabetes	I
mellitus	I
(	I
DM	I
)	I
or	O
uncontrolled	B
DM	B
(	O
patients	O
on	O
insulin	B
therapy	I
or	O
with	O
HbA1c	B
>	B
9	I
%	I
)	O

Patients	O
with	O
severe	B
cardiac	B
conditions	I
:	O
heart	B
failure	I
(	O
NYHA	B
Class	B
3	I
or	I
4	I
)	O
,	O
history	B
of	O
ischemic	B
cardiac	I
disease	I
(	O
unstable	B
angina	I
,	O
myocardial	B
infarction	I
)	O
,	O
peripheral	B
vascular	I
diseases	I
,	O
percutaneous	B
transluminal	I
angioplasty	I
or	O
coronary	B
artery	I
bypass	I
graft	I
within	B
recent	I
6	I
months	I
.	O

Patients	O
with	O
clinically	B
significant	I
ventricular	B
tachycardia	I
,	O
atrial	B
fibrillation	I
,	O
atrial	B
flutter	I
or	O
other	O
clinically	B
significant	I
arrhythmia	B
at	O
the	O
discretion	O
of	O
the	O
investigator	O

Patients	O
with	O
hypertrophic	B
occlusive	I
myocardiopathy	I
,	O
severe	B
occlusive	B
coronary	I
artery	I
disease	I
,	O
aortic	B
stenosis	I
,	O
hemodynamically	B
significant	I
aortic	O
valve	O
or	O
mitral	B
valve	I
stenosis	I

History	B
of	O
cardiogenic	B
shock	I

Presence	O
of	O
severe	B
cerebrovascular	B
disorders	I
(	O
diagnosis	O
of	O
stroke	B
,	O
cerebral	B
infarction	I
or	O
cerebral	B
hemorrhage	I
within	B
recent	I
6	I
months	I
)	O

History	B
or	O
current	B
evidence	O
of	O
wasting	O
,	O
autoimmune	O
(	O
such	O
as	O
rheumatoid	B
arthritis	I
and	O
systemic	B
lupus	I
erythematosus	I
)	O
or	O
connective	B
tissue	I
diseases	I

Known	O
diagnosis	O
of	O
moderate	B
or	O
malignant	B
retinopathy	B
(	O
including	O
retinal	B
hemorrhage	I
,	O
visual	B
disturbance	I
and	O
retinal	B
microaneurysm	I
within	B
6	I
months	I
)	O

Patients	O
with	O
surgical	B
or	O
medical	B
intestinal	B
diseases	I
or	O
having	O
received	O
surgeries	B
that	O
could	B
interfere	I
with	I
drug	I
absorption	I
distribution	I
,	O
metabolism	O
and	O
elimination	O

History	B
of	I
malignancy	B
including	O
leukemia	B
and	O
lymphoma	B
within	B
recent	I
5	I
years	I
except	B
for	I
localized	B
basal	I
cell	I
carcinoma	I
of	I
the	I
skin	I
)	O

Patients	O
with	O
any	O
inflammatory	B
diseases	I
requiring	O
chronic	B
anti	B
-	I
inflammatory	I
therapy	I

Renal	B
failure	I
on	O
dialysis	B

AST	B
or	O
ALT	B
>	B
2	I
x	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I

Serum	B
creatinine	I
>	B
1	I
.	I
5	I
x	I
ULN	I

Serum	B
potassium	I
<	B
3	I
.	I
5	I
mmol	I
/	I
L	I
or	O
>	B
5	I
.	I
5	I
mmol	I
/	I
L	I

Needs	O
for	O
co	O
-	O
administration	O
of	O
non	B
-	I
study	I
antihypertensive	B
agents	I
or	O
contraindicated	B
medications	I
during	O
the	O
study	O

History	B
of	I
hypersensitivity	B
to	O
ARBs	B
or	O
dihydropyridines	B

History	B
of	I
angioedema	B
to	O
treatment	B
with	O
ACE	B
inhibitors	I
or	O
ARBs	B

Pregnant	B
or	O
lactating	B
women	B
and	O
female	B
volunteers	O
of	O
childbearing	O
potential	O
(	O
except	O
for	O
women	O
who	O
are	O
surgically	O
sterile	O
)	O
who	O
are	O
not	B
willing	O
to	O
use	O
an	O
adequate	B
method	I
of	I
contraception	I
(	O
oral	O
contraceptives	O
,	O
intrauterine	O
device	O
,	O
condom	O
,	O
etc	O
.	O
)	O
during	O
the	O
study	O
.	O
Women	O
of	O
childbearing	O
potential	O
who	O
are	O
not	O
surgically	O
sterile	O
will	O
be	O
allowed	O
to	O
participate	O
in	O
the	O
study	O
only	O
if	O
they	O
have	O
negative	O
pregnancy	O
test	O
at	O
Visit	O
1	O
(	O
screening	O
)	O
and	O
should	O
continue	O
to	O
use	O
medically	O
acceptable	O
method	O
of	O
contraception	O
(	O
basic	O
body	O
temperature	O
method	O
and	O
rhythm	O
method	O
will	O
not	O
be	O
allowed	O
)	O
.	O
Women	O
with	O
no	O
menses	O
for	O
=	O
12	O
months	O
will	O
be	O
considered	O
as	O
postmenopausal	O
state	O
and	O
method	O
of	O
contraception	O
using	O
hormonal	O
contraception	O
such	O
as	O
oral	O
contraceptive	O
should	O
be	O
initiated	O
from	O
or	O
prior	O
to	O
the	O
screening	O
.	O

History	B
of	O
drug	O
or	O
alcohol	B
abuse	I
within	B
recent	I
1	I
year	I

Patients	O
having	O
received	O
any	O
other	B
investigational	I
product	I
within	B
recent	I
12	I
weeks	I

Conditions	O
which	O
render	O
a	O
subject	O
ineligible	O
for	O
the	O
study	O
at	O
the	O
discretion	O
of	O
the	O
investigator	O

Adult	O
male	B
and	O
female	B
aged	B
19	B
to	I
75	I
years	I

Voluntarily	O
consented	O
to	O
participate	O
in	O
the	O
study	O
and	O
signed	O
the	O
informed	O
consent	O
form	O
after	O
receiving	O
the	O
explanation	O
of	O
the	O
objectives	O
,	O
methods	O
and	O
effects	O
of	O
the	O
study	O
.	O

Women	B
with	O
multi	B
-	I
fetal	I
pregnancy	I
,	O
diabetes	B
mellitus	I
,	O
chronic	B
hypertension	I
,	O
or	O
chronic	B
renal	I
disease	I

primigravida	B
,	O
singleton	B
pregnancy	I
,	O
maternal	B
age	I
18	B
-	I
35	I
years	I
,	O
and	O
pregnancy	B
duration	I
16	B
-	I
20	I
weeks	I
at	B
the	I
time	I
of	I
study	I
inclusion	I
.	O

Cardiac	B
morbidities	I

Hypertensive	B
disorders	I
of	I
pregnancy	I
,	O

Peripartum	B
bleeding	I

Baseline	B
systolic	B
blood	I
pressure	I
(	O
SBP	B
)	O
<	B
100	I
mmHg	I

Body	B
mass	I
index	I
>	B
35	I

full	B
term	I
singleton	B
pregnant	B
women	B

Scheduled	O
for	O
elective	B
Cesarean	B
Delivery	I

Aged	B
between	B
18	I
and	I
40	I
years	I

Serum	B
phosphate	I
<	B
3	I
.	I
0	I
mg	I
/	I
dL	I

Intravenous	B
(	O
IV	B
)	O
iron	B
administered	O
within	B
4	I
weeks	I
prior	I
to	I
Screening	I

Erythropoiesis	B
-	I
stimulating	I
agents	I
(	O
ESA	B
)	O
administered	O
within	B
4	I
weeks	I
prior	I
to	I
Screening	I

Blood	B
transfusion	I
within	B
4	I
weeks	I
prior	I
to	I
Screening	I

Estimated	B
glomerular	I
filtration	I
rate	I
=	B
20	I
mL	I
/	I
min	I
and	I
<	I
60	I
mL	I
/	I
min	I

Hgb	B
=	B
8	I
.	I
5	I
g	I
/	I
dL	I
and	I
=	I
11	I
.	I
5	I
g	I
/	I
dL	I

Serum	B
ferritin	I
=	B
500	I
ng	I
/	I
mL	I
and	O
transferrin	B
saturation	I
(	O
TSAT	B
)	O
=	B
25	I
%	I

Serum	B
intact	I
parathyroid	I
hormone	I
=	B
600	I
pg	I
/	I
mL	I

Subject	O
has	O
indeterminate	O
,	O
ulcerative	O
,	O
antibiotic	O
-	O
associated	O
colitis	B
.	O

Subject	O
has	O
stool	B
positive	B
for	I
ova	I
and	O
parasite	O
and	O
for	O
Clostridium	O
difficule	O
toxins	O
within	B
3	I
months	I
prior	I
to	O
enrollment	O
.	O

Subject	O
with	O
other	O
known	O
infectious	O
cause	O
of	O
abdominal	O
symptoms	O
.	O

Subject	O
with	O
clinical	O
evidence	O
of	O
renal	B
disease	I
with	B
the	I
past	I
6	I
months	I
,	O
defined	O
as	O
estimated	B
glomerular	I
filtration	I
rate	I
(	I
GFR	I
)	I
outside	B
the	O
normal	O
reference	O
range	O
.	O

Subject	O
with	O
known	O
history	B
of	O
intestinal	B
obstruction	I
or	O
current	B
obstructive	B
symptoms	I
,	O
such	O
as	O
severe	B
abdominal	I
pain	I
with	O
accompanying	O
nausea	B
or	O
vomiting	B
,	O
based	O
on	O
investigator	O
judgment	O
.	O

Subject	O
with	O
a	O
diagnosis	O
of	O
gastroparesis	B
or	O
small	B
bowel	I
or	O
large	B
bowel	I
dysmotility	I
.	O

Subjects	O
with	O
a	O
history	B
of	O
small	O
bowel	O
or	O
colonic	B
resection	I
.	O

Subject	O
with	O
any	O
current	O
condition	O
believed	O
to	O
have	O
an	O
increased	O
risk	O
of	O
capsule	O
retention	O
such	O
as	O
suspected	O
or	O
known	O
bowel	O
obstruction	O
,	O
stricture	O
,	O
or	O
fistula	O
.	O

Subject	O
has	O
used	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drugs	I
including	O
aspirin	B
,	O
two	B
times	I
per	I
week	I
,	O
during	B
the	I
4	I
weeks	I
preceding	I
enrollment	O
.	O

Low	B
dose	I
aspirin	B
regimens	O
(	O
<	B
100	I
mg	I
daily	I
)	O
are	O
acceptable	O
and	O
not	O
exclusionary	O
.	O

Subject	O
suffers	O
from	O
any	O
condition	B
,	O
such	O
as	O
swallowing	B
problems	I
,	O
that	O
precludes	B
compliance	O
with	O
study	O
and	O
/	O
or	O
device	O
instructions	O
.	O

Subject	O
with	O
cardiac	B
pacemaker	I
or	O
other	O
implanted	B
electromedical	I
device	I
.	O

Subject	O
has	O
an	O
allergy	B
or	O
other	O
known	O
contraindication	B
to	O
the	O
medications	B
used	I
in	I
the	I
study	I
.	O

Subject	O
is	O
pregnant	B
(	O
documented	O
by	O
a	O
positive	B
pregnancy	B
test	I
)	O
or	O
is	O
actively	B
breast	O
-	O
feeding	O
.	O

Subject	O
is	O
considered	O
to	O
be	O
a	O
part	B
of	I
a	I
vulnerable	I
population	I
(	O
eg	O
.	O
prisoners	B
or	O
those	O
without	B
sufficient	I
mental	I
capacity	I
)	O
.	O

Subject	O
has	O
a	O
known	O
contraindication	B
to	O
MRE	B
or	O
IC	B
.	O

Subject	O
has	O
participated	O
in	O
a	O
drug	O
or	O
device	O
research	O
study	O
within	O
30	O
days	O
of	O
enrollment	O
that	O
may	O
interfere	O
with	O
the	O
subject	O
'	O
s	O
safety	O
or	O
ability	O
to	O
participate	O
in	O
the	O
study	O
.	O

Subject	O
has	O
any	O
medical	O
condition	O
that	O
would	O
make	O
it	O
unsafe	O
for	O
them	O
to	O
participate	O
,	O
per	O
Investigator	O
'	O
s	O
descretion	O

Subject	O
has	O
provided	O
informed	O
consent	O
.	O

Subject	O
is	O
≥	B
18	I
years	I
of	O
age	B

Subject	O
is	O
willing	O
and	O
able	O
to	O
comply	O
with	O
all	O
aspects	O
of	O
treatment	O
and	O
evaluation	O
schedule	O
.	O

Subject	O
has	O
known	O
CD	O
and	O
a	O
recent	B
history	I
(	O
within	B
last	I
2	I
years	I
)	O
of	O
mucosal	B
disease	I
(	O
diagnosis	O
based	O
on	O
radiologic	O
,	O
endoscopic	O
,	O
or	O
histological	O
evidence	O
)	O
.	O

patient	O
not	B
previously	B
scheduled	O
for	O
radiofrequency	B
ablation	I
of	O
the	O
cervical	O
,	O
thoracic	O
,	O
or	O
lumbar	B
facets	I
,	O
or	O
sacroiliac	B
joints	I

on	O
anticoagulation	B

have	O
a	O
pacemaker	B

age	B
less	B
than	I
18	I
years	I
old	I

non	B
-	O
English	O
speaking	O

patients	O
with	O
a	O
diagnosis	O
of	O
either	O
cervical	O
,	O
thoracic	O
,	O
or	O
lumbar	O
facet	O
or	O
sacroiliac	B
joint	I
pain	I
who	O
have	O
responded	O
to	O
medial	B
branch	I
blocks	I
and	O
are	O
already	O
scheduled	O
for	O
bilateral	B
radiofrequency	I
ablations	I

age	B
greater	B
than	I
18	I
years	I
old	I

English	O
speaking	O

Inability	O
to	O
provide	O
written	O
informed	O
consent	O

Known	O
history	O
of	O
prior	B
intracranial	B
bleeding	I

On	O
treatment	O
with	O
a	O
P2Y12	B
receptor	I
antagonist	I
(	O
ticlopidine	B
,	O
clopidogrel	B
,	O
prasugrel	B
,	O
ticagrelor	B
)	O
in	O
the	O
prior	B
10	I
days	I

Known	O
allergies	B
to	O
aspirin	B
,	O
ticagrelor	B
or	O
cangrelor	B

On	O
treatment	O
with	O
oral	B
anticoagulant	B

Treatment	O
with	O
glycoprotein	B
IIb	I
/	I
IIIa	I
inhibitors	I

Fibrinolytics	B
within	B
24	I
hours	I

Active	B
bleeding	I

High	B
risk	I
of	O
bleeding	B

Known	O
platelet	B
count	I
<	B
80x106	I
/	I
mL	I

Known	O
hemoglobin	B
<	B
10	I
g	I
/	I
dL	I

Intubated	B
patients	O
(	O
prior	B
to	I
randomization	I
)	O

Known	O
creatinine	B
clearance	I
<	B
30	I
mL	I
/	I
minute	I
or	O
on	O
hemodialysis	B
.	O

Known	O
severe	B
hepatic	B
dysfunction	I

Patients	O
with	O
sick	B
sinus	I
syndrome	I
(	O
SSS	B
)	O
or	O
high	B
degree	I
AV	B
block	I
without	B
pacemaker	B
protection	O

Current	O
treatment	O
with	O
drugs	B
interfering	O
with	O
CYP3A4	B
metabolism	I
(	O
to	O
avoid	O
interaction	O
with	O
ticagrelor	B
)	O
:	O
Ketoconazole	B
,	O
itraconazole	B
,	O
voriconazole	B
,	O
clarithromycin	B
,	O
nefazodone	B
,	O
ritonavir	B
,	O
saquinavir	B
,	O
nelfinavir	B
,	O
indinavir	B
,	O
atazanavir	B
,	O
and	O
telithromizycin	B
.	O

Pregnant	B
or	O
lactating	B
females	B
.	O

Patients	O
with	O
STEMI	B
undergoing	O
primary	B
PPCI	I

Age	B
>	B
18	I
years	I
old	I

Decompensated	B
heart	B
failure	I
or	O
hemodynamic	B
instability	I

Prior	B
coronary	B
revascularization	I
(	O
PCI	B
or	O
CABG	B
)	O
or	O
myocardial	B
infarction	I
(	O
as	O
evidenced	O
by	O
previously	B
elevated	B
CPK	O
-	O
MB	O
or	O
troponin	B
levels	I
)	O

Accelerating	B
angina	I
or	O
unstable	B
angina	I

Inability	B
to	I
physically	I
tolerate	I
MRI	B
or	O
implanted	B
objects	I
that	O
are	O
MRI	B
incompatible	I

Inability	O
to	O
provide	O
written	O
informed	O
consent	O
obtained	O
at	O
time	O
of	O
study	O
enrollment	O
.	O

Severe	B
claustrophobia	B

Advanced	B
heart	B
block	I
or	O
sinus	B
node	I
dysfunction	I

Hypersensitivity	B
or	O
allergic	B
reaction	O
to	O
regadenoson	B
or	O
adenosine	B

Hypotension	B

Active	B
bronchospasm	B
or	O
history	B
of	O
hospitalization	B
due	O
to	O
bronchospasm	B

History	B
of	O
seizures	B

Recent	B
cerebrovascular	B
accident	I

Use	O
of	O
dipyridamole	B
within	B
the	I
last	I
5	I
days	I

Contraindication	B
to	O
aminophylline	B

Severe	B
renal	B
insufficiency	I
with	O
estimated	B
glomerular	I
filtration	I
rate	I
<	B
30	I
ml	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I

Pregnant	B
or	O
nursing	B

Men	B
or	O
women	B
aged	B
18	B
years	I
or	I
older	I

Patients	O
presenting	O
for	O
CMR	O
with	O
the	O
clinical	O
diagnosis	O
of	O
hypertrophic	B
cardiomyopathy	I
based	O
on	O
left	B
ventricular	I
wall	I
thickness	I
of	O
at	B
least	I
=	I
15	I
mm	I
in	O
the	O
absence	B
of	O
any	O
other	O
cardiac	O
or	O
systemic	B
cause	I
of	I
hypertrophy	I

Patients	O
presenting	O
for	O
CMR	O
with	O
the	O
clinical	O
diagnosis	O
of	O
idiopathic	B
dilated	I
cardiomyopathy	I
based	O
upon	O
left	B
ventricular	I
ejection	I
fraction	I
=	B
40	I
%	I
,	O
LV	B
end	I
-	I
diastolic	I
diameter	I
=	B
55	I
mm	I
or	O
left	B
ventricular	I
end	I
-	I
systolic	I
diameter	I
=	B
45	I
mm	I
,	O
and	O
the	O
absence	B
of	O
coronary	B
stenoses	I
on	O
angiography	B
.	O

Patients	O
presenting	O
for	O
CMR	O
evaluation	O
of	O
chest	B
pain	I
but	O
without	B
evidence	O
of	O
obstructive	B
coronary	I
artery	I
disease	I
either	O
by	O
coronary	B
angiography	I
or	O
stress	B
testing	I
.	O

Lifetime	O
personal	O
history	O
of	O
diagnosis	O
of	O
major	B
depressive	I
disorder	I
according	O
to	O
the	O
DSM	B
-	I
V	I
(	O
American	O
Psychiatric	O
Association	O
,	O
2013	O
)	O
using	O
the	O
Structured	B
Clinical	I
Interview	I
for	I
DSM	I
-	I
V	I
Axis	I
I	I
Disorders	I
,	I
Research	I
Version	I
,	I
Non	I
-	I
patient	I
Edition	I
(	O
SCID	O
-	O
5	O
-	O
RV	O
for	O
DSM	O
-	O
V	O
;	O
First	O
et	O
al	O
.	O
,	O
2015	O
)	O

A	O
history	O
of	O
suicidal	B
ideation	I
and	O
behaviour	O
,	O
including	O
self	B
-	I
harm	I
and	O
/	O
or	O
harm	B
to	I
others	I
.	O

A	O
history	O
of	O
substance	B
abuse	I
and	O
/	O
or	O
dependence	O
.	O

A	O
positive	B
drug	B
screen	I
for	I
illicit	I
drugs	I

Substantial	B
alcohol	I
use	I

Current	O
use	O
of	O
Monoamine	B
Oxidase	I
Inhibitors	I
(	I
MAOIs	I
)	I
,	O
including	O
the	O
antibiotic	B
linezolid	I
and	O
the	O
thiazine	B
dye	I
methylthioninium	B
chloride	I
(	O
methylene	B
blue	I
)	O

Current	O
use	O
of	O
serotonin	B
-	I
precursors	I
(	O
such	O
as	O
L	B
-	I
tryptophan	I
,	O
oxitriptan	B
)	O

Current	O
use	O
of	O
serotonergic	B
drugs	I
(	O
triptans	B
,	O
certain	O
tricyclic	B
antidepressants	I
,	O
lithium	B
,	O
tramadol	B
,	O
St	B
.	I
John	I
'	I
s	I
Wort	I
)	O

Concomitant	B
use	O
of	O
NSAIDS	B
,	O
ASA	B
,	O
and	O
other	B
anticoagulants	B
.	O

Current	O
use	O
of	O
Thioridazine	B

Current	O
use	O
of	O
CYP1A2	B
Inhibitors	I

Current	O
use	O
of	O
Triptans	B
(	O
5HT1	B
Agonists	I
)	O

Blood	B
pressure	I
greater	B
than	I
140	I
/	I
90	I
and	O
/	O
or	O
a	O
pulse	B
rate	I
greater	B
than	I
90	I
bpm	I

Recent	B
history	B
of	O
myocardial	B
infarction	I
,	O
cerebrovascular	B
accident	I
,	O
cardiac	B
arrhythmias	I
,	O
or	O
unstable	B
heart	I
disease	I
.	O

Evidence	O
of	O
significant	O
physical	B
illness	I
contraindicating	B
the	O
use	O
of	O
levomilnacipran	B
and	O
duloxetine	B
found	O
on	O
the	O
physical	B
exam	I
or	O
in	O
the	O
laboratory	B
data	O
obtained	O
during	B
the	I
first	I
week	I
of	I
the	I
study	I

Current	B
use	O
of	O
medication	B
that	O
may	O
affect	B
voiding	I
(	O
ie	O
-	O
anticholinergics	B
)	O

History	B
of	O
obstructive	B
urinary	I
disorders	I
and	O
dysuria	B
,	O
prostatic	B
hypertrophy	I
,	O
prostatitis	B
,	O
and	O
other	B
lower	B
urinary	I
tract	I
obstructive	I
disorders	I
.	O

History	O
of	O
Stevens	B
-	I
Johnson	I
Syndrome	I
and	O
Erythema	B
multiforme	I
.	O

Diabetes	B
Type	I
I	I
and	O
II	O

Fructose	B
intolerance	I
,	O
glucose	B
-	I
galactose	I
malabsorption	I
or	O
sucrose	B
-	I
isomaltase	I
insufficiency	I
.	O

Hepatic	B
Impairment	I

Uncontrolled	B
narrow	B
-	I
angle	I
glaucoma	I

Severe	B
renal	B
impairment	I

History	B
of	O
seizure	B
disorder	I

Anatomically	B
narrow	I
ocular	I
angles	I
.	O

Osteoporosis	B
or	O
major	O
risk	O
for	O
bone	B
fractures	I
.	O

Male	B
participants	O
between	B
18	I
and	I
40	I
years	I
-	O
old	B

Written	O
informed	O
consent	O
signed	O
by	O
the	O
participant	O

Patient	O
with	O
a	O
chronic	B
pain	I
condition	I
,	O
major	B
unexpected	B
surgical	I
complication	I
,	O
unexpected	B
prolonged	B
intubation	B
,	O
patient	O
refusal	O
,	O
local	B
anesthetic	I
allergy	B
,	O
any	O
contraindication	B
to	O
regional	B
anesthesia	I
,	O
greater	B
than	I
2	I
attempts	O
by	O
resident	B
and	O
greater	B
than	I
1	I
attempt	O
by	O
staff	O
anesthesiologist	B
for	O
TAP	B
block	I
.	O

Elective	B
open	B
abdominal	I
hysterectomy	I
with	O
midline	B
incision	I
,	O
age	B
>	B
18	I
years	I
,	O
American	B
Society	I
of	I
Anesthesiologist	I
classification	I
score	I
(	O
ASA	B
classification	I
)	O
1	B
-	I
3	I
.	O

Clear	B
indication	I
for	I
specific	I
duration	I
of	O
dual	B
anti	I
-	I
platelet	I
therapy	I

Type	B
2	I
myocardial	I
infarction	I

Contraindication	B
to	O
aspirin	B
or	O
P2Y12	B
receptor	I
antagonist	I

Non	B
-	I
resident	I
of	O
Scotland	O

Previous	O
recruitment	O
into	O
the	O
trial	O

Inability	O
or	O
unwilling	O
to	O
give	O
informed	O
consent	O

Aged	B
=	B
18	I
years	I

Clinical	O
diagnosis	O
of	O
acute	B
coronary	I
syndrome	I

In	O
the	O
opinion	O
of	O
the	O
attending	O
clinician	O
requires	O
dual	B
anti	I
-	I
platelet	I
therapy	I
with	O
aspirin	B
and	O
a	O
P2Y12	B
receptor	I
antagonist	I

Resident	B
in	O
Scotland	O
with	O
a	O
Community	O
Health	O
Index	O
(	O
CHI	O
)	O
number	O

The	O
attending	O
clinician	O
has	O
equipoise	O
regarding	O
the	O
duration	O
of	O
therapy	O

Provision	O
of	O
informed	O
consent	O

Has	O
bilateral	B
sacroiliitis	B
Grade	B
2	I
or	O
unilateral	B
sacroiliitis	B
Grade	B
3	I
or	O
Grade	B
4	I

Is	O
a	O
nursing	B
or	O
pregnant	B
female	B
,	O
or	O
intends	O
to	O
become	O
pregnant	B
within	B
6	I
months	I
after	I
receiving	I
trial	I
medication	I

Intends	O
to	O
donate	B
eggs	I
(	O
female	B
participants	O
)	O
or	O
sperm	O
(	O
male	B
participants	O
)	O
while	B
receiving	I
trial	I
medication	I
or	O
within	B
6	I
months	I
after	I
trial	I
medication	I

Has	O
any	O
clinically	O
significant	O
condition	O
or	O
situation	O
that	O
would	O
interfere	O
with	O
the	O
trial	O
evaluations	O
or	O
participation	O
in	O
the	O
trial	O

Has	O
ever	O
received	O
any	O
cytotoxic	B
drugs	I
,	O
including	O
chlorambucil	B
,	O
cyclophosphamide	B
,	O
nitrogen	B
mustard	I
,	O
or	O
other	O
alkylating	B
agents	I

•	O
Disease	B
-	I
modifying	I
anti	I
-	I
rheumatic	I
drugs	I
(	O
30	B
days	I
off	I
drug	I
)	O

•	O
Live	B
vaccinations	I
(	O
3	B
months	I
off	I
drug	I
)	O

•	O
Investigational	B
medications	I
(	O
30	O
days	O
or	O
5	B
half	I
-	I
lives	I
off	I
drug	I
,	O
whichever	O
is	O
longer	O
)	O

•	O
Bacille	B
Calmette	I
-	I
Guerin	I
(	I
BCG	I
)	I
vaccination	I
(	O
12	B
months	I
off	I
drug	I
)	O

Has	O
any	O
systemic	O
inflammatory	B
condition	I
,	O
including	O
psoriatic	B
arthritis	I
,	O
active	B
Lyme	B
disease	I
,	O
systemic	B
lupus	I
erythematosus	I
,	O
infectious	B
arthritis	I
,	O
vasculitis	B
,	O
parvovirus	B
infection	I
,	O
rheumatoid	B
arthritis	I
,	O
active	B
uveitis	I
,	O
or	O
active	B
IBD	I

Has	O
a	O
history	O
of	O
latent	B
or	O
active	B
granulomatous	B
infection	I
prior	B
to	I
Screening	I

Had	O
a	O
nontuberculous	B
mycobacterial	I
infection	I
or	O
opportunistic	B
infection	I
within	B
6	I
months	I
prior	I
to	I
Screening	I

Has	O
a	O
history	B
of	O
an	O
infected	B
joint	B
prosthesis	I
,	O
or	O
has	O
received	O
antibiotics	B
for	O
a	O
suspected	O
infection	B
of	O
a	O
joint	B
prosthesis	I
,	O
if	O
that	O
prosthesis	O
has	O
not	O
been	O
removed	O
or	O
replaced	O

Had	O
a	O
serious	B
infection	I
,	O
has	O
been	O
hospitalized	B
for	O
an	O
infection	B
,	O
or	O
has	O
been	O
treated	O
with	O
IV	B
antibiotics	I
for	O
an	O
infection	B
within	B
2	I
months	I
prior	I
to	I
Baseline	I

Had	O
a	O
history	B
of	O
,	O
or	O
ongoing	B
,	O
chronic	B
or	O
recurrent	B
infectious	B
disease	I

Is	O
known	O
to	O
be	O
infected	O
with	O
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
or	O
seropositive	B
for	I
hepatitis	I
C	I
virus	I
(	I
HCV	I
)	I

Has	O
had	O
a	O
chest	B
x	I
-	I
ray	I
within	B
2	I
months	I
prior	I
to	I
Screening	I
that	O
shows	O
an	O
abnormality	B
suggestive	O
of	O
a	O
current	B
active	B
infection	B
or	O
malignancy	B

Has	O
a	O
history	O
of	O
lymphoproliferative	B
disease	I

Has	O
had	O
a	O
malignancy	B
within	B
5	I
years	I
before	I
screening	I
(	O
exceptions	B
are	O
squamous	O
and	O
basal	B
cell	I
carcinomas	I
of	I
the	I
skin	I
and	O
carcinoma	B
in	I
situ	I
of	O
cervix	B
that	O
has	O
been	O
surgically	B
cured	O
)	O

Has	O
a	O
history	B
of	O
known	O
demyelinating	B
diseases	I
such	O
as	O
multiple	B
sclerosis	I
or	O
optic	B
neuritis	I

Has	O
a	O
history	B
of	O
or	O
concurrent	B
congestive	B
heart	I
failure	I
of	O
any	O
grade	O

Has	O
a	O
transplanted	B
organ	I
(	O
with	O
the	O
exception	B
of	I
a	O
corneal	B
transplant	I
performed	O
>	B
=	I
3	I
months	I
prior	I
to	I
baseline	I
)	O

Has	O
current	O
signs	O
or	O
symptoms	O
of	O
significant	B
medical	B
illness	I
which	O
could	O
interfere	O
with	O
the	O
trial	O
,	O
or	O
require	O
treatment	B
that	O
might	O
interfere	O
with	O
the	O
trial	O

Is	O
a	O
user	O
of	O
recreational	O
or	O
illicit	O
drugs	O
or	O
has	O
or	O
had	O
a	O
substance	O
abuse	O
(	O
drug	O
or	O
alcohol	O
)	O
problem	O
within	O
the	O
previous	O
2	O
years	O

Is	O
not	O
of	O
reproductive	O
potential	O
,	O
or	O
is	O
of	O
reproductive	O
potential	O
and	O
agrees	O
to	O
avoid	O
becoming	O
pregnant	O
or	O
impregnating	O
a	O
partner	O
while	O
receiving	O
trial	O
medication	O
or	O
within	O
6	O
months	O
after	O
the	O
last	O
dose	O
of	O
trial	O
medication	O

Has	O
chronic	B
back	I
pain	I
of	O
=	B
3	I
months	I
duration	B
by	O
history	B

Has	O
physician	O
-	O
diagnosed	O
active	B
nr	B
-	I
axSpA	I
with	O
disease	B
duration	I
<	B
=	I
5	I
years	I

•	O
Inflammatory	B
back	I
pain	I

•	O
Arthritis	B
(	O
physician	O
-	O
diagnosed	O
)	O

•	O
Enthesitis	B
(	O
heel	B
)	O
physician	O
-	O
diagnosed	O
(	O
spontaneous	O
pain	B
or	O
tenderness	B
at	O
examination	O
of	O
the	O
site	B
of	I
the	I
insertion	I
of	I
the	I
Achilles	I
tendon	I
or	O
plantar	B
fascia	I
)	O

•	O
Dactylitis	B
(	O
physician	O
-	O
diagnosed	O
)	O

•	O
Psoriasis	B
(	O
physician	O
-	O
diagnosed	O
)	O

•	O
History	B
of	O
physician	O
-	O
diagnosed	O
inflammatory	B
bowel	I
disease	I
(	I
IBD	I
)	I

•	O
History	B
of	O
uveitis	B
confirmed	O
by	O
an	O
ophthalmologist	O

•	O
Good	O
response	O
to	O
nonsteroidal	B
anti	I
-	I
inflammatory	I
drugs	I
(	I
NSAID	I
)	I

•	O
Family	O
history	O
of	O
SpA	B
(	O
presence	O
of	O
ankylosing	B
spondylitis	I
,	O
psoriasis	B
,	O
acute	B
uveitis	I
,	O
reactive	B
arthritis	I
,	O
or	O
IBD	B
)	O

•	O
Elevated	B
CRP	B

•	O
Human	O
leukocyte	O
antigen	O
B27	O
(	B
HLA	I
-	I
B27	I
)	I
+	I
gene	O

Has	O
a	O
HLA	B
-	I
B27	I
+	I
gene	O
and	O
2	B
or	I
more	I
of	O
the	O
SpA	B
characteristics	O
listed	O
above	O

Has	O
elevated	B
CRP	B
at	B
Screening	I
or	O
evidence	O
of	O
active	B
inflammation	B
in	O
the	O
sacroiliac	B
joints	I
on	O
MRI	B

Has	O
an	O
ASDAS	B
>	B
=	I
2	I
.	I
1	I
at	B
Screening	I

Shows	O
high	B
disease	I
activity	I
at	B
Screening	I
and	I
Baseline	I
of	O
both	O
a	O
Total	B
Back	I
Pain	I
score	I
of	O
=	B
4	I
and	O
a	O
Bath	B
Ankylosing	I
Spondylitis	I
Disease	I
Activity	I
Index	I
(	I
BASDAI	I
)	I
score	I
of	O
>	B
=	I
4	I

Has	O
an	O
acceptable	B
history	B
of	O
NSAID	B
use	O

Has	O
no	B
history	B
of	O
untreated	B
latent	B
or	O
active	B
tuberculosis	B
(	I
TB	I
)	I
prior	B
to	I
Screening	I

Has	O
had	O
no	O
recent	B
close	O
contact	O
with	O
a	O
person	O
with	O
active	O
TB	O
or	O
,	O
if	O
there	O
has	O
been	O
such	O
contact	O
,	O
will	O
undergo	O
additional	O
evaluations	O
and	O
receive	O
appropriate	O
treatment	O
for	O
latent	O
TB	O

Known	O
hypersensitivity	B
to	O
statin	B

Treatment	O
with	O
statins	B
during	B
the	I
past	I
month	I
prior	I
to	I
study	I
.	O

Serum	B
creatinine	I
>	B
3	I
mg	I
/	I
dl	I

Significant	B
liver	B
disease	I
:	O
liver	B
enzymes	I
2	B
.	I
5	I
folds	I
the	I
upper	I
normal	I
limit	I

Malignancy	B

Pregnancy	B
or	O
lactation	B

older	B
than	I
18	I
years	B
(	O
of	O
both	B
sexes	I
)	O

diagnosed	O
with	O
stable	B
chronic	B
heart	I
failure	I
NYHA	B
class	I
II	B
-	I
III	I

ejection	B
fraction	I
<	B
40	I
%	I
as	O
assessed	O
by	O
2D	B
echocardiography	I

who	O
have	O
been	O
optimized	O
on	O
Guideline	O
Directed	O
treatment	O
for	O
heart	O
failure	O
for	O
at	O
least	O
a	O
month	O
prior	O
to	O
enrolling	O
.	O

Patients	O
who	O
are	O
recipients	O
of	O
multiple	B
solid	O
organ	O
or	O
islet	B
cell	I
tissue	I
transplants	I
,	O
or	O
have	O
previously	B
received	O
an	O
organ	O
or	O
tissue	B
transplant	I
.	O

Patients	O
who	O
have	O
a	O
combined	B
liver	I
-	I
kidney	I
transplant	I
.	O

History	B
of	O
malignancy	B
of	O
any	B
organ	I
system	I
(	O
other	B
than	I
localized	B
basal	I
cell	I
carcinoma	I
of	I
the	I
skin	I
)	O
,	O
treated	B
or	O
untreated	B
,	O
within	B
the	I
past	I
5	I
years	I
,	O
regardless	O
of	O
whether	O
there	O
is	O
evidence	O
of	O
local	O
recurrence	O
or	O
metastases	O
.	O

Existence	O
of	O
any	O
surgical	O
,	O
medical	O
or	O
mental	B
conditions	I
,	O
other	B
than	I
the	O
current	B
transplantation	B
,	O
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
might	B
interfere	I
with	I
the	I
objectives	I
of	I
the	I
study	I
.	O

Pregnant	B
or	O
nursing	O
(	O
lactating	O
)	O
women	B
.	O

Liver	B
Transplant	I
Recipients	I
have	O
received	O
liver	B
transplantations	I
for	B
at	I
least	I
6	I
+	I
1	I
months	I
prior	I
to	I
enrollment	I

Liver	B
Transplant	I
Recipients	I
have	O
no	B
acute	B
rejection	B
episodes	I
within	B
3	I
months	I
prior	I
to	I
the	I
enrollment	I
and	O
are	O
clinically	B
stable	I

Liver	B
Transplant	I
Recipients	I
have	O
been	O
treated	O
with	O
twice	B
-	I
daily	I
regimen	O
of	O
tacrolimus	B
(	I
TAC	I
)	I
plus	O
everolimus	B
(	I
EVR	I
)	I
and	O
TAC	O
and	O
EVR	B
trough	I
levels	I
have	O
stayed	O
within	B
targeted	I
ranges	I
for	B
at	I
least	I
6	I
weeks	I
prior	I
to	I
enrollment	I

Provide	O
written	O
informed	O
consent	O
prior	B
to	I
inclusion	I
.	O

Liver	B
transplant	I
recipients	I
who	O
are	O
18	B
-	I
65	I
years	I
of	O
age	B
of	O
a	O
primary	B
liver	I
transplant	I

Allograft	B
functioning	I
at	O
an	O
acceptable	B
level	I
as	O
defined	O
by	O
the	O
AST	B
,	O
ALT	B
,	O
Total	B
Bilirubin	I
levels	O
=	B
3	I
times	I
ULN	I
prior	B
to	I
enrollment	I
.	O

Abbreviated	O
MDRD	B
eGFR	I
=	B
30	I
mL	I
/	I
min	I
/	I
1	I
.	I
73m2	I
.	O

Patient	O
with	O
history	B
of	O
allergy	B
in	O
any	B
kind	I
anesthetic	B
drug	I

Patient	O
who	O
pregnant	B

Patient	O
who	O
sign	O
for	O
single	B
port	I
gynecologic	B
laparoscopic	I
surgery	I
or	O
NOTE	B
surgery	I

Patient	O
whom	O
the	O
surgery	B
is	O
withhold	O
or	O
canceled	O

Patient	O
whom	O
the	O
surgery	B
is	O
converted	O
to	O
laparotomy	B

Patient	O
who	O
undergoing	O
gynecologic	B
laparoscopic	I
surgery	I

Patient	O
who	O
agrees	O
to	O
participate	O
in	O
this	O
study	O

Patient	O
able	O
to	O
speak	O
and	O
understand	O
Thai	O

Patient	O
able	O
to	O
complete	O
the	O
questionnaire	O

Research	O
exemption	O
requested	O

History	B
of	O
PCV	B
-	I
13	I
vaccination	I

History	B
of	O
cochlear	B
implant	I

Cerebrospinal	B
Fluid	I
(	I
CSF	I
)	I
leak	I

Congestive	B
Heart	I
Failure	I
(	I
CHF	I
)	I

Diabetes	B
Mellitus	I
(	I
DM	I
)	I

Chronic	B
Kidney	I
Disease	I
(	I
CKD	I
)	I

Human	B
Immunodeficiency	I
Virus	I
(	I
HIV	I
)	I

Common	B
Variable	I
Immune	I
Deficiency	I
(	I
CVID	I
)	I

Patients	O
who	O
have	O
received	O
the	O
PPSV23	B
vaccine	I
in	B
the	I
last	I
5	I
years	I

Women	B
who	O
are	O
pregnant	B
will	O
also	O
be	O
excluded	O
from	O
the	O
study	O
by	O
performing	O
2	B
point	B
of	I
care	I
urine	I
pregnancy	I
tests	I
(	O
prior	O
to	O
vaccinations	B
)	O

Diagnosis	O
of	O
asthma	B

Patients	O
with	O
a	O
personal	B
or	I
family	I
history	I
of	O
medullary	B
thyroid	I
carcinoma	I
or	O
patients	O
with	O
Multiple	B
Endocrine	I
Neoplasia	I
syndrome	I
type	I
2	I

Patients	O
with	O
a	O
prior	B
serious	B
hypersensitivity	B
reaction	I
to	O
liraglutide	B

Other	B
contra	B
-	I
indications	I
to	O
liraglutide	B
in	O
accordance	O
with	O
risks	O
and	O
safety	O
information	O
included	O
in	O
the	O
latest	O
updated	O
prescribing	O
information	O

Type	B
1	I
diabetes	I
,	O
as	O
defined	O
by	O
ADA	B
criteria	I

Current	O
use	O
of	O
other	B
GLP	B
-	I
1A	I
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
or	O
Sodium	B
Glucose	I
transporters	I
2	I
(	I
SGLT2	I
)	I
inhibitors	I
,	O
thiazolidinediones	B
(	I
TZDs	I
)	I
,	O
pramlintide	B
and	O
fixed	O
prandial	B
insulin	I
.	O

Patients	O
with	O
unstable	B
CAD	I
,	O
assessed	O
by	O
the	O
Cardiology	O
team	O
and	O
defined	O
as	O
new	B
onset	I
angina	I
,	O
rest	B
angina	I
,	O
rapidly	O
increasing	O
or	O
crescendo	B
angina	I

History	B
of	O
diabetic	B
ketoacidosis	I
,	O
pancreas	O
or	O
beta	B
-	I
cell	I
transplantation	I
,	O
or	O
diabetes	B
secondary	B
to	I
pancreatitis	B
or	O
pancreatectomy	B
;	O
acute	B
or	O
chronic	B
infective	B
diseases	I
,	O
cancer	B
or	O
chemotherapy	B
,	O
history	O
of	O
pulmonary	O
,	O
renal	O
or	O
liver	B
diseases	I
,	O
and	O
drug	B
abuse	I

Patients	O
with	O
chronic	B
and	O
acute	B
inflammatory	B
conditions	I
such	O
as	O
sepsis	B
,	O
rheumatoid	B
arthritis	I
,	O
ectopic	B
dermatitis	I
,	O
asthma	B
,	O
ulcerative	B
colitis	I
.	O

Current	B
use	O
of	O
systemic	B
corticosteroids	I
in	B
the	I
3	I
months	I
prior	I
this	I
study	I
.	O

Pregnant	B
or	O
breast	B
-	I
feeding	I
women	I

Females	O
of	O
childbearing	O
potential	O
who	O
are	O
not	O
using	O
adequate	O
contraceptive	O
methods	O
(	O
as	O
required	O
by	O
local	O
law	O
or	O
practice	O
)	O

T2DM	B
as	O
defined	O
by	O
American	B
Diabetes	I
Association	I
(	I
ADA	I
)	I
criteria	I

Adult	B
patients	O
with	O
T2DM	B
who	O
are	O
indicated	O
to	O
receive	O
liraglutide	B
,	O
not	B
as	O
first	B
-	I
line	I
therapy	I
,	O
in	O
addition	O
to	O
diet	O
and	O
exercise	O
to	O
improve	O
glycemic	O
control	O

Hemoglobin	B
A1c	I
(	I
HbA1c	I
)	I
=	B
9	I
%	I

Age	B
=	B
18	I
years	I
old	I

Body	B
mass	I
index	I
(	I
BMI	I
)	I
=	B
27	I
Kg	I
/	I
m2	I
and	O
/	O
or	O
waist	B
circumference	I
=	B
102	I
cm	I
(	O
40	B
inches	I
)	O
in	O
men	B
and	O
88	B
cm	I
(	O
35	B
inches	I
)	O
in	O
women	B
,	O
respectively	O
.	O

Clinically	O
and	O
angiographically	B
stable	I
CAD	B
who	O
requires	O
CABG	B
as	O
part	O
of	O
the	O
standard	O
medical	O
care	O
,	O
as	O
CAD	O
does	O
not	O
represent	O
a	O
contraindication	O
for	O
using	O
liraglutide	O
.	O
The	O
stability	O
of	O
the	O
CAD	O
further	O
warranties	O
that	O
study	O
patients	O
will	O
not	O
be	O
exposed	O
to	O
higher	O
risk	O
by	O
using	O
liraglutide	O

Inability	B
to	O
use	O
verbal	O
or	O
pictorial	B
pain	I
scoring	I
scales	I

hypersensitivity	B
to	O
selective	B
5	I
-	I
HT	I
receptor	I
antagonists	I

diagnosed	O
congenital	B
long	I
QT	I
syndrome	I

severe	B
hepatic	B
impairment	I

pregnancy	B
or	O
nursing	B
mothers	O

3	B
-	I
17	I
years	I

weight	B
<	B
/	I
=	I
100kg	I

scheduled	O
for	O
urologic	O
or	O
orthopedic	B
procedure	I
necessitating	O
intrathecal	B
morphine	B

ability	B
to	O
use	O
verbal	O
or	O
pictorial	B
pain	I
assessment	I
tools	I
and	I
techniques	I

informed	O
consent	O
and	O
(	O
if	O
applicable	O
)	O
assent	O

NA	O

NA	O

Hypersensitivity	B
to	O
B	B
-	I
lactams	I

concomitant	B
disease	B
which	O
must	O
be	O
treated	B
with	O
antibiotics	B

chronic	O
disease	O
-	O
Immunocompromised	B

Antibiotics	B
within	B
72	I
h	I

history	B
of	O
ARF	B
,	O
scarlet	B
fever	I
,	O
impetigo	B
,	O
acute	B
glomerulonephritis	I

Family	O
history	O
of	O
ARF	B

Complicated	B
pharyngitis	B

3	B
-	I
15	I
years	I
old	B

Clinical	O
symptoms	O
suggestive	O
of	O
pharyngitis	B
with	O
MC	B
Isaac	I
score	I
=	B
3	I

Rapid	B
-	I
antigen	I
detection	I
test	I
(	O
RADT	B
)	O
positive	B
for	O
GAS	B
-	I

Signed	O
informed	O
parental	O
/	O
patient	O
consent	O
form	O

Pregnant	B
women	B

Claustrophobic	B
patient	O
unable	B
to	O
undergo	O
the	O
examination	B

Breastfeeding	O
women	O
unwilling	O
to	O
temporarily	O
stop	O
breastfeeding	O

Patient	O
with	O
contra	B
-	I
indication	I
to	O
:	O
dipyridamole	B
,	O
aminophylline	B
,	O
dobutamine	B
or	O
exercise	B
stress	I
test	I
(	O
depending	O
on	O
the	O
method	O
of	O
cardiovascular	O
stress	O
test	O
chosen	O
)	O

Adult	B
patient	O
being	O
referred	O
for	O
clinically	B
indicated	I
positron	B
emission	I
tomography	I
myocardial	I
perfusion	I
imaging	I
at	O
the	O
Centre	O
hospitalier	O
de	O
l	O
'	O
Université	O
de	O
Montréal	O

NA	O

Patients	O
undergoing	O
elective	B
abdominal	B
surgery	I
with	O
an	O
expected	B
blood	I
loss	I
of	O
=	B
500	I
ml	I

ASA	B
Physical	I
Status	I
II	B
-	I
III	I

Signed	O
written	O
informed	O
consent	O
form	O

Body	B
weight	I
=	B
140	I
kg	I

Sepsis	B

Burns	B

Renal	B
impairment	I
(	O
AKIN	B
stage	I
=	B
1	I
)	O
or	O
acute	B
and	O
/	O
or	O
chronic	B
renal	B
replacement	I
therapy	I

Intracranial	O
or	O
cerebral	B
haemorrhage	I

Critically	B
ill	I
patients	O
(	O
typically	O
admitted	B
to	O
the	O
intensive	O
care	O
unit	O
)	O

Hyperhydration	B

Pulmonary	B
oedema	I

Dehydration	B

Hyperkalaemia	B

Severe	B
hypernatraemia	B

Severe	B
hyperchloraemia	B

Severely	B
impaired	B
hepatic	I
function	I

Congestive	B
heart	I
failure	I

Severe	B
coagulopathy	B

Organ	B
transplant	I
patients	O

Metabolic	B
alkalosis	I

Simultaneous	O
participation	O
in	O
another	O
interventional	O
clinical	O
trial	O
(	O
drugs	O
or	O
medical	O
devices	O
studies	O
)	O

History	B
of	O
morphine	B
allergy	B

History	B
of	O
bupivacaine	B
allergy	B

Contraindication	B
for	O
ketamine	B
infusion	O

Contraindication	B
for	O
thoracic	B
paravertebral	B
block	I

Anticipated	O
postoperative	B
positive	B
pressure	I
ventilation	I

Body	B
mass	I
index	I
more	B
than	I
35	I

Any	O
known	O
psychiatric	B
disorder	I

American	B
Society	I
of	I
Anesthesiologist	I
physical	I
status	I
1	B
-	I
3	I

Scheduled	O
for	O
elective	B
video	B
-	I
assisted	I
thoracic	I
surgery	I

Able	O
to	O
operate	O
a	O
patient	B
-	I
controlled	I
analgesia	I
device	I
(	O
PCA	B
)	O

Bacterial	B
infection	I
origin	O
from	O
another	B
organ	I
(	O
e	O
.	O
g	O
.	O
pneumonia	B
)	O

Severe	B
sepsis	I
with	O
multiorgan	B
failure	I

Perinephritic	B
abscess	I

Pyonephrosis	B
requiring	O
drainage	B

Allergy	B
to	O
pivmecillinam	B

E	B
.	I
coli	I
isolate	I
resistant	O
to	O
pivmecillinam	B

Pregnancy	B
/	O
breastfeeding	O

Severe	B
neutropenia	B

Prostatitis	B

Severe	B
kidney	B
failure	I
(	O
eGFR	B
<	B
15	I
ml	I
/	I
min	I
)	O

Using	O
valproate	B

E	B
.	I
coli	I
in	O
blood	B
culture	I

AND	O
identical	B
isolate	I
in	O
urine	B
sample	I
(	O
>	B
=	I
1	I
.	I
000	I
CFU	B
)	O
OR	O
relevant	O
clinical	O
signs	O
of	O
UTI	B

can	O
'	O
t	O
understand	O
patient	O
controlled	O
analgesia	O
device	O
refuse	O
trial	O

elective	B
Laparoscopic	B
myomectomy	B
patients	O
24hr	B
post	I
-	I
operative	I
patient	B
controlled	I
analgesia	I
analgesia	O
no	B
mild	B
or	O
severe	B
liver	O
or	O
renal	B
disfunction	I

Body	B
mass	I
index	I
less	B
than	I
18	I
kg	I
/	I
m2	I
or	O
greater	B
than	I
30	I
kg	I
/	I
m2	I
.	O

History	B
of	O
previous	B
open	B
-	I
laparotomy	I
.	O

Surgery	B
with	O
major	B
complication	I
,	O
or	O
need	O
blood	B
transfusion	I
.	O

History	O
of	O
hypersensitivity	B
or	O
adverse	B
reaction	I
to	O
local	B
anesthetics	I
,	O
opioid	B
,	O
or	O
any	O
ingredient	B
of	I
the	I
medications	I
administered	I
in	I
this	I
study	I
.	O

Severe	B
comorbidity	B
.	O

Chronic	B
preoperative	B
opioid	B
consumption	O
.	O

Pregnant	B
or	O
breastfeeding	O
.	O

Inability	B
to	O
use	B
the	I
PCA	I
device	O
.	O

Male	B
or	O
female	B
who	O
is	O
among	O
20	B
to	I
80	I
years	I
of	O
age	B
at	B
screening	I
.	O

Scheduled	O
to	O
electively	O
undergo	O
open	B
-	I
laparotomy	I
.	O

American	B
Society	I
of	I
Anesthesiology	I
Physical	I
Class	I
1	B
-	I
3	I
.	O

Ability	O
and	O
willingness	O
to	O
provide	O
informed	O
consent	O

Patients	O
with	O
allergies	B
or	O
contraindications	B
to	O
study	B
medications	I

ASA	B
I	B
,	O
II	B
,	O
III	B
presenting	O
for	O
ambulatory	B
surgery	I
to	O
be	O
performed	O
under	O
general	B
anesthesia	I

Optune	O
compliance	O
<	B
75	I
%	I
;	O
they	O
would	O
be	O
excluded	O
from	O
the	O
final	O
analyses	O
.	O

History	O
of	O
craniectomy	B
or	O
significant	B
skull	B
defect	I
(	O
contraindication	B
to	O
Optune	B
)	O
.	O

Active	B
implantable	B
medical	I
device	I
(	O
i	O
.	O
e	O
.	O
DBS	B
,	O
spinal	B
cord	I
stimulator	I
,	O
pacemaker	B
,	O
defibrillator	B
,	O
vagus	B
nerve	I
stimulator	I
,	O
programmable	B
shunt	I
)	O
.	O

Karnofsky	B
Performance	I
Status	I
(	O
KPS	B
)	O
<	B
60	I
.	O

Newly	B
diagnosed	I
glioblastoma	B
(	O
GBM	B
)	O
,	O
WHO	B
grade	B
IV	I
.	O

using	O
daily	B
medication	B
for	O
chronic	B
condition	I

acute	B
narrow	B
angle	I
glaucoma	I

previous	B
adverse	B
experience	I
with	O
study	B
drugs	I

experiences	O
motion	B
sickness	I
in	O
response	O
to	O
driving	O
simulator	O

BMI	B
>	B
30	I

women	B
who	O
are	O
pregnant	B
,	O
lactating	B
,	O
or	O
planning	O
on	O
becoming	O
pregnant	B

regular	B
use	O
of	O
tobacco	O
products	O

current	B
substance	B
use	I
disorder	I

clinically	B
significant	I
ECG	B

current	B
ongoing	B
psychiatric	B
disorder	I

valid	O
driver	O
'	O
s	O
license	O

english	O
-	O
speaking	O
and	O
literate	O

Pregnancy	B

Hemodynamic	B
instability	I

Body	B
mass	I
index	I
greater	B
than	I
40	I
kg	I
/	I
m2	I

Use	O
of	O
intravenous	B
amiodarone	B
or	O
lidocaine	B
in	B
the	I
last	I
24	I
hours	I

Acute	B
coronary	I
syndrome	I

Presence	O
of	O
tachycardia	B
with	O
irregular	O
or	O
supraventricular	B
RR	I

Contraindications	B
to	O
study	B
drugs	I

Adult	B
men	B
and	O
women	B
>	O
18	O
years	O
old	B

Presence	O
of	O
sustained	B
ventricular	B
tachycardia	I
with	O
HR	B
>	B
120	I
bpm	I

Systolic	B
blood	I
pressure	I
>	B
90	I
mmHg	I

No	B
signs	O
of	O
poor	B
peripheral	I
perfusion	I

Absence	B
of	I
dyspnea	B

Absence	B
of	I
severe	B
angina	B

Signed	O
consent	O
form	O

Pregnant	B
.	O

Not	O
have	O
informed	O
consent	O
for	O
the	O
present	O
clinical	O
trial	O
,	O
or	O
do	O
not	O
fully	O
understand	O
the	O
meaning	O
of	O
informed	O
consent	O
.	O

With	O
acute	B
myocardial	I
infarction	I
with	O
ST	B
segment	I
elevation	I
in	B
the	I
first	I
12	I
hours	I
from	I
the	I
onset	I
of	I
symptoms	I
.	O

With	O
any	O
acute	B
coronary	I
syndrome	I
complicated	O
with	O
acute	B
pulmonary	I
edema	I
,	O
cardiogenic	B
shock	I
and	O
/	O
or	O
malignant	B
ventricular	B
arrhythmias	I
.	O

In	O
which	O
a	O
cardiac	B
catheterization	I
is	O
planned	O
a	O
priori	O
to	O
be	O
performed	O
via	O
femoral	B
,	O
brachial	B
or	O
ulnar	B
.	O

Patients	O
in	O
whom	O
first	O
attempt	O
of	O
arterial	O
puncture	O
is	O
performed	O
by	O
2nd	O
year	O
interventional	O
cardiology	O
fellow	O
or	O
by	O
physician	O
in	O
charge	O
.	O

Participating	O
in	O
another	O
clinical	O
trial	O
.	O

Be	O
allergic	B
or	O
have	O
contraindications	B
to	O
nitroglycerin	B
or	O
other	O
nitrates	B
.	O

Any	O
phosphodiesterase	B
5	I
inhibitor	I
(	O
sildenafil	B
,	O
tadalafil	B
,	O
avanafil	B
,	O
vardenafil	B
)	O
has	O
been	O
taken	O
within	B
72	I
hours	I
prior	I
to	I
the	I
study	I
.	O

Men	B
and	O
women	B
older	B
than	I
18	I
years	B
,	O
scheduled	O
consecutively	O
to	O
perform	O
a	O
coronary	B
procedure	I
in	O
the	O
department	O
of	O
hemodynamics	O
of	O
the	O
National	O
Institute	O
of	O
Cardiology	O
"	O
Ignacio	O
Chavez	O
"	O
.	O

Patients	O
may	O
have	O
any	O
of	O
the	O
following	O
indications	B
for	O
cardiac	B
catheterization	I
:	O
Thoracic	B
pain	I
under	O
study	O
.	O

Stable	B
chronic	B
coronary	I
disease	I
.	O

Acute	B
myocardial	I
infarction	I
with	O
ST	B
segment	I
elevation	I
,	O
not	O
perfused	O
(	O
without	B
timely	B
reperfusion	B
therapy	I
)	O
with	B
less	I
than	I
4	I
weeks	I
of	I
evolution	I
.	O

Acute	B
myocardial	I
infarction	I
with	O
ST	B
-	I
segment	I
elevation	I
,	O
successful	B
thrombolytic	B
therapy	I
,	O
which	O
will	O
undergo	O
drug	B
-	I
invasive	I
therapy	I
.	O

Acute	B
myocardial	I
infarction	I
without	B
ST	B
segment	I
elevation	I
.	O

Unstable	B
angina	I
.	O

Any	O
acute	B
coronary	I
syndrome	I
,	O
to	O
intervene	B
non	B
-	I
infarct	I
-	I
related	I
artery	B
.	O

Disease	B
of	O
any	O
heart	B
valve	I
.	O

Myocarditis	B
or	O
pericarditis	B
.	O

Dilated	B
cardiomyopathy	B
.	O

Patients	O
in	O
renal	O
or	O
cardiac	B
transplantation	I
protocol	O
for	O
any	O
etiology	O
.	O

Congenital	B
heart	I
disease	I
that	O
requires	O
knowing	B
the	I
coronary	I
anatomy	I
prior	B
to	I
surgical	I
correction	I
.	I

The	O
planned	O
procedure	B
can	O
be	O
any	O
of	O
the	O
following	O
:	O
For	O
diagnostic	B
purposes	O
(	O
coronary	B
angiography	I
only	B
,	O
left	B
catheterization	I
,	O
left	O
and	O
right	B
catheterization	I
)	O
.	O

For	O
therapeutic	B
purposes	O
:	O
percutaneous	B
coronary	I
intervention	I
(	O
PCI	B
)	O
,	O
with	O
or	O
without	O
stent	B
placement	I
.	O

A	O
priori	B
access	B
must	O
be	O
right	O
or	O
left	B
radial	I
artery	I
.	O

Radial	B
arterial	I
pulse	B
may	O
be	O
present	B
or	O
absent	B
by	O
palpation	B
.	O

Modified	O
Allen	O
or	O
Barbeau	B
test	I
should	O
be	O
positive	B
(	O
presence	B
of	O
collateral	B
palmar	I
flow	I
)	O
.	O

Abdominal	B
and	O
complex	B
cervical	B
cerclage	I
(	O
e	O
.	O
g	O
.	O
bulging	B
bag	I
)	O

Contraindication	B
to	O
neuraxial	B
anesthesia	I

Known	O
hypersensitivity	B
to	O
chloroprocaine	B
(	O
a	O
.	O
k	O
.	O
a	O
.	O
Ester	B
allergy	I
)	O
,	O
paraaminobenzoic	B
acid	I
(	O
PABA	B
)	O
or	O
bupivacaine	B
(	O
a	O
.	O
k	O
.	O
a	O
.	O
Amide	B
allergy	I
)	O

Pseudocholinesterase	B
deficiency	I

Concomitant	B
use	O
with	O
ergot	B
-	I
type	I
oxytocic	I
drugs	I

ASA	B
classification	I
II	B
or	I
III	I
females	B

Age	B
:	O
18	B
-	I
45	I
years	I
old	I

BMI	B
=	B
50	I
kg	I
/	I
m2	I

Singleton	B
pregnancy	I

Simple	B
prophylactic	B
cervical	B
cerclage	I

Planning	O
neuraxial	B
anesthesia	I

Allergy	B
or	O
hypersensitivity	B
to	O
bupivacaine	B

Pregnancy	B

Incarceration	B

Age	B
<	B
18	I
years	I

Indwelling	B
continuous	B
thoracic	B
epidural	I
analgesia	I

Patients	O
undergoing	O
SSRF	B
at	O
Denver	O
Health	O
Medical	O
Center	O

are	O
allergic	B
to	O
influenza	B
vaccination	I

have	O
received	O
influenza	B
vaccination	I
within	B
the	I
past	I
6	I
months	I

require	O
prednisone	B
,	O
methotrexate	B
,	O
or	O
other	B
immunosuppressing	B
medications	I

have	O
HIV	B
infection	I

have	O
a	O
history	B
of	O
solid	O
organ	O
or	O
bone	B
marrow	I
transplant	I

require	O
combination	B
immunotherapy	I

are	O
on	O
other	O
studies	O
requiring	O
blood	O
draws	O
that	O
might	O
exceed	O
450	O
mL	O
total	O
during	O
the	O
period	O
of	O
the	O
influenza	O
vaccine	O
study	O

adults	B
capable	O
of	O
providing	O
consent	O

have	O
a	O
diagnosis	O
of	O
locally	B
advanced	I
or	O
metastatic	B
melanoma	B

Pregnant	O
women	B
and	O
young	B
children	I
aged	B
<	B
18	I
years	I
;	O

Patients	O
with	O
underlying	B
disease	I
cases	O
without	B
the	I
possibility	I
of	I
resuscitation	I
(	O
e	O
.	O
g	O
.	O
,	O
terminal	B
cancer	I
)	O
;	O

Patients	O
with	O
do	O
-	O
not	O
-	O
resuscitate	O
(	O
DNR	O
)	O
status	O
;	O

Death	B
by	I
excessive	I
bleeding	I
(	O
e	O
.	O
g	O
.	O
,	O
abdominal	B
main	B
artery	I
rupture	I
)	O
;	O

Patients	O
who	O
have	O
experienced	O
in	B
-	I
hospital	I
CA	B
;	O

Patients	O
previously	B
treated	B
with	O
steroid	B
,	O
anti	B
-	I
cancer	I
medicine	I
,	O
or	O
immunosuppression	B
treatment	I
before	O
CA	B
;	O

Patients	O
already	O
been	O
registered	O
with	O
other	O
studies	O
;	O
or	O

Patients	O
from	O
whom	O
informed	O
consent	O
cannot	O
be	O
obtained	O

The	O
group	O
of	O
patients	O
who	O
participated	O
in	O
the	O
study	O
included	O
adults	B
aged	B
at	B
least	I
19	I
years	I
among	O
the	O
atraumatic	B
CA	I
outpatients	O
who	O
came	O
to	O
the	O
ER	O
and	O
received	O
CPR	B
.	O

Patients	O
with	O
known	O
or	O
suspected	O
heparin	B
induced	O
thrombocytopenia	B
prior	B
to	I
consent	I

Patients	O
with	O
hepatic	B
failure	I
defined	O
as	O
coagulopathy	B
with	O
elevated	O
transaminases	B
more	O
than	O
three	O
times	O
normal	O
values	O

Patients	O
with	O
plan	O
to	O
decannulate	B
from	I
ECMO	I
within	B
48	I
hours	I

Known	O
or	O
suspected	O
pregnant	B
women	B

Previous	O
enrollment	O
in	O
this	O
study	O

Primary	O
language	O
spoken	O
that	O
is	O
not	O
English	O
or	O
Spanish	O

Age	B
1	B
day	I
to	I
less	I
than	I
18	I
years	I

Cared	O
for	O
in	O
the	O
pediatric	O
intensive	O
care	O
unit	O
or	O
pediatric	O
cardiac	O
intensive	O
care	O
unit	O

receiving	O
venovenous	O
or	O
venoarterial	B
ECMO	I

Glaucoma	B
,	O

Ocular	B
allergy	I

Autoimmune	B
disease	I

Contact	O
lens	O
-	O
wear	O
during	B
study	I

Current	B
punctal	B
plugging	I

Pregnant	B
/	O
lactating	B

Candidate	O
for	O
topical	B
anti	I
-	I
inflammatory	I

Cicatricial	B
meibomian	B
gland	I
dysfunction	I

Meibomian	B
Gland	I
Dysfunction	I

Eligible	O
for	O
heat	B
treatment	I

Ocular	B
Surface	I
Disease	I
Index	I
(	O
OSDI	B
)	O
>	B
12	I

Quality	O
or	O
expressibility	B
score	I
=	O
20	O
years	O
old	O
:	O
>	O
1	O
or	O
>	O
20	O
years	O
old	O
:	O
=	O
1	O

Non	B
-	I
invasive	I
tear	I
film	I
break	I
-	I
up	I
time	I
(	I
NITBUT	I
)	I
<	B
10	I
s	I
in	O
at	B
least	I
one	I
eye	B

Schirmer	B
-	I
1	I
test	I
>	B
5	I
mm	I
after	B
5	I
min	I

Not	O
pregnant	B

Not	O
seeking	O
medication	B
abortion	I

Under	O
the	O
age	B
of	O
15	O

Contraindications	B
for	O
medication	B
abortion	I

Women	B
seeking	O
medication	B
abortion	I
through	B
70	I
days	I
gestation	I

Eligible	O
for	O
Mifeprex	B
(	I
r	I
)	I
at	O
a	O
study	O
clinical	O
site	O

English	O
or	O
Spanish	O
speaking	O

Willing	O
and	O
able	O
to	O
participate	O
in	O
the	O
study	O
,	O
including	O
willing	O
to	O
go	O
to	O
the	O
study	O
pharmacy	O
to	O
obtain	O
mifepristone	B

Patients	O
Level	B
III	I
or	I
greater	I
on	O
the	O
American	B
Society	I
of	I
Anesthesiologists	I
(	I
ASA	I
)	I
physical	I
status	I
classification	O
system	O
(	O
as	O
determined	O
by	O
the	O
anesthesiologist	O
)	O

Patients	O
with	O
chronic	B
conditions	I
that	O
would	O
limit	O
our	O
ability	O
to	O
develop	O
the	O
study	O
according	O
to	O
objectives	O
,	O
such	O
as	O
neurodevelopmental	B
conditions	I
preventing	B
patients	O
from	O
understanding	O
the	O
Oucher	O
tool	O

Hepatic	O
or	O
renal	B
disease	I

cardiac	B
disease	I

active	B
infection	B

diabetes	B
mellitus	I

sickle	B
cell	I
disease	I

known	O
coagulation	B
disorders	I

pre	B
-	I
operative	I
treatment	B
with	O
anti	B
-	I
emetics	I
,	O
steroids	B
,	O
or	O
analgesics	B

Acetaminophen	B
allergy	B
or	O
already	O
receiving	O
acetaminophen	B
within	B
24	I
h	I
of	I
surgery	I

Complicating	B
health	I
factors	I
precluding	B
the	O
use	O
of	O
opioids	B
or	O
acetaminophen	B

any	O
other	B
factors	I
which	O
would	O
interfere	B
with	O
pain	B
assessment	I
and	O
management	B

Patients	O
weighing	B
more	B
than	I
30	I
kg	I
that	O
would	O
exceed	O
maximum	O
dexamethasone	O
dose	O

Patients	O
who	O
live	O
without	O
a	O
home	O
telephone	O

patient	O
living	O
without	O
parental	O
supervision	O
.	O

Healthy	B
patients	O

aged	B
3	B
-	I
13	I
years	I

Level	B
I	I
or	I
level	I
II	I
on	O
the	O
American	B
Society	I
of	I
Anesthesiologists	I
(	I
ASA	I
)	I
physical	I
status	I
classification	O
system	O
(	O
as	O
determined	O
by	O
the	O
anesthesiologist	O
)	O

obstructive	B
sleep	I
apnea	I
or	O
recurrent	B
throat	B
infections	I

undergoing	O
elective	B
tonsillectomy	B
with	O
or	O
without	O
adenoidectomy	B

Parents	O
who	O
agree	O
to	O
complete	O
documentation	O
and	O
follow	O
up	O
at	O
14	O
days	O
post	O
-	O
operation	O
.	O

Ovarian	B
cancer	I
,	O
adrenal	B
gland	I
tumor	I
,	O
endometrial	B
cancer	I
,	O
cervical	B
cancer	I
,	O
breast	B
cancer	I

Congenital	B
adrenal	I
hyperplasia	I
(	O
17	B
-	I
OH	I
-	I
progesterone	I
>	B
2	I
.	I
5	I
ng	I
/	I
mL	I
)	O

Clinically	B
diagnosed	I
Cushing	B
'	I
s	I
disease	I
,	O
acromegaly	B
,	O
gigantism	B

Type	B
I	I
or	I
II	I
diabetes	I

Unexplained	B
bleeding	I
from	O
the	O
genital	B
tract	I

Hormone	B
treatment	O
within	B
the	I
last	I
2	I
months	I

Written	O
consent	O
for	O
participation	O
in	O
the	O
clinical	O
trial	O

Age	B
18	B
to	I
45	I
years	I
Irregular	B
menstruation	I
(	O
>	B
35	I
days	I
)	O
or	O
secondary	B
amenorrhea	I
>	B
3	I
months	I

Diagnosis	O
of	O
a	O
psychotic	B
disorder	I
.	O

History	B
of	O
,	O
or	O
current	B
,	O
open	B
head	I
brain	I
trauma	I
.	O

Candidates	O
with	O
any	O
metal	B
,	O
shrapnel	B
or	O
other	O
similar	O
objects	B
in	I
the	I
head	I
that	O
could	O
affect	B
the	O
QEEG	B

History	B
of	O
:	O
craniotomy	B
,	O
cerebral	B
metastases	I
,	O
cerebrovascular	B
accident	I
;	O
current	O
diagnosis	O
of	O
seizure	B
disorder	I
,	O
schizophrenia	B
,	O
schizo	B
-	I
affective	I
disorder	I
,	O
dementia	B
,	O
mental	B
retardation	I
,	O
or	O
major	B
depression	I
with	O
psychotic	B
features	I
;	O
or	O
use	O
of	O
depot	B
neuroleptics	I
in	B
last	I
12	I
months	I
.	O

Uncontrolled	B
thyroid	B
disorders	I
.	O

Known	O
pregnancy	O
and	O
/	O
or	O
lactation	O
,	O
or	O
intent	O
to	O
become	O
pregnant	O
during	O
this	O
study	O
.	O

Chronic	B
or	O
acute	B
pain	B
requiring	O
prescription	B
pain	I
medication	I
(	O
s	O
)	O
(	O
narcotic	B
or	O
synthetic	B
narcotic	I
)	O

Participation	O
in	O
any	O
other	O
therapeutic	O
drug	O
study	O
within	O
60	O
days	O
preceding	O
inclusion	O
.	O

Patients	O
with	O
a	O
clinical	O
diagnosis	O
of	O
depression	B
who	O
in	O
the	O
judgement	O
of	O
their	O
physician	O
require	O
medication	B
management	O
may	O
be	O
eligible	O
for	O
enrollment	O
.	O

A	O
score	B
of	I
10	I
or	I
more	I
on	O
the	O
PHQ	B
-	I
9	I
instrument	O
will	O
be	O
required	O
for	O
enrollment	O
.	O

Some	O
practices	O
utilize	O
the	O
PHQ	O
-	O
2	O
and	O
PHQ	O
-	O
9	O
are	O
part	O
of	O
routine	O
screening	O
for	O
depression	O
.	O
If	O
the	O
tests	O
are	O
performed	O
routinely	O
,	O
they	O
do	O
not	O
need	O
to	O
be	O
repeated	O
for	O
study	O
eligibility	O
,	O
and	O
may	O
be	O
performed	O
prior	O
to	O
informed	O
consent	O
for	O
this	O
study	O
.	O
If	O
,	O
however	O
,	O
the	O
PHQ	O
-	O
9	O
is	O
not	O
routinely	O
performed	O
,	O
informed	O
consent	O
must	O
be	O
performed	O
prior	O
to	O
administration	O
.	O
Patients	O
with	O
a	O
score	O
below	O
10	O
will	O
be	O
considered	O
screen	O
failures	O
and	O
will	O
not	O
be	O
enrolled	O
or	O
offered	O
the	O
MYnd	O
testing	O
.	O

Patients	O
with	O
non	B
-	I
psychotic	I
comorbid	I
conditions	I
may	O
be	O
included	O
.	O

Patients	O
must	O
be	O
either	O
medication	B
treatment	O
naïve	B
for	O
behavioral	B
illnesses	I
or	O
have	O
no	B
active	B
medication	B
treatments	O
for	B
at	I
least	I
1	I
month	I
prior	I
to	I
enrollment	I
.	O
Prohibited	O
medications	O
at	O
the	O
time	O
of	O
enrollment	O
will	O
include	O
stimulants	B
,	O
benzodiazepines	B
and	O
THC	B
.	O
Prior	O
therapy	O
with	O
these	O
agents	O
is	O
permitted	O
with	O
a	O
washout	O
of	O
>	O
30	O
days	O
.	O

Patients	O
must	O
have	O
private	O
medical	O
insurance	O
coverage	O
through	O
Horizon	O
Blue	O
Cross	O
Blue	O
Shield	O
.	O
This	O
is	O
limited	O
to	O
insured	O
commercial	O
members	O
,	O
including	O
HMO	O
,	O
and	O
excluding	O
,	O
for	O
the	O
avoidance	O
of	O
doubt	O
,	O
members	O
of	O
self	O
-	O
insured	O
customers	O
or	O
Medicare	O
or	O
Medicaid	O
programs	O
.	O

Exclusion	O
criteria	O
are	O
pregnancy	B
,	O
patients	O
with	O
contraindications	B
to	O
regional	B
anesthesia	I
,	O
allergy	B
to	O
LAs	B
,	O
patients	O
taking	O
opioids	B
regularly	B
due	O
to	O
chronic	B
pain	I
,	O
use	O
of	O
anticoagulation	B
drugs	I
other	B
than	I
acetylsalicylic	B
acid	I
or	O
dipyridamole	B
,	O
atrioventricular	B
block	I
,	O
diabetes	B
.	O

.	O
Inclusion	O
criteria	O
are	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	B
)	O
physical	O
status	O
I	B
-	I
III	I
,	O
age	B
between	B
18	I
and	I
70	I
years	I
and	O
body	B
mass	I
index	I
(	O
BMI	B
)	O
between	B
20	I
and	I
35	I
kg	I
/	I
m2	I
.	O

Participants	O
taking	O
CPI	B
combination	I
therapies	I
with	O
chemotherapy	B
are	O
not	O
permitted	O
.	O

Pregnant	B
,	O
lactating	B
,	O
or	O
intending	O
to	O
become	O
pregnant	B
during	B
the	I
study	I
.	O

Response	B
assessment	I
of	O
complete	B
response	I
(	I
CR	I
)	I
,	O
partial	B
response	I
(	I
PR	I
)	I
,	O
long	B
stable	I
disease	I
(	I
SD	I
)	I
for	B
>	I
3	I
months	I
with	O
a	O
cancer	B
immunotherapy	B
treatment	I
for	O
metastatic	B
cancer	I
or	O
hematologic	B
malignancies	I
either	O
through	O
a	O
marketed	B
CPI	I
or	O
through	O
participation	O
in	O
a	O
Roche	O
/	O
Genentech	O
CPI	O
clinical	O
trial	O
.	O

Availability	O
of	O
tumor	O
biopsy	O
material	O
extracted	O
and	O
preserved	O
by	O
the	O
investigating	O
site	O
.	O

use	O
illicit	B
drugs	I
or	O
relapse	B
during	O
the	O
last	B
trimester	I
of	O
pregnancy	B

positive	B
drug	B
screen	I
at	O
the	O
time	O
of	O
delivery	B

allergies	B
to	O
any	O
medications	B
used	I
in	I
the	I
study	I

taking	O
prescribed	B
gabapentin	B
at	O
the	O
time	O
of	O
admission	B
for	O
CD	B

contraindications	B
to	O
neuraxial	B
anesthesia	I
or	O
require	O
general	B
anesthesia	I
for	O
CD	B

designated	O
ASA	B
physical	I
status	I
4	B
or	I
above	I

singleton	B
,	O
term	B
pregnancy	B

currently	B
on	O
buprenorphine	B
maintenance	O
therapy	O

scheduled	O
for	O
elective	B
CD	B
under	O
spinal	B
anesthesia	I

history	B
of	O
hypertension	B

known	O
impaired	B
renal	I
function	I

liver	B
disease	I

heart	B
failure	I

myocardial	B
infarction	I

coronary	B
artery	I
disease	I

smoked	O
within	B
the	I
past	I
year	I

apnea	B
hypopnea	I
index	I
>	B
5	I
events	I
per	I
hour	I

normotensive	B

forced	B
expiratory	I
volume	I
in	I
1s	I
:	I
forced	I
vital	I
capacity	I
ratio	I
>	B
0	I
.	I
75	I

no	B
medical	B
history	I
of	O
cardiovascular	O
and	O
respiratory	B
disease	I

not	B
taking	O
medications	B
other	B
than	I
oral	B
contraceptives	I

free	B
from	I
sleep	B
apnea	I

body	B
mass	I
index	I
less	B
than	I
30	I
kg	I
/	I
m2	I

American	B
Association	I
of	I
Anesthesiology	I
class	I
1	B
-	I
3	I

American	B
Heart	I
Association	I
class	I
>	B
3	I

BMI	B
>	B
37	I

Insulin	B
treated	O
diabetes	B

Pregnancy	B
or	O
breast	O
feeding	O

Sensistivity	B
/	O
allergy	B
against	O
anesthetic	B
agents	I

Inadequate	O
understanding	O
about	O
the	O
study	O

Depressed	B
kidney	B
function	I
and	O
/	O
or	O
AKI	B

Depressed	B
liver	B
function	I

Genetic	B
malignant	B
hyperthermia	I

Scheduled	O
back	B
surgery	I

Acute	B
pain	B
(	O
less	B
than	I
3	I
months	I
in	O
duration	B
)	O

Previous	O
serious	B
adverse	B
event	I
or	O
hypersensitivity	B
to	O
cannabis	B
or	O
cannabinoids	B

Inability	O
to	O
understand	O
and	O
comply	O
with	O
the	O
instructions	O
of	O
the	O
study	O

Presence	O
of	O
significant	B
cardiac	B
disease	I
(	O
history	B
of	O
unstable	B
ischemic	I
heart	I
disease	I
,	O
heart	B
failure	I
,	O
severe	B
and	O
uncontrolled	B
hypertension	B
)	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
put	O
the	O
patient	O
at	O
risk	O
of	O
a	O
clinically	B
significant	I
arrhythmia	B
or	O
myocardial	B
infarction	I

Current	O
substance	B
use	I
disorder	I
according	O
to	O
the	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
Fifth	I
Edition	I
(	I
DSM	I
5	I
)	I

Life	O
-	O
time	O
history	O
of	O
dependence	B
on	I
cannabis	I
or	O
diagnosis	O
of	O
cannabis	B
use	I
disorder	I
(	I
CUD	I
)	I
according	O
to	O
the	O
DSM	B
5	I

Life	O
-	O
time	O
history	O
of	O
DSM	B
5	I
schizophrenia	B
,	O
bipolar	B
disorder	I
,	O
or	O
previous	O
psychosis	B
with	O
or	O
intolerance	B
to	O
cannabinoids	B

Current	B
or	O
history	B
of	O
suicidal	B
ideation	I

Pregnant	O
,	O
breast	O
-	O
feeding	O
or	O
female	O
patients	O
of	O
child	O
-	O
bearing	O
potential	O
and	O
male	O
patients	O
whose	O
partner	O
is	O
of	O
child	O
-	O
bearing	O
potential	O
,	O
unless	O
willing	O
to	O
ensure	O
that	O
they	O
or	O
their	O
partner	O
use	O
effective	O
contraception	O

Hepatic	B
impairment	I
(	O
aspartate	B
aminotransferase	I
more	B
than	I
three	I
times	I
normal	I
)	O
or	O
renal	B
function	I
impairment	I
(	O
serum	B
creatinine	I
level	I
>	B
133	I
µmol	I
/	I
L	I
,	O
Estimated	B
Glomerular	I
Filtration	I
Rate	I
(	I
eGFR	I
)	I
<	B
60	I
)	O

Cognitive	B
impairment	I
according	O
to	O
MiniCog	B

The	O
patient	O
is	O
currently	O
using	O
or	O
has	O
used	O
cannabinoid	B
based	I
medications	I
within	B
90	I
days	I
of	I
study	I
entry	I
and	O
is	O
unwilling	O
to	O
abstain	O
for	O
the	O
duration	O
of	O
the	O
study	O

Positive	B
urine	B
drug	I
screen	I
for	O
cannabinoids	B
and	O
other	O
potential	O
abuse	O
substances	O
(	O
e	O
.	O
g	O
.	O
alcohol	B
,	O
cocaine	B
,	O
amphetamines	B
and	O
methamphetamines	B
,	O
unprescribed	B
opioids	B
)	O

Participation	O
in	O
another	O
clinical	O
trial	O
within	O
30	O
days	O
of	O
enrolment	O
in	O
our	O
trial	O

Written	O
informed	O
consent	O

Adult	B
patients	O
(	O
older	B
than	I
18	I
years	I
of	O
age	B
)	O
,	O
male	B
and	O
female	B
,	O
with	O
chronic	B
non	B
-	I
cancer	I
and	O
cancer	B
pain	B
(	O
at	B
least	I
3	I
months	I
in	I
duration	I
)	O

Patients	O
experiencing	O
an	O
average	O
weekly	O
pain	O
intensity	O
score	O
greater	B
than	I
4	I
on	O
a	O
11	O
points	O
NRS	O

Subject	O
agreed	O
to	O
follow	O
the	O
protocol	O

Naïve	B
cannabis	I
patients	O
with	O
chronic	B
non	B
-	I
cancer	I
and	O
cancer	B
pain	B
(	O
not	B
used	O
cannabis	B
in	O
any	O
presentation	O
in	B
the	I
last	I
12	I
weeks	I
)	O

Patients	O
receiving	O
opioids	B
and	O
other	B
concomitant	O
pain	B
medications	I
should	O
have	O
a	O
stable	B
dose	I
for	B
the	I
last	I
15	I
days	I
.	O

Normal	B
cognitive	I
status	I
according	O
to	O
MiniCog	B

Normal	B
liver	I
function	I
(	O
defined	O
as	O
aspartate	B
aminotransferase	I
10	B
-	I
40	I
U	I
/	I
L	I
and	O
alanine	B
aminotransferase	I
7	B
-	I
56	I
U	I
/	I
L	I
)	O

Normal	B
renal	I
function	I
(	O
defined	O
as	O
serum	B
creatinine	I
level	I
<	B
133	I
µmol	I
/	I
L	I
and	O
Estimated	B
Glomerular	I
Filtration	I
Rate	I
(	I
eGFR	I
)	I
greater	B
than	I
or	I
equal	I
to	I
60	I
)	O

Negative	B
result	O
on	O
ßhuman	B
chorionic	I
gonadotropin	I
pregnancy	I
test	I
(	O
if	O
applicable	O
)	O

Ability	O
to	O
read	O
and	O
respond	O
to	O
questions	O
in	O
French	O
or	O
English	O
.	O

A	O
male	O
volunteer	O
with	O
sexual	O
partners	O
who	O
are	O
pregnant	O
,	O
possibly	O
pregnant	O
,	O
or	O
who	O
could	O
become	O
pregnant	O
must	O
be	O
surgically	O
sterile	O
or	O
agrees	O
to	O
use	O
one	O
of	O
the	O
accepted	O
contraceptive	O
regimens	O
from	O
first	O
drug	O
administration	O
until	O
3	O
months	O
after	O
the	O
last	O
drug	O
administration	O
.	O

allergic	B
to	O
dexmedetomidine	B
,	O
similar	B
active	I
ingredients	I
or	O
excipients	B

G	B
-	I
6	I
-	I
PD	I
deficiency	I

a	O
history	B
of	O
arrhythmia	B
,	O
bronchial	O
and	O
cardiovascular	B
diseases	I
,	O
abnormal	B
liver	I
function	I
and	O
so	O
on	O

a	O
history	B
of	O
use	O
of	O
alpha	B
2	I
receptor	I
agonists	I
or	O
antagonists	O
.	O

selective	O
operation	O
of	O
inguinal	B
hernia	I
repair	I
<	O
U	O
+	O
3001	O
>	O
orthopedics	B
operation	I
or	O
general	B
surgery	I
operation	I
in	O
children	B

aged	B
3	B
-	I
9	I
years	I

ASA	B
I	B
-	I
II	I

enter	O
the	O
operating	O
room	O
by	O
himself	O
without	O
parents	O

normal	B
liver	I
and	I
kidney	I
function	I

no	B
history	B
of	O
anesthesia	B
medication	I
allergy	B
.	O

Clinically	B
significant	I
new	B
illness	B
within	B
1	I
month	I
before	I
randomization	I
that	O
may	O
affect	O
the	O
participant	O
'	O
s	O
ability	O
to	O
fulfill	O
the	O
study	O
requirements	O
or	O
significantly	O
confound	O
the	O
assessments	O

Participants	O
who	O
cannot	O
swallow	O
investigational	B
products	I

Participants	O
with	O
T2DM	B
who	O
have	O
hypoglycemia	B
unawareness	I

Aortic	B
regurgitation	I
mild	B
or	I
greater	I

Mitral	B
regurgitation	I
moderate	B
or	I
greater	I

Mitral	O
or	O
aortic	B
valve	I
stenosis	I
greater	B
than	I
mild	I
(	O
ie	O
,	O
aortic	B
stenosis	I
:	O
jet	B
>	B
3	I
.	I
0	I
meters	I
per	I
second	I
[	I
m	I
/	I
s	I
]	I
,	O
mean	B
gradient	I
>	B
25	I
millimeters	I
of	I
mercury	I
[	I
mmHg	I
]	I
,	O
and	O
aortic	B
valve	I
area	I
<	B
1	I
.	I
5	I
centimeters	I
squared	I
[	I
cm	I
^	I
2	I
]	I
;	O
mitral	B
stenosis	I
:	O
mean	B
gradient	I
>	B
5	I
mmHg	I
and	O
mitral	B
valve	I
area	I
<	B
1	I
.	I
5	I
cm	I
^	I
2	I
)	O

Systolic	B
pulmonary	I
artery	I
pressure	I
(	I
SPAP	I
)	I
>	B
40	I
mmHg	I
(	O
and	O
/	O
or	O
tricuspid	B
regurgitation	I
[	I
TR	I
]	I
jet	I
velocity	I
>	B
2	I
.	I
9	I
m	I
/	I
s	I
)	O
In	O
cases	O
where	O
an	O
actual	O
SPAP	O
value	O
is	O
not	O
measurable	O
due	O
to	O
lack	O
of	O
adequate	O
TR	O
jet	O
,	O
the	O
pulmonary	O
flow	O
acceleration	O
time	O
measured	O
at	O
the	O
right	O
ventricular	O
outflow	O
tract	O
(	O
RVOTAT	O
)	O
will	O
be	O
used	O
to	O
assess	O
eligibility	O
.	O

Participants	O
with	O
a	O
RVOTAT	B
=	B
100	I
milliseconds	I
(	I
msec	I
)	I
will	O
be	O
excluded	O
,	O
suggesting	O
an	O
elevated	O
mean	O
SPAP	O
;	O
eligibility	O
for	O
the	O
those	O
participants	O
with	O
RVOTAT	O
between	O
100	O
and	O
120	O
msec	O
will	O
be	O
determined	O
based	O
on	O
combined	O
assessment	O
of	O
the	O
TR	O
jet	O
,	O
septal	O
motion	O
,	O
and	O
right	O
ventricular	O
size	O
.	O

Left	B
ventricular	I
ejection	I
fraction	I
<	B
45	I
%	I

Intracardiac	B
mass	I
,	O
tumor	B
,	O
or	O
thrombus	B

Evidence	O
of	O
congenital	B
heart	I
disease	I

Clinically	B
significant	I
pericardial	B
effusion	I
(	O
eg	O
,	O
moderate	B
or	I
larger	I
or	O
with	O
hemodynamic	B
compromise	I
)	O

Significant	B
renal	O
or	O
hepatic	B
disease	I
as	O
evidenced	O
by	O
a	O
serum	B
creatinine	I
greater	B
than	I
1	I
.	I
5	I
×	I
upper	I
limit	I
of	I
normal	I
(	I
ULN	I
)	I
,	O
serum	B
transaminases	I
greater	B
than	I
3	I
×	I
ULN	I
,	O
or	O
total	B
bilirubin	I
greater	B
than	I
1	I
.	I
5	I
×	I
ULN	I
in	O
absence	B
of	I
Gilbert	B
'	I
s	I
syndrome	I

Any	O
suicidal	B
ideation	I
with	B
intent	I
with	O
or	O
without	B
a	I
plan	I
,	O
at	O
the	O
time	O
of	O
or	O
within	B
6	I
months	I
of	I
Screening	I
,	O
as	O
indicated	O
by	O
answering	O
"	O
Yes	B
"	O
to	O
questions	B
4	I
or	O
5	O
on	O
the	O
Suicidal	B
Ideation	I
section	I
of	I
the	I
Columbia	I
-	I
Suicide	I
Severity	I
Rating	I
Scale	I
(	I
C	I
-	I
SSRS	I
)	I

Any	O
suicidal	B
behavior	I
in	B
the	I
past	I
based	O
on	O
the	O
C	B
-	I
SSRS	I

Any	O
history	B
of	O
anorexia	B
or	O
bulimia	B
within	B
2	I
years	I
before	I
Screening	I
,	O
Attention	B
Deficit	I
Hyperactivity	I
Disorder	I
,	O
any	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
5th	I
Edition	I
depressive	B
disorder	I
,	O
bipolar	B
disorder	I
,	O
or	O
schizophrenia	B

Known	O
secondary	O
causes	O
(	O
genetic	B
,	O
endocrine	B
,	O
or	O
metabolic	B
)	O
for	O
obesity	O
(	O
eg	O
,	O
Prader	B
-	I
Willi	I
syndrome	I
,	O
Bardet	B
Biedl	I
syndrome	I
,	O
Down	B
'	I
s	I
Syndrome	I
,	O
untreated	B
hypothyroidism	I
,	O
Cushing	B
'	I
s	I
syndrome	I
,	O
daily	B
systemic	B
corticosteroid	I
exposure	O
for	B
longer	I
than	I
30	I
days	I
,	O
history	B
of	O
significant	B
exposure	I
to	O
corticosteroids	B
for	O
chronic	B
illness	I
during	B
the	I
past	I
year	I
;	O
inhaled	O
steroids	O
will	O
be	O
allowed	O
)	O

Use	O
of	O
other	O
products	B
intended	I
for	I
weight	I
loss	I
including	O
prescription	B
drugs	O
,	O
over	B
-	I
the	I
-	I
counter	I
(	I
OTC	I
)	I
drugs	O
,	O
and	O
herbal	B
preparations	O
within	B
1	I
month	I
before	I
Screening	I

selective	B
serotonin	I
reuptake	I
inhibitors	I

serotonin	B
norepinephrine	I
reuptake	I
inhibitors	I

tricyclic	B
antidepressants	I

bupropion	B

triptans	B

St	B
.	I
John	I
'	I
s	I
Wort	I

tryptophan	B

linezolid	B

dextromethorphan	B
in	O
any	B
form	I
(	O
eg	O
,	O
OTC	O
cold	O
medicines	O
)	O

lithium	B

tramadol	B

antipsychotics	B
or	O
other	O
dopamine	B
antagonists	I

antiseizure	B
medications	I
including	O
valproic	B
acid	I
,	O
zonisamide	B
,	O
topiramate	B
,	O
and	O
lamotrigine	B

oral	B
steroids	I
(	O
topical	O
and	O
inhaled	B
steroids	I
are	O
acceptable	B
)	O

stimulant	B
medications	I
(	O
eg	O
,	O
Ritalin	B
,	O
Concerta	B
,	O
Biphetamine	B
,	O
and	O
Dexedrine	B
)	O

benzodiazepines	B

Use	O
of	O
drugs	B
known	O
to	O
increase	O
the	O
risk	O
for	O
cardiac	B
valvulopathy	I
within	B
6	I
months	I
before	I
Screening	I
,	O
including	O
but	O
not	O
limited	O
to	O
pergolide	B
,	O
ergotamine	B
,	O
methysergide	B
,	O
and	O
cabergoline	B

History	B
or	O
evidence	O
of	O
clinically	B
significant	I
disease	B
(	O
eg	O
,	O
malignancy	B
;	O
cardiac	B
,	O
respiratory	B
,	O
gastrointestinal	B
,	O
renal	B
,	O
or	O
psychiatric	B
disease	B
)	O
other	B
than	I
prediabetes	B
(	O
impaired	B
fasting	B
glucose	I
or	O
impaired	B
glucose	I
tolerance	I
)	O
,	O
type	B
2	I
diabetes	I
treated	O
with	O
oral	B
anti	I
-	I
diabetic	I
agents	I
(	O
excluding	B
sulfonylurea	B
)	O
or	O
non	B
-	I
insulin	I
injectable	B
antidiabetic	B
agents	I
,	O
obstructive	B
sleep	I
apnea	I
,	O
dyslipidemia	B
,	O
and	O
nonalcoholic	B
fatty	I
liver	I
disease	I

Use	O
of	O
Belviq	B
XR	I
within	B
6	I
months	I
before	I
Screening	I
or	O
hypersensitivity	B
to	O
Belviq	B
XR	I
or	B
any	I
of	I
the	I
excipients	I

Significant	B
change	O
in	O
diet	O
or	O
level	O
of	O
physical	O
activity	O
within	B
1	I
month	I
before	I
dosing	I
or	O
change	O
in	O
weight	O
of	O
more	B
than	I
5	I
kg	I
within	B
3	I
months	I
before	I
Screening	I

Any	O
use	O
of	O
a	O
very	O
-	O
low	O
-	O
calorie	O
(	O
<	B
1000	I
calories	I
/	I
day	I
)	O
weight	O
loss	O
diet	O
within	B
6	I
months	I
before	I
Screening	I

History	B
of	O
alcohol	O
or	O
drug	B
dependence	I
or	O
abuse	O

Recreational	O
drug	O
use	O
within	B
2	I
years	I
before	I
Screening	I

Known	O
to	O
be	O
human	B
immunodeficiency	I
virus	I
positive	B

Known	O
to	O
have	O
active	B
viral	B
hepatitis	I
(	O
B	B
or	O
C	B
)	O

Malignancy	B
within	B
5	I
years	I
before	I
Screening	I

Unable	O
to	O
attend	O
scheduled	O
visits	O
(	O
eg	O
,	O
lack	O
of	O
transportation	O
)	O
or	O
lack	O
of	O
a	O
caregiver	O
or	O
guardian	O
to	O
supervise	O
study	O
participation	O

Special	O
needs	O
participants	O
who	O
are	O
unable	O
to	O
comprehend	O
study	B
-	I
related	I
instructions	O
(	O
eg	O
,	O
mild	B
to	I
profound	I
mental	B
retardation	I
[	O
intelligence	B
quotient	I
<	B
70	I
]	O
,	O
moderate	B
to	I
severe	I
cognitive	B
developmental	I
delay	I
,	O
pervasive	B
development	I
disorders	I
,	O
autism	B
)	O

Ongoing	B
epilepsy	B
or	O
other	B
seizure	B
disorder	I
,	O
or	O
use	O
of	O
medications	B
for	O
a	O
seizure	B
disorder	I
within	B
6	I
months	I
of	I
screening	I
or	O
any	B
time	I
between	I
screening	I
and	I
randomization	I

Participants	O
with	O
a	O
blood	B
pressure	I
in	O
the	O
95th	B
percentile	I
or	I
greater	I
for	B
age	I
,	O
sex	O
,	O
and	O
height	O
on	O
2	B
separate	I
readings	I
recorded	O
on	O
2	B
separate	I
days	I
.	O

Those	O
participants	O
who	O
had	O
uncontrolled	O
hypertension	O
at	O
Screening	O
can	O
be	O
rescreened	O
more	O
than	O
1	O
month	O
after	O
initiation	O
or	O
adjustment	O
of	O
antihypertensive	O
therapy	O
1	O
time	O
.	O

Currently	B
enrolled	O
in	O
another	B
clinical	O
study	O
or	O
has	O
used	O
any	O
investigational	B
drug	I
or	O
device	B
within	B
30	I
days	I
before	I
providing	I
informed	I
consent	I

Planned	O
bariatric	B
surgery	I
during	B
the	I
study	I
or	O
prior	B
bariatric	B
surgical	I
procedures	I

Not	O
suitable	O
to	O
participate	O
in	O
the	O
study	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
including	O
consideration	O
of	O
any	O
existing	O
physical	O
,	O
medical	O
,	O
or	O
mental	O
condition	O
that	O
prevents	O
compliance	O
with	O
the	O
protocol	O

Female	B
participants	O
who	O
are	O
breastfeeding	O
or	O
pregnant	B
at	B
Screening	I
or	O
Baseline	O
(	O
as	O
documented	O
by	O
a	O
positive	B
beta	B
-	I
human	I
chorionic	I
gonadotropin	I
test	I
)	O
.	O

A	O
separate	B
Baseline	B
assessment	I
is	O
required	O
if	O
a	O
negative	B
screening	B
pregnancy	I
test	I
was	O
obtained	O
more	B
than	I
72	I
hours	I
before	I
the	I
first	I
dose	I
of	I
study	I
drug	I
.	O

Had	O
unprotected	B
sexual	I
intercourse	I
within	B
30	I
days	I
before	I
study	I
entry	I
and	O
who	O
do	O
not	O
agree	O
to	O
use	O
a	O
highly	B
effective	I
method	O
of	O
contraception	O
(	O
eg	O
,	O
total	B
abstinence	B
,	O
an	O
intrauterine	B
device	I
,	O
a	O
double	O
-	O
barrier	O
method	O
[	O
such	O
as	O
condom	B
plus	O
diaphragm	B
with	I
spermicide	I
]	O
,	O
a	O
contraceptive	B
implant	I
,	O
an	O
oral	B
contraceptive	I
,	O
or	O
have	O
a	O
vasectomized	B
partner	B
with	O
confirmed	O
azoospermia	B
)	O
throughout	B
the	I
entire	I
study	I
period	I
and	O
for	O
28	O
days	O
after	O
study	B
drug	I
discontinuation	O

Are	O
currently	B
abstinent	B
and	O
do	O
not	O
agree	O
to	O
use	O
a	O
double	O
-	O
barrier	O
method	O
(	O
as	O
described	O
above	O
)	O
or	O
refrain	B
from	O
sexual	O
activity	O
during	B
the	I
study	I
period	I
and	O
for	O
28	O
days	O
after	O
study	B
drug	I
discontinuation	O

Are	O
using	O
hormonal	B
contraceptives	I
,	O
but	O
are	O
not	B
on	O
a	O
stable	B
dose	I
of	O
the	B
same	I
hormonal	B
contraceptive	I
product	O
for	B
at	I
least	I
4	I
weeks	I
before	I
dosing	I
and	O
who	O
do	O
not	O
agree	O
to	O
use	O
the	B
same	I
contraceptive	B
during	B
the	I
study	I
and	O
for	B
28	I
days	I
after	I
study	I
drug	I
discontinuation	I
(	O
Note	O
:	O
All	O
female	O
participants	O
will	O
be	O
considered	O
to	O
be	O
of	O
childbearing	O
potential	O
unless	O
they	O
have	O
been	O
sterilized	O
surgically	O
[	O
ie	O
,	O
bilateral	O
tubal	O
ligation	O
,	O
total	O
hysterectomy	O
,	O
or	O
bilateral	O
oophorectomy	O
,	O
all	O
with	O
surgery	O
at	O
least	O
1	O
month	O
before	O
dosing	O
]	O
)	O
.	O

Healthy	B
male	B
or	O
female	B
adolescents	B
,	O
age	B
12	B
to	I
17	I
years	I
(	O
inclusive	O
)	O
at	B
Screening	I
,	O
with	O
a	O
body	B
mass	I
index	I
(	I
BMI	I
)	I
that	O
is	O
greater	B
than	I
or	I
equal	I
to	I
the	I
United	I
States	I
-	I
weighted	I
mean	I
of	I
the	I
95th	I
percentile	I
based	B
on	I
age	I
and	O
sex	O
with	O
a	O
body	B
weight	I
greater	B
than	I
60	I
kilograms	I
(	I
kg	I
)	I
.	O

Participants	O
with	O
Type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
may	O
have	O
a	O
pre	O
-	O
existing	O
or	O
new	O
diagnosis	O
of	O
T2DM	O
.	O

HbA1c	B
=	B
6	I
.	I
5	I
%	I

fasting	B
plasma	I
glucose	I
(	I
FPG	I
)	I
=	B
126	I
mg	I
/	I
dL	I
(	O
7	B
.	I
0	I
mmol	I
/	I
L	I
)	O

Participants	O
and	O
their	O
families	O
not	B
planning	O
to	O
move	O
away	O
from	O
the	O
area	O
for	B
the	I
duration	I
of	I
the	I
study	I

Participants	O
able	O
and	O
willing	O
to	O
comply	O
with	O
all	O
aspects	O
of	O
the	O
study	O
,	O
including	O
a	O
standardized	B
,	O
reduced	O
calorie	O
diet	O
and	O
an	O
age	B
appropriate	I
,	O
increased	O
physical	O
activity	O
program	O

Participants	O
considered	O
in	O
stable	O
health	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O

Able	O
and	O
willing	O
to	O
support	O
and	O
supervise	O
study	O
participation	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
including	O
consideration	O
of	O
any	O
existing	O
physical	O
,	O
medical	O
,	O
or	O
mental	O
condition	O
that	O
prevents	O
compliance	O
with	O
the	O
protocol	O

Able	O
and	O
willing	O
to	O
personally	O
comply	O
with	O
and	O
execute	O
all	O
aspects	O
of	O
the	O
study	O
requirements	O
for	O
the	O
caregivers	B
or	O
guardians	B

Involvement	O
in	O
the	O
planning	O
and	O
conduct	O
of	O
the	O
study	O
(	O
applies	O
to	O
both	O
AstraZeneca	O
staff	O
and	O
staff	O
at	O
third	O
party	O
vendor	O
or	O
at	O
the	O
investigational	O
sites	O
)	O
.	O

Previous	O
enrolment	O
in	O
the	O
present	O
study	O
or	O
participation	O
in	O
another	O
clinical	O
study	O
with	O
an	O
investigational	O
product	O
during	O
the	O
last	O
3	O
months	O
or	O
as	O
judged	O
by	O
the	O
Investigator	O
.	O

History	O
of	O
or	O
presence	O
of	O
any	O
clinically	B
significant	I
disease	B
or	O
disorder	B
including	O
a	O
recent	B
(	O
<	B
3	I
months	I
)	O
cardiovascular	B
event	I
which	O
,	O
in	O
the	O
opinion	O
of	O
the	O
Investigator	O
,	O
may	O
either	O
put	O
the	O
patient	O
at	O
risk	O
because	O
of	O
participation	O
in	O
the	O
study	O
or	O
influence	O
the	O
results	O
or	O
the	O
patient	O
'	O
s	O
ability	O
to	O
participate	O
in	O
the	O
study	O
.	O

Clinical	O
diagnosis	O
of	O
Type	B
1	I
diabetes	I
,	O
maturity	B
onset	I
diabetes	I
of	I
the	I
young	I
,	O
secondary	B
diabetes	I
or	O
diabetes	B
insipidus	I
.	O

Unstable	B
/	O
rapidly	B
progressing	I
renal	B
disease	I
or	O
estimated	B
Glomerular	I
Filtration	I
Rate	I
<	B
60	I
mL	I
/	I
min	I
(	O
Cockcroft	B
-	I
Gault	I
formula	I
)	O
.	O

Clinically	B
significant	I
out	B
of	I
range	I
values	I
of	O
serum	O
levels	O
of	O
either	O
alanine	B
aminotransferase	I
(	I
ALT	I
)	I
,	O
aspartate	B
aminotransferase	I
(	I
AST	I
)	I
or	O
alkaline	B
phosphatase	I
(	I
ALP	I
)	I
in	O
the	O
Investigator	O
'	O
s	O
opinion	O
.	O

Contraindications	B
to	O
dapagliflozin	B
according	O
to	O
the	O
local	O
label	O
.	O

Use	O
of	O
antidiabetic	B
drugs	I
other	B
than	I
metformin	B
within	B
3	I
months	I
prior	I
to	I
screening	I
.	O

Weight	B
gain	I
or	O
loss	O
>	B
5	I
kg	I
in	B
the	I
last	I
3	I
months	I
,	O
ongoing	B
weight	O
-	O
loss	O
diet	O
(	O
hypocaloric	O
diet	O
)	O
or	O
use	O
of	O
weight	B
loss	I
agents	I
.	O

History	B
of	O
drug	O
abuse	O
or	O
alcohol	O
abuse	O
in	B
the	I
past	I
12	I
months	I
.	O

Any	O
clinically	O
significant	O
abnormalities	O
in	O
clinical	O
chemistry	O
,	O
hematology	O
or	O
urinalysis	O
or	O
other	O
condition	O
the	O
Investigator	O
believes	O
would	O
interfere	O
with	O
the	O
patient	O
'	O
s	O
ability	O
to	O
provide	O
informed	O
consent	O
,	O
comply	O
with	O
study	O
instructions	O
,	O
or	O
which	O
might	O
confound	O
the	O
interpretation	O
of	O
the	O
study	O
results	O
or	O
put	O
the	O
patient	O
at	O
undue	O
risk	O
.	O

Plasma	B
donation	I
within	B
one	I
month	I
of	I
screening	I
or	O
any	O
blood	B
donation	I
/	O
blood	B
loss	I
>	B
500	I
mL	I
within	B
3	I
months	I
prior	I
to	I
screening	I
or	O
during	B
the	I
study	I
.	O

Anemia	B
defined	O
as	O
Hemoglobin	B
(	I
Hb	I
)	I
<	B
115	I
g	I
/	I
L	I
(	O
7	B
.	I
1	I
mM	I
)	O
in	O
women	B
and	O
<	B
120	I
g	I
/	I
L	I
(	O
7	B
.	I
5	I
mM	I
)	O
in	O
men	B
.	O

Use	O
of	O
anti	B
-	I
coagulant	I
treatment	I
such	O
as	O
heparin	B
,	O
warfarin	B
,	O
platelet	B
inhibitors	I
,	O
thrombin	B
and	O
factor	B
X	I
inhibitors	I
.	O

Use	O
of	O
medication	O
such	O
as	O
oral	B
glucocorticoids	I
,	O
anti	B
-	I
estrogens	I
or	O
other	B
medications	B
that	O
are	O
known	O
to	O
markedly	B
influence	I
insulin	I
sensitivity	I
.	O

Use	O
of	O
loop	B
diuretics	I
.	O

Regular	B
smoking	O
and	O
other	O
regular	B
nicotine	B
use	O
.	O

Central	B
nervous	I
system	I
aneurysm	I
clip	I

Implanted	B
neural	I
stimulator	I

Implanted	O
cardiac	B
pacemaker	I
of	O
defibrillator	B

Cochlear	B
implant	I

Metal	B
containing	I
corpora	B
aliena	I
in	I
the	I
eye	I
or	O
brain	O
.	O

Patients	O
,	O
who	O
do	O
not	O
want	O
to	O
be	O
informed	O
about	O
unexpected	O
medical	O
findings	O
,	O
or	O
do	O
not	O
wish	O
that	O
their	O
physician	O
be	O
informed	O
about	O
coincidental	O
findings	O
,	O
cannot	O
participate	O
in	O
the	O
study	O
.	O

Patients	O
are	O
able	O
to	O
provide	O
signed	O
and	O
dated	O
written	O
informed	O
consent	O
prior	O
to	O
any	O
study	O
specific	O
procedures	O
.	O

Women	B
are	O
post	B
-	I
menopausal	I
(	O
defined	O
as	B
at	I
least	I
1	I
year	I
post	I
cessation	I
of	I
menses	I
)	O
and	O
aged	B
=	B
45	I
and	I
=	I
70	I
years	I
.	O

Males	B
are	O
aged	B
=	B
40	I
years	I
and	I
=	I
70	I
years	I
.	O

Patients	O
should	O
have	O
suitable	O
veins	O
for	O
cannulation	O
or	O
repeated	O
venipuncture	O
.	O

Patients	O
are	O
diagnosed	O
with	O
T2DM	B
for	B
at	I
least	I
the	I
last	I
6	I
months	I
.	O

Patients	O
are	O
on	O
no	B
other	B
anti	B
-	I
diabetic	I
drug	I
treatment	I
,	O
or	O
on	O
stable	B
maximum	B
3000	I
mg	I
daily	I
dose	I
metformin	B
treatment	O
and	O
/	O
or	O
on	O
stable	B
dose	I
of	O
a	O
DPPIV	B
inhibitor	I
treatment	O
for	B
at	I
least	I
the	I
last	I
3	I
months	I
.	O

HbA1c	B
levels	I
=	B
6	I
.	I
0	I
%	I
(	O
=	B
42	I
mmol	I
/	I
mol	I
)	O
and	O
=	B
9	I
.	I
0	I
%	I
(	O
75	B
mmol	I
/	I
mol	I
)	O
.	O

Have	O
a	O
body	B
mass	I
index	I
(	I
BMI	I
)	I
=	B
35	I
kg	I
/	I
m2	I
.	O

age	B
under	B
18y	I
or	I
over	I
85y	I

diabetes	B
type	I
1	I
with	O
complications	B

no	B
co	O
-	O
operation	O
or	O
inadequate	O
finnish	O
language	O
skills	O

persistent	B
pain	I
for	O
other	B
reason	I

severe	B
hepatic	B
insufficiency	I
or	O
paracetamol	B
(	O
acetaminophen	B
)	O
is	O
contraindicated	B
for	O
other	O
reason	O

any	O
type	O
of	O
steroid	B
in	O
regular	B
use	I

oxycodone	B
contraindicated	B

medications	O
changing	O
notably	O
paracetamol	B
(	O
acetaminophen	B
)	O
and	O
/	O
or	O
ropivacaine	B
metabolism	O
in	O
regular	B
use	I

patients	O
with	O
renal	B
cancer	I
coming	O
to	O
the	O
laparoscopic	B
radical	B
nephrectomy	I

Use	O
of	O
antihistamine	B
within	B
the	I
past	I
72	I
hours	I

Chronic	B
Pulmonary	I
Condition	I
other	B
than	O
asthma	B

Other	O
contraindication	B
to	O
cetirizine	B

Severe	B
asthma	B
exacerbation	I
requiring	O
resuscitation	B

History	O
of	O
allergic	B
rhinitis	I

Wheezing	B

no	O
consent	O

known	O
allergy	B
to	O
administered	O
opioid	B

contraindications	B
to	O
epidural	B
analgesia	I

coagulopathies	B
including	O
platelet	B
count	I
of	O
less	B
than	I
100	I
,	I
000	I

spine	B
surgery	I
in	B
past	I

parturient	B
in	O
labour	B
without	B
cervical	B
dilation	I
and	O
regular	B
uterine	I
contractions	I

Patients	O
that	O
do	O
not	B
have	O
a	O
valid	O
Ontario	O
Health	O
Insurance	O
Plan	O
(	O
OHIP	O
)	O
number	O
at	O
time	O
of	O
first	B
transfusion	B

Patients	O
that	O
require	O
emergent	B
release	I
of	O
a	O
RBC	B
transfusion	I
and	O
in	O
whom	O
emergency	B
randomization	I
could	B
not	I
be	I
completed	I

Patients	O
with	O
complex	B
antibody	I
profile	I
in	O
which	O
it	O
is	O
impossible	O
to	O
match	O
RBC	O
units	O

All	O
patients	O
(	O
excluding	B
neonates	B
)	O
requiring	O
one	B
or	I
more	I
allogeneic	B
RBC	B
transfusions	I
for	O
the	O
treatment	B
of	O
anemia	B
will	O
be	O
included	O
.	O

Autoimmune	B
hepatitis	I

Primary	B
sclerosing	I
cholangitis	I

Patients	O
diagnosed	O
with	O
primary	B
biliary	I
cholangitis	I

Treated	O
with	O
Ursodeoxycholic	B
Acid	I
in	O
West	O
China	O
Hospital	O
for	B
at	I
least	I
6	I
month	I
and	O
suboptimal	B
response	I
to	O
Ursodeoxycholic	B
Acid	I

Severe	B
Iron	B
deficiency	I
anemia	I
(	O
hemoglobin	B
<	B
8	I
.	I
0	I
g	I
/	I
dL	I
)	O
.	O

Parasitic	B
worm	I
infection	I
e	O
.	O
g	O
.	O
schistosomiasis	B
,	O
and	O
hook	B
worm	I
by	O
stool	B
analysis	I
.	O

Any	O
cases	O
giving	O
clinical	O
symptoms	O
of	O
gastritis	B
e	O
.	O
g	O
.	O
nausea	B
,	O
vomiting	B
,	O
dull	B
aching	I
pain	I
or	O
soreness	B
in	I
the	I
epigastrium	I
.	O

Cases	O
with	O
history	B
of	O
gastric	B
ulcer	I
diagnosed	O
by	O
upper	B
endoscopy	I
.	O

Cases	O
complaining	O
of	O
hematemesis	B
.	O

Diagnosed	O
Iron	B
deficiency	I
anemia	I
.	O

H	B
-	I
pylori	I
positive	I
cases	O
.	O

Second	B
trimester	I
pregnancy	B
.	O

Drug	B
-	I
induced	I
hypotension	B
,	O
if	O
necessary	O
,	O
evaluate	O
patient	O
after	O
discontinuing	O
the	O
causative	O
drug	O
for	O
one	O
month	O

Heart	B
failure	I
or	O
Chronic	B
renal	I
failure	I

Severe	B
supine	B
hypertension	I
(	O
Systolic	B
Blood	I
Pressure	I
>	B
180	I
or	O
Diastolic	B
Blood	I
Pressure	I
>	B
110mmHg	I
)	O

Pregnant	B
women	B
,	O
breast	B
-	I
feeding	I

Unable	O
to	O
perform	O
questionnaire	O

Age	B
>	B
=	I
19	I
patients	O
who	O
complained	O
of	O
dizziness	B

Orthostatic	B
hypotension	I
after	B
3	I
-	I
minute	I
standing	I
(	O
systolic	B
blood	I
pressure	I
drop	I
>	B
=	I
20	I
or	O
diastolic	B
blood	I
pressure	I
drop	I
>	B
=	I
10	I

NA	O

Understand	O
and	O
communicate	O
with	O
the	O
investigator	O
,	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
study	O
and	O
give	O
a	O
written	O
,	O
signed	O
and	O
dated	O
informed	O
consent	O

Male	O
or	O
non	O
-	O
pregnant	O
,	O
non	O
-	O
lactating	O
female	O
patients	O
at	O
least	O
18	O
years	O
of	O
age	O

Diagnosis	O
of	O
moderate	B
to	O
severe	B
Ankylosing	B
Spondylitis	I
(	I
AS	I
)	I
with	O
prior	B
documented	O
radiologic	B
evidence	O
fulfilling	B
the	O
Modified	B
New	I
York	I
criteria	I
for	I
AS	I

Active	B
AS	B
assessed	O
by	O
total	B
Bath	I
Ankylosing	I
Spondylitis	I
Disease	I
Activity	I
index	I
(	I
BASDAI	I
)	I
=	B
4	I
(	O
0	O
-	O
10	O
)	O
at	B
baseline	I

Spinal	B
pain	I
as	O
measured	O
by	O
BASDAI	B
question	I
#	I
2	I
=	B
4	I
cm	I
(	O
0	O
-	O
10	O
cm	O
)	O
at	B
baseline	I

Total	B
back	I
pain	I
as	O
measured	O
by	O
visual	B
analog	I
scale	I
(	I
VAS	I
)	I
=	B
40	I
mm	I
(	O
0	O
-	O
100	O
mm	O
)	O
at	B
baseline	I

Patients	O
should	O
have	O
been	O
on	O
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drugs	I
(	I
NSAIDs	I
)	I
at	O
the	O
maximum	B
tolerated	I
dose	I
for	B
at	I
least	I
4	I
weeks	I
prior	I
to	I
their	I
Baseline	I
Visit	I
,	O
with	O
an	O
inadequate	B
response	I
or	O
for	B
less	I
than	I
4	I
weeks	I
if	O
withdrawn	B
for	I
intolerance	I
,	O
toxicity	O
or	O
contraindications	B

Stable	O
dose	O
of	O
NSAIDs	B
including	O
Cyclooxygenase	O
-	O
1	O
(	O
COX	O
-	O
1	O
)	O
or	O
Cyclooxygenase	B
-	I
2	I
(	I
COX	I
-	I
2	I
)	I
inhibitors	I
for	B
at	I
least	I
2	I
weeks	I
before	I
their	I
Baseline	I
Visit	I

Patients	O
who	O
have	O
been	O
on	O
a	O
tumor	B
necrosis	I
factor	I
alpha	I
(	I
TNFa	I
)	I
inhibitor	I
(	O
not	B
more	I
than	I
one	I
)	O
must	O
have	O
experienced	O
an	O
inadequate	B
response	I
to	O
previous	B
or	O
current	B
treatment	B
given	O
at	O
an	O
approved	B
dose	I
for	B
at	I
least	I
3	I
months	I
prior	I
to	I
baseline	I
or	O
had	O
been	O
intolerant	B
upon	O
administration	O
of	O
an	O
anti	B
-	I
TNFa	I
agent	I

Total	B
ankylosis	I
of	I
the	I
spine	I

Use	O
of	O
other	O
investigational	O
drugs	O
within	O
5	O
half	O
-	O
lives	O
of	O
enrollment	O
,	O
or	O
within	O
4	O
weeks	O
before	O
the	O
Baseline	O
Visit	O
,	O
whichever	O
is	O
longer	O
.	O

History	O
of	O
hypersensitivity	B
to	O
any	O
of	O
the	O
study	B
drugs	I
or	O
its	O
excipients	B
or	O
to	O
drugs	B
of	I
similar	I
chemical	I
classes	I
.	O

Chest	B
x	I
-	I
ray	I
,	O
computerized	B
tomography	I
(	I
CT	I
)	I
scan	I
,	O
or	O
chest	B
magnetic	I
resonance	I
imaging	I
(	I
MRI	I
)	I
with	O
evidence	O
of	O
ongoing	B
infectious	B
or	O
malignant	B
process	I
,	O
obtained	O
within	B
3	I
months	I
prior	I
to	I
screening	I
and	O
evaluated	O
by	O
a	O
qualified	O
physician	O
.	O

Previous	O
exposure	O
to	O
secukinumab	B
or	O
any	O
other	B
biologic	B
drug	I
directly	O
targeting	B
Interleukin	B
-	I
17	I
(	I
IL	I
-	I
17	I
)	I
,	O
Interleukin	B
-	I
12	I
/	I
23	I
(	I
IL	I
-	I
12	I
/	I
23	I
)	I
,	O
or	O
the	O
IL	B
-	I
17	I
receptor	I
,	O
or	O
any	O
other	O
biologic	B
immunomodulating	I
agent	I
,	O
except	B
those	O
targeting	O
TNFa	B

Patients	O
who	O
have	O
taken	O
more	B
than	I
one	I
anti	B
-	I
TNFa	I
agent	I

Any	O
intramuscular	B
or	O
intravenous	B
corticosteroid	B
injection	I
within	B
2	I
weeks	I
before	I
baseline	I

Any	O
therapy	O
by	O
intra	B
-	I
articular	I
injections	I
(	O
e	O
.	O
g	O
.	O
corticosteroid	B
)	O
within	B
4	I
weeks	I
before	I
baseline	I

Previous	B
treatment	O
with	O
any	O
cell	B
-	I
depleting	I
therapies	I

Patients	O
taking	O
high	B
potency	I
opioid	I
analgesics	I
(	O
e	O
.	O
g	O
.	O
,	O
methadone	B
,	O
hydromorphone	B
,	O
morphine	B
)	O

Has	O
any	O
clinically	B
significant	I
condition	B
or	O
situation	O
(	O
eg	O
,	O
anatomical	B
malformation	I
that	O
complicates	O
intubation	O
)	O
other	B
than	I
the	B
condition	I
being	I
studied	I
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
interfere	O
with	O
the	O
trial	O
evaluations	O
or	O
optimal	O
participation	O
in	O
the	O
trial	O
.	O

Has	O
a	O
neuromuscular	B
disorder	I
that	O
may	O
affect	O
NMB	O
and	O
/	O
or	O
trial	O
assessments	O
.	O

Is	O
dialysis	B
-	I
dependent	I
or	O
has	O
(	O
or	O
is	O
suspected	O
of	O
having	O
)	O
severe	B
renal	I
insufficiency	I
(	O
defined	O
as	O
estimated	B
glomerular	I
filtration	I
rate	I
(	I
eGFR	I
)	I
<	B
30	I
ml	I
/	I
min	I
)	O
.	O

Has	O
or	O
is	O
suspected	O
of	O
having	O
a	O
family	O
or	O
personal	B
history	I
of	O
malignant	B
hyperthermia	I
.	O

Has	O
or	O
is	O
suspected	O
of	O
having	O
an	O
allergy	B
to	O
study	B
treatments	I
or	O
its	O
/	O
their	O
excipients	B
,	O
to	O
opioids	B
/	O
opiates	B
,	O
muscle	B
relaxants	I
or	O
their	O
excipients	B
,	O
or	O
other	B
medication	B
(	O
s	O
)	O
used	O
during	O
general	B
anesthesia	I
.	O

Has	O
received	O
or	O
is	O
planned	O
to	O
receive	O
toremifene	B
and	O
/	O
or	O
fusidic	B
acid	I
via	O
IV	B
administration	I
within	O
24	O
hours	O
before	O
or	O
within	B
24	I
hours	I
after	I
administration	I
of	I
study	I
treatment	I
.	O

Has	O
been	O
previously	B
treated	O
with	O
sugammadex	B
or	O
has	O
participated	O
in	O
a	O
sugammadex	B
clinical	O
trial	O
.	O

Is	O
currently	O
participating	O
in	O
or	O
has	O
participated	O
in	O
an	O
interventional	O
clinical	O
trial	O
with	O
an	O
investigational	B
compound	I
or	O
device	B
within	B
30	I
days	I
of	I
signing	I
the	I
informed	I
consent	I
/	O
assent	O
for	O
this	O
current	O
trial	O
.	O

Be	O
categorized	O
as	O
American	B
Society	I
of	I
Anesthesiologists	I
(	I
ASA	I
)	I
Physical	I
Status	I
Class	I
1	B
,	O
2	B
,	O
or	O
3	B
.	O

Have	O
a	O
planned	O
non	B
-	I
emergent	I
surgical	B
procedure	I
or	O
clinical	B
situation	I
(	O
e	O
.	O
g	O
.	O
,	O
intubation	B
)	O
that	O
requires	O
moderate	B
or	O
deep	B
NMB	B
with	O
either	O
rocuronium	B
or	O
vecuronium	B
.	O

Have	O
a	O
planned	O
surgical	B
procedure	I
or	O
clinical	B
situation	I
that	O
would	O
allow	O
objective	B
neuromuscular	I
monitoring	I
techniques	I
to	O
be	O
applied	O
with	O
access	O
to	O
the	O
arm	O
for	O
neuromuscular	O
transmission	O
monitoring	O
.	O

Age	B
between	B
2	I
to	I
<	I
17	I
years	I
at	B
Visit	I
2	I
.	O

If	O
female	B
,	O
may	O
participate	O
if	O
she	O
is	O
not	B
pregnant	B
,	O
not	B
breastfeeding	O
,	O
and	O
at	B
least	I
one	I
of	O
the	O
following	O
:	O
1	O
)	O
Not	B
a	O
woman	B
of	I
childbearing	I
potential	I
(	I
WOCBP	I
)	I
;	O
or	O
2	O
)	O
A	O
WOCBP	B
who	O
agrees	O
to	O
follow	O
the	O
study	O
contraceptive	B
guidance	I
during	B
the	I
treatment	I
period	I
and	O
for	B
at	I
least	I
7	I
days	I
after	I
the	I
last	I
dose	I
of	I
study	I
treatment	I
.	O

dysphagia	B

severe	B
gastroparesis	B
requiring	O
endoscopic	B
placement	I
of	O
capsule	B

small	B
bowel	I
obstruction	I

pregnancy	B

Adult	B
outpatients	O
(	O
18	B
years	I
or	I
older	I
)	O

routinely	B
referred	I
for	O
small	B
bowel	I
video	I
capsule	I
endoscopy	I
(	O
CE	O
)	O

Except	O
for	O
serious	B
complications	I
(	O
cardiovascular	B
events	I
and	O
recent	O
significant	B
liver	O
,	O
kidney	O
or	O
lung	B
disease	I
within	B
3	I
months	I
)	O

high	O
blood	B
pressure	I
(	O
>	B
160	I
/	I
100mmHg	I
)	O

active	B
infection	I

secondary	B
diabetes	B

pregnancy	B

alcohol	B
abuse	I

allergic	B
to	O
GLP	B
-	I
1	I
receptor	I
agonist	I

Overweight	B
and	O
obese	B
PCOS	B
patients	O
with	O
newly	B
diagnosed	I
IGR	B
;	O

PCOS	B
diagnosis	O
based	O
on	O
2003	B
Rotterdam	I
criteria	I

Overweight	B
/	O
obesity	B
diagnostic	O
criteria	O
according	O
to	O
WHO	B
-	I
WPR	I

Impaired	B
glucose	I
regulation	I
diagnostic	O
criteria	O
according	O
to	O
1998	B
WHO	I
diagnostic	I
criteria	I
.	O

Pregnancy	B
or	O
lactating	B

Allergy	B
to	O
NAC	B

History	B
of	O
chronic	B
pain	I

Use	O
of	O
opioids	B
or	O
neuropathic	B
analgesics	I

Use	O
of	O
NAC	B
prior	B
to	I
trial	I
(	O
<	B
1	I
month	I
of	O
planned	O
surgery	B
)	O

Alcoholism	B

Diabetes	B
Mellitus	I
(	O
insulin	B
therapy	O
)	O

Asthma	B
or	O
Chronic	B
Obstructive	I
pulmonary	I
Disease	I

Known	O
renal	B
function	I
disorders	I
(	O
MDRD	B
<	B
ô0	I
)	O

Known	O
liver	B
failure	I
(	O
bilirubin	B
>	B
1	I
.	I
Sx	I
upper	I
limit	I
of	I
normal	I
)	O

No	O
written	O
lC	O
by	O
patient	O

Subjects	O
scheduled	O
for	O
laparoscopic	B
unilateral	B
inguinal	B
hernia	I
repair	I

ASA	B
1	B
or2	I
.	O

Age	B
>	B
18	I
years	I
.	O

NA	O

Written	O
informed	O
consent	O
prior	O
to	O
beginning	O
specific	O
protocol	O
procedures	O
,	O
including	O
expected	O
cooperation	O
of	O
the	O
patients	O
for	O
the	O
treatment	O
and	O
follow	O
-	O
up	O
,	O
willingness	O
and	O
ability	O
to	O
complete	O
collection	O
of	O
data	O
via	O
wearable	O
device	O
and	O
study	O
mobile	O
must	O
be	O
obtained	O
and	O
documented	O
according	O
to	O
the	O
local	O
regulatory	O
requirements	O
.	O

Female	B
or	O
male	B
patients	O
.	O

Age	B
=	B
18	I
years	I
old	I
.	O

Metastatic	B
invasive	B
hormone	B
receptor	I
positive	I
and	O
HER2	B
negative	I
breast	B
cancer	I
(	O
histologically	O
confirmed	O
)	O
.	O

Patients	O
who	O
in	O
the	O
opinion	O
of	O
the	O
treating	O
physician	O
are	O
candidates	O
suitable	O
for	O
randomization	O
for	O
mono	O
-	O
chemotherapy	O
treatment	O
,	O
that	O
has	O
either	O
an	O
approved	O
label	O
in	O
Europe	O
and	O
/	O
or	O
is	O
supported	O
by	O
guidelines	O
for	O
the	O
treatment	O
of	O
first	O
-	O
line	O
advanced	O
BC	O
,	O
which	O
are	O
based	O
on	O
evidence	O
on	O
safety	O
and	O
efficacy	O
in	O
this	O
setting	O
.	O

Symptomatic	B
or	O
asymptomatic	B
metastatic	B
breast	I
cancer	I
.	O

Resolution	O
of	O
all	O
acute	B
toxic	I
effects	I
of	O
prior	B
anti	B
-	I
cancer	I
therapy	I
or	O
surgical	B
procedures	I
to	O
NCI	B
CTCAE	I
version	I
4	I
.	I
0	I
grade	B
=	I
1	I
(	O
except	B
alopecia	B
or	O
other	O
toxicities	O
not	O
considered	O
a	O
safety	O
risk	O
for	O
the	O
patient	O
at	O
investigator	O
'	O
s	O
discretion	O
)	O
.	O

Life	O
-	O
expectancy	O
>	B
6	I
months	I
.	O

For	O
female	O
patients	O
:	O
The	O
patients	O
need	O
to	O
be	O
either	O
A	O
)	O
of	O
non	O
-	O
childbearing	O
potential	O
(	O
documented	O
postmenopausal	O
or	O
post	O
hysterectomy	O
)	O
B	O
)	O
childbearing	O
potential	O
with	O
negative	O
serum	O
or	O
urinary	O
pregnancy	O
test	O
(	O
in	O
this	O
case	O
patients	O
need	O
to	O
use	O
highly	O
effective	O
non	O
-	O
hormonal	O
contraceptive	O
methods	O
)	O
.	O

Neurological	B
Congenital	I
malformations	I
and	O
/	O
or	O
those	O
known	O
to	O
impair	B
intestinal	I
motility	I

Additional	B
congenital	B
gastrointestinal	B
abnormalities	I
requiring	O
surgical	B
intervention	I

Congenital	B
Cyanotic	B
heart	I
disease	I

Surgical	B
Closure	I
of	O
abdominal	B
wall	I
defect	I
with	O
prosthetic	B
material	I
(	O
e	O
.	O
g	O
.	O
prosthetic	O
or	O
bio	B
-	I
prosthetic	I
mesh	I
)	O

Diagnosis	O
of	O
uncomplicated	B
gastroschisis	B

Gestational	B
age	I
>	B
33	I
weeks	I
at	B
time	I
of	I
delivery	I

Weight	B
>	B
1900g	I
at	B
time	I
of	I
delivery	I

Transfer	B
of	O
patient	O
to	O
Riley	O
Hospital	O
for	O
Children	O
prior	O
to	O
any	O
abdominal	B
surgery	I

Morbidly	B
obese	I
patients	O
(	O
BMI	B
>	B
47	I
kg	I
/	I
m2	I
)	O
and	O
overweight	B
/	O
lean	B
patients	O
(	O
BMI	B
<	B
27	I
kg	I
/	I
m2	I
)	O

Evidence	O
of	O
type	B
1	I
diabetes	I
and	O
diabetics	B
requiring	O
insulin	B
therapy	O
.	O

Subjects	O
who	O
have	O
not	B
been	O
weight	O
stable	O
(	O
>	B
2	I
kg	I
weight	B
change	I
in	B
past	I
3	I
months	I
)	O

Subjects	O
who	O
have	O
been	O
recently	B
active	B
(	O
>	B
30	I
min	I
of	O
moderate	B
/	I
high	I
intensity	I
exercise	I
,	O
2	B
times	I
/	I
week	I
)	O
.	O

Subjects	O
who	O
are	O
smokers	O
or	O
who	O
have	O
quit	O
smoking	O
<	B
5	I
years	I
ago	I

Subjects	O
prescribed	O
metformin	B
or	O
have	O
taken	O
metformin	B
within	B
1	I
year	I
.	O

Subjects	O
with	O
abnormal	B
estimated	B
glomerular	I
filtration	I
rate	I
(	I
eGFR	I
)	I
.	O

Hypertriglyceridemic	B
(	O
>	B
400	I
mg	I
/	I
dl	I
)	O
and	O
hypercholesterolemic	B
(	O
>	B
260	I
mg	I
/	I
dl	I
)	O
subjects	O

Hypertensive	B
(	O
>	B
160	I
/	I
100	I
mmHg	I
)	O

Subjects	O
currently	O
taking	O
medications	B
that	B
affect	I
heart	I
rate	I
and	O
rhythm	O
(	O
i	O
.	O
e	O
.	O
Ca	B
+	I
+	I
channel	I
blockers	I
,	O
nitrates	B
,	O
alpha	O
-	O
or	O
beta	B
-	I
blockers	I
)	O
.	O

Subjects	O
with	O
a	O
history	B
of	O
significant	B
metabolic	B
,	O
cardiac	B
,	O
congestive	B
heart	I
failure	I
,	O
cerebrovascular	B
,	O
hematological	B
,	O
pulmonary	B
,	O
gastrointestinal	B
,	O
liver	B
,	O
renal	B
,	O
or	O
endocrine	B
disease	B
or	O
cancer	B
that	O
in	O
the	O
investigator	O
'	O
s	O
opinion	O
would	O
interfere	O
with	O
or	O
alter	O
the	O
outcome	O
measures	O
,	O
or	O
impact	O
subject	O
safety	O
.	O

Pregnant	B
(	O
as	O
evidenced	O
by	O
positive	B
pregnancy	B
test	I
)	O
or	O
nursing	O
women	B

Subjects	O
with	O
contraindications	B
to	O
participation	O
in	O
an	O
exercise	O
training	O
program	O

Currently	O
taking	O
active	B
weight	I
suppression	I
medication	I
(	O
e	O
.	O
g	O
.	O
phentermine	B
,	O
orlistat	B
,	O
lorcaserin	B
,	O
naltrexone	B
-	I
bupropion	I
in	I
combination	I
,	O
liraglutide	B
,	O
benzephetamine	B
,	O
diethylpropion	B
,	O
phendimetrazine	B
)	O

Known	O
hypersensitivity	B
to	O
perflutren	B
(	O
contained	O
in	O
Definity	B
)	O

Male	B
or	O
female	B
>	B
40	I
and	I
<	I
70	I
years	I
old	B
.	O

Has	O
a	O
body	B
mass	I
index	I
>	B
27	I
and	I
<	I
47	I
kg	I
/	I
m2	I
.	O

Not	B
diagnosed	O
with	O
Type	B
2	I
diabetes	I
.	O

Not	B
currently	B
engaged	O
in	O
>	B
60	I
min	I
/	I
wk	I
of	O
exercise	O

Meet	O
at	B
least	I
3	I
of	I
5	I
National	B
Cholesterol	I
Education	I
Adult	I
Treatment	I
Panel	I
III	I

Increased	B
waist	B
circumference	I
(	O
=	B
102	I
cm	I
in	O
men	B
;	O
=	B
88	I
cm	I
in	O
women	B
)	O

Elevated	B
triglycerides	B
(	O
=	B
150	I
mg	I
/	I
dl	I
)	O
,	O
or	O
on	O
medication	B
for	I
treating	I
the	O
condition	O

Reduced	B
HDL	B
-	I
cholesterol	I
(	O
<	B
40mg	I
/	I
dl	I
in	O
men	B
,	O
<	B
50	I
mg	I
/	I
dl	I
in	O
women	B
)	O
,	O
or	O
on	O
medication	B
for	I
treating	I
the	O
condition	O

High	B
blood	B
pressure	I
(	O
=	B
130	I
mmHg	I
systolic	I
or	O
=	B
85mmHg	I
diastolic	I
)	O
,	O
or	O
on	O
medication	B
for	I
treating	I
the	O
condition	O

Elevated	B
fasting	B
glucose	I
(	O
=	B
100	I
mg	I
/	I
dl	I
)	O
,	O
or	O
on	O
medication	B
for	I
treating	I
the	O
condition	O

Co	B
-	I
infected	I
with	O
HCV	B
,	O
HIV	B
or	O
other	B
viral	B
hepatitis	I
,	O

Diagnosis	O
of	O
HCC	B

Chronic	B
hepatitis	I
B	I
,	O

Antiviral	B
experienced	O
,	O

Currently	O
on	O
long	B
term	I
TDF	B
anti	O
-	O
HBV	B
treatment	O
,	O

HBV	B
DNA	I
<	B
6	I
log	I
IU	I
/	I
ml	I
(	O
LLOD	B
)	O

Able	O
to	O
sign	O
the	O
consent	O
form	O
of	O
anticipating	O
in	O
the	O
study	O

Allergy	B
to	O
narcotic	B
medications	I

Intake	O
of	O
any	B
chronic	B
opioids	B
or	O
pain	B
medications	I
preoperatively	B

Subjects	O
must	O
be	O
female	B

Subjects	O
must	O
be	O
18	O
years	O
or	O
older	B

Subjects	O
must	O
be	O
undergoing	B
unilateral	B
or	O
bilateral	B
mastectomy	B
with	O
tissue	B
expander	I
reconstruction	I

acute	B
myocardial	I
infarction	I
,	O
heart	B
failure	I
,	O
neoplastic	B
disease	I
,	O
chronic	B
diseases	I
that	O
may	B
affect	I
the	I
inflammatory	I
profile	I
both	O
systemic	B
and	O
epicardial	B
(	O
cancer	B
,	O
chronic	B
intestinal	I
inflammation	I
,	O
hepatitis	B
,	O
AIDS	B
)	O
;	O
life	O
expectancy	O
<	B
6	I
months	I
,	O
previous	B
CABG	B
and	O
/	O
or	O
other	B
open	B
heart	I
surgery	I
intervention	I
,	O
acute	B
coronary	I
syndrome	I

patients	O
aged	B
>	B
18	I
,	I
<	I
75	I
,	O
left	B
ventricle	I
ejection	I
fraction	I
(	O
LVEF	B
)	O
>	B
50	I
%	I
,	O
multivessel	B
coronary	I
disease	I
detected	O
by	O
coronarography	B
,	O
indication	O
to	O
receive	O
a	O
CABG	B
,	O
stable	B
CAD	B
.	O

All	O
diabetics	B
and	O
non	B
diabetics	I
.	O

Diabetic	B
patients	O

Patients	O
with	O
any	B
macular	B
changes	I
prior	O
to	O
the	O
surgery	B
(	O
epiretinal	B
membranes	I
,	O
age	B
macular	I
disease	I
,	O
macular	B
edema	I
.	O
.	O
.	O
)	O

Patients	O
who	O
had	O
any	B
complication	B
during	O
phacoemulsification	B
surgery	I

Any	O
patients	O
that	O
will	O
be	O
submitted	O
to	O
phacoemulsification	B
surgery	I
in	O
the	O
Hospital	O
de	O
Clinicas	O
of	O
State	O
University	O
of	O
Campinas	O
(	O
BRAZIL	O
)	O

Patients	O
over	B
18	I
years	I
old	B

Patients	O
who	O
are	O
able	O
to	O
perform	O
SD	B
-	I
OCT	I

Patients	O
who	O
sign	O
the	O
consent	O
form	O

Previous	B
exposure	O
to	O
drugs	B
such	O
as	O
fingolimod	B
,	O
natalizumab	B
,	O
alemtuzumab	B
,	O
mitoxantrone	B
and	O
ocrelizumab	B
.	O

Positive	B
hepatitis	O
C	O
or	O
hepatitis	B
B	I
surface	I
antigen	I
test	I
and	O
/	O
or	O
hepatits	B
B	I
core	I
antibody	I
test	I
for	O
immunoglobulin	B
G	I
(	I
IgG	I
)	I
and	O
/	O
or	O
immunoglobulin	B
M	I
(	I
IgM	I
)	I
.	O

Current	B
or	O
previous	B
history	I
of	O
immune	B
deficiency	I
disorders	I
including	O
a	O
positive	B
human	B
immunodeficiency	I
virus	I
(	I
HIV	I
)	I
result	O
.	O

Currently	B
receiving	O
immunosuppressive	O
or	O
myelosuppressive	B
therapy	I
with	O
,	O
for	O
example	O
,	O
monoclonal	B
antibodies	I
,	O
methotrexate	B
,	O
cyclophosphamide	B
,	O
cyclosporine	B
or	O
azathioprine	B
,	O
or	O
chronic	B
use	I
of	O
corticosteroids	B
.	O

History	B
of	O
tuberculosis	B
,	O
presence	O
of	O
active	B
tuberculosis	B
,	O
or	O
latent	B
tuberculosis	B

Evidence	O
or	O
suspect	O
of	O
Progressive	B
Multifocal	I
Leukoencephalopathy	I
(	I
PML	I
)	I
in	O
Magnetic	B
Resonance	I
Imaging	I
(	I
MRI	I
)	I
.	O

Active	B
malignancy	B
or	O
history	B
of	O
malignancy	B
.	O

Other	O
protocol	O
defined	O
exclusion	O
criteria	O
could	O
apply	O
.	O

Highly	B
active	I
RMS	B
as	O
defined	O
by	O
:	O

One	B
relapse	B
in	B
the	I
previous	I
year	I
and	O
at	B
least	I
1	I
T1	B
Gadolinium	I
(	I
Gd	I
)	I
+	I
lesion	B
or	O
9	B
or	I
more	I
T2	B
lesions	I
,	O
while	O
on	O
therapy	B
with	O
other	B
disease	B
modifying	I
drugs	I
(	I
DMDs	I
)	I

Two	B
or	I
more	I
relapses	B
in	B
the	I
previous	I
year	I
,	O
whether	O
on	O
DMD	O
treatment	O
or	O
not	O
.	O

Expanded	B
Disability	I
Status	I
Scale	I
(	I
EDSS	I
)	I
score	I
less	B
than	I
equals	I
to	I
(	I
<	I
=	I
)	I
5	I
.	I
0	I
.	O

Other	O
protocol	O
defined	O
inclusion	O
criteria	O
could	O
apply	O
.	O

Spondylolisthesis	B
Grade	B
II	B
or	I
higher	I
.	O

Subject	O
requires	O
uni	B
or	O
bilateral	B
facetectomy	B
to	O
treat	O
leg	O
/	O
back	B
pain	I
.	O

Subject	O
has	O
back	O
or	O
non	B
-	I
radicular	I
leg	I
pain	I
of	O
unknown	B
etiology	I
.	O

Prior	B
surgery	B
at	O
the	O
index	B
lumbar	I
level	I
.	O

Subject	O
requiring	O
a	O
spine	B
DEXA	I
(	O
i	O
.	O
e	O
.	O
,	O
patients	O
with	O
SCORE	B
of	O
=	B
6	I
)	O
with	O
a	O
T	B
Score	I
less	B
than	I
-	I
2	I
.	I
0	I
at	O
the	O
index	B
level	I
.	O

For	O
patients	O
with	O
a	O
herniation	B
at	O
L5	B
/	I
S1	I
,	O
the	O
average	B
T	I
score	I
of	O
L1	B
-	I
L4	I
shall	O
be	O
used	O
.	O

Subject	O
has	O
clinically	B
compromised	I
vertebral	I
bodies	I
at	O
the	O
index	B
level	I
(	I
s	I
)	I
due	O
to	O
any	O
traumatic	O
,	O
neoplastic	O
,	O
metabolic	O
,	O
or	O
infectious	B
pathology	I
.	O

Subject	O
has	O
sustained	O
pathologic	B
fractures	B
of	I
the	I
vertebra	I
or	O
multiple	B
fractures	B
of	I
the	I
vertebra	I
or	O
hip	O
.	O

Subject	O
has	O
scoliosis	B
of	O
greater	B
than	I
ten	I
(	I
10	I
)	I
degrees	I
(	O
both	O
angular	B
and	O
rotational	B
)	O
.	O

Any	O
metabolic	B
disease	I
bone	B
disease	I
that	O
has	O
not	B
been	O
stabilized	O
for	B
at	I
least	I
three	I
months	I
(	O
e	O
.	O
g	O
.	O
,	O
Paget	B
'	I
s	I
disease	I
,	O
osteomalacia	B
,	O
osteogenesis	B
imperfecta	I
,	O
thyroid	B
and	O
/	O
or	O
parathyroid	B
gland	I
disorder	I
,	O
etc	O
.	O
)	O
.	O

Subject	O
has	O
an	O
active	B
infection	B
either	O
systemic	B
or	O
local	B
.	O

Subject	O
has	O
cauda	B
equina	I
syndrome	I
or	O
neurogenic	B
bowel	I
/	I
bladder	I
dysfunction	I
.	O

Subject	O
has	O
severe	B
arterial	B
insufficiency	I
of	O
the	O
legs	B
(	O
Screening	B
on	I
physical	I
examination	I
=	O
patients	O
with	O
diminution	B
or	I
absence	I
of	I
dorsalis	I
pedis	I
or	O
posterior	O
tibialis	O
pulses	O
.	O
If	O
diminished	O
or	O
absent	O
by	O
palpation	B
,	O
then	O
an	O
arterial	B
ultrasound	I
is	O
required	O
with	O
vascular	B
plethysmography	I
.	O
If	O
the	O
absolute	B
arterial	I
pressure	I
is	O
below	B
50mm	I
of	I
Hg	I
at	O
the	O
calf	O
or	O
ankle	B
level	I
,	O
then	O
the	O
patient	O
is	O
to	O
be	O
excluded	B
)	O
or	O
other	O
peripheral	B
vascular	I
disease	I
)	O
.	O

Subject	O
has	O
significant	B
peripheral	B
neuropathy	I
,	O
patient	O
defined	O
as	O
a	O
patient	O
with	O
Type	B
I	I
or	O
Type	B
II	I
diabetes	B
or	O
similar	B
systemic	B
metabolic	I
condition	I
causing	O
decreased	B
sensation	I
in	O
a	O
stocking	O
-	O
like	O
or	O
non	O
-	O
radicular	O
and	O
non	B
-	I
dermatomal	I
distribution	I
in	O
the	O
lower	B
extremities	I
.	O

Subject	O
has	O
insulin	B
-	I
dependent	I
diabetes	B
mellitus	I
.	O

Subject	O
is	O
morbidly	B
obese	I
(	O
defined	O
as	O
a	O
body	B
mass	I
index	I
>	B
40	I
,	O
or	O
weighs	B
more	B
than	I
100	I
lbs	I
over	I
ideal	I
body	I
weight	I
)	O
.	O

Subject	O
has	O
been	O
diagnosed	O
with	O
active	B
hepatitis	B
,	O
AIDS	B
,	O
or	O
HIV	B
.	O

Subject	O
has	O
been	O
diagnosed	O
with	O
rheumatoid	B
arthritis	I
or	O
other	B
autoimmune	B
disease	I
.	O

Subject	O
has	O
a	O
known	O
allergy	B
to	O
titanium	B
,	O
polyethylene	B
or	O
polyester	B
materials	O
.	O

Subject	O
is	O
pregnant	B
or	O
interested	O
in	O
becoming	O
pregnant	B
in	B
the	I
next	I
two	I
(	I
2	I
)	I
years	I
.	O

Subject	O
has	O
active	O
tuberculosis	B
or	O
has	O
had	O
tuberculosis	B
in	B
the	I
past	I
three	I
(	I
3	I
)	I
years	I
.	O

Subject	O
has	O
a	O
history	B
of	O
active	B
malignancy	I
:	O
A	O
patient	O
with	O
a	O
history	O
of	O
any	O
invasive	B
malignancy	B
(	O
except	B
non	B
-	I
melanoma	I
skin	I
cancer	I
)	O
,	O
unless	O
he	O
/	O
she	O
has	O
been	O
treated	B
with	I
curative	I
intent	I
and	O
there	O
have	O
been	O
no	B
signs	B
or	I
symptoms	I
of	I
the	I
malignancy	I
for	B
at	I
least	I
two	I
(	I
2	I
)	I
years	I
.	O

Subject	O
is	O
immunologically	B
suppressed	I
,	O
received	O
steroids	B
>	B
1	I
month	I
over	B
the	I
past	I
year	I
.	O

Currently	O
taking	O
anticoagulants	B
,	O
other	B
than	I
aspirin	B
,	O
unless	O
the	O
patient	O
can	O
be	O
taken	O
off	O
the	O
anticoagulant	O
for	O
surgery	O
.	O

Subject	O
has	O
a	O
current	O
chemical	O
/	O
alcohol	B
dependency	I
or	O
significant	B
psychosocial	B
disturbance	I
.	O

Subject	O
has	O
a	O
life	O
expectancy	O
of	O
less	B
than	I
three	I
(	I
3	I
)	I
years	I
.	O

Subject	O
is	O
currently	O
involved	O
in	O
another	O
investigational	O
study	O
.	O

Subject	O
is	O
incarcerated	O
.	O

Age	B
18	B
to	I
75	I
years	I
old	I
(	O
male	B
or	O
female	B
)	O
.	O

Patients	O
with	O
posterior	B
or	O
posterolateral	B
disc	B
herniations	I
at	O
one	B
level	I
between	I
L1	I
and	I
S1	I
with	O
radiographic	B
confirmation	O
of	O
neural	B
compression	I
using	O
CT	B
and	O
/	O
or	O
MRI	B
.	O

At	B
least	I
six	I
(	I
6	I
)	I
weeks	I
of	O
failed	B
,	O
conservative	B
treatment	B
prior	B
to	I
surgery	I
,	O
or	O
requires	O
immediate	B
surgery	B
to	O
prevent	O
permanent	B
disability	I
.	O

Minimum	O
posterior	B
disc	I
height	I
of	O
5mm	O
at	O
the	O
index	B
level	I
(	I
s	I
)	I
.	O

Lower	B
back	I
pain	I
and	O
/	O
or	O
sciatica	B
with	O
or	O
without	O
spinal	B
claudication	I
.	O

Oswestry	B
Questionnaire	I
score	I
of	O
at	B
least	I
40	I
/	I
100	I
at	B
baseline	I
.	O

VAS	B
leg	I
pain	I
of	O
at	B
least	I
40	I
/	I
100	I
at	B
baseline	I
.	O

Psychosocially	O
,	O
mentally	O
and	O
physically	O
able	O
to	O
fully	O
comply	O
with	O
the	O
clinical	O
protocol	O
and	O
willing	O
to	O
adhere	O
to	O
follow	O
-	O
up	O
schedule	O
and	O
requirements	O
.	O

Those	O
subjects	O
with	O
previous	B
use	I
of	O
vitamin	B
D	I
.	O

Known	O
subjects	O
with	O
renal	O
,	O
liver	O
,	O
calcium	B
metabolism	I
disorders	I
,	O
malabsorption	B
disorders	I
,	O
known	O
neoplasms	B
.	O

Subjects	O
with	O
serum	B
calcium	I
levels	I
equal	B
to	I
or	I
greater	I
than	I
10	I
.	I
2	I
mg	I
/	I
dl	I
.	O

Female	B
patients	O
older	O
than	O
18	O
years	B
.	O

Patients	O
who	O
agree	O
to	O
participate	O
in	O
the	O
study	O
.	O

Those	O
that	O
meet	O
the	O
ACR	B
1990	I
and	O
2010	O
criteria	O
for	O
Fibromyalgia	B
.	O

No	B
previous	B
use	O
of	O
vitamin	B
D	I
.	O

Patients	O
diagnosed	O
with	O
primary	B
or	O
secondary	B
fibromyalgia	B
.	O

Allergy	B
to	O
LA	B

Infection	O
in	O
or	O
near	B
insertion	I
site	I
of	O
the	O
peripheral	B
nerve	I
catheter	I

Anatomical	B
abnormalities	I
preventing	B
successful	B
peripheral	B
catheter	I
insertion	B

Habitual	B
use	I
of	O
opioids	B

Pregnancy	B
or	O
breastfeeding	O
(	O
disproved	B
by	I
a	O
negative	B
pregnancy	B
test	I
before	B
trial	I
inclusion	I
)	O

Age	B
=	B
18	I
years	I

American	O
Society	O
of	O
Anesthesiologists	O
Classification	O
I	B
-	I
III	I

Normal	B
cognitive	B
function	I
in	O
order	O
to	O
sign	O
written	O
,	O
informed	O
consent	O
and	O
to	O
understand	O
trial	O
protocol	O

Agreement	O
to	O
the	O
trial	O
protocol	O
,	O
including	O
the	O
randomized	O
manner	O

NA	O

American	B
Society	I
of	I
Anesthesiologists	I
Classification	I
I	B
-	I
III	I

Normal	O
cognitive	O
function	O
in	O
order	O
to	O
sign	O
written	O
,	O
informed	O
consent	O
and	O
to	O
understand	O
trial	O
protocol	O

Agreement	O
to	O
the	O
trial	O
protocol	O
,	O
including	O
the	O
randomized	O
manner	O

Patients	O
who	O
do	O
not	B
meet	O
the	O
inclusion	O
criteria	O
and	O
those	O
who	O
have	O
a	O
history	B
of	O
allergic	B
reactions	O
to	O
human	B
albumin	I
,	O
as	O
well	O
as	O
those	O
who	O
have	O
received	O
iodinated	B
contrast	I
during	O
the	O
7	O
days	O
prior	O
to	O
surgery	B
and	O
pregnant	B
women	B
,	O
will	O
be	O
excluded	O
from	O
the	O
study	O
.	O

Adult	B
patients	O
(	O
>	O
18	O
years	B
)	O
scheduled	O
for	O
cardiopulmonary	B
bypass	I
surgery	I
with	O
Glomerular	B
Filtration	I
Rate	I
(	I
GFR	I
)	I
greater	B
than	I
or	I
equal	I
to	I
60	I
and	O
left	B
ventricular	I
ejection	I
fraction	I
greater	B
than	I
or	I
equal	I
to	I
40	I
%	I

Presence	O
of	O
a	O
significant	B
medical	O
or	O
psychiatric	B
condition	I
(	O
Examples	O
include	O
:	O
Diagnosis	O
and	O
treatment	B
of	O
tuberculosis	B
(	I
TB	I
)	I
or	O
HIV	B
;	O
renal	B
insufficiency	I
;	O
hepatic	B
disease	I
;	O
oral	O
or	O
parenteral	B
medication	I
known	B
to	I
affect	I
the	I
immune	I
function	I
,	O
such	O
as	O
corticosteroids	B
,	O
other	B
immunosuppressant	B
drugs	I
;	O
or	O
behavioural	O
or	O
memory	B
issues	I
)	O

Ever	O
having	O
received	O
oral	B
cholera	I
vaccine	I
.	O

Receipt	O
of	O
an	O
investigational	O
product	O
(	O
within	O
30	O
days	O
before	O
vaccination	O
)	O
.	O

History	B
of	O
diarrhoea	B
in	B
7	I
days	I
prior	I
to	I
first	I
dose	I
of	I
vaccine	I
(	O
defined	O
as	O
=	B
3	I
unformed	B
loose	I
stools	I
in	I
24	I
hours	I
)	O
.	O

History	B
of	O
chronic	B
diarrhea	I
(	O
lasting	B
for	I
more	I
than	I
2	I
weeks	I
in	B
the	I
past	I
6	I
months	I
)	O

Current	O
use	O
of	O
laxatives	B
,	O
antacids	B
,	O
or	O
other	B
agents	B
to	I
lower	I
stomach	I
acidity	I
?	O

Planning	O
to	O
become	O
pregnant	O
in	O
the	O
next	O
2	O
years	O
.	O

Age	B
=	B
1	I
year	I
,	O
stratified	O
into	O
different	O
age	O
groups	O

Living	B
in	O
the	O
Waya	O
Clinic	O
Catchment	O
Area	O

Good	B
health	I
condition	I
,	O
without	B
clinically	B
significant	I
medical	B
history	I
(	O
by	O
participant	O
or	O
guardian	O
,	O
in	O
case	O
of	O
minor	O
)	O

Not	B
pregnant	B
for	O
female	B
subjects	O
.	O

Available	O
to	O
participate	O
for	O
the	O
study	O
duration	O
,	O
including	O
all	O
planned	O
follow	O
-	O
up	O
visits	O
for	O
up	O
to	O
9	O
months	O
from	O
screening	O
.	O

Signed	O
informed	O
consent	O

Subject	O
who	O
showed	O
medically	B
significant	I
adverse	B
events	I
or	O
intolerance	B
with	O
aripiprazole	B
during	B
screening	I
period	I
or	O
as	B
prior	I
experiences	I
.	O

Subjects	O
with	O
a	O
current	O
DSM	B
-	I
<	I
U	I
+	I
2163	I
>	I
-	I
TR	I
or	O
5	O
diagnosis	O
other	B
than	I
schizophrenia	B
,	O
including	O
schizoaffective	B
disorder	I
,	O
major	B
depressive	I
disorder	I
,	O
bipolar	B
disorder	I
,	O
delirium	B
,	O
dementia	B
,	O
amnesia	B
,	O
Borderline	O
,	O
Paranoid	O
,	O
Histrionic	O
,	O
Schizotypal	O
,	O
Schizoid	O
,	O
Antisocial	O
or	O
other	B
cognitive	O
or	O
personality	B
disorders	I
.	O

Subjects	O
with	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
that	O
may	O
impact	O
the	O
assessment	O
of	O
the	O
psychotic	O
symptoms	O
as	O
per	O
investigator	O
'	O
s	O
opinion	O
.	O

Subjects	O
who	O
have	O
been	O
treated	O
with	O
clozapine	B
or	O
long	B
-	I
acting	I
injectable	I
antipsychotic	I
drugs	I
within	B
3	I
months	I
prior	I
to	I
the	I
screening	I
.	O

Subjects	O
who	O
have	O
been	O
treated	O
over	O
maximum	B
maintenance	I
dose	I
(	O
as	O
specified	O
in	O
each	O
label	O
)	O
of	O
oral	B
antipsychotics	I
at	B
screening	I
.	O

(	O
e	O
.	O
g	O
.	O
Aripiprazole	B
>	B
30mg	I
/	I
day	I
,	O
Olanzapine	B
>	B
20mg	I
/	I
day	I
,	O
Risperidone	B
>	B
6mg	I
/	I
day	I
,	O
Quetiapine	B
>	B
750mg	I
/	I
day	I
)	O

Subjects	O
with	O
a	O
significant	O
risk	O
of	O
violent	O
behaviour	O
or	O
a	O
significant	O
risk	O
of	O
committing	B
suicide	I
based	O
on	O
history	O
or	O
investigator	O
'	O
s	O
judgment	O
.	O

Subjects	O
had	O
a	O
history	B
of	O
seizures	B
,	O
neuroleptic	B
malignant	I
syndrome	I
,	O
clinically	B
significant	I
tardive	B
dyskinesia	I
,	O
or	O
other	O
medical	O
condition	O
that	O
would	O
expose	O
them	O
to	O
undue	O
risk	O
or	O
interfere	O
with	O
study	O
assessments	O
.	O

Significant	O
history	O
of	O
drug	O
abuse	O
disorder	O
(	O
including	O
alcohol	O
,	O
as	O
defined	O
in	O
DSM	O
-	O
5	O
substance	O
use	O
disorder	O
or	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
)	O
within	O
the	O
last	O
6	O
months	O
prior	O
to	O
screening	O
.	O

Subjects	O
participating	O
another	O
interventional	O
clinical	O
trial	O
within	O
30	O
days	O
prior	O
to	O
screening	O
.	O

Women	O
who	O
are	O
pregnant	O
,	O
nursing	O
,	O
or	O
who	O
plan	O
to	O
become	O
pregnant	O
while	O
in	O
the	O
trial	O
.	O

Subjects	O
having	O
any	O
other	O
clinically	O
significant	O
finding	O
of	O
the	O
physical	O
examination	O
or	O
laboratory	O
value	O
that	O
make	O
investigator	O
consider	O
that	O
it	O
would	O
be	O
inappropriate	O
to	O
participate	O
in	O
this	O
study	O
.	O

Subjects	O
must	O
be	O
capable	O
of	O
providing	O
signed	O
and	O
dated	O
written	O
informed	O
consent	O
by	O
date	O
of	O
Visit	O
0	O
(	O
-	O
2	O
week	O
)	O
.	O

Male	B
and	O
female	B
aged	B
=	B
19	I
and	I
<	I
65	I
years	I
.	O

Subjects	O
diagnosed	O
of	O
schizophrenia	B
as	O
defined	O
by	O
Diagnostic	B
and	I
Statistical	I
Manual	I
of	I
Mental	I
Disorders	I
,	I
4th	I
edition	I
text	I
revision	I
or	I
5th	I
edition	I
(	I
DSM	I
-	I
<	I
U	I
+	I
2163	I
>	I
-	I
TR	I
or	I
5	I
)	I
criteria	I
,	O
and	O
a	O
history	B
of	I
illness	I
for	B
at	I
least	I
for	I
3	I
years	I
prior	B
to	I
screening	I
.	O

Subjects	O
who	O
take	O
atypical	B
antipsychotic	I
drugs	I
,	O
and	O
should	O
be	O
maintained	O
on	O
current	O
antipsychotic	O
drugs	O
(	O
including	O
atypical	O
antipsychotic	O
drugs	O
)	O
and	O
dose	O
for	O
at	O
least	O
4	O
weeks	O
prior	O
to	O
the	O
screening	O
.	O

Subjects	O
who	O
need	O
antipsychotic	O
treatment	O
(	O
other	O
than	O
clozapine	O
)	O
,	O
and	O
would	O
be	O
stable	O
when	O
switching	O
to	O
long	O
-	O
acting	O
injectable	O
aripiprazole	O
in	O
the	O
investigator	O
'	O
s	O
judgement	O
.	O

Subjects	O
must	O
exhibit	O
willingness	O
,	O
physiologic	O
capability	O
,	O
and	O
an	O
educational	O
level	O
sufficient	O
to	O
comply	O
with	O
all	O
protocol	O
procedures	O
.	O

Subjects	O
with	O
a	O
known	O
or	O
suspected	O
alcohol	O
or	O
drug	O
abuse	O
which	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
could	O
interfere	O
with	O
the	O
subject	O
'	O
s	O
proper	O
completion	O
of	O
the	O
protocol	O
requirement	O
.	O

History	O
of	O
life	B
threatening	I
asthma	B
:	O
Defined	O
as	O
an	O
asthma	B
episode	I
that	O
required	O
intubation	B
and	O
/	O
or	O
was	O
associated	O
with	O
hypercapnea	B
,	O
respiratory	B
arrest	I
or	O
hypoxic	B
seizures	I
within	B
the	I
last	I
6	I
months	I
.	O

A	O
lower	B
respiratory	I
tract	I
infection	I
within	B
7	I
days	I
of	I
the	I
screening	I
visit	I
.	O

Concurrent	O
diagnosis	O
of	O
chronic	B
obstructive	I
pulmonary	I
disease	I
(	I
COPD	I
)	I
or	O
other	B
respiratory	B
disorders	I
including	O
active	B
tuberculosis	B
,	O
lung	B
cancer	I
,	O
bronchiectasis	B
,	O
sarcoidosis	B
,	O
lung	B
fibrosis	I
,	O
pulmonary	B
hypertension	I
,	O
interstitial	B
lung	I
diseases	I
or	O
other	B
active	B
pulmonary	B
diseases	I
.	O

History	O
of	O
hypersensitivity	B
/	O
intolerance	B
to	O
any	O
components	B
of	I
the	I
study	I
inhalers	I
(	O
example	O
,	O
lactose	B
,	O
magnesium	B
stearate	I
)	O
.	O

In	O
addition	O
,	O
subjects	O
with	O
a	O
history	B
of	O
severe	B
milk	B
protein	I
allergy	B
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
study	O
physician	O
,	O
contraindicates	B
participation	I
will	O
also	O
be	O
excluded	O
.	O

Historical	O
or	O
current	B
evidence	O
of	O
clinically	B
significant	I
or	O
rapidly	B
progressing	I
or	O
unstable	B
cardiovascular	O
,	O
neurological	O
,	O
cardiovascular	O
,	O
neurological	O
,	O
renal	O
,	O
hepatic	O
,	O
immunological	O
,	O
endocrine	O
(	O
including	O
uncontrolled	B
diabetes	B
or	O
thyroid	B
disease	I
)	O
or	O
hematological	B
abnormalities	I
that	O
are	O
uncontrolled	B
.	O

Significant	O
is	O
defined	O
as	O
any	O
disease	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
would	O
put	O
the	O
safety	O
of	O
the	O
subject	O
at	O
risk	O
through	O
participation	O
,	O
or	O
which	O
would	O
affect	O
the	O
analysis	O
if	O
the	O
disease	O
/	O
condition	O
exacerbated	O
during	O
the	O
study	O
.	O

Subjects	O
who	O
have	O
ever	O
received	O
treatment	B
with	O
biological	O
based	O
therapy	O
example	O
,	O
omalizumab	B
,	O
mepolizumab	B
,	O
for	O
asthma	B
.	O

Subjects	O
who	O
have	O
received	O
an	O
investigational	O
drug	O
and	O
/	O
or	O
medical	O
device	O
within	O
30	O
days	O
of	O
entry	O
into	O
this	O
study	O
(	O
Screening	O
)	O
,	O
or	O
within	O
five	O
drug	O
half	O
-	O
lives	O
of	O
the	O
investigational	O
drug	O
,	O
whichever	O
is	O
longer	O
.	O

A	O
subject	O
will	O
not	O
be	O
eligible	O
for	O
this	O
study	O
if	O
he	O
/	O
she	O
is	O
an	O
immediate	O
family	O
member	O
of	O
the	O
participating	O
investigator	O
,	O
sub	O
-	O
investigator	O
,	O
study	O
coordinator	O
,	O
employee	O
of	O
the	O
participating	O
investigator	O
,	O
or	O
any	O
family	O
member	O
of	O
a	O
Propeller	O
Health	O
employee	O
.	O

Subjects	O
aged	B
18	B
years	I
or	I
older	I
,	O
at	B
the	I
time	I
of	I
signing	I
the	I
informed	I
consent	I
.	O

Subjects	O
with	O
documented	O
physician	O
diagnosis	O
of	O
asthma	B
as	O
their	O
primary	B
respiratory	I
disease	I
.	O

ACT	B
score	I
<	B
20	I
at	B
screening	I
visit	I
.	O

Non	O
-	O
smokers	O
(	O
never	O
smoked	O
or	O
not	O
smoking	O
for	B
>	I
6	I
months	I
with	O
<	B
10	I
pack	B
years	I
history	O
(	O
Pack	O
years	O
=	O
[	O
cigarettes	O
per	O
day	O
smoked	O
/	O
20	O
]	O
multiplied	O
by	O
number	O
of	O
years	O
smoked	O
)	O
.	O

Male	B
or	O
female	B
subjects	O
will	O
be	O
included	O
.	O

A	O
female	O
subject	O
is	O
eligible	O
to	O
participate	O
if	O
she	O
is	O
not	O
pregnant	O
,	O
not	O
breastfeeding	O
,	O
and	O
at	O
least	O
one	O
of	O
the	O
following	O
conditions	O
applies	O
:	O
(	O
i	O
)	O
Not	O
a	O
woman	O
of	O
childbearing	O
potential	O
(	O
WOCBP	O
)	O
.	O
(	O
ii	O
)	O
A	O
WOCBP	O
who	O
agrees	O
to	O
follow	O
the	O
contraceptive	O
guidance	O
during	O
the	O
treatment	O
period	O
and	O
for	O
at	O
least	O
5	O
days	O
]	O
after	O
the	O
last	O
dose	O
of	O
study	O
treatment	O
.	O

Capable	O
of	O
giving	O
signed	O
informed	O
consent	O
which	O
includes	O
compliance	O
with	O
the	O
requirements	O
and	O
restrictions	O
listed	O
in	O
the	O
consent	O
form	O
and	O
protocol	O
.	O

Subject	O
understands	O
and	O
is	O
willing	O
,	O
able	O
,	O
and	O
likely	O
to	O
comply	O
with	O
study	O
procedures	O
and	O
restrictions	O
.	O

Subject	O
must	O
be	O
able	O
to	O
read	O
in	O
a	O
language	O
supported	O
by	O
the	O
smart	O
phone	O
app	O
in	O
their	O
region	O
.	O

Subject	O
must	O
have	O
been	O
on	O
maintenance	B
therapy	I
(	O
Fixed	B
dose	I
combination	B
ICS	I
/	I
LABA	I
)	O
for	B
3	I
months	I
,	O
cannot	B
have	O
changed	B
dose	I
in	B
the	I
month	I
prior	I
to	I
screening	I
and	O
be	O
able	O
to	O
change	O
to	O
an	O
equivalent	O
dose	O
of	O
RELVAR	O
/	O
BREO	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O
Other	O
background	O
asthma	O
medication	O
such	O
as	O
anti	O
-	O
leukotrienes	O
and	O
oral	O
corticosteroids	O
are	O
permitted	O
provided	O
the	O
dose	O
has	O
been	O
stable	O
for	O
1	O
month	O
prior	O
to	O
screening	O
.	O

Subject	O
must	O
be	O
able	O
to	O
change	B
to	O
Salbutamol	B
/	O
Albuterol	B
MDI	B
rescue	I
for	B
the	I
duration	I
of	I
the	I
study	I
and	O
judged	O
capable	B
of	I
withholding	I
albuterol	B
/	O
salbutamol	B
for	B
at	I
least	I
6	I
hours	I
prior	B
to	I
study	I
visits	I
.	O

Subject	O
must	O
have	O
their	O
own	O
Android	O
or	O
iPhone	O
operating	O
system	O
(	O
IOS	O
)	O
smart	O
phone	O
and	O
a	O
data	O
package	O
suitable	O
for	O
the	O
installation	O
and	O
running	O
of	O
the	O
app	O
and	O
sending	O
and	O
receiving	O
data	O
.	O
Data	O
used	O
by	O
the	O
CIS	O
is	O
approximately	O
1	O
megabyte	O
(	O
MB	O
)	O
per	O
month	O
as	O
a	O
maximum	O
;	O
this	O
is	O
less	O
data	O
than	O
a	O
1	O
minute	O
video	O
streamed	O
from	O
YouTube	O
(	O
2MB	O
)	O
.	O

Subjects	O
must	O
be	O
willing	O
and	O
able	O
to	O
download	O
the	O
app	O
on	O
their	O
personal	O
smart	O
phone	O
and	O
keep	O
it	O
turned	O
on	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O
This	O
will	O
also	O
require	O
Bluetooth	O
to	O
be	O
turned	O
on	O
for	O
duration	O
of	O
the	O
study	O
.	O
Subjects	O
will	O
also	O
have	O
to	O
turn	O
on	O
mobile	O
data	O
for	O
the	O
app	O
for	O
the	O
duration	O
of	O
study	O
;	O
unless	O
travelling	O
and	O
when	O
extra	O
data	O
roaming	O
costs	O
could	O
be	O
incurred	O
.	O

ACT	B
score	I
<	B
20	I
at	B
randomization	I
visit	I
(	O
visit	O
2	O
)	O
.	O

taken	O
adenosine	B
diphosphate	I
(	I
ADP	I
)	I
receptor	I
antagonists	I
within	B
2	I
weeks	I

Platelet	B
count	I
<	B
100g	I
/	I
L	I
;	O

A	O
history	B
of	O
bleeding	B
tendency	I
;	O

Aspirin	B
,	O
ticagrelor	B
or	O
clopidogrel	B
allergies	B
;	O

Severe	B
liver	B
injury	I
.	O

After	O
half	B
-	I
dose	I
ticagrelor	B
(	O
loading	B
dose	I
90mg	B
,	O
and	O
then	O
45mg	B
bidpo	I
.	I
)	O
treatment	B
for	I
3	I
days	I
,	O
the	O
platelet	B
aggregation	I
is	O
effectively	B
inhibited	B
by	O
light	B
transmission	I
aggregometry	I
method	O
and	O
thromboela	B
-	I
stogram	I
.	O

planned	O
to	O
undergo	O
PCI	B
recently	B

planned	O
to	O
DAPT	B
for	B
1	I
year	I
after	O
PCI	B

Women	B
only	O
:	O
Cannot	O
be	O
pregnant	O
or	O
nursing	O
at	O
baseline	O
or	O
plan	O
to	O
become	O
pregnant	O
during	O
the	O
course	O
of	O
the	O
study	O

Body	B
Mass	I
Index	I
(	I
BMI	I
)	I
>	B
32	I

Weight	B
>	B
220	I
pounds	I

Allergies	B
to	O
shell	O
fish	O
,	O
seafood	O
,	O
eggs	O
or	O
iodine	B

Heart	B
disease	I
,	O
kidney	B
disease	I
or	O
diabetes	B

Diagnosis	O
of	O
asthma	B

Any	O
metal	B
in	I
or	I
on	I
the	I
body	I
(	O
that	O
cannot	O
be	O
removed	O
)	O
between	B
the	I
nose	I
and	I
the	I
abdomen	I

Any	O
major	B
organ	I
system	I
disease	I
(	O
by	O
judgment	O
of	O
the	O
study	O
medical	O
team	O
)	O

A	O
glomerular	B
filtration	I
rate	I
of	O
60	B
cc	I
per	I
minute	I
or	I
less	I
.	O

Nitroglycerin	B
usage	O
or	O
nitrates	B
and	O
use	O
of	O
phosphodiesterase	B
5	I
(	I
PDE5	I
)	I
inhibitors	I

Prior	B
history	I
of	O
hypersensitivity	B
to	O
sildenafil	B

Currently	O
prescribed	O
a	O
phosphodiesterase	B
(	I
PDE	I
)	I
inhibitors	I
medication	O
(	O
ex	O
:	O
Viagra	B
,	O
Cialis	B
,	O
etc	O
)	O

Known	O
Pulmonary	B
Hypertension	I

Has	O
used	O
e	O
-	O
cigarettes	O
and	O
marijuana	O
<	B
1	I
years	I

Between	O
the	O
age	B
of	O
25	O
to	O
65	O
at	B
baseline	I

Be	O
willing	O
to	O
participate	O
in	O
a	O
smoking	B
cessation	I
program	I

Be	O
willing	O
to	O
attend	O
all	O
clinic	O
visits	O

Must	O
be	O
currently	O
smoking	O
at	B
least	I
½	I
pack	B
/	I
day	I
at	B
baseline	I
(	O
confirmed	O
with	O
cotinine	B
level	I
and	O
CO	B
Smokerlyzer	I

>	B
5	I
pack	B
-	I
year	I
history	O
of	O
smoking	O

Global	B
Initiative	I
for	I
Chronic	I
Obstructive	I
Lung	I
Disease	I
(	I
GOLD	I
)	I
0	B
:	O
FEV1	B
=	B
0	I
.	I
80	I
and	O
FEV1	B
/	I
FVC	I
>	B
0	I
.	I
70	I
Forced	O
Expiratory	O
Volume	O
in	O
1	O
second	O
(	O
FEV1	O
)	O
,	O
Forced	O
Vital	O
Capacity	O
(	O
FVC	O
)	O

GOLD	B
1	B
:	O
FEV1	B
=	B
0	I
.	I
80	I
and	O
FEV1	B
/	I
FVC	I
<	B
0	I
.	I
70	I

GOLD	B
2	B
:	O
0	O
.	O
50	O
=	O
FEV1	B
<	O
0	O
.	O
80	O
and	O
FEV1	B
/	I
FVC	I
<	B
0	I
.	I
70	I

Be	O
willing	O
to	O
abstain	O
from	O
using	O
any	O
nicotine	O
patches	O
,	O
e	O
-	O
cigarettes	O
,	O
or	O
marijuana	O
for	O
the	O
duration	O
of	O
the	O
study	O
.	O

Clinically	B
significant	I
systemic	B
disease	I
(	O
such	O
as	O
diabetes	B
,	O
metabolic	B
syndrome	I
,	O
immunological	B
diseases	I
,	O
diagnosed	B
thrombophilia	I
,	O
porphyria	B
,	O
or	O
any	O
other	O
medical	B
condition	I
requiring	O
the	O
use	O
of	O
low	B
-	I
molecular	I
weight	I
heparin	I
therapy	O
)	O

Polycystic	B
ovary	I
syndrome	I
(	I
PCOS	I
)	I
according	O
to	O
Rotterdam	B
Consensus	I
Criteria	I
(	O
European	B
Society	I
of	I
Human	I
Reproduction	I
and	I
Embryology	I
[	I
ESHRE	I
]	I
/	I
American	I
Society	I
for	I
Reproductive	I
Medicine	I
[	I
ASRM	I
]	I
,	I
2003	I
)	O

Poor	B
ovarian	I
response	I
(	I
POR	I
)	I
according	O
to	O
the	O
European	B
Society	I
of	I
Human	I
Reproduction	I
and	I
Embryology	I
(	I
ESHRE	I
)	I
Criteria	I

RIF	B
(	I
repeated	I
implantation	I
failure	I
)	I
,	O
defined	O
as	O
greater	B
than	I
or	I
equals	I
to	I
(	I
>	I
=	I
)	I
2	I
previous	B
failed	I
embryo	I
transfers	I

Endometriosis	B
III	B
-	I
IV	I
stage	I
or	O
adenomyosis	B

Clinically	B
significant	I
findings	O
on	O
exam	B
or	O
ultrasound	B
,	O
such	O
as	O
salpingitis	B
,	O
hydrosalpynx	B
or	O
evidence	O
of	O
ovarian	B
cysts	I

Known	O
hypersensitivity	B
to	O
any	O
of	O
the	O
components	B
of	I
the	I
solution	I

Known	O
hypersensitivity	B
to	O
vaginal	B
progesterone	I
or	O
its	O
excipients	B

Other	O
protocol	O
defined	O
exclusion	O
criteria	O
could	O
apply	O

All	O
infertile	B
women	B
treated	O
with	O
intracytoplasmic	B
sperm	I
injection	I
(	I
ICSI	I
)	I
/	O
Fertilization	B
in	I
Vitro	I
and	I
Embryo	I
Transfer	I
(	I
FIVET	I
)	I

Less	B
than	I
or	I
equal	I
to	I
(	I
<	I
=	I
)	I
1	I
previous	B
failed	I
embryo	I
transfer	I

Eumenorrheic	B
normo	B
-	I
gonadotropic	I
women	B

Basal	B
follicle	I
-	I
stimulating	I
hormone	I
(	I
FSH	I
)	I
<	B
=	I
12	I
International	I
unit	I
per	I
liter	I
(	I
IU	I
/	I
L	I
)	I

Anti	B
-	I
mullerian	I
hormone	I
(	I
AMH	I
)	I
greater	B
than	I
(	I
>	I
)	I
1	I
.	I
1	I
nanogram	I
per	I
milliliter	I
(	I
ng	I
/	I
mL	I
)	I

Ovarian	O
Reserve	O
:	O
number	B
of	I
antral	I
follicles	I
2	I
millimeter	I
(	I
mm	I
)	I
between	B
6	I
<	I
=	I
antral	I
follicle	I
count	I
(	I
AFC	I
)	I
<	I
=	I
16	I

Follicles	B
>	I
16	I
mm	I
at	B
the	I
triggering	I
day	I
between	B
5	I
-	I
14	I

Body	B
Mass	I
Index	I
(	I
BMI	I
)	I
between	B
18	I
<	I
=	I
BMI	I
<	I
=	I
27	I
kilogram	I
per	I
meter	I
square	I
(	I
kg	I
/	I
m	I
^	I
2	I
)	I

Indication	O
for	O
Fresh	B
Embryo	I
transfer	I

Normal	O
uterine	O
cavity	O
on	O
ultrasound	B
exam	I
(	O
e	O
.	O
g	O
.	O
,	O
no	B
presence	I
of	I
hydrosalpinx	B
)	O

Undergoing	B
Assisted	B
Reproductive	I
Technique	I
(	I
ART	I
)	I
and	O
oocyte	B
maturation	I
by	O
human	B
chorionic	I
gonadotropin	I
(	I
HCG	I
)	I
triggering	I

Progesterone	B
(	I
P4	I
)	I
serum	I
level	I
at	B
the	I
HCG	I
triggering	I
day	I
<	B
=	I
1	I
.	I
5	I
ng	I
/	I
mL	I
(	O
Day	O
O	O
/	O
Randomization	O
)	O

Estradiol	B
(	I
E2	I
)	I
<	B
=	I
3000	I
picogram	I
/	I
milliliter	I
(	I
pg	I
/	I
mL	I
)	I
at	B
the	I
human	I
chorionic	I
gonadotropin	I
(	I
HCG	I
)	I
triggering	I
day	I
(	O
Day	O
0	O
/	O
Randomization	O
)	O

Subjects	O
must	O
have	O
read	O
and	O
signed	O
the	O
Informed	O
Consent	O
Form	O
prior	O
to	O
study	O
-	O
specific	O
-	O
procedures	O
not	O
part	O
of	O
standard	O
of	O
care	O

Other	O
protocol	O
defined	O
inclusion	O
criteria	O
could	O
apply	O

Patients	O
with	O
Non	B
-	I
androgenetic	I
causes	I
of	I
hair	I
loss	I
.	O

Female	B
patients	O
with	O
androgenetic	B
alopecia	I
.	O

Patients	O
who	O
received	O
anti	B
-	I
hair	I
loss	I
treatment	I
within	B
the	I
past	I
six	I
months	I
.	O

Patients	O
with	O
history	B
of	O
bleeding	B
disorders	I
or	O
on	O
anticoagulant	B
therapy	I
.	O

Patients	O
with	O
history	B
of	O
chronic	B
liver	I
disease	I
,	O
cancer	B
or	O
connective	B
tissue	I
disorders	I
.	O

Patients	O
with	O
current	B
scalp	B
infection	I
.	O

male	B
patients	O
with	O
androgenetic	B
alopecia	I
between	O
18	O
years	O
and	O
60	O
years	B

NA	O

Patients	O
with	O
SOF	B
/	I
VEL	I
treatment	I
for	O
the	O
treatment	O
of	O
chronic	B
HCV	B
genotype	I
1	B
through	I
6	I
.	O

Patient	O
is	O
at	B
least	I
18	I
at	I
the	I
day	I
of	I
screening	I
.	O

Patient	O
is	O
able	O
and	O
willing	O
to	O
sign	O
the	O
Informed	O
Consent	O
Form	O
.	O

Patient	O
is	O
able	O
and	O
willing	O
to	O
follow	O
protocol	O
requirements	O
.	O

on	O
hemodialysis	B
for	B
less	I
than	I
3	I
months	I

comorbid	B
psychotic	B
,	O
bipolar	B
,	O
substance	B
use	I
dependence	I
,	O
Alzheimer	B
'	I
s	I
or	O
dementia	B

currently	B
on	O
hemodialysis	B
at	O
a	O
CDC	O
dialysis	O
unit	O

English	O
speaking	O

able	O
to	O
provide	O
informed	O
consent	O

Age	B
less	B
than	I
one	I
year	I
or	O
over	B
18	I
years	I

Patients	O
with	O
renal	B
impairment	I

Colistin	B
use	O
less	B
than	I
72	I
hours	I

Age	B
between	B
one	I
year	I
and	I
18	I
years	I

Sepsis	B
due	O
to	O
MDR	B
or	O
minimally	B
susceptible	I
gram	I
-	I
negative	I
bacteria	I

History	O
of	O
MDR	B
gram	B
-	I
negative	I
infection	I
or	O
sepsis	B
due	O
to	O
organisms	O
sensitive	B
to	I
colistin	I
.	O

Culture	O
result	O
consistent	O
with	O
MDR	B
gram	B
negative	I
for	O
this	O
febrile	O
neutropenic	O
episode	O
.	O

Patient	O
in	O
sepsis	B
and	O
colistin	B
was	O
administered	B
empirically	I
to	O
increase	O
antibiotic	O
coverage	O
.	O

Pregnancy	B
or	O
breastfeeding	O

Allergy	B
against	O
to	O
penicillin	B
or	O
cephalosporins	B

Renal	B
impairment	I

Active	B
hepatic	B
disease	I

Antibiotic	B
use	O
except	B
study	B
drugs	I

Immunosuppressive	B
therapy	I
before	B
6	I
months	I
of	I
study	I
initiation	I

Use	O
of	O
probenecid	B
like	O
drugs	O

The	O
diagnosis	O
of	O
chronic	B
bronchitis	I

The	O
diagnosis	O
of	O
community	B
-	I
acquired	I
pneumoniae	I

FEV1	B
value	I
=	B
30	I
-	I
80	I
%	I

The	O
diagnosis	O
of	O
mild	B
-	I
severe	I
acute	B
exacerbation	B
of	I
chronic	I
bronchitis	I
(	O
AECB	B
)	O

Oxygen	B
saturation	I
<	B
90	I
%	I

On	O
systemic	B
antibiotics	I
or	O
with	O
an	O
active	B
bacterial	B
infection	I
at	O
the	O
time	O
of	O
surgery	B

Patients	O
previously	O
enrolled	O
in	O
this	O
trial	O

Patients	O
known	O
to	O
be	O
colonized	B
with	O
Methicillin	B
-	I
resistant	I
S	I
.	I
aureus	I
(	I
MRSA	I
)	I
(	O
unethical	O
not	O
to	O
administer	O
glycopeptides	O
)	O
,	O
beta	B
-	I
lactam	I
or	O
vancomycin	B
allergy	B
precluding	O
the	O
use	O
of	O
cefazolin	B
or	O
vancomycin	B
,	O
respectively	O
,	O
or	O
to	O
silver	B
precluding	O
the	O
use	O
of	O
Prevena	O

Participation	O
in	O
other	O
studies	O
that	O
may	O
interfere	O
with	O
this	O
trial	O

≥	B
18	I
years	I
of	O
age	B
undergoing	B
open	B
-	I
heart	I
surgery	I
(	O
sternotomy	B
,	O
including	O
minimally	B
-	I
invasive	I
sternotomies	I
)	O

Secondary	B
knee	B
osteoarthritis	I

Other	B
inflammatory	B
Knee	I
Osteoarthritis	I
(	O
e	O
.	O
g	O
.	O
gout	B
,	O
rheumatoid	B
arthritis	I
,	O
etc	O
.	O
)	O

Patients	O
presenting	O
with	O
gastroesophageal	B
reflux	I
disease	I
,	O
peptic	B
ulcer	I
.	O

Helicobacter	B
infected	I
patients	O
who	O
have	O
not	B
been	O
treated	B
for	I
eradication	I
(	O
recruitment	O
if	O
negative	O
in	O
re	O
-	O
examination	O
after	O
treatment	O
)	O
.	O

Short	B
bowel	I
syndrome	I
that	O
can	O
cause	O
inflammatory	B
bowel	I
disease	I
(	O
ulcerative	B
colitis	I
,	O
Crohn	B
'	I
s	I
disease	I
)	O
and	O
drug	B
absorption	I
disorder	I
.	O

Intestinal	B
obstruction	I
syndrome	I

Unexplained	B
abdominal	B
pain	I

ALT	B
(	I
Alanine	I
aminotransferase	I
)	I
level	I
of	O
liver	B
function	I
test	I
exceeded	B
5	I
times	I
of	I
reference	I
range	I

Total	B
bilirubin	I
level	I
exceeded	B
2	I
mg	I
/	I
dL	I

Serum	B
albumin	I
level	I
less	B
than	I
2	I
g	I
/	I
dL	I

Ascites	B

Hepatic	B
encephalopathy	I

Hepatitis	B
B	I
,	O
hepatitis	B
C	I
(	O
excluding	B
healthy	B
carriers	I
)	O
or	O
HIV	B
positive	I

MDRD	B
(	I
Modification	I
of	I
Diet	I
in	I
Renal	I
Disease	I
)	I
Estimated	B
Glomerular	I
filtration	I
rate	I
less	B
than	I
60	I
mL	I
/	I
m2	I

Patients	O
with	O
hyperkalemia	B
(	O
over	B
5	I
.	I
5	I
meq	I
/	I
L	I
)	O

history	O
of	O
asthma	B
,	O
acute	B
rhinitis	I
,	O
nasal	B
polyps	I
,	O
angioedema	B
,	O
urticaria	B
or	O
allergic	B
reactions	I
to	O
aspirin	B
or	O
other	B
non	B
-	I
steroidal	I
anti	I
-	I
inflammatory	I
drugs	I
(	O
including	O
COX	B
-	I
2	I
inhibitors	I
)	O
.	O

Malignant	B
tumors	I
other	B
than	I
basal	O
cell	O
or	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
skin	I
,	O
CIN	B
(	I
Cervical	I
Intraepitherial	I
Neoplasia	I
)	I
and	O
CIS	B
(	I
Carcinoma	I
in	I
situ	I
)	I
of	I
the	I
cervix	I
,	O
and	O
intraepithelial	B
carcinoma	I
of	O
other	O
areas	O
Within	B
5	I
years	I
of	I
consent	I
date	I
.	O

Medical	O
history	O
of	O
hypersensitivity	B
to	O
the	O
components	B
of	I
the	I
investigational	I
products	I
.	O

(	O
The	O
components	B
of	I
test	I
drug	I
1	I
and	O
2	O
,	O
including	O
the	O
Rhein	B
-	I
based	I
drug	I
)	O

Patients	O
with	O
an	O
allergic	B
reaction	I
to	O
sulfonamide	B
.	O

Patients	O
with	O
galactose	B
intolerance	I
,	O
lapp	B
lactase	I
deficiency	I
or	O
glucose	B
-	I
galactose	I
malabsorption	I
.	O

Subjects	O
who	O
have	O
not	O
reached	O
the	O
prescribed	O
period	O
after	O
receiving	O
contraindicated	O
medication	O
or	O
treatment	O
before	O
participation	O
in	O
this	O
clinical	O
trial	O
.	O

Patients	O
receiving	O
contraindicated	B
medication	I
.	O

Alcohol	O
and	O
other	O
drug	B
abuse	I
cases	O
based	O
on	O
6	B
months	I
before	I
screening	I
.	O

Pregnant	O
women	O
or	O
nursing	O
mothers	O
who	O
are	O
not	O
willing	O
to	O
stop	O
breastfeeding	O
.	O

(	O
1	O
)	O
Menopause	B
(	O
non	B
-	I
therapy	I
-	I
induced	I
amenorrhea	B
of	O
more	B
than	I
12	I
months	I
)	O
Female	B

(	O
2	O
)	O
Female	B
infertility	B
due	B
to	I
surgery	I
(	O
no	B
ovaries	I
and	O
/	O
or	O
uterus	O
)	O

(	O
3	O
)	O
If	O
you	O
have	O
sexual	O
intercourse	O
with	O
only	O
one	O
male	O
partner	O
who	O
has	O
been	O
confirmed	O
to	O
have	O
no	O
semen	O
after	O
fertilization	O
.	O

(	O
4	O
)	O
Female	O
subjects	O
who	O
agreed	O
to	O
abstinence	O
during	O
the	O
clinical	O
trial	O
period	O
.	O

If	O
the	O
subject	O
is	O
assured	O
of	O
an	O
abstinence	O
throughout	O
the	O
trial	O
period	O
.	O
(	O
e	O
.	O
g	O
.	O
clergy	O
)	O

However	O
,	O
intermittent	O
abstinence	O
(	O
eg	O
,	O
contraception	O
using	O
ovulation	O
period	O
,	O
symptothermal	O
)	O
or	O
coitus	O
interrupts	O
is	O
not	O
a	O
case	O
of	O
consent	O
for	O
abstinence	O
.	O

(	O
5	O
)	O
For	O
women	O
of	O
childbearing	O
age	O
,	O
the	O
following	O
methods	O
or	O
methods	O
of	O
contraception	O
use	O
the	O
effective	O
method	O
of	O
contraception	O
to	O
be	O
used	O
during	O
the	O
period	O
of	O
this	O
clinical	O
trial	O
:	O

Oral	B
contraceptive	I

The	O
contraceptive	B
patch	I

Intra	B
uterine	I
device	I
(	I
IUD	I
)	I

contraceptive	B
implant	I

contraceptive	B
injection	I

intrauterine	B
hormonal	I
apparatus	I

Tubal	B
ligation	I
and	O
infertility	B
surgery	I

If	O
30	O
days	O
have	O
not	O
elapsed	O
after	O
the	O
date	O
of	O
signing	O
of	O
the	O
previous	O
clinical	O
trial	O
or	O
currently	O
participating	O
in	O
other	O
clinical	O
trials	O
.	O

Patients	O
who	O
are	O
scheduled	O
for	O
surgery	O
during	O
the	O
clinical	O
trial	O
period	O
or	O
who	O
have	O
difficulties	O
in	O
completing	O
the	O
protocol	O
during	O
this	O
clinical	O
trial	O
due	O
to	O
other	O
reasons	O
.	O

In	O
addition	O
to	O
the	O
above	O
,	O
other	O
diseases	O
that	O
the	O
investigator	O
judges	O
to	O
be	O
inappropriate	O
.	O

Subjects	O
who	O
voluntarily	O
consented	O
,	O
after	O
listening	O
enough	O
explanation	O
for	O
this	O
study	O
and	O
investigational	O
product	O
.	O

Adult	B
over	B
50	I
years	I
of	O
age	B
.	O

At	B
least	I
one	I
of	O
the	O
knee	B
pain	I
VAS	B
score	I
is	O
40mm	B
or	I
more	I
.	O

Patients	O
who	O
require	O
medication	B
for	O
more	B
than	I
12	I
weeks	I
due	O
to	O
osteoarthritis	B
symptoms	I
.	O

Those	O
who	O
are	O
able	O
to	O
follow	O
the	O
requirements	O
of	O
this	O
clinical	O
trial	O
,	O
such	O
as	O
being	O
able	O
to	O
trace	O
during	O
the	O
clinical	O
trial	O
period	O
and	O
to	O
read	O
and	O
write	O
the	O
VAS	O
questionnaire	O
.	O

Those	O
who	O
weigh	B
more	B
than	I
40kg	I

Children	B
will	O
be	O
excluded	O
if	O
they	O
have	O
a	O
history	O
of	O
developmental	B
delay	I
or	O
inability	B
to	I
communicate	I
the	I
effects	I
of	O
an	O
allergic	B
reaction	I
(	O
non	B
-	I
verbal	I
)	O
.	O

Any	O
contraindication	B
to	O
allergy	B
testing	I
will	O
also	O
result	O
in	O
exclusion	O

(	O
i	O
.	O
e	O
.	O
history	B
of	O
a	O
severe	B
allergic	I
reaction	I
to	O
skin	B
tests	I
,	O
,	O

anaphylaxis	B
in	B
the	I
past	I
six	I
weeks	I
,	O

pregnancy	B
,	O

child	O
took	O
any	O
antihistamine	B
in	B
the	I
past	I
three	I
days	I
[	O
including	O
diphenhydramine	B
(	O
Benadryl	B
®	O
)	O
,	O
cetirizine	B
(	O
Zyrtec	B
®	O
)	O
,	O
loratadine	B
(	O
Claritin	B
®	O
)	O
,	O
fexofenadine	B
(	O
Allegra	B
®	O
)	O
,	O
levocetirizine	B
(	O
Xyzal	B
®	O
)	O
,	O
and	O
desloratadine	B
(	O
Clarinex	B
®	O
)	O
]	O
or	O

child	O
has	O
a	O
history	O
of	O
a	O
condition	O
that	O
requires	O
a	O
beta	B
blocker	I
medicine	I
for	O
cardiac	B
conditions	I
,	O
high	B
blood	I
pressure	I
,	O
migraine	B
headaches	I
,	O
or	O
eye	B
drops	I
for	O
glaucoma	B
(	O
e	O
.	O
g	O
.	O
propranolol	B
,	O
metoprolol	B
,	O
atenolol	B
and	O
Timoptic	B
®	O
,	O
or	O
Betoptic	B
®	O
eye	B
drops	I
)	O
.	O

Children	B
who	O
present	O
to	O
the	O
PED	O
with	O
a	O
rash	B
,	O
vomiting	B
or	O
current	B
asthma	B
symptoms	I
including	O
coughing	B
,	O
wheezing	B
or	O
breathing	B
problems	I
will	O
also	O
be	O
excluded	O
to	O
ensure	O
these	O
do	O
not	O
mask	O
reactions	O
to	O
an	O
oral	O
challenge	O
.	O

Patients	O
being	O
admitted	O
to	O
the	O
hospital	O
or	O
those	O
who	O
are	O
deemed	O
too	O
acutely	O
ill	O
for	O
participation	O
(	O
triage	O
level	O
1	O
or	O
2	O
or	O
as	O
determined	O
by	O
the	O
ED	O
patient	O
care	O
team	O
)	O
will	O
be	O
excluded	O
from	O
the	O
study	O
.	O

During	O
this	O
pilot	O
study	O
,	O
we	O
will	O
exclude	O
non	O
-	O
English	O
speaking	O
families	O
.	O

However	O
,	O
in	O
subsequent	O
studies	O
we	O
will	O
include	O
the	O
non	O
-	O
English	O
speaking	O
population	O
.	O

Children	O
who	O
are	O
wards	O
of	O
the	O
state	O
,	O
in	O
foster	O
care	O
or	O
police	O
custody	O
or	O
detention	O
will	O
be	O
excluded	O
.	O

Children	O
with	O
any	O
basal	B
condition	I
(	O
trauma	B
,	O
infection	B
,	O
minor	B
accidents	I
,	O
etc	O
.	O
.	O
)	O
will	O
be	O
able	O
to	O
participate	O
in	O
the	O
study	O
provided	O
they	O
and	O
their	O
family	O
are	O
willing	O
and	O
do	O
not	O
meet	O
the	O
above	O
-	O
mentioned	O
exclusion	O
criteria	O
.	O

Children	B
aged	B
3	B
-	I
16	I
with	O
a	O
parent	O
/	O
guardian	O
(	O
hereafter	O
termed	O
parent	O
)	O
reported	O
history	O
of	O
allergy	B
to	O
a	O
penicillin	B
antibiotic	I
in	O
which	O
the	O
reported	O
allergic	B
reaction	I
occurred	O
at	B
least	I
six	I
months	I
prior	I
to	I
the	I
current	I
PED	I
visit	I
.	O

Only	O
children	O
well	B
enough	I
to	I
be	I
discharged	I
to	I
home	I
at	B
the	I
conclusion	I
of	I
the	I
PED	I
visit	I
are	O
eligible	O
.	O

latex	B
allergy	B

non	B
-	I
reassuring	I
fetal	B
status	I

HIV	B

active	B
herpes	B
outbreak	O

Prior	O
uterine	B
scar	I

Contraindication	B
to	O
prostaglandins	B
according	O
to	O
current	O
Parkland	B
protocol	I

Contraindication	B
to	O
vaginal	B
delivery	I

37	O
weeks	O
gestation	B
or	O
greater	O

Living	B
,	O
singleton	B
fetus	I

No	B
major	B
fetal	I
malformations	I

Cephalic	B
presentation	I

No	B
prior	O
uterine	B
scar	I

Intact	B
fetal	B
membranes	I

Qualifies	O
for	O
prostaglandin	B
administration	I
according	O
to	O
current	O
Parkland	B
protocol	I

Have	O
a	O
cervical	B
dilation	I
of	O
2	B
centimeters	I
or	I
less	I
,	O
measured	O
at	O
the	O
level	O
of	O
the	O
internal	B
os	I

Have	O
an	O
indication	B
for	O
induction	O
or	O
attempted	B
induction	B
of	O
labor	O
according	O
to	O
Parkland	B
protocol	I

Subjects	O
with	O
any	O
condition	O
that	O
as	O
judged	O
by	O
the	O
Investigator	O
would	O
place	O
the	O
subject	O
at	O
increased	O
risk	O
of	O
harm	O
if	O
he	O
/	O
she	O
participated	O
in	O
the	O
study	O
.	O

Pregnancy	O
or	O
lactation	O

Known	O
allergic	B
reaction	O
to	O
tranexamic	B
acid	I

Patients	O
scheduled	O
for	O
dental	B
extraction	I
and	O
treated	O
with	O
edoxaban	B
,	O
apixaban	B
,	O
rivaroxaban	B
or	O
dabigatran	B

Not	B
having	O
taken	O
the	O
direct	O
oral	B
anticoagulant	B
on	B
the	I
day	I
of	I
the	I
extraction	I

Provision	O
of	O
signed	O
and	O
dated	O
informed	O
consent	O
form	O

Stated	O
willingness	O
to	O
comply	O
with	O
all	O
study	O
procedures	O
and	O
availability	O
for	O
the	O
duration	O
of	O
the	O
study	O

Current	B
DVT	B

Recurrent	B
varicose	B
veins	I

Arterial	B
disease	I
(	O
ABPI	B
<	B
0	I
.	I
8	I
)	O

Vein	B
diameter	I
<	B
3mm	I

Preference	O
for	O
one	O
of	O
the	O
treatment	O
options	O

Patient	O
who	O
are	O
unwilling	O
to	O
participate	O

Inability	O
or	O
unwillingness	O
to	O
complete	O
questionnaires	O

Inability	O
to	O
attend	O
follow	O
-	O
up	O
appointments	O

Patient	O
currently	O
included	O
in	O
a	O
study	O
of	O
varicose	O
vein	O
treatment	O

Adults	B
over	O
18	O
years	O
of	O
age	B

Symptomatic	O
GSV	O
or	O
SSV	B
vein	I
reflux	I
>	B
0	I
.	I
5	I
seconds	I
on	O
colour	B
Duplex	I

Varicose	B
vein	I
tributary	I
requiring	O
treatment	B

Presence	O
of	O
severe	B
systemic	B
disease	I

Presence	O
of	O
coagulation	B
disorders	I

Current	B
or	O
previous	B
history	B
of	O
analgesic	B
dependence	O

Allergy	B
to	O
any	O
of	O
the	O
drugs	B
used	I
in	I
the	I
study	I

Women	B
pregnant	B
or	O
lactating	B
,	O
or	O
women	B
planning	O
to	O
become	O
pregnant	B

Presence	O
of	O
hearing	B
loss	I

Presence	O
of	O
cardiovascular	B
comorbidities	I

Presence	O
of	O
hepatic	B
comorbidities	I

Presence	O
of	O
kidney	B
comorbidities	I

Presence	O
of	O
cognitive	B
disabilities	I

Scheduled	O
to	O
undergo	O
bilateral	B
palatine	B
tonsillectomy	I
as	O
the	O
only	O
procedure	B

prior	B
allergic	B
reaction	I
to	O
interferon	B
products	I
,	O
congestive	B
heart	I
failure	I
,	O
elevated	B
liver	I
enzymes	I

diagnosed	O
any	B
form	I
of	O
MS	B
(	O
relapsing	B
remitting	I
,	O
primary	B
progressive	I
,	O
secondary	B
progressive	I
)	O
,	O
any	B
EDSS	O
(	O
expanded	B
stability	I
status	I
scale	I
)	O
score	O

Abnormal	B
resting	B
ECG	I

Current	B
abnormal	B
blood	B
panel	I
(	O
assessed	O
by	O
comprehensive	O
metabolic	B
panel	I
,	O
lipid	B
panel	I
and	O
complete	B
blood	I
count	I
)	O
.	O

Hypertension	B
(	O
currently	O
taking	O
anti	B
-	I
hypertensive	I
medications	I
or	O
resting	B
blood	I
pressure	I
>	B
140	I
/	I
90	I
mmHg	I
)	O

Medical	O
history	O
of	O
cardiovascular	B
disease	I
,	O
malignant	B
cancer	I
,	O
diabetes	B
or	O
kidney	B
disease	I

Obesity	B
(	O
Body	B
Mass	I
Index	I
>	B
30	I
)	O

Current	B
pregnancy	B

Unable	O
to	O
provide	O
consent	O

Habitual	O
dietary	B
sodium	I
intake	I
>	B
3400mg	I
per	I
day	I

type	B
1	I
diabetes	I
,	O
specific	B
types	I
of	O
diabetes	B
,	O
gestational	B
diabetes	I
or	O
pregestational	B
diabetes	I
;	O

acute	B
cardiovascular	O
or	O
cerebrovascular	B
accidents	I
within	B
past	I
3	I
months	I
;	O

severe	B
hepatic	O
or	O
renal	B
dysfunction	I
;	O

malignant	B
tumor	I
;	O

allergic	B
history	B
or	O
contraindication	B
for	O
any	B
drugs	B
in	I
trials	I
;	O

taking	O
part	O
in	O
other	O
clinical	O
trials	O
;	O

obviously	B
poor	O
compliance	O
.	O

35	O
-	O
75	O
years	O
old	B
;	O

diagnosed	O
as	O
type	B
2	I
diabetes	I
according	O
to	O
the	O
criteria	B
of	I
the	I
World	I
Health	I
Organization	I
in	I
1999	I
.	O

Inability	O
to	O
understand	O
and	O
read	O
English	O
.	O

Women	B
pregnant	B
or	O
lactating	B
.	O

persons	O
with	O
terminal	B
illness	I

Overweight	B
/	O
Obese	B
Adult	B
patients	O
(	O
age	B
19	B
years	I
-	I
65	I
)	O

eligible	B
based	O
on	O
WALI	B
screening	I
tool	I

rearthroplasty	B

ASA	B
IV	B
-	I
V	I

inadequate	O
spoken	O
finnish	O
for	O
reliable	B
pain	I
assessment	I

Dementia	B
or	O
otherwise	O
impaired	B
cognition	I

contraindication	B
for	O
any	O
medication	O
or	O
substance	B
used	I
in	I
survey	I
protocol	I

weight	B
<	B
50kg	I
or	O
BMI	B
=	B
35	I
kg	I
/	I
m2	I

preoperative	B
SpO2	B
less	B
than	I
93	I
%	I

clinical	O
suspicion	O
that	O
subject	O
can	O
not	O
use	O
PCA	O
adequately	O

history	B
of	O
substance	B
abuse	I
or	O
current	B
excessive	B
use	I
of	I
alcohol	I

preoperative	B
use	O
of	O
either	O
pregabalin	B
,	O
gabapentin	B
or	O
strong	B
opiates	I

elective	B
primary	B
total	B
knee	I
arthroplasty	I

ASA	B
I	B
-	I
III	I

written	O
consent	O

Women	B
with	O
confirmed	B
or	O
suspected	B
pregnancy	B

Women	B
under	O
lactation	B
and	O
/	O
or	O
puerperium	B

Hypersensibility	B
to	O
ingredients	B
of	I
intervention	I

Physical	O
impossibility	O
for	O
apply	O
the	O
drug	O

Known	O
pancreatic	O
,	O
renal	O
,	O
hepatic	O
,	O
heart	O
or	O
thyroid	B
diseased	I

Hypertension	B
diagnosis	O

Previous	B
treatment	B
for	I
glucose	I

Body	B
Mass	I
Index	I
=	B
39	I
.	I
9	I
kg	I
/	I
m2	I

Triglycerides	B
=	B
500	I
mg	I
/	I
dL	I

Total	B
cholesterol	I
=	B
300	I
mg	I
/	I
dL	I

Night	O
or	O
rotating	B
shift	I
workers	I

Blood	B
Pressure	I
=	B
140	I
/	I
90	I
mmHg	I

Patients	O
both	B
sexes	I

Age	B
between	B
31	I
and	I
60	I
years	I

Diagnosis	O
of	O
diabetes	B
according	O
ADA	B
criteria	I
:	O

indications	B
to	O
dual	B
antiplatelet	I
therapy	I
other	B
than	I
atrial	B
fibrillation	I
or	O
left	B
atrial	I
appendage	I
occlusion	I
at	B
the	I
time	I
of	I
enrollment	I
or	O
predicted	O
appearance	O
of	O
such	O
indications	O
within	B
the	I
duration	I
of	I
the	I
trial	I
(	O
eg	O
.	O
coronary	B
artery	I
disease	I
)	O

indications	B
to	O
anticoagulation	B
at	B
the	I
time	I
of	I
enrollment	I
or	O
predicted	O
appearance	O
of	O
such	O
indications	O
within	B
the	I
duration	I
of	I
the	I
trial	I
(	O
eg	O
.	O
pulmonary	B
embolism	I
)	O

known	O
allergy	B
to	O
clopidogrel	B
or	O
acetylsalicylic	B
acid	I
precluding	O
its	O
administration	O
as	O
specified	O
by	O
the	O
protocol	O

any	O
known	O
inborn	O
or	O
acquired	O
coagulation	B
disorders	I

poor	B
tolerance	I
of	O
or	O
technical	O
difficulties	O
with	O
performing	O
transesophageal	B
echocardiography	I

peridevice	B
leak	I
>	B
5mm	I
on	O
transesophageal	B
echocardiography	I
study	I
preceding	O
enrollment	O

left	B
atrial	I
thrombus	I
on	O
transesophageal	B
echocardiography	I
study	O
performed	O
after	O
successful	B
left	B
atrial	I
appendage	I
closure	I
but	O
before	B
enrollment	I

life	O
expectancy	O
of	O
less	B
than	I
18months	I

participation	O
in	O
other	O
clinical	O
studies	O
with	O
experimental	O
therapies	O
at	O
the	O
time	O
of	O
enrollment	O
and	O
preceding	O
3	O
months	O

chronic	B
kidney	I
disease	I
stage	B
IV	I
and	O
V	O

women	B
who	O
are	O
pregnant	B
or	O
breast	O
feeding	O
;	O
women	O
of	O
childbearing	O
potential	O
who	O
do	O
not	O
consent	O
to	O
apply	O
at	O
least	O
to	O
methods	O
of	O
contraception	O
.	O
This	O
criterion	O
does	O
not	O
apply	O
to	O
postmenopausal	O
women	O

successful	B
left	B
atrial	I
appendage	I
occlusion	I
with	O
Amulet	B
device	I
within	B
37	I
days	I
prior	I
to	I
randomization	I
.	O

treatment	O
with	O
dual	B
antiplatelet	I
therapy	I
(	O
clopidogrel	B
and	O
acetylsalicylic	B
acid	I
)	O
between	O
left	B
atrial	I
appendage	I
closure	I
and	O
randomization	O

participant	O
'	O
s	O
age	B
18	B
years	I
or	I
older	I
at	B
the	I
time	I
of	I
signing	I
the	I
informed	I
consent	I
form	I

participant	O
is	O
willing	O
to	O
follow	O
all	O
study	O
procedures	O
;	O
especially	O
randomized	O
antiplatelet	O
treatment	O
regimen	O
and	O
follow	O
-	O
up	O
visits	O
with	O
transesophageal	O
echocardiography	O
when	O
applicable	O

participant	O
is	O
willing	O
to	O
sign	O
the	O
study	O
informed	O
consent	O
form	O

any	O
medical	B
condition	I
that	O
would	O
contraindicate	B
use	O
of	O
stimulant	B
medication	I

any	O
prior	B
adverse	B
response	I
to	O
lisdexamfetamine	B
dimesylate	I
or	O
other	B
stimulant	B
medication	I

use	O
of	O
concurrent	B
,	O
non	B
-	I
stimulant	I
psychoactive	I
medication	I

diagnosis	O
of	O
schizophrenia	B
or	O
presence	O
of	O
thought	B
disorder	I
symptoms	O

autism	B
spectrum	I
disorder	I

diagnosis	O
of	O
ADHD	B

parental	O
permission	O
and	O
/	O
or	O
teen	O
consent	O
/	O
assent	O
as	O
appropriate	O

between	O
16	B
-	I
25	I
years	I
of	O
age	B

IQ	B
greater	B
than	I
or	I
equal	I
to	I
70	I

permit	O
or	O
license	O
to	O
drive	O

ability	O
to	O
read	O
and	O
understand	O
English	O

the	O
child	B
has	O
temperature	B
>	B
39	I
.	I
0	I
◦	I
C	I
or	O
a	O
severe	B
acute	B
illness	I
as	B
defined	I
by	I
the	I
examining	I
nurse	I

the	O
child	B
has	O
as	O
a	O
mid	B
upper	I
arm	I
circumference	I
<	B
110	I
mm	I
and	O
is	O
older	B
than	O
6	O
months	O
(	O
most	O
feasible	O
local	O
indicator	O
of	O
AIDS	O
and	O
chronic	O
immunosuppressive	O
disease	O
)	O

the	O
child	B
has	O
experienced	O
a	O
severe	B
allergic	I
reaction	I
after	O
previous	B
vaccination	B
,	O
drug	B
or	O
food	B
.	O

the	O
child	O
is	O
enrolled	O
in	O
an	O
ongoing	O
study	O
of	O
Bacillus	O
Calmette	O
Guerin	O
vaccine	O
and	O
is	O
<	O
2	O
months	O
old	O

For	O
the	O
RECAMP	O
-	O
MV	O
trial	O
:	O
the	O
child	O
is	O
enrolled	O
in	O
RECAMP	O
-	O
OPV	O

Children	B
aged	B
0	B
-	I
59	I
months	I
living	O
with	O
families	O
registered	O
in	O
the	O
rural	O
Bandim	O
Health	O
Project	O
Health	O
and	O
Demographic	O
Surveillance	O
Site	O
are	O
included	O
,	O
provided	O
a	O
parent	O
/	O
guardian	O
consent	O
.	O

Unable	O
to	O
consent	O

Chronic	B
opioid	B
consumption	I

Allergy	B
to	O
study	B
medication	I

Lower	B
limb	I
surgery	I
preceding	O
year	O

Unable	O
to	O
complete	O
baseline	O
testing	O
,	O
pre	B
-	I
existing	I
neurological	B
deficit	I

Contraindication	B
to	O
spinal	B
anaesthesia	I

Patients	O
undergoing	O
total	B
knee	I
arthroplasty	I
under	O
spinal	B
anaesthesia	I

45y	B
or	O
older	O

ASA	B
1	B
-	I
3	I

BMI	B
18	B
-	I
35	I

previous	O
use	O
of	O
insulin	B
pump	I

pregnancy	B
or	O
planning	O
to	O
become	O
pregnant	B
in	B
the	I
next	I
2	I
years	I
,	O

lack	B
of	I
ability	O
to	O
use	O
the	O
study	B
devices	I

history	B
of	O
severe	B
chronic	B
diseases	I

recent	B
or	O
concomitant	B
use	O
of	O
corticosteroids	B

drug	O
or	O
alcohol	B
abuse	I

psychiatric	B
complaints	I
that	O
interfere	O
with	O
the	O
correct	O
use	O
of	O
the	O
devices	O

T1DM	B
for	B
at	I
least	I
12	I
months	I

persistent	B
HbA1c	B
levels	I
=	B
7	I
.	I
5	I
%	I
(	O
58	B
mmol	I
/	I
mol	I
)	O
despite	O
optimized	B
education	I
therapy	I
,	O

recurrent	B
severe	B
hypoglycemic	B
episodes	I
or	O
high	B
glucose	I
variability	I

willingness	O
to	O
wear	O
the	O
insulin	B
pump	I

A	O
known	O
allergy	B
to	O
Celecoxib	B
,	O
aspirin	B
or	O
another	B
NSAID	B
.	O

Active	B
peptic	B
ulceration	I
or	O
gastrointestinal	B
bleeding	I
.	O

Inflammatory	B
bowel	I
disease	I
.	O

Congestive	B
heart	I
failure	I
(	O
NYHA	B
II	B
-	I
IV	I
)	O
.	O

Established	O
ischemic	B
heart	I
disease	I
,	O
peripheral	B
arterial	I
disease	I
and	O
/	O
or	O
cerebrovascular	B
disease	I
.	O

History	B
of	O
neurologic	B
deficit	I
.	O

Known	O
hepatic	O
or	O
renal	B
impairment	I
.	O

Pregnancy	B
.	O

Breast	O
-	O
feeding	O
.	O

Post	B
-	O
hysterectomy	B
.	O

Bleeding	B
disorders	I
.	O

Drug	B
abuse	I
.	O

Cervical	O
and	O
vaginal	B
infection	I
.	O

Females	B
18	B
-	I
65	I
years	I
old	B
who	O
undergoing	B
colposcopic	B
directed	I
biopsy	I

Patients	O
with	O
a	O
calculated	B
PRA	I
higher	B
than	I
0	I
%	I
per	I
solid	I
phase	I
and	O
/	O
or	O
anti	B
-	I
HLA	I
class	I
I	I
and	O
/	O
or	O
class	O
II	O
antibodies	O
detectable	O
by	O
single	B
antigen	I
test	I
(	O
Luminex	B
®	O
)	O
.	O

Positive	B
result	O
of	O
Cross	B
Match	I
.	O

Patients	O
who	O
receive	O
a	O
graft	B
from	I
a	I
cadaver	I
donor	I
.	O

Identical	B
HLA	I
patients	O

Patients	O
who	O
have	O
undergone	O
a	O
previous	B
solid	B
organ	I
transplant	I
(	O
including	O
kidney	B
transplant	I
)	O
or	O
who	O
are	O
going	O
to	O
receive	O
another	B
solid	B
organ	I
transplant	I
concomitantly	B
.	O

Glomerular	B
primary	I
focal	I
and	I
segmental	I
sclerosis	I

Atypical	B
hemolytic	I
uremic	I
syndrome	I
(	I
aHUS	I
)	I
/	O
thrombotic	B
thrombocytopenic	I
purpura	I
syndrome	I
.	O

Patients	O
with	O
chronic	B
infection	O
with	O
Hepatitis	B
B	I
virus	I
(	I
HBV	I
)	I
and	O
/	O
or	O
active	B
infection	O
with	O
Hepatitis	B
C	I
virus	I
(	O
positive	B
PCR	B
result	I
)	O
at	B
the	I
time	I
of	I
transplant	I
.	O

Patients	O
with	O
infection	O
with	O
the	O
known	O
Human	B
Immunodeficiency	I
Virus	I
(	I
HIV	I
)	I
.	O

Patients	O
with	O
active	B
systemic	B
infection	I
that	O
requires	O
the	O
continued	B
administration	I
of	O
antibiotics	B
.	O

Patients	O
with	O
any	O
neoplasm	B
except	B
localized	B
skin	I
cancer	I
and	O
who	O
is	O
receiving	O
adequate	O
treatment	O
.	O

Patients	O
with	O
severe	B
anemia	B
(	O
hemoglobin	B
<	B
6g	I
/	I
dl	I
)	O
,	O
leukopenia	B
(	O
WBC	B
<	B
2500	I
/	I
mm3	I
)	O
and	O
/	O
or	O
thrombocytopenia	B
(	O
platelets	B
<	B
80	I
,	I
000	I
/	I
mm3	I
)	O
.	O

Patients	O
who	O
are	O
hemodynamically	B
unstable	I
even	O
if	O
they	O
have	O
hemoglobin	B
levels	I
>	B
6g	I
/	I
dL	I
.	O

Patients	O
with	O
intestinal	B
pathology	I
or	O
severe	B
diarrhea	I
that	O
may	O
decrease	O
absorption	O
according	O
to	O
medical	O
criteria	O
.	O

Patients	O
with	O
known	O
hypersensitivity	B
to	O
any	O
of	O
the	O
drugs	B
used	I
in	I
this	I
study	I
.	O

Patients	O
who	O
have	O
received	O
any	O
investigational	O
drug	O
in	O
the	O
30	O
days	O
prior	O
to	O
their	O
inclusion	O
in	O
this	O
study	O
.	O

Potentially	O
fertile	O
women	O
who	O
do	O
not	O
agree	O
to	O
use	O
reliable	O
contraceptive	O
measures	O
during	O
the	O
trial	O
,	O
who	O
are	O
pregnant	O
,	O
breastfeeding	O
or	O
who	O
present	O
a	O
positive	O
pregnancy	O
test	O
at	O
the	O
time	O
of	O
their	O
inclusion	O
in	O
the	O
study	O
.	O

Patients	O
who	O
are	O
legally	O
detained	O
in	O
an	O
official	O
institution	O
.	O

Adult	B
men	B
and	O
women	B
(	O
=	O
18	O
years	B
)	O
.	O

Receptors	O
of	O
a	O
first	B
kidney	I
transplant	I
from	O
an	O
incompatible	B
HLA	I
living	B
donor	I
(	O
at	B
least	I
1	I
mismatch	O
HLA	O
at	O
any	O
antigenic	O
level	O
)	O
.	O

AB0	B
compatible	I
transplant	B
.	O

Patients	O
with	O
a	O
calculated	B
PRA	I
of	O
0	B
%	I
by	O
solid	B
phase	I
technique	I
and	O
absence	O
of	O
anti	O
-	O
HLA	O
class	O
I	O
and	O
class	O
II	O
antibodies	O
by	O
single	B
antigen	I
test	I
(	I
Luminex	I
®	I
)	I
.	O

Patients	O
who	O
agree	O
to	O
participate	O
in	O
the	O
Trial	O
by	O
signing	O
the	O
Specific	O
Informed	O
Consent	O
of	O
this	O
study	O
.	O

Potentially	O
fertile	O
women	O
should	O
use	O
high	O
reliability	O
contraceptive	O
methods	O
(	O
Pearl	O
-	O
Index	O
<	O
1	O
)	O
in	O
order	O
to	O
avoid	O
pregnancy	O
during	O
the	O
entire	O
duration	O
of	O
the	O
study	O
and	O
up	O
to	O
6	O
weeks	O
after	O
the	O
end	O
of	O
their	O
treatment	O
with	O
Mycophenolate	O
Mofetil	O
(	O
MMF	O
)	O
.	O
Potentially	O
Fertile	O
Women	O
include	O
any	O
woman	O
who	O
has	O
experienced	O
menarche	O
and	O
who	O
has	O
not	O
undergone	O
successful	O
surgical	O
sterilization	O
(	O
hysterectomy	O
,	O
bilateral	O
tubal	O
ligation	O
or	O
bilateral	O
oophorectomy	O
)	O
or	O
who	O
is	O
not	O
post	O
-	O
menopausal	O
(	O
defined	O
as	O
amenorrhea	O
=	O
12	O
consecutive	O
months	O
,	O
or	O
women	O
who	O
are	O
receiving	O
hormone	O
replacement	O
therapy	O
with	O
a	O
documented	O
level	O
of	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
>	O
35	O
mlU	O
/	O
ml	O
)	O
.	O
Potentially	O
fertile	O
women	O
must	O
have	O
a	O
pregnancy	O
test	O
with	O
a	O
negative	O
result	O
in	O
the	O
72	O
hours	O
prior	O
to	O
the	O
start	O
of	O
the	O
trial	O
.	O

Sexually	O
active	O
males	O
(	O
including	O
vasectomized	O
males	O
)	O
who	O
are	O
being	O
treated	O
with	O
MMF	O
must	O
accept	O
the	O
use	O
of	O
barrier	O
contraceptive	O
methods	O
during	O
MMF	O
treatment	O
and	O
for	O
90	O
days	O
thereafter	O
.	O
Potentially	O
fertile	O
partners	O
of	O
these	O
patients	O
should	O
use	O
a	O
reliable	O
contraceptive	O
method	O
during	O
the	O
same	O
period	O
,	O
in	O
order	O
to	O
minimize	O
the	O
risk	O
of	O
pregnancy	O
.	O

Patients	O
must	O
agree	O
not	O
to	O
donate	O
blood	O
during	O
treatment	O
with	O
MMF	O
and	O
during	O
the	O
6	O
subsequent	O
weeks	O
.	O
Males	O
should	O
not	O
make	O
a	O
sperm	O
donation	O
during	O
MMF	O
treatment	O
and	O
up	O
to	O
90	O
days	O
after	O
completion	O
.	O

Known	O
coagulation	B
defect	I

Patients	O
on	O
longstanding	B
NSAID	B
therapy	I

Known	O
renal	B
impairment	I

Patients	O
may	O
also	O
be	O
excluded	O
at	O
the	O
discretion	O
of	O
the	O
investigator	O

Diagnosis	O
of	O
sleep	B
disordered	I
breathing	I
or	O
obstructive	B
sleep	I
apnea	I

Children	B
undergoing	O
elective	B
tonsillectomy	B
or	O
adenotonsillectomy	B
at	O
Children	O
'	O
s	O
Healthcare	O
of	O
Atlanta	O
Egleston	O
location	O

Parent	O
or	O
legal	O
guardian	O
willing	O
to	O
participate	O
,	O
and	O
able	O
to	O
understand	O
and	O
sign	O
the	O
provided	O
informed	O
consent	O

Allergy	B
to	O
Glitazones	B

Myocardial	B
infarction	I

Heart	B
failure	I

Angina	B

History	B
of	O
kidney	B
stones	I

Liver	B
disease	I
(	O
abnormal	B
liver	B
enzymes	I
)	O

Anemia	B
(	O
hemoglobin	B
<	B
8	I
g	I
/	I
dl	I
)	O

Cancer	B
with	O
current	B
treatment	B

Previous	B
organ	B
transplantation	I

Immunosuppressant	B
therapy	I

Human	B
immunodeficiency	I
virus	I
infection	I

Pregnancy	B
or	O
lactating	B

Current	B
tobacco	O
use	O

Dilantin	B
and	O
oral	B
contraceptive	I
usage	O
due	O
to	O
potential	O
drug	B
interaction	I
with	O
glitazones	B

Self	B
-	I
identified	I
history	B
of	O
hypoglycemia	B

CKD	B
patients	O
classified	O
as	O
Stage	B
3	I
and	O
4	O
of	O
National	B
Kidney	I
Foundation	I
Classification	I
with	O
estimated	B
glomerular	I
filtration	I
rate	I
(	I
GFR	I
)	I
between	B
15	I
and	I
59	I
mL	I
/	I
min	I
/	I
1	I
.	I
73	I
m2	I
according	O
to	O
the	O
Modification	B
of	I
Diet	I
in	I
Renal	I
Disease	I
(	I
MDRD	I
)	I
formula	I
based	O
on	O
serum	O
creatinine	O
,	O
age	O
,	O
gender	O
,	O
and	O
race	O
.	O

Men	B
and	O
women	B
35	B
to	I
70	I
years	I
of	O
age	B

Limited	O
English	O
proficiency	O
(	O
LEP	O
)	O

Pregnant	B

Prisoners	B

Wolff	B
Parkinson	I
White	I
syndrome	I

Administration	O
of	O
electrical	O
or	O
chemical	B
cardioversion	I
before	B
screening	I

Administration	O
of	O
other	O
antiarrhythmics	B
for	O
acute	B
heart	B
rate	I
control	I
(	O
excluding	B
adenosine	B
)	O

History	O
of	O
allergy	B
or	O
idiosyncratic	B
reaction	I
to	O
diltiazem	B

Unable	B
to	I
take	I
oral	B
medications	I

Heart	B
rate	I
<	B
60	I
beats	I
/	I
min	I

>	O
/	O
=	O
18	O
years	O
old	B

Atrial	B
fibrillation	I
or	O
flutter	O
on	O
electrocardiogram	B

Heart	B
rate	I
>	B
110	I
beats	I
/	I
min	I

Systolic	B
blood	I
pressure	I
>	B
/	I
=	I
90	I
mmHg	I

(	O
1	O
)	O
Women	B
who	O
are	O
pregnant	B
and	O
/	O
or	O
lactating	O
;	O
or	O
women	B
who	O
intend	O
to	O
conceive	O
within	B
a	I
year	I
;	O

(	O
2	O
)	O
History	B
of	O
allergies	B
to	O
enalapril	B
,	O
folic	B
acid	I
or	O
other	O
components	B
of	I
the	I
compound	I
drug	I
;	O

(	O
3	O
)	O
History	B
of	O
adverse	B
reactions	I
or	O
intolerance	B
to	O
enalapril	B
or	O
other	B
ACE	B
inhibitors	I
,	O
or	O
drugs	O
or	O
supplements	O
containing	O
folic	B
acid	I
;	O

(	O
4	O
)	O
Diagnosis	O
or	O
suspicion	O
of	O
secondary	B
hypertension	I
;	O

(	O
5	O
)	O
Known	O
serious	B
medical	B
conditions	I
,	O
including	O
:	O
Cardiovascular	O
:	O
patients	O
with	O
clinically	B
diagnosed	I
cardiac	B
dysfunction	I
(	O
NYHA	B
class	I
III	B
and	I
above	I
)	O
,	O
hypertrophic	B
obstructive	I
cardiomyopathy	I
,	O
clinically	B
significant	I
valvular	B
heart	I
disease	I
,	O
acute	B
coronary	I
syndrome	I
within	B
the	I
last	I
3	I
months	I
,	O
or	O
percutaneous	B
coronary	I
intervention	I
(	I
PCI	I
)	I
,	O
or	O
coronary	B
artery	I
bypass	I
graft	I
(	I
CABG	I
)	I
;	O
or	O
abnormal	B
pre	B
-	I
enrollment	I
ECG	B
test	I
results	O
with	O
clinically	B
significant	I
arrhythmias	B
(	O
atrial	B
flutter	I
,	O
atrial	B
fibrillation	I
,	O
grade	B
II	I
-	O
III	O
atrioventricular	B
block	I
,	O
etc	O
.	O
)	O
;	O
Digestive	O
:	O
a	O
previous	B
diagnosis	O
of	O
various	O
types	O
of	O
viral	B
hepatitis	I
that	O
are	O
still	O
in	O
the	O
active	B
phase	I
;	O
abnormal	B
pre	B
-	I
enrollment	I
liver	B
function	I
test	I
results	O
(	O
ALT	B
,	O
AST	B
,	O
GGT	B
,	O
TBIL	B
,	O
or	O
DBIL	B
3	B
times	I
higher	I
than	I
normal	I
,	O
ALB	B
=	B
30g	I
/	I
L	I
)	O
;	O
gastrectomy	B
and	O
/	O
or	O
gastrojejunostomy	B
;	O
gastrointestinal	B
dysfunction	I
;	O
Urinary	O
:	O
pre	B
-	I
enrollment	I
serum	B
creatinine	I
greater	B
than	I
200umol	I
/	I
L	I
;	O
clinical	B
diagnosis	I
of	O
renal	B
artery	I
stenosis	I
,	O
isolated	B
kidney	I
,	O
kidney	B
transplantation	I
and	O
/	O
or	O
other	O
diseases	O
;	O
Endocrine	O
:	O
type	B
1	I
diabetes	I
or	O
uncontrolled	B
type	B
2	I
diabetes	I
(	O
fasting	B
blood	I
glucose	I
above	B
11	I
.	I
1	I
mmol	I
/	I
L	I
at	B
pre	I
-	I
enrollment	I
)	O
;	O
previous	B
diagnosis	O
of	O
hyperthyroidism	B
and	O
failure	O
to	O
correct	O
;	O
Respiratory	O
:	O
pulmonary	B
heart	I
disease	I
;	O
chronic	B
obstructive	I
pulmonary	I
disease	I
;	O
Neuropsychiatric	O
:	O
recent	B
transient	B
ischemic	I
attack	I
or	O
stroke	B
(	O
within	B
the	I
last	I
3	I
months	I
)	O
;	O
peripheral	B
or	O
severe	B
autonomic	B
dysfunction	I
;	O
mental	O
or	O
nervous	B
system	I
dysfunction	I
,	O
inability	O
to	O
express	O
desire	O
;	O
known	O
drug	O
or	O
alcohol	B
dependence	I
;	O
Malignancy	B
,	O
malnutrition	B
,	O
hematopoietic	B
disorders	I
and	O
other	O
serious	O
diseases	O
.	O

(	O
6	O
)	O
Significant	B
signs	B
of	I
abnormalities	I
as	O
seen	O
in	O
laboratory	B
tests	I
or	O
physical	O
characteristics	O
,	O
which	O
,	O
at	O
the	O
discretion	O
of	O
the	O
investigators	O
,	O
indicates	O
that	O
the	O
patient	O
is	O
experiencing	O
a	O
serious	O
illness	O
or	O
,	O
may	O
affect	O
the	O
observation	O
and	O
evaluation	O
of	O
the	O
drug	O
'	O
s	O
efficacy	O
or	O
adverse	O
events	O
,	O
or	O
renders	O
the	O
patient	O
unsuitable	O
for	O
participating	O
in	O
this	O
study	O
;	O

(	O
7	O
)	O
Patients	O
currently	B
taking	O
folate	B
,	O
B12	B
,	O
or	O
B6	B
,	O
or	O
any	O
compounds	O
containing	O
them	O
,	O
who	O
express	O
an	O
inability	O
or	O
a	O
refusal	O
to	O
stop	O
usage	O
;	O

(	O
8	O
)	O
Regular	B
usage	I
of	O
folic	B
acid	I
supplements	I
or	O
compounds	B
containing	I
folic	I
acid	I
in	B
the	I
past	I
3	I
months	I
;	O

(	O
9	O
)	O
Participation	O
in	O
a	O
clinical	O
trial	O
for	O
a	O
drug	B
that	I
has	I
not	I
yet	I
been	I
officially	I
approved	I
for	I
marketing	I
within	B
one	I
month	I
prior	I
to	I
the	I
first	I
visit	I
.	O

(	O
1	O
)	O
=	B
45	I
years	I
old	B
;	O

(	O
2	O
)	O
A	O
diagnosis	O
or	O
previous	B
diagnosis	O
of	O
essential	B
hypertension	I
,	O
including	O
anyone	O
currently	B
taking	O
antihypertensive	B
drugs	I
;	O
or	O
for	O
those	O
who	O
have	O
not	B
taken	O
antihypertensive	B
drugs	I
within	B
the	I
last	I
2	I
weeks	I
,	O
two	B
consecutive	I
examinations	I
were	I
conducted	I
at	I
least	I
one	I
day	I
apart	I
,	O
and	O
both	O
sitting	B
blood	I
pressure	I
(	O
mean	O
value	O
of	O
3	O
measurements	O
)	O
met	O
the	O
following	O
criteria	O
:	O
diastolic	B
blood	I
pressure	I
(	I
DBP	I
)	I
=	B
90	I
mmHg	I
or	O
systolic	B
blood	I
pressure	I
(	I
SBP	I
)	I
=	B
140	I
mmHg	I
(	O
the	O
second	O
blood	O
pressure	O
was	O
measured	O
at	O
V1	O
)	O
;	O

(	O
3	O
)	O
If	O
a	O
study	O
participant	O
is	O
a	O
woman	B
of	O
childbearing	O
age	O
,	O
she	O
agrees	O
to	O
use	O
a	O
reliable	B
contraceptive	O
method	O
during	B
the	I
trial	I
;	O

(	O
4	O
)	O
Voluntarily	O
participates	O
and	O
has	O
signed	O
an	O
informed	O
consent	O
form	O
.	O

(	O
1	O
)	O
Completed	O
MTHFR	B
C677T	I
gene	B
polymorphism	I
detection	I
in	O
run	O
-	O
in	O
period	O
or	O
MTHFR	B
C677T	I
genotype	O
already	O
known	O
in	O
advance	O
;	O

(	O
2	O
)	O
Exhibited	O
good	O
tolerance	O
to	O
enalapril	B
and	O
good	B
overall	B
medication	I
compliance	I
(	O
>	B
80	I
%	I
)	O
in	O
run	O
-	O
in	O
period	O
or	O
previously	B
exhibited	O
good	O
tolerance	O
and	O
adherence	O
to	O
ACEI	B
drugs	I
in	O
previous	O
medication	B
history	I
.	O

(	O
3	O
)	O
Voluntarily	B
continues	O
to	O
participate	O
in	O
this	O
study	O
.	O

Diabetes	B
mellitus	I
type	I
1	I

renal	B
insufficiency	I
III	B
-	I
V	I
°	I

Cirrhosis	B
hepatis	I
(	O
Child	B
B	B
or	I
higher	I
)	O

Chronic	B
alcohol	B
abuse	I

rheumatic	B
disease	I
(	O
RA	B
,	O
SpA	B
,	O
SLE	B
)	O

Malignancies	B
(	O
<	B
5	I
years	I
)	O

Eating	B
Disorder	I
(	O
anorexia	B
nervosa	I
,	O
bulimia	B
)	O

bone	B
-	I
specific	I
pretreatment	I
(	O
DMAB	B
,	O
TPTD	B
,	O
strontium	B
ranelate	I
,	O
SERMs	B
)	O
Bisphosphonate	O
treatment	O
is	O
allowed	O

Postmenopausal	B
women	B

Age	B
60	B
-	I
80	I
years	I

T	B
-	I
score	I
according	O
to	O
DXA	B
:	O
<	B
-	I
2	I
.	I
5	I

indication	O
for	O
osteoporosis	B
therapy	O
according	O
to	O
international	B
guidelines	I

recent	B
thrombotic	B
event	I

LVAD	B
on	O
warfarin	B
requiring	B
temporary	I
interruption	I
of	I
anticoagulation	I
for	I
procedures	I

Confirmed	O
allergy	B
to	O
apatinin	B
and	O
or	O
its	O
excipients	B
;	O

Hypertension	B
(	O
high	B
blood	I
pressure	I
)	O
that	O
can	O
not	B
be	O
controlled	O
by	O
drugs	B
;	O

A	O
history	O
of	O
active	B
hemorragge	B
,	O
ulcer	B
,	O
intestinal	B
perforation	I
,	O
intestinal	B
obstruction	I
,	O
or	O
major	B
surgery	I
no	B
older	I
than	I
30	I
days	I
;	O

NYHA	B
III	B
-	I
IV	I
heart	B
function	I
,	O
or	O
severe	B
hepatic	O
or	O
renal	B
insufficiency	I
(	O
Grade	B
4	I
)	O
;	O

Presence	O
of	O
multiple	O
factors	O
that	O
affect	O
oral	O
medications	O
,	O
such	O
as	O
difficulty	B
swallowing	I
,	O
nausea	B
,	O
vomiting	B
,	O
chronic	B
diarrhea	I
and	O
intestinal	B
obstruction	I
;	O

Pregnant	O
or	O
lactating	O
women	O
,	O
or	O
women	O
of	O
child	O
-	O
bearing	O
potential	O
who	O
have	O
planned	O
a	O
pregnancy	O
,	O
or	O
male	O
and	O
female	O
patients	O
who	O
do	O
not	O
agree	O
to	O
practice	O
adequate	O
contraception	O
during	O
this	O
study	O
;	O

Patients	O
who	O
have	O
a	O
history	B
of	O
psychotropics	B
abuse	B
and	O
can	O
not	O
quit	O
,	O
or	O
who	O
have	O
mental	B
disorders	I
;	O

Participation	O
in	O
other	O
drug	O
clinical	O
trial	O
within	O
the	O
last	O
4	O
weeks	O
;	O

Prior	O
therapy	O
with	O
VEGFR	B
inhibitors	I
such	O
as	O
sorafenib	B
and	O
sunitinib	B
;	O

Presence	O
of	O
comorbidities	O
that	O
seriously	O
affect	O
the	O
patient	O
'	O
s	O
safety	O
or	O
ability	O
to	O
complete	O
the	O
study	O
,	O
in	O
the	O
investigator	O
'	O
s	O
judgment	O
;	O

Patients	O
who	O
can	O
not	B
tolerate	B
apatinib	B
treatment	O
as	O
judged	O
by	O
the	O
investigator	O
depending	O
on	O
the	O
their	O
medical	O
history	O
;	O

Patients	O
that	O
are	O
considered	O
ineligible	O
for	O
this	O
study	O
by	O
the	O
investigator	O
.	O

Age	B
of	O
18	B
and	I
over	I
,	O
male	B
or	O
female	B
;	O

Patients	O
with	O
histologically	B
confirmed	O
advanced	B
(	O
stage	B
IV	I
)	O
gastric	B
cancer	I
,	O
NSCLC	B
,	O
breast	B
cancer	I
or	O
ovarian	B
cancer	I
,	O
who	O
choose	O
monotherapy	B
of	O
oral	B
vascular	I
targeting	I
drug	I
(	O
apatinib	B
)	O
due	O
to	O
intolerability	O
or	O
inappropriateness	O
of	O
other	O
therapies	O
;	O

Presence	O
of	O
measurable	B
lesions	I
(	O
=	B
10mm	I
on	O
spiral	B
CT	I
scan	I
)	O
subject	O
to	O
RECIST	B
1	I
.	I
1	I
;	O

Blood	B
pressured	I
controlled	B
at	O
150	B
/	I
100	I
mHg	I
following	O
drug	O
administration	O
;	O

An	O
ECOG	B
PS	I
score	O
of	O
between	B
0	I
and	I
1	I
;	O

A	O
life	O
expectancy	O
of	O
at	B
least	I
3	I
months	I
;	O

Subjects	O
who	O
volunteer	O
to	O
participate	O
in	O
this	O
study	O
and	O
have	O
signed	O
the	O
Informed	O
Consent	O
Form	O
(	O
ICF	O
)	O
,	O
with	O
good	O
compliance	O
with	O
treatment	O
and	O
follow	O
-	O
up	O
.	O

Chronic	B
pain	I
or	O
narcotic	B
usage	O
during	B
the	I
preceding	I
30	I
days	I

Infection	B
at	O
or	O
near	O
the	O
intended	B
needle	I
insertion	I
site	I

Complex	O
or	O
altered	B
abdominal	I
wall	I
anatomy	I

Weight	B
<	B
45kg	I

Patients	O
undergoing	O
laparoscopic	B
assisted	I
donor	I
nephrectomy	I

Patients	O
that	O
have	O
elected	O
to	O
have	O
a	O
nerve	B
block	I

18	O
years	O
of	O
age	B
or	O
older	O

Patients	O
of	O
ASA	B
status	I
I	B
-	I
III	I

No	B
consent	O

Spinal	B
anesthesia	I
or	O
sciatic	B
nerve	I
block	I
contraindicated	B

Known	O
intolerance	B
to	O
tramadol	B
or	O
other	B
contraindications	B
for	O
the	B
drug	I

Patients	O
with	O
foot	B
fracture	I
scheduled	O
for	O
surgical	B
repair	I
in	O
spinal	B
anesthesia	I

Informed	O
consent	O

allergy	B
to	O
Doxycycline	B
or	O
Methylprednisolone	B
,	O

pregnancy	B
,	O

diagnosis	B
,	O

Inflammatory	B
arthritis	I
or	O
diabetes	B
,	O

secondary	B
adhesive	B
capsulitis	I
(	O
history	B
of	O
significant	B
trauma	B
,	O
rotator	B
cuff	I
tear	I
injury	I
,	O
stroke	B
)	O

evidence	O
of	O
arthritis	B
on	O
x	B
-	I
ray	I
,	O

current	B
infectious	B
disease	I
,	O
and	O

any	B
previous	B
treatment	B
for	O
the	O
for	O
adhesive	B
capsulitis	I
of	O
the	O
affected	B
shoulder	I
.	O

18	O
years	O
of	O
age	B
and	O
older	O
,	O

diagnosis	O
of	O
stage	B
II	I
adhesive	B
capsulitis	I
as	O
determined	O
by	O
clinical	B
examination	I
of	O
the	O
treating	O
physician	O
,	O
and	O

absence	B
of	I
abnormal	B
findings	I
on	O
X	B
-	I
ray	I
.	O

known	O
allergy	B
to	O
any	O
of	O
drugs	B
used	I

coagulopathy	B

any	O
wound	B
or	O
infection	B
related	O
to	O
puncture	B
site	I

major	B
illness	B

failure	B
to	I
gain	I
consent	O
of	O
parents	O
.	O

American	O
society	O
of	O
anesthesiologist	O
(	O
ASA	B
)	O
physical	O
status	O
I	B
or	I
II	I

Known	O
hypersensitivity	B
to	O
egg	B
,	O
soybean	B
proteins	I
,	O
peanut	B
proteins	I
,	O
corn	B
or	O
corn	B
products	I
,	O
or	O
to	O
any	O
of	O
the	O
active	B
substances	I
or	O
excipients	B

Severe	B
hyperlipidemia	B
or	O
severe	B
disorders	B
of	I
lipid	I
metabolism	I
characterized	O
by	O
hypertriglyceridemia	B
(	O
serum	B
triglyceride	I
concentration	I
>	B
1	I
,	I
000	I
g	I
/	I
dL	I
)	O
.	O

Inborn	B
errors	I
of	I
amino	I
acid	I
metabolism	I

Cardiopulmonary	B
instability	I
(	O
including	O
pulmonary	B
edema	I
,	O
cardiac	B
insufficiency	I
,	O
myocardial	B
infarction	I
,	O
acidosis	B
and	O
hemodynamic	B
instability	I
requiring	O
significant	B
vasopressor	B
support	O
)	O

Hemophagocytic	B
syndrome	I
.	O

PN	B
in	B
the	I
last	I
7	I
days	I
prior	I
to	I
study	I
enrollment	I
.	O

Need	O
for	O
chronic	B
PN	I
before	B
study	I
start	I

Liver	B
enzymes	I
(	O
either	O
AST	B
,	O
ALT	B
,	O
GGPT	B
)	O
,	O
or	O
direct	B
bilirubin	I
exceeding	B
2	I
x	I
upper	I
limit	I
of	I
normal	I
range	I

Pathologically	B
altered	I
level	B
of	I
any	I
serum	I
electrolyte	I
(	O
sodium	B
,	O
potassium	B
,	O
magnesium	B
,	O
calcium	B
,	O
chloride	B
,	O
phosphate	B
)	O
unless	O
corrected	O
prior	O
to	O
the	O
start	O
of	O
study	O
treatment	O

Pathologically	B
altered	I
blood	B
pH	I
,	O
or	O
oxygen	B
saturation	I
,	O
or	O
carbon	B
dioxide	I
unless	O
corrected	O
prior	O
to	O
the	O
start	O
of	O
study	O
treatment	O

Pregnancy	B
or	O
lactation	B

Participation	O
in	O
another	O
clinical	O
study	O

Male	B
or	O
female	B
patients	O
2	B
to	I
16	I
years	I
of	O
age	B

Patients	O
who	O
require	O
at	B
least	I
80	I
%	I
of	I
their	I
caloric	I
intake	I
as	O
PN	B
at	B
study	I
start	I
,	O
and	O
in	O
whom	O
an	O
indication	B
for	O
PN	B
is	O
expected	O
for	B
at	I
least	I
5	I
days	I

Patients	O
who	O
require	O
a	O
central	B
venous	I
line	I
to	O
receive	O
PN	B
or	O
already	O
have	O
a	O
central	B
venous	I
line	I
in	O
place	O
for	O
other	O
reasons	O

Written	O
informed	O
consent	O
from	O
legal	O
representative	O
(	O
s	O
)	O

Severe	B
deformity	B
(	O
varus	B
or	O
values	B
from	I
mechanical	I
axis	I
more	B
than	I
5	I
degrees	I

Allergy	B
to	O
hyaluronic	B
acid	I

Pain	B
on	O
hip	B
or	O
ankle	B

Post	O
-	O
traumatic	O
or	O
post	B
surgery	I
of	I
lower	I
extremity	I

Post	B
infection	B
of	I
knee	I

Previous	B
hyaluronic	B
acid	I
injection	O
within	B
6	I
months	I

Pregnancy	B
or	O
lactation	B

Underlying	B
Rheumatoid	B
arthritis	I
,	O
stroke	B
,	O
malignancy	B
,	O
venous	B
occlusion	I

Symptomatic	B
primary	B
knee	B
osteoarthritis	B
with	O
failed	B
conservative	B
treatment	I
at	B
least	I
3	I
months	I

Kellgren	B
-	I
Lawrence	I
grade	I
I	B
-	I
III	I

Gave	O
informed	O
consent	O

Can	O
do	O
questionnaires	O

not	B
a	O
regular	B
user	I
of	O
e	B
-	I
cigarettes	I

pregnant	O
or	O
lactating	O
(	O
only	O
excluded	O
from	O
imaging	O
study	O
)	O

prisoner	B

incapable	O
of	O
giving	O
informed	O
consent	O

unable	O
to	O
lie	O
flat	O
on	O
the	O
scanner	O
for	O
extended	O
periods	O
of	O
time	O

unstable	B
medical	B
condition	I
like	O
heart	B
disease	I
,	O
uncontrolled	B
hypertension	B
,	O
thyroid	B
disease	I
,	O
diabetes	B
,	O
renal	O
or	O
liver	B
impairment	I
,	O
or	O
glaucoma	B

prostatic	B
hypertrophy	I
,	O
stroke	B
,	O
or	O
ulcer	B
in	O
past	O
year	O

psychiatric	B
conditions	I
such	O
as	O
schizophrenia	B
,	O
adult	B
ADHD	I
,	O
or	O
bipolar	B
disorder	I

current	O
or	O
regular	O
use	O
of	O
psychiatric	B
medications	I
such	O
as	O
tranquilizers	B
,	O
antipsychotics	B
,	O
and	O
/	O
or	O
antidepressants	B

use	O
of	O
medications	B
that	O
are	O
inducers	B
of	I
CYP2A6	I
(	O
a	O
nicotine	B
metabolizing	I
enzyme	I
)	O
such	O
as	O
rifampicin	B
,	O
dexamethasone	B
,	O
phenobarbital	B
,	O
and	O
other	O
anti	B
-	I
convulsant	I
drugs	I

unable	O
to	O
communicate	O
in	O
English	O

current	O
use	O
of	O
smokeless	B
tobacco	I
,	O
tobacco	B
cigarettes	I
(	O
5	B
and	I
fewer	I
a	I
day	I
)	O

occasional	O
use	O
of	O
pipes	O
is	O
permitted	O
if	O
subject	O
abstains	O
for	O
the	O
week	O
prior	O
to	O
the	O
study	O

older	B
than	I
80	I
years	B

males	B
and	O
females	B
greater	B
than	I
or	I
equal	I
to	I
18	I
years	I
of	O
age	B

current	O
regular	B
user	B
of	O
e	B
-	I
cigarettes	I
(	O
use	O
at	B
least	I
once	I
daily	I
for	B
the	I
past	I
30	I
days	I
)	O
with	O
nicotine	B
strength	I
>	B
6mg	I
/	I
ml	I

health	B
medical	B
history	I

abstinent	B
from	O
any	O
tobacco	B
/	O
nicotine	B
use	O
for	B
4	I
hours	I
prior	I
to	I
imaging	I

Progressive	B
,	O
unstable	B
or	O
uncontrolled	B
clinical	B
conditions	I
.	O

Hypersensitivity	B
,	O
including	O
allergy	B
,	O
to	O
any	O
component	B
of	I
vaccines	I
,	O
medicinal	B
products	I
or	O
medical	B
equipment	I
whose	B
use	I
is	I
foreseen	I
in	I
this	I
study	I
.	O

Clinical	O
conditions	O
representing	O
a	O
contraindication	B
to	O
intramuscular	B
vaccination	I
and	O
blood	B
draws	I
.	O

Clinical	O
conditions	O
.	O

Systemic	B
administration	I
of	O
corticosteroids	B
(	O
PO	B
/	O
IV	B
/	O
IM	B
)	O
within	B
90	I
days	I
prior	I
to	I
informed	I
consent	I
.	O

Administration	O
of	O
antineoplastic	O
and	O
immunomodulating	B
agents	I
or	O
radiotherapy	B
within	B
90	I
days	I
prior	I
to	I
informed	I
consent	I
.	O

Received	O
immunoglobulins	B
or	O
any	O
blood	B
products	I
within	B
180	I
days	I
prior	I
to	I
informed	I
consent	I
.	O

Received	O
an	O
investigational	B
or	O
non	B
-	I
registered	I
medicinal	B
product	I
within	B
30	I
days	I
prior	I
to	I
informed	I
consent	I
.	O

Any	O
other	O
clinical	O
condition	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
might	O
pose	O
additional	O
risk	O
to	O
the	O
subject	O
due	O
to	O
participation	O
in	O
the	O
study	O
.	O

Any	O
history	B
of	O
meningococcal	B
vaccination	I
or	O
meningococcal	O
and	O
gonorrhoea	B
diseases	I
.	O

Enrolment	O
in	O
any	O
activity	O
requiring	O
a	O
blood	B
donation	I
greater	B
than	I
50	I
mL	I
during	B
the	I
period	I
starting	I
30	I
days	I
before	I
the	I
first	I
study	I
visit	I
(	O
Day	O
-	O
83	O
,	O
Day	O
-	O
60	O
or	O
Day	O
-	O
30	O
)	O
or	O
for	B
the	I
duration	I
of	I
the	I
study	I
period	I
.	O

Administration	O
of	O
long	B
-	I
acting	I
immune	B
-	I
modifying	I
drugs	I
at	B
any	I
time	I
during	I
the	I
study	I
period	I

Subjects	O
with	O
blood	B
disorders	I
.	O

Subjects	O
with	O
a	O
history	B
of	O
difficulty	O
in	O
providing	O
blood	O
samples	O

Any	O
antibiotic	B
intake	O
7	B
days	I
prior	I
to	I
blood	I
collection	I
.	O

Subjects	O
who	O
donated	O
>	B
450	I
mL	I
of	O
blood	O
within	B
60	I
days	I
prior	I
to	I
any	I
blood	I
collection	I
visits	I
.	O

Subjects	O
who	O
lost	O
>	B
200	I
mL	I
during	O
a	O
single	B
apheresis	B
or	O
who	O
lost	B
red	I
blood	I
cells	I
on	O
more	B
than	I
one	I
occasion	I
during	O
apheresis	B
within	B
the	I
previous	I
60	I
days	I
.	O

Concurrently	B
participating	O
in	O
another	O
clinical	O
study	O
,	O
at	B
any	I
time	I
during	I
the	I
study	I
period	I
,	O
in	O
which	O
the	O
subject	O
has	O
been	O
or	O
will	O
be	O
exposed	O
to	O
an	O
investigational	B
or	O
a	O
non	B
-	I
investigational	I
vaccine	B
/	O
product	B

Ongoing	B
anaemia	B
as	O
indicated	O
by	O
haemoglobin	B
values	O
below	B
the	I
lower	I
limit	I
of	I
the	I
laboratory	I
-	I
specified	I
reference	I
range	I
.	O

If	O
the	O
finger	B
prick	I
method	I
demonstrates	O
an	O
anaemia	B
,	O
no	O
further	O
protocol	O
procedures	O
will	O
be	O
performed	O
,	O
and	O
the	O
subject	O
will	O
be	O
referred	O
for	O
appropriate	O
medical	O
management	O
.	O
The	O
subject	O
may	O
participate	O
in	O
this	O
study	O
following	O
therapy	O
and	O
evidence	O
that	O
the	O
anaemia	O
has	O
been	O
resolved	O
.	O

History	O
of	O
any	O
reaction	B
or	O
hypersensitivity	B
likely	O
to	O
be	O
exacerbated	O
by	O
any	O
component	B
of	I
the	I
vaccines	I
.	O

Pregnant	B
or	O
lactating	O
female	B
.	O

Female	B
planning	O
to	O
become	O
pregnant	O
or	O
planning	O
to	O
discontinue	O
contraceptive	O
precautions	O
.	O

Any	O
confirmed	B
or	O
suspected	O
immunosuppressive	O
or	O
immunodeficiency	B
condition	I
based	O
on	O
medical	B
history	I
and	O
physical	B
examination	I

Family	O
history	O
of	O
congenital	O
or	O
hereditary	B
immunodeficiency	I
.	O

Serious	B
chronic	B
illness	I
.	O

History	B
of	O
chronic	B
alcohol	I
consumption	I
and	O
/	O
or	O
drug	B
abuse	I
.	O

Subjects	O
who	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
can	O
and	O
will	O
comply	O
with	O
the	O
requirements	O
of	O
the	O
protocol	O
.	O

Written	O
informed	O
consent	O
obtained	O
from	O
the	O
subject	O
prior	O
to	O
performing	O
any	O
study	B
specific	I
procedure	I
.	O

A	O
male	B
or	O
female	B
between	O
,	O
and	O
including	O
,	O
18	B
and	I
50	I
years	I
of	O
age	B
at	B
the	I
time	I
of	I
the	I
first	I
study	I
visit	I
.	O

Healthy	B
subjects	O
as	O
established	O
by	O
medical	B
history	I
and	O
clinical	B
examination	I
before	B
entering	I
into	I
the	I
study	I
.	O

Healthy	O
subjects	O
with	O
no	O
medical	O
conditions	O
that	O
,	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
,	O
prevents	O
the	O
subject	O
from	O
participating	O
in	O
the	O
study	O
.	O

Subjects	O
must	O
weigh	B
at	B
least	I
110	I
pounds	I
(	O
50	O
kg	O
)	O
,	O
but	O
not	B
to	I
present	I
obesity	B
(	O
BMI	B
<	B
32kg	I
/	I
m2	I
)	O
.	O

Female	B
subjects	O
of	O
non	B
-	I
childbearing	O
potential	O
may	O
be	O
enrolled	O
in	O
the	O
study	O
.	O

Non	O
-	O
childbearing	O
potential	O
is	O
defined	O
as	O
pre	O
-	O
menarche	O
,	O
current	B
bilateral	B
tubal	I
ligation	I
or	O
occlusion	O
,	O
hysterectomy	B
,	O
bilateral	B
ovariectomy	I
or	O
post	O
-	O
menopause	O
.	O

has	O
practiced	O
adequate	B
contraception	O
for	O
30	B
days	I
prior	I
to	I
vaccination	I
,	O
and	O

has	O
a	O
negative	B
pregnancy	B
test	I
on	B
the	I
day	I
of	I
vaccination	I
and	O

has	O
agreed	O
to	O
continue	B
adequate	O
contraception	O
during	B
the	I
entire	I
treatment	I
period	I
and	O
for	B
1	I
month	I
,	I
after	I
completion	I
of	I
the	I
vaccination	I
series	I
.	O

Conversion	O
to	O
laparotomy	B

Emergent	B
re	B
intervention	I

Immunosuppression	B

Umbilical	B
hernia	I

Age	B
=	B
18	I
years	I

Laparoscopic	B
cholecystectomy	B

Emergent	B
/	O
elective	B

=	B
2	I
risk	B
factors	I
:	O
diabetes	B
mellitus	I
,	O
age	B
=	B
70	I
years	I
,	O
BMI	B
=	B
30	I
,	O
fascial	B
enlargement	I

History	B
of	O
allergic	B
reaction	I
to	O
compounds	O
of	O
similar	O
chemical	O
or	O
biologic	O
composition	O
to	O
hCG	B

receiving	B
medication	B
that	O
could	B
interfere	I
with	I
the	I
study	I
protocol	I
objectives	I
(	O
hormonal	B
contraceptives	I
,	O
androgens	B
,	O
prednisone	B
,	O
thyroid	B
hormones	I
,	O
insulin	B
)	O

previous	B
treatment	B
with	O
follicle	B
stimulating	I
hormone	I
for	O
assisted	B
reproduction	I

uncontrolled	B
intercurrent	B
illness	I

Heart	B
disease	I

Severe	B
cognitive	B
decline	I

Psychiatric	B
desease	I

HIV	B
positive	I

Hepatitis	B
B	I
or	I
C	I
infection	I

premenopausal	B
women	B

BRCA1	B
carrier	I

UTIs	B
=	O
12	O
within	B
1	I
year	I

Pregnancy	B
or	O
Lactation	B

Immune	B
disease	I

Lactose	B
intolerance	B

Urinary	B
tract	I
anomaly	I

Systemic	B
infection	I

Newly	B
started	I
hormone	B
therapy	I
within	B
the	I
last	I
6	I
months	I

Antibiotic	B
prophylaxis	O
within	B
the	I
last	I
6	I
months	I

a	B
-	I
D	I
-	I
mannose	I
intake	O
within	B
the	I
last	I
month	I

Use	O
of	O
catheters	B

Diabetes	B
mellitus	I

Participation	O
to	O
other	O
studies	O

Women	B

=	B
3	I
UTIs	B
within	B
the	I
last	I
12	I
months	I
or	O
=	B
2	I
UTIs	B
within	B
the	I
last	I
6	I
months	I
;	O

Laboratory	B
urine	I
culture	I
:	O
<	B
103	I
CFUs	I

Age	B
>	B
18	I
years	I

Patients	O
with	O
combined	O
HCV	O
/	O
HBV	B
co	I
-	I
infection	I

hepatocellular	B
carcinoma	I
(	I
HCC	I
)	I

decompensated	B
liver	B
cirrhosis	I
(	O
Child	B
-	I
Pugh	I
score	I
above	B
6	I
)	O

non	B
-	O
genotype	B
4	I

patients	O
were	O
18	O
years	O
old	B
or	O
more	O
,	O

naive	B
to	O
HCV	B
treatment	I
,	O

HCV	B
genotype	I
4	B
,	O

compensated	B
liver	B
disease	I
.	O

Patients	O
requiring	O
emergent	B
cesarean	I
birth	I

Patients	O
allergic	B
to	O
lidocaine	B
or	O
adhesive	B

Patients	O
who	O
have	O
already	O
received	O
an	O
epidural	B
during	B
this	I
admission	I
or	O
requiring	O
general	B
anesthesia	I
for	O
cesarean	B
birth	I

Patients	O
using	O
chronic	B
oral	I
neuromodulators	I

Patients	O
with	O
cardiac	B
disease	I
or	O
using	O
anti	B
-	I
arrhythmic	I
agents	I

Patients	O
with	O
fibromyalgia	B
or	O
chronic	B
pain	I
syndromes	I
such	O
as	O
rheumatoid	B
arthritis	I
,	O
osteoarthritis	B
,	O
or	O
lupus	B
.	O

Daily	B
narcotic	B
or	O
opiate	B
use	O
for	B
greater	I
than	I
the	I
2	I
months	I
prior	I
to	I
enrollment	I
in	I
the	I
study	I
.	O

Pregnant	B
patients	O
who	O
require	O
a	O
scheduled	B
or	O
non	B
-	I
urgent	I
cesarean	B
birth	I

Patient	O
able	O
to	O
receive	O
neuraxial	B
analgesia	I

Patient	O
able	O
to	O
give	O
verbal	O
and	O
written	O
consent	O
for	O
both	O
cesarean	O
birth	O
and	O
study	O

mRS	B
=	B
2	I
;	O

History	O
of	O
stroke	B
within	B
3	I
months	I
;	O

History	O
of	O
intracranial	B
hemorrhage	I
;	O

Suspected	O
subarachnoid	B
hemorrhage	I
;	O

Intracranial	B
tumour	I
,	O
vascular	B
malformation	I
or	O
arterial	B
aneurysm	I
;	O

Major	B
surgery	I
within	B
1	I
month	I
;	O

Systolic	B
pressure	I
=	B
180	I
mmHg	I
or	O
diastolic	B
pressure	I
=	B
110	I
mmHg	I
;	O

Platelet	B
count	I
<	B
105	I
/	I
mm3	I
;	O

Heparin	B
therapy	B
or	O
oral	B
anticoagulation	I
therapy	I
within	B
48	I
hours	I
;	O

Abnormal	B
APTT	B
;	O

Thrombin	B
or	O
Xa	B
factor	I
inhibitor	I
;	O

Severe	B
disease	B
with	O
a	O
life	O
expectancy	O
of	O
less	B
than	I
3	I
months	I
;	O

Blood	B
glucose	I
<	B
50	I
mg	I
/	I
dL	I
(	O
2	B
.	I
7mmol	I
/	I
L	I
)	O
;	O

Patients	O
who	O
have	O
received	O
any	O
other	O
investigational	O
drug	O
or	O
device	O
within	O
3	O
months	O
;	O

Pregnancy	B
;	O

Researchers	O
consider	O
patients	O
inappropriate	O
to	O
participate	O
in	O
the	O
registry	O
.	O

18	O
-	O
80	O
years	O
old	B
;	O

Diagnosis	O
of	O
posterior	B
circulation	I
ischemic	I
stroke	I
;	O

Time	O
from	O
onset	O
to	O
treatment	O
=	B
6	I
hours	I
;	O

NIHSS	B
:	O
4	B
-	I
25	I
;	O

Signed	O
informed	O
consent	O
by	O
patient	O
self	O
or	O
legally	O
authorized	O
representatives	O
.	O

Form	O
of	O
diagnosed	O
psoriasis	B
other	B
than	I
chronic	B
plaque	I
psoriasis	I
(	O
i	O
.	O
e	O
.	O
guttate	B
,	O
erythrodermic	B
,	O
pustular	B
)	O

Diagnosis	O
of	O
other	O
active	B
,	O
ongoing	B
skin	B
diseases	I
or	O
skin	B
infections	I
that	O
may	O
interfere	O
with	O
examination	O
of	O
psoriasis	O
lesions	O

Ongoing	B
use	O
of	O
other	O
psoriasis	B
treatment	B
including	O
but	O
not	O
limited	O
to	O
topical	O
or	O
systemic	B
corticosteroids	I
,	O
other	O
topical	B
medications	I
(	O
i	O
.	O
e	O
.	O
coal	B
tar	I
)	O
,	O
oral	O
or	O
biologic	B
medications	I
for	O
the	O
treatment	O
of	O
psoriasis	O
,	O
and	O
UV	B
therapy	I
.	O

The	O
following	O
washout	O
periods	O
will	O
be	O
required	O
:	O
2	O
weeks	O
for	O
topical	O
therapy	O
;	O
2	O
weeks	O
for	O
phototherapy	O
;	O
12	O
weeks	O
for	O
biologic	O
or	O
targeted	O
therapies	O
;	O
4	O
weeks	O
for	O
other	O
systemic	O
therapies	O

Use	O
of	O
oral	B
estrogen	I
therapy	I
,	O
excluding	B
oral	B
contraceptive	I
pills	I

Women	O
who	O
are	O
pregnant	O
,	O
nursing	O
,	O
or	O
of	O
child	O
-	O
bearing	O
potential	O
who	O
are	O
unwilling	O
to	O
use	O
appropriate	O
method	O
(	O
s	O
)	O
of	O
contraception	O
.	O

Patients	O
unwilling	O
to	O
limit	B
exposure	I
to	I
UV	I
light	I

Current	O
significant	O
medical	O
problems	O
that	O
,	O
in	O
the	O
discretion	O
of	O
the	O
investigator	O
,	O
would	O
put	O
the	O
patient	O
at	O
significant	O
risk	O

Patients	O
with	O
disorders	B
of	I
calcium	I
metabolism	I
and	O
/	O
or	O
hypercalcemia	B

Use	O
of	O
any	O
investigational	O
drug	O
within	O
4	O
weeks	O
prior	O
to	O
randomization	O
,	O
or	O
5	O
pharmacokinetic	O
/	O
pharmacodynamics	O
half	O
-	O
lives	O
,	O
if	O
known	O
(	O
whichever	O
is	O
longer	O
)	O

History	O
of	O
allergy	B
to	O
any	B
component	I
of	I
the	I
IP	I

Provide	O
written	O
,	O
signed	O
and	O
dated	O
informed	O
consent	O
prior	O
to	O
initiating	O
any	O
study	O
-	O
related	O
activities	O
.	O

Male	B
or	O
female	B
>	O
18	O
years	O
of	O
age	B
at	B
the	I
time	I
of	I
screening	I

Fitzpatrick	B
Skin	I
phototype	I
IV	B
-	I
VI	I
,	O
non	B
-	I
white	I
race	I
/	I
ethnicity	I
,	O
including	O
but	O
not	O
limited	O
to	O
-	O
-	O
-	O
African	B
Americans	I
,	O
Asians	B
,	O
Pacific	B
Islanders	I
and	O
Hispanics	B
.	O

Clinical	O
diagnosis	O
of	O
chronic	B
plaque	B
-	I
type	I
psoriasis	B
of	I
the	I
body	I

Plaque	B
psoriasis	I
with	O
=	B
2	I
%	I
Body	I
Surface	I
Area	I
(	I
BSA	I
)	I
involvement	B
(	O
may	O
include	O
scalp	O
involvement	O
)	O
,	O
PASI	B
Score	I
=	B
2	I
,	O
IGA	B
mod	I
2011	I
score	I
of	O
2	B
or	I
greater	I
(	O
based	O
on	O
scale	B
of	I
0	I
-	I
4	I
)	O

Females	O
of	O
childbearing	O
potential	O
(	O
FCBP	O
)	O
must	O
have	O
a	O
negative	O
pregnancy	O
test	O
at	O
Screening	O
and	O
Baseline	O
.	O
While	O
using	O
investigational	O
product	O
and	O
for	O
at	O
least	O
28	O
days	O
after	O
last	O
application	O
of	O
investigational	O
product	O
,	O
FCBP	O
who	O
engage	O
in	O
activity	O
in	O
which	O
conception	O
is	O
possible	O
must	O
use	O
one	O
of	O
the	O
approved	O
contraceptive	O
options	O
d	O

Must	O
be	O
in	O
general	O
good	O
health	O
as	O
judged	O
by	O
the	O
Investigator	O
,	O
based	O
on	O
medical	O
history	O
and	O
physical	O
examination	O
.	O

previous	B
retinal	B
vein	I
occlusion	I
.	O

any	O
intraocular	B
surgery	I
within	B
the	I
previous	I
12	I
months	I
.	O

myopia	B
of	O
>	B
or	I
=	I
to	I
8	I
diopters	I
.	O

active	B
ocular	O
or	O
periocular	B
infection	I

treatment	O
with	O
an	O
investigational	O
agent	O
for	O
any	O
condition	O
60	O
days	O
prior	O
to	O
enrollment	O
.	O

evidence	O
of	O
severe	B
cardiac	B
disease	I
.	O

clinically	B
significant	I
peripheral	B
vascular	I
disease	I
(	O
previous	B
surgery	I
,	O
amputation	B
,	O
or	O
symptoms	B
of	I
claudication	I
)	O

uncontrolled	B
hypertension	B
(	O
treated	B
systolic	B
blood	I
pressure	I
>	B
155	I
mmHg	I
or	O
diastolic	B
blood	I
pressure	I
>	B
95	I
mmHg	I
)	O

stroke	B
within	B
the	I
preceding	I
12	I
months	I
.	O

18	O
years	O
or	O
older	B

Type	B
1	I
or	I
2	I
diabetes	I

PDR	B
patients	O
requiring	O
surgical	B
intervention	I
for	O
complications	O
of	O
vitreous	B
hemorrhage	I
or	O
traction	B
retinal	I
detachment	I
and	O
pre	B
-	I
operative	I
IVC	B
treatment	I
.	O

women	O
postmenopausal	O
for	O
12	O
months	O
before	O
the	O
study	O
,	O
surgically	O
sterile	O
,	O
or	O
not	O
pregnant	O
and	O
on	O
effective	O
contraception	O
.	O

Patients	O
with	O
2	O
or	O
more	O
doses	O
of	O
methylprednisolone	B
/	O
prednisone	B
per	O
day	O

Steroids	B
other	B
than	I
methylprednisolone	B
or	O
prednisone	B

Pregnancy	B

estimated	B
glomerular	I
filtration	I
rate	I
(	I
eGFR	I
)	I
<	B
45	I
ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I

Patients	O
receiving	O
once	B
daily	I
dosing	O
of	O
methylprednisolone	B
or	O
prednisone	B
in	O
a	O
dose	O
of	O
10	B
mg	I
/	I
day	I
or	I
greater	I

Hyperglycemic	B
(	O
Glucose	B
level	I
>	B
126	I
mg	I
/	I
dL	I
)	O

Diabetic	B
and	O
nondiabetic	B
patients	O

Expected	B
duration	I
of	I
hospital	I
stay	I
and	O
time	B
on	I
steroids	I
>	B
=	I
3	I
days	I

Patient	O
of	O
appropriate	O
caregiver	O
able	O
to	O
give	O
Informed	O
Consent	O

Inpatient	O
status	O
,	O
airway	B
abnormalities	I
,	O
allergy	B
to	O
any	O
study	B
medications	I
,	O
eggs	B
and	O
soy	B
,	O
and	O
mitochondrial	B
disorders	I
.	O

All	O
subjects	O
with	O
any	O
cardiac	B
disease	I
or	O
history	B
of	O
cardiac	B
arrhythmias	I
will	O
be	O
excluded	O
.	O

All	O
children	O
scheduled	O
for	O
outpatient	B
MRI	B
scans	I
with	O
expected	B
duration	I
of	I
scan	I
between	B
30	I
minutes	I
and	I
75	I
minutes	I
.	O

History	O
of	O
any	O
malignancy	B
or	O
other	O
severe	B
diseases	I

Female	O
patients	O
who	O
are	O
pregnant	O
or	O
breastfeeding	O
before	O
or	O
during	O
the	O
three	O
-	O
year	O
follow	O
-	O
up	O

Poor	O
compliance	O
or	O
refusal	O
to	O
participate	O
.	O

Type	B
1	I
diabetes	I
according	O
to	O
ADA	B
criterias	I
<	B
5	I
years	I
.	O

Age	B
=	B
18	I
years	I
and	I
less	I
than	I
70	I
years	I
.	O

Non	B
-	O
obese	B
:	O
defined	O
as	O
BMI	B
less	B
than	I
28	I
kg	I
/	I
m2	I

Positive	O
for	O
at	B
least	I
one	I
of	O
the	O
anti	B
-	I
islet	I
autoantibodies	I
:	O
GADA	B
,	O
IA2A	B
,	O
ZnT8A	B

Fasting	O
or	O
postprandial	B
plasma	I
C	I
-	I
peptide	I
more	B
than	I
100	I
pmol	I
/	I
L	I

Written	O
informed	O
consent	O
from	O
the	O
patient	O
or	O
family	O
representative	O
.	O

Participants	O
with	O
congenital	O
or	O
acquired	B
hypogonadism	I
for	O
whom	O
long	O
-	O
term	O
therapy	O
with	O
placebo	O
would	O
not	O
be	O
medically	O
appropriate	O

Participants	O
with	O
prostate	B
specific	I
antigen	I
(	I
PSA	I
)	I
>	B
3	I
.	I
0	I
ng	I
/	I
mL	I
(	O
or	O
1	B
.	I
5	I
if	O
on	O
5	B
-	I
alpha	I
reductase	I
inhibitors	I
)	O

Participants	O
who	O
have	O
been	O
treated	O
with	O
testosterone	B
in	B
the	I
past	I
6	I
months	I
and	O
for	O
whom	O
testosterone	B
therapy	O
is	O
contraindicated	B

Confirmed	B
testosterone	I
<	B
100	I
ng	I
/	I
dL	I

Body	B
Mass	I
Index	I
(	I
BMI	I
)	I
>	B
50	I

Hemoglobin	B
A1c	I
(	I
HbA1C	I
)	I
>	B
11	I
%	I

Hematocrit	B
(	I
Hct	I
)	I
>	B
50	I
%	I

Estimated	B
Glomerular	I
Filtration	I
Rate	I
(	I
eGFR	I
)	I
<	B
30	I
ml	I
/	I
min	I

History	O
of	O
deep	B
vein	I
thrombosis	I
or	O
pulmonary	B
embolism	I
or	O
prostate	B
cancer	I
or	O
heart	B
failure	I
(	O
Class	B
III	I
and	O
IV	O
)	O
.	O

Men	B
between	B
45	I
and	I
80	I
years	I
age	B

Participants	O
with	O
low	B
serum	B
testosterone	I
concentrations	I
(	O
<	B
300	I
ng	I
/	I
dL	I
)	O
who	O
exhibit	O
at	B
least	I
one	I
sign	B
or	O
symptom	B
of	O
hypogonadism	B
and	O
have	O
evidence	O
of	O
cardiovascular	B
(	I
CV	I
)	I
disease	I
or	O
are	O
at	O
an	O
increased	O
risk	O
for	O
CV	B
disease	I
.	O

the	O
history	B
or	O
family	O
history	O
of	O
anaphylaxis	B
,	O
convulsion	B
,	O
epilepsy	B
,	O
encephalopathy	B
and	O
psychosis	B

the	O
history	B
of	O
severe	B
inoculation	B
allergies	I

patients	O
with	O
immunodeficiency	B
and	O
malignant	B
tumors	I
during	B
the	I
treatment	I
period	I
,	O
receiving	O
immunosuppressive	B
therapy	I
(	O
oral	B
steroid	I
)	O
or	O
HIV	B
due	O
to	O
low	O
immunity	O
,	O
or	O
family	O
members	O
have	O
congenital	B
immune	I
disease	I

Nonspecific	B
immunoglobulin	I
was	O
injected	O
within	B
one	I
month	I

temperature	B
=	B
37	I
.	I
1	I
<	I
U	I
+	I
2103	I
>	I
and	O
infectious	B
diseases	I

the	O
history	B
of	O
thrombocytopenia	B
or	O
other	B
thrombocytopenia	B
with	O
a	O
definite	O
diagnosis	O

respiratory	B
disease	I
,	O
acute	B
infection	I
or	O
chronic	B
disease	I
activity	I
period	I

severe	B
cardiovascular	B
disease	I
,	O
liver	O
and	O
kidney	B
disease	I
,	O
and	O
complications	B
of	O
diabetes	B

infectious	O
,	O
suppurative	O
and	O
allergic	B
dermatosis	I

other	O
conditions	O
that	O
may	O
affect	O
the	O
evaluation	O
of	O
the	O
trail	O

any	O
serious	B
adverse	B
events	I
that	O
have	O
a	O
causal	O
relationship	O
with	O
the	O
inoculation	B
of	I
the	I
upper	I
dose	I
of	I
the	I
vaccine	I

the	O
abnormality	O
of	O
4	O
levels	O
(	O
local	O
,	O
systemic	O
adverse	O
reactions	O
and	O
vital	O
signs	O
)	O
was	O
judged	O
to	O
be	O
related	O
to	O
vaccination	O

other	O
new	O
standards	O
of	O
exclusion	O
criteria	O
for	O
first	O
needle	O

other	O
conditions	O
that	O
may	O
affect	O
the	O
evaluation	O
of	O
the	O
trail	O

aged	B
=	B
6	I
months	I

sign	O
the	O
informed	O
consent	O
form	O

the	O
legal	O
guardians	O
participate	O
in	O
all	O
the	O
planned	O
follow	O
-	O
up	O
and	O
be	O
able	O
to	O
comply	O
with	O
all	O
research	O
procedures	O

the	O
subjects	O
have	O
completed	O
the	O
basic	O
immunization	O
of	O
2	B
needle	B
recombinant	I
hepatitis	I
B	I
vaccine	I
,	O
there	O
is	O
no	B
inoculation	B
history	B
of	O
EV71	B
vaccine	I
,	O
and	O
no	B
history	B
of	O
EV71	B
infection	I

the	O
last	O
vaccination	O
intervals	O
=	B
14	I
days	I

temperature	B
=	B
37	I
<	I
U	I
+	I
2103	I
>	I

aged	B
=	B
6	I
months	I

sign	O
the	O
informed	O
consent	O
form	O

the	O
legal	O
guardians	O
participate	O
in	O
all	O
the	O
planned	O
follow	O
-	O
up	O
and	O
be	O
able	O
to	O
comply	O
with	O
all	O
research	O
procedures	O

there	O
is	O
no	B
inoculation	B
history	B
of	O
EV71	B
vaccine	I
,	O
and	O
there	O
is	O
no	B
history	B
of	O
EV71	B
infection	I

the	O
last	O
vaccination	O
intervals	O
=	B
14	I
days	I

temperature	B
=	B
37	I
<	I
U	I
+	I
2103	I
>	I

aged	B
=	B
8	I
months	I

sign	O
the	O
informed	O
consent	O
form	O

the	O
legal	O
guardians	O
participate	O
in	O
all	O
the	O
planned	O
follow	O
-	O
up	O
and	O
be	O
able	O
to	O
comply	O
with	O
all	O
research	O
procedures	O

there	O
is	O
no	B
inoculation	B
history	B
of	O
EV71	B
vaccine	I
,	O
and	O
there	O
is	O
no	B
history	B
of	O
EV71	B
infection	I

the	O
last	O
vaccination	O
intervals	O
=	B
14	I
days	I
and	O
the	O
last	O
attenuated	O
live	O
vaccine	O
intervals	O
=	B
28days	I

temperature	B
=	B
37	I
<	I
U	I
+	I
2103	I
>	I

aged	B
=	B
8	I
months	I

sign	O
the	O
informed	O
consent	O
form	O

the	O
legal	O
guardians	O
participate	O
in	O
all	O
the	O
planned	O
follow	O
-	O
up	O
and	O
be	O
able	O
to	O
comply	O
with	O
all	O
research	O
procedures	O

there	O
is	O
no	B
inoculation	B
history	B
of	O
EV71	B
vaccine	I
,	O
and	O
there	O
is	O
no	B
history	B
of	O
EV71	B
infection	I

the	O
last	O
vaccination	O
intervals	O
=	B
14	I
days	I
and	O
the	O
last	O
attenuated	O
live	O
vaccine	O
intervals	O
=	B
28	I
days	I

temperature	B
=	B
37	I
<	I
U	I
+	I
2103	I
>	I

Receipt	O
of	O
DTaP	B
,	O
IPV	B
,	O
PCV13	B
,	O
or	O
Hib	B
prior	B
to	I
enrollment	I
.	O

Previous	O
administration	O
of	O
the	O
first	O
dose	O
of	O
HBV	O
is	O
permitted	O

Anticipated	O
receipt	O
of	O
any	O
vaccine	O
other	O
than	O
DTaP	B
,	O
IPV	B
,	O
HBV	B
,	O
PCV13	B
,	O
or	O
Hib	B
during	B
the	I
first	I
60	I
hours	I
after	I
randomization	I

History	O
of	O
a	O
severe	B
allergic	B
reaction	I
(	O
e	O
.	O
g	O
.	O
anaphylaxis	B
)	O
to	O
a	O
previous	B
dose	O
of	O
any	O
hepatitis	B
B	I
vaccine	I

History	O
of	O
a	O
severe	B
allergic	B
reaction	I
(	O
e	O
.	O
g	O
.	O
anaphylaxis	B
)	O
to	O
any	O
component	B
of	I
the	I
vaccines	I
used	I
in	I
the	I
study	I
including	O
neomycin	B
,	O
yeast	B
and	O
polymyxin	B
B	I

History	B
of	O
latex	B
allergy	B

History	B
of	O
unstable	B
progressive	B
neurologic	I
disorder	I
of	O
unknown	B
cause	I

Known	B
cause	I
of	I
apnea	I
other	B
than	I
apnea	B
of	I
prematurity	I

Cyanotic	B
heart	I
disease	I
(	O
congenital	B
or	O
acquired	B
)	O

Child	O
or	O
parent	O
/	O
LAR	O
is	O
an	O
immediate	O
relative	O
of	O
study	O
staff	O
or	O
an	O
employee	O
who	O
is	O
supervised	O
by	O
study	O
staff	O
.	O

Any	O
condition	O
that	O
would	O
,	O
in	O
the	O
opinion	O
of	O
the	O
site	O
investigator	O
,	O
place	O
the	O
participant	O
at	O
an	O
unacceptable	O
risk	O
of	O
injury	O
or	O
render	O
the	O
participant	O
unable	O
to	O
meet	O
the	O
requirements	O
of	O
the	O
protocol	O

=	B
32	I
weeks	I
gestational	B
age	I
at	I
birth	I

=	B
6	I
weeks	I
postnatal	B
age	I
at	B
randomization	I

Remains	O
hospitalized	O
after	B
birth	I
(	O
has	O
never	O
been	O
discharged	O
home	O
)	O

Treating	O
clinician	O
deems	O
infant	O
eligible	O
to	O
receive	O
2	B
-	I
month	I
vaccines	I

English	O
-	O
or	O
Spanish	O
-	O
speaking	O
parent	O
(	O
s	O
)	O
/	O
legally	O
authorized	O
representative	O
(	O
s	O
)	O
(	O
LAR	O
(	O
s	O
)	O
)	O

Not	B
planned	O
for	O
discharge	B
within	B
60	I
hours	I
of	I
study	I
entry	I

The	O
parent	O
/	O
guardian	O
must	O
be	O
willing	O
and	O
capable	O
of	O
providing	O
permission	O
for	O
their	O
child	O
to	O
participate	O
through	O
the	O
written	O
informed	O
consent	O
process	O

Past	O
history	O
of	O
hypersensitivity	B
to	O
the	O
study	B
drug	I
;	O

Diagnosed	O
diabetes	B
;	O

Severe	B
liver	B
disease	I
(	O
including	O
ALT	B
or	O
AST	B
=	B
2	I
.	I
5	I
-	I
fold	I
the	I
normal	I
upper	I
limit	I
)	O
,	O
biliary	B
obstruction	I
;	O

Ongoing	B
treatment	B
with	O
cyclosporine	B
within	B
2	I
weeks	I
;	O

Renal	B
dysfunction	I
,	O
including	O
endogenous	B
creatinine	I
clearance	I
male	B
<	B
120ml	I
/	I
min	I
,	O
female	B
<	B
105ml	I
/	I
min	I
,	O
serum	B
creatinine	I
=	B
2mg	I
/	I
dl	I
(	O
186umol	B
/	I
L	I
)	O
,	O
Renal	B
function	I
progressive	B
decline	I
,	O
GFR	B
<	B
30ml	I
•	I
min	I
-	I
1	I
•	I
1	I
.	I
73m	I
-	I
2	I
;	O

Diagnosed	O
or	O
past	O
history	O
of	O
ASCVD	B
(	O
including	O
ACS	B
,	O
SCAD	B
,	O
revascularization	B
,	O
ICM	B
,	O
ischemic	B
stroke	I
,	O
TIA	B
,	O
PASD	B
,	O
etc	O
.	O

SBP	B
=	B
180mmHg	I
,	O
or	O
DBP	B
=	B
110mmHg	I
;	O

Ongoing	B
treatment	B
with	O
Beta	B
blockers	I
,	O
Diuretic	B
;	O

Secondary	B
hypertension	I
,	O
including	O
SAS	B
,	O
PA	B
,	O
RAS	B
,	O
pheochromocytoma	B
,	O
Cushing	B
'	I
s	I
syndrome	I
,	O
aorta	B
diseases	I
,	O
drug	B
induced	I
hypertension	B
;	O

Ongoing	B
treatment	B
with	O
statins	B
,	O
fibrates	B
,	O
and	O
/	O
or	O
cation	B
exchange	I
resins	I
within	B
2	I
weeks	I
;	O

Pancreatic	B
disease	I
;	O

History	B
of	O
gastrectomy	B
,	O
short	B
bowel	I
syndrome	I
;	O

Ongoing	B
hormone	B
replacement	I
therapy	I
;	O

Diagnosed	O
or	O
suspected	O
malignant	B
tumor	I
;	O

Familial	B
hypercholesterolemia	I
;	O

Any	O
diseases	O
may	O
limit	O
the	O
efficacy	O
or	O
safety	O
of	O
the	O
study	O
;	O

Pregnant	O
or	O
possibly	O
pregnant	O
woman	O
,	O
or	O
breastfeeding	O
woman	O
,	O
or	O
woman	O
who	O
wishes	O
to	O
become	O
pregnant	O
during	O
study	O
participation	O
;	O

IFG	O
impaired	O
fast	O
glucose	O
,	O
FPG	O
fasting	O
plasma	O
glucose	O
,	O
IGT	O
impaired	O
glucose	O
tolerance	O
,	O
OGTT	O
oral	O
glucose	O
tolerance	O
test	O
,	O
PG	O
plasma	O
glucose	O
,	O
HbA1C	O
hemoglobin	O
A1C	O
,	O
LDL	O
-	O
C	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
,	O
TG	O
triglycerides	O
,	O
SBP	O
systolic	O
blood	O
pressure	O
,	O
DBP	O
diastolic	O
blood	O
pressure	O
,	O
ALT	O
alanine	O
aminotransferase	O
,	O
AST	O
aspartate	O
aminotransferase	O
,	O
GFR	O
glomerular	O
filtration	O
rate	O
,	O
ASCVD	O
arteriosclerotic	O
cardiovascular	O
disease	O
,	O
ACS	O
acute	O
coronary	O
syndrome	O
,	O
SCAD	O
stable	O
coronary	O
artery	O
disease	O
,	O
ICM	O
ischemic	O
cardiomyopathy	O
,	O
TIA	O
transient	O
ischemic	O
attack	O
,	O
PASD	O
peripheral	O
atherosclerotic	O
disease	O
,	O
SAS	O
sleep	O
apnea	O
syndrome	O
,	O
PA	O
primary	O
aldosteronism	O
,	O
RAS	O
renal	O
arterial	O
stenosis	O

Age	B
18	B
-	I
80	I
years	I
old	I
;	O

IFG	B
:	O
5	B
.	I
6mmol	I
/	I
L	I
(	O
100mg	B
/	I
dl	I
)	O
=	O
FPG	B
<	B
7	I
.	I
0mmol	I
/	I
L	I
(	O
126mg	B
/	I
dl	I
)	O
,	O
or	O
IGT	B
:	O
7	B
.	I
8mmol	I
/	I
L	I
(	O
140mg	B
/	I
dl	I
)	O
=	O
OGTT	B
2	I
-	I
h	I
PG	I
<	B
11	I
.	I
1mmol	I
/	I
L	I
(	O
200mg	B
/	I
dl	I
)	O
,	O
or	O
HbA1C	B
5	B
.	I
7	I
-	I
6	I
.	I
4	I
%	I
(	O
39	B
-	I
47mmol	I
/	I
mol	I
)	O
;	O

2	B
.	I
6mmol	I
/	I
L	I
(	O
100mg	B
/	I
dl	I
)	O
=	O
LDL	B
-	I
C	I
=	O
5	B
.	I
2mmol	I
/	I
L	I
(	O
200mg	B
/	I
dl	I
)	O
,	O
and	O
TG	B
<	B
5	I
.	I
7mmol	I
/	I
L	I
(	O
500mg	B
/	I
dl	I
)	O
;	O

130mmHg	B
=	O
SBP	B
<	B
180mmHg	I
,	O
or	O
80mmHg	B
=	I
DBP	B
<	B
110mmHg	I
or	O
ongoing	B
anti	B
-	I
hypertensive	I
therapy	I
;	O

Patients	O
volunteered	O
for	O
the	O
study	O
and	O
signed	O
informed	O
consent	O
.	O

Any	O
active	B
respiratory	O
,	O
cardiovascular	O
or	O
other	B
disease	B
requiring	O
regular	B
treatment	B
or	O
being	O
otherwise	O
relevant	O
for	O
tolerance	B
of	O
hypoxia	B
or	O
altitude	O
exposure	O
.	O

Any	O
condition	O
that	O
may	O
interfere	O
with	O
protocol	O
compliance	O
including	O
current	O
heavy	O
smoking	O
(	O
>	O
20	O
cigarettes	O
per	O
day	O
or	O
>	O
20	O
pack	O
-	O
years	O
with	O
active	O
smoking	O
during	O
the	O
last	O
10	O
years	O
)	O
,	O
regular	O
use	O
of	O
alcohol	O
.	O

Allergy	B
to	O
acetazolamide	B
and	O
other	O
sulfonamides	B
.	O

Healthy	B
men	B
and	O
women	B
,	O
age	B
40	B
-	I
75	I
yrs	I
,	O
without	B
any	B
disease	B
and	O
need	O
of	O
medication	B
.	O

Born	O
,	O
raised	O
and	O
currently	O
living	O
at	O
low	O
altitude	O
(	O
<	O
800m	O
)	O
.	O

Written	O
informed	O
consent	O
.	O

Kyrgyz	O
ethnicity	O

Any	O
active	B
respiratory	O
,	O
cardiovascular	O
or	O
other	B
disease	B
requiring	O
regular	O
treatment	B
or	O
being	O
otherwise	O
relevant	O
for	O
tolerance	B
of	O
hypoxia	B
or	O
altitude	B
exposure	I
.	O

Any	O
condition	O
that	O
may	O
interfere	O
with	O
protocol	O
compliance	O
including	O
current	O
heavy	B
smoking	I
(	O
>	B
20	I
cigarettes	B
per	I
day	I
or	O
>	B
20	I
pack	B
-	I
years	I
with	O
active	B
smoking	I
during	B
the	I
last	I
10	I
years	I
)	O
,	O
regular	B
use	I
of	I
alcohol	I
.	O

Allergy	B
to	O
acetazolamide	B
and	O
other	B
sulfonamides	B
.	O

Healthy	O
men	B
and	O
women	B
,	O
age	B
40	B
-	I
75	I
yrs	I
,	O
without	B
any	B
disease	I
and	O
need	O
of	O
medication	B
.	O

Born	O
,	O
raised	O
and	O
currently	O
living	O
at	O
low	O
altitude	O
(	O
<	O
800m	O
)	O
.	O

Written	O
informed	O
consent	O
.	O

Kyrgyz	B
ethnicity	I

Patients	O
with	O
intercurrent	B
infections	I
.	O

Patients	O
with	O
sepsis	B
.	O

Patients	O
receiving	O
drugs	B
affecting	I
immune	I
system	I
like	O
immunosuppressive	B
drugs	I
.	O

Patients	O
on	O
antibiotics	B
.	O

Patients	O
on	O
regular	B
hemodialysis	I
3sessions	B
/	I
wk	I
.	O

Recent	B
catheter	B
insertion	I
at	B
beginning	I
of	I
the	I
study	I
.	O

Both	O
males	B
and	O
females	B
.	O

Age	B
group	I
=	B
18	I
ys	I
.	O

Patient	O
with	O
fever	B
(	O
38C	B
or	O
100	B
.	I
4F	I
)	O

Patient	O
less	O
than	O
age	B
4	O
years	O

Patient	O
greater	O
than	O
age	B
16	O
years	O

Patient	O
with	O
hypersensitivity	B
/	O
allergy	B
to	O
either	O
morphine	B
,	O
NSAIDs	B
,	O
or	O
acetaminophen	B

Patient	O
received	O
acetaminophen	B
within	B
the	I
past	I
4	I
hours	I

Patient	O
with	O
known	O
liver	B
disease	I
or	O
renal	B
disease	I

Patient	O
not	B
requiring	O
IV	B
morphine	I
(	O
pain	B
score	I
5	B
/	I
10	I
or	I
less	I
)	O

Patient	O
enrolled	O
in	O
the	O
study	O
within	B
the	I
past	I
72	I
hours	I

Any	O
patient	O
age	B
4	B
-	I
16	I
years	I
with	O
sickle	B
cell	I
disease	I
who	O
presents	O
the	O
Pediatric	O
ER	O
with	O
acute	B
sickle	I
cell	I
pain	I
crisis	I
with	O
a	O
pain	B
of	O
6	B
/	I
10	I
or	I
higher	I

aged	B
less	B
than	I
20	I
years	I

history	O
of	O
gastric	B
resection	I
surgery	I

history	O
of	O
allergy	B
to	O
study	B
drugs	I

pregnancy	B
or	O
lactating	B
women	B

severe	B
underlying	I
illness	I
,	O
such	O
as	O
end	B
stage	I
renal	I
disease	I
,	O
decompensated	B
liver	B
cirrhosis	I
,	O
or	O
non	B
-	I
curative	I
malignancy	B

H	B
pylori	I
infection	I
failed	B
after	O
at	B
least	I
two	I
eradication	B
therapies	I

aged	B
20	B
years	I
or	I
greater	I

willingness	O
to	O
receive	O
rescue	B
therapy	I

Previously	B
enrolled	O
in	O
this	O
study	O
(	O
i	O
.	O
e	O
.	O
patient	O
now	O
at	O
repeat	O
encounter	O
)	O

Concomitant	B
surgical	B
procedure	I
other	B
than	I
CABG	B

Anticoagulant	B
treatment	I
after	O
the	O
operation	B
(	O
e	O
.	O
g	O
.	O
warfarin	B
,	O
direct	B
thrombin	I
inhibitors	I
(	O
dabigatran	B
)	O
,	O
FXa	B
inhibitors	I
(	O
rivaroxaban	B
,	O
apixaban	B
,	O
heparin	B
,	O
low	B
-	I
molecular	I
weight	I
heparin	I
,	O
fondaparinux	B
)	O

Discharge	O
from	O
the	O
operating	O
hospital	O
to	O
an	O
ICU	O
at	O
another	B
hospital	O

Pregnancy	B
or	O
lactation	B

Known	O
intolerance	B
or	O
contraindication	B
to	O
ticagrelor	B
or	O
ASA	B

Any	O
disorder	B
that	O
may	B
interfere	I
with	I
drug	I
absorption	I

Any	O
condition	B
other	B
than	I
coronary	B
artery	I
disease	I
with	O
a	O
life	O
expectancy	O
<	B
12	I
months	I

Known	O
chronic	B
liver	I
disease	I
,	O
renal	B
disease	I
requiring	O
dialysis	B
or	O
bleeding	B
disorder	I

Atrioventricular	B
block	I
II	I
and	O
III	O
in	O
patients	O
without	B
pacemaker	B

Any	O
other	O
indication	B
for	O
dual	B
antiplatelet	I
therapy	I
,	O
i	O
.	O
e	O
.	O
recent	B
stent	B
implantation	I

Debilitating	B
stroke	B
within	B
90	I
days	I
before	I
inclusion	I

Previous	B
intracranial	B
bleeding	I

Treatment	O
with	O
immunosuppressants	B
(	O
e	O
.	O
g	O
.	O
cyclosporine	B
and	O
tacrolimus	B
)	O

Treatment	O
with	O
strong	B
CYP3A4	I
-	I
inhibitors	I
(	O
e	O
.	O
g	O
.	O
ketoconazole	B
,	O
clarithromycin	B
,	O
nefazodone	B
,	O
ritonavir	B
or	O
atazanavir	B
)	O

Any	O
condition	O
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
may	O
interfere	O
with	O
adherence	O
to	O
trial	O
protocol	O

Written	O
informed	O
consent	O

Age	B
=	B
18	I
years	I

Has	O
undergone	O
first	B
time	I
isolated	B
CABG	I
due	O
to	O
an	O
episode	O
of	O
acute	B
coronary	I
syndrome	I
(	O
STEMI	B
,	O
NSTEMI	B
,	O
unstable	B
angina	I
)	O
within	B
6	I
weeks	I
before	I
surgery	I

Tuberculosis	B
resistant	B
to	I
any	O
of	O
the	O
study	B
drugs	I
(	O
isoniazid	B
,	O
rifampin	B
,	O
EMB	B
,	O
PZA	B
,	O
CFZ	B
,	O
Pto	B
)	O

Unable	O
to	O
take	O
oral	O
medications	O
.	O

History	B
of	O
allergy	B
or	O
intolerance	B
to	O
any	O
of	O
the	O
study	B
drugs	I

Serum	B
aminotransferase	I
(	O
AST	B
or	O
ALT	B
)	O
3x	B
upper	I
limit	I
of	I
normal	I
or	I
higher	I

Pregnant	B
or	O
nursing	O
females	B
,	O
or	O
plan	O
to	O
become	O
pregnant	O
or	O
nurse	O
during	B
the	I
study	I
period	I

Males	B
planning	O
to	O
conceive	O
a	O
child	O
during	B
the	I
study	I
or	O
within	B
6	I
months	I
of	I
cessation	I
of	I
treatment	I
.	O

Any	O
treatment	B
directed	O
against	O
active	B
tuberculosis	B
within	B
6	I
months	I
preceding	I
initiation	I
of	I
study	I
drugs	I
.	O

Suspected	O
or	O
documented	O
tuberculosis	B
involving	O
the	O
central	B
nervous	I
system	I
and	O
/	O
or	O
bones	B
and	O
/	O
or	O
joints	B
,	O
and	O
/	O
or	O
miliary	B
tuberculosis	I
and	O
/	O
or	O
pericardial	B
tuberculosis	I
.	O

HIV	B
infected	I

HBV	B
infected	I
or	O
HCV	B
infected	I
(	O
these	O
increase	O
the	O
risk	O
of	O
TB	O
-	O
drug	O
induced	O
hepatotoxicity	O
)	O

Weight	B
less	B
than	I
40	I
.	I
0	I
kg	I
.	O

Known	O
allergy	B
or	O
intolerance	B
to	O
any	O
of	O
the	O
study	B
medications	I
.	O

Individuals	O
will	O
be	O
excluded	O
from	O
enrollment	O
if	O
,	O
at	O
the	O
time	O
of	O
enrollment	O
,	O
their	O
M	B
.	I
tuberculosis	I
isolate	I
is	O
already	O
known	O
to	O
be	O
resistant	O
to	O
any	O
of	O
the	O
study	B
drugs	I
.	O

QTcF	B
>	B
500	I
msec	I

Other	O
medical	O
conditions	O
,	O
that	O
,	O
in	O
the	O
investigator	O
'	O
s	O
judgment	O
,	O
make	O
study	O
participation	O
not	O
in	O
the	O
individual	O
'	O
s	O
best	O
interest	O
.	O

Current	B
or	O
planned	O
incarceration	O
or	O
other	O
involuntary	O
detention	O

Having	O
participated	O
in	O
other	O
clinical	O
studies	O
with	O
dosing	O
of	O
investigational	B
agents	I
within	B
8	I
weeks	I
prior	I
to	I
trial	I
start	I
or	O
currently	B
enrolled	O
in	O
an	O
investigational	O
study	O
that	O
includes	O
treatment	O
with	O
medicinal	B
agents	I
.	O

Subjects	O
who	O
are	O
participating	O
in	O
observational	O
studies	O
or	O
who	O
are	O
in	O
a	O
follow	O
up	O
period	O
of	O
a	O
trial	O
that	O
included	O
drug	O
therapy	O
may	O
be	O
considered	O
for	O
inclusion	O
.	O

Newly	B
diagnosed	I
and	O
untreated	B
sputum	B
smear	I
positive	B
tuberculosis	B
patient	O

Pulmonary	B
lesion	I
consistent	O
with	O
TB	B
by	O
radiological	B
examination	I

Positive	B
sputum	B
culture	I
,	O
identification	O
of	O
bacterial	B
type	I
confirmed	O
Mycobacterium	B
tuberculosis	I
.	O

MGIT	B
drug	I
sensitivity	I
test	I
(	I
DST	I
)	I
results	O
are	O
sensitive	O
of	O
the	O
first	B
-	I
line	I
drugs	I
(	O
isoniazid	B
,	O
streptomycin	B
,	O
rifampicin	B
and	O
ethambutol	B
)	O
.	O

Age	B
18	B
years	I
-	I
65	I
years	I
old	I

Males	B
or	O
non	B
-	I
pregnant	B
,	O
non	B
-	I
nursing	O
females	B

Serum	O
or	O
plasma	B
aminotransferases	I
(	O
AST	B
,	O
ALT	B
)	O
less	B
than	I
3	I
times	I
the	I
upper	I
limit	I
of	I
normal	I

Serum	B
or	O
plasma	B
total	B
bilirubin	I
less	B
than	I
or	I
equal	I
to	I
2	I
.	I
5	I
times	I
the	I
upper	I
limit	I
of	I
normal	I

Serum	B
or	O
plasma	B
creatinine	B
level	I
less	B
than	I
or	I
equal	I
to	I
2	I
times	I
the	I
upper	I
limit	I
of	I
normal	I

Serum	B
or	O
plasma	B
potassium	B
level	I
greater	B
than	I
or	I
equal	I
to	I
3	I
.	I
5	I
meq	I
/	I
L	I

Hemoglobin	B
level	I
of	O
7	B
.	I
0	I
g	I
/	I
dL	I
or	I
greater	I

Platelet	B
count	I
of	O
100	B
,	I
000	I
/	I
mm3	I
or	I
greater	I

For	O
women	B
of	O
childbearing	O
potential	O
,	O
a	O
negative	B
pregnancy	B
test	I
is	O
required	O
during	B
screening	I

Provides	O
written	O
informed	O
consent	O

Willingness	O
and	O
ability	O
to	O
attend	O
scheduled	O
follow	O
-	O
up	O
visits	O
and	O
undergo	O
study	O
assessments	O
.	O

Diagnosis	O
of	O
primary	B
progressive	B
MS	I

Inability	O
to	O
complete	O
an	O
MRI	B
(	O
contraindications	B
for	O
MRI	B
include	O
but	O
are	O
not	O
restricted	O
to	O
weight	B
=	B
140	I
kg	I
,	O
pacemaker	B
,	O
cochlear	B
implants	I
,	O
presence	O
of	O
foreign	B
substances	I
in	I
the	I
eye	I
,	O
intracranial	B
vascular	I
clips	I
,	O
surgery	B
within	B
6	I
weeks	I
of	I
entry	I
into	I
the	I
study	I
,	O
coronary	B
stent	I
implanted	B
within	O
8	O
weeks	O
prior	O
to	O
the	O
time	O
of	O
the	O
intended	O
MRI	B
,	O
etc	O
…	O
)	O

Gadolinium	B
intolerance	B

History	O
of	O
ischemic	B
cerebrovascular	I
disorders	I
(	O
e	O
.	O
g	O
.	O
,	O
stroke	B
,	O
transient	B
ischemic	I
attack	I
)	O
or	O
ischemia	B
of	I
the	I
spinal	I
cord	I

History	O
or	O
known	O
presence	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
or	O
spinal	B
cord	I
tumor	I
(	O
e	O
.	O
g	O
.	O
,	O
meningioma	B
,	O
glioma	B
)	O

History	O
or	O
known	O
presence	O
of	O
potential	O
metabolic	B
causes	I
of	O
myelopathy	B
(	O
e	O
.	O
g	O
.	O
,	O
untreated	B
vitamin	B
B12	I
deficiency	I
)	O

History	O
or	O
known	O
presence	O
of	O
infectious	B
causes	I
of	O
myelopathy	B
(	O
e	O
.	O
g	O
.	O
,	O
syphilis	B
,	O
Lyme	B
disease	I
,	O
human	B
T	I
-	I
lymphotropic	I
virus	I
1	I
(	I
HTLV	I
-	I
1	I
)	I
,	O
herpes	B
zoster	I
myelopathy	I
)	O

History	O
of	O
genetically	B
inherited	I
progressive	B
CNS	I
degenerative	I
disorder	I
(	O
e	O
.	O
g	O
.	O
,	O
hereditary	B
paraparesis	I
;	O
MELAS	O
[	O
mitochondrial	B
myopathy	I
,	O
encephalopathy	B
,	O
lactic	B
acidosis	I
,	O
stroke	B
]	O
syndrome	O
)	O

Neuromyelitis	B
optica	I

History	B
or	O
known	O
presence	O
of	O
systemic	B
autoimmune	I
disorders	I
potentially	O
causing	O
progressive	B
neurologic	I
disease	I
(	O
e	O
.	O
g	O
.	O
,	O
lupus	B
,	O
anti	B
-	I
phospholipid	I
antibody	I
syndrome	I
,	O
Sjogren	B
'	I
s	I
syndrome	I
,	O
Behçet	B
'	I
s	I
disease	I
,	O
sarcoidosis	B
)	O

History	O
of	O
severe	B
,	O
clinically	B
significant	I
brain	O
or	O
spinal	B
cord	I
trauma	I
(	O
e	O
.	O
g	O
.	O
,	O
cerebral	B
contusion	I
,	O
spinal	B
cord	I
compression	I
)	O

Vulnerable	O
patients	O
(	O
Patient	O
referred	O
to	O
in	O
Articles	B
L	I
.	I
1121	I
-	I
5	I
to	I
L	I
.	I
1121	I
-	I
8	I
and	I
L	I
.	I
1122	I
-	I
1	I
-	I
2	I
of	I
the	I
French	I
Public	I
Health	I
Code	I
)	O

Age	B
>	B
/	I
=	I
18	I
years	I
at	B
screening	I

Patients	O
with	O
relapsing	B
forms	I
of	O
multiple	B
sclerosis	I
(	I
RMS	I
)	I
with	O
active	B
disease	I
defined	O
by	O
clinical	O
or	O
imaging	O
features	O
:	O
(	O
i	O
)	O
at	O
least	O
one	O
clinical	B
relapse	I
over	O
a	O
6	O
-	O
month	O
period	O
prior	B
to	I
screening	I
;	O
(	O
ii	O
)	O
AND	O
/	O
OR	O
at	O
least	O
one	O
T1	B
gadolinium	I
-	I
enhancing	I
lesion	I
or	O
new	B
and	O
/	O
or	O
enlarging	B
T2	B
lesion	I
as	O
detected	O
by	O
brain	B
Magnetic	I
Resonance	I
Imaging	I
(	I
MRI	I
)	I
performed	O
over	O
a	O
3	O
months	O
period	O
prior	B
to	I
screening	I
with	O
no	B
change	B
of	I
Disease	B
-	I
Modifying	I
Treatment	I
(	I
s	I
)	I
(	I
DMT	I
)	I
compared	O
to	O
a	O
previous	O
MRI	O
performed	O
within	O
24	O
months	O
before	O
screening	O

For	O
women	O
of	O
childbearing	O
potential	O
:	O
agreement	O
to	O
use	O
an	O
acceptable	O
birth	O
control	O
method	O
during	O
the	O
treatment	O
period	O
and	O
for	O
at	O
least	O
12	O
months	O
after	O
the	O
last	O
dose	O
of	O
ocrelizumab	O

Participants	O
should	O
be	O
beneficiary	O
of	O
healthcare	O
coverage	O
under	O
the	O
social	O
security	O
system	O

NA	O

Horner	B
'	I
s	I
Syndrome	I

History	O
of	O
taking	O
an	O
alpha	B
blocker	I
(	O
tamsulosin	B
/	O
terazosin	B
/	O
doxazosin	B
/	O
alfuzosin	B
/	O
silodosin	B
)	O
medication	O

Preexisting	B
untreated	B
medical	B
condition	I
(	O
thyroid	B
disease	I
,	O
diabetes	B
mellitus	I
,	O
hypertension	B
,	O
pulmonary	B
conditions	I
,	O
cardiac	B
condition	I
…	O
)	O

History	O
of	O
three	B
or	I
more	I
consecutively	B
failed	I
In	B
Vitro	I
Fertilization	I
(	O
IVF	B
)	O
cycles	O
after	O
embryo	B
transfer	I

History	O
of	O
three	B
or	I
more	I
miscarriages	B

Previous	O
allergy	B
reactions	O
to	O
progesterone	B
products	I

Normal	B
uterine	B
cavity	I

Normal	B
Hormonal	B
investigation	I
:	O
TSH	B
,	O
PRL	B
,	O
FBS	B

Frozen	B
embryo	I
transfer	I
cycles	I
:	O
at	B
least	I
2	I
embryos	B

Primary	O
or	O
secondary	B
infertility	I
:	O
tubal	B
occlusion	I
,	O
male	O
factor	O
,	O
unexplained	O
,	O
endometriosis	B
,	O
ovarian	O
factors	O
…	O

Body	B
mass	I
index	I
(	O
BMI	B
)	O
=	B
18	I
to	I
=	I
30	I
kg	I
/	I
m2	I

NA	O

presence	O
of	O
typical	B
HF	B
symptoms	I
and	O
signs	O

LV	B
ejection	I
fraction	I
=	B
50	I

elevated	B
levels	O
of	O
NT	B
-	I
proBNP	I
(	O
at	B
least	I
>	I
125	I
pg	I
/	I
ml	I
)	O

echocardiographic	B
structural	I
(	O
a	O
left	B
atrial	I
volume	I
index	I
>	B
34	I
mL	I
/	I
m2	I
or	O
a	O
left	B
ventricular	I
mass	I
index	I
=	B
115	I
g	I
/	I
m2	I
for	O
males	B
and	O
=	B
95	I
g	I
/	I
m2	I
for	O
females	B
)	O
or	O
functional	B
alterations	I
(	O
E	B
/	I
e	I
'	I
=	B
13	I
and	O
a	O
mean	B
e	I
'	I
septal	I
and	I
lateral	I
wall	I
<	B
9	I
cm	I
/	I
s	I
)	O
.	O

Preoperative	B
Hemoglobin	B
<	B
U	I
+	I
2266	I
>	I
11	I
g	I
/	I
dl	I

History	B
of	O
infection	B
or	O
intraarticular	B
fracture	I
of	O
the	O
affective	B
hip	I

Renal	B
function	I
deficiency	I
(	O
GFR	B
<	B
30	I
ml	I
/	I
min	I
/	I
1	I
.	I
73m2	I
)	O

Elevated	B
liver	B
enzyme	I
(	O
aspartate	B
transaminase	I
(	I
AST	I
)	I
/	I
alanine	I
transaminase	I
(	I
ALT	I
)	I
level	I
are	O
more	B
than	I
twice	I
normal	I
range	I
)	O
,	O
history	B
of	O
liver	B
cirrhosis	I
,	O
impaired	B
liver	I
function	I
(	O
elevated	B
total	B
bilirubin	I
level	I
)	O
and	O
coagulopathy	B
(	O
including	O
long	B
-	I
term	I
use	I
anticoagulant	B
)	O

History	O
of	O
deep	B
vein	I
thrombosis	I
,	O
ischemic	B
heart	I
disease	I
or	O
stroke	B

Contraindications	B
of	O
tranexamic	B
acid	I
,	O
floseal	B
,	O
or	O
rivaroxaban	B

Allergy	B
to	O
tranexamic	B
acid	I
,	O
floseal	B
,	O
rivaroxaban	B
,	O
or	O
the	O
excipients	B

History	B
of	O
heparin	B
-	I
induced	I
thrombocytopenia	I
(	I
HIT	I
)	I

Coagulopathy	B
or	O
bleeding	B
tendency	I
caused	O
by	O
organ	B
dysfunction	I
,	O
such	O
as	O
cirrhosis	B
,	O
bone	B
marrow	I
suppression	I
etc	O
.	O

Patient	O
who	O
have	O
active	B
bleeding	B
disorder	I
,	O
such	O
as	O
intracranial	B
hemorrhage	I
,	O
upper	B
gastrointestinal	I
bleeding	I
,	O
hematuria	B
.	O

Patients	O
with	O
known	O
allergies	B
to	O
materials	B
of	I
bovine	I
origin	I
.	O

Patients	O
with	O
osteoarthritis	B
of	O
the	O
hip	B
secondary	O
to	O
degeneration	B
,	O
inflammatory	B
arthritis	I
,	O
gouty	B
arthritis	I
,	O
acetabular	B
dysplasia	I
or	O
osteonecrosis	B
of	O
the	O
femoral	B
head	I
,	O
and	O
undergoing	B
primary	B
unilateral	B
minimally	B
invasive	I
THA	I

Age	B
>	B
18	I
years	I
and	O
<	B
90	I
years	I

Failure	B
of	O
medical	B
treatment	I
or	O
rehabilitation	B
.	O

Hemoglobin	B
>	B
11g	I
/	I
dl	I
,	O

No	B
use	O
of	O
non	B
-	I
steroid	I
anti	I
-	I
inflammatory	I
agent	I
one	B
week	I
before	I
operation	I

Known	O
upper	B
gastrointestinal	I
malignancy	I

Bleeding	B
from	O
gastric	B
varices	I
,	O
with	O
or	O
without	O
esophageal	B
varices	I

Use	O
of	O
any	B
other	I
endoscopic	B
method	I
to	O
stop	O
GI	B
bleeding	I
beyond	O
endoscopic	B
band	I
ligation	I

Variceal	B
bleeding	I
in	B
the	I
last	I
90	I
days	I

History	B
of	O
transjugular	B
,	I
intrahepatic	I
,	I
portosystemic	I
shunt	I
(	I
TIPS	I
)	I
or	O
vascular	B
decompression	I
surgery	I

Pregnant	B
females	B

Incarcerated	B
individuals	I

Myocardial	B
infarct	I
,	O
cerebrovascular	B
accident	I
,	O
sepsis	B
,	O
respiratory	B
failure	I
,	O
or	O
severe	B
intercurrent	B
illness	I
within	B
the	I
previous	I
6	I
weeks	I

Non	B
-	I
cirrhotic	I
portal	I
hypertension	I
causing	O
esophageal	B
varices	I

Known	O
or	O
suspected	O
allergy	B
to	O
octreotide	B

Adult	B
males	B
and	O
females	B
who	O
are	O
18	B
years	I
of	I
age	I
or	I
older	I
.	O

Evidence	O
or	O
suspicion	O
of	O
upper	B
gastrointestinal	I
bleed	I
(	I
GIB	I
)	I

Patient	O
with	O
known	O
or	O
suspected	O
cirrhosis	B

Upper	B
GIB	I
secondary	B
to	O
bleeding	B
esophageal	B
varices	I
as	O
show	O
by	O
esophageal	B
endoscopy	I
,	O
requiring	O
endoscopic	B
band	I
ligation	I
(	I
EBL	I
)	I
at	B
presentation	I

Willing	O
and	O
able	O
to	O
provide	O
informed	O
consent	O
for	O
study	O
,	O
or	O
have	O
a	O
Legally	O
authorized	O
representative	O
(	O
LAR	O
)	O
provide	O
consent	O
if	O
the	O
patient	O
is	O
unable	O
to	O
do	O
so	O

Previous	B
surgical	O
or	O
catheter	B
ablation	I
for	O
atrial	B
fibrillation	I

Previous	B
cardiac	B
surgery	I
(	O
including	O
CABG	B
)	O
within	B
the	I
past	I
6	I
months	I
(	I
180	I
days	I
)	I

Valvular	B
cardiac	I
surgical	I
/	I
percutaneous	I
procedure	I
(	O
i	O
.	O
e	O
.	O
,	O
ventriculotomy	B
,	O
atriotomy	B
,	O
and	O
valve	B
repair	I
or	O
replacement	O
and	O
presence	O
of	O
a	O
prosthetic	B
valve	I
)	O

Any	O
carotid	B
stenting	I
or	O
endarterectomy	B

Documented	O
LA	B
thrombus	I
on	O
imaging	B

LA	B
size	I
>	B
50	I
mm	I
(	O
parasternal	B
long	I
axis	I
view	I
)	O

LVEF	B
<	B
40	I
%	I

Contraindication	B
to	O
anticoagulation	B
(	O
heparin	B
or	O
warfarin	B
)	O

History	B
of	O
blood	B
clotting	I
or	O
bleeding	B
abnormalities	I

PCI	B
/	O
MI	B
within	B
the	I
past	I
2	I
months	I
(	O
60	O
days	O
)	O

Documented	O
thromboembolic	B
event	I
(	O
including	O
TIA	B
)	O
within	B
the	I
past	I
12	I
months	I
(	O
365	O
days	O
)	O

Rheumatic	B
Heart	I
Disease	I

Uncontrolled	B
heart	B
failure	I
or	O
NYHA	B
function	I
class	I
III	B
or	O
IV	B

Severe	B
mitral	B
regurgitation	I
(	O
Regurgitant	B
volume	I
=	B
60	I
mL	I
/	I
beat	I
,	O
Regurgitant	B
fraction	I
=	B
50	I
%	I
,	O
and	O
/	O
or	O
Effective	B
regurgitant	I
orifice	I
area	I
=	B
0	I
.	I
40cm2	I
)	O

Awaiting	O
cardiac	B
transplantation	I
or	O
other	O
cardiac	B
surgery	I
within	B
the	I
next	I
12	I
months	I
(	O
365	O
days	O
)	O

Unstable	B
angina	I

Acute	B
illness	I
or	O
active	B
systemic	B
infection	I
or	O
sepsis	B

AF	B
secondary	B
to	O
electrolyte	B
imbalance	I
,	O
thyroid	B
disease	I
,	O
or	O
reversible	B
or	O
non	B
-	I
cardiac	I
cause	I
.	O

Presence	O
of	O
implanted	B
ICD	I
/	I
CRT	I
-	I
D	I
.	O

Significant	B
pulmonary	B
disease	I
,	O
(	O
e	O
.	O
g	O
.	O
,	O
restrictive	B
pulmonary	I
disease	I
,	O
constrictive	O
or	O
chronic	B
obstructive	I
pulmonary	I
disease	I
)	O
or	O
any	B
other	I
disease	O
or	O
malfunction	B
of	I
the	I
lungs	I
or	O
respiratory	O
system	O
that	O
produces	O
chronic	B
symptoms	I
.	O

Gastroesophageal	B
Reflux	I
Disease	I
(	O
GERD	B
;	O
active	O
requiring	O
significant	B
intervention	I
not	B
including	O
OTC	B
medication	I
)	O

Significant	B
congenital	B
anomaly	I
or	O
medical	B
problem	I
that	O
in	O
the	O
opinion	O
of	O
the	O
investigator	O
would	O
preclude	O
enrollment	O
in	O
this	O
study	O
.	O

Women	B
who	O
are	O
pregnant	B
(	O
as	O
evidenced	O
by	O
pregnancy	B
test	I
if	O
pre	B
-	I
menopausal	I
)	O

Concurrent	O
enrollment	O
in	O
an	O
investigational	O
study	O
evaluating	O
another	O
device	O
,	O
biologic	O
,	O
or	O
drug	O
.	O

Presence	O
of	O
intracardiac	B
thrombus	I
,	O
myxoma	B
,	O
tumor	B
,	O
interatrial	B
baffle	I
or	O
patch	B
or	O
other	B
abnormality	B
that	O
precludes	B
vascular	B
access	I
,	O
or	O
manipulation	B
of	I
the	I
catheter	I
.	O

Life	O
expectancy	O
less	B
than	I
12	I
months	I

Symptomatic	B
paroxysmal	B
AF	I
who	O
had	O
at	B
least	I
one	I
AF	B
episode	I
electrocardiographically	B
documented	O
within	B
one	I
(	I
1	I
)	I
year	I
prior	I
to	I
enrollment	I
.	O

Documentation	O
may	O
include	O
electrocardiogram	B
(	I
ECG	I
)	I
;	O
Transtelephonic	B
monitoring	I
(	I
TTM	I
)	I
,	O
Holter	B
monitor	I
or	O
telemetry	B
strip	I

Failed	O
at	B
least	I
one	I
antiarrhythmic	B
drug	I
(	I
AAD	I
)	I
(	O
Class	O
I	O
or	O
III	B
antiarrhythmic	I
drugs	I
)	O
as	O
evidenced	O
by	O
recurrent	B
symptomatic	I
AF	I
,	O
or	O
intolerable	B
to	O
the	O
AAD	B

Age	B
18	B
years	I
or	I
older	I

Signed	O
Patient	O
Informed	O
Consent	O
Form	O
(	O
ICF	O
)	O

Able	O
and	O
willing	O
to	O
comply	O
with	O
all	O
pre	O
-	O
,	O
post	O
-	O
,	O
and	O
follow	O
-	O
up	O
testing	O
and	O
requirements	O

Legally	O
incompetent	O
or	O
mentally	B
impaired	I
(	O
e	O
.	O
g	O
.	O
,	O
minors	B
,	O
Alzheimer	B
'	I
s	I
subjects	O
,	O
dementia	B
,	O
etc	O
.	O
)	O

Younger	B
than	I
18	I
years	I
of	O
age	B

Any	O
patient	O
considered	O
a	O
vulnerable	O
subject	O

Have	O
bleeding	O
or	O
clotting	B
disorder	I

Preoperative	B
anticoagulation	B
therapy	O

Abnormal	B
coagulation	B
profile	I

Renal	B
disorder	I
or	O
insufficiency	O

Sickle	B
cell	I
disease	I

Patients	O
undergoing	B
a	O
high	B
tibial	I
osteotomy	I
(	I
HTO	I
)	I

Patients	O
undergoing	B
tibial	B
tubercle	I
osteotomy	I
(	I
TTO	I
)	I
with	O
or	O
without	O
medial	B
patello	I
-	I
femoral	I
ligament	I
(	I
MPFL	I
)	I
reconstruction	I

With	O
severe	B
systemic	B
alteration	I
;	O

In	O
the	O
use	O
of	O
antibiotics	B
and	O
anti	B
-	I
inflammatories	I
in	B
the	I
last	I
three	I
months	I
;	O

With	O
periodontium	O
with	O
periodontal	O
parameters	O
different	O
from	O
those	O
established	O
in	O
the	O
inclusion	O
criteria	O
.	O

Individuals	O
with	O
clinical	B
signs	I
of	I
parafunctional	I
habits	I
;	O

Smoking	O
;	O

Individuals	O
who	O
have	O
performed	O
other	B
restorations	I
in	B
the	I
last	I
12	I
months	I
;	O

Pregnant	B
women	B
and	O
infants	B
;	O

Periodontal	O
sites	O
that	O
presented	O
bleeding	O
during	O
crevicular	O
fluid	O
collection	O
or	O
sites	O
that	O
prevent	O
proper	O
collection	O
of	O
clinical	O
parameters	O
.	O

Over	B
18	I
years	I
of	O
age	B
;	O
Systemically	B
healthy	I
;	O
Non	B
-	I
smoking	I
;	O

With	O
good	O
oral	O
hygiene	O
;	O

Absent	B
irreversible	B
pulpal	I
alteration	I
;	O

With	O
the	O
presence	O
of	O
a	O
non	B
-	I
carious	I
cervical	I
lesion	I
(	I
LCNCs	I
)	I
that	O
needs	O
to	O
be	O
restored	B
.	O

This	O
lesion	B
should	O
be	O
non	B
-	I
carious	I
,	O
non	B
-	I
retentive	I
,	O
with	O
at	B
least	I
1	I
mm	I
and	I
up	I
to	I
3	I
mm	I
depth	B
,	O
should	O
involve	B
both	I
enamel	I
and	I
dentin	I
of	O
vital	O
teeth	O
without	O
mobility	O
,	O
and	O
present	O
hypersensitivity	B
;	O

Presence	O
a	O
natural	O
tooth	O
of	O
the	O
same	O
position	O
of	O
the	O
restored	O
tooth	O
,	O
but	O
in	O
the	O
opposite	O
arch	O
of	O
the	O
same	O
jaw	O
to	O
be	O
considered	O
for	O
the	O
positive	O
control	O
;	O

Periodontal	O
parameters	O
:	O
Depth	B
Probing	I
(	I
PS	I
)	I
,	O
Visible	B
Plaque	I
Index	I
(	I
IPV	I
)	I
,	O
Gingival	B
Index	I
(	I
GI	I
)	I
and	O
Probing	B
Bleed	I
Index	I
(	I
SS	I
)	I
.	O

The	O
normal	O
included	O
were	O
:	O
PS	B
=	B
1	I
to	I
3	I
mm	I
,	O
GI	B
=	B
0	I
,	O
IPV	B
=	O
score	B
0	I
e	O
SS	B
=	O
score	B
0	I
.	O

Allergy	B
to	O
ascorbic	B
acid	I

Asthma	B

COPD	B

Allergy	B
to	O
opioids	B

Previous	B
history	B
of	O
chemical	B
dependence	I

Prior	B
cardiac	B
surgery	I

Known	O
hyperoxaluria	B

History	B
of	O
renal	B
calculi	I

History	O
of	O
allergic	B
or	O
hypersensitivity	B
reaction	O
to	O
ascorbic	B
acid	I
products	O

Currently	O
taking	O
1	B
g	I
or	I
more	I
of	O
ascorbic	B
acid	I
supplementation	O
daily	O

Elective	B
Cardiac	I
surgery	I

American	B
Society	I
of	I
Anesthesiologists	I
physical	I
status	I
class	B
I	I
-	I
III	I

diagnosed	O
advanced	O
heart	O
,	O
kidney	O
or	O
liver	B
failure	I

benign	B
prostatic	I
hyperplasia	I

prostatic	B
carcinoma	I

frequent	B
urinary	B
tract	I
infections	I

non	B
-	I
type	I
1	I
diabetes	I
mellitus	I

diabetes	B
mellitus	I
type	I
1	I

Known	O
hypersensitivity	B
to	O
paracetamol	B
or	O
mannitol	B
(	O
excipient	O
with	O
known	O
effect	O
)	O

Severe	O
hepatocellular	B
insufficiency	I
(	O
ASAT	B
or	O
ALAT	B
>	B
5N	I
,	O
or	O
bilirubin	B
>	B
2N	I
)	O

Pharmacological	B
intervention	O
(	O
administration	O
of	O
corticosteroids	B
,	O
NSAIDs	B
or	O
paracetamol	B
)	O
or	O
physical	B
intervention	I
(	O
external	B
cooling	I
technique	I
)	O
that	O
may	O
influence	O
temperature	B
in	B
the	I
last	I
6	I
hours	I
.	O

Pregnant	B
or	O
breastfeeding	O
women	B

Previous	O
participation	O
in	O
this	O
study	O

18	O
-	O
year	O
or	O
older	B
patients	O

Patient	O
hospitalized	O
in	O
neuro	O
-	O
critical	O
care	O
for	O
:	O

Arachnoid	B
hemorrhage	I

Intra	B
parenchymatous	I
hematoma	B

stroke	B

Acute	B
brain	I
Severe	I
injury	I

Post	B
-	I
operative	I
complication	I
of	O
an	O
act	O
of	O
neurosurgery	B
or	O
programmed	O
neuroradiology	B

Sedation	B
and	O
mechanical	B
ventilation	I
planned	O
>	B
2	I
days	I

Monitoring	O
of	O
intracranial	B
temperature	I
and	O
pressure	O
by	O
intraparenchymal	B
sensor	I
(	O
Sophysa	B
®	I
)	O

Brain	B
temperature	I
>	B
38	I
.	I
5	I
°	I
C	I
for	B
more	I
than	I
30	I
minutes	I

Uncontrolled	B
hypertension	B
or	O
metabolic	B
disease	I

Neurodegenerative	B
disorders	I
(	O
i	O
.	O
e	O
.	O
Parkinson	B
disease	I
.	O
LBD	B
,	O
or	O
FTD	B
)	O
.	O

Dementia	B
or	O
Mild	B
cognitive	B
impairment	I
at	B
baseline	I

Long	B
life	I
major	I
depression	I
.	O

Baseline	B
scores	I
=	B
16	I
on	O
the	O
17	B
-	I
item	I
Hamilton	I
Depression	I
Scale	I
at	B
baseline	I
.	O

Long	B
-	I
life	I
DSM	I
-	I
IV	I
axis	I
1	I
disorders	I
.	O

Mental	B
retardation	I
.	O

Substance	B
abuse	I
.	O

Concurrent	B
medication	B
limiting	B
validity	I
of	I
neuropsychological	I
tests	I
or	O
imaging	O
.	O

Anti	B
-	I
depressants	I
with	O
anti	B
-	I
cholinergic	I
properties	O

Monoamine	B
oxidase	I
inhibitors	I
(	I
MAOi	I
)	I

Regular	B
use	I
of	O
narcotic	B
analgesics	I
(	O
>	B
2	I
doses	I
per	I
week	I
)	O
.	O

Use	O
of	O
neuroleptics	B

Use	O
of	O
anti	B
-	I
dementia	I
medications	I
(	O
Aricept	B
,	O
Exelon	B
,	O
Razadyne	B
)	O
and	O
memantine	B
(	O
Namenda	B
)	O
)	O
or	O
anti	B
-	I
Parkinsonian	I
medications	I
(	O
Sinemet	B
,	O
amantadine	B
,	O
bromocriptine	B
,	O
pergolide	B
,	O
selegeline	B
)	O
.	O

Individuals	O
taking	O
over	B
the	I
counter	I
memory	I
enhancing	I
or	I
protecting	I
medications	I
(	O
e	O
.	O
g	O
.	O
ginkgo	B
biloba	I
,	O
vitamins	B
)	O
are	O
not	O
excluded	O
.	O

Implanted	O
medical	B
devices	I
that	O
are	O
incompatible	O
with	O
MRI	B
imaging	I
.	O

Radiation	B
exposures	I
exceeding	B
annual	I
Rad	I
Worker	I
limits	I
.	O

Heart	B
failure	I
stage	B
D	B
as	O
defined	O
by	O
American	B
Heart	I
Association	I
(	O
7	O
)	O
.	O

Chronic	B
kidney	I
disease	I
in	O
stages	B
=	B
4	I
,	O
as	O
defined	O
per	O
National	B
Kidney	I
Foundation	I
(	O
8	O
)	O
.	O

Brain	B
tumor	I
and	O
other	O
neoplastic	B
disorders	I
outside	B
the	I
brain	I
where	O
disease	O
itself	O
or	O
its	O
treatment	O
(	O
radiation	B
,	O
chemotherapy	B
)	O
is	O
likely	B
to	I
affect	I
brain	I
structure	I
or	O
function	O
.	O

Stroke	B
when	O
meeting	O
criteria	O
for	O
total	B
anterior	I
,	O
partial	B
anterior	I
or	O
posterior	B
circulation	B
infarct	I
according	O
to	O
the	O
Oxford	B
Community	I
Stroke	I
Project	I
classification	I
.	O

Patients	O
with	O
clinically	O
silent	O
of	O
lacunar	O
strokes	O
and	O
transient	O
ischemic	O
attacks	O
will	O
not	O
be	O
excluded	O
.	O

Significant	B
head	B
trauma	I
.	O

Hydrocephalus	B
.	O

Hostility	O
or	O
refusal	O
to	O
cooperate	O

Male	B
and	O
female	B
subjects	O
between	B
40	I
-	I
85	I
years	I
old	B
will	O
be	O
enrolled	O
.	O

Younger	O
subjects	O
are	O
not	O
included	O
as	O
the	O
risk	O
for	O
brain	O
amyloid	O
lesions	O
is	O
too	O
low	O

All	O
subjects	O
will	O
speak	O
English	O
as	O
their	O
first	B
language	I
or	O
demonstrate	O
proficiency	O
in	O
English	O
(	O
defined	O
as	O
reaching	O
a	O
scaled	O
score	O
of	O
>	B
11	I
on	O
the	O
WAIS	B
vocabulary	I
test	I
)	O
.	O

All	O
subjects	O
will	O
have	O
normal	B
cognition	I
at	B
baseline	I
:	O
a	O
Clinical	B
Dementia	I
Rating	I
CDR	I
=	B
0	I
,	O
Global	B
Deterioration	I
Scale	I
GDS	I
<	B
2	I
.	O

All	O
subjects	O
will	O
be	O
in	O
good	B
general	I
health	I
and	O
able	O
to	O
participate	O
in	O
the	O
LP	B
and	O
imaging	B
exams	I
.	O

This	O
determination	O
is	O
made	O
by	O
the	O
study	O
neurologist	O
and	O
reviewed	O
at	O
a	O
consensus	O
meeting	O
for	O
each	O
subject	O
.	O

